<1. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 27072860
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Hussain I
AU  - Mohammed SF
AU  - Forfia PR
AU  - Lewis GD
AU  - Borlaug BA
AU  - Gallup DS
AU  - Redfield MM
FA  - Hussain, Imad
FA  - Mohammed, Selma F
FA  - Forfia, Paul R
FA  - Lewis, Gregory D
FA  - Borlaug, Barry A
FA  - Gallup, Dianne S
FA  - Redfield, Margaret M
IN  - Hussain,Imad. From the Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (I.H., S.F.M., B.A.B., M.M.R.); Temple University, Philadelphia, PA (P.R.F.); Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston (G.D.L.); Duke Clinical Research Institute, Durham, NC (D.S.G.).
IN  - Mohammed,Selma F. From the Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (I.H., S.F.M., B.A.B., M.M.R.); Temple University, Philadelphia, PA (P.R.F.); Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston (G.D.L.); Duke Clinical Research Institute, Durham, NC (D.S.G.).
IN  - Forfia,Paul R. From the Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (I.H., S.F.M., B.A.B., M.M.R.); Temple University, Philadelphia, PA (P.R.F.); Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston (G.D.L.); Duke Clinical Research Institute, Durham, NC (D.S.G.).
IN  - Lewis,Gregory D. From the Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (I.H., S.F.M., B.A.B., M.M.R.); Temple University, Philadelphia, PA (P.R.F.); Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston (G.D.L.); Duke Clinical Research Institute, Durham, NC (D.S.G.).
IN  - Borlaug,Barry A. From the Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (I.H., S.F.M., B.A.B., M.M.R.); Temple University, Philadelphia, PA (P.R.F.); Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston (G.D.L.); Duke Clinical Research Institute, Durham, NC (D.S.G.).
IN  - Gallup,Dianne S. From the Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (I.H., S.F.M., B.A.B., M.M.R.); Temple University, Philadelphia, PA (P.R.F.); Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston (G.D.L.); Duke Clinical Research Institute, Durham, NC (D.S.G.).
IN  - Redfield,Margaret M. From the Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (I.H., S.F.M., B.A.B., M.M.R.); Temple University, Philadelphia, PA (P.R.F.); Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston (G.D.L.); Duke Clinical Research Institute, Durham, NC (D.S.G.). redfield.margaret@mayo.edu.
TI  - Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial.
SO  - Circulation: Heart Failure. 9(4):e002729, 2016 Apr.
AS  - Circ. Heart fail.. 9(4):e002729, 2016 Apr.
NJ  - Circulation. Heart failure
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101479941
OI  - Source: NLM. NIHMS768832 [Available on 04/01/17]
OI  - Source: NLM. PMC4831074 [Available on 04/01/17]
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - *Diastole/de [Drug Effects]
MH  - *Exercise Tolerance/de [Drug Effects]
MH  - Female
MH  - Heart Failure/di [Diagnosis]
MH  - *Heart Failure/dt [Drug Therapy]
MH  - Heart Failure/en [Enzymology]
MH  - Heart Failure/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxygen Consumption/de [Drug Effects]
MH  - Phosphodiesterase 5 Inhibitors/ae [Adverse Effects]
MH  - *Phosphodiesterase 5 Inhibitors/tu [Therapeutic Use]
MH  - *Pulmonary Artery/de [Drug Effects]
MH  - Pulmonary Artery/pp [Physiopathology]
MH  - Pulmonary Artery/us [Ultrasonography]
MH  - *Pulmonary Circulation/de [Drug Effects]
MH  - Pulmonary Ventilation/de [Drug Effects]
MH  - Recovery of Function
MH  - Severity of Illness Index
MH  - Sildenafil Citrate/ae [Adverse Effects]
MH  - *Sildenafil Citrate/tu [Therapeutic Use]
MH  - *Stroke Volume/de [Drug Effects]
MH  - Time Factors
MH  - Treatment Outcome
MH  - Ventricular Dysfunction, Right/di [Diagnosis]
MH  - *Ventricular Dysfunction, Right/dt [Drug Therapy]
MH  - Ventricular Dysfunction, Right/en [Enzymology]
MH  - Ventricular Dysfunction, Right/pp [Physiopathology]
MH  - Ventricular Function, Left/de [Drug Effects]
MH  - *Ventricular Function, Right/de [Drug Effects]
KW  - diastole;  exercise;  heart failure;  hypertension;  pulmonary hypertension
AB  - BACKGROUND: Right ventricular (RV) dysfunction (RVD) is a poor prognostic factor in heart failure with preserved ejection fraction (HFpEF). The physiological perturbations associated with RVD or RV function indexed to load (RV-pulmonary arterial [PA] coupling) in HFpEF have not been defined. HFpEF patients with marked impairment in RV-PA coupling may be uniquely sensitive to sildenafil.
AB  - METHODS AND RESULTS: In a subset of HFpEF patients enrolled in the Phosphodiesteas-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) trial, physiological variables and therapeutic effect of sildenafil were examined relative to the severity of RVD (tricuspid annular plane systolic excursion [TAPSE]) and according to impairment in RV-PA coupling (TAPSE/pulmonary artery systolic pressure) ratio. The prevalence of atrial fibrillation and diuretic use, n-terminal probrain natriuretic peptide levels, renal dysfunction, neurohumoral activation, myocardial necrosis and fibrosis biomarkers, and the severity of diastolic dysfunction all increased with severity of RVD. Peak oxygen consumption decreased and ventilatory inefficiency (VE/VCO2 slope) increased with increasing severity of RVD. Many but not all physiological derangements were more closely associated with the TAPSE/pulmonary artery systolic pressure ratio. Compared with placebo, at 24 weeks, TAPSE decreased, and peak oxygen consumption and VE/CO2 slope were unchanged with sildenafil. There was no interaction between RV-PA coupling and treatment effect, and sildenafil did not improve TAPSE, peak oxygen consumption, or VE/VCO2 in patients with pulmonary hypertension and RVD.
AB  - CONCLUSIONS: HFpEF patients with RVD and impaired RV-PA coupling have more advanced heart failure. In RELAX patients with RVD and impaired RV-PA coupling, sildenafil did not improve RV function, exercise capacity, or ventilatory efficiency.
AB  - CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00763867.Copyright © 2016 American Heart Association, Inc.
RN  - 0 (Phosphodiesterase 5 Inhibitors)
RN  - BW9B0ZE037 (Sildenafil Citrate)
ES  - 1941-3297
IL  - 1941-3289
DI  - e002729
DO  - http://dx.doi.org/10.1161/CIRCHEARTFAILURE.115.002729
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
SI  - ClinicalTrials.gov
SA  - ClinicalTrials.gov/NCT00763867
SL  - http://clinicaltrials.gov/search/term=NCT00763867
NO  - U01 HL084861 (United States NHLBI NIH HHS)
NO  - U01 HL084889 (United States NHLBI NIH HHS)
NO  - U01 HL084890 (United States NHLBI NIH HHS)
NO  - U01 HL084891 (United States NHLBI NIH HHS)
NO  - U01 HL084907 (United States NHLBI NIH HHS)
NO  - U01 HL084931 (United States NHLBI NIH HHS)
NO  - U10 HL084904 (United States NHLBI NIH HHS)
NO  - U10 HL084904 (United States NHLBI NIH HHS)
NO  - U10 HL110262 (United States NHLBI NIH HHS)
NO  - U10 HL110262 (United States NHLBI NIH HHS)
NO  - U10 HL110297 (United States NHLBI NIH HHS)
NO  - U10 HL110302 (United States NHLBI NIH HHS)
NO  - U10 HL110309 (United States NHLBI NIH HHS)
NO  - U10 HL110312 (United States NHLBI NIH HHS)
NO  - U10 HL110336 (United States NHLBI NIH HHS)
NO  - U10 HL110338 (United States NHLBI NIH HHS)
NO  - U10 HL110342 (United States NHLBI NIH HHS)
NO  - U109 HL110337 (United States NHLBI NIH HHS)
LG  - English
DP  - 2016 Apr
DC  - 20160413
YR  - 2016
ED  - 20160801
RD  - 20160416
UP  - 20160802
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=27072860

<2. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26324007
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Jones JM
AU  - Ryan HM
AU  - Tieszen M
AU  - Leedahl DD
FA  - Jones, Justin M
FA  - Ryan, Heather M
FA  - Tieszen, Mark
FA  - Leedahl, David D
IN  - Jones,Justin M. Sanford Medical Center, Fargo, ND. Electronic address: Justin.jones@sanfordhealth.org.
IN  - Ryan,Heather M. Walgreens Pharmacy, Minneapolis, MN. Electronic address: HRyan2015@gmail.com.
IN  - Tieszen,Mark. Sanford Medical Center, Fargo, ND. Electronic address: Mark.Tieszen@sanfordhealth.org.
IN  - Leedahl,David D. Sanford Medical Center, Fargo, ND. Electronic address: David.Leedahl@sanfordhealth.org.
TI  - Successful hemostasis and reversal of highly elevated PT/INR after dabigatran etexilate use in a patient with acute kidney injury.
CM  - Comment in: Am J Emerg Med. 2015 Dec;33(12):1836-7; PMID: 26422190
SO  - American Journal of Emergency Medicine. 34(4):758.e5-6, 2016 Apr.
AS  - Am J Emerg Med. 34(4):758.e5-6, 2016 Apr.
NJ  - The American journal of emergency medicine
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - aa2, 8309942
SB  - Index Medicus
CP  - United States
MH  - *Acute Kidney Injury/co [Complications]
MH  - Aged
MH  - *Antithrombins/ae [Adverse Effects]
MH  - *Dabigatran/ae [Adverse Effects]
MH  - *Gastrointestinal Hemorrhage/ci [Chemically Induced]
MH  - *Gastrointestinal Hemorrhage/th [Therapy]
MH  - *Hemostatic Techniques
MH  - Humans
MH  - *International Normalized Ratio
MH  - Male
MH  - Shock/et [Etiology]
MH  - Shock/th [Therapy]
AB  - Dabigatran etexilate is a novel oral anticoagulant indicated for anticoagulation in the management of atrial fibrillation and venous thromboembolism. Before its approval by the US Food and Drug Administration, warfarin, a vitamin K antagonist, was one of few oral anticoagulant options. The burden of therapeutic drug monitoring, dietary restrictions, and various drug interactions associated with warfarin have countered its extensive history of efficacy. Although dabigatran etexilate may alleviate some concerns encountered with warfarin therapy, there remains a paucity of evidence surrounding emergent reversal strategies in severe hemorrhage. We report here a 71-year-old man who presented to the emergency department with gastrointestinal hemorrhage precipitated by acute kidney injury while on dabigatran etexilate, with laboratory derangements highly uncharacteristic of dabigatran therapy (international normalized ratio, > 10, and activated partial thromboplastin time, 93 seconds). After admission to the intensive care unit and 7 U of fresh frozen plasma, the patient remained hemodynamically unstable due to blood loss. Other observations were made that are poorly characterized in medical literature related to dabigatran: refractory hemorrhagic shock after 7 U of fresh frozen plasma, rapid correction of coagulation parameters (international normalized ratio, 1.7, and activated partial thromboplastin time, 44 seconds) achieved 4 hours after 26 U/kg of 4-factor prothrombin complex concentrate (Kcentra; CSL Behring, King of Prussia, PA), and with subsequent achievement of hemostasis. The patient was discharged to home 7 days later without sequelae.
RN  - 0 (Antithrombins)
RN  - I0VM4M70GC (Dabigatran)
ES  - 1532-8171
IL  - 0735-6757
DI  - S0735-6757(15)00627-0
DO  - http://dx.doi.org/10.1016/j.ajem.2015.07.071
PT  - Case Reports
PT  - Journal Article
LG  - English
EP  - 20150729
DP  - 2016 Apr
DC  - 20160321
YR  - 2016
ED  - 20160729
UP  - 20160801
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26324007

<3. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26492542
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ding Y
AU  - Xing J
AU  - Qiu Z
AU  - Wang Y
AU  - Zhang Y
AU  - Fang Y
AU  - Peng X
AU  - Long Y
AU  - Deng P
FA  - Ding, Yong
FA  - Xing, Jialiu
FA  - Qiu, Zewu
FA  - Wang, Yong
FA  - Zhang, Youren
FA  - Fang, Yi
FA  - Peng, Xiaobo
FA  - Long, Yahong
FA  - Deng, Pei
TI  - RADIOACTIVE IODINE THERAPY WITHOUT RECENT ANTITHYROID DRUG PRETREATMENT FOR HYPERTHYROIDISM COMPLICATED BY SEVERE HYPERBILIRUBINEMIA DUE TO HEPATIC DYSFUNCTION: EXPERIENCE OF A CHINESE MEDICAL CENTER.
SO  - Endocrine Practice. 22(2):173-9, 2016 Feb.
AS  - Endocr Pract. 22(2):173-9, 2016 Feb.
NJ  - Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - 9607439, dy1
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Antithyroid Agents/tu [Therapeutic Use]
MH  - China
MH  - Drug-Induced Liver Injury/co [Complications]
MH  - Drug-Induced Liver Injury/rt [Radiotherapy]
MH  - Female
MH  - Humans
MH  - Hyperbilirubinemia/et [Etiology]
MH  - *Hyperbilirubinemia/rt [Radiotherapy]
MH  - Hyperthyroidism/co [Complications]
MH  - *Hyperthyroidism/rt [Radiotherapy]
MH  - *Iodine Radioisotopes/tu [Therapeutic Use]
MH  - Jaundice/co [Complications]
MH  - Jaundice/rt [Radiotherapy]
MH  - Liver Diseases/co [Complications]
MH  - *Liver Diseases/rt [Radiotherapy]
MH  - Male
MH  - Methimazole/ae [Adverse Effects]
MH  - Middle Aged
MH  - Propylthiouracil/ae [Adverse Effects]
MH  - Retrospective Studies
MH  - Severity of Illness Index
AB  - OBJECTIVE: The objective of this work is to report our experience with (131)I therapy without recent antithyroid drug (ATD) pretreatment for refractory severe hyperthyroidism complicated by hyperbilirubinemia due to hepatic dysfunction.
AB  - METHODS: Five patients with refractory severe hyperthyroidism were treated with (131)I at 90 to 120 muCi/g-thyroid (total activity, 6.2 to 10.1 mCi). The patients previously had received ATD treatment from 2 months to 12 years and discontinued ATDs from 2 months to 4 years before (131)I treatment due to treatment failure or severe jaundice. Prior to (131)I therapy, the patients were asked to take a low-iodine diet and were treated with bisoprolol fumarate, digoxin, furosemide, S-adenosylmethionine, polyene phosphatidylcholine, and plasma exchange as supportive treatment for related clinical conditions. Four of the patients also received lithium carbonate in conjunction with their (131)I treatment. The patients were followed for 4 to 9 years after (131)I therapy.
AB  - RESULTS: After (131)I treatment, jaundice disappeared completely within 3 to 4 months in all patients, and liver function tests returned to normal. Concurrent atrial fibrillation and heart failure, leukopenia and thrombocytopenia, or thrombocytopenia and left cardiac enlargement improved remarkably in 3 patients during the follow-up period. Three to 45 months after (131)I treatment, hypothyroidism was noted in the patients and they were treated with L-thyroxine replacement therapy.
AB  - CONCLUSION: (131)I therapy without recent ATD pretreatment for refractory severe hyperthyroidism complicated by serious jaundice appears to be safe and effective, with good long-term results. It may be the preferred therapy for such patients and should be used as early as possible.
RN  - 0 (Antithyroid Agents)
RN  - 0 (Iodine Radioisotopes)
RN  - 554Z48XN5E (Methimazole)
RN  - 721M9407IY (Propylthiouracil)
IS  - 1530-891X
IL  - 1530-891X
DO  - http://dx.doi.org/10.4158/EP15736.OR
PT  - Case Reports
PT  - Journal Article
LG  - English
EP  - 20151022
DP  - 2016 Feb
DC  - 20160206
YR  - 2016
ED  - 20160729
UP  - 20160801
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26492542

<4. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26402674
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Christou GA
AU  - Christou KA
AU  - Korantzopoulos P
AU  - Rizos EC
AU  - Nikas DN
AU  - Goudevenos JA
FA  - Christou, Georgios A
FA  - Christou, Konstantinos A
FA  - Korantzopoulos, Panagiotis
FA  - Rizos, Evangelos C
FA  - Nikas, Dimitrios N
FA  - Goudevenos, John A
IN  - Christou,Georgios A. Laboratory of Physiology, Medical School, University of Ioannina, 45110 Ioannina, Greece. georgios.christou@yahoo.gr.
IN  - Christou,Konstantinos A. First Department of Internal Medicine, University Hospital of Ioannina, 45110 Ioannina, Greece. kostaschristou1@gmail.com.
IN  - Korantzopoulos,Panagiotis. First Department of Cardiology, University Hospital of Ioannina, 45110 Ioannina, Greece. p.korantzopoulos@yahoo.gr.
IN  - Rizos,Evangelos C. Second Medical Department and Outpatient Lipid Clinic, University Hospital of Ioannina, 45110 Ioannina, Greece. vagrizos@gmail.com.
IN  - Nikas,Dimitrios N. First Department of Cardiology, University Hospital of Ioannina, 45110 Ioannina, Greece. dimitrios.nikas@gmail.com.
IN  - Goudevenos,John A. First Department of Cardiology, University Hospital of Ioannina, 45110 Ioannina, Greece. igoudev@cc.uoi.gr.
TI  - The Current Role of Omega-3 Fatty Acids in the Management of Atrial Fibrillation. [Review]
SO  - International Journal of Molecular Sciences. 16(9):22870-87, 2015.
AS  - Int. j. mol. sci.. 16(9):22870-87, 2015.
NJ  - International journal of molecular sciences
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 101092791
OI  - Source: NLM. PMC4613340
SB  - Index Medicus
CP  - Switzerland
MH  - Animals
MH  - *Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - Cardiac Surgical Procedures/ae [Adverse Effects]
MH  - Dietary Supplements/an [Analysis]
MH  - *Dietary Supplements
MH  - *Fatty Acids, Omega-3/tu [Therapeutic Use]
MH  - Humans
KW  - arrhythmia;  atrial fibrillation;  cardiac surgery;  cardioversion;  docosahexaenoic acid;  eicosapentaenoic acid;  fish oil;  omega-3 fatty acids
AB  - BACKGROUND: The main dietary source of omega-3 polyunsaturated fatty acids (n-3 PUFA) is fish, which contains eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). In the present manuscript, we aimed to review the current evidence regarding the clinical role of n-3 PUFA in the prevention of atrial fibrillation (AF) and the possible underlying mechanisms.
AB  - METHODS: A literature search based on PubMed listings was performed using "Omega-3 fatty acids" and "atrial fibrilation" as key search terms.
AB  - RESULTS: n-3 PUFA have been shown to attenuate structural atrial remodeling, prolong atrial effective refractory period through the prevention of reentry and suppress ectopic firing from pulmonary veins. Dietary fish intake has been found to have no effect on the incidence of AF in the majority of studies. Circulating DHA has been consistently reported to be inversely associated with AF risk, whereas EPA has no such effect. The majority of studies investigating the impact of n-3 PUFA supplementation on the incidence of AF following cardiac surgery reported no benefit, though most of them did not use n-3 PUFA pretreatment for adequate duration. Studies using adequate four-week pretreatment with n-3 PUFA before cardioversion of AF showed a reduction of the AF incidence.
AB  - CONCLUSIONS: Although n-3 PUFA have antiarrhythmogenic properties, their clinical efficacy on the prevention of AF is not consistently supported. Further well-designed studies are needed to overcome the limitations of the existing studies and provide robust conclusions.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Fatty Acids, Omega-3)
ES  - 1422-0067
IL  - 1422-0067
DO  - http://dx.doi.org/10.3390/ijms160922870
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20150922
DP  - 2015
DC  - 20150925
YR  - 2015
ED  - 20160721
RD  - 20151027
UP  - 20160722
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26402674

<5. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26859843
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Clauss S
AU  - Wakili R
AU  - Hildebrand B
AU  - Kaab S
AU  - Hoster E
AU  - Klier I
AU  - Martens E
AU  - Hanley A
AU  - Hanssen H
AU  - Halle M
AU  - Nickel T
FA  - Clauss, Sebastian
FA  - Wakili, Reza
FA  - Hildebrand, Bianca
FA  - Kaab, Stefan
FA  - Hoster, Eva
FA  - Klier, Ina
FA  - Martens, Eimo
FA  - Hanley, Alan
FA  - Hanssen, Henner
FA  - Halle, Martin
FA  - Nickel, Thomas
IN  - Clauss,Sebastian. Medizinische Klinik und Poliklinik 1, Campus Grosshadern, Ludwig-Maximilians-Universitat Munchen (LMU), Munich, Germany.
IN  - Clauss,Sebastian. DZHK (German Centre for Cardiovascular Research), Partner site Munich, Munich Heart Alliance, Munich, Germany.
IN  - Clauss,Sebastian. Cardiovascular Research Center, Massachusetts General Hospital, Charlestown, MA, United States of America.
IN  - Wakili,Reza. Medizinische Klinik und Poliklinik 1, Campus Grosshadern, Ludwig-Maximilians-Universitat Munchen (LMU), Munich, Germany.
IN  - Wakili,Reza. DZHK (German Centre for Cardiovascular Research), Partner site Munich, Munich Heart Alliance, Munich, Germany.
IN  - Hildebrand,Bianca. Medizinische Klinik und Poliklinik 1, Campus Grosshadern, Ludwig-Maximilians-Universitat Munchen (LMU), Munich, Germany.
IN  - Kaab,Stefan. Medizinische Klinik und Poliklinik 1, Campus Grosshadern, Ludwig-Maximilians-Universitat Munchen (LMU), Munich, Germany.
IN  - Kaab,Stefan. DZHK (German Centre for Cardiovascular Research), Partner site Munich, Munich Heart Alliance, Munich, Germany.
IN  - Hoster,Eva. Institute for Medical Informatics Biometry and Epidemiology, Ludwig-Maximilians-UniversitatMunchen, Munich, Germany.
IN  - Klier,Ina. Medizinische Klinik und Poliklinik 1, Campus Grosshadern, Ludwig-Maximilians-Universitat Munchen (LMU), Munich, Germany.
IN  - Martens,Eimo. Medizinische Klinik und Poliklinik 1, Campus Grosshadern, Ludwig-Maximilians-Universitat Munchen (LMU), Munich, Germany.
IN  - Hanley,Alan. Cardiovascular Research Center, Massachusetts General Hospital, Charlestown, MA, United States of America.
IN  - Hanssen,Henner. Department of Prevention and Sports Medicine, TechnischeUniversitatMunchen, Klinikumrechts der Isar (MRI), Munich, Germany.
IN  - Hanssen,Henner. Sports Medicine, Institute of Exercise and Health Sciences, University Basel, Basel, Switzerland.
IN  - Halle,Martin. DZHK (German Centre for Cardiovascular Research), Partner site Munich, Munich Heart Alliance, Munich, Germany.
IN  - Halle,Martin. Department of Prevention and Sports Medicine, TechnischeUniversitatMunchen, Klinikumrechts der Isar (MRI), Munich, Germany.
IN  - Nickel,Thomas. Medizinische Klinik und Poliklinik 1, Campus Grosshadern, Ludwig-Maximilians-Universitat Munchen (LMU), Munich, Germany.
TI  - MicroRNAs as Biomarkers for Acute Atrial Remodeling in Marathon Runners (The miRathon Study--A Sub-Study of the Munich Marathon Study).
SO  - PLoS ONE [Electronic Resource]. 11(2):e0148599, 2016.
AS  - PLoS ONE. 11(2):e0148599, 2016.
NJ  - PloS one
PI  - Journal available in: Electronic-eCollection
PI  - Citation processed from: Internet
JC  - 101285081
OI  - Source: NLM. PMC4747606
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Atrial Fibrillation/bl [Blood]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/ge [Genetics]
MH  - *Atrial Remodeling/ge [Genetics]
MH  - *Atrial Remodeling/ph [Physiology]
MH  - Biomarkers/bl [Blood]
MH  - Creatine Kinase, MB Form/bl [Blood]
MH  - Echocardiography
MH  - Genetic Markers
MH  - Germany
MH  - Heart Ventricles/us [Ultrasonography]
MH  - Hemolysis
MH  - Humans
MH  - Male
MH  - *MicroRNAs/bl [Blood]
MH  - *MicroRNAs/ge [Genetics]
MH  - Middle Aged
MH  - Physical Endurance/ge [Genetics]
MH  - Physical Endurance/ph [Physiology]
MH  - *Running/ph [Physiology]
MH  - Time Factors
MH  - Troponin T/bl [Blood]
AB  - INTRODUCTION: Physical activity is beneficial for individual health, but endurance sport is associated with the development of arrhythmias like atrial fibrillation. The underlying mechanisms leading to this increased risk are still not fully understood. MicroRNAs are important mediators of proarrhythmogenic remodeling and have potential value as biomarkers in cardiovascular diseases. Therefore, the objective of our study was to determine the value of circulating microRNAs as potential biomarkers for atrial remodeling in marathon runners (miRathon study).
AB  - METHODS: 30 marathon runners were recruited into our study and were divided into two age-matched groups depending on the training status: elite (ER, >55 km/week, n = 15) and non-elite runners (NER, <40 km/week, n = 15). All runners participated in a 10 week training program before the marathon. MiRNA plasma levels were measured at 4 time points: at baseline (V1), after a 10 week training period (V2), immediately after the marathon (V3) and 24h later (V4). Additionally, we obtained clinical data including serum chemistry and echocardiography at each time point.
AB  - RESULTS: MiRNA plasma levels were similar in both groups over time with more pronounced changes in ER. After the marathon miR-30a plasma levels increased significantly in both groups. MiR-1 and miR-133a plasma levels also increased but showed significant changes in ER only. 24h after the marathon plasma levels returned to baseline. MiR-26a decreased significantly after the marathon in elite runners only and miR-29b showed a non-significant decrease over time in both groups. In ER miRNA plasma levels showed a significant correlation with LA diameter, in NER miRNA plasma levels did not correlate with echocardiographic parameters.
AB  - CONCLUSION: MiRNAs were differentially expressed in the plasma of marathon runners with more pronounced changes in ER. Plasma levels in ER correlate with left atrial diameter suggesting that circulating miRNAs could potentially serve as biomarkers of atrial remodeling in athletes.
RN  - 0 (Biomarkers)
RN  - 0 (Genetic Markers)
RN  - 0 (MicroRNAs)
RN  - 0 (Troponin T)
RN  - EC 2-7-3-2 (Creatine Kinase, MB Form)
ES  - 1932-6203
IL  - 1932-6203
DO  - http://dx.doi.org/10.1371/journal.pone.0148599
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20160209
DP  - 2016
DC  - 20160210
YR  - 2016
ED  - 20160719
RD  - 20160224
UP  - 20160720
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26859843

<6. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26965550
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Elliott AD
AU  - Pathak RK
AU  - Mahajan R
AU  - Lau DH
AU  - Sanders P
FA  - Elliott, Adrian D
FA  - Pathak, Rajeev K
FA  - Mahajan, Rajiv
FA  - Lau, Dennis H
FA  - Sanders, Prashanthan
TI  - Reply: Benefit of Exercise in Atrial Fibrillation: Diastolic Function Matters!.
CM  - Comment on: J Am Coll Cardiol. 2015 Sep 1;66(9):985-96; PMID: 26113406
CM  - Comment on: J Am Coll Cardiol. 2016 Mar 15;67(10):1257-8; PMID: 26965549
SO  - Journal of the American College of Cardiology. 67(10):1258-9, 2016 Mar 15.
AS  - J Am Coll Cardiol. 67(10):1258-9, 2016 Mar 15.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - h50, 8301365
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - *Exercise Test/mt [Methods]
MH  - Female
MH  - Humans
MH  - Male
MH  - *Obesity/ep [Epidemiology]
MH  - *Physical Fitness/ph [Physiology]
ES  - 1558-3597
IL  - 0735-1097
DI  - S0735-1097(16)00113-3
DO  - http://dx.doi.org/10.1016/j.jacc.2015.12.041
PT  - Comment
PT  - Letter
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2016 Mar 15
DC  - 20160311
YR  - 2016
ED  - 20160718
UP  - 20160719
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26965550

<7. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26965549
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Halle M
AU  - Adams V
AU  - Edelmann F
AU  - Pieske B
AU  - Wisloff U
FA  - Halle, Martin
FA  - Adams, Volker
FA  - Edelmann, Frank
FA  - Pieske, Burkert
FA  - Wisloff, Ulrik
TI  - Benefit of Exercise in Atrial Fibrillation: Diastolic Function Matters!.
CM  - Comment in: J Am Coll Cardiol. 2016 Mar 15;67(10):1258-9; PMID: 26965550
CM  - Comment on: J Am Coll Cardiol. 2015 Sep 1;66(9):985-96; PMID: 26113406
SO  - Journal of the American College of Cardiology. 67(10):1257-8, 2016 Mar 15.
AS  - J Am Coll Cardiol. 67(10):1257-8, 2016 Mar 15.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - h50, 8301365
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - *Exercise Test/mt [Methods]
MH  - Female
MH  - Humans
MH  - Male
MH  - *Obesity/ep [Epidemiology]
MH  - *Physical Fitness/ph [Physiology]
ES  - 1558-3597
IL  - 0735-1097
DI  - S0735-1097(16)00112-1
DO  - http://dx.doi.org/10.1016/j.jacc.2015.09.115
PT  - Comment
PT  - Letter
LG  - English
DP  - 2016 Mar 15
DC  - 20160311
YR  - 2016
ED  - 20160718
UP  - 20160719
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26965549

<8. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26974002
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Korabathina R
FA  - Korabathina, Ravi
IN  - Korabathina,Ravi. University of South Florida Bayfront Health Medical Center, 625 Sixth Avenue South Suite 430, St. Petersburg, FL 33701.
TI  - Heart Failure Update: Inpatient Management.
SO  - Fp Essentials. 442:26-30, 2016 Mar.
AS  - FP essent.. 442:26-30, 2016 Mar.
NJ  - FP essentials
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101578821
SB  - Index Medicus
CP  - United States
MH  - *Adrenergic beta-Antagonists/tu [Therapeutic Use]
MH  - Aged
MH  - Aortic Valve Stenosis/co [Complications]
MH  - Aortic Valve Stenosis/th [Therapy]
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/th [Therapy]
MH  - *Cardiotonic Agents/tu [Therapeutic Use]
MH  - Coronary Artery Disease/co [Complications]
MH  - Coronary Artery Disease/th [Therapy]
MH  - Defibrillators, Implantable
MH  - Diet, Sodium-Restricted
MH  - Disease Progression
MH  - *Diuretics/tu [Therapeutic Use]
MH  - Female
MH  - Heart Failure/co [Complications]
MH  - *Heart Failure/th [Therapy]
MH  - *Hospitalization
MH  - Humans
MH  - Oxygen Inhalation Therapy
MH  - Patient Discharge
AB  - Acute decompensated heart failure (HF) is one of most common reasons for hospitalization among individuals older than 65 years. A thorough evaluation, including history, physical examination, and laboratory assessment, is required to optimize care of these patients. In uncertain cases, serum brain-type natriuretic peptide (BNP) or N-terminal proBNP level, stress testing, and/or invasive coronary angiography may be helpful in establishing the diagnosis. The hospital setting provides an opportunity to identify etiologies and stabilize the patient. The primary goal of inpatient HF therapy is systemic and pulmonary decongestion, achieved most effectively using intravenous diuretic therapy. Rate and rhythm control may be needed for patients with concurrent atrial fibrillation and, in American College of Cardiology/American Heart Association stage D HF, intravenous inotropes may become necessary. New pharmacologic or device therapies also are considered as a means of transitioning patients, especially those with severe disease, to the outpatient setting. Patients hospitalized for acute decompensated HF have high postdischarge mortality and rehospitalization rates and, thus, should be monitored carefully. Copyright Written permission from the American Academy of Family Physicians is required for reproduction of this material in whole or in part in any form or medium.
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Diuretics)
IS  - 2159-3000
IL  - 2159-3000
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2016 Mar
DC  - 20160315
YR  - 2016
ED  - 20160715
UP  - 20160718
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26974002

<9. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26189158
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gonzalez-Perez A
AU  - Saez ME
AU  - Johansson S
AU  - Himmelmann A
AU  - Garcia Rodriguez LA
FA  - Gonzalez-Perez, Antonio
FA  - Saez, Maria Eugenia
FA  - Johansson, Saga
FA  - Himmelmann, Anders
FA  - Garcia Rodriguez, Luis A
IN  - Gonzalez-Perez,Antonio. Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain; Andalusian Bioinformatics Research Center (CAEBi), Seville, Spain.
IN  - Saez,Maria Eugenia. Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain; Andalusian Bioinformatics Research Center (CAEBi), Seville, Spain.
IN  - Johansson,Saga. Global Medicines Development, Medical Affairs, Observational Research Center, AstraZeneca R&D, Molndal, Sweden.
IN  - Himmelmann,Anders. Global Medicines Development, Medical Affairs, Observational Research Center, AstraZeneca R&D, Molndal, Sweden.
IN  - Garcia Rodriguez,Luis A. Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain. Electronic address: lagarcia@ceife.es.
TI  - Incidence and Predictors of Hemorrhagic Stroke in Users of Low-Dose Acetylsalicylic Acid.
SO  - Journal of Stroke & Cerebrovascular Diseases. 24(10):2321-8, 2015 Oct.
AS  - J STROKE CEREBROVASC DIS. 24(10):2321-8, 2015 Oct.
NJ  - Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9111633
SB  - Index Medicus
CP  - United States
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - *Aspirin/ae [Adverse Effects]
MH  - Cohort Studies
MH  - Female
MH  - *Fibrinolytic Agents/ae [Adverse Effects]
MH  - Humans
MH  - Incidence
MH  - Intracranial Hemorrhages/co [Complications]
MH  - *Intracranial Hemorrhages/ep [Epidemiology]
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Risk Factors
MH  - Stroke/di [Diagnosis]
MH  - Stroke/ep [Epidemiology]
MH  - Stroke/et [Etiology]
MH  - *Stroke
KW  - Acetylsalicylic acid;  case-control study;  hemorrhagic stroke;  transient ischemic attack
AB  - BACKGROUND: The use of antithrombotic drugs (anticoagulants and antiplatelet drugs) has been reported to increase the risk of hemorrhagic stroke (HS) relative to no treatment. This study was performed to characterize the incidence and predictors of HS in users of acetylsalicylic acid (ASA) for the secondary prevention of cardiovascular events.
AB  - METHODS: A cohort of 36,775 ASA users aged 50-84 years in 2000-2007 was identified from The Health Improvement Network database. The incidence of HS was calculated, and a nested case-control analysis, adjusted for potential confounding factors, was performed to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) for the association of potential risk factors with HS in current users of ASA.
AB  - RESULTS: The overall incidence of HS was 5.70 cases per 10,000 person-years and increased with age. In current ASA users, the incidence of HS was 4.91 cases per 10,000 person-years. Predictors of HS in patients taking ASA for secondary prevention included a history of HS (OR, 4.84; 95% CI, 1.48-15.88), a history of atrial fibrillation (OR, 4.03; 95% CI, 1.53-10.62), and hypnotic/anxiolytic drug use (OR, 2.67; 95% CI, 1.17-6.05). The small number of patients using warfarin also had an increased risk of HS (OR, 23.42; 95% CI, 4.89-112.10).
AB  - CONCLUSIONS: Physicians should consider additional risk factors for HS, such as a history of HS or atrial fibrillation, and the use of warfarin, before prescribing ASA for the secondary prevention of cardiovascular events.Copyright © 2015 National Stroke Association. Published by Elsevier Inc. All rights reserved.
RN  - 0 (Fibrinolytic Agents)
RN  - R16CO5Y76E (Aspirin)
ES  - 1532-8511
IL  - 1052-3057
DI  - S1052-3057(15)00341-9
DO  - http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2015.06.016
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20150715
DP  - 2015 Oct
DC  - 20151003
YR  - 2015
ED  - 20160712
UP  - 20160713
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26189158

<10. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26260625
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Bottger B
AU  - Thate-Waschke IM
AU  - Bauersachs R
AU  - Kohlmann T
AU  - Wilke T
FA  - Bottger, Bjorn
FA  - Thate-Waschke, Inga-Marion
FA  - Bauersachs, Rupert
FA  - Kohlmann, Thomas
FA  - Wilke, Thomas
IN  - Bottger,Bjorn. Institut fur Pharmakookonomie und Arzneimittellogistik (IPAM), Alter Holzhafen 19, 23966, Wismar, Germany.
IN  - Thate-Waschke,Inga-Marion. Bayer Vital GmbH, Kaiser-Wilhelm-Allee 70, 51373, Leverkusen, Germany.
IN  - Bauersachs,Rupert. Department of Vascular Medicine, Klinikum Darmstadt GmbH, Grafenstr. 9, 64283, Darmstadt, Germany.
IN  - Bauersachs,Rupert. Center for Thrombosis and Hemostasis, University of Mainz, Mainz, Germany.
IN  - Kohlmann,Thomas. Institut fur Community Medicine, University Hospital Greifswald, Walther-Rathenau-Strase 48, 17475, Greifswald, Germany.
IN  - Wilke,Thomas. Institut fur Pharmakookonomie und Arzneimittellogistik (IPAM), Alter Holzhafen 19, 23966, Wismar, Germany. thomas.wilke@ipam-wismar.de.
TI  - Preferences for anticoagulation therapy in atrial fibrillation: the patients' view.
SO  - Journal of Thrombosis & Thrombolysis. 40(4):406-15, 2015 Nov.
AS  - J Thromb Thrombolysis. 40(4):406-15, 2015 Nov.
NJ  - Journal of thrombosis and thrombolysis
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - ddy, 9502018
SB  - Index Medicus
CP  - Netherlands
MH  - Aged
MH  - Aged, 80 and over
MH  - *Anticoagulants/ad [Administration & Dosage]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Female
MH  - Humans
MH  - International Normalized Ratio
MH  - *Interviews as Topic
MH  - Male
MH  - *Patient Preference
KW  - Anticoagulation therapy;  Atrial fibrillation;  Discrete-choice design;  Patients' preferences
AB  - Since the introduction of new oral anticoagulants (NOACs), besides vitamin-K antagonists, an additional option for stroke prevention of patients with atrial fibrillation (AF) is available. The objective of this study was to assess AF patients' preferences with regard to the attributes of these different treatment options. We conducted a multicenter study among randomly selected physicians. Preferences were assessed by computer-assisted telephone interviews. We used a discrete-choice-experiment (DCE) with four convenience-related treatment dependent attributes (need of bridging: yes/no, interactions with food/nutrition: yes/no, need of INR controls/dose adjustment: yes/no; frequency of intake: once/twice daily) and one comparator attribute (distance to practitioner: <1 km/>15 km). Preferences measured in the interviews were analyzed descriptively and based on a conditional logit regression model. A total of 486 AF patients (age: 73.9 +/- 8.2 years; 43.2 % female; mean CHA2DS2-VASc: 3.7 +/- 1.6; current medication: 48.1 % rivaroxaban, 51.9 % VKA) could be interviewed. Regardless of type of medication, patients significantly preferred the attribute levels (in order of patients' importance) "once daily intake" (Level: once = 1 vs. twice = 0; Coefficient = 0.615; p < 0.001), "bridging necessary" (yes = 1 vs. no = 0; -0.558; p < 0.001), "distance to practitioner of <1 km (>15 km = 0 vs. <1 km = 1; 0.494; p < 0.001), "interactions with food/nutrition" (yes = 1 vs. no = 0; -0.332; p < 0.001) and "need of INR controls/dose adjustment" (yes = 1 vs. no = 0; -0.127; p < 0.001). In our analyses, "once daily frequency of intake" was the most important OAC-attribute for patients' choice followed by "no bridging necessary" and "no interactions with food/nutrition". Thus, patients with AF seem to prefer treatment options which are easier to administer.
RN  - 0 (Anticoagulants)
ES  - 1573-742X
IL  - 0929-5305
DO  - http://dx.doi.org/10.1007/s11239-015-1263-x
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2015 Nov
DC  - 20150928
YR  - 2015
ED  - 20160706
UP  - 20160707
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26260625

<11. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26866550
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Newton PJ
AU  - Davidson PM
AU  - Reid CM
AU  - Krum H
AU  - Hayward C
AU  - Sibbritt DW
AU  - Banks E
AU  - MacDonald PS
FA  - Newton, Phillip J
FA  - Davidson, Patricia M
FA  - Reid, Christopher M
FA  - Krum, Henry
FA  - Hayward, Christopher
FA  - Sibbritt, David W
FA  - Banks, Emily
FA  - MacDonald, Peter S
IN  - Newton,Phillip J. Centre for Cardiovascular and Chronic Care, University of Technology Sydney, Sydney, NSW phillip.newton@uts.edu.au.
IN  - Davidson,Patricia M. Centre for Cardiovascular and Chronic Care, University of Technology Sydney, Sydney, NSW.
IN  - Reid,Christopher M. Curtin University, Perth, WA.
IN  - Krum,Henry. Monash Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, VIC.
IN  - Hayward,Christopher. St Vincent's Hospital, Sydney, NSW.
IN  - Sibbritt,David W. Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Sydney, NSW.
IN  - Banks,Emily. National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT.
IN  - MacDonald,Peter S. St Vincent's Hospital, Sydney, NSW.
TI  - Acute heart failure admissions in New South Wales and the Australian Capital Territory: the NSW HF Snapshot Study.
SO  - Medical Journal of Australia. 204(3):113.e1-8, 2016 Feb 15.
AS  - Med J Aust. 204(3):113.e1-8, 2016 Feb 15.
NJ  - The Medical journal of Australia
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 0400714, m26
SB  - Index Medicus
CP  - Australia
MH  - Acute Disease
MH  - Administration, Intravenous
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Fibrillation
MH  - Australian Capital Territory
MH  - Comorbidity
MH  - Continuous Positive Airway Pressure/mt [Methods]
MH  - *Continuous Positive Airway Pressure
MH  - Cross-Sectional Studies
MH  - *Diuretics/ad [Administration & Dosage]
MH  - Female
MH  - Frail Elderly
MH  - Heart Failure/mo [Mortality]
MH  - *Heart Failure/th [Therapy]
MH  - Humans
MH  - Hyperbaric Oxygenation/mt [Methods]
MH  - *Hyperbaric Oxygenation
MH  - Male
MH  - Medical Audit
MH  - Medication Adherence
MH  - Middle Aged
MH  - New South Wales
MH  - Prospective Studies
MH  - Risk Factors
MH  - Treatment Outcome
AB  - OBJECTIVE: The primary aim of the NSW Heart Failure (HF) Snapshot was to obtain a representative cross-sectional view of patients with acute HF and their management in New South Wales and Australian Capital Territory hospitals.
AB  - DESIGN AND SETTING: A prospective audit of consecutive patients admitted to 24 participating hospitals in NSW and the ACT with a diagnosis of acute HF was conducted from 8 July 2013 to 8 August 2013.
AB  - RESULTS: A total of 811 participants were recruited (mean age, 77 +/- 13 years; 58% were men; 42% had a left ventricular ejection fraction > 50%). The median Charlson Comorbidity Index score was 3, with ischaemic heart disease (56%), renal disease (55%), diabetes (38%) and chronic lung disease (32%) the most frequent comorbidities; 71% of patients were assessed as frail. Intercurrent infection (22%), non-adherence to prescribed medication (5%) or to dietary or fluid restrictions (16%), and atrial fibrillation/flutter (15%) were the most commonly identified precipitants of HF. Initial treatment included intravenous diuretics (81%), oxygen therapy (87%), and bimodal positive airways pressure or continuous positive airways pressure ventilation (17%). During the index admission, 6% of patients died. The median length of stay in hospital was 6 days, but ranged between 3 and 12 days at different hospitals. Just over half the patients (59%) were referred to a multidisciplinary HF service. Discharge medications included angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (59%), beta-blockers (66%) and loop diuretics (88%).
AB  - CONCLUSIONS: Patients admitted to hospital with acute HF in NSW and the ACT were generally elderly and frail, with multiple comorbidities. Evidence-based therapies were underused, and there was substantial interhospital variation in the length of stay. We anticipate that the results of the HF Snapshot will inform the development of strategies for improving the uptake of evidence-based therapies, and hence outcomes, for HF patients.
RN  - 0 (Diuretics)
ES  - 1326-5377
IL  - 0025-729X
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2016 Feb 15
DC  - 20160212
YR  - 2016
ED  - 20160629
UP  - 20160630
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26866550

<12. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 27347226
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Patel A
AU  - Goddeau RP Jr
AU  - Henninger N
FA  - Patel, Anand
FA  - Goddeau, Richard P Jr
FA  - Henninger, Nils
IN  - Patel,Anand. Department of Neurology, University of Massachusetts Medical School, Worcester, MA, USA.
IN  - Goddeau,Richard P Jr. Department of Neurology, University of Massachusetts Medical School, Worcester, MA, USA.
IN  - Henninger,Nils. Department of Neurology, University of Massachusetts Medical School, Worcester, MA, USA; Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA, USA.
TI  - Newer Oral Anticoagulants: Stroke Prevention and Pitfalls.
SO  - The Open Cardiovascular Medicine Journal . 10:94-104, 2016.
AS  - Open Cardiovasc Med J. 10:94-104, 2016.
NJ  - The open cardiovascular medicine journal
PI  - Journal available in: Electronic-eCollection
PI  - Citation processed from: Print
JC  - 101480504
OI  - Source: NLM. PMC4897006
CP  - Netherlands
KW  - Atrial fibrillation;  hemorrhage;  ischemic stroke;  oral anticoagulation;  outcome;  review;  therapy;  thrombolysis
AB  - Warfarin is very effective in preventing stroke in patients with atrial fibrillation. However, its use is limited due to fear of hemorrhagic complications, unpredictable anticoagulant effects related to multiple drug interactions and dietary restrictions, a narrow therapeutic window, frequent difficulty maintaining the anticoagulant effect within a narrow therapeutic window, and the need for inconvenient monitoring. Several newer oral anticoagulants have been approved for primary and secondary prevention of stroke in patients with non-valvular atrial fibrillation. These agents have several advantages relative to warfarin therapy. As a group, these direct oral anticoagulants (DOAC), which include the direct thrombin inhibitor, dabigatran, and the factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), are more effective than dose adjusted warfarin for prevention of all-cause stroke (including both ischemic and hemorrhagic stroke), and have an overall more favorable safety profile. Nevertheless, an increased risk of gastrointestinal bleeding (with the exception of apixaban), increased risk for thrombotic complication with sudden discontinuation, and inability to accurately assess and reverse anticoagulant effect require consideration prior to therapy initiation, and pose a challenge for decision making in acute stroke therapy.
ES  - 1874-1924
IL  - 1874-1924
DO  - http://dx.doi.org/10.2174/1874192401610010094
PT  - Journal Article
LG  - English
EP  - 20160527
DP  - 2016
DC  - 20160627
YR  - 2016
ED  - 20160627
RD  - 20160629
UP  - 20160701
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=27347226

<13. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26733608
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Elliott AD
AU  - Mahajan R
AU  - Pathak RK
AU  - Lau DH
AU  - Sanders P
FA  - Elliott, Adrian D
FA  - Mahajan, Rajiv
FA  - Pathak, Rajeev K
FA  - Lau, Dennis H
FA  - Sanders, Prashanthan
IN  - Elliott,Adrian D. From Centre for Heart Rhythm Disorders, South Australian Health and Medical Research Institute, University of Adelaide and Royal Adelaide Hospital, Australia.
IN  - Mahajan,Rajiv. From Centre for Heart Rhythm Disorders, South Australian Health and Medical Research Institute, University of Adelaide and Royal Adelaide Hospital, Australia.
IN  - Pathak,Rajeev K. From Centre for Heart Rhythm Disorders, South Australian Health and Medical Research Institute, University of Adelaide and Royal Adelaide Hospital, Australia.
IN  - Lau,Dennis H. From Centre for Heart Rhythm Disorders, South Australian Health and Medical Research Institute, University of Adelaide and Royal Adelaide Hospital, Australia.
IN  - Sanders,Prashanthan. From Centre for Heart Rhythm Disorders, South Australian Health and Medical Research Institute, University of Adelaide and Royal Adelaide Hospital, Australia. prash.sanders@adelaide.edu.au.
TI  - Exercise Training and Atrial Fibrillation: Further Evidence for the Importance of Lifestyle Change.
CM  - Comment on: Circulation. 2016 Feb 2;133(5):466-73; PMID: 26733609
SO  - Circulation. 133(5):457-9, 2016 Feb 2.
AS  - Circulation. 133(5):457-9, 2016 Feb 2.
NJ  - Circulation
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/rh [Rehabilitation]
MH  - *Cost of Illness
MH  - *Exercise/ph [Physiology]
MH  - *Exercise Therapy/mt [Methods]
MH  - Female
MH  - Humans
MH  - Male
KW  - Editorials;  atrial fibrillation;  exercise physiology;  exercise training
ES  - 1524-4539
IL  - 0009-7322
DO  - http://dx.doi.org/10.1161/CIRCULATIONAHA.115.020800
PT  - Comment
PT  - Editorial
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20160105
DP  - 2016 Feb 2
DC  - 20160202
YR  - 2016
ED  - 20160623
UP  - 20160624
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26733608

<14. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26733609
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Malmo V
AU  - Nes BM
AU  - Amundsen BH
AU  - Tjonna AE
AU  - Stoylen A
AU  - Rossvoll O
AU  - Wisloff U
AU  - Loennechen JP
FA  - Malmo, Vegard
FA  - Nes, Bjarne M
FA  - Amundsen, Brage H
FA  - Tjonna, Arnt-Erik
FA  - Stoylen, Asbjorn
FA  - Rossvoll, Ole
FA  - Wisloff, Ulrik
FA  - Loennechen, Jan P
IN  - Malmo,Vegard. From the K.G. Jebsen Center of Exercise in Medicine (V.M., B.M.N., A.-E.T., U.W., J.P.L.), Department of Circulation and Medical Imaging (B.H.A., A.S., O.R.), Norwegian University of Science and Technology, Trondheim, Norway; and Department of Cardiology, St. Olavs Hospital, Trondheim, Norway (V.M., B.H.A., A.S., O.R., J.P.L.) vegard.malmo@ntnu.no.
IN  - Nes,Bjarne M. From the K.G. Jebsen Center of Exercise in Medicine (V.M., B.M.N., A.-E.T., U.W., J.P.L.), Department of Circulation and Medical Imaging (B.H.A., A.S., O.R.), Norwegian University of Science and Technology, Trondheim, Norway; and Department of Cardiology, St. Olavs Hospital, Trondheim, Norway (V.M., B.H.A., A.S., O.R., J.P.L.).
IN  - Amundsen,Brage H. From the K.G. Jebsen Center of Exercise in Medicine (V.M., B.M.N., A.-E.T., U.W., J.P.L.), Department of Circulation and Medical Imaging (B.H.A., A.S., O.R.), Norwegian University of Science and Technology, Trondheim, Norway; and Department of Cardiology, St. Olavs Hospital, Trondheim, Norway (V.M., B.H.A., A.S., O.R., J.P.L.).
IN  - Tjonna,Arnt-Erik. From the K.G. Jebsen Center of Exercise in Medicine (V.M., B.M.N., A.-E.T., U.W., J.P.L.), Department of Circulation and Medical Imaging (B.H.A., A.S., O.R.), Norwegian University of Science and Technology, Trondheim, Norway; and Department of Cardiology, St. Olavs Hospital, Trondheim, Norway (V.M., B.H.A., A.S., O.R., J.P.L.).
IN  - Stoylen,Asbjorn. From the K.G. Jebsen Center of Exercise in Medicine (V.M., B.M.N., A.-E.T., U.W., J.P.L.), Department of Circulation and Medical Imaging (B.H.A., A.S., O.R.), Norwegian University of Science and Technology, Trondheim, Norway; and Department of Cardiology, St. Olavs Hospital, Trondheim, Norway (V.M., B.H.A., A.S., O.R., J.P.L.).
IN  - Rossvoll,Ole. From the K.G. Jebsen Center of Exercise in Medicine (V.M., B.M.N., A.-E.T., U.W., J.P.L.), Department of Circulation and Medical Imaging (B.H.A., A.S., O.R.), Norwegian University of Science and Technology, Trondheim, Norway; and Department of Cardiology, St. Olavs Hospital, Trondheim, Norway (V.M., B.H.A., A.S., O.R., J.P.L.).
IN  - Wisloff,Ulrik. From the K.G. Jebsen Center of Exercise in Medicine (V.M., B.M.N., A.-E.T., U.W., J.P.L.), Department of Circulation and Medical Imaging (B.H.A., A.S., O.R.), Norwegian University of Science and Technology, Trondheim, Norway; and Department of Cardiology, St. Olavs Hospital, Trondheim, Norway (V.M., B.H.A., A.S., O.R., J.P.L.).
IN  - Loennechen,Jan P. From the K.G. Jebsen Center of Exercise in Medicine (V.M., B.M.N., A.-E.T., U.W., J.P.L.), Department of Circulation and Medical Imaging (B.H.A., A.S., O.R.), Norwegian University of Science and Technology, Trondheim, Norway; and Department of Cardiology, St. Olavs Hospital, Trondheim, Norway (V.M., B.H.A., A.S., O.R., J.P.L.).
TI  - Aerobic Interval Training Reduces the Burden of Atrial Fibrillation in the Short Term: A Randomized Trial.
CM  - Comment in: Circulation. 2016 Feb 2;133(5):457-9; PMID: 26733608
SO  - Circulation. 133(5):466-73, 2016 Feb 2.
AS  - Circulation. 133(5):466-73, 2016 Feb 2.
NJ  - Circulation
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/rh [Rehabilitation]
MH  - *Cost of Illness
MH  - *Exercise/ph [Physiology]
MH  - Exercise Test/mt [Methods]
MH  - *Exercise Therapy/mt [Methods]
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Single-Blind Method
MH  - Time Factors
KW  - arrhythmias, cardiac;  atrial fibrillation;  cardiac imaging;  exercise techniques;  research
AB  - BACKGROUND: Exercise training is an effective treatment for important atrial fibrillation (AF) comorbidities. However, a high level of endurance exercise is associated with an increased AF prevalence. We assessed the effects of aerobic interval training (AIT) on time in AF, AF symptoms, cardiovascular health, and quality of life in AF patients.
AB  - METHODS AND RESULTS: Fifty-one patients with nonpermanent AF were randomized to AIT (n=26) consisting of four 4-minute intervals at 85% to 95% of peak heart rate 3 times a week for 12 weeks or to a control group (n=25) continuing their regular exercise habits. An implanted loop recorder measured time in AF continuously from 4 weeks before to 4 weeks after the intervention period. Cardiac function, peak oxygen uptake (o2peak), lipid status, quality of life, and AF symptoms were evaluated before and after the 12-week intervention period. Mean time in AF increased from 10.4% to 14.6% in the control group and was reduced from 8.1% to 4.8% in the exercise group (P=0.001 between groups). AF symptom frequency (P=0.006) and AF symptom severity (P=0.009) were reduced after AIT. AIT improved o2peak, left atrial and ventricular ejection fraction, quality-of-life measures of general health and vitality, and lipid values compared with the control group. There was a trend toward fewer cardioversions and hospital admissions after AIT.
AB  - CONCLUSIONS: AIT for 12 weeks reduces the time in AF in patients with nonpermanent AF. This is followed by a significant improvement in AF symptoms, o2peak, left atrial and ventricular function, lipid levels, and QoL.
AB  - CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01325675.Copyright © 2016 American Heart Association, Inc.
ES  - 1524-4539
IL  - 0009-7322
DO  - http://dx.doi.org/10.1161/CIRCULATIONAHA.115.018220
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
SI  - ClinicalTrials.gov
SA  - ClinicalTrials.gov/NCT01325675
SL  - http://clinicaltrials.gov/search/term=NCT01325675
LG  - English
EP  - 20160105
DP  - 2016 Feb 2
DC  - 20160202
YR  - 2016
ED  - 20160622
UP  - 20160623
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26733609

<15. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25810248
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Sawires H
AU  - Makar S
AU  - Zekry H
FA  - Sawires, Happy
FA  - Makar, Samuel
FA  - Zekry, Hanan
IN  - Sawires,Happy. Department of Pediatrics, Cairo University, Cairo, Egypt.
IN  - Makar,Samuel. Department of Pediatrics, Cairo University, Cairo, Egypt.
IN  - Zekry,Hanan. Department of Pediatrics, Cairo University, Cairo, Egypt.
TI  - Effect of On-Line Hemodiafiltration on P-Wave Dispersion in Children.
SO  - Therapeutic Apheresis & Dialysis: Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 19(4):399-404, 2015 Aug.
AS  - Therap Apher Dial. 19(4):399-404, 2015 Aug.
NJ  - Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101181252
SB  - Index Medicus
CP  - Australia
MH  - Adolescent
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/pc [Prevention & Control]
MH  - *Atrial Fibrillation
MH  - Child
MH  - Cohort Studies
MH  - Egypt/ep [Epidemiology]
MH  - Electrocardiography/mt [Methods]
MH  - Female
MH  - *Hemodiafiltration/mt [Methods]
MH  - Humans
MH  - Kidney Failure, Chronic/co [Complications]
MH  - Kidney Failure, Chronic/ep [Epidemiology]
MH  - Kidney Failure, Chronic/th [Therapy]
MH  - *Kidney Failure, Chronic
MH  - Male
MH  - Monitoring, Physiologic/mt [Methods]
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Prospective Studies
MH  - Risk Assessment/mt [Methods]
KW  - Atrial fibrillation;  Diastolic dysfunction;  End-stage renal disease;  Online hemodiafiltration;  P-wave dispersion
AB  - P-wave dispersion (PWD) (difference between the maximum and minimum P-wave duration), has been proposed as a useful predictor of paroxysmal atrial fibrillation (AF). The consequences of hemodialysis (HD) on PWD and P-wave duration have not been unequivocally documented and understood, and may be complex. We aimed in this work to demonstrate the effects of online hemodiafiltration (OL-HDF) on the risk of developing AF through assessment of PWD. Thirty-three pediatric patients (14 males and 19 females with mean age of 11.66+/-2.93 years) on conventional HD for at least 6 months underwent echocardiography, 12-lead electrocardiogram and PWD calculation. Then they were switched to OL-HDF for another 6 months and same parameters were reassessed. Thirty sex- and aged-matched healthy children, served as controls. PWD significantly decreased upon switching to OL-HDF (P<0.001) and fractional shortening significantly improved (P<0.001). Mean PWD of controls (24+/-6ms) was significantly less than PWD before and after OL-HDF (P<0.001 and <0.001, respectively). Online HDF significantly decreased PWD and hence also the potential of AF development, which may invite a higher consideration of this renal replacement modality in a pediatric population. Copyright © 2015 The Authors. Therapeutic Apheresis and Dialysis © 2015 International Society for Apheresis.
ES  - 1744-9987
IL  - 1744-9979
DO  - http://dx.doi.org/10.1111/1744-9987.12285
PT  - Journal Article
LG  - English
EP  - 20150321
DP  - 2015 Aug
DC  - 20150920
YR  - 2015
ED  - 20160622
UP  - 20160623
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25810248

<16. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 27326091
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Matthias AT
AU  - Ekanayaka R
FA  - Matthias, Anne Thushara
FA  - Ekanayaka, Ruvan
IN  - Matthias,Anne Thushara. Cardiology Unit , National Hospital of Sri Lanka , Colombo , Sri Lanka.
IN  - Ekanayaka,Ruvan. Cardiology Unit , National Hospital of Sri Lanka , Colombo , Sri Lanka.
TI  - Precipitant profile of acute heart failure: experience of a tertiary level cardiac centre in Sri Lanka.
SO  - Heart Asia. 5(1):86-91, 2013.
AS  - Heart Asia. 5(1):86-91, 2013.
NJ  - Heart Asia
PI  - Journal available in: Electronic-eCollection
PI  - Citation processed from: Print
JC  - 101542742
OI  - Source: NLM. PMC4832650
CP  - England
KW  - Heart Failure
AB  - INTRODUCTION AND OBJECTIVES: Heart failure (HF) is a common cause of hospitalisation in most countries. Data on acute precipitants of HF and hospitalisation is not available in Sri Lanka.
AB  - BACKGROUND AND METHODS: A prospective study of 100 sequential admissions with HF to the cardiology unit (National Hospital of Sri Lanka) to describe the precipitants and clinical outcome of HF.
AB  - RESULTS: Fifty-eight male and 42 female admissions were studied. Mean age was 60.66 years. Mean hospital stay was 5.5(SD 4.6) days. Sixty had de novo HF and 40 had pre-existing HF. The most common identifiable precipitants were acute ischaemia 37 (37%), anaemia 41 (41%), respiratory tract infection 10 (10%), arrhythmia 11 (11%), worsening renal function 11 (11%) and alcohol 5 (5.7%). Non-adherence to medication 4 (4.6%), smoking 3 (3.9%), exposure to environmental stress 3 (3.4%) and uncontrolled hypertension 1 (1%) were also observed as precipitants. The most common arrhythmia was atrial fibrillation. Out of 34 patients in whom angiotensin-converting enzyme inhibitors or angiotensin-converting enzyme receptor blockers were indicated, 11% were not on the drug. Among 29 patients in whom spironolactone was indicated, seven patients were not on the drug.
AB  - CONCLUSIONS: Most precipitating factors of HF are preventable. Early identification and prevention of anaemia, preventing respiratory tract infection by vaccination, aggressive revascularisation for patients with ischaemia, monitoring of renal functions, and patient education regarding drug and diet compliance, would reduce the number of admissions.
ES  - 1759-1104
IL  - 1759-1104
DO  - http://dx.doi.org/10.1136/heartasia-2013-010250
PT  - Journal Article
LG  - English
EP  - 20130605
DP  - 2013
DC  - 20160621
YR  - 2013
ED  - 20160621
RD  - 20160629
UP  - 20160701
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=27326091

<17. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26769182
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Podboy A
AU  - Anderson BW
AU  - Sweetser S
FA  - Podboy, Alexander
FA  - Anderson, Bradley W
FA  - Sweetser, Seth
IN  - Podboy,Alexander. Resident in Internal Medicine, Mayo School of Graduate Medical Education, Rochester, MN.
IN  - Anderson,Bradley W. Resident in Internal Medicine, Mayo School of Graduate Medical Education, Rochester, MN.
IN  - Sweetser,Seth. Advisor to residents and Consultant in Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN. Electronic address: sweetser.seth@mayo.edu.
TI  - 61-Year-Old Man With Chronic Diarrhea.
SO  - Mayo Clinic Proceedings. 91(2):e23-8, 2016 Feb.
AS  - Mayo Clin Proc. 91(2):e23-8, 2016 Feb.
NJ  - Mayo Clinic proceedings
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 0405543, lly
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - Amyloid Neuropathies, Familial/co [Complications]
MH  - Amyloid Neuropathies, Familial/di [Diagnosis]
MH  - Amyloid Neuropathies, Familial/pp [Physiopathology]
MH  - *Amyloid Neuropathies, Familial
MH  - *Anti-Inflammatory Agents, Non-Steroidal/tu [Therapeutic Use]
MH  - *Antidiarrheals/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/et [Etiology]
MH  - Biopsy/mt [Methods]
MH  - *Carpal Tunnel Syndrome/et [Etiology]
MH  - Chromatography, Liquid/mt [Methods]
MH  - Chronic Disease
MH  - Diagnosis, Differential
MH  - Diarrhea/di [Diagnosis]
MH  - Diarrhea/et [Etiology]
MH  - Diarrhea/pp [Physiopathology]
MH  - Diarrhea/th [Therapy]
MH  - *Diarrhea
MH  - *Diet, Fat-Restricted/mt [Methods]
MH  - Endoscopy, Digestive System/mt [Methods]
MH  - Humans
MH  - Intestines/pa [Pathology]
MH  - *Liver Transplantation/mt [Methods]
MH  - Male
MH  - Mass Spectrometry/mt [Methods]
MH  - Middle Aged
MH  - Physical Examination
MH  - Steatorrhea/di [Diagnosis]
MH  - Steatorrhea/th [Therapy]
MH  - Treatment Outcome
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antidiarrheals)
RS  - Amyloidosis, Hereditary, Transthyretin-Related
ES  - 1942-5546
IL  - 0025-6196
DI  - S0025-6196(15)00854-X
DO  - http://dx.doi.org/10.1016/j.mayocp.2015.07.033
PT  - Case Reports
PT  - Journal Article
LG  - English
EP  - 20160105
DP  - 2016 Feb
DC  - 20160205
YR  - 2016
ED  - 20160616
UP  - 20160617
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26769182

<18. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 27278511
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Kurosawa K
AU  - Watanabe H
AU  - Aikawa M
AU  - Mihara H
AU  - Iguchi N
AU  - Asano R
AU  - Umemura J
AU  - Kurabayashi M
AU  - Sumiyoshi T
FA  - Kurosawa, Koji
FA  - Watanabe, Hiroyuki
FA  - Aikawa, Masaru
FA  - Mihara, Hirotsugu
FA  - Iguchi, Nobuo
FA  - Asano, Ryuta
FA  - Umemura, Jun
FA  - Kurabayashi, Masahiko
FA  - Sumiyoshi, Tetsuya
IN  - Kurosawa,Koji. Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan. k-kuro@kss.biglobe.ne.jp.
IN  - Kurosawa,Koji. Department of Medicine and Biological Science, Graduate School of Medicine, Gunma University, 3-39-15 Showamachi, Maebashi, Gunma, 371-8511, Japan. k-kuro@kss.biglobe.ne.jp.
IN  - Watanabe,Hiroyuki. Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
IN  - Aikawa,Masaru. Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
IN  - Mihara,Hirotsugu. Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
IN  - Iguchi,Nobuo. Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
IN  - Asano,Ryuta. Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
IN  - Umemura,Jun. Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
IN  - Kurabayashi,Masahiko. Department of Medicine and Biological Science, Graduate School of Medicine, Gunma University, 3-39-15 Showamachi, Maebashi, Gunma, 371-8511, Japan.
IN  - Sumiyoshi,Tetsuya. Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
TI  - Post-exercise diastolic stunning detected by velocity vector imaging is a useful marker for induced ischemia in ischemic heart disease.
SO  - Journal of Echocardiography. 11(2):50-8, 2013 Jun.
AS  - J. echocardiogr.. 11(2):50-8, 2013 Jun.
NJ  - Journal of echocardiography
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - 101263153
CP  - Japan
KW  - Echocardiography;  Exercise stress test;  Regional diastolic stunning;  Thallium-201 (Tl-201) single photon emission computed tomography (SPECT)
AB  - BACKGROUND: Recently, post-exercise diastolic stunning (PES) has been reported as a new clinical marker of induced ischemia. Velocity vector imaging (VVI) has been developed to visualize regional wall motion abnormalities based on vectors detected by the tissue tracking technique, which has the potential to visualize PES. Thus, the aim of this study was to evaluate the usefulness of PES detection by VVI as an objective marker of ischemia compared to stress thallium-201 (Tl-201) single photon emission computed tomography (SPECT).
AB  - METHODS: We studied consecutive patients who were scheduled to undergo exercise stress Tl-201 SPECT for the diagnosis of ischemic heart disease. Transthoracic echocardiography was recorded digitally before and 20 min after exercise for Tl-201 SPECT, and the data were used subsequently for VVI analysis. We defined PES regions as those with new abnormal vectors observed during isovolumic relaxation.
AB  - RESULTS: After excluding 14 patients with old myocardial infarction and/or atrial fibrillation, echocardiograms suitable for VVI analysis were obtained from 62 of 65 patients (feasibility, 95 %; 44 men; mean age, 64 +/- 11 years). SPECT revealed induced ischemia in 20 patients, whereas VVI identified PES in 18 patients. VVI detected inducible ischemia with 85 % sensitivity and 98 % specificity compared to SPECT.
AB  - CONCLUSIONS: VVI detection of PES is a new clinical tool for induced ischemia. Regional diastolic wall motion abnormalities following induced ischemia can be noninvasively detected by VVI.
IS  - 1349-0222
IL  - 1349-0222
DO  - http://dx.doi.org/10.1007/s12574-012-0163-8
PT  - Journal Article
LG  - English
EP  - 20130125
DP  - 2013 Jun
DC  - 20160609
YR  - 2013
ED  - 20160610
UP  - 20160613
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=27278511

<19. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 27278346
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Fukuda Y
AU  - Yoshimura K
AU  - Fukuda Y
AU  - Fukuda N
FA  - Fukuda, Yamato
FA  - Yoshimura, Kumiko
FA  - Fukuda, Yoshiharu
FA  - Fukuda, Nobuo
IN  - Fukuda,Yamato. Department of Cardiology and Clinical Research, National Hospital Organization Zentsuji Hospital, Senyu-cho 2-1-1, Zentsuji, Kagawa, 765-0806, Japan. svx@muse.dti.ne.jp.
IN  - Yoshimura,Kumiko. Department of Cardiology, Fukuda Cardiovascular Surgery and Digestive Internal Medicine Clinic, Higashijinzenji 67-1, Kochi, 780-0023, Japan.
IN  - Fukuda,Yoshiharu. Department of Cardiology, Fukuda Cardiovascular Surgery and Digestive Internal Medicine Clinic, Higashijinzenji 67-1, Kochi, 780-0023, Japan.
IN  - Fukuda,Nobuo. Department of Cardiology and Clinical Research, National Hospital Organization Zentsuji Hospital, Senyu-cho 2-1-1, Zentsuji, Kagawa, 765-0806, Japan.
TI  - High E/e' disrupts the rapid lowering of blood glucose in response to exercise training.
SO  - Journal of Echocardiography. 10(4):119-24, 2012 Dec.
AS  - J. echocardiogr.. 10(4):119-24, 2012 Dec.
NJ  - Journal of echocardiography
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - 101263153
CP  - Japan
KW  - Cardiac rehabilitation;  Exercise training;  Impaired glucose tolerance;  Tissue Doppler imaging
AB  - BACKGROUND: No relationship between the ratio of peak early velocity of left ventricular inflow to peak systolic longitudinal velocity of the mitral annulus velocity (E/e') and insulin resistance has yet been shown in patients with cardiac disease. We hypothesized that patients with high E/e' values would tend not to show the rapid blood glucose-lowering in response to exercise training characteristic of impaired glucose tolerance (IGT) or diabetes mellitus (DM) patients.
AB  - METHODS: The subjects were continuous IGT/DM patients (n = 27) participating in cardiac rehabilitation. All patients' E/e' values were measured by echocardiography. The patients' blood glucose levels (mg/dl) were measured just before (pre-BS) and after (post-BS) exercise training. Post-BS was subtracted from pre-BS to obtain DELTABS, and the relationship between E/e' and DELTABS was investigated.
AB  - RESULTS: E/e' correlated negatively with DELTABS. Moreover, E/e' was a significant predictor of DELTABS and as such was independent of hemoglobin A1c (HbA1c), pre-BS, and presence of atrial fibrillation on multivariate analysis.
AB  - CONCLUSIONS: Patients with high E/e', indicating high left ventricular filling pressure, were unlikely to exhibit the rapid glucose-lowering response.
IS  - 1349-0222
IL  - 1349-0222
DO  - http://dx.doi.org/10.1007/s12574-012-0134-0
PT  - Journal Article
LG  - English
EP  - 20120805
DP  - 2012 Dec
DC  - 20160609
YR  - 2012
ED  - 20160610
UP  - 20160613
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=27278346

<20. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26238468
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Pikija S
AU  - Trkulja V
AU  - Malojcic B
AU  - Mutzenbach JS
AU  - Sellner J
FA  - Pikija, Slaven
FA  - Trkulja, Vladimir
FA  - Malojcic, Branko
FA  - Mutzenbach, J Sebastian
FA  - Sellner, Johann
IN  - Pikija,Slaven. Christian Doppler Medical Centre, Paracelsus Medical University, Salzburg, Austria. s.pikija@salk.at.
TI  - A High Burden of Ischemic Stroke in Regions of Eastern/Central Europe is Largely Due to Modifiable Risk Factors.
SO  - Current Neurovascular Research. 12(4):341-52, 2015.
AS  - Curr Neurovasc Res. 12(4):341-52, 2015.
NJ  - Current neurovascular research
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101208439
SB  - Index Medicus
CP  - Netherlands
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - *Brain Ischemia/co [Complications]
MH  - Brain Ischemia/ep [Epidemiology]
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Europe/ep [Epidemiology]
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Smoking/ep [Epidemiology]
MH  - Stroke/dt [Drug Therapy]
MH  - *Stroke/ep [Epidemiology]
MH  - *Stroke/et [Etiology]
MH  - Stroke/mo [Mortality]
MH  - Young Adult
AB  - Incidence and mortality of ischemic stroke in Croatia is significantly higher than in many other developed European countries. Here, we aimed to evaluate underlying conditions of this unacceptably high disease burden. An observational prospective cohort study of first-ever ischemic stroke patients identified in a population-based incidence study (N=751) (study 1, S1) and a concurrent case-control trial (215 patients, 125 controls, S2) were conducted in the county of Varazdin from 2007-2010. Atrial fibrillation (AF) was common (36.1% in S1, 40.9% in S2) and mostly (>50%) unrecognized before the index event. In a multivariate analysis, odds of stroke increased with tobacco smoking (OR=3.95, 95%CI 1.33-10.8), unhealthy diet (OR=2.12, 1.12-4.01) and AF (OR=9.40, 4.01-22.0), and decreased with higher education (OR=0.33, 0.11-0.98), moderate alcohol consumption (OR=0.48, 0.25-0.93), higher fasting HDL (OR=0.14, 0.07-0.30) and pre-stroke use of anticoagulants (OR=0.09, 0.01-0.59), antihypertensive drugs (OR=0.52, 0.27-1.00) and statins (OR=0.29, 0.12-0.69). Fourteen-day case fatality was 10.8% (S1) and 6.1% (S2) and the risk was higher with AF, cardioembolic stroke, older age, higher fasting serum glucose, and lower with acute aspirin. Among the acute phase survivors, 30.9% died over the subsequent 1-3 years (p<0.05). We conclude that the incidence of ischemic stroke in Croatia is related to conventional risk factors and largely due to a high rate of unawareness and inadequate treatment of predisposing morbidity.
RN  - 0 (Anti-Arrhythmia Agents)
ES  - 1875-5739
IL  - 1567-2026
PT  - Journal Article
LG  - English
DP  - 2015
DC  - 20150910
YR  - 2015
ED  - 20160607
UP  - 20160608
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26238468

<21. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25288566
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Pignatelli P
AU  - Pastori D
AU  - Farcomeni A
AU  - Nocella C
AU  - Bartimoccia S
AU  - Vicario T
AU  - Bucci T
AU  - Carnevale R
AU  - Violi F
FA  - Pignatelli, Pasquale
FA  - Pastori, Daniele
FA  - Farcomeni, Alessio
FA  - Nocella, Cristina
FA  - Bartimoccia, Simona
FA  - Vicario, Tommasa
FA  - Bucci, Tommaso
FA  - Carnevale, Roberto
FA  - Violi, Francesco
IN  - Pignatelli,Pasquale. I Clinica Medica, Atherothrombosis Center, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy.
IN  - Pastori,Daniele. I Clinica Medica, Atherothrombosis Center, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy.
IN  - Farcomeni,Alessio. Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, Rome, Italy.
IN  - Nocella,Cristina. I Clinica Medica, Atherothrombosis Center, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy.
IN  - Bartimoccia,Simona. I Clinica Medica, Atherothrombosis Center, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy.
IN  - Vicario,Tommasa. I Clinica Medica, Atherothrombosis Center, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy.
IN  - Bucci,Tommaso. I Clinica Medica, Atherothrombosis Center, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy.
IN  - Carnevale,Roberto. I Clinica Medica, Atherothrombosis Center, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy.
IN  - Violi,Francesco. I Clinica Medica, Atherothrombosis Center, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy. Electronic address: francesco.violi@uniroma1.it.
TI  - Mediterranean diet reduces thromboxane A2 production in atrial fibrillation patients.
SO  - Clinical Nutrition. 34(5):899-903, 2015 Oct.
AS  - Clin Nutr. 34(5):899-903, 2015 Oct.
NJ  - Clinical nutrition (Edinburgh, Scotland)
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - c3x, 8309603
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Fibrillation/bl [Blood]
MH  - *Atrial Fibrillation/dh [Diet Therapy]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - Biomarkers/ur [Urine]
MH  - *Diet, Mediterranean
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Italy
MH  - Linear Models
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Olive Oil/ad [Administration & Dosage]
MH  - Patient Compliance
MH  - Platelet Activation
MH  - Platelet Aggregation Inhibitors/ad [Administration & Dosage]
MH  - Prospective Studies
MH  - Surveys and Questionnaires
MH  - *Thromboxane A2/bl [Blood]
MH  - Thromboxane B2/aa [Analogs & Derivatives]
MH  - Thromboxane B2/ur [Urine]
MH  - Warfarin/ad [Administration & Dosage]
MH  - Wine
KW  - Atrial fibrillation;  Mediterranean diet;  Thromboxane
AB  - BACKGROUND & AIMS: Platelet activation plays a major role in cardiovascular events (CVEs). Mediterranean diet (Med-Diet) reduces the incidence of stroke and myocardial infarction but it is still unclear if it affects platelet activation. Aim of the study was to evaluate the effect of Med-Diet on the urinary excretion of 11-dehydro-thromboxane (Tx) B2, a marker of in vivo platelet activation, in patients with atrial fibrillation (AF).
AB  - METHODS: Prospective observational cohort study including 801 non-valvular AF patients on chronic treatment with warfarin/acenocumarol referring to I Medical Clinic - Atherothrombosis Center of Sapienza University of Rome, Italy, from February 2008 to December 2013. Adherence to Med-Diet was evaluated by a short nine-items dietary questionnaire. Urinary excretion of 11-dehydro-TxB2 was measured in all patients.
AB  - RESULTS: Mean follow-up was 33.9 (+/-19.8) months, yielding 2223 patient/year of observation. Mean age of patients was 73.3 (+/-8.9) years, 43.7% were female. Median value of urinary TxB2 was 105.5 [60.0-190.0] ng/mg creatinine. We found a significant inverse correlation between total Med-Diet score and 11-dehydro-TxB2 values (Rs: -0.356, p < 0.001). In a multivariable stepwise linear regression analysis, history of stroke/TIA (beta = 0.146, p = 0.003), olive oil (beta = -0.130, p = 0.007), wine (beta = -0.102, p = 0.036) and antiplatelet drugs (beta = -0.098, p = 0.045) were independently associated to 11-dehydro-TxB2. We found no differences in the rate of ischemic or bleeding events across tertiles of Med-Diet score during follow-up.
AB  - CONCLUSIONS: Med-Diet adherence is inversely associated to urinary excretion of 11-dehydro-TxB2, suggesting that Med-Diet may favorably affect platelet function in AF patients. Clinical Trial Registration: ClinicalTrials.gov NCT01882114.Copyright © 2014 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
RN  - 0 (Biomarkers)
RN  - 0 (Olive Oil)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 54397-85-2 (Thromboxane B2)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 67910-12-7 (11-dehydro-thromboxane B2)
ES  - 1532-1983
IL  - 0261-5614
DI  - S0261-5614(14)00239-8
DO  - http://dx.doi.org/10.1016/j.clnu.2014.09.011
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
SI  - ClinicalTrials.gov
SA  - ClinicalTrials.gov/NCT01882114
SL  - http://clinicaltrials.gov/search/term=NCT01882114
LG  - English
EP  - 20140928
DP  - 2015 Oct
DC  - 20150821
YR  - 2015
ED  - 20160603
UP  - 20160606
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25288566

<22. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 27090042
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Zhou S
AU  - Chen P
AU  - Li H
AU  - Zeng C
AU  - Fang Y
AU  - Shi W
AU  - Yang C
FA  - Zhou, Suping
FA  - Chen, Peng
FA  - Li, Huijie
FA  - Zeng, Chunyu
FA  - Fang, Yuqiang
FA  - Shi, Weibin
FA  - Yang, Chengming
TI  - Noninvasive measurement of cardiac output during 6-minute walk test by inert gas rebreathing to evaluate heart failure.
SO  - Acta Cardiologica. 71(2):199-203, 2016 Apr.
AS  - Acta Cardiol. 71(2):199-203, 2016 Apr.
NJ  - Acta cardiologica
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0370570
SB  - Index Medicus
CP  - Belgium
MH  - Adult
MH  - Aged
MH  - *Breath Tests/mt [Methods]
MH  - *Cardiac Output
MH  - *Exercise Test/mt [Methods]
MH  - Female
MH  - Heart Failure/di [Diagnosis]
MH  - Heart Failure/pp [Physiopathology]
MH  - *Heart Failure
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Noble Gases/pd [Pharmacology]
MH  - Reproducibility of Results
MH  - Statistics as Topic
KW  - 6-minute walk test;  Cardiac output;  heart failure;  inert gas rebreathing
AB  - OBJECTIVE: The objective of this study was to assess the clinical value of cardiac output (CO) measurements using the inert gas rebreathing (IGR) method during the 6-minute walk test (6MWT) in evaluation of chronic heart failure (CHF).
AB  - METHODS AND RESULTS: A total of 56 CHF patients in our hospital who conformed to the Framingham CHF diagnostic criteria were recruited to this study from October 2007 to February 2009. Subjects were asked to complete a 6MWT and a bicycle exercise test. The CO was measured during both tests using IGR. B-type natriuretic peptide (BNP) levels and the left ventricular ejection fraction (LVEF) were measured at rest. The 6MWT did not correlate with BNP, LVEF, peak cardiac output (PCO), or CO during the 6MWT (CO6MWT). A negative correlation between CO6MWT and BNP as well as a strong correlation between CO6MWT and PCO was observed. When atrial fibrillation and valvular heart disease patients were excluded, CO6MWT and LVEF became significantly correlated. After grouping patients into tertiles according to their PCO values, the PCO remained correlated with CO6MWT within each group. The mean difference between CO6MWT and PCO decreased with decreases in the mean PCO in each group. No significant differences were found in the third tertile (PCO < 10.1 L/min).
AB  - CONCLUSIONS: The IGR method during 6MWT is safe and reliable to evaluate cardiac function in patients with CHF.
RN  - 0 (Noble Gases)
IS  - 0001-5385
IL  - 0001-5385
DO  - http://dx.doi.org/10.2143/AC.71.2.3141850
PT  - Journal Article
LG  - English
DP  - 2016 Apr
DC  - 20160419
YR  - 2016
ED  - 20160602
UP  - 20160603
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=27090042

<23. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26718677
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Miller JD
AU  - Aronis KN
AU  - Chrispin J
AU  - Patil KD
AU  - Marine JE
AU  - Martin SS
AU  - Blaha MJ
AU  - Blumenthal RS
AU  - Calkins H
FA  - Miller, Jared D
FA  - Aronis, Konstantinos N
FA  - Chrispin, Jonathan
FA  - Patil, Kaustubha D
FA  - Marine, Joseph E
FA  - Martin, Seth S
FA  - Blaha, Michael J
FA  - Blumenthal, Roger S
FA  - Calkins, Hugh
IN  - Miller,Jared D. Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
IN  - Aronis,Konstantinos N. Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
IN  - Chrispin,Jonathan. Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
IN  - Patil,Kaustubha D. Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
IN  - Marine,Joseph E. Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
IN  - Martin,Seth S. Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
IN  - Blaha,Michael J. Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
IN  - Blumenthal,Roger S. Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
IN  - Calkins,Hugh. Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: hcalkins@jhmi.edu.
TI  - Obesity, Exercise, Obstructive Sleep Apnea, and Modifiable Atherosclerotic Cardiovascular Disease Risk Factors in Atrial Fibrillation. [Review]
SO  - Journal of the American College of Cardiology. 66(25):2899-906, 2015 Dec 29.
AS  - J Am Coll Cardiol. 66(25):2899-906, 2015 Dec 29.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - h50, 8301365
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Atherosclerosis/co [Complications]
MH  - Atherosclerosis/pp [Physiopathology]
MH  - *Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Exercise/ph [Physiology]
MH  - Humans
MH  - *Obesity/co [Complications]
MH  - Obesity/pp [Physiopathology]
MH  - Risk Factors
MH  - *Sleep Apnea, Obstructive/co [Complications]
MH  - Sleep Apnea, Obstructive/pp [Physiopathology]
KW  - diabetes;  hyperlipidemia;  hypertension
AB  - Classically, the 3 pillars of atrial fibrillation (AF) management have included anticoagulation for prevention of thromboembolism, rhythm control, and rate control. In both prevention and management of AF, a growing body of evidence supports an increased role for comprehensive cardiac risk factor modification (RFM), herein defined as management of traditional modifiable cardiac risk factors, weight loss, and exercise. In this narrative review, we summarize the evidence demonstrating the importance of each facet of RFM in AF prevention and therapy. Additionally, we review emerging data on the importance of weight loss and cardiovascular exercise in prevention and management of AF. Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
ES  - 1558-3597
IL  - 0735-1097
DI  - S0735-1097(15)07137-5
DO  - http://dx.doi.org/10.1016/j.jacc.2015.10.047
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
LG  - English
DP  - 2015 Dec 29
DC  - 20151231
YR  - 2015
ED  - 20160524
UP  - 20160525
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26718677

<24. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26300647
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Esenwa C
AU  - Gutierrez J
FA  - Esenwa, Charles
FA  - Gutierrez, Jose
IN  - Esenwa,Charles. Department of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA.
IN  - Gutierrez,Jose. Department of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA.
TI  - Secondary stroke prevention: challenges and solutions. [Review]
SO  - Vascular Health & Risk Management. 11:437-50, 2015.
AS  - Vasc Health Risk Manag. 11:437-50, 2015.
NJ  - Vascular health and risk management
PI  - Journal available in: Electronic-eCollection
PI  - Citation processed from: Internet
JC  - 101273479
OI  - Source: NLM. PMC4536764
SB  - Index Medicus
CP  - New Zealand
MH  - Aged
MH  - Aged, 80 and over
MH  - Cerebral Angiography/mt [Methods]
MH  - Comorbidity
MH  - Female
MH  - Humans
MH  - Magnetic Resonance Angiography
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Recurrence
MH  - Risk Assessment
MH  - Risk Factors
MH  - *Risk Reduction Behavior
MH  - *Secondary Prevention/mt [Methods]
MH  - Stroke/di [Diagnosis]
MH  - Stroke/et [Etiology]
MH  - Stroke/mo [Mortality]
MH  - *Stroke/pc [Prevention & Control]
MH  - Treatment Outcome
MH  - Ultrasonography, Doppler, Transcranial
KW  - diabetes;  dyslipidemia;  hypertension;  stroke mechanisms;  stroke risk
AB  - Stroke is the leading cause of disability in the USA and a major cause of mortality worldwide. One out of four strokes is recurrent. Secondary stroke prevention starts with deciphering the most likely stroke mechanism. In general, one of the main goals in stroke reduction is to control vascular risk factors such as hypertension, diabetes, dyslipidemia, and smoking cessation. Changes in lifestyle like a healthy diet and aerobic exercise are also recommended strategies. In the case of cardioembolism due to atrial fibrillation, mechanical valves, or cardiac thrombus, anticoagulation is the mainstay of therapy. The role of anticoagulation is less evident in the case of bioprosthetic valves, patent foramen ovale, and dilated cardiomyopathy with low ejection fraction. Strokes due to larger artery atherosclerosis account for approximately a third of all strokes. In the case of symptomatic extracranial carotid stenosis, surgical intervention as close as possible in time to the index event seems highly beneficial. In the case of intracranial large artery atherosclerosis, the best medical therapy consists of antiplatelets, high-dose statins, aggressive controls of vascular risk factors, and lifestyle modifications, with no role for intracranial arterial stenting or angioplasty. For patients with small artery occlusion (ie, lacunar stroke), the therapy is similar to that used in patients with intracranial large artery atherosclerosis. Despite the constant new evidence on how to best treat patients who have suffered a stroke, the risk of stroke recurrence remains unacceptably high, thus evidencing the need for novel therapies.
ES  - 1178-2048
IL  - 1176-6344
DO  - http://dx.doi.org/10.2147/VHRM.S63791
PT  - Journal Article
PT  - Review
NO  - T32 NS007153 (United States NINDS NIH HHS)
LG  - English
EP  - 20150807
DP  - 2015
DC  - 20150824
YR  - 2015
ED  - 20160524
RD  - 20160127
UP  - 20160525
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26300647

<25. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26142970
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Sanchis-Gomar F
AU  - Santos-Lozano A
AU  - Garatachea N
AU  - Pareja-Galeano H
AU  - Fiuza-Luces C
AU  - Joyner MJ
AU  - Lucia A
FA  - Sanchis-Gomar, Fabian
FA  - Santos-Lozano, Alejandro
FA  - Garatachea, Nuria
FA  - Pareja-Galeano, Helios
FA  - Fiuza-Luces, Carmen
FA  - Joyner, Michael J
FA  - Lucia, Alejandro
IN  - Sanchis-Gomar,Fabian. Research Institute of Hospital 12 de Octubre ('i+12'), Madrid, Spain. Electronic address: fabian.sanchis@uv.es.
IN  - Santos-Lozano,Alejandro. Research Institute of Hospital 12 de Octubre ('i+12'), Madrid, Spain.
IN  - Garatachea,Nuria. Faculty of Health and Sport Science, University of Zaragoza, Huesca, Spain.
IN  - Pareja-Galeano,Helios. Research Institute of Hospital 12 de Octubre ('i+12'), Madrid, Spain; European University, Madrid, Spain.
IN  - Fiuza-Luces,Carmen. Research Institute of Hospital 12 de Octubre ('i+12'), Madrid, Spain; European University, Madrid, Spain.
IN  - Joyner,Michael J. Department of Anesthesiology, Mayo Clinic, Rochester, MN, USA.
IN  - Lucia,Alejandro. Research Institute of Hospital 12 de Octubre ('i+12'), Madrid, Spain; Department of Anesthesiology, Mayo Clinic, Rochester, MN, USA.
TI  - My patient wants to perform strenuous endurance exercise. What's the right advice?. [Review]
SO  - International Journal of Cardiology. 197:248-53, 2015 Oct 15.
AS  - Int J Cardiol. 197:248-53, 2015 Oct 15.
NJ  - International journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - gqw, 8200291
SB  - Index Medicus
CP  - Netherlands
MH  - Cardiovascular Diseases/et [Etiology]
MH  - Cardiovascular Diseases/mo [Mortality]
MH  - *Exercise/ph [Physiology]
MH  - Humans
MH  - *Physical Endurance/ph [Physiology]
MH  - *Physician's Role
MH  - Risk Factors
MH  - *Running/ph [Physiology]
MH  - *Running/td [Trends]
KW  - Arrhythmia;  Atrial fibrillation;  Health;  Pre-participation screening;  Strenuous endurance exercise;  Sudden cardiac death
AB  - Prolonged strenuous endurance exercise (SEE) such as marathon running has recently been associated with potential deleterious cardiac effects, particularly increased risk of atrial fibrillation (AF). This topic is medically important due to the increasing number of participants in SEE events lasting several hours, including older people. The aim of this narrative review is to provide a summary of the evidence available on SEE and related issues such as cardiovascular mortality, AF, potential cardiac remodeling, cardiovascular events during exertion, or the need for pre-participation screening (with a special focus on beginners). This type of information can help physicians giving advice to their patients and the general public regarding safe SEE practice. Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
ES  - 1874-1754
IL  - 0167-5273
DI  - S0167-5273(15)01315-7
DO  - http://dx.doi.org/10.1016/j.ijcard.2015.06.014
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
LG  - English
EP  - 20150615
DP  - 2015 Oct 15
DC  - 20150804
YR  - 2015
ED  - 20160513
UP  - 20160516
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26142970

<26. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25825798
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Pastori D
AU  - Carnevale R
AU  - Bartimoccia S
AU  - Nocella C
AU  - Tanzilli G
AU  - Cangemi R
AU  - Vicario T
AU  - Catena M
AU  - Violi F
AU  - Pignatelli P
FA  - Pastori, Daniele
FA  - Carnevale, Roberto
FA  - Bartimoccia, Simona
FA  - Nocella, Cristina
FA  - Tanzilli, Gaetano
FA  - Cangemi, Roberto
FA  - Vicario, Tommasa
FA  - Catena, Marco
FA  - Violi, Francesco
FA  - Pignatelli, Pasquale
IN  - Pastori,Daniele. 1 I Clinica Medica, Department of Internal Medicine and Medical Specialties, Atherothrombosis Centre, Sapienza University of Rome , Rome, Italy .
IN  - Carnevale,Roberto. 1 I Clinica Medica, Department of Internal Medicine and Medical Specialties, Atherothrombosis Centre, Sapienza University of Rome , Rome, Italy .
IN  - Carnevale,Roberto. 2 Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome , Latina, Italy .
IN  - Bartimoccia,Simona. 1 I Clinica Medica, Department of Internal Medicine and Medical Specialties, Atherothrombosis Centre, Sapienza University of Rome , Rome, Italy .
IN  - Nocella,Cristina. 1 I Clinica Medica, Department of Internal Medicine and Medical Specialties, Atherothrombosis Centre, Sapienza University of Rome , Rome, Italy .
IN  - Tanzilli,Gaetano. 3 Department of the Heart and Great Vessels Attilio Reale, Sapienza University of Rome , Rome, Italy .
IN  - Cangemi,Roberto. 1 I Clinica Medica, Department of Internal Medicine and Medical Specialties, Atherothrombosis Centre, Sapienza University of Rome , Rome, Italy .
IN  - Vicario,Tommasa. 1 I Clinica Medica, Department of Internal Medicine and Medical Specialties, Atherothrombosis Centre, Sapienza University of Rome , Rome, Italy .
IN  - Catena,Marco. 1 I Clinica Medica, Department of Internal Medicine and Medical Specialties, Atherothrombosis Centre, Sapienza University of Rome , Rome, Italy .
IN  - Violi,Francesco. 1 I Clinica Medica, Department of Internal Medicine and Medical Specialties, Atherothrombosis Centre, Sapienza University of Rome , Rome, Italy .
IN  - Pignatelli,Pasquale. 1 I Clinica Medica, Department of Internal Medicine and Medical Specialties, Atherothrombosis Centre, Sapienza University of Rome , Rome, Italy .
TI  - Does Mediterranean Diet Reduce Cardiovascular Events and Oxidative Stress in Atrial Fibrillation?.
SO  - Antioxidants & Redox Signaling. 23(8):682-7, 2015 Sep 10.
AS  - Antioxid Redox Signal. 23(8):682-7, 2015 Sep 10.
NJ  - Antioxidants & redox signaling
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - dwx, 100888899
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrial Fibrillation/me [Metabolism]
MH  - *Cardiovascular Diseases/me [Metabolism]
MH  - *Diet, Mediterranean
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Oxidative Stress
AB  - Atrial fibrillation (AF) is characterized by enhanced oxidative stress and is complicated by cardiovascular events (CVEs), which are only partially prevented by anticoagulant treatment. The Mediterranean diet (Med-Diet) has a positive effect on atherosclerotic progression. In a prospective cohort of 709 anticoagulated AF patients, adherence to Med-Diet was assessed to investigate whether Med-Diet may reduce CVEs by lowering oxidative stress. The cohort was divided into three groups according to the Med-Diet score: low (0-3 points), medium (4-6 points), and high (7-9 points) adherence. During a mean follow-up of 39.9 months (2604.8 patients/year), we registered 72 (2.8%/year) CVEs: 23.4% in the low-adherence group, 8.4% in the intermediate-adherence group, and 5.3% in the high-adherence group (p<0.001). There were no differences in time in the therapeutic range among groups. The Med-Diet score was inversely correlated with sNOX2-dp (soluble NOX2-derived peptide; Rs: -0.297, p<0.001) and F2-isoprostanes (F2-IsoP; Rs: -0.411, p<0.001). Median values of sNOX2-dp (p<0.001) and F2-IsoP progressively decreased across groups (p<0.001). A Cox regression analysis showed that the Med-Diet score (HR: 0.771, p=0.001), F2-IsoP (HR: 1.002, p=0.004), and heart failure (HR: 1.876, p=0.024) predicted CVEs. In conclusion, these findings raise the hypothesis that adherence to Med-Diet could be associated with a reduction of CVEs, through an antioxidant effect, as shown by a concomitant downregulation of Nox2 and decreased excretion of F2-IsoP.
ES  - 1557-7716
IL  - 1523-0864
DO  - http://dx.doi.org/10.1089/ars.2015.6326
PT  - Journal Article
LG  - English
EP  - 20150428
DP  - 2015 Sep 10
DC  - 20150904
YR  - 2015
ED  - 20160512
UP  - 20160513
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25825798

<27. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25995397
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Pignatelli P
AU  - Pastori D
AU  - Vicario T
AU  - Bucci T
AU  - Del Ben M
AU  - Russo R
AU  - Tanzilli A
AU  - Nardoni ML
AU  - Bartimoccia S
AU  - Nocella C
AU  - Ferro D
AU  - Saliola M
AU  - Cangemi R
AU  - Lip GY
AU  - Violi F
FA  - Pignatelli, Pasquale
FA  - Pastori, Daniele
FA  - Vicario, Tommasa
FA  - Bucci, Tommaso
FA  - Del Ben, Maria
FA  - Russo, Roberta
FA  - Tanzilli, Alessandra
FA  - Nardoni, Maria Lavinia
FA  - Bartimoccia, Simona
FA  - Nocella, Cristina
FA  - Ferro, Domenico
FA  - Saliola, Mirella
FA  - Cangemi, Roberto
FA  - Lip, Gregory Y H
FA  - Violi, Francesco
IN  - Pignatelli,Pasquale. Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica, Viale del Policlinico 155, Rome 00161, Italy.
IN  - Pastori,Daniele. Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica, Viale del Policlinico 155, Rome 00161, Italy.
IN  - Vicario,Tommasa. Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica, Viale del Policlinico 155, Rome 00161, Italy.
IN  - Bucci,Tommaso. Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica, Viale del Policlinico 155, Rome 00161, Italy.
IN  - Del Ben,Maria. Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica, Viale del Policlinico 155, Rome 00161, Italy.
IN  - Russo,Roberta. Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica, Viale del Policlinico 155, Rome 00161, Italy.
IN  - Tanzilli,Alessandra. Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica, Viale del Policlinico 155, Rome 00161, Italy.
IN  - Nardoni,Maria Lavinia. Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica, Viale del Policlinico 155, Rome 00161, Italy.
IN  - Bartimoccia,Simona. Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica, Viale del Policlinico 155, Rome 00161, Italy.
IN  - Nocella,Cristina. Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica, Viale del Policlinico 155, Rome 00161, Italy.
IN  - Ferro,Domenico. Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica, Viale del Policlinico 155, Rome 00161, Italy.
IN  - Saliola,Mirella. Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica, Viale del Policlinico 155, Rome 00161, Italy.
IN  - Cangemi,Roberto. Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica, Viale del Policlinico 155, Rome 00161, Italy.
IN  - Lip,Gregory Y H. University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK.
IN  - Violi,Francesco. Center of Atherothrombosis, I Medical Clinic, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Umberto I Policlinic of Rome, I Clinica Medica, Viale del Policlinico 155, Rome 00161, Italy francesco.violi@uniroma1.it.
TI  - Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking vitamin K antagonists.
SO  - Europace. 17(8):1223-8, 2015 Aug.
AS  - Europace. 17(8):1223-8, 2015 Aug.
NJ  - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - dxd, 100883649
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - *Anticoagulants/ad [Administration & Dosage]
MH  - *Atrial Fibrillation/mo [Mortality]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Comorbidity
MH  - *Diet, Mediterranean/sn [Statistics & Numerical Data]
MH  - Female
MH  - Humans
MH  - Italy/ep [Epidemiology]
MH  - Male
MH  - Prevalence
MH  - Risk Factors
MH  - Survival Rate
MH  - Thromboembolism/mo [Mortality]
MH  - *Thromboembolism/pc [Prevention & Control]
MH  - Treatment Outcome
MH  - *Vitamin K/ai [Antagonists & Inhibitors]
KW  - Atrial fibrillation;  Cardiovascular events;  Food-drug interaction;  Mediterranean diet;  Time in therapeutic range;  Vitamin K
AB  - AIMS: It is unclear if atrial fibrillation (AF) patients treated with oral vitamin K antagonists (VKAs) must follow a specific diet to avoid interference with anticoagulation. The aim of this study was to assess if Mediterranean diet (Med-Diet) may affect quality of anticoagulation, as expressed by the time in therapeutic range (TTR).
AB  - METHODS AND RESULTS: A prospective observational study including 553 non-valvular AF patients. Time in therapeutic range was calculated for all patients treated with VKAs, and adherence to Med-Diet was evaluated with a validated nine-item dietary questionnaire. Cardiovascular events (CVEs), such as cardiovascular death and fatal/non-fatal stroke or myocardial infarction, and bleedings were recorded. The median follow-up was 31.6 months. The median number of international normalized ratios for each patient was 63.0 (35.0-98.0) and 38 730 blood samples were analysed. In the whole cohort, the mean TTR was 65.5 +/- 17.8%. The mean Med-Diet score was 5.19 +/- 1.6, with frequent use of olive oil (90.1%), fruits (88.4%), and vegetables (69.3%) and low meat intake (71.2%). There were no differences among tertiles of Med-Diet score regarding TTR. A multivariable linear regression analysis showed that diabetes (beta: -0.105, P = 0.015) and the use of angiotensin converting enzyme inhibitor/angiotensin receptor blockers (beta: 0.153, P < 0.001) were associated with TTR. Compared with those without, AF patients with a CVE had significantly lower TTR (65.9 +/- 17.9 vs. 59.6 +/- 15.9, P = 0.029) and Med-Diet score (5.2 +/- 1.5 vs. 4.4 +/- 1.9, P = 0.004). A reduction of CVE was observed for each point of the Med-Diet score (hazard ratio 0.790, P = 0.017).
AB  - CONCLUSION: In our cohort of AF patients, Med-Diet is not associated with changes in TTR, and thus can be recommended for AF patients who are taking VKAs.Copyright Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com.
RN  - 0 (Anticoagulants)
RN  - 12001-79-5 (Vitamin K)
ES  - 1532-2092
IL  - 1099-5129
DO  - http://dx.doi.org/10.1093/europace/euv127
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20150519
DP  - 2015 Aug
DC  - 20150814
YR  - 2015
ED  - 20160510
UP  - 20160511
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25995397

<28. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26188837
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Song Y
AU  - Wang X
AU  - Perlstein I
AU  - Wang J
AU  - Badawy S
AU  - Frost C
AU  - LaCreta F
FA  - Song, Yan
FA  - Wang, Xiaoli
FA  - Perlstein, Itay
FA  - Wang, Jessie
FA  - Badawy, Sherif
FA  - Frost, Charles
FA  - LaCreta, Frank
IN  - Song,Yan. Bristol-Myers Squibb, Princeton, New Jersey. Electronic address: yan.song@bms.com.
IN  - Wang,Xiaoli. Bristol-Myers Squibb, Princeton, New Jersey.
IN  - Perlstein,Itay. Bristol-Myers Squibb, Princeton, New Jersey.
IN  - Wang,Jessie. Bristol-Myers Squibb, Princeton, New Jersey.
IN  - Badawy,Sherif. Bristol-Myers Squibb, New Brunswick, New Jersey.
IN  - Frost,Charles. Bristol-Myers Squibb, Princeton, New Jersey.
IN  - LaCreta,Frank. Bristol-Myers Squibb, Princeton, New Jersey.
TI  - Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects.
SO  - Clinical Therapeutics. 37(8):1703-12, 2015 Aug.
AS  - Clin Ther. 37(8):1703-12, 2015 Aug.
NJ  - Clinical therapeutics
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - cpe, 7706726
SB  - Index Medicus
CP  - United States
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Area Under Curve
MH  - Atrial Fibrillation/bl [Blood]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - Biological Availability
MH  - Chemistry, Pharmaceutical
MH  - Cross-Over Studies
MH  - *Factor Xa Inhibitors/ad [Administration & Dosage]
MH  - Factor Xa Inhibitors/ch [Chemistry]
MH  - Factor Xa Inhibitors/pk [Pharmacokinetics]
MH  - Factor Xa Inhibitors/pd [Pharmacology]
MH  - Female
MH  - Humans
MH  - Intubation, Gastrointestinal
MH  - Male
MH  - Middle Aged
MH  - *Pyrazoles/ad [Administration & Dosage]
MH  - Pyrazoles/ch [Chemistry]
MH  - Pyrazoles/pk [Pharmacokinetics]
MH  - Pyrazoles/pd [Pharmacology]
MH  - *Pyridones/ad [Administration & Dosage]
MH  - Pyridones/ch [Chemistry]
MH  - Pyridones/pk [Pharmacokinetics]
MH  - Pyridones/pd [Pharmacology]
MH  - Treatment Outcome
MH  - Young Adult
KW  - apixaban;  bioavailability;  crushed tablet;  nasogastric tube
AB  - PURPOSE: Crushed tablet and solution formulations of apixaban administered orally or via a nasogastric tube (NGT) may be useful in patients unable to swallow solid dose formulations. It is important to understand whether new formulations and/or methods of administration impact apixaban bioavailability and pharmacokinetic properties. These studies evaluated the relative bioavailability (Frel) of apixaban solution administered orally; oral solution administered via NGT flushed with either 5% dextrose in water (D5W) or with infant formula; oral solution via NGT with a nutritional supplement; and crushed tablet suspended in D5W and administered via NGT.
AB  - METHODS: Three open-label, randomized, crossover studies were conducted in healthy adults (study 1: apixaban 10-mg tablet [reference] versus oral solution, both administered PO; study 2: apixaban 5-mg oral solution PO [reference] versus oral solution via NGT flushed with either D5W or infant formula; study 3: apixaban 5-mg oral solution PO [reference] versus apixaban 5-mg oral solution via NGT with a nutritional supplement and versus crushed tablet suspended in D5W and administered via NGT). Point estimates and 90% CIs of the geometric mean ratios (GMRs; test/reference) were generated for Cmax and AUC. Adverse events were recorded throughout each study.
AB  - FINDINGS: Frel of the oral solution was 105% versus tablet, and Frel for oral solution via NGT with D5W flush, infant formula flush, nutritional supplement, and crushed tablet via NGT versus oral solution administration were 96.7%, 92.2%, 81.3%, and 95.1%, respectively. The 90% CIs of the GMRs of all AUCs met the bioequivalence criterion except that of the nutritional supplement (0.766-0.863). The corresponding GMRs for Cmax were 0.977, 0.953, 0.805, 0.682, and 0.884. For the solution via NGT flushed with D5W and for the crushed tablet, the 90% CIs of the Cmax GMRs met the bioequivalence criterion. Apixaban was well tolerated in all 3 studies; most adverse events were mild.
AB  - IMPLICATIONS: Comparable Frel was observed for oral apixaban solution, tablet, NGT administration of solution flushed with D5W and infant formula, and NGT administration of crushed tablet suspension. Exposure was less when oral solution was administered via NGT with nutritional supplement. These results support several alternative methods of administering apixaban that may be useful in certain clinical situations. ClinicalTrials.gov identifiers: NCT02034565, NCT02034578, and NCT02034591.Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridones)
RN  - 3Z9Y7UWC1J (apixaban)
ES  - 1879-114X
IL  - 0149-2918
DI  - S0149-2918(15)00830-9
DO  - http://dx.doi.org/10.1016/j.clinthera.2015.05.497
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
SI  - ClinicalTrials.gov
SA  - ClinicalTrials.gov/NCT02034565
SA  - ClinicalTrials.gov/NCT02034578
SA  - ClinicalTrials.gov/NCT02034591
SL  - http://clinicaltrials.gov/search/term=NCT02034565
SL  - http://clinicaltrials.gov/search/term=NCT02034578
SL  - http://clinicaltrials.gov/search/term=NCT02034591
LG  - English
EP  - 20150715
DP  - 2015 Aug
DC  - 20150906
YR  - 2015
ED  - 20160509
UP  - 20160510
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26188837

<29. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26781925
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Sehgal T
AU  - Hira JK
AU  - Ahluwalia J
AU  - Das R
AU  - Vijayvergiya R
AU  - Rana SS
AU  - Varma N
FA  - Sehgal, Tushar
FA  - Hira, Jasbir Kaur
FA  - Ahluwalia, Jasmina
FA  - Das, Reena
FA  - Vijayvergiya, Rajesh
FA  - Rana, Sandip Singh
FA  - Varma, Neelam
IN  - Sehgal,Tushar. Department of Hematology, Postgraduate Institute of Medical Education and Research.
TI  - High prevalence of VKORC1*3 (G9041A) genetic polymorphism in north Indians: A study on patients with cardiac disorders on acenocoumarol.
SO  - Drug Discoveries & Therapeutics. 9(6):404-10, 2015 Dec.
AS  - Drug discov. ther.. 9(6):404-10, 2015 Dec.
NJ  - Drug discoveries & therapeutics
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101493809
SB  - Index Medicus
CP  - Japan
MH  - *Acenocoumarol/tu [Therapeutic Use]
MH  - Adult
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Cytochrome P-450 CYP2C9/ge [Genetics]
MH  - Female
MH  - Gene Frequency
MH  - Haplotypes
MH  - *Heart Valve Prosthesis Implantation
MH  - Humans
MH  - International Normalized Ratio
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - *Polymorphism, Genetic
MH  - Prospective Studies
MH  - *Vitamin K Epoxide Reductases/ge [Genetics]
AB  - Coumarin derivatives such as warfarin and acenocoumarol are used in various disorders such as deep venous thrombosis, pulmonary embolism, atrial fibrillation and artificial heart valves. They have improved prognosis of patients with thromboembolic disease. An individual's response to coumarins depends on several factors. The non-genetic factors include age, gender, body mass index, diet and interacting drugs. Among the genetic factors, the cytochrome P450 system and vitamin K epoxide reductase complex subunit 1 play a key role in drug metabolism. This was a prospective hospital based study in which allele and genotypic frequencies of CYP2C9 gene polymorphisms; 430C>T and 1075A>C and VKORC1 gene polymorphisms; 1639G>A, 9041G>A and 6009C>T in 106 alleles of north Indian patients with valve replacement on acenocoumarol were determined and their effect on acenocoumarol dosing was studied. To the best of our knowledge, this is first report of VKORC1 9041G>A and 6009C>T gene polymorphisms and their effect on acenocoumarol dosing from north India. In 53 patients with valve replacement on acenocoumarol with stable INR, the allele frequency of CYP2C9*2 and CYP2C9*3 gene polymorphisms was 0.05 and 0.17 respectively and that of VKORC1 *2,*3 and *4 gene polymorphisms was 0.15, 0.72 and 0.11 respectively. The presence of CYP2C9*3 or VKORC1*2 gene polymorphism were associated with decrease in acenocoumarol dose requirements (p values 0.03 and 0.02 respectively).This study confirmed the association of lower mean weekly dosages of acenocoumarol in patients with CYP2C9*3 and VKORC1*2 gene polymorphisms. An unusually high frequency of 9041A polymorphism in VKORC1 was found in study population.
RN  - 0 (Anticoagulants)
RN  - EC 1-1-4-1 (Vitamin K Epoxide Reductases)
RN  - EC 1-14-13 (Cytochrome P-450 CYP2C9)
RN  - EC 1-17-4-4 (VKORC1 protein, human)
RN  - I6WP63U32H (Acenocoumarol)
IS  - 1881-7831
IL  - 1881-7831
DO  - http://dx.doi.org/10.5582/ddt.2015.01066
PT  - Journal Article
LG  - English
DP  - 2015 Dec
DC  - 20160119
YR  - 2015
ED  - 20160505
UP  - 20160506
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26781925

<30. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25479068
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Goudis CA
AU  - Ntalas IV
AU  - Ketikoglou DG
FA  - Goudis, Christos A
FA  - Ntalas, Ioannis V
FA  - Ketikoglou, Dimitrios G
IN  - Goudis,Christos A. From the *Department of Cardiology, General Hospital of Grevena, Grevena, Greece; +Department of Cardiology, University Hospital of Ioannina, Ioannina, Greece; and ++Department of Cardiology, Interbalkan Medical Center, Thessaloniki, Greece.
TI  - Atrial Fibrillation in Athletes. [Review]
SO  - Cardiology in Review. 23(5):247-51, 2015 Sep-Oct.
AS  - Cardiol Rev. 23(5):247-51, 2015 Sep-Oct.
NJ  - Cardiology in review
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - dej, 9304686
SB  - Index Medicus
CP  - United States
MH  - Angiotensin Receptor Antagonists/tu [Therapeutic Use]
MH  - Angiotensin-Converting Enzyme Inhibitors/tu [Therapeutic Use]
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - Athletes/sn [Statistics & Numerical Data]
MH  - *Athletes
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/th [Therapy]
MH  - *Atrial Premature Complexes/pp [Physiopathology]
MH  - *Atrial Remodeling/ph [Physiology]
MH  - *Autonomic Nervous System/pp [Physiopathology]
MH  - Catheter Ablation/mt [Methods]
MH  - Electric Countershock/mt [Methods]
MH  - *Exercise/ph [Physiology]
MH  - Humans
MH  - Inflammation
MH  - *Myocardial Ischemia/pp [Physiopathology]
MH  - Platelet Aggregation Inhibitors/tu [Therapeutic Use]
MH  - Prevalence
MH  - Thromboembolism/et [Etiology]
MH  - Thromboembolism/pc [Prevention & Control]
AB  - Atrial fibrillation is the most common arrhythmia in athletes and may be associated with endurance sport practice. Atrial ectopic beats, chronic systemic inflammation, autonomic system alterations, anatomic adaptation, myocardial injury and illicit drugs seem to be implicated in the increased prevalence of atrial fibrillation in athletes, but clear evidence is lacking. Treatment of the arrhythmia is a challenging issue, as atrial fibrillation may impair athletic performances and deteriorate athletes' quality of life. This review focuses on the epidemiology, possible pathophysiological mechanisms, and management of atrial fibrillation in athletes.
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
ES  - 1538-4683
IL  - 1061-5377
DO  - http://dx.doi.org/10.1097/CRD.0000000000000049
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2015 Sep-Oct
DC  - 20150806
YR  - 2015
ED  - 20160504
UP  - 20160505
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25479068

<31. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25588799
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gimelli A
AU  - Liga R
AU  - Startari U
AU  - Giorgetti A
AU  - Pieraccini L
AU  - Marzullo P
FA  - Gimelli, Alessia
FA  - Liga, Riccardo
FA  - Startari, Umberto
FA  - Giorgetti, Assuero
FA  - Pieraccini, Laura
FA  - Marzullo, Paolo
IN  - Gimelli,Alessia. Fondazione Toscana G. Monasterio, Via Moruzzi, 1, Pisa 56124, Italy gimelli@ftgm.it.
IN  - Liga,Riccardo. University Hospital of Pisa, Pisa, Italy.
IN  - Startari,Umberto. Fondazione Toscana G. Monasterio, Via Moruzzi, 1, Pisa 56124, Italy.
IN  - Giorgetti,Assuero. Fondazione Toscana G. Monasterio, Via Moruzzi, 1, Pisa 56124, Italy.
IN  - Pieraccini,Laura. Fondazione Toscana G. Monasterio, Via Moruzzi, 1, Pisa 56124, Italy.
IN  - Marzullo,Paolo. Fondazione Toscana G. Monasterio, Via Moruzzi, 1, Pisa 56124, Italy CNR, Institute of Clinical Physiology, Pisa, Italy.
TI  - Evaluation of ischaemia in patients with atrial fibrillation: impact of stress protocol on myocardial perfusion imaging accuracy.
SO  - European heart journal cardiovascular Imaging. 16(7):781-7, 2015 Jul.
AS  - Eur Heart J Cardiovasc Imaging. 16(7):781-7, 2015 Jul.
NJ  - European heart journal cardiovascular Imaging
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101573788
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - Case-Control Studies
MH  - Coronary Stenosis/pp [Physiopathology]
MH  - *Coronary Stenosis/ra [Radiography]
MH  - *Exercise Test/mt [Methods]
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Myocardial Ischemia/di [Diagnosis]
MH  - Myocardial Ischemia/ri [Radionuclide Imaging]
MH  - *Myocardial Perfusion Imaging/mt [Methods]
MH  - ROC Curve
MH  - Retrospective Studies
MH  - Sensitivity and Specificity
MH  - Severity of Illness Index
MH  - Stroke Volume
KW  - Atrial fibrillation;  Cadmium-zinc-telluride;  Coronary artery disease;  Diagnostic accuracy;  Myocardial perfusion imaging
AB  - BACKGROUND: To evaluate the accuracy of myocardial perfusion imaging (MPI) on a novel cadmium-zinc-thelluride camera in detecting significant coronary artery disease (CAD) in patients with atrial fibrillation (AF).
AB  - METHODS AND RESULTS: Seventy-four subjects with AF submitted to stress-rest MPI and coronary angiography were consecutively enrolled. One hundred and forty-eight patients in sinus rhythm, matched for age, sex, and type of stress-test protocol and with known coronary anatomy served as controls. The summed difference score, as measure of reversible myocardial ischaemia, was calculated. A coronary stenosis >70% was considered significant. The prevalence of significant CAD did not differ between AF patients and controls. At receiving operating characteristic analysis MPI showed relevant accuracy in unmasking the presence of significant CAD both in AF and in control patients (areas under the curve 0.71 vs. 0.80, P for difference: 0.212). However, after stratifying patients according to the stress protocol, a significant interaction between the presence of AF and MPI diagnostic power was evident. While in the case of a vasodilator stress-test MPI diagnostic accuracy remained high in both groups of patients (P for difference: 0.664), in those submitted to an exercise stress-test the diagnostic power of MPI was significantly lower in the presence of AF (P for difference: 0.039), because of a lower specificity. Interestingly, at multivariate analysis, a lower exercise duration (P = 0.017) was the major predictor of reduced MPI specificity.
AB  - CONCLUSION: The presence of AF impairs MPI accuracy on the detection significant CAD. This effect was only apparent in the case of an exercise stress-test, while disappeared in patients submitted to vasodilator stress.Copyright Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com.
ES  - 2047-2412
DO  - http://dx.doi.org/10.1093/ehjci/jeu322
PT  - Comparative Study
PT  - Evaluation Studies
PT  - Journal Article
LG  - English
EP  - 20150114
DP  - 2015 Jul
DC  - 20150613
YR  - 2015
ED  - 20160502
UP  - 20160503
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25588799

<32. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25588799
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gimelli A
AU  - Liga R
AU  - Startari U
AU  - Giorgetti A
AU  - Pieraccini L
AU  - Marzullo P
FA  - Gimelli, Alessia
FA  - Liga, Riccardo
FA  - Startari, Umberto
FA  - Giorgetti, Assuero
FA  - Pieraccini, Laura
FA  - Marzullo, Paolo
IN  - Gimelli,Alessia. Fondazione Toscana G. Monasterio, Via Moruzzi, 1, Pisa 56124, Italy gimelli@ftgm.it.
IN  - Liga,Riccardo. University Hospital of Pisa, Pisa, Italy.
IN  - Startari,Umberto. Fondazione Toscana G. Monasterio, Via Moruzzi, 1, Pisa 56124, Italy.
IN  - Giorgetti,Assuero. Fondazione Toscana G. Monasterio, Via Moruzzi, 1, Pisa 56124, Italy.
IN  - Pieraccini,Laura. Fondazione Toscana G. Monasterio, Via Moruzzi, 1, Pisa 56124, Italy.
IN  - Marzullo,Paolo. Fondazione Toscana G. Monasterio, Via Moruzzi, 1, Pisa 56124, Italy CNR, Institute of Clinical Physiology, Pisa, Italy.
TI  - Evaluation of ischaemia in patients with atrial fibrillation: impact of stress protocol on myocardial perfusion imaging accuracy.
SO  - European heart journal cardiovascular Imaging. 16(7):781-7, 2015 Jul.
AS  - Eur Heart J Cardiovasc Imaging. 16(7):781-7, 2015 Jul.
NJ  - European heart journal cardiovascular Imaging
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101573788
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - Case-Control Studies
MH  - Coronary Stenosis/pp [Physiopathology]
MH  - *Coronary Stenosis/ra [Radiography]
MH  - *Exercise Test/mt [Methods]
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Myocardial Ischemia/di [Diagnosis]
MH  - Myocardial Ischemia/ri [Radionuclide Imaging]
MH  - *Myocardial Perfusion Imaging/mt [Methods]
MH  - ROC Curve
MH  - Retrospective Studies
MH  - Sensitivity and Specificity
MH  - Severity of Illness Index
MH  - Stroke Volume
KW  - Atrial fibrillation;  Cadmium-zinc-telluride;  Coronary artery disease;  Diagnostic accuracy;  Myocardial perfusion imaging
AB  - BACKGROUND: To evaluate the accuracy of myocardial perfusion imaging (MPI) on a novel cadmium-zinc-thelluride camera in detecting significant coronary artery disease (CAD) in patients with atrial fibrillation (AF).
AB  - METHODS AND RESULTS: Seventy-four subjects with AF submitted to stress-rest MPI and coronary angiography were consecutively enrolled. One hundred and forty-eight patients in sinus rhythm, matched for age, sex, and type of stress-test protocol and with known coronary anatomy served as controls. The summed difference score, as measure of reversible myocardial ischaemia, was calculated. A coronary stenosis >70% was considered significant. The prevalence of significant CAD did not differ between AF patients and controls. At receiving operating characteristic analysis MPI showed relevant accuracy in unmasking the presence of significant CAD both in AF and in control patients (areas under the curve 0.71 vs. 0.80, P for difference: 0.212). However, after stratifying patients according to the stress protocol, a significant interaction between the presence of AF and MPI diagnostic power was evident. While in the case of a vasodilator stress-test MPI diagnostic accuracy remained high in both groups of patients (P for difference: 0.664), in those submitted to an exercise stress-test the diagnostic power of MPI was significantly lower in the presence of AF (P for difference: 0.039), because of a lower specificity. Interestingly, at multivariate analysis, a lower exercise duration (P = 0.017) was the major predictor of reduced MPI specificity.
AB  - CONCLUSION: The presence of AF impairs MPI accuracy on the detection significant CAD. This effect was only apparent in the case of an exercise stress-test, while disappeared in patients submitted to vasodilator stress.Copyright Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com.
ES  - 2047-2412
IL  - 2047-2404
DO  - http://dx.doi.org/10.1093/ehjci/jeu322
PT  - Comparative Study
PT  - Evaluation Studies
PT  - Journal Article
LG  - English
EP  - 20150114
DP  - 2015 Jul
DC  - 20150613
YR  - 2015
ED  - 20160502
RD  - 20160511
UP  - 20160512
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=25588799

<33. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24096163
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Soliman EZ
AU  - Cammarata M
AU  - Li Y
FA  - Soliman, Elsayed Z
FA  - Cammarata, Michael
FA  - Li, Yabing
IN  - Soliman,Elsayed Z. Epidemiological Cardiology Research Center (EPICARE), Department of Epidemiology and Prevention, Division of Public Health Sciences, Winston Salem, North Carolina; Department of Medicine, Section on Cardiology, Wake Forest School of Medicine, Winston Salem, North Carolina. Electronic address: esoliman@wakehealth.edu.
IN  - Cammarata,Michael. Department of Medicine, Section on Cardiology, Wake Forest School of Medicine, Winston Salem, North Carolina.
IN  - Li,Yabing. Epidemiological Cardiology Research Center (EPICARE), Department of Epidemiology and Prevention, Division of Public Health Sciences, Winston Salem, North Carolina.
TI  - Explaining the inconsistent associations of PR interval with mortality: the role of P-duration contribution to the length of PR interval.
CM  - Comment in: Heart Rhythm. 2014 Jan;11(1):99-100; PMID: 24513921
SO  - Heart Rhythm. 11(1):93-8, 2014 Jan.
AS  - Heart Rhythm. 11(1):93-8, 2014 Jan.
NJ  - Heart rhythm : the official journal of the Heart Rhythm Society
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101200317
SB  - Index Medicus
CP  - United States
MH  - Atrial Fibrillation/mo [Mortality]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Cause of Death/td [Trends]
MH  - *Electrocardiography
MH  - Female
MH  - Follow-Up Studies
MH  - *Forecasting
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - North Carolina/ep [Epidemiology]
MH  - Predictive Value of Tests
MH  - Retrospective Studies
MH  - Survival Rate/td [Trends]
KW  - AF;  AV;  BMI;  CI;  ECG;  HR;  P duration;  P duration/PR interval ratio;  P-wave indices;  P/PR;  PR segment;  PR-interval;  SD;  atrial fibrillation;  atrioventricular;  body mass index;  confidence interval;  electrocardiogram;  hazard ratio;  standard deviation
AB  - BACKGROUND: There is a strong interest in PR interval as a predictor for adverse outcomes. However, inconsistent reports have emerged.
AB  - OBJECTIVE: The purpose of this study was to test the hypothesis that the significance of PR interval as a predictor depends on the level of contribution of P duration to its length, a contribution that varies across populations.
AB  - METHODS: We tested our hypothesis in 7501 participants from the Third National Health and Nutrition Examination Survey (NHANES III). Participants were divided into two subgroups based on the median P-duration contribution to PR interval (P duration/PR interval * 100). The risk of mortality associated with prolonged (>200 ms) and short (<120 ms) PR interval compared with normal PR interval was examined in all participants and each subgroup.
AB  - RESULTS: P-duration contribution to the length of PR interval ranged from 30% to 90% (median 70%). During median follow-up of 13.8 years, 2541 deaths occurred. In a multivariable adjusted model, short but not prolonged PR interval was associated with mortality (hazard ratio [HR], (95% confidence interval [CI]): 1.54 (1.18, 2.00) and 1.02 (0.90, 1.16), respectively). However, in a stratified analysis by P-duration contribution to PR interval, both short and prolonged PR interval were associated with mortality in participants with high P-duration contribution (HR (95% CI):1.46 (1.10, 1.94) and 2.00 (1.34, 2.99), respectively) but not in participants with low P-duration contribution (HR (95% CI):1.53 (0.68, 3.41) and 0.99 (0.87, 1.13), respectively); interaction P = .008.
AB  - CONCLUSION: PR-interval associations with outcomes are dictated by the level of contribution of P duration to its length, a contribution that has a wide range and is expected to vary across populations. These findings could explain the inconsistent reports of PR-interval associations in different studies and call for caution when using PR interval in risk prediction models.Copyright © 2013 Heart Rhythm Society Published by Heart Rhythm Society All rights reserved.
ES  - 1556-3871
IL  - 1547-5271
DI  - S1547-5271(13)01140-5
DO  - http://dx.doi.org/10.1016/j.hrthm.2013.10.003
PT  - Journal Article
LG  - English
EP  - 20131003
DP  - 2014 Jan
DC  - 20140106
YR  - 2014
ED  - 20160425
UP  - 20160426
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24096163

<34. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24176784
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Anonymous
TI  - 2013 SYR Accepted Poster Abstracts.
SO  - International Journal of Yoga Therapy. 23 Suppl:32-53, 2013.
AS  - Int. j. yoga therap.. 23 Suppl:32-53, 2013.
NJ  - International journal of yoga therapy
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 100965420
SB  - Index Medicus
CP  - United States
MH  - Anxiety/th [Therapy]
MH  - *Anxiety
MH  - Depressive Disorder, Major
MH  - Humans
MH  - National Institute of Arthritis and Musculoskeletal and Skin Diseases (U.S.)
MH  - Pilot Projects
MH  - *Quality of Life
MH  - Yoga/px [Psychology]
AB  - SYR 2013 Accepted Poster abstracts: 1. Benefits of Yoga as a Wellness Practice in a Veterans Affairs (VA) Health Care Setting: If You Build It, Will They Come? 2. Yoga-based Psychotherapy Group With Urban Youth Exposed to Trauma. 3. Embodied Health: The Effects of a MindBody Course for Medical Students. 4. Interoceptive Awareness and Vegetable Intake After a Yoga and Stress Management Intervention. 5. Yoga Reduces Performance Anxiety in Adolescent Musicians. 6. Designing and Implementing a Therapeutic Yoga Program for Older Women With Knee Osteoarthritis. 7. Yoga and Life Skills Eating Disorder Prevention Among 5th Grade Females: A Controlled Trial. 8. A Randomized, Controlled Trial Comparing the Impact of Yoga and Physical Education on the Emotional and Behavioral Functioning of Middle School Children. 9. Feasibility of a Multisite, Community based Randomized Study of Yoga and Wellness Education for Women With Breast Cancer Undergoing Chemotherapy. 10. A Delphi Study for the Development of Protocol Guidelines for Yoga Interventions in Mental Health. 11. Impact Investigation of Breathwalk Daily Practice: CanadaIndia Collaborative Study. 12. Yoga Improves Distress, Fatigue, and Insomnia in Older Veteran Cancer Survivors: Results of a Pilot Study. 13. Assessment of Kundalini Mantra and Meditation as an Adjunctive Treatment With Mental Health Consumers. 14. Kundalini Yoga Therapy Versus Cognitive Behavior Therapy for Generalized Anxiety Disorder and Co-Occurring Mood Disorder. 15. Baseline Differences in Women Versus Men Initiating Yoga Programs to Aid Smoking Cessation: Quitting in Balance Versus QuitStrong. 16. Pranayam Practice: Impact on Focus and Everyday Life of Work and Relationships. 17. Participation in a Tailored Yoga Program is Associated With Improved Physical Health in Persons With Arthritis. 18. Effects of Yoga on Blood Pressure: Systematic Review and Meta-analysis. 19. A Quasi-experimental Trial of a Yoga based Intervention to Reduce Stress and Promote Health and Well-being Among Middle School Educators. 20. A Systematic Review of Yoga-based Interventions for Objective and Subjective Balance Measures. 21. Disparities in Yoga Use: A Multivariate Analysis of 2007 National Health Interview Survey Data. 22. Implementing Yoga Therapy Adapted for Older Veterans Who Are Cancer Survivors. 23. Randomized, Controlled Trial of Yoga for Women With Major Depressive Disorder: Decreased Ruminations as Potential Mechanism for Effects on Depression? 24. Yoga Beyond the Metropolis: A Yoga Telehealth Program for Veterans. 25. Yoga Practice Frequency, Relationship Maintenance Behaviors, and the Potential Mediating Role of Relationally Interdependent Cognition. 26. Effects of Medical Yoga in Quality of Life, Blood Pressure, and Heart Rate in Patients With Paroxysmal Atrial Fibrillation. 27. Yoga During School May Promote Emotion Regulation Capacity in Adolescents: A Group Randomized, Controlled Study. 28. Integrated Yoga Therapy in a Single Session as a Stress Management Technique in Comparison With Other Techniques. 29. Effects of a Classroom-based Yoga Intervention on Stress and Attention in Second and Third Grade Students. 30. Improving Memory, Attention, and Executive Function in Older Adults with Yoga Therapy. 31. Reasons for Starting and Continuing Yoga. 32. Yoga and Stress Management May Buffer Against Sexual Risk-Taking Behavior Increases in College Freshmen. 33. Whole-systems Ayurveda and Yoga Therapy for Obesity: Outcomes of a Pilot Study. 34. Womens Phenomenological Experiences of Exercise, Breathing, and the Body During Yoga for Smoking Cessation Treatment. 35. Mindfulness as a Tool for Trauma Recovery: Examination of a Gender-responsive Trauma-informed Integrative Mindfulness Program for Female Inmates. 36. Yoga After Stroke Leads to Multiple Physical Improvements. 37. Tele-Yoga in Patients With Chronic Obstructive Pulmonary Disease and Heart Failure: A Mixed-methods Study of Feasibility, Acceptability, and Safety. 38. Effects of an Ashtanga Yoga-based Health and Wellness Curriculum on Physical and Emotional Well-being, Engagement Toward School, and Academic Performance of K-6 Students. 39. Yoga as a Facilitator for Participation Following an 8-week Yoga for Individuals With Chronic Stroke. 40. Standardization of Design and Reporting of Yoga Interventions for Musculoskeletal Conditions: A Delphi Approach. 41. Creating S.P.A.C.E. Through Yoga: Africa Yoga Project Teachers Promote Personal Transformation, Peaceful Communities, and Purpose-filled Service.
IS  - 1531-2054
IL  - 1531-2054
PT  - Journal Article
PT  - Meta-Analysis
PT  - Randomized Controlled Trial
LG  - English
DP  - 2013
DC  - 20131101
YR  - 2013
ED  - 20160423
UP  - 20160425
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24176784

<35. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 27024228
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Zimetbaum P
FA  - Zimetbaum, Peter
TI  - Ask the doctor. I'm 64 and have had lone atrial fibrillation for about a decade. I have an echocardiogram every year to make sure the rest of my heart is okay. (It is.) My doctor hasn't prescribed and medications for me, but she wants me to take a blood thinner when I hit my 65th birthday. I'd rather not do this. Should I follow her recommendation? Also, is it possible that the endurance-type exercise regimens I have performed over many years led to my developing lone atrial fibrillation?.
SO  - Harvard Heart Letter. 22(1):8, 2011 Sep.
AS  - Harv Heart Lett. 22(1):8, 2011 Sep.
NJ  - Harvard heart letter : from Harvard Medical School
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9425723, c2z
SB  - Consumer Health Journals
CP  - United States
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - *Anticoagulants
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation
MH  - Echocardiography
MH  - Exercise
MH  - Female
MH  - Heart
MH  - Humans
MH  - Rest
RN  - 0 (Anticoagulants)
IS  - 1051-5313
IL  - 1051-5313
PT  - Journal Article
LG  - English
DP  - 2011 Sep
DC  - 20110914
YR  - 2011
ED  - 20160423
UP  - 20160425
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=27024228

<36. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24298185
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Shapiro S
AU  - Laffan M
FA  - Shapiro, Susie
FA  - Laffan, Mike
IN  - Shapiro,Susie. Imperial College Centre for Haematology, Hammersmith Hospital, London, UK.
TI  - New oral anticoagulants: their role and future.
SO  - Clinical Medicine. 13 Suppl 6:s53-7, 2013 Dec.
AS  - Clin Med. 13 Suppl 6:s53-7, 2013 Dec.
NJ  - Clinical medicine (London, England)
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - d1y, 101092853
SB  - Index Medicus
CP  - England
MH  - Administration, Oral
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - Benzimidazoles/tu [Therapeutic Use]
MH  - Dabigatran
MH  - Humans
MH  - Morpholines/tu [Therapeutic Use]
MH  - Pyrazoles/tu [Therapeutic Use]
MH  - Pyridones/tu [Therapeutic Use]
MH  - *Pyridones
MH  - Rivaroxaban
MH  - Stroke/pc [Prevention & Control]
MH  - Thiophenes/tu [Therapeutic Use]
MH  - Venous Thromboembolism/dt [Drug Therapy]
MH  - Warfarin/tu [Therapeutic Use]
MH  - beta-Alanine/tu [Therapeutic Use]
MH  - *beta-Alanine
KW  - Anticoagulation;  apixaban;  dabigatran;  rivaroxaban;  warfarin
AB  - After 60 years in which warfarin has been the only practical oral anticoagulant, a number of new oral anticoagulants are entering practice. These drugs differ in a several important respects from warfarin; most notably they have a reliable dose-response effect which means they can be given without the need for monitoring. Their simpler metabolism and mode of action also results in fewer interactions with other drugs and with diet. However, some of their other properties such as renal clearance (to varying degrees), short half-life and lack of an available antidote may slow their rate of introduction. Large trials have established their non-inferiority to warfarin in a number of indications and in some cases their superiority. To date they have been licensed for prophylaxis following high risk orthopaedic procedures, non-valvular atrial fibrillation and treatment of venous thromboembolism, but is not clear that they will supplant warfarin in all areas.
RN  - 0 (Anticoagulants)
RN  - 0 (Benzimidazoles)
RN  - 0 (Morpholines)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridones)
RN  - 0 (Thiophenes)
RN  - 11P2JDE17B (beta-Alanine)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - I0VM4M70GC (Dabigatran)
ES  - 1473-4893
IL  - 1470-2118
DO  - http://dx.doi.org/10.7861/clinmedicine.13-6-s53
PT  - Journal Article
LG  - English
DP  - 2013 Dec
DC  - 20131203
YR  - 2013
ED  - 20160422
UP  - 20160425
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24298185

<37. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23892837
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ayca B
AU  - Akin F
AU  - Sahin I
AU  - Yildiz SS
AU  - Can MM
AU  - Avci II
AU  - Celik O
AU  - Okuyan E
AU  - Dinckal MH
FA  - Ayca, Burak
FA  - Akin, Fatih
FA  - Sahin, Irfan
FA  - Yildiz, Suleyman Sezai
FA  - Can, Mehmet Mustafa
FA  - Avci, Ilker Ilhan
FA  - Celik, Omer
FA  - Okuyan, Ertugrul
FA  - Dinckal, Mustafa Hakan
IN  - Ayca,Burak. 1Cardiology Clinic, Bagcilar Education and Research Hospital, Istanbul, 2 Department of Cardiology, Mugla University, Mugla, 3Department of Cardiology, Mehmet Akif Education and Research Hospital, Istanbul; Turkey.
TI  - The effect of atorvastatin on P wave dispersion in hyperlipidemic patients.
SO  - Medicinski Glasnik Ljekarske Komore Zenickodobojskog Kantona. 10(2):234-8, 2013 Aug.
AS  - Med. glas. Ljek. komore Zenicko-doboj. kantona. 10(2):234-8, 2013 Aug.
NJ  - Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101250177
SB  - Index Medicus
CP  - Bosnia and Herzegovina
MH  - *Atorvastatin Calcium
MH  - Atrial Fibrillation/bl [Blood]
MH  - *Electrocardiography
MH  - Humans
AB  - AIM: P wave dispersion (PWD) has been shown to be a noninvasive predictor for the development of atrial fibrillation (AF). Atorvastatin is a 3 hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor that lowers blood cholesterol levels. The beneficial effect of atorvastatin on atrial arrhythmias is controversial. Aim of this study was to investigate the effect of atorvastatin treatment on PWD in hyperlipidemic patients.
AB  - METHODS: Seventy-nine newly diagnosed hyperlipidemic patients and 30 normolipidemic healthy subjects were enrolled in this study. All hyperlipidemic patients received atorvastatin 20-40 mg/ day according to their cholesterol levels and hypolipidemic diet treatment. Twelve-lead surface electrocardiogram (ECG) were recorded from hyperlipidemic patients before and after 6-months of atorvastatin therapy and from control group at their first visit. The P-wave duration measurements were calculated from these surfaces of ECG.
AB  - RESULTS: When pretreatment PWD, P maximum and P minimum values were compared with post-treatment values, a statistically significant decrease was found after 6 months (p less than 0.001, p=0.012 and p=0.007, respectively).
AB  - CONCLUSION: Atorvastatin lowered PWD significantly, so this finding may be important in the prevention of AF in hyperlipidemic patients.
RN  - 48A5M73Z4Q (Atorvastatin Calcium)
ES  - 1840-2445
IL  - 1840-0132
PT  - Journal Article
LG  - English
DP  - 2013 Aug
DC  - 20130729
YR  - 2013
ED  - 20160422
UP  - 20160425
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23892837

<38. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23536449
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Armstrong M
FA  - Armstrong, Michael
TI  - Atrial Fibrillation with Rapid Ventricular Response following use of Dietary Supplement Containing 1,3 Dimethylamylamine and Caffeine.
SO  - Journal of Special Operations Medicine. 12(4):1-4, 2012.
AS  - J Spec Oper Med. 12(4):1-4, 2012.
NJ  - Journal of special operations medicine : a peer reviewed journal for SOF medical professionals
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101158402
SB  - Index Medicus
CP  - United States
MH  - *Atrial Fibrillation
MH  - *Caffeine
MH  - Dietary Supplements
MH  - Humans
MH  - Military Personnel
AB  - Our nation?s servicemembers commonly use dietary supplements to enhance their performance. Despite this prolific use, many of these products have detrimental side-effects that compromise servicemembers? health and could, by proxy, compromise a mission. This paper presents the case of a 32-year old Navy Special Operations Forces (SOF) Sailor who, prior to physical training, used a supplement containing 1,3 Dimethylamylamine (DMAA), and then developed atrial fibrillation with rapid ventricular response. He required intravenous calcium channel blocker administration, followed by beta blockers, for rate control. As military providers, we routinely ask our patients about their use of supplements and while the regulation of these products is beyond the scope of practice for most of us, it is our duty to become better educated about the risks and benefits of these supplements. We must educate our patients and our commands on the potential harm that these supplements may pose.Copyright 2012.
RN  - 3G6A5W338E (Caffeine)
IS  - 1553-9768
IL  - 1553-9768
PT  - Journal Article
LG  - English
DP  - 2012
DC  - 20130328
YR  - 2012
ED  - 20160422
UP  - 20160425
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23536449

<39. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26703006
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Geisler BP
FA  - Geisler, Benjamin P
IN  - Geisler,Benjamin P. NYU School of Medicine, New York.
TI  - Cardiovascular Benefits of the Mediterranean Diet Are Driven by Stroke Reduction and Possibly by Decreased Atrial Fibrillation Incidence.
CM  - Comment on: Am J Med. 2015 Mar;128(3):229-38; PMID: 25447615
SO  - American Journal of Medicine. 129(1):e11, 2016 Jan.
AS  - Am J Med. 129(1):e11, 2016 Jan.
NJ  - The American journal of medicine
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 0267200, 3ju
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Cardiovascular Diseases/pc [Prevention & Control]
MH  - *Diet, Mediterranean
MH  - Humans
ES  - 1555-7162
IL  - 0002-9343
DI  - S0002-9343(15)00546-X
DO  - http://dx.doi.org/10.1016/j.amjmed.2015.04.046
PT  - Comment
PT  - Letter
LG  - English
DP  - 2016 Jan
DC  - 20151225
YR  - 2016
ED  - 20160415
UP  - 20160418
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26703006

<40. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26700015
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Qureshi WT
AU  - Alirhayim Z
AU  - Blaha MJ
AU  - Juraschek SP
AU  - Keteyian SJ
AU  - Brawner CA
AU  - Al-Mallah MH
FA  - Qureshi, Waqas T
FA  - Alirhayim, Zaid
FA  - Blaha, Michael J
FA  - Juraschek, Stephen P
FA  - Keteyian, Steven J
FA  - Brawner, Clinton A
FA  - Al-Mallah, Mouaz H
IN  - Qureshi,Waqas T. Henry Ford Hospital, Detroit, MIWake Forest University School of Medicine, Winston Salem, NC.
IN  - Alirhayim,Zaid. Henry Ford Hospital, Detroit, MIUniversity of Kansas Medical Center, Kansas City, KS.
IN  - Blaha,Michael J. Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD.
IN  - Juraschek,Stephen P. Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD.
IN  - Keteyian,Steven J. Henry Ford Hospital, Detroit, MI.
IN  - Brawner,Clinton A. Henry Ford Hospital, Detroit, MI.
IN  - Al-Mallah,Mouaz H. Henry Ford Hospital, Detroit, MIKing Abdulaziz Cardiac Center, Riyadh, Saudia ArabiaWayne State University, Detroit, MI.
TI  - Response to Letter Regarding Article, "Cardiorespiratory Fitness and Risk of Incident Atrial Fibrillation: Results From the Henry Ford Exercise Testing (FIT) Project".
CM  - Comment on: Circulation. 2015 Dec 22;132(25):e394; PMID: 26700014
CM  - Comment on: Circulation. 2015 May 26;131(21):1827-34; PMID: 25904645
SO  - Circulation. 132(25):e395, 2015 Dec 22.
AS  - Circulation. 132(25):e395, 2015 Dec 22.
NJ  - Circulation
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Female
MH  - Humans
MH  - Male
MH  - *Physical Fitness
ES  - 1524-4539
IL  - 0009-7322
DO  - http://dx.doi.org/10.1161/CIRCULATIONAHA.115.018758
PT  - Comment
PT  - Letter
LG  - English
DP  - 2015 Dec 22
DC  - 20151224
YR  - 2015
ED  - 20160415
UP  - 20160418
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26700015

<41. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26700014
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Patane S
FA  - Patane, Salvatore
IN  - Patane,Salvatore. Cardiologia Ospedale San Vincenzo-Taormina (Me) Azienda Sanitaria Provinciale di Messina, Contrada Sirina, Taormina, Messina, Italy.
TI  - Letter by Patane Regarding Article, "Cardiorespiratory Fitness and Risk of Incident Atrial Fibrillation: Results From the Henry Ford Exercise Testing (FIT) Project".
CM  - Comment in: Circulation. 2015 Dec 22;132(25):e395; PMID: 26700015
CM  - Comment on: Circulation. 2015 May 26;131(21):1827-34; PMID: 25904645
SO  - Circulation. 132(25):e394, 2015 Dec 22.
AS  - Circulation. 132(25):e394, 2015 Dec 22.
NJ  - Circulation
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Female
MH  - Humans
MH  - Male
MH  - *Physical Fitness
ES  - 1524-4539
IL  - 0009-7322
DO  - http://dx.doi.org/10.1161/CIRCULATIONAHA.115.017549
PT  - Comment
PT  - Letter
LG  - English
DP  - 2015 Dec 22
DC  - 20151224
YR  - 2015
ED  - 20160415
UP  - 20160418
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26700014

<42. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 27073731
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Zhang F
AU  - Hartnett S
AU  - Sample A
AU  - Schnack S
AU  - Li Y
FA  - Zhang, Fan
FA  - Hartnett, Sigurd
FA  - Sample, Alex
FA  - Schnack, Sabrina
FA  - Li, Yifan
IN  - Zhang,Fan. Division of Basic Biomedical Sciences, Sanford School of Medicine, University of South Dakota Vermillion, SD 57069, USA.
IN  - Hartnett,Sigurd. Division of Basic Biomedical Sciences, Sanford School of Medicine, University of South Dakota Vermillion, SD 57069, USA.
IN  - Sample,Alex. Division of Basic Biomedical Sciences, Sanford School of Medicine, University of South Dakota Vermillion, SD 57069, USA.
IN  - Schnack,Sabrina. Division of Basic Biomedical Sciences, Sanford School of Medicine, University of South Dakota Vermillion, SD 57069, USA.
IN  - Li,Yifan. Division of Basic Biomedical Sciences, Sanford School of Medicine, University of South Dakota Vermillion, SD 57069, USA.
TI  - High fat diet induced alterations of atrial electrical activities in mice.
SO  - American Journal of Cardiovascular Disease. 6(1):1-9, 2016.
AS  - Am J Cardiovasc Dis. 6(1):1-9, 2016.
NJ  - American journal of cardiovascular disease
PI  - Journal available in: Electronic-eCollection
PI  - Citation processed from: Print
JC  - 101569582
OI  - Source: NLM. PMC4788723
CP  - United States
KW  - High fat diet;  atrial arrhythmia;  mice;  obesity;  potassium channels
AB  - Obesity is a well-known risk factor for various cardiovascular diseases. Recent clinical data showed that overweight and obese patients have higher incidence of atrial fibrillation (AF) compared with individuals with normal body weights, but the underlying mechanisms remain to be elucidated. In this study, we investigated the effects of a high fat diet on atrial activities in mice. ICR male mice were fed a regular diet (RD) or a high fat diet (HFD) for 8 weeks. Mice fed HFD showed significantly greater body weight gains and visceral fat accumulation compared with RD mice. Under anesthetic condition, baseline arterial blood pressure and heart rate were not significantly different between RD and HFD groups. Although no spontaneous or atrial stimulation-induced atrial fibrillation was observed, this study revealed several alterations in the activities and protein levels in the atria in HFD mice. Surface electrocardiogram (ECG) revealed significantly shortened PR interval in HFD mice. In the atrial stimulation experiments, the sinoatrial (SA) node recovery time was significantly prolonged whereas the atrial effective refractory period was significantly reduced in HFD mice as compared with RD mice. Western blot showed protein levels of two major potassium channels, Kv1.5 and Kv4.2/3, were significantly increased in atria of HFD mice. These data indicate that HFD induces atrial electrophysiological remodeling in mice, which may be a potential mechanism underlying the increased risk for atrial arrhythmias in obesity and metabolic disorders.
ES  - 2160-200X
IL  - 2160-200X
PT  - Journal Article
LG  - English
EP  - 20160301
DP  - 2016
DC  - 20160413
YR  - 2016
ED  - 20160413
RD  - 20160415
UP  - 20160418
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=27073731

<43. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25261267
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Magri D
AU  - Agostoni P
AU  - Corra U
AU  - Passino C
AU  - Scrutinio D
AU  - Perrone-Filardi P
AU  - Correale M
AU  - Cattadori G
AU  - Metra M
AU  - Girola D
AU  - Piepoli MF
AU  - Iorio A
AU  - Emdin M
AU  - Raimondo R
AU  - Re F
AU  - Cicoira M
AU  - Belardinelli R
AU  - Guazzi M
AU  - Limongelli G
AU  - Clemenza F
AU  - Parati G
AU  - Frigerio M
AU  - Casenghi M
AU  - Scardovi AB
AU  - Ferraironi A
AU  - Di Lenarda A
AU  - Bussotti M
AU  - Apostolo A
AU  - Paolillo S
AU  - La Gioia R
AU  - Gargiulo P
AU  - Palermo P
AU  - Mina C
AU  - Farina S
AU  - Battaia E
AU  - Maruotti A
AU  - Pacileo G
AU  - Contini M
AU  - Oliva F
AU  - Ricci R
AU  - Sinagra G
AU  - Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) Score Research Group
FA  - Magri, Damiano
FA  - Agostoni, Piergiuseppe
FA  - Corra, Ugo
FA  - Passino, Claudio
FA  - Scrutinio, Domenico
FA  - Perrone-Filardi, Pasquale
FA  - Correale, Michele
FA  - Cattadori, Gaia
FA  - Metra, Marco
FA  - Girola, Davide
FA  - Piepoli, Massimo F
FA  - Iorio, AnnaMaria
FA  - Emdin, Michele
FA  - Raimondo, Rosa
FA  - Re, Federica
FA  - Cicoira, Mariantonietta
FA  - Belardinelli, Romualdo
FA  - Guazzi, Marco
FA  - Limongelli, Giuseppe
FA  - Clemenza, Francesco
FA  - Parati, Gianfranco
FA  - Frigerio, Maria
FA  - Casenghi, Matteo
FA  - Scardovi, Angela B
FA  - Ferraironi, Alessandro
FA  - Di Lenarda, Andrea
FA  - Bussotti, Maurizio
FA  - Apostolo, Anna
FA  - Paolillo, Stefania
FA  - La Gioia, Rocco
FA  - Gargiulo, Paola
FA  - Palermo, Pietro
FA  - Mina, Chiara
FA  - Farina, Stefania
FA  - Battaia, Elisa
FA  - Maruotti, Antonello
FA  - Pacileo, Giuseppe
FA  - Contini, Mauro
FA  - Oliva, Fabrizio
FA  - Ricci, Roberto
FA  - Sinagra, Gianfranco
FA  - Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) Score Research Group
IN  - Magri,Damiano. Department of Clinical and Molecular Medicine, "La Sapienza" University of Rome, Italy Centro Cardiologico Monzino, IRCCS, Italy.
IN  - Agostoni,Piergiuseppe. Centro Cardiologico Monzino, IRCCS, Italy Department of Clinical Sciences and Community Health, University of Milano, Italy piergiuseppe.agostoni@unimi.it.
IN  - Corra,Ugo. Divisione di Cardiologia Riabilitativa, Fondazione Salvatore Maugeri, IRCCS, Istituto Scientifico di Veruno, Italy.
IN  - Passino,Claudio. Fondazione Gabriele Monasterio, CNR-Regione Toscana, Italy Scuola Superiore S. Anna, Italy.
IN  - Scrutinio,Domenico. Division of Cardiology, "S. Maugeri" Foundation, IRCCS, Institute of Cassano Murge, Italy.
IN  - Perrone-Filardi,Pasquale. Department of Advanced Biomedical Sciences, "Federico II" University, Italy.
IN  - Correale,Michele. Department of Cardiology, University of Foggia, Italy.
IN  - Cattadori,Gaia. Centro Cardiologico Monzino, IRCCS, Italy.
IN  - Metra,Marco. Cardiology, Department of Medical and Surgical Specialities, Radiological Sciences, and Public Health, University of Brescia, Italy.
IN  - Girola,Davide. Dipartimento Cardiologico "A. De Gasperis", Ospedale Ca Granda- A.O. Niguarda, Italy.
IN  - Piepoli,Massimo F. UOC Cardiologia, G da Saliceto Hospital, Italy.
IN  - Iorio,AnnaMaria. Cardiovascular Department, Ospedali Riuniti and University of Trieste, Italy.
IN  - Emdin,Michele. Fondazione Gabriele Monasterio, CNR-Regione Toscana, Italy.
IN  - Raimondo,Rosa. Fondazione Salvatore Maugeri, IRCCS, Istituto Scientifico di Tradate, Italy.
IN  - Re,Federica. Cardiology Division, Cardiac Arrhythmia Center and Cardiomyopathies Unit, San Camillo-Forlanini Hospital, Italy.
IN  - Cicoira,Mariantonietta. Section of Cardiology, Department of Medicine, University of Verona, Italy.
IN  - Belardinelli,Romualdo. Cardiologia Riabilitativa, Azienda Ospedali Riuniti di Ancona, Italy.
IN  - Guazzi,Marco. Heart Failure Unit, IRCCS Policlinico San Donato, Italy.
IN  - Limongelli,Giuseppe. Cardiologia SUN, Ospedale Monaldi (Azienda dei Colli), Seconda Universita di Napoli, Italy.
IN  - Clemenza,Francesco. Mediterranean Institute for Transplantation and Advanced Specialized Therapies, Italy.
IN  - Parati,Gianfranco. Department of Health Science, University of Milano Bicocca, Italy.
IN  - Frigerio,Maria. Dipartimento Cardiologico "A. De Gasperis", Ospedale Ca Granda- A.O. Niguarda, Italy.
IN  - Casenghi,Matteo. Department of Clinical and Molecular Medicine, "La Sapienza" University of Rome, Italy.
IN  - Scardovi,Angela B. Cardiology Division, Santo Spirito Hospital, Italy.
IN  - Ferraironi,Alessandro. Cardiology Division, Santo Spirito Hospital, Italy.
IN  - Di Lenarda,Andrea. Centro Cardiovascolare, Azienda per i Servizi Sanitari ndegree1, Italy.
IN  - Bussotti,Maurizio. Division of Cardiology, Salvatore Maugeri Foundation, IRCCS, Institute of Milan, Italy.
IN  - Apostolo,Anna. Centro Cardiologico Monzino, IRCCS, Italy.
IN  - Paolillo,Stefania. Department of Advanced Biomedical Sciences, "Federico II" University, Italy.
IN  - La Gioia,Rocco. Division of Cardiology, "S. Maugeri" Foundation, IRCCS, Institute of Cassano Murge, Italy.
IN  - Gargiulo,Paola. SDN Foundation, Institute of Diagnostic and Nuclear Development, Napoli, Italy.
IN  - Palermo,Pietro. Centro Cardiologico Monzino, IRCCS, Italy.
IN  - Mina,Chiara. Mediterranean Institute for Transplantation and Advanced Specialized Therapies, Italy.
IN  - Farina,Stefania. Centro Cardiologico Monzino, IRCCS, Italy.
IN  - Battaia,Elisa. Section of Cardiology, Department of Medicine, University of Verona, Italy.
IN  - Maruotti,Antonello. Southampton Statistical Sciences Research Institute & School of Mathematics, University of Southampton, United Kingdom Department of Politic Sciences, Universita "Roma Tre", Italy.
IN  - Pacileo,Giuseppe. Cardiologia SUN, Ospedale Monaldi (Azienda dei Colli), Seconda Universita di Napoli, Italy.
IN  - Contini,Mauro. Centro Cardiologico Monzino, IRCCS, Italy.
IN  - Oliva,Fabrizio. Dipartimento Cardiologico "A. De Gasperis", Ospedale Ca Granda- A.O. Niguarda, Italy.
IN  - Ricci,Roberto. Cardiology Division, Santo Spirito Hospital, Italy.
IN  - Sinagra,Gianfranco. Cardiovascular Department, Ospedali Riuniti and University of Trieste, Italy.
IR  - Salvioni E
IR  - Giovannardi M
IR  - Veglia F
IR  - Mantegazza V
IR  - Bertella E
IR  - Giannuzzi P
IR  - Giordano A
IR  - Mezzani A
IR  - Pietrucci F
IR  - Malfatto G
IR  - Roselli T
IR  - Buono A
IR  - Calabro R
IR  - Masarone D
IR  - De Maria R
IR  - Passantino A
IR  - Santoro D
IR  - Vaninetti R
IR  - Bertipaglia D
IR  - Confalonieri M
IR  - Berton E
IR  - Torregiani C
IR  - Pastormerlo LE
IR  - Cas LD
IR  - Carubelli V
IR  - Vassanelli C
TI  - Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation.
SO  - European Journal of Preventive Cardiology. 22(8):1046-55, 2015 Aug.
AS  - Eur J Prev Cardiolog. 22(8):1046-55, 2015 Aug.
NJ  - European journal of preventive cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101564430
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - *Anaerobic Threshold
MH  - Area Under Curve
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/me [Metabolism]
MH  - Atrial Fibrillation/mo [Mortality]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/th [Therapy]
MH  - *Exercise Test
MH  - Female
MH  - *Heart Failure, Systolic/di [Diagnosis]
MH  - Heart Failure, Systolic/me [Metabolism]
MH  - Heart Failure, Systolic/mo [Mortality]
MH  - Heart Failure, Systolic/pp [Physiopathology]
MH  - Heart Failure, Systolic/th [Therapy]
MH  - Heart Transplantation
MH  - Humans
MH  - Italy
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - *Oxygen Consumption
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - ROC Curve
MH  - Reproducibility of Results
MH  - Risk Factors
MH  - Time Factors
KW  - Heart failure;  anaerobic threshold;  atrial fibrillation;  exercise;  prognosis
AB  - BACKGROUND: Oxygen uptake at the anaerobic threshold (VO2AT), a submaximal exercise-derived variable, independent of patients' motivation, is a marker of outcome in heart failure (HF). However, previous evidence of VO2AT values paradoxically higher in HF patients with permanent atrial fibrillation (AF) than in those with sinus rhythm (SR) raised uncertainties.
AB  - DESIGN: We tested the prognostic role of VO2AT in a large cohort of systolic HF patients, focusing on possible differences between SR and AF.
AB  - METHODS: Altogether 2976 HF patients (2578 with SR and 398 with AF) were prospectively followed. Besides a clinical examination, each patient underwent a maximal cardiopulmonary exercise test (CPET).
AB  - RESULTS: The follow-up was analysed for up to 1500 days. Cardiovascular death or urgent cardiac transplantation occurred in 303 patients (250 (9.6%) patients with SR and 53 (13.3%) patients with AF, p=0.023). In the entire population, multivariate analysis including peak oxygen uptake (VO2) showed a prognostic capacity (C-index) similar to that obtained including VO2AT (0.76 vs 0.72). Also, left ventricular ejection fraction, ventilation vs carbon dioxide production slope, beta-blocker and digoxin therapy proved to be significant prognostic indexes. The receiver-operating characteristic (ROC) curves analysis showed that the best predictive VO2AT cut-off for the SR group was 11.7ml/kg/min, while it was 12.8ml/kg/min for the AF group.
AB  - CONCLUSIONS: VO2AT, a submaximal CPET-derived parameter, is reliable for long-term cardiovascular mortality prognostication in stable systolic HF. However, different VO2AT cut-off values between SR and AF HF patients should be adopted.Copyright © The European Society of Cardiology 2014.
ES  - 2047-4881
IL  - 2047-4873
DO  - http://dx.doi.org/10.1177/2047487314551546
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
LG  - English
EP  - 20140926
DP  - 2015 Aug
DC  - 20150710
YR  - 2015
ED  - 20160411
UP  - 20160412
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25261267

<44. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25261267
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Magri D
AU  - Agostoni P
AU  - Corra U
AU  - Passino C
AU  - Scrutinio D
AU  - Perrone-Filardi P
AU  - Correale M
AU  - Cattadori G
AU  - Metra M
AU  - Girola D
AU  - Piepoli MF
AU  - Iorio A
AU  - Emdin M
AU  - Raimondo R
AU  - Re F
AU  - Cicoira M
AU  - Belardinelli R
AU  - Guazzi M
AU  - Limongelli G
AU  - Clemenza F
AU  - Parati G
AU  - Frigerio M
AU  - Casenghi M
AU  - Scardovi AB
AU  - Ferraironi A
AU  - Di Lenarda A
AU  - Bussotti M
AU  - Apostolo A
AU  - Paolillo S
AU  - La Gioia R
AU  - Gargiulo P
AU  - Palermo P
AU  - Mina C
AU  - Farina S
AU  - Battaia E
AU  - Maruotti A
AU  - Pacileo G
AU  - Contini M
AU  - Oliva F
AU  - Ricci R
AU  - Sinagra G
AU  - Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) Score Research Group
FA  - Magri, Damiano
FA  - Agostoni, Piergiuseppe
FA  - Corra, Ugo
FA  - Passino, Claudio
FA  - Scrutinio, Domenico
FA  - Perrone-Filardi, Pasquale
FA  - Correale, Michele
FA  - Cattadori, Gaia
FA  - Metra, Marco
FA  - Girola, Davide
FA  - Piepoli, Massimo F
FA  - Iorio, AnnaMaria
FA  - Emdin, Michele
FA  - Raimondo, Rosa
FA  - Re, Federica
FA  - Cicoira, Mariantonietta
FA  - Belardinelli, Romualdo
FA  - Guazzi, Marco
FA  - Limongelli, Giuseppe
FA  - Clemenza, Francesco
FA  - Parati, Gianfranco
FA  - Frigerio, Maria
FA  - Casenghi, Matteo
FA  - Scardovi, Angela B
FA  - Ferraironi, Alessandro
FA  - Di Lenarda, Andrea
FA  - Bussotti, Maurizio
FA  - Apostolo, Anna
FA  - Paolillo, Stefania
FA  - La Gioia, Rocco
FA  - Gargiulo, Paola
FA  - Palermo, Pietro
FA  - Mina, Chiara
FA  - Farina, Stefania
FA  - Battaia, Elisa
FA  - Maruotti, Antonello
FA  - Pacileo, Giuseppe
FA  - Contini, Mauro
FA  - Oliva, Fabrizio
FA  - Ricci, Roberto
FA  - Sinagra, Gianfranco
FA  - Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) Score Research Group
IN  - Magri,Damiano. Department of Clinical and Molecular Medicine, "La Sapienza" University of Rome, Italy Centro Cardiologico Monzino, IRCCS, Italy.
IN  - Agostoni,Piergiuseppe. Centro Cardiologico Monzino, IRCCS, Italy Department of Clinical Sciences and Community Health, University of Milano, Italy piergiuseppe.agostoni@unimi.it.
IN  - Corra,Ugo. Divisione di Cardiologia Riabilitativa, Fondazione Salvatore Maugeri, IRCCS, Istituto Scientifico di Veruno, Italy.
IN  - Passino,Claudio. Fondazione Gabriele Monasterio, CNR-Regione Toscana, Italy Scuola Superiore S. Anna, Italy.
IN  - Scrutinio,Domenico. Division of Cardiology, "S. Maugeri" Foundation, IRCCS, Institute of Cassano Murge, Italy.
IN  - Perrone-Filardi,Pasquale. Department of Advanced Biomedical Sciences, "Federico II" University, Italy.
IN  - Correale,Michele. Department of Cardiology, University of Foggia, Italy.
IN  - Cattadori,Gaia. Centro Cardiologico Monzino, IRCCS, Italy.
IN  - Metra,Marco. Cardiology, Department of Medical and Surgical Specialities, Radiological Sciences, and Public Health, University of Brescia, Italy.
IN  - Girola,Davide. Dipartimento Cardiologico "A. De Gasperis", Ospedale Ca Granda- A.O. Niguarda, Italy.
IN  - Piepoli,Massimo F. UOC Cardiologia, G da Saliceto Hospital, Italy.
IN  - Iorio,AnnaMaria. Cardiovascular Department, Ospedali Riuniti and University of Trieste, Italy.
IN  - Emdin,Michele. Fondazione Gabriele Monasterio, CNR-Regione Toscana, Italy.
IN  - Raimondo,Rosa. Fondazione Salvatore Maugeri, IRCCS, Istituto Scientifico di Tradate, Italy.
IN  - Re,Federica. Cardiology Division, Cardiac Arrhythmia Center and Cardiomyopathies Unit, San Camillo-Forlanini Hospital, Italy.
IN  - Cicoira,Mariantonietta. Section of Cardiology, Department of Medicine, University of Verona, Italy.
IN  - Belardinelli,Romualdo. Cardiologia Riabilitativa, Azienda Ospedali Riuniti di Ancona, Italy.
IN  - Guazzi,Marco. Heart Failure Unit, IRCCS Policlinico San Donato, Italy.
IN  - Limongelli,Giuseppe. Cardiologia SUN, Ospedale Monaldi (Azienda dei Colli), Seconda Universita di Napoli, Italy.
IN  - Clemenza,Francesco. Mediterranean Institute for Transplantation and Advanced Specialized Therapies, Italy.
IN  - Parati,Gianfranco. Department of Health Science, University of Milano Bicocca, Italy.
IN  - Frigerio,Maria. Dipartimento Cardiologico "A. De Gasperis", Ospedale Ca Granda- A.O. Niguarda, Italy.
IN  - Casenghi,Matteo. Department of Clinical and Molecular Medicine, "La Sapienza" University of Rome, Italy.
IN  - Scardovi,Angela B. Cardiology Division, Santo Spirito Hospital, Italy.
IN  - Ferraironi,Alessandro. Cardiology Division, Santo Spirito Hospital, Italy.
IN  - Di Lenarda,Andrea. Centro Cardiovascolare, Azienda per i Servizi Sanitari ndegree1, Italy.
IN  - Bussotti,Maurizio. Division of Cardiology, Salvatore Maugeri Foundation, IRCCS, Institute of Milan, Italy.
IN  - Apostolo,Anna. Centro Cardiologico Monzino, IRCCS, Italy.
IN  - Paolillo,Stefania. Department of Advanced Biomedical Sciences, "Federico II" University, Italy.
IN  - La Gioia,Rocco. Division of Cardiology, "S. Maugeri" Foundation, IRCCS, Institute of Cassano Murge, Italy.
IN  - Gargiulo,Paola. SDN Foundation, Institute of Diagnostic and Nuclear Development, Napoli, Italy.
IN  - Palermo,Pietro. Centro Cardiologico Monzino, IRCCS, Italy.
IN  - Mina,Chiara. Mediterranean Institute for Transplantation and Advanced Specialized Therapies, Italy.
IN  - Farina,Stefania. Centro Cardiologico Monzino, IRCCS, Italy.
IN  - Battaia,Elisa. Section of Cardiology, Department of Medicine, University of Verona, Italy.
IN  - Maruotti,Antonello. Southampton Statistical Sciences Research Institute & School of Mathematics, University of Southampton, United Kingdom Department of Politic Sciences, Universita "Roma Tre", Italy.
IN  - Pacileo,Giuseppe. Cardiologia SUN, Ospedale Monaldi (Azienda dei Colli), Seconda Universita di Napoli, Italy.
IN  - Contini,Mauro. Centro Cardiologico Monzino, IRCCS, Italy.
IN  - Oliva,Fabrizio. Dipartimento Cardiologico "A. De Gasperis", Ospedale Ca Granda- A.O. Niguarda, Italy.
IN  - Ricci,Roberto. Cardiology Division, Santo Spirito Hospital, Italy.
IN  - Sinagra,Gianfranco. Cardiovascular Department, Ospedali Riuniti and University of Trieste, Italy.
IR  - Salvioni E
IR  - Giovannardi M
IR  - Veglia F
IR  - Mantegazza V
IR  - Bertella E
IR  - Giannuzzi P
IR  - Giordano A
IR  - Mezzani A
IR  - Pietrucci F
IR  - Malfatto G
IR  - Roselli T
IR  - Buono A
IR  - Calabro R
IR  - Masarone D
IR  - De Maria R
IR  - Passantino A
IR  - Santoro D
IR  - Vaninetti R
IR  - Bertipaglia D
IR  - Confalonieri M
IR  - Berton E
IR  - Torregiani C
IR  - Pastormerlo LE
IR  - Cas LD
IR  - Carubelli V
IR  - Vassanelli C
TI  - Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation.[Erratum appears in Eur J Prev Cardiol. 2016 Jul;23(11):NP97; PMID: 27189817]
SO  - European Journal of Preventive Cardiology. 22(8):1046-55, 2015 Aug.
AS  - Eur J Prev Cardiolog. 22(8):1046-55, 2015 Aug.
NJ  - European journal of preventive cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101564430
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - *Anaerobic Threshold
MH  - Area Under Curve
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/me [Metabolism]
MH  - Atrial Fibrillation/mo [Mortality]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/th [Therapy]
MH  - *Exercise Test
MH  - Female
MH  - *Heart Failure, Systolic/di [Diagnosis]
MH  - Heart Failure, Systolic/me [Metabolism]
MH  - Heart Failure, Systolic/mo [Mortality]
MH  - Heart Failure, Systolic/pp [Physiopathology]
MH  - Heart Failure, Systolic/th [Therapy]
MH  - Heart Transplantation
MH  - Humans
MH  - Italy
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - *Oxygen Consumption
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - ROC Curve
MH  - Reproducibility of Results
MH  - Risk Factors
MH  - Time Factors
KW  - Heart failure;  anaerobic threshold;  atrial fibrillation;  exercise;  prognosis
AB  - BACKGROUND: Oxygen uptake at the anaerobic threshold (VO2AT), a submaximal exercise-derived variable, independent of patients' motivation, is a marker of outcome in heart failure (HF). However, previous evidence of VO2AT values paradoxically higher in HF patients with permanent atrial fibrillation (AF) than in those with sinus rhythm (SR) raised uncertainties.
AB  - DESIGN: We tested the prognostic role of VO2AT in a large cohort of systolic HF patients, focusing on possible differences between SR and AF.
AB  - METHODS: Altogether 2976 HF patients (2578 with SR and 398 with AF) were prospectively followed. Besides a clinical examination, each patient underwent a maximal cardiopulmonary exercise test (CPET).
AB  - RESULTS: The follow-up was analysed for up to 1500 days. Cardiovascular death or urgent cardiac transplantation occurred in 303 patients (250 (9.6%) patients with SR and 53 (13.3%) patients with AF, p=0.023). In the entire population, multivariate analysis including peak oxygen uptake (VO2) showed a prognostic capacity (C-index) similar to that obtained including VO2AT (0.76 vs 0.72). Also, left ventricular ejection fraction, ventilation vs carbon dioxide production slope, beta-blocker and digoxin therapy proved to be significant prognostic indexes. The receiver-operating characteristic (ROC) curves analysis showed that the best predictive VO2AT cut-off for the SR group was 11.7ml/kg/min, while it was 12.8ml/kg/min for the AF group.
AB  - CONCLUSIONS: VO2AT, a submaximal CPET-derived parameter, is reliable for long-term cardiovascular mortality prognostication in stable systolic HF. However, different VO2AT cut-off values between SR and AF HF patients should be adopted.Copyright © The European Society of Cardiology 2014.
ES  - 2047-4881
IL  - 2047-4873
DO  - http://dx.doi.org/10.1177/2047487314551546
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
LG  - English
EP  - 20140926
DP  - 2015 Aug
DC  - 20150710
YR  - 2015
ED  - 20160411
RD  - 20160712
UP  - 20160713
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=25261267

<45. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25984822
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Roll M
AU  - Rosenqvist M
AU  - Sjoborg B
AU  - Wettermark B
FA  - Roll, Martin
FA  - Rosenqvist, Marten
FA  - Sjoborg, Bengt
FA  - Wettermark, Bjorn
IN  - Roll,Martin. From the Departments of Clinical Sciences (Roll, Rosenqvist) and Cardiology (Roll, Rosenqvist), Division of Cardiovascular Medicine, Danderyd University Hospital, Karolinska Institutet, Stockholm, Sweden; Public Healthcare Services Committee (Sjoborg, Wettermark), Stockholm County Council, Stockholm, Sweden; and Centre for Pharmacoepidemiology and Clinical Pharmacology (Wettermark), Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
TI  - Unexplained acute chest pain in young adults: disease patterns and medication use 25 years later.
SO  - Psychosomatic Medicine. 77(5):567-74, 2015 Jun.
AS  - Psychosom Med. 77(5):567-74, 2015 Jun.
NJ  - Psychosomatic medicine
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - qgr, 0376505
SB  - Index Medicus
CP  - United States
MH  - *Acute Pain/ep [Epidemiology]
MH  - Acute Pain/mo [Mortality]
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - *Chest Pain/ep [Epidemiology]
MH  - Chest Pain/mo [Mortality]
MH  - *Drug Prescriptions/sn [Statistics & Numerical Data]
MH  - Female
MH  - Follow-Up Studies
MH  - *Health Services/sn [Statistics & Numerical Data]
MH  - Health Services/ut [Utilization]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Registries
MH  - Sweden/ep [Epidemiology]
MH  - Young Adult
AB  - BACKGROUND: Patients with unexplained chest pain are commonly revisiting an emergency department with various symptoms, but comprehensive long-term studies are lacking.
AB  - METHODS: A total of 150 young adults (aged 18-40 years) with unexplained chest pain who presented at an emergency unit for 16 weeks in mid-1980s were included in a prospective cohort study. An age- and sex-matched control group was randomly selected from the same area. Data were retrieved from registers that recorded death, income, education, country of birth, diagnoses, hospitalizations, outpatient visits, and medications dispensed.
AB  - RESULTS: Patients with unexplained acute chest pain had lower levels of education and income and were more often immigrants. Long-term mortality rates did not differ between cases (4%) and controls (5%) during 25 years of follow-up, nor were there differences in diagnosis of ischemic heart disease. Patients with unexplained acute chest pain had more outpatient visits (median, 5 versus 2; p < .0001) and had more often been hospitalized (61.6% ever versus 41.8%; p < .001) during the follow-up period. Several disorders were more common among patients 20 to 25 years later, including atrial fibrillation, esophageal/gastric disorders, chest pain, palpitations, abdominal discomfort, musculoskeletal symptoms, sleeping disturbance, and stress reactions (p values < .05). More patients had been given antihypertensives, anticoagulants, antidepressants, analgesics, and hypnotics/tranquilizers (p values < .05).
AB  - CONCLUSIONS: Young patients admitted to the emergency department with unexplained acute chest pain showed no increased risk of mortality or ischemic heart disease during 25 years of follow-up, but they had higher incidence of a wide range of disorders and used more medications. Early identification and preventive interventions may improve health outcomes in these patients.
ES  - 1534-7796
IL  - 0033-3174
DO  - http://dx.doi.org/10.1097/PSY.0000000000000188
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2015 Jun
DC  - 20150608
YR  - 2015
ED  - 20160404
UP  - 20160405
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25984822

<46. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25534309
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Feng J
FA  - Feng, Jun
IN  - Feng,Jun. Division of Cardiothoracic Surgery, Department of Surgery, Cardiovascular Research Center, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI. Electronic address: jfeng@lifespan.org.
TI  - Mediterranean-style diet to prevent postoperative atrial fibrillation: Role of antioxidants?.
CM  - Comment on: J Thorac Cardiovasc Surg. 2015 Apr;149(4):1175-82.e1; PMID: 25534306
SO  - Journal of Thoracic & Cardiovascular Surgery. 149(4):1182-4, 2015 Apr.
AS  - J Thorac Cardiovasc Surg. 149(4):1182-4, 2015 Apr.
NJ  - The Journal of thoracic and cardiovascular surgery
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - k9j, 0376343
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Antioxidants/ad [Administration & Dosage]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - *Coronary Artery Bypass/ae [Adverse Effects]
MH  - *Diet
MH  - Female
MH  - *Heart Valve Prosthesis Implantation/ae [Adverse Effects]
MH  - Humans
MH  - Male
RN  - 0 (Antioxidants)
ES  - 1097-685X
IL  - 0022-5223
DI  - S0022-5223(14)01979-5
DO  - http://dx.doi.org/10.1016/j.jtcvs.2014.11.063
PT  - Comment
PT  - Editorial
LG  - English
EP  - 20141127
DP  - 2015 Apr
DC  - 20150424
YR  - 2015
ED  - 20160331
UP  - 20160401
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25534309

<47. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25534306
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Costanzo S
AU  - De Curtis A
AU  - di Niro V
AU  - Olivieri M
AU  - Morena M
AU  - De Filippo CM
AU  - Caradonna E
AU  - Krogh V
AU  - Serafini M
AU  - Pellegrini N
AU  - Donati MB
AU  - de Gaetano G
AU  - Iacoviello L
AU  - Polyphemus Observational Study Investigators
FA  - Costanzo, Simona
FA  - De Curtis, Amalia
FA  - di Niro, Veronica
FA  - Olivieri, Marco
FA  - Morena, Mariarosaria
FA  - De Filippo, Carlo Maria
FA  - Caradonna, Eugenio
FA  - Krogh, Vittorio
FA  - Serafini, Mauro
FA  - Pellegrini, Nicoletta
FA  - Donati, Maria Benedetta
FA  - de Gaetano, Giovanni
FA  - Iacoviello, Licia
FA  - Polyphemus Observational Study Investigators
IN  - Costanzo,Simona. Department of Epidemiology and Prevention, IRCCS Istituto Neurologico Mediterraneo Neuromed, Pozzilli (IS), Italy. Electronic address: simona.costanzo@neuromed.it.
IN  - De Curtis,Amalia. Department of Epidemiology and Prevention, IRCCS Istituto Neurologico Mediterraneo Neuromed, Pozzilli (IS), Italy.
IN  - di Niro,Veronica. Nuovo Ospedale Civile di Sassuolo, Sassuolo, Italy.
IN  - Olivieri,Marco. EPICOMED Research, srl, Campobasso, Italy.
IN  - Morena,Mariarosaria. Department of Cardiovascular Disease, Fondazione di Ricerca e Cura "Giovanni Paolo II," Campobasso, Italy.
IN  - De Filippo,Carlo Maria. Department of Cardiovascular Disease, Fondazione di Ricerca e Cura "Giovanni Paolo II," Campobasso, Italy.
IN  - Caradonna,Eugenio. Department of Cardiovascular Disease, Fondazione di Ricerca e Cura "Giovanni Paolo II," Campobasso, Italy.
IN  - Krogh,Vittorio. Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
IN  - Serafini,Mauro. Functional Food and Metabolic Stress Prevention Laboratory, Agricultural Research Center, CRA-NUT, Rome, Italy.
IN  - Pellegrini,Nicoletta. Department of Food Science, University of Parma, Parma, Italy.
IN  - Donati,Maria Benedetta. Department of Epidemiology and Prevention, IRCCS Istituto Neurologico Mediterraneo Neuromed, Pozzilli (IS), Italy.
IN  - de Gaetano,Giovanni. Department of Epidemiology and Prevention, IRCCS Istituto Neurologico Mediterraneo Neuromed, Pozzilli (IS), Italy.
IN  - Iacoviello,Licia. Department of Epidemiology and Prevention, IRCCS Istituto Neurologico Mediterraneo Neuromed, Pozzilli (IS), Italy.
IR  - Iacoviello L
IR  - Costanzo S
IR  - Bonaccio M
IR  - Bonanni A
IR  - Cerletti C
IR  - Costanzo S
IR  - De Curtis A
IR  - de Gaetano G
IR  - Di Castelnuovo A
IR  - Donati MB
IR  - Iacoviello L
IR  - Barilaro C
IR  - Caradonna E
IR  - Calvo E
IR  - Cianci V
IR  - De Filippo CM
IR  - Testa N
IR  - Zappacosta B
IR  - Bredice D
IR  - D'versa F
IR  - Di Niro V
IR  - Mercurio S
IR  - Morena M
IR  - Panzera T
IR  - Zeoli M
IR  - Cugino D
IR  - Cutrone A
IR  - D'Imperio M
IR  - Santimone I
IR  - Olivieri M
TI  - Postoperative atrial fibrillation and total dietary antioxidant capacity in patients undergoing cardiac surgery: The Polyphemus Observational Study.
CM  - Comment in: J Thorac Cardiovasc Surg. 2015 Apr;149(4):1182-4; PMID: 25534309
SO  - Journal of Thoracic & Cardiovascular Surgery. 149(4):1175-82.e1, 2015 Apr.
AS  - J Thorac Cardiovasc Surg. 149(4):1175-82.e1, 2015 Apr.
NJ  - The Journal of thoracic and cardiovascular surgery
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - k9j, 0376343
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Antioxidants/ad [Administration & Dosage]
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - *Coronary Artery Bypass/ae [Adverse Effects]
MH  - *Diet
MH  - Female
MH  - Food Habits
MH  - *Heart Valve Prosthesis Implantation/ae [Adverse Effects]
MH  - Humans
MH  - Incidence
MH  - Italy/ep [Epidemiology]
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Nutrition Assessment
MH  - Nutritional Status
MH  - Odds Ratio
MH  - Prospective Studies
MH  - Protective Factors
MH  - Risk Factors
MH  - Surveys and Questionnaires
MH  - Time Factors
MH  - Treatment Outcome
AB  - OBJECTIVE: Postoperative atrial fibrillation is a major cause of morbidity and mortality for stroke after cardiac surgery. Both systemic inflammation and oxidative stress play a role in the initiation of postoperative atrial fibrillation after cardiac surgery. The possible association between long-term intake of antioxidant-rich foods and postoperative atrial fibrillation incidence was examined in patients undergoing cardiac surgery.
AB  - METHODS: A total of 217 consecutive patients (74% were men; median age, 68.4 years) undergoing cardiac surgery, mainly coronary artery bypass grafting and valve replacement or repair, were recruited from January 2010 to September 2012. Total antioxidant capacity was measured in foods by the Trolox equivalent antioxidant capacity assay. The European Prospective Investigation into Cancer and Nutrition Food Frequency Questionnaire was used for dietary total antioxidant capacity assessment. The association among tertiles of dietary total antioxidant capacity and postoperative atrial fibrillation incidence was assessed using multivariable logistic analysis.
AB  - RESULTS: The overall incidence of total arrhythmias and postoperative atrial fibrillation was 42.4% and 38.2%, respectively. In multivariable analysis, after adjustment for age, gender, use of hypoglycemic drugs, physical activity, education, previous diagnosis of atrial fibrillation, and total energy intake, patients in the highest tertile of dietary total antioxidant capacity had a lower risk of postoperative atrial fibrillation than patients in the 2 lowest tertiles (odds ratio, 0.46; 95% confidence interval, 0.22-0.95; P = .048). A restricted cubic spline transformation confirmed the nonlinear relationship between total antioxidant capacity (in continuous scale) and postoperative atrial fibrillation (P = .023). When considering only coronary artery bypass grafting, valve replacement/repair, and combined surgeries, the protective effect on postoperative atrial fibrillation of a diet rich in antioxidants was confirmed.
AB  - CONCLUSIONS: Long-term consumption of antioxidant-rich foods is associated with a reduced incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery.Copyright © 2015 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.
RN  - 0 (Antioxidants)
ES  - 1097-685X
IL  - 0022-5223
DI  - S0022-5223(14)01815-7
DO  - http://dx.doi.org/10.1016/j.jtcvs.2014.11.035
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20141121
DP  - 2015 Apr
DC  - 20150424
YR  - 2015
ED  - 20160331
UP  - 20160401
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25534306

<48. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25741556
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Anonymous
TI  - Visualizing a safe place reduces pain during ablation of atrial fibrillation.
SO  - European Heart Journal. 36(3):140, 2015 Jan 14.
AS  - Eur Heart J. 36(3):140, 2015 Jan 14.
NJ  - European heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - em8, 8006263
SB  - Index Medicus
CP  - England
MH  - *Atrial Fibrillation/su [Surgery]
MH  - *Catheter Ablation/ae [Adverse Effects]
MH  - Humans
MH  - *Imagery (Psychotherapy)/mt [Methods]
MH  - *Intraoperative Complications/pc [Prevention & Control]
MH  - *Pain/pc [Prevention & Control]
ES  - 1522-9645
IL  - 0195-668X
PT  - Journal Article
LG  - English
DP  - 2015 Jan 14
DC  - 20150304
YR  - 2015
ED  - 20160321
UP  - 20160322
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25741556

<49. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26603907
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - O'Neal WT
AU  - Qureshi WT
AU  - Blaha MJ
AU  - Ehrman JK
AU  - Brawner CA
AU  - Nasir K
AU  - Al-Mallah MH
FA  - O'Neal, Wesley T
FA  - Qureshi, Waqas T
FA  - Blaha, Michael J
FA  - Ehrman, Jonathan K
FA  - Brawner, Clinton A
FA  - Nasir, Khurram
FA  - Al-Mallah, Mouaz H
IN  - O'Neal,Wesley T. Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.
IN  - Qureshi,Waqas T. Section on Cardiovascular Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.
IN  - Blaha,Michael J. Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, Maryland.
IN  - Ehrman,Jonathan K. Division of Cardiovascular Medicine, Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan.
IN  - Brawner,Clinton A. Division of Cardiovascular Medicine, Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan.
IN  - Nasir,Khurram. Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, Maryland; Center for Prevention and Wellness Research, Baptist Health Medical Group, Miami Beach, Florida.
IN  - Al-Mallah,Mouaz H. Division of Cardiovascular Medicine, Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan; Department of Internal Medicine, Wayne State University, Detroit, Michigan; Department of Cardiac Imaging, King Abdul Aziz Cardiac Center, Riyadh, Saudi Arabia. Electronic address: mouaz74@gmail.com.
TI  - Relation of Risk of Atrial Fibrillation With Systolic Blood Pressure Response During Exercise Stress Testing (from the Henry Ford ExercIse Testing Project).
SO  - American Journal of Cardiology. 116(12):1858-62, 2015 Dec 15.
AS  - Am J Cardiol. 116(12):1858-62, 2015 Dec 15.
NJ  - The American journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Autonomic Nervous System/pp [Physiopathology]
MH  - *Blood Pressure/ph [Physiology]
MH  - *Exercise Test/mt [Methods]
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Michigan/ep [Epidemiology]
MH  - Middle Aged
MH  - Prognosis
MH  - Risk Factors
AB  - Decreases in systolic blood pressure during exercise may predispose to arrhythmias such as atrial fibrillation (AF) because of underlying abnormal autonomic tone. We examined the association between systolic blood pressure response and incident AF in 57,442 (mean age 54 +/- 13 years, 47% women, and 29% black) patients free of baseline AF who underwent exercise treadmill stress testing from the Henry Ford ExercIse Testing project. Exercise systolic blood pressure response was examined as a categorical variable across clinically relevant categories (>20 mm Hg: referent; 1 to 20 mm Hg, and <0 mm Hg) and per 1-SD decrease. Cox regression, adjusting for demographics, cardiovascular risk factors, medications, history of coronary heart disease, history of heart failure, and metabolic equivalent of task achieved, was used to compute hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between systolic blood pressure response and incident AF. Over a median follow-up of 5.0 years, a total of 3,381 cases (5.9%) of AF were identified. An increased risk of AF was observed with decreasing systolic blood pressure response (>20 mm Hg: HR 1.0, referent; 1 to 20 mm Hg: HR 1.09, 95% CI 0.99, 1.20; <0 mm Hg: HR 1.22, 95% CI 1.06 to 1.40). Similar results were obtained per 1-SD decrease in systolic blood pressure response (HR 1.08, 95% CI 1.04 to 1.12). The results were consistent when stratified by age, sex, race, hypertension, and coronary heart disease. In conclusion, our results suggest that a decreased systolic blood pressure response during exercise may identify subjects who are at risk for developing AF.Copyright © 2015 Elsevier Inc. All rights reserved.
ES  - 1879-1913
IL  - 0002-9149
DI  - S0002-9149(15)02003-2
DO  - http://dx.doi.org/10.1016/j.amjcard.2015.09.024
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
NO  - 5T32HL076132-10 (United States NHLBI NIH HHS)
LG  - English
EP  - 20151003
DP  - 2015 Dec 15
DC  - 20151127
YR  - 2015
ED  - 20160315
UP  - 20160316
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26603907

<50. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25839670
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Sharma S
AU  - Merghani A
AU  - Mont L
FA  - Sharma, Sanjay
FA  - Merghani, Ahmed
FA  - Mont, Lluis
IN  - Sharma,Sanjay. Department of Cardiovascular Sciences, St Georges, University of London, Cranmer Terrace, London SW17 0RE, UK sasharma@sgul.ac.uk.
IN  - Merghani,Ahmed. Department of Cardiovascular Sciences, St Georges, University of London, Cranmer Terrace, London SW17 0RE, UK.
IN  - Mont,Lluis. Institut del Torax, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain.
TI  - Exercise and the heart: the good, the bad, and the ugly. [Review]
SO  - European Heart Journal. 36(23):1445-53, 2015 Jun 14.
AS  - Eur Heart J. 36(23):1445-53, 2015 Jun 14.
NJ  - European heart journal
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - em8, 8006263
SB  - Index Medicus
CP  - England
MH  - Adolescent
MH  - Adult
MH  - Arrhythmias, Cardiac/pp [Physiopathology]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Cardiomegaly, Exercise-Induced/ph [Physiology]
MH  - Death, Sudden, Cardiac/et [Etiology]
MH  - Electrocardiography
MH  - *Exercise/ph [Physiology]
MH  - Female
MH  - Heart Diseases/et [Etiology]
MH  - Heart Diseases/pp [Physiopathology]
MH  - *Heart Diseases/pc [Prevention & Control]
MH  - Humans
MH  - Male
MH  - Sports/ph [Physiology]
MH  - Ventricular Remodeling/ph [Physiology]
KW  - Arrhythmias;  Athlete's heart;  Athletes;  Cardiomyopathy;  Exercise;  Sudden death
AB  - The benefits of exercise are irrefutable. Individuals engaging in regular exercise have a favourable cardiovascular risk profile for coronary artery disease and reduce their risk of myocardial infarction by 50%. Exercise promotes longevity of life, reduces the risk of some malignancies, retards the onset of dementia, and is as considered an antidepressant. Most of these benefits are attributable to moderate exercise, whereas athletes perform way beyond the recommended levels of physical activity and constantly push back the frontiers of human endurance. The cardiovascular adaptation for generating a large and sustained increase in cardiac output during prolonged exercise includes a 10-20% increase in cardiac dimensions. In rare instances, these physiological increases in cardiac size overlap with morphologically mild expressions of the primary cardiomyopathies and resolving the diagnostic dilemma can be challenging. Intense exercise may infrequently trigger arrhythmogenic sudden cardiac death in an athlete harbouring asymptomatic cardiac disease. In parallel with the extraordinary athletic milieu of physical performances previously considered unachievable, there is emerging data indicating that long-standing vigorous exercise may be associated with adverse electrical and structural remodelling in otherwise normal hearts. Finally, in the current era of celebrity athletes and lucrative sport contracts, several athletes have succumbed to using performance enhancing agents for success which are detrimental to cardiac health. This article discusses the issues abovementioned, which can be broadly classified as the good, bad, and ugly aspects of sports cardiology. Copyright Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com.
ES  - 1522-9645
IL  - 0195-668X
DO  - http://dx.doi.org/10.1093/eurheartj/ehv090
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
NO  - (United Kingdom British Heart Foundation)
LG  - English
EP  - 20150402
DP  - 2015 Jun 14
DC  - 20150615
YR  - 2015
ED  - 20160315
UP  - 20160316
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25839670

<51. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25577429
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Alphonsa A
AU  - Sharma KK
AU  - Sharma G
AU  - Bhatia R
FA  - Alphonsa, Annu
FA  - Sharma, Kamlesh K
FA  - Sharma, Gautam
FA  - Bhatia, Rohit
IN  - Alphonsa,Annu. College of Nursing, All India Institute of Medical Sciences, New Delhi, India.
IN  - Sharma,Kamlesh K. College of Nursing, All India Institute of Medical Sciences, New Delhi, India.
IN  - Sharma,Gautam. Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India.
IN  - Bhatia,Rohit. Department of Neurology, All India Institute of Medical Sciences, New Delhi, India. Electronic address: rohitbhatia71@yahoo.com.
TI  - Knowledge regarding oral anticoagulation therapy among patients with stroke and those at high risk of thromboembolic events.
SO  - Journal of Stroke & Cerebrovascular Diseases. 24(3):668-72, 2015 Mar.
AS  - J STROKE CEREBROVASC DIS. 24(3):668-72, 2015 Mar.
NJ  - Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9111633
SB  - Index Medicus
CP  - United States
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - *Anticoagulants/ad [Administration & Dosage]
MH  - Anticoagulants/ae [Adverse Effects]
MH  - Blood Coagulation/de [Drug Effects]
MH  - Consumer Health Information
MH  - Cross-Sectional Studies
MH  - Drug Monitoring/mt [Methods]
MH  - Female
MH  - Health Care Surveys
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - India/ep [Epidemiology]
MH  - International Normalized Ratio
MH  - Male
MH  - Middle Aged
MH  - *Patient Education as Topic
MH  - *Patients/px [Psychology]
MH  - Prothrombin Time
MH  - Quality Improvement
MH  - Quality Indicators, Health Care
MH  - Recurrence
MH  - Risk Assessment
MH  - Risk Factors
MH  - *Secondary Prevention
MH  - Stroke/bl [Blood]
MH  - Stroke/di [Diagnosis]
MH  - Stroke/ep [Epidemiology]
MH  - *Stroke/th [Therapy]
MH  - Surveys and Questionnaires
MH  - Tertiary Care Centers
MH  - Thromboembolism/bl [Blood]
MH  - Thromboembolism/di [Diagnosis]
MH  - Thromboembolism/ep [Epidemiology]
MH  - *Thromboembolism/pc [Prevention & Control]
MH  - Young Adult
KW  - Knowledge;  atrial fibrillation;  oral anticoagulation therapy;  rheumatic heart disease;  stroke;  thromboembolic events
AB  - BACKGROUND: Apart from atrial fibrillation, indications for oral anticoagulation common in our clinical practice include rheumatic heart disease and mechanical heart valve replacement. Evaluation of current patient knowledge regarding oral anticoagulation therapy (OAT) is the first step in improving the quality of anticoagulation therapy and patient care. The aim of the present study was to assess the knowledge regarding OAT among patients with stroke and those at high risk of thromboembolic events in a tertiary care hospital in India.
AB  - METHODS: A descriptive cross-sectional design was used; 240 patients on OAT because of various indications (mechanical heart valve replacement, rheumatic heart disease, atrial fibrillation, and stroke) attending the neurology and cardiology outpatient clinics and inpatient services were recruited. A structured self-developed questionnaire was used to assess the knowledge in these patients.
AB  - RESULTS: Most patients (62.9%) were ignorant about the target prothrombin time/international normalized ratio (PT/INR) levels with only 30% having their recent INR within the target range; 50% of the patients had a poor knowledge score, and the knowledge gap was most prominent in the domains of dietary interactions followed by drug interactions, adverse effects, and PT/INR monitoring. Knowledge score also had a significant association with gender, education, monthly income, and place of residence (P < .05).
AB  - CONCLUSION: Patient's knowledge about OAT was suboptimal. The findings support the need for educational interventions to improve the knowledge regarding OAT and, thereby, achieve an appropriate and safe secondary prevention of stroke.Copyright © 2015 National Stroke Association. Published by Elsevier Inc. All rights reserved.
RN  - 0 (Anticoagulants)
ES  - 1532-8511
IL  - 1052-3057
DI  - S1052-3057(14)00565-5
DO  - http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2014.11.007
PT  - Journal Article
LG  - English
EP  - 20150107
DP  - 2015 Mar
DC  - 20150313
YR  - 2015
ED  - 20160314
UP  - 20160315
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25577429

<52. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25668355
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Trachsel LD
AU  - Carlen F
AU  - Brugger N
AU  - Seiler C
AU  - Wilhelm M
FA  - Trachsel, Lukas D
FA  - Carlen, Frederik
FA  - Brugger, Nicolas
FA  - Seiler, Christian
FA  - Wilhelm, Matthias
IN  - Trachsel,Lukas D. University Clinic for Cardiology, Inselspital, University Hospital and University of Bern, Bern, Switzerland *Lukas D. Trachsel and Frederik Carlen contributed equally to the writing of this article.
TI  - Masked hypertension and cardiac remodeling in middle-aged endurance athletes.
SO  - Journal of Hypertension. 33(6):1276-83, 2015 Jun.
AS  - J Hypertens. 33(6):1276-83, 2015 Jun.
NJ  - Journal of hypertension
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - iew, 8306882
SB  - Index Medicus
CP  - England
MH  - Adult
MH  - *Athletes
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Blood Pressure/ph [Physiology]
MH  - Blood Pressure Determination
MH  - Blood Pressure Monitoring, Ambulatory
MH  - Diastole/ph [Physiology]
MH  - Heart Atria/pa [Pathology]
MH  - *Heart Ventricles/pa [Pathology]
MH  - Humans
MH  - Male
MH  - *Masked Hypertension/ep [Epidemiology]
MH  - Masked Hypertension/pa [Pathology]
MH  - Masked Hypertension/pp [Physiopathology]
MH  - *Physical Endurance
MH  - Risk Factors
MH  - *Running
MH  - Switzerland
MH  - Systole/ph [Physiology]
MH  - Ventricular Function, Left/ph [Physiology]
AB  - OBJECTIVES: Extensive endurance training and arterial hypertension are established risk factors for atrial fibrillation. We aimed to assess the proportion of masked hypertension in endurance athletes and the impact on cardiac remodeling, mechanics, and supraventricular tachycardias (SVT).
AB  - METHODS: Male participants of a 10-mile race were recruited and included if office blood pressure was normal (<140/90 mmHg). Athletes were stratified into a masked hypertension and normotension group by ambulatory blood pressure. Primary endpoint was diastolic function, expressed as peak early diastolic mitral annulus velocity (E'). Left ventricular global strain, left ventricular mass/volume ratio, left atrial volume index, signal-averaged P-wave duration (SAPWD), and SVT during 24-h Holter monitoring were recorded.
AB  - RESULTS: From 108 runners recruited, 87 were included in the final analysis. Thirty-three (38%) had masked hypertension. The mean age was 42 +/- 8 years. Groups did not differ with respect to age, body composition, cumulative training hours, and 10-mile race time. Athletes with masked hypertension had a lower E' and a higher left ventricular mass/volume ratio. Left ventricular global strain, left atrial volume index, SAPWD, and SVT showed no significant differences between the groups. In multiple linear regression analysis, masked hypertension was independently associated with E' (beta = -0.270, P = 0.004) and left ventricular mass/volume ratio (beta = 0.206, P = 0.049). Cumulative training hours was the only independent predictor for left atrial volume index (beta = 0.474, P < 0.001) and SAPWD (beta = 0.481, P < 0.001).
AB  - CONCLUSION: In our study, a relevant proportion of middle-aged athletes had masked hypertension, associated with a lower diastolic function and a higher left ventricular mass/volume ratio, but unrelated to left ventricular systolic function, atrial remodeling, or SVT.
ES  - 1473-5598
IL  - 0263-6352
DO  - http://dx.doi.org/10.1097/HJH.0000000000000558
PT  - Journal Article
LG  - English
DP  - 2015 Jun
DC  - 20150501
YR  - 2015
ED  - 20160311
UP  - 20160314
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25668355

<53. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25059930
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Pfister R
AU  - Bragelmann J
AU  - Michels G
AU  - Wareham NJ
AU  - Luben R
AU  - Khaw KT
FA  - Pfister, Roman
FA  - Bragelmann, Johannes
FA  - Michels, Guido
FA  - Wareham, Nick J
FA  - Luben, Robert
FA  - Khaw, Kay-Tee
IN  - Pfister,Roman. Department III of Internal Medicine, Heart Centre of the University of Cologne, Germany roman.pfister@uk-koeln.de.
IN  - Bragelmann,Johannes. Department III of Internal Medicine, Heart Centre of the University of Cologne, Germany.
IN  - Michels,Guido. Department III of Internal Medicine, Heart Centre of the University of Cologne, Germany.
IN  - Wareham,Nick J. Medical Research Council Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, UK.
IN  - Luben,Robert. Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, UK.
IN  - Khaw,Kay-Tee. Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, UK.
TI  - Performance of the CHARGE-AF risk model for incident atrial fibrillation in the EPIC Norfolk cohort.
SO  - European Journal of Preventive Cardiology. 22(7):932-9, 2015 Jul.
AS  - Eur J Prev Cardiolog. 22(7):932-9, 2015 Jul.
NJ  - European journal of preventive cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101564430
SB  - Index Medicus
CP  - England
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/eh [Ethnology]
MH  - Chi-Square Distribution
MH  - Comorbidity
MH  - Discriminant Analysis
MH  - England/ep [Epidemiology]
MH  - European Continental Ancestry Group
MH  - Female
MH  - *Health Status
MH  - *Health Status Indicators
MH  - Humans
MH  - Incidence
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Primary Health Care
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Reproducibility of Results
MH  - Risk Assessment
MH  - Risk Factors
MH  - Smoking/ae [Adverse Effects]
MH  - Time Factors
KW  - Atrial fibrillation;  risk prediction;  score
AB  - BACKGROUND: Identification of individuals at risk for developing atrial fibrillation (AF) will help to target screening and preventive interventions. We aimed to validate the CHARGE-AF model (including variables age, race, height, weight, blood pressure, smoking, antihypertensive medication, diabetes, myocardial infarction and heart failure) for prediction of five-year incident AF in a representative European population with a wide age range.
AB  - METHODS AND RESULTS: The CHARGE-AF model was calculated in 24,020 participants of the population-based EPIC Norfolk study with 236 cases of hospitalization with diagnosis of AF within five years. The model showed good discrimination (c-statistic 0.81, 95% confidence interval (CI) 0.75-0.85), but weak calibration (Chi(2)-statistic 142) with an almost two-fold overestimation of AF incidence. A recalibration to characteristics of the European Prospective Investigation into Cancer and Nutrition (EPIC) Norfolk cohort improved calibration considerably (Chi(2)-statistic 13.3), with acceptable discrimination in participants both >65 and <65 years of age (c-statistics 0.70, 95% CI 0.61-0.77 and 0.83, 95% CI 0.74-0.88). The recalibrated model also showed good discrimination in participants free of cardiovascular disease (c-statistics 0.80, 95% CI 0.75-0.84). Categories of predicted risk (<2.5%, 2.5-5% or >5%) showed good concordance with observed five-year AF incidence of 0.62%, 3.49% and 8.74% (log rank test p<0.001), respectively.
AB  - CONCLUSION: A recalibration of the CHARGE-AF model is necessary for accurate predictions of five-year risk of AF in the EPIC Norfolk population. The recalibrated model showed good discrimination across a wide age range and in individuals free of cardiovascular disease, and hence is broadly applicable in primary care to identify people at risk for development of AF.Copyright © The European Society of Cardiology 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.
ES  - 2047-4881
IL  - 2047-4873
DO  - http://dx.doi.org/10.1177/2047487314544045
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Studies
NO  - 14136 (United Kingdom Cancer Research UK)
NO  - C864/A8257 (United Kingdom Cancer Research UK)
NO  - G0401527 (United Kingdom Medical Research Council)
NO  - G1000143 (United Kingdom Medical Research Council)
NO  - G1000143 (United Kingdom Medical Research Council)
NO  - MC_U106179471 (United Kingdom Medical Research Council)
NO  - MC_UU_12015/1 (United Kingdom Medical Research Council)
LG  - English
EP  - 20140724
DP  - 2015 Jul
DC  - 20150606
YR  - 2015
ED  - 20160303
RD  - 20160301
UP  - 20160304
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25059930

<54. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25680239
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Granziera S
AU  - Cohen AT
AU  - Nante G
AU  - Manzato E
AU  - Sergi G
FA  - Granziera, Serena
FA  - Cohen, Alexander T
FA  - Nante, Giovanni
FA  - Manzato, Enzo
FA  - Sergi, Giuseppe
IN  - Granziera,Serena. University of Padova, Department of Medicine- DIMED, Padova, Italy; King's College Hospital, London, United Kingdom. Electronic address: serena.granziera@gmail.com.
IN  - Cohen,Alexander T. Department of Thrombosis and Hemostasis, Guy's and St Thomas' Hospitals, London, United Kingdom.
IN  - Nante,Giovanni. University of Padova, Department of Medicine- DIMED, Padova, Italy.
IN  - Manzato,Enzo. University of Padova, Department of Medicine- DIMED, Padova, Italy.
IN  - Sergi,Giuseppe. University of Padova, Department of Medicine- DIMED, Padova, Italy. Electronic address: giuseppe.sergi@unipd.it.
TI  - Thromboembolic prevention in frail elderly patients with atrial fibrillation: a practical algorithm. [Review]
SO  - Journal of the American Medical Directors Association. 16(5):358-64, 2015 May 1.
AS  - J AM MED DIR ASSOC. 16(5):358-64, 2015 May 1.
NJ  - Journal of the American Medical Directors Association
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 100893243
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - Algorithms
MH  - *Anti-Arrhythmia Agents/ad [Administration & Dosage]
MH  - Anticoagulants/ad [Administration & Dosage]
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Brain Ischemia/et [Etiology]
MH  - *Brain Ischemia/pc [Prevention & Control]
MH  - Controlled Clinical Trials as Topic
MH  - Female
MH  - *Frail Elderly/sn [Statistics & Numerical Data]
MH  - Humans
MH  - Male
MH  - Practice Guidelines as Topic
MH  - Thromboembolism/et [Etiology]
MH  - *Thromboembolism/pc [Prevention & Control]
KW  - Elderly;  atrial fibrillation;  bleeding risk;  frailty;  oral anticoagulants;  stroke prevention
AB  - Atrial fibrillation is a common condition in the elderly, and the incidence of thromboembolic events secondary to atrial fibrillation increases with age. Antithrombotic therapy effectively prevents stroke and systemic embolism but also exposes patients to the risk of bleeding. Because the risk of bleeding also increases with age, clinicians tend to withhold anticoagulation in the elderly. Anticoagulation is particularly complex in the frail elderly patient, who presents additional risk factors affecting both efficacy and safety of thromboembolic prevention. The main clinical trials rarely include frail elderly patients and, consequently, the guidelines do not provide guidance for their management. In the absence of clear indications for this class of patients, we identified some areas that should be taken into account both before starting and when discontinuing anticoagulation: comorbidities, polypharmacotherapy, adherence, cognitive impairment, mobility and monitoring barriers, nutritional status and swallowing disorders, risk of falls, and reduced life expectancy. We also suggest a multidimensional algorithm covering both a standard ischemic and bleeding risk assessment and an additional anticoagulation-focused frailty assessment. This is of particular relevance given the recent introduction of the oral direct inhibitors, as they are likely to widen the treatment options for the frail elderly. Depending on which aspect of frailty is present, anticoagulation can now be tailored accordingly. Copyright © 2015 AMDA - The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Anticoagulants)
ES  - 1538-9375
IL  - 1525-8610
DI  - S1525-8610(14)00803-2
DO  - http://dx.doi.org/10.1016/j.jamda.2014.12.008
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20150211
DP  - 2015 May 1
DC  - 20150430
YR  - 2015
ED  - 20160303
UP  - 20160304
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25680239

<55. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26078311
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Borne Y
AU  - Barregard L
AU  - Persson M
AU  - Hedblad B
AU  - Fagerberg B
AU  - Engstrom G
FA  - Borne, Yan
FA  - Barregard, Lars
FA  - Persson, Margaretha
FA  - Hedblad, Bo
FA  - Fagerberg, Bjorn
FA  - Engstrom, Gunnar
IN  - Borne,Yan. Department of Clinical Sciences in Malmo, Lund University, Malmo, Sweden.
IN  - Barregard,Lars. Department of Occupational and Environmental Medicine, Sahlgrenska University Hospital and University of Gothenburg, Gothenburg, Sweden.
IN  - Persson,Margaretha. Department of Clinical Sciences in Malmo, Lund University, Malmo, Sweden Clinical Research Unit, Emergency Department, Skane University Hospital, Malmo, Sweden.
IN  - Hedblad,Bo. Department of Clinical Sciences in Malmo, Lund University, Malmo, Sweden.
IN  - Fagerberg,Bjorn. Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
IN  - Engstrom,Gunnar. Department of Clinical Sciences in Malmo, Lund University, Malmo, Sweden.
TI  - Cadmium exposure and incidence of heart failure and atrial fibrillation: a population-based prospective cohort study.
SO  - BMJ Open. 5(6):e007366, 2015.
AS  - BMJ Open. 5(6):e007366, 2015.
NJ  - BMJ open
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 101552874
OI  - Source: NLM. PMC4480021
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - *Atrial Fibrillation/bl [Blood]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Biomarkers/bl [Blood]
MH  - Cadmium/bl [Blood]
MH  - *Cadmium Poisoning/bl [Blood]
MH  - *Cadmium Poisoning/ep [Epidemiology]
MH  - Cohort Studies
MH  - Female
MH  - *Heart Failure/bl [Blood]
MH  - *Heart Failure/ep [Epidemiology]
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Factors
MH  - Sweden/ep [Epidemiology]
KW  - EPIDEMIOLOGY;  PUBLIC HEALTH;  TOXICOLOGY
AB  - OBJECTIVES: Cadmium is a non-essential toxic metal with multiple adverse health effects. Cadmium has been shown to be associated with cardiovascular diseases, but few studies have investigated heart failure (HF) and none of them reported atrial fibrillation (AF). We examined whether cadmium exposure is associated with incidence of HF or AF.
AB  - DESIGN: A prospective, observational cohort study with a 17-year follow-up.
AB  - SETTING: The city of Malmo, Sweden.
AB  - PARTICIPANTS: Blood cadmium levels were measured in 4378 participants without a history of HF or AF (aged 46-67 years, 60% women), who participated in the Malmo Diet and Cancer (MDC) study during 1992-1994.
AB  - PRIMARY AND SECONDARY OUTCOME MEASURES: Incidence of HF and AF were identified from the Swedish hospital discharge register.
AB  - RESULTS: 143 participants (53% men) were diagnosed with new-onset HF and 385 individuals (52% men) were diagnosed with new-onset AF during follow-up for 17 years. Blood cadmium in the sex-specific 4th quartile of the distribution was significantly associated with incidence of HF. The (HR, 4th vs 1st quartile) was 2.64 (95% CI 1.60 to 4.36), adjusted for age, and 1.95 (1.02 to 3.71) after adjustment also for conventional risk factors and biomarkers. The blood cadmium level was not significantly associated with risk of incident AF.
AB  - CONCLUSIONS: Blood cadmium levels in the 4th quartile were associated with increased incidence of HF in this cohort with comparatively low exposure to cadmium. Incidence of AF was not associated with cadmium.Copyright Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
RN  - 0 (Biomarkers)
RN  - 00BH33GNGH (Cadmium)
ES  - 2044-6055
DO  - http://dx.doi.org/10.1136/bmjopen-2014-007366
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20150615
DP  - 2015
DC  - 20150616
YR  - 2015
ED  - 20160302
RD  - 20150703
UP  - 20160303
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26078311

<56. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26078311
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Borne Y
AU  - Barregard L
AU  - Persson M
AU  - Hedblad B
AU  - Fagerberg B
AU  - Engstrom G
FA  - Borne, Yan
FA  - Barregard, Lars
FA  - Persson, Margaretha
FA  - Hedblad, Bo
FA  - Fagerberg, Bjorn
FA  - Engstrom, Gunnar
IN  - Borne,Yan. Department of Clinical Sciences in Malmo, Lund University, Malmo, Sweden.
IN  - Barregard,Lars. Department of Occupational and Environmental Medicine, Sahlgrenska University Hospital and University of Gothenburg, Gothenburg, Sweden.
IN  - Persson,Margaretha. Department of Clinical Sciences in Malmo, Lund University, Malmo, Sweden Clinical Research Unit, Emergency Department, Skane University Hospital, Malmo, Sweden.
IN  - Hedblad,Bo. Department of Clinical Sciences in Malmo, Lund University, Malmo, Sweden.
IN  - Fagerberg,Bjorn. Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
IN  - Engstrom,Gunnar. Department of Clinical Sciences in Malmo, Lund University, Malmo, Sweden.
TI  - Cadmium exposure and incidence of heart failure and atrial fibrillation: a population-based prospective cohort study.
SO  - BMJ Open. 5(6):e007366, 2015.
AS  - BMJ Open. 5(6):e007366, 2015.
NJ  - BMJ open
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 101552874
OI  - Source: NLM. PMC4480021
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - *Atrial Fibrillation/bl [Blood]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Biomarkers/bl [Blood]
MH  - Cadmium/bl [Blood]
MH  - *Cadmium Poisoning/bl [Blood]
MH  - *Cadmium Poisoning/ep [Epidemiology]
MH  - Cohort Studies
MH  - Female
MH  - *Heart Failure/bl [Blood]
MH  - *Heart Failure/ep [Epidemiology]
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Factors
MH  - Sweden/ep [Epidemiology]
KW  - EPIDEMIOLOGY;  PUBLIC HEALTH;  TOXICOLOGY
AB  - OBJECTIVES: Cadmium is a non-essential toxic metal with multiple adverse health effects. Cadmium has been shown to be associated with cardiovascular diseases, but few studies have investigated heart failure (HF) and none of them reported atrial fibrillation (AF). We examined whether cadmium exposure is associated with incidence of HF or AF.
AB  - DESIGN: A prospective, observational cohort study with a 17-year follow-up.
AB  - SETTING: The city of Malmo, Sweden.
AB  - PARTICIPANTS: Blood cadmium levels were measured in 4378 participants without a history of HF or AF (aged 46-67 years, 60% women), who participated in the Malmo Diet and Cancer (MDC) study during 1992-1994.
AB  - PRIMARY AND SECONDARY OUTCOME MEASURES: Incidence of HF and AF were identified from the Swedish hospital discharge register.
AB  - RESULTS: 143 participants (53% men) were diagnosed with new-onset HF and 385 individuals (52% men) were diagnosed with new-onset AF during follow-up for 17 years. Blood cadmium in the sex-specific 4th quartile of the distribution was significantly associated with incidence of HF. The (HR, 4th vs 1st quartile) was 2.64 (95% CI 1.60 to 4.36), adjusted for age, and 1.95 (1.02 to 3.71) after adjustment also for conventional risk factors and biomarkers. The blood cadmium level was not significantly associated with risk of incident AF.
AB  - CONCLUSIONS: Blood cadmium levels in the 4th quartile were associated with increased incidence of HF in this cohort with comparatively low exposure to cadmium. Incidence of AF was not associated with cadmium.Copyright Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
RN  - 0 (Biomarkers)
RN  - 00BH33GNGH (Cadmium)
ES  - 2044-6055
IL  - 2044-6055
DO  - http://dx.doi.org/10.1136/bmjopen-2014-007366
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20150615
DP  - 2015
DC  - 20150616
YR  - 2015
ED  - 20160302
RD  - 20160603
UP  - 20160606
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=26078311

<57. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25766513
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Tashiro N
AU  - Takahashi S
AU  - Takasaki T
AU  - Katayama K
AU  - Taguchi T
AU  - Watanabe M
AU  - Kurosaki T
AU  - Imai K
AU  - Kimura H
AU  - Sueda T
FA  - Tashiro, Naonori
FA  - Takahashi, Shinya
FA  - Takasaki, Taiichi
FA  - Katayama, Keijiro
FA  - Taguchi, Takahiro
FA  - Watanabe, Masazumi
FA  - Kurosaki, Tatsuya
FA  - Imai, Katsuhiko
FA  - Kimura, Hiroaki
FA  - Sueda, Taijiro
IN  - Tashiro,Naonori. Department of Rehabilitation, Hiroshima University Hospital.
TI  - Efficacy of cardiopulmonary rehabilitation with adaptive servo-ventilation in patients undergoing off-pump coronary artery bypass grafting.
CM  - Comment in: Circ J. 2015;79(6):1204-5; PMID: 25925978
SO  - Circulation Journal. 79(6):1290-8, 2015.
AS  - Circ J. 79(6):1290-8, 2015.
NJ  - Circulation journal : official journal of the Japanese Circulation Society
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101137683
SB  - Index Medicus
CP  - Japan
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/pc [Prevention & Control]
MH  - Breathing Exercises
MH  - Cardiovascular Agents/tu [Therapeutic Use]
MH  - Combined Modality Therapy
MH  - Comorbidity
MH  - *Coronary Artery Bypass, Off-Pump/rh [Rehabilitation]
MH  - Coronary Disease/pp [Physiopathology]
MH  - *Coronary Disease/rh [Rehabilitation]
MH  - Coronary Disease/su [Surgery]
MH  - Coronary Disease/us [Ultrasonography]
MH  - Exercise Test
MH  - Exercise Therapy
MH  - Female
MH  - Hemodynamics
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Oxygen Inhalation Therapy
MH  - Positive-Pressure Respiration/is [Instrumentation]
MH  - *Positive-Pressure Respiration/mt [Methods]
MH  - Postoperative Care/is [Instrumentation]
MH  - *Postoperative Care/mt [Methods]
MH  - Postoperative Complications/ep [Epidemiology]
MH  - Postoperative Complications/et [Etiology]
MH  - *Postoperative Complications/pc [Prevention & Control]
MH  - Pulmonary Ventilation
MH  - Respiration Disorders/ep [Epidemiology]
MH  - Respiration Disorders/et [Etiology]
MH  - Respiration Disorders/pc [Prevention & Control]
AB  - BACKGROUND: Postoperative complications after cardiac surgery increase mortality. This study aimed to evaluate the efficacy of cardiopulmonary rehabilitation with adaptive servo-ventilation (ASV) in patients undergoing off-pump coronary artery bypass grafting (OPCAB).
AB  - METHODS AND RESULTS: A total of 66 patients undergoing OPCAB were enrolled and divided into 2 groups according to the use of ASV (ASV group, 30 patients; non-ASV group, 36 patients). During the perioperative period, all patients undertook cardiopulmonary rehabilitation. ASV was used from postoperative day (POD) 1 to POD5. Hemodynamics showed a different pattern in the 2 groups. Blood pressure (BP) on POD6 in the ASV group was significantly lower than that in the non-ASV group (systolic BP, 112.9+/-12.6 vs. 126.2+/-15.8 mmHg, P=0.0006; diastolic BP, 62.3+/-9.1 vs. 67.6+/-9.3 mmHg, P=0.0277). The incidence of postoperative atrial fibrillation (POAF) was lower in the ASV group than in the non-ASV group (10% vs. 33%, P=0.0377). The duration of oxygen inhalation in the ASV group was significantly shorter than that in the non-ASV group (5.1+/-2.2 vs. 7.6+/-6.0 days, P=0.0238). The duration of postoperative hospitalization was significantly shorter in the ASV group than in the non-ASV group (23.5+/-6.6 vs. 29.0+/-13.1 days, P=0.0392).
AB  - CONCLUSIONS: Cardiopulmonary rehabilitation with ASV after OPCAB reduces both POAF occurrence and the duration of hospitalization.
RN  - 0 (Cardiovascular Agents)
ES  - 1347-4820
IL  - 1346-9843
DO  - http://dx.doi.org/10.1253/circj.CJ-14-1078
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
EP  - 20150313
DP  - 2015
DC  - 20150525
YR  - 2015
ED  - 20160301
UP  - 20160302
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25766513

<58. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25944628
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Schmiegelow MD
AU  - Hedlin H
AU  - Stefanick ML
AU  - Mackey RH
AU  - Allison M
AU  - Martin LW
AU  - Robinson JG
AU  - Hlatky MA
FA  - Schmiegelow, Michelle D
FA  - Hedlin, Haley
FA  - Stefanick, Marcia L
FA  - Mackey, Rachel H
FA  - Allison, Matthew
FA  - Martin, Lisa W
FA  - Robinson, Jennifer G
FA  - Hlatky, Mark A
IN  - Schmiegelow,Michelle D. From the The Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA (M.D.S., M.A.H.); Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark (M.D.S.); The Department of Medicine, Stanford University School of Medicine, Stanford, CA (H.H., M.L.S., M.A.H.); Department of Epidemiology Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA (R.H.M.); Department of Family and Preventive Medicine, University of California, San Diego (M.A.); Division of Cardiology, George Washington University School of Medicine and Health Sciences, Washington, DC (L.W.M.); and Department of Epidemiology, College of Public Health, University of Iowa, Iowa City (J.G.R.). mdschmiegelow@gmail.com.
IN  - Hedlin,Haley. From the The Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA (M.D.S., M.A.H.); Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark (M.D.S.); The Department of Medicine, Stanford University School of Medicine, Stanford, CA (H.H., M.L.S., M.A.H.); Department of Epidemiology Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA (R.H.M.); Department of Family and Preventive Medicine, University of California, San Diego (M.A.); Division of Cardiology, George Washington University School of Medicine and Health Sciences, Washington, DC (L.W.M.); and Department of Epidemiology, College of Public Health, University of Iowa, Iowa City (J.G.R.).
IN  - Stefanick,Marcia L. From the The Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA (M.D.S., M.A.H.); Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark (M.D.S.); The Department of Medicine, Stanford University School of Medicine, Stanford, CA (H.H., M.L.S., M.A.H.); Department of Epidemiology Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA (R.H.M.); Department of Family and Preventive Medicine, University of California, San Diego (M.A.); Division of Cardiology, George Washington University School of Medicine and Health Sciences, Washington, DC (L.W.M.); and Department of Epidemiology, College of Public Health, University of Iowa, Iowa City (J.G.R.).
IN  - Mackey,Rachel H. From the The Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA (M.D.S., M.A.H.); Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark (M.D.S.); The Department of Medicine, Stanford University School of Medicine, Stanford, CA (H.H., M.L.S., M.A.H.); Department of Epidemiology Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA (R.H.M.); Department of Family and Preventive Medicine, University of California, San Diego (M.A.); Division of Cardiology, George Washington University School of Medicine and Health Sciences, Washington, DC (L.W.M.); and Department of Epidemiology, College of Public Health, University of Iowa, Iowa City (J.G.R.).
IN  - Allison,Matthew. From the The Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA (M.D.S., M.A.H.); Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark (M.D.S.); The Department of Medicine, Stanford University School of Medicine, Stanford, CA (H.H., M.L.S., M.A.H.); Department of Epidemiology Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA (R.H.M.); Department of Family and Preventive Medicine, University of California, San Diego (M.A.); Division of Cardiology, George Washington University School of Medicine and Health Sciences, Washington, DC (L.W.M.); and Department of Epidemiology, College of Public Health, University of Iowa, Iowa City (J.G.R.).
IN  - Martin,Lisa W. From the The Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA (M.D.S., M.A.H.); Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark (M.D.S.); The Department of Medicine, Stanford University School of Medicine, Stanford, CA (H.H., M.L.S., M.A.H.); Department of Epidemiology Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA (R.H.M.); Department of Family and Preventive Medicine, University of California, San Diego (M.A.); Division of Cardiology, George Washington University School of Medicine and Health Sciences, Washington, DC (L.W.M.); and Department of Epidemiology, College of Public Health, University of Iowa, Iowa City (J.G.R.).
IN  - Robinson,Jennifer G. From the The Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA (M.D.S., M.A.H.); Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark (M.D.S.); The Department of Medicine, Stanford University School of Medicine, Stanford, CA (H.H., M.L.S., M.A.H.); Department of Epidemiology Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA (R.H.M.); Department of Family and Preventive Medicine, University of California, San Diego (M.A.); Division of Cardiology, George Washington University School of Medicine and Health Sciences, Washington, DC (L.W.M.); and Department of Epidemiology, College of Public Health, University of Iowa, Iowa City (J.G.R.).
IN  - Hlatky,Mark A. From the The Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA (M.D.S., M.A.H.); Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark (M.D.S.); The Department of Medicine, Stanford University School of Medicine, Stanford, CA (H.H., M.L.S., M.A.H.); Department of Epidemiology Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA (R.H.M.); Department of Family and Preventive Medicine, University of California, San Diego (M.A.); Division of Cardiology, George Washington University School of Medicine and Health Sciences, Washington, DC (L.W.M.); and Department of Epidemiology, College of Public Health, University of Iowa, Iowa City (J.G.R.).
TI  - Insulin Resistance and Risk of Cardiovascular Disease in Postmenopausal Women: A Cohort Study From the Women's Health Initiative.
SO  - Circulation. Cardiovascular Quality & Outcomes. 8(3):309-16, 2015 May.
AS  - Circ Cardiovasc Qual Outcomes. 8(3):309-16, 2015 May.
NJ  - Circulation. Cardiovascular quality and outcomes
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101489148
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Body Mass Index
MH  - *Cardiovascular Diseases
MH  - Cohort Studies
MH  - Exercise
MH  - Female
MH  - Humans
MH  - *Insulin Resistance
MH  - Middle Aged
MH  - *Postmenopause
MH  - Risk Assessment
MH  - Risk Factors
MH  - Women's Health
KW  - coronary heart disease;  insulin resistance;  ischemic stroke;  women
AB  - BACKGROUND: Insulin resistance is associated with diabetes mellitus, but it is uncertain whether it improves cardiovascular disease (CVD) risk prediction beyond traditional cardiovascular risk factors.
AB  - METHODS AND RESULTS: We identified 15,288 women from the Women's Health Initiative Biomarkers studies with no history of CVD, atrial fibrillation, or diabetes mellitus at baseline (1993-1998). We assessed the prognostic value of adding fasting serum insulin, HOMA-IR (homeostasis model assessment-insulin resistance), serum-triglyceride-to-serum-high-density lipoprotein-cholesterol ratio TG/HDL-C, or impaired fasting glucose (serum glucose >110 mg/dL) to traditional risk factors in separate Cox multivariable analyses and assessed risk discrimination and reclassification. The study end point was major CVD events (nonfatal and fatal coronary heart disease and ischemic stroke) within 10 years, which occurred in 894 (5.8%) women. Insulin resistance was associated with CVD risk after adjusting for age and race/ethnicity with hazard ratios (95% confidence interval [CI]) per doubling in insulin of 1.21 (CI, 1.12-1.31), in HOMA-IR of 1.19 (CI, 1.11-1.28), in TG/HDL-C of 1.35 (CI, 1.26-1.45), and for impaired fasting glucose of 1.31 (CI, 1.05-1.64). Although insulin, HOMA-IR, and TG/HDL-C remained associated with increased CVD risk after adjusting for most CVD risk factors, none remained significant after adjusting for HDL-C: hazard ratios for insulin, 1.06 (CI, 0.98-1.16); for HOMA-IR, 1.06 (CI, 0.98-1.15); for TG/HDL-C, 1.11 (CI, 0.99-1.25); and for glucose, 1.20 (CI, 0.96-1.50). Insulin resistance measures did not improve CVD risk discrimination and reclassification.
AB  - CONCLUSIONS: Measures of insulin resistance were no longer associated with CVD risk after adjustment for high-density lipoprotein-cholesterol and did not provide independent prognostic information in postmenopausal women without diabetes mellitus.
AB  - CLINICAL TRIAL REGISTRATION INFORMATION: URL: http://www.clinicaltrial.gov. Unique identifier: NCT00000611.Copyright © 2015 American Heart Association, Inc.
ES  - 1941-7705
IL  - 1941-7713
DO  - http://dx.doi.org/10.1161/CIRCOUTCOMES.114.001563
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
SI  - ClinicalTrials.gov
SA  - ClinicalTrials.gov/NCT00000611
SL  - http://clinicaltrials.gov/search/term=NCT00000611
NO  - HHSN268201100001C (United States PHS HHS)
NO  - HHSN268201100002C (United States PHS HHS)
NO  - HHSN268201100003C (United States PHS HHS)
NO  - HHSN268201100004C (United States PHS HHS)
NO  - HHSN268201100046C (United States PHS HHS)
LG  - English
EP  - 20150505
DP  - 2015 May
DC  - 20150520
YR  - 2015
ED  - 20160301
UP  - 20160302
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25944628

<59. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26102886
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Goncalves-Rosa N
AU  - Tavares C
AU  - Nunes-Da-Silva C
AU  - Geraldes V
AU  - Rocha I
FA  - Goncalves-Rosa, N
FA  - Tavares, C
FA  - Nunes-Da-Silva, C
FA  - Geraldes, V
FA  - Rocha, I
IN  - Goncalves-Rosa,N. 1Instituto de Medicina Molecular & Faculdade de Medicina da Universidade de Lisboa, Lisbon, PORTUGAL 2Faculdade de Medicina da Universidade de Lisboa, Lisbon, PORTUGAL 3Centro de Cardiologia da Universidade de Lisboa & Faculdade de Medicina da Universidade de Lisboa, Lisbon, PORTUGAL.
TI  - 5A.04: AN INCREASED VAGAL TONUS IS CRITICAL FOR THE INDUCTION AND MAINTENANCE OF ATRIAL FIBRILLATION IN A SYMPATHOEXCITATORY BACKGROUND AS METABOLIC SYNDROME.
SO  - Journal of Hypertension. 33 Suppl 1:e65, 2015 Jun.
AS  - J Hypertens. 33 Suppl 1:e65, 2015 Jun.
NJ  - Journal of hypertension
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - iew, 8306882
CP  - England
AB  - OBJECTIVE: Evaluate the effects of acute vagal stimulation on atrial conduction, atria and pulmonary veins (PV) refractoriness and AFib inducibility in a MetS rabbit model.
AB  - DESIGN AND METHOD: MetS was induced in male NZW rabbits, 8 weeks, by a high sucrose diet given for 6 months, after which, under anaesthesia, a thoracotomy was performed to expose the heart. An array of 5 microelectrodes was placed in PV vicinity and in the atrial epicardium to record cardiac electrograms. The right vagus nerve was prepared for electrical stimulation (1ms, 50 Hz, ~100 muA). ECG electrodes were placed in 3 of the 4 limbs. The epicardial recordings were made in sinus rhythm. Stimulation bursts (10 s, 50 Hz) were used, alone or combined with vagal stimulation, in the right atrial appendage, left atrial appendage and PV to evaluate AFib inducibility. The effective refractory periods (ERP) and conduction times from the high-lateral right atrium to the high-lateral left atrium and PV were quantified before and after vagal stimulation. Heart rate variability using Fast Fourier Transform (FFT) was applied on autonomic evaluation. A control group matching age and sex was used.
AB  - RESULTS: AFib inducibility was greater in MetS-rabbits with a 50 Hz pacing (38 +/- 7% vs 21 +/- 7%) and after vagal stimulation (53 +/- 6% vs 33 +/- 4%). The evoked AFib duration was longer in MetS rabbits than in controls and increased significantly after vagal stimulation. ERPs were lower in MetS rabbits and decreased at all evaluated sites during vagal stimulation. MetS-rabbits had an higher interatrial conduction time than controls (22 +/- 1 vs 11 +/- 1ms, p < 0.05). FFT analysis confirmed a sympathoexcitatory condition in MetS comparing to controls (0.40 +/- 0.09 vs 0.11 +/- 0.06mmHg2, p < 0.05).
AB  - CONCLUSIONS: Despite MetS-rabbits have an increased basal sympathetic activity which favoured AFib induction, a simultaneous increased vagal tonus seems to be critical not only for the inducibility but also for the maintenance of AFib in this animal model of MetS.
ES  - 1473-5598
IL  - 0263-6352
DO  - http://dx.doi.org/10.1097/01.hjh.0000467520.36510.9f
PT  - Journal Article
LG  - English
DP  - 2015 Jun
DC  - 20150624
YR  - 2015
ED  - 20160301
UP  - 20160302
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=26102886

<60. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25608614
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ogah OS
AU  - Davison BA
AU  - Sliwa K
AU  - Mayosi BM
AU  - Damasceno A
AU  - Sani MU
AU  - Mondo C
AU  - Dzudie A
AU  - Ojji DB
AU  - Kouam C
AU  - Suliman A
AU  - Schrueder N
AU  - Yonga G
AU  - Ba SA
AU  - Maru F
AU  - Alemayehu B
AU  - Edwards C
AU  - Cotter G
FA  - Ogah, Okechukwu S
FA  - Davison, Beth A
FA  - Sliwa, Karen
FA  - Mayosi, Bongani M
FA  - Damasceno, Albertino
FA  - Sani, Mahmoud U
FA  - Mondo, Charles
FA  - Dzudie, Anastase
FA  - Ojji, Dike B
FA  - Kouam, Charles
FA  - Suliman, Ahmed
FA  - Schrueder, Neshaad
FA  - Yonga, Gerald
FA  - Ba, Sergine Abdou
FA  - Maru, Fikru
FA  - Alemayehu, Bekele
FA  - Edwards, Christopher
FA  - Cotter, Gad
IN  - Ogah,Okechukwu S. Division of Cardiovascular Medicine, Department of Medicine, University College Hospital, Ibadan, 5116, Nigeria, osogah56156@gmail.com.
TI  - Gender differences in clinical characteristics and outcome of acute heart failure in sub-Saharan Africa: results of the THESUS-HF study.
SO  - Clinical Research in Cardiology. 104(6):481-90, 2015 Jun.
AS  - Clin. res. cardiol.. 104(6):481-90, 2015 Jun.
NJ  - Clinical research in cardiology : official journal of the German Cardiac Society
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101264123
SB  - Index Medicus
CP  - Germany
MH  - Acute Disease
MH  - Adult
MH  - Africa South of the Sahara/ep [Epidemiology]
MH  - Age Factors
MH  - Aged
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - Female
MH  - Heart Failure/ep [Epidemiology]
MH  - Heart Failure/et [Etiology]
MH  - *Heart Failure/pp [Physiopathology]
MH  - Heart Valve Diseases/ep [Epidemiology]
MH  - Humans
MH  - *Hypertension/ep [Epidemiology]
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Factors
MH  - Sex Factors
MH  - *Smoking/ep [Epidemiology]
AB  - BACKGROUND: The impact of gender on the clinical characteristics, risk factors, co-morbidities, etiology, treatment and outcome of acute heart failure in sub-Saharan Africa has not been described before. The aim of this study was to evaluate the sex differences in acute heart failure in sub-Saharan Africa using the data from The sub-Saharan Africa Survey of Heart Failure (THESUS-HF).
AB  - METHODS AND RESULTS: 1,006 subjects were recruited into this prospective multicenter, international observational heart failure survey. The mean age of total population was 52.4 years (54.0 years for men and 50.7 years for women). The men were significantly older (p = 0.0045). Men also presented in poorer NYHA functional class (III and IV), p = 0.0364). Cigarette smoking and high blood pressure were significantly commoner in men (17.3 vs. 2.6% and 60.0 vs. 51.0% respectively). On the other hand, atrial fibrillation and valvular heart disease were significantly more frequent in women. The mean hemoglobin concentration was lower in women compared to men (11.7 vs. 12.6 g/dl, p < 0.0001), while the blood urea and creatinine levels were higher in men (p < 0.0001). LV systolic dysfunctional was also seen more in men. Men also had higher E/A ratio indicating higher LV filling pressure. Outcomes were similar in both sexes.
AB  - CONCLUSIONS: Although the outcome of patients admitted for AHF in sub-Saharan regions is similar in men and women, some gender differences are apparent suggesting that in men more emphasis should be put on modifiable life risk factors, while in women prevention of rheumatic heart diseases and improved nutrition should be addressed vigorously.
ES  - 1861-0692
IL  - 1861-0684
DO  - http://dx.doi.org/10.1007/s00392-015-0810-y
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
LG  - English
EP  - 20150122
DP  - 2015 Jun
DC  - 20150528
YR  - 2015
ED  - 20160223
UP  - 20160224
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25608614

<61. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25828628
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kim YE
AU  - Woo HI
AU  - On YK
AU  - Kim JS
AU  - Lee SY
FA  - Kim, Y-E
FA  - Woo, H I
FA  - On, Y K
FA  - Kim, J S
FA  - Lee, S-Y
IN  - Kim,Y-E. Departments of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
IN  - Woo,H I. Departments of Laboratory Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.
IN  - On,Y K. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
IN  - Kim,J S. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
IN  - Lee,S-Y. 1] Departments of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea [2] Department of Clinical Pharmacology and Therapeutics, Samsung Medical Center, Seoul, Korea.
TI  - High intra- and inter-individual variability of plasma vitamin K concentrations in patients with atrial fibrillation under warfarin therapy.
SO  - European Journal of Clinical Nutrition. 69(6):703-6, 2015 Jun.
AS  - Eur J Clin Nutr. 69(6):703-6, 2015 Jun.
NJ  - European journal of clinical nutrition
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - ejc, 8804070
SB  - Index Medicus
CP  - England
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Anticoagulants/ae [Adverse Effects]
MH  - Anticoagulants/bl [Blood]
MH  - Anticoagulants/pk [Pharmacokinetics]
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/bl [Blood]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Diet/ae [Adverse Effects]
MH  - Drug Monitoring
MH  - Enzyme Inhibitors/ae [Adverse Effects]
MH  - Enzyme Inhibitors/bl [Blood]
MH  - Enzyme Inhibitors/pk [Pharmacokinetics]
MH  - Enzyme Inhibitors/tu [Therapeutic Use]
MH  - Female
MH  - *Food-Drug Interactions
MH  - Hematuria/ci [Chemically Induced]
MH  - Humans
MH  - International Normalized Ratio
MH  - Male
MH  - Middle Aged
MH  - *Nutritional Status/de [Drug Effects]
MH  - Republic of Korea
MH  - Retrospective Studies
MH  - Vitamin K/ae [Adverse Effects]
MH  - *Vitamin K/ai [Antagonists & Inhibitors]
MH  - Vitamin K/bl [Blood]
MH  - Vitamin K/tu [Therapeutic Use]
MH  - *Vitamin K Deficiency/ci [Chemically Induced]
MH  - Vitamin K Deficiency/pc [Prevention & Control]
MH  - Vitamin K Epoxide Reductases/ai [Antagonists & Inhibitors]
MH  - Vitamin K Epoxide Reductases/me [Metabolism]
MH  - *Warfarin/ae [Adverse Effects]
MH  - Warfarin/bl [Blood]
MH  - Warfarin/pk [Pharmacokinetics]
MH  - Warfarin/tu [Therapeutic Use]
AB  - BACKGROUND/OBJECTIVES: Vitamin K intake is considered as a controllable contributor to warfarin sensitivity. It is restricted in warfarin-treated patients. However, little study has assessed the vitamin K status in warfarin-treated patients. We directly measured plasma vitamin K in warfarin-treated patients and evaluated its effect on anticoagulation.
AB  - SUBJECTS/METHODS: A total of 302 plasma vitamin K concentrations were assessed using high-performance liquid chromatography for 203 outpatients with atrial fibrillation under warfarin treatment. Clinical and laboratory information including warfarin dosage, plasma warfarin concentrations, prothrombin time international normalized ratio (PT INR) and CYP2C9/VKORC1 genotypes was reviewed retrospectively. The anticoagulation stability (intra-individual variability, frequency of PT INR tests and complications) was investigated in 163 patients with long-term warfarin therapy. Plasma vitamin K was measured in 40 healthy subjects and in 40 patients before and after initial warfarin treatment.
AB  - RESULTS: Vitamin K concentrations were significantly decreased after the initiation of warfarin treatment (before treatment: 1.72ng/ml; after treatment: 0.59ng/ml, P<0.05). There was a large inter-individual variability in vitamin K levels (0.2-4.2ng/ml) in warfarin-treated patients. PT INR was more frequently checked in patients with low plasma vitamin K levels than in those with high vitamin K levels (9.5 times/year vs 7.5 times/year, P=0.029). Two patients with gross hematuria showed very low vitamin K levels (<0.4ng/ml).
AB  - CONCLUSIONS: We found high inter- and intra-individual variability in vitamin K concentration in warfarin-treated patients. Low vitamin K concentration in warfarin-treated patients suggested excessive dietary restriction. Plasma vitamin K measurement would be helpful for dietary control and anticoagulation stability.
RN  - 0 (Anticoagulants)
RN  - 0 (Enzyme Inhibitors)
RN  - 12001-79-5 (Vitamin K)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - EC 1-1-4-1 (Vitamin K Epoxide Reductases)
ES  - 1476-5640
IL  - 0954-3007
DO  - http://dx.doi.org/10.1038/ejcn.2015.41
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20150401
DP  - 2015 Jun
DC  - 20150603
YR  - 2015
ED  - 20160222
UP  - 20160223
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25828628

<62. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25691245
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Muscari A
AU  - Puddu GM
AU  - Conte C
AU  - Falcone R
AU  - Kolce B
AU  - Lega MV
AU  - Zoli M
FA  - Muscari, A
FA  - Puddu, G M
FA  - Conte, C
FA  - Falcone, R
FA  - Kolce, B
FA  - Lega, M V
FA  - Zoli, M
IN  - Muscari,A. Stroke Unit-Medical Department of Continuity of Care and Disability, S.Orsola-Malpighi Hospital, Bologna, Italy.
IN  - Muscari,A. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
IN  - Puddu,G M. Stroke Unit-Medical Department of Continuity of Care and Disability, S.Orsola-Malpighi Hospital, Bologna, Italy.
IN  - Conte,C. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
IN  - Falcone,R. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
IN  - Kolce,B. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
IN  - Lega,M V. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
IN  - Zoli,M. Stroke Unit-Medical Department of Continuity of Care and Disability, S.Orsola-Malpighi Hospital, Bologna, Italy.
IN  - Zoli,M. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
TI  - Clinical predictors of fever in stroke patients: relevance of nasogastric tube.
SO  - Acta Neurologica Scandinavica. 132(3):196-202, 2015 Sep.
AS  - Acta Neurol Scand. 132(3):196-202, 2015 Sep.
NJ  - Acta neurologica Scandinavica
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 0370336
SB  - Index Medicus
CP  - Denmark
MH  - Aged
MH  - Female
MH  - *Fever/et [Etiology]
MH  - Humans
MH  - *Intubation, Gastrointestinal/ae [Adverse Effects]
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Odds Ratio
MH  - Prognosis
MH  - Risk Factors
MH  - *Stroke/co [Complications]
MH  - United States
KW  - determinants;  fever;  nasogastric tube;  risk factors;  stroke
AB  - OBJECTIVES: Fever frequently occurs in stroke patients and worsens their prognosis. However, only few studies have assessed the determinants of fever in acute stroke, and no study has specifically addressed the possible prediction of the development of fever.
AB  - MATERIALS AND METHODS: This investigation included 536 patients with acute stroke and a body temperature <=37degreeC during the first 24 h of stay. Ninety-two of them (17.2%) subsequently developed fever (defined as a temperature >=37.5degreeC starting after 24 h). Among the clinical variables available during the first 24 h from admission, those predictive of the subsequent appearance of fever were searched for. One hundred further patients had a temperature >37degreeC during the first 24 h.
AB  - RESULTS: In univariate analysis, many variables were predictive of the subsequent development of fever, but in multivariate analysis, only the following four predictors remained significant (odds ratio [95% confidence interval], P value): nasogastric tube (4.0 [2.2-7.4], <0.0001), atrial fibrillation (2.3 [1.4-3.8], 0.001), total anterior circulation syndrome (2.0 [1.2-3.5], 0.01), and urinary catheter (1.9 [1.1-3.3], 0.01). Among the 52 (9.7%) patients with three or four predictors, 31 (59.6%) subsequently developed fever. In addition, the factors independently associated with a temperature >37degreeC during the first 24 h were as follows: National Institutes of Health Stroke Scale (P < 0.0001), hemorrhagic stroke (P = 0.0008), atrial fibrillation (P = 0.002), and total parenteral nutrition (P = 0.03).
AB  - CONCLUSIONS: In patients with acute stroke, four clinical variables were found to be independently associated with the risk of developing fever and, of them, nasogastric tube was the strongest and most significant one.Copyright © 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
ES  - 1600-0404
IL  - 0001-6314
DO  - http://dx.doi.org/10.1111/ane.12383
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20150218
DP  - 2015 Sep
DC  - 20150716
YR  - 2015
ED  - 20160218
UP  - 20160219
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25691245

<63. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26607287
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Eijsvogels TM
AU  - Fernandez AB
AU  - Thompson PD
FA  - Eijsvogels, Thijs M H
FA  - Fernandez, Antonio B
FA  - Thompson, Paul D
IN  - Eijsvogels,Thijs M H. Department of Cardiology, Hartford Hospital, Hartford, Connecticut; and Department of Physiology, Radboud University Medical Center, Nijmegen, The Netherlands.
IN  - Fernandez,Antonio B. Department of Cardiology, Hartford Hospital, Hartford, Connecticut; and Department of Physiology, Radboud University Medical Center, Nijmegen, The Netherlands.
IN  - Thompson,Paul D. Department of Cardiology, Hartford Hospital, Hartford, Connecticut; and Department of Physiology, Radboud University Medical Center, Nijmegen, The Netherlands.
TI  - Are There Deleterious Cardiac Effects of Acute and Chronic Endurance Exercise?. [Review]
SO  - Physiological Reviews. 96(1):99-125, 2016 Jan.
AS  - Physiol Rev. 96(1):99-125, 2016 Jan.
NJ  - Physiological reviews
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - p7m, 0231714
OI  - Source: NLM. PMC4698394 [Available on 01/01/17]
SB  - Index Medicus
CP  - United States
MH  - Adaptation, Physiological
MH  - Animals
MH  - Biomarkers/me [Metabolism]
MH  - *Cardiomegaly, Exercise-Induced
MH  - *Exercise
MH  - Genetic Predisposition to Disease
MH  - *Heart Diseases/et [Etiology]
MH  - Heart Diseases/ge [Genetics]
MH  - Heart Diseases/me [Metabolism]
MH  - Heart Diseases/pp [Physiopathology]
MH  - Humans
MH  - Longevity
MH  - Phenotype
MH  - *Physical Endurance
MH  - Risk Factors
MH  - Time Factors
AB  - Multiple epidemiological studies document that habitual physical activity reduces the risk of atherosclerotic cardiovascular disease (ASCVD), and most demonstrate progressively lower rates of ASCVD with progressively more physical activity. Few studies have included individuals performing high-intensity, lifelong endurance exercise, however, and recent reports suggest that prodigious amounts of exercise may increase markers for, and even the incidence of, cardiovascular disease. This review examines the evidence that extremes of endurance exercise may increase cardiovascular disease risk by reviewing the causes and incidence of exercise-related cardiac events, and the acute effects of exercise on cardiovascular function, the effect of exercise on cardiac biomarkers, including "myocardial" creatine kinase, cardiac troponins, and cardiac natriuretic peptides. This review also examines the effect of exercise on coronary atherosclerosis and calcification, the frequency of atrial fibrillation in aging athletes, and the possibility that exercise may be deleterious in individuals genetically predisposed to such cardiac abnormalities as long QT syndrome, right ventricular cardiomyopathy, and hypertrophic cardiomyopathy. This review is to our knowledge unique because it addresses all known potentially adverse cardiovascular effects of endurance exercise. The best evidence remains that physical activity and exercise training benefit the population, but it is possible that prolonged exercise and exercise training can adversely affect cardiac function in some individuals. This hypothesis warrants further examination. Copyright © 2016 the American Physiological Society.
RN  - 0 (Biomarkers)
ES  - 1522-1210
IL  - 0031-9333
DO  - http://dx.doi.org/10.1152/physrev.00029.2014
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
LG  - English
DP  - 2016 Jan
DC  - 20151126
YR  - 2016
ED  - 20160216
RD  - 20160114
UP  - 20160217
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26607287

<64. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24256074
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Myrstad M
AU  - Lochen ML
AU  - Graff-Iversen S
AU  - Gulsvik AK
AU  - Thelle DS
AU  - Stigum H
AU  - Ranhoff AH
FA  - Myrstad, M
FA  - Lochen, M-L
FA  - Graff-Iversen, S
FA  - Gulsvik, A K
FA  - Thelle, D S
FA  - Stigum, H
FA  - Ranhoff, A H
IN  - Myrstad,M. Medical Department, Diakonhjemmet Hospital, Oslo, Norway.
IN  - Myrstad,M. Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway.
IN  - Lochen,M-L. Department of Community Health, UiT The Arctic University of Norway, Tromso, Norway.
IN  - Graff-Iversen,S. Department of Community Health, UiT The Arctic University of Norway, Tromso, Norway.
IN  - Graff-Iversen,S. Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway.
IN  - Gulsvik,A K. Department of General Internal Medicine, Oslo University Hospital, Oslo, Norway.
IN  - Thelle,D S. Department of Biostatistics, Institute of Basal Medical Sciences, University of Oslo, Oslo, Norway.
IN  - Thelle,D S. Department of Public Health and Community Medicine, Gothenburg University, Gothenburg, Sweden.
IN  - Stigum,H. Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway.
IN  - Stigum,H. Department of Biostatistics, Institute of Basal Medical Sciences, University of Oslo, Oslo, Norway.
IN  - Ranhoff,A H. Medical Department, Diakonhjemmet Hospital, Oslo, Norway.
IN  - Ranhoff,A H. Kavli Research Centre for Ageing and Dementia, Department of Clinical Science, University of Bergen, Bergen, Norway.
TI  - Increased risk of atrial fibrillation among elderly Norwegian men with a history of long-term endurance sport practice.
SO  - Scandinavian Journal of Medicine & Science in Sports. 24(4):e238-44, 2014 Aug.
AS  - Scand J Med Sci Sports. 24(4):e238-44, 2014 Aug.
NJ  - Scandinavian journal of medicine & science in sports
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9111504, cac
OI  - Source: NLM. PMC4282367
SB  - Index Medicus
CP  - Denmark
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Male
MH  - Norway/ep [Epidemiology]
MH  - *Physical Endurance/ph [Physiology]
MH  - Physical Exertion/ph [Physiology]
MH  - Practice (Psychology)
MH  - Risk Factors
MH  - *Running/ph [Physiology]
MH  - *Skiing/ph [Physiology]
MH  - Surveys and Questionnaires
MH  - Time Factors
KW  - arrhythmias;  cross-country skiing;  elderly;  endurance exercise;  heart disease;  master athletes;  skiers;  sports cardiology
AB  - Atrial fibrillation (AF) is the most common cardiac arrhythmia. The prevalence increases with increasing age. In middle-aged men, endurance sport practice is associated with increased risk of AF but there are few studies among elderly people. The aim of this study was to investigate the role of long-term endurance sport practice as a risk factor for AF in elderly men. A cross-sectional study compared 509 men aged 65-90 years who participated in a long-distance cross-country ski race with 1768 men aged 65-87 years from the general population. Long-term endurance sport practice was the main exposure. Self-reported AF and covariates were assessed by questionnaires. Risk differences (RDs) for AF were estimated by using a linear regression model. After multivariable adjustment, a history of endurance sport practice gave an added risk for AF of 6.0 percent points (pp) (95% confidence interval 0.8-11.1). Light and moderate leisure-time physical activity during the last 12 months reduced the risk with 3.7 and 4.3 pp, respectively, but the RDs were not statistically significant. This study suggests that elderly men with a history of long-term endurance sport practice have an increased risk of AF compared with elderly men in the general population. Copyright © 2013 The Authors. Scandinavian Journal of Medicine & Science in Sports published by John Wiley & Sons Ltd.
ES  - 1600-0838
IL  - 0905-7188
DO  - http://dx.doi.org/10.1111/sms.12150
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20131121
DP  - 2014 Aug
DC  - 20150527
YR  - 2014
ED  - 20160209
RD  - 20150528
UP  - 20160210
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24256074

<65. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24256074
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Myrstad M
AU  - Lochen ML
AU  - Graff-Iversen S
AU  - Gulsvik AK
AU  - Thelle DS
AU  - Stigum H
AU  - Ranhoff AH
FA  - Myrstad, M
FA  - Lochen, M-L
FA  - Graff-Iversen, S
FA  - Gulsvik, A K
FA  - Thelle, D S
FA  - Stigum, H
FA  - Ranhoff, A H
IN  - Myrstad,M. Medical Department, Diakonhjemmet Hospital, Oslo, Norway.
IN  - Myrstad,M. Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway.
IN  - Lochen,M-L. Department of Community Health, UiT The Arctic University of Norway, Tromso, Norway.
IN  - Graff-Iversen,S. Department of Community Health, UiT The Arctic University of Norway, Tromso, Norway.
IN  - Graff-Iversen,S. Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway.
IN  - Gulsvik,A K. Department of General Internal Medicine, Oslo University Hospital, Oslo, Norway.
IN  - Thelle,D S. Department of Biostatistics, Institute of Basal Medical Sciences, University of Oslo, Oslo, Norway.
IN  - Thelle,D S. Department of Public Health and Community Medicine, Gothenburg University, Gothenburg, Sweden.
IN  - Stigum,H. Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway.
IN  - Stigum,H. Department of Biostatistics, Institute of Basal Medical Sciences, University of Oslo, Oslo, Norway.
IN  - Ranhoff,A H. Medical Department, Diakonhjemmet Hospital, Oslo, Norway.
IN  - Ranhoff,A H. Kavli Research Centre for Ageing and Dementia, Department of Clinical Science, University of Bergen, Bergen, Norway.
TI  - Increased risk of atrial fibrillation among elderly Norwegian men with a history of long-term endurance sport practice.
SO  - Scandinavian Journal of Medicine & Science in Sports. 24(4):e238-44, 2014 Aug.
AS  - Scand J Med Sci Sports. 24(4):e238-44, 2014 Aug.
NJ  - Scandinavian journal of medicine & science in sports
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9111504, cac
OI  - Source: NLM. PMC4282367
SB  - Index Medicus
CP  - Denmark
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Male
MH  - Norway/ep [Epidemiology]
MH  - *Physical Endurance/ph [Physiology]
MH  - Physical Exertion/ph [Physiology]
MH  - Practice (Psychology)
MH  - Risk Factors
MH  - *Running/ph [Physiology]
MH  - *Skiing/ph [Physiology]
MH  - Surveys and Questionnaires
MH  - Time Factors
KW  - arrhythmias;  cross-country skiing;  elderly;  endurance exercise;  heart disease;  master athletes;  skiers;  sports cardiology
AB  - Atrial fibrillation (AF) is the most common cardiac arrhythmia. The prevalence increases with increasing age. In middle-aged men, endurance sport practice is associated with increased risk of AF but there are few studies among elderly people. The aim of this study was to investigate the role of long-term endurance sport practice as a risk factor for AF in elderly men. A cross-sectional study compared 509 men aged 65-90 years who participated in a long-distance cross-country ski race with 1768 men aged 65-87 years from the general population. Long-term endurance sport practice was the main exposure. Self-reported AF and covariates were assessed by questionnaires. Risk differences (RDs) for AF were estimated by using a linear regression model. After multivariable adjustment, a history of endurance sport practice gave an added risk for AF of 6.0 percent points (pp) (95% confidence interval 0.8-11.1). Light and moderate leisure-time physical activity during the last 12 months reduced the risk with 3.7 and 4.3 pp, respectively, but the RDs were not statistically significant. This study suggests that elderly men with a history of long-term endurance sport practice have an increased risk of AF compared with elderly men in the general population. Copyright © 2013 The Authors. Scandinavian Journal of Medicine & Science in Sports published by John Wiley & Sons Ltd.
ES  - 1600-0838
IL  - 0905-7188
DO  - http://dx.doi.org/10.1111/sms.12150
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20131121
DP  - 2014 Aug
DC  - 20150527
YR  - 2014
ED  - 20160209
RD  - 20160229
UP  - 20160301
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=24256074

<66. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25755060
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Myrstad M
AU  - Aaronaes M
AU  - Graff-Iversen S
AU  - Nystad W
AU  - Ranhoff AH
FA  - Myrstad, Marius
FA  - Aaronaes, Marit
FA  - Graff-Iversen, Sidsel
FA  - Nystad, Wenche
FA  - Ranhoff, Anette Hylen
IN  - Myrstad,Marius. Department of Internal Medicine, Diakonhjemmet Hospital, Oslo, Norway. Electronic address: m-myrsta@online.no.
IN  - Aaronaes,Marit. Department of Internal Medicine, Diakonhjemmet Hospital, Oslo, Norway.
IN  - Graff-Iversen,Sidsel. Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway.
IN  - Nystad,Wenche. Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway.
IN  - Ranhoff,Anette Hylen. Department of Internal Medicine, Diakonhjemmet Hospital, Oslo, Norway; Kavli Research Centre for Geriatrics and Dementia, Department of Clinical Science, University of Bergen, Bergen, Norway.
TI  - Does endurance exercise cause atrial fibrillation in women?.
SO  - International Journal of Cardiology. 184:431-2, 2015 Apr 1.
AS  - Int J Cardiol. 184:431-2, 2015 Apr 1.
NJ  - International journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - gqw, 8200291
SB  - Index Medicus
CP  - Netherlands
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Body Mass Index
MH  - *Exercise/ph [Physiology]
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Norway
MH  - *Physical Endurance/ph [Physiology]
MH  - Risk Assessment/mt [Methods]
MH  - Risk Factors
MH  - Sports/sn [Statistics & Numerical Data]
MH  - Women's Health
KW  - Athletes;  Atrial fibrillation;  Endurance sport;  Exercise;  Heart disease in women;  Physical activity
ES  - 1874-1754
IL  - 0167-5273
DI  - S0167-5273(15)00256-9
DO  - http://dx.doi.org/10.1016/j.ijcard.2015.03.018
PT  - Letter
LG  - English
EP  - 20150303
DP  - 2015 Apr 1
DC  - 20150502
YR  - 2015
ED  - 20160208
UP  - 20160209
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25755060

<67. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26532258
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Daacke I
AU  - Hau N
AU  - Williams J
AU  - Natarajan I
FA  - Daacke, I
FA  - Hau, N
FA  - Williams, J
FA  - Natarajan, I
IN  - Daacke,I. Boehringer Ingelheim, Bracknell, UK.
IN  - Hau,N. Boehringer Ingelheim, Bracknell, UK.
IN  - Williams,J. University Hospital of North Midlands NHS Trust, Stoke-on-Trent, UK.
IN  - Natarajan,I. University Hospital of North Midlands NHS Trust, Stoke-on-Trent, UK.
TI  - Atrial Fibrillation And Anti-Coagulation Service Run By A Clinical Nurse Specialist.
SO  - Value in Health. 18(7):A400, 2015 Nov.
AS  - Value Health. 18(7):A400, 2015 Nov.
NJ  - Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 100883818
CP  - United States
ES  - 1524-4733
IL  - 1098-3015
DI  - S1098-3015(15)02997-6
DO  - http://dx.doi.org/10.1016/j.jval.2015.09.921
PT  - Journal Article
LG  - English
EP  - 20151020
DP  - 2015 Nov
DC  - 20151104
YR  - 2015
ED  - 20160204
UP  - 20160205
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=26532258

<68. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25627780
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - D'Ascenzi F
AU  - Pelliccia A
AU  - Natali BM
AU  - Cameli M
AU  - Andrei V
AU  - Incampo E
AU  - Alvino F
AU  - Lisi M
AU  - Padeletti M
AU  - Focardi M
AU  - Bonifazi M
AU  - Mondillo S
FA  - D'Ascenzi, Flavio
FA  - Pelliccia, Antonio
FA  - Natali, Benedetta Maria
FA  - Cameli, Matteo
FA  - Andrei, Valentina
FA  - Incampo, Eufemia
FA  - Alvino, Federico
FA  - Lisi, Matteo
FA  - Padeletti, Margherita
FA  - Focardi, Marta
FA  - Bonifazi, Marco
FA  - Mondillo, Sergio
IN  - D'Ascenzi,Flavio. Department of Cardiovascular Diseases, University of Siena, Viale M. Bracci, 16 53100, Siena, Italy, flavio.dascenzi@libero.it.
TI  - Increased left atrial size is associated with reduced atrial stiffness and preserved reservoir function in athlete's heart.
SO  - The International Journal of Cardiovascular Imaging. 31(4):699-705, 2015 Apr.
AS  - Int J Cardiovasc Imaging. 31(4):699-705, 2015 Apr.
NJ  - The international journal of cardiovascular imaging
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 100969716
SB  - Index Medicus
CP  - United States
MH  - Adaptation, Physiological
MH  - Adolescent
MH  - Adult
MH  - *Atrial Function, Left
MH  - *Atrial Remodeling
MH  - *Cardiomegaly, Exercise-Induced
MH  - Case-Control Studies
MH  - Echocardiography, Doppler, Pulsed
MH  - Elasticity
MH  - *Exercise/ph [Physiology]
MH  - Female
MH  - Heart Atria/us [Ultrasonography]
MH  - Humans
MH  - Male
MH  - *Myocardial Contraction
MH  - Sedentary Lifestyle
MH  - Stress, Mechanical
MH  - Ventricular Function, Left
MH  - Young Adult
AB  - Left atrial (LA) fibrosis with increased stiffness has been assumed to be the substrates for occurrence of atrial arrhythmias in athletes. However, this hypothesis has not yet been confirmed in humans. Aim of this study was, therefore, to assess LA remodeling and stiffness in competitive athletes. 150 competitive athletes and 90 age and sex-matched sedentary subjects were analyzed by speckle-tracking echocardiography to measure peak atrial longitudinal strain (PALS) and peak atrial contraction strain (PACS). LA stiffness was determined using E/e' ratio in conjunction with PALS. Left ventricular (LV) stiffness was also calculated. LA volume index was greater in athletes as compared with controls (24.6 +/- 7.3 vs. 18.4 +/- 7.8 mL/m(2), p < .0001). LA PALS, LA PACS, and E/e' ratio were lower in athletes in comparison with controls (p < .05, p < .001, and p < .0001, respectively). Despite greater LA size, competitive athletes had lower LA stiffness as compared with controls (0.13 +/- 0.04 vs. 0.16 +/- 0.06, p < .001). In addition, LV stiffness was lower in athletes (0.84 +/- 0.27 vs. 1.07 +/- 0.46, p < .001). The only independent predictor of LA stiffness was LV stiffness (beta = 0.46, p < .0001), while the only independent predictor of LA volume index was LV end-systolic volume index (beta = 0.25, p = .002). Competitive athletes showed greater LA size associated with lower stiffness as compared with controls. Thus, LA remodeling in the context of the athlete's heart is not associated with increased LA stiffness. These findings support the benign nature of LA remodeling in athletes, occurring as a physiological adaptation to exercise conditioning.
ES  - 1875-8312
IL  - 1569-5794
DO  - http://dx.doi.org/10.1007/s10554-015-0600-7
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20150128
DP  - 2015 Apr
DC  - 20150421
YR  - 2015
ED  - 20160203
UP  - 20160204
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25627780

<69. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25635403
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lebwohl B
AU  - Emilsson L
AU  - Frobert O
AU  - Einstein AJ
AU  - Green PH
AU  - Ludvigsson JF
FA  - Lebwohl, Benjamin
FA  - Emilsson, Louise
FA  - Frobert, Ole
FA  - Einstein, Andrew J
FA  - Green, Peter H R
FA  - Ludvigsson, Jonas F
IN  - Lebwohl,Benjamin. Celiac Disease Center, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, United States of America; Department of Medical Epidemiology and Biostatistics, Karolinska University Hospital and Karolinska Institute, Stockholm, Swede0060045.
IN  - Emilsson,Louise. Primary care research unit, Vardcentralen Varmlands Nysater, Varmland County, and the Department of Medicine, Orebro University, Orebro, Sweden.
IN  - Frobert,Ole. Department of Cardiology, Orebro University Hospital, Orebro, Sweden.
IN  - Einstein,Andrew J. Division of Cardiology, Department of Medicine, and Department of Radiology, Columbia University College of Physicians and Surgeons and New York-Presbyterian Hospital, New York, New York, United States of America.
IN  - Green,Peter H R. Celiac Disease Center, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, United States of America.
IN  - Ludvigsson,Jonas F. Department of Medical Epidemiology and Biostatistics, Karolinska University Hospital and Karolinska Institute, Stockholm, Swede0060045; Department of Pediatrics, Orebro University Hospital, Orebro, Sweden.
TI  - Mucosal healing and the risk of ischemic heart disease or atrial fibrillation in patients with celiac disease; a population-based study.
SO  - PLoS ONE [Electronic Resource]. 10(1):e0117529, 2015.
AS  - PLoS ONE. 10(1):e0117529, 2015.
NJ  - PloS one
PI  - Journal available in: Electronic-eCollection
PI  - Citation processed from: Internet
JC  - 101285081
OI  - Source: NLM. PMC4312018
SB  - Index Medicus
CP  - United States
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Atrophy
MH  - Biopsy
MH  - *Celiac Disease/co [Complications]
MH  - Child
MH  - Child, Preschool
MH  - Cohort Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - *Intestinal Mucosa/pa [Pathology]
MH  - Male
MH  - Middle Aged
MH  - *Myocardial Ischemia/co [Complications]
MH  - *Myocardial Ischemia/ep [Epidemiology]
MH  - Risk Factors
MH  - Sweden/ep [Epidemiology]
MH  - Time Factors
MH  - *Wound Healing
MH  - Young Adult
AB  - BACKGROUND: Patients with celiac disease (CD), characterized histologically by villous atrophy (VA) of the small intestine, have an increased risk of ischemic heart disease (IHD) and atrial fibrillation (AF), risks that persist for years after commencing the gluten-free diet. It is unknown whether persistent VA on follow-up biopsy, rather than mucosal healing, affects the risk of IHD or AF.
AB  - METHODS: We identified patients with histologic evidence of CD diagnosed at all 28 pathology departments in Sweden. Among patients who underwent a follow-up small intestinal biopsy, we compared patients with persistent VA to those who showed histologic improvement, with regard to the development of IHD (angina pectoris or myocardial infarction) or AF.
AB  - RESULTS: Among patients with CD and a follow-up biopsy (n = 7,440), the median age at follow-up biopsy was 25 years, with 1,063 (14%) patients who were > 60 years at the time of follow-up biopsy. Some 196 patients developed IHD and 205 patients developed AF. After adjusting for age, gender, duration of CD, calendar period, and educational attainment, there was no significant effect of persistent VA on IHD (adjusted HR 0.97; 95%CI 0.73-1.30). Adjusting for diabetes had a negligible effect (adjusted HR 0.98; 95%CI 0.73-1.31). There was no significant association between persistent VA and the risk of AF (adjusted HR 0.98; 95%CI 0.74-1.30).
AB  - CONCLUSIONS: In this population-based study of patients with CD, persistent VA on follow-up biopsy was not associated with an increased risk of IHD or AF. Failed mucosal healing does not influence the risk of these cardiac events.
ES  - 1932-6203
IL  - 1932-6203
DO  - http://dx.doi.org/10.1371/journal.pone.0117529
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
NO  - UL1 TR000040 (United States NCATS NIH HHS)
LG  - English
EP  - 20150130
DP  - 2015
DC  - 20150131
YR  - 2015
ED  - 20160130
RD  - 20150213
UP  - 20160201
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25635403

<70. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25528529
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Turagam MK
AU  - Velagapudi P
AU  - Alpert MA
FA  - Turagam, Mohit K
FA  - Velagapudi, Poonam
FA  - Alpert, Martin A
IN  - Turagam,Mohit K. Division of Cardiovascular Medicine, University of Missouri School of Medicine, Columbia, MO, USA. Electronic address: turagamm@health.missouri.edu.
IN  - Velagapudi,Poonam. Division of Cardiovascular Medicine, University of Missouri School of Medicine, Columbia, MO, USA.
IN  - Alpert,Martin A. Division of Cardiovascular Medicine, University of Missouri School of Medicine, Columbia, MO, USA.
TI  - Does exercise cause atrial fibrillation?. [Review]
SO  - International Journal of Cardiology. 181:245-6, 2015 Feb 15.
AS  - Int J Cardiol. 181:245-6, 2015 Feb 15.
NJ  - International journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - gqw, 8200291
SB  - Index Medicus
CP  - Netherlands
MH  - Animals
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/et [Etiology]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Exercise/ph [Physiology]
MH  - *Exercise
MH  - Humans
MH  - Physical Endurance/ph [Physiology]
MH  - *Physical Endurance
KW  - Atrial fibrillation;  Atrial remodeling;  Exercise;  Physical activity;  Vagal tone
ES  - 1874-1754
IL  - 0167-5273
DI  - S0167-5273(14)02431-0
DO  - http://dx.doi.org/10.1016/j.ijcard.2014.12.024
PT  - Letter
PT  - Review
LG  - English
EP  - 20141203
DP  - 2015 Feb 15
DC  - 20150404
YR  - 2015
ED  - 20160115
UP  - 20160118
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25528529

<71. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25665699
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Chen Y
FA  - Chen, Ying
IN  - Chen,Ying. Department of Gastroenterology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Ruijin Er Road 197, Shanghai, 200025, People's Republic of China.
TI  - Gastroesophageal reflux disease and non-digestive tract diseases. [Review]
SO  - Expert review of gastroenterology & hepatology. 9(5):685-92, 2015 May.
AS  - Expert rev. gastroenterol. hepatol.. 9(5):685-92, 2015 May.
NJ  - Expert review of gastroenterology & hepatology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101278199
SB  - Index Medicus
CP  - England
MH  - *Atrial Fibrillation/co [Complications]
MH  - *Diabetes Mellitus, Type 2/co [Complications]
MH  - *Gastroesophageal Reflux/co [Complications]
MH  - Gastroesophageal Reflux/di [Diagnosis]
MH  - Gastroesophageal Reflux/pp [Physiopathology]
MH  - Gastroesophageal Reflux/th [Therapy]
MH  - Humans
MH  - *Obesity/co [Complications]
MH  - *Pulmonary Disease, Chronic Obstructive/co [Complications]
MH  - *Pulmonary Fibrosis/co [Complications]
KW  - atrial fibrillation;  atypical symptom;  etiology;  gastroesophageal reflux disease;  non-digestive tract disease
AB  - Over the past decade, incidence of gastroesophageal reflux disease (GERD) showed an increasing trend resulting from factors, including lifestyle and dietary habits; however, both etiology and pathological mechanisms remain controversial. GERD occurs as a result of a variety of mechanisms and there is no single factor. Symptoms of GERD are often non-typical, with a likelihood of being overlooked by non-gastroenterology professionals. Therefore, improving GERD awareness in non-gastroenterology practitioners, along with early diagnosis and treatment, provide potential benefit to clinicians and patients alike. Increasing evidence suggests GERD has specific connections with a variety of non-digestive tract conditions, may contribute an aggravating compounding effect on other diseases, prolong hospitalization, and increase subsequent medical costs. This review considers and emphasizes the association between GERD and non-digestive tract conditions, including atrial fibrillation, chronic obstructive pulmonary disease, primary pulmonary fibrosis and energy metabolism related to diet.
ES  - 1747-4132
IL  - 1747-4124
DO  - http://dx.doi.org/10.1586/17474124.2015.1012495
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20150210
DP  - 2015 May
DC  - 20150421
YR  - 2015
ED  - 20160111
UP  - 20160112
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25665699

<72. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25721817
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Marjanski T
AU  - Wnuk D
AU  - Bosakowski D
AU  - Szmuda T
AU  - Sawicka W
AU  - Rzyman W
FA  - Marjanski, Tomasz
FA  - Wnuk, Damian
FA  - Bosakowski, Damian
FA  - Szmuda, Tomasz
FA  - Sawicka, Wioletta
FA  - Rzyman, Witold
IN  - Marjanski,Tomasz. Thoracic Surgery Department, Medical University of Gdansk, Gdansk, Poland marjanski@gumed.edu.pl.
IN  - Wnuk,Damian. Department of Physiotherapy, Medical University of Gdansk, Gdansk, Poland.
IN  - Bosakowski,Damian. Thoracic Surgery Department, Medical University of Gdansk, Gdansk, Poland.
IN  - Szmuda,Tomasz. Department of Neurosurgery, Medical University of Gdansk, Gdansk, Poland.
IN  - Sawicka,Wioletta. Department of Anaesthesiology and Intensive Care, Medical University of Gdansk, Gdansk, Poland.
IN  - Rzyman,Witold. Thoracic Surgery Department, Medical University of Gdansk, Gdansk, Poland.
TI  - Patients who do not reach a distance of 500 m during the 6-min walk test have an increased risk of postoperative complications and prolonged hospital stay after lobectomy.
SO  - European Journal of Cardio-Thoracic Surgery. 47(5):e213-9, 2015 May.
AS  - Eur J Cardiothorac Surg. 47(5):e213-9, 2015 May.
NJ  - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - aoj, 8804069
SB  - Index Medicus
CP  - Germany
MH  - Aged
MH  - *Carcinoma, Non-Small-Cell Lung/su [Surgery]
MH  - Exercise Test/mt [Methods]
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Length of Stay/td [Trends]
MH  - *Lung Neoplasms/su [Surgery]
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - *Pneumonectomy/ae [Adverse Effects]
MH  - Poland/ep [Epidemiology]
MH  - *Postoperative Complications/ep [Epidemiology]
MH  - Postoperative Complications/pp [Physiopathology]
MH  - Predictive Value of Tests
MH  - ROC Curve
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Survival Rate/td [Trends]
MH  - Time Factors
MH  - *Walking/ph [Physiology]
KW  - Complication;  Lobectomy;  Lung cancer;  Risk assessment
AB  - OBJECTIVES: Exercise testing is an additional tool to standard pulmonary assessment before radical pulmonary resection in lung cancer patients. Evidence is lacking, supporting the significance of routine implementation of these simple physiological tests in preoperative evaluation.
AB  - METHODS: Between April 2009 and October 2011, 253 lung cancer patients, who underwent lobectomy in a single institution, were entered into this study. All of the patients were accepted for resection based on a standard evaluation protocol. Additionally on the day before the surgery, patients performed a 6-min walk test (6MWT). Patients were categorized, depending on the result of 6MWT, in order to stratify their risk of postoperative complications. Threshold values of 6MWT were assessed on the basis of maximum area under ROC curves.
AB  - RESULTS: There were 148 men and 105 women with a mean age of 63 years. All patients underwent lobectomies due to primary lung cancer. A distance of 500 m and 100% of the predicted 6MWT were taken as threshold values differentiating risk of postoperative complications. The cut-off value of 500 m separates individuals with an increased risk of postoperative complications [60.6 vs 36.9%, odds ratio (OR): 2631; 95% confidence interval (CI): 1.423-4.880] and prolonged hospitalization (7 vs 6 days). By applying a cut-off value of 500 m, the higher incidence of atrial fibrillation (21.2 vs 11.7%; OR: 2019; 95% CI: 0.904-4.484) and higher requirement for blood transfusion (18.1 vs 9.0%; OR: 2222; 95% CI: 0.928-5.289) fairly reached the level of significance. There were no early postoperative deaths in the analysed groups.
AB  - CONCLUSIONS: Patients who walk <500 m during the 6MWT before lobectomy have an increased risk of postoperative complications and prolonged hospital stay.Copyright © The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.
ES  - 1873-734X
IL  - 1010-7940
DO  - http://dx.doi.org/10.1093/ejcts/ezv049
PT  - Journal Article
LG  - English
EP  - 20150226
DP  - 2015 May
DC  - 20150410
YR  - 2015
ED  - 20160107
UP  - 20160108
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25721817

<73. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25646399
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Pozzoli A
AU  - Taramasso M
AU  - Colombo DF
AU  - Ancona F
AU  - Cianflone D
AU  - Della Bella P
AU  - Alfieri O
AU  - Benussi S
FA  - Pozzoli, Alberto
FA  - Taramasso, Maurizio
FA  - Colombo, Daniele Filippo
FA  - Ancona, Francesco
FA  - Cianflone, Domenico
FA  - Della Bella, Paolo
FA  - Alfieri, Ottavio
FA  - Benussi, Stefano
IN  - Pozzoli,Alberto. Department of Cardiothoracic Surgery, San Raffaele University Hospital, Milan, Italy albertopozzoli@gmail.com.
IN  - Taramasso,Maurizio. Department of Cardiothoracic Surgery, San Raffaele University Hospital, Milan, Italy.
IN  - Colombo,Daniele Filippo. Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
IN  - Ancona,Francesco. Cardiac Rehabilitation Unit, San Raffaele University Hospital, Milan, Italy.
IN  - Cianflone,Domenico. Cardiac Rehabilitation Unit, San Raffaele University Hospital, Milan, Italy.
IN  - Della Bella,Paolo. Arrhythmia Unit and Electrophysiology Laboratories, San Raffaele University Hospital, Milan, Italy.
IN  - Alfieri,Ottavio. Department of Cardiothoracic Surgery, San Raffaele University Hospital, Milan, Italy.
IN  - Benussi,Stefano. Department of Cardiothoracic Surgery, San Raffaele University Hospital, Milan, Italy.
TI  - Electrophysiological efficacy of temperature-controlled bipolar radiofrequency.
SO  - European Journal of Cardio-Thoracic Surgery. 47(5):e188-92; discussion e192, 2015 May.
AS  - Eur J Cardiothorac Surg. 47(5):e188-92; discussion e192, 2015 May.
NJ  - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - aoj, 8804069
SB  - Index Medicus
CP  - Germany
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/su [Surgery]
MH  - *Catheter Ablation/mt [Methods]
MH  - *Electrocardiography, Ambulatory
MH  - Female
MH  - Follow-Up Studies
MH  - *Heart Conduction System/pp [Physiopathology]
MH  - Heart Conduction System/su [Surgery]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Pulmonary Veins/su [Surgery]
MH  - Retrospective Studies
MH  - Temperature
MH  - Treatment Outcome
KW  - Arrhythmia;  Atrial fibrillation;  Cardiac surgery;  Conduction block;  Temperature-controlled bipolar radiofrequency ablation
AB  - OBJECTIVE: Clinical success of atrial fibrillation (AF) ablation depends on persistent block of electrical conduction across the ablation lines. The fate of ablations performed with temperature-controlled bipolar radiofrequency (RF) is unknown. The purpose of this study was to validate the electrophysiological (EP) efficacy of these lesions, recording pulmonary vein isolation (PVI) after open chest ablation, in the human being.
AB  - METHODS: Ten consecutive mitral patients (mean age: 53 +/- 12 years) with concomitant AF were treated with the Cobra Revolution (Estech, San Ramon, CA, USA) bipolar RF device were enrolled for EP assessment. During surgery, pairs of additional temporary wires were positioned on the right PVs (RPV) and on the roof of the left atrium (RLA), before ablation. Pacing thresholds (PTs) were assessed before, after a single encircling ablation and at chest's closure. EP study was repeated before discharge and at 3 weeks. RLA wires served as control.
AB  - RESULTS: Baseline PTs were 0.83 +/- 0.81 mA (range 0.2-3 mA) from RPV and 1.13 +/- 0.78 mA (range 0.3-3 mA) from RLA. PVI was reached in all patients acutely, and was maintained at 1 week. At 3 weeks, the PTs were 14.3 +/- 4.3 mA from RPV (range 7-20 mA) and 3.1 +/- 1.3 mA (range 1.5-7 mA) from RLA. All patients were discharged in sinus rhythm.
AB  - CONCLUSIONS: Cobra Revolution temperature-controlled bipolar RF provides complete PVI after a single ablation up to 1 week. This notwithstanding, only 30% of patients were completely isolated (exit block validation) at 3 weeks.Copyright © The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.
ES  - 1873-734X
IL  - 1010-7940
DO  - http://dx.doi.org/10.1093/ejcts/ezv016
PT  - Journal Article
LG  - English
EP  - 20150201
DP  - 2015 May
DC  - 20150410
YR  - 2015
ED  - 20160107
UP  - 20160108
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25646399

<74. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26734131
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Sandhu A
AU  - Krantz MJ
AU  - Taylor M
AU  - Aleong RG
AU  - Stichman J
AU  - Schuller JL
FA  - Sandhu, Amneet
FA  - Krantz, Mori J
FA  - Taylor, Matthew
FA  - Aleong, Ryan G
FA  - Stichman, Jennifer
FA  - Schuller, Joseph L
IN  - Sandhu,Amneet. Division of Cardiovascular MedicineDepartment of Internal MedicineThe University of ColoradoDenverColorado; Division of Cardiovascular MedicineDenver Health HospitalDenverColorado.
IN  - Krantz,Mori J. Division of Cardiovascular MedicineDepartment of Internal MedicineThe University of ColoradoDenverColorado; Division of Cardiovascular MedicineDenver Health HospitalDenverColorado.
IN  - Taylor,Matthew. Division of Cardiovascular Medicine Department of Internal Medicine The University of Colorado Denver Colorado.
IN  - Aleong,Ryan G. Division of Cardiovascular Medicine Department of Internal Medicine The University of Colorado Denver Colorado.
IN  - Stichman,Jennifer. Division of General Medicine Denver Health Hospital Denver Colorado.
IN  - Schuller,Joseph L. Division of Cardiovascular MedicineDepartment of Internal MedicineThe University of ColoradoDenverColorado; Division of Cardiovascular MedicineDenver Health HospitalDenverColorado.
TI  - Syncope and cardiac arrest during strenuous exercise associated with a novel mutation in LQTS1.
SO  - Clinical Case Reports. 3(12):971-4, 2015 Dec.
AS  - Clin Case Rep. 3(12):971-4, 2015 Dec.
NJ  - Clinical case reports
PI  - Journal available in: Electronic-eCollection
PI  - Citation processed from: Print
JC  - 101620385
OI  - Source: NLM. PMC4693705
CP  - England
KW  - Cardiac arrest;  exercise-induced syncope;  long QT syndrome;  malignant syncope
AB  - Exercise-induced syncope should alert clinicians to the possibility of LQTS and must be distinguished from other malignant causes of syncope such as hypertrophic cardiomyopathy, catecholaminergic ventricular tachycardia, and arrhythmogenic right ventricular cardiomyopathy. Emerging genotype-phenotype links have connected mutations resulting in LQTS with risk of developing atrial fibrillation and cardiomyopathy.
ES  - 2050-0904
IL  - 2050-0904
DO  - http://dx.doi.org/10.1002/ccr3.394
PT  - Journal Article
LG  - English
EP  - 20150928
DP  - 2015 Dec
DC  - 20160106
YR  - 2015
ED  - 20160106
RD  - 20160108
UP  - 20160111
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=26734131

<75. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26318357
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Desai MY
AU  - Smedira NG
AU  - Bhonsale A
AU  - Thamilarasan M
AU  - Lytle BW
AU  - Lever HM
FA  - Desai, Milind Y
FA  - Smedira, Nicholas G
FA  - Bhonsale, Aditya
FA  - Thamilarasan, Maran
FA  - Lytle, Bruce W
FA  - Lever, Harry M
IN  - Desai,Milind Y. Hypertrophic Cardiomyopathy Center, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: desaim2@ccf.org.
IN  - Smedira,Nicholas G. Hypertrophic Cardiomyopathy Center, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
IN  - Bhonsale,Aditya. Hypertrophic Cardiomyopathy Center, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
IN  - Thamilarasan,Maran. Hypertrophic Cardiomyopathy Center, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
IN  - Lytle,Bruce W. Hypertrophic Cardiomyopathy Center, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
IN  - Lever,Harry M. Hypertrophic Cardiomyopathy Center, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
TI  - Symptom assessment and exercise impairment in surgical decision making in hypertrophic obstructive cardiomyopathy: Relationship to outcomes.
CM  - Comment in: J Thorac Cardiovasc Surg. 2015 Oct;150(4):936-7; PMID: 26424373
SO  - Journal of Thoracic & Cardiovascular Surgery. 150(4):928-35.e1, 2015 Oct.
AS  - J Thorac Cardiovasc Surg. 150(4):928-35.e1, 2015 Oct.
NJ  - The Journal of thoracic and cardiovascular surgery
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - k9j, 0376343
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Cardiomyopathy, Hypertrophic/di [Diagnosis]
MH  - *Cardiomyopathy, Hypertrophic/pp [Physiopathology]
MH  - *Clinical Decision-Making
MH  - *Exercise Test
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Symptom Assessment
MH  - Ventricular Function, Left
KW  - hypertrophic cardiomyopathy;  outcomes;  surgical myectomy
AB  - OBJECTIVES: We sought to assess the long-term outcomes in patients with hypertrophic cardiomyopathy and severe left ventricular outflow tract obstruction, in whom the decision regarding surgery (vs conservative management) was based on assessment of symptoms or exercise capacity.
AB  - METHODS: This was an observational study of 1530 patients with hypertrophic cardiomyopathy (aged 50 +/- 13 years, 63% were men) with severe left ventricular outflow tract obstruction (excluding those aged <18 years, with left ventricular ejection fraction <50%, and with left ventricular outflow tract gradient <30 mm Hg). A composite end point of death (excluding noncardiac causes) and/or implantable defibrillator discharge was assessed.
AB  - RESULTS: Coronary artery disease, family history of hypertrophic cardiomyopathy, and syncope were present in 15%, 17%, and 18% of patients, respectively, whereas 73% patients were in New York Heart Association class II or greater. Mean left ventricular ejection fraction, basal septal thickness, and left ventricular outflow tract gradient (resting or provocable) were 62% +/- 5%, 2.2 +/- 1 cm, and 101 +/- 39 mm Hg, respectively. A total of 858 patients (56%) underwent exercise echocardiography, of whom 503 (59%) had exercise capacity impairment. At 8.1 +/- 6 years, 990 patients (65%) underwent surgical relief of left ventricular outflow tract obstruction, and 540 patients (35%) did not. There were 156 events (10%) (134 deaths), with 0% 30-day mortality in the surgical group. On multivariable Cox proportional hazard analysis, increasing age (hazard ratio [HR], 1.20), coronary artery disease (HR, 1.68), worse New York Heart Association class (HR, 1.46), and atrial fibrillation (HR, 1.90) predicted higher events, whereas surgery (time-dependent covariate HR, 0.57) was associated with improved event-free survival (all P < .01).
AB  - CONCLUSIONS: In patients with hypertrophic cardiomyopathy and severe left ventricular outflow tract obstruction, in whom the decision regarding surgery was based on the presence of intractable symptoms and impaired exercise capacity, surgery was associated with significant improvement in long-term composite outcomes.Copyright © 2015 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.
ES  - 1097-685X
IL  - 0022-5223
DI  - S0022-5223(15)01281-7
DO  - http://dx.doi.org/10.1016/j.jtcvs.2015.07.063
PT  - Journal Article
PT  - Observational Study
LG  - English
EP  - 20150726
DP  - 2015 Oct
DC  - 20151001
YR  - 2015
ED  - 20151231
UP  - 20160104
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26318357

<76. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26378015
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Andersen K
AU  - Rasmussen F
AU  - Held C
AU  - Neovius M
AU  - Tynelius P
AU  - Sundstrom J
FA  - Andersen, Kasper
FA  - Rasmussen, Finn
FA  - Held, Claes
FA  - Neovius, Martin
FA  - Tynelius, Per
FA  - Sundstrom, Johan
IN  - Andersen,Kasper. Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, SE-751 85, Sweden kasper.andersen@medsci.uu.se.
IN  - Rasmussen,Finn. Child and Adolescent Public Health Epidemiology Unit, Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden.
IN  - Held,Claes. Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, SE-751 85, Sweden.
IN  - Neovius,Martin. Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
IN  - Tynelius,Per. Child and Adolescent Public Health Epidemiology Unit, Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden.
IN  - Sundstrom,Johan. Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, SE-751 85, Sweden.
TI  - Exercise capacity and muscle strength and risk of vascular disease and arrhythmia in 1.1 million young Swedish men: cohort study.
SO  - BMJ. 351:h4543, 2015.
AS  - BMJ. 351:h4543, 2015.
NJ  - BMJ (Clinical research ed.)
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 8900488, bmj, 101090866
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - Adolescent
MH  - *Arrhythmias, Cardiac/et [Etiology]
MH  - Arrhythmias, Cardiac/pp [Physiopathology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Bradycardia/pp [Physiopathology]
MH  - Cohort Studies
MH  - *Exercise
MH  - Exercise Test
MH  - Humans
MH  - Male
MH  - *Muscle Strength
MH  - Risk Assessment
MH  - Sweden
MH  - *Vascular Diseases/et [Etiology]
MH  - Vascular Diseases/pp [Physiopathology]
MH  - Young Adult
AB  - OBJECTIVE: To investigate the associations of exercise capacity and muscle strength in late adolescence with risk of vascular disease and arrhythmia.
AB  - DESIGN: Cohort study.
AB  - SETTING: General population in Sweden.
AB  - PARTICIPANTS: 1.1 million men who participated in mandatory military conscription between 1 August 1972 and 31 December 1995, at a median age of 18.2 years. Participants were followed until 31 December 2010.
AB  - MAIN OUTCOMES: Associations between exercise capacity and muscle strength with risk of vascular disease and subgroups (ischaemic heart disease, heart failure, stroke, and cardiovascular death) and risk of arrhythmia and subgroups (atrial fibrillation or flutter, bradyarrhythmia, supraventricular tachycardia, and ventricular arrhythmia or sudden cardiac death). Maximum exercise capacity was estimated by the ergometer bicycle test, and muscle strength was measured as handgrip strength by a hand dynamometer. High exercise capacity or muscle strength was deemed as above the median level.
AB  - RESULTS: During a median follow-up of 26.3 years, 26088 vascular disease events and 17312 arrhythmia events were recorded. Exercise capacity was inversely associated with risk of vascular disease and its subgroups. Muscle strength was also inversely associated with vascular disease risk, driven by associations of higher muscle strength with lower risk of heart failure and cardiovascular death. Exercise capacity had a U shaped association with risk of arrhythmia, driven by a direct association with risk of atrial fibrillation and a U shaped association with bradyarrhythmia. Higher muscle strength was associated with lower risk of arrhythmia (specifically, lower risk of bradyarrhythmia and ventricular arrhythmia). The combination of high exercise capacity and high muscle strength was associated with a hazard ratio of 0.67 (95% confidence interval 0.65 to 0.70) for vascular events and 0.92 (0.88 to 0.97) for arrhythmia compared with the combination of low exercise capacity and low muscle strength.
AB  - CONCLUSIONS: Exercise capacity and muscle strength in late adolescence are independently and jointly associated with long term risk of vascular disease and arrhythmia. The health benefit of lower risk of vascular events with higher exercise capacity was not outweighed by higher risk of arrhythmia.Copyright © Andersen et al 2015.
ES  - 1756-1833
IL  - 0959-535X
DO  - http://dx.doi.org/10.1136/bmj.h4543
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20150916
DP  - 2015
DC  - 20150917
YR  - 2015
ED  - 20151231
UP  - 20160104
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26378015

<77. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26318357
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Desai MY
AU  - Smedira NG
AU  - Bhonsale A
AU  - Thamilarasan M
AU  - Lytle BW
AU  - Lever HM
FA  - Desai, Milind Y
FA  - Smedira, Nicholas G
FA  - Bhonsale, Aditya
FA  - Thamilarasan, Maran
FA  - Lytle, Bruce W
FA  - Lever, Harry M
IN  - Desai,Milind Y. Hypertrophic Cardiomyopathy Center, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: desaim2@ccf.org.
IN  - Smedira,Nicholas G. Hypertrophic Cardiomyopathy Center, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
IN  - Bhonsale,Aditya. Hypertrophic Cardiomyopathy Center, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
IN  - Thamilarasan,Maran. Hypertrophic Cardiomyopathy Center, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
IN  - Lytle,Bruce W. Hypertrophic Cardiomyopathy Center, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
IN  - Lever,Harry M. Hypertrophic Cardiomyopathy Center, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
TI  - Symptom assessment and exercise impairment in surgical decision making in hypertrophic obstructive cardiomyopathy: Relationship to outcomes.
CM  - Comment in: J Thorac Cardiovasc Surg. 2015 Oct;150(4):936-7; PMID: 26424373
CM  - Comment in: J Thorac Cardiovasc Surg. 2016 Feb;151(2):303-4; PMID: 26481280
SO  - Journal of Thoracic & Cardiovascular Surgery. 150(4):928-35.e1, 2015 Oct.
AS  - J Thorac Cardiovasc Surg. 150(4):928-35.e1, 2015 Oct.
NJ  - The Journal of thoracic and cardiovascular surgery
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - k9j, 0376343
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Cardiomyopathy, Hypertrophic/di [Diagnosis]
MH  - *Cardiomyopathy, Hypertrophic/pp [Physiopathology]
MH  - *Clinical Decision-Making
MH  - *Exercise Test
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Symptom Assessment
MH  - Ventricular Function, Left
KW  - hypertrophic cardiomyopathy;  outcomes;  surgical myectomy
AB  - OBJECTIVES: We sought to assess the long-term outcomes in patients with hypertrophic cardiomyopathy and severe left ventricular outflow tract obstruction, in whom the decision regarding surgery (vs conservative management) was based on assessment of symptoms or exercise capacity.
AB  - METHODS: This was an observational study of 1530 patients with hypertrophic cardiomyopathy (aged 50 +/- 13 years, 63% were men) with severe left ventricular outflow tract obstruction (excluding those aged <18 years, with left ventricular ejection fraction <50%, and with left ventricular outflow tract gradient <30 mm Hg). A composite end point of death (excluding noncardiac causes) and/or implantable defibrillator discharge was assessed.
AB  - RESULTS: Coronary artery disease, family history of hypertrophic cardiomyopathy, and syncope were present in 15%, 17%, and 18% of patients, respectively, whereas 73% patients were in New York Heart Association class II or greater. Mean left ventricular ejection fraction, basal septal thickness, and left ventricular outflow tract gradient (resting or provocable) were 62% +/- 5%, 2.2 +/- 1 cm, and 101 +/- 39 mm Hg, respectively. A total of 858 patients (56%) underwent exercise echocardiography, of whom 503 (59%) had exercise capacity impairment. At 8.1 +/- 6 years, 990 patients (65%) underwent surgical relief of left ventricular outflow tract obstruction, and 540 patients (35%) did not. There were 156 events (10%) (134 deaths), with 0% 30-day mortality in the surgical group. On multivariable Cox proportional hazard analysis, increasing age (hazard ratio [HR], 1.20), coronary artery disease (HR, 1.68), worse New York Heart Association class (HR, 1.46), and atrial fibrillation (HR, 1.90) predicted higher events, whereas surgery (time-dependent covariate HR, 0.57) was associated with improved event-free survival (all P < .01).
AB  - CONCLUSIONS: In patients with hypertrophic cardiomyopathy and severe left ventricular outflow tract obstruction, in whom the decision regarding surgery was based on the presence of intractable symptoms and impaired exercise capacity, surgery was associated with significant improvement in long-term composite outcomes.Copyright © 2015 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.
ES  - 1097-685X
IL  - 0022-5223
DI  - S0022-5223(15)01281-7
DO  - http://dx.doi.org/10.1016/j.jtcvs.2015.07.063
PT  - Journal Article
PT  - Observational Study
LG  - English
EP  - 20150726
DP  - 2015 Oct
DC  - 20151001
YR  - 2015
ED  - 20151231
RD  - 20160519
UP  - 20160520
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=26318357

<78. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26378015
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Andersen K
AU  - Rasmussen F
AU  - Held C
AU  - Neovius M
AU  - Tynelius P
AU  - Sundstrom J
FA  - Andersen, Kasper
FA  - Rasmussen, Finn
FA  - Held, Claes
FA  - Neovius, Martin
FA  - Tynelius, Per
FA  - Sundstrom, Johan
IN  - Andersen,Kasper. Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, SE-751 85, Sweden kasper.andersen@medsci.uu.se.
IN  - Rasmussen,Finn. Child and Adolescent Public Health Epidemiology Unit, Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden.
IN  - Held,Claes. Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, SE-751 85, Sweden.
IN  - Neovius,Martin. Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
IN  - Tynelius,Per. Child and Adolescent Public Health Epidemiology Unit, Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden.
IN  - Sundstrom,Johan. Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, SE-751 85, Sweden.
TI  - Exercise capacity and muscle strength and risk of vascular disease and arrhythmia in 1.1 million young Swedish men: cohort study.
SO  - BMJ. 351:h4543, 2015.
AS  - BMJ. 351:h4543, 2015.
NJ  - BMJ (Clinical research ed.)
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 8900488, bmj, 101090866
OI  - Source: NLM. PMC4768156
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - Adolescent
MH  - *Arrhythmias, Cardiac/et [Etiology]
MH  - Arrhythmias, Cardiac/pp [Physiopathology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Bradycardia/pp [Physiopathology]
MH  - Cohort Studies
MH  - *Exercise
MH  - Exercise Test
MH  - Humans
MH  - Male
MH  - *Muscle Strength
MH  - Risk Assessment
MH  - Sweden
MH  - *Vascular Diseases/et [Etiology]
MH  - Vascular Diseases/pp [Physiopathology]
MH  - Young Adult
AB  - OBJECTIVE: To investigate the associations of exercise capacity and muscle strength in late adolescence with risk of vascular disease and arrhythmia.
AB  - DESIGN: Cohort study.
AB  - SETTING: General population in Sweden.
AB  - PARTICIPANTS: 1.1 million men who participated in mandatory military conscription between 1 August 1972 and 31 December 1995, at a median age of 18.2 years. Participants were followed until 31 December 2010.
AB  - MAIN OUTCOMES: Associations between exercise capacity and muscle strength with risk of vascular disease and subgroups (ischaemic heart disease, heart failure, stroke, and cardiovascular death) and risk of arrhythmia and subgroups (atrial fibrillation or flutter, bradyarrhythmia, supraventricular tachycardia, and ventricular arrhythmia or sudden cardiac death). Maximum exercise capacity was estimated by the ergometer bicycle test, and muscle strength was measured as handgrip strength by a hand dynamometer. High exercise capacity or muscle strength was deemed as above the median level.
AB  - RESULTS: During a median follow-up of 26.3 years, 26088 vascular disease events and 17312 arrhythmia events were recorded. Exercise capacity was inversely associated with risk of vascular disease and its subgroups. Muscle strength was also inversely associated with vascular disease risk, driven by associations of higher muscle strength with lower risk of heart failure and cardiovascular death. Exercise capacity had a U shaped association with risk of arrhythmia, driven by a direct association with risk of atrial fibrillation and a U shaped association with bradyarrhythmia. Higher muscle strength was associated with lower risk of arrhythmia (specifically, lower risk of bradyarrhythmia and ventricular arrhythmia). The combination of high exercise capacity and high muscle strength was associated with a hazard ratio of 0.67 (95% confidence interval 0.65 to 0.70) for vascular events and 0.92 (0.88 to 0.97) for arrhythmia compared with the combination of low exercise capacity and low muscle strength.
AB  - CONCLUSIONS: Exercise capacity and muscle strength in late adolescence are independently and jointly associated with long term risk of vascular disease and arrhythmia. The health benefit of lower risk of vascular events with higher exercise capacity was not outweighed by higher risk of arrhythmia.Copyright © Andersen et al 2015.
ES  - 1756-1833
IL  - 0959-535X
DO  - http://dx.doi.org/10.1136/bmj.h4543
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20150916
DP  - 2015
DC  - 20150917
YR  - 2015
ED  - 20151231
RD  - 20160302
UP  - 20160304
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=26378015

<79. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26279110
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Chaikriangkrai K
AU  - Valderrabano M
AU  - Bala SK
AU  - Alchalabi S
AU  - Graviss EA
AU  - Nabi F
AU  - Mahmarian J
AU  - Chang SM
FA  - Chaikriangkrai, Kongkiat
FA  - Valderrabano, Miguel
FA  - Bala, Sayf Khaleel
FA  - Alchalabi, Sama
FA  - Graviss, Edward A
FA  - Nabi, Faisal
FA  - Mahmarian, John
FA  - Chang, Su Min
IN  - Chaikriangkrai,Kongkiat. Department of Medicine, Houston Methodist Hospital, Houston, Texas. Electronic address: supersoon@gmail.com.
IN  - Valderrabano,Miguel. Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas.
IN  - Bala,Sayf Khaleel. Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas.
IN  - Alchalabi,Sama. Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas.
IN  - Graviss,Edward A. Houston Methodist Research Institute, Houston Methodist Hospital, Houston, Texas.
IN  - Nabi,Faisal. Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas.
IN  - Mahmarian,John. Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas.
IN  - Chang,Su Min. Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas.
TI  - Prevalence and Implications of Subclinical Coronary Artery Disease in Patients With Atrial Fibrillation.
SO  - American Journal of Cardiology. 116(8):1219-23, 2015 Oct 15.
AS  - Am J Cardiol. 116(8):1219-23, 2015 Oct 15.
NJ  - The American journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Age Factors
MH  - Aged
MH  - *Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/ra [Radiography]
MH  - *Coronary Artery Disease/ep [Epidemiology]
MH  - Coronary Artery Disease/ra [Radiography]
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multidetector Computed Tomography
MH  - Prevalence
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Vascular Calcification/co [Complications]
MH  - Vascular Calcification/ra [Radiography]
AB  - The objective of this study was to examine prevalence and clinical implications of subclinical coronary artery disease (CAD) detected by coronary artery calcium score (CACS) testing in patients with atrial fibrillation (AF). CACS was assessed in patients without history of CAD undergoing catheter ablation of AF. Age- and gender-matched patients with normal sinus rhythm (NSR) presenting with chest pain served as controls. Predicted arterial age using the Multi-Ethnic Study of Atherosclerosis registry was also compared to the chronologic age. A total of 860 patients (430 AF and 430 NSR, age 63 +/- 10 years, 65% men) were included. Subclinical CAD prevalence (CACS >0) was 74% (319 of 430) in the AF group. Compared to the patients with NSR, patients with AF had higher prevalence of Subclinical CAD (74% vs 63%; p <0.001). In multivariate analysis, AF was independently associated with Subclinical CAD (hazard ratio 1.60; p = 0.002) but only with persistent AF (hazard ratio 2.28; p <0.001). Predicted arterial age was greater than chronologic age in patients with AF (69 +/- 12 vs 64 +/- 9 years). CACS-diagnosed subclinical CAD identified new potential candidates for statin therapy (12%; 33 of 267) and for oral anticoagulation (19%; 40 of 206) by addition of subclinical CAD to the CHA2DS2-VASc scores. In conclusion, in patients without known history of CAD, prevalence of subclinical CAD was significantly higher in those with persistent AF than those with NSR. AF was associated with subclinical CAD independently and complimentarily to clinical risk factors. Identifying subclinical CAD has potential clinical indications for prevention of CAD progression and stroke. Copyright © 2015 Elsevier Inc. All rights reserved.
ES  - 1879-1913
IL  - 0002-9149
DI  - S0002-9149(15)01701-4
DO  - http://dx.doi.org/10.1016/j.amjcard.2015.07.041
PT  - Journal Article
PT  - Observational Study
LG  - English
EP  - 20150728
DP  - 2015 Oct 15
DC  - 20150929
YR  - 2015
ED  - 20151229
UP  - 20151230
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26279110

<80. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26205342
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Baczko I
AU  - Light PE
FA  - Baczko, Istvan
FA  - Light, Peter E
IN  - Baczko,Istvan. Department of Pharmacology and Pharmacotherapy, University of Szeged, Szeged, Hungary.
IN  - Light,Peter E. Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada.
TI  - Resveratrol and derivatives for the treatment of atrial fibrillation. [Review]
SO  - Annals of the New York Academy of Sciences. 1348(1):68-74, 2015 Aug.
AS  - Ann N Y Acad Sci. 1348(1):68-74, 2015 Aug.
NJ  - Annals of the New York Academy of Sciences
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 5nm, 7506858
SB  - Index Medicus
CP  - United States
MH  - Animals
MH  - Anti-Arrhythmia Agents/pd [Pharmacology]
MH  - *Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Cardiotonic Agents/pd [Pharmacology]
MH  - Cardiotonic Agents/tu [Therapeutic Use]
MH  - Humans
MH  - Stilbenes/pd [Pharmacology]
MH  - *Stilbenes/tu [Therapeutic Use]
KW  - arrhythmias;  atrial fibrillation;  drug design;  ion channels;  resveratrol
AB  - Resveratrol is a bioactive polyphenol, found in grapes, red wine, and peanuts, and has recently garnered much media and scientific attention for its diverse beneficial health effects as a nutritional supplement or nutraceutical. Of particular interest are the well-documented cardioprotective effects of resveratrol that are mediated by diverse mechanisms, including its antioxidant and vascular effects. However, it is now becoming clear that resveratrol may also exhibit direct effects on cardiac function and rhythm through modulation of signaling pathways that regulate cardiac remodeling and ion channel activity that controls cardiac excitability. Resveratrol may therefore possess antiarrhythmic properties that contribute to the cardiovascular benefits of resveratrol. Atrial fibrillation (AF) is the most common cardiac arrhythmia, although current therapies are suboptimal. Our laboratory has been studying resveratrol's effects on cardiac ion channels and remodeling pathways, and we initiated a drug development program aimed at generating novel resveratrol derivatives with improved efficacy against AF when compared to currently available therapeutics. This review therefore focuses on the effects of resveratrol and new derivatives on a variety of cardiac ion channels and molecular pathways that contribute to the development and maintenance of atrial fibrillation. Copyright © 2015 New York Academy of Sciences.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Stilbenes)
RN  - Q369O8926L (resveratrol)
ES  - 1749-6632
IL  - 0077-8923
DO  - http://dx.doi.org/10.1111/nyas.12843
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
LG  - English
EP  - 20150723
DP  - 2015 Aug
DC  - 20150828
YR  - 2015
ED  - 20151229
UP  - 20151230
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26205342

<81. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25616425
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Stollberger C
AU  - Finsterer J
FA  - Stollberger, C
FA  - Finsterer, J
IN  - Stollberger,C. 2. Medizinische Abteilung, Krankenanstalt Rudolfstiftung, Juchgasse 25, 1030, Vienna, Austria, claudia.stoellberger@chello.at.
TI  - Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban. [Review]
SO  - Herz. 40 Suppl 2:140-5, 2015 Apr.
AS  - Herz. 40 Suppl 2:140-5, 2015 Apr.
NJ  - Herz
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - f88, 7801231
SB  - Index Medicus
CP  - Germany
MH  - Administration, Oral
MH  - *Antithrombins/pk [Pharmacokinetics]
MH  - *Antithrombins/tu [Therapeutic Use]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/me [Metabolism]
MH  - Dabigatran/pk [Pharmacokinetics]
MH  - Dabigatran/tu [Therapeutic Use]
MH  - Drug Interactions
MH  - Factor Xa Inhibitors/pk [Pharmacokinetics]
MH  - Factor Xa Inhibitors/tu [Therapeutic Use]
MH  - Humans
MH  - *P-Glycoprotein/me [Metabolism]
MH  - Pyrazoles/pk [Pharmacokinetics]
MH  - Pyrazoles/tu [Therapeutic Use]
MH  - Pyridones/pk [Pharmacokinetics]
MH  - Pyridones/tu [Therapeutic Use]
MH  - Rivaroxaban/pk [Pharmacokinetics]
MH  - Rivaroxaban/tu [Therapeutic Use]
MH  - *Stroke/me [Metabolism]
MH  - *Stroke/pc [Prevention & Control]
MH  - Treatment Outcome
AB  - BACKGROUND: The new oral anticoagulants (NOAC) dabigatran etexilate, rivaroxaban, and apixaban show similar efficacy for stroke prevention in patients with atrial fibrillation (AF) as the vitamin K antagonist warfarin. Absorption of NOACs is dependent on the intestinal P-glycoprotein (P-gp) system and P-gp activity is modulated by a variety of drugs and food components.
AB  - OBJECTIVE: The aim of this review is to give an overview of P-gp-associated drug-drug and drug-food interactions with NOACs in AF patients.
AB  - METHODS: A literature search was carried out by screening MEDLINE for the terms dabigatran, rivaroxaban, apixaban, P-glycoprotein, and atrial fibrillation from 1998 to 2013. Randomized clinical trials, longitudinal studies, case series, and case reports were included.
AB  - RESULTS: Concomitant medication with proton pump inhibitors, amiodarone, clarithromycin, and verapamil increased bioavailability whereas rifampicin decreased the bioavailability of dabigatran. Coadministration of erythromycin, clarithromycin, fluconazole, ketoconazole, and ritonavir increased rivaroxaban plasma concentrations. No data were found on apixaban and P-gp-modulating drugs or on NOACs and food components modulating P-gp. The clinical relevance of interactions between NOACs and P-gp-modulating drugs or food components is largely unknown as bleeding complications under NOACs and P-gp-inhibiting drugs are mainly reported from patients with concomitant renal failure.
AB  - CONCLUSION: There is an urgent need to investigate the role of P-gp-modulating substances as potential sources of drug-drug and drug-food interactions. A thorough analysis of the data accumulated in the three large NOAC trials regarding the role of P-gp-modulating drugs in bleeding and embolic events is desirable. Pharmacological studies should investigate the influence of P-gp-modulating drugs and food on NOAC plasma concentrations and coagulation parameters. When prescribing NOACs, patients should be informed about the potential interactions with drugs and herbal drugs. Patients who develop bleeding or embolic events under treatment with NOACs should be investigated for co-medications as well as for over-the-counter drugs and dietary habits. In post-marketing surveillance of NOACs, the association with drug or food intake with complications, bleeding, and embolic events should be registered.
RN  - 0 (Antithrombins)
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (P-Glycoprotein)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridones)
RN  - 3Z9Y7UWC1J (apixaban)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - I0VM4M70GC (Dabigatran)
ES  - 1615-6692
IL  - 0340-9937
DO  - http://dx.doi.org/10.1007/s00059-014-4188-9
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20150125
DP  - 2015 Apr
DC  - 20150409
YR  - 2015
ED  - 20151228
UP  - 20151229
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25616425

<82. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25854443
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Souvatzis X
AU  - Kalogridaki M
AU  - Mavrakis HE
AU  - Kanoupakis EM
AU  - Marouli D
AU  - Vardas P
AU  - Askitopoulou H
FA  - Souvatzis, Xenia
FA  - Kalogridaki, Marina
FA  - Mavrakis, Hercules E
FA  - Kanoupakis, Emmanouel M
FA  - Marouli, Diamantina
FA  - Vardas, Panos
FA  - Askitopoulou, Helen
IN  - Souvatzis,Xenia. Department of Anaesthesiology, Faculty of Medicine, University of Crete, Heraklion, Crete, Greece.
TI  - Adding fentanyl to etomidate fails to reduce painful recall of external direct current cardioversion in adults: a randomised trial.
SO  - Hjc Hellenic Journal of Cardiology. 56(2):142-8, 2015 Mar-Apr.
AS  - HJC Hell. J. Cardiol.. 56(2):142-8, 2015 Mar-Apr.
NJ  - Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101257381
SB  - Index Medicus
CP  - Greece
MH  - Aged
MH  - Analgesics, Opioid/ad [Administration & Dosage]
MH  - Analgesics, Opioid/pk [Pharmacokinetics]
MH  - Anesthesia/mt [Methods]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Double-Blind Method
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Electric Countershock/ae [Adverse Effects]
MH  - Electric Countershock/mt [Methods]
MH  - *Electric Countershock
MH  - Etomidate/ad [Administration & Dosage]
MH  - Etomidate/pk [Pharmacokinetics]
MH  - *Etomidate
MH  - Female
MH  - Fentanyl/ad [Administration & Dosage]
MH  - Fentanyl/pk [Pharmacokinetics]
MH  - *Fentanyl
MH  - Humans
MH  - Hypnotics and Sedatives/ad [Administration & Dosage]
MH  - Hypnotics and Sedatives/pk [Pharmacokinetics]
MH  - Male
MH  - Middle Aged
MH  - Pain/et [Etiology]
MH  - Pain/pc [Prevention & Control]
MH  - *Pain
MH  - Pain Measurement/mt [Methods]
MH  - Treatment Failure
AB  - INTRODUCTION: External electrical cardioversion under hypnotics, even when combined with opioids, has been consistently described as distressing or painful. The main objective of the present study was to determine if adding an opioid to a hypnotic, in comparison to the same hypnotic alone, would decrease the incidence of unpleasant or painful recall during anaesthesia for external electrical cardioversion.
AB  - METHODS: This was a single-centre, prospective, randomised, double-blinded clinical trial that took place from September 2011 to March 2012. Fifty-two adult patients with persistent atrial fibrillation, scheduled for external direct current cardioversion, were enrolled. Exclusion criteria were age >80 years, previous cardiac surgery, implanted pacemaker or defibrillator, and haemodynamic instability. Patients received intravenously either (group EF) fentanyl 50 g and after 60 s etomidate 0.1 mg/kg, or (group E) only etomidate 0.1 mg/kg. If the patients did not lose their eyelid reflex, repeated doses of etomidate 4 mg were given. Cardioversion was attempted with an extracardiac biphasic electrical shock from 200 to 300 J, at most three times. The primary endpoint was recall of something unpleasant or painful. Secondary outcome measures were predictors of the requirement for repeat doses of etomidate, and the number of shocks needed.
AB  - RESULTS: Fifty-one patients (35 male, 16 female), aged 62.1 +/- 10.2 years, completed the study. There were no differences between group EF and group E regarding recall (unpleasant recall 0 vs. 2 patients, p=0.235; painful recall 1 vs. 0 patients, p=0.510). The administration of etomidate alone was a significant predictor for subsequent repeated doses of etomidate (p=0.049, odds ratio 4.312, 95% confidence interval 1.007-18.460). The number of shocks needed to restore sinus rhythm did not differ between the groups (p=0.846).
AB  - CONCLUSIONS: In the present study, the addition of fentanyl to etomidate did not diminish distressing or painful experience during anaesthesia for external cardioversion.
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Hypnotics and Sedatives)
RN  - UF599785JZ (Fentanyl)
RN  - Z22628B598 (Etomidate)
ES  - 2241-5955
IL  - 1109-9666
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 2015 Mar-Apr
DC  - 20150409
YR  - 2015
ED  - 20151228
UP  - 20151229
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25854443

<83. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26702314
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Okumura Y
AU  - Watanabe I
AU  - Nagashima K
AU  - Sonoda K
AU  - Sasaki N
AU  - Kogawa R
AU  - Takahashi K
AU  - Iso K
AU  - Ohkubo K
AU  - Nakai T
AU  - Takahashi R
AU  - Taniguchi Y
AU  - Mitsumata M
AU  - Nikaido M
AU  - Hirayama A
FA  - Okumura, Yasuo
FA  - Watanabe, Ichiro
FA  - Nagashima, Koichi
FA  - Sonoda, Kazumasa
FA  - Sasaki, Naoko
FA  - Kogawa, Rikitake
FA  - Takahashi, Keiko
FA  - Iso, Kazuki
FA  - Ohkubo, Kimie
FA  - Nakai, Toshiko
FA  - Takahashi, Rie
FA  - Taniguchi, Yoshiki
FA  - Mitsumata, Masako
FA  - Nikaido, Mizuki
FA  - Hirayama, Atsushi
IN  - Okumura,Yasuo. Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Ohyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan.
IN  - Watanabe,Ichiro. Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Ohyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan.
IN  - Nagashima,Koichi. Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Ohyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan.
IN  - Sonoda,Kazumasa. Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Ohyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan.
IN  - Sasaki,Naoko. Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Ohyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan.
IN  - Kogawa,Rikitake. Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Ohyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan.
IN  - Takahashi,Keiko. Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Ohyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan.
IN  - Iso,Kazuki. Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Ohyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan.
IN  - Ohkubo,Kimie. Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Ohyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan.
IN  - Nakai,Toshiko. Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Ohyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan.
IN  - Takahashi,Rie. Department of Advanced Cardiovascular Imaging, Nihon University School of Medicine, Tokyo, Japan.
IN  - Taniguchi,Yoshiki. Institute of Medical Science, Medical Research Support Center, Section of Laboratory for Animal Experiments, Nihon University School of Medicine, Tokyo, Japan.
IN  - Mitsumata,Masako. Department of Pathology, Nihon University School of Medicine, Tokyo, Japan.
IN  - Nikaido,Mizuki. Nihon Kohden Corporation Tokyo, Japan.
IN  - Hirayama,Atsushi. Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Ohyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan.
TI  - Effects of a high-fat diet on the electrical properties of porcine atria.
SO  - Journal of Arrhythmia. 31(6):352-8, 2015 Dec.
AS  - J. of arrhythm.. 31(6):352-8, 2015 Dec.
NJ  - Journal of arrhythmia
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - 101263026
OI  - Source: NLM. PMC4672030
CP  - Japan
KW  - Atrial fibrillation;  Electrical properties;  High-fat diet
AB  - BACKGROUND: Because obesity is an important risk factor for atrial fibrillation (AF), we conducted an animal study to examine the effect of a high-fat diet (HFD) on atrial properties and AF inducibility.
AB  - METHODS: Ten 8-week-old pigs (weight, 18-23 kg) were divided into two groups. For 18 weeks, five pigs were fed a HFD (HFD group) and five were fed a normal diet (control group). Maps of atrial activation and voltages during sinus rhythm were created for all pigs using the EnSite NavX system. Effective refractory period (ERP) and AF inducibility were also determined. When AF was induced, complex fractionated atrial electrogram (CFAE) mapping was performed. At 18 weeks, hearts were removed for comparing the results of histological analysis between the two groups. Body weight, lipid levels, hemodynamics, cardiac structures, and electrophysiological properties were also compared.
AB  - RESULTS: Total cholesterol levels were significantly higher (347 [191-434] vs. 81 [67-88] mg/dL, P=0.0088), and left atrium pressure was higher (34.5 [25.6-39.5] vs. 24.5 [21.3-27.8] mmHg, P=0.0833) in the HFD group than in the control group, although body weight only increased marginally (89 [78-101] vs. 70 [66-91] kg, P=0.3472). ERPs of the pulmonary vein (PV) were shorter (P<0.05) and AF lasted longer in the HFD group than in the control group (80 [45-1350] vs. 22 [3-30] s, P=0.0212). Neither CFAE site distribution nor histopathological characteristics differed between the two groups.
AB  - CONCLUSIONS: The shorter ERPs for the PV observed in response to the HFD increased vulnerability to AF, and these electrophysiological characteristics may underlie obesity-related AF.
IS  - 1880-4276
IL  - 1880-4276
DO  - http://dx.doi.org/10.1016/j.joa.2015.05.004
PT  - Journal Article
LG  - English
EP  - 20150617
DP  - 2015 Dec
DC  - 20151224
YR  - 2015
ED  - 20151224
RD  - 20151226
UP  - 20151228
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=26702314

<84. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26702311
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Deutsch SB
AU  - Krivitsky EL
FA  - Deutsch, Steven Brent
FA  - Krivitsky, Eric Lawrence
IN  - Deutsch,Steven Brent. University of South Florida Morsani College of Medicine, 1 Tampa General Circle, Tampa, FL 33606, USA.
IN  - Krivitsky,Eric Lawrence. University of South Florida Morsani College of Medicine, 1 Tampa General Circle, Tampa, FL 33606, USA.
TI  - The impact of yoga on atrial fibrillation: A review of The Yoga My Heart Study. [Review]
SO  - Journal of Arrhythmia. 31(6):337-8, 2015 Dec.
AS  - J. of arrhythm.. 31(6):337-8, 2015 Dec.
NJ  - Journal of arrhythmia
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - 101263026
OI  - Source: NLM. PMC4672029
CP  - Japan
KW  - Arrhythmia;  Atrial fibrillation;  Exercise;  Health care cost reduction;  Medication alternative
AB  - Atrial fibrillation is a common arrhythmia affecting thousands of individuals worldwide. It is a conduction disorder that causes the heart to beat irregularly and rapidly. There are a few medical approaches to manage this costly health care burden: antiarrhythmics to maintain normal sinus rhythm, beta blockers to achieve rate control while allowing atrial fibrillation to persist, and electro-physiologic intervention for rate and rhythm control. These treatments can be costly and are not without side effects. Yoga, an intervention that is available to people worldwide, has shown some promise in combating this widespread heart disorder.
IS  - 1880-4276
IL  - 1880-4276
DO  - http://dx.doi.org/10.1016/j.joa.2015.05.001
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20150606
DP  - 2015 Dec
DC  - 20151224
YR  - 2015
ED  - 20151224
RD  - 20151226
UP  - 20151228
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=26702311

<85. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26206849
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Guasch E
AU  - Mont L
AI  - Guasch, Eduard; ORCID: http://orcid.org/0000-0003-4238-5319
FA  - Guasch, Eduard
FA  - Mont, Lluis
IN  - Guasch,Eduard. Arrhythmia Unit, Unitat de Fibril.lacio Auricular, Hospital Clinic, Universitat de Barcelona and Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.
IN  - Mont,Lluis. Arrhythmia Unit, Unitat de Fibril.lacio Auricular, Hospital Clinic, Universitat de Barcelona and Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.
TI  - Exercise, sex and atrial fibrillation: arrhythmogenesis beyond Y-chromosome?.
CM  - Comment on: Heart. 2015 Oct;101(20):1627-30; PMID: 26019224
SO  - Heart. 101(20):1607-9, 2015 Oct.
AS  - Heart. 101(20):1607-9, 2015 Oct.
NJ  - Heart (British Cardiac Society)
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9602087
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - *Exercise Therapy/mt [Methods]
MH  - Female
MH  - Humans
MH  - *Motor Activity/ph [Physiology]
MH  - *Risk Assessment/mt [Methods]
ES  - 1468-201X
IL  - 1355-6037
DO  - http://dx.doi.org/10.1136/heartjnl-2015-308036
PT  - Comment
PT  - Editorial
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20150723
DP  - 2015 Oct
DC  - 20150926
YR  - 2015
ED  - 20151218
UP  - 20151221
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26206849

<86. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26206848
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gjesdal K
AU  - Grundvold I
FA  - Gjesdal, Knut
FA  - Grundvold, Irene
IN  - Gjesdal,Knut. Department of Cardiology, Oslo University Hospital Ulleval, Oslo, Norway Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
IN  - Grundvold,Irene. Department of Cardiology, Oslo University Hospital Ulleval, Oslo, Norway.
TI  - Atrial fibrillation and exercise in women: some answers given, some questions remain.
CM  - Comment on: Heart. 2015 Oct;101(20):1627-30; PMID: 26019224
SO  - Heart. 101(20):1605-6, 2015 Oct.
AS  - Heart. 101(20):1605-6, 2015 Oct.
NJ  - Heart (British Cardiac Society)
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9602087
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - *Exercise Therapy/mt [Methods]
MH  - Female
MH  - Humans
MH  - *Motor Activity/ph [Physiology]
MH  - *Risk Assessment/mt [Methods]
ES  - 1468-201X
IL  - 1355-6037
DO  - http://dx.doi.org/10.1136/heartjnl-2015-307836
PT  - Comment
PT  - Editorial
LG  - English
EP  - 20150723
DP  - 2015 Oct
DC  - 20150926
YR  - 2015
ED  - 20151218
UP  - 20151221
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26206848

<87. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25573076
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Murray JM
AU  - Hellinger A
AU  - Dionne R
AU  - Brown L
AU  - Galvin R
AU  - Griggs S
AU  - Mittler K
AU  - Harney K
AU  - Manzi S
AU  - VanderPluym C
AU  - Baker A
AU  - O'Brien P
AU  - O'Connell C
AU  - Almond CS
FA  - Murray, Jenna M
FA  - Hellinger, Amy
FA  - Dionne, Roger
FA  - Brown, Loren
FA  - Galvin, Rosemary
FA  - Griggs, Suzanne
FA  - Mittler, Karen
FA  - Harney, Kathy
FA  - Manzi, Shannon
FA  - VanderPluym, Christina
FA  - Baker, Annette
FA  - O'Brien, Patricia
FA  - O'Connell, Cheryl
FA  - Almond, Christopher S
IN  - Murray,Jenna M. Department of Cardiology, Boston Children's Hospital, Boston, USA.
TI  - Utility of a dedicated pediatric cardiac anticoagulation program: the Boston Children's Hospital experience.
SO  - Pediatric Cardiology. 36(4):842-50, 2015 Apr.
AS  - Pediatr Cardiol. 36(4):842-50, 2015 Apr.
NJ  - Pediatric cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - pa3, 8003849
SB  - Index Medicus
CP  - United States
MH  - Adolescent
MH  - Adult
MH  - Anticoagulants/ad [Administration & Dosage]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - *Blood Coagulation/de [Drug Effects]
MH  - Boston
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - *Heart Defects, Congenital/co [Complications]
MH  - Heart Defects, Congenital/pp [Physiopathology]
MH  - Humans
MH  - Infant
MH  - International Normalized Ratio
MH  - Male
MH  - Middle Aged
MH  - *Primary Health Care/mt [Methods]
MH  - Primary Health Care/og [Organization & Administration]
MH  - *Primary Health Care/ut [Utilization]
MH  - Warfarin/ad [Administration & Dosage]
MH  - *Warfarin/tu [Therapeutic Use]
MH  - Young Adult
AB  - Congenital heart disease is the leading cause of stroke in children. Warfarin therapy can be difficult to manage safely in this population because of its narrow therapeutic index, multiple drug and dietary interactions, small patient size, high-risk cardiac indications, and lack of data to support anticoagulation recommendations. We sought to describe our institution's effort to develop a dedicated cardiac anticoagulation service to address the special needs of this population and to review the literature. In 2009, in response to Joint Commission National Patient Safety Goals for Anticoagulation, Boston Children's Hospital created a dedicated pediatric Cardiac Anticoagulation Monitoring Program (CAMP). The primary purpose was to provide centralized management of outpatient anticoagulation to cardiac patients, to serve as a disease-specific resource to families and providers, and to devise strategies to evolve clinical care with rapidly emerging trends in anticoagulation care. Over 5 years the CAMP Service, staffed by a primary pediatric cardiology attending, a full-time nurse practitioner, and administrative assistant with dedicated support from pharmacy and nutrition, has enrolled over 240 patients ranging in age from 5 months to 55 years. The most common indications include a prosthetic valve (34 %), Fontan prophylaxis (20 %), atrial arrhythmias (11 %), cardiomyopathy (10 %), Kawasaki disease (7 %), and a ventricular assist device (2 %). A patient-centered multi-disciplinary cardiac anticoagulation clinic was created in 2012. Overall program international normalized ratio (INR) time in therapeutic range (TTR) is favorable at 67 % (81 % with a 0.2 margin) and has improved steadily over 5 years. Pediatric-specific guidelines for VKOR1 and CYP2C9 pharmacogenomics testing, procedural bridging with enoxaparin, novel anticoagulant use, and quality metrics have been developed. Program satisfaction is rated highly among families and providers. A dedicated pediatric cardiac anticoagulation program offers a safe and effective strategy to standardize anticoagulation care for pediatric cardiology patients, is associated with high patient and provider satisfaction, and is capable of evolving care strategies with emerging trends in anticoagulation.
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
ES  - 1432-1971
IL  - 0172-0643
DO  - http://dx.doi.org/10.1007/s00246-014-1089-x
PT  - Journal Article
LG  - English
EP  - 20150109
DP  - 2015 Apr
DC  - 20150319
YR  - 2015
ED  - 20151217
UP  - 20151218
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25573076

<88. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26648615
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Tideman PA
AU  - Tirimacco R
AU  - St John A
AU  - Roberts GW
FA  - Tideman, Philip A
FA  - Tirimacco, Rosy
FA  - St John, Andrew
FA  - Roberts, Gregory W
IN  - Tideman,Philip A. Australian Point of Care Practitioners Network ; Integrated Cardiovascular Clinical Network, Country Health South Australia, Adelaide.
IN  - Tirimacco,Rosy. Australian Point of Care Practitioners Network ; Integrated Cardiovascular Clinical Network, Country Health South Australia, Adelaide.
IN  - St John,Andrew. Australian Point of Care Practitioners Network.
IN  - Roberts,Gregory W. Pharmacy Department, Flinders Medical Centre, Adelaide.
TI  - How to manage warfarin therapy. [Review][Erratum appears in Aust Prescr. 2016 Apr;39(2):66; PMID: 27346790]
CM  - Comment in: Aust Prescr. 2016 Apr;39(2):32-3; PMID: 27340114
SO  - Australian Prescriber. 38(2):44-8, 2015 Apr.
AS  - AUST. PRESCR.. 38(2):44-8, 2015 Apr.
NJ  - Australian prescriber
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - 7804938
OI  - Source: NLM. PMC4653986
CP  - Australia
KW  - INR;  anticoagulants;  point-of-care services;  warfarin
AB  - Long-term treatment with warfarin is recommended for patients with atrial fibrillation at risk of stroke and those with recurrent venous thrombosis or prosthetic heart valves. Patient education before commencing warfarin - regarding signs and symptoms of bleeding, the impact of diet, potential drug interactions and the actions to take if a dose is missed - is pivotal to successful use. Scoring systems such as the CHADS2 score are used to determine if patients with atrial fibrillation are suitable for warfarin treatment. To rapidly achieve stable anticoagulation, use an age-adjusted protocol for starting warfarin. Regular monitoring of the anticoagulant effect is required. Evidence suggests that patients who self-monitor using point-of-care testing have better outcomes than other patients.
IS  - 0312-8008
IL  - 0312-8008
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20150401
DP  - 2015 Apr
DC  - 20151209
YR  - 2015
ED  - 20151209
RD  - 20160627
UP  - 20160628
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=26648615

<89. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25788509
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Biszewski M
AU  - Nitzki-George D
AU  - Zhou Y
FA  - Biszewski, Matthew
FA  - Nitzki-George, Diane
FA  - Zhou, Ying
IN  - Biszewski,Matthew. Matthew Biszewski, Pharm.D., BCACP, is Clinical Specialist; and Diane Nitzki-George, Pharm.D., M.B.A., is Clinical Specialist, Thrombosis and Anticoagulation Unit, NorthShore University HealthSystem, Glenbrook Hospital, Glenview, IL. Ying Zhou, Ph.D., is Statistician, Center for Biomedical and Research Informatics, NorthShore University HealthSystem, Evanston, IL.
IN  - Nitzki-George,Diane. Matthew Biszewski, Pharm.D., BCACP, is Clinical Specialist; and Diane Nitzki-George, Pharm.D., M.B.A., is Clinical Specialist, Thrombosis and Anticoagulation Unit, NorthShore University HealthSystem, Glenbrook Hospital, Glenview, IL. Ying Zhou, Ph.D., is Statistician, Center for Biomedical and Research Informatics, NorthShore University HealthSystem, Evanston, IL. dgeorge@northshore.org.
IN  - Zhou,Ying. Matthew Biszewski, Pharm.D., BCACP, is Clinical Specialist; and Diane Nitzki-George, Pharm.D., M.B.A., is Clinical Specialist, Thrombosis and Anticoagulation Unit, NorthShore University HealthSystem, Glenbrook Hospital, Glenview, IL. Ying Zhou, Ph.D., is Statistician, Center for Biomedical and Research Informatics, NorthShore University HealthSystem, Evanston, IL.
TI  - Comparison of warfarin time in the therapeutic range at a pharmacist-run anticoagulation clinic and the RE-LY trial.
SO  - American Journal of Health-System Pharmacy. 72(7):557-62, 2015 Apr 1.
AS  - Am J Health-Syst Pharm. 72(7):557-62, 2015 Apr 1.
NJ  - American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 9503023, cbh
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Algorithms
MH  - Ambulatory Care Facilities
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - Endpoint Determination
MH  - Female
MH  - Humans
MH  - International Normalized Ratio
MH  - Male
MH  - Middle Aged
MH  - *Pharmacists
MH  - Point-of-Care Systems
MH  - *Warfarin/tu [Therapeutic Use]
AB  - PURPOSE: An audit was conducted to determine if the benefits of dabigatran treatment, as demonstrated in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial, are applicable to patients with nonvalvular atrial fibrillation managed by a pharmacist-run anticoagulation clinic (PAC).
AB  - METHODS: The records of warfarin-treated patients managed by a PAC program over a three-year period were screened to identify patients with diagnosed nonvalvular atrial fibrillation and a goal International Normalized Ratio (INR) of 2-3; the case selection criteria were similar to those used in the RE-LY trial. Abstracted data included dates and results of INR monitoring and information needed to calculate CHADS2 (Congestive Heart Failure, Hypertension, Age, Diabetes, and Stroke [doubled]) scores. Warfarin time in the therapeutic range (TTR) was the primary endpoint. A pairwise comparison of TTR distributions in subsets of patients grouped by CHADS2 score was performed to test the hypothesis that any two groups had identical distributions.
AB  - RESULTS: Data on 314 PAC patients, including 9772 INR values, were analyzed. The mean+/-S.D. TTR was 62.4%+/-24.5% (median, 66.7%), which was similar to the mean TTR reported in the RE-LY trial (p=0.092). The distribution of TTR values in the PAC population differed significantly in patients with a CHADS2 score of 2 versus a score of 3 (p=0.0333 for Kuiper test), but no other significant differences were noted.
AB  - CONCLUSION: TTR values among PAC-managed patients with nonvalvular atrial fibrillation were comparable to those reported in the RE-LY trial.Copyright © 2015 by the American Society of Health-System Pharmacists, Inc. All rights reserved.
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
ES  - 1535-2900
IL  - 1079-2082
DO  - http://dx.doi.org/10.2146/ajhp130800
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 2015 Apr 1
DC  - 20150319
YR  - 2015
ED  - 20151208
UP  - 20151217
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25788509

<90. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25757005
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lavie CJ
AU  - O'Keefe JH
AU  - Sallis RE
FA  - Lavie, Carl J
FA  - O'Keefe, James H
FA  - Sallis, Robert E
IN  - Lavie,Carl J. 1Department of Cardiovascular Diseases, John Ochsner Heart and Vascular Institute, Ochsner Clinical School, University of Queensland School of Medicine, New Orleans, LA; 2St. Luke's Mid America Heart Institute, University of Missouri, Kansas City, MO; and 3Department of Family Medicine, Kaiser Permanente Medical Center, Fontana, CA.
TI  - Exercise and the heart--the harm of too little and too much. [Review]
SO  - Current Sports Medicine Reports. 14(2):104-9, 2015 Mar-Apr.
AS  - Curr Sports Med Rep. 14(2):104-9, 2015 Mar-Apr.
NJ  - Current sports medicine reports
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101134380
SB  - Index Medicus
CP  - United States
MH  - Arrhythmias, Cardiac/ep [Epidemiology]
MH  - Arrhythmias, Cardiac/et [Etiology]
MH  - *Arrhythmias, Cardiac/pc [Prevention & Control]
MH  - Death, Sudden, Cardiac/ep [Epidemiology]
MH  - Death, Sudden, Cardiac/et [Etiology]
MH  - Death, Sudden, Cardiac/pc [Prevention & Control]
MH  - *Exercise/ph [Physiology]
MH  - *Heart/ph [Physiology]
MH  - Humans
MH  - *Physical Endurance/ph [Physiology]
MH  - Physical Exertion/ph [Physiology]
MH  - *Sedentary Lifestyle
AB  - Physical activity and exercise training are underutilized by much of Westernized society, and physical inactivity may be the greatest threat to health in the 21st century. Many studies have shown a linear relationship between one's activity level and heart health, leading to the conclusion that "if some exercise is good, more must be better." However, there is evolving evidence that high levels of exercise may produce similar or less overall cardiovascular (CV) benefits compared with those produced by lower doses of exercise. Very high doses of exercise may be associated with increased risk of atrial fibrillation, coronary artery disease, and malignant ventricular arrhythmias. These acute bouts of excessive exercise may lead to cardiac dilatation, cardiac dysfunction, and release of troponin and brain natriuretic peptide. The effects of too little and too much exercise on the heart are reviewed in this article, along with recommendations to optimize the dose of exercise to achieve heart health.
ES  - 1537-8918
IL  - 1537-890X
DO  - http://dx.doi.org/10.1249/JSR.0000000000000134
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2015 Mar-Apr
DC  - 20150311
YR  - 2015
ED  - 20151204
UP  - 20151217
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25757005

<91. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25384613
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ghosh RM
AU  - Gates GJ
AU  - Walsh CA
AU  - Schiller MS
AU  - Pass RH
AU  - Ceresnak SR
FA  - Ghosh, Reena M
FA  - Gates, Gregory J
FA  - Walsh, Christine A
FA  - Schiller, Myles S
FA  - Pass, Robert H
FA  - Ceresnak, Scott R
IN  - Ghosh,Reena M. Division of Pediatric Cardiology, Department of Pediatrics, The Children's Hospital at Montefiore - Albert Einstein College of Medicine, 3415 Bainbridge Ave, Bronx, NY, 10467, USA.
TI  - The prevalence of arrhythmias, predictors for arrhythmias, and safety of exercise stress testing in children.
SO  - Pediatric Cardiology. 36(3):584-90, 2015 Mar.
AS  - Pediatr Cardiol. 36(3):584-90, 2015 Mar.
NJ  - Pediatric cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - pa3, 8003849
SB  - Index Medicus
CP  - United States
MH  - Adolescent
MH  - Arrhythmias, Cardiac/ep [Epidemiology]
MH  - *Arrhythmias, Cardiac/pp [Physiopathology]
MH  - Child
MH  - *Electrocardiography
MH  - *Exercise Test/ae [Adverse Effects]
MH  - *Exercise Test/mt [Methods]
MH  - Female
MH  - Heart Defects, Congenital/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Multivariate Analysis
MH  - Pacemaker, Artificial/ae [Adverse Effects]
MH  - Prevalence
MH  - Retrospective Studies
MH  - *Risk
MH  - Ventricular Dysfunction, Left/pp [Physiopathology]
MH  - Ventricular Dysfunction, Left/us [Ultrasonography]
MH  - Young Adult
AB  - Exercise testing is commonly performed in children for evaluation of cardiac disease. Few data exist, however, on the prevalence, types of arrhythmias, predictors for arrhythmias, and safety of exercise testing in children. A retrospective review of all patients <21 years undergoing exercise testing at our center from 2008 to 2012 was performed. Patients with clinically relevant arrhythmias were compared to those not experiencing a significant arrhythmia. 1,037 tests were performed in 916 patients. The mean age was 14 +/- 4 years, 537 (55 %) were male, 281 (27 %) had congenital heart disease, 178 (17 %) had a history of a prior arrhythmia, and 17 (2 %) had a pacemaker or ICD. 291 (28 %) patients had a rhythm disturbance during the procedure. Clinically important arrhythmias were noted in 34 (3 %) patients and included: 19 (1.8 %) increasing ectopy with exercise, 5 (0.5 %) VT, 5 (0.5 %) second degree AV block, 3 (0.3 %) SVT, and 2 (0.2 %) AFIB. On multivariate logistic regression, variables associated with the development of clinically relevant arrhythmias included severe left ventricular (LV) dysfunction on echo (OR 1.99, CI 1.20-3.30) and prior history of a documented arrhythmia (OR 2.94, CI 1.25-6.88). There were no adverse events related to testing with no patient requiring cardioversion, defibrillation, or acute anti-arrhythmic therapy. A total of 28 % of children developed a rhythm disturbance during exercise testing and 3 % were clinically important. Severe LV dysfunction and a history of documented arrhythmia were associated with the development of a clinically important arrhythmia.
ES  - 1432-1971
IL  - 0172-0643
DO  - http://dx.doi.org/10.1007/s00246-014-1053-9
PT  - Journal Article
LG  - English
EP  - 20141111
DP  - 2015 Mar
DC  - 20150220
YR  - 2015
ED  - 20151204
UP  - 20151217
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25384613

<92. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26180251
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Chiuve SE
AU  - Sandhu RK
AU  - Moorthy MV
AU  - Glynn RJ
AU  - Albert CM
FA  - Chiuve, Stephanie E
FA  - Sandhu, Roopinder K
FA  - Moorthy, M Vinayaga
FA  - Glynn, Robert J
FA  - Albert, Christine M
IN  - Chiuve,Stephanie E. Center for Arrhythmia Prevention, Division of Preventive Medicine, and Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA; and schiuve@hsph.harvard.edu.
IN  - Sandhu,Roopinder K. Division of Preventive Medicine, and Division of Cardiology, University of Alberta, Edmonton, Canada.
IN  - Moorthy,M Vinayaga. Division of Preventive Medicine, and.
IN  - Glynn,Robert J. Division of Preventive Medicine, and.
IN  - Albert,Christine M. Center for Arrhythmia Prevention, Division of Preventive Medicine, and Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA;
TI  - Dietary Fat Intake Is Differentially Associated with Risk of Paroxysmal Compared with Sustained Atrial Fibrillation in Women.
SO  - Journal of Nutrition. 145(9):2092-101, 2015 Sep.
AS  - J Nutr. 145(9):2092-101, 2015 Sep.
NJ  - The Journal of nutrition
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - jev, 0404243
OI  - Source: NLM. PMC4548164 [Available on 09/01/16]
SB  - Index Medicus
CP  - United States
MH  - Atrial Fibrillation/cl [Classification]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - *Dietary Fats/ad [Administration & Dosage]
MH  - Fatty Acids/ad [Administration & Dosage]
MH  - Fatty Acids, Monounsaturated/ad [Administration & Dosage]
MH  - Fatty Acids, Omega-3/ad [Administration & Dosage]
MH  - Fatty Acids, Omega-6/ad [Administration & Dosage]
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Risk Factors
MH  - Surveys and Questionnaires
KW  - atrial fibrillation;  epidemiology;  monounsaturated fatty acids;  saturated fatty acids;  women
AB  - BACKGROUND: Dietary fats have effects on biological pathways that may influence the development and maintenance of atrial fibrillation (AF). However, associations between n-3 (omega-3) polyunsaturated fatty acids and AF are inconsistent, and data on other dietary fats and AF risk are sparse.
AB  - OBJECTIVES: We examined the association between dietary fatty acid (FA) subclasses and risk of incident AF and explored whether these associations differed for sustained and paroxysmal AF.
AB  - METHODS: We conducted a prospective cohort study in 33,665 women >45 y old without cardiovascular disease (CVD) and AF at baseline in 1993. Fat intake was estimated from food frequency questionnaires at baseline and in 2004. Incident AF was confirmed by medical records through October 2013. AF patterns were classified according to the most sustained form of AF within 2 y of diagnosis. Cox proportional hazards models with the use of a competing risk model approach estimated the RR.
AB  - RESULTS: Over 19.2 y, 1441 cases of incident AF (929 paroxysmal and 467 persistent/chronic) were confirmed. Intakes of total fat and FA subclasses were not associated with risk of AF. Saturated fatty acids (SFAs) and monounsaturated fatty acids (MUFAs) were differentially associated with AF patterns. The RR for a 5% increment of energy from SFAs was 1.47 (95% CI: 1.04, 2.09) for persistent/chronic and 0.85 (95% CI: 0.66, 1.08) for paroxysmal AF (P-difference = 0.01). For MUFAs, the RR for a 5% increment was 0.67 (95% CI: 0.46, 0.98) for persistent/chronic and 1.03 (95% CI: 0.78, 1.34) for paroxysmal AF, although the difference between patterns was not significant (P-difference = 0.07).
AB  - CONCLUSIONS: Dietary fat was not associated with risk of incident AF in women without established CVD or AF. High SFA and low MUFA intakes were associated with greater risk of persistent or chronic, but not paroxysmal, AF. Improving dietary fat quality may play a role in the prevention of sustained forms of AF. The Women's Health Study was registered at clinicaltrials.gov as NCT00000479.Copyright © 2015 American Society for Nutrition.
RN  - 0 (Dietary Fats)
RN  - 0 (Fatty Acids)
RN  - 0 (Fatty Acids, Monounsaturated)
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Fatty Acids, Omega-6)
ES  - 1541-6100
IL  - 0022-3166
DO  - http://dx.doi.org/10.3945/jn.115.212860
PT  - Journal Article
PT  - Observational Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
SI  - ClinicalTrials.gov
SA  - ClinicalTrials.gov/NCT00000479
SL  - http://clinicaltrials.gov/search/term=NCT00000479
NO  - CA047988 (United States NCI NIH HHS)
NO  - HL043851 (United States NHLBI NIH HHS)
NO  - HL080467 (United States NHLBI NIH HHS)
NO  - HL093613 (United States NHLBI NIH HHS)
NO  - HL099355 (United States NHLBI NIH HHS)
NO  - K99 HL097068 (United States NHLBI NIH HHS)
NO  - K99 HL097068 (United States NHLBI NIH HHS)
NO  - R00 HL097068 (United States NHLBI NIH HHS)
LG  - English
EP  - 20150715
DP  - 2015 Sep
DC  - 20150902
YR  - 2015
ED  - 20151201
RD  - 20150922
UP  - 20151217
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26180251

<93. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26180251
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Chiuve SE
AU  - Sandhu RK
AU  - Moorthy MV
AU  - Glynn RJ
AU  - Albert CM
FA  - Chiuve, Stephanie E
FA  - Sandhu, Roopinder K
FA  - Moorthy, M Vinayaga
FA  - Glynn, Robert J
FA  - Albert, Christine M
IN  - Chiuve,Stephanie E. Center for Arrhythmia Prevention, Division of Preventive Medicine, and Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA; and schiuve@hsph.harvard.edu.
IN  - Sandhu,Roopinder K. Division of Preventive Medicine, and Division of Cardiology, University of Alberta, Edmonton, Canada.
IN  - Moorthy,M Vinayaga. Division of Preventive Medicine, and.
IN  - Glynn,Robert J. Division of Preventive Medicine, and.
IN  - Albert,Christine M. Center for Arrhythmia Prevention, Division of Preventive Medicine, and Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA;
TI  - Dietary Fat Intake Is Differentially Associated with Risk of Paroxysmal Compared with Sustained Atrial Fibrillation in Women.
SO  - Journal of Nutrition. 145(9):2092-101, 2015 Sep.
AS  - J Nutr. 145(9):2092-101, 2015 Sep.
NJ  - The Journal of nutrition
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - jev, 0404243
OI  - Source: NLM. PMC4548164 [Available on 09/01/16]
SB  - Index Medicus
CP  - United States
MH  - Atrial Fibrillation/cl [Classification]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - *Dietary Fats/ad [Administration & Dosage]
MH  - Fatty Acids/ad [Administration & Dosage]
MH  - Fatty Acids, Monounsaturated/ad [Administration & Dosage]
MH  - Fatty Acids, Omega-3/ad [Administration & Dosage]
MH  - Fatty Acids, Omega-6/ad [Administration & Dosage]
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Risk Factors
MH  - Surveys and Questionnaires
KW  - atrial fibrillation;  epidemiology;  monounsaturated fatty acids;  saturated fatty acids;  women
AB  - BACKGROUND: Dietary fats have effects on biological pathways that may influence the development and maintenance of atrial fibrillation (AF). However, associations between n-3 (omega-3) polyunsaturated fatty acids and AF are inconsistent, and data on other dietary fats and AF risk are sparse.
AB  - OBJECTIVES: We examined the association between dietary fatty acid (FA) subclasses and risk of incident AF and explored whether these associations differed for sustained and paroxysmal AF.
AB  - METHODS: We conducted a prospective cohort study in 33,665 women >45 y old without cardiovascular disease (CVD) and AF at baseline in 1993. Fat intake was estimated from food frequency questionnaires at baseline and in 2004. Incident AF was confirmed by medical records through October 2013. AF patterns were classified according to the most sustained form of AF within 2 y of diagnosis. Cox proportional hazards models with the use of a competing risk model approach estimated the RR.
AB  - RESULTS: Over 19.2 y, 1441 cases of incident AF (929 paroxysmal and 467 persistent/chronic) were confirmed. Intakes of total fat and FA subclasses were not associated with risk of AF. Saturated fatty acids (SFAs) and monounsaturated fatty acids (MUFAs) were differentially associated with AF patterns. The RR for a 5% increment of energy from SFAs was 1.47 (95% CI: 1.04, 2.09) for persistent/chronic and 0.85 (95% CI: 0.66, 1.08) for paroxysmal AF (P-difference = 0.01). For MUFAs, the RR for a 5% increment was 0.67 (95% CI: 0.46, 0.98) for persistent/chronic and 1.03 (95% CI: 0.78, 1.34) for paroxysmal AF, although the difference between patterns was not significant (P-difference = 0.07).
AB  - CONCLUSIONS: Dietary fat was not associated with risk of incident AF in women without established CVD or AF. High SFA and low MUFA intakes were associated with greater risk of persistent or chronic, but not paroxysmal, AF. Improving dietary fat quality may play a role in the prevention of sustained forms of AF. The Women's Health Study was registered at clinicaltrials.gov as NCT00000479.Copyright © 2015 American Society for Nutrition.
RN  - 0 (Dietary Fats)
RN  - 0 (Fatty Acids)
RN  - 0 (Fatty Acids, Monounsaturated)
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Fatty Acids, Omega-6)
ES  - 1541-6100
IL  - 0022-3166
DO  - http://dx.doi.org/10.3945/jn.115.212860
PT  - Journal Article
PT  - Observational Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
SI  - ClinicalTrials.gov
SA  - ClinicalTrials.gov/NCT00000479
SL  - http://clinicaltrials.gov/search/term=NCT00000479
NO  - CA047988 (United States NCI NIH HHS)
NO  - HL043851 (United States NHLBI NIH HHS)
NO  - HL080467 (United States NHLBI NIH HHS)
NO  - HL093613 (United States NHLBI NIH HHS)
NO  - HL099355 (United States NHLBI NIH HHS)
NO  - K99 HL097068 (United States NHLBI NIH HHS)
NO  - K99 HL097068 (United States NHLBI NIH HHS)
NO  - R00 HL097068 (United States NHLBI NIH HHS)
NO  - UM1 CA182913 (United States NCI NIH HHS)
LG  - English
EP  - 20150715
DP  - 2015 Sep
DC  - 20150902
YR  - 2015
ED  - 20151201
RD  - 20160520
UP  - 20160523
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=26180251

<94. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25746543
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Scrutinio D
AU  - Agostoni P
AU  - Gesualdo L
AU  - Corra U
AU  - Mezzani A
AU  - Piepoli M
AU  - Di Lenarda A
AU  - Iorio A
AU  - Passino C
AU  - Magri D
AU  - Masarone D
AU  - Battaia E
AU  - Girola D
AU  - Re F
AU  - Cattadori G
AU  - Parati G
AU  - Sinagra G
AU  - Villani GQ
AU  - Limongelli G
AU  - Pacileo G
AU  - Guazzi M
AU  - Metra M
AU  - Frigerio M
AU  - Cicoira M
AU  - Mina C
AU  - Malfatto G
AU  - Caravita S
AU  - Bussotti M
AU  - Salvioni E
AU  - Veglia F
AU  - Correale M
AU  - Scardovi AB
AU  - Emdin M
AU  - Giannuzzi P
AU  - Gargiulo P
AU  - Giovannardi M
AU  - Perrone-Filardi P
AU  - Raimondo R
AU  - Ricci R
AU  - Paolillo S
AU  - Farina S
AU  - Belardinelli R
AU  - Passantino A
AU  - La Gioia R
AU  - Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) Score Research Group
FA  - Scrutinio, Domenico
FA  - Agostoni, Piergiuseppe
FA  - Gesualdo, Loreto
FA  - Corra, Ugo
FA  - Mezzani, Alessandro
FA  - Piepoli, Massimo
FA  - Di Lenarda, Andrea
FA  - Iorio, Annamaria
FA  - Passino, Claudio
FA  - Magri, Damiano
FA  - Masarone, Daniele
FA  - Battaia, Elisa
FA  - Girola, Davide
FA  - Re, Federica
FA  - Cattadori, Gaia
FA  - Parati, Gianfranco
FA  - Sinagra, Gianfranco
FA  - Villani, Giovanni Quinto
FA  - Limongelli, Giuseppe
FA  - Pacileo, Giuseppe
FA  - Guazzi, Marco
FA  - Metra, Marco
FA  - Frigerio, Maria
FA  - Cicoira, Mariantonietta
FA  - Mina, Chiara
FA  - Malfatto, Gabriella
FA  - Caravita, Sergio
FA  - Bussotti, Maurizio
FA  - Salvioni, Elisabetta
FA  - Veglia, Fabrizio
FA  - Correale, Michele
FA  - Scardovi, Angela B
FA  - Emdin, Michele
FA  - Giannuzzi, Pantaleo
FA  - Gargiulo, Paola
FA  - Giovannardi, Marta
FA  - Perrone-Filardi, Pasquale
FA  - Raimondo, Rosa
FA  - Ricci, Roberto
FA  - Paolillo, Stefania
FA  - Farina, Stefania
FA  - Belardinelli, Romualdo
FA  - Passantino, Andrea
FA  - La Gioia, Rocco
FA  - Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) Score Research Group
IN  - Scrutinio,Domenico. Division of Cardiology, "S. Maugeri" Foundation, IRCCS, Institute of Cassano Murge.
IR  - Fiorentini C
IR  - Apostolo A
IR  - Palermo P
IR  - Contini M
IR  - Bertella E
IR  - Mantegazza V
IR  - Pietrucci F
IR  - Ferraironi A
IR  - Casenghi M
IR  - Clemenza F
IR  - Roselli T
IR  - Buono A
IR  - Calabro R
IR  - Murge C
IR  - Santoro D
IR  - Campanale S
IR  - Caputo D
IR  - Bertipaglia D
IR  - Vaninetti R
IR  - Confalonieri M
IR  - Zambon E
IR  - Berton E
IR  - Torregiani C
IR  - Dei Cas L
IR  - Carubelli V
IR  - Binno S
IR  - Marchese G
IR  - Oliva F
IR  - Pastormerlo L
TI  - Renal function and peak exercise oxygen consumption in chronic heart failure with reduced left ventricular ejection fraction.
SO  - Circulation Journal. 79(3):583-91, 2015.
AS  - Circ J. 79(3):583-91, 2015.
NJ  - Circulation journal : official journal of the Japanese Circulation Society
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101137683
SB  - Index Medicus
CP  - Japan
MH  - Adult
MH  - Aged
MH  - Chronic Disease
MH  - *Exercise
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/co [Complications]
MH  - Heart Failure/me [Metabolism]
MH  - Heart Failure/pp [Physiopathology]
MH  - *Heart Failure
MH  - Humans
MH  - Kidney Diseases/et [Etiology]
MH  - Kidney Diseases/mo [Mortality]
MH  - Kidney Diseases/pp [Physiopathology]
MH  - *Kidney Diseases
MH  - Kidney Function Tests
MH  - Male
MH  - Middle Aged
MH  - *Oxygen Consumption
MH  - *Stroke Volume
AB  - BACKGROUND: Chronic kidney disease is associated with sympathetic activation and muscle abnormalities, which may contribute to decreased exercise capacity. We investigated the correlation of renal function with peak exercise oxygen consumption (VO2) in heart failure (HF) patients. METHODS AND RESULTS: We recruited 2,938 systolic HF patients who underwent clinical, laboratory, echocardiographic and cardiopulmonary exercise testing. The patients were stratified according to estimated glomerular filtration rate (eGFR). Mean follow-up was 3.7 years. The primary outcome was a composite of cardiovascular death and urgent heart transplantation at 3 years. On multivariable regression, eGFR was predictor of peakVO2(P<0.0001). Other predictors were age, sex, body mass index, HF etiology, NYHA class, atrial fibrillation, resting heart rate, B-type natriuretic peptide, hemoglobin, and treatment. After adjusting for significant covariates, the hazard ratio for primary outcome associated with peakVO2<12 ml.kg(-1).min(-1)was 1.75 (95% confidence interval (CI): 1.06-2.91; P=0.0292) in patients with eGFR >60, 1.77 (0.87-3.61; P=0.1141) in those with eGFR of 45-59, and 2.72 (1.01-7.37; P=0.0489) in those with eGFR <45 ml.min(-1).1.73 m(-2). The area under the receiver-operating characteristic curve for peakVO2<12 ml.kg(-1).min(-1)was 0.63 (95% CI: 0.54-0.71), 0.67 (0.56-0.78), and 0.57 (0.47-0.69), respectively. Testing for interaction was not significant.
AB  - CONCLUSIONS: Renal dysfunction is correlated with peakVO2. A peakVO2cutoff of 12 ml.kg(-1).min(-1)offers limited prognostic information in HF patients with more severely impaired renal function.
ES  - 1347-4820
IL  - 1346-9843
DO  - http://dx.doi.org/10.1253/circj.CJ-14-0806
PT  - Journal Article
PT  - Multicenter Study
LG  - English
EP  - 20150126
DP  - 2015
DC  - 20150309
YR  - 2015
ED  - 20151130
UP  - 20151217
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25746543

<95. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26354789
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Martinez-Gonzalez MA
AU  - Toledo E
AU  - Aros F
AU  - Fiol M
AU  - Corella D
AU  - Salas-Salvado J
AU  - Ros E
AU  - Covas MI
AU  - Fernandez-Crehuet J
AU  - Lapetra J
AU  - Munoz MA
AU  - Fito M
AU  - Serra-Majem L
AU  - Pinto X
AU  - Lamuela-Raventos RM
AU  - Sorli JV
AU  - Babio N
AU  - Buil-Cosiales P
AU  - Ruiz-Gutierrez V
AU  - Estruch R
AU  - Alonso A
FA  - Martinez-Gonzalez, Miguel A
FA  - Toledo, Estefania
FA  - Aros, Fernando
FA  - Fiol, Miquel
FA  - Corella, Dolores
FA  - Salas-Salvado, Jordi
FA  - Ros, Emilio
FA  - Covas, Maria I
FA  - Fernandez-Crehuet, Joaquin
FA  - Lapetra, Jose
FA  - Munoz, Miguel A
FA  - Fito, Monserrat
FA  - Serra-Majem, Luis
FA  - Pinto, Xavier
FA  - Lamuela-Raventos, Rosa M
FA  - Sorli, Jose V
FA  - Babio, Nancy
FA  - Buil-Cosiales, Pilar
FA  - Ruiz-Gutierrez, Valentina
FA  - Estruch, Ramon
FA  - Alonso, Alvaro
IN  - Martinez-Gonzalez,Miguel A. Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain, PREDIMED (Prevencion con Dieta Mediterranea) Research Network, Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III, Madrid, Spain.
IN  - Toledo,Estefania. Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain, PREDIMED (Prevencion con Dieta Mediterranea) Research Network, Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III, Madrid, Spain.
IN  - Aros,Fernando. PREDIMED (Prevencion con Dieta Mediterranea) Research Network, Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III, Madrid, Spain, Department of Cardiology, University Hospital of Alava, Vitoria, Spain.
IN  - Fiol,Miquel. Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III, Madrid, Spain, Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain.
IN  - Corella,Dolores. Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III, Madrid, Spain, Department of Preventive Medicine, University of Valencia, Valencia, Spain.
IN  - Salas-Salvado,Jordi. PREDIMED (Prevencion con Dieta Mediterranea) Research Network, Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III, Madrid, Spain, Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain.
IN  - Ros,Emilio. Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III, Madrid, Spain, Institut d'Investigacions Biomediques August Pi i Sunyer, Endocrinology & Nutrition Service, Hospital Clinic, University of Barcelona, Barcelona, Spain.
IN  - Covas,Maria I. Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III, Madrid, Spain, Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, Primary Care Division of Barcelona, Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain.
IN  - Fernandez-Crehuet,Joaquin. PREDIMED (Prevencion con Dieta Mediterranea) Research Network, Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III, Madrid, Spain, Department of Preventive Medicine, University of Malaga, Malaga, Spain.
IN  - Lapetra,Jose. Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III, Madrid, Spain, Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain.
IN  - Munoz,Miguel A. Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, Primary Care Division of Barcelona, Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain.
IN  - Fito,Monserrat. Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III, Madrid, Spain, Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, Primary Care Division of Barcelona, Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain.
IN  - Serra-Majem,Luis. Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III, Madrid, Spain, Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain.
IN  - Pinto,Xavier. Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III, Madrid, Spain, Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.
IN  - Lamuela-Raventos,Rosa M. Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III, Madrid, Spain, Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria, University of Barcelona, Barcelona, Spain.
IN  - Sorli,Jose V. Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III, Madrid, Spain, Department of Preventive Medicine, University of Valencia, Valencia, Spain.
IN  - Babio,Nancy. PREDIMED (Prevencion con Dieta Mediterranea) Research Network, Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III, Madrid, Spain, Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain.
IN  - Buil-Cosiales,Pilar. Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain, PREDIMED (Prevencion con Dieta Mediterranea) Research Network, Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III, Madrid, Spain, Servicio Navarro de Salud-Osasunbidea, Pamplona, Spain.
IN  - Ruiz-Gutierrez,Valentina. PREDIMED (Prevencion con Dieta Mediterranea) Research Network, Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III, Madrid, Spain, Instituto de la Grasa, Consejo Superior de Investigaciones Cientificas, Sevilla, Spain.
IN  - Estruch,Ramon. Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III, Madrid, Spain, Institut d'Investigacions Biomediques August Pi i Sunyer, Department of Internal Medicine, Hospital Clinic, University of Barcelona, Barcelona, Spain.
IN  - Alonso,Alvaro. Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain, PREDIMED (Prevencion con Dieta Mediterranea) Research Network, Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III, Madrid, Spain, Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN.
TI  - Response to Letter Regarding Article, "Extravirgin Olive Oil Consumption Reduces Risk of Atrial Fibrillation: The PREDIMED (Prevencion con Dieta Mediterranea) Trial".
CM  - Comment on: Circulation. 2014 Jul 1;130(1):18-26; PMID: 24787471
CM  - Comment on: Circulation. 2015 Sep 8;132(10):e139; PMID: 26354788
SO  - Circulation. 132(10):e140-2, 2015 Sep 8.
AS  - Circulation. 132(10):e140-2, 2015 Sep 8.
NJ  - Circulation
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - *Diet, Mediterranean
MH  - *Dietary Fats/tu [Therapeutic Use]
MH  - Female
MH  - Humans
MH  - Male
MH  - *Plant Oils
RN  - 0 (Dietary Fats)
RN  - 0 (Plant Oils)
ES  - 1524-4539
IL  - 0009-7322
DO  - http://dx.doi.org/10.1161/CIRCULATIONAHA.114.013272
PT  - Comment
PT  - Letter
LG  - English
DP  - 2015 Sep 8
DC  - 20150910
YR  - 2015
ED  - 20151123
UP  - 20151217
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26354789

<96. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26354788
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gonzalez-Salvado V
AU  - Raposeiras-Roubin S
AU  - Gonzalez-Juanatey JR
FA  - Gonzalez-Salvado, Violeta
FA  - Raposeiras-Roubin, Sergio
FA  - Gonzalez-Juanatey, Jose Ramon
IN  - Gonzalez-Salvado,Violeta. Cardiology Department, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
IN  - Raposeiras-Roubin,Sergio. Cardiology Department, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
IN  - Gonzalez-Juanatey,Jose Ramon. Cardiology Department, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
TI  - Letter by Gonzalez-Salvado et al Regarding Article, "Extravirgin Olive Oil Consumption Reduces Risk of Atrial Fibrillation: The PREDIMED (Prevencion con Dieta Mediterranea) Trial".
CM  - Comment in: Circulation. 2015 Sep 8;132(10):e140-2; PMID: 26354789
CM  - Comment on: Circulation. 2014 Jul 1;130(1):18-26; PMID: 24787471
SO  - Circulation. 132(10):e139, 2015 Sep 8.
AS  - Circulation. 132(10):e139, 2015 Sep 8.
NJ  - Circulation
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - *Diet, Mediterranean
MH  - *Dietary Fats/tu [Therapeutic Use]
MH  - Female
MH  - Humans
MH  - Male
MH  - *Plant Oils
RN  - 0 (Dietary Fats)
RN  - 0 (Plant Oils)
ES  - 1524-4539
IL  - 0009-7322
DO  - http://dx.doi.org/10.1161/CIRCULATIONAHA.114.012242
PT  - Comment
PT  - Letter
LG  - English
DP  - 2015 Sep 8
DC  - 20150910
YR  - 2015
ED  - 20151123
UP  - 20151217
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26354788

<97. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25604001
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Woodward A
AU  - Tin Tin S
AU  - Doughty RN
AU  - Ameratunga S
FA  - Woodward, Alistair
FA  - Tin Tin, Sandar
FA  - Doughty, Rob N
FA  - Ameratunga, Shanthi
IN  - Woodward,Alistair. Section of Epidemiology and Biostatistics, School of Population Health, University of Auckland, Auckland, New Zealand. a.woodward@auckland.ac.nz.
IN  - Tin Tin,Sandar. Section of Epidemiology and Biostatistics, School of Population Health, University of Auckland, Auckland, New Zealand. s.tintin@auckland.ac.nz.
IN  - Doughty,Rob N. National Institute of Health Innovation and Department of Medicine, University of Auckland, Auckland, New Zealand. r.doughty@auckland.ac.nz.
IN  - Ameratunga,Shanthi. Section of Epidemiology and Biostatistics, School of Population Health, University of Auckland, Auckland, New Zealand. s.ameratunga@auckland.ac.nz.
TI  - Atrial fibrillation and cycling: six year follow-up of the Taupo bicycle study.
SO  - BMC Public Health. 15:23, 2015.
AS  - BMC Public Health. 15:23, 2015.
NJ  - BMC public health
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 100968562
OI  - Source: NLM. PMC4311486
SB  - Index Medicus
CP  - England
MH  - Adolescent
MH  - Adult
MH  - Arrhythmias, Cardiac/ep [Epidemiology]
MH  - Athletes
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - *Bicycling/ph [Physiology]
MH  - Databases, Factual
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Conduction System/ab [Abnormalities]
MH  - Hospitalization/sn [Statistics & Numerical Data]
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - New Zealand/ep [Epidemiology]
MH  - Risk Factors
MH  - Surveys and Questionnaires
MH  - Young Adult
AB  - BACKGROUND: Atrial Fibrillation (AF) is the most common sustained cardiac arrhythmia, and the incidence of AF is increased markedly among elite athletes. It is not clear how lesser levels of physical activity in the general population influence AF. We asked whether participation in the Taupo Cycle Challenge was associated with increased hospital admissions due to AF, and within the cohort, whether admissions for AF were related to frequency and intensity of cycling.
AB  - METHODS: Participants in the 2006 Lake Taupo Cycle Challenge, New Zealand's largest mass cycling event, were invited to complete an on-line questionnaire. Those who agreed (n = 2590, response rate = 43.1%) were followed up by record linkage via the National Minimum Health Database from December 1 2006 until June 30 2013, to identify admissions to hospital due to AF.
AB  - RESULTS: The age and gender standardized admission rate for AF was similar in the Taupo cohort (19.60 per 10,000 per year) and the national population over the same period (2006-2011) (19.45 per 10,000 per year). Within the study cohort (men only), for every additional hour spent cycling per week the risk changed by 0.90 (95% confidence interval 0.79 - 1.01). This result did not change appreciably after adjustment for age and height.
AB  - CONCLUSIONS: Hospital admission due to AF was not increased above the national rate in this group of non-elite cyclists, and within the group the rate of AF did not increase with amount of cycling. The level of activity undertaken by this cohort of cyclists was, on average, not sufficient to increase the risk of hospitalization for AF.
RS  - Cardiac Conduction Defect
ES  - 1471-2458
IL  - 1471-2458
DO  - http://dx.doi.org/10.1186/s12889-014-1341-6
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20150121
DP  - 2015
DC  - 20150422
YR  - 2015
ED  - 20151120
RD  - 20150423
UP  - 20151217
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25604001

<98. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26314525
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Thompson PD
FA  - Thompson, Paul D
IN  - Thompson,Paul D. Department of Cardiology, Hartford Hospital, Hartford, Connecticut. Electronic address: paul.thompson@hhchealth.org.
TI  - Physical Fitness, Physical Activity, Exercise Training, and Atrial Fibrillation: First the Good News, Then the Bad.
CM  - Comment on: J Am Coll Cardiol. 2015 Sep 1;66(9):985-96; PMID: 26113406
SO  - Journal of the American College of Cardiology. 66(9):997-9, 2015 Sep 1.
AS  - J Am Coll Cardiol. 66(9):997-9, 2015 Sep 1.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - h50, 8301365
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - *Exercise Test/mt [Methods]
MH  - Female
MH  - Humans
MH  - Male
MH  - *Obesity/ep [Epidemiology]
MH  - *Physical Fitness/ph [Physiology]
KW  - atrial fibrillation;  cardiac arrhythmia;  cardiopulmonary fitness;  exercise;  exercise training;  fitness
ES  - 1558-3597
IL  - 0735-1097
DI  - S0735-1097(15)04366-1
DO  - http://dx.doi.org/10.1016/j.jacc.2015.07.003
PT  - Comment
PT  - Editorial
LG  - English
DP  - 2015 Sep 1
DC  - 20150828
YR  - 2015
ED  - 20151117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26314525

<99. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26189040
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Bapat A
AU  - Zhang Y
AU  - Post WS
AU  - Guallar E
AU  - Soliman EZ
AU  - Heckbert SR
AU  - Lima J
AU  - Bertoni AG
AU  - Alonso A
AU  - Nazarian S
FA  - Bapat, Aneesh
FA  - Zhang, Yiyi
FA  - Post, Wendy S
FA  - Guallar, Eliseo
FA  - Soliman, Elsayed Z
FA  - Heckbert, Susan R
FA  - Lima, Joao
FA  - Bertoni, Alain G
FA  - Alonso, Alvaro
FA  - Nazarian, Saman
IN  - Bapat,Aneesh. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
IN  - Zhang,Yiyi. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
IN  - Post,Wendy S. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
IN  - Guallar,Eliseo. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
IN  - Soliman,Elsayed Z. Epidemiological Cardiology Research Center (EPICARE), Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, North Carolina; Department of Internal Medicine, Cardiology Section, Wake Forest School of Medicine, Winston-Salem, North Carolina.
IN  - Heckbert,Susan R. Department of Epidemiology, University of Washington, Seattle, Washington.
IN  - Lima,Joao. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
IN  - Bertoni,Alain G. Maya Angelou Center for Health Equity, Wake Forest University, Winston-Salem, North Carolina.
IN  - Alonso,Alvaro. Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, Minnesota.
IN  - Nazarian,Saman. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. Electronic address: snazarian@jhmi.edu.
TI  - Relation of Physical Activity and Incident Atrial Fibrillation (from the Multi-Ethnic Study of Atherosclerosis).
SO  - American Journal of Cardiology. 116(6):883-8, 2015 Sep 15.
AS  - Am J Cardiol. 116(6):883-8, 2015 Sep 15.
NJ  - The American journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 3dq, 0207277
OI  - Source: NLM. NIHMS705408 [Available on 09/15/16]
OI  - Source: NLM. PMC4554984 [Available on 09/15/16]
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Cohort Studies
MH  - Coronary Disease/ep [Epidemiology]
MH  - Databases, Factual
MH  - *Exercise
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - *Motor Activity
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Protective Factors
MH  - *Sedentary Lifestyle
MH  - Surveys and Questionnaires
AB  - Previous studies have raised the question of whether an association exists between physical activity and atrial fibrillation (AF). We used the Multi-Ethnic Study of Atherosclerosis (MESA) database to examine the association between physical activity and AF in a diverse population without clinically recognized cardiovascular disease (CVD). MESA participants (n = 5,793) with complete baseline physical activity and covariate data were included. Cox proportional hazards models were used to calculate hazard ratios (HRs) for incident AF by levels of total intentional exercise and vigorous physical activity, independently and in combination. Multivariate models were adjusted for demographics and CVD risk factors. During a mean follow-up of 7.7 +/- 1.9 years, 199 AF cases occurred. In the overall MESA population, neither vigorous physical activity nor total intentional exercise was independently associated with incident AF after adjusting for covariates. However, within the group that reported any vigorous physical activity, there was a statistically significant inverse association between total intentional exercise (modeled as a continuous variable) and incident AF. In those who reported any vigorous physical activity, the top tertile of total intentional exercise was associated with a significantly lower risk of incident AF compared with the group with no total intentional exercise in the fully adjusted model (HR 0.46, 95% confidence interval 0.22 to 0.98). In conclusion, neither total intentional exercise nor vigorous physical activity alone was associated with incident AF, but greater total intentional exercise was associated with a lower risk of incident AF in those who participated in any vigorous physical activity. As importantly, no subgroup of participants demonstrated an increased risk of incident AF with greater physical activity. The results re-emphasize the beneficial role of physical activity for cardiovascular health. Copyright © 2015 Elsevier Inc. All rights reserved.
ES  - 1879-1913
IL  - 0002-9149
DI  - S0002-9149(15)01527-1
DO  - http://dx.doi.org/10.1016/j.amjcard.2015.06.013
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
NO  - K23 HL089333 (United States NHLBI NIH HHS)
NO  - K23HL089333 (United States NHLBI NIH HHS)
NO  - N01-HC-95159 (United States NHLBI NIH HHS)
NO  - N01-HC95169 (United States NHLBI NIH HHS)
NO  - R01 HL116280 (United States NHLBI NIH HHS)
NO  - R01HL116280 (United States NHLBI NIH HHS)
LG  - English
EP  - 20150624
DP  - 2015 Sep 15
DC  - 20150831
YR  - 2015
ED  - 20151116
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26189040

<100. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25708674
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Boden-Albala B
AU  - Southwick L
AU  - Carman H
FA  - Boden-Albala, Bernadette
FA  - Southwick, Lauren
FA  - Carman, Heather
IN  - Boden-Albala,Bernadette. Division of Social Epidemiology, Global Institute of Public Health, New York University, 41 East 11th Street, 7th Floor, New York, NY, 10003, USA, bb109@nyu.edu.
TI  - Dietary interventions to lower the risk of stroke. [Review]
SO  - Current Neurology & Neuroscience Reports. 15(4):15, 2015 Apr.
AS  - Curr Neurol Neurosci Rep. 15(4):15, 2015 Apr.
NJ  - Current neurology and neuroscience reports
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 100931790
SB  - Index Medicus
CP  - United States
MH  - *Dietary Supplements
MH  - Food Habits
MH  - Humans
MH  - Life Style
MH  - Risk Factors
MH  - *Stroke/ep [Epidemiology]
MH  - *Stroke/pc [Prevention & Control]
AB  - Stroke is a major cause of death and permanent disability in the USA; primary prevention and risk reduction are a critical health concern. A wealth of research investigated stroke risk factors, including primary hypertension, diabetes, and atrial fibrillation. Research has expanded to examine lifestyle factors, such as diet/dietary patterns, physical activity, cigarette smoking, and obesity distribution, as critical modifiable risk factors. Emerging evidence suggests diet/dietary patterns may lead to heightened risk of stroke. Despite a growing literature, research has yet to implement dietary interventions to explore this relationship within a US sample. This review discusses available clinical research findings reporting on the relationship among diet/dietary patterns, cardiovascular disease, and risk of stroke. We will assess challenges, limitations, and controversies, and address future research directions.
ES  - 1534-6293
IL  - 1528-4042
DO  - http://dx.doi.org/10.1007/s11910-015-0538-0
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
NO  - P50NS049060 (United States NINDS NIH HHS)
NO  - U01U54NS057405 (United States NINDS NIH HHS)
NO  - U10NS086531 (United States NINDS NIH HHS)
NO  - U24MD006961 (United States NIMHD NIH HHS)
LG  - English
DP  - 2015 Apr
DC  - 20150224
YR  - 2015
ED  - 20151109
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25708674

<101. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26415070
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - St Leger Dowse M
AU  - Waterman MK
AU  - Penny CE
AU  - Smerdon GR
FA  - St Leger Dowse, Marguerite
FA  - Waterman, Matthew K
FA  - Penny, Christine El
FA  - Smerdon, Gary R
IN  - St Leger Dowse,Marguerite. DDRC Healthcare, Hyperbaric Medical Centre, Plymouth Science Park, Research Way, Plymouth PL6 8BU, Devon, United Kingdom Phone: +44 (0) 1752 209999, E-mail: mstld@btinternet.com.
IN  - Waterman,Matthew K. Diving Diseases Reasearch Centre Healthcare, Plymouth, United Kingdom.
IN  - Penny,Christine El. Diving Diseases Reasearch Centre Healthcare, Plymouth, United Kingdom.
IN  - Smerdon,Gary R. Diving Diseases Reasearch Centre Healthcare, Plymouth, United Kingdom.
TI  - Does self-certification reflect the cardiac health of UK sport divers?.
SO  - Diving & Hyperbaric Medicine. 45(3):184-9, 2015 Sep.
AS  - Diving Hyperb Med. 45(3):184-9, 2015 Sep.
NJ  - Diving and hyperbaric medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101282742
SB  - Index Medicus
CP  - Australia
MH  - Adolescent
MH  - Adult
MH  - Age Distribution
MH  - Aged
MH  - Alcohol Drinking/ep [Epidemiology]
MH  - Angina Pectoris/ep [Epidemiology]
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - Body Mass Index
MH  - *Cardiovascular Agents/tu [Therapeutic Use]
MH  - *Cardiovascular Diseases/ep [Epidemiology]
MH  - Cardiovascular Diseases/th [Therapy]
MH  - *Certification/mt [Methods]
MH  - Coronary Artery Bypass/sn [Statistics & Numerical Data]
MH  - Decompression Sickness/ep [Epidemiology]
MH  - *Diving/sn [Statistics & Numerical Data]
MH  - Exercise
MH  - Female
MH  - Foramen Ovale, Patent/ep [Epidemiology]
MH  - Foramen Ovale, Patent/su [Surgery]
MH  - Great Britain/ep [Epidemiology]
MH  - *Health Status
MH  - Humans
MH  - Hypertension/dt [Drug Therapy]
MH  - Hypertension/ep [Epidemiology]
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/ep [Epidemiology]
MH  - Myocardial Infarction/su [Surgery]
MH  - Recreation
MH  - Smoking/ep [Epidemiology]
MH  - *Surveys and Questionnaires
MH  - Time Factors
KW  - Health surveys;  cardiovascular;  fitness to dive;  medicals - diving;  recreational divers
AB  - BACKGROUND: Since 2009, the United Kingdom diving incident data show an increasing number of fatalities in the over-50s age group. Previous studies also suggest some divers take cardiac medications. Since 2001, diving medicals have not been mandatory for UK sport divers. Instead, an annual medical self-certification form, submitted to their club/school or training establishment, is required. We documented in a survey of UK sport divers the prevalence of cardiac events and medications and the frequency of medical certifications.
AB  - METHODS: An anonymous on-line questionnaire was publicised. Measures included diver and diving demographics, prescribed medications, diagnosed hypertension, cardiac issues, events and procedures, other health issues, year of last diving medical, diagnosed persistent foramen ovale (PFO), smoking and alcohol habits, exercise and body mass index.
AB  - RESULTS: Of 672 completed surveys, hypertension was reported by 119 (18%) with 25 of these (21%) having not had a diving medical. Myocardial infarction 6 (1%), coronary artery bypass grafting 3 (< 1%), atrial fibrillation 19 (3%) and angina 12 (2%) were also reported. PFOs were reported by 28 (4%), with 20 of these opting for a closure procedure. From 83 treated incidences of decompression illness (DCI), 19 divers reported that a PFO was diagnosed.
AB  - CONCLUSIONS: Divers inevitably develop health problems. Some continue to dive with cardiac issues, failing to seek specialised diving advice or fully understand the role of the diving medical. Physicians without appropriate training in diving medicine may inform a diver they are safe to continue diving with their condition without appreciating the potential risks. The current procedure for medical screening for fitness to dive may not be adequate for all divers.
RN  - 0 (Cardiovascular Agents)
IS  - 1833-3516
IL  - 1833-3516
PT  - Journal Article
LG  - English
DP  - 2015 Sep
DC  - 20150929
YR  - 2015
ED  - 20151030
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26415070

<102. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26516423
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Abumuaileq RR
AU  - Abu-Assi E
AU  - Lopez-Lopez A
AU  - Raposeiras-Roubin S
AU  - Rodriguez-Manero M
AU  - Martinez-Sande L
AU  - Garcia-Seara FJ
AU  - Fernandez-Lopez XA
AU  - Gonzalez-Juanatey JR
FA  - Abumuaileq, Rami Riziq-Yousef
FA  - Abu-Assi, Emad
FA  - Lopez-Lopez, Andrea
FA  - Raposeiras-Roubin, Sergio
FA  - Rodriguez-Manero, Moises
FA  - Martinez-Sande, Luis
FA  - Garcia-Seara, Francisco Javier
FA  - Fernandez-Lopez, Xesus Alberte
FA  - Gonzalez-Juanatey, Jose Ramon
IN  - Abumuaileq,Rami Riziq-Yousef. Rami Riziq-Yousef Abumuaileq, Emad Abu-Assi, Andrea Lopez-Lopez, Sergio Raposeiras-Roubin, Moises Rodriguez-Manero, Luis Martinez-Sande, Francisco Javier Garcia-Seara, Xesus Alberte Fernandez-Lopez, Jose Ramon Gonzalez-Juanatey, Cardiology Department, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain.
IN  - Abu-Assi,Emad. Rami Riziq-Yousef Abumuaileq, Emad Abu-Assi, Andrea Lopez-Lopez, Sergio Raposeiras-Roubin, Moises Rodriguez-Manero, Luis Martinez-Sande, Francisco Javier Garcia-Seara, Xesus Alberte Fernandez-Lopez, Jose Ramon Gonzalez-Juanatey, Cardiology Department, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain.
IN  - Lopez-Lopez,Andrea. Rami Riziq-Yousef Abumuaileq, Emad Abu-Assi, Andrea Lopez-Lopez, Sergio Raposeiras-Roubin, Moises Rodriguez-Manero, Luis Martinez-Sande, Francisco Javier Garcia-Seara, Xesus Alberte Fernandez-Lopez, Jose Ramon Gonzalez-Juanatey, Cardiology Department, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain.
IN  - Raposeiras-Roubin,Sergio. Rami Riziq-Yousef Abumuaileq, Emad Abu-Assi, Andrea Lopez-Lopez, Sergio Raposeiras-Roubin, Moises Rodriguez-Manero, Luis Martinez-Sande, Francisco Javier Garcia-Seara, Xesus Alberte Fernandez-Lopez, Jose Ramon Gonzalez-Juanatey, Cardiology Department, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain.
IN  - Rodriguez-Manero,Moises. Rami Riziq-Yousef Abumuaileq, Emad Abu-Assi, Andrea Lopez-Lopez, Sergio Raposeiras-Roubin, Moises Rodriguez-Manero, Luis Martinez-Sande, Francisco Javier Garcia-Seara, Xesus Alberte Fernandez-Lopez, Jose Ramon Gonzalez-Juanatey, Cardiology Department, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain.
IN  - Martinez-Sande,Luis. Rami Riziq-Yousef Abumuaileq, Emad Abu-Assi, Andrea Lopez-Lopez, Sergio Raposeiras-Roubin, Moises Rodriguez-Manero, Luis Martinez-Sande, Francisco Javier Garcia-Seara, Xesus Alberte Fernandez-Lopez, Jose Ramon Gonzalez-Juanatey, Cardiology Department, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain.
IN  - Garcia-Seara,Francisco Javier. Rami Riziq-Yousef Abumuaileq, Emad Abu-Assi, Andrea Lopez-Lopez, Sergio Raposeiras-Roubin, Moises Rodriguez-Manero, Luis Martinez-Sande, Francisco Javier Garcia-Seara, Xesus Alberte Fernandez-Lopez, Jose Ramon Gonzalez-Juanatey, Cardiology Department, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain.
IN  - Fernandez-Lopez,Xesus Alberte. Rami Riziq-Yousef Abumuaileq, Emad Abu-Assi, Andrea Lopez-Lopez, Sergio Raposeiras-Roubin, Moises Rodriguez-Manero, Luis Martinez-Sande, Francisco Javier Garcia-Seara, Xesus Alberte Fernandez-Lopez, Jose Ramon Gonzalez-Juanatey, Cardiology Department, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain.
IN  - Gonzalez-Juanatey,Jose Ramon. Rami Riziq-Yousef Abumuaileq, Emad Abu-Assi, Andrea Lopez-Lopez, Sergio Raposeiras-Roubin, Moises Rodriguez-Manero, Luis Martinez-Sande, Francisco Javier Garcia-Seara, Xesus Alberte Fernandez-Lopez, Jose Ramon Gonzalez-Juanatey, Cardiology Department, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain.
TI  - Renal function assessment in atrial fibrillation: Usefulness of chronic kidney disease epidemiology collaboration vs re-expressed 4 variable modification of diet in renal disease.
SO  - World Journal of Cardiology. 7(10):685-94, 2015 Oct 26.
AS  - World J Cardiol. 7(10):685-94, 2015 Oct 26.
NJ  - World journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101537090
OI  - Source: NLM. PMC4620080
CP  - United States
KW  - Anticoagulants;  Atrial fibrillation;  Follow-up studies;  Kidney;  Prognosis
AB  - AIM: To compare the performance of the re-expressed Modification of Diet in Renal Disease equation vs the new Chronic Kidney Disease Epidemiology Collaboration equation in patients with non-valvular atrial fibrillation.
AB  - METHODS: We studied 911 consecutive patients with non-valvular atrial fibrillation on vitamin-K antagonist. The performance of the re-expressed Modification of Diet in Renal Disease equation vs the new Chronic Kidney Disease Epidemiology Collaboration equation in patients with non-valvular atrial fibrillation with respect to either a composite endpoint of major bleeding, thromboembolic events and all-cause mortality or each individual component of the composite endpoint was assessed using continuous and categorical > 60, 59-30, and < 30 mL/min per 1.73 m(2) estimated glomerular filtration rate.
AB  - RESULTS: During 10 +/- 3 mo, the composite endpoint occurred in 98 (10.8%) patients: 30 patients developed major bleeding, 18 had thromboembolic events, and 60 died. The new equation provided lower prevalence of renal dysfunction < 60 mL/min per 1.73 m(2) (32.9%), compared with the re-expressed equation (34.1%). Estimated glomerular filtration rate from both equations was independent predictor of composite endpoint (HR = 0.98 and 0.97 for the re-expressed and the new equation, respectively; P < 0.0001) and all-cause mortality (HR = 0.98 for both equations, P < 0.01). Strong association with thromboembolic events was observed only when estimated glomerular filtration rate was < 30 mL/min per 1.73 m(2): HR is 5.1 for the re-expressed equation, and HR = 5.0 for the new equation. No significant association with major bleeding was observed for both equations.
AB  - CONCLUSION: The new equation reduced the prevalence of renal dysfunction. Both equations performed similarly in predicting major adverse outcomes.
ES  - 1949-8462
DO  - http://dx.doi.org/10.4330/wjc.v7.i10.685
PT  - Journal Article
LG  - English
DP  - 2015 Oct 26
DC  - 20151030
YR  - 2015
ED  - 20151030
RD  - 20151101
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=26516423

<103. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25672368
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Naji P
AU  - Asfahan F
AU  - Barr T
AU  - Rodriguez LL
AU  - Grimm RA
AU  - Agarwal S
AU  - Thomas JD
AU  - Gillinov AM
AU  - Mihaljevic T
AU  - Griffin BP
AU  - Desai MY
FA  - Naji, Peyman
FA  - Asfahan, Fadi
FA  - Barr, Tyler
FA  - Rodriguez, L Leonardo
FA  - Grimm, Richard A
FA  - Agarwal, Shikhar
FA  - Thomas, James D
FA  - Gillinov, A Marc
FA  - Mihaljevic, Tomislav
FA  - Griffin, Brian P
FA  - Desai, Milind Y
IN  - Naji,Peyman. Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH (P.N., F.A., T.B., L.R., R.A.G., S.A., J.D.T., M.G., T.M., B.P.G., M.Y.D.).
IN  - Asfahan,Fadi. Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH (P.N., F.A., T.B., L.R., R.A.G., S.A., J.D.T., M.G., T.M., B.P.G., M.Y.D.).
IN  - Barr,Tyler. Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH (P.N., F.A., T.B., L.R., R.A.G., S.A., J.D.T., M.G., T.M., B.P.G., M.Y.D.).
IN  - Rodriguez,L Leonardo. Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH (P.N., F.A., T.B., L.R., R.A.G., S.A., J.D.T., M.G., T.M., B.P.G., M.Y.D.).
IN  - Grimm,Richard A. Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH (P.N., F.A., T.B., L.R., R.A.G., S.A., J.D.T., M.G., T.M., B.P.G., M.Y.D.).
IN  - Agarwal,Shikhar. Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH (P.N., F.A., T.B., L.R., R.A.G., S.A., J.D.T., M.G., T.M., B.P.G., M.Y.D.).
IN  - Thomas,James D. Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH (P.N., F.A., T.B., L.R., R.A.G., S.A., J.D.T., M.G., T.M., B.P.G., M.Y.D.).
IN  - Gillinov,A Marc. Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH (P.N., F.A., T.B., L.R., R.A.G., S.A., J.D.T., M.G., T.M., B.P.G., M.Y.D.).
IN  - Mihaljevic,Tomislav. Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH (P.N., F.A., T.B., L.R., R.A.G., S.A., J.D.T., M.G., T.M., B.P.G., M.Y.D.).
IN  - Griffin,Brian P. Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH (P.N., F.A., T.B., L.R., R.A.G., S.A., J.D.T., M.G., T.M., B.P.G., M.Y.D.).
IN  - Desai,Milind Y. Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH (P.N., F.A., T.B., L.R., R.A.G., S.A., J.D.T., M.G., T.M., B.P.G., M.Y.D.).
TI  - Impact of duration of mitral regurgitation on outcomes in asymptomatic patients with myxomatous mitral valve undergoing exercise stress echocardiography.
SO  - Journal of the American Heart Association. 4(2), 2015 Feb.
AS  - J Am Heart Assoc. 4(2), 2015 Feb.
NJ  - Journal of the American Heart Association
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 101580524
OI  - Source: NLM. PMC4345867
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/us [Ultrasonography]
MH  - Echocardiography, Doppler
MH  - *Echocardiography, Stress/mt [Methods]
MH  - *Exercise
MH  - Female
MH  - Heart Failure/ep [Epidemiology]
MH  - Heart Failure/et [Etiology]
MH  - Heart Failure/us [Ultrasonography]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve/pp [Physiopathology]
MH  - *Mitral Valve Insufficiency/co [Complications]
MH  - Mitral Valve Insufficiency/et [Etiology]
MH  - *Mitral Valve Insufficiency/pp [Physiopathology]
MH  - Mitral Valve Insufficiency/us [Ultrasonography]
MH  - Mitral Valve Prolapse/co [Complications]
MH  - *Mitral Valve Prolapse/pp [Physiopathology]
MH  - Mitral Valve Prolapse/us [Ultrasonography]
MH  - Prognosis
MH  - Severity of Illness Index
MH  - Time Factors
MH  - *Ventricular Function, Left
KW  - mitral regurgitation duration;  stress echocardiography and outcomes
AB  - BACKGROUND: Significant mitral regurgitation (MR) typically occurs as holosystolic (HS) or mid-late systolic (MLS), with differences in volumetric impact on the left ventricle (LV). We sought to assess outcomes of degenerative MR patients undergoing exercise echocardiography, separated based on MR duration (MLS versus HS).
AB  - METHODS AND RESULTS: We included 609 consecutive patients with >III+myxomatous MR undergoing exercise echocardiography: HS (n=487) and MLS (n=122). MLS MR was defined as delayed appearance of MR signal during mid-late systole on continuous-wave Doppler while HS MR occurred throughout systole. Composite events of death and congestive heart failure were recorded. Compared to MLS MR, HS MR patients were older (60+/-14 versus 53+/-14 years), more were males (72% versus 53%), and had greater prevalence of atrial fibrillation (16% versus 7%; all P<0.01). HS MR patients had higher right ventricular systolic pressure (RVSP) at rest (33+/-11 versus 27+/-9 mm Hg), more flail leaflets (36% versus 6%), and a lower number of metabolic equivalents (METs) achieved (9.5+/-3 versus 10.5+/-3), compared to the MLS MR group (all P<0.05). There were 54 events during 7.1+/-3 years of follow-up. On step-wise multivariable analysis, HS versus MLS MR (HR 4.99 [1.21 to 20.14]), higher LV ejection fraction (hazard ratio [HR], 0.94 [0.89 to 0.98]), atrial fibrillation (HR, 2.59 [1.33 to 5.11]), higher RVSP (HR, 1.05 [1.03 to 1.09]), and higher percentage of age- and gender-predicted METs (HR, 0.98 [0.97 to 0.99]) were independently associated with adverse outcomes (all P<0.05).
AB  - CONCLUSION: In patients with >III+myxomatous MR undergoing exercise echocardiography, holosystolic MR is associated with adverse outcomes, independent of other predictors.Copyright © 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.
ES  - 2047-9980
IL  - 2047-9980
DI  - e001348
DO  - http://dx.doi.org/10.1161/JAHA.114.001348
PT  - Journal Article
LG  - English
EP  - 20150211
DP  - 2015 Feb
DC  - 20150212
YR  - 2015
ED  - 20151029
RD  - 20150311
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25672368

<104. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25439172
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Cuende JI
AU  - Lahoz C
AU  - Armario P
AU  - Garcia-Alegria J
AU  - Ena J
AU  - Garcia de Casasola G
AU  - Mostaza JM
FA  - Cuende, J I
FA  - Lahoz, C
FA  - Armario, P
FA  - Garcia-Alegria, J
FA  - Ena, J
FA  - Garcia de Casasola, G
FA  - Mostaza, J M
IN  - Cuende,J I. Servicio de Medicina Interna, Complejo Asistencial Universitario de Palencia, Palencia, Espana.
IN  - Lahoz,C. Servicio de Medicina Interna, Hospital Carlos III, Madrid, Espana.
IN  - Armario,P. Servicio de Medicina Interna, Hospital Transversal (Moises Broggi, Hospital General de l'Hospitalet), Consorci Sanitari Integral, Barcelona, Espana.
IN  - Garcia-Alegria,J. Servicio de Medicina Interna, Hospital Costa del Sol, Marbella, Malaga, Espana.
IN  - Ena,J. Servicio de Medicina Interna, Hospital Marina Baixa, Villajoyosa, Alicante, Espana.
IN  - Garcia de Casasola,G. Servicio de Medicina Interna, Hospital Infanta Cristina, Parla, Madrid, Espana.
IN  - Mostaza,J M. Servicio de Medicina Interna, Hospital Carlos III, Madrid, Espana. Electronic address: jmostaza.hciii@salud.madrid.org.
TI  - Cardiovascular news 2013/2014.
OT  - Novedades cardiovasculares 2013/2014.
SO  - Revista Clinica Espanola. 215(1):33-42, 2015 Jan-Feb.
AS  - Rev Clin Esp. 215(1):33-42, 2015 Jan-Feb.
NJ  - Revista clinica espanola
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - rnl, 8608576
CP  - Spain
KW  - Antiagregantes;  Anticoagulantes;  Anticoagulants;  Antiplatelets;  Arterial hypertension;  Cholesterol;  Colesterol;  Denervacion simpatica;  Diabetes;  Hipertension arterial;  Lipids;  Lipidos;  Nicotinic acid;  PCSK-9;  Riesgo vascular;  Sympathetic denervation;  Vascular risk;  Acido nicotinico
AB  - During 2013 and the first months of 2014, numerous studies have been published in the cardiovascular field. New guidelines have appeared for managing arterial hypertension and reducing cardiovascular risk by lowering cholesterol levels. New data have emerged on the considerable lipid-lowering efficacy of monoclonal antibodies against PCSK-9, in contrast, however, to the clinical trials directed towards raising HDL-cholesterol with nicotinic acid, which have not shown a reduction in the rate of cardiovascular complications. In the field of hypertension, neither stent placement in patients with renovascular hypertension nor sympathetic denervation in patients with resistant hypertension has been shown to be effective in reducing blood pressure. In terms of antithrombotic treatment, the pharmacogenetic tests do not seem useful for maintaining patients anticoagulated with warfarin within the therapeutic range for longer periods. Moreover, there is increasing evidence that, for patients with coronary artery disease and atrial fibrillation, antiplatelet therapy adds no benefit to anticoagulation therapy and is associated with a greater risk of bleeding. Lastly, a Mediterranean diet could prevent the onset of diabetes, while bariatric surgery could be a reasonable option for improving the disease in patients with obesity. Many of these studies have immediate practice applications in daily clinical practice. Copyright © 2014 Elsevier Espana, S.L.U. All rights reserved.
ES  - 1578-1860
IL  - 0014-2565
DI  - S0014-2565(14)00348-8
DO  - http://dx.doi.org/10.1016/j.rce.2014.07.012
PT  - Journal Article
LG  - English
LG  - Spanish
EP  - 20141101
DP  - 2015 Jan-Feb
DC  - 20150113
YR  - 2015
ED  - 20151026
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=25439172

<105. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25837164
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kim JB
AU  - Yang DH
AU  - Kang JW
AU  - Jung SH
AU  - Choo SJ
AU  - Chung CH
AU  - Song JK
AU  - Lee JW
FA  - Kim, Joon Bum
FA  - Yang, Dong Hyun
FA  - Kang, Joon-Won
FA  - Jung, Sung-Ho
FA  - Choo, Suk Jung
FA  - Chung, Cheol Hyun
FA  - Song, Jae-Kwan
FA  - Lee, Jae Won
IN  - Kim,Joon Bum. Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
IN  - Yang,Dong Hyun. Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
IN  - Kang,Joon-Won. Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
IN  - Jung,Sung-Ho. Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
IN  - Choo,Suk Jung. Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
IN  - Chung,Cheol Hyun. Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
IN  - Song,Jae-Kwan. Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
IN  - Lee,Jae Won. Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. jwlee@amc.seoul.kr.
TI  - Left atrial function following surgical ablation of atrial fibrillation: prospective evaluation using dual-source cardiac computed tomography.
SO  - Yonsei Medical Journal. 56(3):608-16, 2015 May.
AS  - Yonsei Med J. 56(3):608-16, 2015 May.
NJ  - Yonsei medical journal
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - xrr, 0414003
OI  - Source: NLM. PMC4397428
SB  - Index Medicus
CP  - Korea (South)
MH  - *Ablation Techniques
MH  - Adult
MH  - Aged
MH  - *Atrial Appendage/pp [Physiopathology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/su [Surgery]
MH  - *Atrial Function, Left/ph [Physiology]
MH  - Case-Control Studies
MH  - Electrocardiography/mt [Methods]
MH  - Female
MH  - Heart Atria
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Recovery of Function
MH  - Tomography, X-Ray Computed
KW  - Atrial fibrillation;  ablation;  left atrial systolic function;  surgery
AB  - PURPOSE: The Maze procedure has shown excellent efficacy in the elimination of atrial fibrillation (AF); however, little is known about the quality of functional recovery in the left atrium (LA) following successful sinus rhythm conversion by the Maze procedure.
AB  - MATERIALS AND METHODS: We prospectively enrolled 12 patients (aged 52.5+/-10.1 years, 1 female) with valvular AF undergoing mitral valve surgery combined with the Maze procedure. Parameters of LA function in three anatomic compartments [anterior, posterior, and LA appendage (LAA)] were evaluated using electrocardiography-gated dual-source cardiac CT at one month and at six months after surgery. Twelve subjects matched by age, gender, and body surface area served as controls.
AB  - RESULTS: At one month after surgery, ejection fraction (EF) and emptying volume (EV) of the LA were 14.9+/-7.4% and 21.3+/-9.7 mL, respectively, and they were significantly lower than those of the control group (EF, 47.9+/-11.2%; EV, 46.0+/-10.7%; p<0001). These values did not significantly change throughout late periods (p=0.22 and 0.21, respectively). Functional contributions of the anterior, posterior, and appendage compartments (EV of each compartment/overall EV) were 80.4%, -0.9%, and 20.5%, respectively, for those with LAA preservation (n=6); 100.1%, -0.1%, and 0% for those with LAA resection (n=6; p<0.05); and 62.2%, 28.2%, and 9.7% in the control subjects (p<0.001).
AB  - CONCLUSION: Contractile functions of the LA significantly decreased after the Maze procedure. Functional contributions of three compartments of the LA were also altered. The influence of LAA preservation on postoperative LA functions needs to be evaluated through studies of larger populations.
ES  - 1976-2437
IL  - 0513-5796
DO  - http://dx.doi.org/10.3349/ymj.2015.56.3.608
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2015 May
DC  - 20150403
YR  - 2015
ED  - 20151021
RD  - 20151026
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25837164

<106. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26076989
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Khawaja O
AU  - Petrone AB
AU  - Kanjwal Y
AU  - Gaziano JM
AU  - Djousse L
FA  - Khawaja, Owais
FA  - Petrone, Andrew B
FA  - Kanjwal, Yousuf
FA  - Gaziano, John M
FA  - Djousse, Luc
IN  - Khawaja,Owais. Department of Cardiology, Mercy St. Vincent Medical Center, Toledo, Ohio. Electronic address: oajaz@yahoo.com.
IN  - Petrone,Andrew B. Division of Aging, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
IN  - Kanjwal,Yousuf. Department of Cardiology, Mercy St. Vincent Medical Center, Toledo, Ohio.
IN  - Gaziano,John M. Division of Aging, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Massachusetts Veterans Epidemiology and Research Information Center (MAVERIC), Boston Veterans Affairs Healthcare System, Boston, Massachusetts; Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Geriatric Research, Education, and Clinical Center (GRECC), Boston Veterans Affairs Healthcare System, Boston, Massachusetts.
IN  - Djousse,Luc. Division of Aging, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Massachusetts Veterans Epidemiology and Research Information Center (MAVERIC), Boston Veterans Affairs Healthcare System, Boston, Massachusetts; Geriatric Research, Education, and Clinical Center (GRECC), Boston Veterans Affairs Healthcare System, Boston, Massachusetts.
TI  - Chocolate Consumption and Risk of Atrial Fibrillation (from the Physicians' Health Study).
SO  - American Journal of Cardiology. 116(4):563-6, 2015 Aug 15.
AS  - Am J Cardiol. 116(4):563-6, 2015 Aug 15.
NJ  - The American journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 3dq, 0207277
OI  - Source: NLM. NIHMS700402 [Available on 08/15/16]
OI  - Source: NLM. PMC4522217 [Available on 08/15/16]
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aspirin/tu [Therapeutic Use]
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - *Cacao
MH  - Cohort Studies
MH  - *Diet
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/pc [Prevention & Control]
MH  - Physicians
MH  - Platelet Aggregation Inhibitors/tu [Therapeutic Use]
MH  - Proportional Hazards Models
MH  - Risk Factors
MH  - Sex Factors
MH  - Surveys and Questionnaires
MH  - Vitamins/tu [Therapeutic Use]
MH  - beta Carotene/tu [Therapeutic Use]
AB  - Chocolate consumption has been shown to protect against various cardiovascular end points; however, little is known about the association between chocolate consumption and incident atrial fibrillation (AF). Therefore, we prospectively examined the association between chocolate consumption and incident AF in a cohort of 18,819 US male physicians. Chocolate consumption was ascertained from 1999 to 2002 through a self-administered food frequency questionnaire. Incident AF was ascertained through yearly follow-up questionnaires. Cox regression was used to estimate relative risks of AF. The average age at baseline was 66 years (+/-9.1). During a mean follow-up of 9.0 years (+/-3.0), 2,092 cases of AF occurred. Using <1 per month of chocolate consumption as the reference group, multivariable adjusted hazard ratios (95% confidence interval) for AF were 1.04 (0.93 to 1.18), 1.10 (0.96 to 1.25), 1.14 (0.99 to 1.31), and 1.05 (0.89 to 1.25) for chocolate intake of 1 to 3 per month and 1, 2 to 4, and >5 per week (p for trend 0.25), respectively. In a secondary analysis, there was no evidence of effect modification by adiposity (p interaction = 0.71) or age (p interaction = 0.26). In conclusion, our data did not support an association between chocolate consumption and risk of AF in US male physicians. Copyright © 2015 Elsevier Inc. All rights reserved.
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Vitamins)
RN  - 01YAE03M7J (beta Carotene)
RN  - R16CO5Y76E (Aspirin)
ES  - 1879-1913
IL  - 0002-9149
DI  - S0002-9149(15)01333-8
DO  - http://dx.doi.org/10.1016/j.amjcard.2015.05.009
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
NO  - CA-097193 (United States NCI NIH HHS)
NO  - CA-34944 (United States NCI NIH HHS)
NO  - CA-40360 (United States NCI NIH HHS)
NO  - HL-26490 (United States NHLBI NIH HHS)
NO  - HL-34595 (United States NHLBI NIH HHS)
NO  - R01 CA034944 (United States NCI NIH HHS)
NO  - R01 CA034944-03 (United States NCI NIH HHS)
NO  - R01 CA040360 (United States NCI NIH HHS)
NO  - R01 CA097193 (United States NCI NIH HHS)
NO  - R01 HL026490 (United States NHLBI NIH HHS)
NO  - R01 HL026490-03 (United States NHLBI NIH HHS)
NO  - R01 HL034595 (United States NHLBI NIH HHS)
NO  - R01 HL034595-07 (United States NHLBI NIH HHS)
NO  - R21 HL088081 (United States NHLBI NIH HHS)
NO  - R21 HL088081 (United States NHLBI NIH HHS)
LG  - English
EP  - 20150521
DP  - 2015 Aug 15
DC  - 20150803
YR  - 2015
ED  - 20151019
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26076989

<107. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25142057
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Azarbal F
AU  - Stefanick ML
AU  - Salmoirago-Blotcher E
AU  - Manson JE
AU  - Albert CM
AU  - LaMonte MJ
AU  - Larson JC
AU  - Li W
AU  - Martin LW
AU  - Nassir R
AU  - Garcia L
AU  - Assimes TL
AU  - Tharp KM
AU  - Hlatky MA
AU  - Perez MV
FA  - Azarbal, Farnaz
FA  - Stefanick, Marcia L
FA  - Salmoirago-Blotcher, Elena
FA  - Manson, JoAnn E
FA  - Albert, Christine M
FA  - LaMonte, Michael J
FA  - Larson, Joseph C
FA  - Li, Wenjun
FA  - Martin, Lisa W
FA  - Nassir, Rami
FA  - Garcia, Lorena
FA  - Assimes, Themistocles L
FA  - Tharp, Katie M
FA  - Hlatky, Mark A
FA  - Perez, Marco V
IN  - Azarbal,Farnaz. Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA (F.A., T.L.A., M.A.H., M.V.P.).
IN  - Stefanick,Marcia L. Department of Medicine, Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA (M.L.S.).
IN  - Salmoirago-Blotcher,Elena. Department of Medicine, Brown University School of Medicine, Providence, RI (E.S.B.).
IN  - Manson,JoAnn E. Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (J.A.E.M., C.M.A.).
IN  - Albert,Christine M. Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (J.A.E.M., C.M.A.) Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (C.M.A.).
IN  - LaMonte,Michael J. Department of Social and Prevention Medicine, School of Public Health and Health Professions, University of Buffalo, Buffalo, NY (M.J.L.M.).
IN  - Larson,Joseph C. Data Coordinating Center, Fred Hutchinson Cancer Research Center, Seattle, WA (J.C.L.).
IN  - Li,Wenjun. Division of Preventive and Behavioral Medicine, University of Massachusetts Medical School, Worcester, MA (W.L.).
IN  - Martin,Lisa W. School of Medicine and Health Sciences, George Washington University, Washington, DC (L.W.M.).
IN  - Nassir,Rami. Department of Biochemistry and Molecular Medicine, University of California Davis, Davis, CA (R.N.).
IN  - Garcia,Lorena. Department of Public Health Sciences, University of California Davis, Davis, CA (L.G.).
IN  - Assimes,Themistocles L. Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA (F.A., T.L.A., M.A.H., M.V.P.).
IN  - Tharp,Katie M. Institutional Research and Assessment, Loras College, Dubuque, IA (K.M.T.).
IN  - Hlatky,Mark A. Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA (F.A., T.L.A., M.A.H., M.V.P.) Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA (M.A.H.).
IN  - Perez,Marco V. Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA (F.A., T.L.A., M.A.H., M.V.P.).
TI  - Obesity, physical activity, and their interaction in incident atrial fibrillation in postmenopausal women.
SO  - Journal of the American Heart Association. 3(4), 2014 Aug.
AS  - J Am Heart Assoc. 3(4), 2014 Aug.
NJ  - Journal of the American Heart Association
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 101580524
OI  - Source: NLM. PMC4310412
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Cardiovascular Diseases/ep [Epidemiology]
MH  - Diabetes Mellitus/ep [Epidemiology]
MH  - *Exercise
MH  - Female
MH  - Humans
MH  - Hyperlipidemias/ep [Epidemiology]
MH  - *Hypertension/ep [Epidemiology]
MH  - Incidence
MH  - Longitudinal Studies
MH  - Middle Aged
MH  - Motor Activity
MH  - *Obesity/ep [Epidemiology]
MH  - Overweight/ep [Epidemiology]
MH  - *Postmenopause
MH  - Prospective Studies
MH  - Risk Factors
MH  - Sedentary Lifestyle
KW  - atrial fibrillation;  electrophysiology;  epidemiology;  exercise;  obesity
AB  - BACKGROUND: Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with increased risk of stroke and death. Obesity is an independent risk factor for AF, but modifiers of this risk are not well known. We studied the roles of obesity, physical activity, and their interaction in conferring risk of incident AF.
AB  - METHODS AND RESULTS: The Women's Health Initiative (WHI) Observational Study was a prospective observational study of 93 676 postmenopausal women followed for an average of 11.5 years. Incident AF was identified using WHI-ascertained hospitalization records and diagnostic codes from Medicare claims. A multivariate Cox's hazard regression model adjusted for demographic and clinical risk factors was used to evaluate the interaction between obesity and physical activity and its association with incident AF. After exclusion of women with prevalent AF, incomplete data, or underweight body mass index (BMI), 9792 of the remaining 81 317 women developed AF. Women were, on average, 63.4 years old, 7.8% were African American, and 3.6% were Hispanic. Increased BMI (hazard ratio [HR], 1.12 per 5-kg/m(2) increase; 95% confidence interval [CI], 1.10 to 1.14) and reduced physical activity (>9 vs. 0 metabolic equivalent task hours per week; HR, 0.90; 95% CI, 0.85 to 0.96) were independently associated with higher rates of AF after multivariate adjustment. Higher levels of physical activity reduced the AF risk conferred by obesity (interaction P=0.033).
AB  - CONCLUSIONS: Greater physical activity is associated with lower rates of incident AF and modifies the association between obesity and incident AF.Copyright © 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.
ES  - 2047-9980
IL  - 2047-9980
DI  - e001127
DO  - http://dx.doi.org/10.1161/JAHA.114.001127
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, U.S. Gov't, P.H.S.
NO  - HHSN268201100001C (United States PHS HHS)
NO  - HHSN268201100002C (United States PHS HHS)
NO  - HHSN268201100003C (United States PHS HHS)
NO  - HHSN268201100004C (United States PHS HHS)
NO  - HHSN268201100046C (United States PHS HHS)
NO  - HHSN271201100004C (United States PHS HHS)
LG  - English
EP  - 20140820
DP  - 2014 Aug
DC  - 20140821
YR  - 2014
ED  - 20151012
RD  - 20150211
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25142057

<108. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24464777
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Borne Y
AU  - Persson M
AU  - Melander O
AU  - Smith JG
AU  - Engstrom G
FA  - Borne, Yan
FA  - Persson, Margaretha
FA  - Melander, Olle
FA  - Smith, J Gustav
FA  - Engstrom, Gunnar
TI  - Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation.
SO  - European Journal of Heart Failure. 16(4):377-83, 2014 Apr.
AS  - Eur J Heart Fail. 16(4):377-83, 2014 Apr.
NJ  - European journal of heart failure
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - dr4, 100887595
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - Atrial Fibrillation/bl [Blood]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Biomarkers/bl [Blood]
MH  - C-Reactive Protein/me [Metabolism]
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Heart Failure/bl [Blood]
MH  - *Heart Failure/ep [Epidemiology]
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/bl [Blood]
MH  - Peptide Fragments/bl [Blood]
MH  - *Receptors, Urokinase Plasminogen Activator/bl [Blood]
MH  - Risk Factors
AB  - AIMS: Soluble urokinase plasminogen activator receptor (suPAR) in plasma is a novel inflammatory marker thought to be released from the cell surface of neutrophils, T cells, and macrophages. Other inflammatory markers, mainly acute phase proteins produced in the liver, have been associated with the incidence of heart failure (HF) and atrial fibrillation (AF). We investigated the association between suPAR and incident HF and AF in a population-based cohort.
AB  - METHODS AND RESULTS: Soluble urokinase plasminogen activator receptor was measured in 4530 subjects (aged 46-68years, 61% women), who participated in the Malmo Diet and Cancer study during 1991-1996. Incident cases of HF and AF were identified from the Swedish hospital discharge register during a median follow-up of 16.3years. During follow-up, 109 subjects (55% men) were diagnosed with new-onset HF and 321 individuals (50% men) with AF. suPAR was significantly associated with increased plasma levels of NT-proBNP (P<0.001). suPAR was significantly associated with incidence of HF [hazard ratio (HR) for the third vs. first tertile 3.33, 95% confidence interval (CI) 1.91-5.81 after adjustment for age and sex; and HR 1.82, 95% CI 1.02-3.27, P for trend 0.018 after adjustment for conventional risk factors and biomarkers]. suPAR was significantly associated with incidence of AF, when adjusted for age and sex (HR 1.40, 95% CI 1.06-1.85). However, this relationship was non-significant after adjustment for conventional risk factors and biomarkers.
AB  - CONCLUSION: Soluble urokinase plasminogen activator receptor was associated with increased plasma levels of NT-proBNP and incidence of HF, but not with AF among middle-aged subjects.Copyright © 2014 The Authors. European Journal of Heart Failure © 2014 European Society of Cardiology.
RN  - 0 (Biomarkers)
RN  - 0 (Peptide Fragments)
RN  - 0 (Receptors, Urokinase Plasminogen Activator)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 9007-41-4 (C-Reactive Protein)
ES  - 1879-0844
IL  - 1388-9842
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2014 Apr
DC  - 20150130
YR  - 2014
ED  - 20150903
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24464777

<109. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25470147
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - da Silva RM
FA  - da Silva, Rose M F L
IN  - da Silva,Rose M F L. Avenue Alfredo Balena, 190, room 246, Santa Efigenia, Code 30.130-100, Belo Horizonte/Minas Gerais, Brazil. roselisboa@uol.com.br.
TI  - Novel oral anticoagulants in non-valvular atrial fibrillation. [Review]
SO  - Cardiovascular & Hematological Agents in Medicinal Chemistry. 12(1):3-8, 2014.
AS  - Cardiovasc Hematol Agents Med Chem. 12(1):3-8, 2014.
NJ  - Cardiovascular & hematological agents in medicinal chemistry
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101266881
OI  - Source: NLM. PMC4428103
SB  - Index Medicus
CP  - Netherlands
MH  - Administration, Oral
MH  - Anticoagulants/ae [Adverse Effects]
MH  - Anticoagulants/ec [Economics]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Benzimidazoles/ae [Adverse Effects]
MH  - Benzimidazoles/tu [Therapeutic Use]
MH  - Chemistry, Pharmaceutical/st [Standards]
MH  - Chemistry, Pharmaceutical/td [Trends]
MH  - Dabigatran
MH  - Humans
MH  - Morpholines/ae [Adverse Effects]
MH  - Morpholines/tu [Therapeutic Use]
MH  - Rivaroxaban
MH  - Thiophenes/ae [Adverse Effects]
MH  - Thiophenes/tu [Therapeutic Use]
MH  - beta-Alanine/ae [Adverse Effects]
MH  - beta-Alanine/aa [Analogs & Derivatives]
MH  - beta-Alanine/tu [Therapeutic Use]
AB  - Atrial fibrillation is the most frequent arrhythmia in clinical practice, reaching 2% of the people in the world and is associated with systemic embolism. Thus, the use of anticoagulants is indicated if CHA2DS2-VASc score > 2 or in patients with previous transient ischemic attack or stroke. For decades, warfarin, a vitamin K antagonist, was the only choice for chronic oral anticoagulation. Recently, novel oral anticoagulants (NOACs) have been introduced, offering similar (or better) effectiveness, safety, and convenience to the vitamin K antagonists. Dabigatran was the first NOAC approved and is a direct thrombin inhibitor. Rivaroxaban and apixaban are factor Xa inhibitors. They display rapid onset of action, more predictable of pharmacological profile, less interactions with other drugs, lack of significant effects in the diet, and less risk of intracranial hemorrhage than warfarin. Despite that dose adjustment is necessary for patients with chronic kidney disease or according to body weight, these new drugs do not require regular monitoring. There are recommendations for the start and follow-up therapy with NOACs, planning for cardioversion, ablation and surgical interventions and the management of bleeding. This article is a review of the major studies of the NOACs. The clinical use of these drugs in patients with non-valvular atrial fibrillation is presented.
RN  - 0 (Anticoagulants)
RN  - 0 (Benzimidazoles)
RN  - 0 (Morpholines)
RN  - 0 (Thiophenes)
RN  - 11P2JDE17B (beta-Alanine)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - I0VM4M70GC (Dabigatran)
ES  - 1875-6182
IL  - 1871-5257
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2014
DC  - 20141204
YR  - 2014
ED  - 20150903
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25470147

<110. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24464106
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Manchanda SC
AU  - Madan K
FA  - Manchanda, S C
FA  - Madan, Kushal
IN  - Manchanda,S C. Dharma Vira Heart Center, Sir Ganga Ram Hospital, New Delhi, 110060, India, doctormanchanda@yahoo.com.
TI  - Yoga and meditation in cardiovascular disease. [Review][Erratum appears in Clin Res Cardiol. 2014 Sep;103(9):763]
SO  - Clinical Research in Cardiology. 103(9):675-80, 2014 Sep.
AS  - Clin. res. cardiol.. 103(9):675-80, 2014 Sep.
NJ  - Clinical research in cardiology : official journal of the German Cardiac Society
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101264123
SB  - Index Medicus
CP  - Germany
MH  - Cardiovascular Diseases/et [Etiology]
MH  - Cardiovascular Diseases/px [Psychology]
MH  - *Cardiovascular Diseases/th [Therapy]
MH  - Humans
MH  - *Meditation/mt [Methods]
MH  - Primary Prevention/mt [Methods]
MH  - Risk Factors
MH  - Secondary Prevention/mt [Methods]
MH  - *Yoga
AB  - Yoga is a holistic mind-body intervention aimed at physical, mental, emotional and spiritual well being. Several studies have shown that yoga and/or meditation can control risk factors for cardiovascular disease like hypertension, type II diabetes and insulin resistance, obesity, lipid profile, psychosocial stress and smoking. Some randomized studies suggest that yoga/meditation could retard or even regress early and advanced coronary atherosclerosis. A recent study suggests that transcendental meditation may be extremely useful in secondary prevention of coronary heart disease and may reduce cardiovascular events by 48% over a 5-year period. Another small study suggests that yoga may be helpful in prevention of atrial fibrillation. However, most studies have several limitations like lack of adequate controls, small sample size, inconsistencies in baseline and different methodologies, etc. and therefore large trials with improved methodologies are required to confirm these findings. However, in view of the existing knowledge and yoga being a cost-effective technique without side effects, it appears appropriate to incorporate yoga/meditation for primary and secondary prevention of cardiovascular disease.
ES  - 1861-0692
IL  - 1861-0684
DO  - http://dx.doi.org/10.1007/s00392-014-0663-9
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20140125
DP  - 2014 Sep
DC  - 20140812
YR  - 2014
ED  - 20150903
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24464106

<111. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25449515
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Chen JJ
AU  - Lin LY
AU  - Yang YH
AU  - Hwang JJ
AU  - Chen PC
AU  - Lin JL
FA  - Chen, Jien-Jiun
FA  - Lin, Lian-Yu
FA  - Yang, Yao-Hsu
FA  - Hwang, Juey-Jen
FA  - Chen, Pau-Chung
FA  - Lin, Jiunn-Lee
IN  - Chen,Jien-Jiun. Cardiovascular Center, National Taiwan University Hospital Yun-Lin Branch, Douliou, Taiwan.
IN  - Lin,Lian-Yu. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
IN  - Yang,Yao-Hsu. Department for Traditional Chinese Medicine, Chang Gung Memorial Hospital Chia-Yi, Taiwan; Institute of Occupational Medicine and Industrial Hygiene, National Taiwan University College of Public Health, Taipei, Taiwan.
IN  - Hwang,Juey-Jen. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
IN  - Chen,Pau-Chung. Department for Traditional Chinese Medicine, Chang Gung Memorial Hospital Chia-Yi, Taiwan. Electronic address: pcchen@ntu.edu.tw.
IN  - Lin,Jiunn-Lee. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: jiunnlee@ntu.edu.tw.
TI  - Anti-platelet or anti-coagulant agent for the prevention of ischemic stroke in patients with end-stage renal disease and atrial fibrillation--a nation-wide database analyses.
CM  - Comment in: Int J Cardiol. 2015 Jul 1;190:349; PMID: 25935627
CM  - Comment in: Int J Cardiol. 2015 Oct 1;196:53; PMID: 26073213
SO  - International Journal of Cardiology. 177(3):1008-11, 2014 Dec 20.
AS  - Int J Cardiol. 177(3):1008-11, 2014 Dec 20.
NJ  - International journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - gqw, 8200291
SB  - Index Medicus
CP  - Netherlands
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - Brain Ischemia/ep [Epidemiology]
MH  - *Brain Ischemia/pc [Prevention & Control]
MH  - Cohort Studies
MH  - Databases, Factual/td [Trends]
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - *Kidney Failure, Chronic/dt [Drug Therapy]
MH  - Kidney Failure, Chronic/ep [Epidemiology]
MH  - Male
MH  - Middle Aged
MH  - *Platelet Aggregation Inhibitors/tu [Therapeutic Use]
MH  - Stroke/ep [Epidemiology]
MH  - *Stroke/pc [Prevention & Control]
MH  - Taiwan/ep [Epidemiology]
MH  - Young Adult
KW  - Atrial fibrillation;  End-stage renal disease;  Stroke;  Warfarin
AB  - OBJECTIVE: The risk/benefit profiles of anti-coagulant or anti-platelet agents in patients with end-stage renal disease (ESRD) and atrial fibrillation (AF) remained unclear. We aimed to investigate the stroke risks in these patients with or without anti-coagulant/anti-platelet therapy by using our national database.
AB  - METHOD: By using our national health insurance ESRD claim database, we searched patients with AF, more than 18 years old and without prior history of ischemic stroke. Medication information as well as the events of ischemic stroke, hemorrhagic stroke, and transient ischemic accident during follow-up were identified from the database. Propensity score method was used to match all the potential confounders between patients with and without anti-platelets/warfarin treatment.
AB  - RESULT: A total of 134,410 ESRD patients were identified in the database. Among them, patients with non-valvular AF, over 18 years old, without prior history of ischemic stroke and received monotherapy with anti-platelets (1622) or warfarin (294) served as case groups while patients (2983) without taking any anti-platelets and warfarin served as control groups. The incidences of ischemic stroke or transient ischemic attack (TIA) were not different among the control (6.6%), anti-platelet (6.2%) and warfarin (5.1%) groups in a follow-up period of approximately 4 years. The results remained unchanged after propensity match. Cox-regression analyses also showed no beneficial effect of anti-platelet or warfarin therapy in overall and any subgroups.
AB  - CONCLUSION: In this nationwide cohort analyses, we found that anti-platelet or warfarin treatment could not lower the risk of ischemic stroke in patients with ESRD.Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
ES  - 1874-1754
IL  - 0167-5273
DI  - S0167-5273(14)01860-9
DO  - http://dx.doi.org/10.1016/j.ijcard.2014.09.140
PT  - Journal Article
LG  - English
EP  - 20141005
DP  - 2014 Dec 20
DC  - 20150202
YR  - 2014
ED  - 20150824
RD  - 20150929
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25449515

<112. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25934859
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Larsson SC
AU  - Akesson A
AU  - Wolk A
FA  - Larsson, Susanna C
FA  - Akesson, Agneta
FA  - Wolk, Alicja
IN  - Larsson,Susanna C. From the Unit of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. susanna.larsson@ki.se.
IN  - Akesson,Agneta. From the Unit of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
IN  - Wolk,Alicja. From the Unit of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
TI  - Primary prevention of stroke by a healthy lifestyle in a high-risk group.
SO  - Neurology. 84(22):2224-8, 2015 Jun 2.
AS  - Neurology. 84(22):2224-8, 2015 Jun 2.
NJ  - Neurology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 0401060, nz0
OI  - Source: NLM. PMC4456657 [Available on 12/02/15]
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - Cohort Studies
MH  - Follow-Up Studies
MH  - Humans
MH  - *Life Style
MH  - Male
MH  - Middle Aged
MH  - *Primary Prevention/mt [Methods]
MH  - Prospective Studies
MH  - Risk Factors
MH  - *Risk Reduction Behavior
MH  - Stroke/dh [Diet Therapy]
MH  - *Stroke/ep [Epidemiology]
MH  - *Stroke/pc [Prevention & Control]
MH  - Sweden/ep [Epidemiology]
AB  - OBJECTIVE: To examine the impact of a healthy lifestyle on stroke risk in men at higher risk of stroke because of other cardiovascular diseases or conditions.
AB  - METHODS: Our study population comprised 11,450 men in the Cohort of Swedish Men who had a history of hypertension, high cholesterol levels, diabetes, heart failure, or atrial fibrillation. Participants had completed a questionnaire about diet and lifestyle and were free from stroke and ischemic heart disease at baseline (January 1, 1998). We defined a healthy lifestyle as a low-risk diet (>5 servings/d of fruits and vegetables and <30 g/d of processed meat), not smoking, >150 min/wk of physical activity, body mass index of 18.5 to 25 kg/m(2), and low to moderate alcohol consumption (>0 to <30 g/d). Ascertainment of stroke cases was accomplished through linkage with the National Inpatient Register and the Swedish Cause of Death Register.
AB  - RESULTS: During a mean follow-up of 9.8 years, we ascertained 1,062 incident stroke cases. The risk of total stroke and stroke types decreased with increasing number of healthy lifestyle factors. The multivariable relative risk of total stroke for men who achieved all 5 healthy lifestyle factors compared with men who achieved 0 or 1 factor was 0.28 (95% confidence interval 0.14-0.55). The corresponding relative risks (95% confidence interval) were 0.31 (0.15-0.66) for ischemic stroke and 0.32 (0.04-2.51) for hemorrhagic stroke.
AB  - CONCLUSIONS: A healthy lifestyle is associated with a substantially reduced risk of stroke in men at higher risk of stroke.Copyright © 2015 American Academy of Neurology.
ES  - 1526-632X
IL  - 0028-3878
DO  - http://dx.doi.org/10.1212/WNL.0000000000001637
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20150501
DP  - 2015 Jun 2
DC  - 20150602
YR  - 2015
ED  - 20150819
RD  - 20151111
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25934859

<113. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25934859
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Larsson SC
AU  - Akesson A
AU  - Wolk A
FA  - Larsson, Susanna C
FA  - Akesson, Agneta
FA  - Wolk, Alicja
IN  - Larsson,Susanna C. From the Unit of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. susanna.larsson@ki.se.
IN  - Akesson,Agneta. From the Unit of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
IN  - Wolk,Alicja. From the Unit of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
TI  - Primary prevention of stroke by a healthy lifestyle in a high-risk group.
SO  - Neurology. 84(22):2224-8, 2015 Jun 2.
AS  - Neurology. 84(22):2224-8, 2015 Jun 2.
NJ  - Neurology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 0401060, nz0
OI  - Source: NLM. PMC4456657
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - Cohort Studies
MH  - Follow-Up Studies
MH  - Humans
MH  - *Life Style
MH  - Male
MH  - Middle Aged
MH  - *Primary Prevention/mt [Methods]
MH  - Prospective Studies
MH  - Risk Factors
MH  - *Risk Reduction Behavior
MH  - Stroke/dh [Diet Therapy]
MH  - *Stroke/ep [Epidemiology]
MH  - *Stroke/pc [Prevention & Control]
MH  - Sweden/ep [Epidemiology]
AB  - OBJECTIVE: To examine the impact of a healthy lifestyle on stroke risk in men at higher risk of stroke because of other cardiovascular diseases or conditions.
AB  - METHODS: Our study population comprised 11,450 men in the Cohort of Swedish Men who had a history of hypertension, high cholesterol levels, diabetes, heart failure, or atrial fibrillation. Participants had completed a questionnaire about diet and lifestyle and were free from stroke and ischemic heart disease at baseline (January 1, 1998). We defined a healthy lifestyle as a low-risk diet (>5 servings/d of fruits and vegetables and <30 g/d of processed meat), not smoking, >150 min/wk of physical activity, body mass index of 18.5 to 25 kg/m(2), and low to moderate alcohol consumption (>0 to <30 g/d). Ascertainment of stroke cases was accomplished through linkage with the National Inpatient Register and the Swedish Cause of Death Register.
AB  - RESULTS: During a mean follow-up of 9.8 years, we ascertained 1,062 incident stroke cases. The risk of total stroke and stroke types decreased with increasing number of healthy lifestyle factors. The multivariable relative risk of total stroke for men who achieved all 5 healthy lifestyle factors compared with men who achieved 0 or 1 factor was 0.28 (95% confidence interval 0.14-0.55). The corresponding relative risks (95% confidence interval) were 0.31 (0.15-0.66) for ischemic stroke and 0.32 (0.04-2.51) for hemorrhagic stroke.
AB  - CONCLUSIONS: A healthy lifestyle is associated with a substantially reduced risk of stroke in men at higher risk of stroke.Copyright © 2015 American Academy of Neurology.
ES  - 1526-632X
IL  - 0028-3878
DO  - http://dx.doi.org/10.1212/WNL.0000000000001637
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20150501
DP  - 2015 Jun 2
DC  - 20150602
YR  - 2015
ED  - 20150819
RD  - 20151202
UP  - 20151217
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=25934859

<114. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25633371
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Konecny T
AU  - Geske JB
AU  - Ludka O
AU  - Orban M
AU  - Brady PA
AU  - Abudiab MM
AU  - Albuquerque FN
AU  - Placek A
AU  - Kara T
AU  - Sahakyan KR
AU  - Gersh BJ
AU  - Tajik AJ
AU  - Allison TG
AU  - Ommen SR
AU  - Somers VK
FA  - Konecny, Tomas
FA  - Geske, Jeffrey B
FA  - Ludka, Ondrej
FA  - Orban, Marek
FA  - Brady, Peter A
FA  - Abudiab, Muaz M
FA  - Albuquerque, Felipe N
FA  - Placek, Alexander
FA  - Kara, Tomas
FA  - Sahakyan, Karine R
FA  - Gersh, Bernard J
FA  - Tajik, A Jamil
FA  - Allison, Thomas G
FA  - Ommen, Steve R
FA  - Somers, Virend K
TI  - Decreased exercise capacity and sleep-disordered breathing in patients with hypertrophic cardiomyopathy.
SO  - Chest. 147(6):1574-81, 2015 Jun.
AS  - Chest. 147(6):1574-81, 2015 Jun.
NJ  - Chest
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 0231335, d1c
OI  - Source: NLM. PMC4451712 [Available on 06/01/16]
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - *Cardiomyopathy, Hypertrophic/ep [Epidemiology]
MH  - *Cardiomyopathy, Hypertrophic/pp [Physiopathology]
MH  - Comorbidity
MH  - Cross-Sectional Studies
MH  - Exercise Test
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oximetry
MH  - Oxygen Consumption/ph [Physiology]
MH  - Prevalence
MH  - Severity of Illness Index
MH  - *Sleep Apnea, Central/ep [Epidemiology]
MH  - *Sleep Apnea, Central/pp [Physiopathology]
MH  - Stroke Volume/ph [Physiology]
AB  - BACKGROUND: Mechanisms of decreased exercise capacity in patients with hypertrophic cardiomyopathy (HCM) are not well understood. Sleep-disordered breathing (SDB) is a highly prevalent but treatable disorder in patients with HCM. The role of comorbid SDB in the attenuated exercise capacity in HCM has not been studied previously.
AB  - METHODS: Overnight oximetry, cardiopulmonary exercise testing, and echocardiographic studies were performed in consecutive patients with HCM seen at the Mayo Clinic. SDB was considered present if the oxygen desaturation index (number of > 4% desaturations/h) was > 10. Peak oxygen consumption (VO2 peak) (the most reproducible and prognostic measure of cardiovascular fitness) was then correlated with the presence and severity of SDB.
AB  - RESULTS: A total of 198 patients with HCM were studied (age, 53 +/- 16 years; 122 men), of whom 32% met the criteria for the SDB diagnosis. Patients with SDB had decreased VO2 peak compared with those without SDB (16 mL O2/kg/min vs 21 mL O2/kg/min, P < .001). SDB remained significantly associated with VO2 peak after accounting for confounding clinical variables (P < .001) including age, sex, BMI, atrial fibrillation, and coronary artery disease.
AB  - CONCLUSIONS: In patients with HCM, the presence of SDB is associated with decreased VO2 peak. SDB may represent an important and potentially modifiable contributor to impaired exercise tolerance in this unique population.
ES  - 1931-3543
IL  - 0012-3692
DO  - http://dx.doi.org/10.1378/chest.14-1498
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
NO  - HL65176 (United States NHLBI NIH HHS)
NO  - UL1 TR000135 (United States NCATS NIH HHS)
LG  - English
DP  - 2015 Jun
DC  - 20150602
YR  - 2015
ED  - 20150818
RD  - 20151028
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25633371

<115. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25389655
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Redpath CJ
AU  - Backx PH
FA  - Redpath, Calum J
FA  - Backx, Peter H
IN  - Redpath,Calum J. aArrhythmia Service and the Cellular Electrophysiology Laboratory, University of Ottawa Heart Institute, Ottawa bDivision of Cardiology, Departments of Physiology and Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada.
TI  - Atrial fibrillation and the athletic heart. [Review]
SO  - Current Opinion in Cardiology. 30(1):17-23, 2015 Jan.
AS  - Curr Opin Cardiol. 30(1):17-23, 2015 Jan.
NJ  - Current opinion in cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - bda, 8608087
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Athletes/sn [Statistics & Numerical Data]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Disease Progression
MH  - Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Patient Safety
MH  - Physical Education and Training/st [Standards]
MH  - Physical Education and Training/td [Trends]
MH  - *Physical Endurance/ph [Physiology]
MH  - Risk Assessment
MH  - Severity of Illness Index
MH  - *Sports/ph [Physiology]
MH  - Survival Rate
MH  - Young Adult
AB  - PURPOSE OF REVIEW: Endurance exercise, despite a plethora of proven health benefits, is increasingly recognized as a potential cause of lone atrial fibrillation. Moderate exercise reduces all-cause mortality and protects against developing atrial fibrillation. However, more intense exercise regimes confer modest incremental health benefits, induce cardiac remodelling and negate some of the cardiovascular benefits of exercise. The implications of endurance exercise and athletic heart are becoming increasingly relevant as the popularity of endurance exercise has increased 20-fold within a generation.
AB  - RECENT FINDINGS: An apparent dose-response relationship exists between endurance exercise and left atrial dilatation. Repeated strenuous endurance exercise overloads atria, resulting in stretch-induced 'microtears', inflammation and endocardial scarring. Although these findings are observational in humans, similar mechanisms have recently been confirmed in animal models suggesting causation.
AB  - SUMMARY: Currently, it is not known whether a ceiling for endurance exercise exists, and, if so, what factors determine the threshold of harm. Although preliminary research is promising, much work remains if we are to understand the mechanisms underpinning atrial fibrillation in athletes.
ES  - 1531-7080
IL  - 0268-4705
DO  - http://dx.doi.org/10.1097/HCO.0000000000000130
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2015 Jan
DC  - 20141204
YR  - 2015
ED  - 20150818
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25389655

<116. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25633371
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Konecny T
AU  - Geske JB
AU  - Ludka O
AU  - Orban M
AU  - Brady PA
AU  - Abudiab MM
AU  - Albuquerque FN
AU  - Placek A
AU  - Kara T
AU  - Sahakyan KR
AU  - Gersh BJ
AU  - Tajik AJ
AU  - Allison TG
AU  - Ommen SR
AU  - Somers VK
FA  - Konecny, Tomas
FA  - Geske, Jeffrey B
FA  - Ludka, Ondrej
FA  - Orban, Marek
FA  - Brady, Peter A
FA  - Abudiab, Muaz M
FA  - Albuquerque, Felipe N
FA  - Placek, Alexander
FA  - Kara, Tomas
FA  - Sahakyan, Karine R
FA  - Gersh, Bernard J
FA  - Tajik, A Jamil
FA  - Allison, Thomas G
FA  - Ommen, Steve R
FA  - Somers, Virend K
TI  - Decreased exercise capacity and sleep-disordered breathing in patients with hypertrophic cardiomyopathy.
SO  - Chest. 147(6):1574-81, 2015 Jun.
AS  - Chest. 147(6):1574-81, 2015 Jun.
NJ  - Chest
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 0231335, d1c
OI  - Source: NLM. PMC4451712
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - *Cardiomyopathy, Hypertrophic/ep [Epidemiology]
MH  - *Cardiomyopathy, Hypertrophic/pp [Physiopathology]
MH  - Comorbidity
MH  - Cross-Sectional Studies
MH  - Exercise Test
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oximetry
MH  - Oxygen Consumption/ph [Physiology]
MH  - Prevalence
MH  - Severity of Illness Index
MH  - *Sleep Apnea, Central/ep [Epidemiology]
MH  - *Sleep Apnea, Central/pp [Physiopathology]
MH  - Stroke Volume/ph [Physiology]
AB  - BACKGROUND: Mechanisms of decreased exercise capacity in patients with hypertrophic cardiomyopathy (HCM) are not well understood. Sleep-disordered breathing (SDB) is a highly prevalent but treatable disorder in patients with HCM. The role of comorbid SDB in the attenuated exercise capacity in HCM has not been studied previously.
AB  - METHODS: Overnight oximetry, cardiopulmonary exercise testing, and echocardiographic studies were performed in consecutive patients with HCM seen at the Mayo Clinic. SDB was considered present if the oxygen desaturation index (number of > 4% desaturations/h) was > 10. Peak oxygen consumption (VO2 peak) (the most reproducible and prognostic measure of cardiovascular fitness) was then correlated with the presence and severity of SDB.
AB  - RESULTS: A total of 198 patients with HCM were studied (age, 53 +/- 16 years; 122 men), of whom 32% met the criteria for the SDB diagnosis. Patients with SDB had decreased VO2 peak compared with those without SDB (16 mL O2/kg/min vs 21 mL O2/kg/min, P < .001). SDB remained significantly associated with VO2 peak after accounting for confounding clinical variables (P < .001) including age, sex, BMI, atrial fibrillation, and coronary artery disease.
AB  - CONCLUSIONS: In patients with HCM, the presence of SDB is associated with decreased VO2 peak. SDB may represent an important and potentially modifiable contributor to impaired exercise tolerance in this unique population.
ES  - 1931-3543
IL  - 0012-3692
DO  - http://dx.doi.org/10.1378/chest.14-1498
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
NO  - HL65176 (United States NHLBI NIH HHS)
NO  - R01 HL065176 (United States NHLBI NIH HHS)
NO  - UL1 TR000135 (United States NCATS NIH HHS)
NO  - UL1 TR000135 (United States NCATS NIH HHS)
LG  - English
DP  - 2015 Jun
DC  - 20150602
YR  - 2015
ED  - 20150818
RD  - 20160601
UP  - 20160603
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=25633371

<117. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24132684
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Uchida N
AU  - Suda T
AU  - Ishiguro K
FA  - Uchida, Naotaka
FA  - Suda, Takako
FA  - Ishiguro, Kiyosuke
IN  - Uchida,Naotaka. Department of Surgery, Tottori Prefectural Kousei Hospital, 150 Higashisyouwa-machi, Kurayoshi, Tottori, 682-0804, Japan, uchidana@pref.tottori.jp.
TI  - Thyroidectomy in a patient with thyroid storm: report of a case.
SO  - Surgery Today. 45(1):110-4, 2015 Jan.
AS  - SURG. TODAY. 45(1):110-4, 2015 Jan.
NJ  - Surgery today
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - bfy, 9204360
SB  - Index Medicus
CP  - Japan
MH  - Adult
MH  - Antithyroid Agents/ad [Administration & Dosage]
MH  - Betamethasone/ad [Administration & Dosage]
MH  - Betamethasone/aa [Analogs & Derivatives]
MH  - Combined Modality Therapy
MH  - Digoxin/ad [Administration & Dosage]
MH  - Diuretics/ad [Administration & Dosage]
MH  - Female
MH  - Graves Disease/co [Complications]
MH  - Humans
MH  - Multiple Organ Failure/et [Etiology]
MH  - Multiple Organ Failure/th [Therapy]
MH  - Potassium Iodide/ad [Administration & Dosage]
MH  - Thyroid Crisis/et [Etiology]
MH  - *Thyroid Crisis/su [Surgery]
MH  - Thyroidectomy/ct [Contraindications]
MH  - *Thyroidectomy/mt [Methods]
MH  - Treatment Outcome
AB  - Thyroid storm is a life-threatening condition that is generally considered to be a contradiction to surgical intervention. We herein describe the case of a 37-year-old patient with a history of Graves' disease who was transferred to Tottori University Hospital with thyroid storm. She had been followed by her family doctor since 2006, but she had stopped taking her medication of her own volition in 2010. About ten days prior to her admission at our hospital, she consulted her family doctor with complaints of dyspnea, palpitations and general fatigue. Subsequent thyroid function tests showed TSH < 0.01 muU/ml, FT3 25.0 pg/ml and FT4 8.0 ng/dl. She also had acute heart failure, atrial fibrillation and hepatic failure. A diagnosis of thyroid storm was made and she was transferred to our hospital. She received steroids, beta blockade, potassium iodide, and plasma exchange, but her hepatic failure did not resolve and her clinical condition deteriorated. The decision was made to proceed with thyroidectomy. Postoperatively, her hepatic function normalized. Thus, thyroidectomy is a potential therapeutic choice for cases of thyroid storm refractory to medical management.
RN  - 0 (Antithyroid Agents)
RN  - 0 (Diuretics)
RN  - 1C4QK22F9J (Potassium Iodide)
RN  - 73K4184T59 (Digoxin)
RN  - 7BK02SCL3W (betamethasone sodium phosphate)
RN  - 9842X06Q6M (Betamethasone)
ES  - 1436-2813
IL  - 0941-1291
DO  - http://dx.doi.org/10.1007/s00595-013-0754-7
PT  - Case Reports
PT  - Journal Article
LG  - English
EP  - 20131017
DP  - 2015 Jan
DC  - 20141216
YR  - 2015
ED  - 20150817
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24132684

<118. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25443248
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kwok CS
AU  - Anderson SG
AU  - Myint PK
AU  - Mamas MA
AU  - Loke YK
FA  - Kwok, Chun Shing
FA  - Anderson, Simon G
FA  - Myint, Phyo K
FA  - Mamas, Mamas A
FA  - Loke, Yoon K
IN  - Kwok,Chun Shing. Cardiovascular Institute, University of Manchester, Manchester, United Kingdom. Electronic address: shingkwok@doctors.org.uk.
IN  - Anderson,Simon G. Cardiovascular Institute, University of Manchester, Manchester, United Kingdom.
IN  - Myint,Phyo K. Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, Scotland, United Kingdom.
IN  - Mamas,Mamas A. Cardiovascular Institute, University of Manchester, Manchester, United Kingdom.
IN  - Loke,Yoon K. Norwich Medical School, University of East Anglia, Norwich, United Kingdom.
TI  - Physical activity and incidence of atrial fibrillation: a systematic review and meta-analysis. [Review]
SO  - International Journal of Cardiology. 177(2):467-76, 2014 Dec 15.
AS  - Int J Cardiol. 177(2):467-76, 2014 Dec 15.
NJ  - International journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - gqw, 8200291
SB  - Index Medicus
CP  - Netherlands
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Exercise/ph [Physiology]
MH  - Humans
MH  - Incidence
MH  - *Motor Activity/ph [Physiology]
KW  - Atrial fibrillation;  Meta-analysis;  Physical activity
AB  - Whether physical activity increases or decreases the risk of atrial fibrillation (AF) remains controversial. We conducted a systematic review and meta-analysis to evaluate the relationship between AF and extent of physical activity. We searched Medline and EMBASE in June 2014 for studies that reported on the associated risk of AF according to history of physical activity. Pooled risk ratios for AF were calculated using inverse variance random effects model, and heterogeneity assessed using I(2). Subgroup analysis was performed according to the nature of the physical activity, and the quality of the studies. We identified 19 relevant studies with a total of over half a million participants (n=511,503). The pooled analysis showed no association between intensive physical activity and AF (RR 1.00 95% CI 0.82-1.22, I(2)=73%, 8 studies, 152,925 participants) with no difference considering low and moderate to high risk of bias studies. Pooled analysis of studies reporting on increasing amount of time spent on physical activities did not show a significant association with AF (RR 0.95 95% CI 0.72-1.26, I(2)=84%, 4 studies, 112,784 participants). Studies of athletes or participants with a history of sports activity which were of poor methodology quality showed a borderline significant association with AF (pooled RR 1.98 95% CI 1.00-3.94, I(2)=59%, 6 studies, 1973 participants). In conclusion, we found no significant increase in AF with a higher level of physical activity. These findings support clinical guidelines encouraging patients to exercise as there is no evidence for harm associated with increased physical activity. Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
ES  - 1874-1754
IL  - 0167-5273
DI  - S0167-5273(14)01824-5
DO  - http://dx.doi.org/10.1016/j.ijcard.2014.09.104
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
LG  - English
EP  - 20140928
DP  - 2014 Dec 15
DC  - 20141203
YR  - 2014
ED  - 20150817
RD  - 20150708
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25443248

<119. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22487774
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Carag MR
AU  - Arora RR
FA  - Carag, Michael R
FA  - Arora, Rohit R
IN  - Carag,Michael R. 1Department of Medicine, School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY; and 2Department of Medicine, Chief of Medicine (NCVA), James Lovell Federal Health Care Center, North Chicago, IL.
TI  - The efficacy of rivaroxaban in patients with atrial fibrillation. [Review]
SO  - American Journal of Therapeutics. 21(5):412-8, 2014 Sep-Oct.
AS  - Am J Ther. 21(5):412-8, 2014 Sep-Oct.
NJ  - American journal of therapeutics
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - db7, 9441347
SB  - Index Medicus
CP  - United States
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - *Factor Xa Inhibitors/tu [Therapeutic Use]
MH  - Humans
MH  - Morpholines/ae [Adverse Effects]
MH  - *Morpholines/tu [Therapeutic Use]
MH  - Rivaroxaban
MH  - Stroke/pc [Prevention & Control]
MH  - Thiophenes/ae [Adverse Effects]
MH  - *Thiophenes/tu [Therapeutic Use]
MH  - Warfarin/tu [Therapeutic Use]
AB  - Atrial fibrillation (AF), the most common form of cardiac arrhythmia, is a major risk factor for cardioembolic stroke. Dose-adjusted warfarin has been the gold standard for stroke prophylaxis in moderate- to high-risk patients with AF. However, the use of warfarin therapy is greatly limited by its narrow therapeutic window, numerous dietary restrictions, and drug-drug interactions, and an increased risk of hemorrhage. As a result, great emphasis has been placed on developing a new anticoagulant agent with fewer risks and limitations. Current data suggest that the oral direct factor Xa inhibitor rivaroxaban is a safe and effective alternative to warfarin. Furthermore, rivaroxaban does not require routine coagulation monitoring, which may improve patient compliance to anticoagulant therapy. The ROCKET AF trial demonstrated that 20-mg oral rivaroxaban taken once daily was noninferior to dose-adjusted warfarin in the prevention of stroke and non-central nervous system systemic embolism and had a comparable risk of bleeding. Based primarily on the ROCKET AF trial results, the US Food and Drug Administration recently approved the use of rivaroxaban for stroke prophylaxis in patients with nonvalvular AF. However, additional postmarketing studies on its safety and cost effectiveness are needed before it can be widely accepted as a sound alternative to warfarin.
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Morpholines)
RN  - 0 (Thiophenes)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
ES  - 1536-3686
IL  - 1075-2765
DO  - http://dx.doi.org/10.1097/MJT.0b013e3182491d8b
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2014 Sep-Oct
DC  - 20140911
YR  - 2014
ED  - 20150814
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22487774

<120. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25904645
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Qureshi WT
AU  - Alirhayim Z
AU  - Blaha MJ
AU  - Juraschek SP
AU  - Keteyian SJ
AU  - Brawner CA
AU  - Al-Mallah MH
FA  - Qureshi, Waqas T
FA  - Alirhayim, Zaid
FA  - Blaha, Michael J
FA  - Juraschek, Stephen P
FA  - Keteyian, Steven J
FA  - Brawner, Clinton A
FA  - Al-Mallah, Mouaz H
IN  - Qureshi,Waqas T. From Henry Ford Hospital/Wayne State University, Detroit, MI (W.T.Q., Z.A., S.J.K., C.A.B., M.H.A.-M.); Wake Forest University School of Medicine, Winston Salem, NC (W.T.Q.); University of Kansas Medical Center, Kansas City (Z.A.); Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD (M.J.B., S.P.J.); Wayne State University, Detroit, MI (M.H.A.-M.); and King Abdul-Aziz Cardiac Center, National Guard Health Affairs, Riyadh, Saudi Arabia (M.H.A.-M.).
IN  - Alirhayim,Zaid. From Henry Ford Hospital/Wayne State University, Detroit, MI (W.T.Q., Z.A., S.J.K., C.A.B., M.H.A.-M.); Wake Forest University School of Medicine, Winston Salem, NC (W.T.Q.); University of Kansas Medical Center, Kansas City (Z.A.); Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD (M.J.B., S.P.J.); Wayne State University, Detroit, MI (M.H.A.-M.); and King Abdul-Aziz Cardiac Center, National Guard Health Affairs, Riyadh, Saudi Arabia (M.H.A.-M.).
IN  - Blaha,Michael J. From Henry Ford Hospital/Wayne State University, Detroit, MI (W.T.Q., Z.A., S.J.K., C.A.B., M.H.A.-M.); Wake Forest University School of Medicine, Winston Salem, NC (W.T.Q.); University of Kansas Medical Center, Kansas City (Z.A.); Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD (M.J.B., S.P.J.); Wayne State University, Detroit, MI (M.H.A.-M.); and King Abdul-Aziz Cardiac Center, National Guard Health Affairs, Riyadh, Saudi Arabia (M.H.A.-M.).
IN  - Juraschek,Stephen P. From Henry Ford Hospital/Wayne State University, Detroit, MI (W.T.Q., Z.A., S.J.K., C.A.B., M.H.A.-M.); Wake Forest University School of Medicine, Winston Salem, NC (W.T.Q.); University of Kansas Medical Center, Kansas City (Z.A.); Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD (M.J.B., S.P.J.); Wayne State University, Detroit, MI (M.H.A.-M.); and King Abdul-Aziz Cardiac Center, National Guard Health Affairs, Riyadh, Saudi Arabia (M.H.A.-M.).
IN  - Keteyian,Steven J. From Henry Ford Hospital/Wayne State University, Detroit, MI (W.T.Q., Z.A., S.J.K., C.A.B., M.H.A.-M.); Wake Forest University School of Medicine, Winston Salem, NC (W.T.Q.); University of Kansas Medical Center, Kansas City (Z.A.); Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD (M.J.B., S.P.J.); Wayne State University, Detroit, MI (M.H.A.-M.); and King Abdul-Aziz Cardiac Center, National Guard Health Affairs, Riyadh, Saudi Arabia (M.H.A.-M.).
IN  - Brawner,Clinton A. From Henry Ford Hospital/Wayne State University, Detroit, MI (W.T.Q., Z.A., S.J.K., C.A.B., M.H.A.-M.); Wake Forest University School of Medicine, Winston Salem, NC (W.T.Q.); University of Kansas Medical Center, Kansas City (Z.A.); Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD (M.J.B., S.P.J.); Wayne State University, Detroit, MI (M.H.A.-M.); and King Abdul-Aziz Cardiac Center, National Guard Health Affairs, Riyadh, Saudi Arabia (M.H.A.-M.).
IN  - Al-Mallah,Mouaz H. From Henry Ford Hospital/Wayne State University, Detroit, MI (W.T.Q., Z.A., S.J.K., C.A.B., M.H.A.-M.); Wake Forest University School of Medicine, Winston Salem, NC (W.T.Q.); University of Kansas Medical Center, Kansas City (Z.A.); Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD (M.J.B., S.P.J.); Wayne State University, Detroit, MI (M.H.A.-M.); and King Abdul-Aziz Cardiac Center, National Guard Health Affairs, Riyadh, Saudi Arabia (M.H.A.-M.). mouaz74@gmail.com.
TI  - Cardiorespiratory Fitness and Risk of Incident Atrial Fibrillation: Results From the Henry Ford Exercise Testing (FIT) Project.
CM  - Comment in: Circulation. 2015 May 26;131(21):1821-3; PMID: 25904644
SO  - Circulation. 131(21):1827-34, 2015 May 26.
AS  - Circulation. 131(21):1827-34, 2015 May 26.
NJ  - Circulation
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Flutter/ep [Epidemiology]
MH  - Atrial Flutter/pp [Physiopathology]
MH  - Body Mass Index
MH  - Chronic Disease
MH  - Comorbidity
MH  - Confounding Factors (Epidemiology)
MH  - Coronary Disease/ep [Epidemiology]
MH  - Coronary Disease/ge [Genetics]
MH  - Coronary Disease/pp [Physiopathology]
MH  - Diabetes Mellitus/ep [Epidemiology]
MH  - Diabetes Mellitus/pp [Physiopathology]
MH  - Dyslipidemias/ep [Epidemiology]
MH  - Dyslipidemias/pp [Physiopathology]
MH  - Ethnic Groups
MH  - Exercise Test
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hypertension/ep [Epidemiology]
MH  - Hypertension/pp [Physiopathology]
MH  - Incidence
MH  - Lung Diseases/ep [Epidemiology]
MH  - Lung Diseases/pp [Physiopathology]
MH  - Male
MH  - Michigan/ep [Epidemiology]
MH  - Middle Aged
MH  - Obesity/ep [Epidemiology]
MH  - Obesity/pp [Physiopathology]
MH  - *Physical Fitness
MH  - Proportional Hazards Models
MH  - Risk
MH  - Risk Factors
MH  - Thyroid Diseases/ep [Epidemiology]
MH  - Thyroid Diseases/pp [Physiopathology]
KW  - atrial fibrillation;  exercise;  prevention and control
AB  - BACKGROUND: Poor cardiorespiratory fitness (CRF) is an independent risk factor for cardiovascular morbidity and mortality. However, the relationship between CRF and atrial fibrillation (AF) is less clear. The aim of this analysis was to investigate the association between CRF and incident AF in a large, multiracial cohort that underwent graded exercise treadmill testing.
AB  - METHODS AND RESULTS: From 1991 to 2009, a total of 64561 adults (mean age, 54.5+/-12.7 years; 46% female; 64% white) without AF underwent exercise treadmill testing at a tertiary care center. Baseline demographic and clinical variables were collected. Incident AF was ascertained by use of International Classification of Diseases, Ninth Revision code 427.31 and confirmed by linkage to medical claim files. Nested, multivariable Cox proportional hazards models were used to estimate the independent association of CRF with incident AF. During a median follow-up of 5.4 years (interquartile range, 3-9 years), 4616 new cases of AF were diagnosed. After adjustment for potential confounders, 1 higher metabolic equivalent achieved during treadmill testing was associated with a 7% lower risk of incident AF (hazard ratio, 0.93; 95% confidence interval, 0.92-0.94; P<0.001). This relationship remained significant after adjustment for incident coronary artery disease (hazard ratio, 0.92; 95% confidence interval, 0.91-0.93; P<0.001). The magnitude of the inverse association between CRF and incident AF was greater among obese compared with nonobese individuals (P for interaction=0.02).
AB  - CONCLUSIONS: There is a graded, inverse relationship between cardiorespiratory fitness and incident AF, especially among obese patients. Future studies should examine whether changes in fitness increase or decrease risk of atrial fibrillation. This association was stronger for obese compared with nonobese, especially among obese patients.Copyright © 2015 American Heart Association, Inc.
ES  - 1524-4539
IL  - 0009-7322
DO  - http://dx.doi.org/10.1161/CIRCULATIONAHA.114.014833
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
NO  - 5T32HL076132-10 (United States NHLBI NIH HHS)
LG  - English
EP  - 20150422
DP  - 2015 May 26
DC  - 20150527
YR  - 2015
ED  - 20150813
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25904645

<121. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25904645
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Qureshi WT
AU  - Alirhayim Z
AU  - Blaha MJ
AU  - Juraschek SP
AU  - Keteyian SJ
AU  - Brawner CA
AU  - Al-Mallah MH
FA  - Qureshi, Waqas T
FA  - Alirhayim, Zaid
FA  - Blaha, Michael J
FA  - Juraschek, Stephen P
FA  - Keteyian, Steven J
FA  - Brawner, Clinton A
FA  - Al-Mallah, Mouaz H
IN  - Qureshi,Waqas T. From Henry Ford Hospital/Wayne State University, Detroit, MI (W.T.Q., Z.A., S.J.K., C.A.B., M.H.A.-M.); Wake Forest University School of Medicine, Winston Salem, NC (W.T.Q.); University of Kansas Medical Center, Kansas City (Z.A.); Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD (M.J.B., S.P.J.); Wayne State University, Detroit, MI (M.H.A.-M.); and King Abdul-Aziz Cardiac Center, National Guard Health Affairs, Riyadh, Saudi Arabia (M.H.A.-M.).
IN  - Alirhayim,Zaid. From Henry Ford Hospital/Wayne State University, Detroit, MI (W.T.Q., Z.A., S.J.K., C.A.B., M.H.A.-M.); Wake Forest University School of Medicine, Winston Salem, NC (W.T.Q.); University of Kansas Medical Center, Kansas City (Z.A.); Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD (M.J.B., S.P.J.); Wayne State University, Detroit, MI (M.H.A.-M.); and King Abdul-Aziz Cardiac Center, National Guard Health Affairs, Riyadh, Saudi Arabia (M.H.A.-M.).
IN  - Blaha,Michael J. From Henry Ford Hospital/Wayne State University, Detroit, MI (W.T.Q., Z.A., S.J.K., C.A.B., M.H.A.-M.); Wake Forest University School of Medicine, Winston Salem, NC (W.T.Q.); University of Kansas Medical Center, Kansas City (Z.A.); Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD (M.J.B., S.P.J.); Wayne State University, Detroit, MI (M.H.A.-M.); and King Abdul-Aziz Cardiac Center, National Guard Health Affairs, Riyadh, Saudi Arabia (M.H.A.-M.).
IN  - Juraschek,Stephen P. From Henry Ford Hospital/Wayne State University, Detroit, MI (W.T.Q., Z.A., S.J.K., C.A.B., M.H.A.-M.); Wake Forest University School of Medicine, Winston Salem, NC (W.T.Q.); University of Kansas Medical Center, Kansas City (Z.A.); Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD (M.J.B., S.P.J.); Wayne State University, Detroit, MI (M.H.A.-M.); and King Abdul-Aziz Cardiac Center, National Guard Health Affairs, Riyadh, Saudi Arabia (M.H.A.-M.).
IN  - Keteyian,Steven J. From Henry Ford Hospital/Wayne State University, Detroit, MI (W.T.Q., Z.A., S.J.K., C.A.B., M.H.A.-M.); Wake Forest University School of Medicine, Winston Salem, NC (W.T.Q.); University of Kansas Medical Center, Kansas City (Z.A.); Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD (M.J.B., S.P.J.); Wayne State University, Detroit, MI (M.H.A.-M.); and King Abdul-Aziz Cardiac Center, National Guard Health Affairs, Riyadh, Saudi Arabia (M.H.A.-M.).
IN  - Brawner,Clinton A. From Henry Ford Hospital/Wayne State University, Detroit, MI (W.T.Q., Z.A., S.J.K., C.A.B., M.H.A.-M.); Wake Forest University School of Medicine, Winston Salem, NC (W.T.Q.); University of Kansas Medical Center, Kansas City (Z.A.); Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD (M.J.B., S.P.J.); Wayne State University, Detroit, MI (M.H.A.-M.); and King Abdul-Aziz Cardiac Center, National Guard Health Affairs, Riyadh, Saudi Arabia (M.H.A.-M.).
IN  - Al-Mallah,Mouaz H. From Henry Ford Hospital/Wayne State University, Detroit, MI (W.T.Q., Z.A., S.J.K., C.A.B., M.H.A.-M.); Wake Forest University School of Medicine, Winston Salem, NC (W.T.Q.); University of Kansas Medical Center, Kansas City (Z.A.); Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD (M.J.B., S.P.J.); Wayne State University, Detroit, MI (M.H.A.-M.); and King Abdul-Aziz Cardiac Center, National Guard Health Affairs, Riyadh, Saudi Arabia (M.H.A.-M.). mouaz74@gmail.com.
TI  - Cardiorespiratory Fitness and Risk of Incident Atrial Fibrillation: Results From the Henry Ford Exercise Testing (FIT) Project.
CM  - Comment in: Circulation. 2015 Dec 22;132(25):e395; PMID: 26700015
CM  - Comment in: Circulation. 2015 May 26;131(21):1821-3; PMID: 25904644
CM  - Comment in: Circulation. 2015 Dec 22;132(25):e394; PMID: 26700014
SO  - Circulation. 131(21):1827-34, 2015 May 26.
AS  - Circulation. 131(21):1827-34, 2015 May 26.
NJ  - Circulation
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Flutter/ep [Epidemiology]
MH  - Atrial Flutter/pp [Physiopathology]
MH  - Body Mass Index
MH  - Chronic Disease
MH  - Comorbidity
MH  - Confounding Factors (Epidemiology)
MH  - Coronary Disease/ep [Epidemiology]
MH  - Coronary Disease/ge [Genetics]
MH  - Coronary Disease/pp [Physiopathology]
MH  - Diabetes Mellitus/ep [Epidemiology]
MH  - Diabetes Mellitus/pp [Physiopathology]
MH  - Dyslipidemias/ep [Epidemiology]
MH  - Dyslipidemias/pp [Physiopathology]
MH  - Ethnic Groups
MH  - Exercise Test
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hypertension/ep [Epidemiology]
MH  - Hypertension/pp [Physiopathology]
MH  - Incidence
MH  - Lung Diseases/ep [Epidemiology]
MH  - Lung Diseases/pp [Physiopathology]
MH  - Male
MH  - Michigan/ep [Epidemiology]
MH  - Middle Aged
MH  - Obesity/ep [Epidemiology]
MH  - Obesity/pp [Physiopathology]
MH  - *Physical Fitness
MH  - Proportional Hazards Models
MH  - Risk
MH  - Risk Factors
MH  - Thyroid Diseases/ep [Epidemiology]
MH  - Thyroid Diseases/pp [Physiopathology]
KW  - atrial fibrillation;  exercise;  prevention and control
AB  - BACKGROUND: Poor cardiorespiratory fitness (CRF) is an independent risk factor for cardiovascular morbidity and mortality. However, the relationship between CRF and atrial fibrillation (AF) is less clear. The aim of this analysis was to investigate the association between CRF and incident AF in a large, multiracial cohort that underwent graded exercise treadmill testing.
AB  - METHODS AND RESULTS: From 1991 to 2009, a total of 64561 adults (mean age, 54.5+/-12.7 years; 46% female; 64% white) without AF underwent exercise treadmill testing at a tertiary care center. Baseline demographic and clinical variables were collected. Incident AF was ascertained by use of International Classification of Diseases, Ninth Revision code 427.31 and confirmed by linkage to medical claim files. Nested, multivariable Cox proportional hazards models were used to estimate the independent association of CRF with incident AF. During a median follow-up of 5.4 years (interquartile range, 3-9 years), 4616 new cases of AF were diagnosed. After adjustment for potential confounders, 1 higher metabolic equivalent achieved during treadmill testing was associated with a 7% lower risk of incident AF (hazard ratio, 0.93; 95% confidence interval, 0.92-0.94; P<0.001). This relationship remained significant after adjustment for incident coronary artery disease (hazard ratio, 0.92; 95% confidence interval, 0.91-0.93; P<0.001). The magnitude of the inverse association between CRF and incident AF was greater among obese compared with nonobese individuals (P for interaction=0.02).
AB  - CONCLUSIONS: There is a graded, inverse relationship between cardiorespiratory fitness and incident AF, especially among obese patients. Future studies should examine whether changes in fitness increase or decrease risk of atrial fibrillation. This association was stronger for obese compared with nonobese, especially among obese patients.Copyright © 2015 American Heart Association, Inc.
ES  - 1524-4539
IL  - 0009-7322
DO  - http://dx.doi.org/10.1161/CIRCULATIONAHA.114.014833
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
NO  - 5T32HL076132-10 (United States NHLBI NIH HHS)
LG  - English
EP  - 20150422
DP  - 2015 May 26
DC  - 20150527
YR  - 2015
ED  - 20150813
RD  - 20160415
UP  - 20160418
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=25904645

<122. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26004726
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Chandriah H
AU  - Kumolosasi E
AU  - Islahudin F
AU  - Makmor-Bakry M
FA  - Chandriah, Haarathi
FA  - Kumolosasi, Endang
FA  - Islahudin, Farida
FA  - Makmor-Bakry, Mohd
IN  - Chandriah,Haarathi. Pharmaceutical Services Division, Ministry of Health Malaysia, Lot 36, Jalan University, Petaling Jaya, Selangor, Malaysia.
IN  - Kumolosasi,Endang. Faculty of Pharmacy, University Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, Kuala Lumpur, Malaysia.
IN  - Islahudin,Farida. Faculty of Pharmacy, University Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, Kuala Lumpur, Malaysia.
IN  - Makmor-Bakry,Mohd. Faculty of Pharmacy, University Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, Kuala Lumpur, Malaysia.
TI  - Effectiveness and safety of a 10mg warfarin initiation nomogram in Asian population.
SO  - Pakistan Journal of Pharmaceutical Sciences. 28(3):927-32, 2015 May.
AS  - Pak. j. pharm. Sci.. 28(3):927-32, 2015 May.
NJ  - Pakistan journal of pharmaceutical sciences
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9426356
SB  - Index Medicus
CP  - Pakistan
MH  - Adult
MH  - Aged
MH  - *Anticoagulants/ad [Administration & Dosage]
MH  - Asian Continental Ancestry Group
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - *Coronary Thrombosis/dt [Drug Therapy]
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Malaysia
MH  - Male
MH  - Middle Aged
MH  - *Nomograms
MH  - *Pulmonary Embolism/dt [Drug Therapy]
MH  - Retrospective Studies
MH  - Stroke/dt [Drug Therapy]
MH  - Stroke/et [Etiology]
MH  - *Stroke/pc [Prevention & Control]
MH  - *Venous Thrombosis/dt [Drug Therapy]
MH  - *Warfarin/ad [Administration & Dosage]
AB  - Anticoagulant responses to warfarin vary among patients, based on genetic factors, diet, concomitant medications, and disease state. We evaluated the effectiveness and safety of a 10mg warfarin initiation nomogram in an Asian population. Retrospective cross-sectional audit studies were conducted from March 2009 to March 2010. The use of a 10mg-loading dose to initiate warfarin treatment resulted in 33(84.6%) patients attaining a therapeutic INR within four days (mean time, 2.6 days). There was no significant correlation between age, gender, race, and serum albumin for the time to reach a therapeutic INR. A significant correlation was noted for patient's baseline INR and time to reach a therapeutic INR (P<0.05). No significant differences were observed in time to reach a therapeutic INR in patients treated with specific class of concomitant drugs or patients with specific disease states. The overall incidence of over-anticoagulation was 35.9%; however, no bleeding episodes were encountered. In conclusion, the use of a 10mg warfarin nomogram was effective in rapidly achieving a therapeutic INR. However, the nomogram's safety is debatable owing to the high over-anticoagulation rate warfarin-administered patients. Caution is recommended in the initiation of warfarin treatment using the 10mg nomogram.
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
IS  - 1011-601X
IL  - 1011-601X
PT  - Journal Article
LG  - English
DP  - 2015 May
DC  - 20150525
YR  - 2015
ED  - 20150810
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=26004726

<123. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25262162
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lowe BS
AU  - Kusunose K
AU  - Motoki H
AU  - Varr B
AU  - Shrestha K
AU  - Whitman C
AU  - Tang WH
AU  - Thomas JD
AU  - Klein AL
FA  - Lowe, Boris S
FA  - Kusunose, Kenya
FA  - Motoki, Hirohiko
FA  - Varr, Brandon
FA  - Shrestha, Kevin
FA  - Whitman, Christine
FA  - Tang, W H Wilson
FA  - Thomas, James D
FA  - Klein, Allan L
IN  - Lowe,Boris S. Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.
IN  - Kusunose,Kenya. Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.
IN  - Motoki,Hirohiko. Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.
IN  - Varr,Brandon. Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.
IN  - Shrestha,Kevin. Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.
IN  - Whitman,Christine. Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.
IN  - Tang,W H Wilson. Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.
IN  - Thomas,James D. Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.
IN  - Klein,Allan L. Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio. Electronic address: kleina@ccf.org.
TI  - Prognostic significance of left atrial appendage "sludge" in patients with atrial fibrillation: a new transesophageal echocardiographic thromboembolic risk factor.
SO  - Journal of the American Society of Echocardiography. 27(11):1176-83, 2014 Nov.
AS  - J Am Soc Echocardiogr. 27(11):1176-83, 2014 Nov.
NJ  - Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - aof, 8801388
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Atrial Fibrillation/mo [Mortality]
MH  - *Atrial Fibrillation/us [Ultrasonography]
MH  - Causality
MH  - Comorbidity
MH  - *Echocardiography, Transesophageal/sn [Statistics & Numerical Data]
MH  - Female
MH  - Humans
MH  - Image Interpretation, Computer-Assisted/mt [Methods]
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Ohio/ep [Epidemiology]
MH  - Prognosis
MH  - Reproducibility of Results
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Sensitivity and Specificity
MH  - Survival Rate
MH  - *Thromboembolism/mo [Mortality]
MH  - *Thromboembolism/us [Ultrasonography]
KW  - Atrial fibrillation;  Cardioversion;  Echocardiography;  Mortality;  Stroke
AB  - BACKGROUND: When stratifying thromboembolic risk to patients with atrial fibrillation (AF), left atrial appendage (LAA) thrombus is currently the only echocardiographic index that absolutely contraindicates cardioversion. The aim of this study was to identify the predictors of LAA "sludge" and its impact on subsequent thromboembolism and survival in patients with AF.
AB  - METHODS: A total of 340 patients (mean age, 66 +/- 12 years; 75% men) who underwent transesophageal echocardiography to exclude LAA thrombus before electrical cardioversion or radiofrequency pulmonary vein isolation) for AF were retrospectively studied. LAA sludge was defined as a dynamic, viscid, layered echodensity without a discrete mass, visualized throughout the cardiac cycle. Follow-up was obtained after a mean of 6.7 +/- 3.7 years, and patients were analyzed according to LAA thrombus (n = 62 [18%]), sludge (n = 47 [14%]), or spontaneous echocardiographic contrast (n = 84 [25%]). Patients without these transesophageal echocardiographic characteristics served as controls (n = 147 [43%]).
AB  - RESULTS: LAA sludge was independently predicted by enlarged left atrial area (odds ratio, 4.54; 95% confidence interval [CI], 2.38-8.67; P < .001), reduced LAA emptying velocity (odds ratio, 12.7; 95% CI, 6.11-26.44; P < .001), and reduced left ventricular ejection fraction (odds ratio, 2.11; 95% CI, 1.03-4.32; P < .001). Thromboembolic event and all-cause mortality rates in patients with sludge were 23% and 57%, respectively. Multiple logistic regression analyses identified the presence of LAA sludge to be independently associated with thromboembolic complications (adjusted hazard ratio, 3.43; 95% CI, 1.42-8.28; P = .006) and all-cause mortality (adjusted hazard ratio, 2.02; 95% CI, 1.22-3.36; P = .007).
AB  - CONCLUSION: Sludge within the LAA is independently associated with subsequent thromboembolic events and all-cause mortality in patients with AF.Copyright © 2014 American Society of Echocardiography. Published by Elsevier Inc. All rights reserved.
ES  - 1097-6795
IL  - 0894-7317
DI  - S0894-7317(14)00610-5
DO  - http://dx.doi.org/10.1016/j.echo.2014.08.016
PT  - Journal Article
LG  - English
EP  - 20140926
DP  - 2014 Nov
DC  - 20141202
YR  - 2014
ED  - 20150806
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25262162

<124. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25240493
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kobayashi Y
AU  - Okura H
AU  - Kobayashi Y
AU  - Okawa K
AU  - Banba K
AU  - Hirohata A
AU  - Tamada T
AU  - Obase K
AU  - Hayashida A
AU  - Yoshida K
FA  - Kobayashi, Yukari
FA  - Okura, Hiroyuki
FA  - Kobayashi, Yuhei
FA  - Okawa, Keisuke
FA  - Banba, Kimikazu
FA  - Hirohata, Atsushi
FA  - Tamada, Tomoko
FA  - Obase, Kikuko
FA  - Hayashida, Akihiro
FA  - Yoshida, Kiyoshi
IN  - Kobayashi,Yukari. Department of Cardiology, Sakakibara Heart Institute of Okayama, Okayama, Japan. Electronic address: yukari_kobayashi@aol.com.
IN  - Okura,Hiroyuki. Department of Cardiology, Kawasaki Medical School, Kurashiki, Japan.
IN  - Kobayashi,Yuhei. Department of Cardiology, Sakakibara Heart Institute of Okayama, Okayama, Japan.
IN  - Okawa,Keisuke. Department of Cardiology, Sakakibara Heart Institute of Okayama, Okayama, Japan.
IN  - Banba,Kimikazu. Department of Cardiology, Sakakibara Heart Institute of Okayama, Okayama, Japan.
IN  - Hirohata,Atsushi. Department of Cardiology, Sakakibara Heart Institute of Okayama, Okayama, Japan.
IN  - Tamada,Tomoko. Department of Cardiology, Kawasaki Medical School, Kurashiki, Japan.
IN  - Obase,Kikuko. Department of Cardiology, Kawasaki Medical School, Kurashiki, Japan.
IN  - Hayashida,Akihiro. Department of Cardiology, Kawasaki Medical School, Kurashiki, Japan.
IN  - Yoshida,Kiyoshi. Department of Cardiology, Kawasaki Medical School, Kurashiki, Japan.
TI  - Assessment of atrial synchrony in paroxysmal atrial fibrillation and impact of pulmonary vein isolation for atrial dyssynchrony and global strain by three-dimensional strain echocardiography.
SO  - Journal of the American Society of Echocardiography. 27(11):1193-9, 2014 Nov.
AS  - J Am Soc Echocardiogr. 27(11):1193-9, 2014 Nov.
NJ  - Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - aof, 8801388
SB  - Index Medicus
CP  - United States
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/su [Surgery]
MH  - *Atrial Fibrillation/us [Ultrasonography]
MH  - *Echocardiography, Three-Dimensional/mt [Methods]
MH  - *Elasticity Imaging Techniques/mt [Methods]
MH  - Female
MH  - Heart Conduction System/pp [Physiopathology]
MH  - *Heart Conduction System/su [Surgery]
MH  - Heart Conduction System/us [Ultrasonography]
MH  - Humans
MH  - *Image Interpretation, Computer-Assisted/mt [Methods]
MH  - Male
MH  - Middle Aged
MH  - Pulmonary Veins/pp [Physiopathology]
MH  - *Pulmonary Veins/su [Surgery]
MH  - Pulmonary Veins/us [Ultrasonography]
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
KW  - Atrial fibrillation;  Left atrium;  Three-dimensional echocardiography
AB  - BACKGROUND: Atrial fibrillation (AF) is a risk factor for ischemic stroke and congestive heart failure. AF may cause left atrial (LA) dyssynchrony as well as electrical and mechanical remodeling. The aim of this study was to investigate LA dyssynchrony in patients with paroxysmal AF (PAF) and its recovery after pulmonary vein isolation (PVI), using a three-dimensional strain method.
AB  - METHODS: Thirty patients with PAF who underwent PVI were enrolled. Three-dimensional echocardiography was performed before and 3 months after PVI. Twenty subjects in whom AF had never been detected served as controls. LA dyssynchrony was quantified by the standard deviation of time to peak strain (TP-SD) from end-diastole by area tracking. Serial changes in TP-SD, LA volume, and global strain in three-dimensional echocardiography were investigated.
AB  - RESULTS: In the PAF group, TP-SD was significantly higher (9.19 +/- 4.98% vs 4.80 +/- 2.30% in controls, P < .02) and global strain significantly lower (48.2 +/- 20.2% vs 84.4 +/- 32.9% in controls, P = .0003) than in the control group. TP-SD, global strain, and LA volume all improved significantly from before to after PVI (TP-SD, from 9.19 +/- 4.98% to 6.31 +/- 2.94%, P = .005; global strain, from 48.2 +/- 20.2% to 58.1 +/- 21.2%, P = .018; LA volume index, 29.5 +/- 10.6 to 25.8 +/- 7.1 mL/m(2), P = .04). Despite the improvement after PVI, TP-SD was still significantly higher and global strain lower than in controls.
AB  - CONCLUSIONS: In patients with PAF, impaired LA function was documented by three-dimensional echocardiography. Despite early LA structural reverse remodeling, LA dyssynchrony was still observed 3 months after PVI. These results may affect medical therapy after successful PVI.Copyright © 2014 American Society of Echocardiography. Published by Elsevier Inc. All rights reserved.
ES  - 1097-6795
IL  - 0894-7317
DI  - S0894-7317(14)00585-9
DO  - http://dx.doi.org/10.1016/j.echo.2014.08.004
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
EP  - 20140917
DP  - 2014 Nov
DC  - 20141202
YR  - 2014
ED  - 20150806
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25240493

<125. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25827177
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ruiz-Nunez B
AU  - van den Hurk GH
AU  - de Vries JH
AU  - Mariani MA
AU  - de Jongste MJ
AU  - Dijck-Brouwer DA
AU  - Muskiet FA
FA  - Ruiz-Nunez, B
FA  - van den Hurk, G H A M
FA  - de Vries, J H M
FA  - Mariani, M A
FA  - de Jongste, M J L
FA  - Dijck-Brouwer, D A J
FA  - Muskiet, F A J
IN  - Ruiz-Nunez,B. Laboratory Medicine, University Medical Centre Groningen (UMCG),Building 33, 3rd floor, Room Y3.181, Internal Zip Code EA61, Hanzeplein 1, PO Box 30.001,9700RBGroningen,The Netherlands.
IN  - van den Hurk,G H A M. Laboratory Medicine, University Medical Centre Groningen (UMCG),Building 33, 3rd floor, Room Y3.181, Internal Zip Code EA61, Hanzeplein 1, PO Box 30.001,9700RBGroningen,The Netherlands.
IN  - de Vries,J H M. Division of Human Nutrition, Wageningen University,Wageningen,The Netherlands.
IN  - Mariani,M A. Thorax Centre, University Medical Centre Groningen (UMCG),Groningen,The Netherlands.
IN  - de Jongste,M J L. Thorax Centre, University Medical Centre Groningen (UMCG),Groningen,The Netherlands.
IN  - Dijck-Brouwer,D A J. Laboratory Medicine, University Medical Centre Groningen (UMCG),Building 33, 3rd floor, Room Y3.181, Internal Zip Code EA61, Hanzeplein 1, PO Box 30.001,9700RBGroningen,The Netherlands.
IN  - Muskiet,F A J. Laboratory Medicine, University Medical Centre Groningen (UMCG),Building 33, 3rd floor, Room Y3.181, Internal Zip Code EA61, Hanzeplein 1, PO Box 30.001,9700RBGroningen,The Netherlands.
TI  - Patients undergoing elective coronary artery bypass grafting exhibit poor pre-operative intakes of fruit, vegetables, dietary fibre, fish and vitamin D.
SO  - British Journal of Nutrition. 113(9):1466-76, 2015 May 14.
AS  - Br J Nutr. 113(9):1466-76, 2015 May 14.
NJ  - The British journal of nutrition
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - az4, 0372547
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - Aged, 80 and over
MH  - Animals
MH  - *Coronary Artery Bypass
MH  - *Coronary Disease/su [Surgery]
MH  - *Diet
MH  - Dietary Fiber/ad [Administration & Dosage]
MH  - Docosahexaenoic Acids/ad [Administration & Dosage]
MH  - Eicosapentaenoic Acid/ad [Administration & Dosage]
MH  - Fatty Acids/ad [Administration & Dosage]
MH  - Female
MH  - Fishes
MH  - Fruit
MH  - Humans
MH  - Intraoperative Complications/pc [Prevention & Control]
MH  - Male
MH  - Middle Aged
MH  - Netherlands
MH  - Nutrition Policy
MH  - Postoperative Complications/pc [Prevention & Control]
MH  - *Preoperative Period
MH  - Risk Factors
MH  - Surveys and Questionnaires
MH  - *Treatment Outcome
MH  - United States
MH  - Vegetables
MH  - Vitamin D/ad [Administration & Dosage]
KW  - Coronary artery bypass grafting surgery;  Coronary artery disease;  Diets;  Low-grade inflammation
AB  - CHD may ensue from chronic systemic low-grade inflammation. Diet is a modifiable risk factor for both, and its optimisation may reduce post-operative mortality, atrial fibrillation and cognitive decline. In the present study, we investigated the usual dietary intakes of patients undergoing elective coronary artery bypass grafting (CABG), emphasising on food groups and nutrients with putative roles in the inflammatory/anti-inflammatory balance. From November 2012 to April 2013, we approached ninety-three consecutive patients (80% men) undergoing elective CABG. Of these, fifty-five were finally included (84% men, median age 69 years; range 46-84 years). The median BMI was 27 (range 18-36) kg/m(2). The dietary intake items were fruits (median 181 g/d; range 0-433 g/d), vegetables (median 115 g/d; range 0-303 g/d), dietary fibre (median 22 g/d; range 9-45 g/d), EPA+DHA (median 0.14 g/d; range 0.01-1.06 g/d), vitamin D (median 4.9 mug/d; range 1.9-11.2 mug/d), saturated fat (median 13.1% of energy (E%); range 9-23 E%) and linoleic acid (LA; median 6.3 E%; range 1.9-11.3 E%). The percentages of patients with dietary intakes below recommendations were 62% (fruits; recommendation 200 g/d), 87 % (vegetables; recommendation 150-200 g/d), 73% (dietary fibre; recommendation 30-45 g/d), 91% (EPA+DHA; recommendation 0.45 g/d), 98% (vitamin D; recommendation 10-20 mug/d) and 13% (LA; recommendation 5-10 E%). The percentages of patients with dietary intakes above recommendations were 95% (saturated fat; recommendation < 10 E%) and 7% (LA). The dietary intakes of patients proved comparable with the average nutritional intake of the age- and sex-matched healthy Dutch population. These unbalanced pre-operative diets may put them at risk of unfavourable surgical outcomes, since they promote a pro-inflammatory state. We conclude that there is an urgent need for intervention trials aiming at rapid improvement of their diets to reduce peri-operative risks.
RN  - 0 (Fatty Acids)
RN  - 1406-16-2 (Vitamin D)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - AAN7QOV9EA (Eicosapentaenoic Acid)
ES  - 1475-2662
IL  - 0007-1145
DO  - http://dx.doi.org/10.1017/S0007114515000434
PT  - Journal Article
LG  - English
EP  - 20150401
DP  - 2015 May 14
DC  - 20150520
YR  - 2015
ED  - 20150803
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25827177

<126. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25311633
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Petrone AB
AU  - Gaziano JM
AU  - Djousse L
FA  - Petrone, Andrew B
FA  - Gaziano, J Michael
FA  - Djousse, Luc
IN  - Petrone,Andrew B. Division of Aging and the Department of Preventive Medicine, Brigham and Women's Hospital, 1620 Tremont St. 3rd floor, Boston, MA, 02120, USA; Massachusetts Veterans Epidemiology and Research Information Center (MAVERIC) and Geriatric Research (GRECC), Boston, MA, USA.
TI  - Chocolate consumption and risk of heart failure in the Physicians' Health Study.
SO  - European Journal of Heart Failure. 16(12):1372-6, 2014 Dec.
AS  - Eur J Heart Fail. 16(12):1372-6, 2014 Dec.
NJ  - European journal of heart failure
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - dr4, 100887595
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/ad [Administration & Dosage]
MH  - Blood Pressure/de [Drug Effects]
MH  - *Cacao
MH  - *Candy
MH  - Cohort Studies
MH  - Diet Surveys
MH  - Double-Blind Method
MH  - Flavonoids/ad [Administration & Dosage]
MH  - *Heart Failure/ep [Epidemiology]
MH  - Heart Failure/pc [Prevention & Control]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Physicians/sn [Statistics & Numerical Data]
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Risk Factors
MH  - Surveys and Questionnaires
MH  - United States/ep [Epidemiology]
KW  - Epidemiology;  Heart failure;  Nutrition;  Risk factors
AB  - AIMS: To test the hypothesis that chocolate consumption is associated with a lower risk of heart failure (HF).
AB  - METHODS AND RESULTS: We prospectively studied 20 278 men from the Physicians' Health Study. Chocolate consumption was assessed between 1999 and 2002 via a self-administered food frequency questionnaire and HF was ascertained through annual follow-up questionnaires with validation in a subsample. We used Cox regression to estimate multivariable adjusted relative risk of HF. During a mean follow-up of 9.3years there were 876 new cases of HF. The mean age at baseline was 66.4+/-9.2years. Hazard ratios [95% confidence intervals (CI)] for HF were 1.0 (ref), 0.86 (0.72-1.03), 0.80 (0.66-0.98), 0.92 (0.74-1.13), and 0.82 (0.63-1.07), for chocolate consumption of less than 1/month, 1-3/week, 2-4/week, and 5+/week, respectively, after adjusting for age, body mass index (BMI), smoking, alcohol, exercise, energy intake, and history of atrial fibrillation (P for quadratic trend=0.62). In a secondary analysis, chocolate consumption was inversely associated with risk of HF in men whose BMI was <25kg/m(2) [HR (95% CI)=0.59 (0.37-0.94) for consumption of 5+ servings/week, P for linear trend=0.03) but not in those with BMI of 25+ kg/m(2) [HR (95% CI)=1.01 (0.73-1.39), P for linear trend=0.42, P for interaction=0.17).
AB  - CONCLUSIONS: Our data suggest that moderate consumption of chocolate might be associated with a lower risk of HF in male physicians.Copyright © 2014 The Authors. European Journal of Heart Failure © 2014 European Society of Cardiology.
RN  - 0 (Flavonoids)
RN  - R16CO5Y76E (Aspirin)
ES  - 1879-0844
IL  - 1388-9842
DO  - http://dx.doi.org/10.1002/ejhf.180
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
NO  - CA-097193 (United States NCI NIH HHS)
NO  - CA-34944 (United States NCI NIH HHS)
NO  - CA-40360 (United States NCI NIH HHS)
NO  - HL-26490 (United States NHLBI NIH HHS)
NO  - HL-34595 (United States NHLBI NIH HHS)
NO  - R01 CA034944 (United States NCI NIH HHS)
NO  - R01 CA040360 (United States NCI NIH HHS)
NO  - R01 CA097193 (United States NCI NIH HHS)
NO  - R01 HL026490 (United States NHLBI NIH HHS)
NO  - R01 HL034595 (United States NHLBI NIH HHS)
NO  - R21 HL088081 (United States NHLBI NIH HHS)
NO  - R21 HL088081 (United States NHLBI NIH HHS)
LG  - English
EP  - 20141014
DP  - 2014 Dec
DC  - 20141202
YR  - 2014
ED  - 20150730
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25311633

<127. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25311633
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Petrone AB
AU  - Gaziano JM
AU  - Djousse L
FA  - Petrone, Andrew B
FA  - Gaziano, J Michael
FA  - Djousse, Luc
IN  - Petrone,Andrew B. Division of Aging and the Department of Preventive Medicine, Brigham and Women's Hospital, 1620 Tremont St. 3rd floor, Boston, MA, 02120, USA; Massachusetts Veterans Epidemiology and Research Information Center (MAVERIC) and Geriatric Research (GRECC), Boston, MA, USA.
TI  - Chocolate consumption and risk of heart failure in the Physicians' Health Study.
SO  - European Journal of Heart Failure. 16(12):1372-6, 2014 Dec.
AS  - Eur J Heart Fail. 16(12):1372-6, 2014 Dec.
NJ  - European journal of heart failure
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - dr4, 100887595
OI  - Source: NLM. NIHMS629798
OI  - Source: NLM. PMC4646420
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/ad [Administration & Dosage]
MH  - Blood Pressure/de [Drug Effects]
MH  - *Cacao
MH  - *Candy
MH  - Cohort Studies
MH  - Diet Surveys
MH  - Double-Blind Method
MH  - Flavonoids/ad [Administration & Dosage]
MH  - *Heart Failure/ep [Epidemiology]
MH  - Heart Failure/pc [Prevention & Control]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Physicians/sn [Statistics & Numerical Data]
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Risk Factors
MH  - Surveys and Questionnaires
MH  - United States/ep [Epidemiology]
KW  - Epidemiology;  Heart failure;  Nutrition;  Risk factors
AB  - AIMS: To test the hypothesis that chocolate consumption is associated with a lower risk of heart failure (HF).
AB  - METHODS AND RESULTS: We prospectively studied 20 278 men from the Physicians' Health Study. Chocolate consumption was assessed between 1999 and 2002 via a self-administered food frequency questionnaire and HF was ascertained through annual follow-up questionnaires with validation in a subsample. We used Cox regression to estimate multivariable adjusted relative risk of HF. During a mean follow-up of 9.3years there were 876 new cases of HF. The mean age at baseline was 66.4+/-9.2years. Hazard ratios [95% confidence intervals (CI)] for HF were 1.0 (ref), 0.86 (0.72-1.03), 0.80 (0.66-0.98), 0.92 (0.74-1.13), and 0.82 (0.63-1.07), for chocolate consumption of less than 1/month, 1-3/week, 2-4/week, and 5+/week, respectively, after adjusting for age, body mass index (BMI), smoking, alcohol, exercise, energy intake, and history of atrial fibrillation (P for quadratic trend=0.62). In a secondary analysis, chocolate consumption was inversely associated with risk of HF in men whose BMI was <25kg/m(2) [HR (95% CI)=0.59 (0.37-0.94) for consumption of 5+ servings/week, P for linear trend=0.03) but not in those with BMI of 25+ kg/m(2) [HR (95% CI)=1.01 (0.73-1.39), P for linear trend=0.42, P for interaction=0.17).
AB  - CONCLUSIONS: Our data suggest that moderate consumption of chocolate might be associated with a lower risk of HF in male physicians.Copyright © 2014 The Authors. European Journal of Heart Failure © 2014 European Society of Cardiology.
RN  - 0 (Flavonoids)
RN  - R16CO5Y76E (Aspirin)
ES  - 1879-0844
IL  - 1388-9842
DO  - http://dx.doi.org/10.1002/ejhf.180
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
NO  - CA-097193 (United States NCI NIH HHS)
NO  - CA-34944 (United States NCI NIH HHS)
NO  - CA-40360 (United States NCI NIH HHS)
NO  - HL-26490 (United States NHLBI NIH HHS)
NO  - HL-34595 (United States NHLBI NIH HHS)
NO  - R01 CA034944 (United States NCI NIH HHS)
NO  - R01 CA034944-03 (United States NCI NIH HHS)
NO  - R01 CA040360 (United States NCI NIH HHS)
NO  - R01 CA097193 (United States NCI NIH HHS)
NO  - R01 HL026490 (United States NHLBI NIH HHS)
NO  - R01 HL026490-03 (United States NHLBI NIH HHS)
NO  - R01 HL034595 (United States NHLBI NIH HHS)
NO  - R01 HL034595-07 (United States NHLBI NIH HHS)
NO  - R21 HL088081 (United States NHLBI NIH HHS)
NO  - R21 HL088081 (United States NHLBI NIH HHS)
LG  - English
EP  - 20141014
DP  - 2014 Dec
DC  - 20141202
YR  - 2014
ED  - 20150730
RD  - 20160218
UP  - 20160222
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=25311633

<128. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25210054
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Swan H
AU  - Amarouch MY
AU  - Leinonen J
AU  - Marjamaa A
AU  - Kucera JP
AU  - Laitinen-Forsblom PJ
AU  - Lahtinen AM
AU  - Palotie A
AU  - Kontula K
AU  - Toivonen L
AU  - Abriel H
AU  - Widen E
FA  - Swan, Heikki
FA  - Amarouch, Mohamed Yassine
FA  - Leinonen, Jaakko
FA  - Marjamaa, Annukka
FA  - Kucera, Jan P
FA  - Laitinen-Forsblom, Paivi J
FA  - Lahtinen, Annukka M
FA  - Palotie, Aarno
FA  - Kontula, Kimmo
FA  - Toivonen, Lauri
FA  - Abriel, Hugues
FA  - Widen, Elisabeth
IN  - Swan,Heikki. From the Heart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland (H.S., A.M., L.T.); Department of Clinical Research (M.Y.A., H.A), and Department of Physiology (J.P.K), University of Bern, Bern, Switzerland. and Institute for Molecular Medicine Finland (FIMM), University of Helsinki (J.L., A.P., E.W.), and Department of Medicine, University of Helsinki and Helsinki University Central Hospital (P.J.L.-F., A.M.L., K.K.), Helsinki, Finland. heikki.swan@helsinki.fi.
IN  - Amarouch,Mohamed Yassine. From the Heart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland (H.S., A.M., L.T.); Department of Clinical Research (M.Y.A., H.A), and Department of Physiology (J.P.K), University of Bern, Bern, Switzerland. and Institute for Molecular Medicine Finland (FIMM), University of Helsinki (J.L., A.P., E.W.), and Department of Medicine, University of Helsinki and Helsinki University Central Hospital (P.J.L.-F., A.M.L., K.K.), Helsinki, Finland.
IN  - Leinonen,Jaakko. From the Heart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland (H.S., A.M., L.T.); Department of Clinical Research (M.Y.A., H.A), and Department of Physiology (J.P.K), University of Bern, Bern, Switzerland. and Institute for Molecular Medicine Finland (FIMM), University of Helsinki (J.L., A.P., E.W.), and Department of Medicine, University of Helsinki and Helsinki University Central Hospital (P.J.L.-F., A.M.L., K.K.), Helsinki, Finland.
IN  - Marjamaa,Annukka. From the Heart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland (H.S., A.M., L.T.); Department of Clinical Research (M.Y.A., H.A), and Department of Physiology (J.P.K), University of Bern, Bern, Switzerland. and Institute for Molecular Medicine Finland (FIMM), University of Helsinki (J.L., A.P., E.W.), and Department of Medicine, University of Helsinki and Helsinki University Central Hospital (P.J.L.-F., A.M.L., K.K.), Helsinki, Finland.
IN  - Kucera,Jan P. From the Heart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland (H.S., A.M., L.T.); Department of Clinical Research (M.Y.A., H.A), and Department of Physiology (J.P.K), University of Bern, Bern, Switzerland. and Institute for Molecular Medicine Finland (FIMM), University of Helsinki (J.L., A.P., E.W.), and Department of Medicine, University of Helsinki and Helsinki University Central Hospital (P.J.L.-F., A.M.L., K.K.), Helsinki, Finland.
IN  - Laitinen-Forsblom,Paivi J. From the Heart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland (H.S., A.M., L.T.); Department of Clinical Research (M.Y.A., H.A), and Department of Physiology (J.P.K), University of Bern, Bern, Switzerland. and Institute for Molecular Medicine Finland (FIMM), University of Helsinki (J.L., A.P., E.W.), and Department of Medicine, University of Helsinki and Helsinki University Central Hospital (P.J.L.-F., A.M.L., K.K.), Helsinki, Finland.
IN  - Lahtinen,Annukka M. From the Heart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland (H.S., A.M., L.T.); Department of Clinical Research (M.Y.A., H.A), and Department of Physiology (J.P.K), University of Bern, Bern, Switzerland. and Institute for Molecular Medicine Finland (FIMM), University of Helsinki (J.L., A.P., E.W.), and Department of Medicine, University of Helsinki and Helsinki University Central Hospital (P.J.L.-F., A.M.L., K.K.), Helsinki, Finland.
IN  - Palotie,Aarno. From the Heart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland (H.S., A.M., L.T.); Department of Clinical Research (M.Y.A., H.A), and Department of Physiology (J.P.K), University of Bern, Bern, Switzerland. and Institute for Molecular Medicine Finland (FIMM), University of Helsinki (J.L., A.P., E.W.), and Department of Medicine, University of Helsinki and Helsinki University Central Hospital (P.J.L.-F., A.M.L., K.K.), Helsinki, Finland.
IN  - Kontula,Kimmo. From the Heart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland (H.S., A.M., L.T.); Department of Clinical Research (M.Y.A., H.A), and Department of Physiology (J.P.K), University of Bern, Bern, Switzerland. and Institute for Molecular Medicine Finland (FIMM), University of Helsinki (J.L., A.P., E.W.), and Department of Medicine, University of Helsinki and Helsinki University Central Hospital (P.J.L.-F., A.M.L., K.K.), Helsinki, Finland.
IN  - Toivonen,Lauri. From the Heart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland (H.S., A.M., L.T.); Department of Clinical Research (M.Y.A., H.A), and Department of Physiology (J.P.K), University of Bern, Bern, Switzerland. and Institute for Molecular Medicine Finland (FIMM), University of Helsinki (J.L., A.P., E.W.), and Department of Medicine, University of Helsinki and Helsinki University Central Hospital (P.J.L.-F., A.M.L., K.K.), Helsinki, Finland.
IN  - Abriel,Hugues. From the Heart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland (H.S., A.M., L.T.); Department of Clinical Research (M.Y.A., H.A), and Department of Physiology (J.P.K), University of Bern, Bern, Switzerland. and Institute for Molecular Medicine Finland (FIMM), University of Helsinki (J.L., A.P., E.W.), and Department of Medicine, University of Helsinki and Helsinki University Central Hospital (P.J.L.-F., A.M.L., K.K.), Helsinki, Finland.
IN  - Widen,Elisabeth. From the Heart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland (H.S., A.M., L.T.); Department of Clinical Research (M.Y.A., H.A), and Department of Physiology (J.P.K), University of Bern, Bern, Switzerland. and Institute for Molecular Medicine Finland (FIMM), University of Helsinki (J.L., A.P., E.W.), and Department of Medicine, University of Helsinki and Helsinki University Central Hospital (P.J.L.-F., A.M.L., K.K.), Helsinki, Finland.
TI  - Gain-of-function mutation of the SCN5A gene causes exercise-induced polymorphic ventricular arrhythmias.
SO  - Circulation. Cardiovascular Genetics. 7(6):771-81, 2014 Dec.
AS  - Circ Cardiovasc Genet. 7(6):771-81, 2014 Dec.
NJ  - Circulation. Cardiovascular genetics
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101489144
SB  - Index Medicus
CP  - United States
MH  - Action Potentials
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Amino Acid Sequence
MH  - Animals
MH  - Child
MH  - Child, Preschool
MH  - Death, Sudden, Cardiac
MH  - Exercise Test
MH  - Female
MH  - Follow-Up Studies
MH  - Genotype
MH  - HEK293 Cells
MH  - Humans
MH  - Linkage Disequilibrium
MH  - Male
MH  - Microsatellite Repeats
MH  - Middle Aged
MH  - Molecular Sequence Data
MH  - Mutation, Missense
MH  - *NAV1.5 Voltage-Gated Sodium Channel/ge [Genetics]
MH  - NAV1.5 Voltage-Gated Sodium Channel/me [Metabolism]
MH  - Pedigree
MH  - Phenotype
MH  - Purkinje Cells/ph [Physiology]
MH  - *Tachycardia, Ventricular/ge [Genetics]
MH  - Tachycardia, Ventricular/us [Ultrasonography]
KW  - SCN5A;  arrhythmia (heart rhythm disorders);  catecholaminergic polymorphic ventricular tachycardia;  exercise test;  genetic testing;  mutation
AB  - BACKGROUND: Over the past 15 years, a myriad of mutations in genes encoding cardiac ion channels and ion channel interacting proteins have been linked to a long list of inherited atrial and ventricular arrhythmias. The purpose of this study was to identify the genetic and functional determinants underlying exercise-induced polymorphic ventricular arrhythmia present in a large multigenerational family.
AB  - METHODS AND RESULTS: A large 4-generation family presenting with exercise-induced polymorphic ventricular arrhythmia, which was followed for 10 years, was clinically characterized. A novel SCN5A mutation was identified via whole exome sequencing and further functionally evaluated by patch-clamp studies using human embryonic kidney 293 cells. Of 37 living family members, a total of 13 individuals demonstrated >50 multiformic premature ventricular complexes or ventricular tachycardia upon exercise stress tests when sinus rate exceeded 99+/-17 beats per minute. Sudden cardiac arrest occurred in 1 individual during follow-up. Exome sequencing identified a novel missense mutation (p.I141V) in a highly conserved region of the SCN5A gene, encoding the Nav1.5 sodium channel protein that cosegregated with the arrhythmia phenotype. The mutation p.I141V shifted the activation curve toward more negative potentials and increased the window current, whereas action potential simulations suggested that it lowered the excitability threshold of cardiac cells.
AB  - CONCLUSIONS: Gain-of-function of Nav1.5 may cause familial forms of exercise-induced polymorphic ventricular arrhythmias.Copyright © 2014 American Heart Association, Inc.
RN  - 0 (NAV1.5 Voltage-Gated Sodium Channel)
RN  - 0 (SCN5A protein, human)
ES  - 1942-3268
IL  - 1942-3268
DO  - http://dx.doi.org/10.1161/CIRCGENETICS.114.000703
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20140910
DP  - 2014 Dec
DC  - 20141217
YR  - 2014
ED  - 20150723
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25210054

<129. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24837486
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Tereshchenko LG
AU  - Shah AJ
AU  - Li Y
AU  - Soliman EZ
FA  - Tereshchenko, Larisa G
FA  - Shah, Amit J
FA  - Li, Yabing
FA  - Soliman, Elsayed Z
IN  - Tereshchenko,Larisa G. Knight Cardiovascular Institute, Oregon Health and Science University, Portland, Oregon, USA.
TI  - Electrocardiographic deep terminal negativity of the P wave in V1 and risk of mortality: the National Health and Nutrition Examination Survey III.
SO  - Journal of Cardiovascular Electrophysiology. 25(11):1242-8, 2014 Nov.
AS  - J Cardiovasc Electrophysiol. 25(11):1242-8, 2014 Nov.
NJ  - Journal of cardiovascular electrophysiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - by4, 9010756
OI  - Source: NLM. NIHMS597268
OI  - Source: NLM. PMC4213235
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Cardiovascular Diseases/di [Diagnosis]
MH  - *Cardiovascular Diseases/mo [Mortality]
MH  - *Cardiovascular Diseases/pp [Physiopathology]
MH  - Electrocardiography/mt [Methods]
MH  - *Electrocardiography/mo [Mortality]
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mortality/td [Trends]
MH  - Nutrition Surveys/mt [Methods]
MH  - *Nutrition Surveys
MH  - Risk Factors
MH  - United States/ep [Epidemiology]
KW  - NHANES III;  P-wave indices;  all-cause mortality;  cardiovascular mortality
AB  - INTRODUCTION: Deep terminal negativity of P wave in V1 (DTNPV1), defined as negative P prime larger than one small box (1 mm, or 0.1 mV), could be easily detected by simple visual inspection of the resting 12-lead ECG. The objective of this study was to determine the relationship between DTNPV1 and all-cause-, cardiovascular disease (CVD), and ischemic heart disease (IHD) mortality in the National Health and Nutrition Examination Survey III (NHANES III).
AB  - METHODS AND RESULTS: After exclusion of participants with atrial fibrillation and missing data, DTNPV1 was automatically measured from standard 12-lead ECG in 8,146 participants. Minnesota and Novacode algorithms were used for the determination of major and minor ECG abnormalities. National Death Index was used to identify the date and cause of death. During a median follow-up of 13.8 years, a total of 2,975 deaths (1,303 CVD and 742 IHD deaths) occurred. After adjustment for age, gender, race/ethnicity, IHD, heart failure, chronic obstructive pulmonary disease, cancer, diabetes, body mass index, smoking, dyslipidemia, hypertension, use of antihypertensive and lipid-lowering medications, and ECG abnormalities, DTNPV1 was associated with significantly increased risk of all-cause death (HR [95% CI]: 1.30 [1.10, 1.53]; P = 0.002), CVD death (HR [95% CI]: 1.36 [1.08, 1.72]; P = 0.010), and IHD death (HR [95% CI]: 1.36 [1.00, 1.85]; P = 0.047).
AB  - CONCLUSION: In a large sample of the adult United States population, DTNPV1 is independently associated with increased risk of death due to all-cause, CVD, and IHD, findings suggesting its potential usefulness as a simple marker to identify individuals at risk of poor outcomes.Copyright © 2014 Wiley Periodicals, Inc.
ES  - 1540-8167
IL  - 1045-3873
DO  - http://dx.doi.org/10.1111/jce.12453
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
NO  - 1R01HL118277 (United States NHLBI NIH HHS)
NO  - KL2 TR000455 (United States NCATS NIH HHS)
NO  - KL2TR000455 (United States NCATS NIH HHS)
NO  - R01 HL118277 (United States NHLBI NIH HHS)
NO  - UL1 TR000454 (United States NCATS NIH HHS)
NO  - UL1TR000454 (United States NCATS NIH HHS)
LG  - English
EP  - 20140611
DP  - 2014 Nov
DC  - 20141028
YR  - 2014
ED  - 20150720
RD  - 20151101
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24837486

<130. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24442420
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mizrahi I
AU  - Alkurd A
AU  - Ghanem M
AU  - Zugayar D
AU  - Mazeh H
AU  - Eid A
AU  - Beglaibter N
AU  - Grinbaum R
FA  - Mizrahi, Ido
FA  - Alkurd, Abbas
FA  - Ghanem, Muhammad
FA  - Zugayar, Diaa
FA  - Mazeh, Haggi
FA  - Eid, Ahmed
FA  - Beglaibter, Nahum
FA  - Grinbaum, Ronit
IN  - Mizrahi,Ido. Department of Surgery, Hadassah-Hebrew University Medical Center, P.O.B. 24035, Mount Scopus, Jerusalem, 91240, Israel, idomiz17@gmail.com.
TI  - Outcomes of laparoscopic sleeve gastrectomy in patients older than 60 years.
SO  - Obesity Surgery. 24(6):855-60, 2014 Jun.
AS  - Obes Surg. 24(6):855-60, 2014 Jun.
NJ  - Obesity surgery
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - c0v, 9106714
SB  - Index Medicus
CP  - United States
MH  - Body Mass Index
MH  - Comorbidity
MH  - Diabetes Mellitus, Type 2/ep [Epidemiology]
MH  - Female
MH  - Gastrectomy/mt [Methods]
MH  - *Gastrectomy
MH  - Humans
MH  - Hyperlipidemias/ep [Epidemiology]
MH  - Hypertension/ep [Epidemiology]
MH  - Laparoscopy
MH  - Male
MH  - Middle Aged
MH  - Obesity, Morbid/ep [Epidemiology]
MH  - Obesity, Morbid/su [Surgery]
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Weight Loss
AB  - BACKGROUND: Morbidity and mortality following laparoscopic sleeve gastrectomy (LSG) occur at acceptable rates, but its safety and efficacy in the elderly are unknown.
AB  - METHODS: A retrospective review was performed of all patients aged >60 years who underwent LSG from 2008 to 2012. These patients were 1:2 matched, by gender and body mass index (BMI) to young patients, 18<age<50. Data analyzed included demographics, preoperative and postoperative BMI, postoperative complications, and improvement or resolution of obesity-related comorbidities.
AB  - RESULTS: Fifty-two morbid obese patients older than 60 years underwent LSG (mean age, 62.9+/-0.3 years). These were matched to 104 young patients, age 18-50 years (mean age, 35.7+/-0.8 years). Groups did not differ in male gender (44 vs. 43%, p=0.9), preoperative BMI (42.6+/-0.7 vs. 42.6+/-0.6, p=0.97), and length of follow-up (17+/-2 vs. 22+/-1.4 months, p=0.06). Obesity-related comorbidities were significantly higher in the older group (96 vs. 65%, p<0.001). Excess weight loss (EWL) was higher in the younger group (75+/-2.4 vs. 62+/-3%, p=0.001). Older patients had a significantly higher rate of a concurrent hiatal hernia repair (23 vs. 1.9%, p<0.001). Overall postoperative minor complication rate was higher in the older group (25 vs. 4.8%, p<0.001). This included atrial fibrillation (9.5%), urinary tract infection (7%), trocar site hernia (4%), dysphagia, surgical site infection, bleeding, bowel obstruction, colitis, and nutritional deficiency (2%, each). No perioperative mortality occurred. Comorbidity resolution or improvement was comparable between groups (88 vs. 80%, p=0.13).
AB  - CONCLUSIONS: LSG is safe and very efficient in patients aged >60, despite higher rates of perioperative comorbidities.
ES  - 1708-0428
IL  - 0960-8923
DO  - http://dx.doi.org/10.1007/s11695-014-1177-2
PT  - Journal Article
LG  - English
DP  - 2014 Jun
DC  - 20140516
YR  - 2014
ED  - 20150714
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24442420

<131. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25443575
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - El Husseini N
AU  - Kaskar O
AU  - Goldstein LB
FA  - El Husseini, Nada
FA  - Kaskar, Omran
FA  - Goldstein, Larry B
IN  - El Husseini,Nada. Department of Neurology, Duke University Medical Center, Durham, NC; and Department of Neurology, Wake Forest University Baptist Medical Center, Winston-Salem, NC. Electronic address: nelhusse@wakehealth.edu.
IN  - Kaskar,Omran. Department of Neurology, Duke University Medical Center, Durham, NC; and Department of Neurology, Wake Forest University Baptist Medical Center, Winston-Salem, NC.
IN  - Goldstein,Larry B. Department of Neurology, Duke University Medical Center, Durham, NC; and Department of Neurology, Wake Forest University Baptist Medical Center, Winston-Salem, NC.
TI  - Chronic kidney disease and stroke. [Review]
SO  - Advances in Chronic Kidney Disease. 21(6):500-8, 2014 Nov.
AS  - Adv Chronic Kidney Dis. 21(6):500-8, 2014 Nov.
NJ  - Advances in chronic kidney disease
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101209214
SB  - Index Medicus
CP  - United States
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - Blood Platelet Disorders/co [Complications]
MH  - *Brain Ischemia/et [Etiology]
MH  - Fibrinolytic Agents/tu [Therapeutic Use]
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use]
MH  - *Intracranial Hemorrhages/et [Etiology]
MH  - Patient Care Team
MH  - Platelet Aggregation Inhibitors/tu [Therapeutic Use]
MH  - *Renal Insufficiency, Chronic/co [Complications]
MH  - Renal Insufficiency, Chronic/ep [Epidemiology]
MH  - *Renal Insufficiency, Chronic/pp [Physiopathology]
MH  - Renal Insufficiency, Chronic/th [Therapy]
MH  - Renal Replacement Therapy/ae [Adverse Effects]
MH  - Secondary Prevention
MH  - Stroke/dt [Drug Therapy]
MH  - Stroke/ep [Epidemiology]
MH  - *Stroke/et [Etiology]
MH  - *Stroke/pc [Prevention & Control]
MH  - Tissue Plasminogen Activator/tu [Therapeutic Use]
KW  - Alteplase;  Chronic kidney disease;  Stroke;  Stroke prevention;  Thrombolysis
AB  - Chronic kidney disease (CKD) is associated with an increased risk of both ischemic and hemorrhagic stroke. In addition to shared risk factors, this higher cerebrovascular risk is mediated by several CKD-associated mechanisms including platelet dysfunction, coagulation disorders, endothelial dysfunction, inflammation, and increased risk of atrial fibrillation. CKD can also modify the effect of treatments used in acute stroke and in secondary stroke prevention. We review the epidemiology and pathophysiology that link CKD and stroke and the impact of CKD on stroke outcomes. Interdisciplinary collaboration between nephrologists, pharmacists, hematologists, nutrition therapists, primary care physicians, and neurologists in providing care to these subjects may potentially improve outcomes. Copyright © 2014 National Kidney Foundation, Inc. All rights reserved.
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - EC 3-4-21-68 (Tissue Plasminogen Activator)
ES  - 1548-5609
IL  - 1548-5595
DI  - S1548-5595(14)00146-3
DO  - http://dx.doi.org/10.1053/j.ackd.2014.09.001
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20141024
DP  - 2014 Nov
DC  - 20141202
YR  - 2014
ED  - 20150713
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25443575

<132. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25392439
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Douketis J
AU  - Bell AD
AU  - Eikelboom J
AU  - Liew A
FA  - Douketis, James
FA  - Bell, Alan David
FA  - Eikelboom, John
FA  - Liew, Aaron
IN  - Douketis,James. Professor in the Department of Medicine at McMaster University in Hamilton, Ont. jdouket@mcmaster.ca.
IN  - Bell,Alan David. Assistant Professor in the Department of Family and Community Medicine at the University of Toronto in Ontario.
IN  - Eikelboom,John. Associate Professor in the Department of Medicine at McMaster University.
IN  - Liew,Aaron. Research fellow in the Department of Medicine at McMaster University.
TI  - Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.
CM  - Comment in: Can Fam Physician. 2015 Jan;61(1):23-4; PMID: 25609516
CM  - Comment in: Can Fam Physician. 2015 Jan;61(1):24-5; PMID: 25609517
SO  - Canadian Family Physician. 60(11):997-1001, 2014 Nov.
AS  - Can Fam Physician. 60(11):997-1001, 2014 Nov.
NJ  - Canadian family physician Medecin de famille canadien
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - blo, 0120300
OI  - Source: NLM. PMC4229158
SB  - Index Medicus
CP  - Canada
MH  - Acute Disease
MH  - Administration, Oral
MH  - Anticoagulants/ad [Administration & Dosage]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/co [Complications]
MH  - Benzimidazoles/ad [Administration & Dosage]
MH  - *Benzimidazoles/tu [Therapeutic Use]
MH  - Dabigatran
MH  - *Family Practice
MH  - Hemorrhage/ci [Chemically Induced]
MH  - Hemorrhage/th [Therapy]
MH  - Humans
MH  - Morpholines/ad [Administration & Dosage]
MH  - *Morpholines/tu [Therapeutic Use]
MH  - Preoperative Care
MH  - Pyrazoles/ad [Administration & Dosage]
MH  - *Pyrazoles/tu [Therapeutic Use]
MH  - Pyridones/ad [Administration & Dosage]
MH  - *Pyridones/tu [Therapeutic Use]
MH  - Rivaroxaban
MH  - Stroke/et [Etiology]
MH  - *Stroke/pc [Prevention & Control]
MH  - Thiophenes/ad [Administration & Dosage]
MH  - *Thiophenes/tu [Therapeutic Use]
MH  - Time Factors
MH  - *Venous Thromboembolism/dt [Drug Therapy]
MH  - beta-Alanine/ad [Administration & Dosage]
MH  - *beta-Alanine/aa [Analogs & Derivatives]
MH  - beta-Alanine/tu [Therapeutic Use]
AB  - OBJECTIVE: To address common "what if" questions that arise relating to the long-term clinical follow-up and management of patients receiving the new oral anticoagulants (NOACs).
AB  - SOURCES OF INFORMATION: For this narrative review, we searched the PubMed database for recent (January 2008 to week 32 of 2013) clinical studies relating to NOAC use for stroke prevention in atrial fibrillation and for the treatment of acute venous thromboembolism. We used this evidence base to address prespecified questions relating to NOAC use in primary care settings.
AB  - MAIN MESSAGE: Dabigatran and rivaroxaban should be taken with meals to decrease dyspepsia and increase absorption, respectively. There are no dietary restrictions with any of the NOACs, beyond moderating alcohol intake, and rivaroxaban and apixaban can be crushed if required. The use of acid suppressive therapies does not appear to affect the efficacy of the NOACs. As with warfarin, patients taking NOACs should avoid long-term use of nonsteroidal anti-inflammatory and antiplatelet drugs. For patients requiring surgery, generally NOACs should be stopped 2 to 5 days before the procedure, depending on bleeding risk, and the NOAC should usually be resumed at least 24 hours after surgery. Preoperative coagulation testing is generally unnecessary. In patients who develop bleeding, minor bleeding typically does not require laboratory testing or discontinuation of NOACs; with major bleeding, the focus should be on local measures to control the bleeding and supportive care, and coagulation testing should be performed. There are currently no antidotes to reverse NOACs. The NOACs should not be used in patients with valvular heart disease, prosthetic heart valves, cancer-associated deep vein thrombosis, or superficial thrombophlebitis.
AB  - CONCLUSION: Management of "what if" scenarios for patients taking NOACs have been proposed, but additional study is needed to address these issues, especially periprocedural management and bleeding.Copyright© the College of Family Physicians of Canada.
RN  - 0 (Anticoagulants)
RN  - 0 (Benzimidazoles)
RN  - 0 (Morpholines)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridones)
RN  - 0 (Thiophenes)
RN  - 11P2JDE17B (beta-Alanine)
RN  - 3Z9Y7UWC1J (apixaban)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - I0VM4M70GC (Dabigatran)
ES  - 1715-5258
IL  - 0008-350X
PT  - Journal Article
LG  - English
DP  - 2014 Nov
DC  - 20141113
YR  - 2014
ED  - 20150709
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25392439

<133. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24408890
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Predel HG
FA  - Predel, Hans-Georg
IN  - Predel,Hans-Georg. Institute of Cardiovascular Research and Sports Medicine, German Sport University Cologne, Am Sportpark Mungersdorf 6, Cologne 50933, Germany predel@dshs-koeln.de.
TI  - Marathon run: cardiovascular adaptation and cardiovascular risk.
SO  - European Heart Journal. 35(44):3091-8, 2014 Nov 21.
AS  - Eur Heart J. 35(44):3091-8, 2014 Nov 21.
NJ  - European heart journal
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - em8, 8006263
SB  - Index Medicus
CP  - England
MH  - *Adaptation, Physiological/ph [Physiology]
MH  - Arrhythmias, Cardiac/et [Etiology]
MH  - Arrhythmias, Cardiac/pp [Physiopathology]
MH  - Cardiomyopathies/et [Etiology]
MH  - Cardiomyopathies/pp [Physiopathology]
MH  - *Cardiovascular Diseases/et [Etiology]
MH  - Cardiovascular Diseases/pp [Physiopathology]
MH  - Coronary Disease/pp [Physiopathology]
MH  - Coronary Disease/pc [Prevention & Control]
MH  - Death, Sudden, Cardiac/pc [Prevention & Control]
MH  - Early Diagnosis
MH  - Female
MH  - Heart Ventricles
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Risk Assessment
MH  - Risk Factors
MH  - *Running/ph [Physiology]
MH  - Ventricular Function/ph [Physiology]
KW  - Cardiovascular adaptation;  Endurance exercise;  Marathon run;  Middle-aged athletes
AB  - The first marathon run as an athletic event took place in the context of the Olympic Games in 1896 in Athens, Greece. Today, participation in a 'marathon run' has become a global phenomenon attracting young professional athletes as well as millions of mainly middle-aged amateur athletes worldwide each year. One of the main motives for these amateur marathon runners is the expectation that endurance exercise (EE) delivers profound beneficial health effects. However, with respect to the cardiovascular system, a controversial debate has emerged whether the marathon run itself is healthy or potentially harmful to the cardiovascular system, especially in middle-aged non-elite male amateur runners. In this cohort, exercise-induced increases in cardiac biomarkers-troponin and brain natriuretic peptide-and acute functional cardiac alterations have been observed and interpreted as potential cardiac damage. Furthermore, in the cohort of 40- to 65-year-old males engaged in intensive EE, a significant risk for the development of atrial fibrillation has been identified. Fortunately, recent studies demonstrated a normalization of the cardiac biomarkers and the functional alterations within a short time frame. Therefore, these alterations may be perceived as physiological myocardial reactions to the strenuous exercise and the term 'cardiac fatigue' has been coined. This interpretation is supported by a recent analysis of 10.9 million marathon runners demonstrating that there was no significantly increased overall risk of cardiac arrest during long-distance running races. In conclusion, intensive and long-lasting EE, e.g. running a full-distance Marathon, results in high cardiovascular strain whose clinical relevance especially for middle-aged and older athletes is unclear and remains a matter of controversy. Furthermore, there is a need for evidence-based recommendations with respect to medical screening and training strategies especially in male amateur runners over the age of 35 years engaged in regular and intensive EE. Copyright Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2013. For permissions please email: journals.permissions@oup.com.
ES  - 1522-9645
IL  - 0195-668X
DO  - http://dx.doi.org/10.1093/eurheartj/eht502
PT  - Journal Article
LG  - English
EP  - 20140109
DP  - 2014 Nov 21
DC  - 20141122
YR  - 2014
ED  - 20150707
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24408890

<134. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25055988
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Overvad TF
AU  - Rasmussen LH
AU  - Skjoth F
AU  - Overvad K
AU  - Albertsen IE
AU  - Lane DA
AU  - Lip GY
AU  - Larsen TB
FA  - Overvad, Thure Filskov
FA  - Rasmussen, Lars Hvilsted
FA  - Skjoth, Flemming
FA  - Overvad, Kim
FA  - Albertsen, Ida Ehlers
FA  - Lane, Deirdre A
FA  - Lip, Gregory Y H
FA  - Larsen, Torben Bjerregaard
IN  - Overvad,Thure Filskov. Thure Filskov Overvad, MD, Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Forskningens Hus, Sondre Skovvej 15, DK-9100 Aalborg, Denmark, Tel.: +45 99 32 81 00, Fax: +45 99 32 80 99, Email: t.overvad@rn.dk.
TI  - Female sex as a risk factor for thromboembolism and death in patients with incident atrial fibrillation. The prospective Danish Diet, Cancer and Health study.
SO  - Thrombosis & Haemostasis. 112(4):789-95, 2014 Oct.
AS  - Thromb Haemost. 112(4):789-95, 2014 Oct.
NJ  - Thrombosis and haemostasis
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - vq7, 7608063
SB  - Index Medicus
CP  - Germany
MH  - Aged
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/mo [Mortality]
MH  - Blood Platelets
MH  - Denmark
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Life Style
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Registries
MH  - Risk Factors
MH  - Sex Factors
MH  - Surveys and Questionnaires
MH  - *Thromboembolism/di [Diagnosis]
MH  - *Thromboembolism/ep [Epidemiology]
MH  - Thromboembolism/mo [Mortality]
MH  - Warfarin/tu [Therapeutic Use]
KW  - Atrial fibrillation;  death;  epidemiology;  sex differences;  stroke;  thromboembolism
AB  - Several studies have demonstrated sex differences in risk of thromboembolism and death among patients with atrial fibrillation, but it is unclear to what extent these associations relate to actual physiological differences. To date, no study has investigated sex differences with concomitant control for lifestyle related factors known to influence stroke risk. We used data from the Danish Diet, Cancer and Health study, including 57,053 participants (52% female) aged 50-64 years. The study population for this study included the 2,895 patients (36% female) with incident atrial fibrillation after inclusion. Data were linked to outcomes identified using nationwide registries. Risk of thromboembolism and death according to female sex were analysed using Cox proportional hazards models. After a median follow-up of 5.0 years, 137 men and 62 women suffered a thromboembolic event, and 349 men and 151 women died. In a crude analysis, female sex was associated with a non-significant lower risk of thromboembolism (hazard ratio [HR] 0.82, 95% confidence interval [CI] 0.61-1.11). Adjustment for differences in antithrombotic therapy, relevant comorbidities and lifestyle did not change this association (HR 0.77, 95% CI 0.55-1.13). In the final model, female sex was associated with a lower risk of death (HR 0.65, 95% CI 0.51-0.84). The associations were similar in a sensitivity analysis of women not taking hormone replacement therapy, and the effect of hormone replacement therapy use within females was non-significant for both endpoints of thromboembolism and death. In conclusion, in a relatively young population of patients with atrial fibrillation, female sex was associated with a lower risk of thromboembolism and death.
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
IS  - 0340-6245
IL  - 0340-6245
DO  - http://dx.doi.org/10.1160/TH14-06-0545
PT  - Journal Article
LG  - English
EP  - 20140724
DP  - 2014 Oct
DC  - 20140930
YR  - 2014
ED  - 20150707
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25055988

<135. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24574493
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Rix TA
AU  - Joensen AM
AU  - Riahi S
AU  - Lundbye-Christensen S
AU  - Tjonneland A
AU  - Schmidt EB
AU  - Overvad K
FA  - Rix, Thomas A
FA  - Joensen, Albert M
FA  - Riahi, Sam
FA  - Lundbye-Christensen, Soren
FA  - Tjonneland, Anne
FA  - Schmidt, Erik B
FA  - Overvad, Kim
IN  - Rix,Thomas A. Department of Cardiology, Aalborg AF Study Group, Center for Cardiovascular Research, Aalborg University Hospital, 9100 Aalborg, Denmark Section for Epidemiology, Department of Public Health, Aarhus University, 8000 Aarhus, Denmark tar@rn.dk.
IN  - Joensen,Albert M. Department of Cardiology, Aalborg AF Study Group, Center for Cardiovascular Research, Aalborg University Hospital, 9100 Aalborg, Denmark.
IN  - Riahi,Sam. Department of Cardiology, Aalborg AF Study Group, Center for Cardiovascular Research, Aalborg University Hospital, 9100 Aalborg, Denmark Department of Health Science and Technology, Faculty of Medicine, Aalborg University, 9220 Aalborg, Denmark.
IN  - Lundbye-Christensen,Soren. Department of Cardiology, Aalborg AF Study Group, Center for Cardiovascular Research, Aalborg University Hospital, 9100 Aalborg, Denmark.
IN  - Tjonneland,Anne. Danish Cancer Society Research Center, 2100 Copenhagen, Denmark.
IN  - Schmidt,Erik B. Department of Cardiology, Aalborg AF Study Group, Center for Cardiovascular Research, Aalborg University Hospital, 9100 Aalborg, Denmark.
IN  - Overvad,Kim. Department of Cardiology, Aalborg AF Study Group, Center for Cardiovascular Research, Aalborg University Hospital, 9100 Aalborg, Denmark Section for Epidemiology, Department of Public Health, Aarhus University, 8000 Aarhus, Denmark.
TI  - A U-shaped association between consumption of marine n-3 fatty acids and development of atrial fibrillation/atrial flutter-a Danish cohort study.
SO  - Europace. 16(11):1554-61, 2014 Nov.
AS  - Europace. 16(11):1554-61, 2014 Nov.
NJ  - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - dxd, 100883649
SB  - Index Medicus
CP  - England
MH  - Animals
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - Atrial Flutter/di [Diagnosis]
MH  - Atrial Flutter/ep [Epidemiology]
MH  - *Atrial Flutter/pc [Prevention & Control]
MH  - Denmark/ep [Epidemiology]
MH  - *Diet
MH  - Docosahexaenoic Acids/ad [Administration & Dosage]
MH  - Eicosapentaenoic Acid/ad [Administration & Dosage]
MH  - *Fatty Acids, Omega-3/ad [Administration & Dosage]
MH  - Fatty Acids, Unsaturated/ad [Administration & Dosage]
MH  - Female
MH  - *Fishes
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Nonlinear Dynamics
MH  - Proportional Hazards Models
MH  - Protective Factors
MH  - Registries
MH  - Risk Assessment
MH  - Risk Factors
MH  - Risk Reduction Behavior
MH  - *Seafood
MH  - Surveys and Questionnaires
KW  - Atrial fibrillation;  Diet;  Fish;  n-3 Polyunsaturated fatty acids
AB  - AIMS: Previous studies have suggested a lower risk of atrial fibrillation (AF) with higher intakes of fish and marine n-3 polyunsaturated fatty acids (PUFAs), but the results have been inconsistent. The aim was to investigate the association between consumption of marine n-3 PUFA and development of AF.
AB  - METHODS AND RESULTS: A total of 57 053 Danish participants 50-64 years of age were enrolled in the Diet, Cancer, and Health Cohort Study between 1993 and 1997. Dietary intake of fish and marine n-3 PUFA was assessed by a semi-quantitative food frequency questionnaire. In total, 3345 incident cases of AF occurred over 13.6 years. Multivariate Cox regression analyses (3284 cases and 55 246 participants) using cubic splines showed a U-shaped association between consumption of marine n-3 PUFA and risk of incident AF, with the lowest risk of AF at a moderate intake of 0.63 g/day. For quintiles of marine n-3 PUFA intake, a 13% statistically significant lower risk of AF was seen in the middle vs. lowest quintile: Q1 reference, Q2 HR 0.92 (95% CI 0.82-1.03), Q3 HR 0.87 (95% CI 0.78-0.98), Q4 HR 0.96 (95% CI 0.86-1.08), and Q5 HR 1.05 (95% CI 0.93-1.18). Intake of total fish, fatty fish, and the individual n-3 PUFA eicosapentaenoic acid, docosahexaenoic acid, and docosapentaenoic acid also showed U-shaped associations with incident AF.
AB  - CONCLUSION: We found a U-shaped association between consumption of marine n-3 PUFA and risk of incident AF, with the lowest risk close to the median intake of total marine n-3 PUFA (0.63 g/day).Copyright Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2014. For permissions please email: journals.permissions@oup.com.
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Fatty Acids, Unsaturated)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - 25448-00-4 (docosapentaenoic acid)
RN  - AAN7QOV9EA (Eicosapentaenoic Acid)
ES  - 1532-2092
IL  - 1099-5129
DO  - http://dx.doi.org/10.1093/europace/euu019
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20140226
DP  - 2014 Nov
DC  - 20141027
YR  - 2014
ED  - 20150629
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24574493

<136. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25060145
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Berntsson J
AU  - Zia E
AU  - Borne Y
AU  - Melander O
AU  - Hedblad B
AU  - Engstrom G
FA  - Berntsson, John
FA  - Zia, Elisabet
FA  - Borne, Yan
FA  - Melander, Olle
FA  - Hedblad, Bo
FA  - Engstrom, Gunnar
IN  - Berntsson,John. Department of Clinical Sciences in Malmo, Lund University, Lund, Sweden.
TI  - Plasma natriuretic peptides and incidence of subtypes of ischemic stroke.
SO  - Cerebrovascular Diseases. 37(6):444-50, 2014.
AS  - Cerebrovasc Dis. 37(6):444-50, 2014.
NJ  - Cerebrovascular diseases (Basel, Switzerland)
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - c2g, 9100851
SB  - Index Medicus
CP  - Switzerland
MH  - Adult
MH  - Aged
MH  - Atherosclerosis/bl [Blood]
MH  - *Atherosclerosis/ep [Epidemiology]
MH  - Atrial Fibrillation/bl [Blood]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Biomarkers/bl [Blood]
MH  - Brain Ischemia/bl [Blood]
MH  - *Brain Ischemia/ep [Epidemiology]
MH  - Female
MH  - Heart Failure/bl [Blood]
MH  - *Heart Failure/ep [Epidemiology]
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - *Natriuretic Peptides/bl [Blood]
MH  - Prospective Studies
MH  - Risk
MH  - Risk Factors
MH  - Stroke/bl [Blood]
MH  - *Stroke/ep [Epidemiology]
AB  - BACKGROUND AND PURPOSE: Natriuretic peptides predict poor outcomes in cardiovascular disease. However, the knowledge of their relationship to stroke is limited and prospective studies from the general population are few. The purpose of this study was to explore the relationship between N-terminal pro-brain natriuretic peptide (NT-proBNP) and midregional pro-atrial natriuretic peptide (MR-proANP) plasma levels and the risk for ischemic stroke and its subtypes.
AB  - METHODS: NT-proBNP and MR-proANP were measured in fasting blood samples from 4,862 subjects (40.2% men, mean age 57.5 +/- 6.0 years) without cardiovascular disease from the Malmo Diet and Cancer Study, a prospective, population-based study in Sweden. Incidence of ischemic stroke was monitored over a mean follow-up of 14.9 +/- 3.0 years. Stroke cases were etiologically classified according to the TOAST classification. Cox proportional-hazards regression was used to study the incidence of stroke in relationship to NT-proBNP and MR-proANP.
AB  - RESULTS: During follow-up, 227 had a first-ever ischemic stroke (large-artery atherosclerosis, n = 35; cardioembolic stroke, n = 44; small-artery occlusion, n = 80; undetermined cause, n = 68). In the age- and sex-adjusted model, only NT-proBNP was associated with total ischemic stroke. This association was completely explained by an increased incidence of cardioembolic stroke. Adjusted for cardiovascular risk factors (age, sex, hypertension, diabetes, smoking, body mass index and low-density lipoprotein cholesterol), the hazard ratios (HRs, 95% confidence interval, 95% CI) for cardioembolic stroke were 1.00 (reference), 1.42 (0.34-6.00), 2.79 (0.77-10.12) and 5.64 (1.66-19.20), respectively, for the 1st, 2nd, 3rd and 4th quartiles of NT-proBNP. The corresponding HRs (95% CIs) for quartiles of MR-proANP were 1.00 (reference), 1.83 (0.55-6.14), 1.20 (0.33-4.34) and 3.96 (1.31-11.99), respectively. In total, 335 (6.9%) subjects were diagnosed with atrial fibrillation during follow-up. Among the cardioembolic stroke cases, 30% were diagnosed with atrial fibrillation before the stroke event and another 36% within 6 months after the stroke. Of the cardioembolic stroke cases with atrial fibrillation, 59% were in the top quartile of NT-proBNP, 69% in the top quartile of MR-proANP and 79% were either in the top quartile of NT-proBNP or in the top quartile of MR-proANP.
AB  - CONCLUSION: High plasma levels of NT-proBNP and MR-proANP are associated with a substantially increased risk of cardioembolic stroke, but not with other subtypes of ischemic stroke. The results suggest that assessment of stroke risk, including electrocardiography, is warranted in subjects with high NT-proBNP or MR-proANP.Copyright © 2014 S. Karger AG, Basel.
RN  - 0 (Biomarkers)
RN  - 0 (Natriuretic Peptides)
ES  - 1421-9786
IL  - 1015-9770
DO  - http://dx.doi.org/10.1159/000363279
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20140723
DP  - 2014
DC  - 20140820
YR  - 2014
ED  - 20150622
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25060145

<137. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22583512
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Moschietto S
AU  - Doyen D
AU  - Grech L
AU  - Dellamonica J
AU  - Hyvernat H
AU  - Bernardin G
FA  - Moschietto, Sebastien
FA  - Doyen, Denis
FA  - Grech, Ludovic
FA  - Dellamonica, Jean
FA  - Hyvernat, Herve
FA  - Bernardin, Gilles
TI  - Transthoracic Echocardiography with Doppler Tissue Imaging predicts weaning failure from mechanical ventilation: evolution of the left ventricle relaxation rate during a spontaneous breathing trial is the key factor in weaning outcome.
CM  - Comment in: Crit Care. 2012;16(3):433; PMID: 22734644
CM  - Comment in: Crit Care. 2012;16(4):137; PMID: 22770365
SO  - Critical Care (London, England). 16(3):R81, 2012.
AS  - Crit Care. 16(3):R81, 2012.
NJ  - Critical care (London, England)
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 9801902
OI  - Source: NLM. PMC3580624
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - *Echocardiography, Doppler/mt [Methods]
MH  - Echocardiography, Doppler/td [Trends]
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - *Respiration, Artificial/mt [Methods]
MH  - Respiration, Artificial/td [Trends]
MH  - *Respiratory Mechanics/ph [Physiology]
MH  - Treatment Failure
MH  - Treatment Outcome
MH  - *Ventilator Weaning/mt [Methods]
MH  - Ventilator Weaning/td [Trends]
MH  - *Ventricular Function, Left/ph [Physiology]
AB  - INTRODUCTION: There is growing evidence to suggest that transthoracic echocardiography (TTE) should be used to identify the cardiac origin of respiratory weaning failure.
AB  - THE AIMS OF OUR STUDY WERE: first, to evaluate the ability of transthoracic echocardiography, with mitral Doppler inflow E velocity to annular tissue Doppler Ea wave velocity (E/Ea) ratio measurement, to predict weaning failure from mechanical ventilation in patients, including those with atrial fibrillation; and second, to determine whether the depressed left ejection fraction and/or diastolic dysfunction participate in weaning outcome.
AB  - METHODS: The sample included patients on mechanical ventilation for over 48 hours. A complete echocardiography was performed just before the spontaneous breathing trial (SBT) and 10 minutes after starting the SBT. Systolic dysfunction was defined by a left ventricle ejection fraction under 50% and relaxation impairment by a protodiastolic annulus mitral velocity Ea under or equal to 8 cm/second.
AB  - RESULTS: A total of 68 patients were included. Twenty failed the weaning process and the other 48 patients succeeded. Before the SBT, the E/Ea ratio was higher in the failed group than in the successful group. The E/Ea measured during the SBT was also higher in the failed group. The cut-off value, obtained from receiver operating characteristics (ROC) curve analysis, to predict weaning failure gave an E/Ea ratio during the SBT of 14.5 with a sensitivity of 75% and a specificity of 95.8%. The left ventricular ejection fraction did not differ between the two groups whereas Ea was lower in the failed group. Ea increased during SBT in the successful group while no change occurred in the failed group.
AB  - CONCLUSIONS: Measurement of the E/Ea ratio with TTE could predict weaning failure. Diastolic dysfunction with relaxation impairment is strongly associated with weaning failure. Moreover, the impossibility of enhancing the left ventricle relaxation rate during the SBT seems to be the key factor of weaning failure. In contrast, the systolic dysfunction was not associated with weaning outcome.
ES  - 1466-609X
IL  - 1364-8535
DO  - http://dx.doi.org/10.1186/cc11339
PT  - Journal Article
PT  - Observational Study
LG  - English
EP  - 20120514
DP  - 2012
DC  - 20140801
YR  - 2012
ED  - 20150622
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22583512

<138. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24903064
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mohanty S
AU  - Santangeli P
AU  - Mohanty P
AU  - Di Biase L
AU  - Holcomb S
AU  - Trivedi C
AU  - Bai R
AU  - Burkhardt D
AU  - Hongo R
AU  - Hao S
AU  - Beheiry S
AU  - Santoro F
AU  - Forleo G
AU  - Gallinghouse JG
AU  - Horton R
AU  - Sanchez JE
AU  - Bailey S
AU  - Hranitzky PM
AU  - Zagrodzky J
AU  - Natale A
FA  - Mohanty, Sanghamitra
FA  - Santangeli, Pasquale
FA  - Mohanty, Prasant
FA  - Di Biase, Luigi
FA  - Holcomb, Shawna
FA  - Trivedi, Chintan
FA  - Bai, Rong
FA  - Burkhardt, David
FA  - Hongo, Richard
FA  - Hao, Steven
FA  - Beheiry, Salwa
FA  - Santoro, Francesco
FA  - Forleo, Giovanni
FA  - Gallinghouse, Joseph G
FA  - Horton, Rodney
FA  - Sanchez, Javier E
FA  - Bailey, Shane
FA  - Hranitzky, Patrick M
FA  - Zagrodzky, Jason
FA  - Natale, Andrea
IN  - Mohanty,Sanghamitra. Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA; College of Natural Sciences, University of Texas at Austin, Texas, USA.
TI  - Catheter ablation of asymptomatic longstanding persistent atrial fibrillation: impact on quality of life, exercise performance, arrhythmia perception, and arrhythmia-free survival.
SO  - Journal of Cardiovascular Electrophysiology. 25(10):1057-64, 2014 Oct.
AS  - J Cardiovasc Electrophysiol. 25(10):1057-64, 2014 Oct.
NJ  - Journal of cardiovascular electrophysiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - by4, 9010756
SB  - Index Medicus
CP  - United States
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/px [Psychology]
MH  - Attitude to Health
MH  - *Catheter Ablation/px [Psychology]
MH  - *Catheter Ablation/st [Standards]
MH  - Chronic Disease
MH  - Disease-Free Survival
MH  - Exercise Test/px [Psychology]
MH  - *Exercise Test/sn [Statistics & Numerical Data]
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Patient Satisfaction/sn [Statistics & Numerical Data]
MH  - Prevalence
MH  - *Quality of Life/px [Psychology]
MH  - Risk Factors
MH  - Texas/ep [Epidemiology]
MH  - Treatment Outcome
KW  - arrhythmia perception;  asymptomatic longstanding persistent AF;  exercise performance;  quality of life
AB  - BACKGROUND: Impact of catheter ablation on exercise performance, quality of life (QoL) and symptom perception in asymptomatic longstanding persistent AF (LSP-AF) patients has not been reported yet.
AB  - METHODS AND RESULTS: Sixty-one consecutive patients (mean age 62 +/-13 years, 71% males) with asymptomatic LSP-AF undergoing first catheter ablation were enrolled. Extended pulmonary vein antrum isolation plus ablation of complex fractionated atrial electrograms and nonpulmonary vein triggers was performed in all. QoL survey was taken at baseline and 12-months postablation, using Short Form-36 (SF-36). Information on arrhythmia perception was obtained using a standard questionnaire and corroborating symptoms with documented evidence of arrhythmia. Exercise tests were performed on 38 patients at baseline and 5 months after procedure. Recurrence was assessed using event recorder, cardiology evaluation, electrocardiogram, and 7-day holter monitoring. After 20 +/- 5 months follow-up, 36 (57%) patients remained recurrence-free off-AAD. Of the 25 patients experiencing recurrence, 21 (84%) were symptomatic. Compared to baseline, follow-up SF-36 scores improved significantly in many measures. For patients with successful ablation, physical component summary (PCS) and mental component summary (MCS) demonstrated substantial improvement (
AB  - MCS: 64.2 +/- 22.3 to 70.1 +/- 18.6 [P = 0.041]; PCS: 62.6 +/- 18.4 to 70.0 +/- 14.4 [P = 0.032]). Postablation exercise study in recurrence-free patients showed significant reduction in resting and peak heart rate (75 +/- 11 vs. 90 +/- 17 and 132 +/- 20 vs. 154.5 +/- 36, respectively, P < 0.001), increase in peak oxygen pulse (13.4 +/- 3 vs. 18.9 +/- 16 mL/beat, DELTA5.5 +/- 15, P = 0.001), peak VO2 /kg (19.7 +/- 5 to 23.4 +/- 13 mL/kg/min [DELTA 3.7 +/- 10, P = 0.043]), and corresponding MET (5.6 +/- 1 to 6.7 +/- 4 [DELTA1.1 +/- 3, P = 0.03]). No improvement was observed in patients with failed procedures.
AB  - CONCLUSION: Successful ablation improves exercise performance and QoL in asymptomatic LSP-AF patients.Copyright © 2014 Wiley Periodicals, Inc.
ES  - 1540-8167
IL  - 1045-3873
DO  - http://dx.doi.org/10.1111/jce.12467
PT  - Clinical Trial
PT  - Journal Article
SI  - ClinicalTrials.gov
SA  - ClinicalTrials.gov/NCT01892774
SL  - http://clinicaltrials.gov/search/term=NCT01892774
LG  - English
EP  - 20140707
DP  - 2014 Oct
DC  - 20141011
YR  - 2014
ED  - 20150616
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24903064

<139. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25091540
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Laible M
AU  - Horstmann S
AU  - Rizos T
AU  - Rauch G
AU  - Zorn M
AU  - Veltkamp R
FA  - Laible, M
FA  - Horstmann, S
FA  - Rizos, T
FA  - Rauch, G
FA  - Zorn, M
FA  - Veltkamp, R
IN  - Laible,M. Department of Neurology, University of Heidelberg, Heidelberg, Germany.
TI  - Prevalence of renal dysfunction in ischaemic stroke and transient ischaemic attack patients with or without atrial fibrillation.
SO  - European Journal of Neurology. 22(1):64-9, e4-5, 2015 Jan.
AS  - Eur J Neurol. 22(1):64-9, e4-5, 2015 Jan.
NJ  - European journal of neurology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - daf, 9506311
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - *Brain Ischemia/ep [Epidemiology]
MH  - Cohort Studies
MH  - Comorbidity
MH  - Electrocardiography
MH  - Female
MH  - Germany/ep [Epidemiology]
MH  - Glomerular Filtration Rate
MH  - Humans
MH  - Ischemic Attack, Transient/ep [Epidemiology]
MH  - Kidney Diseases/cl [Classification]
MH  - Kidney Diseases/di [Diagnosis]
MH  - *Kidney Diseases/ep [Epidemiology]
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - *Registries
MH  - *Stroke/ep [Epidemiology]
KW  - atrial fibrillation;  oral anticoagulation;  renal function impairment;  stroke
AB  - BACKGROUND AND PURPOSE: Chronic kidney disease (CKD) is associated with a higher risk of stroke and atrial fibrillation (AF). There are limited data on the comorbidity of renal dysfunction and AF in stroke patients. Our aim was to determine the frequency of kidney dysfunction in ischaemic stroke patients with and without AF.
AB  - METHODS: In a prospectively collected, single center cohort of acute ischaemic stroke and transient ischaemic attack (TIA) patients, glomerular filtration rate (eGFR) was estimated using the Modification of Diet in Renal Disease equation on admission. Renal function was graded into five categories (cat.): cat. 1, eGRF >90 ml/min/1.73 m(2); cat. 2, 60-89; cat. 3, 30-59; cat. 4, 15-29; cat. 5, <15. The diagnosis of AF was based on medical history, a 12-lead electrocardiogram (ECG) and 24-h Holter or continuous ECG monitoring.
AB  - RESULTS: In total, 2274 patients (1727 stroke, 547 TIA; median age 71.0) were included. Median eGFR was 78.6 ml/min/1.73 m(2) (interquartile range 61/95); 21.1% were in cat. 3, 2.1% in cat. 4, 0.7% in cat. 5. In all, 535 patients (23.5%) suffered from AF; 28.0% of these were in cat. 3, 2.6% and 0.8% in cat. 4 and cat. 5, respectively. In multivariable analysis, age [odds ratio (OR) 1.1], diabetes (OR 1.8), heart failure (OR 1.7) and AF (OR 1.4) were independently associated with kidney dysfunction (eGFR < 60).
AB  - CONCLUSIONS: Renal dysfunction is far more common in stroke patients than in the general population and more common in AF-related stroke. These findings may have implications for the choice of anticoagulants.Copyright © 2014 EAN.
ES  - 1468-1331
IL  - 1351-5101
DO  - http://dx.doi.org/10.1111/ene.12528
PT  - Journal Article
PT  - Observational Study
LG  - English
EP  - 20140804
DP  - 2015 Jan
DC  - 20141216
YR  - 2015
ED  - 20150611
RD  - 20151113
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25091540

<140. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24771262
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wutzler A
AU  - Wolber T
AU  - Parwani AS
AU  - Huemer M
AU  - Attanasio P
AU  - Blaschke F
AU  - Haegeli L
AU  - Haverkamp W
AU  - Duru F
AU  - Boldt LH
FA  - Wutzler, Alexander
FA  - Wolber, Thomas
FA  - Parwani, Abdul Shokor
FA  - Huemer, Martin
FA  - Attanasio, Philipp
FA  - Blaschke, Florian
FA  - Haegeli, Laurent
FA  - Haverkamp, Wilhelm
FA  - Duru, Firat
FA  - Boldt, Leif-Hendrik
IN  - Wutzler,Alexander. Department of Cardiology, Charite-Universitatsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany, alexander.wutzler@charite.de.
TI  - Robotic ablation of atrial fibrillation with a new remote catheter system.
SO  - Journal of Interventional Cardiac Electrophysiology. 40(3):215-9, 2014 Sep.
AS  - J Interv Card Electrophysiol. 40(3):215-9, 2014 Sep.
NJ  - Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - c8k, 9708966
SB  - Index Medicus
CP  - Netherlands
MH  - Aged
MH  - *Atrial Fibrillation/su [Surgery]
MH  - *Cardiac Surgical Procedures/is [Instrumentation]
MH  - *Catheter Ablation/is [Instrumentation]
MH  - Equipment Design
MH  - Female
MH  - Fluoroscopy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pulmonary Veins/su [Surgery]
MH  - *Robotics
AB  - PURPOSE: Pulmonary vein isolation (PVI) is widely established as a curative treatment option for atrial fibrillation (AF). A wide range of techniques to improve catheter manipulation and steerability has been developed over the past years. A new remote catheter system (RCS) has recently become available (Amigo Remote Catheter System, Catheter Robotics, Budd Lake, NJ, USA). Here, we present a dual-center study on the RCS for left atrial mapping and PVI in patients with paroxysmal AF compared to a control group undergoing conventional PVI.
AB  - METHODS: One hundred nineteen patients who underwent PVI for paroxysmal AF were studied. Forty patients underwent PVI with the use of the RCS. Seventy-nine patients, who underwent conventional PVI, served as control group. Procedural data were compared between the two groups.
AB  - RESULTS: PVI was achieved in all patients. In the RCS group compared to standard ablation group, there were no significant differences in procedure duration (159.1+/-45.4 vs. 146+/-30.1 min, p=0.19), total energy delivery (78,146.3+/-26,992.4 vs. 87,963.9+/-79,202.1 Ws, p=0.57), and total fluoroscopy time (21.2+/-8.6 vs. 23.9+/-5.4 min, p=0.15). Operator fluoroscopy exposure was significantly reduced in the RCS group (13.4+/-6.1 vs. 23.9+/-5.4 min, p<0.001).
AB  - CONCLUSIONS: These initial results suggest that left atrial mapping and PVI are feasible with the use of the Amigo RCS. Acute procedural efficacy is comparable to the standard approach. The use of the Amigo RCS leads to a significant reduction of operator fluoroscopy exposure.
ES  - 1572-8595
IL  - 1383-875X
DO  - http://dx.doi.org/10.1007/s10840-014-9895-x
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
LG  - English
EP  - 20140429
DP  - 2014 Sep
DC  - 20140903
YR  - 2014
ED  - 20150515
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24771262

<141. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25032726
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Fang F
AU  - Lee AP
AU  - Yu CM
FA  - Fang, Fang
FA  - Lee, Alex Pui-Wai
FA  - Yu, Cheuk-Man
IN  - Fang,Fang. Division of Cardiology, Department of Medicine and Therapeutics, Prince of Wales Hospital, and Institute of Vascular Medicine, The Chinese University of Hong Kong, Hong Kong.
TI  - Left atrial function in heart failure with impaired and preserved ejection fraction.
SO  - Current Opinion in Cardiology. 29(5):430-6, 2014 Sep.
AS  - Curr Opin Cardiol. 29(5):430-6, 2014 Sep.
NJ  - Current opinion in cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - bda, 8608087
SB  - Index Medicus
CP  - United States
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Atrial Function, Left
MH  - Exercise/ph [Physiology]
MH  - Heart Atria/pa [Pathology]
MH  - Heart Failure, Systolic/co [Complications]
MH  - Heart Failure, Systolic/pa [Pathology]
MH  - *Heart Failure, Systolic/pp [Physiopathology]
MH  - Humans
MH  - Prognosis
MH  - *Stroke Volume
AB  - PURPOSE OF REVIEW: Left atrial structural and functional changes in heart failure are relatively ignored parts of cardiac assessment. This review illustrates the pathophysiological and functional changes in left atrium in heart failure as well as their prognostic value.
AB  - RECENT FINDINGS: Heart failure can be divided into those with systolic dysfunction and heart failure with preserved ejection fraction (HFPEF). Left atrial enlargement and dysfunction commonly occur in systolic heart failure, in particular, in idiopathic dilated cardiomyopathy. Atrial enlargement and dysfunction also carry important prognostic value in systolic heart failure, independently of known parameters such as left ventricular ejection fraction. In HFPEF, there is evidence of left atrial enlargement, impaired atrial compliance, and reduction of atrial pump function. This occurs not only at rest but also during exercise, indicating significant impairment of atrial contractile reserve. Furthermore, atrial dyssynchrony is common in HFPEF. These factors further contribute to the development of new onset or progression of atrial arrhythmias, in particular, atrial fibrillation.
AB  - SUMMARY: Left atrial function is an integral part of cardiac function and its structural and functional changes in heart failure are common. As changes of left atrial structure and function have different clinical implications in systolic heart failure and HFPEF, routine assessment is warranted.
ES  - 1531-7080
IL  - 0268-4705
DO  - http://dx.doi.org/10.1097/HCO.0000000000000091
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2014 Sep
DC  - 20140806
YR  - 2014
ED  - 20150512
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25032726

<142. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25010379
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Reed JL
AU  - Pipe AL
FA  - Reed, Jennifer L
FA  - Pipe, Andrew L
IN  - Reed,Jennifer L. Prevention and Rehabilitation Centre, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
TI  - The talk test: a useful tool for prescribing and monitoring exercise intensity. [Review]
SO  - Current Opinion in Cardiology. 29(5):475-80, 2014 Sep.
AS  - Curr Opin Cardiol. 29(5):475-80, 2014 Sep.
NJ  - Current opinion in cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - bda, 8608087
SB  - Index Medicus
CP  - United States
MH  - Atrial Fibrillation/rh [Rehabilitation]
MH  - *Exercise/ph [Physiology]
MH  - *Exercise Test
MH  - Heart Rate
MH  - Humans
MH  - *Speech/ph [Physiology]
MH  - Validation Studies as Topic
AB  - PURPOSE OF REVIEW: This review focuses on recent literature examining the validity and reliability of the talk test for prescribing and monitoring exercise intensity. The utility of the talk test for high-intensity interval training and recently proposed exercise training guidelines for patients with atrial fibrillation is also examined.
AB  - RECENT FINDINGS: In healthy adults and patients with cardiovascular disease, comfortable speech is likely possible (equivocal or last positive talk test stage) when exercise intensity is below the ventilatory or lactate threshold, and not likely possible (negative talk test stage) when exercise intensity exceeds the ventilatory or lactate threshold. The talk test can be used to produce exercise intensities (moderate-to-vigorous intensity, 40-80% (Equation is included in full-text article.)) within accepted Canadian Association of Cardiovascular Prevention and Rehabilitation and American College of Sports Medicine guidelines for exercise training, to monitor exercise training for patients with atrial fibrillation, and help avoid exertional ischemia. The talk test has been shown to be consistent across various modes of exercise (i.e., walking, jogging, cycling, elliptical trainer and stair stepper). It may not be practical for high-intensity interval training.
AB  - SUMMARY: The talk test is a valid, reliable, practical and inexpensive tool for prescribing and monitoring exercise intensity in competitive athletes, healthy active adults and patients with cardiovascular disease. Healthcare professionals should feel comfortable in advocating its use in a variety of clinical and health-promotion settings.
ES  - 1531-7080
IL  - 0268-4705
DO  - http://dx.doi.org/10.1097/HCO.0000000000000097
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2014 Sep
DC  - 20140806
YR  - 2014
ED  - 20150512
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25010379

<143. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25779474
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Sherzai AZ
AU  - Elkind MS
FA  - Sherzai, Ayesha Z
FA  - Elkind, Mitchell S V
IN  - Sherzai,Ayesha Z. Departments of Neurology and Epidemiology, Columbia University Medical Center, New York, New York.
TI  - Advances in stroke prevention. [Review]
SO  - Annals of the New York Academy of Sciences. 1338:1-15, 2015 Mar.
AS  - Ann N Y Acad Sci. 1338:1-15, 2015 Mar.
NJ  - Annals of the New York Academy of Sciences
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 5nm, 7506858
SB  - Index Medicus
CP  - United States
MH  - Atrial Fibrillation/co [Complications]
MH  - Health Behavior
MH  - Humans
MH  - Hypertension/co [Complications]
MH  - Primary Prevention
MH  - Risk Factors
MH  - Secondary Prevention
MH  - Stroke/et [Etiology]
MH  - *Stroke/pc [Prevention & Control]
KW  - epidemiology;  prevention;  risk factors;  stroke
AB  - Stroke remains to be a leading cause of disability. However, optimal strategies can prevent up to 80% of strokes. A large body of evidence supports many strategies for primary and secondary prevention of stroke. The purpose of this paper is to highlight recent major advances for management of modifiable medical and behavioral risk factors of stroke. Specific studies are highlighted, including those related to atrial fibrillation (AF), hypertension, revascularization, hyperlipidemia, antiplatelets, smoking, diet, and physical activity. Effective strategies include the use of novel oral anticoagulants for AF, antiplatelet therapy, and intensive lowering of atherosclerosis risk factors. Copyright © 2015 New York Academy of Sciences.
ES  - 1749-6632
IL  - 0077-8923
DO  - http://dx.doi.org/10.1111/nyas.12723
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
NO  - T32NS07153 (United States NINDS NIH HHS)
LG  - English
DP  - 2015 Mar
DC  - 20150317
YR  - 2015
ED  - 20150511
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25779474

<144. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25326443
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Magne J
AU  - Donal E
AU  - Mahjoub H
AU  - Miltner B
AU  - Dulgheru R
AU  - Thebault C
AU  - Pierard LA
AU  - Pibarot P
AU  - Lancellotti P
FA  - Magne, Julien
FA  - Donal, Erwan
FA  - Mahjoub, Haifa
FA  - Miltner, Beatrice
FA  - Dulgheru, Raluca
FA  - Thebault, Christophe
FA  - Pierard, Luc A
FA  - Pibarot, Philippe
FA  - Lancellotti, Patrizio
IN  - Magne,Julien. Department of Cardiology, University of Liege Hospital, GIGA Cardiovascular Sciences, Heart Valve Clinic, CHU Sart Tilman, Liege, Belgium.
IN  - Donal,Erwan. Cardiologie & CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France LTSI, Universite Rennes 1, INSERM 1099, Rennes, France.
IN  - Mahjoub,Haifa. Quebec Heart and Lung Institute, Quebec, Canada.
IN  - Miltner,Beatrice. Department of Cardiology, University of Liege Hospital, GIGA Cardiovascular Sciences, Heart Valve Clinic, CHU Sart Tilman, Liege, Belgium.
IN  - Dulgheru,Raluca. Department of Cardiology, University of Liege Hospital, GIGA Cardiovascular Sciences, Heart Valve Clinic, CHU Sart Tilman, Liege, Belgium.
IN  - Thebault,Christophe. Cardiologie & CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France LTSI, Universite Rennes 1, INSERM 1099, Rennes, France.
IN  - Pierard,Luc A. Department of Cardiology, University of Liege Hospital, GIGA Cardiovascular Sciences, Heart Valve Clinic, CHU Sart Tilman, Liege, Belgium.
IN  - Pibarot,Philippe. Quebec Heart and Lung Institute, Quebec, Canada.
IN  - Lancellotti,Patrizio. Department of Cardiology, University of Liege Hospital, GIGA Cardiovascular Sciences, Heart Valve Clinic, CHU Sart Tilman, Liege, Belgium.
TI  - Impact of exercise pulmonary hypertension on postoperative outcome in primary mitral regurgitation.
SO  - Heart. 101(5):391-6, 2015 Mar.
AS  - Heart. 101(5):391-6, 2015 Mar.
NJ  - Heart (British Cardiac Society)
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9602087
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - Age Factors
MH  - Aged
MH  - Asymptomatic Diseases
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - Belgium/ep [Epidemiology]
MH  - *Echocardiography, Stress
MH  - Female
MH  - Follow-Up Studies
MH  - France/ep [Epidemiology]
MH  - Heart Atria/us [Ultrasonography]
MH  - Heart Failure/mo [Mortality]
MH  - Heart Ventricles/us [Ultrasonography]
MH  - Hospitalization/sn [Statistics & Numerical Data]
MH  - Humans
MH  - *Hypertension, Pulmonary/ep [Epidemiology]
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve Insufficiency/ep [Epidemiology]
MH  - *Mitral Valve Insufficiency/su [Surgery]
MH  - Multivariate Analysis
MH  - *Postoperative Complications/ep [Epidemiology]
MH  - Prospective Studies
MH  - Quebec/ep [Epidemiology]
MH  - Stroke/ep [Epidemiology]
KW  - VALVULAR DISEASE
AB  - AIMS: The management of asymptomatic patients with mitral regurgitation (MR) remains controversial. Exercise-induced pulmonary hypertension (ExPHT) was recently reported as a strong predictor of rapid onset of symptoms. We hypothesised that ExPHT is a predictor of postoperative cardiovascular events in patients with primary MR.
AB  - METHODS AND RESULTS: One hundred and two patients with primary MR, no or mild symptoms (New York heart association (NYHA) <2), and no LV dysfunction/dilatation, were prospectively recruited in 3 centres and underwent exercise-stress echocardiography. The presence of ExPHT was defined as an exercise systolic pulmonary arterial pressure >60 mm Hg. All patients were closely followed up and operated on when indication for surgery was reached. Postoperative events were defined as the occurrence of atrial fibrillation (AF), stroke, cardiac-related hospitalisation or death. Among the 102 patients included, 59 developed ExPHT (58%). These patients were significantly older than those without ExPHT (p=0.01). During a mean postoperative follow-up of 50+/-23 months, 28 patients (26%) experienced a predefined cardiovascular event. Patients with ExPHT had significantly higher rate of postoperative events (39% vs 12%, p=0.005); the rate of events was still higher in these patients (32% vs 9%, p=0.013), even when excluding early postoperative AF (ie, within 48 h). Event-free survival was significantly lower in the ExPHT group (all events: 5-year: 60+/-8% vs 88+/-5%, p=0.007, events without early AF: 5-year: 67+/-7% vs 90+/-4%, p=0.02). Using Cox multivariable analysis, ExPHT remained independently associated with higher risk of postoperative events in all models (all p<0.04).
AB  - CONCLUSIONS: ExPHT is associated with increased risk of adverse cardiac events following mitral valve surgery in patients with primary MR.Copyright Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
ES  - 1468-201X
IL  - 1355-6037
DO  - http://dx.doi.org/10.1136/heartjnl-2014-306296
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
NO  - 102737 (Canada Canadian Institutes of Health Research)
LG  - English
EP  - 20141017
DP  - 2015 Mar
DC  - 20150214
YR  - 2015
ED  - 20150511
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25326443

<145. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24993310
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Chuang SY
AU  - Wu CC
AU  - Hsu PF
AU  - Chia-Yu Chen R
AU  - Liu WL
AU  - Hsu YY
AU  - Pan WH
FA  - Chuang, S-Y
FA  - Wu, C-C
FA  - Hsu, P-F
FA  - Chia-Yu Chen, R
FA  - Liu, W-L
FA  - Hsu, Y-Y
FA  - Pan, W-H
IN  - Chuang,S-Y. Institute of Population Health Sciences, National Health Research Institutes, Miaoli, Taiwan.
IN  - Wu,C-C. Department of Medicine, Branch of Hsinchu, National Taiwan University Hospital, Taiwan; School of Medicine, National Yang-Ming University, Taipei, Taiwan.
IN  - Hsu,P-F. School of Medicine, National Yang-Ming University, Taipei, Taiwan; Healthcare and Management Center, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Medicine, National Yang-Ming University, Taiwan.
IN  - Chia-Yu Chen,R. Institute of Population Health Sciences, National Health Research Institutes, Miaoli, Taiwan.
IN  - Liu,W-L. Institute of Population Health Sciences, National Health Research Institutes, Miaoli, Taiwan.
IN  - Hsu,Y-Y. Institute of Population Health Sciences, National Health Research Institutes, Miaoli, Taiwan.
IN  - Pan,W-H. Institute of Population Health Sciences, National Health Research Institutes, Miaoli, Taiwan; Institute of Epidemiology and Institute of Microbiology and Biochemistry, National Taiwan University, Taipei, Taiwan; School of Public Health, Department of medicine, National Yang Ming University, Taipei, Taiwan; Institute of BioMedical Sciences, Academia Sinica, Taipei, Taiwan. Electronic address: pan@ibms.sinica.edu.tw.
TI  - Hyperuricemia and incident atrial fibrillation in a normotensive elderly population in Taiwan.
SO  - Nutrition Metabolism & Cardiovascular Diseases. 24(9):1020-6, 2014 Sep.
AS  - Nutr Metab Cardiovasc Dis. 24(9):1020-6, 2014 Sep.
NJ  - Nutrition, metabolism, and cardiovascular diseases : NMCD
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9111474, DGW
SB  - Index Medicus
CP  - Netherlands
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - *Blood Pressure/ph [Physiology]
MH  - Electrocardiography
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hypertension/dt [Drug Therapy]
MH  - *Hypertension/ep [Epidemiology]
MH  - Hyperuricemia/co [Complications]
MH  - *Hyperuricemia/ep [Epidemiology]
MH  - Incidence
MH  - Male
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Risk Factors
MH  - Surveys and Questionnaires
MH  - Taiwan/ep [Epidemiology]
MH  - Uric Acid/bl [Blood]
KW  - Atrial fibrillation;  Elderly population;  Hyperuricemia
AB  - BACKGROUND AND AIM: Atrial fibrillation (AF) is an important cardiovascular disease in the elderly. The association between hyperuricemia and AF is unclear. Therefore, we aimed to investigate the prospective relationship between uric acid and development of AF in a nationally representative cohort of elderly people.
AB  - METHODS AND RESULTS: A total of 1485 elderly people (age > 65 yrs) from the Elderly Nutrition and Health Survey in Taiwan (1999-2000) were without AF on "electrocardiography" at baseline. Incident AF events (International Classification of Diseases, Ninth Revision, Clinical Modification, ICD-9-CM: 427.31) were identified using data from the National Health Insurance Dataset. Hyperuricemia was defined as levels of uric acid >7.0 mg/dL in men and 6.0 mg/dL in women. A Cox proportional hazards model was used to evaluate the association between hyperuricemia and incident AF. The follow-up period was from 1999 to 2000 to 2008. During the follow-up period (median: 9.16 yrs), 90 AF events occurred (44 in men and 46 in women). Older age, elevated systolic blood pressure, being an ex-smoker, and high uric acid were positively associated with incident AF. Hyperuricemia was positively associated with incident AF in normotensive (age-adjusted hazard ratio (HR): 2.65 and 95% confidence intervals: 1.05-6.69), but not in (1.20:0.74-1.94) hypertensive individuals (systolic blood pressure >130 or diastolic blood pressure >85 or using hypertensive medicine). A significant association between hyperuricemia and AF (3.78; 1.24-11.59) remained after adjusting for other potential confounders among normotensive older persons.
AB  - CONCLUSION: Hyperuricemia is associated with the development of AF in elderly people with normal blood pressure.Copyright © 2014 Elsevier B.V. All rights reserved.
RN  - 268B43MJ25 (Uric Acid)
ES  - 1590-3729
IL  - 0939-4753
DI  - S0939-4753(14)00135-5
DO  - http://dx.doi.org/10.1016/j.numecd.2014.03.012
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20140513
DP  - 2014 Sep
DC  - 20140811
YR  - 2014
ED  - 20150511
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24993310

<146. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25779474
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Sherzai AZ
AU  - Elkind MS
FA  - Sherzai, Ayesha Z
FA  - Elkind, Mitchell S V
IN  - Sherzai,Ayesha Z. Departments of Neurology and Epidemiology, Columbia University Medical Center, New York, New York.
TI  - Advances in stroke prevention. [Review]
SO  - Annals of the New York Academy of Sciences. 1338:1-15, 2015 Mar.
AS  - Ann N Y Acad Sci. 1338:1-15, 2015 Mar.
NJ  - Annals of the New York Academy of Sciences
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 5nm, 7506858
SB  - Index Medicus
CP  - United States
MH  - Atrial Fibrillation/co [Complications]
MH  - Health Behavior
MH  - Humans
MH  - Hypertension/co [Complications]
MH  - Primary Prevention
MH  - Risk Factors
MH  - Secondary Prevention
MH  - Stroke/et [Etiology]
MH  - *Stroke/pc [Prevention & Control]
KW  - epidemiology;  prevention;  risk factors;  stroke
AB  - Stroke remains to be a leading cause of disability. However, optimal strategies can prevent up to 80% of strokes. A large body of evidence supports many strategies for primary and secondary prevention of stroke. The purpose of this paper is to highlight recent major advances for management of modifiable medical and behavioral risk factors of stroke. Specific studies are highlighted, including those related to atrial fibrillation (AF), hypertension, revascularization, hyperlipidemia, antiplatelets, smoking, diet, and physical activity. Effective strategies include the use of novel oral anticoagulants for AF, antiplatelet therapy, and intensive lowering of atherosclerosis risk factors. Copyright © 2015 New York Academy of Sciences.
ES  - 1749-6632
IL  - 0077-8923
DO  - http://dx.doi.org/10.1111/nyas.12723
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
NO  - T32NS07153 (United States NINDS NIH HHS)
LG  - English
DP  - 2015 Mar
DC  - 20150317
YR  - 2015
ED  - 20150511
RD  - 20160127
UP  - 20160129
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=25779474

<147. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22951852
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Akgullu C
AU  - Erdogan E
FA  - Akgullu, Cagdas
FA  - Erdogan, Ercan
IN  - Akgullu,Cagdas. Department of Cardiology Adnan Menderes University Faculty of Medicine, Aydin, Turkey. cagdasakgullu@gmail.com
TI  - Adult patient with Shone's syndrome and patent ductus arteriosus: a case report.
SO  - Turk Kardiyoloji Dernegi Arsivi. 40(4):350-3, 2012 Jun.
AS  - TURK KARDIYOLOJI DERNEGI ARS.. 40(4):350-3, 2012 Jun.
NJ  - Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9426239
SB  - Index Medicus
CP  - Turkey
MH  - Adult
MH  - Aortic Coarctation
MH  - Aortic Stenosis, Supravalvular
MH  - Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/th [Therapy]
MH  - Discrete Subaortic Stenosis/su [Surgery]
MH  - Diuretics/ad [Administration & Dosage]
MH  - Ductus Arteriosus, Patent/co [Complications]
MH  - *Ductus Arteriosus, Patent/di [Diagnosis]
MH  - Ductus Arteriosus, Patent/us [Ultrasonography]
MH  - Dyspnea
MH  - Electric Countershock
MH  - Exercise/ph [Physiology]
MH  - Heart Defects, Congenital/co [Complications]
MH  - *Heart Defects, Congenital/di [Diagnosis]
MH  - Heart Defects, Congenital/us [Ultrasonography]
MH  - Humans
MH  - Male
MH  - Mitral Valve Prolapse/su [Surgery]
MH  - Syndrome
MH  - Treatment Refusal
AB  - Shone's syndrome is a very rare cardiac malformation composed of four obstructive congenital lesions, which include the parachute mitral valve (PMV), supravalvular ring, subaortic stenosis, and coarctation of aorta. Diagnosis requires a comprehensive examination including a carefully performed echocardiography. It is extremely unusual for a patient to remain undiagnosed during adulthood. Here we report a 26-year-old male patient with Shone's syndrome and patent ductus arteriosus (PDA). The patient reported that he had been suffering from exercise intolerance and aggravating dyspnea. Two years ago, he was operated on in another hospital based on the wrong diagnosis of mitral valve prolapse and subaortic membrane. Transthoracic echocardiography revealed the existence of a PMV, which led to severe mitral stenosis through a previously implanted mitral annular ring. Other components of Shone's syndrome, subaortic membrane and aortic coarctation, together with PDA, were also observed. Another operation was suggested, but the patient refused. During the two year follow-up period, in spite of an atrial fibrillation attack and deteriorating dyspnea, the patient still did not want another operation. Once any of the four components of the Shone's complex is detected, clinicians must look for the presence of other lesions.
RN  - 0 (Diuretics)
IS  - 1016-5169
IL  - 1016-5169
DO  - http://dx.doi.org/10.5543/tkda.2012.27003
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2012 Jun
DC  - 20120906
YR  - 2012
ED  - 20150508
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22951852

<148. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24930651
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Fukuoka T
AU  - Hayashi T
AU  - Kato Y
AU  - Ohe Y
AU  - Deguchi I
AU  - Maruyama H
AU  - Horiuchi Y
AU  - Sano H
AU  - Nagamine Y
AU  - Tanahashi N
FA  - Fukuoka, Takuya
FA  - Hayashi, Takeshi
FA  - Kato, Yuji
FA  - Ohe, Yasuko
FA  - Deguchi, Ichiro
FA  - Maruyama, Hajime
FA  - Horiuchi, Yohsuke
FA  - Sano, Hiroyasu
FA  - Nagamine, Yuito
FA  - Tanahashi, Norio
IN  - Fukuoka,Takuya. Department of Neurology, Saitama Medical University International Medical Center, Japan.
TI  - Clinical review of 24 patients with acute cholecystitis after acute cerebral infarction.
SO  - Internal Medicine. 53(12):1321-3, 2014.
AS  - Intern Med. 53(12):1321-3, 2014.
NJ  - Internal medicine (Tokyo, Japan)
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - bd6, 9204241
SB  - Index Medicus
CP  - Japan
MH  - Acute Disease
MH  - Aged
MH  - Aged, 80 and over
MH  - *Cerebral Infarction/co [Complications]
MH  - Cerebral Infarction/di [Diagnosis]
MH  - Cerebral Infarction/th [Therapy]
MH  - *Cholecystitis, Acute/di [Diagnosis]
MH  - *Cholecystitis, Acute/et [Etiology]
MH  - Cholecystitis, Acute/th [Therapy]
MH  - Cohort Studies
MH  - Fasting
MH  - Female
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Paresis/et [Etiology]
MH  - Risk Factors
AB  - OBJECTIVE: Acute cholecystitis (AC) after acute cerebral infarction is rare and has not been fully investigated. Because patients with acute cerebral infarction often cannot complain of abdominal pain due to loss of consciousness, hemiparesis and aphasia, delays in diagnosis may increase the severity of the condition. It is clearly important to identify symptoms, reach a diagnosis and provide treatment as soon as possible. The purpose of this study was to investigate the clinical features of AC after acute cerebral infarction.
AB  - METHODS: Among the 1,682 patients with acute cerebral infarction admitted to our hospital between April 2007 and July 2012, AC after acute cerebral infarction was diagnosed in 24 (1.4%). Data regarding age, sex, past history, fasting period, period from admission to the onset of cholecystitis, clinical type, severity of cholecystitis, diffusion-weighted imaging Alberta Stroke Program Early Computed Tomography Score, National Institutes of Health Stroke Scale (NIHSS) score at onset and modified Rankin scale at 90 days were investigated.
AB  - RESULTS: The mean age of the 24 patients (15 men, 9 women) was 74.2+/-11.9 years (range, 45-90 years). The clinical type was atherothrombosis in five patients, lacunar infarction in seven patients, cardiac embolism in 10 patients and dissection in two patients. The past history included atrial fibrillation in 10 (42%) patients, hypertension in 20 (83%) patients and diabetes in 11 (46%) patients. The mean duration of fasting was 10.7 days (range, 1-32 days). The mean interval between the onset of cholecystitis and admission was 8.3 days (range, 0-24 days). The median NIHSS score at onset of cerebral infarction was 10, and 23 (96%) patients were bedridden at the onset of cholecystitis.
AB  - CONCLUSION: AC after acute cerebral infarction was frequently observed in the patients with severe hemiparesis and those who were fasted. It is important to identify symptoms, accurately diagnose the condition and provide treatment as soon as possible in order to achieve early ambulation and resumption of food intake using a feeding tube.
ES  - 1349-7235
IL  - 0918-2918
PT  - Journal Article
LG  - English
EP  - 20140615
DP  - 2014
DC  - 20140616
YR  - 2014
ED  - 20150504
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24930651

<149. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24496251
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Darnell SW
AU  - Davis SC
AU  - Whitcomb JJ
AU  - Manfredi JA
AU  - McLaurin BT
FA  - Darnell, Stan W
FA  - Davis, Stephanie C
FA  - Whitcomb, John J
FA  - Manfredi, Joseph A
FA  - McLaurin, Brent T
IN  - Darnell,Stan W. Stan W. Darnell, MS, APRN, AGPCNP-BC, CCRN, is an adult-gerontology nurse practitioner at the Southeastern Neurosurgical & Spine Institute of the Greenville Health System, South Carolina. Stephanie C. Davis, PhD, RN, FNP, BC, is graduate coordinator and associate professor at Clemson University School of Nursing, South Carolina. John J. Whitcomb, PhD, RN, CCRN, FCCM, is second degree coordinator and assistant professor at Clemson University School of Nursing, South Carolina. Joseph A. Manfredi, MD, is a clinical cardiac electrophysiologist at AnMed Health Arrhythmia Specialists, Anderson, South Carolina. Brent T. McLaurin, MD, is a cardiologist at Anderson Heart, AnMed Health, Anderson, South Carolina. He also serves as director for the Research Division at Anderson Heart and the AnMed Research Division.
TI  - Bleeding risk factors affecting warfarin therapy in the elderly with atrial fibrillation. [Review]
SO  - DCCN - Dimensions of Critical Care Nursing. 33(2):57-63, 2014 Mar-Apr.
AS  - DCCN. 33(2):57-63, 2014 Mar-Apr.
NJ  - Dimensions of critical care nursing : DCCN
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 8211489
SB  - Nursing Journal
CP  - United States
MH  - Aged
MH  - Anticoagulants/ae [Adverse Effects]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Aspirin/ae [Adverse Effects]
MH  - Aspirin/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Critical Care Nursing
MH  - *Hemorrhage/ci [Chemically Induced]
MH  - *Hemorrhage/pc [Prevention & Control]
MH  - Humans
MH  - Risk Factors
MH  - Stroke/pp [Physiopathology]
MH  - Stroke/pc [Prevention & Control]
MH  - Warfarin/ae [Adverse Effects]
MH  - *Warfarin/tu [Therapeutic Use]
AB  - PURPOSE: Inadequate anticoagulation among elderly individuals with atrial fibrillation (AF) is a common problem. This synthesis of the literature review describes the pathophysiology of AF, explains the mechanism of action of warfarin (Coumadin), identifies factors that contribute to warfarin (Coumadin)-associated bleeding in the elderly population, and explores alternatives to warfarin (Coumadin) therapy. Implications for advanced practice nurse practice, education, and research will be discussed.
AB  - METHODS: A literature search was conducted using Academic Search Premier, CINAHL Plus with Full Text, and Medline from 1999 to 2012. Search terms included warfarin (Coumadin), warfarin (Coumadin) genetics, diet, interactions, bleeding, atrial fibrillation, genetics, anticoagulation clinic, dabigatran, apixaban, rivaroxaban, and elderly.
AB  - RESULTS: The literature indicates that the potential bleeding risk associated with warfarin (Coumadin) therapy limits its use in the elderly population. However, some studies have found warfarin (Coumadin) to be more effective than aspirin in preventing stroke. The safety profiles of both medications were comparable; also, effective alternatives to warfarin (Coumadin) that do not require routine testing are now available.
AB  - CONCLUSIONS: Atrial fibrillation increases the probability of an embolic stroke, especially for the elderly population. Stroke risk and bleeding risk tools, in conjunction with patient preference, determine the best stroke prevention treatment. Anticoagulant clinics manage long-term warfarin (Coumadin) therapy effectively. Newer anticoagulants offer effective alternatives to warfarin (Coumadin) therapy.
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
ES  - 1538-8646
IL  - 0730-4625
DO  - http://dx.doi.org/10.1097/DCC.0000000000000022
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2014 Mar-Apr
DC  - 20140205
YR  - 2014
ED  - 20150413
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24496251

<150. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25016562
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wang W
AU  - Zhang F
AU  - Xhen J
AU  - Chen X
AU  - Fu F
AU  - Tang M
AU  - Chen L
FA  - Wang, Weiwei
FA  - Zhang, Feilong
FA  - Xhen, Jianhua
FA  - Chen, Xuehai
FA  - Fu, Fayuan
FA  - Tang, Mirong
FA  - Chen, Lianglong
IN  - Wang,Weiwei. Union Hospital, Union Clinic Medical College, Fujian Medical University, Fuzhou, People's Republic of China.
IN  - Zhang,Feilong. Union Hospital, Union Clinic Medical College, Fujian Medical University, Fuzhou, People's Republic of China.
IN  - Xhen,Jianhua. Union Hospital, Union Clinic Medical College, Fujian Medical University, Fuzhou, People's Republic of China.
IN  - Chen,Xuehai. Union Hospital, Union Clinic Medical College, Fujian Medical University, Fuzhou, People's Republic of China.
IN  - Fu,Fayuan. Union Hospital, Union Clinic Medical College, Fujian Medical University, Fuzhou, People's Republic of China.
IN  - Tang,Mirong. Union Hospital, Union Clinic Medical College, Fujian Medical University, Fuzhou, People's Republic of China.
IN  - Chen,Lianglong. Union Hospital, Union Clinic Medical College, Fujian Medical University, Fuzhou, People's Republic of China. Electronic address: lianglongchenxhyy@126.com.
TI  - P-wave dispersion and maximum duration are independently associated with insulin resistance in metabolic syndrome.
SO  - Annales d Endocrinologie. 75(3):156-61, 2014 Jul.
AS  - Ann Endocrinol (Paris). 75(3):156-61, 2014 Jul.
NJ  - Annales d'endocrinologie
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 54o, 0116744
SB  - Index Medicus
CP  - France
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Blood Glucose/an [Analysis]
MH  - Body Mass Index
MH  - Cross-Sectional Studies
MH  - Echocardiography
MH  - *Electrocardiography
MH  - Fasting
MH  - Female
MH  - Humans
MH  - *Insulin Resistance
MH  - Male
MH  - *Metabolic Syndrome X/pp [Physiopathology]
MH  - Middle Aged
MH  - Risk Factors
MH  - Waist Circumference
KW  - Atrial conduction;  Conduction auriculaire;  Dispersion des ondes P;  Insulin resistance;  Metabolic syndrome;  P-wave dispersion;  Resistance a l'insuline;  Syndrome metabolique
AB  - BACKGROUND: Metabolic syndrome (MS) is an important risk factor for atrial fibrillation. P-wave indices, including P-wave dispersion (PWD) and P-wave duration, can be used as non-invasive markers of heterogeneous atrial conduction. The aim of our study was to evaluate the relationship between P-wave indices and insulin resistance in patients with MS.
AB  - METHODS: Seventy-four patients with MS (44 men, 30 women) and 81 patients without MS (48 men, 33 women) were enrolled in the study. A diagnosis of MS was made as defined by the Adult Treatment Panel III of the National Cholesterol Education Program. Insulin resistance was estimated using the homeostasis model assessment (HOMA) index. P-wave maximum duration (Pmax) and P-wave minimum duration (Pmin) were calculated on a 12-lead electrocardiogram, and the difference between the Pmax and the Pmin was defined as PWD.
AB  - RESULTS: Patients with MS had a longer PWD and a higher Pmax compared with patients without MS (PWD, 35.65+/-4.36 vs. 26.27+/-4.04, P<0.001; Pmax, 117.12+/-10.77 vs. 105.98+/-9.02, P<0.001), whereas no difference was found between Pmin values from MS patients and controls (81.47+/-9.54 vs. 79.70+/-8.76, P=0.231). Stepwise multivariate analysis revealed only the HOMA index to be an independent predictor of PWD (beta=3.115, P<0.001) and Pmax (beta=7.175, P<0.001).
AB  - CONCLUSION: This study suggests that patients with MS have a prolonged PWD and Pmax. The increase in these parameters may be an indicator for identification of patients at an increased risk for atrial fibrillation.Copyright © 2014. Published by Elsevier Masson SAS.
RN  - 0 (Blood Glucose)
IS  - 0003-4266
IL  - 0003-4266
DI  - S0003-4266(14)00070-5
DO  - http://dx.doi.org/10.1016/j.ando.2014.05.004
PT  - Journal Article
LG  - English
EP  - 20140709
DP  - 2014 Jul
DC  - 20140811
YR  - 2014
ED  - 20150410
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25016562

<151. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24560692
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Corradi D
AU  - Callegari S
AU  - Manotti L
AU  - Ferrara D
AU  - Goldoni M
AU  - Alinovi R
AU  - Pinelli S
AU  - Mozzoni P
AU  - Andreoli R
AU  - Asimaki A
AU  - Pozzoli A
AU  - Becchi G
AU  - Mutti A
AU  - Benussi S
AU  - Saffitz JE
AU  - Alfieri O
FA  - Corradi, Domenico
FA  - Callegari, Sergio
FA  - Manotti, Laura
FA  - Ferrara, David
FA  - Goldoni, Matteo
FA  - Alinovi, Rossella
FA  - Pinelli, Silvana
FA  - Mozzoni, Paola
FA  - Andreoli, Roberta
FA  - Asimaki, Angeliki
FA  - Pozzoli, Alberto
FA  - Becchi, Gabriella
FA  - Mutti, Antonio
FA  - Benussi, Stefano
FA  - Saffitz, Jeffrey E
FA  - Alfieri, Ottavio
IN  - Corradi,Domenico. Department of Biomedical, Biotechnological, and Translational Sciences (S.Bi.Bi.T.), Unit of Pathology, University of Parma, Parma, Italy. Electronic address: domenico.corradi@unipr.it.
IN  - Callegari,Sergio. Division of Cardiology, Vaio Hospital, Fidenza, Italy.
IN  - Manotti,Laura. Department of Biomedical, Biotechnological, and Translational Sciences (S.Bi.Bi.T.), Unit of Pathology, University of Parma, Parma, Italy.
IN  - Ferrara,David. Cardiothoracic Surgery Unit, Department of Cardiology, San Raffaele University Hospital, Milan, Italy.
IN  - Goldoni,Matteo. Department of Clinical and Experimental Medicine, Laboratory of Industrial Toxicology, University of Parma, Parma, Italy.
IN  - Alinovi,Rossella. Department of Clinical and Experimental Medicine, Laboratory of Industrial Toxicology, University of Parma, Parma, Italy.
IN  - Pinelli,Silvana. Department of Clinical and Experimental Medicine, Laboratory of Industrial Toxicology, University of Parma, Parma, Italy.
IN  - Mozzoni,Paola. Department of Clinical and Experimental Medicine, Laboratory of Industrial Toxicology, University of Parma, Parma, Italy; Italian Workers' Compensation Authority (INAIL) Research Center at the University of Parma, Parma, Italy.
IN  - Andreoli,Roberta. Department of Clinical and Experimental Medicine, Laboratory of Industrial Toxicology, University of Parma, Parma, Italy; Italian Workers' Compensation Authority (INAIL) Research Center at the University of Parma, Parma, Italy.
IN  - Asimaki,Angeliki. Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
IN  - Pozzoli,Alberto. Cardiothoracic Surgery Unit, Department of Cardiology, San Raffaele University Hospital, Milan, Italy.
IN  - Becchi,Gabriella. Department of Biomedical, Biotechnological, and Translational Sciences (S.Bi.Bi.T.), Unit of Pathology, University of Parma, Parma, Italy.
IN  - Mutti,Antonio. Department of Clinical and Experimental Medicine, Laboratory of Industrial Toxicology, University of Parma, Parma, Italy.
IN  - Benussi,Stefano. Cardiothoracic Surgery Unit, Department of Cardiology, San Raffaele University Hospital, Milan, Italy.
IN  - Saffitz,Jeffrey E. Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
IN  - Alfieri,Ottavio. Cardiothoracic Surgery Unit, Department of Cardiology, San Raffaele University Hospital, Milan, Italy.
TI  - Persistent lone atrial fibrillation: clinicopathologic study of 19 cases.
SO  - Heart Rhythm. 11(7):1250-8, 2014 Jul.
AS  - Heart Rhythm. 11(7):1250-8, 2014 Jul.
NJ  - Heart rhythm : the official journal of the Heart Rhythm Society
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101200317
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - Atrial Fibrillation/me [Metabolism]
MH  - *Atrial Fibrillation/pa [Pathology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Remodeling
MH  - Biomarkers/me [Metabolism]
MH  - Female
MH  - *Heart Atria/pa [Pathology]
MH  - Heart Atria/pp [Physiopathology]
MH  - Humans
MH  - Inflammation/me [Metabolism]
MH  - Male
MH  - Middle Aged
MH  - *Myocardium/pa [Pathology]
MH  - Oxidative Stress
KW  - Atrial cardiomyocyte;  Lone atrial fibrillation;  Pathology;  Remodeling;  Structure
AB  - BACKGROUND: The extent to which atrial myocardium is remodeled in patients with persistent lone atrial fibrillation (LAF) is largely unknown.
AB  - OBJECTIVE: The purpose of this study was to perform a clinicopathologic investigation in patients with persistent LAF.
AB  - METHODS: We characterized structural and molecular remodeling in atrial biopsies from 19 patients (17 males, mean age 49 years) with persistent (>7 days; n = 8) or long-lasting persistent (>1 year; n = 11) LAF who underwent surgical ablation. Atrial tissue from 15 autopsy samples without clinicopathologic evidence of heart disease served as controls.
AB  - RESULTS: Morphometric analysis showed cardiomyocyte hypertrophy and greater amounts of myolytic damage and interstitial fibrosis in persistent LAF patients compared to controls (P <.0001). Atrial tissue levels of heme oxygenase-1 and 3-nitrotyrosine were increased in persistent LAF patients (P <.001), consistent with oxidative stress. Levels of superoxide dismutase-2, interleukin-8, interleukin-10, tumor necrosis factor-alpha, and thiobarbituric acid reactive substance were greater in controls than in persistent LAF patients. Immunoreactive signal for connexin43 was reduced more frequently in persistent LAF patients than controls. There was no correlation between features of structural or molecular remodeling and clinical parameters, including persistent LAF duration.
AB  - CONCLUSION: In persistent LAF patients, the atria are modified by structural remodeling and molecular changes of oxidative stress. Tissue changes in persistent LAF appear to occur early after its onset and are qualitatively no different than those observed in patients with atrial fibrillation related to conventional risk factors. These findings suggest that different types of atrial fibrillation are associated with the same spectrum of tissue lesions. Early intervention to restore sinus rhythm in persistent LAF patients may prevent irreversible tissue change, especially interstitial fibrosis.Copyright © 2014 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.
RN  - 0 (Biomarkers)
ES  - 1556-3871
IL  - 1547-5271
DI  - S1547-5271(14)00128-3
DO  - http://dx.doi.org/10.1016/j.hrthm.2014.02.008
PT  - Journal Article
LG  - English
EP  - 20140218
DP  - 2014 Jul
DC  - 20140623
YR  - 2014
ED  - 20150330
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24560692

<152. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23587172
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Nasim S
AU  - Nadeem N
AU  - Zahidie A
AU  - Sharif T
FA  - Nasim, Sumera
FA  - Nadeem, Najaf
FA  - Zahidie, Aysha
FA  - Sharif, Tabbasum
TI  - Relationship between exercise induced dyspnea and functional capacity with doppler-derived diastolic function'.
SO  - BMC Research Notes. 6:150, 2013.
AS  - BMC Res Notes. 6:150, 2013.
NJ  - BMC research notes
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 101462768
OI  - Source: NLM. PMC3636105
SB  - Index Medicus
CP  - England
MH  - Adult
MH  - Diabetes Mellitus/pp [Physiopathology]
MH  - *Diastole
MH  - *Dyspnea/et [Etiology]
MH  - Dyspnea/pp [Physiopathology]
MH  - Echocardiography, Doppler
MH  - *Exercise
MH  - Female
MH  - Humans
MH  - Hypertension/pp [Physiopathology]
MH  - Male
MH  - Smoking
AB  - BACKGROUND: Dyspnea is the frequent cause of exercise intolerance and physical inactivity among patients referred for exercise tolerance test. Diastolic dysfunction has shown significant correlation with exercise capacity and exercise induced dyspnea. To find out the frequency of diastolic dysfunction (DD) and the relationships between impaired exercise capacity and exercise induced dyspnea with DD by Doppler-derived indices among patients referred for stress test in a tertiary care hospital of Karachi.
AB  - METHODS: For this study 135 consecutive patients who were referred for stress test at our non-invasive lab were screened for eligibility. Patients with valvular pathology, atrial fibrillation (AF) and coronary artery disease (CAD) were excluded. Stress test was performed on treadmill using Bruce protocol. Assessment of diastolic function as determined by trans-mitral flow velocity pattern was carried at baseline and at peak exercise. We evaluated impaired exercise capacity and exercise induced dyspnea using validated Borg Scale among study subjects.
AB  - RESULTS: Study subjects 88% were males, mean age was 46+/-16 years, BMI 27+/-5 kg/m2, prevalence of diabetes mellitus (DM) 15%, hypertension 28% and smoking 21%. Exercise induced DD occurred among 44.6%. Patients with exercise induced DD had lower exercise capacity (9.2 vs. 10.2 METS; p=0.04) and higher Borg Scale (5.2 vs. 4.0; p<0.001). DD at baseline was present in 25(26%) of patients so they were excluded from the study. Five patients develop ischemia during stress test so were also excluded. So final analysis was done on 105 patients. Among patients without DD at baseline, there was significant vicariate linear inverse correlation between post exercise E/A ratio and Borg scale (r=-0.23; p=0.02) and exercise capacity was assessed by exercise duration and MET (r-0.825; p=0.04). Multivariate regression analysis revealed post exercise E/A ratio as an independent determinant of severity of exercise induced dyspnea and impaired exercise tolerance.
AB  - CONCLUSION: DD is significantly associated with impaired functional capacity and dyspnea among patients referred for exercise tolerance test.
ES  - 1756-0500
IL  - 1756-0500
DO  - http://dx.doi.org/10.1186/1756-0500-6-150
PT  - Journal Article
LG  - English
EP  - 20130415
DP  - 2013
DC  - 20140805
YR  - 2013
ED  - 20150330
RD  - 20150427
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23587172

<153. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25784948
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Park J
AU  - Kim HS
AU  - Lee SM
AU  - Yoon K
AU  - Kim WS
AU  - Woo JS
AU  - Lee S
AU  - Kim JB
AU  - Kim W
FA  - Park, Jimin
FA  - Kim, Hyun Soo
FA  - Lee, Seung Min
FA  - Yoon, Kanghyun
FA  - Kim, Woo-Shik
FA  - Woo, Jong Shin
FA  - Lee, Sanghoon
FA  - Kim, Jin-Bae
FA  - Kim, Weon
IN  - Park,Jimin. Department of Acupuncture and Moxibustion, College of Korean Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea.
IN  - Kim,Hyun Soo. Division of Cardiology, Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea.
IN  - Lee,Seung Min. Department of Acupuncture and Moxibustion, College of Korean Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea.
IN  - Yoon,Kanghyun. Department of Acupuncture and Moxibustion, College of Korean Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea.
IN  - Kim,Woo-Shik. Division of Cardiology, Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea.
IN  - Woo,Jong Shin. Division of Cardiology, Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea.
IN  - Lee,Sanghoon. Department of Acupuncture and Moxibustion, College of Korean Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea.
IN  - Kim,Jin-Bae. Division of Cardiology, Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea.
IN  - Kim,Weon. Division of Cardiology, Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea.
TI  - Acupuncture antiarrhythmic effects on drug refractory persistent atrial fibrillation: study protocol for a randomized, controlled trial.
SO  - Evidence-Based Complementary & Alternative Medicine: eCAM. 2015:613970, 2015.
AS  - Evid Based Complement Alternat Med. 2015:613970, 2015.
NJ  - Evidence-based complementary and alternative medicine : eCAM
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - 101215021
OI  - Source: NLM. PMC4346697
CP  - United States
AB  - Background. Atrial fibrillation (AF) is the most common form of arrhythmia. Several trials have suggested that acupuncture may prevent AF. However, the efficacy of acupuncture for AF prevention has not been well investigated. Therefore, we designed a prospective, two-parallel-armed, participant and assessor blinded, randomized, sham-controlled clinical trial to investigate acupuncture in persistent AF (ACU-AF). Methods. A total of 80 participants will be randomly assigned to active acupuncture or sham acupuncture groups in a 1:1 ratio. Both groups will take the same antiarrhythmic medication during the study period. Patients will receive 10 sessions of acupuncture treatment once a week for 10 weeks. The primary endpoint is AF recurrence rate. Secondary endpoints are left atrium (LA) and left atrial appendage (LAA) changes in function and volume, and inflammatory biomarker changes. Ethics. This study protocol was approved by the institutional review boards (IRBs) of Kyung Hee University Hospital (number 1335-04). This trial is registered with clinicaltrials.gov NCT02110537.
IS  - 1741-427X
IL  - 1741-427X
DO  - http://dx.doi.org/10.1155/2015/613970
PT  - Journal Article
LG  - English
EP  - 20150217
DP  - 2015
DC  - 20150318
YR  - 2015
ED  - 20150318
RD  - 20150321
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=25784948

<154. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25713735
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Kanmanthareddy A
AU  - Reddy M
AU  - Ponnaganti G
AU  - Sanjani HP
AU  - Koripalli S
AU  - Adabala N
AU  - Buddam A
AU  - Janga P
AU  - Lakkireddy T
AU  - Bommana S
AU  - Vallakati A
AU  - Atkins D
AU  - Lakkireddy D
FA  - Kanmanthareddy, Arun
FA  - Reddy, Madhu
FA  - Ponnaganti, Gopi
FA  - Sanjani, Hari Priya
FA  - Koripalli, Sandeep
FA  - Adabala, Nivedita
FA  - Buddam, Avanija
FA  - Janga, Pramod
FA  - Lakkireddy, Thanmay
FA  - Bommana, Sudharani
FA  - Vallakati, Ajay
FA  - Atkins, Donita
FA  - Lakkireddy, Dhanunjaya
IN  - Kanmanthareddy,Arun. 1 School of Medicine, Creighton University, Omaha, Nebraska, USA ; 2 VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska, USA ; 3 The University of Kansas Medical Center and Hospital, Kansas City, Kansas, USA ; 4 Case Western Reserve University, MetroHealth Medical Center, Cleveland, Ohio, USA.
IN  - Reddy,Madhu. 1 School of Medicine, Creighton University, Omaha, Nebraska, USA ; 2 VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska, USA ; 3 The University of Kansas Medical Center and Hospital, Kansas City, Kansas, USA ; 4 Case Western Reserve University, MetroHealth Medical Center, Cleveland, Ohio, USA.
IN  - Ponnaganti,Gopi. 1 School of Medicine, Creighton University, Omaha, Nebraska, USA ; 2 VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska, USA ; 3 The University of Kansas Medical Center and Hospital, Kansas City, Kansas, USA ; 4 Case Western Reserve University, MetroHealth Medical Center, Cleveland, Ohio, USA.
IN  - Sanjani,Hari Priya. 1 School of Medicine, Creighton University, Omaha, Nebraska, USA ; 2 VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska, USA ; 3 The University of Kansas Medical Center and Hospital, Kansas City, Kansas, USA ; 4 Case Western Reserve University, MetroHealth Medical Center, Cleveland, Ohio, USA.
IN  - Koripalli,Sandeep. 1 School of Medicine, Creighton University, Omaha, Nebraska, USA ; 2 VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska, USA ; 3 The University of Kansas Medical Center and Hospital, Kansas City, Kansas, USA ; 4 Case Western Reserve University, MetroHealth Medical Center, Cleveland, Ohio, USA.
IN  - Adabala,Nivedita. 1 School of Medicine, Creighton University, Omaha, Nebraska, USA ; 2 VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska, USA ; 3 The University of Kansas Medical Center and Hospital, Kansas City, Kansas, USA ; 4 Case Western Reserve University, MetroHealth Medical Center, Cleveland, Ohio, USA.
IN  - Buddam,Avanija. 1 School of Medicine, Creighton University, Omaha, Nebraska, USA ; 2 VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska, USA ; 3 The University of Kansas Medical Center and Hospital, Kansas City, Kansas, USA ; 4 Case Western Reserve University, MetroHealth Medical Center, Cleveland, Ohio, USA.
IN  - Janga,Pramod. 1 School of Medicine, Creighton University, Omaha, Nebraska, USA ; 2 VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska, USA ; 3 The University of Kansas Medical Center and Hospital, Kansas City, Kansas, USA ; 4 Case Western Reserve University, MetroHealth Medical Center, Cleveland, Ohio, USA.
IN  - Lakkireddy,Thanmay. 1 School of Medicine, Creighton University, Omaha, Nebraska, USA ; 2 VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska, USA ; 3 The University of Kansas Medical Center and Hospital, Kansas City, Kansas, USA ; 4 Case Western Reserve University, MetroHealth Medical Center, Cleveland, Ohio, USA.
IN  - Bommana,Sudharani. 1 School of Medicine, Creighton University, Omaha, Nebraska, USA ; 2 VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska, USA ; 3 The University of Kansas Medical Center and Hospital, Kansas City, Kansas, USA ; 4 Case Western Reserve University, MetroHealth Medical Center, Cleveland, Ohio, USA.
IN  - Vallakati,Ajay. 1 School of Medicine, Creighton University, Omaha, Nebraska, USA ; 2 VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska, USA ; 3 The University of Kansas Medical Center and Hospital, Kansas City, Kansas, USA ; 4 Case Western Reserve University, MetroHealth Medical Center, Cleveland, Ohio, USA.
IN  - Atkins,Donita. 1 School of Medicine, Creighton University, Omaha, Nebraska, USA ; 2 VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska, USA ; 3 The University of Kansas Medical Center and Hospital, Kansas City, Kansas, USA ; 4 Case Western Reserve University, MetroHealth Medical Center, Cleveland, Ohio, USA.
IN  - Lakkireddy,Dhanunjaya. 1 School of Medicine, Creighton University, Omaha, Nebraska, USA ; 2 VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska, USA ; 3 The University of Kansas Medical Center and Hospital, Kansas City, Kansas, USA ; 4 Case Western Reserve University, MetroHealth Medical Center, Cleveland, Ohio, USA.
TI  - Alternative medicine in atrial fibrillation treatment-Yoga, acupuncture, biofeedback and more. [Review]
SO  - Journal of Thoracic Disease. 7(2):185-92, 2015 Feb.
AS  - J. thorac. dis.. 7(2):185-92, 2015 Feb.
NJ  - Journal of thoracic disease
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101533916
OI  - Source: NLM. PMC4321072
CP  - China
KW  - Atrial fibrillation (AF) and alternative therapy;  complementary therapy;  yoga and AF
AB  - The last decade has seen a significant improvement in the management of atrial fibrillation (AF) with the development of newer medications and improvement in catheter ablation techniques. Recurrence of AF remains a significant problem in these patients and medications offer limited supportive role. Complementary and alternative treatment strategies therefore remain a viable option for these AF patients. Several studies have shown improvement in AF symptoms with yoga therapy, acupuncture and biofeedback. There are also several herbal medicine and supplements such as omega-3 fatty acids, antioxidant vitamins, barberry, motherwort, cinchona, Shensongyangxin, hawthorn, Kella and Wenxin Keli that have been evaluated as potential therapeutic options in AF. These studies are however limited by small sample sizes with mixed results. Besides the pharmacological action, metabolism, interactions with other medications and the adverse effects of the herbal medications and supplements remain poorly understood. In spite of the above limitations, complementary therapies remain a promising option in the management of AF and further studies are necessary to validate their safety and efficacy.
IS  - 2072-1439
IL  - 2072-1439
DO  - http://dx.doi.org/10.3978/j.issn.2072-1439.2015.01.13
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2015 Feb
DC  - 20150225
YR  - 2015
ED  - 20150225
RD  - 20150227
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=25713735

<155. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24504429
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Aagaard P
AU  - Sahlen A
AU  - Bergfeldt L
AU  - Braunschweig F
FA  - Aagaard, Philip
FA  - Sahlen, Anders
FA  - Bergfeldt, Lennart
FA  - Braunschweig, Frieder
IN  - Aagaard,Philip. 1Department of Cardiology, Karolinska Institutet, Karolinska University Hospital, Stockholm, SWEDEN; 2Department of Medicine, Montefiore Medical Center, The University Hospital of Albert Einstein School of Medicine, Bronx, NY; and 3Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, SWEDEN.
TI  - Heart rate and its variability in response to running-associations with troponin.
SO  - Medicine & Science in Sports & Exercise. 46(8):1624-30, 2014 Aug.
AS  - Med Sci Sports Exerc. 46(8):1624-30, 2014 Aug.
NJ  - Medicine and science in sports and exercise
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 8005433, mg8
SB  - Index Medicus
CP  - United States
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Echocardiography
MH  - Electrocardiography, Ambulatory
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Myocardium/me [Metabolism]
MH  - *Physical Endurance/ph [Physiology]
MH  - *Running/ph [Physiology]
MH  - Stress, Physiological
MH  - *Troponin/bl [Blood]
AB  - PURPOSE: The objective of this study is to investigate the time course of autonomic tone changes after a first-time endurance running race participation and associations with postexertional high-sensitivity troponin (hsTnT) levels in middle-aged males.
AB  - METHODS: Male (n = 42) first-time long-distance running race (Lidingoloppet 30 km) participants >45 yr (50.5 +/- 5) were examined. HR and HR variability (HRV) in the time domain (SDANN) was measured continuously from 2 d before to 4 d after the race using a wireless cardiovascular monitor that also recorded arrhythmia episodes. In addition, subjects were assessed pre- and postrace by medical history and physical examination, 12-lead ECG, blood tests including hsTnT, and echocardiography.
AB  - RESULTS: Compared with corresponding prerace values, nighttime (2:00-4:00 a.m.) HR was significantly elevated (63.6 +/- 9.4 vs 53.9 +/- 8.3 bpm, P < 0.001) on the first night postrace, whereas HRV remained reduced for a median of 64 h (interquartile range, 51-102 h). A prolonged HR recovery period (r = 0.48, P = 0.005) and a larger reduction in postrace HRV (r = -0.49, P = 0.003) correlated with higher postrace hsTnT levels. The association between reduced HRV and higher hsTnT remained significant after multivariate analysis (beta = -0.48, P = 0.01). No sustained ventricular arrhythmias were recorded, but atrial fibrillation occurred in two subjects.
AB  - CONCLUSION: Endurance running race participation caused a prolonged alteration of autonomic tone. More marked and prolonged changes were associated with higher levels of hsTnT, suggesting that the magnitude of troponin increase after strenuous exercise may reflect the magnitude of exercise-induced cardiovascular stress.
RN  - 0 (Troponin)
ES  - 1530-0315
IL  - 0195-9131
DO  - http://dx.doi.org/10.1249/MSS.0000000000000270
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2014 Aug
DC  - 20140716
YR  - 2014
ED  - 20150221
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24504429

<156. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24762748
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kutner NG
AU  - Zhang R
AU  - Huang Y
AU  - McClellan WM
AU  - Soltow QA
AU  - Lea J
FA  - Kutner, Nancy G
FA  - Zhang, Rebecca
FA  - Huang, Yijian
FA  - McClellan, William M
FA  - Soltow, Quinlyn A
FA  - Lea, Janice
IN  - Kutner,Nancy G. Department of Rehabilitation Medicine (NGK), Emory University School of Medicine, Atlanta, Georgia; Department of Biostatistics and Bioinformatics (RZ, YH), Rollins School of Public Health, Emory University, Atlanta, Georgia; Department of Medicine (WMM, JL), Division of Nephrology, Emory University School of Medicine, Atlanta, Georgia; Department of Epidemiology (WMM), Rollins School of Public Health, Emory University, Atlanta, Georgia; and Department of Medicine (QAS), Division of Pulmonology, Emory University School of Medicine, Atlanta, Georgia.
TI  - Risk factors for frailty in a large prevalent cohort of hemodialysis patients.
SO  - American Journal of the Medical Sciences. 348(4):277-82, 2014 Oct.
AS  - Am J Med Sci. 348(4):277-82, 2014 Oct.
NJ  - The American journal of the medical sciences
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 3l2, 0370506
OI  - Source: NLM. NIHMS606374
OI  - Source: NLM. PMC4169714
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - Cardiovascular Diseases/di [Diagnosis]
MH  - *Cardiovascular Diseases/ep [Epidemiology]
MH  - Cardiovascular Diseases/pp [Physiopathology]
MH  - Cohort Studies
MH  - Exercise/ph [Physiology]
MH  - Fatigue/di [Diagnosis]
MH  - Fatigue/ep [Epidemiology]
MH  - Fatigue/pp [Physiopathology]
MH  - Female
MH  - Hand Strength/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscle Weakness/di [Diagnosis]
MH  - *Muscle Weakness/ep [Epidemiology]
MH  - Muscle Weakness/pp [Physiopathology]
MH  - Obesity/di [Diagnosis]
MH  - *Obesity/ep [Epidemiology]
MH  - Obesity/pp [Physiopathology]
MH  - Prevalence
MH  - Renal Dialysis/ae [Adverse Effects]
MH  - *Renal Dialysis/td [Trends]
MH  - Risk Factors
AB  - BACKGROUND: Although individuals with kidney disease, including those dependent on dialysis, often present clinically with signs and symptoms consistent with frailty, there is limited information about sociodemographic and clinical risk factors that may be associated.
AB  - METHODS: Seven hundred forty-five patients undergoing hemodialysisbetween 2009 and 2011 in 7 Atlanta dialysis clinics and 7 San Francisco bay area dialysis clinics were assessed using the validated Fried frailty index (recent unintentional weight loss, reported exhaustion, low grip strength, slow walk speed, low physical activity) that defines frailty as the presence of 3 or more criteria. Study coordinators interviewed participants; measured grip strength, walk speed, and body composition; and reviewed records for clinical and laboratory parameters. Logistic regression models were used to estimate the association of patient characteristics with frailty.
AB  - RESULTS: In adjusted analyses, peripheral vascular disease and cardiac diseases, including dysrhythmia, atrial fibrillation, tachycardia, pericarditis, and cardiac arrest, were associated with higher odds for frailty, whereas black race and higher serum albumin concentration were associated with lower odds for frailty.
AB  - CONCLUSIONS: In multivariable analyses, the risk for frailty in patients undergoing hemodialysis, as assessed by the presence of 3 or more criteria that comprise the Fried frailty index, was increased in association with peripheral vascular disease and cardiac conditions, such as dysrhythmia and atrial fibrillation, and was decreased for those with higher serum albumin concentration and for blacks compared with whites. Among patients who met the Fried definition of frailty, 78% scored as frail on walk speed and 56% scored as frail on grip strength, the 2 physical performance measures.
ES  - 1538-2990
IL  - 0002-9629
DO  - http://dx.doi.org/10.1097/MAJ.0000000000000250
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
NO  - HHSN267200715004C (United States NIDDK NIH HHS)
NO  - HHSN267200715004C (United States PHS HHS)
NO  - N01 DK012471 (United States NIDDK NIH HHS)
NO  - N01 DK075004 (United States NIDDK NIH HHS)
NO  - N01-DK-7-5004 (United States NIDDK NIH HHS)
LG  - English
DP  - 2014 Oct
DC  - 20140920
YR  - 2014
ED  - 20150220
RD  - 20151001
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24762748

<157. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23918529
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Elewa HF
AU  - DeRemer CE
AU  - Keller K
AU  - Gujral J
AU  - Joshua TV
FA  - Elewa, Hazem F
FA  - DeRemer, Christina E
FA  - Keller, Kimble
FA  - Gujral, Jaspal
FA  - Joshua, Thomas V
IN  - Elewa,Hazem F. Pharmacy Department, Georgia Regents Health System, 1120 15th Street, BI 2101, Augusta, GA, 30912, USA, hazemfelewa@gmail.com.
TI  - Patients satisfaction with warfarin and willingness to switch to dabigatran: a patient survey.
SO  - Journal of Thrombosis & Thrombolysis. 38(1):115-20, 2014 Jul.
AS  - J Thromb Thrombolysis. 38(1):115-20, 2014 Jul.
NJ  - Journal of thrombosis and thrombolysis
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - ddy, 9502018
SB  - Index Medicus
CP  - Netherlands
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Anticoagulants/ad [Administration & Dosage]
MH  - Anticoagulants/ae [Adverse Effects]
MH  - Anticoagulants/ec [Economics]
MH  - *Benzimidazoles/ad [Administration & Dosage]
MH  - Benzimidazoles/ae [Adverse Effects]
MH  - Benzimidazoles/ec [Economics]
MH  - Costs and Cost Analysis
MH  - Dabigatran
MH  - *Drug Substitution
MH  - Female
MH  - Humans
MH  - Male
MH  - *Medication Adherence
MH  - Middle Aged
MH  - *Patient Satisfaction
MH  - *Warfarin/ad [Administration & Dosage]
MH  - Warfarin/ae [Adverse Effects]
MH  - Warfarin/ec [Economics]
MH  - beta-Alanine/ad [Administration & Dosage]
MH  - beta-Alanine/ae [Adverse Effects]
MH  - *beta-Alanine/aa [Analogs & Derivatives]
MH  - beta-Alanine/ec [Economics]
AB  - Warfarin is an anticoagulant medication that is challenging to manage. Dabigatran has been approved by the FDA for stroke and systemic embolism prevention in non-valvular atrial fibrillation as an alternative to warfarin. Dabigatran does not require routine monitoring, has an established dose, and lacks many of the drug, herbal, and food interactions that afflict warfarin. To evaluate patients' satisfaction with their current warfarin treatment and their opinion on switching to a newly marketed medication (dabigatran) through a brief survey. Two separate surveys were administered to (1) evaluate the patients' opinion of their warfarin therapy and (2) evaluate their thoughts on switching to a newer anticoagulant. Responses were recorded on a rating scale of 1-5; 1 being the least and 5 being the highest. Study was conducted at the Georgia Regents Health System (GRHS) pharmacy-based anticoagulation clinic. Two hundred sixty patients on warfarin treatment were enrolled. Patients expressed high satisfaction with warfarin treatment (4.7 +/- 0.78). However, a vast majority of the patients were willing to switch to an agent that: requires less frequent follow-up visits (3.9 +/- 1.35); lacks interaction with food and/or beverage (4.1 +/- 1.25); is as efficacious as warfarin (3.7 +/- 1.38). Patients expressed that out-of-pocket cost would be a major barrier to switch to this new medication (1.3 +/- 0.58). Patients are satisfied with their warfarin treatment but willing to consider a new anticoagulant. Cost was highlighted as the most significant barrier. Efficacy, dietary freedom and less frequent visits are the major factors affecting the patients' decision.
RN  - 0 (Anticoagulants)
RN  - 0 (Benzimidazoles)
RN  - 11P2JDE17B (beta-Alanine)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - I0VM4M70GC (Dabigatran)
ES  - 1573-742X
IL  - 0929-5305
DO  - http://dx.doi.org/10.1007/s11239-013-0976-y
PT  - Clinical Trial
PT  - Journal Article
PT  - Observational Study
LG  - English
DP  - 2014 Jul
DC  - 20140609
YR  - 2014
ED  - 20150212
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23918529

<158. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24200846
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Xie X
AU  - Liu Y
AU  - Gao S
AU  - Wu B
AU  - Hu X
AU  - Chen J
FA  - Xie, Xudong
FA  - Liu, Yanrong
FA  - Gao, Shilong
FA  - Wu, Bifeng
FA  - Hu, Xiaosheng
FA  - Chen, Junzhu
IN  - Xie,Xudong. Department of Cardiology, First Affiliated Hospital, Medical School of Zhejiang University.
TI  - Possible involvement of fibrocytes in atrial fibrosis in patients with chronic atrial fibrillation.
SO  - Circulation Journal. 78(2):338-44, 2014.
AS  - Circ J. 78(2):338-44, 2014.
NJ  - Circulation journal : official journal of the Japanese Circulation Society
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101137683
SB  - Index Medicus
CP  - Japan
MH  - *Actins/bi [Biosynthesis]
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/me [Metabolism]
MH  - Atrial Fibrillation/pa [Pathology]
MH  - Chronic Disease
MH  - *Collagen Type I/bi [Biosynthesis]
MH  - Female
MH  - Fibrosis
MH  - Heart Atria/me [Metabolism]
MH  - Heart Atria/pa [Pathology]
MH  - Heart Valve Diseases/co [Complications]
MH  - *Heart Valve Diseases/me [Metabolism]
MH  - Heart Valve Diseases/pa [Pathology]
MH  - Humans
MH  - Male
MH  - Middle Aged
AB  - BACKGROUND: Chronic atrial fibrillation (AF) is characterized by a remodeling process with prominent atrial fibrosis. Fibrocytes, a bone marrow-derived population of fibroblast-like cells, have been placed at the center of a number of fibrosing conditions. The purpose of this study was to evaluate the contribution of fibrocytes to atrial fibrosis in patients with chronic AF and the possible mechanisms.
AB  - METHODS AND RESULTS:  We enrolled 22 consecutive valvular heart disease patients with chronic AF (>6 months: CAF group) and 15 valvular heart disease patients in sinus rhythm served as controls (SR group). Left atrial tissue samples were obtained during cardiac surgery. The infiltration of fibrocytes into the atrial interstitium was observed by confocal microscopy. The number of atrial fibrocytes was approximately three-fold higher in the CAF group compared with the SR controls, and positively correlated with both the atrial collagen volume fraction (r=0.713; P=0.0002) and the left atrial volume index (r=0.631; P=0.002). In the peripheral blood samples collected before the operation, approximately 2.5-fold higher percentage of circulating fibrocytes was identified in the CAF group. These fibrocytes showed a stronger proliferative capacity (2.5-fold) and higher level expression of collagen I and alpha-SMA (2-fold and 4-fold, respectively) compared with the SR controls.
AB  - CONCLUSIONS: The results suggested that fibrocytes may be involved in atrial fibrosis in chronic AF through enhanced profibrotic characteristics.  
RN  - 0 (ACTA2 protein, human)
RN  - 0 (Actins)
RN  - 0 (Collagen Type I)
ES  - 1347-4820
IL  - 1346-9843
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20131107
DP  - 2014
DC  - 20140127
YR  - 2014
ED  - 20150212
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24200846

<159. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24944031
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Magill SB
FA  - Magill, Steven B
IN  - Magill,Steven B. Division of Endocrinology, Metabolism, and Clinical Nutrition, Department of Medicine, Medical College of Wisconsin, Menomonee Falls, Wisconsin.
TI  - Pathophysiology, diagnosis, and treatment of mineralocorticoid disorders. [Review]
SO  - Comprehensive Physiology. 4(3):1083-119, 2014 Jul.
AS  - Compr Physiol. 4(3):1083-119, 2014 Jul.
NJ  - Comprehensive Physiology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101574442
SB  - Index Medicus
CP  - United States
MH  - Aldosterone/me [Metabolism]
MH  - Animals
MH  - Humans
MH  - Hyperaldosteronism/di [Diagnosis]
MH  - Hyperaldosteronism/me [Metabolism]
MH  - Hyperaldosteronism/pp [Physiopathology]
MH  - Hyperaldosteronism/th [Therapy]
MH  - *Hyperaldosteronism
MH  - Hypoaldosteronism/di [Diagnosis]
MH  - Hypoaldosteronism/ge [Genetics]
MH  - Hypoaldosteronism/me [Metabolism]
MH  - Hypoaldosteronism/th [Therapy]
MH  - *Hypoaldosteronism
MH  - *Mineralocorticoids/me [Metabolism]
MH  - Renin-Angiotensin System/ph [Physiology]
AB  - The renin-angiotensin-aldosterone system (RAAS) is a major regulator of blood pressure control, fluid, and electrolyte balance in humans. Chronic activation of mineralocorticoid production leads to dysregulation of the cardiovascular system and to hypertension. The key mineralocorticoid is aldosterone. Hyperaldosteronism causes sodium and fluid retention in the kidney. Combined with the actions of angiotensin II, chronic elevation in aldosterone leads to detrimental effects in the vasculature, heart, and brain. The adverse effects of excess aldosterone are heavily dependent on increased dietary salt intake as has been demonstrated in animal models and in humans. Hypertension develops due to complex genetic influences combined with environmental factors. In the last two decades, primary aldosteronism has been found to occur in 5% to 13% of subjects with hypertension. In addition, patients with hyperaldosteronism have more end organ manifestations such as left ventricular hypertrophy and have significant cardiovascular complications including higher rates of heart failure and atrial fibrillation compared to similarly matched patients with essential hypertension. The pathophysiology, diagnosis, and treatment of primary aldosteronism will be extensively reviewed. There are many pitfalls in the diagnosis and confirmation of the disorder that will be discussed. Other rare forms of hyper- and hypo-aldosteronism and unusual disorders of hypertension will also be reviewed in this article.Copyright © 2014 American Physiological Society
RN  - 0 (Mineralocorticoids)
RN  - 4964P6T9RB (Aldosterone)
ES  - 2040-4603
IL  - 2040-4603
DO  - http://dx.doi.org/10.1002/cphy.c130042
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2014 Jul
DC  - 20140619
YR  - 2014
ED  - 20150204
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24944031

<160. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23253265
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wilhelm M
AU  - Zueger T
AU  - De Marchi S
AU  - Rimoldi SF
AU  - Brugger N
AU  - Steiner R
AU  - Stettler C
AU  - Nuoffer JM
AU  - Seiler C
AU  - Ith M
FA  - Wilhelm, M
FA  - Zueger, T
FA  - De Marchi, S
FA  - Rimoldi, S F
FA  - Brugger, N
FA  - Steiner, R
FA  - Stettler, C
FA  - Nuoffer, J-M
FA  - Seiler, C
FA  - Ith, M
IN  - Wilhelm,M. University Clinic for Cardiology, University Hospital and University of Bern, Bern, Switzerland.
TI  - Inflammation and atrial remodeling after a mountain marathon.
SO  - Scandinavian Journal of Medicine & Science in Sports. 24(3):519-25, 2014 Jun.
AS  - Scand J Med Sci Sports. 24(3):519-25, 2014 Jun.
NJ  - Scandinavian journal of medicine & science in sports
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9111504, cac
SB  - Index Medicus
CP  - Denmark
MH  - Adult
MH  - Atrial Natriuretic Factor/bl [Blood]
MH  - *Atrial Remodeling/ph [Physiology]
MH  - C-Reactive Protein/me [Metabolism]
MH  - Electrocardiography
MH  - Heart Atria/pp [Physiopathology]
MH  - Heart Atria/us [Ultrasonography]
MH  - Humans
MH  - *Inflammation/bl [Blood]
MH  - Interleukin-6/bl [Blood]
MH  - Leukocyte Count
MH  - Longitudinal Studies
MH  - Male
MH  - *Neutrophils
MH  - Prospective Studies
MH  - *Running/ph [Physiology]
MH  - Troponin/bl [Blood]
MH  - Tumor Necrosis Factor-alpha/bl [Blood]
KW  - atrial remodeling;  marathon running;  pro atrial natriuretic peptide;  proinflammatory cytokines;  signal-averaged P-wave duration
AB  - Endurance athletes have an increased risk of atrial fibrillation. We performed a longitudinal study on elite runners of the 2010 Jungfrau Marathon, a Swiss mountain marathon, to determine acute effects of long-distance running on the atrial myocardium. Ten healthy male athletes were included and examined 9 to 1 week prior to the race, immediately after, and 1, 5, and 8 days after the race. Mean age was 34.9 +/- 4.2 years, and maximum oxygen consumption was 66.8 +/- 5.8 mL/kg*min. Mean race time was 243.9 +/- 17.7 min. Electrocardiographic-determined signal-averaged P-wave duration (SAPWD) increased significantly after the race and returned to baseline levels during follow-up (128.7 +/- 10.9 vs. 137.6 +/- 9.8 vs. 131.5 +/- 8.6 ms; P < 0.001). Left and right atrial volumes showed no significant differences over time, and there were no correlations of atrial volumes and SAPWD. Prolongation of the SAPWD was accompanied by a transient increase in levels of high-sensitivity C-reactive protein, proinflammatory cytokines, total leucocytes, neutrophil granulocytes, pro atrial natriuretic peptide and high-sensitivity troponin. In conclusion, marathon running was associated with a transient conduction delay in the atria, acute inflammation and increased atrial wall tension. This may reflect exercise-induced atrial myocardial edema and may contribute to atrial remodeling over time, generating a substrate for atrial arrhythmias.Copyright © 2012 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
RN  - 0 (Interleukin-6)
RN  - 0 (Troponin)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
RN  - 9007-41-4 (C-Reactive Protein)
ES  - 1600-0838
IL  - 0905-7188
DO  - http://dx.doi.org/10.1111/sms.12030
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
SI  - ClinicalTrials.gov
SA  - ClinicalTrials.gov/NCT01179802
SL  - http://clinicaltrials.gov/search/term=NCT01179802
LG  - English
EP  - 20121218
DP  - 2014 Jun
DC  - 20140516
YR  - 2014
ED  - 20150202
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23253265

<161. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25123217
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Tada H
AU  - Shiffman D
AU  - Smith JG
AU  - Sjogren M
AU  - Lubitz SA
AU  - Ellinor PT
AU  - Louie JZ
AU  - Catanese JJ
AU  - Engstrom G
AU  - Devlin JJ
AU  - Kathiresan S
AU  - Melander O
FA  - Tada, Hayato
FA  - Shiffman, Dov
FA  - Smith, J Gustav
FA  - Sjogren, Marketa
FA  - Lubitz, Steven A
FA  - Ellinor, Patrick T
FA  - Louie, Judy Z
FA  - Catanese, Joseph J
FA  - Engstrom, Gunnar
FA  - Devlin, James J
FA  - Kathiresan, Sekar
FA  - Melander, Olle
IN  - Tada,Hayato. From the Center for Human Genetic Research and Cardiovascular Research Center (H.T., S.A.L., P.T.E., S.K.) and Cardiac Arrhythmia Service (S.A.L., P.T.E.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, Broad Institute, Cambridge, MA (H.T., S.K.); Department of Medicine, Harvard Medical School, Boston, MA (H.T., P.T.E., S.K.); Quest Diagnostics, Science and Innovation Group, Alameda, CA (D.S., J.Z.L., J.J.C., J.J.D.); Department of Cardiology, Lund University, Lund, Sweden (J.G.S.); Department of Clinical Sciences, Lund University, Malmo, Sweden (M.S., G.E., O.M.); and Department of Internal Medicine, Skane University Hospital, Malmo, Sweden (O.M.).
IN  - Shiffman,Dov. From the Center for Human Genetic Research and Cardiovascular Research Center (H.T., S.A.L., P.T.E., S.K.) and Cardiac Arrhythmia Service (S.A.L., P.T.E.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, Broad Institute, Cambridge, MA (H.T., S.K.); Department of Medicine, Harvard Medical School, Boston, MA (H.T., P.T.E., S.K.); Quest Diagnostics, Science and Innovation Group, Alameda, CA (D.S., J.Z.L., J.J.C., J.J.D.); Department of Cardiology, Lund University, Lund, Sweden (J.G.S.); Department of Clinical Sciences, Lund University, Malmo, Sweden (M.S., G.E., O.M.); and Department of Internal Medicine, Skane University Hospital, Malmo, Sweden (O.M.). dov.shiffman@celera.com sekar@broadinstitute.org olle.melander@med.lu.se.
IN  - Smith,J Gustav. From the Center for Human Genetic Research and Cardiovascular Research Center (H.T., S.A.L., P.T.E., S.K.) and Cardiac Arrhythmia Service (S.A.L., P.T.E.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, Broad Institute, Cambridge, MA (H.T., S.K.); Department of Medicine, Harvard Medical School, Boston, MA (H.T., P.T.E., S.K.); Quest Diagnostics, Science and Innovation Group, Alameda, CA (D.S., J.Z.L., J.J.C., J.J.D.); Department of Cardiology, Lund University, Lund, Sweden (J.G.S.); Department of Clinical Sciences, Lund University, Malmo, Sweden (M.S., G.E., O.M.); and Department of Internal Medicine, Skane University Hospital, Malmo, Sweden (O.M.).
IN  - Sjogren,Marketa. From the Center for Human Genetic Research and Cardiovascular Research Center (H.T., S.A.L., P.T.E., S.K.) and Cardiac Arrhythmia Service (S.A.L., P.T.E.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, Broad Institute, Cambridge, MA (H.T., S.K.); Department of Medicine, Harvard Medical School, Boston, MA (H.T., P.T.E., S.K.); Quest Diagnostics, Science and Innovation Group, Alameda, CA (D.S., J.Z.L., J.J.C., J.J.D.); Department of Cardiology, Lund University, Lund, Sweden (J.G.S.); Department of Clinical Sciences, Lund University, Malmo, Sweden (M.S., G.E., O.M.); and Department of Internal Medicine, Skane University Hospital, Malmo, Sweden (O.M.).
IN  - Lubitz,Steven A. From the Center for Human Genetic Research and Cardiovascular Research Center (H.T., S.A.L., P.T.E., S.K.) and Cardiac Arrhythmia Service (S.A.L., P.T.E.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, Broad Institute, Cambridge, MA (H.T., S.K.); Department of Medicine, Harvard Medical School, Boston, MA (H.T., P.T.E., S.K.); Quest Diagnostics, Science and Innovation Group, Alameda, CA (D.S., J.Z.L., J.J.C., J.J.D.); Department of Cardiology, Lund University, Lund, Sweden (J.G.S.); Department of Clinical Sciences, Lund University, Malmo, Sweden (M.S., G.E., O.M.); and Department of Internal Medicine, Skane University Hospital, Malmo, Sweden (O.M.).
IN  - Ellinor,Patrick T. From the Center for Human Genetic Research and Cardiovascular Research Center (H.T., S.A.L., P.T.E., S.K.) and Cardiac Arrhythmia Service (S.A.L., P.T.E.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, Broad Institute, Cambridge, MA (H.T., S.K.); Department of Medicine, Harvard Medical School, Boston, MA (H.T., P.T.E., S.K.); Quest Diagnostics, Science and Innovation Group, Alameda, CA (D.S., J.Z.L., J.J.C., J.J.D.); Department of Cardiology, Lund University, Lund, Sweden (J.G.S.); Department of Clinical Sciences, Lund University, Malmo, Sweden (M.S., G.E., O.M.); and Department of Internal Medicine, Skane University Hospital, Malmo, Sweden (O.M.).
IN  - Louie,Judy Z. From the Center for Human Genetic Research and Cardiovascular Research Center (H.T., S.A.L., P.T.E., S.K.) and Cardiac Arrhythmia Service (S.A.L., P.T.E.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, Broad Institute, Cambridge, MA (H.T., S.K.); Department of Medicine, Harvard Medical School, Boston, MA (H.T., P.T.E., S.K.); Quest Diagnostics, Science and Innovation Group, Alameda, CA (D.S., J.Z.L., J.J.C., J.J.D.); Department of Cardiology, Lund University, Lund, Sweden (J.G.S.); Department of Clinical Sciences, Lund University, Malmo, Sweden (M.S., G.E., O.M.); and Department of Internal Medicine, Skane University Hospital, Malmo, Sweden (O.M.).
IN  - Catanese,Joseph J. From the Center for Human Genetic Research and Cardiovascular Research Center (H.T., S.A.L., P.T.E., S.K.) and Cardiac Arrhythmia Service (S.A.L., P.T.E.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, Broad Institute, Cambridge, MA (H.T., S.K.); Department of Medicine, Harvard Medical School, Boston, MA (H.T., P.T.E., S.K.); Quest Diagnostics, Science and Innovation Group, Alameda, CA (D.S., J.Z.L., J.J.C., J.J.D.); Department of Cardiology, Lund University, Lund, Sweden (J.G.S.); Department of Clinical Sciences, Lund University, Malmo, Sweden (M.S., G.E., O.M.); and Department of Internal Medicine, Skane University Hospital, Malmo, Sweden (O.M.).
IN  - Engstrom,Gunnar. From the Center for Human Genetic Research and Cardiovascular Research Center (H.T., S.A.L., P.T.E., S.K.) and Cardiac Arrhythmia Service (S.A.L., P.T.E.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, Broad Institute, Cambridge, MA (H.T., S.K.); Department of Medicine, Harvard Medical School, Boston, MA (H.T., P.T.E., S.K.); Quest Diagnostics, Science and Innovation Group, Alameda, CA (D.S., J.Z.L., J.J.C., J.J.D.); Department of Cardiology, Lund University, Lund, Sweden (J.G.S.); Department of Clinical Sciences, Lund University, Malmo, Sweden (M.S., G.E., O.M.); and Department of Internal Medicine, Skane University Hospital, Malmo, Sweden (O.M.).
IN  - Devlin,James J. From the Center for Human Genetic Research and Cardiovascular Research Center (H.T., S.A.L., P.T.E., S.K.) and Cardiac Arrhythmia Service (S.A.L., P.T.E.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, Broad Institute, Cambridge, MA (H.T., S.K.); Department of Medicine, Harvard Medical School, Boston, MA (H.T., P.T.E., S.K.); Quest Diagnostics, Science and Innovation Group, Alameda, CA (D.S., J.Z.L., J.J.C., J.J.D.); Department of Cardiology, Lund University, Lund, Sweden (J.G.S.); Department of Clinical Sciences, Lund University, Malmo, Sweden (M.S., G.E., O.M.); and Department of Internal Medicine, Skane University Hospital, Malmo, Sweden (O.M.).
IN  - Kathiresan,Sekar. From the Center for Human Genetic Research and Cardiovascular Research Center (H.T., S.A.L., P.T.E., S.K.) and Cardiac Arrhythmia Service (S.A.L., P.T.E.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, Broad Institute, Cambridge, MA (H.T., S.K.); Department of Medicine, Harvard Medical School, Boston, MA (H.T., P.T.E., S.K.); Quest Diagnostics, Science and Innovation Group, Alameda, CA (D.S., J.Z.L., J.J.C., J.J.D.); Department of Cardiology, Lund University, Lund, Sweden (J.G.S.); Department of Clinical Sciences, Lund University, Malmo, Sweden (M.S., G.E., O.M.); and Department of Internal Medicine, Skane University Hospital, Malmo, Sweden (O.M.). dov.shiffman@celera.com sekar@broadinstitute.org olle.melander@med.lu.se.
IN  - Melander,Olle. From the Center for Human Genetic Research and Cardiovascular Research Center (H.T., S.A.L., P.T.E., S.K.) and Cardiac Arrhythmia Service (S.A.L., P.T.E.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, Broad Institute, Cambridge, MA (H.T., S.K.); Department of Medicine, Harvard Medical School, Boston, MA (H.T., P.T.E., S.K.); Quest Diagnostics, Science and Innovation Group, Alameda, CA (D.S., J.Z.L., J.J.C., J.J.D.); Department of Cardiology, Lund University, Lund, Sweden (J.G.S.); Department of Clinical Sciences, Lund University, Malmo, Sweden (M.S., G.E., O.M.); and Department of Internal Medicine, Skane University Hospital, Malmo, Sweden (O.M.). dov.shiffman@celera.com sekar@broadinstitute.org olle.melander@med.lu.se.
TI  - Twelve-single nucleotide polymorphism genetic risk score identifies individuals at increased risk for future atrial fibrillation and stroke.
SO  - Stroke. 45(10):2856-62, 2014 Oct.
AS  - Stroke. 45(10):2856-62, 2014 Oct.
NJ  - Stroke; a journal of cerebral circulation
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - v2j, 0235266
OI  - Source: NLM. NIHMS664710
OI  - Source: NLM. PMC4346099
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Atrial Fibrillation/ge [Genetics]
MH  - Cohort Studies
MH  - Female
MH  - *Genetic Predisposition to Disease/ge [Genetics]
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiplex Polymerase Chain Reaction
MH  - *Polymorphism, Single Nucleotide/ge [Genetics]
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Risk Factors
MH  - *Stroke/ge [Genetics]
KW  - atrial fibrillation;  polymorphism, single nucleotide;  stroke
AB  - BACKGROUND AND PURPOSE: Atrial fibrillation (AF) is prevalent and there is a clinical need for biomarkers to identify individuals at higher risk for AF. Fixed throughout a life course and assayable early in life, genetic biomarkers may meet this need. Here, we investigate whether multiple single nucleotide polymorphisms together as an AF genetic risk score (AF-GRS) can improve prediction of one's risk for AF.
AB  - METHODS: In 27 471 participants of the Malmo Diet and Cancer Study, a prospective, community-based cohort, we used Cox models that adjusted for established AF risk factors to assess the association of AF-GRS with incident AF and ischemic stroke. Median follow-up was 14.4 years for incident AF and 14.5 years for ischemic stroke. The AF-GRS comprised 12 single nucleotide polymorphisms that had been previously shown to be associated with AF at genome-wide significance.
AB  - RESULTS: During follow-up, 2160 participants experienced a first AF event and 1495 had a first ischemic stroke event. Participants in the top AF-GRS quintile were at increased risk for incident AF (hazard ratio, 2.00; 95% confidence interval, 1.73-2.31; P=2.7x10(-21)) and ischemic stroke (hazard ratio, 1.23; 95% confidence interval, 1.04-1.46; P=0.02) when compared with the bottom quintile. Addition of the AF-GRS to established AF risk factors modestly improved both discrimination and reclassification (P<0.0001 for both).
AB  - CONCLUSIONS: An AF-GRS can identify 20% of individuals who are at =2-fold increased risk for incident AF and at 23% increased risk for ischemic stroke. Targeting diagnostic or therapeutic interventions to this subset may prove clinically useful.Copyright © 2014 American Heart Association, Inc.
ES  - 1524-4628
IL  - 0039-2499
DO  - http://dx.doi.org/10.1161/STROKEAHA.114.006072
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
NO  - 1K23HL114724 (United States NHLBI NIH HHS)
NO  - 282255 (International European Research Council)
NO  - K23 HL114724 (United States NHLBI NIH HHS)
LG  - English
EP  - 20140814
DP  - 2014 Oct
DC  - 20140923
YR  - 2014
ED  - 20150126
RD  - 20150911
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25123217

<162. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24452600
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wang Y
AU  - Bajorek B
FA  - Wang, Yishen
FA  - Bajorek, Beata
IN  - Wang,Yishen. Graduate School of Health: School of Pharmacy, University of Technology Sydney (UTS), CB01.13, PO Box 123, Broadway, NSW, 2007, Australia, Yishen.Wang@student.uts.edu.au.
TI  - New oral anticoagulants in practice: pharmacological and practical considerations. [Review]
SO  - American Journal of Cardiovascular Drugs. 14(3):175-89, 2014 Jun.
AS  - Am J Cardiovasc Drugs. 14(3):175-89, 2014 Jun.
NJ  - American journal of cardiovascular drugs : drugs, devices, and other interventions
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 100967755
SB  - Index Medicus
CP  - New Zealand
MH  - Administration, Oral
MH  - Aging
MH  - Anticoagulants/ae [Adverse Effects]
MH  - Anticoagulants/pk [Pharmacokinetics]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/co [Complications]
MH  - Benzimidazoles/tu [Therapeutic Use]
MH  - Complementary Therapies
MH  - Dabigatran
MH  - Drug Interactions
MH  - Drug Monitoring
MH  - Humans
MH  - International Normalized Ratio
MH  - Kidney Diseases/ep [Epidemiology]
MH  - Liver Diseases/ep [Epidemiology]
MH  - Morpholines/tu [Therapeutic Use]
MH  - Pyrazoles/tu [Therapeutic Use]
MH  - Pyridones/tu [Therapeutic Use]
MH  - Rivaroxaban
MH  - Sex Factors
MH  - *Stroke/et [Etiology]
MH  - *Stroke/pc [Prevention & Control]
MH  - Thiophenes/tu [Therapeutic Use]
MH  - Warfarin/tu [Therapeutic Use]
MH  - beta-Alanine/aa [Analogs & Derivatives]
MH  - beta-Alanine/tu [Therapeutic Use]
AB  - Although highly effective, warfarin use is complicated by its unpredictable narrow therapeutic window, genetic heterogeneity in pharmacokinetic response, numerous food and drug interactions, and the need for regular international normalized ratio (INR) monitoring. Currently, several novel oral anticoagulant (NOAC) drugs (dabigatran, rivaroxaban, apixaban) are available on the market as alternatives to warfarin. These agents all feature more predictable pharmacodynamic and pharmacokinetic properties than warfarin. Additionally, the NOACs do not require routine monitoring of coagulation parameters, and have a relatively lower potential for interactions with drug, herb, and dietary constituents, which enhances the convenience of management for both patients and health professionals alike. However, there are other considerations regarding the use of NOACs that must be taken into account during management of therapy. In contrast to warfarin, most NOACs need dosage adjustments in renal impairment and are contraindicated in severe liver impairment, and there are no specific antidotes for treating NOAC-related over-anticoagulation. The more frequent dosing needed for NOACs may reduce adherence, especially in elderly patients with polypharmacy. Furthermore, NOACs, especially dabigatran, are not as well tolerated as warfarin in patients with gastrointestinal diseases. Overall, the availability of the NOACs has expanded the treatment armamentarium, but they are not without risk. Given the limited experience with the NOACs, their limited range of indications, and their cost, the characteristics of each anticoagulant must be carefully considered to carefully select the agent that will provide the optimal risk/benefit profile in the individual patient.
RN  - 0 (Anticoagulants)
RN  - 0 (Benzimidazoles)
RN  - 0 (Morpholines)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridones)
RN  - 0 (Thiophenes)
RN  - 11P2JDE17B (beta-Alanine)
RN  - 3Z9Y7UWC1J (apixaban)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - I0VM4M70GC (Dabigatran)
ES  - 1179-187X
IL  - 1175-3277
DO  - http://dx.doi.org/10.1007/s40256-013-0061-0
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2014 Jun
DC  - 20140527
YR  - 2014
ED  - 20150126
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24452600

<163. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25439450
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Aladin AI
AU  - Whelton SP
AU  - Al-Mallah MH
AU  - Blaha MJ
AU  - Keteyian SJ
AU  - Juraschek SP
AU  - Rubin J
AU  - Brawner CA
AU  - Michos ED
FA  - Aladin, Amer I
FA  - Whelton, Seamus P
FA  - Al-Mallah, Mouaz H
FA  - Blaha, Michael J
FA  - Keteyian, Steven J
FA  - Juraschek, Stephen P
FA  - Rubin, Jonathan
FA  - Brawner, Clinton A
FA  - Michos, Erin D
IN  - Aladin,Amer I. Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins School of Medicine, Baltimore, Maryland.
IN  - Whelton,Seamus P. Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins School of Medicine, Baltimore, Maryland.
IN  - Al-Mallah,Mouaz H. Division of Cardiovascular Medicine, Henry Ford Health System, Detroit, Michigan; King Abdulaziz Cardiac Center, Riyadh, Kingdom of Saudi Arabia.
IN  - Blaha,Michael J. Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins School of Medicine, Baltimore, Maryland.
IN  - Keteyian,Steven J. Division of Cardiovascular Medicine, Henry Ford Health System, Detroit, Michigan.
IN  - Juraschek,Stephen P. Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins School of Medicine, Baltimore, Maryland.
IN  - Rubin,Jonathan. Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins School of Medicine, Baltimore, Maryland.
IN  - Brawner,Clinton A. Division of Cardiovascular Medicine, Henry Ford Health System, Detroit, Michigan.
IN  - Michos,Erin D. Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins School of Medicine, Baltimore, Maryland. Electronic address: edonnell@jhmi.edu.
TI  - Relation of resting heart rate to risk for all-cause mortality by gender after considering exercise capacity (the Henry Ford exercise testing project).
SO  - American Journal of Cardiology. 114(11):1701-6, 2014 Dec 1.
AS  - Am J Cardiol. 114(11):1701-6, 2014 Dec 1.
NJ  - The American journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - Cause of Death
MH  - Cohort Studies
MH  - Exercise Test
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - Follow-Up Studies
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mortality
MH  - *Myocardial Infarction/ep [Epidemiology]
MH  - *Myocardial Revascularization/sn [Statistics & Numerical Data]
MH  - Proportional Hazards Models
MH  - *Rest/ph [Physiology]
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
AB  - Whether resting heart rate (RHR) predicts mortality independent of fitness is not well established, particularly among women. We analyzed data from 56,634 subjects (49% women) without known coronary artery disease or atrial fibrillation who underwent a clinically indicated exercise stress test. Baseline RHR was divided into 5 groups with <60 beats/min as reference. The Social Security Death Index was used to ascertain vital status. Cox hazard models were performed to determine the association of RHR with all-cause mortality, major adverse cardiovascular events, myocardial infarction, or revascularization after sequential adjustment for demographics, cardiovascular disease risk factors, medications, and fitness (metabolic equivalents). The mean age was 53 +/- 12 years and mean RHR was 73 +/- 12 beats/min. More than half of the participants were referred for chest pain; 81% completed an adequate stress test and mean metabolic equivalents achieved was 9.2 +/- 3. There were 6,255 deaths over 11.0-year mean follow-up. There was an increased risk of all-cause mortality with increasing RHR (p trend <0.001). Compared with the lowest RHR group, participants with an RHR >90 beats/min had a significantly increased risk of mortality even after adjustment for fitness (hazard ratio 1.22, 95% confidence interval 1.10 to 1.35). This relationship remained significant for men, but not significant for women after adjustment for fitness (p interaction <0.001). No significant associations were seen for men or women with major adverse cardiovascular events, myocardial infarction, or revascularization after accounting for fitness. In conclusion, after adjustment for fitness, elevated RHR was an independent risk factor for all-cause mortality in men but not women, suggesting gender differences in the utility of RHR for risk stratification.Copyright © 2014 Elsevier Inc. All rights reserved.
ES  - 1879-1913
IL  - 0002-9149
DI  - S0002-9149(14)01778-0
DO  - http://dx.doi.org/10.1016/j.amjcard.2014.08.042
PT  - Journal Article
LG  - English
EP  - 20140916
DP  - 2014 Dec 1
DC  - 20141202
YR  - 2014
ED  - 20150120
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25439450

<164. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25150967
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Johnson LS
AU  - Juhlin T
AU  - Engstrom G
AU  - Nilsson PM
FA  - Johnson, Linda S B
FA  - Juhlin, Tord
FA  - Engstrom, Gunnar
FA  - Nilsson, Peter M
IN  - Johnson,Linda S B. Department of Clinical Sciences, Lund University, Skane University Hospital, Inga-Marie Nilssons vag 49, 20502 Malmo, Sweden. linda.johnson@med.lu.se.
TI  - Low fasting plasma insulin is associated atrial fibrillation in men from a cohort study--the Malmo preventive project.
SO  - BMC Cardiovascular Disorders. 14:107, 2014.
AS  - BMC Cardiovasc Disord. 14:107, 2014.
NJ  - BMC cardiovascular disorders
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 100968539
OI  - Source: NLM. PMC4236524
SB  - Index Medicus
CP  - England
MH  - Adult
MH  - Atrial Fibrillation/bl [Blood]
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Biomarkers/bl [Blood]
MH  - Blood Glucose/me [Metabolism]
MH  - Body Mass Index
MH  - *Fasting/bl [Blood]
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - *Insulin/bl [Blood]
MH  - Male
MH  - Proportional Hazards Models
MH  - Risk Factors
MH  - Sex Factors
MH  - Sweden/ep [Epidemiology]
MH  - Time Factors
AB  - BACKGROUND: Type 2 diabetes has been associated with increased incidence of atrial fibrillation (AF) and cardiovascular disease. Controversy remains regarding the role of insulin in the epidemiology of AF risk. The aim of the present study was to study the association between fasting plasma insulin (FPI) and incidence of AF, as well as any effect modification by fasting blood glucose (FBG) or 2 h post-load blood glucose and body mass index (BMI).
AB  - METHODS: The study population consisted of 6052 men and 1014 women followed for an average of 26.2 years. There were 983 cases of incident AF. Analysis was performed using Cox regression and competing risks regression approaches. The population was analysed as a whole, and by subgroups according to glucose levels and BMI.
AB  - RESULTS: After adjustment for age, height, weight, systolic blood pressure and smoking there was a significant inverse association between FPI and AF (hazard ratio; HR) for 4th vs. 1st quartile: 0.69 (95% confidence interval (CI): 0.57-0.83, p < 0.0001) in the cohort as a whole. Among men the corresponding values were HR 0.64 (95% CI 0.52-0.78, p < 0.001) and among women HR 1.16 (95% CI 0.69-1.93, p = 0.58); p-value for interaction 0.06. The protective effects of insulin tended to be weaker in subjects with elevated fasting glucose, implying that the relation between FPI and incident AF could be dependent on the status of individual's glucose metabolism.
AB  - CONCLUSIONS: High levels of FPI are associated with lower risk of incident AF in a middle-aged population with a long follow-up.
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Insulin)
ES  - 1471-2261
IL  - 1471-2261
DO  - http://dx.doi.org/10.1186/1471-2261-14-107
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20140824
DP  - 2014
DC  - 20140910
YR  - 2014
ED  - 20150120
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25150967

<165. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24436019
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Frost L
AU  - Benjamin EJ
AU  - Fenger-Gron M
AU  - Pedersen A
AU  - Tjonneland A
AU  - Overvad K
FA  - Frost, Lars
FA  - Benjamin, Emelia J
FA  - Fenger-Gron, Morten
FA  - Pedersen, Asger
FA  - Tjonneland, Anne
FA  - Overvad, Kim
IN  - Frost,Lars. Department of Medicine, Silkeborg Hospital & Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.
TI  - Body fat, body fat distribution, lean body mass and atrial fibrillation and flutter. A Danish cohort study.
SO  - Obesity. 22(6):1546-52, 2014 Jun.
AS  - Obesity (Silver Spring). 22(6):1546-52, 2014 Jun.
NJ  - Obesity (Silver Spring, Md.)
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101264860
OI  - Source: NLM. NIHMS623476
OI  - Source: NLM. PMC4169701
SB  - Index Medicus
CP  - United States
MH  - *Adipose Tissue
MH  - *Arrhythmias, Cardiac/ep [Epidemiology]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - *Body Fat Distribution
MH  - Body Height
MH  - *Body Mass Index
MH  - Body Weight
MH  - Denmark/ep [Epidemiology]
MH  - Electric Impedance
MH  - Energy Intake
MH  - Female
MH  - Follow-Up Studies
MH  - Health Surveys
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Factors
MH  - Socioeconomic Factors
MH  - Waist Circumference
MH  - Waist-Hip Ratio
AB  - OBJECTIVE: It is recognized that higher height and weight are associated with higher risk of atrial fibrillation or flutter (AF) but it is unclear whether risk of AF is related to body fat, body fat location, or lean body mass.
AB  - METHODS: This article reports the Danish population-based prospective cohort Diet, Cancer and Health study conducted among 55,273 men and women 50-64 years of age at recruitment. The associations between bioelectrical impedance derived measures of body composition and combinations of anthropometric measures of body fat distribution and risk of an incident record of AF in the Danish Registry of Patients were investigated.
AB  - RESULTS: During follow-up (median 13.5 years) AF developed in 1,669 men and 912 women. Higher body fat at any measured location was associated with higher risk of AF. The adjusted hazard ratio (HR) per 1 sex-specific standard deviation (SD) increment in body fat mass was 1.29 (95% confidence interval [CI], 1.24-1.33). Higher lean body mass was also associated with a higher risk of AF. The adjusted HR for 1 sex-specific SD increment was 1.40 (95% CI, 1.35-1.45).
AB  - CONCLUSION: Higher body fat and higher lean body mass were both associated with higher risk of AF.Copyright © 2014 The Obesity Society.
ES  - 1930-739X
IL  - 1930-7381
DO  - http://dx.doi.org/10.1002/oby.20706
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
NO  - 1R01 HL102214 (United States NHLBI NIH HHS)
NO  - 1R01HL092577 (United States NHLBI NIH HHS)
NO  - R01 HL092577 (United States NHLBI NIH HHS)
NO  - R01 HL102214 (United States NHLBI NIH HHS)
LG  - English
EP  - 20140218
DP  - 2014 Jun
DC  - 20140527
YR  - 2014
ED  - 20150116
RD  - 20150515
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24436019

<166. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24280266
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Sauer EM
AU  - Sauer R
AU  - Kallmunzer B
AU  - Blinzler C
AU  - Breuer L
AU  - Huttner HB
AU  - Schwab S
AU  - Kohrmann M
FA  - Sauer, Eva-Maria
FA  - Sauer, Roland
FA  - Kallmunzer, Bernd
FA  - Blinzler, Christian
FA  - Breuer, Lorenz
FA  - Huttner, Hagen B
FA  - Schwab, Stefan
FA  - Kohrmann, Martin
IN  - Sauer,Eva-Maria. Department of Neurology, Universitatsklinikum Erlangen, Erlangen, Germany. Electronic address: Eva-Maria.Sauer@uk-erlangen.de.
IN  - Sauer,Roland. Department of Neuroradiology, Universitatsklinikum Erlangen, Erlangen, Germany.
IN  - Kallmunzer,Bernd. Department of Neurology, Universitatsklinikum Erlangen, Erlangen, Germany.
IN  - Blinzler,Christian. Department of Neurology, Universitatsklinikum Erlangen, Erlangen, Germany.
IN  - Breuer,Lorenz. Department of Neurology, Universitatsklinikum Erlangen, Erlangen, Germany.
IN  - Huttner,Hagen B. Department of Neurology, Universitatsklinikum Erlangen, Erlangen, Germany.
IN  - Schwab,Stefan. Department of Neurology, Universitatsklinikum Erlangen, Erlangen, Germany.
IN  - Kohrmann,Martin. Department of Neurology, Universitatsklinikum Erlangen, Erlangen, Germany.
TI  - Impaired renal function in stroke patients with atrial fibrillation.
SO  - Journal of Stroke & Cerebrovascular Diseases. 23(5):1225-8, 2014 May-Jun.
AS  - J STROKE CEREBROVASC DIS. 23(5):1225-8, 2014 May-Jun.
NJ  - Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9111633
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/mo [Mortality]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/th [Therapy]
MH  - Chi-Square Distribution
MH  - Comorbidity
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Humans
MH  - *Kidney/pp [Physiopathology]
MH  - *Kidney Diseases/co [Complications]
MH  - Kidney Diseases/di [Diagnosis]
MH  - Kidney Diseases/mo [Mortality]
MH  - Kidney Diseases/pp [Physiopathology]
MH  - Kidney Diseases/th [Therapy]
MH  - Logistic Models
MH  - Male
MH  - Multivariate Analysis
MH  - Odds Ratio
MH  - Patient Admission
MH  - Prognosis
MH  - Recovery of Function
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Stroke/di [Diagnosis]
MH  - *Stroke/et [Etiology]
MH  - Stroke/mo [Mortality]
MH  - Stroke/pp [Physiopathology]
MH  - Stroke/th [Therapy]
MH  - Time Factors
KW  - Acute ischemic stroke;  atrial fibrillation;  direct oral anticoagulants;  kidney disease;  oral anticoagulation;  renal dysfunction
AB  - BACKGROUND: Stroke patients with atrial fibrillation (AF) are prone to have comorbidities such as impaired renal function. Because poly-pharmacotherapy is often required in those patients, renal function is important to consider in light of renally cleared medications such as direct oral anticoagulants. In this study, we analyzed frequency and predictors for impaired renal function and its impact on functional outcome in stroke patients with underlying AF.
AB  - METHODS: We analyzed 272 patients with acute ischemic stroke and AF of our prospective, observational stroke database. Estimated glomerular filtration rate (eGFR) was calculated on admission and during hospitalization from the equation of the Modification Diet for Renal Disease. Outcome measures included mortality and functional outcome at 90 days, assessed as modified Rankin Scale (mRS) score.
AB  - RESULTS: On admission, impaired renal function was found in 41.5% (n = 113) and was associated with worse 90-day outcome (mRS score < 2: 26.5% versus 45.9%, P = .001) and a higher mortality rate (23.9% versus 14.5%, P = .043). Multivariate logistic regression identified older age and history of myocardial infarction as independent predictors of renal dysfunction on admission (P < .05). Normalization of eGFR during hospitalization was achieved in 55.8%.
AB  - CONCLUSIONS: In patients with acute ischemic stroke and AF, impaired renal function on admission is frequent and associated with worse outcome. Normalization of eGFR can often be achieved during hospitalization, but in everyday life, fluctuations of renal function because of infection or dehydration have to be considered. Careful monitoring of renal status is indispensable and should influence drug treatment decisions.Copyright © 2014 National Stroke Association. Published by Elsevier Inc. All rights reserved.
ES  - 1532-8511
IL  - 1052-3057
DI  - S1052-3057(13)00430-8
DO  - http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2013.10.020
PT  - Journal Article
LG  - English
EP  - 20131123
DP  - 2014 May-Jun
DC  - 20140526
YR  - 2014
ED  - 20150109
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24280266

<167. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24290569
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Desai MY
AU  - Bhonsale A
AU  - Patel P
AU  - Naji P
AU  - Smedira NG
AU  - Thamilarasan M
AU  - Lytle BW
AU  - Lever HM
FA  - Desai, Milind Y
FA  - Bhonsale, Aditya
FA  - Patel, Parag
FA  - Naji, Peyman
FA  - Smedira, Nicholas G
FA  - Thamilarasan, Maran
FA  - Lytle, Bruce W
FA  - Lever, Harry M
IN  - Desai,Milind Y. Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: desaim2@ccf.org.
IN  - Bhonsale,Aditya. Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
IN  - Patel,Parag. Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
IN  - Naji,Peyman. Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
IN  - Smedira,Nicholas G. Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
IN  - Thamilarasan,Maran. Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
IN  - Lytle,Bruce W. Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
IN  - Lever,Harry M. Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
TI  - Exercise echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract gradient predicts long-term outcomes.
CM  - Comment in: JACC Cardiovasc Imaging. 2014 Jan;7(1):37-9; PMID: 24433709
SO  - Jacc: Cardiovascular Imaging. 7(1):26-36, 2014 Jan.
AS  - JACC Cardiovasc Imaging. 7(1):26-36, 2014 Jan.
NJ  - JACC. Cardiovascular imaging
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101467978
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Cardiomyopathy, Hypertrophic/pp [Physiopathology]
MH  - *Cardiomyopathy, Hypertrophic/us [Ultrasonography]
MH  - *Echocardiography, Stress/mt [Methods]
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - Follow-Up Studies
MH  - *Heart Ventricles/pp [Physiopathology]
MH  - Heart Ventricles/us [Ultrasonography]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Reproducibility of Results
MH  - Rest/ph [Physiology]
MH  - Retrospective Studies
MH  - Time Factors
MH  - *Ventricular Function, Left/ph [Physiology]
KW  - AF;  CHF;  HCM;  HR;  HRR;  ICD;  LVOT;  METs;  MR;  VT;  atrial fibrillation;  congestive heart failure;  exercise echocardiography;  hazard ratio;  heart rate recovery;  hypertrophic cardiomyopathy;  implantable cardioverter-defibrillator;  left ventricular outflow tract;  metabolic equivalents;  mitral regurgitation;  outcomes;  ventricular tachycardia
AB  - OBJECTIVES: This study sought to assess long-term outcomes in asymptomatic or minimally symptomatic patients with hypertrophic cardiomyopathy (HCM) who underwent exercise echocardiography, without invasive therapies for relief of left ventricular outflow tract (LVOT) obstruction.
AB  - BACKGROUND: Many HCM patients present with LVOT obstruction, mitral regurgitation (MR), and diastolic dysfunction, often requiring invasive therapies for symptomatic relief. However, a significant proportion of truly asymptomatic patients can be closely monitored. In HCM patients, exercise echocardiography has been shown to be a useful assessment of functional capacity and risk stratification.
AB  - METHODS: We included 426 HCM patients (44 +/- 14 years; 78% men) undergoing exercise echocardiography, excluding hypertensive heart disease of elderly, ejection fraction <50% and invasive therapy (myectomy or alcohol ablation) during follow-up. Clinical, echocardiographic (LV thickness, LVOT gradient, and MR) and exercise variables (percent of age-sex predicted metabolic equivalents [METs] and heart rate recovery [HRR] at 1 min post-exercise) were recorded. A composite endpoint of death, appropriate internal defibrillator discharge, and admission for congestive heart failure was recorded.
AB  - RESULTS: Patients were asymptomatic or minimally symptomatic on history, but 82% of patients achieved <100% of age-sex predicted METs, and 43% had >II+ post-stress MR. The mean LV septal thickness, post-exercise LVOT gradient, and HRR were 2.0 +/- 0.5 cm, 62 +/- 47 mm Hg, and 31 +/- 14 beats/min, respectively. During a mean follow-up of 8.7 +/- 3 years, there were 52 events (12%). Patients achieving >100% of age-sex predicted METs had 1% event rate versus 12% in those achieving <85%. On stepwise multivariate survival analysis, percent of age-sex predicted METs (hazard ratio [HR]: 0.76; 95% confidence interval [CI]: 0.64 to 0.90), abnormal HRR (HR: 0.89; 95% CI: 0.82 to 0.97), and atrial fibrillation (HR: 2.73; 95% CI: 1.30 to 5.74) (overall, p < 0.001) independently predicted outcomes.
AB  - CONCLUSIONS: In asymptomatic or minimally symptomatic HCM patients, exercise stress testing provides excellent risk stratification, with a low event rate in patients achieving >100% of predicted METs.Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
ES  - 1876-7591
DI  - S1936-878X(13)00737-7
DO  - http://dx.doi.org/10.1016/j.jcmg.2013.08.010
PT  - Journal Article
LG  - English
EP  - 20131127
DP  - 2014 Jan
DC  - 20140117
YR  - 2014
ED  - 20150106
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24290569

<168. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24290569
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Desai MY
AU  - Bhonsale A
AU  - Patel P
AU  - Naji P
AU  - Smedira NG
AU  - Thamilarasan M
AU  - Lytle BW
AU  - Lever HM
FA  - Desai, Milind Y
FA  - Bhonsale, Aditya
FA  - Patel, Parag
FA  - Naji, Peyman
FA  - Smedira, Nicholas G
FA  - Thamilarasan, Maran
FA  - Lytle, Bruce W
FA  - Lever, Harry M
IN  - Desai,Milind Y. Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: desaim2@ccf.org.
IN  - Bhonsale,Aditya. Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
IN  - Patel,Parag. Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
IN  - Naji,Peyman. Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
IN  - Smedira,Nicholas G. Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
IN  - Thamilarasan,Maran. Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
IN  - Lytle,Bruce W. Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
IN  - Lever,Harry M. Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
TI  - Exercise echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract gradient predicts long-term outcomes.
CM  - Comment in: JACC Cardiovasc Imaging. 2014 Jan;7(1):37-9; PMID: 24433709
SO  - Jacc: Cardiovascular Imaging. 7(1):26-36, 2014 Jan.
AS  - JACC Cardiovasc Imaging. 7(1):26-36, 2014 Jan.
NJ  - JACC. Cardiovascular imaging
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101467978
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Cardiomyopathy, Hypertrophic/pp [Physiopathology]
MH  - *Cardiomyopathy, Hypertrophic/us [Ultrasonography]
MH  - *Echocardiography, Stress/mt [Methods]
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - Follow-Up Studies
MH  - *Heart Ventricles/pp [Physiopathology]
MH  - Heart Ventricles/us [Ultrasonography]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Reproducibility of Results
MH  - Rest/ph [Physiology]
MH  - Retrospective Studies
MH  - Time Factors
MH  - *Ventricular Function, Left/ph [Physiology]
KW  - AF;  CHF;  HCM;  HR;  HRR;  ICD;  LVOT;  METs;  MR;  VT;  atrial fibrillation;  congestive heart failure;  exercise echocardiography;  hazard ratio;  heart rate recovery;  hypertrophic cardiomyopathy;  implantable cardioverter-defibrillator;  left ventricular outflow tract;  metabolic equivalents;  mitral regurgitation;  outcomes;  ventricular tachycardia
AB  - OBJECTIVES: This study sought to assess long-term outcomes in asymptomatic or minimally symptomatic patients with hypertrophic cardiomyopathy (HCM) who underwent exercise echocardiography, without invasive therapies for relief of left ventricular outflow tract (LVOT) obstruction.
AB  - BACKGROUND: Many HCM patients present with LVOT obstruction, mitral regurgitation (MR), and diastolic dysfunction, often requiring invasive therapies for symptomatic relief. However, a significant proportion of truly asymptomatic patients can be closely monitored. In HCM patients, exercise echocardiography has been shown to be a useful assessment of functional capacity and risk stratification.
AB  - METHODS: We included 426 HCM patients (44 +/- 14 years; 78% men) undergoing exercise echocardiography, excluding hypertensive heart disease of elderly, ejection fraction <50% and invasive therapy (myectomy or alcohol ablation) during follow-up. Clinical, echocardiographic (LV thickness, LVOT gradient, and MR) and exercise variables (percent of age-sex predicted metabolic equivalents [METs] and heart rate recovery [HRR] at 1 min post-exercise) were recorded. A composite endpoint of death, appropriate internal defibrillator discharge, and admission for congestive heart failure was recorded.
AB  - RESULTS: Patients were asymptomatic or minimally symptomatic on history, but 82% of patients achieved <100% of age-sex predicted METs, and 43% had >II+ post-stress MR. The mean LV septal thickness, post-exercise LVOT gradient, and HRR were 2.0 +/- 0.5 cm, 62 +/- 47 mm Hg, and 31 +/- 14 beats/min, respectively. During a mean follow-up of 8.7 +/- 3 years, there were 52 events (12%). Patients achieving >100% of age-sex predicted METs had 1% event rate versus 12% in those achieving <85%. On stepwise multivariate survival analysis, percent of age-sex predicted METs (hazard ratio [HR]: 0.76; 95% confidence interval [CI]: 0.64 to 0.90), abnormal HRR (HR: 0.89; 95% CI: 0.82 to 0.97), and atrial fibrillation (HR: 2.73; 95% CI: 1.30 to 5.74) (overall, p < 0.001) independently predicted outcomes.
AB  - CONCLUSIONS: In asymptomatic or minimally symptomatic HCM patients, exercise stress testing provides excellent risk stratification, with a low event rate in patients achieving >100% of predicted METs.Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
ES  - 1876-7591
IL  - 1876-7591
DI  - S1936-878X(13)00737-7
DO  - http://dx.doi.org/10.1016/j.jcmg.2013.08.010
PT  - Journal Article
LG  - English
EP  - 20131127
DP  - 2014 Jan
DC  - 20140117
YR  - 2014
ED  - 20150106
RD  - 20160518
UP  - 20160519
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=24290569

<169. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24367007
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Nakaya H
FA  - Nakaya, Haruaki
IN  - Nakaya,Haruaki. 1Department of Pharmacology, Chiba University Graduate School of Medicine, Chiba, Japan.
TI  - Role of ATP-sensitive K+ channels in cardiac arrhythmias. [Review]
SO  - Journal of Cardiovascular Pharmacology & Therapeutics. 19(3):237-43, 2014 May.
AS  - J Cardiovasc Pharmacol Ther. 19(3):237-43, 2014 May.
NJ  - Journal of cardiovascular pharmacology and therapeutics
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - dk2, 9602617
SB  - Index Medicus
CP  - United States
MH  - *Arrhythmias, Cardiac/pp [Physiopathology]
MH  - Exercise/ph [Physiology]
MH  - Humans
MH  - *KATP Channels/me [Metabolism]
MH  - Potassium Channels/me [Metabolism]
MH  - Potassium Channels, Inwardly Rectifying/me [Metabolism]
MH  - *Reperfusion Injury/pp [Physiopathology]
MH  - Sarcolemma/me [Metabolism]
KW  - ATP-sensitive K+ channel;  J wave syndrome;  Kir6.1;  Kir6.2
AB  - The sarcolemmal adenosine triphosphate (ATP)-sensitive K(+) (sarcKATP) channel in the heart is a hetero-octamer comprising the pore-forming subunit Kir6.2 and the regulatory subunit sulfonylurea receptor SUR2A. By functional analysis of genetically engineered mice lacking sarcKATP channels, the pathophysiological roles of the K(+) channel in the heart have been extensively evaluated. Although mitochondrial KATP (mitoKATP) channel is proposed to be an important effector for the protection of ischemic myocardium and the inhibition of ischemia/reperfusion-induced ventricular arrhythmias, the molecular identity of mitoKATP channel has not been established. Although selective sarcKATP-channel blockers can prevent ischemia/reperfusion-induced ventricular arrhythmias by inhibiting the action potential shortening in the acute phase, the drugs may aggravate the ischemic damages due to intracellular Ca(2+) overload. The sarcKATP channel is also mandatory for optimal adaptation to hemodynamic stress such as sympathetic activation. Dysfunction of mutated sarcKATP channels in atrial cells may lead to electrical instability and atrial fibrillation. Recently, it has been proposed that the gain-of-function mutation of cardiac Kir6.1 channel can be a pathogenic substrate for J wave syndromes, a cause of idiopathic ventricular fibrillation as early repolarization syndrome or Brugada syndrome, whereas loss of function of the channel mutations can underlie sudden infant death syndrome. However, precise role of Kir6.1 channels in cardiac cells remains to be defined and further study may be needed to clarify the role of Kir6.1 channel in the heart.
RN  - 0 (KATP Channels)
RN  - 0 (Kir6.2 channel)
RN  - 0 (Potassium Channels)
RN  - 0 (Potassium Channels, Inwardly Rectifying)
RN  - 0 (mitochondrial K(ATP) channel)
RN  - 0 (uK-ATP-1 potassium channel)
ES  - 1940-4034
IL  - 1074-2484
DO  - http://dx.doi.org/10.1177/1074248413515078
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
LG  - English
EP  - 20131223
DP  - 2014 May
DC  - 20140417
YR  - 2014
ED  - 20150105
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24367007

<170. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24762248
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Barrios V
AU  - Escobar C
AU  - Calderon A
AU  - Zamorano JL
FA  - Barrios, Vivencio
FA  - Escobar, Carlos
FA  - Calderon, Alberto
FA  - Zamorano, Jose L
IN  - Barrios,Vivencio. Cardiology Department, Hospital Ramon y Cajal, Madrid, Spain.
TI  - Prevalence of renal dysfunction according to the type of atrial fibrillation and anticoagulation treatment in patients who attended primary care in Spain.
SO  - Future Cardiology. 10(2):215-20, 2014 Mar.
AS  - Future Cardiol. 10(2):215-20, 2014 Mar.
NJ  - Future cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101239345
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/cl [Classification]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Cross-Sectional Studies
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/tu [Therapeutic Use]
MH  - Prevalence
MH  - Primary Health Care
MH  - *Renal Insufficiency, Chronic/ep [Epidemiology]
MH  - Spain/ep [Epidemiology]
AB  - AIM: To determine the prevalence of renal dysfunction according to the type of atrial fibrillation (AF) and anticoagulation treatment in patients attended in primary care in Spain. METHODS & PARTICIPANTS: The VAL-FAAP study was a national, descriptive, epidemiological and cross-sectional study that included patients of both sexes, >18 years of age, with a previous diagnosis of AF by an ECG, attended in a primary-care setting. Renal function was defined by estimated glomerular filtration rate (eGFR), calculated by the modification of diet in renal disease-4 formula.
AB  - RESULTS: A total of 3287 patients with atrial fibrillation were included (mean age: 71.9 +/- 10.1 years; 52.3% male). Overall, 31.6% of patients had an eGFR <60 ml/min/1.73m(2) and 1.6% <30 ml/min/1.73m(2). The proportion of patients with permanent AF increased as the eGFR decreased. Similarly, as congestive heart failure, hypertension, age >75 years (doubled), diabetes mellitus, stroke (doubled), vascular disease, age 65-74 years, sex category (CHA2DS2-VASc) increased, chronic kidney disease was more frequent. A third of patients with CHA2DS2-VASc >2 had moderate renal dysfunction; however, 35.5% of them did not receive anticoagulants (compared with 31.5% of those with CHA2DS2-VASc >2 and normal renal function).
AB  - CONCLUSION: Chronic kidney disease is common in patients with AF, particularly in those patients with permanent AF or CHA2DS2-VASc >2. Although indicated, 35.5% of patients with AF, a CHA2DS2-VASc >2 and moderate renal dysfunction did not receive appropriate anticoagulation, despite the high risk of stroke.
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
ES  - 1744-8298
IL  - 1479-6678
DO  - http://dx.doi.org/10.2217/fca.14.2
PT  - Journal Article
LG  - English
DP  - 2014 Mar
DC  - 20140425
YR  - 2014
ED  - 20150101
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24762248

<171. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24563055
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gabrielli L
AU  - Bijnens BH
AU  - Butakoff C
AU  - Duchateau N
AU  - Montserrat S
AU  - Merino B
AU  - Gutierrez J
AU  - Pare C
AU  - Mont L
AU  - Brugada J
AU  - Sitges M
FA  - Gabrielli, Luigi
FA  - Bijnens, Bart H
FA  - Butakoff, Constantine
FA  - Duchateau, Nicolas
FA  - Montserrat, Silvia
FA  - Merino, Beatriz
FA  - Gutierrez, Josep
FA  - Pare, Carles
FA  - Mont, Lluis
FA  - Brugada, Josep
FA  - Sitges, Marta
IN  - Gabrielli,Luigi. Thorax Clinic Institute, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain, lgabrielli@med.puc.cl.
TI  - Atrial functional and geometrical remodeling in highly trained male athletes: for better or worse?.
SO  - European Journal of Applied Physiology. 114(6):1143-52, 2014 Jun.
AS  - Eur J Appl Physiol. 114(6):1143-52, 2014 Jun.
NJ  - European journal of applied physiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 100954790, dos
SB  - Index Medicus
CP  - Germany
MH  - Adult
MH  - Athletes
MH  - *Atrial Function
MH  - *Atrial Remodeling
MH  - Case-Control Studies
MH  - *Exercise/ph [Physiology]
MH  - Heart Atria/us [Ultrasonography]
MH  - Humans
MH  - Male
MH  - Models, Cardiovascular
AB  - PURPOSE: Highly trained athletes have an increased risk of atrial arrhythmias. Atrial geometrical and functional remodeling may be the underlying substrate. We analyze and relate atrial size, deformation and performance in professional handball players compared with non-sportive subjects.
AB  - METHODS: 24 Professional handball players and 20 non-sportive males were compared. All subjects underwent an echocardiographic study with evaluation of left (LA), right atrial (RA) dimensions and deformation by strain (Sa) and strain rate (SRa). Atrial performance was assessed from the atrial stroke volume (SV). With computational geometrical models, we studied the relation between atrial volumes, strains and SV and compared atrial working conditions. We estimated the functional reserve and a resulting average wall stress.
AB  - RESULTS: LA and RA volumes were larger in athletes than in controls (35.2 +/- 8.8 vs. 24.8 +/- 4.3 ml/m(2), p < 0.01 and 29.0 +/- 8.4 vs. 19.0 +/- 5.1 ml/m(2), p < 0.01 respectively). LASa and RASa during active atrial contraction were decreased in athletes (-12.2 +/- 2.0 vs. -14.5 +/- 2.1%, p < 0.01 and -12.1 +/- 1.8 vs. -14.2 +/- 1.5%, p < 0.01 respectively). LASV was similar between groups (6.6 +/- 1.4 vs. 7.3 +/- 1.1 ml, p = 0.19) and RASV was lower in athletes (6.2 +/- 1.3 vs. 7.2 +/- 1.1 ml, p < 0.01). Computational models showed that this different operational mode potentially increases performance reserve, but at the cost of higher atrial wall stress.
AB  - CONCLUSION: A proportion of athletes with enlarged LA and RA showed different atrial contractile performance, likely resulting in atria working at higher wall stress.
ES  - 1439-6327
IL  - 1439-6319
DO  - http://dx.doi.org/10.1007/s00421-014-2845-6
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20140222
DP  - 2014 Jun
DC  - 20140514
YR  - 2014
ED  - 20141228
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24563055

<172. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23664436
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Monz BU
AU  - Connolly SJ
AU  - Korhonen M
AU  - Noack H
AU  - Pooley J
FA  - Monz, B U
FA  - Connolly, S J
FA  - Korhonen, M
FA  - Noack, H
FA  - Pooley, J
IN  - Monz,B U. Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany.
TI  - Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study.
SO  - International Journal of Cardiology. 168(3):2540-7, 2013 Oct 3.
AS  - Int J Cardiol. 168(3):2540-7, 2013 Oct 3.
NJ  - International journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - gqw, 8200291
SB  - Index Medicus
CP  - Netherlands
MH  - Aged
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - *Antithrombins/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - *Benzimidazoles/tu [Therapeutic Use]
MH  - Dabigatran
MH  - Female
MH  - Humans
MH  - Male
MH  - Prospective Studies
MH  - *Quality of Life
MH  - *Warfarin/tu [Therapeutic Use]
MH  - *beta-Alanine/aa [Analogs & Derivatives]
MH  - beta-Alanine/tu [Therapeutic Use]
KW  - Atrial fibrillation;  Dabigatran;  Health-related quality of life;  Oral anticoagulation;  Warfarin
AB  - BACKGROUND: Anticoagulation is recommended in patients with atrial fibrillation (AF) to prevent strokes. Vitamin K antagonists, such as warfarin, are associated with numerous practical limitations--frequent anticoagulation monitoring, lifestyle and dietary restrictions--that complicate patient management and may impact health-related quality of life (HRQoL). This study derived HRQoL estimates for AF patients receiving warfarin or dabigatran etexilate (dabigatran), a new oral anticoagulant not requiring anticoagulation monitoring, during one year of stable treatment, i.e. in the absence of outcome events, such as strokes or major bleedings.
AB  - METHODS: Changes in HRQoL over time and between treatments were assessed using the EQ-5D (utility and Visual Analogue Scale (VAS) scores) at baseline, 3 and 12 months in a sub-group of 1435 patients participating in the RE-LY trial. RE-LY was a phase III study that compared the safety and efficacy of warfarin, dabigatran 150 mg bid and dabigatran 110 mg bid for stroke prevention in patients with AF.
AB  - RESULTS: Utilities ranged from 0.805 (dabigatran 150 mg bid) to 0.811 (dabigatran 110 mg bid) at baseline, and did not change over the one year observation period. No differences between the dabigatran groups and warfarin were statistically significant except for the dabigatran 150 mg bid group at 3 months. Similarly, none of the within-group or between-group differences in VAS scores were statistically significant.
AB  - CONCLUSIONS: Over the course of one year, all anticoagulated patients without outcome events (e.g. strokes or major bleedings) had stable HRQoL. Scores between dabigatran and warfarin were comparable, which was unexpected given the known complexities of warfarin treatment.Copyright © 2013. Published by Elsevier Ireland Ltd.
RN  - 0 (Anticoagulants)
RN  - 0 (Antithrombins)
RN  - 0 (Benzimidazoles)
RN  - 11P2JDE17B (beta-Alanine)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - I0VM4M70GC (Dabigatran)
ES  - 1874-1754
IL  - 0167-5273
DI  - S0167-5273(13)00478-6
DO  - http://dx.doi.org/10.1016/j.ijcard.2013.03.059
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20130508
DP  - 2013 Oct 3
DC  - 20131014
YR  - 2013
ED  - 20141222
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23664436

<173. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24781247
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Bos MJ
AU  - Koudstaal PJ
AU  - Hofman A
AU  - Ikram MA
FA  - Bos, Michiel J
FA  - Koudstaal, Peter J
FA  - Hofman, Albert
FA  - Ikram, M Arfan
IN  - Bos,Michiel J. Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.
IN  - Koudstaal,Peter J. Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands.
IN  - Hofman,Albert. Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.
IN  - Ikram,M Arfan. Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands; Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands; Department of Radiology, Erasmus Medical Center, Rotterdam, The Netherlands.
TI  - Modifiable etiological factors and the burden of stroke from the Rotterdam study: a population-based cohort study.
CM  - Comment in: PLoS Med. 2014 Apr;11(4):e1001637; PMID: 24781372
SO  - PLoS Medicine / Public Library of Science. 11(4):e1001634, 2014 Apr.
AS  - PLoS Med. 11(4):e1001634, 2014 Apr.
NJ  - PLoS medicine
PI  - Journal available in: Electronic-eCollection
PI  - Citation processed from: Internet
JC  - 101231360
OI  - Source: NLM. PMC4004543
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Cohort Studies
MH  - *Cost of Illness
MH  - Diet
MH  - Female
MH  - Humans
MH  - Hypertension/co [Complications]
MH  - Male
MH  - Middle Aged
MH  - Netherlands/ep [Epidemiology]
MH  - Prospective Studies
MH  - Risk Factors
MH  - Smoking/ae [Adverse Effects]
MH  - *Stroke/ep [Epidemiology]
MH  - *Stroke/et [Etiology]
AB  - BACKGROUND: Stroke prevention requires effective treatment of its causes. Many etiological factors for stroke have been identified, but the potential gain of effective intervention on these factors in terms of numbers of actually prevented strokes remains unclear because of the lack of data from cohort studies. We assessed the impact of currently known potentially modifiable etiological factors on the occurrence of stroke.
AB  - METHODS AND FINDINGS: This population-based cohort study was based on 6,844 participants of the Rotterdam Study who were aged >55 y and free from stroke at baseline (1990-1993). We computed population attributable risks (PARs) for individual risk factors and for risk factors in combination to estimate the proportion of strokes that could theoretically be prevented by the elimination of etiological factors from the population. The mean age at baseline was 69.4 y (standard deviation 6.3 y). During follow-up (mean follow-up 12.9 y, standard deviation 6.3 y), 1,020 strokes occurred. The age- and sex-adjusted combined PAR of prehypertension/hypertension, smoking, diabetes mellitus, atrial fibrillation, coronary disease, and overweight/obesity was 0.51 (95% CI 0.41-0.62) for any stroke; hypertension and smoking were the most important etiological factors. C-reactive protein, fruit and vegetable consumption, and carotid intima-media thickness in combination raised the total PAR by 0.06. The PAR was 0.55 (95% CI 0.41-0.68) for ischemic stroke and 0.70 (95% CI 0.45-0.87) for hemorrhagic stroke. The main limitations of our study are that our study population comprises almost exclusively Caucasians who live in a middle and high income area, and that risk factor awareness is higher in a study cohort than in the general population.
AB  - CONCLUSIONS: About half of all strokes are attributable to established causal and modifiable factors. This finding encourages not only intervention on established etiological factors, but also further study of less well established factors. Please see later in the article for the Editors' Summary.
ES  - 1549-1676
IL  - 1549-1277
DO  - http://dx.doi.org/10.1371/journal.pmed.1001634
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20140429
DP  - 2014 Apr
DC  - 20140430
YR  - 2014
ED  - 20141211
RD  - 20150806
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24781247

<174. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24569020
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Adamsson Eryd S
AU  - Ostling G
AU  - Rosvall M
AU  - Persson M
AU  - Smith JG
AU  - Melander O
AU  - Hedblad B
AU  - Engstrom G
FA  - Adamsson Eryd, Samuel
FA  - Ostling, Gerd
FA  - Rosvall, Maria
FA  - Persson, Margaretha
FA  - Smith, J Gustav
FA  - Melander, Olle
FA  - Hedblad, Bo
FA  - Engstrom, Gunnar
IN  - Adamsson Eryd,Samuel. Cardiovascular Epidemiology Research Group, Department of Clinical Sciences, Lund University, Skane University Hospital, Clinical Research Centre Building 60, Floor 13, Jan Waldenstroms Gata 35, 20502 Malmo, Sweden. Electronic address: samuel.adamsson_eryd@med.lu.se.
IN  - Ostling,Gerd. Cardiovascular Epidemiology Research Group, Department of Clinical Sciences, Lund University, Skane University Hospital, Clinical Research Centre Building 60, Floor 13, Jan Waldenstroms Gata 35, 20502 Malmo, Sweden.
IN  - Rosvall,Maria. Cardiovascular Epidemiology Research Group, Department of Clinical Sciences, Lund University, Skane University Hospital, Clinical Research Centre Building 60, Floor 13, Jan Waldenstroms Gata 35, 20502 Malmo, Sweden.
IN  - Persson,Margaretha. Cardiovascular Epidemiology Research Group, Department of Clinical Sciences, Lund University, Skane University Hospital, Clinical Research Centre Building 60, Floor 13, Jan Waldenstroms Gata 35, 20502 Malmo, Sweden.
IN  - Smith,J Gustav. Department of Cardiology, Lund University, Lund, Sweden.
IN  - Melander,Olle. Cardiovascular Epidemiology Research Group, Department of Clinical Sciences, Lund University, Skane University Hospital, Clinical Research Centre Building 60, Floor 13, Jan Waldenstroms Gata 35, 20502 Malmo, Sweden.
IN  - Hedblad,Bo. Cardiovascular Epidemiology Research Group, Department of Clinical Sciences, Lund University, Skane University Hospital, Clinical Research Centre Building 60, Floor 13, Jan Waldenstroms Gata 35, 20502 Malmo, Sweden.
IN  - Engstrom,Gunnar. Cardiovascular Epidemiology Research Group, Department of Clinical Sciences, Lund University, Skane University Hospital, Clinical Research Centre Building 60, Floor 13, Jan Waldenstroms Gata 35, 20502 Malmo, Sweden.
TI  - Carotid intima-media thickness is associated with incidence of hospitalized atrial fibrillation.
CM  - Comment in: Atherosclerosis. 2014 Apr;233(2):679-81; PMID: 24569021
SO  - Atherosclerosis. 233(2):673-8, 2014 Apr.
AS  - Atherosclerosis. 233(2):673-8, 2014 Apr.
NJ  - Atherosclerosis
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 95x, 0242543
SB  - Index Medicus
CP  - Ireland
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Fibrillation/bl [Blood]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/pa [Pathology]
MH  - Carotid Artery Diseases/bl [Blood]
MH  - *Carotid Artery Diseases/ep [Epidemiology]
MH  - Carotid Artery Diseases/pa [Pathology]
MH  - Carotid Artery, Common/us [Ultrasonography]
MH  - *Carotid Intima-Media Thickness
MH  - Comorbidity
MH  - Diet
MH  - Female
MH  - Hospitalization/sn [Statistics & Numerical Data]
MH  - Humans
MH  - Hypertension/ep [Epidemiology]
MH  - Incidence
MH  - Lipids/bl [Blood]
MH  - Male
MH  - Middle Aged
MH  - Overweight/ep [Epidemiology]
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Prospective Studies
MH  - Risk Factors
MH  - Sex Factors
MH  - Smoking/ep [Epidemiology]
MH  - Socioeconomic Factors
MH  - Sweden/ep [Epidemiology]
KW  - Atrial fibrillation;  Epidemiology;  Intima-media thickness;  Population;  Risk factors
AB  - OBJECTIVE: Carotid intima-media thickness (IMT) is a measure of arterial thickening and a risk predictor for myocardial infarction and stroke. It is unclear whether IMT also predicts atrial fibrillation (AF). We explored the association between IMT and incidence of first AF hospitalization in a population-based cohort.
AB  - METHODS: IMT was measured in 4846 subjects from the general population (aged 46-68 years, 60% women) without a history of AF, heart failure or myocardial infarction. The Swedish in-patient register was used for retrieval of AF cases. IMT was studied in relation to incidence of AF.
AB  - RESULTS: During a mean follow-up of 15.3 years, 353 subjects (181 men, 172 women, 4.8 per 1000 person-years) were hospitalized with a diagnosis of AF. After adjustment for cardiovascular risk factors, the hazard ratio (HR) for incidence of AF was 1.61 (95% confidence interval (CI): 1.14-2.27) for 4th vs. 1st quartile of IMT in the common carotid artery. This relationship was also independent of occurrence of carotid plaque. The results were similar for IMT in the bifurcation.
AB  - CONCLUSION: Carotid IMT was independently associated with incidence of hospitalized AF in this study of middle-aged subjects from the general population. The results suggest that arterial thickening can predict future AF.Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
RN  - 0 (Lipids)
ES  - 1879-1484
IL  - 0021-9150
DI  - S0021-9150(14)00077-X
DO  - http://dx.doi.org/10.1016/j.atherosclerosis.2014.01.050
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20140205
DP  - 2014 Apr
DC  - 20140324
YR  - 2014
ED  - 20141211
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24569020

<175. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25399274
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Reddy VY
AU  - Sievert H
AU  - Halperin J
AU  - Doshi SK
AU  - Buchbinder M
AU  - Neuzil P
AU  - Huber K
AU  - Whisenant B
AU  - Kar S
AU  - Swarup V
AU  - Gordon N
AU  - Holmes D
AU  - PROTECT AF Steering Committee and Investigators
FA  - Reddy, Vivek Y
FA  - Sievert, Horst
FA  - Halperin, Jonathan
FA  - Doshi, Shephal K
FA  - Buchbinder, Maurice
FA  - Neuzil, Petr
FA  - Huber, Kenneth
FA  - Whisenant, Brian
FA  - Kar, Saibal
FA  - Swarup, Vijay
FA  - Gordon, Nicole
FA  - Holmes, David
FA  - PROTECT AF Steering Committee and Investigators
IN  - Reddy,Vivek Y. Mount Sinai School of Medicine, New York City, New York2St John's Health Center, Santa Monica, California3Homolka Hospital, Prague, Czech Republic.
IN  - Sievert,Horst. Cardiovascular Center Frankfurt, Sankt Katharinen, Frankfurt, Germany.
IN  - Halperin,Jonathan. Mount Sinai School of Medicine, New York City, New York.
IN  - Doshi,Shephal K. St John's Health Center, Santa Monica, California.
IN  - Buchbinder,Maurice. Foundation for Cardiovascular Medicine, La Jolla, California.
IN  - Neuzil,Petr. Homolka Hospital, Prague, Czech Republic.
IN  - Huber,Kenneth. St Luke's Hospital, Kansas City, Missouri.
IN  - Whisenant,Brian. Intermountain Medical Center, Murray, Utah.
IN  - Kar,Saibal. Cedars Sinai Medical Center, Los Angeles, California.
IN  - Swarup,Vijay. Arizona Heart Rhythm Center, Scottsdale.
IN  - Gordon,Nicole. Boston Scientific, St Paul, Minnesota.
IN  - Holmes,David. Mayo Clinic College of Medicine, Rochester, Minnesota.
IR  - Holmes DR
IR  - Buchbinder M
IR  - Chinitz L
IR  - Douglas P
IR  - Gurley J
IR  - Reddy VY
IR  - Sick P
IR  - Turi ZG
IR  - Hustead ST
IR  - Asinger RW
IR  - Shear W
IR  - Pulling C
IR  - Lew B
IR  - Plucinski D
IR  - Rogers E
IR  - Neuzil P
IR  - Sievert H
IR  - Mobius-Winkler S
IR  - Sick P
IR  - Tucker K
IR  - Doshi S
IR  - Swarup V
IR  - Bahu M
IR  - Quesada R
IR  - Huber K
IR  - Reddy V
IR  - Buchbinder M
IR  - Whisenant B
IR  - Almany S
IR  - Holmes DR
IR  - Siegel RM
IR  - Garg A
IR  - Mishkel G
IR  - Ramee S
IR  - Kar S
IR  - Maini B
IR  - Matthews R
IR  - Burstein S
IR  - Horton R
IR  - Mahoney P
IR  - Onufer J
IR  - Baran K
IR  - Adler S
IR  - Skelding K
IR  - Gurley J
IR  - Shah M
IR  - Yakubov SJ
IR  - Leon A
IR  - Block PC
IR  - Fail P
IR  - Abben R
IR  - Reisman M
IR  - Tomassoni G
IR  - Bhoopalam V
IR  - Anderson W
IR  - Pickett RA
IR  - Wolfe D
IR  - Low R
IR  - Feldman T
IR  - Sallinger M
IR  - Irwin J
IR  - Lopez J
IR  - Knight B
IR  - Lim S
IR  - Chinitz L
IR  - Razavi M
IR  - Wilbur D
IR  - Leya F
IR  - Turi ZG
IR  - Raybuck B
IR  - Waksman R
IR  - Sievert H
IR  - Kalbfleisch S
IR  - Mooney M
IR  - Gray W
IR  - Kunz G
IR  - Foster M
IR  - Good E
IR  - Tuzcu M
IR  - St Goar F
IR  - Josephson R
IR  - Jacobs W
IR  - Dave R
IR  - Young J
IR  - Lasorda D
TI  - Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial.[Erratum appears in JAMA. 2015 Mar 10;313(10):1061]
CM  - Comment in: JAMA. 2015 Mar 10;313(10):1057-8; PMID: 25756446
CM  - Comment in: Evid Based Med. 2015 Jun;20(3):101; PMID: 25786799
CM  - Comment in: Ann Intern Med. 2015 Apr 21;162(8):JC4; PMID: 25894049
CM  - Comment in: JAMA. 2015 Mar 10;313(10):1057; PMID: 25756445
SO  - JAMA. 312(19):1988-98, 2014 Nov 19.
AS  - JAMA. 312(19):1988-98, 2014 Nov 19.
NJ  - JAMA
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 7501160
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - *Atrial Appendage/pp [Physiopathology]
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Bayes Theorem
MH  - Cardiac Catheterization
MH  - Cardiovascular Diseases/pc [Prevention & Control]
MH  - *Embolism/pc [Prevention & Control]
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Prosthesis Implantation
MH  - Risk Factors
MH  - *Stroke/pc [Prevention & Control]
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - *Warfarin/tu [Therapeutic Use]
AB  - IMPORTANCE: While effective in preventing stroke in patients with atrial fibrillation (AF), warfarin is limited by a narrow therapeutic profile, a need for lifelong coagulation monitoring, and multiple drug and diet interactions.
AB  - OBJECTIVE: To determine whether a local strategy of mechanical left atrial appendage (LAA) closure was noninferior to warfarin.
AB  - DESIGN, SETTING, AND PARTICIPANTS: PROTECT AF was a multicenter, randomized (2:1), unblinded, Bayesian-designed study conducted at 59 hospitals of 707 patients with nonvalvular AF and at least 1 additional stroke risk factor (CHADS2 score >1). Enrollment occurred between February 2005 and June 2008 and included 4-year follow-up through October 2012. Noninferiority required a posterior probability greater than 97.5% and superiority a probability of 95% or greater; the noninferiority margin was a rate ratio of 2.0 comparing event rates between treatment groups.
AB  - INTERVENTIONS: Left atrial appendage closure with the device (n=463) or warfarin (n=244; target international normalized ratio, 2-3).
AB  - MAIN OUTCOMES AND MEASURES: A composite efficacy end point including stroke, systemic embolism, and cardiovascular/unexplained death, analyzed by intention-to-treat.
AB  - RESULTS: At a mean (SD) follow-up of 3.8 (1.7) years (2621 patient-years), there were 39 events among 463 patients (8.4%) in the device group for a primary event rate of 2.3 events per 100 patient-years, compared with 34 events among 244 patients (13.9%) for a primary event rate of 3.8 events per 100 patient-years with warfarin (rate ratio, 0.60; 95% credible interval, 0.41-1.05), meeting prespecified criteria for both noninferiority (posterior probability, >99.9%) and superiority (posterior probability, 96.0%). Patients in the device group demonstrated lower rates of both cardiovascular mortality (1.0 events per 100 patient-years for the device group [17/463 patients, 3.7%] vs 2.4 events per 100 patient-years with warfarin [22/244 patients, 9.0%]; hazard ratio [HR], 0.40; 95% CI, 0.21-0.75; P=.005) and all-cause mortality (3.2 events per 100 patient-years for the device group [57/466 patients, 12.3%] vs 4.8 events per 100 patient-years with warfarin [44/244 patients, 18.0%]; HR, 0.66; 95% CI, 0.45-0.98; P=.04).
AB  - CONCLUSIONS AND RELEVANCE: After 3.8 years of follow-up among patients with nonvalvular AF at elevated risk for stroke, percutaneous LAA closure met criteria for both noninferiority and superiority, compared with warfarin, for preventing the combined outcome of stroke, systemic embolism, and cardiovascular death, as well as superiority for cardiovascular and all-cause mortality.
AB  - TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00129545.
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
ES  - 1538-3598
IL  - 0098-7484
DO  - http://dx.doi.org/10.1001/jama.2014.15192
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
SI  - ClinicalTrials.gov
SA  - ClinicalTrials.gov/NCT00129545
SL  - http://clinicaltrials.gov/search/term=NCT00129545
LG  - English
DP  - 2014 Nov 19
DC  - 20141117
YR  - 2014
ED  - 20141208
RD  - 20150721
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25399274

<176. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25230424
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Anonymous
TI  - Extra-virgin olive oil may lower afib risk.
SO  - Harvard Heart Letter. 24(12):8, 2014 Aug.
AS  - Harv Heart Lett. 24(12):8, 2014 Aug.
NJ  - Harvard heart letter : from Harvard Medical School
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9425723, c2z
SB  - Consumer Health Journals
CP  - United States
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - *Diet, Mediterranean
MH  - *Dietary Fats, Unsaturated/ad [Administration & Dosage]
MH  - Humans
MH  - Olive Oil
MH  - *Plant Oils/ad [Administration & Dosage]
MH  - *Risk Reduction Behavior
MH  - Stroke/pc [Prevention & Control]
RN  - 0 (Dietary Fats, Unsaturated)
RN  - 0 (Olive Oil)
RN  - 0 (Plant Oils)
IS  - 1051-5313
IL  - 1051-5313
PT  - News
LG  - English
DP  - 2014 Aug
DC  - 20140917
YR  - 2014
ED  - 20141204
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25230424

<177. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25169984
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Myrstad M
AU  - Nystad W
AU  - Graff-Iversen S
AU  - Thelle DS
AU  - Stigum H
AU  - Aaronaes M
AU  - Ranhoff AH
FA  - Myrstad, Marius
FA  - Nystad, Wenche
FA  - Graff-Iversen, Sidsel
FA  - Thelle, Dag S
FA  - Stigum, Hein
FA  - Aaronaes, Marit
FA  - Ranhoff, Anette H
IN  - Myrstad,Marius. Department of Internal Medicine, Diakonhjemmet Hospital, Oslo, Norway; Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway. Electronic address: marius.myrstad@fhi.no.
IN  - Nystad,Wenche. Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway.
IN  - Graff-Iversen,Sidsel. Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway.
IN  - Thelle,Dag S. Department of Biostatistics, Institute of Basal Medical Sciences, University of Oslo, Oslo, Norway; Department of Public Health and Community Medicine, Gothenburg University, Gothenburg, Sweden.
IN  - Stigum,Hein. Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway; Department of Preventive Medicine and Epidemiology, Institute of Health and Society, University of Oslo, Oslo, Norway.
IN  - Aaronaes,Marit. Department of Internal Medicine, Diakonhjemmet Hospital, Oslo, Norway.
IN  - Ranhoff,Anette H. Department of Internal Medicine, Diakonhjemmet Hospital, Oslo, Norway; Department of Clinical Science, Kavli Research Center for Geriatrics and Dementia, University of Bergen, Bergen, Norway.
TI  - Effect of years of endurance exercise on risk of atrial fibrillation and atrial flutter.
SO  - American Journal of Cardiology. 114(8):1229-33, 2014 Oct 15.
AS  - Am J Cardiol. 114(8):1229-33, 2014 Oct 15.
NJ  - The American journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Flutter/ep [Epidemiology]
MH  - Atrial Flutter/et [Etiology]
MH  - Atrial Flutter/pp [Physiopathology]
MH  - Electrocardiography
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Norway/ep [Epidemiology]
MH  - *Physical Endurance/ph [Physiology]
MH  - Retrospective Studies
MH  - *Risk Assessment
MH  - Risk Factors
MH  - *Skiing/ph [Physiology]
MH  - Surveys and Questionnaires
MH  - Time Factors
AB  - Emerging evidence suggests that endurance exercise increases the risk for atrial fibrillation (AF) in men, but few studies have investigated the dose-response relation between exercise and risk for atrial arrhythmias. Both exposure to exercise and reference points vary among studies, and previous studies have not differentiated between AF and atrial flutter. The aim of this study was to assess the risk for atrial arrhythmias by cumulative years of regular endurance exercise in men. To cover the range from physical inactivity to long-term endurance exercise, the study sample in this retrospective cohort study was based on 2 distinct cohorts: male participants in a long-distance cross-country ski race and men from the general population, in total 3,545 men aged > 53 years. Arrhythmia diagnoses were validated by electrocardiograms during review of medical records. Regular endurance exercise was self-reported by questionnaire. A broad range of confounding factors was available for adjustment. The adjusted odds ratios per 10 years of regular endurance exercise were 1.16 (95% confidence interval 1.06 to 1.29) for AF and 1.42 (95% confidence interval 1.20 to 1.69) for atrial flutter. In stratified analyses, the associations were significant in cross-country skiers and in men from the general population. In conclusion, cumulative years of regular endurance exercise were associated with a gradually increased risk for AF and atrial flutter.Copyright © 2014 Elsevier Inc. All rights reserved.
ES  - 1879-1913
IL  - 0002-9149
DI  - S0002-9149(14)01508-2
DO  - http://dx.doi.org/10.1016/j.amjcard.2014.07.047
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20140730
DP  - 2014 Oct 15
DC  - 20140927
YR  - 2014
ED  - 20141125
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25169984

<178. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24379127
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Rozanski A
AU  - Gransar H
AU  - Min JK
AU  - Hayes SW
AU  - Friedman JD
AU  - Thomson LE
AU  - Berman DS
FA  - Rozanski, Alan
FA  - Gransar, Heidi
FA  - Min, James K
FA  - Hayes, Sean W
FA  - Friedman, John D
FA  - Thomson, Louise E J
FA  - Berman, Daniel S
IN  - Rozanski,Alan. Division of Cardiology, St. Lukes Roosevelt Hospital, New York, NY, USA, ar77@columbia.edu.
TI  - Long-term mortality following normal exercise myocardial perfusion SPECT according to coronary disease risk factors.
SO  - Journal of Nuclear Cardiology. 21(2):341-50, 2014 Apr.
AS  - J Nucl Cardiol. 21(2):341-50, 2014 Apr.
NJ  - Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - cmd, 9423534
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Age Distribution
MH  - Aged
MH  - *Coronary Artery Disease/mo [Mortality]
MH  - *Coronary Artery Disease/ri [Radionuclide Imaging]
MH  - *Exercise Test/sn [Statistics & Numerical Data]
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Myocardial Perfusion Imaging/sn [Statistics & Numerical Data]
MH  - New York/ep [Epidemiology]
MH  - Prevalence
MH  - Prognosis
MH  - Reference Values
MH  - Reproducibility of Results
MH  - Risk Factors
MH  - Sensitivity and Specificity
MH  - Sex Distribution
MH  - Survival Rate
MH  - *Tomography, Emission-Computed, Single-Photon/sn [Statistics & Numerical Data]
AB  - BACKGROUND: While normal exercise myocardial perfusion imaging (SPECT-MPI) is a robust predictor of low short-term clinical risk, there is increasing interest in ascertaining how clinical factors influence long-term risk following SPECT-MPI.
AB  - METHODS: We evaluated the predictors of outcome from clinical data obtained at the time of testing in 12,232 patients with normal exercise SPECT-MPI studies. All-cause mortality (ACM) was assessed at a mean of 11.2 +/- 4.5 years using the Social Security Death Index.
AB  - RESULTS: The ACM rate was 0.8%/year, but varied markedly according to the presence of CAD risk factors. Hypertension, smoking, diabetes, exercise capacity, dyspnea, obesity, higher resting heart rate, an abnormal ECG, LVH, atrial fibrillation, and LVEF < 45% were all predictors of increased mortality. Risk factors were synergistic in predicting mortality: annualized age and gender-adjusted ACM rates ranged from only 0.2%/year among patients exercising for >9 minutes having none of three significant risk factors (among hypertension, diabetes, and smoking) to 1.6%/year among patients exercising <6 minutes and having > 2 of these three risk factors. The age and gender-adjusted hazard ratio for mortality was increased by 7.3 (95% confidence interval 5.5-9.7) in the latter patients compared to those patients who exercised >9 minutes and had no significant risk factors (P < .001).
AB  - CONCLUSIONS: Long-term mortality risk varies markedly in accordance with baseline CAD risk factors and functional capacity among patients with normal exercise SPECT-MPI studies. Further study is indicated to determine whether the prospective characterization of both short-term and long-term risks following the performance of stress SPECT-MPI leads to improved clinical management.
ES  - 1532-6551
IL  - 1071-3581
DO  - http://dx.doi.org/10.1007/s12350-013-9830-z
PT  - Journal Article
LG  - English
EP  - 20131231
DP  - 2014 Apr
DC  - 20140326
YR  - 2014
ED  - 20141118
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24379127

<179. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24206389
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Chen WR
AU  - Liu ZY
AU  - Shi Y
AU  - Yin da W
AU  - Wang H
AU  - Sha Y
AU  - Chen YD
FA  - Chen, Wei Ren
FA  - Liu, Zhi Ying
FA  - Shi, Yang
FA  - Yin, Da Wei
FA  - Wang, Hao
FA  - Sha, Yuan
FA  - Chen, Yun Dai
IN  - Chen,Wei Ren. Department of Cardiology, South-Building, PLA General Hospital, Beijing, China.
TI  - Relation of low vitamin D to nonvalvular persistent atrial fibrillation in Chinese patients.
SO  - Annals of Noninvasive Electrocardiology. 19(2):166-73, 2014 Mar.
AS  - Ann Noninvasive Electrocardiol. 19(2):166-73, 2014 Mar.
NJ  - Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - dzb, 9607443
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Atrial Fibrillation/bl [Blood]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Blood Pressure/ph [Physiology]
MH  - C-Reactive Protein
MH  - China
MH  - Female
MH  - Heart Atria/pp [Physiopathology]
MH  - Heart Atria/us [Ultrasonography]
MH  - Humans
MH  - Luminescent Measurements/mt [Methods]
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - *Vitamin D/aa [Analogs & Derivatives]
MH  - Vitamin D/bl [Blood]
KW  - atrial fibrillation;  echocardiography;  high-sensitivity C-reactive protein (hsCRP);  vitamin D
AB  - BACKGROUND: Low vitamin D status has been associated with increased risk of cardiovascular disease. Atrial fibrillation (AF) is the most common cardiac arrhythmia. We evaluated the association between low vitamin D and AF.
AB  - METHODS: We analyzed data from 162 Chinese patients with nonvalvular persistent AF and no other cardiovascular disease whose serum 25-hydroxyvitamin D [25(OH)D] levels were measured in our hospital (AF group). Healthy subjects without AF who underwent health screening at our hospital served as controls (non-AF group, n = 160). 25(OH)D was measured by chemiluminescence assay.
AB  - RESULTS: The serum 25(OH)D level was significantly lower in the AF group than in the non-AF group (18.5 +/- 10.3 vs 21.4 +/- 10.7 ng/mL, P < 0.05). The high-sensitivity C-reactive protein (hsCRP) level was significantly higher in the AF group than in the non-AF group (0.35 +/- 0.19 vs 0.2 +/- 0.17 mg/dL, P < 0.01). The average left atrial diameter was significantly larger in the AF group than in the non-AF group (P < 0.01). The serum 25(OH)D level showed a negative correlation with left atrial diameter, hsCRP level, and pulmonary artery systolic pressure. Logistic regression analysis identified that 25(OH)D was related to AF. Patients whose vitamin D levels were in the lowest 25(OH)D category (<20 ng/mL) were more often in the AF group, with their incidence about twofold higher than those in the highest 25(OH)D category (>30 ng/mL).
AB  - CONCLUSIONS: Low vitamin D levels are associated with AF. It may be involved in its development.Copyright ©2013 Wiley Periodicals, Inc.
RN  - 1406-16-2 (Vitamin D)
RN  - 64719-49-9 (25-hydroxyvitamin D)
RN  - 9007-41-4 (C-Reactive Protein)
ES  - 1542-474X
IL  - 1082-720X
DO  - http://dx.doi.org/10.1111/anec.12105
PT  - Journal Article
LG  - English
EP  - 20131108
DP  - 2014 Mar
DC  - 20140313
YR  - 2014
ED  - 20141118
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24206389

<180. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25244269
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Yaylaci S
AU  - Kocayigit I
AU  - Aydin E
AU  - Osken A
AU  - Genc AB
AU  - Cakar MA
AU  - Tamer A
FA  - Yaylaci, S
FA  - Kocayigit, I
FA  - Aydin, E
FA  - Osken, A
FA  - Genc, A B
FA  - Cakar, M A
FA  - Tamer, A
IN  - Yaylaci,S. Department of Internal Medicine, Findikli State Hospital, Rize, Turkey.
TI  - Clinical and laboratory findings in mad honey poisoning: a single center experience.
SO  - Nigerian Journal of Clinical Practice. 17(5):589-93, 2014 Sep-Oct.
AS  - Niger J Clin Pract. 17(5):589-93, 2014 Sep-Oct.
NJ  - Nigerian journal of clinical practice
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101150032
SB  - Index Medicus
CP  - India
MH  - Adult
MH  - Aged
MH  - Arrhythmias, Cardiac/pp [Physiopathology]
MH  - *Diterpenes/po [Poisoning]
MH  - Female
MH  - *Honey/po [Poisoning]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Plant Nectar
MH  - Retrospective Studies
MH  - Rhododendron
MH  - Turkey
AB  - OBJECTIVE: This study is aimed at analyzing the demographic and clinical characteristics, as well as the hematological-biochemical parameters of patients who admitted to the hospital with the diagnosis of mad honey poisoning.
AB  - MATERIALS AND METHODS: A total of 16 patients who were admitted with mad honey intoxication symptoms and treated in Emergency Department of Sakarya Education and Research Hospital between January 2009 and December 2012 were included in the study. Demographic and clinical characteristics of the patients and hematological, biochemical parameters were obtained from hospital records. Heart rate, systolic and diastolic blood pressure on admission and at discharge were obtained retrospectively.
AB  - RESULTS: Sixteen patients (10 males and 6 females, mean age 58.5 +/- 10 years, range between 41 and 79) were included in our study. Heart rate was 42 +/- 6 beats/min, systolic blood pressure was 73 +/- 19 mmHg, and diastolic blood pressure was 45 +/- 17 mmHg on admission. In the evaluation of the patients' heart rhythms on admission to the emergency room, nine (56.3%) patients had sinus bradycardia, three (18.8%) patients had nodal rhythm, two (12.5%) patients had first degree atrioventricular block, and two (12.5%) patients had atrial fibrillation. Atropine 1.1 +/- 0.4 mg and saline 1125 +/- 465 ml were used to treat patients. Patients were discharged with a stable condition after an average 27.7 +/- 7.2 h of follow-up. Heart rate was 75 +/- 8 beats/min, systolic blood pressure was 132 +/- 7 mmHg, and diastolic blood pressure was 82 +/- 6 mmHg at discharge. Mortality was not observed. Hematological and biochemical parameters measured at the time of admission were within normal ranges.
AB  - CONCLUSION: Mad honey poisoning should be considered in previously healthy patients with unexplained symptoms of bradycardia, hypotension, and cardiac dysrhythmias. Therefore, diet history should carefully be obtained from the patients admitted with bradycardia and hypotension, and mad honey intoxication should also be considered in the differential diagnosis, as well as primary cardiac, neurologic, and metabolic disorders. Mad honey poisoning may be presented with life-threatening symptoms without any hematological and biochemical disorder.
RN  - 0 (Diterpenes)
RN  - 0 (Plant Nectar)
RN  - 4720-09-6 (grayanotoxin I)
IS  - 1119-3077
DO  - http://dx.doi.org/10.4103/1119-3077.141424
PT  - Journal Article
LG  - English
DP  - 2014 Sep-Oct
DC  - 20140923
YR  - 2014
ED  - 20141117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25244269

<181. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23936756
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Piccini JP
AU  - Hellkamp AS
AU  - Whellan DJ
AU  - Ellis SJ
AU  - Keteyian SJ
AU  - Kraus WE
AU  - Hernandez AF
AU  - Daubert JP
AU  - Pina lL
AU  - O'Connor CM
AU  - HF-ACTION Investigators
FA  - Piccini, Jonathan P
FA  - Hellkamp, Anne S
FA  - Whellan, David J
FA  - Ellis, Stephen J
FA  - Keteyian, Steven J
FA  - Kraus, William E
FA  - Hernandez, Adrian F
FA  - Daubert, James P
FA  - Pina, leana L
FA  - O'Connor, Christopher M
FA  - HF-ACTION Investigators
TI  - Exercise training and implantable cardioverter-defibrillator shocks in patients with heart failure: results from HF-ACTION (Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing).
SO  - JACC Heart Failure. 1(2):142-8, 2013 Apr.
AS  - JACC Heart Fail. 1(2):142-8, 2013 Apr.
NJ  - JACC. Heart failure
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101598241
OI  - Source: NLM. NIHMS451531
OI  - Source: NLM. PMC3735226
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Defibrillators, Implantable
MH  - *Equipment Failure
MH  - *Exercise Therapy/ae [Adverse Effects]
MH  - Female
MH  - *Heart Failure/th [Therapy]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Treatment Outcome
AB  - OBJECTIVES: The purpose of this study was to determine whether exercise training is associated with an increased risk of implantable cardioverter-defibrillator (ICD) therapy in patients with heart failure (HF).
AB  - BACKGROUND: Few data are available regarding the safety of exercise training in patients with ICDs and HF.
AB  - METHODS: HF-ACTION (Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing) randomized 2,331 outpatients with HF and an ejection fraction (EF) <35% to exercise training or usual care. Cox proportional hazards modeling was used to examine the relationship between exercise training and ICD shocks.
AB  - RESULTS: We identified 1,053 patients (45%) with an ICD at baseline who were randomized to exercise training (n = 546) or usual care (n = 507). Median age was 61 years old, and median EF was 24%. Over a median of 2.2 years of follow-up, 20% (n = 108) of the exercise patients had a shock versus 22% (n = 113) of the control patients. A history of sustained ventricular tachycardia/fibrillation (hazard ratio [HR]: 1.93 [95% confidence interval (CI): 1.47 to 2.54]), previous atrial fibrillation/flutter (HR: 1.63 [95% CI: 1.22 to 2.18]), exercise-induced dysrhythmia (HR: 1.67 [95% CI: 1.23 to 2.26]), lower diastolic blood pressure (HR for 5-mm Hg decrease <60: 1.35 [95% CI: 1.12 to 1.61]), and nonwhite race (HR: 1.50 [95% CI: 1.13 to 2.00]) were associated with an increased risk of ICD shocks. Exercise training was not associated with the occurrence of ICD shocks (HR: 0.90 [95% CI: 0.69 to 1.18], p = 0.45). The presence of an ICD was not associated with the primary efficacy composite endpoint of death or hospitalization (HR: 0.99 [95% CI: 0.86 to 1.14], p = 0.90).
AB  - CONCLUSIONS: We found no evidence of increased ICD shocks in patients with HF and reduced left ventricular function who underwent exercise training. Exercise therapy should not be prohibited in ICD recipients with HF. (Exercise Training Program to Improve Clinical Outcomes in Individuals With Congestive Heart Failure; NCT00047437)
ES  - 2213-1787
IL  - 2213-1779
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
SI  - ClinicalTrials.gov
SA  - ClinicalTrials.gov/NCT00047437
SL  - http://clinicaltrials.gov/search/term=NCT00047437
NO  - 5U01HL063747 (United States NHLBI NIH HHS)
NO  - RU01HL066482 (United States NHLBI NIH HHS)
NO  - U01 HL063747 (United States NHLBI NIH HHS)
LG  - English
DP  - 2013 Apr
DC  - 20140423
YR  - 2013
ED  - 20141117
RD  - 20150423
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23936756

<182. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24354801
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lai YF
AU  - Cheen MH
AU  - Lim SH
AU  - Yeo FH
AU  - Nah SC
AU  - Kong MC
AU  - Mya D
AU  - Lee LH
AU  - Ng HJ
FA  - Lai, Y F
FA  - Cheen, M H H
FA  - Lim, S H
FA  - Yeo, F H I
FA  - Nah, S C
FA  - Kong, M C
FA  - Mya, D
FA  - Lee, L H
FA  - Ng, H J
IN  - Lai,Y F. Department of Pharmacy, Singapore General Hospital, Singapore.
TI  - The effects of fasting in Muslim patients taking warfarin.
CM  - Comment in: J Thromb Haemost. 2014 May;12(5):807-8; PMID: 24571232
SO  - Journal of Thrombosis & Haemostasis. 12(3):349-54, 2014.
AS  - J Thromb Haemost. 12(3):349-54, 2014.
NJ  - Journal of thrombosis and haemostasis : JTH
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101170508
SB  - Index Medicus
CP  - England
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/ad [Administration & Dosage]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Fasting
MH  - Female
MH  - Humans
MH  - International Normalized Ratio
MH  - *Islam
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Venous Thromboembolism/dt [Drug Therapy]
MH  - *Warfarin/ad [Administration & Dosage]
MH  - Young Adult
KW  - Muslim;  fasting;  humans;  international normalized ratio;  warfarin
AB  - BACKGROUND: Anticoagulation with warfarin is influenced by dietary changes but the effect of fasting on warfarin therapy is unknown.
AB  - OBJECTIVES: To study changes in international normalized ratio (INR) and the percentage of time within therapeutic range (%TTR) before, during and after the Muslim fasting month (Ramadan) in stable warfarinised Muslim patients.
AB  - METHODS/PATIENTS: In this prospective study, weekly INR readings were taken at home visits from participating patients during three study periods: before, during and after Ramadan. Readings were blinded to patients and their primary physicians except for when pre-set study endpoints were reached.
AB  - RESULTS: Among 32 participating patients, mean INR increased by 0.23 (P = 0.006) during Ramadan from the pre-Ramadan month and decreased by 0.28 (P < 0.001) after Ramadan. There was no significant difference (P = 1.000) in mean INR between the non-Ramadan months. %TTR declined from 80.99% before Ramadan to 69.56% during Ramadan (P = 0.453). The first out-of-range INR was seen around 12.1 days (95% CI, 9.0-15.1) after the start of fasting and returned to range at about 10.8 days (95% CI, 7.9-13.7) after Ramadan. Time above range increased from 10.80% pre-Ramadan to 29.87% during Ramadan (P = 0.027), while time below range increased from 0.57% during Ramadan to 15.49% post-Ramadan (P = 0.006). No bleeding or thrombotic events were recorded.
AB  - CONCLUSIONS: Fasting significantly increases the mean INR of medically stable patients taking warfarin and the likelihood of having an INR above therapeutic targets. For patients maintained at the higher end of INR target ranges or at increased risk of bleeding, closer monitoring or dosage adjustment may be necessary during fasting.Copyright © 2013 International Society on Thrombosis and Haemostasis.
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
ES  - 1538-7836
IL  - 1538-7836
DO  - http://dx.doi.org/10.1111/jth.12496
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2014
DC  - 20140306
YR  - 2014
ED  - 20141114
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24354801

<183. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24135831
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ulimoen SR
AU  - Enger S
AU  - Pripp AH
AU  - Abdelnoor M
AU  - Arnesen H
AU  - Gjesdal K
AU  - Tveit A
FA  - Ulimoen, Sara R
FA  - Enger, Steve
FA  - Pripp, Are Hugo
FA  - Abdelnoor, Michael
FA  - Arnesen, Harald
FA  - Gjesdal, Knut
FA  - Tveit, Arnljot
IN  - Ulimoen,Sara R. Department of Medical Research, Vestre Viken Hospital Trust, Baerum Hospital, PO. Box 83, Sogneprest Munthe Kaas' vei 100, N-1309 Rud, Norway.
TI  - Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation.
CM  - Comment in: Eur Heart J. 2014 Feb;35(8):480-1; PMID: 24258074
SO  - European Heart Journal. 35(8):517-24, 2014 Feb.
AS  - Eur Heart J. 35(8):517-24, 2014 Feb.
NJ  - European heart journal
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - em8, 8006263
SB  - Index Medicus
CP  - England
MH  - *Adrenergic beta-Antagonists/ad [Administration & Dosage]
MH  - Aged
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - *Calcium Channel Blockers/ad [Administration & Dosage]
MH  - Carbazoles/ad [Administration & Dosage]
MH  - Cross-Over Studies
MH  - Delayed-Action Preparations
MH  - Diltiazem/ad [Administration & Dosage]
MH  - *Exercise Tolerance/de [Drug Effects]
MH  - Female
MH  - Humans
MH  - Male
MH  - Metoprolol/ad [Administration & Dosage]
MH  - Natriuretic Peptide, Brain/de [Drug Effects]
MH  - *Natriuretic Peptide, Brain/me [Metabolism]
MH  - Oxygen Consumption/de [Drug Effects]
MH  - Peptide Fragments/de [Drug Effects]
MH  - *Peptide Fragments/me [Metabolism]
MH  - Propanolamines/ad [Administration & Dosage]
MH  - Prospective Studies
MH  - Verapamil/ad [Administration & Dosage]
KW  - Atrial fibrillation;  Exercise capacity;  Natriuretic peptides;  Rate control
AB  - AIMS: Rate control of atrial fibrillation (AF) has become a main treatment modality, but we need more knowledge regarding the different drugs used for this purpose. In this study, we aimed to compare the effect of four common rate-reducing drugs on exercise capacity and levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with permanent AF.
AB  - METHODS AND RESULTS: We included 60 patients (mean age 71 +/- 9 years, 18 women) with permanent AF and normal left ventricular function in a randomized, cross-over, investigator-blind study. Diltiazem 360 mg, verapamil 240 mg, metoprolol 100 mg, and carvedilol 25 mg were administered o.d. for 3 weeks. At baseline and on the last day of each treatment period, the patients underwent a maximal cardiopulmonary exercise test and blood samples were obtained at rest and at peak exercise. The exercise capacity (peak VO2) was significantly lower during treatment with metoprolol and carvedilol compared with baseline (no treatment) or treatment with diltiazem and verapamil (P < 0.001 for all). Compared with baseline, treatment with diltiazem and verapamil significantly reduced the NT-proBNP levels both at rest and at peak exercise, whereas treatment with metoprolol and carvedilol increased the levels (P < 0.05 for all).
AB  - CONCLUSION: Rate-reducing treatment with diltiazem or verapamil preserved exercise capacity and reduced levels of NT-proBNP compared with baseline, whereas treatment with metoprolol or carvedilol reduced the exercise capacity and increased levels of NT-proBNP.
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Carbazoles)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Peptide Fragments)
RN  - 0 (Propanolamines)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 0K47UL67F2 (carvedilol)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - CJ0O37KU29 (Verapamil)
RN  - EE92BBP03H (Diltiazem)
RN  - GEB06NHM23 (Metoprolol)
ES  - 1522-9645
IL  - 0195-668X
DO  - http://dx.doi.org/10.1093/eurheartj/eht429
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20131017
DP  - 2014 Feb
DC  - 20140224
YR  - 2014
ED  - 20141028
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24135831

<184. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23012689
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Bang CN
AU  - Gislason GH
AU  - Greve AM
AU  - Torp-Pedersen C
AU  - Kober L
AU  - Wachtell K
FA  - Bang, Casper N
FA  - Gislason, Gunnar H
FA  - Greve, Anders M
FA  - Torp-Pedersen, Christian
FA  - Kober, Lars
FA  - Wachtell, Kristian
IN  - Bang,Casper N. Department of Cardiology, The Heart Center, Rigshospitalet, Copenhagen, Denmark.
TI  - Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study.
SO  - European Journal of Preventive Cardiology. 21(3):330-8, 2014 Mar.
AS  - Eur J Prev Cardiolog. 21(3):330-8, 2014 Mar.
NJ  - European journal of preventive cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101564430
SB  - Index Medicus
CP  - England
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Atorvastatin Calcium
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - Chi-Square Distribution
MH  - Comorbidity
MH  - Denmark/ep [Epidemiology]
MH  - Female
MH  - Heptanoic Acids/tu [Therapeutic Use]
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use]
MH  - Male
MH  - Medication Adherence
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Myocardial Infarction/di [Diagnosis]
MH  - Myocardial Infarction/ep [Epidemiology]
MH  - *Myocardial Infarction/th [Therapy]
MH  - Polypharmacy
MH  - Pravastatin/tu [Therapeutic Use]
MH  - Propensity Score
MH  - Proportional Hazards Models
MH  - Pyrroles/tu [Therapeutic Use]
MH  - Registries
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Sex Factors
MH  - Simvastatin/tu [Therapeutic Use]
MH  - Time Factors
MH  - Treatment Outcome
KW  - Inflammation;  myocardial infarction;  new-onset atrial fibrillation;  statins
AB  - AIM: To evaluate the effect of statins on reducing new-onset atrial fibrillation (AF) in a large real-world post-myocardial infarction (MI) population. Subsequently, to test if different statin doses, various types and compliance affected the incidence of new-onset AF post MI.
AB  - METHODS: All patients with first-time acute MI between 1997 and 2009 in Denmark and claimed prescriptions of statins after discharge were identified from the Danish nationwide administrative registers. Patients with a history of AF were excluded. Risk of new-onset AF according to statin use were analysed by multivariable time-dependent Cox regressions models adjusted for age, gender, year, concomitant medication, and comorbidity, and additionally in a propensity score-matched analysis.
AB  - RESULTS: A total of 89,703 patients with average follow up of 5.0+/-3.5 years were included in this study. In the 56,044 patients receiving statins, 5698 (10%) had new-onset AF vs. 5010 (15%) in the 33,659 patients serving as controls. The adjusted Cox regression analysis showed significant reduction in new-onset AF (HR 0.83, 95% CI 0.80-0.87, p<0.001) in statin users. Adjustment for propensity score yielded nearly identical results (HR 0.82, 95% CI 0.78-0.85, p<0.001). Furthermore, patients compliant to statin treatment had significant reduction in new-onset AF (HR 0.84, 95% CI 0.80-0.87, p<0.001). Finally, simvastatin and atorvastatin were significantly more effective than pravastatin (both p<0.01) in reducing new-onset AF.
AB  - CONCLUSIONS: Statin therapy was significantly associated with less new-onset AF in a nationwide cohort of post-MI patients. Furthermore, statins showed a type-dependent effect in preventing new-onset AF. These results support the beneficial effect of statin therapy beyond lipid lowering in patients with MI and underline the importance of statin adherence and choice of statin type.
RN  - 0 (Heptanoic Acids)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Pyrroles)
RN  - 48A5M73Z4Q (Atorvastatin Calcium)
RN  - AGG2FN16EV (Simvastatin)
RN  - KXO2KT9N0G (Pravastatin)
ES  - 2047-4881
IL  - 2047-4873
DO  - http://dx.doi.org/10.1177/2047487312462804
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20120925
DP  - 2014 Mar
DC  - 20140220
YR  - 2014
ED  - 20141021
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23012689

<185. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24521763
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lin WY
AU  - Lin YJ
AU  - Chung FP
AU  - Chao TF
AU  - Liao JN
AU  - Chang SL
AU  - Lo LW
AU  - Hu YF
AU  - Chiang CE
AU  - Cheng SM
AU  - Lin WS
AU  - Chen SA
FA  - Lin, Wen-Yu
FA  - Lin, Yenn-Jiang
FA  - Chung, Fa-Po
FA  - Chao, Tze-Fan
FA  - Liao, Jo-Nan
FA  - Chang, Shih-Lin
FA  - Lo, Li-Wei
FA  - Hu, Yu-Feng
FA  - Chiang, Chern-En
FA  - Cheng, Shu-Meng
FA  - Lin, Wei-Shiang
FA  - Chen, Shih-Ann
IN  - Lin,Wen-Yu. Division of Cardiology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center.
TI  - Impact of renal dysfunction on clinical outcome in patients with low risk of atrial fibrillation.
SO  - Circulation Journal. 78(4):853-8, 2014.
AS  - Circ J. 78(4):853-8, 2014.
NJ  - Circulation journal : official journal of the Japanese Circulation Society
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101137683
SB  - Index Medicus
CP  - Japan
MH  - Adult
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/mo [Mortality]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/th [Therapy]
MH  - *Atrial Fibrillation
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Kidney Diseases/et [Etiology]
MH  - Kidney Diseases/mo [Mortality]
MH  - Kidney Diseases/pa [Pathology]
MH  - Kidney Diseases/pp [Physiopathology]
MH  - *Kidney Diseases
MH  - Kidney Function Tests
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Survival Rate
MH  - Thromboembolism/et [Etiology]
MH  - Thromboembolism/mo [Mortality]
MH  - Thromboembolism/pa [Pathology]
MH  - Thromboembolism/pp [Physiopathology]
AB  - BACKGROUND:  The impact of renal dysfunction has been investigated in patients with non-valvular atrial fibrillation (AF). The aim of this study was to assess its additive prognostic value in low thromboembolic risk AF patients with CHA2DS2-VASc score 0-1.
AB  - METHODS AND RESULTS:  A total of 617 non-valvular AF patients were enrolled and baseline serum creatinine was measured. Estimated glomerular filtration rate and estimated clearance of creatinine were calculated using the Modification of Diet in Renal Disease equation and Cockcroft-Gault formula, respectively. The primary endpoint was cardiovascular death and systemic thromboembolic events, including acute ischemic stroke, transient ischemic attack, and peripheral artery embolism. Of these, 338 individuals had clinical CHA2DS2-VASc score 0-1. Among these individuals, 23 patients had impaired renal function. During the follow-up period of 53.6+/-32.1 months, the annual composite outcome rate in AF patients with CHA2DS2-VASc score 0-1 was 0.40%/year. As compared with patients with preserved renal function, the annual composite outcome rate was significantly higher in patients with impaired renal function (2.92%/year vs. 0.21%/year, P<0.001). Moreover, on multivariate Cox regression analysis, renal dysfunction was the only risk predictor in these low-risk patients.
AB  - CONCLUSIONS:  Impaired renal function has an additive prognostic value for thromboembolic events and cardiovascular mortality in low-risk AF patients with CHA2DS2-VASc score 0-1.  
ES  - 1347-4820
IL  - 1346-9843
PT  - Clinical Trial
PT  - Journal Article
LG  - English
EP  - 20140213
DP  - 2014
DC  - 20140327
YR  - 2014
ED  - 20141020
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24521763

<186. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25076691
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Alexandrescu DM
AU  - Costache II
FA  - Alexandrescu, D M
FA  - Costache, Irina Iuliana
TI  - Acute cardiogenic pulmonary edema--etiological spectrum and precipitating factors.
SO  - Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi. 118(2):301-6, 2014 Apr-Jun.
AS  - Rev Med Chir Soc Med Nat Iasi. 118(2):301-6, 2014 Apr-Jun.
NJ  - Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - shp, 0413735
SB  - Index Medicus
CP  - Romania
MH  - Aged
MH  - Aged, 80 and over
MH  - Arrhythmias, Cardiac/co [Complications]
MH  - Cardiomyopathy, Dilated/co [Complications]
MH  - Emergencies
MH  - Female
MH  - Heart Valve Diseases/co [Complications]
MH  - Humans
MH  - Hypertension/co [Complications]
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/co [Complications]
MH  - Precipitating Factors
MH  - Prognosis
MH  - Pulmonary Edema/di [Diagnosis]
MH  - *Pulmonary Edema/et [Etiology]
MH  - *Pulmonary Edema/th [Therapy]
MH  - Risk Factors
MH  - Romania
AB  - AIM: The analysis of the predisposing and precipitating factors encountered in the anamnesis of the patients hospitalized with acute pulmonary oedema, in order to establish some correlations with the evolution and prognosis.
AB  - MATERIAL AND METHODS: The study included 50 patients, 32 males and 18 females, admitted to the Cardiology I Clinic between 2009 and 2013, diagnosed with acute pulmonary oedema upon admission. The following aspects were investigated: cardiovascular antecedents, prodromal elements of the current episode of acute pulmonary oedema (APE), risk factors and associated co morbidities, previous treatments followed at home as well as the triggering factors of the acute episode.
AB  - RESULTS: The main pathology on which the acute pulmonary oedema (APE) episode occurred was represented by: arterial high blood pressure (HBP), dilated cardiomyopathy, ischemic heart disease, valvular heart disease, pre-existing atrial rhythm disorders. The analysis of the factors that precipitated the acute pulmonary oedema episode revealed the following possible triggering conditions: inadequate physical effort on the background of treatment discontinuation, high sodium diet, a prolonged ischemic episode due to inadequate physical effort, rhythm disorder with rapid ventricular response (atrial fibrillation, atrial flutter). In some cases, the risk factors were cumulated.
AB  - CONCLUSIONS: Acute pulmonary oedema represents a major emergency that requires immediate admission to hospital and rapid treatment in the emergency department concurrent with the identification of the triggering and precipitating factors.
IS  - 0048-7848
IL  - 0048-7848
PT  - Journal Article
LG  - English
DP  - 2014 Apr-Jun
DC  - 20140731
YR  - 2014
ED  - 20141010
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25076691

<187. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24487673
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Chavez E
AU  - Gonzalez E
AU  - Llanes Mdel C
AU  - Gari M
AU  - Garcia Y
AU  - Garcia J
AU  - Fernandez E
FA  - Chavez, Elibet
FA  - Gonzalez, Emilio
FA  - Llanes, Maria del Carmen
FA  - Gari, Merlin
FA  - Garcia, Yosvany
FA  - Garcia, Julieta
FA  - Fernandez, Elizabet
IN  - Chavez,Elibet. Ernesto Che Guevara Heart Center, Santa Clara, Cuba. elibetcg@cardiovc.sld.cu.
TI  - P-wave dispersion: a possible warning sign of hypertension in children.
SO  - MEDICC review. 16(1):31-6, 2014 Jan.
AS  - MEICC REV. 16(1):31-6, 2014 Jan.
NJ  - MEDICC review
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 100964771
SB  - Index Medicus
CP  - United States
MH  - Adolescent
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Blood Pressure
MH  - Child
MH  - Cross-Sectional Studies
MH  - Cuba/ep [Epidemiology]
MH  - *Electrocardiography
MH  - Female
MH  - Health Status
MH  - Humans
MH  - Hypertension/ep [Epidemiology]
MH  - *Hypertension/pp [Physiopathology]
MH  - Linear Models
MH  - Male
MH  - Nutritional Status
MH  - Prehypertension/ep [Epidemiology]
MH  - *Prehypertension/pp [Physiopathology]
AB  - INTRODUCTION: Hypertension and obesity in adults have been linked to increased EKG P-wave dispersion; the association has been shown in relation to hypertension, left ventricular hypertrophy and atrial enlargement. Though studies in children have linked P-wave dispersion to left ventricular hypertrophy, scant pediatric literature relates P-wave dispersion to hypertension and obesity.
AB  - OBJECTIVE: Assess the association of P-wave dispersion with blood pressure and nutritional status in a pediatric population.
AB  - METHODS: This cross-sectional study is part of the PROCDEC II project for pediatric hypertension diagnosis and control in Santa Clara, Cuba. Twelve-lead EKG and four blood pressure readings were conducted on a sample of 656 children aged 8-11 years. Blood pressure <90th percentile for age, sex and height was considered normal; 90th-95th percentile, prehypertension; and >95th percentile, hypertension. The main study variables were P-wave dispersion and systolic, diastolic and mean arterial pressure (MAP). Secondary variables were sex, height, weight, and body mass index. Comparisons of means, analysis of variance and linear correlations were done.
AB  - RESULTS: Mean P-wave dispersion differed significantly (p <0.05) among normotensive (30.10 ms), prehypertensive (32.99 ms) and hypertensive children (39.14 ms), as did mean MAP (p <0.05). P-wave dispersion and MAP were significantly correlated in prehypertensive and hypertensive children. Most overweight and obese children with high P-wave dispersion were prehypertensive or hypertensive.
AB  - CONCLUSIONS: Associations observed between P-wave dispersion and MAP in normotensive, prehypertensive and hypertensive children suggest potential for early detection of EKG patterns showing vulnerability. Given the relationship between increased P-wave dispersion and hypertension already described in adults, use of P-wave dispersion could be a simple, economical and noninvasive method of predicting risk of hypertensive cardiomyopathy in prehypertensive and hypertensive children; this in turn could guide timely, effective treatment and secondary prevention. Similar studies on a larger sample are needed to corroborate these results.
ES  - 1527-3172
IL  - 1527-3172
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 2014 Jan
DC  - 20140203
YR  - 2014
ED  - 20141010
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24487673

<188. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25295192
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Denoel P
AU  - Vanderstraeten J
AU  - Mols P
AU  - Pepersack T
AI  - Denoel, Paule; ORCID: http://orcid.org/0000-0003-0735-4664
AI  - Mols, Pierre; ORCID: http://orcid.org/0000-0001-8320-1171
AI  - Pepersack, Thierry; ORCID: http://orcid.org/0000-0001-6197-582X
FA  - Denoel, Paule
FA  - Vanderstraeten, Jacques
FA  - Mols, Pierre
FA  - Pepersack, Thierry
IN  - Denoel,Paule. Emergency Service, Europe Hospital, 1040 Brussels, Belgium.
IN  - Vanderstraeten,Jacques. Centre de Recherche en Sante Environnementale et en Sante du Travail, Ecole de Sante Publique, Universite Libre de Bruxelles, 1070 Brussels, Belgium.
IN  - Mols,Pierre. Emergency Service, Saint-Pierre University Hospital, Universite Libre de Bruxelles, 1000 Brussels, Belgium.
IN  - Pepersack,Thierry. Department of Geriatrics, Erasme Hospital, Universite Libre de Bruxelles, Lennik Street 808, 1070 Brussels, Belgium.
TI  - Could some geriatric characteristics hinder the prescription of anticoagulants in atrial fibrillation in the elderly?.
SO  - Journal of Aging Research. 2014:693740, 2014.
AS  - J Aging Res. 2014:693740, 2014.
NJ  - Journal of aging research
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - 101543460
OI  - Source: NLM. PMC4175391
CP  - United States
AB  - Several studies have reported underprescription of anticoagulants in atrial fibrillation (AF). We conducted an observational study on 142 out of a total of 995 consecutive >75 years old patients presenting AF (14%) when admitted in an emergency unit of a general hospital, in search of geriatric characteristics that might be associated with the underprescription of anticoagulation therapy (mostly antivitamin K at the time of the study). The following data was collected from patients presenting AF: medical history including treatment and comorbidities, CHADS2 score, ISAR scale (frailty), Lawton's scale (ADL), GDS scale (mood status), MUST (nutrition), and blood analysis (INR, kidney function, and albumin). Among those patients for who anticoagulation treatment was recommended (73%), only 61% were treated with it. In the group with anticoagulation therapy, the following characteristics were observed more often than in the group without such therapy: a recent (<6 months) hospitalization and medical treatment including digoxin or based on >3 different drugs. Neither the value of the CHADS2 score, nor the geriatric characteristics could be correlated with the presence or the absence of an anticoagulation therapy. More research is thus required to identify and clarify the relative importance of patient-, physician-, and health care system-related hurdles for the prescription of oral anticoagulation therapy in older patients with AF.
IS  - 2090-2204
IL  - 2090-2204
DO  - http://dx.doi.org/10.1155/2014/693740
PT  - Journal Article
LG  - English
EP  - 20140910
DP  - 2014
DC  - 20141008
YR  - 2014
ED  - 20141008
RD  - 20141010
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=25295192

<189. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23902651
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wutzler A
AU  - Nee J
AU  - Boldt LH
AU  - Kuhnle Y
AU  - Graser S
AU  - Schroder T
AU  - Haverkamp W
AU  - Storm C
FA  - Wutzler, Alexander
FA  - Nee, Jens
FA  - Boldt, Leif-Hendrik
FA  - Kuhnle, York
FA  - Graser, Saskia
FA  - Schroder, Tim
FA  - Haverkamp, Wilhelm
FA  - Storm, Christian
IN  - Wutzler,Alexander. Department of Cardiology, Charite - Universitaetsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany.
TI  - Improvement of cerebral oxygen saturation after successful electrical cardioversion of atrial fibrillation.
SO  - Europace. 16(2):189-94, 2014 Feb.
AS  - Europace. 16(2):189-94, 2014 Feb.
NJ  - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - dxd, 100883649
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - Aged, 80 and over
MH  - Arterial Pressure
MH  - Atrial Fibrillation/bl [Blood]
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Biomarkers/bl [Blood]
MH  - Case-Control Studies
MH  - *Cerebrovascular Circulation
MH  - *Electric Countershock
MH  - Female
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oximetry/mt [Methods]
MH  - *Oxygen/bl [Blood]
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Spectroscopy, Near-Infrared
MH  - Time Factors
MH  - Treatment Outcome
KW  - Atrial fibrillation;  Cardioversion;  Cerebral oxygen saturation;  Monitoring;  Near-infrared spectroscopy
AB  - AIMS: Cerebral and microvascular perfusion is reduced in atrial fibrillation (AF). Maintenance of brain perfusion is important in acute disease and long-term course. Assessment of brain perfusion and oxygenation is difficult in clinical practice. Our study aimed to determine changes in cerebral tissue oxygen saturation (SctO2) with bedside near-infrared spectroscopy (NIRS).
AB  - METHODS AND RESULTS: Twenty patients (mean age 67.7 +/- 10.2 years, 50% men) in whom electrical cardioversion (CV) was successful were prospectively studied. Ten patients (mean age 64.2 +/- 7.7 years, 80% men) in whom CV was not successful served as control group. Bilateral SctO2, mean arterial pressure (MAP), arterial oxygen saturation (SaO2), and heart rate were recorded and changes of all parameters before and after CV were compared between the groups. Our results show an increase in SctO2 after successful CV that was significantly higher compared with patients who remained in AF (right SctO2 3.25 +/- 2.5 vs. -0.13 +/- 0.52%, P = 0.001; left SctO2 4.27 +/- 3.56 vs. -0.38 +/- 2.4%, P < 0.001). Neither arterial blood pressure nor SaO2 changes differed significantly between the two groups. No correlation could be detected between the significant increase of SctO2 after successful CV and arterial blood pressure, SaO2, or heart rate.
AB  - CONCLUSION: Cerebral tissue oxygen saturation increases significantly after restoration of sinus rhythm. Near-infrared spectroscopy monitoring can identify changes of SctO2 after successful CV of AF independent from standard monitoring parameters (MAP, SaO2). Near-infrared spectroscopy can be used to detect cerebral oxygen saturation deficits in AF patients or patients at high risk for AF. Clinical applications may include monitoring during ablation procedures and in critical care.
RN  - 0 (Biomarkers)
RN  - S88TT14065 (Oxygen)
ES  - 1532-2092
IL  - 1099-5129
DO  - http://dx.doi.org/10.1093/europace/eut246
PT  - Journal Article
LG  - English
EP  - 20130731
DP  - 2014 Feb
DC  - 20140130
YR  - 2014
ED  - 20140929
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23902651

<190. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24012433
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Takagi T
AU  - Takagi A
AU  - Yoshikawa J
FA  - Takagi, Tsutomu
FA  - Takagi, Atsushi
FA  - Yoshikawa, Junichi
IN  - Takagi,Tsutomu. Takagi Cardiology Clinic, Kyoto, Japan. Electronic address: tcardiol@qb4.so-net.ne.jp.
IN  - Takagi,Atsushi. Tokyo Women's Medical University, Tokyo, Japan.
IN  - Yoshikawa,Junichi. Nishinomiya Watanabe Cardiovascular Center, Nishinomiya, Japan.
TI  - Elevated left ventricular filling pressure estimated by E/E' ratio after exercise predicts development of new-onset atrial fibrillation independently of left atrial enlargement among elderly patients without obvious myocardial ischemia.
SO  - Journal of Cardiology. 63(2):128-33, 2014 Feb.
AS  - J Cardiol. 63(2):128-33, 2014 Feb.
NJ  - Journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - joa, 8804703
SB  - Index Medicus
CP  - Netherlands
MH  - Aged
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Cardiomegaly
MH  - *Echocardiography, Doppler, Color
MH  - *Exercise Test/mt [Methods]
MH  - Female
MH  - Follow-Up Studies
MH  - Forecasting
MH  - Heart Atria/pa [Pathology]
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Myocardial Ischemia
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - *Ventricular Dysfunction, Left/pp [Physiopathology]
MH  - *Ventricular Dysfunction, Left/us [Ultrasonography]
MH  - *Ventricular Function, Left/ph [Physiology]
KW  - Atrial fibrillation;  Diastolic function;  Doppler echocardiography;  Exercise stress echocardiography;  Tissue Doppler echocardiography
AB  - OBJECTIVE: To determine whether elevated left ventricular (LV) filling pressure estimated by raised Doppler E velocity to tissue Doppler E' velocity ratio (E/E') after exercise is associated with increased risk of new-onset atrial fibrillation (AF) in non-ischemic elderly patients.
AB  - BACKGROUND: Prognostic importance of exercise induced LV diastolic dysfunction remains uncertain.
AB  - PATIENTS AND METHODS: We studied 147 elderly patients (73 +/- 5 years) who underwent treadmill stress echocardiography. Patients with exercise induced LV wall motion abnormality were not included. Doppler and tissue Doppler measurements were done before treadmill exercise and immediately after the post-stress image acquisition, and E/E' ratio was measured. Raised E/E' was defined as E/E'> 15, and left atrial (LA) enlargement was defined as LA volume index > 34 ml/m(2). Using Cox proportional hazards regression analysis, predictor of new-onset AF was determined. Using Kaplan-Meier analysis, we evaluated association between raised post-exercise E/E' or LA enlargement with new-onset AF.
AB  - RESULTS: During the follow-up period (median=67 months), there were 25 new-onset AF. Cox proportional hazards regression analysis demonstrated that male gender [hazard ratio (HR) 3.294; p=0.0117], LA enlargement (HR 3.576; p=0.0017), and raised post-exercise E/E' (HR 3147; p=0.0068) were the best predictors of new-onset AF. Kaplan-Meier survival plot demonstrated that patients with both LA enlargement and raised post-exercise E/E' developed new-onset AF most frequently. There was no significant difference in outcome between patients with isolated raised post-exercise E/E' or isolated LA enlargement.
AB  - CONCLUSIONS: Raised E/E' ratio after exercise provides significant prognostic information for predicting new-onset AF in non-ischemic elderly patients. This prognostic value of raised post-exercise E/E' is independent of and incremental to the LA enlargement.Copyright © 2013 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
ES  - 1876-4738
IL  - 0914-5087
DI  - S0914-5087(13)00221-9
DO  - http://dx.doi.org/10.1016/j.jjcc.2013.06.019
PT  - Journal Article
LG  - English
EP  - 20130905
DP  - 2014 Feb
DC  - 20140213
YR  - 2014
ED  - 20140925
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24012433

<191. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24224462
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wood P
FA  - Wood, Peter
IN  - Wood,Peter. Pathology Queensland, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.
TI  - New oral anticoagulants: an emergency department overview.
SO  - Emergency Medicine Australasia. 25(6):503-14, 2013 Dec.
AS  - Emerg Med Australas. 25(6):503-14, 2013 Dec.
NJ  - Emergency medicine Australasia : EMA
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101199824
SB  - Index Medicus
CP  - Australia
MH  - Administration, Oral
MH  - *Anticoagulants/ad [Administration & Dosage]
MH  - Anticoagulants/ae [Adverse Effects]
MH  - Anticoagulants/pk [Pharmacokinetics]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Australia
MH  - Benzimidazoles/ad [Administration & Dosage]
MH  - Benzimidazoles/ae [Adverse Effects]
MH  - Dabigatran
MH  - *Emergency Service, Hospital
MH  - Humans
MH  - Morpholines/ad [Administration & Dosage]
MH  - Morpholines/ae [Adverse Effects]
MH  - *Pulmonary Embolism/dt [Drug Therapy]
MH  - Pyrazoles/ad [Administration & Dosage]
MH  - Pyrazoles/ae [Adverse Effects]
MH  - Pyridones/ad [Administration & Dosage]
MH  - Pyridones/ae [Adverse Effects]
MH  - Rivaroxaban
MH  - *Stroke/pc [Prevention & Control]
MH  - Thiophenes/ad [Administration & Dosage]
MH  - Thiophenes/ae [Adverse Effects]
MH  - *Venous Thrombosis/dt [Drug Therapy]
MH  - beta-Alanine/ad [Administration & Dosage]
MH  - beta-Alanine/ae [Adverse Effects]
MH  - beta-Alanine/aa [Analogs & Derivatives]
KW  - NOAC;  apixaban;  dabigatran;  rivaroxaban
AB  - As of September 2013, three new oral anticoagulants (NOACs) are now available for clinical use on the Pharmaceutical Benefits Scheme in Australia. All three are for stroke prevention in atrial fibrillation, and one will also be available for the treatment of deep venous thrombosis and pulmonary embolism. All have been evaluated in large, multicentre randomised clinical trials. These drugs show at least equivalent efficacy to the current standard of care, the vitamin K antagonist warfarin. Major bleeding rates are overall comparable with warfarin, but there is an important reduction in intracranial bleeding of approximately 50% with all NOAC agents. The NOACs are administered in a simple, fixed dose regimen. There are a few clinically important interactions with other medications or diet. Concerns exist about the potential for irreversible bleeding in the small number of patients in which that occurs. This short report will discuss the pharmacology of these agents, the indications for use, aspects of laboratory monitoring and the management of bleeding with these agents. Copyright © 2013 Australasian College for Emergency Medicine and Australasian Society for Emergency Medicine.
RN  - 0 (Anticoagulants)
RN  - 0 (Benzimidazoles)
RN  - 0 (Morpholines)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridones)
RN  - 0 (Thiophenes)
RN  - 11P2JDE17B (beta-Alanine)
RN  - 3Z9Y7UWC1J (apixaban)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - I0VM4M70GC (Dabigatran)
ES  - 1742-6723
IL  - 1742-6723
DO  - http://dx.doi.org/10.1111/1742-6723.12156
PT  - Journal Article
LG  - English
EP  - 20131113
DP  - 2013 Dec
DC  - 20131206
YR  - 2013
ED  - 20140925
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24224462

<192. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24571038
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Tofield A
FA  - Tofield, Andros
TI  - Eating fish and atrial fibrillation.
SO  - European Heart Journal. 35(3):135, 2014 Jan.
AS  - Eur Heart J. 35(3):135, 2014 Jan.
NJ  - European heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - em8, 8006263
SB  - Index Medicus
CP  - England
MH  - Animals
MH  - *Atrial Fibrillation/et [Etiology]
MH  - Diet
MH  - Dose-Response Relationship, Drug
MH  - *Fatty Acids, Omega-3/ad [Administration & Dosage]
MH  - Fishes
MH  - Humans
MH  - Observational Studies as Topic
MH  - Risk Factors
RN  - 0 (Fatty Acids, Omega-3)
ES  - 1522-9645
IL  - 0195-668X
PT  - Journal Article
LG  - English
DP  - 2014 Jan
DC  - 20140225
YR  - 2014
ED  - 20140910
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24571038

<193. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25029715
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Bhatt DL
FA  - Bhatt, Deepak L
TI  - Ask the doctor. Is it okay to eat leafy greens while taking warfarin? I was surprised to see spinach and kale recommended as "superfoods" for heart health in your March issue. I take Coumadin for atrial fibrillation and have been told to avoid green leafy vegetables. I had always enjoyed these foods in the past, so I'd be glad to know if it's okay to eat them.
SO  - Harvard Heart Letter. 24(10):2, 2014 Jun.
AS  - Harv Heart Lett. 24(10):2, 2014 Jun.
NJ  - Harvard heart letter : from Harvard Medical School
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9425723, c2z
SB  - Consumer Health Journals
CP  - United States
MH  - *Anticoagulants/ae [Adverse Effects]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - *Diet/ct [Contraindications]
MH  - *Drug-Related Side Effects and Adverse Reactions/pc [Prevention & Control]
MH  - Herb-Drug Interactions
MH  - Humans
MH  - *Vegetables/ae [Adverse Effects]
MH  - *Warfarin/ae [Adverse Effects]
MH  - *Warfarin/tu [Therapeutic Use]
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
IS  - 1051-5313
IL  - 1051-5313
PT  - Journal Article
LG  - English
DP  - 2014 Jun
DC  - 20140716
YR  - 2014
ED  - 20140904
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25029715

<194. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24787471
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Martinez-Gonzalez MA
AU  - Toledo E
AU  - Aros F
AU  - Fiol M
AU  - Corella D
AU  - Salas-Salvado J
AU  - Ros E
AU  - Covas MI
AU  - Fernandez-Crehuet J
AU  - Lapetra J
AU  - Munoz MA
AU  - Fito M
AU  - Serra-Majem L
AU  - Pinto X
AU  - Lamuela-Raventos RM
AU  - Sorli JV
AU  - Babio N
AU  - Buil-Cosiales P
AU  - Ruiz-Gutierrez V
AU  - Estruch R
AU  - Alonso A
AU  - PREDIMED Investigators
FA  - Martinez-Gonzalez, Miguel A
FA  - Toledo, Estefania
FA  - Aros, Fernando
FA  - Fiol, Miquel
FA  - Corella, Dolores
FA  - Salas-Salvado, Jordi
FA  - Ros, Emilio
FA  - Covas, Maria I
FA  - Fernandez-Crehuet, Joaquin
FA  - Lapetra, Jose
FA  - Munoz, Miguel A
FA  - Fito, Monserrat
FA  - Serra-Majem, Luis
FA  - Pinto, Xavier
FA  - Lamuela-Raventos, Rosa M
FA  - Sorli, Jose V
FA  - Babio, Nancy
FA  - Buil-Cosiales, Pilar
FA  - Ruiz-Gutierrez, Valentina
FA  - Estruch, Ramon
FA  - Alonso, Alvaro
FA  - PREDIMED Investigators
IN  - Martinez-Gonzalez,Miguel A. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Toledo,Estefania. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Aros,Fernando. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Fiol,Miquel. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Corella,Dolores. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Salas-Salvado,Jordi. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Ros,Emilio. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Covas,Maria I. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Fernandez-Crehuet,Joaquin. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Lapetra,Jose. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Munoz,Miguel A. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Fito,Monserrat. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Serra-Majem,Luis. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Pinto,Xavier. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Lamuela-Raventos,Rosa M. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Sorli,Jose V. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Babio,Nancy. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Buil-Cosiales,Pilar. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Ruiz-Gutierrez,Valentina. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Estruch,Ramon. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Alonso,Alvaro. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IR  - Estruch R
IR  - Corella D
IR  - Covas MI
IR  - Ros E
IR  - Salas-Salvado J
IR  - Martinez-Gonzalez MA
IR  - Aldamiz M
IR  - Alonso A
IR  - Berjon J
IR  - Forga L
IR  - Gallego J
IR  - Layana A
IR  - Larrauri A
IR  - Portu J
IR  - Timiraus J
IR  - Serrano-Martinez M
IR  - Ros E
IR  - Martinez-Gonzalez MA
IR  - Covas MI
IR  - Perez-Heras A
IR  - Salas-Salvado J
IR  - Serra M
IR  - Pi-Sunyer X
IR  - Gonzalez CA
IR  - Hu FB
IR  - Sabate J
IR  - Ruiz-Canela M
IR  - Sanchez-Tainta A
IR  - Sanjulian B
IR  - Diez--Espino J
IR  - Extremera-Urabayen V
IR  - Garcia-Arellano A
IR  - Zazpe I
IR  - Basterra-Gortari FJ
IR  - Goni JM
IR  - Razquin C
IR  - Serrano-Martinez M
IR  - Bes-Rastrollo M
IR  - Gea A
IR  - Martinez-Lapiscina EH
IR  - Nunez-Cordoba JM
IR  - Arroyo-Azpa C
IR  - Garcia-Perez L
IR  - Villanueva-Telleria J
IR  - Cortes-Ugalde F
IR  - Sagredo-Arce T
IR  - Garcia de la Noceda-Montoy MD
IR  - Vigata-Lopez MD
IR  - Arceiz-Campo MT
IR  - Urtasun-Samper A
IR  - Gueto-Rubio MV
IR  - Churio-Beraza B
IR  - Bullo M
IR  - Gonzalez R
IR  - Molina C
IR  - Marquez F
IR  - Babio N
IR  - Sorli M
IR  - Garcia Rosello J
IR  - Guasch-Ferre M
IR  - Diaz-Lopez A
IR  - Martin AF
IR  - Tort R
IR  - Isach A
IR  - Costa B
IR  - Cabre JJ
IR  - Fernandez-Ballart J
IR  - Ibarrola-Jurado N
IR  - Alegret C
IR  - Martinez P
IR  - Millan S
IR  - Pinol JL
IR  - Basora T
IR  - Hernandez JM
IR  - Serra M
IR  - Perez-Heras A
IR  - Vinas C
IR  - Casas R
IR  - de Santamaria L
IR  - Romero S
IR  - Sacanella E
IR  - Chiva G
IR  - Valderas P
IR  - Arranz S
IR  - Baena JM
IR  - Garcia M
IR  - Oller M
IR  - Amat J
IR  - Duaso I
IR  - Garcia Y
IR  - Iglesias C
IR  - Simon C
IR  - Quinzavos L
IR  - Parra L
IR  - Liroz M
IR  - Benavent J
IR  - Clos J
IR  - Pla I
IR  - Amoros M
IR  - Bonet MT
IR  - Martin MT
IR  - Sanchez MS
IR  - Altirriba J
IR  - Manzano E
IR  - Altes A
IR  - Cofan M
IR  - Valls-Pedret C
IR  - Sala-Vila A
IR  - Domenech M
IR  - Gilabert R
IR  - Bargallo N
IR  - Tello S
IR  - Vila J
IR  - Schroder H
IR  - De la Torre R
IR  - Munoz-Aguayo D
IR  - Elosua R
IR  - Marrugat J
IR  - Ferrer M
IR  - Carrasco P
IR  - Osma R
IR  - Guillem-Saiz P
IR  - Portoles O
IR  - Pascual V
IR  - Riera C
IR  - Valderrama J
IR  - Serrano A
IR  - Lazaro E
IR  - Sanmartin A
IR  - Girbes A
IR  - Santamari V
IR  - Sanchez C
IR  - Pla Z
IR  - Sanchez E
IR  - Ortega-Azorin C
IR  - Gonzalez JI
IR  - Saiz C
IR  - Coltell O
IR  - Asensio EM
IR  - Salaverria I
IR  - del Hierro T
IR  - Algorta J
IR  - Francisco S
IR  - Alonso A
IR  - San Vicente J
IR  - Sanz E
IR  - Felipe I
IR  - Alonso Gomez A
IR  - Loma-Osorio A
IR  - Gomez-Gracia E
IR  - Benitez Pont R
IR  - Bianchi Alba M
IR  - Warnberg J
IR  - Gomez-Huelgas R
IR  - Martinez-Gonzalez J
IR  - Velasco Garcia V
IR  - de Diego Salas J
IR  - Baca Osorio A
IR  - Zarzosa JG
IR  - Sanchez Luque JJ
IR  - Vargas Lopez E
IR  - Jurado Ruiz E
IR  - Romero M
IR  - Garcia Garcia M
IR  - Garcia-Valdueza M
IR  - Monino M
IR  - Proenza A
IR  - Prieto R
IR  - Frontera G
IR  - Ginard M
IR  - Fiol F
IR  - Jover A
IR  - Garcia J
IR  - Leal M
IR  - Martinez E
IR  - Santos JM
IR  - Ortega-Calvo M
IR  - Roman P
IR  - Garcia FJ
IR  - Iglesias P
IR  - Corchado Y
IR  - Mayoral E
IR  - Lama C
IR  - Lopez-Sabater MC
IR  - Castellote-Bargallo AI
IR  - Medina-Remon A
IR  - Tresserra-Rimbau A
IR  - Alvarez-Perez J
IR  - DiazBenitez E
IR  - Bautista-Castano I
IR  - Maldonado-Diaz I
IR  - Sanchez-Villegas A
IR  - Castro I
IR  - Henriquez P
IR  - Ruano C
IR  - Ortiz AP
IR  - Sarmiendo de la Fe F
IR  - Simon-Garcia C
IR  - Falcon-Sanabria I
IR  - Macias-Gutierrez B
IR  - Santana-Santana AJ
IR  - de la Cruz E
IR  - Galera A
IR  - Soler Y
IR  - Trias F
IR  - Sarasa I
IR  - Padres E
IR  - Figueras R
IR  - Solanich X
IR  - Pujol R
IR  - Corbella E
IR  - Cabezas C
IR  - Vinyoles E
IR  - Rovira MA
IR  - Garcia L
IR  - Flores G
IR  - Verdu JM
IR  - Baby P
IR  - Ramos A
IR  - Mengual L
IR  - Roura P
IR  - Yuste MC
IR  - Guarner A
IR  - Rovira A
IR  - Santamaria MI
IR  - Mata M
IR  - de Juan C
IR  - Brau A
IR  - Martinez JA
IR  - Marti A
IR  - Mitjavila MT
IR  - Portillo MP
IR  - Saez G
IR  - Tur J
TI  - Extravirgin olive oil consumption reduces risk of atrial fibrillation: the PREDIMED (Prevencion con Dieta Mediterranea) trial.
SO  - Circulation. 130(1):18-26, 2014 Jul 1.
AS  - Circulation. 130(1):18-26, 2014 Jul 1.
NJ  - Circulation
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/me [Metabolism]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - Diet, Fat-Restricted
MH  - *Diet, Mediterranean
MH  - *Dietary Fats/tu [Therapeutic Use]
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Inflammation
MH  - Male
MH  - Middle Aged
MH  - Nuts
MH  - Olive Oil
MH  - Oxidative Stress
MH  - *Plant Oils
MH  - Proportional Hazards Models
MH  - Risk
MH  - Risk Factors
MH  - Spain/ep [Epidemiology]
MH  - Stroke/ep [Epidemiology]
MH  - Stroke/pc [Prevention & Control]
MH  - Treatment Outcome
KW  - antioxidants;  arrhythmia;  atrial fibrillation;  diet;  epidemiology;  fatty acids, monounsaturated;  inflammation
AB  - BACKGROUND: The PREDIMED (Prevencion con Dieta Mediterranea) randomized primary prevention trial showed that a Mediterranean diet enriched with either extravirgin olive oil or mixed nuts reduces the incidence of stroke, myocardial infarction, and cardiovascular mortality. We assessed the effect of these diets on the incidence of atrial fibrillation in the PREDIMED trial.
AB  - METHODS AND RESULTS: Participants were randomly assigned to 1 of 3 diets: Mediterranean diet supplemented with extravirgin olive oil, Mediterranean diet supplemented with mixed nuts, or advice to follow a low-fat diet (control group). Incident atrial fibrillation was adjudicated during follow-up by an events committee blinded to dietary group allocation. Among 6705 participants without prevalent atrial fibrillation at randomization, we observed 72 new cases of atrial fibrillation in the Mediterranean diet with extravirgin olive oil group, 82 in the Mediterranean diet with mixed nuts group, and 92 in the control group after median follow-up of 4.7 years. The Mediterranean diet with extravirgin olive oil significantly reduced the risk of atrial fibrillation (hazard ratio, 0.62; 95% confidence interval, 0.45-0.85 compared with the control group). No effect was found for the Mediterranean diet with nuts (hazard ratio, 0.89; 95% confidence interval, 0.65-1.20).
AB  - CONCLUSIONS: In the absence of proven interventions for the primary prevention of atrial fibrillation, this post hoc analysis of the PREDIMED trial suggests that extravirgin olive oil in the context of a Mediterranean dietary pattern may reduce the risk of atrial fibrillation.
AB  - CLINICAL TRIAL REGISTRATION URL: http://www.controlled-trials.com. Unique identifier: ISRCTN35739639.Copyright © 2014 American Heart Association, Inc.
RN  - 0 (Dietary Fats)
RN  - 0 (Olive Oil)
RN  - 0 (Plant Oils)
ES  - 1524-4539
IL  - 0009-7322
DO  - http://dx.doi.org/10.1161/CIRCULATIONAHA.113.006921
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
SI  - ISRCTN
SA  - ISRCTN/ISRCTN35739639
SL  - http://www.controlled-trials.com/ISRCTN35739639
LG  - English
EP  - 20140430
DP  - 2014 Jul 1
DC  - 20140701
YR  - 2014
ED  - 20140902
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24787471

<195. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24648742
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Haas S
AU  - Bode C
AU  - Norrving B
AU  - Turpie AG
FA  - Haas, Sylvia
FA  - Bode, Christoph
FA  - Norrving, Bo
FA  - Turpie, Alexander Gg
IN  - Haas,Sylvia. Technical University Munich, Munich, Germany.
IN  - Bode,Christoph. Department of Cardiology and Angiology, University of Freiburg, Freiburg, Germany.
IN  - Norrving,Bo. Department of Clinical Neuroscience, Lund University Hospital, Lund, Sweden.
IN  - Turpie,Alexander Gg. Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
TI  - Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. [Review]
SO  - Vascular Health & Risk Management. 10:101-14, 2014.
AS  - Vasc Health Risk Manag. 10:101-14, 2014.
NJ  - Vascular health and risk management
PI  - Journal available in: Electronic-eCollection
PI  - Citation processed from: Internet
JC  - 101273479
OI  - Source: NLM. PMC3956810
SB  - Index Medicus
CP  - New Zealand
MH  - Administration, Oral
MH  - Anticoagulants/ad [Administration & Dosage]
MH  - Anticoagulants/ae [Adverse Effects]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/bl [Blood]
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - *Blood Coagulation/de [Drug Effects]
MH  - Drug Administration Schedule
MH  - Drug Interactions
MH  - Drug Substitution
MH  - Hemorrhage/ci [Chemically Induced]
MH  - Humans
MH  - Morpholines/ad [Administration & Dosage]
MH  - Morpholines/ae [Adverse Effects]
MH  - *Morpholines/tu [Therapeutic Use]
MH  - Patient Selection
MH  - Perioperative Care
MH  - Practice Guidelines as Topic
MH  - *Preventive Health Services
MH  - Risk Assessment
MH  - Risk Factors
MH  - Rivaroxaban
MH  - Stroke/bl [Blood]
MH  - Stroke/et [Etiology]
MH  - *Stroke/pc [Prevention & Control]
MH  - Thiophenes/ad [Administration & Dosage]
MH  - Thiophenes/ae [Adverse Effects]
MH  - *Thiophenes/tu [Therapeutic Use]
MH  - Treatment Outcome
KW  - direct factor Xa inhibitor;  novel oral anticoagulants;  peri-interventional management;  practical guidance;  rivaroxaban;  stroke prevention
AB  - Rivaroxaban is a direct factor Xa inhibitor that is widely available to reduce the risk of stroke or systemic embolism in patients with nonvalvular atrial fibrillation and one or more risk factors for stroke. Rivaroxaban provides practical advantages compared with warfarin and other vitamin K antagonists, including a rapid onset of action, few drug interactions, no dietary interactions, a predictable anticoagulant effect, and no requirement for routine coagulation monitoring. However, questions have emerged relating to the responsible use of rivaroxaban in day-to-day clinical practice, including patient selection, dosing, treatment of patients with renal impairment, conversion from use of vitamin K antagonists to rivaroxaban and vice versa, coagulation tests, and management of patients requiring invasive procedures or experiencing bleeding or an ischemic event. This article provides practical recommendations relating to the use of rivaroxaban in patients with nonvalvular atrial fibrillation, based on clinical trial evidence, relevant guidelines, prescribing information, and the authors' clinical experience.
RN  - 0 (Anticoagulants)
RN  - 0 (Morpholines)
RN  - 0 (Thiophenes)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
ES  - 1178-2048
IL  - 1176-6344
DO  - http://dx.doi.org/10.2147/VHRM.S55246
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20140310
DP  - 2014
DC  - 20140320
YR  - 2014
ED  - 20140902
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24648742

<196. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24787471
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Martinez-Gonzalez MA
AU  - Toledo E
AU  - Aros F
AU  - Fiol M
AU  - Corella D
AU  - Salas-Salvado J
AU  - Ros E
AU  - Covas MI
AU  - Fernandez-Crehuet J
AU  - Lapetra J
AU  - Munoz MA
AU  - Fito M
AU  - Serra-Majem L
AU  - Pinto X
AU  - Lamuela-Raventos RM
AU  - Sorli JV
AU  - Babio N
AU  - Buil-Cosiales P
AU  - Ruiz-Gutierrez V
AU  - Estruch R
AU  - Alonso A
AU  - PREDIMED Investigators
FA  - Martinez-Gonzalez, Miguel A
FA  - Toledo, Estefania
FA  - Aros, Fernando
FA  - Fiol, Miquel
FA  - Corella, Dolores
FA  - Salas-Salvado, Jordi
FA  - Ros, Emilio
FA  - Covas, Maria I
FA  - Fernandez-Crehuet, Joaquin
FA  - Lapetra, Jose
FA  - Munoz, Miguel A
FA  - Fito, Monserrat
FA  - Serra-Majem, Luis
FA  - Pinto, Xavier
FA  - Lamuela-Raventos, Rosa M
FA  - Sorli, Jose V
FA  - Babio, Nancy
FA  - Buil-Cosiales, Pilar
FA  - Ruiz-Gutierrez, Valentina
FA  - Estruch, Ramon
FA  - Alonso, Alvaro
FA  - PREDIMED Investigators
IN  - Martinez-Gonzalez,Miguel A. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Toledo,Estefania. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Aros,Fernando. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Fiol,Miquel. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Corella,Dolores. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Salas-Salvado,Jordi. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Ros,Emilio. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Covas,Maria I. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Fernandez-Crehuet,Joaquin. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Lapetra,Jose. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Munoz,Miguel A. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Fito,Monserrat. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Serra-Majem,Luis. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Pinto,Xavier. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Lamuela-Raventos,Rosa M. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Sorli,Jose V. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Babio,Nancy. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Buil-Cosiales,Pilar. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Ruiz-Gutierrez,Valentina. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Estruch,Ramon. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IN  - Alonso,Alvaro. From the Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (M.A.M.-G., E.T., P.B.-C., A.A.); the PREDIMED (Prevencion con Dieta Mediterranea) Research Network (M.A.M.-G., E.T., F.A., J.S.-S., J.F.-C., N.B., P.B.-C., V.R.-G., A.A.) and Centro de Investigacion Biomedica en Red Fisiopatologia de la Obesidad y Nutricion (M.A.M.-G., E.T., F.A., M. Fiol, D.C., J.S.-S., E.R., M.I.C., J.F.-C., J.L., M.A.M., M. Fito, L.S.-M., X.P., R.M.L.-R., J.V.S., N.B., P.B.-C., V.R.-G., R.E., A.A.), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Institute of Health Sciences, Instituto de Investigacion Sanitaria de Palma, Palma de Mallorca, Spain (M.Fiol); Department of Preventive Medicine, University of Valencia, Valencia, Spain (D.C., J.V.S.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain (J.S.-S., N.B.); Institut d'Investigacions Biomediques August Pi i Sunyer, Hospital Clinic (E.R., R.E.) and Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referencia en Tecnologia dels Aliments, Instituto de Investigacion en Nutricion y Seguridad Alimentaria (R.M.L.-R.), University of Barcelona, Barcelona, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, and Primary Care Division of Barcelona. Institut Catala de la Salut and IDiap-Jordi Gol, Barcelona, Spain (M.I.C., M.A.M., M. Fito); Department of Preventive Medicine, University of Malaga, Malaga, Spain (J.F.-C.); Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville, Spain (J.L.); Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital
IR  - Estruch R
IR  - Corella D
IR  - Covas MI
IR  - Ros E
IR  - Salas-Salvado J
IR  - Martinez-Gonzalez MA
IR  - Aldamiz M
IR  - Alonso A
IR  - Berjon J
IR  - Forga L
IR  - Gallego J
IR  - Layana A
IR  - Larrauri A
IR  - Portu J
IR  - Timiraus J
IR  - Serrano-Martinez M
IR  - Ros E
IR  - Martinez-Gonzalez MA
IR  - Covas MI
IR  - Perez-Heras A
IR  - Salas-Salvado J
IR  - Serra M
IR  - Pi-Sunyer X
IR  - Gonzalez CA
IR  - Hu FB
IR  - Sabate J
IR  - Ruiz-Canela M
IR  - Sanchez-Tainta A
IR  - Sanjulian B
IR  - Diez--Espino J
IR  - Extremera-Urabayen V
IR  - Garcia-Arellano A
IR  - Zazpe I
IR  - Basterra-Gortari FJ
IR  - Goni JM
IR  - Razquin C
IR  - Serrano-Martinez M
IR  - Bes-Rastrollo M
IR  - Gea A
IR  - Martinez-Lapiscina EH
IR  - Nunez-Cordoba JM
IR  - Arroyo-Azpa C
IR  - Garcia-Perez L
IR  - Villanueva-Telleria J
IR  - Cortes-Ugalde F
IR  - Sagredo-Arce T
IR  - Garcia de la Noceda-Montoy MD
IR  - Vigata-Lopez MD
IR  - Arceiz-Campo MT
IR  - Urtasun-Samper A
IR  - Gueto-Rubio MV
IR  - Churio-Beraza B
IR  - Bullo M
IR  - Gonzalez R
IR  - Molina C
IR  - Marquez F
IR  - Babio N
IR  - Sorli M
IR  - Garcia Rosello J
IR  - Guasch-Ferre M
IR  - Diaz-Lopez A
IR  - Martin AF
IR  - Tort R
IR  - Isach A
IR  - Costa B
IR  - Cabre JJ
IR  - Fernandez-Ballart J
IR  - Ibarrola-Jurado N
IR  - Alegret C
IR  - Martinez P
IR  - Millan S
IR  - Pinol JL
IR  - Basora T
IR  - Hernandez JM
IR  - Serra M
IR  - Perez-Heras A
IR  - Vinas C
IR  - Casas R
IR  - de Santamaria L
IR  - Romero S
IR  - Sacanella E
IR  - Chiva G
IR  - Valderas P
IR  - Arranz S
IR  - Baena JM
IR  - Garcia M
IR  - Oller M
IR  - Amat J
IR  - Duaso I
IR  - Garcia Y
IR  - Iglesias C
IR  - Simon C
IR  - Quinzavos L
IR  - Parra L
IR  - Liroz M
IR  - Benavent J
IR  - Clos J
IR  - Pla I
IR  - Amoros M
IR  - Bonet MT
IR  - Martin MT
IR  - Sanchez MS
IR  - Altirriba J
IR  - Manzano E
IR  - Altes A
IR  - Cofan M
IR  - Valls-Pedret C
IR  - Sala-Vila A
IR  - Domenech M
IR  - Gilabert R
IR  - Bargallo N
IR  - Tello S
IR  - Vila J
IR  - Schroder H
IR  - De la Torre R
IR  - Munoz-Aguayo D
IR  - Elosua R
IR  - Marrugat J
IR  - Ferrer M
IR  - Carrasco P
IR  - Osma R
IR  - Guillem-Saiz P
IR  - Portoles O
IR  - Pascual V
IR  - Riera C
IR  - Valderrama J
IR  - Serrano A
IR  - Lazaro E
IR  - Sanmartin A
IR  - Girbes A
IR  - Santamari V
IR  - Sanchez C
IR  - Pla Z
IR  - Sanchez E
IR  - Ortega-Azorin C
IR  - Gonzalez JI
IR  - Saiz C
IR  - Coltell O
IR  - Asensio EM
IR  - Salaverria I
IR  - del Hierro T
IR  - Algorta J
IR  - Francisco S
IR  - Alonso A
IR  - San Vicente J
IR  - Sanz E
IR  - Felipe I
IR  - Alonso Gomez A
IR  - Loma-Osorio A
IR  - Gomez-Gracia E
IR  - Benitez Pont R
IR  - Bianchi Alba M
IR  - Warnberg J
IR  - Gomez-Huelgas R
IR  - Martinez-Gonzalez J
IR  - Velasco Garcia V
IR  - de Diego Salas J
IR  - Baca Osorio A
IR  - Zarzosa JG
IR  - Sanchez Luque JJ
IR  - Vargas Lopez E
IR  - Jurado Ruiz E
IR  - Romero M
IR  - Garcia Garcia M
IR  - Garcia-Valdueza M
IR  - Monino M
IR  - Proenza A
IR  - Prieto R
IR  - Frontera G
IR  - Ginard M
IR  - Fiol F
IR  - Jover A
IR  - Garcia J
IR  - Leal M
IR  - Martinez E
IR  - Santos JM
IR  - Ortega-Calvo M
IR  - Roman P
IR  - Garcia FJ
IR  - Iglesias P
IR  - Corchado Y
IR  - Mayoral E
IR  - Lama C
IR  - Lopez-Sabater MC
IR  - Castellote-Bargallo AI
IR  - Medina-Remon A
IR  - Tresserra-Rimbau A
IR  - Alvarez-Perez J
IR  - DiazBenitez E
IR  - Bautista-Castano I
IR  - Maldonado-Diaz I
IR  - Sanchez-Villegas A
IR  - Castro I
IR  - Henriquez P
IR  - Ruano C
IR  - Ortiz AP
IR  - Sarmiendo de la Fe F
IR  - Simon-Garcia C
IR  - Falcon-Sanabria I
IR  - Macias-Gutierrez B
IR  - Santana-Santana AJ
IR  - de la Cruz E
IR  - Galera A
IR  - Soler Y
IR  - Trias F
IR  - Sarasa I
IR  - Padres E
IR  - Figueras R
IR  - Solanich X
IR  - Pujol R
IR  - Corbella E
IR  - Cabezas C
IR  - Vinyoles E
IR  - Rovira MA
IR  - Garcia L
IR  - Flores G
IR  - Verdu JM
IR  - Baby P
IR  - Ramos A
IR  - Mengual L
IR  - Roura P
IR  - Yuste MC
IR  - Guarner A
IR  - Rovira A
IR  - Santamaria MI
IR  - Mata M
IR  - de Juan C
IR  - Brau A
IR  - Martinez JA
IR  - Marti A
IR  - Mitjavila MT
IR  - Portillo MP
IR  - Saez G
IR  - Tur J
TI  - Extravirgin olive oil consumption reduces risk of atrial fibrillation: the PREDIMED (Prevencion con Dieta Mediterranea) trial.
CM  - Comment in: Circulation. 2015 Sep 8;132(10):e139; PMID: 26354788
CM  - Comment in: Circulation. 2015 Sep 8;132(10):e140-2; PMID: 26354789
SO  - Circulation. 130(1):18-26, 2014 Jul 1.
AS  - Circulation. 130(1):18-26, 2014 Jul 1.
NJ  - Circulation
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/me [Metabolism]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - Diet, Fat-Restricted
MH  - *Diet, Mediterranean
MH  - *Dietary Fats/tu [Therapeutic Use]
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Inflammation
MH  - Male
MH  - Middle Aged
MH  - Nuts
MH  - Olive Oil
MH  - Oxidative Stress
MH  - *Plant Oils
MH  - Proportional Hazards Models
MH  - Risk
MH  - Risk Factors
MH  - Spain/ep [Epidemiology]
MH  - Stroke/ep [Epidemiology]
MH  - Stroke/pc [Prevention & Control]
MH  - Treatment Outcome
KW  - antioxidants;  arrhythmia;  atrial fibrillation;  diet;  epidemiology;  fatty acids, monounsaturated;  inflammation
AB  - BACKGROUND: The PREDIMED (Prevencion con Dieta Mediterranea) randomized primary prevention trial showed that a Mediterranean diet enriched with either extravirgin olive oil or mixed nuts reduces the incidence of stroke, myocardial infarction, and cardiovascular mortality. We assessed the effect of these diets on the incidence of atrial fibrillation in the PREDIMED trial.
AB  - METHODS AND RESULTS: Participants were randomly assigned to 1 of 3 diets: Mediterranean diet supplemented with extravirgin olive oil, Mediterranean diet supplemented with mixed nuts, or advice to follow a low-fat diet (control group). Incident atrial fibrillation was adjudicated during follow-up by an events committee blinded to dietary group allocation. Among 6705 participants without prevalent atrial fibrillation at randomization, we observed 72 new cases of atrial fibrillation in the Mediterranean diet with extravirgin olive oil group, 82 in the Mediterranean diet with mixed nuts group, and 92 in the control group after median follow-up of 4.7 years. The Mediterranean diet with extravirgin olive oil significantly reduced the risk of atrial fibrillation (hazard ratio, 0.62; 95% confidence interval, 0.45-0.85 compared with the control group). No effect was found for the Mediterranean diet with nuts (hazard ratio, 0.89; 95% confidence interval, 0.65-1.20).
AB  - CONCLUSIONS: In the absence of proven interventions for the primary prevention of atrial fibrillation, this post hoc analysis of the PREDIMED trial suggests that extravirgin olive oil in the context of a Mediterranean dietary pattern may reduce the risk of atrial fibrillation.
AB  - CLINICAL TRIAL REGISTRATION URL: http://www.controlled-trials.com. Unique identifier: ISRCTN35739639.Copyright © 2014 American Heart Association, Inc.
RN  - 0 (Dietary Fats)
RN  - 0 (Olive Oil)
RN  - 0 (Plant Oils)
ES  - 1524-4539
IL  - 0009-7322
DO  - http://dx.doi.org/10.1161/CIRCULATIONAHA.113.006921
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
SI  - ISRCTN
SA  - ISRCTN/ISRCTN35739639
SL  - http://www.controlled-trials.com/ISRCTN35739639
LG  - English
EP  - 20140430
DP  - 2014 Jul 1
DC  - 20140701
YR  - 2014
ED  - 20140902
RD  - 20151123
UP  - 20151217
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=24787471

<197. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24342396
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Brugger N
AU  - Krause R
AU  - Carlen F
AU  - Rimensberger C
AU  - Hille R
AU  - Steck H
AU  - Wilhelm M
AU  - Seiler C
FA  - Brugger, Nicolas
FA  - Krause, Rene
FA  - Carlen, Frederik
FA  - Rimensberger, Caroline
FA  - Hille, Ron
FA  - Steck, Helene
FA  - Wilhelm, Matthias
FA  - Seiler, Christian
IN  - Brugger,Nicolas. Cardiology Department, Bern University Hospital, Bern, Switzerland. Electronic address: nicolas.brugger@insel.ch.
IN  - Krause,Rene. Cardiology Department, Bern University Hospital, Bern, Switzerland.
IN  - Carlen,Frederik. Cardiology Department, Bern University Hospital, Bern, Switzerland.
IN  - Rimensberger,Caroline. Cardiology Department, Bern University Hospital, Bern, Switzerland.
IN  - Hille,Ron. Cardiology Department, Bern University Hospital, Bern, Switzerland.
IN  - Steck,Helene. Cardiology Department, Bern University Hospital, Bern, Switzerland.
IN  - Wilhelm,Matthias. Cardiology Department, Bern University Hospital, Bern, Switzerland.
IN  - Seiler,Christian. Cardiology Department, Bern University Hospital, Bern, Switzerland.
TI  - Effect of lifetime endurance training on left atrial mechanical function and on the risk of atrial fibrillation.
SO  - International Journal of Cardiology. 170(3):419-25, 2014 Jan 1.
AS  - Int J Cardiol. 170(3):419-25, 2014 Jan 1.
NJ  - International journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - gqw, 8200291
SB  - Index Medicus
CP  - Netherlands
MH  - Adaptation, Physiological/ph [Physiology]
MH  - Adult
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/us [Ultrasonography]
MH  - *Atrial Function, Left/ph [Physiology]
MH  - *Atrial Remodeling/ph [Physiology]
MH  - Cross-Sectional Studies
MH  - Echocardiography
MH  - Electrocardiography
MH  - Fibrosis/ep [Epidemiology]
MH  - Fibrosis/pp [Physiopathology]
MH  - Fibrosis/us [Ultrasonography]
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Physical Endurance/ph [Physiology]
MH  - Risk Factors
MH  - *Running/ph [Physiology]
MH  - Vagus Nerve/ph [Physiology]
KW  - Atrial fibrillation;  Atrial function;  Atrial remodeling;  Endurance exercise training;  Left atrium
AB  - BACKGROUND: Left atrium (LA) dilation and P-wave duration are linked to the amount of endurance training and are risk factors for atrial fibrillation (AF). The aim of this study was to evaluate the impact of LA anatomical and electrical remodeling on its conduit and pump function measured by two-dimensional speckle tracking echocardiography (STE).
AB  - METHOD: Amateur male runners >30 years were recruited. Study participants (n=95) were stratified in 3 groups according to lifetime training hours: low (<1500 h, n=33), intermediate (1500 to 4500 h, n=32) and high training group (>4500 h, n=30).
AB  - RESULTS: No differences were found, between the groups, in terms of age, blood pressure, and diastolic function. LA maximal volume (30+/-5, 33+/-5 vs. 37+/-6 ml/m(2), p<0.001), and conduit volume index (9+/-3, 11+/-3 vs. 12+/-3 ml/m(2), p<0.001) increased significantly from the low to the high training group, unlike the STE parameters: pump strain -15.0+/-2.8, -14.7+/-2.7 vs. -14.9+/-2.6%, p=0.927; conduit strain 23.3+/-3.9, 22.1+/-5.3 vs. 23.7+/-5.7%, p=0.455. Independent predictors of LA strain conduit function were age, maximal early diastolic velocity of the mitral annulus, heart rate and peak early diastolic filling velocity. The signal-averaged P-wave (135+/-11, 139+/-10 vs. 148+/-14 ms, p<0.001) increased from the low to the high training group. Four episodes of non-sustained AF were recorded in one runner of the high training group.
AB  - CONCLUSION: The LA anatomical and electrical remodeling does not have a negative impact on atrial mechanical function. Hence, a possible link between these risk factors for AF and its actual, rare occurrence in this athlete population, could not be uncovered in the present study.Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.
ES  - 1874-1754
IL  - 0167-5273
DI  - S0167-5273(13)02050-0
DO  - http://dx.doi.org/10.1016/j.ijcard.2013.11.032
PT  - Journal Article
PT  - Observational Study
LG  - English
EP  - 20131123
DP  - 2014 Jan 1
DC  - 20131224
YR  - 2014
ED  - 20140821
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24342396

<198. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23086101
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Merli GJ
FA  - Merli, Geno J
IN  - Merli,Geno J. Thomas Jefferson University Hospitals, Philadelphia, PA. geno.merli@jefferson.edu.
TI  - The new oral anticoagulants: a challenge for hospital formularies.
SO  - Hospital practice (1995) Hospital practice. 40(3):126-8, 2012 Aug.
AS  - Hosp Pract (Minneap). 40(3):126-8, 2012 Aug.
NJ  - Hospital practice (1995)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101268948
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Administration, Oral
MH  - *Anticoagulants/ad [Administration & Dosage]
MH  - Anticoagulants/pk [Pharmacokinetics]
MH  - *Antithrombins/ad [Administration & Dosage]
MH  - Antithrombins/pk [Pharmacokinetics]
MH  - Benzamides/ad [Administration & Dosage]
MH  - Benzamides/pk [Pharmacokinetics]
MH  - Benzimidazoles/ad [Administration & Dosage]
MH  - Benzimidazoles/pk [Pharmacokinetics]
MH  - Dabigatran
MH  - *Formularies, Hospital
MH  - Humans
MH  - Morpholines/ad [Administration & Dosage]
MH  - Morpholines/pk [Pharmacokinetics]
MH  - Pennsylvania
MH  - Pyrazoles/ad [Administration & Dosage]
MH  - Pyrazoles/pk [Pharmacokinetics]
MH  - Pyridines/ad [Administration & Dosage]
MH  - Pyridines/pk [Pharmacokinetics]
MH  - Pyridones/ad [Administration & Dosage]
MH  - Pyridones/pk [Pharmacokinetics]
MH  - Rivaroxaban
MH  - Thiophenes/ad [Administration & Dosage]
MH  - Thiophenes/pk [Pharmacokinetics]
MH  - Warfarin/ad [Administration & Dosage]
MH  - Warfarin/pk [Pharmacokinetics]
MH  - beta-Alanine/ad [Administration & Dosage]
MH  - beta-Alanine/aa [Analogs & Derivatives]
MH  - beta-Alanine/pk [Pharmacokinetics]
AB  - Introduction Over the past 60 years, clinicians have used vitamin K antagonists, primarily warfarin, as the sole oral anticoagulants for managing a variety of thrombotic disorders. Warfarin, which requires frequent monitoring, has a variable dose response, a narrow therapeutic index, and numerous drug and dietary interactions. However, intravenous and subcutaneous agents, such as unfractionated heparin, low-molecular-weight heparin, direct thrombin inhibitors, and pentasaccharide, have been introduced over the past 30 years for managing thromboembolic disorders. Recently, 5 new oral anticoagulants, dabigatran, rivaroxaban, apixaban, endoxaban, and betrixaban, have been introduced into clinical trials. Apixaban, rivaroxaban, endoxaban, and betrixaban are specific direct inhibitors of factor Xa, while dabigatran inhibits factor IIa. These drugs have a pharmacological profile that does not require monitoring in order to adjust therapy, which is the mainstay of warfarin management. In addition, these new medications have not shown any major issues regarding food interactions; rather, they demonstrate the potential for limited drug-drug interactions due to their limited metabolism through the cytochrome P450 system. This unique pharmacokinetic profile may provide clinicians with a new era of managing thromboembolic disorders. Two of these agents, dabigatran and rivaroxaban, have been approved by the US Food and Drug Administration (FDA) for stroke prevention in patients with nonvalvular atrial fibrillation (AF); in addition, rivaroxaban can be used in the prevention of venous thromboembolism (VTE) in total hip and knee arthroplasty during the acute and extended periods of risk. However, the challenge for hospital formularies will be the appropriate use and management of these new medications as they become integrated into outpatient care. In order to better understand the issues that pharmacy and therapeutics committees will encounter, a review of the 2 FDA-approved oral anticoagulants will be evaluated.
RN  - 0 (Anticoagulants)
RN  - 0 (Antithrombins)
RN  - 0 (Benzamides)
RN  - 0 (Benzimidazoles)
RN  - 0 (Morpholines)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridines)
RN  - 0 (Pyridones)
RN  - 0 (Thiophenes)
RN  - 11P2JDE17B (beta-Alanine)
RN  - 3Z9Y7UWC1J (apixaban)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 74RWP7W0J9 (betrixaban)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - I0VM4M70GC (Dabigatran)
IS  - 2154-8331
IL  - 2154-8331
DO  - http://dx.doi.org/10.3810/hp.2012.08.996
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2012 Aug
DC  - 20121022
YR  - 2012
ED  - 20140821
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23086101

<199. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23884920
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - La Gerche A
AU  - Schmied CM
FA  - La Gerche, Andre
FA  - Schmied, Christian Marc
IN  - La Gerche,Andre. St Vincent's Hospital Department of Medicine, University of Melbourne, Fitzroy, Australia.
TI  - Atrial fibrillation in athletes and the interplay between exercise and health.
CM  - Comment on: Eur Heart J. 2013 Dec;34(47):3624-31; PMID: 23756332
SO  - European Heart Journal. 34(47):3599-602, 2013 Dec.
AS  - Eur Heart J. 34(47):3599-602, 2013 Dec.
NJ  - European heart journal
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - em8, 8006263
SB  - Index Medicus
CP  - England
MH  - *Arrhythmias, Cardiac/ep [Epidemiology]
MH  - Female
MH  - Humans
MH  - Male
MH  - *Skiing/ph [Physiology]
ES  - 1522-9645
IL  - 0195-668X
DO  - http://dx.doi.org/10.1093/eurheartj/eht265
PT  - Comment
PT  - Editorial
LG  - English
EP  - 20130724
DP  - 2013 Dec
DC  - 20131216
YR  - 2013
ED  - 20140819
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23884920

<200. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23972369
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Guo Y
AU  - Wang H
AU  - Zhao X
AU  - Zhang Y
AU  - Zhang D
AU  - Ma J
AU  - Wang Y
AU  - Lip GY
FA  - Guo, Yutao
FA  - Wang, Haijun
FA  - Zhao, Xiaoning
FA  - Zhang, Yu
FA  - Zhang, Dexian
FA  - Ma, Jingling
FA  - Wang, Yutang
FA  - Lip, Gregory Y H
IN  - Guo,Yutao. University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom; Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing, China.
TI  - Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation.
SO  - International Journal of Cardiology. 168(5):4678-84, 2013 Oct 12.
AS  - Int J Cardiol. 168(5):4678-84, 2013 Oct 12.
NJ  - International journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - gqw, 8200291
SB  - Index Medicus
CP  - Netherlands
MH  - Aged
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/mo [Mortality]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Cause of Death/td [Trends]
MH  - China/ep [Epidemiology]
MH  - Female
MH  - Follow-Up Studies
MH  - *Glomerular Filtration Rate/ph [Physiology]
MH  - *Hemorrhage/ep [Epidemiology]
MH  - Hemorrhage/et [Etiology]
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Renal Insufficiency/ep [Epidemiology]
MH  - Renal Insufficiency/et [Etiology]
MH  - *Renal Insufficiency/pp [Physiopathology]
MH  - Retrospective Studies
MH  - *Risk Assessment/mt [Methods]
MH  - Risk Factors
MH  - Stroke/ep [Epidemiology]
MH  - *Stroke/et [Etiology]
MH  - Survival Rate/td [Trends]
MH  - Time Factors
KW  - Atrial fibrillation;  Bleeding;  Death;  Renal function;  Stroke
AB  - BACKGROUND: Renal dysfunction has been proposed for the risk factor for stroke and bleeding in atrial fibrillation (AF). The impact of changes in renal dysfunction over time and the relationship to stroke and bleeding risk in these patients remain unknown. We investigated sequential change in renal function (estimated glomerular filtration rate, eGFR) and the risk for clinical events (ischaemic stroke, death and major bleeding) over time in a cohort of 617 AF patients followed up for 2 years.
AB  - METHODS: eGFR was estimated at baseline, 6 months and 12 months using three formulas (Modification of Diet in Renal Disease equation, MDRD, Chronic Kidney Disease Epidemiology Collaboration, CKD-EPI, and Cockcroft-Gault equation). Changes in eGFR and the risk for clinical events were analysed by Cox models, receiver operating curves (ROC), and Kaplan-Meier survival curves.
AB  - RESULTS: When patients with eGFR<60 ml/min/1.73 m(2) were compared to patients with eGFR>60 ml/min/1.73 m(2), there was an increase over time in stroke or death, or death, with impaired renal function (all p<0.05). An absolute decrease in eGFR>15 ml/min/1.73 m(2) on Cockcroft-Gault and CKD-EPI and >25 ml/min/1.73 m(2) on MDRD were associated with an increased risk for stroke or death, death, and ischaemic stroke at 6 months (all p<0.05), but not major bleeding. A relative reduction (decline of >25%) in eGFR was also an independent risk. ROC analysis showed that a relative reduction in eGFR >25% at 6 months and 12 months modestly predicted the occurrence of stroke or death in patients with AF (c-indexes: 0.57 to 0.61, p<0.05).
AB  - CONCLUSION: In patients with AF, an absolute decrease in eGFR >15 ml/min/1.73 m(2) on Cockcroft-Gault and CKD-EPI, and >25 ml/min/1.73 m(2) on MDRD, or a relative reduction (>25%) in eGFR, independently predicted the risk for the endpoints 'stroke or death', 'death' or (at 6 months) ischaemic stroke. Deteriorating renal function increases the risk of death in AF patients.Copyright © 2013.
ES  - 1874-1754
IL  - 0167-5273
DI  - S0167-5273(13)01404-6
DO  - http://dx.doi.org/10.1016/j.ijcard.2013.07.179
PT  - Journal Article
LG  - English
EP  - 20130730
DP  - 2013 Oct 12
DC  - 20131025
YR  - 2013
ED  - 20140819
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23972369

<201. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25132960
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Leischik R
AU  - Spelsberg N
AU  - Niggemann H
AU  - Dworrak B
AU  - Tiroch K
FA  - Leischik, Roman
FA  - Spelsberg, Norman
FA  - Niggemann, Hiltrud
FA  - Dworrak, Birgit
FA  - Tiroch, Klaus
IN  - Leischik,Roman. Department of Cardiology, Section of Prevention, Health Promotion and Sports Medicine, Faculty of Health, School of Medicine, Witten/Herdecke University, Hagen, 58095, Germany.
IN  - Spelsberg,Norman. Department of Cardiology, Section of Prevention, Health Promotion and Sports Medicine, Faculty of Health, School of Medicine, Witten/Herdecke University, Hagen, 58095, Germany.
IN  - Niggemann,Hiltrud. Department of Cardiology, Section of Prevention, Health Promotion and Sports Medicine, Faculty of Health, School of Medicine, Witten/Herdecke University, Hagen, 58095, Germany.
IN  - Dworrak,Birgit. Department of Cardiology, Section of Prevention, Health Promotion and Sports Medicine, Faculty of Health, School of Medicine, Witten/Herdecke University, Hagen, 58095, Germany.
IN  - Tiroch,Klaus. Department of Cardiology, Faculty of Health, School of Medicine, Witten/Herdecke University, Helios Hospital Wuppertal, 42117, Germany.
TI  - Exercise-induced arterial hypertension - an independent factor for hypertrophy and a ticking clock for cardiac fatigue or atrial fibrillation in athletes?.
SO  - F1000Research. 3:105, 2014.
AS  - F1000Res. 3:105, 2014.
NJ  - F1000Research
PI  - Journal available in: Electronic-eCollection
PI  - Citation processed from: Print
JC  - 101594320
OI  - Source: NLM. PMC4118759
CP  - England
AB  - UNLABELLED: Background : Exercise-induced arterial hypertension (EIAH) leads to myocardial hypertrophy and is associated with a poor prognosis. EIAH might be related to the "cardiac fatigue" caused by endurance training. The goal of this study was to examine whether there is any relationship between EIAH and left ventricular hypertrophy in Ironman-triathletes.
AB  - METHODS: We used echocardiography and spiroergometry to determine the left ventricular mass (LVM), the aerobic/anaerobic thresholds and the steady-state blood pressure of 51 healthy male triathletes. The main inclusion criterion was the participation in at least one middle or long distance triathlon.
AB  - RESULTS: When comparing triathletes with LVM <220g  and athletes with LVM >220g there was a significant difference between blood pressure values (BP) at the anaerobic threshold (185.2+/- 21.5 mmHg vs. 198.8 +/-22.3 mmHg, p=0.037). The spiroergometric results were: maximum oxygen uptake (relative VO 2max) 57.3 +/-7.5ml/min/kg vs. 59.8+/-9.5ml/min/kg (p=ns). Cut-point analysis for the relationship of BP >170 mmHg at the aerobic threshold and the probability of LVM >220g showed a sensitivity of 95.8%, a specificity of 33.3%, with a positive predictive value of 56.8 %, a good negative predictive value of 90%. The probability of LVM >220g increased with higher BP during exercise (OR: 1.027, 95% CI 1.002-1.052, p= 0.034) or with higher training volume (OR: 1.23, 95% CI 1.04 -1.47, p = 0.019). Echocardiography showed predominantly concentric remodelling, followed by concentric hypertrophy.
AB  - CONCLUSION: Significant left ventricular hypertrophy with LVM >220g is associated with higher arterial blood pressure at the aerobic or anaerobic threshold. The endurance athletes with EIAH may require a therapeutic intervention to at least prevent extensive stiffening of the heart muscle and exercise-induced cardiac fatigue.
ES  - 2046-1402
IL  - 2046-1402
DO  - http://dx.doi.org/10.12688/f1000research.4001.1
PT  - Journal Article
LG  - English
EP  - 20140512
DP  - 2014
DC  - 20140818
YR  - 2014
ED  - 20140818
RD  - 20140820
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=25132960

<202. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23796313
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ettema RG
AU  - Van Koeven H
AU  - Peelen LM
AU  - Kalkman CJ
AU  - Schuurmans MJ
FA  - Ettema, Roelof G A
FA  - Van Koeven, Heleen
FA  - Peelen, Linda M
FA  - Kalkman, Cor J
FA  - Schuurmans, Marieke J
IN  - Ettema,Roelof G A. Nursing and Paramedical Care for People With Chronic Illnesses, University of Applied Science Utrecht, Faculty of Health Care, Bolognalaan 101, 3584 CJ Utrecht, The Netherlands; Julius Center for Health Sciences and Primary Care, Department of Epidemiology, University Medical Center Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands. Electronic address: Roelof.Ettema@hu.nl.
IN  - Van Koeven,Heleen. Division of Anesthesiology, Intensive Care and Emergency Medicine, University Medical Center Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands.
IN  - Peelen,Linda M. Julius Center for Health Sciences and Primary Care, Department of Epidemiology, University Medical Center Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands.
IN  - Kalkman,Cor J. Professor of Anesthesiology, Division of Anesthesiology, Intensive Care and Emergency Medicine, University Medical Center Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands.
IN  - Schuurmans,Marieke J. Nursing and Paramedical Care for People With Chronic Illnesses, University of Applied Science Utrecht, Faculty of Health Care, Bolognalaan 101, 3584 CJ Utrecht, The Netherlands; Professor of Nursing Science, Department of Rehabilitation, Nursing Science & Sports, University Medical Center Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands.
TI  - Preadmission interventions to prevent postoperative complications in older cardiac surgery patients: a systematic review. [Review]
SO  - International Journal of Nursing Studies. 51(2):251-60, 2014 Feb.
AS  - Int J Nurs Stud. 51(2):251-60, 2014 Feb.
NJ  - International journal of nursing studies
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - gs8, 0400675
SB  - Index Medicus
SB  - Nursing Journal
CP  - England
MH  - Aged
MH  - *Cardiac Surgical Procedures/ae [Adverse Effects]
MH  - Humans
MH  - Middle Aged
MH  - *Patient Admission
MH  - *Postoperative Complications/pc [Prevention & Control]
MH  - *Preoperative Period
KW  - Cardiac surgical procedure;  Older patients;  Postoperative complications;  Preadmission preventive measures
AB  - OBJECTIVE(S): The literature on postoperative complications in cardiac surgery patients shows high incidences of postoperative complications such as delirium, depression, pressure ulcer, infection, pulmonary complications and atrial fibrillation. These complications are associated with functional and cognitive decline and a decrease in the quality of life after discharge. Several studies attempted to prevent one or more postoperative complications by preoperative interventions. Here we provide a comprehensive overview of both single and multiple component preadmission interventions designed to prevent postoperative complications.
AB  - METHODS: We systematically reviewed the literature following the PRISMA statement guidelines.
AB  - RESULTS: Of 1335 initial citations, 31 were subjected to critical appraisal. Finally, 23 studies were included, of which we derived a list of interventions that can be applied in the preadmission period to effectively reduce postoperative depression, infection, pulmonary complications, atrial fibrillation, prolonged intensive care unit stay and hospital stay in older elective cardiac surgery patients. No high quality studies were found describing effective interventions to prevent postoperative delirium. We did not find studies specifically targeting the prevention of pressure ulcers in this patient population.
AB  - CONCLUSIONS: Multi-component approaches that include different single interventions have the strongest effect in preventing postoperative depression, pulmonary complications, prolonged intensive care unit stay and hospital stay. Postoperative infection can be best prevented by disinfection with chlorhexidine combined with immune-enhancing nutritional supplements. Atrial fibrillation might be prevented by ingestion of N-3 polyunsaturated fatty acids. High quality studies are urgently needed to evaluate preadmission preventive strategies to reduce postoperative delirium or pressure ulcers in older elective cardiac surgery patients.Copyright © 2013 Elsevier Ltd. All rights reserved.
ES  - 1873-491X
IL  - 0020-7489
DI  - S0020-7489(13)00154-5
DO  - http://dx.doi.org/10.1016/j.ijnurstu.2013.05.011
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20130621
DP  - 2014 Feb
DC  - 20140101
YR  - 2014
ED  - 20140815
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23796313

<203. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24829373
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Drca N
AU  - Wolk A
AU  - Jensen-Urstad M
AU  - Larsson SC
FA  - Drca, Nikola
FA  - Wolk, Alicja
FA  - Jensen-Urstad, Mats
FA  - Larsson, Susanna C
IN  - Drca,Nikola. Department of Cardiology at the Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
IN  - Wolk,Alicja. Division of Nutritional Epidemiology, The National Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden.
IN  - Jensen-Urstad,Mats. Department of Cardiology at the Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
IN  - Larsson,Susanna C. Division of Nutritional Epidemiology, The National Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden.
TI  - Atrial fibrillation is associated with different levels of physical activity levels at different ages in men.
CM  - Comment in: Heart. 2014 Jul;100(13):999-1000; PMID: 24829372
SO  - Heart. 100(13):1037-42, 2014 Jul.
AS  - Heart. 100(13):1037-42, 2014 Jul.
NJ  - Heart (British Cardiac Society)
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9602087
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - *Aging
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/pc [Prevention & Control]
MH  - Bicycling
MH  - Confounding Factors (Epidemiology)
MH  - *Exercise
MH  - Humans
MH  - Linear Models
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Odds Ratio
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Registries
MH  - Risk Factors
MH  - Sex Factors
MH  - Surveys and Questionnaires
MH  - Sweden
MH  - Time Factors
MH  - Walking
AB  - OBJECTIVE: This study examines the influence of physical activity at different ages and of different types, on the risk of developing atrial fibrillation (AF) in a large cohort of Swedish men.
AB  - METHODS: Information about physical activity was obtained from 44 410 AF-free men, aged 45-79 years (mean age=60), who had completed a self-administered questionnaire at baseline in 1997. Participants reported retrospectively their time spent on leisure-time exercise and on walking or bicycling throughout their lifetime (at 15, 30 and 50 years of age, and at baseline (mean age=60)). Participants were followed-up in the Swedish National Inpatient Register for ascertainment of AF. Cox proportional hazards regression models were used to estimate relative risks (RR) with 95% CIs, adjusted for potential confounders.
AB  - RESULTS: During a median follow-up of 12 years, 4568 cases of AF were diagnosed. We observed a RR of 1.19 (95% CI 1.05 to 1.36) of developing AF in men who at the age of 30 years had exercised for >5 h/week compared with <1 h/week. The risk was even higher (RR 1.49, 95% CI 1.14 to 1.95) among the men who exercised >5 h/week at age 30 and quit exercising later in life (<1 h/week at baseline). Walking/bicycling at baseline was inversely associated with risk of AF (RR 0.87, 95% CI 0.77 to 0.97 for >1 h/day vs almost never) and the association was similar after excluding men with previous coronary heart disease or heart failure at baseline (corresponding RR 0.88, 95% CI 0.77 to 0.998).
AB  - CONCLUSIONS: Leisure-time exercise at younger age is associated with an increased risk of AF, whereas walking/bicycling at older age is associated with a decreased risk.Copyright Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
ES  - 1468-201X
IL  - 1355-6037
DO  - http://dx.doi.org/10.1136/heartjnl-2013-305304
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20140514
DP  - 2014 Jul
DC  - 20140610
YR  - 2014
ED  - 20140801
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24829373

<204. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24829372
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Guasch E
AU  - Mont L
AI  - Guasch, Eduard; ORCID: http://orcid.org/0000-0003-4238-5319
FA  - Guasch, Eduard
FA  - Mont, Lluis
IN  - Guasch,Eduard. Thorax Institute, Unitat de Fibril.lacio Auricular, Hospital Clinic, Universitat de Barcelona and Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.
IN  - Mont,Lluis. Thorax Institute, Unitat de Fibril.lacio Auricular, Hospital Clinic, Universitat de Barcelona and Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.
TI  - Exercise and the heart: unmasking Mr. Hyde.
CM  - Comment on: Heart. 2014 Jul;100(13):1043-9; PMID: 24829374
CM  - Comment on: Heart. 2014 Jul;100(13):1037-42; PMID: 24829373
SO  - Heart. 100(13):999-1000, 2014 Jul.
AS  - Heart. 100(13):999-1000, 2014 Jul.
NJ  - Heart (British Cardiac Society)
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9602087
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - *Aging
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - *Coronary Disease/ep [Epidemiology]
MH  - *Exercise
MH  - Female
MH  - Humans
MH  - *Leisure Activities
MH  - Male
KW  - Coronary Artery Disease
ES  - 1468-201X
IL  - 1355-6037
DO  - http://dx.doi.org/10.1136/heartjnl-2014-305780
PT  - Comment
PT  - Editorial
LG  - English
EP  - 20140514
DP  - 2014 Jul
DC  - 20140610
YR  - 2014
ED  - 20140801
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24829372

<205. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23973092
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Blessberger H
AU  - Kammler J
AU  - Wichert-Schmitt B
AU  - Steinwender C
FA  - Blessberger, Hermann
FA  - Kammler, Jurgen
FA  - Wichert-Schmitt, Barbara
FA  - Steinwender, Clemens
IN  - Blessberger,Hermann. Department of Internal Medicine I, Cardiology, Linz General Hospital, Linz, Austria; University-affiliated Teaching Hospital of the Medical Universities of Vienna and Innsbruck. Electronic address: hermann.blessberger@akh.linz.at.
TI  - Exercise-induced vasospastic angina after left atrial catheter ablation: a case report.
SO  - Journal of Electrocardiology. 46(6):649-52, 2013 Nov-Dec.
AS  - J Electrocardiol. 46(6):649-52, 2013 Nov-Dec.
NJ  - Journal of electrocardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - i0r, 0153605
SB  - Index Medicus
CP  - United States
MH  - *Angina Pectoris/di [Diagnosis]
MH  - *Angina Pectoris/et [Etiology]
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/su [Surgery]
MH  - *Catheter Ablation/ae [Adverse Effects]
MH  - *Coronary Vasospasm/di [Diagnosis]
MH  - *Coronary Vasospasm/et [Etiology]
MH  - Diagnosis, Differential
MH  - *Electrocardiography/mt [Methods]
MH  - Exercise
MH  - Heart Atria/su [Surgery]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Treatment Outcome
KW  - Autonomic nervous system;  Left atrial catheter ablation;  ST-segment elevation;  Vasospasm;  Vasospastic angina
AB  - INTRODUCTION: Left atrial catheter ablation (LACA) is routinely used in the management of recurrent atrial fibrillation.
AB  - CASE PRESENTATION: We report a patient suffering from vasospastic angina 2 months after a LACA procedure. Typical clinical symptoms, ST-segment changes during exercise test and successful treatment with nicorandil led to the diagnosis. According to our hypothesis, destruction of autonomic ganglia in the left atrium and resulting autonomic nerve tone imbalance might be the main determinants that have caused this phenomenon.
AB  - CONCLUSION: Coronary spasms even weeks after LACA should draw attention to a possible association with the procedure.Copyright © 2013.
ES  - 1532-8430
IL  - 0022-0736
DI  - S0022-0736(13)00366-X
DO  - http://dx.doi.org/10.1016/j.jelectrocard.2013.07.015
PT  - Case Reports
PT  - Journal Article
LG  - English
EP  - 20130820
DP  - 2013 Nov-Dec
DC  - 20131111
YR  - 2013
ED  - 20140731
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23973092

<206. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24030706
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Vaughan Sarrazin MS
AU  - Cram P
AU  - Mazur A
AU  - Ward M
AU  - Reisinger HS
FA  - Vaughan Sarrazin, Mary S
FA  - Cram, Peter
FA  - Mazur, Alexandur
FA  - Ward, Melissa
FA  - Reisinger, Heather Schacht
IN  - Vaughan Sarrazin,Mary S. Comprehensive Access and Delivery Research and Evaluation (CADRE) Center, Iowa City VA Health Care System, Iowa City, IA, USA, mary-vaughan-sarrazin@uiowa.edu.
TI  - Patient perspectives of dabigatran: analysis of online discussion forums.
SO  - The Patient: Patient-Centered Outcomes Research. 7(1):47-54, 2014.
AS  - Patient. 7(1):47-54, 2014.
NJ  - The patient
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101309314
SB  - Index Medicus
CP  - New Zealand
MH  - Benzimidazoles/ad [Administration & Dosage]
MH  - Benzimidazoles/ae [Adverse Effects]
MH  - *Benzimidazoles/tu [Therapeutic Use]
MH  - *Consumer Health Information/mt [Methods]
MH  - Dabigatran
MH  - Drug Interactions
MH  - Fibrinolytic Agents/ad [Administration & Dosage]
MH  - Fibrinolytic Agents/ae [Adverse Effects]
MH  - *Fibrinolytic Agents/tu [Therapeutic Use]
MH  - Food-Drug Interactions
MH  - Humans
MH  - Patient Safety
MH  - *Perception
MH  - *Social Media
MH  - beta-Alanine/ad [Administration & Dosage]
MH  - beta-Alanine/ae [Adverse Effects]
MH  - *beta-Alanine/aa [Analogs & Derivatives]
MH  - beta-Alanine/tu [Therapeutic Use]
AB  - BACKGROUND: In 2010 the US FDA approved dabigatran, the first new anticoagulant for stroke prevention in non-valvular atrial fibrillation (AF) since 1954. To date there is little data that reflects the experiences and perceptions of real-world patients with dabigatran. The abundance of Internet-based discussion forums and support groups related to AF or anticoagulation may provide a low-cost resource for assessing patient experiences.
AB  - OBJECTIVE: The aim of this study was to determine patient experiences and perceptions regarding dabigatran through qualitative thematic content analysis of comments posted on publicly accessible virtual discussion forums and Internet support groups.
AB  - MEASUREMENTS: Comments posted between January 2011 and September 2012 were downloaded from websites focusing on support of patients with AF or on anticoagulation therapy. Comments were analyzed for thematic content.
AB  - RESULTS: Five broad thematic categories emerged from the posted comments: general concerns about safety and efficacy, questions about indications and contraindications, questions about proper use and storage, questions about diet and drug restrictions, and experiences with perceived side effects. Our data revealed that a primary concern for patients taking dabigatran is the lack of antidote to reverse the effects of dabigatran if bleeding occurs. Several questions pertaining to the use of dabigatran with other medications or medical conditions were noted, and multiple patients expressed confusion about instructions for using dabigatran before and after medical procedures. An unexpected finding included several criticisms of the medication packaging, which many patients found inconvenient or difficult to open. Finally, several perceived side effects were noted, including some not reported in clinical trials.
AB  - CONCLUSIONS: Online communities may provide information about topics that are a concern to patients and that may not be discernible in clinical trials, such as medication side effects, proper use, and safety. Our data also highlighted potential topics that may not be a priority to researchers but are nevertheless important to patients (e.g. medication convenience or packaging). Despite the growing use of online health-related communities, very little research makes use of this low-cost resource for identifying patient interests regarding therapeutic treatments to guide patient-oriented research.
RN  - 0 (Benzimidazoles)
RN  - 0 (Fibrinolytic Agents)
RN  - 11P2JDE17B (beta-Alanine)
RN  - I0VM4M70GC (Dabigatran)
IS  - 1178-1653
IL  - 1178-1653
DO  - http://dx.doi.org/10.1007/s40271-013-0027-y
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
NO  - AR062133 (United States NIAMS NIH HHS)
NO  - K24 AR062133 (United States NIAMS NIH HHS)
LG  - English
DP  - 2014
DC  - 20140220
YR  - 2014
ED  - 20140729
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24030706

<207. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 25071596
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Young DW
FA  - Young, David W
IN  - Young,David W. HEAL Research Chehalis, WA, USA.
TI  - Self-measure of heart rate variability (HRV) and arrhythmia to monitor and to manage atrial arrhythmias: personal experience with high intensity interval exercise (HIIE) for the conversion to sinus rhythm.
SO  - Frontiers in Physiology. 5:251, 2014.
AS  - Front Physiol. 5:251, 2014.
NJ  - Frontiers in physiology
PI  - Journal available in: Electronic-eCollection
PI  - Citation processed from: Print
JC  - 101549006
OI  - Source: NLM. PMC4085876
CP  - Switzerland
KW  - HIIE;  HRV-with-aging;  arrhythmia-reduction;  cardiac-arrhythmia-conversion;  heart-rate-variability;  high-intensity-interval-exercise;  premature-contractors
ES  - 1664-042X
IL  - 1664-042X
DO  - http://dx.doi.org/10.3389/fphys.2014.00251
PT  - Journal Article
LG  - English
EP  - 20140708
DP  - 2014
DC  - 20140729
YR  - 2014
ED  - 20140729
RD  - 20140731
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=25071596

<208. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24818557
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Silver B
AU  - Wulf Silver R
FA  - Silver, Brian
FA  - Wulf Silver, Rachel
IN  - Silver,Brian. Warren Alpert Medical School of Brown University, 110 Lockwood Street #324, Providence, RI 02903, brian_silver@brown.edu.
IN  - Wulf Silver,Rachel. Sturdy Memorial Hospital, 211 Park St, Attleboro, MA 02703.
TI  - Stroke: posthospital management and recurrence prevention. [Review]
SO  - Fp Essentials. 420:28-38, 2014 May.
AS  - FP essent.. 420:28-38, 2014 May.
NJ  - FP essentials
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101578821
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - Antihypertensive Agents/tu [Therapeutic Use]
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - Carotid Stenosis/co [Complications]
MH  - Carotid Stenosis/th [Therapy]
MH  - Female
MH  - Humans
MH  - Hypertension/co [Complications]
MH  - Hypertension/dt [Drug Therapy]
MH  - *Occupational Therapy/mt [Methods]
MH  - *Physical Therapy Modalities
MH  - Secondary Prevention
MH  - *Speech Therapy/mt [Methods]
MH  - Stroke/co [Complications]
MH  - *Stroke/pc [Prevention & Control]
MH  - *Stroke/rh [Rehabilitation]
AB  - There is no defined duration of therapy for stroke patients, who may continue to experience recovery for several months after the event. Physical, occupational, and speech therapy should be offered as long as benefit is experienced. Patients may benefit from self-directed therapy. Constraint-induced movement therapy, a rigorous program for upper extremity weakness, has been proven effective for improving arm function. Other areas of investigation include repetitive transcranial magnetic stimulation, cellular management, robotic therapy, and pharmacologic strategies to enhance recovery. OnabotulinumtoxinA (formerly botulinum toxin A) is effective for treating spasticity in the arm after stroke. Depression, experienced by at least one-third of patients after stroke, should be managed, and selective serotonin reuptake inhibitors may offer an additional advantage of improved motor recovery. Proven interventions for secondary prevention after stroke include carotid revascularization, anticoagulation for patients with atrial fibrillation, aggressive medical management for those with significant intracranial atherosclerosis, statin treatment for patients with atherosclerotic stroke and low-density lipoprotein cholesterol levels of 100 to 190 mg/dL, antiplatelet therapy for nonatrial fibrillation stroke, and blood pressure reduction. Vitamin and dietary supplements are of unproven benefit for stroke patients. Exercise, smoking cessation, and a healthful diet should be encouraged. Return to driving and sexual activity also should be addressed during outpatient follow-up. Copyright Written permission from the American Academy of Family Physicians is required for reproduction of this material in whole or in part in any form or medium.
RN  - 0 (Anticoagulants)
RN  - 0 (Antihypertensive Agents)
IS  - 2159-3000
IL  - 2159-3000
PT  - Case Reports
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2014 May
DC  - 20140513
YR  - 2014
ED  - 20140710
RD  - 20141120
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24818557

<209. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23511351
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Bilotta F
AU  - Lauretta MP
AU  - Borozdina A
AU  - Mizikov VM
AU  - Rosa G
FA  - Bilotta, F
FA  - Lauretta, M P
FA  - Borozdina, A
FA  - Mizikov, V M
FA  - Rosa, G
IN  - Bilotta,F. Department of Anesthesiology, Critical Care and Pain Medicine, "Sapienza" University of Rome, Rome, Italy - bilotta@tiscali.it.
TI  - Postoperative delirium: risk factors, diagnosis and perioperative care. [Review]
SO  - Minerva Anestesiologica. 79(9):1066-76, 2013 Sep.
AS  - Minerva Anestesiol. 79(9):1066-76, 2013 Sep.
NJ  - Minerva anestesiologica
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - n26, 0375272
SB  - Index Medicus
CP  - Italy
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - *Delirium/di [Diagnosis]
MH  - Delirium/ep [Epidemiology]
MH  - *Delirium/th [Therapy]
MH  - Humans
MH  - Incidence
MH  - Middle Aged
MH  - Perioperative Care/mt [Methods]
MH  - *Postoperative Complications/di [Diagnosis]
MH  - Postoperative Complications/ep [Epidemiology]
MH  - *Postoperative Complications/th [Therapy]
MH  - Psychiatric Status Rating Scales
MH  - Risk Factors
MH  - Socioeconomic Factors
AB  - UNLABELLED: Postoperative delirium (PD) relates to increased morbidity -associated with prolonged hospital stay, institutionalization and persistent functional and cognitive decline- poor long term outcome and higher perioperative mortality. Aim of this literature review is to identify established risk factors for PD and to categorize them according timing of occurrence (pre, intra and post operative), and clinical impact (Odds ratio [OR], % increase in incidence of PD).
AB  - SOURCE OF INFORMATION: medical literature databases (medline and embase) were searched for published manuscripts on "postoperative delirium". Predictors and preoperative risk factors for PD were categorized into 4 groups: demographics; co morbidities; surgery and anesthesia-related (age, education, laboratory anomalies, smoking habits, benzodiazepines premedication, cardiac and thoracic surgery, etc). Intra operative risk factors for PD were categorized into 2 groups: surgery and anesthesia-related (anemia, duration and type of surgery, selected opioid, intraoperative hypotension, etc). Post operative risk factors and precipitating factors include various pathophysiological and environmental conditions, (i.e., ICU admission, low cardiac output requiring inotropes infusion; new onset atrial fibrillation; persistent hypoxia or hypercarbia; use of narcotic analgesics, delayed ambulation, inadequate nutritional status; sensory deprivation, etc). In conclusion, the effective identification, prevention and treatment of pre, intra and postoperative risk factors are the cornerstones for the prevention of PD. A dedicated perioperative care path that encompasses a tailored selection of drugs used perioperatively, the appropriate anesthesia strategy, qualified nursing surveillance, systematic use of diagnostic tools and accurate staff communication reduces the incidence and clinical impact of PD.
ES  - 1827-1596
IL  - 0375-9393
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20130319
DP  - 2013 Sep
DC  - 20130917
YR  - 2013
ED  - 20140708
RD  - 20140731
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23511351

<210. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23934075
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Opie LH
FA  - Opie, Lionel H
IN  - Opie,Lionel H. Hatter Institute for Cardiovascular Research in Africa, Department of Medicine, University of Cape Town Medical School, Anzio Road, Observatory, Cape Town, 7925, South Africa, lionel.opie@uct.ac.za.
TI  - Exercise-induced myalgia may limit the cardiovascular benefits of statins. [Review]
SO  - Cardiovascular Drugs & Therapy. 27(6):569-72, 2013 Dec.
AS  - Cardiovasc Drugs Ther. 27(6):569-72, 2013 Dec.
NJ  - Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - ayg, 8712220
SB  - Index Medicus
CP  - United States
MH  - Creatine Kinase/bl [Blood]
MH  - *Exercise/ph [Physiology]
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/ae [Adverse Effects]
MH  - Mitochondria/ph [Physiology]
MH  - *Myalgia/et [Etiology]
AB  - The positive health benefits of statins extend beyond the cardiovascular and include increased flow mediated dilation, decreased atrial fibrillation, modest antihypertensive effects and reduced risks of malignancies. Prominent among the statin side-effects are myalgia and muscular weakness, which may be associated with a rise in circulating creatine kinase values. In increasing severity and decreasing incidence, the statin-induced muscle related conditions are myalgia, myopathy with elevated creatine kinase (CK) levels with or without symptoms, and rhabdomyolysis. Statin use may increase CK levels without decreasing average muscle strength or exercise performance. In one large study, only about 2 % had myalgia that could be attributed to statin use. A novel current hypothesis is that statins optimize cardiac mitochondrial function but impair the vulnerable skeletal muscle by inducing different levels of reactive oxygen species (ROS) in these two sites. In an important observational study, both statins and exercise reduced the adverse outcomes of cardiovascular disease, and the effects were additive. The major unresolved problem is that either can cause muscular symptoms with elevation of blood creatine kinase levels. There is, as yet, no clearly defined outcomes based policy to deal with such symptoms from use of either statins or exercise or both. A reasonable practical approach is to assess the creatine kinase levels, and if elevated to reduce the statin dose or the intensity of exercise.
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - EC 2-7-3-2 (Creatine Kinase)
ES  - 1573-7241
IL  - 0920-3206
DO  - http://dx.doi.org/10.1007/s10557-013-6483-8
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2013 Dec
DC  - 20131118
YR  - 2013
ED  - 20140626
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23934075

<211. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24113852
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Shin JH
AU  - Khunnawat C
AU  - Baez-Escudero J
AU  - Knight BP
AU  - Beshai JF
FA  - Shin, John H
FA  - Khunnawat, Chotikorn
FA  - Baez-Escudero, Jose
FA  - Knight, Bradley P
FA  - Beshai, John F
IN  - Shin,John H. Section of Cardiology, Department of Medicine, University of Chicago, 5758 S. Maryland Ave, Chicago, IL, USA.
TI  - Effect of defibrillation threshold testing-induced ventricular fibrillation on renal function.
SO  - Journal of Interventional Cardiac Electrophysiology. 38(3):209-15, 2013 Dec.
AS  - J Interv Card Electrophysiol. 38(3):209-15, 2013 Dec.
NJ  - Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - c8k, 9708966
SB  - Index Medicus
CP  - Netherlands
MH  - Acute Kidney Injury/di [Diagnosis]
MH  - *Acute Kidney Injury/ep [Epidemiology]
MH  - Causality
MH  - Chicago/ep [Epidemiology]
MH  - Comorbidity
MH  - Defibrillators, Implantable/ae [Adverse Effects]
MH  - *Defibrillators, Implantable/sn [Statistics & Numerical Data]
MH  - Differential Threshold
MH  - *Equipment Failure Analysis/sn [Statistics & Numerical Data]
MH  - Female
MH  - Humans
MH  - Incidence
MH  - *Kidney Function Tests/sn [Statistics & Numerical Data]
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Ventricular Fibrillation/di [Diagnosis]
MH  - *Ventricular Fibrillation/ep [Epidemiology]
MH  - Ventricular Fibrillation/et [Etiology]
MH  - *Ventricular Fibrillation/pc [Prevention & Control]
AB  - INTRODUCTION: The effect of defibrillation threshold (DFT) testing with induction of ventricular fibrillation (VF) on renal function is currently unknown. This study examined the acute effect of DFT testing on renal function in patients undergoing implantable cardioverter defibrillator (ICD) implantation.
AB  - METHODS AND RESULTS: We performed a prospective cohort study of 148 consecutive patients who underwent ICD implantation from January 1, 2007 to May 30, 2008. Patients were assigned to one of two cohorts: a DFT group who underwent DFT testing at device implantation and a no-DFT group that was not tested. Baseline and 24-h postprocedure renal function were assessed with measurements of serum creatinine and estimated glomerular filtration rate (GFR) by the Modified Diet in Renal Disease equation. Changes in serum creatinine and estimated GFR were compared between cohorts. Ninety-eight patients (66%) underwent DFT testing (average VF induction count, 1.5+/-0.9; mean VF duration, 10+/-4 s). Fifty patients (34%) were not tested. Patients in the no-DFT group had lower mean left ventricular ejection fraction, higher New York Heart Association class, higher atrial fibrillation incidence, and greater intravenous contrast utilization at device implant. Baseline and postprocedure serum creatinine values were similar between groups (baseline, 1.25+/-0.45 mg/dL; post-ICD, 1.26+/-0.5 mg/dL). Baseline GFR was lower in the DFT cohort (55.2+/-18.8 mL/min/BSA vs 63.7+/-22.7 mL/min/BSA, p=0.023). No significant differences between groups were observed in the mean change in serum creatinine or estimated GFR.
AB  - CONCLUSIONS: DFT testing at the time of ICD implantation is not associated with acute adverse effects on renal function.
ES  - 1572-8595
IL  - 1383-875X
DO  - http://dx.doi.org/10.1007/s10840-013-9840-4
PT  - Journal Article
PT  - Observational Study
LG  - English
EP  - 20131011
DP  - 2013 Dec
DC  - 20131106
YR  - 2013
ED  - 20140626
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24113852

<212. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24183073
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Fenton JI
AU  - Hord NG
AU  - Ghosh S
AU  - Gurzell EA
FA  - Fenton, Jenifer I
FA  - Hord, Norman G
FA  - Ghosh, Sanjoy
FA  - Gurzell, Eric A
IN  - Fenton,Jenifer I. Department of Food Science and Human, College of Agriculture and Natural Resources, Michigan State University, East Lansing, MI, United States; College of Osteopathic Medicine, Michigan State University, East Lansing, MI 48824, United States. Electronic address: imigjeni@msu.edu.
TI  - Immunomodulation by dietary long chain omega-3 fatty acids and the potential for adverse health outcomes. [Review]
SO  - Prostaglandins Leukotrienes & Essential Fatty Acids. 89(6):379-90, 2013 Nov-Dec.
AS  - Prostaglandins Leukot Essent Fatty Acids. 89(6):379-90, 2013 Nov-Dec.
NJ  - Prostaglandins, leukotrienes, and essential fatty acids
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - p04, 8802730
OI  - Source: NLM. NIHMS536210
OI  - Source: NLM. PMC3912985
SB  - Index Medicus
CP  - Scotland
MH  - Animals
MH  - Cardiovascular Diseases
MH  - *Dietary Fats/pd [Pharmacology]
MH  - Docosahexaenoic Acids/ae [Adverse Effects]
MH  - Docosahexaenoic Acids/pd [Pharmacology]
MH  - Eicosapentaenoic Acid/ae [Adverse Effects]
MH  - Eicosapentaenoic Acid/pd [Pharmacology]
MH  - *Fatty Acids, Omega-3/ae [Adverse Effects]
MH  - *Fatty Acids, Omega-3/pd [Pharmacology]
MH  - Humans
MH  - Immunity/de [Drug Effects]
MH  - *Immunologic Factors/pd [Pharmacology]
MH  - Infection
MH  - Inflammation
MH  - Neoplasms
MH  - Nutrition Policy
MH  - Risk Factors
KW  - B cell;  CHD;  Cancer;  Colitis;  Coronary heart disease;  Fish oil;  Immune function;  RA;  Rheumatoid arthritis;  TLR;  Toll-like receptor
AB  - Recommendations to consume fish for prevention of cardiovascular disease (CVD), along with the U.S. Food and Drug Administration-approved generally recognized as safe (GRAS) status for long chain omega-3 fatty acids, may have had the unanticipated consequence of encouraging long-chain omega-3 (omega-3) fatty acid [(eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)] supplementation and fortification practices. While there is evidence supporting a protective role for EPA/DHA supplementation in reducing sudden cardiac events, the safety and efficacy of supplementation with LComega-3PUFA in the context of other disease outcomes is unclear. Recent studies of bacterial, viral, and fungal infections in animal models of infectious disease demonstrate that LComega-3PUFA intake dampens immunity and alters pathogen clearance and can result in reduced survival. The same physiological properties of EPA/DHA that are responsible for the amelioration of inflammation associated with chronic cardiovascular pathology or autoimmune states, may impair pathogen clearance during acute infections by decreasing host resistance or interfere with tumor surveillance resulting in adverse health outcomes. Recent observations that high serum LComega-3PUFA levels are associated with higher risk of prostate cancer and atrial fibrillation raise concern for adverse outcomes. Given the widespread use of supplements and fortification of common food items with LComega-3PUFA, this review focuses on the immunomodulatory effects of the dietary LComega-3PUFAs, EPA and DHA, the mechanistic basis for potential negative health outcomes, and calls for biomarker development and validation as rational first steps towards setting recommended dietary intake levels. Copyright © 2013 Published by Elsevier Ltd.
RN  - 0 (Dietary Fats)
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Immunologic Factors)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - AAN7QOV9EA (Eicosapentaenoic Acid)
ES  - 1532-2823
IL  - 0952-3278
DI  - S0952-3278(13)00192-0
DO  - http://dx.doi.org/10.1016/j.plefa.2013.09.011
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
NO  - R03 CA162427 (United States NCI NIH HHS)
NO  - R03CA162427 (United States NCI NIH HHS)
LG  - English
EP  - 20130930
DP  - 2013 Nov-Dec
DC  - 20131125
YR  - 2013
ED  - 20140616
RD  - 20150422
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24183073

<213. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23642825
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Salam AM
AU  - AlBinali HA
AU  - Salim I
AU  - Singh R
AU  - Asaad N
AU  - Al-Qahtani A
AU  - Al Suwaidi J
FA  - Salam, Amar M
FA  - AlBinali, Hajar A
FA  - Salim, Imtiaz
FA  - Singh, Rajvir
FA  - Asaad, Nidal
FA  - Al-Qahtani, Awad
FA  - Al Suwaidi, Jassim
IN  - Salam,Amar M. Department of Cardiology and Cardiovascular Surgery, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar; Cardiology Section, Al-Khor Hospital, Hamad Medical Corporation, Doha, Qatar.
TI  - Impact of religious fasting on the burden of atrial fibrillation: a population-based study.
SO  - International Journal of Cardiology. 168(3):3042-3, 2013 Oct 3.
AS  - Int J Cardiol. 168(3):3042-3, 2013 Oct 3.
NJ  - International journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - gqw, 8200291
SB  - Index Medicus
CP  - Netherlands
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/et [Etiology]
MH  - *Fasting/ae [Adverse Effects]
MH  - Female
MH  - Hospitalization/sn [Statistics & Numerical Data]
MH  - Humans
MH  - *Islam
MH  - Male
MH  - Middle Aged
MH  - Qatar
MH  - Retrospective Studies
MH  - Severity of Illness Index
KW  - Atrial fibrillation;  Population;  Ramadan;  Religious fasting;  Study
ES  - 1874-1754
IL  - 0167-5273
DI  - S0167-5273(13)00778-X
DO  - http://dx.doi.org/10.1016/j.ijcard.2013.04.131
PT  - Letter
LG  - English
EP  - 20130501
DP  - 2013 Oct 3
DC  - 20131014
YR  - 2013
ED  - 20140616
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23642825

<214. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23839902
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Aleksova A
AU  - Masson S
AU  - Maggioni AP
AU  - Lucci D
AU  - Fabbri G
AU  - Beretta L
AU  - Mos L
AU  - Paino AM
AU  - Nicolosi GL
AU  - Marchioli R
AU  - Tognoni G
AU  - Tavazzi L
AU  - Sinagra G
AU  - Latini R
AU  - GISSI-Heart Failure Investigators
FA  - Aleksova, Aneta
FA  - Masson, Serge
FA  - Maggioni, Aldo P
FA  - Lucci, Donata
FA  - Fabbri, Gianna
FA  - Beretta, Luciano
FA  - Mos, Lucio
FA  - Paino, Anna Maria
FA  - Nicolosi, Gian Luigi
FA  - Marchioli, Roberto
FA  - Tognoni, Gianni
FA  - Tavazzi, Luigi
FA  - Sinagra, Gianfranco
FA  - Latini, Roberto
FA  - GISSI-Heart Failure Investigators
IN  - Aleksova,Aneta. Cardiovascular Department, 'Ospedali Riuniti' and University of Trieste, Trieste, Italy.
TI  - n-3 polyunsaturated fatty acids and atrial fibrillation in patients with chronic heart failure: the GISSI-HF trial.
SO  - European Journal of Heart Failure. 15(11):1289-95, 2013 Nov.
AS  - Eur J Heart Fail. 15(11):1289-95, 2013 Nov.
NJ  - European journal of heart failure
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - dr4, 100887595
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - Atrial Fibrillation/bl [Blood]
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - Chronic Disease
MH  - Double-Blind Method
MH  - Fatty Acids, Omega-3/bl [Blood]
MH  - *Fatty Acids, Omega-3/tu [Therapeutic Use]
MH  - Female
MH  - Heart Failure/bl [Blood]
MH  - Heart Failure/co [Complications]
MH  - *Heart Failure/dt [Drug Therapy]
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Treatment Outcome
KW  - Atrial fibrillation;  Chronic heart failure;  Fish consumption;  n-3 PUFAs
AB  - AIMS: In the last few years, n-3 polyunsaturated acids (PUFAs) have been extensively studied for the prevention of AF, mostly in patients without heart failure (HF) or LV dysfunction. This post-hoc analysis of the GISSI-HF trial assessed the effect of n-3 PUFAs on AF in patients with chronic HF without AF at study entry over a median follow-up of 3.9 years.
AB  - METHODS AND RESULTS: In the GISSI-HF trial, 6975 patients with chronic HF were randomized to 1 g daily of n-3 PUFAs or placebo on top of recommended therapy for HF. Of these, 1140 (16.3%) had AF at baseline ECG and were excluded from the present analysis. AF during the trial was defined as the presence of AF on the ECGs done at each visit during the trial or AF as a cause of worsening HF or hospital admission or as an event during hospitalization. Dietary fish consumption and the circulating levels of n-3 PUFAs (the latter in a subset of 1203 patients) were also available. Among the 5835 patients without AF at study entry, 444 randomized to n-3 PUFAs (15.2%) and 408 to placebo (14.0%) developed AF (unadjusted hazard 1.10, P = 0.19). Lower circulating n-3 PUFA levels were independently associated with higher AF prevalence at study entry, but not with its new occurrence.
AB  - CONCLUSIONS: Despite an inverse relationship between plasma n-3 PUFA levels and prevalent AF, this study found no evidence that 1 g daily n-3 PUFA supplementation in patients with chronic HF reduces incident AF.
RN  - 0 (Fatty Acids, Omega-3)
ES  - 1879-0844
IL  - 1388-9842
DO  - http://dx.doi.org/10.1093/eurjhf/hft103
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20130709
DP  - 2013 Nov
DC  - 20131024
YR  - 2013
ED  - 20140610
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23839902

<215. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23659362
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Chadaide S
AU  - Domsik P
AU  - Kalapos A
AU  - Saghy L
AU  - Forster T
AU  - Nemes A
FA  - Chadaide, Szami
FA  - Domsik, Peter
FA  - Kalapos, Anita
FA  - Saghy, Laszlo
FA  - Forster, Tamas
FA  - Nemes, Attila
IN  - Chadaide,Szami. 2nd Department of Medicine and Cardiology Center, Medical Faculty, Albert Szent-Gyorgyi Clinical Center, University of Szeged, Szeged, Hungary.
TI  - Three-dimensional speckle tracking echocardiography-derived left atrial strain parameters are reduced in patients with atrial fibrillation (results from the MAGYAR-path study).
SO  - Echocardiography. 30(9):1078-83, 2013 Oct.
AS  - Echocardiography. 30(9):1078-83, 2013 Oct.
NJ  - Echocardiography (Mount Kisco, N.Y.)
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - bcn, 8511187
SB  - Index Medicus
CP  - United States
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/us [Ultrasonography]
MH  - *Atrial Remodeling
MH  - *Echocardiography, Three-Dimensional/mt [Methods]
MH  - Elastic Modulus
MH  - *Elasticity Imaging Techniques/mt [Methods]
MH  - Female
MH  - *Heart Atria/pp [Physiopathology]
MH  - *Heart Atria/us [Ultrasonography]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - Stress, Mechanical
KW  - atrial fibrillation;  echocardiography;  speckle tracking;  strain;  three-dimensional
AB  - OBJECTIVE: Three-dimensional (3D) speckle tracking echocardiography (3DSTE) is a novel imaging modality for assessing cardiac function. We aimed to analyze left atrial (LA) function using 3DSTE in patients with atrial fibrillation (AF).
AB  - METHODS: 3DSTE was performed in 20 patients prior to their pulmonary vein isolation for AF. Every patient underwent a complete two-dimensional echocardiographic study at the same time. 3DSTE-derived circumferential (CS), longitudinal (LS), radial (RS), 3D (3DS), and area strain (AS) values were measured in the basal (b), mid (m), and superior (s) regions of the LA. 3DSTE-defined maximal (LAmax ) and minimal LA volumes (LAmin ) and LA total emptying fraction were calculated automatically. Eleven randomly selected age- and gender-matched healthy volunteers served as controls.
AB  - RESULTS: Patients with AF had significantly larger LAmax and LAmin and reduced LS, RS and CS.3DS and AS were significantly lower throughout the LA in cases with AF (3DS-b, -m, -s [AF patients vs. controls]: -18 +/- 8% vs. -29 +/- 8%, P = 0.001; -14 +/- 6% vs. -22 +/- 7%, P = 0.002; -10 +/- 7% vs. -20 +/- 9%, P = 0.002; AS-b, -m, -s [AF patients vs. controls]: 35 +/- 15% vs. 52 +/- 13%, P = 0.004; 50 +/- 21% vs. 72 +/- 19%, P = 0.009; 31 +/- 21% vs. 65 +/- 27%, P < 0.0001, respectively).
AB  - CONCLUSIONS: 3DSTE-derived "uni-dimensional" LS, RS, CS, as well as novel strain parameters (3DS, AS) are significantly reduced in patients with AF compared to matched controls. 3DS and AS might be new strain parameters providing further insights into the alterations of LA function in patients developing AF.Copyright © 2013, Wiley Periodicals, Inc.
ES  - 1540-8175
IL  - 0742-2822
DO  - http://dx.doi.org/10.1111/echo.12218
PT  - Controlled Clinical Trial
PT  - Journal Article
LG  - English
EP  - 20130510
DP  - 2013 Oct
DC  - 20131011
YR  - 2013
ED  - 20140604
RD  - 20140731
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23659362

<216. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24052915
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lum CJ
AU  - Azuma S
FA  - Lum, Corey J
FA  - Azuma, Steven
IN  - Lum,Corey J. Department of Medicine, John A. Burns School of Medicine, University of Hawai'i, Honolulu, HI.
TI  - A comparison of methods for estimating glomerular filtration rate for a population in Hawai'i with non-valvular atrial fibrillation.
SO  - Hawai'i Journal of Medicine & Public Health : A Journal of Asia Pacific Medicine & Public Health. 72(9 Suppl 4):27-9, 2013 Sep.
AS  - Hawaii J Med Public Health. 72(9 Suppl 4):27-9, 2013 Sep.
NJ  - Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101579076
OI  - Source: NLM. PMC3764554
SB  - Index Medicus
CP  - United States
MH  - Aged, 80 and over
MH  - *Anticoagulants/ad [Administration & Dosage]
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - Asian Continental Ancestry Group
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Benzimidazoles/ad [Administration & Dosage]
MH  - Benzimidazoles/tu [Therapeutic Use]
MH  - Dabigatran
MH  - Female
MH  - *Glomerular Filtration Rate
MH  - Hawaii
MH  - Humans
MH  - Male
MH  - Morpholines/tu [Therapeutic Use]
MH  - Pipecolic Acids/tu [Therapeutic Use]
MH  - Retrospective Studies
MH  - Rivaroxaban
MH  - Thiophenes/tu [Therapeutic Use]
MH  - Warfarin/tu [Therapeutic Use]
MH  - beta-Alanine/ad [Administration & Dosage]
MH  - *beta-Alanine/aa [Analogs & Derivatives]
MH  - beta-Alanine/tu [Therapeutic Use]
AB  - Warfarin is the primary treatment for those with atrial fibrillation at increased risk for stroke. The Randomized Evaluation of Long-Term Anticoagulation Therapy (RELY) trial demonstrated that dabigatran, a direct thrombin inhibitor, was associated with lower rates of systemic embolism compared to warfarin.1 Although individuals with a creatinine clearance of less than 30 mL/min were excluded from the trial, the FDA approved the use of dabigatran for those with creatinine clearances as low as 15 mL/min, with a lower dose of dabigatran recommended for individuals with creatinine clearances below 30 mL/min. This study calculated Glomerular Filtration Rates (GFR) via three existing formulas with varying levels of accuracy (ie, the Cockcroft-Gault, Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) to evaluate how patient eligibility for the RELY trial may have varied depending upon the formula used. A retrospective study was performed based on a chart review conducted at a private cardiologist's office in Honolulu, Hawai'i using patients with non-valvular atrial fibrillation. Patients included were those with a BUN/Creatinine assessment within 12 months of the chart review and a CHADS2 (Congestive Heart Disease, hypertension, age greater than 75, diabetes mellitus, and stroke or transient ischemic attack) score of 1 or greater. Of 376 subjects assessed, 64 subjects who failed to meet criteria for the RELY trial when using the Cockcroft-Gault formula (ie, GFR estimates were lower than 30 mL/min) met eligibility criteria when the MDRD formula was used (ie, GFR estimates exceeded 30 mL/min). Subgroup analysis of the 64 subjects revealed that subjects were 89-years-old on average, predominantly female (76.5%), and mostly Japanese (62.5%). Nearly one in five individuals (17%) in the studied population would have received a lower dose of dabigatran if the Cockcroft-Gaunt formula was used for estimating GFRs. The authors recommend caution while dosing dabigatran in the Asian population, as the estimates of kidney functioning vary substantially depending on the formula used to estimate GFR, which may in turn lead in some cases of inadequate dosing of dabigatran.
RN  - 0 (Anticoagulants)
RN  - 0 (Benzimidazoles)
RN  - 0 (Morpholines)
RN  - 0 (Pipecolic Acids)
RN  - 0 (Thiophenes)
RN  - 11P2JDE17B (beta-Alanine)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 74863-84-6 (argatroban)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - I0VM4M70GC (Dabigatran)
ES  - 2165-8242
IL  - 2165-8242
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 2013 Sep
DC  - 20130920
YR  - 2013
ED  - 20140603
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24052915

<217. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24323795
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Hijazi Z
AU  - Hohnloser SH
AU  - Oldgren J
AU  - Andersson U
AU  - Connolly SJ
AU  - Eikelboom JW
AU  - Ezekowitz MD
AU  - Reilly PA
AU  - Siegbahn A
AU  - Yusuf S
AU  - Wallentin L
FA  - Hijazi, Ziad
FA  - Hohnloser, Stefan H
FA  - Oldgren, Jonas
FA  - Andersson, Ulrika
FA  - Connolly, Stuart J
FA  - Eikelboom, John W
FA  - Ezekowitz, Michael D
FA  - Reilly, Paul A
FA  - Siegbahn, Agneta
FA  - Yusuf, Salim
FA  - Wallentin, Lars
IN  - Hijazi,Ziad. From Uppsala Clinical Research Center (Z.H., J.O., U.A., A.S., L.W.), Department of Medical Sciences, Cardiology (Z.H., J.O., L.W.), and Department of Medical Sciences, Clinical Chemistry (A.S.), Uppsala University, Sweden; Department of Cardiology, J.W. Goethe University, Frankfurt, Germany (S.H.H.); Population Health Research Institute, Hamilton, Ontario, Canada (S.J.C., J.W.E., S.Y.); Thomas Jefferson Medical College and the Heart Center, Wynnewood, PA (M.D.E.); and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (P.A.R.).
TI  - Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
CM  - Comment in: Ann Intern Med. 2014 Aug 19;161(4):JC7; PMID: 25133386
CM  - Comment in: Circulation. 2014 Nov 25;130(22):e195; PMID: 25421051
CM  - Comment in: Circulation. 2014 Nov 25;130(22):e194; PMID: 25421050
SO  - Circulation. 129(9):961-70, 2014 Mar 4.
AS  - Circulation. 129(9):961-70, 2014 Mar 4.
NJ  - Circulation
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/ae [Adverse Effects]
MH  - Anticoagulants/pd [Pharmacology]
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Benzimidazoles/ae [Adverse Effects]
MH  - Benzimidazoles/pd [Pharmacology]
MH  - *Benzimidazoles/tu [Therapeutic Use]
MH  - Dabigatran
MH  - Dose-Response Relationship, Drug
MH  - Embolism/ep [Epidemiology]
MH  - Female
MH  - Glomerular Filtration Rate/de [Drug Effects]
MH  - Glomerular Filtration Rate/ph [Physiology]
MH  - Humans
MH  - Internationality
MH  - Kidney/de [Drug Effects]
MH  - *Kidney/ph [Physiology]
MH  - Male
MH  - Middle Aged
MH  - Models, Biological
MH  - Risk Factors
MH  - Stroke/ep [Epidemiology]
MH  - Treatment Outcome
MH  - *Warfarin/ae [Adverse Effects]
MH  - Warfarin/pd [Pharmacology]
MH  - *Warfarin/tu [Therapeutic Use]
MH  - beta-Alanine/ae [Adverse Effects]
MH  - *beta-Alanine/aa [Analogs & Derivatives]
MH  - beta-Alanine/pd [Pharmacology]
MH  - beta-Alanine/tu [Therapeutic Use]
KW  - anticoagulants;  atrial fibrillation;  dabigatran;  hemorrhage;  renal insufficiency;  stroke;  warfarin
AB  - BACKGROUND: Renal impairment increases the risk of stroke and bleeding in patients with atrial fibrillation. In the Randomized Evaluation of Long-Term Anticoagulant Therapy (RELY) trial, dabigatran, with =80% renal elimination, displayed superiority over warfarin for prevention of stroke and systemic embolism in the 150-mg dose and significantly less major bleeding in the 110-mg dose in 18 113 patients with nonvalvular atrial fibrillation. This prespecified study investigated these outcomes in relation to renal function.
AB  - METHODS AND RESULTS: Glomerular filtration rate was estimated with the Cockcroft-Gault, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), and Modification of Diet in Renal Disease (MDRD) equations in all randomized patients with available creatinine at baseline (n=17 951), and cystatin C-based glomerular filtration rate was estimated in a subpopulation with measurements available (n=6190). A glomerular filtration rate >80, 50 to <80, and <50 mL/min was estimated in 32.6%, 47.6%, and 19.8% and in 21.6%, 59.6%, and 18.8% of patients based on Cockcroft-Gault and CKD-EPI, respectively. Rates of stroke or systemic embolism, major bleeding, and all-cause mortality increased as renal function decreased. The rates of stroke or systemic embolism were lower with dabigatran 150 mg and similar with 110 mg twice daily compared with warfarin, without significant heterogeneity in subgroups defined by renal function (interaction P>0.1 for all). For the outcome of major bleeding, there were significant interactions between treatment and renal function according to CKD-EPI and MDRD equations, respectively (P<0.05). The relative reduction in major bleeding with either dabigatran dose compared with warfarin was greater in patients with glomerular filtration rate >80 mL/min.
AB  - CONCLUSIONS: The efficacy of both dosages of dabigatran was consistent with the overall trial irrespective of renal function. However, with the CKD-EPI and MDRD equations, both dabigatran dosages displayed significantly lower rates of major bleeding in patients with glomerular filtration rate >80 mL/min.
AB  - CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00262600.
RN  - 0 (Anticoagulants)
RN  - 0 (Benzimidazoles)
RN  - 11P2JDE17B (beta-Alanine)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - I0VM4M70GC (Dabigatran)
ES  - 1524-4539
IL  - 0009-7322
DO  - http://dx.doi.org/10.1161/CIRCULATIONAHA.113.003628
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
SI  - ClinicalTrials.gov
SA  - ClinicalTrials.gov/NCT00262600
SL  - http://clinicaltrials.gov/search/term=NCT00262600
LG  - English
EP  - 20131209
DP  - 2014 Mar 4
DC  - 20140304
YR  - 2014
ED  - 20140527
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24323795

<218. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24162898
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Zakeri R
AU  - Borlaug BA
AU  - McNulty SE
AU  - Mohammed SF
AU  - Lewis GD
AU  - Semigran MJ
AU  - Deswal A
AU  - LeWinter M
AU  - Hernandez AF
AU  - Braunwald E
AU  - Redfield MM
FA  - Zakeri, Rosita
FA  - Borlaug, Barry A
FA  - McNulty, Steven E
FA  - Mohammed, Selma F
FA  - Lewis, Gregory D
FA  - Semigran, Marc J
FA  - Deswal, Anita
FA  - LeWinter, Martin
FA  - Hernandez, Adrian F
FA  - Braunwald, Eugene
FA  - Redfield, Margaret M
IN  - Zakeri,Rosita. Division of Cardiology, Mayo Clinic, Rochester, MN.
TI  - Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study.
SO  - Circulation: Heart Failure. 7(1):123-30, 2014 Jan.
AS  - Circ. Heart fail.. 7(1):123-30, 2014 Jan.
NJ  - Circulation. Heart failure
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101479941
OI  - Source: NLM. NIHMS552655
OI  - Source: NLM. PMC3972021
SB  - Index Medicus
CP  - United States
MH  - Age Factors
MH  - Aged
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Blood Pressure/de [Drug Effects]
MH  - Blood Pressure/ph [Physiology]
MH  - Cohort Studies
MH  - Comorbidity
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - *Heart Failure/dt [Drug Therapy]
MH  - Heart Failure/ep [Epidemiology]
MH  - *Heart Failure/pp [Physiopathology]
MH  - Heart Rate/de [Drug Effects]
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxygen Consumption/de [Drug Effects]
MH  - Oxygen Consumption/ph [Physiology]
MH  - Phosphodiesterase 5 Inhibitors/pd [Pharmacology]
MH  - *Phosphodiesterase 5 Inhibitors/tu [Therapeutic Use]
MH  - Piperazines/pd [Pharmacology]
MH  - *Piperazines/tu [Therapeutic Use]
MH  - Purines/pd [Pharmacology]
MH  - Purines/tu [Therapeutic Use]
MH  - Sildenafil Citrate
MH  - Stroke Volume/de [Drug Effects]
MH  - *Stroke Volume/ph [Physiology]
MH  - Sulfones/pd [Pharmacology]
MH  - *Sulfones/tu [Therapeutic Use]
MH  - Treatment Outcome
KW  - atrial fibrillation;  exercise;  heart failure
AB  - BACKGROUND: Atrial fibrillation (AF) is common among patients with heart failure and preserved ejection fraction (HFpEF), but its clinical profile and impact on exercise capacity remain unclear. RELAX (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in HFpEF) was a multicenter randomized trial testing the impact of sildenafil on peak VO2 in stable outpatients with chronic HFpEF. We sought to compare clinical features and exercise capacity among patients with HFpEF who were in sinus rhythm (SR) or AF.
AB  - METHODS AND RESULTS: RELAX enrolled 216 patients with HFpEF, of whom 79 (37%) were in AF, 124 (57%) in SR, and 13 in other rhythms. Participants underwent baseline cardiopulmonary exercise testing, echocardiogram, biomarker assessment, and rhythm status assessment before randomization. Patients with AF were older than those in SR but had similar symptom severity, comorbidities, and renal function. beta-blocker use and chronotropic indices were also similar. Despite comparable left ventricular size and mass, AF was associated with worse systolic (lower EF, stroke volume, and cardiac index) and diastolic (shorter deceleration time and larger left atria) function compared with SR. Pulmonary artery systolic pressure was higher in AF. Patients with AF had higher N-terminal pro-B-type natriuretic peptide, aldosterone, endothelin-1, troponin I, and C-telopeptide for type I collagen levels, suggesting more severe neurohumoral activation, myocyte necrosis, and fibrosis. Peak VO2 was lower in AF, even after adjustment for age, sex, and chronotropic response, and VE/VCO2 was higher.
AB  - CONCLUSIONS: AF identifies an HFpEF cohort with more advanced disease and significantly reduced exercise capacity. These data suggest that evaluation of the impact of different rate or rhythm control strategies on exercise tolerance in patients with HFpEF and AF is warranted.
AB  - CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00763867.
RN  - 0 (Phosphodiesterase 5 Inhibitors)
RN  - 0 (Piperazines)
RN  - 0 (Purines)
RN  - 0 (Sulfones)
RN  - BW9B0ZE037 (Sildenafil Citrate)
ES  - 1941-3297
IL  - 1941-3289
DO  - http://dx.doi.org/10.1161/CIRCHEARTFAILURE.113.000568
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, P.H.S.
SI  - ClinicalTrials.gov
SA  - ClinicalTrials.gov/NCT00763867
SL  - http://clinicaltrials.gov/search/term=NCT00763867
NO  - R01 HL105418 (United States NHLBI NIH HHS)
NO  - T32 HL007111 (United States NHLBI NIH HHS)
NO  - T32 HL007111 (United States NHLBI NIH HHS)
NO  - U01 HL084861 (United States NHLBI NIH HHS)
NO  - U01 HL084875 (United States NHLBI NIH HHS)
NO  - U01 HL084877 (United States NHLBI NIH HHS)
NO  - U01 HL084889 (United States NHLBI NIH HHS)
NO  - U01 HL084890 (United States NHLBI NIH HHS)
NO  - U01 HL084891 (United States NHLBI NIH HHS)
NO  - U01 HL084899 (United States NHLBI NIH HHS)
NO  - U01 HL084904 (United States NHLBI NIH HHS)
NO  - U01 HL084907 (United States NHLBI NIH HHS)
NO  - U01 HL084931 (United States NHLBI NIH HHS)
NO  - U01HL084861 (United States NHLBI NIH HHS)
NO  - U01HL084875 (United States NHLBI NIH HHS)
NO  - U01HL084877 (United States NHLBI NIH HHS)
NO  - U01HL084889 (United States NHLBI NIH HHS)
NO  - U01HL084890 (United States NHLBI NIH HHS)
NO  - U01HL084891 (United States NHLBI NIH HHS)
NO  - U01HL084899 (United States NHLBI NIH HHS)
NO  - U01HL084904 (United States NHLBI NIH HHS)
NO  - U01HL084907 (United States NHLBI NIH HHS)
NO  - U01HL084931 (United States NHLBI NIH HHS)
NO  - U10 HL084904 (United States NHLBI NIH HHS)
NO  - U10 HL110262 (United States NHLBI NIH HHS)
NO  - U10HL110262 (United States NHLBI NIH HHS)
NO  - U54 MD007588 (United States NIMHD NIH HHS)
NO  - U54 MD007588 (United States NIMHD NIH HHS)
NO  - UL1 TR000135 (United States NCATS NIH HHS)
NO  - UL1 TR000454 (United States NCATS NIH HHS)
NO  - UL1TR000135 (United States NCATS NIH HHS)
NO  - UL1TR000454 (United States NCATS NIH HHS)
LG  - English
EP  - 20131025
DP  - 2014 Jan
DC  - 20140122
YR  - 2014
ED  - 20140527
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24162898

<219. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24162898
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Zakeri R
AU  - Borlaug BA
AU  - McNulty SE
AU  - Mohammed SF
AU  - Lewis GD
AU  - Semigran MJ
AU  - Deswal A
AU  - LeWinter M
AU  - Hernandez AF
AU  - Braunwald E
AU  - Redfield MM
FA  - Zakeri, Rosita
FA  - Borlaug, Barry A
FA  - McNulty, Steven E
FA  - Mohammed, Selma F
FA  - Lewis, Gregory D
FA  - Semigran, Marc J
FA  - Deswal, Anita
FA  - LeWinter, Martin
FA  - Hernandez, Adrian F
FA  - Braunwald, Eugene
FA  - Redfield, Margaret M
IN  - Zakeri,Rosita. Division of Cardiology, Mayo Clinic, Rochester, MN.
TI  - Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study.
SO  - Circulation: Heart Failure. 7(1):123-30, 2014 Jan.
AS  - Circ. Heart fail.. 7(1):123-30, 2014 Jan.
NJ  - Circulation. Heart failure
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101479941
OI  - Source: NLM. NIHMS552655
OI  - Source: NLM. PMC3972021
SB  - Index Medicus
CP  - United States
MH  - Age Factors
MH  - Aged
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Blood Pressure/de [Drug Effects]
MH  - Blood Pressure/ph [Physiology]
MH  - Cohort Studies
MH  - Comorbidity
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - *Heart Failure/dt [Drug Therapy]
MH  - Heart Failure/ep [Epidemiology]
MH  - *Heart Failure/pp [Physiopathology]
MH  - Heart Rate/de [Drug Effects]
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxygen Consumption/de [Drug Effects]
MH  - Oxygen Consumption/ph [Physiology]
MH  - Phosphodiesterase 5 Inhibitors/pd [Pharmacology]
MH  - *Phosphodiesterase 5 Inhibitors/tu [Therapeutic Use]
MH  - Piperazines/pd [Pharmacology]
MH  - *Piperazines/tu [Therapeutic Use]
MH  - Purines/pd [Pharmacology]
MH  - Purines/tu [Therapeutic Use]
MH  - Sildenafil Citrate
MH  - Stroke Volume/de [Drug Effects]
MH  - *Stroke Volume/ph [Physiology]
MH  - Sulfones/pd [Pharmacology]
MH  - *Sulfones/tu [Therapeutic Use]
MH  - Treatment Outcome
KW  - atrial fibrillation;  exercise;  heart failure
AB  - BACKGROUND: Atrial fibrillation (AF) is common among patients with heart failure and preserved ejection fraction (HFpEF), but its clinical profile and impact on exercise capacity remain unclear. RELAX (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in HFpEF) was a multicenter randomized trial testing the impact of sildenafil on peak VO2 in stable outpatients with chronic HFpEF. We sought to compare clinical features and exercise capacity among patients with HFpEF who were in sinus rhythm (SR) or AF.
AB  - METHODS AND RESULTS: RELAX enrolled 216 patients with HFpEF, of whom 79 (37%) were in AF, 124 (57%) in SR, and 13 in other rhythms. Participants underwent baseline cardiopulmonary exercise testing, echocardiogram, biomarker assessment, and rhythm status assessment before randomization. Patients with AF were older than those in SR but had similar symptom severity, comorbidities, and renal function. beta-blocker use and chronotropic indices were also similar. Despite comparable left ventricular size and mass, AF was associated with worse systolic (lower EF, stroke volume, and cardiac index) and diastolic (shorter deceleration time and larger left atria) function compared with SR. Pulmonary artery systolic pressure was higher in AF. Patients with AF had higher N-terminal pro-B-type natriuretic peptide, aldosterone, endothelin-1, troponin I, and C-telopeptide for type I collagen levels, suggesting more severe neurohumoral activation, myocyte necrosis, and fibrosis. Peak VO2 was lower in AF, even after adjustment for age, sex, and chronotropic response, and VE/VCO2 was higher.
AB  - CONCLUSIONS: AF identifies an HFpEF cohort with more advanced disease and significantly reduced exercise capacity. These data suggest that evaluation of the impact of different rate or rhythm control strategies on exercise tolerance in patients with HFpEF and AF is warranted.
AB  - CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00763867.
RN  - 0 (Phosphodiesterase 5 Inhibitors)
RN  - 0 (Piperazines)
RN  - 0 (Purines)
RN  - 0 (Sulfones)
RN  - BW9B0ZE037 (Sildenafil Citrate)
ES  - 1941-3297
IL  - 1941-3289
DO  - http://dx.doi.org/10.1161/CIRCHEARTFAILURE.113.000568
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, P.H.S.
SI  - ClinicalTrials.gov
SA  - ClinicalTrials.gov/NCT00763867
SL  - http://clinicaltrials.gov/search/term=NCT00763867
NO  - R01 HL105418 (United States NHLBI NIH HHS)
NO  - T32 HL007111 (United States NHLBI NIH HHS)
NO  - T32 HL007111 (United States NHLBI NIH HHS)
NO  - U01 HL084861 (United States NHLBI NIH HHS)
NO  - U01 HL084875 (United States NHLBI NIH HHS)
NO  - U01 HL084877 (United States NHLBI NIH HHS)
NO  - U01 HL084889 (United States NHLBI NIH HHS)
NO  - U01 HL084890 (United States NHLBI NIH HHS)
NO  - U01 HL084891 (United States NHLBI NIH HHS)
NO  - U01 HL084899 (United States NHLBI NIH HHS)
NO  - U01 HL084904 (United States NHLBI NIH HHS)
NO  - U01 HL084907 (United States NHLBI NIH HHS)
NO  - U01 HL084931 (United States NHLBI NIH HHS)
NO  - U01HL084861 (United States NHLBI NIH HHS)
NO  - U01HL084875 (United States NHLBI NIH HHS)
NO  - U01HL084877 (United States NHLBI NIH HHS)
NO  - U01HL084889 (United States NHLBI NIH HHS)
NO  - U01HL084890 (United States NHLBI NIH HHS)
NO  - U01HL084891 (United States NHLBI NIH HHS)
NO  - U01HL084899 (United States NHLBI NIH HHS)
NO  - U01HL084904 (United States NHLBI NIH HHS)
NO  - U01HL084907 (United States NHLBI NIH HHS)
NO  - U01HL084931 (United States NHLBI NIH HHS)
NO  - U10 HL084904 (United States NHLBI NIH HHS)
NO  - U10 HL110262 (United States NHLBI NIH HHS)
NO  - U10HL110262 (United States NHLBI NIH HHS)
NO  - U54 MD007588 (United States NIMHD NIH HHS)
NO  - U54 MD007588 (United States NIMHD NIH HHS)
NO  - UL1 TR000135 (United States NCATS NIH HHS)
NO  - UL1 TR000454 (United States NCATS NIH HHS)
NO  - UL1TR000135 (United States NCATS NIH HHS)
NO  - UL1TR000454 (United States NCATS NIH HHS)
LG  - English
EP  - 20131025
DP  - 2014 Jan
DC  - 20140122
YR  - 2014
ED  - 20140527
RD  - 20160130
UP  - 20160201
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=24162898

<220. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24396041
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Naji P
AU  - Griffin BP
AU  - Asfahan F
AU  - Barr T
AU  - Rodriguez LL
AU  - Grimm R
AU  - Agarwal S
AU  - Stewart WJ
AU  - Mihaljevic T
AU  - Gillinov AM
AU  - Desai MY
FA  - Naji, Peyman
FA  - Griffin, Brian P
FA  - Asfahan, Fadi
FA  - Barr, Tyler
FA  - Rodriguez, L Leonardo
FA  - Grimm, Richard
FA  - Agarwal, Shikhar
FA  - Stewart, William J
FA  - Mihaljevic, Tomislav
FA  - Gillinov, A Marc
FA  - Desai, Milind Y
IN  - Naji,Peyman. Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH.
TI  - Predictors of long-term outcomes in patients with significant myxomatous mitral regurgitation undergoing exercise echocardiography.
SO  - Circulation. 129(12):1310-9, 2014 Mar 25.
AS  - Circulation. 129(12):1310-9, 2014 Mar 25.
NJ  - Circulation
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - *Echocardiography
MH  - *Exercise Test
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - *Mitral Valve Insufficiency/mo [Mortality]
MH  - *Mitral Valve Insufficiency/us [Ultrasonography]
MH  - *Mitral Valve Prolapse/mo [Mortality]
MH  - *Mitral Valve Prolapse/us [Ultrasonography]
MH  - Predictive Value of Tests
MH  - Proportional Hazards Models
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Time
KW  - echocardiography;  exercise test;  mitral valve insufficiency;  outcome assessment (health care)
AB  - BACKGROUND: Significant myxomatous mitral regurgitation leads to progressive left ventricular (LV) decline, resulting in congestive heart failure and death. Such patients benefit from mitral valve surgery. Exercise echocardiography aids in risk stratification and helps decide surgical timing. We sought to assess predictors of outcomes in such patients undergoing exercise echocardiography.
AB  - METHODS AND RESULTS: This is an observational study of 884 consecutive patients (age, 58 +/- 14 years; 67% men) with grade III+ or greater myxomatous mitral regurgitation who underwent exercise echocardiography between January 2000 and December 2011 (excluding functional mitral regurgitation, prior valvular surgery, hypertrophic cardiomyopathy, rheumatic valvular disease, or greater than mild mitral stenosis). Clinical and echocardiographic data (mitral regurgitation, LV ejection fraction, LV dimensions, right ventricular systolic pressure) and exercise variables (metabolic equivalents, heart rate recovery at 1 minute after exercise) were recorded. Composite events of death, myocardial infarction, stroke, and progression to congestive heart failure were recorded. Mean LV ejection fraction, indexed LV end-systolic dimension, resting right ventricular systolic pressure, peak stress right ventricular systolic pressure, metabolic equivalents achieved, and heart rate recovery were 58 +/- 5%, 1.6 +/- 0.4 mm/m(2), 31 +/- 12 mm Hg, 46 +/- 17 mm Hg, 9.6 +/- 3, and 33 +/- 14 beats, respectively. During 6.4 +/- 4 years of follow-up, there were 87 events. On stepwise multivariable Cox analysis, percent of age/sex-predicted metabolic equivalents (hazard ratio, 0.99; 95% confidence interval, 0.98-0.99; P=0.005), heart rate recovery (hazard ratio, 0.29; 95% confidence interval, 0.17-0.50; P<0.001), resting right ventricular systolic pressure (hazard ratio, 1.03; 95% confidence interval, 1.004-1.05; P=0.02), atrial fibrillation (hazard ratio, 1.91; 95% confidence interval, 1.07-3.41; P=0.03), and LV ejection fraction (hazard ratio, 0.96; 95% confidence interval, 0.92-0.99; P=0.04) predicted outcomes.
AB  - CONCLUSIONS: In patients with grade III+ or greater myxomatous mitral regurgitation undergoing exercise echocardiography, lower percent of age/sex-predicted metabolic equivalents, lower heart rate recovery, atrial fibrillation, lower LV ejection fraction, and high resting right ventricular systolic pressure predicted worse outcomes.
ES  - 1524-4539
IL  - 0009-7322
DO  - http://dx.doi.org/10.1161/CIRCULATIONAHA.113.005287
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20140106
DP  - 2014 Mar 25
DC  - 20140325
YR  - 2014
ED  - 20140526
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24396041

<221. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24818280
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Anonymous
TI  - Yoga and acupressure help control blood pressure in people with atrial fibrillation.
SO  - Harvard Women's Health Watch. 20(11):8, 2013 Jul.
AS  - Harv Womens Health Watch. 20(11):8, 2013 Jul.
NJ  - Harvard women's health watch
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - c22, 9423147
SB  - Consumer Health Journals
CP  - United States
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - Blood Pressure/ph [Physiology]
MH  - Humans
MH  - Hypertension/co [Complications]
MH  - *Hypertension/pc [Prevention & Control]
MH  - *Risk Reduction Behavior
MH  - *Yoga
IS  - 1070-910X
IL  - 1070-910X
PT  - News
LG  - English
DP  - 2013 Jul
DC  - 20131122
YR  - 2013
ED  - 20140522
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24818280

<222. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23999454
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Metra M
AU  - Ponikowski P
AU  - Cotter G
AU  - Davison BA
AU  - Felker GM
AU  - Filippatos G
AU  - Greenberg BH
AU  - Hua TA
AU  - Severin T
AU  - Unemori E
AU  - Voors AA
AU  - Teerlink JR
FA  - Metra, Marco
FA  - Ponikowski, Piotr
FA  - Cotter, Gad
FA  - Davison, Beth A
FA  - Felker, G Michael
FA  - Filippatos, Gerasimos
FA  - Greenberg, Barry H
FA  - Hua, Tsushung A
FA  - Severin, Thomas
FA  - Unemori, Elaine
FA  - Voors, Adriaan A
FA  - Teerlink, John R
IN  - Metra,Marco. Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
TI  - Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF.
CM  - Comment in: Eur Heart J. 2013 Oct;34(40):3100-1; PMID: 23999455
SO  - European Heart Journal. 34(40):3128-36, 2013 Oct.
AS  - Eur Heart J. 34(40):3128-36, 2013 Oct.
NJ  - European heart journal
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - em8, 8006263
OI  - Source: NLM. PMC3800849
SB  - Index Medicus
CP  - England
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - *Cardiotonic Agents/ad [Administration & Dosage]
MH  - Cause of Death
MH  - Double-Blind Method
MH  - Dyspnea/mo [Mortality]
MH  - Dyspnea/pc [Prevention & Control]
MH  - Female
MH  - *Heart Failure/dt [Drug Therapy]
MH  - Heart Failure/mo [Mortality]
MH  - Hospitalization/sn [Statistics & Numerical Data]
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/bl [Blood]
MH  - Peptide Fragments/bl [Blood]
MH  - Recombinant Proteins/ad [Administration & Dosage]
MH  - *Relaxin/ad [Administration & Dosage]
MH  - Treatment Outcome
KW  - Acute heart failure;  Mortality;  Serelaxin;  Subgroups
AB  - AIM: Patients hospitalized for acute heart failure (AHF) differ with respect of many clinical characteristics which may influence their prognosis and response to treatment. We have assessed possible differences in the effects of serelaxin on dyspnoea relief, 60 Day outcomes and 180 Day mortality across patient subgroups in the RELAX-AHF trial.
AB  - METHODS AND RESULTS: Subgroups were based on pre-specified covariates (age, sex, race, geographic region, estimated glomerular filtration rate, time from presentation to randomization, baseline systolic blood pressure, history of diabetes, atrial fibrillation, ischaemic heart disease, cardiac devices, i.v. nitrates at randomization). Other covariates which may modify the efficacy of AHF treatment were also analysed. Subgroup analyses did not show any difference in the effects of serelaxin vs. placebo on dyspnoea relief or on the incidence of cardiovascular death or rehospitalizations for heart failure or renal failure at 60 days. Nominally significant interactions between some patient subgroups and the effects of serelaxin on 180 days cardiovascular and all-cause mortality were noted but should be interpreted cautiously due to the number of comparisons and the low incidence of deaths in the subgroups at lower risk.
AB  - CONCLUSION: The effects of serelaxin vs. placebo appeared to be similar across subgroups of patients in RELAX-AHF.
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Peptide Fragments)
RN  - 0 (Recombinant Proteins)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 0 (serelaxin protein, human)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 9002-69-1 (Relaxin)
ES  - 1522-9645
IL  - 0195-668X
DO  - http://dx.doi.org/10.1093/eurheartj/eht371
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20130902
DP  - 2013 Oct
DC  - 20131022
YR  - 2013
ED  - 20140522
RD  - 20150423
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23999454

<223. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24071782
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Bhatti SK
AU  - O'Keefe JH
AU  - Lavie CJ
FA  - Bhatti, Salman K
FA  - O'Keefe, James H
FA  - Lavie, Carl J
IN  - Bhatti,Salman K. aSaint Luke's Mid America Heart Institute & University of Missouri-Kansas City, Kansas City, Missouri bJohn Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans cDepartment of Preventive Medicine, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana, USA.
TI  - Coffee and tea: perks for health and longevity?. [Review]
SO  - Current Opinion in Clinical Nutrition & Metabolic Care. 16(6):688-97, 2013 Nov.
AS  - Curr Opin Clin Nutr Metab Care. 16(6):688-97, 2013 Nov.
NJ  - Current opinion in clinical nutrition and metabolic care
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 9804399, dgn
SB  - Index Medicus
CP  - England
MH  - Antioxidants/pd [Pharmacology]
MH  - Anxiety/et [Etiology]
MH  - Anxiety/pp [Physiopathology]
MH  - Blood Glucose/me [Metabolism]
MH  - Blood Pressure/de [Drug Effects]
MH  - Caffeine/pd [Pharmacology]
MH  - Calcium/bl [Blood]
MH  - Cardiovascular Diseases/pc [Prevention & Control]
MH  - Coffee/ae [Adverse Effects]
MH  - *Coffee/ch [Chemistry]
MH  - Diabetes Mellitus/pc [Prevention & Control]
MH  - Dose-Response Relationship, Drug
MH  - Fractures, Bone/et [Etiology]
MH  - Fractures, Bone/pp [Physiopathology]
MH  - Humans
MH  - *Longevity/de [Drug Effects]
MH  - Neoplasms/pc [Prevention & Control]
MH  - Obesity/pc [Prevention & Control]
MH  - Observational Studies as Topic
MH  - *Polyphenols/pd [Pharmacology]
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Sleep Initiation and Maintenance Disorders/et [Etiology]
MH  - Sleep Initiation and Maintenance Disorders/pp [Physiopathology]
MH  - Tea/ae [Adverse Effects]
MH  - *Tea/ch [Chemistry]
AB  - PURPOSE OF REVIEW: Tea and coffee, after water, are the most commonly consumed beverages in the world and are the top sources of caffeine and antioxidant polyphenols in the American diet. The purpose of this review is to assess the health effects of chronic tea and/or coffee consumption.
AB  - RECENT FINDINGS: Tea consumption, especially green tea, is associated with significantly reduced risks for stroke, diabetes and depression, and improved levels of glucose, cholesterol, abdominal obesity and blood pressure. Habitual coffee consumption in large epidemiological studies is associated with reduced mortality, both for all-cause and cardiovascular deaths. In addition, coffee intake is associated with risks of heart failure, stroke, diabetes mellitus and some cancers in an inverse dose-dependent fashion. Surprisingly, coffee is associated with neutral to reduced risks for both atrial and ventricular arrhythmias. However, caffeine at high doses can increase anxiety, insomnia, calcium loss and possibly the risk of fractures.
AB  - SUMMARY: Coffee and tea can generally be recommended as health-promoting additions to an adult diet. Adequate dietary calcium intake may be particularly important for tea and coffee drinkers.
RN  - 0 (Antioxidants)
RN  - 0 (Blood Glucose)
RN  - 0 (Coffee)
RN  - 0 (Polyphenols)
RN  - 0 (Tea)
RN  - 3G6A5W338E (Caffeine)
RN  - SY7Q814VUP (Calcium)
ES  - 1473-6519
IL  - 1363-1950
DO  - http://dx.doi.org/10.1097/MCO.0b013e328365b9a0
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2013 Nov
DC  - 20131010
YR  - 2013
ED  - 20140521
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24071782

<224. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24470324
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Owens DS
FA  - Owens, David S
TI  - Hypertrophic cardiomyopathy: exercising a strategy of personalised medicine.
CM  - Comment on: Heart. 2014 Apr;100(8):639-46; PMID: 24449719
CM  - Comment on: Heart. 2014 Apr;100(8):624-30; PMID: 24326897
SO  - Heart. 100(8):603-4, 2014 Apr.
AS  - Heart. 100(8):603-4, 2014 Apr.
NJ  - Heart (British Cardiac Society)
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9602087
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - *Atrial Fibrillation/et [Etiology]
MH  - *Cardiac Output
MH  - *Cardiomyopathy, Hypertrophic/co [Complications]
MH  - *Exercise Tolerance
MH  - Female
MH  - Humans
MH  - Male
MH  - *Oxygen Consumption
MH  - *Ventricular Outflow Obstruction/et [Etiology]
ES  - 1468-201X
IL  - 1355-6037
DO  - http://dx.doi.org/10.1136/heartjnl-2013-305154
PT  - Comment
PT  - Editorial
LG  - English
EP  - 20140127
DP  - 2014 Apr
DC  - 20140324
YR  - 2014
ED  - 20140515
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24470324

<225. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24326897
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Azarbal F
AU  - Singh M
AU  - Finocchiaro G
AU  - Le VV
AU  - Schnittger I
AU  - Wang P
AU  - Myers J
AU  - Ashley E
AU  - Perez M
FA  - Azarbal, Farnaz
FA  - Singh, Maneesh
FA  - Finocchiaro, Gherardo
FA  - Le, Vy-Van
FA  - Schnittger, Ingela
FA  - Wang, Paul
FA  - Myers, Jonathan
FA  - Ashley, Euan
FA  - Perez, Marco
IN  - Azarbal,Farnaz. Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, , Stanford, California, USA.
TI  - Exercise capacity and paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy.
CM  - Comment in: Heart. 2014 Apr;100(8):603-4; PMID: 24470324
SO  - Heart. 100(8):624-30, 2014 Apr.
AS  - Heart. 100(8):624-30, 2014 Apr.
NJ  - Heart (British Cardiac Society)
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9602087
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - Adult
MH  - Aged
MH  - Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Breath Tests
MH  - California
MH  - *Cardiomyopathy, Hypertrophic/co [Complications]
MH  - Cardiomyopathy, Hypertrophic/di [Diagnosis]
MH  - Cardiomyopathy, Hypertrophic/pp [Physiopathology]
MH  - Chi-Square Distribution
MH  - Echocardiography, Doppler
MH  - Electrocardiography
MH  - Exercise Test
MH  - *Exercise Tolerance
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Odds Ratio
MH  - Oxygen Consumption
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Risk Factors
KW  - Hypertrophic cardiomyopathy;  atrial fibrillation;  exercise capacity
AB  - BACKGROUND: Atrial fibrillation (AF) is the most common arrhythmia among patients with hypertrophic cardiomyopathy (HCM). The relationship between paroxysmal AF and exercise capacity in this population is incompletely understood.
AB  - METHODS: Patients with HCM underwent symptom-limited cardiopulmonary testing with expired gas analysis at Stanford Hospital between October 2006 and October 2012. Baseline demographics, medical histories and resting echocardiograms were obtained for all subjects. Diagnosis of AF was established by review of medical records and baseline ECG. Those with paroxysmal AF were in sinus rhythm at the time of cardiopulmonary testing with expired gas analysis. Exercise intolerance was defined as peak VO2<20 mL/kg/min. We used multivariate logistic regression to evaluate the association between exercise intolerance and paroxysmal AF.
AB  - RESULTS: Among the 265 patients recruited, 55 had AF (28 paroxysmal and 27 permanent). Compared with those without AF, subjects with paroxysmal AF were older, more likely to use antiarrhythmic and anticoagulant medications, and had larger left atria. Patients with paroxysmal AF achieved lower peak VO2 (21.9+/-9.2 mL/kg/min vs 26.9+/-10.8 mL/kg/min, p=0.02) and were more likely to have exercise intolerance (61% vs 28%, p<0.001) compared with those without AF. After adjustment for age, sex and body mass index (BMI) exercise intolerance remained significantly associated with paroxysmal AF (OR 4.65, 95% CI 1.83 to 11.83, p=0.001).
AB  - CONCLUSIONS: Patients with HCM and paroxysmal AF demonstrate exercise intolerance despite being in sinus rhythm at the time of exercise testing.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Anticoagulants)
ES  - 1468-201X
IL  - 1355-6037
DO  - http://dx.doi.org/10.1136/heartjnl-2013-304908
PT  - Journal Article
LG  - English
EP  - 20131210
DP  - 2014 Apr
DC  - 20140324
YR  - 2014
ED  - 20140515
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24326897

<226. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24625726
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Shen MJ
AU  - Zipes DP
FA  - Shen, Mark J
FA  - Zipes, Douglas P
IN  - Shen,Mark J. From Krannert Institute of Cardiology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN.
TI  - Role of the autonomic nervous system in modulating cardiac arrhythmias. [Review]
SO  - Circulation Research. 114(6):1004-21, 2014 Mar 14.
AS  - Circ Res. 114(6):1004-21, 2014 Mar 14.
NJ  - Circulation research
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - daj, 0047103
SB  - Index Medicus
CP  - United States
MH  - Acupuncture Therapy
MH  - Animals
MH  - Arrhythmias, Cardiac/ge [Genetics]
MH  - *Arrhythmias, Cardiac/pp [Physiopathology]
MH  - Arrhythmias, Cardiac/pc [Prevention & Control]
MH  - Arrhythmias, Cardiac/th [Therapy]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/th [Therapy]
MH  - *Autonomic Nervous System/pp [Physiopathology]
MH  - Cardiovascular Agents/tu [Therapeutic Use]
MH  - Catheter Ablation
MH  - Cryosurgery
MH  - Death, Sudden, Cardiac
MH  - Disease Models, Animal
MH  - Electric Stimulation Therapy/mt [Methods]
MH  - Ganglia, Autonomic/pp [Physiopathology]
MH  - Heart Conduction System/pp [Physiopathology]
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Medulla Oblongata/pp [Physiopathology]
MH  - Models, Cardiovascular
MH  - Models, Neurological
MH  - Spinal Cord
MH  - Vagus Nerve/pp [Physiopathology]
MH  - Vagus Nerve Stimulation
MH  - Ventricular Fibrillation/pp [Physiopathology]
MH  - Ventricular Fibrillation/th [Therapy]
KW  - atrial fibrillation;  autonomic nervous system;  ventricular fibrillation
AB  - The autonomic nervous system plays an important role in the modulation of cardiac electrophysiology and arrhythmogenesis. Decades of research has contributed to a better understanding of the anatomy and physiology of cardiac autonomic nervous system and provided evidence supporting the relationship of autonomic tone to clinically significant arrhythmias. The mechanisms by which autonomic activation is arrhythmogenic or antiarrhythmic are complex and different for specific arrhythmias. In atrial fibrillation, simultaneous sympathetic and parasympathetic activations are the most common trigger. In contrast, in ventricular fibrillation in the setting of cardiac ischemia, sympathetic activation is proarrhythmic, whereas parasympathetic activation is antiarrhythmic. In inherited arrhythmia syndromes, sympathetic stimulation precipitates ventricular tachyarrhythmias and sudden cardiac death except in Brugada and J-wave syndromes where it can prevent them. The identification of specific autonomic triggers in different arrhythmias has brought the idea of modulating autonomic activities for both preventing and treating these arrhythmias. This has been achieved by either neural ablation or stimulation. Neural modulation as a treatment for arrhythmias has been well established in certain diseases, such as long QT syndrome. However, in most other arrhythmia diseases, it is still an emerging modality and under investigation. Recent preliminary trials have yielded encouraging results. Further larger-scale clinical studies are necessary before widespread application can be recommended.
RN  - 0 (Cardiovascular Agents)
ES  - 1524-4571
IL  - 0009-7330
DO  - http://dx.doi.org/10.1161/CIRCRESAHA.113.302549
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2014 Mar 14
DC  - 20140314
YR  - 2014
ED  - 20140514
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24625726

<227. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24791067
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Ohnishi T
AU  - Hisaoka F
AU  - Morishima M
AU  - Takahashi A
AU  - Harada N
AU  - Mawatari K
AU  - Arai H
AU  - Yoshioka E
AU  - Toda S
AU  - Keisuke I
AU  - Nakaya Y
FA  - Ohnishi, Takamasa
FA  - Hisaoka, Fumiko
FA  - Morishima, Masaki
FA  - Takahashi, Akira
FA  - Harada, Nagakatsu
FA  - Mawatari, Kazuaki
FA  - Arai, Hidekazu
FA  - Yoshioka, Emiko
FA  - Toda, Satomi
FA  - Keisuke, Izumi
FA  - Nakaya, Yutaka
IN  - Ohnishi,Takamasa. Department of Nutrition Management, Faculty of Health Science, Hyogo University, 2301 Shinzaike, Hiraoka-cho, Kakogawa, Hyogo 675-0195, Japan ; Department of Molecular and Environmental Pathology, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, Tokushima 770-8503, Japan.
IN  - Hisaoka,Fumiko. Faculty of Human Life Science, Shikoku University, 23-1 Ebisuno Furukawa, Oujinn-cho, Tokushima, Tokushima 771-1192, Japan.
IN  - Morishima,Masaki. Department of Nutrition, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, Tokushima 770-8503, Japan.
IN  - Takahashi,Akira. Department of Nutrition, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, Tokushima 770-8503, Japan.
IN  - Harada,Nagakatsu. Department of Nutrition, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, Tokushima 770-8503, Japan.
IN  - Mawatari,Kazuaki. Department of Nutrition, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, Tokushima 770-8503, Japan.
IN  - Arai,Hidekazu. Department of Laboratory of Clinical Nutrition Management, School of Food and Nutritional Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, 422-8526 Shizuoka, Japan.
IN  - Yoshioka,Emiko. Department of Nutrition, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, Tokushima 770-8503, Japan.
IN  - Toda,Satomi. Department of Nutrition, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, Tokushima 770-8503, Japan.
IN  - Keisuke,Izumi. Department of Molecular and Environmental Pathology, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, Tokushima 770-8503, Japan.
IN  - Nakaya,Yutaka. Department of Nutrition, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, Tokushima 770-8503, Japan.
TI  - Establishment of a model of spontaneously-running-Tokushima-shikoku rats with left atrial thrombosis.[Erratum appears in J Toxicol Pathol. 2016 Jan;29(1):74; PMID: 26989306]
SO  - Journal of Toxicologic Pathology. 27(1):51-6, 2014 Apr.
AS  - J. toxicol. pathol.. 27(1):51-6, 2014 Apr.
NJ  - Journal of toxicologic pathology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - 9306408
OI  - Source: NLM. PMC4000073
CP  - Japan
KW  - atrial thrombosis;  heart;  rat
AB  - Studies that investigate the underlying mechanisms of disease and treatment options typically require the use of a suitable animal model. Few suitable animal models exist for left atrial thrombosis. Here, we demonstrated that the Spontaneously-Running-Tokushima-Shikoku (SPORTS) rat - a Wistar strain known for its running ability-is predisposed to the development of thrombi in the left atrium. We investigated the incidence of left atrial thrombosis in male (n = 16) and female (n = 17) SPORTS rats and observed organized atrial thrombosis in 57% and 38% of males and female rats, respectively. In the male rats, systolic blood pressures and heart rates were significantly higher in SPORTS rats than in control Wistar rats. We could not find any evidence of arrhythmias, such as atrial fibrillation, during electrocardiographic examination of SPORTS rats. We believe that the SPORTS rat could serve as a new research model for left atrial thrombosis; further, it may be suitable for research investigating the development of new antithrombotic approaches for the control of atrial thrombosis or familial thrombophilia in humans.
IS  - 0914-9198
IL  - 0914-9198
DO  - http://dx.doi.org/10.1293/tox.2012-0032
PT  - Journal Article
LG  - English
EP  - 20140430
DP  - 2014 Apr
DC  - 20140505
YR  - 2014
ED  - 20140505
RD  - 20160506
UP  - 20160509
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=24791067

<228. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24091709
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Albertsen IE
AU  - Rasmussen LH
AU  - Lane DA
AU  - Overvad TF
AU  - Skjoth F
AU  - Overvad K
AU  - Lip GY
AU  - Larsen TB
FA  - Albertsen, Ida Ehlers
FA  - Rasmussen, Lars Hvilsted
FA  - Lane, Deirdre A
FA  - Overvad, Thure Filskov
FA  - Skjoth, Flemming
FA  - Overvad, Kim
FA  - Lip, Gregory Y H
FA  - Larsen, Torben Bjerregaard
TI  - The impact of smoking on thromboembolism and mortality in patients with incident atrial fibrillation: insights from the Danish Diet, Cancer, and Health study.
SO  - Chest. 145(3):559-66, 2014 Mar 1.
AS  - Chest. 145(3):559-66, 2014 Mar 1.
NJ  - Chest
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 0231335, d1c
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/mo [Mortality]
MH  - Cause of Death/td [Trends]
MH  - Denmark/ep [Epidemiology]
MH  - *Diet
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Prospective Studies
MH  - *Registries
MH  - Risk Factors
MH  - *Smoking/ae [Adverse Effects]
MH  - Smoking/mo [Mortality]
MH  - *Thromboembolism/ep [Epidemiology]
MH  - Thromboembolism/et [Etiology]
MH  - Thromboembolism/pc [Prevention & Control]
MH  - Time Factors
AB  - BACKGROUND: Smoking and atrial fibrillation (AF) are major health problems worldwide and are responsible for substantial health-care costs. Our aim was to investigate whether smoking impacts the risk of stroke and death in patients with AF. To test this hypothesis, we analyzed data from a large Danish cohort: the Diet, Cancer, and Health study.
AB  - METHODS: This was a cohort study of 57,053 people (27,178 men; 29,876 women) aged 50 to 64 years. The risk of thromboembolism (ischemic stroke/arterial thromboembolism) or death according to smoking habits among 3,161 patients with incident AF (mean age, 66.9 years; 2,032 men, 1,129 women) was assessed using Cox proportional hazard models after a median follow-up of 4.9 years.
AB  - RESULTS: Of those with AF, 34% were current smokers and 37% former smokers. After adjustment for vitamin K antagonist treatment, the hazard ratios (HRs) (95% CI) of thromboembolism or death were 3.13 (1.72-6.37) and 2.73 (2.02-3.70) among women and men who currently were heavy smokers (>25 g/d), respectively. The associations remained after adjustment for well-established risk factors with HRs of 3.64 (1.88-7.07) and 2.17 (1.59-2.95) among women and men, respectively. In a sensitivity analysis, smoking was still strongly associated with thromboembolism or death after censoring people with a cancer diagnosis during follow-up.
AB  - CONCLUSIONS: Smoking is associated with a higher risk of thromboembolism or death in patients with AF even after adjusting for well-recognized risk factors used in stroke risk stratification schemes. The associations may be modified by sex, as the associations were strongest among women.
ES  - 1931-3543
IL  - 0012-3692
DO  - http://dx.doi.org/10.1378/chest.13-1740
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2014 Mar 1
DC  - 20140304
YR  - 2014
ED  - 20140423
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24091709

<229. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23524987
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Coleman CI
AU  - Coleman SM
AU  - Vanderpoel J
AU  - Nelson W
AU  - Colby JA
AU  - Scholle JM
AU  - Kluger J
FA  - Coleman, Craig I
FA  - Coleman, Stacey M
FA  - Vanderpoel, Julie
FA  - Nelson, Winnie
FA  - Colby, Jennifer A
FA  - Scholle, Jennifer M
FA  - Kluger, Jeffrey
IN  - Coleman,Craig I. University of Connecticut School of Pharmacy, Storrs, CT 06102-5037, USA. ccolema@harthosp.org
TI  - Patient satisfaction with warfarin- and non-warfarin-containing thromboprophylaxis regimens for atrial fibrillation.
SO  - Journal of Investigative Medicine. 61(5):878-81, 2013 Jun.
AS  - J Investig Med. 61(5):878-81, 2013 Jun.
NJ  - Journal of investigative medicine : the official publication of the American Federation for Clinical Research
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - b9k, 9501229
SB  - Index Medicus
CP  - Canada
MH  - Aged
MH  - Anticoagulants/pd [Pharmacology]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Blood Coagulation/de [Drug Effects]
MH  - Female
MH  - Humans
MH  - Male
MH  - *Patient Satisfaction
MH  - Thrombosis/co [Complications]
MH  - *Thrombosis/dt [Drug Therapy]
MH  - Thrombosis/pp [Physiopathology]
MH  - *Thrombosis/pc [Prevention & Control]
MH  - Warfarin/pd [Pharmacology]
MH  - *Warfarin/tu [Therapeutic Use]
AB  - OBJECTIVE: To compare patient-reported limitations, concerns, and burdens in those receiving and not receiving warfarin for thromboprophylaxis in atrial fibrillation (AF).
AB  - METHODS: We conducted a cross-sectional survey study of patients with AF receiving thromboprophylaxis for stroke prevention. Patients were administered the validated Anti-Clot Treatment Scale (ACTS). Mean scores of patients receiving and not receiving warfarin were compared for each ACTS item, and for the Burden and Benefit subscales.
AB  - RESULTS: From July 2010 to August 2011, 80 patients with AF were administered the survey, with 65 patients receiving a regimen containing warfarin and 15 patients not receiving a regimen containing warfarin. Six of the 17 individual questions depicting patient- perceived limitations in physical activity due to bleeding, limitations on diet, feelings of inconvenience of occasional aspects of thromboprophylaxis therapy, and frustration, and burden had less favorable scores in the warfarin-managed patients compared with the patients not receiving warfarin (P < 0.05 for all). Mean ACTS Burden scores were more favorable in the no-warfarin group (44.5 +/- 6.4) compared with the warfarin group (39.8 +/- 8.0; P = 0.003). No difference was seen between the 2 groups on the ACTS Benefits score (11.1 +/- 3.4 vs 10.4 +/- 3.7; P = 0.38).
AB  - CONCLUSION: Patients with AF receiving warfarin may have less favorable feelings regarding thromboprophylaxis versus those receiving non-warfarin thromboprophylaxis. Patients report having more limitations and having greater feelings of burden on warfarin.
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
ES  - 1708-8267
IL  - 1081-5589
DO  - http://dx.doi.org/10.231/JIM.0b013e31828df1bf
PT  - Journal Article
LG  - English
DP  - 2013 Jun
DC  - 20130517
YR  - 2013
ED  - 20140423
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23524987

<230. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24565821
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Olshansky B
AU  - Sullivan R
FA  - Olshansky, Brian
FA  - Sullivan, Renee
IN  - Olshansky,Brian. Professor Emeritus, University of Iowa Hospitals, Iowa City and Mercy Hospital, Mason City, IA. brian-olshansky@uiowa.edu.
TI  - Increased prevalence of atrial fibrillation in the endurance athlete: potential mechanisms and sport specificity. [Review]
SO  - Physician & Sportsmedicine. 42(1):45-51, 2014 Feb.
AS  - Phys Sportsmed. 42(1):45-51, 2014 Feb.
NJ  - The Physician and sportsmedicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0427461
SB  - Index Medicus
CP  - United States
MH  - *Athletes/sn [Statistics & Numerical Data]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Exercise
MH  - Humans
MH  - Physical Endurance
MH  - *Sports/sn [Statistics & Numerical Data]
AB  - Atrial fibrillation is a common, often symptomatic, and concerning arrhythmia that can lead to heart failure, decreased athletic tolerance, and thromboembolic events; it has also been associated with increased mortality. Although atrial fibrillation is an uncommon condition in younger and otherwise healthy people, recent emerging evidence indicates that endurance athletes may be at particularly high risk of developing atrial fibrillation. We review the evidence that atrial fibrillation is associated with intense endurance athletics and we also explore the mechanisms by which this may occur. Finally, we consider some of the options that are available to treat athletes who develop atrial fibrillation.
IS  - 0091-3847
IL  - 0091-3847
DO  - http://dx.doi.org/10.3810/psm.2014.02.2047
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2014 Feb
DC  - 20140225
YR  - 2014
ED  - 20140422
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24565821

<231. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23884291
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Jonkman FA
AU  - Jonkman-Buidin ML
FA  - Jonkman, F A M
FA  - Jonkman-Buidin, M L
IN  - Jonkman,F A M. Department of Acupuncture, Acupuncture Outpatient Clinic Heel de Mens, Heelsum, The Netherlands. info@humanbalance.nl
TI  - Integrated approach to treatment-resistant atrial fibrillation: additional value of acupuncture.
SO  - Acupuncture in Medicine. 31(3):327-30, 2013 Sep.
AS  - Acupunct Med. 31(3):327-30, 2013 Sep.
NJ  - Acupuncture in medicine : journal of the British Medical Acupuncture Society
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - dz2, 9304117
OI  - Source: NLM. PMC3786618
SB  - Index Medicus
CP  - England
MH  - *Acupuncture Therapy
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Electric Countershock
MH  - Humans
MH  - Male
MH  - Middle Aged
KW  - ACUPUNCTURE;  CARDIOLOGY;  CLINICAL PHARMACOLOGY;  COMPLEMENTARY MEDICINE
AB  - A 62-year-old patient with chronic bronchitis had treatment-resistant atrial fibrillation. Electrical cardioversion was performed, but sinus rhythm (SR) lasted only for some minutes. Administration of amiodarone was withheld in favour of a course of acupuncture treatment in order to increase the success rate of a second attempt of electrical cardioversion. After two acupuncture treatments, spontaneous conversion to SR occurred. Relapses into atrial fibrillation in the following five winters, associated with attacks of bronchitis, also responded to acupuncture. The mechanisms of action of the acupuncture treatment and the value of this integrated approach to treatment are discussed.
ES  - 1759-9873
IL  - 0964-5284
DO  - http://dx.doi.org/10.1136/acupmed-2013-010380
PT  - Case Reports
PT  - Journal Article
LG  - English
EP  - 20130724
DP  - 2013 Sep
DC  - 20130902
YR  - 2013
ED  - 20140421
RD  - 20150423
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23884291

<232. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24446025
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Chang CH
AU  - Lin JW
AU  - Chiu FC
AU  - Caffrey JL
AU  - Wu LC
AU  - Lai MS
FA  - Chang, Chia-Hsuin
FA  - Lin, Jou-Wei
FA  - Chiu, Fu-Chun
FA  - Caffrey, James L
FA  - Wu, Li-Chiu
FA  - Lai, Mei-Shu
IN  - Chang,Chia-Hsuin. Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan.
TI  - Effect of radiofrequency catheter ablation for atrial fibrillation on morbidity and mortality: a nationwide cohort study and propensity score analysis.
SO  - Circulation: Arrhythmia and Electrophysiology. 7(1):76-82, 2014 Feb.
AS  - Circ. Arrhythm. electrophysiol.. 7(1):76-82, 2014 Feb.
NJ  - Circulation. Arrhythmia and electrophysiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101474365
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/mo [Mortality]
MH  - *Atrial Fibrillation/su [Surgery]
MH  - Catheter Ablation/ae [Adverse Effects]
MH  - Catheter Ablation/mo [Mortality]
MH  - *Catheter Ablation
MH  - Comorbidity
MH  - Confounding Factors (Epidemiology)
MH  - Female
MH  - Heart Failure/mo [Mortality]
MH  - Heart Failure/th [Therapy]
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Propensity Score
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Stroke/mo [Mortality]
MH  - Taiwan/ep [Epidemiology]
MH  - Treatment Outcome
KW  - atrial fibrillation;  catheter ablation;  heart failure;  mortality;  stroke
AB  - BACKGROUND: This study examined the effect of radiofrequency catheter ablation (RFA) on reducing morbidity and mortality among patients with atrial fibrillation (AF).
AB  - METHODS AND RESULTS: A retrospective cohort of patients with AF without prior stroke or heart failure (HF) who underwent RFA between 2003 and 2009 was identified using Taiwan's National Health Insurance claims database. Outpatients with AF who met the same enrollment criteria but did not receive RFA were matched (<1:20) by hospitals and dates to serve as controls. Outcomes of interest were death, stroke, or hospitalization for HF. A proportional hazard Cox regression model adjusted by propensity scores (based on age, sex, hypertension, diabetes mellitus, comorbidities, medications, and medical resource utilization) was applied to estimate the hazard ratio and 95% confidence interval. A total of 846 patients with AF who received RFA and 11 324 matched AF controls were included, with a mean follow-up of 3.74 and 3.96 years, respectively. RFA was associated with a lower hazard for stroke (hazard ratio, 0.57; 95% confidence interval, 0.35-0.94; P=0.026). The reduction in the hazard for death and HF did not reach statistical significance (hazard ratio, 0.88; 95% confidence interval, 0.62-1.23; P=0.451 and hazard ratio, 0.78; 95% confidence interval, 0.55-1.12; P=0.185, respectively). Additional analysis using death as a competing risk showed similar results for stroke and HF.
AB  - CONCLUSIONS: RFA did not reduce mortality or hospitalization for HF during the immediate 3.5-year follow-up. Although a beneficial effect on stroke prevention associated with RFA was suggested, residual confounding attributable to unmeasured factors remains a concern.
ES  - 1941-3084
IL  - 1941-3084
DO  - http://dx.doi.org/10.1161/CIRCEP.113.000597
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20140120
DP  - 2014 Feb
DC  - 20140219
YR  - 2014
ED  - 20140418
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24446025

<233. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24108193
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wolkanin-Bartnik J
AU  - Pogorzelska H
AU  - Szperl M
AU  - Bartnik A
AU  - Koziarek J
AU  - Bilinska ZT
FA  - Wolkanin-Bartnik, Jolanta
FA  - Pogorzelska, Hanna
FA  - Szperl, Malgorzata
FA  - Bartnik, Aleksandra
FA  - Koziarek, Jacek
FA  - Bilinska, Zofia T
IN  - Wolkanin-Bartnik,Jolanta. aOutpatient Clinic bLaboratory of Molecular Biology cDepartment of Epidemiology, Cardiovascular Diseases Prevention and Health Promotion dUnit for Screening Studies in Inherited Cardiovascular Diseases, Institute of Cardiology, Warsaw, Poland.
TI  - Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm.
SO  - Pharmacogenetics and Genomics. 23(11):611-8, 2013 Nov.
AS  - Pharmacogenet Genomics. 23(11):611-8, 2013 Nov.
NJ  - Pharmacogenetics and genomics
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101231005
SB  - Index Medicus
CP  - United States
MH  - *Acenocoumarol/ad [Administration & Dosage]
MH  - Acenocoumarol/tu [Therapeutic Use]
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Algorithms
MH  - *Anticoagulants/ad [Administration & Dosage]
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - *Aryl Hydrocarbon Hydroxylases/ge [Genetics]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Body Mass Index
MH  - Creatinine/bl [Blood]
MH  - Cytochrome P-450 CYP2C9
MH  - Dose-Response Relationship, Drug
MH  - Drug Dosage Calculations
MH  - Female
MH  - Genetic Markers
MH  - Genetic Variation
MH  - Genotype
MH  - Heart Valve Prosthesis
MH  - Humans
MH  - Linear Models
MH  - Male
MH  - Middle Aged
MH  - Poland
MH  - Polymorphism, Single Nucleotide
MH  - *Venous Thrombosis/dt [Drug Therapy]
MH  - Vitamin K/me [Metabolism]
MH  - *Vitamin K Epoxide Reductases/ge [Genetics]
AB  - BACKGROUND: Despite the recent emergence of new oral anticoagulants, vitamin K antagonists remain the primary therapy in patients with atrial fibrillation and the only therapy licensed for use in patients with artificial heart valves.
AB  - OBJECTIVE: The aim of this study was (a) to assess the impact of clinical and genetic factors on acenocoumarol (AC) dose requirements and the percentage of time in therapeutic range (%TTR) and (b) to develop pharmacogenetic-guided AC dose calculation algorithm.
AB  - MATERIALS AND METHODS: We included 235 outpatients of the Institute of Cardiology (Warsaw), mean age 69.3, 46.9% women, receiving AC for artificial heart valves and/or atrial fibrillation. A multiple linear-regression analysis was performed using log-transformed effective AC dose as the dependent variable, and combining CYP2C9 and VKORC1 genotyping with other clinical factors as independent predictors.
AB  - RESULTS: We identified factors that influenced the AC dose: CYP2C9 polymorphisms (P=0.004), VKORC1 polymorphisms (P<0.0001), age (P<0.0001), creatinine clearance lower than 40 ml/min (P=0.035), body mass (P=0.02), and dietary vitamin K intake (P=0.026). Clinical and genetic factors explained 49.0% of AC dose variability. We developed a dosing calculation algorithm that is, to the best of our knowledge, the first one to assess the effect of such clinical factors as creatinine clearance and dietary vitamin K intake on the AC dose. The clinical usefulness of the algorithm was assessed on separate validation group (n=50) with 70% accuracy. Dietary vitamin K intake higher than 200 mcg/day improved international normalized ratio control (%TTR 73.3+/-17 vs. 67.7+/-18, respectively, P=0.04).
AB  - CONCLUSION: Inclusion of a variety of genetic and clinical factors in the dosing calculation algorithm allows for precise AC dose estimation in most patients and thus improves the efficacy and safety of the therapy.
RN  - 0 (Anticoagulants)
RN  - 0 (Genetic Markers)
RN  - 12001-79-5 (Vitamin K)
RN  - AYI8EX34EU (Creatinine)
RN  - EC 1-1-4-1 (Vitamin K Epoxide Reductases)
RN  - EC 1-14-13 (CYP2C9 protein, human)
RN  - EC 1-14-13 (Cytochrome P-450 CYP2C9)
RN  - EC 1-14-14-1 (Aryl Hydrocarbon Hydroxylases)
RN  - EC 1-17-4-4 (VKORC1 protein, human)
RN  - I6WP63U32H (Acenocoumarol)
ES  - 1744-6880
IL  - 1744-6872
DO  - http://dx.doi.org/10.1097/FPC.0000000000000004
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2013 Nov
DC  - 20131010
YR  - 2013
ED  - 20140414
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24108193

<234. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24112470
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Adamsson Eryd S
AU  - Borne Y
AU  - Melander O
AU  - Persson M
AU  - Smith JG
AU  - Hedblad B
AU  - Engstrom G
FA  - Adamsson Eryd, S
FA  - Borne, Y
FA  - Melander, O
FA  - Persson, M
FA  - Smith, J G
FA  - Hedblad, B
FA  - Engstrom, G
IN  - Adamsson Eryd,S. Department of Clinical Sciences, Lund University, Malmo , Sweden.
TI  - Red blood cell distribution width is associated with incidence of atrial fibrillation.
CM  - Comment in: J Intern Med. 2014 May;275(5):544; PMID: 24344999
CM  - Comment in: J Intern Med. 2014 May;275(5):545; PMID: 24345033
SO  - Journal of Internal Medicine. 275(1):84-92, 2014 Jan.
AS  - J Intern Med. 275(1):84-92, 2014 Jan.
NJ  - Journal of internal medicine
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - i2g, 8904841
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - Atrial Fibrillation/bl [Blood]
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation
MH  - Cohort Studies
MH  - Confidence Intervals
MH  - Confounding Factors (Epidemiology)
MH  - *Erythrocyte Indices
MH  - Female
MH  - Hospitalization/sn [Statistics & Numerical Data]
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Registries
MH  - Risk Factors
MH  - Sweden/ep [Epidemiology]
KW  - atrial fibrillation;  cohort study;  epidemiology;  red blood cell distribution width;  risk factors
AB  - OBJECTIVES: Red blood cell distribution width (RDW), a measure of variation in erythrocyte volume, has been associated with several cardiovascular disorders, but the relationship with atrial fibrillation (AF) remains unclear. We investigated the association between RDW and incidence of first hospitalization due to AF in a population-based cohort.
AB  - DESIGN: Red blood cell distribution width was measured in 27,124 subjects from the general population (age 45-73 years, 62% women) with no history of AF, heart failure, myocardial infarction or stroke. The association between baseline RDW and incidence of AF identified from the Swedish Hospital Discharge Register was evaluated.
AB  - RESULTS: During a mean follow-up of 13.6 years, 1894 subjects (53% men) were hospitalized with a diagnosis of AF. After adjustment for potential confounding factors, including cardiovascular disease risk factors, nutrient intake (iron, vitamin B12 and folate) and several haematological parameters (haemoglobin concentration, mean corpuscular volume and corpuscular haemoglobin content), the hazard ratio (HR) for incidence of AF was 1.33 [95% confidence interval (CI) 1.16-1.53] for the fourth versus first quartile of RDW (P for trend <0.001). The results were essentially unchanged when subjects with incident myocardial infarction or hospitalizations because of heart failure were censored from the analysis (HR 1.30, 95% CI 1.13-1.51; P for trend = 0.001).
AB  - CONCLUSION: Red blood cell distribution width was associated with incidence of AF independently of several cardiovascular, nutritional and haematological factors in this study of middle-aged subjects from the general population.Copyright © 2013 The Association for the Publication of the Journal of Internal Medicine.
ES  - 1365-2796
IL  - 0954-6820
DO  - http://dx.doi.org/10.1111/joim.12143
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20131025
DP  - 2014 Jan
DC  - 20131216
YR  - 2014
ED  - 20140407
RD  - 20140528
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24112470

<235. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24228077
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Vanstone M
AU  - Giacomini M
AU  - Smith A
AU  - Brundisini F
AU  - DeJean D
AU  - Winsor S
FA  - Vanstone, M
FA  - Giacomini, M
FA  - Smith, A
FA  - Brundisini, F
FA  - DeJean, D
FA  - Winsor, S
TI  - How diet modification challenges are magnified in vulnerable or marginalized people with diabetes and heart disease: a systematic review and qualitative meta-synthesis. [Review]
SO  - Ontario Health Technology Assessment Series. 13(14):1-40, 2013.
AS  - Ont Health Technol Assess Ser. 13(14):1-40, 2013.
NJ  - Ontario health technology assessment series
PI  - Journal available in: Electronic-eCollection
PI  - Citation processed from: Internet
JC  - 101521610
OI  - Source: NLM. PMC3817924
SB  - Index Medicus
CP  - Canada
MH  - Adaptation, Psychological
MH  - Australasia
MH  - Chronic Disease
MH  - *Diabetes Mellitus/dh [Diet Therapy]
MH  - Diabetes Mellitus/ep [Epidemiology]
MH  - Diabetes Mellitus/px [Psychology]
MH  - Europe
MH  - Family Health
MH  - Food Habits/eh [Ethnology]
MH  - *Food Habits/px [Psychology]
MH  - Food Preferences/eh [Ethnology]
MH  - Food Preferences/px [Psychology]
MH  - *Health Knowledge, Attitudes, Practice
MH  - Health Status Disparities
MH  - *Heart Diseases/dh [Diet Therapy]
MH  - Heart Diseases/ep [Epidemiology]
MH  - Heart Diseases/px [Psychology]
MH  - Humans
MH  - North America
MH  - Qualitative Research
MH  - Self Care/mt [Methods]
MH  - *Self Care/px [Psychology]
MH  - Social Marginalization
MH  - Socioeconomic Factors
MH  - Stress, Psychological
MH  - Vulnerable Populations/eh [Ethnology]
MH  - *Vulnerable Populations/px [Psychology]
AB  - BACKGROUND: Diet modification is an important part of self-management for patients with diabetes and/or heart disease (including coronary artery disease, heart failure, and atrial fibrillation). Many health care providers and community-based programs advise lifestyle and diet modification as part of care for people with these conditions. This report synthesizes qualitative information on how patients respond differently to the challenges of diet modification. Qualitative and descriptive evidence can illuminate challenges that may affect the success and equitable impact of dietary modification interventions.
AB  - OBJECTIVES: To (a) examine the diet modification challenges faced by diabetes and/or heart disease patients; and (b) compare and contrast the challenges faced by patients who are members of vulnerable and nonvulnerable groups as they change their diet in response to clinical recommendations.
AB  - DATA SOURCES: This report synthesizes 65 primary qualitative studies on the topic of dietary modification challenges encountered by patients with diabetes and/or heart disease. Included papers were published between 2002 and 2012 and studied adult patients in North America, Europe, and Australia/New Zealand.
AB  - REVIEW METHODS: Qualitative meta-synthesis was used to integrate findings across primary research studies.
AB  - RESULTS: Analysis identified 5 types of challenges that are common to both vulnerable and nonvulnerable patients: self-discipline, knowledge, coping with everyday stress, negotiating with family members, and managing the social significance of food. Vulnerable patients may experience additional barriers, many of which can magnify or exacerbate those common challenges.
AB  - LIMITATIONS: While qualitative insights are robust and often enlightening for understanding experiences and planning services in other settings, they are not intended to be generalizable. The findings of the studies reviewed here--and of this synthesis--do not strictly generalize to the Ontario (or any specific) population. This evidence must be interpreted and applied carefully, in light of expertise and the experiences of the relevant community.
AB  - CONCLUSIONS: Diet modification is not simply a matter of knowing what to eat and making the rational choice to change dietary practices. Rather, diet and eating practices should be considered as part of the situated lives of patients, requiring an individualized approach that is responsive to the conditions in which each patient is attempting to make a change. Common challenges include self-discipline, knowledge, coping with everyday stress, negotiating with family members, and managing the social significance of food. An individualized approach is particularly important when working with patients who have vulnerabilities.
AB  - PLAIN LANGUAGE SUMMARY: Health care providers often encourage people with diabetes and/or heart disease to change their diet. They advise people with diabetes to eat less sugar, starch, and fat. They advise people with heart disease to eat less fat and salt. However, many patients find it difficult to change what they eat. This report examines the challenges people may face when making such changes. It also examines the special challenges faced by people who are vulnerable due to other factors, such as poverty, lack of education, and difficulty speaking English. Five themes were common to all people who make diet changes: self-discipline, knowledge, coping with stress, negotiating with family members, and managing the social aspect of food. Members of vulnerable groups also reported other challenges, such as affording fresh fruit and vegetables or understanding English instructions. This report may help health care providers work with patients more effectively to make diet changes.
ES  - 1915-7398
IL  - 1915-7398
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
LG  - English
EP  - 20130901
DP  - 2013
DC  - 20131114
YR  - 2013
ED  - 20140407
RD  - 20150422
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24228077

<236. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24485136
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Chandra SM
AU  - Chon TY
FA  - Chandra, Suparna M
FA  - Chon, Tony Y
IN  - Chandra,Suparna M. Resident in Internal Medicine, Mayo School of Graduate Medical Education, Rochester, MN. Electronic address: chandra.suparna@mayo.edu.
IN  - Chon,Tony Y. Advisor to resident and Consultant in General Internal Medicine, Mayo Clinic, Rochester, MN.
TI  - 86-year-old man with atrial fibrillation and dyspnea on exertion.
SO  - Mayo Clinic Proceedings. 89(2):254-8, 2014 Feb.
AS  - Mayo Clin Proc. 89(2):254-8, 2014 Feb.
NJ  - Mayo Clinic proceedings
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 0405543, lly
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - Aged, 80 and over
MH  - *Amyloidosis/di [Diagnosis]
MH  - Amyloidosis/pp [Physiopathology]
MH  - Amyloidosis/th [Therapy]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Cardiomyopathies/di [Diagnosis]
MH  - Cardiomyopathies/pp [Physiopathology]
MH  - Cardiomyopathies/th [Therapy]
MH  - Diagnosis, Differential
MH  - Diagnostic Imaging
MH  - Disease Progression
MH  - Dyspnea/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Physical Exertion
ES  - 1942-5546
IL  - 0025-6196
DI  - S0025-6196(13)00787-8
DO  - http://dx.doi.org/10.1016/j.mayocp.2013.05.029
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2014 Feb
DC  - 20140203
YR  - 2014
ED  - 20140403
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24485136

<237. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22999824
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Bang CN
AU  - Greve AM
AU  - Abdulla J
AU  - Kober L
AU  - Gislason GH
AU  - Wachtell K
FA  - Bang, Casper N
FA  - Greve, Anders M
FA  - Abdulla, Jawdat
FA  - Kober, Lars
FA  - Gislason, Gunnar H
FA  - Wachtell, Kristian
IN  - Bang,Casper N. Department of Cardiology, The Heart Center, Rigshospitalet, Copenhagen, Denmark. casperbang@hotmail.com
TI  - The preventive effect of statin therapy on new-onset and recurrent atrial fibrillation in patients not undergoing invasive cardiac interventions: a systematic review and meta-analysis. [Review]
SO  - International Journal of Cardiology. 167(3):624-30, 2013 Aug 10.
AS  - Int J Cardiol. 167(3):624-30, 2013 Aug 10.
NJ  - International journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - gqw, 8200291
SB  - Index Medicus
CP  - Netherlands
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - *Cardiac Surgical Procedures
MH  - Clinical Trials as Topic/mt [Methods]
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use]
MH  - Secondary Prevention
MH  - Treatment Outcome
KW  - AF;  Atrial fibrillation;  CABG;  CI;  Confidence interval;  Coronary artery bypass grafting;  ICD;  Implantable cardioverter-defibrillator;  Inflammation;  MI;  Meta-analysis;  Myocardial infarction;  Non-invasive;  PCI;  Percutaneous coronary intervention;  RCT;  RR;  Randomized controlled trial/trials;  Relative risk;  Statins
AB  - BACKGROUND: Previous meta-analyses suggest that pre-procedural use of statin therapy may reduce atrial fibrillation (AF) following invasive cardiac interventions (coronary artery by-pass grafting and percutaneous coronary intervention). However, the current evidence on the benefit of statins unrelated to invasive cardiac interventions has not been clarified systematically.
AB  - METHODS: Through a systematic literature search, trials examining the effect of statin therapy on AF were selected. Trials using statins before any percutaneous or surgical cardiac interventions were excluded.
AB  - RESULTS: The search identified 11 randomized and 16 observational eligible studies, totaling 106,640 patients receiving statin therapy and 129,305 serving as controls. Fourteen studies investigated the effect of statins on new-onset AF, 13 studies investigated the effect of statins on recurrent AF and one in both new-onset and recurrent AF. In the statin versus control group the mean age was 60.7 +/- 8.3 versus 68.6 +/- 6.2 years and females comprised 8.4% versus 10.3%. Statin therapy was associated with significant reduction of AF (Risk ratio (RR): 0.81 [95% confidence interval (CI): 0.80-0.83], p<0.001) combining all studies. Assessing exclusively randomized trials, statin therapy showed no significant risk reduction (RR: 0.97 [95%CI: 0.90-1.05], p=0.509), heterogeneity p>0.05. Assessing exclusively observational studies the risk reduction of new-onset AF was 12% (RR: 0.88 [95%CI: 0.85-0.91], p<0.001) and recurrent AF 15% (RR: 0.85 [95%CI: 0.80-0.90], p<0.001), heterogeneity p<0.001.
AB  - CONCLUSION: The hitherto published randomized clinical trials do not support a beneficial effect of statins on AF in patients not undergoing invasive cardiac interventions. This is in contrast to the results of observational and interventional studies.Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
ES  - 1874-1754
IL  - 0167-5273
DI  - S0167-5273(12)01085-6
DO  - http://dx.doi.org/10.1016/j.ijcard.2012.08.056
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
LG  - English
EP  - 20120919
DP  - 2013 Aug 10
DC  - 20130731
YR  - 2013
ED  - 20140402
RD  - 20141120
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22999824

<238. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23375217
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Brem E
AU  - Koyfman A
AU  - Foran M
FA  - Brem, Elizabeth
FA  - Koyfman, Alex
FA  - Foran, Mark
IN  - Brem,Elizabeth. Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
TI  - Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians. [Review]
SO  - Journal of Emergency Medicine. 45(1):143-9, 2013 Jul.
AS  - J Emerg Med. 45(1):143-9, 2013 Jul.
NJ  - The Journal of emergency medicine
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - ibo, 8412174
SB  - Index Medicus
CP  - United States
MH  - Anticoagulants/ae [Adverse Effects]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - Benzimidazoles/ae [Adverse Effects]
MH  - *Benzimidazoles/tu [Therapeutic Use]
MH  - Dabigatran
MH  - Drug Approval
MH  - Emergencies
MH  - *Hemorrhage/ci [Chemically Induced]
MH  - *Hemorrhage/th [Therapy]
MH  - Humans
MH  - Morpholines/ae [Adverse Effects]
MH  - *Morpholines/tu [Therapeutic Use]
MH  - Rivaroxaban
MH  - Stroke/et [Etiology]
MH  - Stroke/pc [Prevention & Control]
MH  - Thiophenes/ae [Adverse Effects]
MH  - *Thiophenes/tu [Therapeutic Use]
MH  - United States
MH  - United States Food and Drug Administration
MH  - Warfarin/tu [Therapeutic Use]
MH  - beta-Alanine/ae [Adverse Effects]
MH  - *beta-Alanine/aa [Analogs & Derivatives]
MH  - beta-Alanine/tu [Therapeutic Use]
AB  - BACKGROUND: Dabigatran and rivaroxaban are novel anticoagulants that have been approved for the prevention of thromboembolic events in atrial fibrillation. These medications are attractive to both patients and clinicians, as, unlike warfarin, they do not require laboratory monitoring or dietary restrictions. However, they carry bleeding risks similar to that of warfarin and are without a reliable reversal agent.
AB  - OBJECTIVES: The objectives of this article are to 1) summarize the pivotal trials leading to the U.S. Food and Drug Administration approvals of dabigatran (Pradaxa; Boehringer Ingelheim, Ridgefield, CT) and rivaroxaban (Xarelto; Janssen Pharmaceuticals, Inc., Titusville, NJ); 2) present the limited data available regarding the management of bleeding patients on these agents; and 3) provide suggestions to guide emergency providers given the limited data.
AB  - DISCUSSION: Dabigatran and rivaroxaban were approved based on large, non-inferiority trials comparing the new agents to warfarin with stroke or systemic embolism as the primary outcome. Traditional coagulation studies cannot be used to determine the degree of anti-coagulation produced by these agents. Fresh frozen plasma is unlikely to be effective in patients on these drugs who are acutely bleeding. Prothrombin complex concentrate can be considered in patients on rivaroxaban. Dabigatran is renally cleared, so dabigatran could be removed by hemodialysis. Theoretically, DDAVP (Sanofi-Aventis U.S. LLC, Bridgewater, NJ), aminocaproic acid, tranexamic acid, or recombinant activated factor VII could also be used in an attempt to control bleeding.
AB  - CONCLUSION: There is a need for assays for the degree of anticoagulation produced by drugs such as dabigatran and rivaroxaban. Additionally, studies are needed to evaluate reversal agents that could be effective in the setting of acute bleeding.Copyright © 2013 Elsevier Inc. All rights reserved.
RN  - 0 (Anticoagulants)
RN  - 0 (Benzimidazoles)
RN  - 0 (Morpholines)
RN  - 0 (Thiophenes)
RN  - 11P2JDE17B (beta-Alanine)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - I0VM4M70GC (Dabigatran)
IS  - 0736-4679
IL  - 0736-4679
DI  - S0736-4679(12)01470-9
DO  - http://dx.doi.org/10.1016/j.jemermed.2012.11.032
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20130130
DP  - 2013 Jul
DC  - 20130701
YR  - 2013
ED  - 20140402
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23375217

<239. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23084819
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Hirota S
AU  - Sadanaga T
AU  - Mitamura H
AU  - Fukuda K
AU  - Ogawa S
FA  - Hirota, Shinichi
FA  - Sadanaga, Tsuneaki
FA  - Mitamura, Hideo
FA  - Fukuda, Keiichi
FA  - Ogawa, Satoshi
TI  - B-type natriuretic peptide levels are decreased by reducing dietary salt intake in patients with permanent atrial fibrillation.
SO  - International Journal of Cardiology. 167(1):294-6, 2013 Jul 15.
AS  - Int J Cardiol. 167(1):294-6, 2013 Jul 15.
NJ  - International journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - gqw, 8200291
SB  - Index Medicus
CP  - Netherlands
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrial Fibrillation/bl [Blood]
MH  - *Atrial Fibrillation/dh [Diet Therapy]
MH  - Atrial Fibrillation/ur [Urine]
MH  - Biomarkers/bl [Blood]
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Natriuretic Peptide, Brain/bl [Blood]
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - *Sodium Chloride, Dietary/ad [Administration & Dosage]
MH  - Sodium Chloride, Dietary/ur [Urine]
RN  - 0 (Biomarkers)
RN  - 0 (Sodium Chloride, Dietary)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
ES  - 1874-1754
IL  - 0167-5273
DI  - S0167-5273(12)01322-8
DO  - http://dx.doi.org/10.1016/j.ijcard.2012.09.201
PT  - Letter
LG  - English
EP  - 20121017
DP  - 2013 Jul 15
DC  - 20130604
YR  - 2013
ED  - 20140303
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23084819

<240. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24309587
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lackland DT
AU  - Roccella EJ
AU  - Deutsch AF
AU  - Fornage M
AU  - George MG
AU  - Howard G
AU  - Kissela BM
AU  - Kittner SJ
AU  - Lichtman JH
AU  - Lisabeth LD
AU  - Schwamm LH
AU  - Smith EE
AU  - Towfighi A
AU  - American Heart Association Stroke Council
AU  - Council on Cardiovascular and Stroke Nursing
AU  - Council on Quality of Care and Outcomes Research
AU  - Council on Functional Genomics and Translational Biology
FA  - Lackland, Daniel T
FA  - Roccella, Edward J
FA  - Deutsch, Anne F
FA  - Fornage, Myriam
FA  - George, Mary G
FA  - Howard, George
FA  - Kissela, Brett M
FA  - Kittner, Steven J
FA  - Lichtman, Judith H
FA  - Lisabeth, Lynda D
FA  - Schwamm, Lee H
FA  - Smith, Eric E
FA  - Towfighi, Amytis
FA  - American Heart Association Stroke Council
FA  - Council on Cardiovascular and Stroke Nursing
FA  - Council on Quality of Care and Outcomes Research
FA  - Council on Functional Genomics and Translational Biology
TI  - Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. [Review]
SO  - Stroke. 45(1):315-53, 2014 Jan.
AS  - Stroke. 45(1):315-53, 2014 Jan.
NJ  - Stroke; a journal of cerebral circulation
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - v2j, 0235266
SB  - Index Medicus
CP  - United States
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Air Pollution/ae [Adverse Effects]
MH  - *American Heart Association
MH  - Aspirin/tu [Therapeutic Use]
MH  - *Association
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/mo [Mortality]
MH  - Blood Pressure/ph [Physiology]
MH  - Clinical Trials as Topic
MH  - Diabetes Mellitus/mo [Mortality]
MH  - Exercise
MH  - Female
MH  - Heart Diseases/mo [Mortality]
MH  - Humans
MH  - Hyperlipidemias/co [Complications]
MH  - Hyperlipidemias/mo [Mortality]
MH  - Hypertension/co [Complications]
MH  - Hypertension/th [Therapy]
MH  - Incidence
MH  - International Classification of Diseases
MH  - Male
MH  - Middle Aged
MH  - Obesity/ep [Epidemiology]
MH  - Observational Studies as Topic
MH  - Platelet Aggregation Inhibitors/tu [Therapeutic Use]
MH  - Population
MH  - Prevalence
MH  - Secondary Prevention
MH  - Sex Factors
MH  - Smoking/ep [Epidemiology]
MH  - *Stroke/mo [Mortality]
MH  - Stroke/th [Therapy]
MH  - Thrombolytic Therapy/sn [Statistics & Numerical Data]
MH  - Thrombolytic Therapy/td [Trends]
MH  - United States/ep [Epidemiology]
MH  - Young Adult
KW  - AHA Scientific Statements;  diabetes mellitus;  hyperlipidemias;  hypertension;  risk factors;  stroke
AB  - BACKGROUND AND PURPOSE: Stroke mortality has been declining since the early 20th century. The reasons for this are not completely understood, although the decline is welcome. As a result of recent striking and more accelerated decreases in stroke mortality, stroke has fallen from the third to the fourth leading cause of death in the United States. This has prompted a detailed assessment of the factors associated with the change in stroke risk and mortality. This statement considers the evidence for factors that have contributed to the decline and how they can be used in the design of future interventions for this major public health burden.
AB  - METHODS: Writing group members were nominated by the committee chair and co-chair on the basis of their previous work in relevant topic areas and were approved by the American Heart Association Stroke Council's Scientific Statements Oversight Committee and the American Heart Association Manuscript Oversight Committee. The writers used systematic literature reviews, references to published clinical and epidemiological studies, morbidity and mortality reports, clinical and public health guidelines, authoritative statements, personal files, and expert opinion to summarize evidence and to indicate gaps in current knowledge. All members of the writing group had the opportunity to comment on this document and approved the final version. The document underwent extensive American Heart Association internal peer review, Stroke Council leadership review, and Scientific Statements Oversight Committee review before consideration and approval by the American Heart Association Science Advisory and Coordinating Committee.
AB  - RESULTS: The decline in stroke mortality over the past decades represents a major improvement in population health and is observed for both sexes and for all racial/ethnic and age groups. In addition to the overall impact on fewer lives lost to stroke, the major decline in stroke mortality seen among people <65 years of age represents a reduction in years of potential life lost. The decline in mortality results from reduced incidence of stroke and lower case-fatality rates. These significant improvements in stroke outcomes are concurrent with cardiovascular risk factor control interventions. Although it is difficult to calculate specific attributable risk estimates, efforts in hypertension control initiated in the 1970s appear to have had the most substantial influence on the accelerated decline in stroke mortality. Although implemented later, diabetes mellitus and dyslipidemia control and smoking cessation programs, particularly in combination with treatment of hypertension, also appear to have contributed to the decline in stroke mortality. The potential effects of telemedicine and stroke systems of care appear to be strong but have not been in place long enough to indicate their influence on the decline. Other factors had probable effects, but additional studies are needed to determine their contributions.
AB  - CONCLUSIONS: The decline in stroke mortality is real and represents a major public health and clinical medicine success story. The repositioning of stroke from third to fourth leading cause of death is the result of true mortality decline and not an increase in mortality from chronic lung disease, which is now the third leading cause of death in the United States. There is strong evidence that the decline can be attributed to a combination of interventions and programs based on scientific findings and implemented with the purpose of reducing stroke risks, the most likely being improved control of hypertension. Thus, research studies and the application of their findings in developing intervention programs have improved the health of the population. The continued application of aggressive evidence-based public health programs and clinical interventions is expected to result in further declines in stroke mortality.
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
ES  - 1524-4628
IL  - 0039-2499
DO  - http://dx.doi.org/10.1161/01.str.0000437068.30550.cf
PT  - Journal Article
PT  - Review
NO  - R01 HL093029 (United States NHLBI NIH HHS)
LG  - English
EP  - 20131205
DP  - 2014 Jan
DC  - 20131224
YR  - 2014
ED  - 20140220
RD  - 20160113
UP  - 20160115
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24309587

<241. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23714090
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Martinez-Mateo V
AU  - Plaza J
AU  - Paule A
FA  - Martinez-Mateo, Virgilio
FA  - Plaza, Jose
FA  - Paule, Antonio
IN  - Martinez-Mateo,Virgilio. Hospital La Mancha Centro, Alcazar de San Juan, Ciudad Real, Spain. virgiliomed@me.com
TI  - Exercise-induced atrial fibrillation by myocardial ischemia in a young male: a rare case report.
SO  - Annals of Noninvasive Electrocardiology. 18(3):297-8, 2013 May.
AS  - Ann Noninvasive Electrocardiol. 18(3):297-8, 2013 May.
NJ  - Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - dzb, 9607443
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - *Atrial Fibrillation/et [Etiology]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/th [Therapy]
MH  - Drug-Eluting Stents
MH  - *Electrocardiography
MH  - Exercise Test
MH  - Humans
MH  - Male
MH  - *Myocardial Ischemia/co [Complications]
MH  - *Myocardial Ischemia/pp [Physiopathology]
MH  - Myocardial Ischemia/th [Therapy]
ES  - 1542-474X
IL  - 1082-720X
DO  - http://dx.doi.org/10.1111/anec.12017
PT  - Case Reports
PT  - Journal Article
LG  - English
EP  - 20121122
DP  - 2013 May
DC  - 20130529
YR  - 2013
ED  - 20140220
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23714090

<242. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24532967
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Choi JC
AU  - Dibonaventura MD
AU  - Kopenhafer L
AU  - Nelson WW
FA  - Choi, Jiyoon C
FA  - Dibonaventura, Marco D
FA  - Kopenhafer, Lewis
FA  - Nelson, Winnie W
IN  - Choi,Jiyoon C. LifeScan, Inc, West Chester, PA.
IN  - Dibonaventura,Marco D. Health Sciences Practice, Kantar Health, New York, NY.
IN  - Kopenhafer,Lewis. Health Sciences Practice, Kantar Health, New York, NY.
IN  - Nelson,Winnie W. Janssen Scientific Affairs LLC, Raritan, NJ, USA.
TI  - Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation.
SO  - Patient preference & adherence. 8:167-77, 2014.
AS  - Patient Prefer Adherence. 8:167-77, 2014.
NJ  - Patient preference and adherence
PI  - Journal available in: Electronic-eCollection
PI  - Citation processed from: Print
JC  - 101475748
OI  - Source: NLM. PMC3923612
CP  - New Zealand
KW  - atrial fibrillation;  dabigatran;  warfarin
AB  - BACKGROUND: Oral dabigatran was recently approved as an alternative to warfarin for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Unlike warfarin, dabigatran has a fixed dosage and few drug interactions, and does not require anticoagulation monitoring or dietary restrictions.
AB  - METHODS: This study aimed to describe and compare characteristics of patients with atrial fibrillation who used dabigatran or only warfarin. Patients with a self-reported diagnosis of atrial fibrillation aged >18 years who were receiving (or had received) warfarin or dabigatran completed an online survey. Differences in characteristics of dabigatran and warfarin users were tested using chi-squared tests and analysis of variance for categorical and continuous variables, respectively.
AB  - RESULTS: Overall, 364 patients were surveyed (204 warfarin users, 160 dabigatran users). The mean age was 65.1 years, and 68.7% were male. Dabigatran users were more likely than warfarin users to be female (36.9% versus 27.0%) and to have experienced adverse events, including gastrointestinal bleeding, in the 3 months before the survey (21.9% versus 6.9%; P<0.05). Both groups reported high medication adherence (dabigatran users 0.65 versus warfarin users 0.63 missed doses/month). Dabigatran users were more likely than warfarin users to discuss treatment options with their physician before beginning therapy (36.9% versus 24.5%; P<0.05) and less likely to switch anticoagulant medication (10.7% versus 31.9%; P<0.05). Although dabigatran users were more likely to experience adverse events, they reported greater satisfaction with anticoagulation treatment than warfarin users.
AB  - CONCLUSION: The efficacy and convenience reported by dabigatran users resulted in greater treatment satisfaction among dabigatran users, even though adverse events decreased it. Treatment strategies that minimize adverse events may improve treatment satisfaction and adherence among patients with atrial fibrillation.
ES  - 1177-889X
IL  - 1177-889X
DO  - http://dx.doi.org/10.2147/PPA.S56187
PT  - Journal Article
LG  - English
EP  - 20140207
DP  - 2014
DC  - 20140217
YR  - 2014
ED  - 20140217
RD  - 20140219
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=24532967

<243. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22891819
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Jaremo P
AU  - Eriksson M
AU  - Lindahl TL
AU  - Nilsson S
AU  - Milovanovic M
FA  - Jaremo, P
FA  - Eriksson, M
FA  - Lindahl, T L
FA  - Nilsson, S
FA  - Milovanovic, M
IN  - Jaremo,P. Department of Internal Medicine, The Vrinnevi Hospital, Norrkoping, Sweden. petter.jaremo@telia.com
TI  - Platelets and acute cerebral infarction.
SO  - Platelets. 24(5):407-11, 2013.
AS  - Platelets. 24(5):407-11, 2013.
NJ  - Platelets
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - dsj, 9208117
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/me [Metabolism]
MH  - *Blood Platelets/me [Metabolism]
MH  - *Cerebral Infarction/et [Etiology]
MH  - Female
MH  - Fibrinogen/me [Metabolism]
MH  - Humans
MH  - Inflammation/me [Metabolism]
MH  - Leukocyte Count
MH  - Male
MH  - Middle Aged
MH  - Neutrophils/cy [Cytology]
MH  - Neutrophils/me [Metabolism]
MH  - P-Selectin/me [Metabolism]
MH  - Platelet Activation/ph [Physiology]
MH  - Platelet Count
MH  - Prospective Studies
MH  - Protein Binding
MH  - Stroke/me [Metabolism]
AB  - Stroke is worldwide a leading cause of death and disability. Its etiology is regarded as heterogeneous. Platelets are implicated in its pathophysiology, but our understanding of their specific role is incomplete. Only sparse and conflicting information exists about platelet reactivity and activity in acute stroke. Some scientists take the view that platelets activate in conjunction with acute cerebral infarctions. Others put forward evidence corroborating the contrary notion. Increased soluble P-selectin as a sign of platelet and/or endothelial activity seems to be a feature of the disease. The latter point of view is opposed by other researchers. Due to these conflicting opinions, this study is devoted to platelet characteristics in acute cerebral infarctions. We studied subjects (n=72; age 74+/-10(SD) years; 31 females) having acute stroke. As controls served atrial fibrillation (AF) patients (n=58; age 69+/-7(SD) years; 12 females) subject to electrical cardioversion, a flow cytometer was put to use for measuring platelet reactivity and activity. After agonist provocation, both platelet bound P-selectin and fibrinogen were employed as estimates of platelet reactivity. Dilutions of a thrombin-receptor-activating peptide (TRAP-6) (74 and 57micro mol/l) (P-selectin and fibrinogen) and ADP (8.5 and 1.7micro mol/l) (fibrinogen only) were put to use as platelet agonists. Membrane-bound P-selectin without agonist stimulation served as a measure of in vivo platelet activation. Soluble P-selectin, as determined from a commercial ELISA, was used to assess platelet and/or endothelial activity. In acute stroke neither platelet-bound P-selectin nor fibrinogen after stimulation, i.e. reactivity, differed from AF controls. In contrast, lower platelet activity as judged from surface attached and circulating P-selectin without agonist stimulation proved to be a feature of cerebral infarctions. The p-values were p<0.001 and p<0.01, respectively. It is concluded that acute stroke is not associated with platelet reactivity platelets circulate less activated during the disease. It is evident that the mechanisms reflecting platelet reactivity and activity being investigated in this study play minor roles in stroke pathophysiology. New powerful platelet inhibitory drugs are currently introduced. To avoid major bleeding studies on platelet, behavior in acute stroke are necessary before including these medications in stroke treatment protocols.
RN  - 0 (P-Selectin)
RN  - 9001-32-5 (Fibrinogen)
ES  - 1369-1635
IL  - 0953-7104
DO  - http://dx.doi.org/10.3109/09537104.2012.712168
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20120814
DP  - 2013
DC  - 20130701
YR  - 2013
ED  - 20140130
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22891819

<244. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23582310
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mascitelli L
AU  - Goldstein MR
FA  - Mascitelli, L
FA  - Goldstein, M R
TI  - Mediterranean diet, lower iron stores and atrial fibrillation.
CM  - Comment on: Nutr Metab Cardiovasc Dis. 2013 Feb;23(2):115-21; PMID: 21798731
SO  - Nutrition Metabolism & Cardiovascular Diseases. 23(6):e28-9, 2013 Jun.
AS  - Nutr Metab Cardiovasc Dis. 23(6):e28-9, 2013 Jun.
NJ  - Nutrition, metabolism, and cardiovascular diseases : NMCD
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9111474, DGW
SB  - Index Medicus
CP  - Netherlands
MH  - *Antioxidants/ad [Administration & Dosage]
MH  - *Atrial Fibrillation/dh [Diet Therapy]
MH  - *Diet, Mediterranean
MH  - Female
MH  - Humans
MH  - Male
MH  - *Patient Compliance
RN  - 0 (Antioxidants)
ES  - 1590-3729
IL  - 0939-4753
DI  - S0939-4753(13)00052-5
DO  - http://dx.doi.org/10.1016/j.numecd.2013.02.005
PT  - Comment
PT  - Letter
LG  - English
EP  - 20130410
DP  - 2013 Jun
DC  - 20130614
YR  - 2013
ED  - 20140130
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23582310

<245. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23762337
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Williams PT
AU  - Franklin BA
FA  - Williams, Paul T
FA  - Franklin, Barry A
IN  - Williams,Paul T. Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California, United States of America. ptwilliams@lbl.gov
TI  - Reduced incidence of cardiac arrhythmias in walkers and runners.
SO  - PLoS ONE [Electronic Resource]. 8(6):e65302, 2013.
AS  - PLoS ONE. 8(6):e65302, 2013.
NJ  - PloS one
PI  - Journal available in: Electronic-Print
PI  - Citation processed from: Internet
JC  - 101285081
OI  - Source: NLM. PMC3676466
SB  - Index Medicus
CP  - United States
MH  - Arrhythmias, Cardiac/di [Diagnosis]
MH  - *Arrhythmias, Cardiac/ep [Epidemiology]
MH  - *Arrhythmias, Cardiac/pp [Physiopathology]
MH  - Confidence Intervals
MH  - Energy Metabolism
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Risk Reduction Behavior
MH  - *Running
MH  - Self Report
MH  - United States/ep [Epidemiology]
MH  - *Walking
AB  - PURPOSE: Walking is purported to reduce the risk of atrial fibrillation by 48%, whereas jogging is purported to increase its risk by 53%, suggesting a strong anti-arrhythmic benefit of walking over running. The purpose of these analyses is to compare incident self-reported physician-diagnosed cardiac arrhythmia to baseline energy expenditure (metabolic equivalent hours per day, METhr/d) from walking, running and other exercise.
AB  - METHODS: Proportional hazards analysis of 14,734 walkers and 32,073 runners.
AB  - RESULTS: There were 1,060 incident cardiac arrhythmias (412 walkers, 648 runners) during 6.2 years of follow-up. The risk for incident cardiac arrhythmias declined 4.4% per baseline METhr/d walked by the walkers, or running in the runners (P = 0.0001). Specifically, the risk declined 14.2% (hazard ratio: 0.858) for 1.8 to 3.6 METhr/d, 26.5% for 3.6 to 5.4 METhr/d, and 31.7% for >5.4 METhr/d, relative to <1.8 METhr/d. The risk reduction per METhr/d was significantly greater for walking than running (P<0.01), but only because walkers were at 34% greater risk than runners who fell below contemporary physical activity guideline recommendations; otherwise the walkers and runners had similar risks for cardiac arrhythmias. Cardiac arrhythmias were unrelated to walking and running intensity, and unrelated to marathon participation and performance.
AB  - CONCLUSIONS: The risk for cardiac arrhythmias was similar in walkers and runners who expended comparable METhr/d during structured exercise. We found no significant risk increase for self-reported cardiac arrhythmias associated with running distance, exercise intensity, or marathon participation. Rhythm abnormalities were based on self-report, precluding definitive categorization of the nature of the rhythm disturbance. However, even if the runners' arrhythmias include sinus bradycardia due to running itself, there was no increase in arrhythmias with greater running distance.
ES  - 1932-6203
IL  - 1932-6203
DO  - http://dx.doi.org/10.1371/journal.pone.0065302
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
NO  - HL094717 (United States NHLBI NIH HHS)
NO  - R01 HL094717 (United States NHLBI NIH HHS)
LG  - English
EP  - 20130607
DP  - 2013
DC  - 20130613
YR  - 2013
ED  - 20140122
RD  - 20150423
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23762337

<246. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23397554
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Hylek EM
FA  - Hylek, Elaine M
IN  - Hylek,Elaine M. Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA. ehylek@bu.edu
TI  - Anticoagulation therapy for atrial fibrillation. [Review]
SO  - Seminars in Thrombosis & Hemostasis. 39(2):147-52, 2013 Mar.
AS  - Semin Thromb Hemost. 39(2):147-52, 2013 Mar.
NJ  - Seminars in thrombosis and hemostasis
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - uks, 0431155
SB  - Index Medicus
CP  - United States
MH  - Anticoagulants/ae [Adverse Effects]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/bl [Blood]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Hemorrhage/dt [Drug Therapy]
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Stroke/dt [Drug Therapy]
MH  - Stroke/pc [Prevention & Control]
MH  - Warfarin/ae [Adverse Effects]
MH  - Warfarin/tu [Therapeutic Use]
AB  - Atrial fibrillation (AF) is the most common significant cardiac rhythm disorder, and its prevalence is increasing worldwide. Atrial fibrillation confers a fivefold increased risk of stroke, and these strokes are associated with significant mortality and disability. The vitamin K antagonist, warfarin, has been the mainstay of anticoagulant therapy for patients with AF, reducing the risk of stroke by 65%. Despite its efficacy, warfarin remains underused in clinical practice because of its variable dose response, diet and medication interactions, and need for frequent monitoring. Stroke prevention in AF has entered an exciting therapeutic era with new classes of targeted anticoagulants that avoid the many pitfalls of the vitamin K antagonists. Dabigatran, an oral thrombin inhibitor, and the factor Xa inhibitors, rivaroxaban and apixaban, have demonstrated efficacy for stroke prevention and a reduced risk of intracranial hemorrhage relative to warfarin. Translating the efficacy of clinical trials into effective use of these novel agents in clinical practice will require an understanding of their pharmacokinetic profiles, dose selection, and management in select clinical situations.Copyright Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
ES  - 1098-9064
IL  - 0094-6176
DO  - http://dx.doi.org/10.1055/s-0033-1334812
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Review
NO  - R01NS070307 (United States NINDS NIH HHS)
LG  - English
EP  - 20130208
DP  - 2013 Mar
DC  - 20130221
YR  - 2013
ED  - 20140122
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23397554

<247. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24267810
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Reed JL
AU  - Mark AE
AU  - Reid RD
AU  - Pipe AL
FA  - Reed, Jennifer L
FA  - Mark, Amy E
FA  - Reid, Robert D
FA  - Pipe, Andrew L
IN  - Reed,Jennifer L. Minto Prevention and Rehabilitation Centre, University of Ottawa Heart Institute, Ottawa, Ontario, Canada. Electronic address: jreed@ottawaheart.ca.
TI  - The effects of chronic exercise training in individuals with permanent atrial fibrillation: a systematic review. [Review]
SO  - Canadian Journal of Cardiology. 29(12):1721-8, 2013 Dec.
AS  - Can J Cardiol. 29(12):1721-8, 2013 Dec.
NJ  - The Canadian journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - chp, 8510280
SB  - Index Medicus
CP  - England
MH  - Adult
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Chronic Disease
MH  - Evidence-Based Medicine
MH  - *Exercise/ph [Physiology]
MH  - Exercise Tolerance/ph [Physiology]
MH  - Humans
MH  - Randomized Controlled Trials as Topic
AB  - BACKGROUND: Atrial fibrillation, the most common sustained cardiac arrhythmia, is associated with significant morbidity and mortality. Chronic exercise training is a recognized form of treatment for those with many forms of heart disease. There might also be a role for exercise in the management of permanent atrial fibrillation; few studies have explored the effects of chronic exercise training in persons with this condition. The purpose of this study was to systematically evaluate and summarize the evidence surrounding the effects of chronic exercise training in persons with permanent atrial fibrillation.
AB  - METHODS: A systematic and comprehensive literature review was undertaken of all English language literature. A total of 6 studies, 3 randomized controlled trials with a total of 118 participants, and 3 observational studies with a total of 93 participants, were identified.
AB  - RESULTS: The literature suggests that short-term chronic exercise training of low, moderate, or vigorous intensity in adults with permanent atrial fibrillation significantly improved rate control, functional capacity, muscular strength and power, activities of daily living, and quality of life. The effect of short-term chronic exercise training on aerobic capacity in adults with permanent atrial fibrillation is conflicting.
AB  - CONCLUSIONS: Chronic exercise training appears to play a promising role in the management of permanent atrial fibrillation. Future studies examining the effect of various forms of exercise training interventions in improving clinical outcomes and exercise tolerance in those with permanent atrial fibrillation are needed.Copyright © 2013 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
ES  - 1916-7075
IL  - 0828-282X
DI  - S0828-282X(13)01468-2
DO  - http://dx.doi.org/10.1016/j.cjca.2013.09.020
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2013 Dec
DC  - 20131125
YR  - 2013
ED  - 20140121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24267810

<248. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23075089
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ginde S
AU  - Bartz PJ
AU  - Hill GD
AU  - Danduran MJ
AU  - Biller J
AU  - Sowinski J
AU  - Tweddell JS
AU  - Earing MG
FA  - Ginde, Salil
FA  - Bartz, Peter J
FA  - Hill, Garick D
FA  - Danduran, Michael J
FA  - Biller, Julie
FA  - Sowinski, Jane
FA  - Tweddell, James S
FA  - Earing, Michael G
IN  - Ginde,Salil. Division of Cardiology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226, USA. sginde@chw.org
TI  - Restrictive lung disease is an independent predictor of exercise intolerance in the adult with congenital heart disease.
SO  - Congenital Heart Disease. 8(3):246-54, 2013 May-Jun.
AS  - Congenit. heart dis.. 8(3):246-54, 2013 May-Jun.
NJ  - Congenital heart disease
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101256510
SB  - Index Medicus
CP  - United States
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Exercise Test
MH  - *Exercise Tolerance
MH  - Female
MH  - Heart Defects, Congenital/co [Complications]
MH  - Heart Defects, Congenital/di [Diagnosis]
MH  - Heart Defects, Congenital/pp [Physiopathology]
MH  - *Heart Defects, Congenital/su [Surgery]
MH  - Humans
MH  - Logistic Models
MH  - *Lung/pp [Physiopathology]
MH  - *Lung Diseases/co [Complications]
MH  - Lung Diseases/di [Diagnosis]
MH  - Lung Diseases/pp [Physiopathology]
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Odds Ratio
MH  - Predictive Value of Tests
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Spirometry
MH  - Young Adult
AB  - BACKGROUND/OBJECTIVES: Following repair of congenital heart disease (CHD), adult patients are at risk for reduced exercise capacity. Restrictive lung disease (RLD) may contribute to reduced exercise capacity in this population. The aim of this study was to determine the prevalence of RLD and its impact on exercise tolerance in the adult with CHD.
AB  - METHODS: One hundred consecutive adult patients with CHD, who underwent routine cardiopulmonary exercise testing with spirometry, were evaluated. Clinical data were obtained by retrospective chart review.
AB  - RESULTS: Patients from 10 major diagnostic groups were identified. The median age for the cohort was 31 years (range 18-63) and included 43 males and 57 females. Most patients, 79%, had at least one previous surgical procedure. Based on spirometry and flow/volume loops, 50 patients were classified as normal pulmonary function, 44 patients had patterns suggestive of RLD, 4 suggestive of mixed (obstructive and restrictive), and 2 indeterminate. Risk factors associated with RLD include history of multiple thoracotomies (odds ratio = 9.01, P =.05) and history of atrial arrhythmias (odd ratio = 4.25, P =.05). Overall, 56% of the patients had abnormal exercise capacity. Spirometry suggestive of RLD was a significant risk factor for decreased exercise capacity (odds ratio = 3.65, P =.03). Patients with spirometry suggesting RLD also had lower exercise duration (P =.004) and a higher New York Heart Association Functional Class (P =.02). History of previous surgery and decreased heart rate reserve were also significant risk factors for decreased exercise capacity.
AB  - CONCLUSION: Abnormal spirometry suggestive of RLD is common in the adult with CHD and is a significant risk factor for decreased exercise tolerance in this population. Further studies are needed to evaluate the relationship between RLD and exercise intolerance and its relationship to mortality in the adult with CHD.Copyright © 2012 Wiley Periodicals, Inc.
ES  - 1747-0803
IL  - 1747-079X
DO  - http://dx.doi.org/10.1111/chd.12010
PT  - Journal Article
NO  - UL1 TR000055 (United States NCATS NIH HHS)
LG  - English
EP  - 20121018
DP  - 2013 May-Jun
DC  - 20130604
YR  - 2013
ED  - 20140109
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23075089

<249. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23075089
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ginde S
AU  - Bartz PJ
AU  - Hill GD
AU  - Danduran MJ
AU  - Biller J
AU  - Sowinski J
AU  - Tweddell JS
AU  - Earing MG
FA  - Ginde, Salil
FA  - Bartz, Peter J
FA  - Hill, Garick D
FA  - Danduran, Michael J
FA  - Biller, Julie
FA  - Sowinski, Jane
FA  - Tweddell, James S
FA  - Earing, Michael G
IN  - Ginde,Salil. Division of Cardiology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226, USA. sginde@chw.org
TI  - Restrictive lung disease is an independent predictor of exercise intolerance in the adult with congenital heart disease.
SO  - Congenital Heart Disease. 8(3):246-54, 2013 May-Jun.
AS  - Congenit. heart dis.. 8(3):246-54, 2013 May-Jun.
NJ  - Congenital heart disease
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101256510
OI  - Source: NLM. NIHMS767728
OI  - Source: NLM. PMC4832600
SB  - Index Medicus
CP  - United States
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Exercise Test
MH  - *Exercise Tolerance
MH  - Female
MH  - Heart Defects, Congenital/co [Complications]
MH  - Heart Defects, Congenital/di [Diagnosis]
MH  - Heart Defects, Congenital/pp [Physiopathology]
MH  - *Heart Defects, Congenital/su [Surgery]
MH  - Humans
MH  - Logistic Models
MH  - *Lung/pp [Physiopathology]
MH  - *Lung Diseases/co [Complications]
MH  - Lung Diseases/di [Diagnosis]
MH  - Lung Diseases/pp [Physiopathology]
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Odds Ratio
MH  - Predictive Value of Tests
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Spirometry
MH  - Young Adult
AB  - BACKGROUND/OBJECTIVES: Following repair of congenital heart disease (CHD), adult patients are at risk for reduced exercise capacity. Restrictive lung disease (RLD) may contribute to reduced exercise capacity in this population. The aim of this study was to determine the prevalence of RLD and its impact on exercise tolerance in the adult with CHD.
AB  - METHODS: One hundred consecutive adult patients with CHD, who underwent routine cardiopulmonary exercise testing with spirometry, were evaluated. Clinical data were obtained by retrospective chart review.
AB  - RESULTS: Patients from 10 major diagnostic groups were identified. The median age for the cohort was 31 years (range 18-63) and included 43 males and 57 females. Most patients, 79%, had at least one previous surgical procedure. Based on spirometry and flow/volume loops, 50 patients were classified as normal pulmonary function, 44 patients had patterns suggestive of RLD, 4 suggestive of mixed (obstructive and restrictive), and 2 indeterminate. Risk factors associated with RLD include history of multiple thoracotomies (odds ratio = 9.01, P =.05) and history of atrial arrhythmias (odd ratio = 4.25, P =.05). Overall, 56% of the patients had abnormal exercise capacity. Spirometry suggestive of RLD was a significant risk factor for decreased exercise capacity (odds ratio = 3.65, P =.03). Patients with spirometry suggesting RLD also had lower exercise duration (P =.004) and a higher New York Heart Association Functional Class (P =.02). History of previous surgery and decreased heart rate reserve were also significant risk factors for decreased exercise capacity.
AB  - CONCLUSION: Abnormal spirometry suggestive of RLD is common in the adult with CHD and is a significant risk factor for decreased exercise tolerance in this population. Further studies are needed to evaluate the relationship between RLD and exercise intolerance and its relationship to mortality in the adult with CHD.Copyright © 2012 Wiley Periodicals, Inc.
ES  - 1747-0803
IL  - 1747-079X
DO  - http://dx.doi.org/10.1111/chd.12010
PT  - Journal Article
NO  - UL1 TR000055 (United States NCATS NIH HHS)
LG  - English
EP  - 20121018
DP  - 2013 May-Jun
DC  - 20130604
YR  - 2013
ED  - 20140109
RD  - 20160416
UP  - 20160418
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=23075089

<250. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24064226
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Marshall T
FA  - Marshall, Tom
TI  - Physical activity and atrial fibrillation.
CM  - Comment on: Heart. 2013 Dec;99(23):1755-60; PMID: 23749790
SO  - Heart. 99(23):1713, 2013 Dec.
AS  - Heart. 99(23):1713, 2013 Dec.
NJ  - Heart (British Cardiac Society)
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9602087
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - *Atrial Fibrillation/et [Etiology]
MH  - *Exercise/ph [Physiology]
MH  - Female
MH  - Humans
MH  - Male
ES  - 1468-201X
IL  - 1355-6037
DO  - http://dx.doi.org/10.1136/heartjnl-2013-304541
PT  - Comment
PT  - Editorial
LG  - English
EP  - 20130923
DP  - 2013 Dec
DC  - 20131106
YR  - 2013
ED  - 20131224
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24064226

<251. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23749790
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Thelle DS
AU  - Selmer R
AU  - Gjesdal K
AU  - Sakshaug S
AU  - Jugessur A
AU  - Graff-Iversen S
AU  - Tverdal A
AU  - Nystad W
FA  - Thelle, Dag S
FA  - Selmer, Randi
FA  - Gjesdal, Knut
FA  - Sakshaug, Solveig
FA  - Jugessur, Astanand
FA  - Graff-Iversen, Sidsel
FA  - Tverdal, Aage
FA  - Nystad, Wenche
IN  - Thelle,Dag S. Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, , Oslo, Norway.
TI  - Resting heart rate and physical activity as risk factors for lone atrial fibrillation: a prospective study of 309,540 men and women.
CM  - Comment in: Heart. 2013 Dec;99(23):1713; PMID: 24064226
SO  - Heart. 99(23):1755-60, 2013 Dec.
AS  - Heart. 99(23):1755-60, 2013 Dec.
NJ  - Heart (British Cardiac Society)
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9602087
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - Adult
MH  - Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Early Diagnosis
MH  - *Exercise/ph [Physiology]
MH  - Female
MH  - Flecainide/tu [Therapeutic Use]
MH  - Heart Rate/de [Drug Effects]
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Risk Factors
MH  - Sotalol/tu [Therapeutic Use]
AB  - OBJECTIVE: To study the impact of resting heart rate and leisure time physical activity at middle age on long term risk of drug treated lone atrial fibrillation (AF).
AB  - DESIGN: Longitudinal cohort study of 309 540 Norwegian men and women aged 40-45 years examined during 1985-1999 followed from 2005 through 2009.
AB  - SETTING: Data from a national health screening programme were linked to the Norwegian Prescription Database (NorPD).
AB  - PATIENTS: The cohort comprised 162 078 women and 147 462 men; 575 (0.4%) men and 288 women (0.2%) received flecainide and 568 men and 256 women sotalol and were defined as patients with AF.
AB  - INTERVENTIONS: No interventions.
AB  - MAIN OUTCOME MEASURES: The outcome was lone fibrillation defined by having at least one prescription of flecainide or sotalol registered in NorPD between 2005 and 2009. Cox proportional hazard regression models were used to assess time to first prescription.
AB  - RESULTS: The risk for being prescribed these drugs increased with decreasing baseline resting heart. Adjusted hazard ratio (HR) per 10 beats/min decrease in resting heart rate for flecainide prescription was 1.26 in men (95% CI 1.17 to 1.35) and 1.15 (95% CI 1.05 to 1.27) in women. Similar effects were seen for sotalol in men, but not in women. Men who reported intensive physical activity were more often prescribed flecainide than those in the sedentary group (adjusted HR=3.14, 95% CI 2.17 to 4.54).
AB  - CONCLUSIONS: This population based study supports the hypothesis that the risk of drug treated lone AF increases with declining resting heart rate in both sexes, and with increasing levels of self-reported physical activity in men.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - A6D97U294I (Sotalol)
RN  - K94FTS1806 (Flecainide)
ES  - 1468-201X
IL  - 1355-6037
DO  - http://dx.doi.org/10.1136/heartjnl-2013-303825
PT  - Journal Article
LG  - English
EP  - 20130608
DP  - 2013 Dec
DC  - 20131106
YR  - 2013
ED  - 20131224
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23749790

<252. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23652453
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Iseki K
FA  - Iseki, Kunitoshi
IN  - Iseki,Kunitoshi. Dialysis Unit, University Hospital of the Ryukyus, Okinawa, Japan. chihokun@med.u-ryukyu.ac.jp
TI  - Stroke feature and management in dialysis patients. [Review]
SO  - Contributions to Nephrology. 179:100-9, 2013.
AS  - Contrib Nephrol. 179:100-9, 2013.
NJ  - Contributions to nephrology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - dqv, 7513582
SB  - Index Medicus
CP  - Switzerland
MH  - Atrial Fibrillation/co [Complications]
MH  - Comorbidity
MH  - Female
MH  - Humans
MH  - Hypertension/co [Complications]
MH  - Hypertension/dt [Drug Therapy]
MH  - Incidence
MH  - Inflammation/co [Complications]
MH  - Kidney Failure, Chronic/co [Complications]
MH  - *Kidney Failure, Chronic/th [Therapy]
MH  - Male
MH  - Malnutrition/co [Complications]
MH  - Malnutrition/pc [Prevention & Control]
MH  - *Renal Dialysis
MH  - Risk Factors
MH  - Stroke/co [Complications]
MH  - *Stroke/dt [Drug Therapy]
MH  - Stroke/ep [Epidemiology]
MH  - Stroke/pp [Physiopathology]
MH  - Thrombophilia/et [Etiology]
AB  - Strokes remain the major complication among dialysis population as the number of diabetes and elderly is increasing. In chronic hemodialysis patients, prevalence and incidence of stroke is higher than that of the general population. According to the annual registry data of the Japanese Society for Dialysis Therapy, prevalence of stroke death has been declining, yet the incidence of nonfatal incidence of stroke is not known. Underlying mechanisms of stroke are multiple. Among them, control of hypertension is important for the primary prevention; however, the ideal target level of blood pressure is not determined. Other than hypertension, maintaining good nutritional status is utmost important. Most observational studies suggested that the target was 140/90 mm Hg at prehemodialysis session. However, blood pressure levels are variable in both at office (before and after dialysis session) and at home. It is advisable to measure blood pressure multiple occasions and also at home. In case of acute cerebral hemorrhage, glycerol is indicated to prevent cerebral edema. Blood pressure is recommended to control as systolic <180 mm Hg or mean arterial pressure <130 mm Hg, and lower blood pressure gradually to 80% of the baseline level. In case of acute cerebral infarction hypertension is not treated unless severely hypertensive, systolic >220 mm Hg or diastolic >120 mm Hg and lower blood pressure gradually to 85-90% of the baseline level. Use of warfarin is controversial in case of acute cerebral infarction. Modification of dialysis modality is needed to prevent the increase in intracranial pressure and/or recurrence of stroke.Copyright © 2013 S. Karger AG, Basel.
ES  - 1662-2782
IL  - 0302-5144
DO  - http://dx.doi.org/10.1159/000346728
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20130503
DP  - 2013
DC  - 20130508
YR  - 2013
ED  - 20131223
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23652453

<253. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23438615
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Samaras TT
FA  - Samaras, Thomas T
IN  - Samaras,Thomas T. Reventropy Associates, San Diego, CA, USA. samarastt@aol.com
TI  - Shorter height is related to lower cardiovascular disease risk - a narrative review. [Review]
SO  - Indian Heart Journal. 65(1):66-71, 2013 Jan-Feb.
AS  - Indian Heart J. 65(1):66-71, 2013 Jan-Feb.
NJ  - Indian heart journal
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - ghr, 0374675
OI  - Source: NLM. PMC3861069
SB  - Index Medicus
CP  - India
MH  - Animals
MH  - *Body Height
MH  - *Cardiovascular Diseases/mo [Mortality]
MH  - Humans
MH  - Risk Factors
AB  - Numerous Western studies have shown a negative correlation between height and cardiovascular disease. However, these correlations do not prove causation. This review provides a variety of studies showing short people have little to no cardiovascular disease. When shorter people are compared to taller people, a number of biological mechanisms evolve favoring shorter people, including reduced telomere shortening, lower atrial fibrillation, higher heart pumping efficiency, lower DNA damage, lower risk of blood clots, lower left ventricular hypertrophy and superior blood parameters. The causes of increased heart disease among shorter people in the developed world are related to lower income, excessive weight, poor diet, lifestyle factors, catch-up growth, childhood illness and poor environmental conditions. For short people in developed countries, the data indicate that a plant-based diet, leanness and regular exercise can substantially reduce the risk of cardiovascular disease.Copyright © 2013 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.
IS  - 0019-4832
IL  - 0019-4832
DI  - S0019-4832(12)00317-3
DO  - http://dx.doi.org/10.1016/j.ihj.2012.12.016
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20121226
DP  - 2013 Jan-Feb
DC  - 20130226
YR  - 2013
ED  - 20131217
RD  - 20150218
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23438615

<254. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24240932
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Abed HS
AU  - Wittert GA
AU  - Leong DP
AU  - Shirazi MG
AU  - Bahrami B
AU  - Middeldorp ME
AU  - Lorimer MF
AU  - Lau DH
AU  - Antic NA
AU  - Brooks AG
AU  - Abhayaratna WP
AU  - Kalman JM
AU  - Sanders P
FA  - Abed, Hany S
FA  - Wittert, Gary A
FA  - Leong, Darryl P
FA  - Shirazi, Masoumeh G
FA  - Bahrami, Bobak
FA  - Middeldorp, Melissa E
FA  - Lorimer, Michelle F
FA  - Lau, Dennis H
FA  - Antic, Nicholas A
FA  - Brooks, Anthony G
FA  - Abhayaratna, Walter P
FA  - Kalman, Jonathan M
FA  - Sanders, Prashanthan
IN  - Abed,Hany S. Centre for Heart Rhythm Disorders, University of Adelaide, and Royal Adelaide Hospital, Adelaide, Australia2Department of Medicine, University of Adelaide, and Royal Adelaide Hospital, Adelaide, Australia.
TI  - Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial.
SO  - JAMA. 310(19):2050-60, 2013 Nov 20.
AS  - JAMA. 310(19):2050-60, 2013 Nov 20.
NJ  - JAMA
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 7501160
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/dh [Diet Therapy]
MH  - *Diet, Reducing
MH  - Echocardiography
MH  - Fish Oils/ad [Administration & Dosage]
MH  - Heart Atria/pa [Pathology]
MH  - Heart Atria/us [Ultrasonography]
MH  - Humans
MH  - Life Style
MH  - Male
MH  - Middle Aged
MH  - Obesity/co [Complications]
MH  - *Obesity/dh [Diet Therapy]
MH  - Overweight/co [Complications]
MH  - Overweight/dh [Diet Therapy]
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - *Weight Loss
AB  - IMPORTANCE: Obesity is a risk factor for atrial fibrillation. Whether weight reduction and cardiometabolic risk factor management can reduce the burden of atrial fibrillation is not known.
AB  - OBJECTIVE: To determine the effect of weight reduction and management of cardiometabolic risk factors on atrial fibrillation burden and cardiac structure.
AB  - DESIGN, SETTING, AND PATIENTS: Single-center, partially blinded, randomized controlled study conducted between June 2010 and December 2011 in Adelaide, Australia, among overweight and obese ambulatory patients (N=150) with symptomatic atrial fibrillation. Patients underwent a median of 15 months of follow-up.
AB  - INTERVENTIONS: Patients were randomized to weight management (intervention) or general lifestyle advice (control). Both groups underwent intensive management of cardiometabolic risk factors.
AB  - MAIN OUTCOMES AND MEASURES: The primary outcomes were Atrial Fibrillation Severity Scale scores: symptom burden and symptom severity. Scores were measured every 3 months from baseline to 15 months. Secondary outcomes performed at baseline and 12 months were total atrial fibrillation episodes and cumulative duration measured by 7-day Holter, echocardiographic left atrial area, and interventricular septal thickness.
AB  - RESULTS: Of 248 patients screened, 150 were randomized (75 per group) and underwent follow-up. The intervention group showed a significantly greater reduction, compared with the control group, in weight (14.3 and 3.6 kg, respectively; P<.001) and in atrial fibrillation symptom burden scores (11.8 and 2.6 points, P<.001), symptom severity scores (8.4 and 1.7 points, P<.001), number of episodes (2.5 and no change, P=.01), and cumulative duration (692-minute decline and 419-minute increase, P=.002). Additionally, there was a reduction in interventricular septal thickness in the intervention and control groups (1.1 and 0.6 mm, P=.02) and left atrial area (3.5 and 1.9 cm2, P=.02).
AB  - CONCLUSIONS AND RELEVANCE: In this study, weight reduction with intensive risk factor management resulted in a reduction in atrial fibrillation symptom burden and severity and in beneficial cardiac remodeling. These findings support therapy directed at weight and risk factors in the management of atrial fibrillation.
AB  - TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12610000497000.
RN  - 0 (Fish Oils)
ES  - 1538-3598
IL  - 0098-7484
DO  - http://dx.doi.org/10.1001/jama.2013.280521
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2013 Nov 20
DC  - 20131118
YR  - 2013
ED  - 20131204
RD  - 20140917
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24240932

<255. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22958623
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Silvet H
AU  - Hawkins LA
AU  - Jacobson AK
FA  - Silvet, Helme
FA  - Hawkins, Lee Ann
FA  - Jacobson, Alan K
IN  - Silvet,Helme. VA Loma Linda Healthcare System, Section of Cardiology, Loma Linda, CA 92357, USA. helmesilvet@yahoo.com
TI  - Heart rate control in patients with chronic atrial fibrillation and heart failure.
SO  - Congestive Heart Failure. 19(1):25-8, 2013 Jan-Feb.
AS  - Congest Heart Fail. 19(1):25-8, 2013 Jan-Feb.
NJ  - Congestive heart failure (Greenwich, Conn.)
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9714174
SB  - Index Medicus
CP  - United States
MH  - Adrenergic beta-Antagonists/ad [Administration & Dosage]
MH  - Aged
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Chronic Disease
MH  - Cross-Over Studies
MH  - Dose-Response Relationship, Drug
MH  - Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/co [Complications]
MH  - Heart Failure/dt [Drug Therapy]
MH  - *Heart Failure/pp [Physiopathology]
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Metoprolol/ad [Administration & Dosage]
MH  - *Metoprolol/aa [Analogs & Derivatives]
MH  - Rest/ph [Physiology]
MH  - Retrospective Studies
MH  - Treatment Outcome
AB  - The goal of this study was to determine whether aggressive heart rate (HR) control in patients with both chronic atrial fibrillation (AF) and heart failure (HF) is associated with improved outcomes. HR control is one of the mainstays in management of patients with AF. However, rate control can be challenging in patients with HF. This study was designed as an interventional clinical trial, using patients with chronic AF and left ventricular systolic dysfunction with left ventricular ejection fraction <40% (n=20) as their own controls. Intervention consisted of increasing doses of metoprolol succinate to achieve target resting HR <70 beats per minute. Clinical data were collected at baseline and after intervention, with paired t test used to evaluate statistically significant change. After 3 months of intervention, average resting HR decreased from 94+/-14 beats per minute to 85+/-12 beats per minute. Average metoprolol succinate dose at the end of the study was 121 mg. None of the outcomes improved significantly after the intervention, including exercise tolerance (meters walked on 6-minute walk test 326+/-83 vs 330+/-86), quality of life (Minnesota Living With Heart Failure Questionnaire score of 42.5+/-19 vs 38+/-21), and brain natriuretic peptide (242+/-306 pg/mL vs 279+/-395 pg/mL). Aggressive HR control was difficult in this group of patients with chronic AF and HF due to patient intolerance of increasing doses of beta-blockade, and not associated with improved outcomes. Further studies are needed to establish guidelines for target HR in patients with chronic AF who also have significant HF.Copyright © 2012 Wiley Periodicals, Inc.
RN  - 0 (Adrenergic beta-Antagonists)
RN  - GEB06NHM23 (Metoprolol)
ES  - 1751-7133
IL  - 1527-5299
DO  - http://dx.doi.org/10.1111/j.1751-7133.2012.00309.x
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
EP  - 20120909
DP  - 2013 Jan-Feb
DC  - 20130123
YR  - 2013
ED  - 20131203
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22958623

<256. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23007810
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Trovato GM
AU  - Pace P
AU  - Cangemi E
AU  - Martines GF
AU  - Trovato FM
AU  - Catalano D
FA  - Trovato, G M
FA  - Pace, P
FA  - Cangemi, E
FA  - Martines, G F
FA  - Trovato, F M
FA  - Catalano, D
IN  - Trovato,G M. Department of Internal Medicine, Institute of Internal Medicine and Medical Therapy, Faculty of Medicine and Surgery, University of Catania, Italy. guglielmotrovato@unict.it
TI  - Gender, lifestyles, illness perception and stress in stable atrial fibrillation.
SO  - Clinica Terapeutica. 163(4):281-6, 2012 Jul.
AS  - Clin Ter. 163(4):281-6, 2012 Jul.
NJ  - La Clinica terapeutica
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - dkn, 0372604
SB  - Index Medicus
CP  - Italy
MH  - Anxiety/et [Etiology]
MH  - *Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/px [Psychology]
MH  - *Attitude to Health
MH  - Depression/et [Etiology]
MH  - Female
MH  - Humans
MH  - *Life Style
MH  - Male
MH  - Middle Aged
MH  - Self Efficacy
MH  - Sex Factors
MH  - *Stress, Psychological/et [Etiology]
AB  - AIMS: The study is aimed at investigating if perceived stress in Stable Atrial Fibrillation (AF) has any gender-associated feature and relationships with lifestyle indicators and education level, and which relationship self efficacy, anxiety and depression and illness perception have, if any.
AB  - PATIENTS AND METHODS: 88 consecutive patients referred for stable AF are studied by Psychological Stress Measure (PSM) test, Illness Perception Questionnaire (IPQ-R), Generalized Self-Efficacy scale (GSE) and Hospital Anxiety and Depression Scale (HADS). Mediterranean diet, physical activity increase and smoking withdrawal counseling were provided.
AB  - RESULTS: AF patients have higher PSM associated with gender (women), older age, anxiety and depression. Higher GSE, greater Adherence to Mediterranean Diet profile and coffee habits (greater coffee users) are associated with a reduced hazard of perceived stress. By multiple linear regression, PSM is explained by Anxiety and IPQr (statistically significant are emotional representation and illness coherence subscales), which account for 92.2% of the variance (p<0.0001).
AB  - CONCLUSION: Our results outline that psychological stress is greater in women in comparison with men. Illness perceptions are important in the context of perceived stress in AF. This effect appears to be modulated by greater self-efficacy and by Adherence to Mediterranean Diet profile, that when higher, are associated with a reduced hazard of perceived stress. We suggest that therapeutic interventions on illness perceptions can be warranted in order to achieve a lower psychological distress in AF patients.
ES  - 1972-6007
IL  - 0009-9074
PT  - Journal Article
LG  - English
DP  - 2012 Jul
DC  - 20120925
YR  - 2012
ED  - 20131202
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23007810

<257. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23962865
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ip JE
AU  - Seidman CE
AU  - Liu CF
AU  - Cheung JW
AU  - Thomas G
AU  - Markowitz SM
AU  - Lerman BB
FA  - Ip, James E
FA  - Seidman, Christine E
FA  - Liu, Christopher F
FA  - Cheung, Jim W
FA  - Thomas, George
FA  - Markowitz, Steven M
FA  - Lerman, Bruce B
IN  - Ip,James E. Department of Medicine, Division of Cardiology, Cornell University Medical Center, New York Presbyterian Hospital, New York, NY.
TI  - Conundrum of sudden cardiac death: making sense of missense.
SO  - Circulation: Arrhythmia and Electrophysiology. 6(4):e58-63, 2013 Aug.
AS  - Circ. Arrhythm. electrophysiol.. 6(4):e58-63, 2013 Aug.
NJ  - Circulation. Arrhythmia and electrophysiology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101474365
SB  - Index Medicus
CP  - United States
MH  - Accessory Atrioventricular Bundle/et [Etiology]
MH  - Accessory Atrioventricular Bundle/ge [Genetics]
MH  - Accessory Atrioventricular Bundle/pp [Physiopathology]
MH  - Adult
MH  - Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/ge [Genetics]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Cardiopulmonary Resuscitation
MH  - Catheter Ablation
MH  - DNA Mutational Analysis
MH  - *Death, Sudden, Cardiac/et [Etiology]
MH  - Death, Sudden, Cardiac/pc [Prevention & Control]
MH  - Defibrillators
MH  - Electric Countershock/is [Instrumentation]
MH  - Electrocardiography
MH  - Electrophysiologic Techniques, Cardiac
MH  - Exercise
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Hypertrophy, Right Ventricular/et [Etiology]
MH  - Hypertrophy, Right Ventricular/ge [Genetics]
MH  - Hypertrophy, Right Ventricular/pp [Physiopathology]
MH  - *Mutation, Missense
MH  - *Out-of-Hospital Cardiac Arrest/et [Etiology]
MH  - Out-of-Hospital Cardiac Arrest/ge [Genetics]
MH  - Out-of-Hospital Cardiac Arrest/pp [Physiopathology]
MH  - Out-of-Hospital Cardiac Arrest/th [Therapy]
MH  - Phenotype
MH  - *Plakophilins/ge [Genetics]
MH  - Predictive Value of Tests
MH  - Risk Factors
MH  - Treatment Outcome
MH  - Ventricular Fibrillation/et [Etiology]
MH  - Ventricular Fibrillation/ge [Genetics]
MH  - Ventricular Fibrillation/pp [Physiopathology]
KW  - Mahaim pathway;  Wolff-Parkinson-White syndrome;  accessory pathway;  death, sudden, cardiac;  genetic testing
RN  - 0 (PKP2 protein, human)
RN  - 0 (Plakophilins)
ES  - 1941-3084
IL  - 1941-3084
DO  - http://dx.doi.org/10.1161/CIRCEP.113.000553
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2013 Aug
DC  - 20130821
YR  - 2013
ED  - 20131126
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23962865

<258. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23945170
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Rix TA
AU  - Joensen AM
AU  - Riahi S
AU  - Lundbye-Christensen S
AU  - Overvad K
AU  - Schmidt EB
FA  - Rix, Thomas Andersen
FA  - Joensen, Albert Marni
FA  - Riahi, Sam
FA  - Lundbye-Christensen, Soren
FA  - Overvad, Kim
FA  - Schmidt, Erik Berg
IN  - Rix,Thomas Andersen. Department of Cardiology, Aalborg AF Study Group, Center for Cardiovascular Research, Aalborg University Hospital, , Aalborg, Denmark.
TI  - Marine n-3 fatty acids in adipose tissue and development of atrial fibrillation: a Danish cohort study.
SO  - Heart. 99(20):1519-24, 2013 Oct.
AS  - Heart. 99(20):1519-24, 2013 Oct.
NJ  - Heart (British Cardiac Society)
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9602087
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - *Adipose Tissue/ch [Chemistry]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/me [Metabolism]
MH  - Biomarkers
MH  - Biopsy
MH  - Denmark/ep [Epidemiology]
MH  - *Dietary Fats, Unsaturated/pd [Pharmacology]
MH  - *Fatty Acids, Omega-3/an [Analysis]
MH  - Fatty Acids, Omega-3/me [Metabolism]
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - *Population Surveillance/mt [Methods]
MH  - Retrospective Studies
MH  - *Seafood
AB  - OBJECTIVE: Consumption of fish and marine n-3 polyunsaturated fatty acids (PUFA) may be associated with a lower risk of atrial fibrillation (AF), but results have been inconsistent. The aim was to investigate this further by measurements of marine n-3 PUFA in adipose tissue.
AB  - DESIGN: Cohort study.
AB  - SETTING: A total of 57 053 Danish participants 50-64 years of age were enrolled into the Diet, Cancer and Health Cohort Study.
AB  - PATIENTS: A randomly drawn subcohort of 3440 participants with available data from baseline adipose tissue biopsies.
AB  - INTERVENTIONS: Exposure was the adipose tissue content of marine n-3 PUFA, which reflects the endogenous exposure and is also an objective marker of the long-term dietary intake.
AB  - MAIN OUTCOME MEASURES: Incident AF during follow-up.
AB  - RESULTS: 179 cases of AF occurred over 13.6 years. Multivariate, sex-stratified Cox proportional hazards regression analyses using cubic splines showed a monotonic, negative, dose-response trend, but not statistically significant association, between total marine n-3 PUFA in adipose tissue and incident AF. A similar trend towards a lower risk of AF was seen in the second (HR 0.87, 95% CI 0.60 to 1.24) and third tertiles (HR 0.77, 95% CI 0.53 to 1.10) of marine n-3 PUFA compared with the lowest tertile. Similar trends, but also not statistically significant, were found separately for eicosapentaenoic, docosahexaenoic and docosapentaenoic acids.
AB  - CONCLUSIONS: There was no statistically significant association between the content of marine n-3 PUFA in adipose tissue and the development of AF; however, data showed a monotonic, negative dose-response trend suggestive of a negative association.
RN  - 0 (Biomarkers)
RN  - 0 (Dietary Fats, Unsaturated)
RN  - 0 (Fatty Acids, Omega-3)
ES  - 1468-201X
IL  - 1355-6037
DO  - http://dx.doi.org/10.1136/heartjnl-2013-304385
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20130814
DP  - 2013 Oct
DC  - 20130923
YR  - 2013
ED  - 20131119
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23945170

<259. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23750346
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Njovane XW
AU  - Fasinu PS
AU  - Rosenkranz B
FA  - Njovane, Xolani W
FA  - Fasinu, Pius S
FA  - Rosenkranz, Bernd
IN  - Njovane,Xolani W. Division of Pharmacology, Faculty of Medicine and Health Sciences, University of Stellenbosch, Cape Town, South Africa.
TI  - Comparative evaluation of warfarin utilisation in two primary healthcare clinics in the Cape Town area.
SO  - Cardiovascular Journal of Africa. 24(2):19-23, 2013 Mar.
AS  - Cardiovasc. j. Afr.. 24(2):19-23, 2013 Mar.
NJ  - Cardiovascular journal of Africa
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101313864
OI  - Source: NLM. PMC3736381
SB  - Index Medicus
CP  - South Africa
MH  - Adult
MH  - Anticoagulants/ae [Adverse Effects]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Chi-Square Distribution
MH  - Comorbidity
MH  - Drug Interactions
MH  - Drug Monitoring/mt [Methods]
MH  - Drug Utilization
MH  - Drug Utilization Review
MH  - Female
MH  - Humans
MH  - International Normalized Ratio
MH  - Male
MH  - *Outpatient Clinics, Hospital
MH  - Polypharmacy
MH  - *Practice Patterns, Physicians'
MH  - *Primary Health Care
MH  - Quality Indicators, Health Care
MH  - Retrospective Studies
MH  - South Africa
MH  - Treatment Outcome
MH  - Warfarin/ae [Adverse Effects]
MH  - *Warfarin/tu [Therapeutic Use]
AB  - BACKGROUND: Although warfarin remains the anticoagulant drug of choice in a wide range of patients, its narrow therapeutic window makes patients susceptible to a high risk of bleeding complications or failure to prevent clotting. This has necessitated therapeutic monitoring in warfarinised patients. Factors that could be responsible for the fluctuating responses to warfarin vary from pharmacogenetic to concomitant morbidity, diet and medication. In order to assess the quality of management of warfarin treatment in a local primary-care setting, the current study evaluated warfarin utilisation and monitoring records in two hospitals with different patient groups.
AB  - METHODS: A retrospective study was undertaken in the specialised warfarin clinics at Wesfleur and Gugulethu hospitals (Western Cape, South Africa) covering all warfarin-related therapy records over a 12-month period. Data extracted from the patients' folders included age, gender, race, weight, address, concurrent chronic illnesses, treatment and medication, indication for warfarin and INR history.
AB  - RESULTS: A total of 119 patients' folders were analysed. Attendance at the clinics reflects the demographics and racial distribution of the host location of the hospitals. While all the patients were maintained above the minimum international normalised ratio (INR) value of 2, about 50% had at least one record of INR above the cut-off value of 3.5. However, over a third of the patients (32.2%) had at least one record of INR greater than 3.5 in Gugulethu Hospital, compared to over half (58.3%) in Wesfleur Hospital. In total, atrial fibrillation was the most common indication for warfarinisation while hypertension was the most common concurrent chronic condition in warfarinised patients. All patients who received quinolone antibiotics had INR values above the cut-off point of 3.5 within the same month of the initiation of antibiotic therapy, suggesting drug-induced warfarin potentiation. Other co-medications, including beta-lactam antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs) and anti-ulcer drugs appeared to alter warfarin responses as measured by recorded INR values.
AB  - CONCLUSION: The study found inter-individual variability in the response to warfarin therapy, which cut across racial classifications. It also confirms the possible influence of concomitant morbidity on patient response to anticoagulant therapy.
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
ES  - 1680-0745
IL  - 1015-9657
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 2013 Mar
DC  - 20130607
YR  - 2013
ED  - 20131119
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23750346

<260. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23137563
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mediratta N
AU  - Chalmers J
AU  - Pullan M
AU  - McShane J
AU  - Shaw M
AU  - Poullis M
FA  - Mediratta, Neeraj
FA  - Chalmers, John
FA  - Pullan, Mark
FA  - McShane, James
FA  - Shaw, Mathew
FA  - Poullis, Michael
IN  - Mediratta,Neeraj. Department of Cardiac Surgery, Liverpool Heart and Chest Hospital, Liverpool, UK.
TI  - In-hospital mortality and long-term survival after coronary artery bypass surgery in young patients.
SO  - European Journal of Cardio-Thoracic Surgery. 43(5):1014-21, 2013 May.
AS  - Eur J Cardiothorac Surg. 43(5):1014-21, 2013 May.
NJ  - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - aoj, 8804069
SB  - Index Medicus
CP  - Germany
MH  - Analysis of Variance
MH  - Computational Biology
MH  - *Coronary Artery Bypass/mo [Mortality]
MH  - Databases, Factual
MH  - Female
MH  - Great Britain/ep [Epidemiology]
MH  - *Hospital Mortality
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Neural Networks (Computer)
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Regression Analysis
MH  - Retrospective Studies
AB  - OBJECTIVES: Coronary artery bypass graft (CABG) is performed for symptomatic and prognostic reasons. We aimed to determine the factors that contribute to in-hospital mortality and long-term survival in young patients (aged less than 65) undergoing CABG.
AB  - METHODS: A prospective database was retrospectively analysed and cross-correlated with the United Kingdom's Strategic Tracing Service to evaluate survival in patients under the age of 65, following isolated primary CABG. Univariate-, multivariate logistic with Cox regression- and neural network analyses were performed.
AB  - RESULTS: Patients under the age of 65, who had undergone isolated CABG between April 1997 and March 2010 were studied;n = 5967. In-hospital mortality was 1.1% and long-term mortality was 13.5%; median follow-up 7.9 years. Multivariate analysis demonstrated that atrial fibrillation, 'urgent' operation status, postoperative creatinine kinase (CKMB), moderate or poor left ventricular (LV) function, and female sex were significant factors predicting in-hospital mortality. Cox regression demonstrated that age, diabetes (oral and insulin controlled), moderate and poor LV function, cerebrovascular disease, dialysis, left internal mammary artery (LIMA) usage, postoperative CKMB, atrial fibrillation, 'urgent' operation status, and peripheral vascular disease were significant factors determining long-term survival. Radial artery use, off-pump surgery, composite arterial grating and graft number had no effect on in-hospital mortality or long-term survival. Neural network analysis confirmed the factors identified by logistic and Cox multivariate analysis.
AB  - CONCLUSIONS: The risk factors for in-hospital mortality in patients under the age of 65 include postoperative CKMB, urgent operation status, LV function, female sex and atrial fibrillation. Significant factors determining long-term survival in the under-65 age group include age, atrial fibrillation, diabetes (diet and insulin controlled), LV function, cerebrovascular disease, dialysis, LIMA usage, 'urgent' operation status, CKMB and peripheral vascular disease.
ES  - 1873-734X
IL  - 1010-7940
DO  - http://dx.doi.org/10.1093/ejcts/ezs459
PT  - Journal Article
LG  - English
EP  - 20121108
DP  - 2013 May
DC  - 20130409
YR  - 2013
ED  - 20131118
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23137563

<261. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22675087
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lyon P
AU  - Nambi R
AU  - Faruqi F
FA  - Lyon, Paul
FA  - Nambi, Rabi
FA  - Faruqi, Faisal
IN  - Lyon,Paul. Cardiology Department, Royal Derby NHS Trust, Derby, Derbyshire, UK.
TI  - Atypical presentation of purpura fulminans following sepsis in an adult.
SO  - BMJ Case Reports. 2011, 2011.
AS  - BMJ Case Rep. 2011, 2011.
NJ  - BMJ case reports
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 101526291
OI  - Source: NLM. PMC3207729
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - Calciphylaxis/co [Complications]
MH  - *Calciphylaxis/di [Diagnosis]
MH  - Diabetes Mellitus, Type 2/co [Complications]
MH  - Diagnosis, Differential
MH  - Fatal Outcome
MH  - Female
MH  - Humans
MH  - *Purpura Fulminans/di [Diagnosis]
MH  - *Purpura Fulminans/et [Etiology]
MH  - Purpura Fulminans/th [Therapy]
MH  - Renal Insufficiency, Chronic/co [Complications]
MH  - *Sepsis/co [Complications]
AB  - A 67-year-old morbidly obese female with a background of stage 4 chronic renal failure, ischaemic heart disease, congestive cardiac failure, atrial fibrillation and type 2 diabetes mellitus presented with sepsis and necrotic lesions of the proximal lower limbs. Initial histological findings were consistent with the clinical diagnosis of calciphylaxis and supportive treatment was commenced with addition of a phosphate binder and dietary restriction. Due to high anaesthetic risk, her wounds were managed with larva therapy in the first instance, however, ultimately surgical debridement was the required. Repeat histology from a further biopsy revealed necrosis secondary to numerous thrombi in the cutaneous vessels and a new diagnosis of purpura fulminans was made, likely secondary to her sepsis. Unfortunately, despite aggressive medical and surgical treatment measures, this patient died of multiple organ dysfunction following a prolonged admission.
ES  - 1757-790X
IL  - 1757-790X
DI  - bcr0320113996
DO  - http://dx.doi.org/10.1136/bcr.03.2011.3996
PT  - Case Reports
PT  - Journal Article
LG  - English
EP  - 20111028
DP  - 2011
DC  - 20120607
YR  - 2011
ED  - 20131105
RD  - 20160519
UP  - 20160520
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=22675087

<262. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22675087
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lyon P
AU  - Nambi R
AU  - Faruqi F
FA  - Lyon, Paul
FA  - Nambi, Rabi
FA  - Faruqi, Faisal
IN  - Lyon,Paul. Cardiology Department, Royal Derby NHS Trust, Derby, Derbyshire, UK.
TI  - Atypical presentation of purpura fulminans following sepsis in an adult.
SO  - BMJ Case Reports. 2011, 2011.
AS  - BMJ Case Rep. 2011, 2011.
NJ  - BMJ case reports
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 101526291
OI  - Source: NLM. PMC3207729
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - Calciphylaxis/co [Complications]
MH  - *Calciphylaxis/di [Diagnosis]
MH  - Diabetes Mellitus, Type 2/co [Complications]
MH  - Diagnosis, Differential
MH  - Fatal Outcome
MH  - Female
MH  - Humans
MH  - *Purpura Fulminans/di [Diagnosis]
MH  - *Purpura Fulminans/et [Etiology]
MH  - Purpura Fulminans/th [Therapy]
MH  - Renal Insufficiency, Chronic/co [Complications]
MH  - *Sepsis/co [Complications]
AB  - A 67-year-old morbidly obese female with a background of stage 4 chronic renal failure, ischaemic heart disease, congestive cardiac failure, atrial fibrillation and type 2 diabetes mellitus presented with sepsis and necrotic lesions of the proximal lower limbs. Initial histological findings were consistent with the clinical diagnosis of calciphylaxis and supportive treatment was commenced with addition of a phosphate binder and dietary restriction. Due to high anaesthetic risk, her wounds were managed with larva therapy in the first instance, however, ultimately surgical debridement was the required. Repeat histology from a further biopsy revealed necrosis secondary to numerous thrombi in the cutaneous vessels and a new diagnosis of purpura fulminans was made, likely secondary to her sepsis. Unfortunately, despite aggressive medical and surgical treatment measures, this patient died of multiple organ dysfunction following a prolonged admission.
ES  - 1757-790X
DI  - bcr0320113996
DO  - http://dx.doi.org/10.1136/bcr.03.2011.3996
PT  - Case Reports
PT  - Journal Article
LG  - English
EP  - 20111028
DP  - 2011
DC  - 20120607
YR  - 2011
ED  - 20131105
RD  - 20150224
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=22675087

<263. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24066371
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wahlqvist ML
AU  - Tanaka K
AU  - Tzeng BH
FA  - Wahlqvist, Mark L
FA  - Tanaka, Kiyoshi
FA  - Tzeng, Bing-Hsiean
IN  - Wahlqvist,Mark L. Institute of Population Health Sciences, National Health Research Institutes, Miaoli County, Taiwan, Republic of China.
TI  - Clinical decision-making for vitamin K-1 and K-2 deficiency and coronary artery calcification with warfarin therapy: are diet, factor Xa inhibitors or both the answer?.
SO  - Asia Pacific Journal of Clinical Nutrition. 22(3):492-6, 2013.
AS  - Asia Pac J Clin Nutr. 22(3):492-6, 2013.
NJ  - Asia Pacific journal of clinical nutrition
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9440304
SB  - Index Medicus
CP  - Australia
MH  - Calcinosis/et [Etiology]
MH  - *Calcinosis/th [Therapy]
MH  - Coronary Artery Disease/et [Etiology]
MH  - *Coronary Artery Disease/th [Therapy]
MH  - *Diet
MH  - *Factor Xa Inhibitors
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Monckeberg Medial Calcific Sclerosis/et [Etiology]
MH  - Monckeberg Medial Calcific Sclerosis/th [Therapy]
MH  - Vitamin K 1/ad [Administration & Dosage]
MH  - Vitamin K 2/ad [Administration & Dosage]
MH  - *Vitamin K Deficiency/ci [Chemically Induced]
MH  - Vitamin K Deficiency/co [Complications]
MH  - Vitamin K Deficiency/dh [Diet Therapy]
MH  - *Warfarin/ae [Adverse Effects]
MH  - Warfarin/tu [Therapeutic Use]
AB  - Coronary artery calcification is a recognised risk factor for ischaemic heart disease and mortality. Evidence is now strong that Monckeberg's arteriosclerosis, a form of vascular calcification, can be attributable to vitamin K deficiency, but that vitamin K-2, especially the MK-4 form from foods like cheese can be protective. Warfarin blocks the recycling of hepatic and peripheral vitamin K leading to secondary vitamin K deficiency with adverse effects on vasculature, bone, kidneys, brain and other tissues and systems (inflammatory, immune function and neoplasia at least). There is individual susceptibility to vitamin K deficiency and warfarin sensitivity, partly explicable in terms of genetic polymorphisms, epigenetics, diet and pharmacotherapy. The emergence of extensive coronary calcification in a man with atrial fibrillation treated for a decade with warfarin is described by way of illustration and to raise the present clinical management conundrums. Finally, a putative set of recommendations is provided.
RN  - 0 (Factor Xa Inhibitors)
RN  - 11032-49-8 (Vitamin K 2)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 84-80-0 (Vitamin K 1)
IS  - 0964-7058
IL  - 0964-7058
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2013
DC  - 20130925
YR  - 2013
ED  - 20131101
RD  - 20141120
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24066371

<264. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23255045
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Venditti P
AU  - Di Stefano L
AU  - Di Meo S
FA  - Venditti, Paola
FA  - Di Stefano, Lisa
FA  - Di Meo, Sergio
IN  - Venditti,Paola. Dipartimento delle Scienze Biologiche, Sezione di Fisiologia, Universita di Napoli Federico II, Via Mezzocannone 8, 80134 Naples, Italy. venditti@unina.it
TI  - Vitamin E management of oxidative damage-linked dysfunctions of hyperthyroid tissues. [Review]
SO  - Cellular & Molecular Life Sciences. 70(17):3125-44, 2013 Sep.
AS  - Cell Mol Life Sci. 70(17):3125-44, 2013 Sep.
NJ  - Cellular and molecular life sciences : CMLS
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - cle, 9705402
SB  - Index Medicus
CP  - Switzerland
MH  - Animals
MH  - *Antioxidants/pd [Pharmacology]
MH  - Humans
MH  - *Hyperthyroidism/pa [Pathology]
MH  - *Oxidative Stress/de [Drug Effects]
MH  - *Vitamin E/pd [Pharmacology]
AB  - INTRODUCTION: Thyroid hormones affect growth, development, and metabolism of vertebrates, and are considered the major regulators of their homeostasis. On the other hand, elevated circulating levels of thyroid hormones are associated with modifications in the whole organism (weight loss and increased metabolism and temperature) and in several body regions. Indeed, tachycardia, atrial arrhythmias, heart failure, muscle weakness and wasting, bone mass loss, and hepatobiliary complications are commonly found in hyperthyroid animals and humans.
AB  - RESULTS: Most thyroid hormone actions result from influences on transcription of T3-responsive genes, which are mediated through nuclear receptors. However, there is significant evidence that tissue oxidative stress underlies some dysfunctions produced by hyperthyroidism.
AB  - DISCUSSION: During the last decades, increasing interest has been turned to the use of antioxidants as therapeutic agents in various diseases and pathophysiological disorders believed to be mediated by oxidative stress. In particular, because elevated circulating levels of thyroid hormones are associated with tissue oxidative injury, more attention has been paid to explore the application of antioxidants as therapeutic agents in thyroid related disorders.
AB  - CONCLUSIONS: At present, vitamin E is among the most commonly consumed dietary supplements due to the belief that it, as an antioxidant, may attenuate morbidity and mortality. This is due to the results of numerous scientific studies, which demonstrate that vitamin E has a primary function to destroy peroxyl radicals, thus protecting polyunsaturated fatty acids biological membranes from oxidative damage. However, results are also available indicating that protective vitamin E effects against oxidative damage can be obtained even through different mechanisms.
RN  - 0 (Antioxidants)
RN  - 1406-18-4 (Vitamin E)
ES  - 1420-9071
IL  - 1420-682X
DO  - http://dx.doi.org/10.1007/s00018-012-1217-9
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20121220
DP  - 2013 Sep
DC  - 20130814
YR  - 2013
ED  - 20131031
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23255045

<265. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23525379
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Huang RT
AU  - Xue S
AU  - Xu YJ
AU  - Zhou M
AU  - Yang YQ
FA  - Huang, Ri-Tai
FA  - Xue, Song
FA  - Xu, Ying-Jia
FA  - Zhou, Min
FA  - Yang, Yi-Qing
IN  - Huang,Ri-Tai. Department of Cardiothoracic Surgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, P.R. China.
TI  - A novel NKX2.5 loss-of-function mutation responsible for familial atrial fibrillation.
SO  - International Journal of Molecular Medicine. 31(5):1119-26, 2013 May.
AS  - Int J Mol Med. 31(5):1119-26, 2013 May.
NJ  - International journal of molecular medicine
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - c8h, 9810955
SB  - Index Medicus
CP  - Greece
MH  - Aged
MH  - Amino Acid Sequence
MH  - *Atrial Fibrillation/ge [Genetics]
MH  - Base Sequence
MH  - DNA Mutational Analysis
MH  - Demography
MH  - Exons/ge [Genetics]
MH  - Female
MH  - *Genetic Predisposition to Disease
MH  - Homeodomain Proteins/ch [Chemistry]
MH  - *Homeodomain Proteins/ge [Genetics]
MH  - Humans
MH  - Male
MH  - Molecular Sequence Data
MH  - Mutant Proteins/ch [Chemistry]
MH  - Mutant Proteins/ge [Genetics]
MH  - Mutant Proteins/me [Metabolism]
MH  - *Mutation/ge [Genetics]
MH  - Pedigree
MH  - Sequence Alignment
MH  - Transcription Factors/ch [Chemistry]
MH  - *Transcription Factors/ge [Genetics]
MH  - Transcription, Genetic
AB  - Atrial fibrillation (AF) represents the most common form of sustained cardiac arrhythmia and accounts for substantial morbidity and mortality. Increasing evidence demonstrates that abnormal cardiovascular development is involved in the pathogenesis of AF. In this study, the coding exons and splice sites of the NKX2.5 gene, which encodes a homeodomain-containing transcription factor pivotal for normal cardiovascular morphogenesis, were sequenced in 110 unrelated index patients with familial AF. The available relatives of the mutation carrier and 200 unrelated ethnically-matched healthy individuals serving as controls were subsequently genotyped. The disease-causing potential of the identified NKX2.5 variation was predicted by MutationTaster. The functional characteristics of the mutant NKX2.5 protein were analyzed using a dual-luciferase reporter assay system. As a result, a novel heterozygous NKX2.5 mutation, p.F145S, was identified in a family with AF transmitted as an autosomal dominant trait, which co-segregated with AF in the family with complete penetrance. The detected substitution, which altered the amino acid completely conserved evolutionarily across species, was absent in 400 control chromosomes and was automatically predicted to be causative. Functional analysis demonstrated that the NKX2.5 mutant was associated with significantly decreased transcriptional activity compared with its wild-type counterpart. To the best of our knowledge, this is the first report on the association of the NKX2.5 loss-of-function mutation with increased susceptibility to familial AF. The findings of the present study provide novel insights into the molecular mechanism underlying AF, suggesting the potential implications for the early prophylaxis and allele-specific therapy of AF.
RN  - 0 (Homeodomain Proteins)
RN  - 0 (Mutant Proteins)
RN  - 0 (NKX2-5 protein, human)
RN  - 0 (Transcription Factors)
ES  - 1791-244X
IL  - 1107-3756
DO  - http://dx.doi.org/10.3892/ijmm.2013.1316
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20130322
DP  - 2013 May
DC  - 20130408
YR  - 2013
ED  - 20131029
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23525379

<266. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23769405
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Hanon O
AU  - Assayag P
AU  - Belmin J
AU  - Collet JP
AU  - Emeriau JP
AU  - Fauchier L
AU  - Forette F
AU  - Friocourt P
AU  - Gentric A
AU  - Leclercq C
AU  - Komajda M
AU  - Le Heuzey JY
AU  - French Society of Geriatrics and Gerantology
AU  - French Society of Cardiology
FA  - Hanon, Olivier
FA  - Assayag, Patrick
FA  - Belmin, Joel
FA  - Collet, Jean Philippe
FA  - Emeriau, Jean Paul
FA  - Fauchier, Laurent
FA  - Forette, Francoise
FA  - Friocourt, Patrick
FA  - Gentric, Armelle
FA  - Leclercq, Christophe
FA  - Komajda, Michel
FA  - Le Heuzey, Jean Yves
FA  - French Society of Geriatrics and Gerantology
FA  - French Society of Cardiology
IN  - Hanon,Olivier. Societe francaise de geriatrie et gerontologie, Suresnes, France; AP-HP, hopital Broca, service de gerontologie, Paris, France. Olivier.hanon@brc.aphp.fr
TI  - Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people.
SO  - Archives of cardiovascular diseases. 106(5):303-23, 2013 May.
AS  - Arch Cardiovasc Dis. 106(5):303-23, 2013 May.
NJ  - Archives of cardiovascular diseases
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101465655
SB  - Index Medicus
CP  - Netherlands
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Arrhythmia Agents/ae [Adverse Effects]
MH  - Anticoagulants/ae [Adverse Effects]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Cardiology/st [Standards]
MH  - Comorbidity
MH  - Consensus
MH  - Drug Interactions
MH  - France
MH  - Geriatric Assessment
MH  - *Geriatrics/st [Standards]
MH  - Hemorrhage/ci [Chemically Induced]
MH  - Humans
MH  - Middle Aged
MH  - Polypharmacy
MH  - Predictive Value of Tests
MH  - Risk Factors
MH  - *Societies, Medical/st [Standards]
MH  - Stroke/ep [Epidemiology]
MH  - *Stroke/pc [Prevention & Control]
MH  - Treatment Outcome
AB  - Atrial fibrillation (AF) is a common and serious condition in the elderly. AF affects between 600,000 and one million patients in France, two-thirds of whom are aged above 75 years. AF is a predictive factor for mortality in the elderly and a major risk factor for stroke. Co-morbidities are frequent and worsen the prognosis. The management of AF in the elderly should involve a comprehensive geriatric assessment (CGA), which analyses both medical and psychosocial elements, enabling evaluation of the patient's functional status and social situation and the identification of co-morbidities. The CGA enables the detection of "frailty" using screening tools assessing cognitive function, risk of falls, nutritional status, mood disorders, autonomy and social environment. The objectives of AF treatment in the elderly are to prevent AF complications, particularly stroke, and improve quality of life. Specific precautions for treatment must be taken because of the co-morbidities and age-related changes in pharmacokinetics or pharmacodynamics. Preventing AF complications relies mainly on anticoagulant therapy. Anticoagulants are recommended in patients with AF aged 75 years or above after assessing the bleeding risk using the HEMORR2HAGES or HAS-BLED scores. Novel oral anticoagulants (NOACs) are promising treatments, especially due to a lower risk of intracerebral haemorrhage. However, their prescriptions should take into account renal function (creatinine clearance assessed with Cockcroft formula) and cognitive function (for adherence to treatment). Studies including frail patients in "real life" are necessary to evaluate tolerance of NOACs. Management of AF also involves the treatment of underlying cardiomyopathy and heart rate control rather than a rhythm-control strategy as first-line therapy for elderly patients, especially if they are paucisymptomatic. Antiarrhythmic drugs should be used carefully in elderly patients because of the frequency of metabolic abnormalities and higher risk of drug interactions and bradycardia.Copyright © 2013 Elsevier Masson SAS. All rights reserved.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Anticoagulants)
ES  - 1875-2128
IL  - 1875-2128
DI  - S1875-2136(13)00137-X
DO  - http://dx.doi.org/10.1016/j.acvd.2013.04.001
PT  - Journal Article
PT  - Practice Guideline
LG  - English
EP  - 20130529
DP  - 2013 May
DC  - 20130617
YR  - 2013
ED  - 20131022
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23769405

<267. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23933899
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wanat MA
FA  - Wanat, Matthew A
IN  - Wanat,Matthew A. Department of Clinical Sciences and Administration, University of Houston College of Pharmacy, Houston, TX 77030, USA. mawanat@uh.edu
TI  - Novel oral anticoagulants: a review of new agents. [Review]
SO  - Postgraduate Medicine. 125(4):103-14, 2013 Jul.
AS  - Postgrad Med. 125(4):103-14, 2013 Jul.
NJ  - Postgraduate medicine
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 0401147, pfk
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Benzimidazoles/tu [Therapeutic Use]
MH  - Dabigatran
MH  - Drug Administration Schedule
MH  - Humans
MH  - *Morpholines/tu [Therapeutic Use]
MH  - Postoperative Complications/pc [Prevention & Control]
MH  - Practice Guidelines as Topic
MH  - Pulmonary Embolism/et [Etiology]
MH  - Pulmonary Embolism/pc [Prevention & Control]
MH  - *Pyrazoles/tu [Therapeutic Use]
MH  - *Pyridones/tu [Therapeutic Use]
MH  - Rivaroxaban
MH  - Stroke/et [Etiology]
MH  - Stroke/pc [Prevention & Control]
MH  - *Thiophenes/tu [Therapeutic Use]
MH  - Venous Thromboembolism/dt [Drug Therapy]
MH  - Venous Thromboembolism/et [Etiology]
MH  - Venous Thromboembolism/pc [Prevention & Control]
MH  - Venous Thrombosis/dt [Drug Therapy]
MH  - Venous Thrombosis/et [Etiology]
MH  - Venous Thrombosis/pc [Prevention & Control]
MH  - *beta-Alanine/aa [Analogs & Derivatives]
MH  - beta-Alanine/tu [Therapeutic Use]
AB  - Until recently, warfarin had been one of the only treatment options for long-term anticoagulation of patients with atrial fibrillation, venous thromboembolism, or other medical conditions that require chronic anticoagulation. A main concern when treating patients with anticoagulants is balancing the benefits of preventing a thromboembolic event with the risks of bleeding events. The US Food and Drug Administration recently approved 2 new oral anticoagulants, dabigatran and rivaroxaban, for stroke prevention in patients with atrial fibrillation, and is currently reviewing a drug application for a third new oral anticoagulant, apixaban. These new anticoagulants do not require strict and frequent laboratory monitoring, dosing adjustments, or dietary restrictions, and they incur fewer drug-drug interactions than warfarin. However, these new medications do not have specific reversal agents, may require dosage adjustment based on patient renal function, and lack clinical data regarding their long-term safety and efficacy. The 2012 American College of Chest Physicians Evidence-Based Clinical Practice Guidelines for antithrombotic therapy and prevention of thrombosis include recommendations for dabigatran, rivaroxaban, and apixaban for certain indications. Each of the 3 novel oral anticoagulants has specific pharmacokinetic and pharmacodynamic properties that may make them suitable agents for use in specific patient populations. Knowledge of dosing, drug-drug interactions, monitoring parameters, and clinical considerations for each of these new medications will help clinicians decide for which patients they may be best suited to replace conventional therapy with warfarin.
RN  - 0 (Anticoagulants)
RN  - 0 (Benzimidazoles)
RN  - 0 (Morpholines)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridones)
RN  - 0 (Thiophenes)
RN  - 11P2JDE17B (beta-Alanine)
RN  - 3Z9Y7UWC1J (apixaban)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - I0VM4M70GC (Dabigatran)
ES  - 1941-9260
IL  - 0032-5481
DO  - http://dx.doi.org/10.3810/pgm.2013.07.2683
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2013 Jul
DC  - 20130812
YR  - 2013
ED  - 20131021
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23933899

<268. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23313169
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Goette A
FA  - Goette, Andreas
IN  - Goette,Andreas. Medical Clinic II, Department of Cardiology and Intensive Care Medicine, St. Vincenz-Hospital, Am Busdorf 2, 33098 Paderborn, Germany. andreas.goette@med.ovgu.de
TI  - Novel oral anticoagulants for stroke prevention in atrial fibrillation: key trial findings and clinical implications. [Review]
SO  - Trends in Cardiovascular Medicine. 23(4):128-34, 2013 May.
AS  - Trends Cardiovasc Med. 23(4):128-34, 2013 May.
NJ  - Trends in cardiovascular medicine
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - dbd, 9108337
SB  - Index Medicus
CP  - United States
MH  - Anticoagulants/cl [Classification]
MH  - Anticoagulants/pd [Pharmacology]
MH  - *Anticoagulants
MH  - Atrial Fibrillation/bl [Blood]
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - *Blood Coagulation/de [Drug Effects]
MH  - Clinical Trials, Phase III as Topic/mt [Methods]
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Drug Monitoring
MH  - Hemorrhage/ci [Chemically Induced]
MH  - Hemorrhage/th [Therapy]
MH  - Humans
MH  - Risk Assessment
MH  - Stroke/et [Etiology]
MH  - *Stroke/pc [Prevention & Control]
AB  - Novel oral anticoagulants have the potential to improve stroke prevention in patients who have atrial fibrillation and an elevated risk of stroke by overcoming several limitations of warfarin, such as the need for regular monitoring and dose adjustment, and the existence of multiple drug interactions and dietary restrictions. In recently completed phase III trials in patients with non-valvular atrial fibrillation, common findings for dabigatran, rivaroxaban, and apixaban compared with warfarin included: risk reductions for stroke and systemic embolism, significantly fewer hemorrhagic strokes and intracranial hemorrhages, and reductions in mortality, although different trends were seen in several endpoints. However, the trials had important differences in terms of design, populations studied, and statistical analysis that preclude comparison between trials and should be considered when interpreting findings. In this article, data for novel anticoagulants are reviewed and some potential practical implications are highlighted.Copyright © 2013 Elsevier Inc. All rights reserved.
RN  - 0 (Anticoagulants)
ES  - 1873-2615
IL  - 1050-1738
DI  - S1050-1738(12)00400-8
DO  - http://dx.doi.org/10.1016/j.tcm.2012.10.001
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20130111
DP  - 2013 May
DC  - 20130410
YR  - 2013
ED  - 20130930
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23313169

<269. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24078751
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Maccallum PK
AU  - Mathur R
AU  - Hull SA
AU  - Saja K
AU  - Green L
AU  - Morris JK
AU  - Ashman N
FA  - Maccallum, Peter K
FA  - Mathur, Rohini
FA  - Hull, Sally A
FA  - Saja, Khalid
FA  - Green, Laura
FA  - Morris, Joan K
FA  - Ashman, Neil
IN  - Maccallum,Peter K. Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
TI  - Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study.
SO  - BMJ Open. 3(9):e003343, 2013.
AS  - BMJ Open. 3(9):e003343, 2013.
NJ  - BMJ open
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 101552874
OI  - Source: NLM. PMC3787476
CP  - England
AB  - OBJECTIVE: In clinical trials of dabigatran and rivaroxaban for stroke prevention in atrial fibrillation (AF), drug eligibility and dosing were determined using the Cockcroft-Gault equation to estimate creatine clearance as a measure of renal function. This cross-sectional study aimed to compare whether using estimated glomerular filtration rate (eGFR) by the widely available and widely used Modified Diet in Renal Disease (MDRD) equation would alter prescribing or dosing of the renally excreted new oral anticoagulants.
AB  - PARTICIPANTS: Of 4712 patients with known AF within a general practitioner-registered population of 930 079 in east London, data were available enabling renal function to be calculated by both Cockcroft-Gault and MDRD methods in 4120 (87.4%).
AB  - RESULTS: Of 4120 patients, 2706 were <80 years and 1414 were >80 years of age. Among those >80 years, 14.9% were ineligible for dabigatran according to Cockcroft-Gault equation but would have been judged eligible applying MDRD method. For those <80 years, 0.8% would have been incorrectly judged eligible for dabigatran and 5.3% would have received too high a dose. For rivaroxaban, 0.3% would have been incorrectly judged eligible for treatment and 13.5% would have received too high a dose.
AB  - CONCLUSIONS: Were the MDRD-derived eGFR to be used instead of Cockcroft-Gault in prescribing these new agents, many elderly patients with AF would either incorrectly become eligible for them or would receive too high a dose. Safety has not been established using the MDRD equation, a concern since the risk of major bleeding would be increased in patients with unsuspected renal impairment. Given the potentially widespread use of these agents, particularly in primary care, regulatory authorities and drug companies should alert UK doctors of the need to use the Cockcroft-Gault formula to calculate eligibility for and dosing of the new oral anticoagulants in elderly patients with AF and not rely on the MDRD-derived eGFR.
ES  - 2044-6055
IL  - 2044-6055
DO  - http://dx.doi.org/10.1136/bmjopen-2013-003343
PT  - Journal Article
LG  - English
EP  - 20130927
DP  - 2013
DC  - 20130930
YR  - 2013
ED  - 20130930
RD  - 20160603
UP  - 20160606
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=24078751

<270. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23059863
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Doutreleau S
AU  - Pistea C
AU  - Lonsdorfer E
AU  - Charloux A
FA  - Doutreleau, Stephane
FA  - Pistea, Cristina
FA  - Lonsdorfer, Evelyne
FA  - Charloux, Anne
IN  - Doutreleau,Stephane. Service de Physiologie et d'Explorations Fonctionnelles, CHU de Strasbourg, Strasbourg, France. stephane.doutreleau@chru-strasbourg.fr
TI  - Exercise-induced second-degree atrioventricular block in endurance athletes.
SO  - Medicine & Science in Sports & Exercise. 45(3):411-4, 2013 Mar.
AS  - Med Sci Sports Exerc. 45(3):411-4, 2013 Mar.
NJ  - Medicine and science in sports and exercise
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 8005433, mg8
SB  - Index Medicus
SB  - National Aeronautics and Space Administration (NASA) Journals
CP  - United States
MH  - *Atrioventricular Block/et [Etiology]
MH  - *Atrioventricular Block/pp [Physiopathology]
MH  - Electrocardiography
MH  - Electrophysiologic Techniques, Cardiac
MH  - *Exercise/ph [Physiology]
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Running/ph [Physiology]
AB  - Training induces volume- and time-dependent morphological and functional changes in the heart. Heart rhythm disorders, such as atrial arrhythmia (including atrial fibrillation and atrial flutter), are a well-established consequence of such long-term endurance practice. Although resting bradycardia and first-degree atrioventricular persist in veteran athletes, a higher conduction system impairment has never been reported neither at rest nor during exercise. We report here two cases of Type II second-degree atrioventricular block occurring during exercise in middle-age well-trained athletes. Because animal and human studies suggest that a progressive myocardial fibrosis could explain such phenomenon, long-term training could also have consequences on the conduction pathways.
ES  - 1530-0315
IL  - 0195-9131
DO  - http://dx.doi.org/10.1249/MSS.0b013e318276c9a4
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2013 Mar
DC  - 20130222
YR  - 2013
ED  - 20130926
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23059863

<271. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23419900
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Mearns BM
FA  - Mearns, Bryony M
TI  - Arrhythmias: Benefits of yoga in patients with atrial fibrillation.
CM  - Comment on: J Am Coll Cardiol. 2013 Mar 19;61(11):1177-82; PMID: 23375926
SO  - Nature Reviews Cardiology. 10(4):182, 2013 Apr.
AS  - Nat Rev Cardiol. 10(4):182, 2013 Apr.
NJ  - Nature reviews. Cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101500075
CP  - England
ES  - 1759-5010
IL  - 1759-5002
DO  - http://dx.doi.org/10.1038/nrcardio.2013.21
PT  - Comment
PT  - Journal Article
LG  - English
EP  - 20130219
DP  - 2013 Apr
DC  - 20130322
YR  - 2013
ED  - 20130925
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=23419900

<272. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 24043952
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Finsterer J
AU  - Stollberger C
AU  - Stubenberger E
AU  - Tschakoschian S
FA  - Finsterer, Josef
FA  - Stollberger, Claudia
FA  - Stubenberger, Elisabeth
FA  - Tschakoschian, Sasan
IN  - Finsterer,Josef. Krankenanstalt Rudolfstiftung, Vienna, Austria.
TI  - Lymphangiopathy in neurofibromatosis 1 manifesting with chylothorax, pericardial effusion, and leg edema.
SO  - International journal of general medicine. 6:743-6, 2013.
AS  - Int J Gen Med. 6:743-6, 2013.
NJ  - International journal of general medicine
PI  - Journal available in: Electronic-eCollection
PI  - Citation processed from: Print
JC  - 101515487
OI  - Source: NLM. PMC3772692
CP  - New Zealand
KW  - Recklinghausen's disease;  angiodysplasia;  genetics;  lymph edema;  lymph fluid;  mutation
AB  - BACKGROUND: This case report documents the affliction of the lymph vessels as a phenotypic feature of neurofibromatosis-1 (NF-1).
AB  - METHODOLOGY: Routine transthoracic echocardiography, computed tomography scan of the thorax, magnetic resonance angiography of the renal arteries, and conventional digital subtraction angiography were applied. Comprehensive NF-1 mutation analysis was carried out by fluorescence in situ hybridization analysis, long-range reverse transcriptase polymerase chain reaction, and multiple-ligation probe assay. All other investigations were performed using routine, well-established techniques.
AB  - RESULTS: The subject is a 34-year-old, half-Chinese male; NF-1 was suspected at age 15 years for the first time. His medical history included preterm birth, mild facial dysmorphism, "cafe au lait" spots, subcutaneous and paravertebral fibromas, multifocal tachycardia, atrial fibrillation, and heart failure in early infancy. Noncalcified bone fibromas in the femur and tibia were detected at age 8 years. Surgical right leg lengthening was carried out at age 11 years. Bilateral renal artery stenosis, stenosis and aneurysm of the superior mesenteric artery, and an infrarenal aortic stenosis were detected at age 15 years. Leg edema and ectasia of the basilar artery were diagnosed at age 18 years. After an episode with an erysipela at age 34 years, he developed pericardial and pleural effusion during a 4-month period. Stenosis of the left subclavian vein at the level of thoracic duct insertion was detected. After repeated pleural punctures, pleural effusion was interpreted as chylothorax. Reduction of lymph fluid production by diet and injection of talcum into the pleural cavity had a long-term beneficial effect on the chylothorax. Leg edema and chylothorax were attributed to affliction of the lymph vessels by the NF-1.
AB  - DISCUSSION: Lymphangiopathy resulting in impaired lymph fluid flow and sequestration of lymph fluid into the pleural sinus and the legs may be a rare phenotypic feature of NF-1.
ES  - 1178-7074
IL  - 1178-7074
DO  - http://dx.doi.org/10.2147/IJGM.S45825
PT  - Journal Article
LG  - English
EP  - 20130909
DP  - 2013
DC  - 20130917
YR  - 2013
ED  - 20130917
RD  - 20140124
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=24043952

<273. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23525429
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Fretts AM
AU  - Mozaffarian D
AU  - Siscovick DS
AU  - Heckbert SR
AU  - McKnight B
AU  - King IB
AU  - Rimm EB
AU  - Psaty BM
AU  - Sacks FM
AU  - Song X
AU  - Spiegelman D
AU  - Lemaitre RN
FA  - Fretts, Amanda M
FA  - Mozaffarian, Dariush
FA  - Siscovick, David S
FA  - Heckbert, Susan R
FA  - McKnight, Barbara
FA  - King, Irena B
FA  - Rimm, Eric B
FA  - Psaty, Bruce M
FA  - Sacks, Frank M
FA  - Song, Xiaoling
FA  - Spiegelman, Donna
FA  - Lemaitre, Rozenn N
IN  - Fretts,Amanda M. Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA 98101, USA. amfretts@u.washington.edu
TI  - Associations of plasma phospholipid and dietary alpha linolenic acid with incident atrial fibrillation in older adults: the Cardiovascular Health Study.
CM  - Comment in: J Am Heart Assoc. 2013 Feb;2(1):e000030; PMID: 23525415
SO  - Journal of the American Heart Association. 2(1):e003814, 2013 Feb.
AS  - J Am Heart Assoc. 2(1):e003814, 2013 Feb.
NJ  - Journal of the American Heart Association
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 101580524
OI  - Source: NLM. PMC3603242
SB  - Index Medicus
CP  - England
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrial Fibrillation/bl [Blood]
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Biomarkers/bl [Blood]
MH  - *Diet
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Linear Models
MH  - Longitudinal Studies
MH  - Male
MH  - Nutritional Status
MH  - *Phospholipids/bl [Blood]
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - United States/ep [Epidemiology]
MH  - *alpha-Linolenic Acid/bl [Blood]
AB  - BACKGROUND: Few studies have examined the relationship of alpha-linolenic acid (ALA 18:3n-3), an intermediate-chain essential n-3 polyunsaturated fatty acid derived from plants and vegetable oils, with incident atrial fibrillation (AF).
AB  - METHODS AND RESULTS: The study population included participants from the Cardiovascular Health Study, a community-based longitudinal cohort of adults aged 65 or older, free of prevalent coronary heart disease and atrial fibrillation. We assessed the associations of plasma phospholipid and dietary ALA with incident AF using Cox regression. The biomarker analysis comprised a total of 2899 participants, and the dietary analysis comprised 4337 participants. We found no association of plasma phospholipid ALA and incident AF. Comparing each of the second, third, and fourth quartiles to the lowest quartile, the hazard ratios for AF were 1.11 (95% CI, 0.90 to 1.37), 1.09 (95% CI, 0.88 to 1.35), and 0.92 (95% CI, 0.74 to 1.15), after adjustment for age, sex, race, clinic, education, smoking, alcohol, body mass index, waist circumference, diabetes, heart failure, stroke, treated hypertension, and physical activity (P trend=0.48). When dietary ALA was considered the exposure of interest, results were similar.
AB  - CONCLUSIONS: Results from this prospective cohort study of older adults indicate no association of plasma phospholipid or dietary ALA and incident AF.
RN  - 0 (Biomarkers)
RN  - 0 (Phospholipids)
RN  - 0RBV727H71 (alpha-Linolenic Acid)
ES  - 2047-9980
IL  - 2047-9980
DO  - http://dx.doi.org/10.1161/JAHA.112.003814
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
NO  - AG-023629 (United States NIA NIH HHS)
NO  - AG-027058 (United States NIA NIH HHS)
NO  - AG-15928 (United States NIA NIH HHS)
NO  - AG-20098 (United States NIA NIH HHS)
NO  - HL080295 (United States NHLBI NIH HHS)
NO  - HL102214 (United States NHLBI NIH HHS)
NO  - N01 HC-15103 (United States NHLBI NIH HHS)
NO  - N01 HC-55222 (United States NHLBI NIH HHS)
NO  - N01-HC-35129 (United States NHLBI NIH HHS)
NO  - N01-HC-45133 (United States NHLBI NIH HHS)
NO  - N01-HC-75150 (United States NHLBI NIH HHS)
NO  - N01-HC-85079 (United States NHLBI NIH HHS)
NO  - N01-HC-85080 (United States NHLBI NIH HHS)
NO  - N01-HC-85081 (United States NHLBI NIH HHS)
NO  - N01-HC-85082 (United States NHLBI NIH HHS)
NO  - N01-HC-85083 (United States NHLBI NIH HHS)
NO  - N01-HC-85084 (United States NHLBI NIH HHS)
NO  - N01-HC-85085 (United States NHLBI NIH HHS)
NO  - N01-HC-85086 (United States NHLBI NIH HHS)
NO  - N01-HC-85239 (United States NHLBI NIH HHS)
NO  - R01-HL-085710-01 (United States NHLBI NIH HHS)
LG  - English
EP  - 20130131
DP  - 2013 Feb
DC  - 20130325
YR  - 2013
ED  - 20130913
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23525429

<274. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23525415
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kastner DW
AU  - Van Wagoner DR
FA  - Kastner, Devera W
FA  - Van Wagoner, David R
TI  - Diet and atrial fibrillation: does alpha-linolenic acid, a plant derived essential fatty acid, have an impact?.
CM  - Comment on: J Am Heart Assoc. 2013 Feb;2(1):e003814; PMID: 23525429
SO  - Journal of the American Heart Association. 2(1):e000030, 2013 Feb.
AS  - J Am Heart Assoc. 2(1):e000030, 2013 Feb.
NJ  - Journal of the American Heart Association
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 101580524
OI  - Source: NLM. PMC3603232
SB  - Index Medicus
CP  - England
MH  - *Atrial Fibrillation/bl [Blood]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - *Diet
MH  - Female
MH  - Humans
MH  - Male
MH  - *Phospholipids/bl [Blood]
MH  - *alpha-Linolenic Acid/bl [Blood]
RN  - 0 (Phospholipids)
RN  - 0RBV727H71 (alpha-Linolenic Acid)
ES  - 2047-9980
IL  - 2047-9980
DO  - http://dx.doi.org/10.1161/JAHA.112.000030
PT  - Comment
PT  - Editorial
NO  - R01 HL090620 (United States NHLBI NIH HHS)
NO  - R01 HL111314 (United States NHLBI NIH HHS)
LG  - English
EP  - 20130222
DP  - 2013 Feb
DC  - 20130325
YR  - 2013
ED  - 20130913
RD  - 20150427
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23525415

<275. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23291664
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Bramlage P
AU  - Cuneo A
AU  - Zeymer U
AU  - Hochadel M
AU  - Richardt G
AU  - Silber S
AU  - Senges J
AU  - Nienaber CA
AU  - Tebbe U
AU  - Kuck KH
FA  - Bramlage, Peter
FA  - Cuneo, Alessandro
FA  - Zeymer, Uwe
FA  - Hochadel, Matthias
FA  - Richardt, Gert
FA  - Silber, Sigmund
FA  - Senges, Jochen
FA  - Nienaber, Christoph A
FA  - Tebbe, Ulrich
FA  - Kuck, Karl-Heinz
IN  - Bramlage,Peter. Institut fur Pharmakologie und praventive Medizin, Mahlow, Germany.
TI  - Prognosis of patients with atrial fibrillation undergoing percutaneous coronary intervention receiving drug eluting stents.
SO  - Clinical Research in Cardiology. 102(4):289-97, 2013 Apr.
AS  - Clin. res. cardiol.. 102(4):289-97, 2013 Apr.
NJ  - Clinical research in cardiology : official journal of the German Cardiac Society
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101264123
SB  - Index Medicus
CP  - Germany
MH  - Age Factors
MH  - Aged
MH  - Atrial Fibrillation/mo [Mortality]
MH  - *Atrial Fibrillation/su [Surgery]
MH  - Cardiovascular Diseases/ep [Epidemiology]
MH  - Cardiovascular Diseases/et [Etiology]
MH  - *Drug-Eluting Stents
MH  - Follow-Up Studies
MH  - Germany
MH  - Hemorrhage/ep [Epidemiology]
MH  - Hemorrhage/et [Etiology]
MH  - Humans
MH  - Logistic Models
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - *Percutaneous Coronary Intervention/mt [Methods]
MH  - Prognosis
MH  - Registries
MH  - Stroke/ep [Epidemiology]
MH  - Stroke/et [Etiology]
MH  - Time Factors
AB  - BACKGROUND: Atrial fibrillation (AF) is increasingly prevalent in elderly patients and adversely affects clinical outcomes after coronary artery bypass grafting, non-cardiac surgery or myocardial infarction. Aim of the present analysis was to investigate the prognostic impact of AF in patients undergoing drug eluting stent (DES) implantation during a 1-year follow-up.
AB  - PATIENTS AND METHODS: 5,772 consecutive patients undergoing percutaneous coronary intervention were enrolled into the German Drug Eluting Stent Registry (DES.DE) and were followed for 12 months. Of these 455 had AF and 5,317 in sinus rhythm served as controls. Univariate and multivariate logistic regression analyses were used to determine the risk of major adverse cardiac and cerebrovascular events (MACCE) and bleeding complications.
AB  - RESULTS: Patients with AF were older (71.3 +/- 7.6 vs. 64.7 +/- 10.5 years) and had a higher prevalence of diabetes, hypertension, renal insufficiency as well as more prior bypass surgery, stroke and peripheral arterial disease. Cardiogenic shock (2.9 vs. 1.4 %; p < 0.05), left ventricular ejection fraction <40 % (21.0 vs. 11.4 %; p < 0.0001) and triple vessel disease (44.4 vs. 37.9 %; p < 0.01) were more frequent in patients with AF than in controls. MACCE (OR 2.08, 95 % CI 1.56-2.77), total mortality (OR 3.27, 95 % CI 2.32-4.62) and non-fatal stroke (OR 2.03, 95 % CI 1.03-4.00) as well as bleeding complications (OR 1.88, 95 % CI 1.13-3.12) during the 1-year follow-up were more frequent in patients with AF (univariate analysis). In multivariate analyses adjusting for covariates determined to be relevant at baseline, the risk for total mortality remained elevated (OR 1.63, 95 % CI 1.05-2.52).
AB  - CONCLUSIONS: AF is an important predictor of long-term mortality in patients undergoing DES implantation.
ES  - 1861-0692
IL  - 1861-0684
DO  - http://dx.doi.org/10.1007/s00392-012-0533-2
PT  - Journal Article
LG  - English
EP  - 20130105
DP  - 2013 Apr
DC  - 20130319
YR  - 2013
ED  - 20130913
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23291664

<276. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23766449
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Overvad TF
AU  - Rasmussen LH
AU  - Skjoth F
AU  - Overvad K
AU  - Albertsen IE
AU  - Lane DA
AU  - Lip GY
AU  - Larsen TB
FA  - Overvad, Thure Filskov
FA  - Rasmussen, Lars Hvilsted
FA  - Skjoth, Flemming
FA  - Overvad, Kim
FA  - Albertsen, Ida Ehlers
FA  - Lane, Deirdre A
FA  - Lip, Gregory Y H
FA  - Larsen, Torben Bjerregaard
IN  - Overvad,Thure Filskov. Department of Cardiology, Cardiovascular Research Centre, Aalborg University Hospital, Aalborg, Denmark.
TI  - Alcohol intake and prognosis of atrial fibrillation.
SO  - Heart. 99(15):1093-9, 2013 Aug.
AS  - Heart. 99(15):1093-9, 2013 Aug.
NJ  - Heart (British Cardiac Society)
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9602087
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - Age Factors
MH  - Aged
MH  - Alcohol Drinking/ae [Adverse Effects]
MH  - Alcohol Drinking/ep [Epidemiology]
MH  - *Alcohol Drinking
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation
MH  - Cohort Studies
MH  - Comorbidity
MH  - Denmark/ep [Epidemiology]
MH  - Female
MH  - Humans
MH  - Male
MH  - Medical Records, Problem-Oriented/sn [Statistics & Numerical Data]
MH  - Middle Aged
MH  - Outcome Assessment (Health Care)/sn [Statistics & Numerical Data]
MH  - Risk Assessment
MH  - Risk Factors
MH  - Sex Factors
MH  - Thromboembolism/ep [Epidemiology]
MH  - Thromboembolism/et [Etiology]
MH  - Thromboembolism/pc [Prevention & Control]
MH  - *Thromboembolism
AB  - OBJECTIVE: To assess alcohol intake as a risk factor for adverse events among patients with incident atrial fibrillation (AF).
AB  - DESIGN: Prospective cohort study.
AB  - SETTING: Population based cohort study and nationwide Danish registries.
AB  - PATIENTS: The Danish Diet, Cancer and Health study included 57 053 participants (27 178 men and 29 875 women) aged between 50 and 64 years. The study population for this study included the 3107 participants (1999 men, 1108 women) who developed incident AF after inclusion.
AB  - MAIN OUTCOME MEASURES: A composite of thromboembolism or death.
AB  - RESULTS: During a median follow-up of 4.9 years 608 deaths and 211 thromboembolic events occurred. Of those who developed AF, 690 (35%) men and 233 (21%) women had a high intake of alcohol (>20 drinks/week for men and >13 drinks/week for women). After adjustment for use of oral anticoagulation and components of the CHA2DS2-VASc score, men with an intake of >27 drinks/week had a higher risk for thromboembolism or death (hazard ratio (HR) 1.33, 95% CI 1.08 to 1.63) than men with an intake of <14 drinks/week. Women with an intake of >20 drinks/week also had a higher risk (HR 1.23, 95% CI 0.78 to 1.96) than women in the low intake category. The higher risk among men was primarily driven by mortality (HR 1.51, 95% CI 1.20 to 1.89), whereas the risk found among women was driven by thromboembolism (HR 1.71, 95% CI 0.81 to 3.60).
AB  - CONCLUSIONS: High alcohol intake predicts thromboembolism or death, even after adjustment for established clinical risk factors, and may help identify high risk AF patients who could be targeted for stroke and cardiovascular prevention strategies.
RN  - 0 (Anticoagulants)
ES  - 1468-201X
IL  - 1355-6037
DO  - http://dx.doi.org/10.1136/heartjnl-2013-304036
PT  - Journal Article
LG  - English
EP  - 20130613
DP  - 2013 Aug
DC  - 20130708
YR  - 2013
ED  - 20130910
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23766449

<277. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23371818
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Garcia DA
FA  - Garcia, David A
IN  - Garcia,David A. University of Washington, Seattle, WA 98109, USA. davidg99@u.washington.edu
TI  - Patients with stable, therapeutic INR values should remain on warfarin. [Review]
SO  - Journal of Thrombosis & Thrombolysis. 35(3):336-8, 2013 Apr.
AS  - J Thromb Thrombolysis. 35(3):336-8, 2013 Apr.
NJ  - Journal of thrombosis and thrombolysis
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - ddy, 9502018
SB  - Index Medicus
CP  - Netherlands
MH  - Administration, Oral
MH  - Anticoagulants/ae [Adverse Effects]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Female
MH  - Humans
MH  - *International Normalized Ratio
MH  - Male
MH  - *Monitoring, Physiologic
MH  - Warfarin/ae [Adverse Effects]
MH  - *Warfarin/tu [Therapeutic Use]
AB  - The second decade of the 21st century will be remembered as a significant milestone in the treatment and prevention of thromboembolic diseases. The approval of target-specific oral anticoagulants (TSOACs) means that patients with atrial fibrillation (AF) have, for the first time ever, multiple treatment options for the prevention of embolic stroke. Evidence from the landmark registration trials convincingly shows that the TSOACs are at least as safe and effective as warfarin in this setting. Because the new agents do not require routine coagulation monitoring and have very few drug or dietary interactions, they offer both convenience and, possibly, a public health benefit if they are used by patients who otherwise would have declined to take warfarin. However, patients on a highly stable, therapeutic dose of warfarin should not expect better health outcomes if switching to a TSOAC.
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
ES  - 1573-742X
IL  - 0929-5305
DO  - http://dx.doi.org/10.1007/s11239-013-0867-2
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2013 Apr
DC  - 20130327
YR  - 2013
ED  - 20130910
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23371818

<278. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23816780
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Truffa AA
AU  - Lopes RD
AU  - Newby LK
FA  - Truffa, Adriano A
FA  - Lopes, Renato D
FA  - Newby, L Kristin
IN  - Truffa,Adriano A. Duke Clinical Research Institute and the Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, NC 27705, USA.
TI  - Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012. [Review]
SO  - Postgraduate Medicine. 125(2):146-57, 2013 Mar.
AS  - Postgrad Med. 125(2):146-57, 2013 Mar.
NJ  - Postgraduate medicine
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 0401147, pfk
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/co [Complications]
MH  - Benzimidazoles/tu [Therapeutic Use]
MH  - Dabigatran
MH  - Humans
MH  - Morpholines/tu [Therapeutic Use]
MH  - Pyrazoles/tu [Therapeutic Use]
MH  - Pyridines/tu [Therapeutic Use]
MH  - Pyridones/tu [Therapeutic Use]
MH  - Rivaroxaban
MH  - Stroke/et [Etiology]
MH  - *Stroke/pc [Prevention & Control]
MH  - Thiazoles/tu [Therapeutic Use]
MH  - Thiophenes/tu [Therapeutic Use]
MH  - Warfarin/ae [Adverse Effects]
MH  - Warfarin/tu [Therapeutic Use]
MH  - beta-Alanine/aa [Analogs & Derivatives]
MH  - beta-Alanine/tu [Therapeutic Use]
AB  - Stroke is the most feared complication among patients with atrial fibrillation. Oral anticoagulation therapy with vitamin K antagonists (VKAs) has been the gold standard for stroke prevention for the past 60 years. However, VKA therapy has many downsides, including risk for bleeding, a narrow therapeutic window, and the need for frequent monitoring, as well as numerous diet and lifestyle considerations that make its use cumbersome. Thus, development of new drugs that can preserve the benefits of VKAs while eliminating the negative aspects of VKA therapy has been enthusiastically sought. This article reviews the anticoagulant agents that are clinically available or under development as alternatives to VKAs for stroke prevention in patients with nonvalvular atrial fibrillation.
RN  - 0 (Anticoagulants)
RN  - 0 (Benzimidazoles)
RN  - 0 (Morpholines)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridines)
RN  - 0 (Pyridones)
RN  - 0 (Thiazoles)
RN  - 0 (Thiophenes)
RN  - 11P2JDE17B (beta-Alanine)
RN  - 3Z9Y7UWC1J (apixaban)
RN  - 480449-70-5 (edoxaban)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - I0VM4M70GC (Dabigatran)
ES  - 1941-9260
IL  - 0032-5481
DO  - http://dx.doi.org/10.3810/pgm.2013.03.2648
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2013 Mar
DC  - 20130702
YR  - 2013
ED  - 20130903
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23816780

<279. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23601271
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Overvad TF
AU  - Rasmussen LH
AU  - Skjoth F
AU  - Overvad K
AU  - Lip GY
AU  - Larsen TB
FA  - Overvad, Thure Filskov
FA  - Rasmussen, Lars Hvilsted
FA  - Skjoth, Flemming
FA  - Overvad, Kim
FA  - Lip, Gregory Y H
FA  - Larsen, Torben Bjerregaard
IN  - Overvad,Thure Filskov. Department of Cardiology, Cardiovascular Research Centre, Aalborg University Hospital, Aalborg, Denmark.
TI  - Body mass index and adverse events in patients with incident atrial fibrillation.
SO  - American Journal of Medicine. 126(7):640.e9-17, 2013 Jul.
AS  - Am J Med. 126(7):640.e9-17, 2013 Jul.
NJ  - The American journal of medicine
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 0267200, 3ju
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - Body Mass Index
MH  - Cohort Studies
MH  - Denmark/ep [Epidemiology]
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - *Obesity/co [Complications]
MH  - Obesity/ep [Epidemiology]
MH  - *Overweight/co [Complications]
MH  - Overweight/ep [Epidemiology]
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Sex Factors
MH  - Stroke/ep [Epidemiology]
MH  - *Stroke/et [Etiology]
MH  - Thromboembolism/ep [Epidemiology]
MH  - *Thromboembolism/et [Etiology]
AB  - BACKGROUND: Obesity is associated with the development of atrial fibrillation and may impact atrial fibrillation-related outcomes. To date, no anthropometric measure is included in any risk stratification scheme for stroke and death in atrial fibrillation patients.
AB  - METHODS: The prospective Danish Diet, Cancer and Health study is a cohort including 57,053 participants (27,178 men and 29,875 women) aged between 50 and 64 years. The study population for this study included the 3135 patients (2025 men and 1110 women) who developed incident atrial fibrillation during follow-up.
AB  - RESULTS: Of the subjects with atrial fibrillation, 1414 (45%) had a body mass index (BMI) in the overweight category (BMI 25 to <30 kg/m(2)) and 767 (24%) were categorized as obese (BMI >30 kg/m(2)). During a median follow-up of 4.9 years, 609 deaths and 216 thromboembolic events (98% ischemic strokes) occurred. Using normal-weight patients as reference, the risk of a composite end point of "ischemic stroke, thromboembolism, or death" was significantly higher in overweight (crude hazard ratio [HR] 1.31; 95% confidence interval [CI], 1.09-1.56) and obese patients (crude HR 1.55; 95% CI 1.27-1.90). After adjustment for CHADS2 and CHA2DS2-VASc scores, the HRs for the composite end point were 1.21 (95% CI 1.02-1.45) and 1.31 (95% CI 1.10-1.56), respectively, for overweight and 1.25 (95% CI 1.03-1.53) and 1.36 (95% CI 1.11-1.65), respectively, for obese. Continuous analyses of BMI stratified by sex identified obese men and normal-weight women as the sex-specific "high-risk" categories.
AB  - CONCLUSION: Overweight and obesity are risk factors for "ischemic stroke, thromboembolism or death" in patients with atrial fibrillation, even after adjustment for CHADS2 and CHA2DS2-VASc scores. The association between BMI and outcomes among atrial fibrillation patients may be modified by sex.Copyright © 2013 Elsevier Inc. All rights reserved.
ES  - 1555-7162
IL  - 0002-9343
DI  - S0002-9343(13)00090-9
DO  - http://dx.doi.org/10.1016/j.amjmed.2012.11.024
PT  - Journal Article
LG  - English
EP  - 20130417
DP  - 2013 Jul
DC  - 20130621
YR  - 2013
ED  - 20130828
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23601271

<280. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21798731
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mattioli AV
AU  - Miloro C
AU  - Pennella S
AU  - Pedrazzi P
AU  - Farinetti A
FA  - Mattioli, A V
FA  - Miloro, C
FA  - Pennella, S
FA  - Pedrazzi, P
FA  - Farinetti, A
IN  - Mattioli,A V. Department of Biomedical Science, Sect of Cardiology, University of Modena and Reggio Emilia, Modena, Italy. annavittoria.mattioli@unimore.it
TI  - Adherence to Mediterranean diet and intake of antioxidants influence spontaneous conversion of atrial fibrillation.
CM  - Comment in: Nutr Metab Cardiovasc Dis. 2013 Jun;23(6):e28-9; PMID: 23582310
SO  - Nutrition Metabolism & Cardiovascular Diseases. 23(2):115-21, 2013 Feb.
AS  - Nutr Metab Cardiovasc Dis. 23(2):115-21, 2013 Feb.
NJ  - Nutrition, metabolism, and cardiovascular diseases : NMCD
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9111474, DGW
SB  - Index Medicus
CP  - Netherlands
MH  - Adult
MH  - Aged
MH  - *Antioxidants/ad [Administration & Dosage]
MH  - *Atrial Fibrillation/dh [Diet Therapy]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Body Mass Index
MH  - Case-Control Studies
MH  - *Diet, Mediterranean
MH  - Female
MH  - Humans
MH  - Life Style
MH  - Male
MH  - Middle Aged
MH  - Nutrition Assessment
MH  - Nutritional Status
MH  - *Patient Compliance
MH  - Surveys and Questionnaires
AB  - BACKGROUND AND AIM: The Mediterranean diet (MedD) has long been associated with lower incidence of cardiovascular disease. Little information is available on association between MedD, vitamins intake and arrhythmias. We sought to investigate the relationship between adherence to MedD, antioxidants intake and spontaneous conversion of atrial fibrillation (AF).
AB  - METHODS AND RESULTS: A group of 800 subjects was included in a case-control study; 400 of them had a first detected episode of AF. Nutritional parameters were assessed by a self-administered food frequency validated questionnaire and completed by an interviewer-administered 7 days diet recall. Adherence to MedD was evaluated using the Mediterranean Score and intake of antioxidants from food was calculated. Adherence to the Med Diet was lower in patients that developed AF compared to control (mean Med Score: 22.3 +/- 3.1 vs 27.9 +/- 5.6; p < 0.001). The median value was 23.5 (Q1-Q3 range 23-30) in patients with AF and 27.4 (Q1-Q3 range 26-33). The estimated intake of total antioxidants was lower in patients with AF (13.5 +/- 8.3 vs 18.2 +/- 9.4 mmol/d; p < 0.001). Patients in the highest quartile of Mediterranean Score had higher probability of spontaneous conversion of atrial fibrillation (OR1.9; 95%CI 1.58-2.81). High levels of antioxidants intake were also associated with an increasing probability of spontaneous conversion of arrhythmia (O.R. 1.8; 95%CI 1.56-2.99; P < 0.01).
AB  - CONCLUSIONS: Patients with atrial fibrillation had lower adherence to MedD and lower antioxidant intake compared to control population. Moreover patients with arrhythmia showing a higher Med Score had more probability of a spontaneous conversion of atrial fibrillation.Copyright © 2011 Elsevier B.V. All rights reserved.
RN  - 0 (Antioxidants)
ES  - 1590-3729
IL  - 0939-4753
DI  - S0939-4753(11)00072-X
DO  - http://dx.doi.org/10.1016/j.numecd.2011.03.005
PT  - Journal Article
LG  - English
EP  - 20110727
DP  - 2013 Feb
DC  - 20130211
YR  - 2013
ED  - 20130812
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=21798731

<281. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23047297
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Misialek JR
AU  - Lopez FL
AU  - Lutsey PL
AU  - Huxley RR
AU  - Peacock JM
AU  - Chen LY
AU  - Soliman EZ
AU  - Agarwal SK
AU  - Alonso A
FA  - Misialek, Jeffrey R
FA  - Lopez, Faye L
FA  - Lutsey, Pamela L
FA  - Huxley, Rachel R
FA  - Peacock, James M
FA  - Chen, Lin Y
FA  - Soliman, Elsayed Z
FA  - Agarwal, Sunil K
FA  - Alonso, Alvaro
IN  - Misialek,Jeffrey R. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN 55454, USA.misi0020@umn.edu
TI  - Serum and dietary magnesium and incidence of atrial fibrillation in whites and in African Americans--Atherosclerosis Risk in Communities (ARIC) study.
SO  - Circulation Journal. 77(2):323-9, 2013.
AS  - Circ J. 77(2):323-9, 2013.
NJ  - Circulation journal : official journal of the Japanese Circulation Society
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101137683
OI  - Source: NLM. NIHMS634560
OI  - Source: NLM. PMC4228988
SB  - Index Medicus
CP  - Japan
MH  - *African Americans/sn [Statistics & Numerical Data]
MH  - Atherosclerosis/dh [Diet Therapy]
MH  - *Atherosclerosis/eh [Ethnology]
MH  - Atherosclerosis/me [Metabolism]
MH  - *Atrial Fibrillation/dh [Diet Therapy]
MH  - *Atrial Fibrillation/eh [Ethnology]
MH  - Atrial Fibrillation/me [Metabolism]
MH  - *European Continental Ancestry Group/sn [Statistics & Numerical Data]
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Magnesium/ad [Administration & Dosage]
MH  - *Magnesium/bl [Blood]
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Residence Characteristics
MH  - Risk Factors
MH  - Sex Distribution
MH  - United States/ep [Epidemiology]
AB  - BACKGROUND: Low serum magnesium (Mg) has been associated with an increased risk of cardiovascular disease (CVD), including ventricular arrhythmias, but the association between serum or dietary Mg and atrial fibrillation (AF) has not been investigated.
AB  - METHODS AND RESULTS: A total of 14,290 men and women (75% white; 53% female; mean age, 54 years) free of AF at baseline participating in the Atherosclerosis Risk in Communities study in the United States, were studied. Incident AF cases through 2009 were ascertained from electrocardiograms, hospital discharge codes, and death certificates. Multivariate Cox proportional hazards regression was used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for AF associated with serum and dietary Mg quintiles. Over a median follow-up time of 20.6 years, 1,755 incident AF cases were identified. In multivariate models, lower serum Mg was associated with higher AF risk: compared to individuals in the middle quintile (> 0.80-0.83 mmol/L), the HR (95% CI) of AF in quintiles 1, 2, 4, and 5 were 1.34 (1.16-1.54), 0.99 (0.85-1.16), 1.04 (0.90-1.22), and 1.06 (0.91-1.23), respectively. There was no evidence of significant interactions between serum Mg and sex or race. No association between dietary Mg and AF risk was observed.
AB  - CONCLUSIONS: Lower serum Mg was associated with a higher AF risk, and this association was not different between whites and African Americans. Dietary Mg was not associated with AF risk.
RN  - I38ZP9992A (Magnesium)
ES  - 1347-4820
IL  - 1346-9843
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
NO  - HHSN268201100005C (United States NHLBI NIH HHS)
NO  - HHSN268201100006C (United States NHLBI NIH HHS)
NO  - HHSN268201100007C (United States NHLBI NIH HHS)
NO  - HHSN268201100008C (United States NHLBI NIH HHS)
NO  - HHSN268201100009C (United States NHLBI NIH HHS)
NO  - HHSN268201100010C (United States NHLBI NIH HHS)
NO  - HHSN268201100011C (United States NHLBI NIH HHS)
NO  - HHSN268201100012C (United States NHLBI NIH HHS)
NO  - N01 HC055019 (United States NHLBI NIH HHS)
NO  - R01 HL103706 (United States NHLBI NIH HHS)
NO  - R01-HL103706S1 (United States NHLBI NIH HHS)
NO  - RC1 HL099452 (United States NHLBI NIH HHS)
NO  - RC1-HL099452 (United States NHLBI NIH HHS)
LG  - English
EP  - 20121006
DP  - 2013
DC  - 20130129
YR  - 2013
ED  - 20130812
RD  - 20150222
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23047297

<282. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23430665
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Borghi C
AU  - Pareo I
FA  - Borghi, Claudio
FA  - Pareo, Ilenia
IN  - Borghi,Claudio. Division of Internal Medicine, University of Bologna, Sant'Orsola Malpighi Hospital, Via Massarenti 9, 40138, Bologna, Italy. claudio.borghi@unibo.it
TI  - Omega-3 in antiarrhythmic therapy : cons position. [Review]
CM  - Comment in: High Blood Press Cardiovasc Prev. 2012 Dec;19(4):199-200; PMID: 23430663
SO  - High Blood Pressure & Cardiovascular Prevention. 19(4):207-11, 2012 Dec.
AS  - High blood press. cardiovasc. prev.. 19(4):207-11, 2012 Dec.
NJ  - High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9421087
SB  - Index Medicus
CP  - New Zealand
MH  - Anti-Arrhythmia Agents/ae [Adverse Effects]
MH  - *Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - *Arrhythmias, Cardiac/dt [Drug Therapy]
MH  - Arrhythmias, Cardiac/et [Etiology]
MH  - Arrhythmias, Cardiac/mo [Mortality]
MH  - Arrhythmias, Cardiac/pp [Physiopathology]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Death, Sudden, Cardiac/et [Etiology]
MH  - *Death, Sudden, Cardiac/pc [Prevention & Control]
MH  - Evidence-Based Medicine
MH  - Fatty Acids, Omega-3/ae [Adverse Effects]
MH  - *Fatty Acids, Omega-3/tu [Therapeutic Use]
MH  - Humans
MH  - Myocardial Infarction/co [Complications]
MH  - *Myocardial Infarction/dt [Drug Therapy]
MH  - Myocardial Infarction/mo [Mortality]
MH  - Myocardial Infarction/pp [Physiopathology]
MH  - Tachycardia, Ventricular/dt [Drug Therapy]
MH  - Tachycardia, Ventricular/et [Etiology]
MH  - Treatment Outcome
MH  - Ventricular Fibrillation/dt [Drug Therapy]
MH  - Ventricular Fibrillation/et [Etiology]
AB  - The association between omega-3 (n-3 polyunsaturated fatty acids) and the clinical outcome of patients with cardiovascular diseases such as coronary heart disease is currently unclear, especially regarding its possible antiarrhythmic effects and the not quite understood mechanisms of action. In the last 15 years, several epidemiological studies have shown a lower incidence of sudden cardiac death with a diet rich in omega-3 or fish consumption. The antiarrhythmic properties related to omega-3 have been related to modulation of sodium-dependent ion channels or sodium-calcium exchangers of myocytes through a reduction of their excitability especially in ischaemic or damaged myocardial tissue. However, the results of experimental studies have not always been consistent. Although the role of omega-3 in preventing sudden cardiac death has been evaluated in several clinical trials that included patients with coronary artery disease (particularly in patients with post-myocardial infarction), the interpretation of such data must be treated with extreme caution. In particular, while a reduction in cardiac death was demonstrated by a meta-analysis of several randomized clinical trials, a reduced risk of sudden cardiac death has been described only in the GISSI-Prevenzione study, while in other studies the evidence that emerged is more controversial, with wide confidence intervals that support the possibility of heterogeneity in the distribution of the factors involved in the efficacy of treatment. Omega-3 is probably involved in the prevention of cardiovascular mortality through different mechanisms, and it is crucial to study its association with other drugs such as ACE inhibitors or calcium channel blockers. The study of antiarrhythmic drugs has been divided into prevention of supraventricular and ventricular arrhythmias. In these conditions, the role of omega-3 seems to be more pronounced in atrial tachyarrhythmias such as atrial fibrillation, but does not have a role in ventricular arrhythmias. In summary, the antiarrhythmic effect of omega-3 is not clearly evident and further studies are needed to investigate its beneficial effect in cardiac mortality compared with arrhythmic death.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Fatty Acids, Omega-3)
ES  - 1179-1985
IL  - 1120-9879
DO  - http://dx.doi.org/10.1007/BF03297632
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20130219
DP  - 2012 Dec
DC  - 20130222
YR  - 2012
ED  - 20130812
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23430665

<283. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23700039
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Alings M
AU  - Smit MD
AU  - Moes ML
AU  - Crijns HJ
AU  - Tijssen JG
AU  - Brugemann J
AU  - Hillege HL
AU  - Lane DA
AU  - Lip GY
AU  - Smeets JR
AU  - Tieleman RG
AU  - Tukkie R
AU  - Willems FF
AU  - Vermond RA
AU  - Van Veldhuisen DJ
AU  - Van Gelder IC
FA  - Alings, M
FA  - Smit, M D
FA  - Moes, M L
FA  - Crijns, H J G M
FA  - Tijssen, J G P
FA  - Brugemann, J
FA  - Hillege, H L
FA  - Lane, D A
FA  - Lip, G Y H
FA  - Smeets, J R L M
FA  - Tieleman, R G
FA  - Tukkie, R
FA  - Willems, F F
FA  - Vermond, R A
FA  - Van Veldhuisen, D J
FA  - Van Gelder, I C
IN  - Alings,M. Department of Cardiology, Amphia Hospital, Breda, the Netherlands.
TI  - Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 study.
SO  - Netherlands Heart Journal. 21(7-8):354-63, 2013 Jul.
AS  - Neth Heart J. 21(7-8):354-63, 2013 Jul.
NJ  - Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101095458
OI  - Source: NLM. PMC3722377
CP  - Netherlands
AB  - BACKGROUND: Rhythm control for atrial fibrillation (AF) is cumbersome because of its progressive nature caused by structural remodelling. Upstream therapy refers to therapeutic interventions aiming to modify the atrial substrate, leading to prevention of AF.
AB  - OBJECTIVE: The Routine versus Aggressive upstream rhythm Control for prevention of Early AF in heart failure (RACE 3) study hypothesises that aggressive upstream rhythm control increases persistence of sinus rhythm compared with conventional rhythm control in patients with early AF and mild-to-moderate early systolic or diastolic heart failure undergoing electrical cardioversion.
AB  - DESIGN: RACE 3 is a prospective, randomised, open, multinational, multicenter trial. Upstream rhythm control consists of angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers, mineralocorticoid receptor antagonists, statins, cardiac rehabilitation therapy, and intensive counselling on dietary restrictions, exercise maintenance, and drug adherence. Conventional rhythm control consists of routine rhythm control therapy without cardiac rehabilitation therapy and intensive counselling. In both arms, every effort is made to keep patients in the rhythm control strategy, and ion channel antiarrhythmic drugs or pulmonary vein ablation may be instituted if AF relapses. Total inclusion will be 250 patients. If upstream therapy proves to be effective in improving maintenance of sinus rhythm, it could become a new approach to rhythm control supporting conventional pharmacological and non-pharmacological rhythm control.
IS  - 1568-5888
IL  - 1568-5888
DO  - http://dx.doi.org/10.1007/s12471-013-0428-5
PT  - Journal Article
LG  - English
DP  - 2013 Jul
DC  - 20130725
YR  - 2013
ED  - 20130725
RD  - 20130802
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=23700039

<284. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23546173
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Borne RT
AU  - Varosy PD
AU  - Masoudi FA
FA  - Borne, Ryan T
FA  - Varosy, Paul D
FA  - Masoudi, Frederick A
IN  - Borne,Ryan T. Department of Medicine, Denver Health and Hospital Authority, Denver, CO, USA. ryan.borne@dhha.org
TI  - Implantable cardioverter-defibrillator shocks: epidemiology, outcomes, and therapeutic approaches. [Review]
CM  - Comment in: JAMA Intern Med. 2013 Dec 9-23;173(22):2094; PMID: 24322468
CM  - Comment in: JAMA Intern Med. 2013 Dec 9-23;173(22):2093-4; PMID: 24322466
SO  - JAMA Internal Medicine. 173(10):859-65, 2013 May 27.
AS  - JAMA Intern Med. 173(10):859-65, 2013 May 27.
NJ  - JAMA internal medicine
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101589534
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Anti-Arrhythmia Agents/ad [Administration & Dosage]
MH  - Anti-Arrhythmia Agents/ae [Adverse Effects]
MH  - *Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - Atrial Fibrillation/co [Complications]
MH  - Catheter Ablation
MH  - Clinical Trials as Topic
MH  - Death, Sudden, Cardiac/et [Etiology]
MH  - *Death, Sudden, Cardiac/pc [Prevention & Control]
MH  - Defibrillators, Implantable/ae [Adverse Effects]
MH  - *Defibrillators, Implantable
MH  - Disease Progression
MH  - Evidence-Based Medicine
MH  - Exercise
MH  - Health Status
MH  - Heart Failure/co [Complications]
MH  - Heart Failure/pp [Physiopathology]
MH  - *Heart Failure/th [Therapy]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Quality of Life
MH  - Tachycardia, Ventricular/et [Etiology]
MH  - Tachycardia, Ventricular/pp [Physiopathology]
MH  - Tachycardia, Ventricular/su [Surgery]
MH  - *Tachycardia, Ventricular/th [Therapy]
MH  - Treatment Outcome
MH  - Ventricular Function, Left
AB  - IMPORTANCE: Implantable cardioverter-defibrillators (ICDs) have revolutionized the approach to the prevention of sudden cardiac death and are commonly used in a wide range of high-risk patients, including the large population of patients with severe left ventricular systolic dysfunction. The benefit of these devices derives from their therapies, including both antitachycardia pacing and high-energy shocks. However, although these therapies may be life saving, devices can also deliver inappropriate shocks.
AB  - OBJECTIVE: To review ICD therapies (shocks and antitachycardia pacing), their effects on health outcomes, and current methods to reduce these therapies.
AB  - EVIDENCE REVIEW: We reviewed clinical evidence on ICD shocks and reference lists of retrieved articles. We also examined literature about the methods of reducing ICD therapy.
AB  - FINDINGS: Both appropriate and inappropriate ICD shocks are common and are associated with an adverse effect on health outcomes, quality of life, and mortality. Several methods are available to reduce the risk of inappropriate ICD therapies.
AB  - CONCLUSIONS AND RELEVANCE: Implantable cardioverter-defibrillators reduce the risk of sudden cardiac death and prolong life in selected populations; however, many patients will receive an ICD shock, either appropriate or inappropriate. It is imperative that patients be counseled regarding this risk and adverse outcomes associated with shocks. Reduction of ICD shock should be individualized to ensure that patients receiving these devices experience the maximal benefits of therapy while minimizing the adverse consequences.
RN  - 0 (Anti-Arrhythmia Agents)
ES  - 2168-6114
IL  - 2168-6106
DO  - http://dx.doi.org/10.1001/jamainternmed.2013.428
PT  - Case Reports
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2013 May 27
DC  - 20130528
YR  - 2013
ED  - 20130722
RD  - 20140127
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23546173

<285. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23295101
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Jung PH
AU  - Mueller M
AU  - Schuhmann C
AU  - Eickhoff M
AU  - Schneider P
AU  - Seemueller G
AU  - Dutton R
AU  - Rieber J
AU  - Kaab S
AU  - Sohn HY
FA  - Jung, Philip H
FA  - Mueller, Marisa
FA  - Schuhmann, Christoph
FA  - Eickhoff, Madeleine
FA  - Schneider, Philip
FA  - Seemueller, Gueler
FA  - Dutton, Raphael
FA  - Rieber, Johannes
FA  - Kaab, Stefan
FA  - Sohn, Hae-Young
IN  - Jung,Philip H. Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Ziemssenstrasse 1, 80336, Munich, Germany. philip.jung@med.uni-muenchen.de
TI  - Contrast enhanced transesophageal echocardiography in patients with atrial fibrillation referred to electrical cardioversion improves atrial thrombus detection and may reduce associated thromboembolic events.
SO  - Cardiovascular Ultrasound. 11(1):1, 2013.
AS  - Cardiovasc. ultrasound. 11(1):1, 2013.
NJ  - Cardiovascular ultrasound
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 101159952
OI  - Source: NLM. PMC3554518
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - *Atrial Fibrillation/us [Ultrasonography]
MH  - Causality
MH  - Comorbidity
MH  - Contrast Media
MH  - *Echocardiography, Transesophageal/sn [Statistics & Numerical Data]
MH  - *Electric Countershock/sn [Statistics & Numerical Data]
MH  - Female
MH  - Germany/ep [Epidemiology]
MH  - Humans
MH  - Image Enhancement/mt [Methods]
MH  - Incidence
MH  - Male
MH  - *Phospholipids
MH  - Referral and Consultation/sn [Statistics & Numerical Data]
MH  - Reproducibility of Results
MH  - Risk Factors
MH  - Sensitivity and Specificity
MH  - *Sulfur Hexafluoride
MH  - *Thromboembolism/us [Ultrasonography]
MH  - Treatment Outcome
AB  - AIMS: Transesophageal echocardiography (TEE) is the gold standard for the detection of thrombi in patients with atrial fibrillation (AF) before undergoing early electrical cardioversion (CV). However, TEE generates inconclusive results in a considerable number of patients. This study investigated the influence of contrast enhancement on interpretability of TEE for the detection of left atrial (LA) thrombi compared to conventional TEE and assessed, whether there are differences in the rate of thromboembolic events after electrical cardioversion.
AB  - METHODS: Of 180 patients with AF (51 females, 65.2+/-13 years) who were referred to CV, 90 were examined with native imaging and contrast enhancement within the same examination (group 1), and 90 were examined with native TEE alone and served as control (group 2). Cineloops of the multiplane examination of the LA and LA appendage (LAA) were stored digitally before and, in group 1, after intravenous bolus application of a transpulmonary contrast agent. Images of group 1 were assessed offline and the diagnosis of LA thrombi was made semi-quantitatively: 1= thrombus present; 2=inconclusive result; 3=no thrombus. The presence of spontaneous echocontrast (SEC) was registered and flow velocity in the LA appendage (LAA-flow) was measured. All patients in whom CV was performed were followed up for 1 year or until relapse of AF. CV related adverse events were defined as any thromboembolic event within 1 week after CV.
AB  - RESULTS: No serious adverse events occurred during TEE and contrast enhanced imaging. In group 1 atrial thrombi were diagnosed in 14 (15.6%) during native and in 10 (11.1%) patients during contrast enhanced imaging (p<0.001). Of the 10 patients with thrombi in the contrast TEE group, 7 revealed a decreased LAA-flow (<0,3m/s) and 8 showed moderate or marked SEC. Uncertain results were significantly more common during native imaging than with contrast enhanced TEE (16 vs. 5 patients, p<0.01). Thrombi could definitely be excluded in 60 (66.7%) during conventional and in 75 patients (83.3%) during contrast enhanced TEE (p<0.01). CV was performed subsequently after exclusion of thrombi and at the discretion of the investigator. In group 1, 74 patients (82.2%) were cardioverted and no patient suffered a CV related complication (p=0.084). In group 2, 76 patients (84.4%) underwent CV, of whom 3 suffered a thromboembolic complication after CV (2 strokes, 1 peripheral embolism).
AB  - CONCLUSION: In patients with AF planned for CV contrast enhancement renders TEE images more interpretable, facilitates the exclusion of atrial thrombi and may reduce the rate of embolic adverse events.
RN  - 0 (Contrast Media)
RN  - 0 (Phospholipids)
RN  - 0 (contrast agent BR1)
RN  - WS7LR3I1D6 (Sulfur Hexafluoride)
ES  - 1476-7120
IL  - 1476-7120
DO  - http://dx.doi.org/10.1186/1476-7120-11-1
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
EP  - 20130107
DP  - 2013
DC  - 20130125
YR  - 2013
ED  - 20130711
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23295101

<286. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23497780
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Supino PG
AU  - Hai OY
AU  - Saraon TS
AU  - Herrold EM
AU  - Diaz M
AU  - Khan N
AU  - Hochreiter CA
AU  - Kligfield PD
AU  - Krieger KH
AU  - Girardi LN
AU  - Isom OW
AU  - Borer JS
FA  - Supino, Phyllis G
FA  - Hai, Ofek Y
FA  - Saraon, Tajinderpal S
FA  - Herrold, Edmund M
FA  - Diaz, Monica
FA  - Khan, Nasimullah
FA  - Hochreiter, Clare A
FA  - Kligfield, Paul D
FA  - Krieger, Karl H
FA  - Girardi, Leonard N
FA  - Isom, O Wayne
FA  - Borer, Jeffrey S
IN  - Supino,Phyllis G. The Howard Gilman Institute for Valvular Heart Diseases, State University of New York Downstate Medical Center, Brooklyn, NY, USA. phyllis.supino@downstate.edu
TI  - Usefulness of preoperative exercise tolerance to predict late survival and symptom persistence after surgery for chronic nonischemic mitral regurgitation.
SO  - American Journal of Cardiology. 111(11):1625-30, 2013 Jun 1.
AS  - Am J Cardiol. 111(11):1625-30, 2013 Jun 1.
NJ  - The American journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Chronic Disease
MH  - Echocardiography
MH  - Exercise Test
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - Follow-Up Studies
MH  - *Heart Valve Prosthesis Implantation
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mitral Valve Insufficiency/mo [Mortality]
MH  - Mitral Valve Insufficiency/su [Surgery]
MH  - Mitral Valve Insufficiency/us [Ultrasonography]
MH  - New York/ep [Epidemiology]
MH  - Preoperative Period
MH  - Prognosis
MH  - Prospective Studies
MH  - Survival Rate/td [Trends]
MH  - Time Factors
MH  - Treatment Outcome
AB  - Exercise duration during exercise treadmill testing (ETT) predicts long-term outcome among asymptomatic patients with mitral regurgitation. However, the prognostic value of preoperative exercise duration in patients who undergo mitral valve surgery is unknown. We examined findings among 45 prospectively followed (average 9.2 +/- 4.3 years) patients (aged 54.8 +/- 12.0 years, 45% men) with chronic isolated severe MR who underwent ETT before mitral valve surgery to test the hypotheses that exercise duration predicts long-term postoperative survival and persistent symptoms within 2 years after operation. During follow-up, 11 patients died; of these, 8 had persistent symptoms. Among patients who exercised >7 minutes, average annual postoperative all-cause and cardiovascular mortality risks were 0.75% (both endpoints) versus 5.4% and 4.8%, respectively, versus those who exercised <7 minutes (p = 0.003 all-cause, p = 0.007 cardiovascular). Exercise duration predicted postoperative deaths (p <.02 all cause, p <.04 cardiovascular) even when analysis was adjusted for preoperative variations in age, gender, medications, history of atrial fibrillation, and peak exercise heart rates. Other ETT, echocardiographic, and clinical variables were not independently associated with these outcomes when exercise duration was considered in the analysis. Preoperative exercise duration also predicted postoperative (New York Heart Association functional class >II) symptom persistence (p = 0.012), whereas other ETT, echocardiographic and clinical variables did not (NS, all). In conclusion, among patients who undergo surgery for chronic nonischemic mitral regurgitation, preoperative exercise duration, unlike many commonly used descriptors, is useful for predicting postoperative mortality and symptom persistence. Future research should determine whether interventions to improve exercise tolerance before mitral valve surgery can modify these postoperative outcomes.Copyright © 2013 Elsevier Inc. All rights reserved.
ES  - 1879-1913
IL  - 0002-9149
DI  - S0002-9149(13)00539-0
DO  - http://dx.doi.org/10.1016/j.amjcard.2013.02.007
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20130313
DP  - 2013 Jun 1
DC  - 20130517
YR  - 2013
ED  - 20130709
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23497780

<287. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23541013
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Menezes AR
AU  - Lavie CJ
AU  - DiNicolantonio JJ
AU  - O'Keefe J
AU  - Morin DP
AU  - Khatib S
AU  - Milani RV
FA  - Menezes, Arthur R
FA  - Lavie, Carl J
FA  - DiNicolantonio, James J
FA  - O'Keefe, James
FA  - Morin, Daniel P
FA  - Khatib, Sammy
FA  - Milani, Richard V
IN  - Menezes,Arthur R. Department of Cardiovascular Diseases, John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA 70121-2483, USA.
TI  - Atrial fibrillation in the 21st century: a current understanding of risk factors and primary prevention strategies. [Review]
SO  - Mayo Clinic Proceedings. 88(4):394-409, 2013 Apr.
AS  - Mayo Clin Proc. 88(4):394-409, 2013 Apr.
NJ  - Mayo Clinic proceedings
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 0405543, lly
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - Age Factors
MH  - Alcohol Drinking/ae [Adverse Effects]
MH  - *Atrial Fibrillation/et [Etiology]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - Diet
MH  - Exercise
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Metabolic Syndrome X/co [Complications]
MH  - *Primary Prevention/mt [Methods]
MH  - Risk Factors
MH  - Sex Factors
MH  - Sleep Apnea, Obstructive/co [Complications]
AB  - Atrial fibrillation (AF) is the most common arrhythmia worldwide, and it has a significant effect on morbidity and mortality. It is a significant risk factor for stroke and peripheral embolization, and it has an effect on cardiac function. Despite widespread interest and extensive research on this topic, our understanding of the etiology and pathogenesis of this disease process is still incomplete. As a result, there are no set primary preventive strategies in place apart from general cardiology risk factor prevention goals. It seems intuitive that a better understanding of the risk factors for AF would better prepare medical professionals to initially prevent or subsequently treat these patients. In this article, we discuss widely established risk factors for AF and explore newer risk factors currently being investigated that may have implications in the primary prevention of AF. For this review, we conducted a search of PubMed and used the following search terms (or a combination of terms): atrial fibrillation, metabolic syndrome, obesity, dyslipidemia, hypertension, type 2 diabetes mellitus, omega-3 fatty acids, vitamin D, exercise toxicity, alcohol abuse, and treatment. We also used additional articles that were identified from the bibliographies of the retrieved articles to examine the published evidence for the risk factors of AF.Copyright © 2013 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.
ES  - 1942-5546
IL  - 0025-6196
DI  - S0025-6196(13)00080-3
DO  - http://dx.doi.org/10.1016/j.mayocp.2013.01.022
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2013 Apr
DC  - 20130401
YR  - 2013
ED  - 20130701
RD  - 20131213
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23541013

<288. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23329076
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Tablazon IL
AU  - Al-Dabagh A
AU  - Davis SA
AU  - Feldman SR
FA  - Tablazon, Ingrid L D
FA  - Al-Dabagh, Amir
FA  - Davis, Scott A
FA  - Feldman, Steven R
IN  - Tablazon,Ingrid L D. Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1071, USA.
TI  - Risk of cardiovascular disorders in psoriasis patients: current and future. [Review]
SO  - American Journal of Clinical Dermatology. 14(1):1-7, 2013 Feb.
AS  - Am J Clin Dermatol. 14(1):1-7, 2013 Feb.
NJ  - American journal of clinical dermatology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 100895290
SB  - Index Medicus
CP  - New Zealand
MH  - Alcohol Drinking/pc [Prevention & Control]
MH  - *Cardiovascular Diseases/et [Etiology]
MH  - Cardiovascular Diseases/pc [Prevention & Control]
MH  - Humans
MH  - *Life Style
MH  - Mass Screening/mt [Methods]
MH  - Metabolic Syndrome X/ep [Epidemiology]
MH  - Patient Care
MH  - Practice Guidelines as Topic
MH  - *Psoriasis/co [Complications]
MH  - Psoriasis/pa [Pathology]
MH  - Psoriasis/th [Therapy]
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Smoking Cessation/mt [Methods]
AB  - Psoriasis is an inflammatory autoimmune disease that affects the skin. Recently, psoriasis and its consequential lifestyle and dietary habits have been associated with increased risks for cardiovascular diseases. This article discusses the connection between cardiovascular disorders and psoriasis and the effects of available treatment options on cardiovascular risk. A PubMed search revealed 11 articles that were analyzed for information regarding this association, its effects, and potential courses of treatment. Both the presence and severity of psoriasis increases the risk for cardiovascular disorders and co-morbidities. Forty percent of psoriasis patients met metabolic syndrome criteria as compared with 23 % of non-psoriasis control subjects. Rate ratios for atrial fibrillation are correlated with the severity of psoriasis; patients with severe and mild psoriasis produced rate ratios of 1.63 and 1.31, respectively. Studies also show an increase in the risks for myocardial infarction, atherosclerosis, ischemic stroke, and other cardiovascular disorders. The exact mechanisms behind this affiliation are still uncertain; however, the psychological and physiological effects of psoriasis and the overlapping pathogenesis behind atherosclerosis and psoriasis may play a role. Since the risk for cardiovascular disorders increases with the presence and severity of psoriasis, psoriasis treatment should not only address the disease and its symptoms, but also its co-morbidities. Recent National Psoriasis Foundation (NPF) guidelines have provided recommendations for psoriasis patient care. Histories of co-morbidities, screenings for potential diseases, increased exercise, decreased alcohol consumption, and smoking cessation should be implemented. Unfortunately, while there are data for the increased risk for cardiovascular diseases within psoriasis patients, there are presently no data stating that increasing cardiovascular screening rates in patients produces a significant difference.
IS  - 1175-0561
IL  - 1175-0561
DO  - http://dx.doi.org/10.1007/s40257-012-0005-5
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
LG  - English
DP  - 2013 Feb
DC  - 20130118
YR  - 2013
ED  - 20130627
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23329076

<289. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23329076
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Tablazon IL
AU  - Al-Dabagh A
AU  - Davis SA
AU  - Feldman SR
FA  - Tablazon, Ingrid L D
FA  - Al-Dabagh, Amir
FA  - Davis, Scott A
FA  - Feldman, Steven R
IN  - Tablazon,Ingrid L D. Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1071, USA.
TI  - Risk of cardiovascular disorders in psoriasis patients: current and future. [Review]
SO  - American Journal of Clinical Dermatology. 14(1):1-7, 2013 Feb.
AS  - Am J Clin Dermatol. 14(1):1-7, 2013 Feb.
NJ  - American journal of clinical dermatology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 100895290
SB  - Index Medicus
CP  - New Zealand
MH  - Alcohol Drinking/pc [Prevention & Control]
MH  - *Cardiovascular Diseases/et [Etiology]
MH  - Cardiovascular Diseases/pc [Prevention & Control]
MH  - Humans
MH  - *Life Style
MH  - Mass Screening/mt [Methods]
MH  - Metabolic Syndrome X/ep [Epidemiology]
MH  - Patient Care
MH  - Practice Guidelines as Topic
MH  - *Psoriasis/co [Complications]
MH  - Psoriasis/pa [Pathology]
MH  - Psoriasis/th [Therapy]
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Smoking Cessation/mt [Methods]
AB  - Psoriasis is an inflammatory autoimmune disease that affects the skin. Recently, psoriasis and its consequential lifestyle and dietary habits have been associated with increased risks for cardiovascular diseases. This article discusses the connection between cardiovascular disorders and psoriasis and the effects of available treatment options on cardiovascular risk. A PubMed search revealed 11 articles that were analyzed for information regarding this association, its effects, and potential courses of treatment. Both the presence and severity of psoriasis increases the risk for cardiovascular disorders and co-morbidities. Forty percent of psoriasis patients met metabolic syndrome criteria as compared with 23 % of non-psoriasis control subjects. Rate ratios for atrial fibrillation are correlated with the severity of psoriasis; patients with severe and mild psoriasis produced rate ratios of 1.63 and 1.31, respectively. Studies also show an increase in the risks for myocardial infarction, atherosclerosis, ischemic stroke, and other cardiovascular disorders. The exact mechanisms behind this affiliation are still uncertain; however, the psychological and physiological effects of psoriasis and the overlapping pathogenesis behind atherosclerosis and psoriasis may play a role. Since the risk for cardiovascular disorders increases with the presence and severity of psoriasis, psoriasis treatment should not only address the disease and its symptoms, but also its co-morbidities. Recent National Psoriasis Foundation (NPF) guidelines have provided recommendations for psoriasis patient care. Histories of co-morbidities, screenings for potential diseases, increased exercise, decreased alcohol consumption, and smoking cessation should be implemented. Unfortunately, while there are data for the increased risk for cardiovascular diseases within psoriasis patients, there are presently no data stating that increasing cardiovascular screening rates in patients produces a significant difference.
ES  - 1179-1888
IL  - 1175-0561
DO  - http://dx.doi.org/10.1007/s40257-012-0005-5
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
LG  - English
DP  - 2013 Feb
DC  - 20130118
YR  - 2013
ED  - 20130627
RD  - 20160707
UP  - 20160708
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=23329076

<290. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22892551
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Abidi MH
AU  - Agarwal R
AU  - Tageja N
AU  - Ayash L
AU  - Deol A
AU  - Al-Kadhimi Z
AU  - Abrams J
AU  - Cronin S
AU  - Ventimiglia M
AU  - Lum L
AU  - Ratanatharathorn V
AU  - Zonder J
AU  - Uberti J
FA  - Abidi, Muneer H
FA  - Agarwal, Rishi
FA  - Tageja, Nishant
FA  - Ayash, Lois
FA  - Deol, Abhinav
FA  - Al-Kadhimi, Zaid
FA  - Abrams, Judith
FA  - Cronin, Simon
FA  - Ventimiglia, Marie
FA  - Lum, Lawrence
FA  - Ratanatharathorn, Voravit
FA  - Zonder, Jeffrey
FA  - Uberti, Joseph
IN  - Abidi,Muneer H. Karmanos Cancer Institute, Department of Bone Marrow Transplantation, Detroit, Michigan 48201, USA. abidim@karmanos.org
TI  - A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function.
SO  - Biology of Blood & Marrow Transplantation. 19(1):56-61, 2013 Jan.
AS  - Biol Blood Marrow Transplant. 19(1):56-61, 2013 Jan.
NJ  - Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9600628, cua
OI  - Source: NLM. NIHMS512014
OI  - Source: NLM. PMC3786738
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - *Cytoprotection/de [Drug Effects]
MH  - Female
MH  - *Fibroblast Growth Factor 7/ad [Administration & Dosage]
MH  - Fibroblast Growth Factor 7/ae [Adverse Effects]
MH  - Humans
MH  - *Kidney/pp [Physiopathology]
MH  - Male
MH  - *Melphalan/ad [Administration & Dosage]
MH  - Melphalan/ae [Adverse Effects]
MH  - Middle Aged
MH  - Multiple Myeloma/bl [Blood]
MH  - Multiple Myeloma/pp [Physiopathology]
MH  - Multiple Myeloma/th [Therapy]
MH  - *Multiple Myeloma
MH  - *Myeloablative Agonists/ad [Administration & Dosage]
MH  - Myeloablative Agonists/ae [Adverse Effects]
MH  - *Stem Cell Transplantation
MH  - Stomatitis/bl [Blood]
MH  - Stomatitis/dt [Drug Therapy]
MH  - Stomatitis/et [Etiology]
MH  - Stomatitis/pp [Physiopathology]
MH  - Transplantation, Autologous
AB  - Melphalan 200 mg/m(2) is the standard conditioning regimen for patients with multiple myeloma (MM) with normal renal function (NRF) undergoing autologous stem cell transplant (ASCT). In an effort to escalate the dose of melphalan and to improve the efficacy, we designed a dose-escalation study of melphalan in conjunction with palifermin in patients with NRF, with the hope that a higher dose of melphalan can be administered with an acceptable degree of oral mucositis (OM). We enrolled 19 patients (18 evaluable) with NRF. Dose-escalation of melphalan administered on day -2 began at 200 mg/m(2) with palifermin administered at a fixed dose of 60 mcg/kg/day. Palifermin was given as an i.v. bolus on day -5, -4, and -3, and then on day +1, +2, and +3. Subsequent dose escalations of melphalan were done at 20 mg/m(2) increments up to a maximum dose of 280 mg/m(2). Of 18 evaluable patients, there were no treatment-related deaths by day 100. The median age was 48.5 years (range, 33-65 years). The most common adverse events related to palifermin included rash (18 events, no > grade 3 events), elevation of amylase (10 events, 4 were grade 3 but asymptomatic), and lipase (5 events, 2 were grade 3 but asymptomatic), edema (11 events, no > grade 3). The overall incidence of OM grade 3 was 44% (8/18) with a median duration of severe mucositis of 5 days (range, 3-6 days). Eleven patients (61%) required opioid analgesics. None of the patients received total parenteral nutrition (TPN)/nasogastric feeding. Two of 6 patients who were given melphalan 280 mg/m(2) did not develop OM. Cardiac dose-limiting toxicity (DLT) in the form of atrial fibrillation did occur in 1 of 6 patients treated with melphalan 280 mg/m(2). Palifermin has permitted safe dose escalation of melphalan up to 280 mg/m(2), thus reaching the cumulative dosage of melphalan administered in tandem ASCT. This higher dose of melphalan has the potential to improve the efficacy and, hopefully, outcomes of patients with MM with a single ASCT. A phase 2 trial is necessary to better delineate the antimyeloma efficacy of this regimen.Copyright © 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
RN  - 0 (Myeloablative Agonists)
RN  - 126469-10-1 (Fibroblast Growth Factor 7)
RN  - Q41OR9510P (Melphalan)
ES  - 1523-6536
IL  - 1083-8791
DI  - S1083-8791(12)00315-1
DO  - http://dx.doi.org/10.1016/j.bbmt.2012.08.003
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
NO  - P30 CA022453 (United States NCI NIH HHS)
LG  - English
EP  - 20120811
DP  - 2013 Jan
DC  - 20130107
YR  - 2013
ED  - 20130607
RD  - 20150224
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22892551

<291. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23283615
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Simonetta F
AU  - Christou F
AU  - Vandoni RE
AU  - Nierle T
FA  - Simonetta, Federico
FA  - Christou, Fotini
FA  - Vandoni, Riccardo E
FA  - Nierle, Thomas
IN  - Simonetta,Federico. Department of Internal Medicine, Hopital du Jura bernois SA, Moutier, Switzerland.
TI  - Walking unsteadily: a case of acute cerebellar ataxia.
SO  - BMJ Case Reports. 2013, 2013.
AS  - BMJ Case Rep. 2013, 2013.
NJ  - BMJ case reports
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 101526291
OI  - Source: NLM. PMC3604282
SB  - Index Medicus
CP  - England
MH  - Acute Disease
MH  - Aged
MH  - *Cerebellar Ataxia/pp [Physiopathology]
MH  - Female
MH  - Humans
MH  - *Walking
AB  - Acute cerebellar ataxia is an infrequent neurological syndrome in adults especially if complicated by additional neurological deficits. We report the case of a 69-year-old woman who presented with sudden onset of left facial droop, dizziness, slurred speech and impaired balance. Her medical history included paroxysmal atrial fibrillation and a sigmoid diverticular abscess treated with ciprofloxacin and metronidazole. Cranial computed tomographic angiography and MRI showed no signs of acute ischaemia or haemorrhage but demonstrated symmetrically distributed lesions in the cerebellar dentate nuclei. A diagnosis of metronidazole-induced encephalopathy was suspected. Metronidazole was stopped and the patient completely recovered. Metronidazole is a commonly prescribed medication. Clinicians should be aware of the clinical and radiological presentation of metronidazole-induced encephalopathy so that this serious but completely reversible condition can be promptly diagnosed.
ES  - 1757-790X
DI  - bcr2012007688
DO  - http://dx.doi.org/10.1136/bcr-2012-007688
PT  - Case Reports
PT  - Journal Article
LG  - English
EP  - 20130102
DP  - 2013
DC  - 20130103
YR  - 2013
ED  - 20130603
RD  - 20150219
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23283615

<292. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23283615
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Simonetta F
AU  - Christou F
AU  - Vandoni RE
AU  - Nierle T
FA  - Simonetta, Federico
FA  - Christou, Fotini
FA  - Vandoni, Riccardo E
FA  - Nierle, Thomas
IN  - Simonetta,Federico. Department of Internal Medicine, Hopital du Jura bernois SA, Moutier, Switzerland.
TI  - Walking unsteadily: a case of acute cerebellar ataxia.
SO  - BMJ Case Reports. 2013, 2013.
AS  - BMJ Case Rep. 2013, 2013.
NJ  - BMJ case reports
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 101526291
OI  - Source: NLM. PMC3604282
SB  - Index Medicus
CP  - England
MH  - Acute Disease
MH  - Aged
MH  - *Cerebellar Ataxia/pp [Physiopathology]
MH  - Female
MH  - Humans
MH  - *Walking
AB  - Acute cerebellar ataxia is an infrequent neurological syndrome in adults especially if complicated by additional neurological deficits. We report the case of a 69-year-old woman who presented with sudden onset of left facial droop, dizziness, slurred speech and impaired balance. Her medical history included paroxysmal atrial fibrillation and a sigmoid diverticular abscess treated with ciprofloxacin and metronidazole. Cranial computed tomographic angiography and MRI showed no signs of acute ischaemia or haemorrhage but demonstrated symmetrically distributed lesions in the cerebellar dentate nuclei. A diagnosis of metronidazole-induced encephalopathy was suspected. Metronidazole was stopped and the patient completely recovered. Metronidazole is a commonly prescribed medication. Clinicians should be aware of the clinical and radiological presentation of metronidazole-induced encephalopathy so that this serious but completely reversible condition can be promptly diagnosed.
ES  - 1757-790X
IL  - 1757-790X
DI  - bcr2012007688
DO  - http://dx.doi.org/10.1136/bcr-2012-007688
PT  - Case Reports
PT  - Journal Article
LG  - English
EP  - 20130102
DP  - 2013
DC  - 20130103
YR  - 2013
ED  - 20130603
RD  - 20160519
UP  - 20160520
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=23283615

<293. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23415514
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Seicean S
AU  - Strohl KP
AU  - Seicean A
AU  - Gibby C
AU  - Marwick TH
FA  - Seicean, Sinziana
FA  - Strohl, Kingman P
FA  - Seicean, Andreea
FA  - Gibby, Conrad
FA  - Marwick, Thomas H
IN  - Seicean,Sinziana. Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA.
TI  - Sleep disordered breathing as a risk of cardiac events in subjects with diabetes mellitus and normal exercise echocardiographic findings.
SO  - American Journal of Cardiology. 111(8):1214-20, 2013 Apr 15.
AS  - Am J Cardiol. 111(8):1214-20, 2013 Apr 15.
NJ  - The American journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Cardiovascular Diseases/pp [Physiopathology]
MH  - *Cardiovascular Diseases/us [Ultrasonography]
MH  - Chi-Square Distribution
MH  - Confidence Intervals
MH  - *Diabetes Mellitus, Type 2/pp [Physiopathology]
MH  - Echocardiography, Stress
MH  - Exercise Test
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Polysomnography
MH  - Proportional Hazards Models
MH  - Risk Factors
MH  - *Sleep Apnea Syndromes/pp [Physiopathology]
AB  - Sleep disordered breathing (SDB) is associated with type 2 diabetes mellitus (T2DM) and cardiovascular disease; however, the contribution of SDB to incident heart failure (HF), coronary artery disease (CAD), and atrial fibrillation (AF) in patients with T2DM is unknown. We followed up 834 consecutive asymptomatic patients with T2DM (age 56 +/- 11 years, 369 women) with normal exercise echocardiographic findings for <8 years using electronic health records. The demographics, cardiac risk factors, symptoms, diagnoses, and medications were collected at the echocardiography and validated from the electronic health records. SDB was confirmed by a comprehensive sleep evaluation and/or polysomnography before echocardiography. SDB was diagnosed in 188 patients (21%) at baseline; 116 were untreated. During a median follow-up of 4.9 years (interquartile range 3.9 to 6.1), 22 congestive HF, 72 CAD, and 40 AF incident events were observed. In the Cox proportional hazards models, SDB was associated with incident CAD (hazard ratio 1.8, 95% confidence interval 1.1 to 3.0, p = 0.01; adjusted hazard ratio 1.9, 95% confidence interval 1.2 to 3.2, p <0.01) and AF (hazard ratio 2.6, 95% confidence interval 1.4 to 4.7, p = 0.01; adjusted hazard ratio 2.9, 95% confidence interval 1.5 to 5.9, p <0.01). Limiting SDB to only those patients diagnosed using polysomnography (n = 132), SDB was associated with incident CAD (hazard ratio 1.9, 95% confidence interval 1.1 to 3.3, p = 0.03; adjusted hazard ratio 2.2, 95% confidence interval 1.2 to 3.9, p = 0.01) and HF (hazard ratio 2.7, 95% confidence interval 1.1 to 7.0, p = 0.03; adjusted hazard ratio 3.5, 95% confidence interval 1.4 to 9.0, p <0.01). Female gender, age, elevated blood pressure, and left ventricular mass were additional correlates of CAD in those with asymptomatic T2DM. In conclusion, the association of SDB with incident CAD, AF, and HF in patients with T2DM justifies more liberal screening for SDB in patients with T2DM, realizing that SDB is a potentially modifiable risk factor.Copyright © 2013 Elsevier Inc. All rights reserved.
ES  - 1879-1913
IL  - 0002-9149
DI  - S0002-9149(12)02656-2
DO  - http://dx.doi.org/10.1016/j.amjcard.2012.12.053
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
NO  - HL007913 (United States NHLBI NIH HHS)
NO  - HS00059-14 (United States AHRQ HHS)
LG  - English
EP  - 20130212
DP  - 2013 Apr 15
DC  - 20130405
YR  - 2013
ED  - 20130527
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23415514

<294. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23337836
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Roldan V
AU  - Marin F
AU  - Fernandez H
AU  - Manzano-Fernandez S
AU  - Gallego P
AU  - Valdes M
AU  - Vicente V
AU  - Lip GY
FA  - Roldan, Vanessa
FA  - Marin, Francisco
FA  - Fernandez, Hermogenes
FA  - Manzano-Fernandez, Sergio
FA  - Gallego, Pilar
FA  - Valdes, Mariano
FA  - Vicente, Vicente
FA  - Lip, Gregory Y H
IN  - Roldan,Vanessa. Hematology and Medical Oncology Unit, Hospital Universitario Morales Meseguer, University of Murcia, Murcia, Spain.
TI  - Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding).
SO  - American Journal of Cardiology. 111(8):1159-64, 2013 Apr 15.
AS  - Am J Cardiol. 111(8):1159-64, 2013 Apr 15.
NJ  - The American journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/mo [Mortality]
MH  - Creatinine/bl [Blood]
MH  - Female
MH  - *Glomerular Filtration Rate
MH  - Hemorrhage/mo [Mortality]
MH  - Hemorrhage/pp [Physiopathology]
MH  - Humans
MH  - International Normalized Ratio
MH  - Logistic Models
MH  - Male
MH  - Proportional Hazards Models
MH  - Renal Insufficiency/mo [Mortality]
MH  - *Renal Insufficiency/pp [Physiopathology]
MH  - Risk Factors
MH  - Statistics, Nonparametric
MH  - Thromboembolism/mo [Mortality]
MH  - Thromboembolism/pp [Physiopathology]
AB  - Renal dysfunction is highly prevalent among patients with atrial fibrillation (AF) and confers an increased risk of thrombotic and bleeding complications. We evaluated the effect of renal function on prognosis in anticoagulated patients with AF and assessed the changes in renal function during a long-term follow-up period. We recruited 978 consecutive stable anticoagulated patients with AF from our outpatient anticoagulation clinic (international normalized ratio 2.0 to 3.0 within the previous 6 months). The estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease equation at inclusion and 2 years of follow-up. Adverse events were recorded during follow-up (thrombotic/vascular events, major bleeding episodes, and mortality). Longitudinal changes in renal function were analyzed in 886 patients (90.6%). At baseline, the median eGFR using the Modification of Diet in Renal Disease equation was 70.24 ml/min/1.73 m(2) (interquartile range 46.79 to 72.52). During follow-up, a low eGFR was associated with thrombotic/vascular events, with every 30 ml/min/1.73 m(2) eGFR decrease (hazard ratio 1.42, 95% confidence interval [CI] 1.11 to 1.83, p = 0.006), bleeding (hazard ratio 1.44, 95% CI 1.08 to 1.94, p = 0.015), and mortality (hazard ratio 1.47, 95% CI 1.13 to 1.91, p = 0.004). After excluding patients with a baseline eGFR <30 ml/min/1.73 m(2), the mean eGFR in our cohort decreased >10 ml/min/1.73 m(2) in 181 patients (21%) during the follow-up period. The variables associated with severe renal impairment during follow-up were heart failure (odds ratio 3.58, 95% CI 1.36 to 9.42, p = 0.010), basal eGFR (odds ratio 6.34, 95% CI 2.44 to 16.50, p <0.001), and CHADS2 (Congestive heart failure, Hypertension, Age >75 years, Diabetes mellitus, and previous Stroke or transient ischemic attack [doubled]) score (odds ratio 1.63, 95% CI 1.19 to 2.23, p = 0.003). In conclusion, the presence of impaired renal function was closely related to thrombotic/vascular events, bleeding, and mortality in anticoagulated patients with AF. During follow-up, 1/5 of the patients had significant impairment in renal function. Importantly, normal or mild renal dysfunction at baseline did not exclude the subsequent development of severe renal dysfunction during the follow-up period.Crown Copyright © 2013. Published by Elsevier Inc. All rights reserved.
RN  - 0 (Anticoagulants)
RN  - AYI8EX34EU (Creatinine)
ES  - 1879-1913
IL  - 0002-9149
DI  - S0002-9149(12)02648-3
DO  - http://dx.doi.org/10.1016/j.amjcard.2012.12.045
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20130118
DP  - 2013 Apr 15
DC  - 20130405
YR  - 2013
ED  - 20130527
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23337836

<295. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23200094
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Giacomantonio NB
AU  - Bredin SS
AU  - Foulds HJ
AU  - Warburton DE
FA  - Giacomantonio, Nicholas B
FA  - Bredin, Shannon S D
FA  - Foulds, Heather J A
FA  - Warburton, Darren E R
IN  - Giacomantonio,Nicholas B. Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada. Nicholas.Giacomantonio@cdha.nshealth.ca
TI  - A systematic review of the health benefits of exercise rehabilitation in persons living with atrial fibrillation. [Review]
SO  - Canadian Journal of Cardiology. 29(4):483-91, 2013 Apr.
AS  - Can J Cardiol. 29(4):483-91, 2013 Apr.
NJ  - The Canadian journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - chp, 8510280
SB  - Index Medicus
CP  - England
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/rh [Rehabilitation]
MH  - Evidence-Based Medicine
MH  - *Exercise
MH  - Exercise Therapy/ae [Adverse Effects]
MH  - *Exercise Therapy
MH  - Exercise Tolerance
MH  - Humans
MH  - Incidence
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
AB  - BACKGROUND: This systematic review sought to evaluate critically the health benefits of physical activity among persons with atrial fibrillation (AF). AF is increasing in Western society. While health benefits of physical activity are well established, benefits of physical activity among individuals with AF are not clearly identified.
AB  - METHODS: Literature was retrieved systematically through searching electronic databases (MEDLINE, EMBASE, Cochrane), cross-referencing, and drawing on the authors' knowledge. Identified original research articles evaluated health benefits of physical activity among persons with AF or effects of physical activity on AF incidence. From 1056 individual citations, 36 eligible articles were identified.
AB  - RESULTS: Moderate-intensity physical activity was found to improve exercise capacity, quality of life, and the ability to carry out activities of daily living among persons with AF (n = 6). Increased incidence of AF was not associated with physical activity among the general population (n = 2), although long-term vigorous endurance exercise may be associated with increased incidence of AF (n = 7), and greater risks may be associated with high-intensity physical activity among those with AF (n = 2). Moderate-intensity physical activity among individuals with AF does not adversely alter training outcomes, functional capacity, morbidity, or mortality compared with those in sinus rhythm (n = 12). Physical activity may improve management and treatment of AF (n = 6) and, among at-risk populations, may reduce incidence of AF (n = 3).
AB  - CONCLUSIONS: In conclusion, moderate-intensity physical activity should be encouraged among persons with or at risk of AF. Further research is needed.Copyright © 2013 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
ES  - 1916-7075
IL  - 0828-282X
DI  - S0828-282X(12)00336-4
DO  - http://dx.doi.org/10.1016/j.cjca.2012.07.003
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
NO  - (Canada Canadian Institutes of Health Research)
LG  - English
EP  - 20121128
DP  - 2013 Apr
DC  - 20130329
YR  - 2013
ED  - 20130513
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23200094

<296. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23375926
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lakkireddy D
AU  - Atkins D
AU  - Pillarisetti J
AU  - Ryschon K
AU  - Bommana S
AU  - Drisko J
AU  - Vanga S
AU  - Dawn B
FA  - Lakkireddy, Dhanunjaya
FA  - Atkins, Donita
FA  - Pillarisetti, Jayasree
FA  - Ryschon, Kay
FA  - Bommana, Sudharani
FA  - Drisko, Jeanne
FA  - Vanga, Subbareddy
FA  - Dawn, Buddhadeb
IN  - Lakkireddy,Dhanunjaya. Division of Cardiovascular Diseases, Cardiovascular Research Institute, University of Kansas Hospital & Medical Center, Kansas City, Kansas. dlakkireddy@mac.md
TI  - Effect of yoga on arrhythmia burden, anxiety, depression, and quality of life in paroxysmal atrial fibrillation: the YOGA My Heart Study.
CM  - Comment in: Nat Rev Cardiol. 2013 Apr;10(4):182; PMID: 23419900
SO  - Journal of the American College of Cardiology. 61(11):1177-82, 2013 Mar 19.
AS  - J Am Coll Cardiol. 61(11):1177-82, 2013 Mar 19.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - h50, 8301365
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Anxiety/th [Therapy]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Depression/th [Therapy]
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - *Quality of Life
MH  - *Yoga
AB  - OBJECTIVES: The purpose of this study was to examine the impact of yoga on atrial fibrillation (AF) burden, quality of life (QoL), depression, and anxiety scores.
AB  - BACKGROUND: Yoga is known to have significant benefit on cardiovascular health. The effect of yoga in reducing AF burden is unknown.
AB  - METHODS: This single-center, pre-post study enrolled patients with symptomatic paroxysmal AF with an initial 3-month noninterventional observation period followed by twice-weekly 60-min yoga training for next 3 months. AF episodes during the control and study periods as well as SF-36, Zung self-rated anxiety, and Zung self-rated depression scores at baseline, before, and after the study phase were assessed.
AB  - RESULTS: Yoga training reduced symptomatic AF episodes (3.8 +/- 3 vs. 2.1 +/- 2.6, p < 0.001), symptomatic non-AF episodes (2.9 +/- 3.4 vs. 1.4 +/- 2.0; p < 0.001), asymptomatic AF episodes (0.12 +/- 0.44 vs. 0.04 +/- 0.20; p < 0.001), and depression and anxiety (p < 0.001), and improved the QoL parameters of physical functioning, general health, vitality, social functioning, and mental health domains on SF-36 (p = 0.017, p < 0.001, p < 0.001, p = 0.019, and p < 0.001, respectively). There was significant decrease in heart rate, and systolic and diastolic blood pressure before and after yoga (p < 0.001).
AB  - CONCLUSIONS: In patients with paroxysmal AF, yoga improves symptoms, arrhythmia burden, heart rate, blood pressure, anxiety and depression scores, and several domains of QoL.Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
ES  - 1558-3597
IL  - 0735-1097
DI  - S0735-1097(13)00044-2
DO  - http://dx.doi.org/10.1016/j.jacc.2012.11.060
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
SI  - ClinicalTrials.gov
SA  - ClinicalTrials.gov/NCT00798356
SL  - http://clinicaltrials.gov/search/term=NCT00798356
LG  - English
EP  - 20130130
DP  - 2013 Mar 19
DC  - 20130318
YR  - 2013
ED  - 20130506
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23375926

<297. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22198071
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Attaya S
AU  - Bornstein T
AU  - Ronquillo N
AU  - Volgman R
AU  - Braun LT
AU  - Trohman R
AU  - Volgman A
FA  - Attaya, Shariff
FA  - Bornstein, Tammi
FA  - Ronquillo, Nemencio
FA  - Volgman, Robert
FA  - Braun, Lynne T
FA  - Trohman, Richard
FA  - Volgman, Annabelle
IN  - Attaya,Shariff. Department of Cardiology, Rush University Medical Center, Chicago, IL 60612, USA.
TI  - Study of warfarin patients investigating attitudes toward therapy change (SWITCH Survey).
SO  - American Journal of Therapeutics. 19(6):432-5, 2012 Nov.
AS  - Am J Ther. 19(6):432-5, 2012 Nov.
NJ  - American journal of therapeutics
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - db7, 9441347
SB  - Index Medicus
CP  - United States
MH  - Administration, Oral
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/ad [Administration & Dosage]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Data Collection
MH  - Drug Monitoring/mt [Methods]
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Patient Acceptance of Health Care
MH  - Sex Factors
MH  - Stroke/et [Etiology]
MH  - Stroke/pc [Prevention & Control]
MH  - Warfarin/ad [Administration & Dosage]
MH  - *Warfarin/tu [Therapeutic Use]
AB  - Although the oral anticoagulant warfarin has undoubtedly saved lives and reduced the number of strokes in patients with atrial fibrillation, it is a cumbersome medication to manage and take. Novel oral anticoagulants, such as dabigatran, offer therapeutic anticoagulation without requisite blood testing or dietary restrictions. We conducted a survey of the attitudes of patients enrolled in a warfarin clinic toward switching to a novel anticoagulant. From September to December 2010, a written survey was offered to 180 patients in the Warfarin Clinic of the Rush University Medical Center and 155 patients filled out the survey (86% response rate). Inclusion criteria included being 18 years of age or older, on warfarin for 2 months. Fifty-eight percent of patients were willing to switch anticoagulants. Women were significantly less willing to switch from warfarin than men (31 of 71, 44% vs. 54 of 78, 69%; P = 0.003). Patients older than 70 years were significantly more willing to switch anticoagulants than those younger than 70 years (48 of 68, 71% vs. 38 of 75, 51%; P = 0.017). There are significant differences across age and gender in the initial willingness of patients to accept novel anticoagulants. These differences may have important implications in the prevention and treatment of thromboembolic events.
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
ES  - 1536-3686
IL  - 1075-2765
DO  - http://dx.doi.org/10.1097/MJT.0b013e3182373591
PT  - Journal Article
LG  - English
DP  - 2012 Nov
DC  - 20121116
YR  - 2012
ED  - 20130501
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22198071

<298. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22724413
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kirshner HS
FA  - Kirshner, Howard S
IN  - Kirshner,Howard S. Department of Neurology, A- 0118 Medical Center North, Vanderbilt University School of Medicine, Nashville, TN 37232-2551, USA. howard.kirshner@vanderbilt.edu
TI  - Antiplatelet and anticoagulation strategies in the prevention and treatment of ischemic stroke. [Review]
SO  - Current Pharmaceutical Design. 18(33):5261-72, 2012.
AS  - Curr Pharm Des. 18(33):5261-72, 2012.
NJ  - Current pharmaceutical design
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - da0, 9602487
SB  - Index Medicus
CP  - Netherlands
MH  - Animals
MH  - Anticoagulants/ae [Adverse Effects]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Comorbidity
MH  - Endovascular Procedures
MH  - Humans
MH  - *Ischemic Attack, Transient/dt [Drug Therapy]
MH  - Ischemic Attack, Transient/ep [Epidemiology]
MH  - *Ischemic Attack, Transient/pc [Prevention & Control]
MH  - Patient Selection
MH  - Platelet Aggregation Inhibitors/ae [Adverse Effects]
MH  - *Platelet Aggregation Inhibitors/tu [Therapeutic Use]
MH  - Practice Guidelines as Topic
MH  - *Primary Prevention
MH  - Risk Factors
MH  - Risk Reduction Behavior
MH  - *Secondary Prevention
MH  - *Stroke/dt [Drug Therapy]
MH  - Stroke/ep [Epidemiology]
MH  - *Stroke/pc [Prevention & Control]
MH  - Treatment Outcome
MH  - Vascular Surgical Procedures
AB  - Stroke prevention is highly effective but underutilized in medical care. Lifestyle modification, in the form of diet, exercise, smoking cessation, antihypertensive therapy, close control of diabetes and hyperlipidemia, can prevent most strokes. Selected subgroups can benefit from carotid surgery or stenting, anticoagulation for atrial fibrillation, and antiplatelet therapy. Evidence for these approaches and alternative management strategies are discussed.
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
ES  - 1873-4286
IL  - 1381-6128
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2012
DC  - 20121115
YR  - 2012
ED  - 20130425
RD  - 20141120
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22724413

<299. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23097477
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Calvo N
AU  - Brugada J
AU  - Sitges M
AU  - Mont L
FA  - Calvo, Naiara
FA  - Brugada, Josep
FA  - Sitges, Marta
FA  - Mont, Lluis
IN  - Calvo,Naiara. Arrhythmia Unit, Department of Cardiology and Cardiovascular Surgery, University of Navarra, Navarra, Pamplona, Spain.
TI  - Atrial fibrillation and atrial flutter in athletes. [Review]
SO  - British Journal of Sports Medicine. 46 Suppl 1:i37-43, 2012 Nov.
AS  - BJSM online. 46 Suppl 1:i37-43, 2012 Nov.
NJ  - British journal of sports medicine
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 0432520
SB  - Index Medicus
CP  - England
MH  - Ablation Techniques/mt [Methods]
MH  - Animals
MH  - Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - *Athletes
MH  - *Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/th [Therapy]
MH  - *Atrial Flutter/et [Etiology]
MH  - Atrial Flutter/pp [Physiopathology]
MH  - Atrial Flutter/th [Therapy]
MH  - Atrial Function/ph [Physiology]
MH  - Autonomic Nervous System/ph [Physiology]
MH  - Cardiomegaly, Exercise-Induced/ph [Physiology]
MH  - Cardiomyopathies/et [Etiology]
MH  - Cardiomyopathies/pp [Physiopathology]
MH  - Exercise/ph [Physiology]
MH  - Fibrosis/et [Etiology]
MH  - Fibrosis/pp [Physiopathology]
MH  - Heart Atria/ah [Anatomy & Histology]
MH  - Humans
MH  - Male
MH  - Physical Endurance/ph [Physiology]
MH  - Rats
MH  - *Sports/ph [Physiology]
AB  - Atrial fibrillation (AF) is the most common arrhythmia in clinical practice, with an estimated prevalence of 0.4% to 1% in the general population, increasing with age to 8% in those above 80 years. The recognised risk factors for developing AF include age, structural heart disease, hypertension, diabetes mellitus or hyperthyroidism. However, the mechanisms underlying the initiation of AF in patients below 60 years of age, in whom no cardiovascular disease or any other known causal factor is present, remain to be clarified. This condition, termed as lone AF, may be responsible for as many as 30% of patients with paroxysmal AF seeking medical attention. Recent studies suggest that long-term endurance exercise may increase the incidence of AF and atrial flutter (AFl) in this population. This review article is intended to analyse the prevalence of AF and AFl, the pathophysiological mechanisms responsible for the association between endurance sport practice and AF or AFl and the recommended therapeutic options in endurance athletes.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Anticoagulants)
ES  - 1473-0480
IL  - 0306-3674
DO  - http://dx.doi.org/10.1136/bjsports-2012-091171
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2012 Nov
DC  - 20121025
YR  - 2012
ED  - 20130419
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23097477

<300. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23410545
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Passman R
FA  - Passman, Rod
TI  - Rate control for permanent atrial fibrillation: a Race (II) worth running?.
CM  - Comment on: J Am Coll Cardiol. 2013 Feb 19;61(7):741-8; PMID: 23410544
SO  - Journal of the American College of Cardiology. 61(7):749-51, 2013 Feb 19.
AS  - J Am Coll Cardiol. 61(7):749-51, 2013 Feb 19.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - h50, 8301365
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Female
MH  - *Heart Rate/de [Drug Effects]
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
RN  - 0 (Anti-Arrhythmia Agents)
ES  - 1558-3597
IL  - 0735-1097
DI  - S0735-1097(12)05834-2
DO  - http://dx.doi.org/10.1016/j.jacc.2012.11.039
PT  - Comment
PT  - Editorial
LG  - English
DP  - 2013 Feb 19
DC  - 20130215
YR  - 2013
ED  - 20130416
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23410545

<301. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22951598
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Osbak PS
AU  - Mourier M
AU  - Henriksen JH
AU  - Kofoed KF
AU  - Jensen GB
FA  - Osbak, Philip Samuel
FA  - Mourier, Malene
FA  - Henriksen, Jens Henrik
FA  - Kofoed, Klaus Fuglsang
FA  - Jensen, Gorm Boje
IN  - Osbak,Philip Samuel. Department of Cardiology, Hvidovre Hospital, Faculty of Health Sciences, University of Copenhagen, Hvidovre, Denmark. philiposbak@yahoo.dk
TI  - Effect of physical exercise training on muscle strength and body composition, and their association with functional capacity and quality of life in patients with atrial fibrillation: a randomized controlled trial.
SO  - Journal of Rehabilitation Medicine. 44(11):975-9, 2012 Nov.
AS  - J Rehabil Med. 44(11):975-9, 2012 Nov.
NJ  - Journal of rehabilitation medicine
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101088169
SB  - Index Medicus
CP  - Sweden
MH  - *Activities of Daily Living
MH  - Adipose Tissue
MH  - Aged
MH  - Atrial Fibrillation/rh [Rehabilitation]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Body Composition
MH  - Body Fluid Compartments
MH  - Exercise
MH  - *Exercise Therapy/mt [Methods]
MH  - *Exercise Tolerance
MH  - Female
MH  - Health
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Minnesota
MH  - *Muscle Strength
MH  - Perception
MH  - Physical Fitness
MH  - *Quality of Life
MH  - Surveys and Questionnaires
MH  - Walking
AB  - OBJECTIVE: Atrial fibrillation diminishes cardiac function, exercise tolerance and quality of life. The objective of this study was to determine whether exercise training in atrial fibrillation affects muscle strength, body composition, maximal exercise capacity and walking capacity positively, thus improving quality of life.
AB  - DESIGN: Randomized clinical trial. Twelve weeks of physical exercise training or control.
AB  - PATIENTS: Forty-nine patients in permanent atrial fibrillation were randomized to training or control.
AB  - METHODS: Intervention consisted of aerobic training for 1 h 3 times per week at 70% of maximal exercise capacity vs control. Muscle strength, exercise capacity, 6-minute walk test, lean body mass, fat percentage, and quality of life were assessed.
AB  - RESULTS: Muscle strength increased in the training group (p = 0.01), but no change was observed in controls. Lean body mass was unchanged in both groups. Fat percentage decreased in both groups, but there was no significant difference between the groups. Exercise capacity improved in the training group (p < 0.001), with no change in the control group. There was a significant difference after the training period between the training and control groups in terms of exercise capacity. (p = 0.001). Six-min walk test improved in the training group compared with controls (p < 0.01). Overall quality of life score, as measured by the Minnesota Living with Heart Failure Questionnaire, improved in the training group (p = 0.03). Quality of life, measured by Short Form-36, improved in the training group in 3 out of 8 subscales: physical functioning (p = 0.02), general health perceptions (p = 0.001) and vitality (p = 0.02).
AB  - CONCLUSION: Muscle strength, exercise capacity and quality of life increased with exercise training in subjects with atrial fibrillation. Lean body mass was unchanged.
ES  - 1651-2081
IL  - 1650-1977
DO  - http://dx.doi.org/10.2340/16501977-1039
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 2012 Nov
DC  - 20121105
YR  - 2012
ED  - 20130415
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22951598

<302. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22577069
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Trees DW
AU  - Smith JM
AU  - Hockert S
FA  - Trees, Darin W
FA  - Smith, James M
FA  - Hockert, Steven
IN  - Trees,Darin W. Rehabilitation and Wound Care, Solara Hospital Conroe, 1500 Grand Lake Dr, Conroe, TX 77304, USA. darintrees@yahoo.com
TI  - Innovative mobility strategies for the patient with intensive care unit-acquired weakness: a case report.
SO  - Physical Therapy. 93(2):237-47, 2013 Feb.
AS  - Phys Ther. 93(2):237-47, 2013 Feb.
NJ  - Physical therapy
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 0022623, p6w
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Atrial Fibrillation/co [Complications]
MH  - *Early Ambulation
MH  - Female
MH  - Humans
MH  - *Intensive Care Units
MH  - Muscle Weakness/et [Etiology]
MH  - Muscle Weakness/pp [Physiopathology]
MH  - *Muscle Weakness/rh [Rehabilitation]
MH  - Resistance Training
MH  - Respiratory Insufficiency/co [Complications]
MH  - Sepsis/co [Complications]
AB  - BACKGROUND AND PURPOSE: Although the benefits of early mobilization in the intensive care unit (ICU) have been well documented in recent years, the decision-making process and customization of treatment strategies for patients with ICU-acquired weakness have not been well defined in the literature. This case report will describe a patient with ICU-acquired weakness in the long-term acute care hospital (LTACH) setting and mobilization strategies that include novel devices for therapeutic exercise and gait training.
AB  - CASE DESCRIPTION: A 73-year-old, active woman underwent a routine cardioversion for atrial fibrillation but developed multiple complications, including sepsis and respiratory failure. The patient spent 3 weeks of limited activity in the ICU and was transferred to our LTACH for continued medical intervention and rehabilitation. A 4-phase graded mobilization program was initiated in the LTACH ICU. Within that program, the physical therapy interventions included partial weight-bearing antigravity strength training with a mobile leg press and gait training with a hydraulic-assist platform walker.
AB  - OUTCOME: Before interventions, the patient had severe weakness (Medical Research Council [MRC] sum score of 18/60) and displayed complete dependence for all functioning. She progressed to being able to ambulate 150 ft (1 ft=0.3048 m) using a rolling walker with accompanying strength increases to an MRC sum score of 52/60.
AB  - DISCUSSION: This case report describes novel mobility strategies for managing a patient with ICU-acquired weakness. The application of a graded mobilization program using a mobile leg press and a hydraulic-assist platform walker was safe and feasible, and appeared to expedite the patient's recovery process while decreasing the amount of manual lifting for the therapists.
ES  - 1538-6724
IL  - 0031-9023
DO  - http://dx.doi.org/10.2522/ptj.20110401
PT  - Case Reports
PT  - Journal Article
LG  - English
EP  - 20120510
DP  - 2013 Feb
DC  - 20130204
YR  - 2013
ED  - 20130405
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22577069

<303. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23286971
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Svensson LG
AU  - Blackstone EH
AU  - Alsalihi M
AU  - Batizy LH
AU  - Roselli EE
AU  - McCullough R
AU  - Vivacqua A
AU  - Moran RT
AU  - Gillinov AM
AU  - Thamilarasan M
AU  - Griffin B
AU  - Hammer DF
AU  - Stewart WJ
AU  - Sabik JF 3rd
AU  - Lytle BW
FA  - Svensson, Lars G
FA  - Blackstone, Eugene H
FA  - Alsalihi, Mazin
FA  - Batizy, Lillian H
FA  - Roselli, Eric E
FA  - McCullough, Rebecca
FA  - Vivacqua, Alessandro
FA  - Moran, Rocio T
FA  - Gillinov, A Marc
FA  - Thamilarasan, Maran
FA  - Griffin, Brian
FA  - Hammer, Donald F
FA  - Stewart, William J
FA  - Sabik, Joseph F 3rd
FA  - Lytle, Bruce W
IN  - Svensson,Lars G. Marfan Syndrome and Connective Tissue Disorder Clinic, Cleveland, Ohio 44195, USA. svenssl@ccf.org
TI  - Midterm results of David reimplantation in patients with connective tissue disorder.
SO  - Annals of Thoracic Surgery. 95(2):555-62, 2013 Feb.
AS  - Ann Thorac Surg. 95(2):555-62, 2013 Feb.
NJ  - The Annals of thoracic surgery
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 15030100R
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - Netherlands
MH  - Cardiac Surgical Procedures/mt [Methods]
MH  - *Connective Tissue Diseases/co [Complications]
MH  - *Heart Valve Diseases/co [Complications]
MH  - *Heart Valve Diseases/su [Surgery]
MH  - Humans
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Factors
MH  - Time Factors
AB  - BACKGROUND: Few series have examined follow-up risks of the David reimplantation operation in patients with connective tissue disorder. Hence, we assessed its midterm safety and effectiveness for Marfan syndrome and other connective tissue disorders, such as Ehlers-Danlos, Loeys-Dietz, and marfanoid syndromes.
AB  - METHODS: Of 313 patients who underwent modified David reimplantation, 178 identified as having connective tissue disorders underwent operation from January 1, 1991, to December 31, 2010. These disorders included Marfan (84%), marfanoid (8.4%), Loeys-Dietz (5.6%), Ehlers-Danlos (1.1%), and other syndromes (1.1%). Concomitant procedures included mitral valve repair in 7.3% and an atrial fibrillation procedure in 3.4%.
AB  - RESULTS: There were no operative or 30-day deaths. Complications included prolonged ventilation (3%), renal failure (3%), reoperation for bleeding (2.2%), and permanent stroke (0.56%). Eight-year survival was 94% and freedom from aortic valve reoperation at 6 years was 92%. Of the 7 aortic valve reoperations, 3 were attributable to endocarditis and 3 to technical failure. One reoperation was performed at another hospital, and the reason could not be determined. There were no late strokes or hemorrhagic events. At 4 years, approximately 70% of patients had no aortic valve regurgitation, and 18% were in grade 1+.
AB  - CONCLUSIONS: Prophylactic root and valve preservation using David reimplantation is safe and provides excellent midterm effectiveness and low risk of late events except for endocarditis.Copyright © 2013 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
ES  - 1552-6259
IL  - 0003-4975
DI  - S0003-4975(12)01875-9
DO  - http://dx.doi.org/10.1016/j.athoracsur.2012.08.043
PT  - Journal Article
LG  - English
EP  - 20121231
DP  - 2013 Feb
DC  - 20130122
YR  - 2013
ED  - 20130326
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23286971

<304. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21948529
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - D'Amico TA
FA  - D'Amico, Thomas A
TI  - Improving outcomes after esophagectomy: the importance of preventing postoperative pneumonia.
SO  - Zhonghua Weichang Waike Zazhi. 14(9):660-6, 2011 Sep.
AS  - Zhonghua Wei Chang Wai Ke Za Zhi. 14(9):660-6, 2011 Sep.
NJ  - Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101177990
SB  - Index Medicus
CP  - China
MH  - Esophageal Neoplasms/su [Surgery]
MH  - *Esophagectomy/ae [Adverse Effects]
MH  - Humans
MH  - *Pneumonia/et [Etiology]
MH  - *Pneumonia/pc [Prevention & Control]
MH  - *Postoperative Complications/pc [Prevention & Control]
MH  - Risk Factors
AB  - Outcomes after esophagectomy may be related to many factors, including the age of the patient, the stage of the tumor, the operative approach, and the incidence of postoperative morbidity. Pulmonary complications are the major source of morbidity and mortality following esophageal resection, and numerous studies have identified various factors associated with these complications. Preoperative factors affecting pulmonary complications include advanced age, poor nutritional status, and poor cardiopulmonary reserve, whereas preoperative chemoradiation therapy is not clearly associated with increased pulmonary complications. Intraoperative factors associated with increased rates of pulmonary complications include increased blood loss, prolonged operative times, advanced or proximal esophageal tumors, and more extensive operations, including the McKeown resection with three-field lymph node dissection. Postoperative factors associated with pulmonary complications include the development of atrial fibrillation, recurrent laryngeal nerve injury, and aspiration or other abnormality of deglutition. Potential maneuvers to limit the severity of pulmonary complications include smoking cessation prior to surgery, aggressive pulmonary toilet, and documentation of intact swallowing mechanisms prior to the resumption of oral intake after surgery.
IS  - 1671-0274
IL  - 1671-0274
PT  - Editorial
LG  - English
DP  - 2011 Sep
DC  - 20110928
YR  - 2011
ED  - 20130318
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21948529

<305. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21193237
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Tivig C
AU  - Dang L
AU  - Brunner-La Rocca HP
AU  - Ozcan S
AU  - Duru F
AU  - Scharf C
FA  - Tivig, Christine
FA  - Dang, Lam
FA  - Brunner-La Rocca, Hans-Peter
FA  - Ozcan, Sibel
FA  - Duru, Firat
FA  - Scharf, Christoph
IN  - Tivig,Christine. Cardiovascular Center, Clinic im Park, Seestrasse 220, 8027 Zurich, Switzerland.
TI  - Duty-cycled unipolar/bipolar versus conventional radiofrequency ablation in paroxysmal and persistent atrial fibrillation.
SO  - International Journal of Cardiology. 157(2):185-91, 2012 May 31.
AS  - Int J Cardiol. 157(2):185-91, 2012 May 31.
NJ  - International journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - gqw, 8200291
SB  - Index Medicus
CP  - Netherlands
MH  - Aged
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/su [Surgery]
MH  - Case-Control Studies
MH  - Catheter Ablation/is [Instrumentation]
MH  - *Catheter Ablation/mt [Methods]
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Treatment Outcome
AB  - BACKGROUND: Duty-cycled (DC) radiofrequency ablation (RFA) for atrial fibrillation (AF) has been introduced, however, data on large patient series and comparison to conventional RFA are scarce.
AB  - METHODS: Between 2006 and 2008 DC RFA was performed in 209 consecutive patients (143 (68%) paroxysmal and 66 (32%) persistent AF). As controls served 211 patients, 155 (73%) with paroxysmal and 56 (27%) with persistent AF (p=0.3). In DC RFA, the pulmonary veins (PV) were isolated followed by ablation at the septum and left atrium, if AF persisted. Conventional PV isolation was followed by anatomical lines at the roof and mitral isthmus.
AB  - RESULTS: Freedom of paroxysmal AF was demonstrated after 1.08 DC RFA procedures per patient in 82% and after 1.19 conventional procedures in 87% after 8.5 +/- 6.5 months (ns). In persistent AF, success rates were 79% after 1.35 DC RFA procedures and 80% after 1.34 conventional procedures after 11.5 +/- 8.5 months (ns). The subgroup analysis of 119 patients with follow-up > 12 months (17.5 [14.1-23.6] months) showed similar results. Left atrial flutter occurred in 3% and 8% after paroxysmal AF ablation (p < 0.05) and in 12% and 23% after persistent AF ablation (p=0.1). Multivariate predictors for success in both groups were age, left atrial size, presence of persistent vs. paroxysmal AF and previous pacemaker implantation, but not the ablation technique used. Non-fatal complications were seen in 2.8% with no differences between the groups.
AB  - CONCLUSION: Outcome in DC RFA is similar to conventional RFA with a final success rate exceeding 80% in both paroxysmal and persistent AF in the absence of fatal complications.Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
ES  - 1874-1754
IL  - 0167-5273
DO  - http://dx.doi.org/10.1016/j.ijcard.2010.12.010
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20101230
DP  - 2012 May 31
DC  - 20120514
YR  - 2012
ED  - 20130311
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=21193237

<306. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22713434
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Limantoro I
AU  - Crijns H
FA  - Limantoro, Ione
FA  - Crijns, Harry
TI  - When predicting atrial fibrillation, think 'scene of calamity'!.
CM  - Comment on: Europace. 2012 Sep;14(9):1302-10; PMID: 22654096
SO  - Europace. 14(9):1223-4, 2012 Sep.
AS  - Europace. 14(9):1223-4, 2012 Sep.
NJ  - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - dxd, 100883649
SB  - Index Medicus
CP  - England
MH  - *Atrial Fibrillation/bl [Blood]
MH  - *Atrial Natriuretic Factor/bl [Blood]
MH  - *Exercise
MH  - Female
MH  - *Heart Atria/ah [Anatomy & Histology]
MH  - Humans
MH  - Male
RN  - 85637-73-6 (Atrial Natriuretic Factor)
ES  - 1532-2092
IL  - 1099-5129
DO  - http://dx.doi.org/10.1093/europace/eus183
PT  - Comment
PT  - Editorial
LG  - English
EP  - 20120619
DP  - 2012 Sep
DC  - 20120829
YR  - 2012
ED  - 20130221
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22713434

<307. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22654096
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Govindan M
AU  - Borgulya G
AU  - Kiotsekoglou A
AU  - Saha SK
AU  - Camm AJ
FA  - Govindan, Malini
FA  - Borgulya, Gabor
FA  - Kiotsekoglou, Anatoli
FA  - Saha, Samir K
FA  - Camm, A John
IN  - Govindan,Malini. Division of Cardiac and Vascular Sciences, St George's University of London, London SW17 0RE, UK. mgovinda@sgul.ac.uk
TI  - Prognostic value of left atrial expansion index and exercise-induced change in atrial natriuretic peptide as long-term predictors of atrial fibrillation recurrence.
CM  - Comment in: Europace. 2012 Sep;14(9):1223-4; PMID: 22713434
SO  - Europace. 14(9):1302-10, 2012 Sep.
AS  - Europace. 14(9):1302-10, 2012 Sep.
NJ  - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - dxd, 100883649
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - *Atrial Fibrillation/bl [Blood]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/th [Therapy]
MH  - *Atrial Natriuretic Factor/bl [Blood]
MH  - Disease-Free Survival
MH  - Electric Countershock
MH  - Electrocardiography
MH  - *Exercise
MH  - Female
MH  - *Heart Atria/ah [Anatomy & Histology]
MH  - Heart Atria/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/bl [Blood]
MH  - Organ Size
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Prospective Studies
MH  - Recurrence
MH  - Treatment Outcome
AB  - AIMS: We propose to assess the value of exercise-induced change in N-terminal-pro atrial natriuretic peptide (NT-proANP) and left atrial expansion index (LAEI) in predicting AFR after cardioversion and their effect on AF-free survival.
AB  - METHODS AND RESULTS: Fifty-five patients with persistent AF of <18 months duration needing cardioversion were recruited for the study. Fifty-four patients were successfully cardioverted. At 3 months 28/54 (51%) were in SR and at 12 months 21/53 (39%). On multivariate analysis, only exercise-induced change in NT-proANP and LAEI were found to be predictive of AFR up to 12 months post-cardioversion and had an effect on AF-free survival. N-terminal-pro brain natriuretic peptide was elevated in all persistent AF patients but did not predict recurrent AF.
AB  - CONCLUSIONS: Left atrial expansion index and exercise-induced atrial natriuretic peptide change show promise as predictors of AFR after cardioversion. These predictors may identify patients at an early stage in their disease with intact neurohumoral feedback systems and less advanced atrial remodelling. Further studies are required to confirm these findings.
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
ES  - 1532-2092
IL  - 1099-5129
DO  - http://dx.doi.org/10.1093/europace/eus088
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
NO  - PG/08/038/24217 (United Kingdom British Heart Foundation)
LG  - English
EP  - 20120531
DP  - 2012 Sep
DC  - 20120829
YR  - 2012
ED  - 20130221
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22654096

<308. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22938148
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Haeusler KG
AU  - Herm J
AU  - Kunze C
AU  - Krull M
AU  - Brechtel L
AU  - Lock J
AU  - Hohenhaus M
AU  - Heuschmann PU
AU  - Fiebach JB
AU  - Haverkamp W
AU  - Endres M
AU  - Jungehulsing GJ
FA  - Haeusler, Karl Georg
FA  - Herm, Juliane
FA  - Kunze, Claudia
FA  - Krull, Matthias
FA  - Brechtel, Lars
FA  - Lock, Jurgen
FA  - Hohenhaus, Marc
FA  - Heuschmann, Peter U
FA  - Fiebach, Jochen B
FA  - Haverkamp, Wilhelm
FA  - Endres, Matthias
FA  - Jungehulsing, Gerhard Jan
IN  - Haeusler,Karl Georg. Department of Neurology, Charite Berlin Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany. georg.haeusler@charite.de
TI  - Rate of cardiac arrhythmias and silent brain lesions in experienced marathon runners: rationale, design and baseline data of the Berlin Beat of Running study.
SO  - BMC Cardiovascular Disorders. 12:69, 2012.
AS  - BMC Cardiovasc Disord. 12:69, 2012.
NJ  - BMC cardiovascular disorders
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 100968539
OI  - Source: NLM. PMC3458995
SB  - Index Medicus
CP  - England
MH  - Adult
MH  - Arrhythmias, Cardiac/di [Diagnosis]
MH  - *Arrhythmias, Cardiac/ep [Epidemiology]
MH  - Asymptomatic Diseases
MH  - Biomarkers/bl [Blood]
MH  - Cerebral Infarction/di [Diagnosis]
MH  - *Cerebral Infarction/ep [Epidemiology]
MH  - Electrocardiography, Ambulatory
MH  - Female
MH  - Germany/ep [Epidemiology]
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - *Physical Endurance
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - *Research Design
MH  - Risk Assessment
MH  - Risk Factors
MH  - *Running
MH  - Time Factors
MH  - Troponin/bl [Blood]
AB  - BACKGROUND: Regular exercise is beneficial for cardiovascular health but a recent meta-analysis indicated a relationship between extensive endurance sport and a higher risk of atrial fibrillation, an independent risk factor for stroke. However, data on the frequency of cardiac arrhythmias or (clinically silent) brain lesions during and after marathon running are missing.
AB  - METHODS/DESIGN: In the prospective observational "Berlin Beat of Running" study experienced endurance athletes underwent clinical examination (CE), 3 Tesla brain magnetic resonance imaging (MRI), carotid ultrasound imaging (CUI) and serial blood sampling (BS) within 2-3 days prior (CE, MRI, CUI, BS), directly after (CE, BS) and within 2 days after (CE, MRI, BS) the 38th BMW BERLIN-MARATHON 2011. All participants wore a portable electrocardiogram (ECG)-recorder throughout the 4 to 5 days baseline study period. Participants with pathological MRI findings after the marathon, troponin elevations or detected cardiac arrhythmias will be asked to undergo cardiac MRI to rule out structural abnormalities. A follow-up is scheduled after one year.
AB  - RESULTS: Here we report the baseline data of the enrolled 110 athletes aged 36-61 years. Their mean age was 48.8 +/- 6.0 years, 24.5% were female, 8.2% had hypertension and 2.7% had hyperlipidaemia. Participants have attended a mean of 7.5 +/- 6.6 marathon races within the last 5 years and a mean of 16 +/- 36 marathon races in total. Their weekly running distance prior to the 38th BMW BERLIN-MARATHON was 65 +/- 17 km. Finally, 108 (98.2%) Berlin Beat-Study participants successfully completed the 38th BMW BERLIN-MARATHON 2011.
AB  - DISCUSSION: Findings from the "Berlin Beats of Running" study will help to balance the benefits and risks of extensive endurance sport. ECG-recording during the marathon might contribute to identify athletes at risk for cardiovascular events. MRI results will give new insights into the link between physical stress and brain damage.
AB  - TRIAL REGISTRATION: clinicaltrials.gov NCT01428778.
RN  - 0 (Biomarkers)
RN  - 0 (Troponin)
ES  - 1471-2261
IL  - 1471-2261
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
SI  - ClinicalTrials.gov
SA  - ClinicalTrials.gov/NCT01428778
SL  - http://clinicaltrials.gov/search/term=NCT01428778
LG  - English
EP  - 20120831
DP  - 2012
DC  - 20120927
YR  - 2012
ED  - 20130129
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22938148

<309. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22570739
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gronroos NN
AU  - Chamberlain AM
AU  - Folsom AR
AU  - Soliman EZ
AU  - Agarwal SK
AU  - Nettleton JA
AU  - Alonso A
FA  - Gronroos, Noelle N
FA  - Chamberlain, Alanna M
FA  - Folsom, Aaron R
FA  - Soliman, Elsayed Z
FA  - Agarwal, Sunil K
FA  - Nettleton, Jennifer A
FA  - Alonso, Alvaro
IN  - Gronroos,Noelle N. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.
TI  - Fish, fish-derived n-3 fatty acids, and risk of incident atrial fibrillation in the Atherosclerosis Risk in Communities (ARIC) study.
SO  - PLoS ONE [Electronic Resource]. 7(5):e36686, 2012.
AS  - PLoS ONE. 7(5):e36686, 2012.
NJ  - PloS one
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101285081
OI  - Source: NLM. PMC3343018
SB  - Index Medicus
CP  - United States
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/et [Etiology]
MH  - Docosahexaenoic Acids
MH  - Eicosapentaenoic Acid
MH  - *Fatty Acids, Omega-3/me [Metabolism]
MH  - Female
MH  - *Fish Products
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phospholipids
MH  - Risk Assessment
MH  - Surveys and Questionnaires
AB  - BACKGROUND: Results of observational and experimental studies investigating the association between intake of long-chain n-3 polyunsaturated fatty acids (PUFAs) and risk of atrial fibrillation (AF) have been inconsistent.
AB  - METHODS: We studied the association of fish and the fish-derived n-3 PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) with the risk of incident AF in individuals aged 45-64 from the Atherosclerosis Risk in Communities (ARIC) cohort (n = 14,222, 27% African Americans). Intake of fish and of DHA and EPA were measured via food frequency questionnaire. Plasma levels of DHA and EPA were measured in phospholipids in a subset of participants (n = 3,757). Incident AF was identified through the end of 2008 using ECGs, hospital discharge codes and death certificates. Cox proportional hazards regression was used to estimate hazard ratios of AF by quartiles of n-3 PUFAs or by fish intake.
AB  - RESULTS: During the average follow-up of 17.6 years, 1,604 AF events were identified. In multivariable analyses, total fish intake and dietary DHA and EPA were not associated with AF risk. Higher intake of oily fish and canned tuna was associated with a nonsignificant lower risk of AF (p for trend = 0.09). Phospholipid levels of DHA+EPA were not related to incident AF. However, DHA and EPA showed differential associations with AF risk when analyzed separately, with lower risk of AF in those with higher levels of DHA but no association between EPA levels and AF risk.
AB  - CONCLUSIONS: In this racially diverse sample, dietary intake of fish and fish-derived n-3 fatty acids, as well as plasma biomarkers of fish intake, were not associated with AF risk.
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Phospholipids)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - AAN7QOV9EA (Eicosapentaenoic Acid)
ES  - 1932-6203
IL  - 1932-6203
DO  - http://dx.doi.org/10.1371/journal.pone.0036686
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
NO  - RC1HL099452 (United States NHLBI NIH HHS)
LG  - English
EP  - 20120503
DP  - 2012
DC  - 20120509
YR  - 2012
ED  - 20130124
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22570739

<310. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23189370
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Anonymous
TI  - Yoga may help reduce episodes of atrial fibrillation. The calming and balancing effects of yoga may cut down on common triggers for AF episodes and may have other health benefits, too.
SO  - Heart Advisor. 14(6):7, 2011 Jun.
AS  - Heart Advis. 14(6):7, 2011 Jun.
NJ  - Heart advisor / the Cleveland Clinic
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9892190
SB  - Consumer Health Journals
CP  - United States
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - Atrial Fibrillation/px [Psychology]
MH  - Humans
MH  - *Yoga
IS  - 1523-9004
IL  - 1523-9004
PT  - Journal Article
LG  - English
DP  - 2011 Jun
DC  - 20120713
YR  - 2011
ED  - 20130107
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=23189370

<311. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22812913
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Fava C
AU  - Montagnana M
AU  - Danese E
AU  - Sjogren M
AU  - Almgren P
AU  - Engstrom G
AU  - Hedblad B
AU  - Guidi GC
AU  - Minuz P
AU  - Melander O
FA  - Fava, Cristiano
FA  - Montagnana, Martina
FA  - Danese, Elisa
FA  - Sjogren, Marketa
FA  - Almgren, Peter
FA  - Engstrom, Gunnar
FA  - Hedblad, Bo
FA  - Guidi, Gian Cesare
FA  - Minuz, Pietro
FA  - Melander, Olle
IN  - Fava,Cristiano. Department of Clinical Sciences, Lund University, University Hospital of Malmo, Sweden. cristiano.fava@med.lu.se
TI  - The Renalase Asp37Glu polymorphism is not associated with hypertension and cardiovascular events in an urban-based prospective cohort: the Malmo Diet and cancer study.
SO  - BMC Medical Genetics. 13:57, 2012.
AS  - BMC Med Genet. 13:57, 2012.
NJ  - BMC medical genetics
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 100968552
OI  - Source: NLM. PMC3458972
SB  - Index Medicus
CP  - England
MH  - Age Factors
MH  - Aged
MH  - Cardiovascular Diseases/ep [Epidemiology]
MH  - *Cardiovascular Diseases/ge [Genetics]
MH  - Female
MH  - Health Surveys
MH  - Humans
MH  - Hypertension/ep [Epidemiology]
MH  - *Hypertension/ge [Genetics]
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - *Monoamine Oxidase/ge [Genetics]
MH  - Neoplasms/ep [Epidemiology]
MH  - *Neoplasms/ge [Genetics]
MH  - *Polymorphism, Genetic
MH  - Prevalence
MH  - Prospective Studies
MH  - Risk
MH  - Stroke/ep [Epidemiology]
MH  - Stroke/ge [Genetics]
AB  - BACKGROUND: Renalase (gene name RNLS), a recently discovered enzyme with monoamine oxidase activity, is implicated in the degradation of catecholamines. Recent studies delineate a possible role of this enzyme in blood pressure (BP) maintenance and cardiac protection and two single nucleotide polymorphisms, RNLS rs2576178 A > G and rs2296545 C > G have been associated with hypertension. The latter SNP leads to a non synonymous Asp to Glu substitution deleting a flavin adenine dinucleotide (FAD) binding site with possible impaired functionality. We tested the hypothesis that these polymorphisms could affect BP levels, hypertension prevalence, and risk of incident cardiovascular events in middle-aged Swedes.
AB  - METHODS: The polymorphisms were genotyped in 5696 participants of the population-based Cardiovascular Cohort of the "Malmo Diet and Cancer" (MDC-CC). The incidence of cardiovascular events (coronary events [n = 408], strokes [n = 330], heart failure [n = 190] and atrial fibrillation/flutter [n = 406]) was monitored for an average of approximately 15 years of follow-up.
AB  - RESULTS: Both before and after adjustment for sex, age and BMI the polymorphisms did not show any effect on BP level and hypertension prevalence. Before and after adjustment for major cardiovascular risk factors, the hazard ratio for cardiac and cerebrovascular events was not significantly different in carriers of different genotypes. A significant interaction was found between the rs2296545 C > G and age with respect to BP/hypertension.
AB  - CONCLUSIONS: Our data do not support a major role for these RNLS polymorphisms in determining BP level and incident events at population level. The positive interaction with age suggest that the effect of the rs2296545 C > G polymorphism, if any, could vary between different ages.
RN  - EC 1-4-3-4 (Monoamine Oxidase)
RN  - EC 1-4-3-4 (renalase)
ES  - 1471-2350
IL  - 1471-2350
PT  - Journal Article
LG  - English
EP  - 20120719
DP  - 2012
DC  - 20120927
YR  - 2012
ED  - 20130103
RD  - 20150224
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22812913

<312. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22125198
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Heffernan KS
FA  - Heffernan, Kevin S
TI  - How healthy were the arteries of Phidippides?.
SO  - Clinical Cardiology. 35(2):65-8, 2012 Feb.
AS  - Clin Cardiol. 35(2):65-8, 2012 Feb.
NJ  - Clinical cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - de9, 7903272
SB  - Index Medicus
CP  - United States
MH  - *Arteries/pa [Pathology]
MH  - Arteries/pp [Physiopathology]
MH  - Cardiac Output
MH  - *Cardiomyopathies/pp [Physiopathology]
MH  - *Death, Sudden, Cardiac/et [Etiology]
MH  - Elasticity
MH  - Humans
MH  - Physical Endurance/ph [Physiology]
MH  - *Running/ph [Physiology]
MH  - *Ventricular Remodeling/ph [Physiology]
AB  - Subacute and chronic cardiac adaptations to marathon running may increase risk for sudden death. Herein, it is proposed that cardiac arrhythmogenic remodeling resulting from prolonged strenuous exertion may also have a systemic vascular component. Marathon running reduces coronary perfusion pressure and causes acute endothelial damage, possibly via altering concentrations of circulating angiogenic growth factors with novel vasoregulatory properties. Marathon runners have increased arterial stiffness and augmented pressure from wave reflections contributing to a widening of pulse pressure. Pulsatile hemodynamics may contribute to target organ damage. Moreover, each of these vascular maladaptations (increased arterial stiffness, augmented pressure from wave reflections, and widened pulse pressure) has been associated with atrial fibrillation and may provide a substrate for lethal arrhythmogenesis in the marathon runner.Copyright © 2012 Wiley Periodicals, Inc.
ES  - 1932-8737
IL  - 0160-9289
DO  - http://dx.doi.org/10.1002/clc.21009
PT  - Editorial
LG  - English
EP  - 20111128
DP  - 2012 Feb
DC  - 20120207
YR  - 2012
ED  - 20121213
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22125198

<313. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22858920
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Destephan C
AU  - Waller AH
AU  - Patel RJ
AU  - Dhruvakumar S
AU  - Mazza V
AU  - Gerula C
AU  - Maher J
AU  - Kaluski E
FA  - Destephan, C
FA  - Waller, A H
FA  - Patel, R J
FA  - Dhruvakumar, S
FA  - Mazza, V
FA  - Gerula, C
FA  - Maher, J
FA  - Kaluski, E
IN  - Destephan,C. Department of Medicine, University Hospital and New Jersey Medical School, Newark, NJ, USA.
TI  - Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation. [Review]
SO  - Minerva Cardioangiologica. 60(4):425-31, 2012 Aug.
AS  - Minerva Cardioangiol. 60(4):425-31, 2012 Aug.
NJ  - Minerva cardioangiologica
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - n2m, 0400725
SB  - Index Medicus
CP  - Italy
MH  - Administration, Oral
MH  - *Anticoagulants/ad [Administration & Dosage]
MH  - Antithrombins/ad [Administration & Dosage]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Benzimidazoles/ad [Administration & Dosage]
MH  - Dabigatran
MH  - Humans
MH  - Morpholines/ad [Administration & Dosage]
MH  - Pyrazoles/ad [Administration & Dosage]
MH  - Pyridones/ad [Administration & Dosage]
MH  - Randomized Controlled Trials as Topic
MH  - Rivaroxaban
MH  - *Stroke/pc [Prevention & Control]
MH  - Thiophenes/ad [Administration & Dosage]
MH  - Treatment Outcome
MH  - Warfarin/ad [Administration & Dosage]
MH  - beta-Alanine/ad [Administration & Dosage]
MH  - beta-Alanine/aa [Analogs & Derivatives]
AB  - In patients with atrial fibrillation (AF) warfarin has been the mainstay therapy for stroke prevention. In recent randomized clinical trials (RCTs) oral direct thrombin inhibitor (Dabigatran) and factor Xa inhibitors (Rivaroxaban and Apixaban) challenged the efficacy and safety benchmarks set by warfarin. These drugs boast a rapid onset of action, shorter half-life and fewer drug and dietary interactions. Moreover, these new anticoagulants do not require monitoring, titration or dose adjustments. These agents have already been approved for prevention of stroke or systemic embolism in patients with AF. Uncertainty regarding suitability, efficacy and safety in certain patient subsets and issues related to the ability effectively monitor the pharmacodynamic effects and reverse the therapeutic effects of these drugs should be addressed as we engage in a widespread use of these agents in various patient subsets.
RN  - 0 (Anticoagulants)
RN  - 0 (Antithrombins)
RN  - 0 (Benzimidazoles)
RN  - 0 (Morpholines)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridones)
RN  - 0 (Thiophenes)
RN  - 11P2JDE17B (beta-Alanine)
RN  - 3Z9Y7UWC1J (apixaban)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - I0VM4M70GC (Dabigatran)
IS  - 0026-4725
IL  - 0026-4725
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2012 Aug
DC  - 20120803
YR  - 2012
ED  - 20121207
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22858920

<314. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22828895
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Shan J
AU  - Xie W
AU  - Betzenhauser M
AU  - Reiken S
AU  - Chen BX
AU  - Wronska A
AU  - Marks AR
FA  - Shan, Jian
FA  - Xie, Wenjun
FA  - Betzenhauser, Matthew
FA  - Reiken, Steven
FA  - Chen, Bi-Xing
FA  - Wronska, Anetta
FA  - Marks, Andrew R
IN  - Shan,Jian. Clyde and Helen Wu Center for Molecular Cardiology, Department of Physiology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA. arm42@columbia.edu
TI  - Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia.
CM  - Comment in: Circ Res. 2012 Aug 31;111(6):662-5; PMID: 22935529
SO  - Circulation Research. 111(6):708-17, 2012 Aug 31.
AS  - Circ Res. 111(6):708-17, 2012 Aug 31.
NJ  - Circulation research
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - daj, 0047103
OI  - Source: NLM. NIHMS403461
OI  - Source: NLM. PMC3734386
SB  - Index Medicus
CP  - United States
MH  - Animals
MH  - Atrial Fibrillation/ge [Genetics]
MH  - *Atrial Fibrillation/me [Metabolism]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Caffeine/pd [Pharmacology]
MH  - *Calcium/me [Metabolism]
MH  - Cardiac Pacing, Artificial
MH  - Cells, Cultured
MH  - *Disease Models, Animal
MH  - Electrocardiography/de [Drug Effects]
MH  - Epinephrine/pd [Pharmacology]
MH  - Gene Knock-In Techniques
MH  - Heart/de [Drug Effects]
MH  - Heart/pp [Physiopathology]
MH  - Humans
MH  - Immunoblotting
MH  - Mice
MH  - Mice, Knockout
MH  - Mutation
MH  - Myocytes, Cardiac/cy [Cytology]
MH  - Myocytes, Cardiac/me [Metabolism]
MH  - Physical Conditioning, Animal/ph [Physiology]
MH  - Ryanodine Receptor Calcium Release Channel/ge [Genetics]
MH  - *Ryanodine Receptor Calcium Release Channel/me [Metabolism]
MH  - Sarcoplasmic Reticulum/de [Drug Effects]
MH  - Sarcoplasmic Reticulum/me [Metabolism]
MH  - Tachycardia, Ventricular/ge [Genetics]
MH  - *Tachycardia, Ventricular/me [Metabolism]
MH  - Tachycardia, Ventricular/pp [Physiopathology]
MH  - Tacrolimus Binding Proteins/ge [Genetics]
MH  - Tacrolimus Binding Proteins/me [Metabolism]
MH  - Thiazepines/pd [Pharmacology]
AB  - RATIONALE: Atrial fibrillation (AF) is the most common cardiac arrhythmia, however the mechanism(s) causing AF remain poorly understood and therapy is suboptimal. The ryanodine receptor (RyR2) is the major calcium (Ca2+) release channel on the sarcoplasmic reticulum (SR) required for excitation-contraction coupling in cardiac muscle.
AB  - OBJECTIVE: In the present study, we sought to determine whether intracellular diastolic SR Ca2+ leak via RyR2 plays a role in triggering AF and whether inhibiting this leak can prevent AF.
AB  - METHODS AND RESULTS: We generated 3 knock-in mice with mutations introduced into RyR2 that result in leaky channels and cause exercise induced polymorphic ventricular tachycardia in humans [catecholaminergic polymorphic ventricular tachycardia (CPVT)]. We examined AF susceptibility in these three CPVT mouse models harboring RyR2 mutations to explore the role of diastolic SR Ca2+ leak in AF. AF was stimulated with an intra-esophageal burst pacing protocol in the 3 CPVT mouse models (RyR2-R2474S+/-, 70%; RyR2-N2386I+/-, 60%; RyR2-L433P+/-, 35.71%) but not in wild-type (WT) mice (P<0.05). Consistent with these in vivo results, there was a significant diastolic SR Ca2+ leak in atrial myocytes isolated from the CPVT mouse models. Calstabin2 (FKBP12.6) is an RyR2 subunit that stabilizes the closed state of RyR2 and prevents a Ca2+ leak through the channel. Atrial RyR2 from RyR2-R2474S+/- mice were oxidized, and the RyR2 macromolecular complex was depleted of calstabin2. The Rycal drug S107 stabilizes the closed state of RyR2 by inhibiting the oxidation/phosphorylation induced dissociation of calstabin2 from the channel. S107 reduced the diastolic SR Ca2+ leak in atrial myocytes and decreased burst pacing-induced AF in vivo. S107 did not reduce the increased prevalence of burst pacing-induced AF in calstabin2-deficient mice, confirming that calstabin2 is required for the mechanism of action of the drug.
AB  - CONCLUSIONS: The present study demonstrates that RyR2-mediated diastolic SR Ca2+ leak in atrial myocytes is associated with AF in CPVT mice. Moreover, the Rycal S107 inhibited diastolic SR Ca2+ leak through RyR2 and pacing-induced AF associated with CPVT mutations.
RN  - 0 (FKBP12.6 protein, mouse)
RN  - 0 (Ryanodine Receptor Calcium Release Channel)
RN  - 0 (S-107 compound)
RN  - 0 (Thiazepines)
RN  - 3G6A5W338E (Caffeine)
RN  - EC 5-2-1 (Tacrolimus Binding Proteins)
RN  - SY7Q814VUP (Calcium)
RN  - YKH834O4BH (Epinephrine)
RS  - Polymorphic catecholergic ventricular tachycardia
ES  - 1524-4571
IL  - 0009-7330
DO  - http://dx.doi.org/10.1161/CIRCRESAHA.112.273342
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
NO  - 1R01HL102040-01A1 (United States NHLBI NIH HHS)
NO  - F32-HL107029 (United States NHLBI NIH HHS)
NO  - R01 HL061503 (United States NHLBI NIH HHS)
NO  - R01 HL102040 (United States NHLBI NIH HHS)
LG  - English
EP  - 20120724
DP  - 2012 Aug 31
DC  - 20120831
YR  - 2012
ED  - 20121130
RD  - 20150224
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22828895

<315. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22014714
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Geuzebroek GS
AU  - van Amersfoorth SC
AU  - Hoogendijk MG
AU  - Kelder JC
AU  - van Hemel NM
AU  - de Bakker JM
AU  - Coronel R
FA  - Geuzebroek, Guillaume S C
FA  - van Amersfoorth, Shirley C M
FA  - Hoogendijk, Mark G
FA  - Kelder, Johannes C
FA  - van Hemel, Norbert M
FA  - de Bakker, Jacques M T
FA  - Coronel, Ruben
IN  - Geuzebroek,Guillaume S C. Department of Cardiothoracic Surgery, St Antonius Hospital, Nieuwegein, The Netherlands. G.S.C.Geuzebroek@gmail.com
TI  - Increased amount of atrial fibrosis in patients with atrial fibrillation secondary to mitral valve disease.
SO  - Journal of Thoracic & Cardiovascular Surgery. 144(2):327-33, 2012 Aug.
AS  - J Thorac Cardiovasc Surg. 144(2):327-33, 2012 Aug.
NJ  - The Journal of thoracic and cardiovascular surgery
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - k9j, 0376343
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - *Atrial Appendage/pa [Pathology]
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Atrial Fibrillation/pa [Pathology]
MH  - Cardiac Catheterization
MH  - Female
MH  - Fibrosis
MH  - Heart Septal Defects, Atrial/co [Complications]
MH  - Heart Septal Defects, Atrial/pa [Pathology]
MH  - Heart Valve Diseases/pa [Pathology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
AB  - OBJECTIVE: Atrial fibrosis is related to atrial fibrillation but may differ in patients with mitral valve disease or lone atrial fibrillation. Therefore, we studied atrial fibrosis in patients with atrial fibrillation+mitral valve disease or with lone atrial fibrillation and compared it with controls.
AB  - METHODS: Left and right atrial appendages amputated during Maze III surgery for lone atrial fibrillation (n=85) or atrial fibrillation+mitral valve disease (n=26) were embedded in paraffin, sectioned, and stained with picrosirius red. Atria from 10 deceased patients without a cardiovascular history served as controls. A total of 1048 images (4-mum sections, 10-fold magnification, 4 images per appendage) were obtained and digitized. The percentage of fibrous tissue was calculated by quantitative morphometry.
AB  - RESULTS: Irrespective of the presence or absence of atrial fibrillation or mitral valve disease, more fibrous tissue was present in right atrial appendages than in left atrial appendages (12.7%+/-5.7% vs 8.2%+/-3.9%; P<.0001). The mean amount of fibrous tissue in the atria was significantly larger in patients with atrial fibrillation+mitral valve disease than in patients with lone AF and controls (13.6%+/-5.8%, 9.7%+/-3.2%, and 8.8%+/-2.4%, respectively; P<.01). No significant differences existed between patients with lone atrial fibrillation and patients without a cardiovascular history (controls).
AB  - CONCLUSIONS: Atria of patients with atrial fibrillation and mitral valve disease have more fibrosis than atria of patients with lone atrial fibrillation. However, patients with lone atrial fibrillation have an equal amount of atrial fibrosis compared with controls. These findings support the notion that fibrosis plays a more important role in the pathogenesis of atrial fibrillation secondary to mitral valve disease than in lone atrial fibrillation and potentially explains the relatively poor success of antiarrhythmic surgery in patients with mitral valve disease.Copyright © 2012 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
ES  - 1097-685X
IL  - 0022-5223
DO  - http://dx.doi.org/10.1016/j.jtcvs.2011.09.022
PT  - Journal Article
LG  - English
EP  - 20111019
DP  - 2012 Aug
DC  - 20120720
YR  - 2012
ED  - 20121129
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22014714

<316. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21946769
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Muller-Riemenschneider F
AU  - Andersohn F
AU  - Ernst S
AU  - Willich SN
FA  - Muller-Riemenschneider, Falk
FA  - Andersohn, Frank
FA  - Ernst, Sabine
FA  - Willich, Stefan N
IN  - Muller-Riemenschneider,Falk. Institute for Social Medicine, Epidemiology, and Health Economics, Charite University Medical Centre, Berlin, Germany.
TI  - Association of physical activity and atrial fibrillation. [Review]
SO  - Journal of Physical Activity & Health. 9(5):605-16, 2012 Jul.
AS  - J Phys Act Health. 9(5):605-16, 2012 Jul.
NJ  - Journal of physical activity & health
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101189457
SB  - Index Medicus
CP  - United States
MH  - *Atrial Fibrillation/et [Etiology]
MH  - *Exercise/ph [Physiology]
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Physical Exertion
MH  - Risk Assessment
MH  - Sports
AB  - BACKGROUND: There is controversy regarding the association of physical activity (PA) and atrial fibrillation (AF). This systematic review aims to summarize the evidence regarding the association of PA at different levels and AF.
AB  - METHODS: A structured search of databases was performed until December 2009. Studies that investigated the association between PA and AF were included and assessed by 2 researchers according to selection criteria and methodological quality. The overall quality of evidence was rated according to the Grade system.
AB  - RESULTS: Of 855 publications, 10 met the inclusion criteria. The risk of uncontrolled bias and confounding was profound and there was substantial heterogeneity regarding observed associations. One methodologically rigorous study reported substantial risk reductions associated with moderate intensity PA. Another indicated modest increases in risk with high levels of vigorous PA. Five methodologically less reliable studies reported large increases in risk due to regular sport practice.
AB  - CONCLUSION: The overall quality of evidence indicating increases in risk of AF is low. Most reports of large increases in risk appear to be overestimated substantially. In light of the public health importance of regular PA, contradictory recommendations concerning the participation in PA should be considered cautiously before more rigorous studies have investigated this issue.
ES  - 1543-5474
IL  - 1543-3080
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20110729
DP  - 2012 Jul
DC  - 20120626
YR  - 2012
ED  - 20121129
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=21946769

<317. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22729296
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Feguri GR
AU  - Lima PR
AU  - Lopes AM
AU  - Roledo A
AU  - Marchese M
AU  - Trevisan M
AU  - Ahmad H
AU  - Freitas BB
AU  - Aguilar-Nascimento JE
FA  - Feguri, Gibran Roder
FA  - Lima, Paulo Ruiz Lucio
FA  - Lopes, Andrea Mazoni
FA  - Roledo, Andrea
FA  - Marchese, Miriam
FA  - Trevisan, Monica
FA  - Ahmad, Haitham
FA  - Freitas, Bruno Baranhuk de
FA  - Aguilar-Nascimento, Jose Eduardo de
IN  - Feguri,Gibran Roder. gibranrf@sbccv.org.br
TI  - Clinical and metabolic results of fasting abbreviation with carbohydrates in coronary artery bypass graft surgery.
SO  - Revista Brasileira de Cirurgia Cardiovascular: Orgao Oficial da Sociedade Brasileira de Cirurgia Cardiovascular. 27(1):7-17, 2012 Jan-Mar.
AS  - Rev Bras Cir Cardiovasc. 27(1):7-17, 2012 Jan-Mar.
NJ  - Revista brasileira de cirurgia cardiovascular : orgao oficial da Sociedade Brasileira de Cirurgia Cardiovascular
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 9104279
SB  - Index Medicus
CP  - Brazil
MH  - Beverages/ae [Adverse Effects]
MH  - Beverages/an [Analysis]
MH  - *Beverages
MH  - *Coronary Artery Bypass
MH  - *Dietary Carbohydrates/ad [Administration & Dosage]
MH  - Epidemiologic Methods
MH  - *Fasting/ph [Physiology]
MH  - Female
MH  - Humans
MH  - *Insulin Resistance/ph [Physiology]
MH  - Length of Stay/sn [Statistics & Numerical Data]
MH  - Male
MH  - Middle Aged
MH  - Perioperative Care/ae [Adverse Effects]
MH  - *Perioperative Care/mt [Methods]
MH  - Polysaccharides/ad [Administration & Dosage]
MH  - Time Factors
MH  - Treatment Outcome
AB  - INTRODUCTION: Limited information is available about preoperative fasting abbreviation with administration of liquid enriched with carbohydrates (CHO) in cardiovascular surgeries.
AB  - OBJECTIVES: To evaluate clinical variables, security of the method and effects on the metabolism of patients undergoing fasting abbreviation in coronary artery bypass graft (CABG) surgery.
AB  - METHODS: Forty patients undergoing CABG were randomized to receive 400 ml (6 hours before) and 200 ml (2 hours before) of maltodextrin at 12.5% (Group I, n=20) or just water (Group II, n=20) before anesthetic induction. Perioperative clinical variables were evaluated. Insulin resistance (IR) was evaluated by Homa-IR index and also by the need of exogenous insulin; pancreatic beta-cell excretory function by Homa-Beta index and glycemic control by tests of capillary glucose.
AB  - RESULTS: Deaths, bronchoaspiration, mediastinitis, stroke and acute myocardial infarction did not occur. Atrial fibrillation occurred in two patients of each group and infectious complications did not differ among groups (P=0.611). Patients of Group I presented two days less of hospital stay (P=0.025) and one day less in the ICU (P<0.001). The length of time using dobutamine was shorter in Group I (P=0.034). Glycemic control in the first 6h after surgery was worse for Group II (P=0.012). IR was verified and did not differ among groups (P>0.05). A decline in the endogenous production of insulin was observed in both groups (P<0.001).
AB  - CONCLUSION: Preoperative fasting abbreviation with the administration of CHO in the CABG was safe. The glycemic control improved in the ICU; there was less time in the use of dobutamine and length of hospital and ICU stay was reduced. However, neither IR nor morbimortality during hospital phase were influenced.
RN  - 0 (Dietary Carbohydrates)
RN  - 0 (Polysaccharides)
RN  - 7CVR7L4A2D (maltodextrin)
ES  - 1678-9741
IL  - 0102-7638
DI  - S0102-76382012000100004
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
LG  - Portuguese
DP  - 2012 Jan-Mar
DC  - 20120625
YR  - 2012
ED  - 20121031
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22729296

<318. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22729296
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Feguri GR
AU  - Lima PR
AU  - Lopes AM
AU  - Roledo A
AU  - Marchese M
AU  - Trevisan M
AU  - Ahmad H
AU  - Freitas BB
AU  - Aguilar-Nascimento JE
FA  - Feguri, Gibran Roder
FA  - Lima, Paulo Ruiz Lucio
FA  - Lopes, Andrea Mazoni
FA  - Roledo, Andrea
FA  - Marchese, Miriam
FA  - Trevisan, Monica
FA  - Ahmad, Haitham
FA  - Freitas, Bruno Baranhuk de
FA  - Aguilar-Nascimento, Jose Eduardo de
IN  - Feguri,Gibran Roder. gibranrf@sbccv.org.br
TI  - Clinical and metabolic results of fasting abbreviation with carbohydrates in coronary artery bypass graft surgery.
SO  - Revista Brasileira de Cirurgia Cardiovascular: Orgao Oficial da Sociedade Brasileira de Cirurgia Cardiovascular. 27(1):7-17, 2012 Jan-Mar.
AS  - Rev Bras Cir Cardiovasc. 27(1):7-17, 2012 Jan-Mar.
NJ  - Revista brasileira de cirurgia cardiovascular : orgao oficial da Sociedade Brasileira de Cirurgia Cardiovascular
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 9104279
SB  - Index Medicus
CP  - Brazil
MH  - Beverages/ae [Adverse Effects]
MH  - Beverages/an [Analysis]
MH  - *Beverages
MH  - *Coronary Artery Bypass
MH  - *Dietary Carbohydrates/ad [Administration & Dosage]
MH  - Epidemiologic Methods
MH  - *Fasting/ph [Physiology]
MH  - Female
MH  - Humans
MH  - *Insulin Resistance/ph [Physiology]
MH  - Length of Stay/sn [Statistics & Numerical Data]
MH  - Male
MH  - Middle Aged
MH  - Perioperative Care/ae [Adverse Effects]
MH  - *Perioperative Care/mt [Methods]
MH  - Polysaccharides/ad [Administration & Dosage]
MH  - Time Factors
MH  - Treatment Outcome
AB  - INTRODUCTION: Limited information is available about preoperative fasting abbreviation with administration of liquid enriched with carbohydrates (CHO) in cardiovascular surgeries.
AB  - OBJECTIVES: To evaluate clinical variables, security of the method and effects on the metabolism of patients undergoing fasting abbreviation in coronary artery bypass graft (CABG) surgery.
AB  - METHODS: Forty patients undergoing CABG were randomized to receive 400 ml (6 hours before) and 200 ml (2 hours before) of maltodextrin at 12.5% (Group I, n=20) or just water (Group II, n=20) before anesthetic induction. Perioperative clinical variables were evaluated. Insulin resistance (IR) was evaluated by Homa-IR index and also by the need of exogenous insulin; pancreatic beta-cell excretory function by Homa-Beta index and glycemic control by tests of capillary glucose.
AB  - RESULTS: Deaths, bronchoaspiration, mediastinitis, stroke and acute myocardial infarction did not occur. Atrial fibrillation occurred in two patients of each group and infectious complications did not differ among groups (P=0.611). Patients of Group I presented two days less of hospital stay (P=0.025) and one day less in the ICU (P<0.001). The length of time using dobutamine was shorter in Group I (P=0.034). Glycemic control in the first 6h after surgery was worse for Group II (P=0.012). IR was verified and did not differ among groups (P>0.05). A decline in the endogenous production of insulin was observed in both groups (P<0.001).
AB  - CONCLUSION: Preoperative fasting abbreviation with the administration of CHO in the CABG was safe. The glycemic control improved in the ICU; there was less time in the use of dobutamine and length of hospital and ICU stay was reduced. However, neither IR nor morbimortality during hospital phase were influenced.
RN  - 0 (Dietary Carbohydrates)
RN  - 0 (Polysaccharides)
RN  - 7CVR7L4A2D (maltodextrin)
DI  - S0102-76382012000100004
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
LG  - Portuguese
DP  - 2012 Jan-Mar
DC  - 20120625
YR  - 2012
ED  - 20121031
RD  - 20160303
UP  - 20160304
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=22729296

<319. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22726632
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Buellesfeld L
AU  - Stortecky S
AU  - Heg D
AU  - Hausen S
AU  - Mueller R
AU  - Wenaweser P
AU  - Pilgrim T
AU  - Gloekler S
AU  - Khattab AA
AU  - Huber C
AU  - Carrel T
AU  - Eberle B
AU  - Meier B
AU  - Boekstegers P
AU  - Juni P
AU  - Gerckens U
AU  - Grube E
AU  - Windecker S
FA  - Buellesfeld, Lutz
FA  - Stortecky, Stefan
FA  - Heg, Dik
FA  - Hausen, Sven
FA  - Mueller, Ralf
FA  - Wenaweser, Peter
FA  - Pilgrim, Thomas
FA  - Gloekler, Steffen
FA  - Khattab, Ahmed A
FA  - Huber, Christoph
FA  - Carrel, Thierry
FA  - Eberle, Balthasar
FA  - Meier, Bernhard
FA  - Boekstegers, Peter
FA  - Juni, Peter
FA  - Gerckens, Ulrich
FA  - Grube, Eberhard
FA  - Windecker, Stephan
IN  - Buellesfeld,Lutz. Department of Cardiology, Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland.
TI  - Impact of permanent pacemaker implantation on clinical outcome among patients undergoing transcatheter aortic valve implantation.
CM  - Comment in: J Am Coll Cardiol. 2012 Dec 4;60(22):2339-40; author reply 2340-1; PMID: 23194946
SO  - Journal of the American College of Cardiology. 60(6):493-501, 2012 Aug 7.
AS  - J Am Coll Cardiol. 60(6):493-501, 2012 Aug 7.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - h50, 8301365
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged, 80 and over
MH  - *Aortic Valve/su [Surgery]
MH  - Aortic Valve Stenosis/mo [Mortality]
MH  - Aortic Valve Stenosis/su [Surgery]
MH  - Atrial Fibrillation/mo [Mortality]
MH  - Atrial Fibrillation/th [Therapy]
MH  - Case-Control Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Block/mo [Mortality]
MH  - Heart Block/th [Therapy]
MH  - Heart Valve Prosthesis
MH  - Heart Valve Prosthesis Implantation/ae [Adverse Effects]
MH  - *Heart Valve Prosthesis Implantation
MH  - Humans
MH  - Ischemic Attack, Transient/ep [Epidemiology]
MH  - Male
MH  - Myocardial Infarction/ep [Epidemiology]
MH  - Pacemaker, Artificial/ae [Adverse Effects]
MH  - *Pacemaker, Artificial
MH  - Risk Assessment
MH  - Stroke/ep [Epidemiology]
AB  - OBJECTIVES: This study sought to assess the impact of permanent pacemaker (PPM) implantation on clinical outcomes among patients undergoing transfemoral transcatheter aortic valve implantation (TAVI).
AB  - BACKGROUND: TAVI is associated with atrioventricular-conduction abnormalities requiring PPM implantation in up to 40% among patients treated with self-expanding prostheses.
AB  - METHODS: Between 2007 and 2010, 353 consecutive patients (mean age: 82.6 +/- 6.1 years, log EuroSCORE: 25.0 +/- 15.0%) with severe aortic stenosis underwent transfemoral TAVI at 2 institutions. Clinical outcomes were compared among 3 groups: (1) patients requiring PPM implantation after TAVI (PPM after TAVI), (2) patients without PPM before or after TAVI (no PPM), and (3) patients with PPM before TAVI (PPM before TAVI). The primary endpoint was all-cause mortality at 12 months, and an age-, sex-, and origin-matched standardized population served as controls.
AB  - RESULTS: Of 353 patients, 98 patients (27.8%) belonged to the PPM after TAVI group, 48 patients (13.6%) belonged to the PPM before TAVI group, and 207 patients (58.6%) belonged to the no PPM group. The PPM before TAVI patients had a significantly higher baseline risk compared with the PPM after TAVI and no PPM patients (coronary artery disease: 77.1% vs. 52.7% and 58.2%, respectively, p = 0.009; atrial fibrillation: 43.8% vs. 22.7% and 20.4%, respectively, p = 0.005). At 12 months of follow-up, all-cause mortality was similar in all 3 groups (PPM after TAVI group: 19.4%, PPM before TAVI group: 22.9%, no PPM group: 18.0%) in unadjusted analyses (p = 0.77) and adjusted analyses (p = 0.90). Compared with the standardized population, adjusted hazard ratios for death were 2.37 (95% confidence interval [CI]: 1.51 to 3.72) for the PPM after TAVI group, 2.75 (95% CI: 1.52 to 4.97) for the PPM before TAVI group, and 2.24 (95% CI: 1.62 to 3.09) for the no PPM group.
AB  - CONCLUSIONS: Although prognosis remains impaired compared with an age-, sex-, and origin-matched standardized population, periprocedural PPM implantation does not seem to affect clinical outcomes adversely among patients undergoing transfemoral TAVI.Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
ES  - 1558-3597
IL  - 0735-1097
DO  - http://dx.doi.org/10.1016/j.jacc.2012.03.054
PT  - Journal Article
LG  - English
EP  - 20120620
DP  - 2012 Aug 7
DC  - 20120803
YR  - 2012
ED  - 20121025
RD  - 20130117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22726632

<320. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22314739
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Graff-Iversen S
AU  - Gjesdal K
AU  - Jugessur A
AU  - Myrstad M
AU  - Nystad W
AU  - Selmer R
AU  - Thelle DS
FA  - Graff-Iversen, Sidsel
FA  - Gjesdal, Knut
FA  - Jugessur, Astanand
FA  - Myrstad, Marius
FA  - Nystad, Wenche
FA  - Selmer, Randi
FA  - Thelle, Dag S
IN  - Graff-Iversen,Sidsel. Division of Epidemiology, Norwegian Institute of Public Health andInstitute of Community Health, University of Tromso, Norway. sgri@fhi.no
TI  - Atrial fibrillation, physical activity and endurance training.
SO  - Tidsskrift for Den Norske Laegeforening. 132(3):295-9, 2012 Feb 7.
AS  - Tidsskr Nor Laegeforen. 132(3):295-9, 2012 Feb 7.
NJ  - Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 0413423, 101086543, vrv
SB  - Index Medicus
CP  - Norway
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/et [Etiology]
MH  - *Exercise
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Motor Activity
MH  - Risk Factors
MH  - *Sports
AB  - INTRODUCTION: Clinical practice and the results of some studies may indicate that physical exercise in the form of endurance training may influence the development of atrial fibrillation (AF). The aim of this paper is to evaluate the scientific background for the hypothesis that there is a connection between physical activity and AF.
AB  - MATERIAL AND METHOD: This paper is a review article based on searches in PubMed on specific topics, limited to the period 1995 through March 2011. We found 17 original articles and three relatively recent reviews. Each was read by at least two of the authors and then discussed. Seven of the original articles were excluded for methodological reasons, and we therefore discuss the other ten.
AB  - RESULTS: We found support for the hypothesis that systematic high intensity endurance training such as running can increase the risk of AF, whereas the studies provide no evidence that less intensive physical exercise such as walking increases the risk. Several of the studies have methodological weaknesses.
AB  - INTERPRETATION: Important questions remain unanswered. There is a need for more studies that can shed light on the connection between training intensity, total volume of intensive endurance training, age-related changes and AF. Studies that include women are also needed.
ES  - 0807-7096
IL  - 0029-2001
DO  - http://dx.doi.org/10.4045/tidsskr.11.0567
PT  - Journal Article
LG  - English
LG  - Norwegian
DP  - 2012 Feb 7
DC  - 20120208
YR  - 2012
ED  - 20121022
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22314739

<321. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22535516
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Poli D
AU  - Antonucci E
AU  - Zanazzi M
AU  - Grifoni E
AU  - Testa S
AU  - Ageno W
AU  - Palareti G
FA  - Poli, Daniela
FA  - Antonucci, Emilia
FA  - Zanazzi, Maria
FA  - Grifoni, Elisa
FA  - Testa, Sophie
FA  - Ageno, Walter
FA  - Palareti, Gualtiero
IN  - Poli,Daniela. Thrombosis Centre Department of Heart and Vessels, AOU-Careggi, Florence, Italy. polida@aou-careggi.toscana.it
TI  - Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics).
CM  - Comment in: Thromb Haemost. 2012 Jul;108(1):3-5; PMID: 22628077
SO  - Thrombosis & Haemostasis. 107(6):1100-6, 2012 Jun.
AS  - Thromb Haemost. 107(6):1100-6, 2012 Jun.
NJ  - Thrombosis and haemostasis
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - vq7, 7608063
SB  - Index Medicus
CP  - Germany
MH  - Age Factors
MH  - Aged, 80 and over
MH  - *Anticoagulants/ae [Adverse Effects]
MH  - Atrial Fibrillation/bl [Blood]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Blood Coagulation/de [Drug Effects]
MH  - Chronic Disease
MH  - Female
MH  - *Glomerular Filtration Rate
MH  - *Hemorrhage/ci [Chemically Induced]
MH  - Hemorrhage/mo [Mortality]
MH  - Humans
MH  - Incidence
MH  - Italy/ep [Epidemiology]
MH  - *Kidney/pp [Physiopathology]
MH  - Kidney Diseases/di [Diagnosis]
MH  - *Kidney Diseases/ep [Epidemiology]
MH  - Kidney Diseases/pp [Physiopathology]
MH  - Male
MH  - Odds Ratio
MH  - Prevalence
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Stroke/bl [Blood]
MH  - Stroke/ep [Epidemiology]
MH  - Stroke/pp [Physiopathology]
MH  - *Stroke/pc [Prevention & Control]
MH  - Treatment Outcome
MH  - Venous Thromboembolism/bl [Blood]
MH  - Venous Thromboembolism/ep [Epidemiology]
MH  - Venous Thromboembolism/pp [Physiopathology]
MH  - *Venous Thromboembolism/pc [Prevention & Control]
MH  - *Vitamin K/ai [Antagonists & Inhibitors]
AB  - Vitamin K antagonists (VKA) therapy is increasingly used in elderly for prevention of venous thromboembolism (VTE) and of stroke in atrial fibrillation (AF). Glomerular filtration rate (GFR), usually estimated from different equations, decreases progressively with age and it is a risk factor for bleeding. In the frame of the EPICA study, a multicentre prospective observational study including 4,093 patients >80 years naive to VKA treated for AF or after VTE, we performed this ancillary study to evaluate the prevalence of chronic kidney diseases (CKD) by estimated GFR (eGFR). Incidence of bleedings was recorded and bleeding risk was evaluated in relation to eGFR calculated by Cockroft-Gault (C-G); Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formulas. In addition, the agreement among the three eGFR formulas was evaluated. We recorded 179 major bleedings (rate 1.87 x100 patient-years [py]), 26 fatal (rate 0.27 x100 py). Moderate CKD was detected in 69.3%, 59.3% and 47.0% and severe CKD in 5.8%, 7.4% and 10.0% of cases by C-G, MDRD and CKD-EPI, respectively. Bleeding risk was higher in patients with severe CKD irrespective of the applied equation. This study confirms that CKD represents an independent risk factor for bleeding and that a wide proportion of elderly on VKA had severe or moderate CKD, suggesting the need for frequent monitoring. Although the different available equations yield different eGFR, all appear to similarly predict the risk of major bleeding.
RN  - 0 (Anticoagulants)
RN  - 12001-79-5 (Vitamin K)
IS  - 0340-6245
IL  - 0340-6245
DO  - http://dx.doi.org/10.1160/TH11-10-0721
PT  - Journal Article
PT  - Multicenter Study
LG  - English
EP  - 20120426
DP  - 2012 Jun
DC  - 20120531
YR  - 2012
ED  - 20121016
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22535516

<322. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22953596
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Patil HR
AU  - O'Keefe JH
AU  - Lavie CJ
AU  - Magalski A
AU  - Vogel RA
AU  - McCullough PA
FA  - Patil, Harshal R
FA  - O'Keefe, James H
FA  - Lavie, Carl J
FA  - Magalski, Anthony
FA  - Vogel, Robert A
FA  - McCullough, Peter A
IN  - Patil,Harshal R. Saint Luke's Hospital of Kansas City, USA.
TI  - Cardiovascular damage resulting from chronic excessive endurance exercise. [Review]
SO  - Missouri Medicine. 109(4):312-21, 2012 Jul-Aug.
AS  - Mo Med. 109(4):312-21, 2012 Jul-Aug.
NJ  - Missouri medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - new, 0400744
SB  - Index Medicus
CP  - United States
MH  - Animals
MH  - *Cardiovascular System/pp [Physiopathology]
MH  - Coronary Artery Disease/pp [Physiopathology]
MH  - Death, Sudden, Cardiac/ep [Epidemiology]
MH  - Exercise/ph [Physiology]
MH  - Heart Injuries/pp [Physiopathology]
MH  - Hemodynamics
MH  - Humans
MH  - Myocardium/pa [Pathology]
MH  - *Physical Endurance/ph [Physiology]
MH  - Physical Fitness
MH  - Risk Assessment
MH  - *Running/ph [Physiology]
MH  - Ventricular Function, Left/ph [Physiology]
MH  - Ventricular Remodeling/ph [Physiology]
AB  - A daily routine of physical activity is highly beneficial in the prevention and treatment of many prevalent chronic diseases, especially of the cardiovascular (CV) system. However, chronic, excessive sustained endurance exercise may cause adverse structural remodeling of the heart and large arteries. An evolving body of data indicates that chronically training for and participating in extreme endurance competitions such as marathons, ultra-marathons, Iron-man distance triathlons, very long distance bicycle racing, etc., can cause transient acute volume overload of the atria and right ventricle, with transient reductions in right ventricular ejection fraction and elevations of cardiac biomarkers, all of which generally return to normal within seven to ten days. In veteran extreme endurance athletes, this recurrent myocardial injury and repair may eventually result in patchy myocardial fibrosis, particularly in the atria, interventricular septum and right ventricle, potentially creating a substrate for atrial and ventricular arrhythmias. Furthermore, chronic, excessive, sustained, high-intensity endurance exercise may be associated with diastolic dysfunction, large-artery wall stiffening and coronary artery calcification. Not all veteran extreme endurance athletes develop pathological remodeling, and indeed lifelong exercisers generally have low mortality rates and excellent functional capacity. The aim of this review is to discuss the emerging understanding of the cardiac pathophysiology of extreme endurance exercise, and make suggestions about healthier fitness patterns for promoting optimal CV health and longevity.
IS  - 0026-6620
IL  - 0026-6620
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2012 Jul-Aug
DC  - 20120907
YR  - 2012
ED  - 20121009
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22953596

<323. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22433984
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Eagle K
FA  - Eagle, Ken
IN  - Eagle,Ken. eaglek2011@gmail.com
TI  - Toxicological effects of red wine, orange juice, and other dietary SULT1A inhibitors via excess catecholamines.
SO  - Food & Chemical Toxicology. 50(6):2243-9, 2012 Jun.
AS  - Food Chem Toxicol. 50(6):2243-9, 2012 Jun.
NJ  - Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - f3u, 8207483
SB  - Index Medicus
CP  - England
MH  - Alcoholic Beverages/to [Toxicity]
MH  - *Arylsulfotransferase/ai [Antagonists & Inhibitors]
MH  - Atrial Fibrillation/ci [Chemically Induced]
MH  - *Beverages/to [Toxicity]
MH  - Blood Pressure/de [Drug Effects]
MH  - *Catecholamines/bl [Blood]
MH  - *Citrus sinensis/to [Toxicity]
MH  - Coffee
MH  - Diet
MH  - Dopamine/bl [Blood]
MH  - Epinephrine/bl [Blood]
MH  - Fruit/ch [Chemistry]
MH  - Humans
MH  - Migraine Disorders/ci [Chemically Induced]
MH  - Norepinephrine/bl [Blood]
MH  - Polyphenols/ch [Chemistry]
MH  - Polyphenols/pd [Pharmacology]
MH  - Quercetin/pd [Pharmacology]
MH  - Tea/ch [Chemistry]
MH  - *Wine/to [Toxicity]
AB  - SULT1A enzymes protect humans from catecholamines, but natural substances in many foods have been found to inhibit these enzymes in vitro. Given the hormonal roles of catecholamines, any in vivo SULT1A inhibition could have serious consequences. This paper uses a re-analysis of published data to confirm that SULT1A inhibitors have effect in vivo in at least some patients. Nineteen studies are cited that show ingestion of SULT1A inhibitors leading to catecholamine increases, blood pressure changes, migraine headaches, or atrial fibrillation. SULT1A inhibition does not create the catecholamines, but prevents normal catecholamine deactivation. Susceptible patients probably have lower-activity SULT1A alleles. The paper discusses new hypotheses that SULT1A inhibition can cause "holiday heart" arrhythmias and type 2 diabetes in susceptible patients. Subgroup analysis based on SULT1A alleles, and addition of a catecholamine source, should improve the consistency of results from tests of SULT1A inhibitors. SULT1A inhibition may be a key contributor to cheese-induced migraines (via annatto), false positives in metanephrine testing, and the cardiovascular impacts of recreational alcohols.Copyright © 2012 Elsevier Ltd. All rights reserved.
RN  - 0 (Catecholamines)
RN  - 0 (Coffee)
RN  - 0 (Polyphenols)
RN  - 0 (Tea)
RN  - 9IKM0I5T1E (Quercetin)
RN  - EC 2-8-2-1 (Arylsulfotransferase)
RN  - EC 2-8-2-1 (SULT1A1 protein, human)
RN  - VTD58H1Z2X (Dopamine)
RN  - X4W3ENH1CV (Norepinephrine)
RN  - YKH834O4BH (Epinephrine)
ES  - 1873-6351
IL  - 0278-6915
DO  - http://dx.doi.org/10.1016/j.fct.2012.03.004
PT  - Journal Article
LG  - English
EP  - 20120313
DP  - 2012 Jun
DC  - 20120528
YR  - 2012
ED  - 20121009
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22433984

<324. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22450862
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Delise P
AU  - Sitta N
AU  - Berton G
FA  - Delise, Pietro
FA  - Sitta, Nadir
FA  - Berton, Giuseppe
IN  - Delise,Pietro. Division of Cardiology, S. Maria dei Battuti Hospital, Conegliano, Italy. pietro.delise@libero.it
TI  - Does long-lasting sports practice increase the risk of atrial fibrillation in healthy middle-aged men? Weak suggestions, no objective evidence. [Review]
SO  - Journal of Cardiovascular Medicine. 13(6):381-5, 2012 Jun.
AS  - J Cardiovasc Med (Hagerstown). 13(6):381-5, 2012 Jun.
NJ  - Journal of cardiovascular medicine (Hagerstown, Md.)
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101259752
SB  - Index Medicus
CP  - United States
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Exercise
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - *Sports
MH  - Time Factors
AB  - BACKGROUND: Some authors have suggested that sports activity can increase the risk of atrial fibrillation in healthy middle-aged men. Therefore, sport activity, although it prevents coronary artery disease, might be the cause of a potentially dangerous arrhythmia.
AB  - METHODS: To verify this assumption, we critically analyzed the current literature including original articles, reviews and meta-analyses.
AB  - RESULTS AND CONCLUSIONS: All published articles showed several limitations. The data provided by published studies support the following conclusions: the incidence of atrial fibrillation in sporting middle-aged men is rare (<0.5% per year); a possible facilitating effect on atrial fibrillation is limited to vigorous endurance exercise, not to less vigorous sports; there are no convincing data to demonstrate that sport itself may be the cause of atrial fibrillation in healthy middle-aged men; and a facilitating effect of long-lasting sport cannot be excluded in middle-aged individuals with cardiovascular disorders. Nevertheless, the beneficial effects of exercise should offset this supposed risk, which, albeit increased, remains low.
ES  - 1558-2035
IL  - 1558-2027
DO  - http://dx.doi.org/10.2459/JCM.0b013e3283522485
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2012 Jun
DC  - 20120503
YR  - 2012
ED  - 20121009
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22450862

<325. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22773537
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Lip GY
AU  - Rasmussen LH
AU  - Skjoth F
AU  - Overvad K
AU  - Larsen TB
FA  - Lip, Gregory Y H
FA  - Rasmussen, Lars Hvilsted
FA  - Skjoth, Flemming
FA  - Overvad, Kim
FA  - Larsen, Torben Bjerregaard
IN  - Lip,Gregory Y H. Centre for Cardiovascular Sciences, University of Birmingham, City Hospital, Birmingham, UK.
TI  - Stroke and mortality in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study.
SO  - BMJ Open. 2(4), 2012.
AS  - BMJ Open. 2(4), 2012.
NJ  - BMJ open
PI  - Journal available in: Electronic-Print
PI  - Citation processed from: Internet
JC  - 101552874
OI  - Source: NLM. PMC4400696
CP  - England
AB  - OBJECTIVE: The objective was to test the hypothesis that the risk of stroke, death and the composite of 'stroke and death' would be increased among patients with incident heart failure (HF). While HF increases the risk of mortality, stroke and thromboembolism in general, the 'extreme high-risk' nature of incident HF is perhaps under-recognised in everyday clinical practice.
AB  - DESIGN: Prospective cohort study.
AB  - SETTING: Large Danish prospective epidemiological cohort.
AB  - PARTICIPANTS: Subjects in the Diet, Cancer and Health study.
AB  - OUTCOME MEASURES: Stroke, death and the composite of 'stroke and death' among patients with incident cases of HF, without concomitant atrial fibrillation.
AB  - RESULTS: From the original cohort, 1239 patients with incident HF were identified. Incidence rates show a higher incidence in the initial period following the diagnosis of HF, with a markedly higher rate of death and stroke (ischaemic or haemorrhagic) in the initial 30 days following the diagnosis of incident HF. While lower than the risk at 0-30 days, the higher risk did not return to normal at 6+ months after the diagnosis of incident HF. This risk increase was apparent for the end points of stroke (ischaemic or haemorrhagic or both) whether or not a vitamin K antagonist (VKA) was used. With VKA use, there was a lower adjusted HR for death and the composite of 'death or stroke' compared to non-VKA use at the three time intervals following diagnosis of HF, whether 0-30 days, 30 days to 6 months and 6+ months. On multivariate analysis, previous stroke/transient ischaemic attack/thromboembolism was a predictor of higher risk of stroke, death and the composite of 'stroke and death', while VKA treatment was a highly significant predictor of a lower risk for death (adjusted HR 0.46, 95% CI 0.28 to 0.74, p<0.001) and the combined end point of death or stroke (adjusted HR 0.64, 95% CI 0.43 to 0.96, p=0.003).
AB  - CONCLUSIONS: Based on relative hazards, incident HF is clearly a major risk factor for stroke, death and the composite of 'stroke and death', especially in the initial 30 days following initial diagnosis. The use of VKA therapy was associated with a lower risk of these end points. These findings would have major implications for the approach to management of patients presenting with incident HF, given the high risk of this population for death and stroke, which may be ameliorated by VKA therapy.
ES  - 2044-6055
IL  - 2044-6055
DI  - e000975
DO  - http://dx.doi.org/10.1136/bmjopen-2012-000975
PT  - Journal Article
LG  - English
EP  - 20120707
DP  - 2012
DC  - 20120709
YR  - 2012
ED  - 20121002
RD  - 20160603
UP  - 20160606
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=22773537

<326. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 23015791
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Salvador-Montanes O
AU  - Gomez-Gallanti A
AU  - Garofalo D
AU  - Noujaim SF
AU  - Peinado R
AU  - Filgueiras-Rama D
FA  - Salvador-Montanes, Oscar
FA  - Gomez-Gallanti, Alfonso
FA  - Garofalo, Daniel
FA  - Noujaim, Sami F
FA  - Peinado, Rafael
FA  - Filgueiras-Rama, David
IN  - Salvador-Montanes,Oscar. Cardiac Electrophysiology Unit, Department of Cardiology, Hospital Universitario la Paz Madrid, Spain.
TI  - Polyunsaturated Fatty acids in atrial fibrillation: looking for the proper candidates.
SO  - Frontiers in Physiology. 3:370, 2012.
AS  - Front Physiol. 3:370, 2012.
NJ  - Frontiers in physiology
PI  - Journal available in: Electronic-eCollection
PI  - Citation processed from: Internet
JC  - 101549006
OI  - Source: NLM. PMC3449334
CP  - Switzerland
KW  - atrial fibrillation;  drug therapy;  omega-3 polyunsaturated fatty acids;  prevention;  remodeling
AB  - Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in clinical practice with growing prevalence in developed countries. Several medical and interventional therapies, such as atrial specific drugs and pulmonary vein isolation, have demonstrated prevention of recurrences. However, their suboptimal long-term success and significant rate of secondary effects have led to intensive research in the last decade focused on novel alternative and supplemental therapies. One such candidate is polyunsaturated fatty acids (PUFAs). Because of their biological properties, safety, simplicity, and relatively cheap cost, there is a special clinical interest in omega-3 PUFAs as a possible antiarrhythmic agent. Obtained from diets rich in fish, they represent one of the current supplemental therapies. At the cellular level, an increasing body of evidence has shown that n-3 PUFAs exert a variety of effects on cardiac ion channels, membrane dynamic properties, inflammatory cascade, and other targets related to AF prevention. In this article, we review the current basic and clinical evidence pertinent to n-3 PUFAs in AF treatment and prevention. We also discuss controversial outcomes among clinical studies and propose specific subsets of AF patients who will benefit most from n-3 PUFAs.
ES  - 1664-042X
IL  - 1664-042X
PT  - Journal Article
LG  - English
EP  - 20120917
DP  - 2012
DC  - 20120927
YR  - 2012
ED  - 20121002
RD  - 20130813
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=23015791

<327. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22865244
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Glatter KA
AU  - Myers R
AU  - Chiamvimonvat N
FA  - Glatter, Kathryn A
FA  - Myers, Richard
FA  - Chiamvimonvat, Nipavan
IN  - Glatter,Kathryn A. Woodland Clinic Medical Group, 632 West Gibson Road, Woodland, CA, 95695, USA, kaglatter@gmail.com.
TI  - Recommendations regarding dietary intake and caffeine and alcohol consumption in patients with cardiac arrhythmias: what do you tell your patients to do or not to do?.
SO  - Current Treatment Options in Cardiovascular Medicine. 14(5):529-35, 2012 Oct.
AS  - Curr Treat Options Cardiovasc Med. 14(5):529-35, 2012 Oct.
NJ  - Current treatment options in cardiovascular medicine
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 9815942
OI  - Source: NLM. NIHMS505573
OI  - Source: NLM. PMC3742445
CP  - United States
AB  - OPINION STATEMENT: The etiology of arrhythmias including atrial fibrillation is multifactorial. Most arrhythmias are associated with comorbid illnesses like hypertension, diabetes, thyroid disease, or advanced age. Although it is tempting to blame a stimulant like caffeine as a trigger for arrhythmias, the literature does not support this idea. There is no real benefit to having patients with arrhythmias limit their caffeine intake. Caffeine is a vasoactive substance that also may promote the release of norepinephrine and epinephrine. However, acute ingestion of caffeine (as coffee or tea) does not cause atrial fibrillation. Even patients suffering a myocardial infarction do not have an increased incidence of ventricular or other arrhythmias after ingesting several cups of coffee. Large epidemiologic studies have also failed to find a connection between the amount of coffee/caffeine used and the development of arrhythmias. As such, it does not make sense to suggest that patients with palpitations, paroxysmal atrial fibrillation, or supraventricular tachycardia, abstain from caffeine use. Energy drinks are a new phenomenon on the beverage market, with 30-50 % of young adults and teens using them regularly. Energy drinks are loaded with caffeine, sugar, and other chemicals that can stimulate the cardiac system. There is an increasing body of mainly anecdotal case reports describing arrhythmias or even sudden death triggered by exercise plus using energy drinks. Clearly, there must be more study in this area, but it is wise to either limit or avoid their use in patients with arrhythmias. Moderate to heavy alcohol use seems to be associated with the development of atrial fibrillation. The term "holiday heart" was coined back in 1978, to describe patients who had atrial fibrillation following binge alcohol use. Thus, it is reasonable to recommend to patients with arrhythmias that they limit their alcohol use, although unfortunately this treatment will likely not completely resolve their arrhythmia.
ES  - 1534-3189
IL  - 1092-8464
DO  - http://dx.doi.org/10.1007/s11936-012-0193-6
PT  - Journal Article
NO  - I01 BX000576 (United States BLRD VA)
NO  - R01 HL075274 (United States NHLBI NIH HHS)
NO  - R01 HL085727 (United States NHLBI NIH HHS)
NO  - R01 HL085844 (United States NHLBI NIH HHS)
NO  - T32 HL086350 (United States NHLBI NIH HHS)
LG  - English
DP  - 2012 Oct
DC  - 20120905
YR  - 2012
ED  - 20121002
RD  - 20131017
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=22865244

<328. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22936848
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Decker C
AU  - Garavalia L
AU  - Garavalia B
AU  - Simon T
AU  - Loeb M
AU  - Spertus JA
AU  - Daniel WC
FA  - Decker, Carole
FA  - Garavalia, Linda
FA  - Garavalia, Brian
FA  - Simon, Teresa
FA  - Loeb, Matthew
FA  - Spertus, John A
FA  - Daniel, William C
IN  - Decker,Carole. Mid America Heart Institute at Saint Luke's Hospital in Kansas City Missouri, University of Missouri-Kansas City School of Nursing, Kansas City, MO.
TI  - Exploring barriers to optimal anticoagulation for atrial fibrillation: interviews with clinicians.
SO  - Journal of multidisciplinary healthcare. 5:129-35, 2012.
AS  - J Multidiscip Healthc. 5:129-35, 2012.
NJ  - Journal of multidisciplinary healthcare
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101512691
OI  - Source: NLM. PMC3426274
CP  - New Zealand
KW  - anticoagulants;  atrial fibrillation;  risk factors
AB  - BACKGROUND: Warfarin, the most commonly used antithrombotic agent for stroke prophylaxis in atrial fibrillation (AF), requires regular monitoring, frequent dosage adjustments, and dietary restrictions. Clinicians' perceptions of barriers to optimal AF management are an important factor in treatment. Anticoagulation management for AF is overseen by both cardiology and internal medicine (IM) practices. Thus, gaining the perspective of specialists and generalists is essential in understanding barriers to treatment. We used qualitative research methods to define key issues in the prescription of warfarin therapy for AF by cardiology specialists and IM physicians.
AB  - METHODS AND RESULTS: Clinicians were interviewed to identify barriers to warfarin treatment in a large Midwestern city. Interviews were conducted until thematic saturation occurred. Content analysis yielded several themes. The most salient theme that emerged from clinician interviews was use of characteristics other than the patient's CHADS(2) score to enact a treatment plan, such as the patient's social situation and past medication-taking behavior. Other themes included patient knowledge, real-world problems, breakdown in communication, and clinician reluctance.
AB  - CONCLUSION: Warfarin treatment is associated with many challenges. The barriers identified by clinicians highlight the unmet need associated with stroke prophylaxis in AF and the opportunity to improve anticoagulation treatment in AF. Social and lifestyle factors were important considerations in determining treatment.
ES  - 1178-2390
IL  - 1178-2390
DO  - http://dx.doi.org/10.2147/JMDH.S33045
PT  - Journal Article
LG  - English
EP  - 20120613
DP  - 2012
DC  - 20120831
YR  - 2012
ED  - 20121002
RD  - 20130530
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=22936848

<329. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22451853
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Lombardi F
AU  - Belletti S
AU  - Battezzati PM
AU  - Lomuscio A
FA  - Lombardi, Federico
FA  - Belletti, Sebastiano
FA  - Battezzati, Pier Maria
FA  - Lomuscio, Alberto
IN  - Lombardi,Federico. Federico Lombardi, Sebastiano Belletti, Pier Maria Battezzati, Alberto Lomuscio, Department of Medicine, Surgery and Dentistry, University of Milan, 20147 Milan, Italy.
TI  - Acupuncture for paroxysmal and persistent atrial fibrillation: An effective non-pharmacological tool?.
SO  - World Journal of Cardiology. 4(3):60-5, 2012 Mar 26.
AS  - World J Cardiol. 4(3):60-5, 2012 Mar 26.
NJ  - World journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101537090
OI  - Source: NLM. PMC3312232
CP  - China
KW  - Antiarrhythmic drugs;  Atrial arrhythmias;  Autonomic mechanisms;  Chinese medicine
AB  - In Traditional Chinese Medicine, stimulation of the Neiguan spot has been utilized to treat palpitations and symptoms related to different cardiovascular diseases. We evaluated whether acupuncture might exert an antiarrhythmic effect on patients with paroxysmal or persistent atrial fibrillation (AF). Two sets of data are reviewed. The first included patients with persistent AF who underwent electrical cardioversion to restore sinus rhythm. The second included patients with symptomatic paroxysmal AF. All subjects had normal ventricular function. Acupuncture treatment consisted of 10 acupuncture sessions on a once a week basis with puncturing of the Neiguan, Shenmen and Xinshu spots. In patients with persistent AF, the recurrence rate after acupuncture treatment was similar to that observed in patients on amiodarone, but significantly smaller than that measured after sham acupuncture treatment or in the absence of any antiarrhythmic drugs. In a small group of patients with paroxysmal AF, acupuncture resulted in a significant reduction in the number and duration of symptomatic AF episodes. In conclusion, we observed that acupuncture of the Neiguan spot was associated with an antiarrhythmic effect, which was evident in patients with both persistent and paroxysmal AF. These preliminary data, observed in 2 small groups of AF patients, need to be validated in a larger population but strongly suggest that acupuncture may be an effective non-invasive and safe antiarrhythmic tool in the management of these patients.
ES  - 1949-8462
DO  - http://dx.doi.org/10.4330/wjc.v4.i3.60
PT  - Journal Article
LG  - English
DP  - 2012 Mar 26
DC  - 20120327
YR  - 2012
ED  - 20121002
RD  - 20130529
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=22451853

<330. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22810026
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Elkind MS
FA  - Elkind, Mitchell S V
TI  - Epidemiology and risk factors.
SO  - CONTINUUM: Lifelong Learning in Neurology. 17(6 2ndary Stroke Prevention):1213-32, 2011 Dec.
AS  - Continuum. 17(6 2ndary Stroke Prevention):1213-32, 2011 Dec.
NJ  - Continuum (Minneapolis, Minn.)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9509333
CP  - United States
AB  - PURPOSE OF REVIEW: : This article presents current knowledge on stroke epidemiology. It covers recent data on the global burden of stroke, disparities, silent stroke, traditional and novel risk factors, and stroke triggers as well as the clinical implications of these findings.
AB  - RECENT FINDINGS: : Stroke is the third leading cause of death and the leading cause of chronic disability in the United States, and the burden of stroke worldwide is even greater. Large international and US case-control and prospective cohort studies have demonstrated disparities in stroke mortality and incidence. They have also shed light on the relative importance of several well-established, modifiable risk factors for ischemic stroke, such as hypertension, atrial fibrillation, other cardiac diseases, hyperlipidemia, diabetes, cigarette smoking, physical inactivity, alcohol consumption, abdominal obesity, diet, and TIA. Research on other putative stroke risk factors (including inflammation, infection, renal disease, depression, stress, and others) is ongoing. Identifying stroke triggers may be another way to minimize stroke incidence if high-risk time windows can be determined.
AB  - SUMMARY: : Stroke is a major global health burden. While many of the risk factors for stroke are well known and have been studied for decades, recent studies continue to shed light on the distribution and severity of these problems.
IS  - 1080-2371
IL  - 1080-2371
DO  - http://dx.doi.org/10.1212/01.CON.0000410031.34477.8d
PT  - Journal Article
LG  - English
DP  - 2011 Dec
DC  - 20120719
YR  - 2011
ED  - 20121002
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=22810026

<331. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17449392
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Lip GY
AU  - Agnelli G
AU  - Thach AA
AU  - Knight E
AU  - Rost D
AU  - Tangelder MJ
FA  - Lip, G Y H
FA  - Agnelli, G
FA  - Thach, A A
FA  - Knight, E
FA  - Rost, D
FA  - Tangelder, M J D
IN  - Lip,G Y H. Haemostasis, Thrombosis & Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, B18 7QH, UK.
TI  - Oral anticoagulation in atrial fibrillation: A pan-European patient survey.
SO  - European Journal of Internal Medicine. 18(3):202-8, 2007 May.
AS  - EUR. J. INTERN. MED.. 18(3):202-8, 2007 May.
NJ  - European journal of internal medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9003220
CP  - Netherlands
AB  - BACKGROUND: Anticoagulation with vitamin K antagonists (VKAs) provides effective stroke prophylaxis in patients with atrial fibrillation (AF). Optimisation of such therapy requires frequent monitoring, dose adjustments and stringent lifestyle restrictions. We conducted a large multinational survey in patients with chronic AF to gain insights into their perceptions and understanding of VKA use.
AB  - METHODS: Eligible patients were adults with AF who had been prescribed VKAs for at least 1 year. A total of 711 patient interviews were conducted in seven European countries during June and July 2004.
AB  - RESULTS: The majority of patients (58% male; mean age 68 years) claimed to understand their treatment programme; despite this, only 7% knew that VKA use is aimed at preventing strokes and 24% stated that they would have liked more information. Patients attended an average of 14 monitoring sessions in the previous year; however, 21% missed appointments, especially younger patients (<65 years). The International Normalized Ratio (INR) was within the target range in most or all of the last five to ten visits in 64% of patients; nonetheless, 38% were not aware that an INR outside the target range is associated with health risks. On average, patients required dose adjustments every four sessions. VKA treatment impacted 67% of patients in terms of diet, socialising, career and independence, especially younger patients (74%).
AB  - CONCLUSIONS: Monitoring, dose adjustments and lifestyle restrictions to optimise the intensity of anticoagulation with VKAs are problematic for patients with AF, and their knowledge of the consequences of such therapy is often poor.
IS  - 0953-6205
IL  - 0953-6205
PT  - Journal Article
LG  - English
DP  - 2007 May
DC  - 20070423
YR  - 2007
ED  - 20121002
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=17449392

<332. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20086889
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Cantwell JD
AU  - Shrake L
AU  - Murray PM
FA  - Cantwell, J D
FA  - Shrake, L
FA  - Murray, P M
IN  - Cantwell,J D. Georgia Baptist Medical Center, Atlanta, GA, 30312, USA.
TI  - ECG Quiz: Dizziness in a Cardiac Rehabilitation Patient.
SO  - Physician & Sportsmedicine. 25(2):89-90, 1997 Feb.
AS  - Phys Sportsmed. 25(2):89-90, 1997 Feb.
NJ  - The Physician and sportsmedicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0427461
CP  - United States
AB  - A 62-year-old woman entered a cardiac rehabilitation program for help with weight loss and fitness, and also for monitoring of episodic atrial fibrillation, which had begun in 1992. She was able to exercise without triggering atrial fibrillation. Additional past medical problems included glucose intolerance (treated with diet), hyperlipidemia, hypertension, migraine headaches, degenerative disease of the spine, and a duodenal ulcer.
IS  - 0091-3847
IL  - 0091-3847
DO  - http://dx.doi.org/10.3810/psm.1997.02.1172
PT  - Journal Article
LG  - English
DP  - 1997 Feb
DC  - 20100120
YR  - 1997
ED  - 20121002
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=20086889

<333. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22245946
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Golwala H
AU  - Dib C
AU  - Tafur A
AU  - Abu-Fadel MS
FA  - Golwala, Harsh
FA  - Dib, Chadi
FA  - Tafur, Alfonso
FA  - Abu-Fadel, Mazen S
IN  - Golwala,Harsh. Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, USA.
TI  - A new era of antithrombotic therapy in patients with atrial fibrillation. [Review]
SO  - American Journal of the Medical Sciences. 344(2):128-35, 2012 Aug.
AS  - Am J Med Sci. 344(2):128-35, 2012 Aug.
NJ  - The American journal of the medical sciences
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 3l2, 0370506
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Benzimidazoles/tu [Therapeutic Use]
MH  - Dabigatran
MH  - *Fibrinolytic Agents/tu [Therapeutic Use]
MH  - Humans
MH  - Morpholines/tu [Therapeutic Use]
MH  - Platelet Aggregation Inhibitors/tu [Therapeutic Use]
MH  - Pyrazoles/tu [Therapeutic Use]
MH  - Pyridones/tu [Therapeutic Use]
MH  - Rivaroxaban
MH  - Stroke/et [Etiology]
MH  - *Stroke/pc [Prevention & Control]
MH  - Thiophenes/tu [Therapeutic Use]
MH  - Warfarin/tu [Therapeutic Use]
MH  - beta-Alanine/aa [Analogs & Derivatives]
MH  - beta-Alanine/tu [Therapeutic Use]
AB  - Atrial fibrillation/flutter is the most common cardiac arrhythmia that can potentially result in stroke and death. For many years, aspirin and warfarin have been the cornerstone of stroke prevention among such patients. Although warfarin therapy has been advocated for patients with high likelihood of stroke, it requires close surveillance and monitoring, has a narrow therapeutic window and is quite often affected by medication interactions and diet. Thus, the need for a better and more consistent anticoagulant therapy was necessary and has been under development with various successes for many years. This article will review 3 new antithrombotic medications that may potentially become the mainstay for treatment of patients with atrial fibrillation in the near future.
RN  - 0 (Anticoagulants)
RN  - 0 (Benzimidazoles)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Morpholines)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridones)
RN  - 0 (Thiophenes)
RN  - 11P2JDE17B (beta-Alanine)
RN  - 3Z9Y7UWC1J (apixaban)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - I0VM4M70GC (Dabigatran)
ES  - 1538-2990
IL  - 0002-9629
DO  - http://dx.doi.org/10.1097/MAJ.0b013e3182429b1e
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2012 Aug
DC  - 20120725
YR  - 2012
ED  - 20121001
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22245946

<334. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22910132
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Nguyen T
AU  - Wong E
FA  - Nguyen, Timothy
FA  - Wong, Elaine
IN  - Nguyen,Timothy. Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, USA. timothy.nguyen@liu.edu
TI  - Evaluating and assessing dabigatran drug interactions.
SO  - Consultant Pharmacist. 27(7):509-12, 2012 Jul.
AS  - Consult Pharm. 27(7):509-12, 2012 Jul.
NJ  - The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9013983
SB  - Index Medicus
CP  - United States
MH  - *Antithrombins/ae [Adverse Effects]
MH  - Antithrombins/pk [Pharmacokinetics]
MH  - Antithrombins/tu [Therapeutic Use]
MH  - *Benzimidazoles/ae [Adverse Effects]
MH  - Benzimidazoles/pk [Pharmacokinetics]
MH  - Benzimidazoles/tu [Therapeutic Use]
MH  - Consultants
MH  - Cytochrome P-450 Enzyme System/de [Drug Effects]
MH  - Cytochrome P-450 Enzyme System/me [Metabolism]
MH  - Dabigatran
MH  - Drug Interactions
MH  - Drug Monitoring/mt [Methods]
MH  - Female
MH  - Humans
MH  - International Normalized Ratio
MH  - Middle Aged
MH  - Pharmaceutical Services/og [Organization & Administration]
MH  - *Pharmacists/og [Organization & Administration]
MH  - Professional Role
MH  - Warfarin/ad [Administration & Dosage]
MH  - Warfarin/tu [Therapeutic Use]
MH  - beta-Alanine/ae [Adverse Effects]
MH  - *beta-Alanine/aa [Analogs & Derivatives]
MH  - beta-Alanine/pk [Pharmacokinetics]
MH  - beta-Alanine/tu [Therapeutic Use]
AB  - Dabigatran is a novel oral direct thrombin inhibitor that has been shown to have beneficial outcomes in the prevention of thromboembolic stroke in patients with atrial fibrillation. Its advantages compared with warfarin may include decreased laboratory monitoring (e.g., international normalized ratio), minimal cytochrome P450 drug interactions, lack of dietary interactions, and faster onset of action. However, dabigatran is still associated with drug interactions, as will be reviewed through a patient case. Consultant pharmacists should carefully review a patient&s medication profile and evaluate the pros and cons of dabigatran therapy as its use becomes more prevalent.
RN  - 0 (Antithrombins)
RN  - 0 (Benzimidazoles)
RN  - 11P2JDE17B (beta-Alanine)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9035-51-2 (Cytochrome P-450 Enzyme System)
RN  - I0VM4M70GC (Dabigatran)
IS  - 0888-5109
IL  - 0888-5109
DO  - http://dx.doi.org/10.4140/TCP.n.2012.509
PT  - Case Reports
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 2012 Jul
DC  - 20120822
YR  - 2012
ED  - 20120925
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22910132

<335. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22321570
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Andreasen JJ
AU  - Schmidt EB
FA  - Andreasen, Jan Jesper
FA  - Schmidt, Erik Berg
IN  - Andreasen,Jan Jesper. Department of Cardiothoracic Surgery, Center for Cardiovascular Research, Aalborg Hospital, Aalborg, Denmark. jan.jesper.andreasen@stofanet.dk
TI  - Therapeutic potential of marine n-3 fatty acids in CABG patients. [Review]
SO  - Current Opinion in Pharmacology. 12(2):142-6, 2012 Apr.
AS  - Curr Opin Pharmacol. 12(2):142-6, 2012 Apr.
NJ  - Current opinion in pharmacology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 100966133
SB  - Index Medicus
CP  - England
MH  - Animals
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - *Cardiotonic Agents/tu [Therapeutic Use]
MH  - *Coronary Artery Bypass/ae [Adverse Effects]
MH  - *Fatty Acids, Omega-3/tu [Therapeutic Use]
MH  - Fish Oils
MH  - Humans
MH  - Vascular Patency/de [Drug Effects]
AB  - Dietary intake of marine n-3 polyunsaturated fatty acids (PUFA) has beneficial effects in various cardiac disorders. Few studies have, however, investigated the therapeutic potential of n-3 PUFA in patients undergoing coronary artery bypass grafting (CABG). Five heterogeneous randomized studies on n-3 PUFA for prevention of postoperative atrial fibrillation have yielded conflicting results. Increased venous graft patency rates following CABG were seen in another study in patients treated with n-3 PUFA. Finally, supplements with n-3 PUFA postoperatively have been associated with a lower risk of repeat revascularization and lower mortality in patients with poor ventricular function. Data are still few, and more studies are needed to clarify the therapeutic potential of n-3 PUFA in patients undergoing CABG.Copyright © 2012 Elsevier Ltd. All rights reserved.
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Fish Oils)
ES  - 1471-4973
IL  - 1471-4892
DO  - http://dx.doi.org/10.1016/j.coph.2012.01.012
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20120208
DP  - 2012 Apr
DC  - 20120604
YR  - 2012
ED  - 20120918
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22321570

<336. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22453988
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Voigt N
AU  - Nattel S
AU  - Dobrev D
FA  - Voigt, Niels
FA  - Nattel, Stanley
FA  - Dobrev, Dobromir
IN  - Voigt,Niels. Division of Experimental Cardiology, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany. niels.voigt@medma.uni-heidelberg.de
TI  - Proarrhythmic atrial calcium cycling in the diseased heart. [Review]
SO  - Advances in Experimental Medicine & Biology. 740:1175-91, 2012.
AS  - Adv Exp Med Biol. 740:1175-91, 2012.
NJ  - Advances in experimental medicine and biology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0121103, 2lu
SB  - Index Medicus
CP  - United States
MH  - Animals
MH  - *Arrhythmias, Cardiac/et [Etiology]
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Calcium/me [Metabolism]
MH  - Excitation Contraction Coupling
MH  - Heart Atria/me [Metabolism]
MH  - Heart Diseases
MH  - Humans
MH  - *Myocytes, Cardiac/me [Metabolism]
MH  - Sarcoplasmic Reticulum Calcium-Transporting ATPases/ph [Physiology]
AB  - During the last decades Ca(2+) has been found to play a crucial role in cardiac arrhythmias associated with heart failure and a number of congenital arrhythmia syndromes. Recent studies demonstrated that altered atrial Ca(2+) cycling may promote the initiation and maintenance of atrial fibrillation, the most common clinical arrhythmia that contributes significantly to population morbidity and mortality. This article describes physiological Ca(2+) cycling mechanisms in atrial cardiomyocytes and relates them to fundamental cellular proarrhythmic mechanisms involving Ca(2+) signaling abnormalities in the atrium during atrial fibrillation.
RN  - EC 3-6-3-8 (Sarcoplasmic Reticulum Calcium-Transporting ATPases)
RN  - SY7Q814VUP (Calcium)
IS  - 0065-2598
IL  - 0065-2598
DO  - http://dx.doi.org/10.1007/978-94-007-2888-2_53
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
NO  - MOP44365 (Canada Canadian Institutes of Health Research)
LG  - English
DP  - 2012
DC  - 20120328
YR  - 2012
ED  - 20120918
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22453988

<337. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22397620
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Rix TA
AU  - Riahi S
AU  - Overvad K
AU  - Lundbye-Christensen S
AU  - Schmidt EB
AU  - Joensen AM
FA  - Rix, Thomas Andersen
FA  - Riahi, Sam
FA  - Overvad, Kim
FA  - Lundbye-Christensen, Soren
FA  - Schmidt, Erik Berg
FA  - Joensen, Albert Marni
IN  - Rix,Thomas Andersen. Department of Cardiology, Aalborg AF Study Group, Center for Cardiovascular Research, Aalborg Hospital, Aarhus University Hospital, Denmark. tar@rn.dk
TI  - Validity of the diagnoses atrial fibrillation and atrial flutter in a Danish patient registry.
SO  - Scandinavian Cardiovascular Journal. 46(3):149-53, 2012 Jun.
AS  - Scand Cardiovasc J. 46(3):149-53, 2012 Jun.
NJ  - Scandinavian cardiovascular journal : SCJ
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - cta, 9708377
SB  - Index Medicus
CP  - England
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Flutter/di [Diagnosis]
MH  - Atrial Flutter/ep [Epidemiology]
MH  - Atrial Flutter/pp [Physiopathology]
MH  - Denmark/ep [Epidemiology]
MH  - Diagnosis, Differential
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Registries
MH  - Reproducibility of Results
MH  - Risk Factors
AB  - OBJECTIVES: To assess the validity of the diagnoses of atrial fibrillation (AF) and atrial flutter (AFL) for men and women recorded in the Danish National Patient Registry, and to assess the relative distribution of AF and AFL.
AB  - DESIGN: Review of medical records for incident cases of AF and/or AFL in the Diet, Cancer, and Health cohort study. Participants were enrolled in 1993-97 with 13.6 years of follow-up until 30 December, 2009.
AB  - RESULTS: The positive predictive value of the combined diagnosis of AF and/or AFL was 92.6% (95% CI 88.8%; 95.2%) with no significant difference between sexes (men 93.7% (133/142), women 90.8% (129/142)). The proportion of AFL either alone or in combination with AF was significantly higher in men than in women (13.5% (18/133) vs. 5.4% (7/129), p =0.03). The positive predictive value of the specified diagnosis of AFL was 57.5% for men (46/80) and 29.6% for women (8/27).
AB  - CONCLUSIONS: This study shows that the validity of the diagnosis of AF and/or AFL is high and may be used for registry-based studies. A specified diagnosis of AFL was rarely used and was not reliable to distinguish between cases of AF and AFL.
ES  - 1651-2006
IL  - 1401-7431
DO  - http://dx.doi.org/10.3109/14017431.2012.673728
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20120329
DP  - 2012 Jun
DC  - 20120510
YR  - 2012
ED  - 20120913
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22397620

<338. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22534406
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Larsen TB
AU  - Lip GY
AU  - Skjoth F
AU  - Due KM
AU  - Overvad K
AU  - Hvilsted Rasmussen L
FA  - Larsen, Torben Bjerregaard
FA  - Lip, Gregory Y H
FA  - Skjoth, Flemming
FA  - Due, Karen Margrete
FA  - Overvad, Kim
FA  - Hvilsted Rasmussen, Lars
IN  - Larsen,Torben Bjerregaard. Department of Cardiology, Aalborg AF Study Group, Cardiovascular Research Centre, Aarhus University Hospital, Aalborg, Denmark. tobl@rn.dk
TI  - Added predictive ability of the CHA2DS2VASc risk score for stroke and death in patients with atrial fibrillation: the prospective Danish Diet, Cancer, and Health cohort study.
SO  - Circulation. Cardiovascular Quality & Outcomes. 5(3):335-42, 2012 May.
AS  - Circ Cardiovasc Qual Outcomes. 5(3):335-42, 2012 May.
NJ  - Circulation. Cardiovascular quality and outcomes
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101489148
SB  - Index Medicus
CP  - United States
MH  - Administration, Oral
MH  - Aged
MH  - Anticoagulants/ad [Administration & Dosage]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/mo [Mortality]
MH  - Denmark/ep [Epidemiology]
MH  - Diet/ae [Adverse Effects]
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Life Style
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/ep [Epidemiology]
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Prospective Studies
MH  - ROC Curve
MH  - Registries
MH  - Risk Assessment
MH  - Risk Factors
MH  - *Stroke/ep [Epidemiology]
MH  - Stroke/mo [Mortality]
MH  - Stroke/pc [Prevention & Control]
MH  - Time Factors
AB  - BACKGROUND: The objective of this study was to evaluate the added predictive ability of the CHA(2)DS(2)VASc prediction rule for stroke and death in a nonanticoagulated population of patients with atrial fibrillation.
AB  - METHODS AND RESULTS: We included 1603 nonanticoagulated patients with incident atrial fibrillation from a Danish prospective cohort study of 57 053 middle-aged men and women. The Net Reclassification Improvement was calculated as a measure to estimate any overall improvement in reclassification with the CHA(2)DS(2)VASc sore as an alternative to the CHADS(2) score. After 1-year follow-up, crude incidence rates were 3.4 per 100 person-years for stroke and 13.6 for death. After a mean follow-up of 5.4 years (+/- 3.7 years), the crude incidence rates for stroke and death were 1.9 and 5.6, respectively. During the entire observation period, the c-statistics and negative predictive values were similar for both risk scores. The Net Reclassification Improvement analysis showed that 1 of 10 reclassified atrial fibrillation patients would have been upgraded correctly using the CHA(2)DS(2)VASc score.
AB  - CONCLUSIONS: Both the CHADS(2) as well as the CHA(2)DS(2)VASc risk score can exclude a large proportion of patients from having high risk of stroke or death. However, using the CHA(2)DS(2)VASc risk score, fewer patients will fulfill the criterion for low risk (and are truly low risk for thromboembolism). For every 10 extra patients transferred to the treatment group at 5 years, using the CHA(2)DS(2)VASc risk score, 1 patient would have had a stroke that might have been avoided with effective treatment.
RN  - 0 (Anticoagulants)
ES  - 1941-7705
IL  - 1941-7713
DO  - http://dx.doi.org/10.1161/CIRCOUTCOMES.111.964023
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20120424
DP  - 2012 May
DC  - 20120517
YR  - 2012
ED  - 20120911
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22534406

<339. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22875558
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ng SM
AU  - Wang CW
AU  - Ho RT
AU  - Ziea TC
AU  - He J
AU  - Wong VC
AU  - Chan CL
FA  - Ng, Siu-Man
FA  - Wang, Chong-Wen
FA  - Ho, Rainbow Tin-Hung
FA  - Tin-Hung Ho, Rainbow
FA  - Ziea, Tat-Chi
FA  - Tat-Chi Ziea, Eric
FA  - He, J
FA  - Wong, Vivian Chi-Woon
FA  - Chi-Woon Taam Wong, Vivian
FA  - Chan, Cecilia Lai-Wan
FA  - Lai-Wan Chan, Cecilia
IN  - Ng,Siu-Man. Centre on Behavioral Health and Department of Social Work and Social Administration, University of Hong Kong.
TI  - Tai chi exercise for patients with heart disease: a systematic review of controlled clinical trials. [Review][Erratum appears in Altern Ther Health Med. 2012 Nov-Dec;18(6):79 Note: Tin-Hung Ho, Rainbow [corrected to Ho, Rainbow Tin-Hung]; Tat-Chi Ziea, Eric [corrected to Ziea, Tat-Chi]; He, J [removed]; Chi-Woon Taam Wong, Vivian [corrected to Wong, Vivian Chi-Woon]; Lai-Wan Chan, Cecilia [corrected to Chan, Cecilia Lai-Wan]]
SO  - Alternative Therapies in Health & Medicine. 18(3):16-22, 2012 May-Jun.
AS  - Altern Ther Health Med. 18(3):16-22, 2012 May-Jun.
NJ  - Alternative therapies in health and medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9502013, clw
SB  - Index Medicus
CP  - United States
MH  - Activities of Daily Living
MH  - Controlled Clinical Trials as Topic
MH  - *Coronary Disease/rh [Rehabilitation]
MH  - *Evidence-Based Medicine
MH  - Health Behavior
MH  - Humans
MH  - Myocardial Infarction/rh [Rehabilitation]
MH  - Outcome Assessment (Health Care)
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - *Tai Ji
AB  - CONTEXT: To summarize and evaluate the available evidence from controlled clinical trials of tai chi (TC) exercise for patients with heart disease.
AB  - SEARCH METHODS: Fourteen databases were searched up to November 2010 with the terms tai chi, taichi, tai ji, taiji, taijichuan, cardiac, heart, coronary, myocardial, and atrial fibrillation in the title, abstract, or key words. No language restrictions were imposed. The quality and validity of randomized clinical trials (RCTs) were evaluated using the Jadad Scale. The strength of the evidence for all included studies was evaluated using the Oxford Centre for Evidence-based Medicine Levels of Evidence.
AB  - RESULTS: Nine studies including 5 RCTs and 4 nonrandomized controlled clinical trials met the inclusion criteria. Three studies examined the effectiveness of TC exercise for patients with chronic heart failure (CHF), and 6 studies examined the effectiveness of TC exercise among patients with coronary heart disease (CHD). Overall, these studies demonstrated favorable effects of TC exercise for the patients with heart disease.
AB  - CONCLUSIONS: The existing evidence suggests that TC exercise is a good option for heart patients with very limited exercise tolerance and can be an adjunct to rehabilitation programs for patients with CHD or CHF.
IS  - 1078-6791
IL  - 1078-6791
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
LG  - English
DP  - 2012 May-Jun
DC  - 20120809
YR  - 2012
ED  - 20120906
RD  - 20121220
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22875558

<340. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22459307
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wilhelm M
AU  - Roten L
AU  - Tanner H
AU  - Schmid JP
AU  - Wilhelm I
AU  - Saner H
FA  - Wilhelm, Matthias
FA  - Roten, Laurent
FA  - Tanner, Hildegard
FA  - Schmid, Jean-Paul
FA  - Wilhelm, Ilca
FA  - Saner, Hugo
IN  - Wilhelm,Matthias. Department of Cardiology, University of Bern, Bern, Switzerland. matthias.wilhelm@insel.ch
TI  - Long-term cardiac remodeling and arrhythmias in nonelite marathon runners.
SO  - American Journal of Cardiology. 110(1):129-35, 2012 Jul 1.
AS  - Am J Cardiol. 110(1):129-35, 2012 Jul 1.
NJ  - The American journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Arrhythmias, Cardiac/ep [Epidemiology]
MH  - *Arrhythmias, Cardiac/pp [Physiopathology]
MH  - Arrhythmias, Cardiac/us [Ultrasonography]
MH  - Electrocardiography, Ambulatory
MH  - Female
MH  - Follow-Up Studies
MH  - *Heart Atria/pp [Physiopathology]
MH  - Heart Atria/us [Ultrasonography]
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - *Running/ph [Physiology]
MH  - Switzerland/ep [Epidemiology]
MH  - Time Factors
MH  - *Ventricular Remodeling/ph [Physiology]
AB  - Long-term endurance sports are associated with atrial remodeling and atrial arrhythmias. More importantly, high-level endurance training may promote right ventricular (RV) dysfunction and complex ventricular arrhythmias. We investigated the long-term consequences of marathon running on cardiac remodeling as a potential substrate for arrhythmias with a focus on the right heart. We invited runners of the 2010 Grand Prix of Bern, a 10-mile race. Of 873 marathon and nonmarathon runners who applied, 122 (61 women) entered the final analysis. Subjects were stratified according to former marathon participations: control group (nonmarathon runners, n = 34), group 1 (1 marathon to 5 marathons, mean 2.7, n = 46), and group 2 (>6 marathons, mean 12.8, n = 42). Mean age was 42 +/- 7 years. Results were adjusted for gender, age, and lifetime training hours. Right and left atrial sizes increased with marathon participations. In group 2, right and left atrial enlargements were present in 60% and 74% of athletes, respectively. RV and left ventricular (LV) dimensions showed no differences among groups, and RV or LV dilatation was present in only 2.4% or 4.3% of marathon runners, respectively. In multiple linear regression analysis, marathon participation was an independent predictor of right and left atrial sizes but had no effect on RV and LV dimensions and function. Atrial and ventricular ectopic complexes during 24-hour Holter monitoring were low and equally distributed among groups. In conclusion, in nonelite athletes, marathon running was not associated with RV enlargement, dysfunction, or ventricular ectopy. Marathon running promoted biatrial remodeling.Copyright © 2012 Elsevier Inc. All rights reserved.
ES  - 1879-1913
IL  - 0002-9149
DO  - http://dx.doi.org/10.1016/j.amjcard.2012.02.058
PT  - Comparative Study
PT  - Journal Article
LG  - English
EP  - 20120328
DP  - 2012 Jul 1
DC  - 20120618
YR  - 2012
ED  - 20120904
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22459307

<341. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22876439
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Zhao XF
AU  - Su SJ
AU  - Yun G
AU  - Guo YH
AU  - Wang S
FA  - Zhao, Xiao-feng
FA  - Su, Shi-jun
FA  - Yun, Guo
FA  - Guo, Yun-hong
FA  - Wang, Shu
IN  - Zhao,Xiao-feng. Institute of Acupuncture and Moxibustion, the First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, China.
TI  - Mortality and recurrence of vascular disease among stroke patients treated with combined TCM therapy.
SO  - Journal of Traditional Chinese Medicine. 32(2):173-8, 2012 Jun.
AS  - J Tradit Chin Med. 32(2):173-8, 2012 Jun.
NJ  - Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan / sponsored by All-China Association of Traditional Chinese Medicine, Academy of Traditional Chinese Medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 8211546, k9k
SB  - Index Medicus
CP  - China
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - *Medicine, Chinese Traditional
MH  - Middle Aged
MH  - Recurrence
MH  - Retrospective Studies
MH  - *Stroke/dt [Drug Therapy]
MH  - Stroke/mo [Mortality]
MH  - *Vascular Diseases/et [Etiology]
AB  - OBJECTIVE: To confirm the long-term outcomes of stroke patients and determine predicting factors for death, recurrence of vascular events and poor outcome (either recurrence or death) after the use of combined TCM therapy.
AB  - METHODS: This was a retrospective hospital-based cohort study and was performed in the First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine in Tianjin. All subjects with stroke consecutively admitted to an inpatient ward of the Acupuncture Department from January 1, 2008, to December 31, 2008 were retrospectively followed through one year. The main outcomes were either a recurrence of vascular events, mortality or both. Risk factors were recorded from medical records. Multivariate regression models were used to analyze predictors. The following independent variables were used: age, gender, hypertension, ischemic heart disease, atrial fibrillation, diabetes mellitus, carotid arterial lesions and history of stroke.
AB  - RESULTS: Four-hundred and five patients were included. The 1-year mortality rate was 11.11%. 23.70% of the patients had a recurrent vascular event, and 30.86% suffered a poor outcome. Multiple logistic regression analysis found that previous stroke, and advanced age were predictors of death within one year, Recurrence of vascular events was associated with carotid arterial lesions, history of diabetes and previous stroke. Long-term poor outcome was predicted by advanced age, history of diabetes, and previous stroke.
AB  - CONCLUSION: Age, previous stroke, carotid arterial lesions and diabetes history seem to have different impacts on the three outcomes within one year. Our findings provide important data for planning future hospital register studies of stroke patients in TCM hospitals.
IS  - 0255-2922
IL  - 0255-2922
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2012 Jun
DC  - 20120810
YR  - 2012
ED  - 20120830
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22876439

<342. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22688313
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Tsuneoka H
AU  - Koike A
AU  - Nagayama O
AU  - Sakurada K
AU  - Kato J
AU  - Sato A
AU  - Yamashita T
AU  - Aonuma K
FA  - Tsuneoka, Hidekazu
FA  - Koike, Akira
FA  - Nagayama, Osamu
FA  - Sakurada, Koji
FA  - Kato, Jo
FA  - Sato, Akira
FA  - Yamashita, Takeshi
FA  - Aonuma, Kazutaka
IN  - Tsuneoka,Hidekazu. Cardiovascular Institute, Tokyo, Japan.
TI  - Prognostic value of cardiopulmonary exercise testing in cardiac patients with atrial fibrillation.
SO  - International Heart Journal. 53(2):102-7, 2012.
AS  - Int Heart J. 53(2):102-7, 2012.
NJ  - International heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101244240
SB  - Index Medicus
CP  - Japan
MH  - Aged
MH  - Arrhythmia, Sinus/mo [Mortality]
MH  - *Arrhythmia, Sinus/pp [Physiopathology]
MH  - Atrial Fibrillation/mo [Mortality]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Exercise/ph [Physiology]
MH  - *Exercise Test
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxygen Consumption/ph [Physiology]
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Pulmonary Ventilation/ph [Physiology]
AB  - Parameters obtained from cardiopulmonary exercise testing (CPX) are recognized for their high prognostic value in predicting future cardiac events in cardiac patients. Our group compared the prognostic value of CPX parameters between patients with sinus rhythm (SR) and patients with atrial fibrillation (AF).Peak O2 uptake (VO2), the ratio of the increase in VO2 to the increase in work rate (DELTAVO2/DELTAWR), and the slope of the increase in ventilation to the increase in CO2 output (VE-VCO2 slope) were obtained from CPX in 72 AF patients and 478 SR patients. The prognostic values of these indices were compared between the two groups.Six cardiac deaths and 25 cardiac events were observed in the AF group and 9 cardiac deaths and 96 cardiac events were observed in the SR group, over a prospective follow-up period of 1,192 days. The percentages of cardiac deaths and cardiac events were higher in the AF group than in the SR group. In a multivariate Cox proportional hazards analysis, peak VO2 was identified as a sole significant predictor of cardiac death and cardiac events in SR patients and VE-VCO2 slope was identified as a sole significant predictor of cardiac death and cardiac events in AF patients.Our results suggest that the VE-VCO2 slope is strongly predictive of future cardiac events in patients with AF and that peak VO2 is strongly predictive of future cardiac events in SR patients.
ES  - 1349-3299
IL  - 1349-2365
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 2012
DC  - 20120612
YR  - 2012
ED  - 20120823
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22688313

<343. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22436091
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Khawaja O
AU  - Gaziano JM
AU  - Djousse L
FA  - Khawaja, O
FA  - Gaziano, J M
FA  - Djousse, L
IN  - Khawaja,O. Harvard Medical School, Boston, MA, USA. oajaz@yahoo.com
TI  - Nut consumption and risk of atrial fibrillation in the Physicians' Health Study.
SO  - Nutrition Journal. 11:17, 2012.
AS  - Nutr J. 11:17, 2012.
NJ  - Nutrition journal
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 101152213
OI  - Source: NLM. PMC3361489
SB  - Index Medicus
CP  - England
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/pc [Prevention & Control]
MH  - Body Mass Index
MH  - Diet
MH  - Follow-Up Studies
MH  - *Health Status
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - *Nuts
MH  - Odds Ratio
MH  - *Physicians/sn [Statistics & Numerical Data]
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Surveys and Questionnaires
AB  - BACKGROUND: Atrial Fibrillation is highly prevalent in clinical practice affecting approximately 2.3 million people in USA and 4.5 million people in European Union. The aim of the study was to examine the association between nut consumption and incident atrial fibrillation.
AB  - METHODS: Prospective cohort of 21,054 male participants of Physicians' Health Study I. Nut consumption was estimated using food frequency questionnaire and incident atrial fibrillation was ascertained through yearly follow-up questionnaires. Cox regression was used to estimate relative risks of atrial fibrillation.
AB  - RESULTS: The average age was 54.6 +/- 9.5 years (40.7-87.1). During a mean follow up of 20 years (median 24 years), 3,317 cases of atrial fibrillation occurred. The crude incidence rate was 7.6, 7.4, 8.2, 7.9, and 6.8 cases/1000 person-years for people reporting nut consumption of rarely/never, 1-3/month, 1/per week, 2-6/week, and > 7/week, respectively. Multivariable adjusted hazard ratios (95% CI) for incident atrial fibrillation were 1.00 (ref), 1.00 (0.90-1.11), 1.09 (0.97-1.21), 1.07 (0.95-1.21), and 0.91 (0.70-1.17) for nut consumption from the lowest to the highest category of nut consumption (p for trend 0.26). No statistically significant association between nut consumption and atrial fibrillation was found when stratified by body mass index (BMI < 25 vs > 25 kg/m2) or age (< 65 vs. > 65 years).
AB  - CONCLUSIONS: Our data did not show an association between nut consumption and incident atrial fibrillation among US male physicians.
ES  - 1475-2891
IL  - 1475-2891
DO  - http://dx.doi.org/10.1186/1475-2891-11-17
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
NO  - CA-097193 (United States NCI NIH HHS)
NO  - CA-34944 (United States NCI NIH HHS)
NO  - CA-40360 (United States NCI NIH HHS)
NO  - HL-26490 (United States NHLBI NIH HHS)
NO  - HL-34595 (United States NHLBI NIH HHS)
NO  - R01 CA097193 (United States NCI NIH HHS)
LG  - English
EP  - 20120321
DP  - 2012
DC  - 20120529
YR  - 2012
ED  - 20120823
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22436091

<344. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20851477
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Efthimiadis GK
AU  - Giannakoulas G
AU  - Parcharidou DG
AU  - Pagourelias ED
AU  - Kouidi EJ
AU  - Spanos G
AU  - Kamperidis V
AU  - Gavrielides S
AU  - Karvounis H
AU  - Styliadis I
AU  - Parcharidis GE
FA  - Efthimiadis, Georgios K
FA  - Giannakoulas, Georgios
FA  - Parcharidou, Despina G
FA  - Pagourelias, Efstathios D
FA  - Kouidi, Evangelia J
FA  - Spanos, Georgios
FA  - Kamperidis, Vasileios
FA  - Gavrielides, Stavros
FA  - Karvounis, Haralambos
FA  - Styliadis, Ioannis
FA  - Parcharidis, Georgios E
IN  - Efthimiadis,Georgios K. Cardiomyopathies Laboratory, First Cardiology Department, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. efthymos@med.auth.gr
TI  - Chronotropic incompetence and its relation to exercise intolerance in hypertrophic cardiomyopathy.
SO  - International Journal of Cardiology. 153(2):179-84, 2011 Dec 1.
AS  - Int J Cardiol. 153(2):179-84, 2011 Dec 1.
NJ  - International journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - gqw, 8200291
SB  - Index Medicus
CP  - Netherlands
MH  - Adult
MH  - *Cardiomyopathy, Hypertrophic/di [Diagnosis]
MH  - *Cardiomyopathy, Hypertrophic/pp [Physiopathology]
MH  - *Exercise Test/mt [Methods]
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
AB  - BACKGROUND: Diminished functional capacity is common in hypertrophic cardiomyopathy (HCM), although the underlying mechanisms are complicated. We studied the prevalence of chronotropic incompetence and its relation to exercise intolerance in patients with HCM.
AB  - METHODS: Cardiopulmonary exercise testing was performed in 68 patients with HCM (age 44.8 +/- 14.6 years, 45 males). Chronotropic incompetence was defined by chronotropic index (heart rate reserve)/(220-age-resting heart rate) and exercise capacity was assessed by peak oxygen consumption (peak Vo(2)).
AB  - RESULTS: Chronotropic incompetence was present in 50% of the patients and was associated with higher NYHA class, history of atrial fibrillation, higher fibrosis burden on cardiac MRI, and treatment with beta-blockers, amiodarone and warfarin. On univariate analysis, male gender, age, NYHA class, maximal wall thickness, left atrial diameter, peak early diastolic myocardial velocity of the lateral mitral annulus, history of atrial fibrillation, presence of left ventricular outflow tract obstruction (LVOTO) at rest, and treatment with beta-blockers were related to peak Vo(2). Peak heart rate during exercise, heart rate reserve, chronotropic index, and peak systolic blood pressure were also related to peak Vo(2). On multivariate analysis male gender, atrial fibrillation, presence of LVOTO and heart rate reserve were independent predictors of exercise capacity (R(2) = 76.7%). A cutoff of 62 bpm for the heart rate reserve showed a negative predictive value of 100% in predicting patients with a peak Vo(2) <80%.
AB  - CONCLUSIONS: Blunted heart rate response to exercise is common in HCM and represents an important determinant of exercise capacity.Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
ES  - 1874-1754
IL  - 0167-5273
DO  - http://dx.doi.org/10.1016/j.ijcard.2010.08.026
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20100920
DP  - 2011 Dec 1
DC  - 20111121
YR  - 2011
ED  - 20120816
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20851477

<345. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22525440
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Agarwal M
AU  - Parameswari RP
AU  - Vasanthi HR
AU  - Das DK
FA  - Agarwal, Mahesh
FA  - Parameswari, Royapuram P
FA  - Vasanthi, Hannah R
FA  - Das, Dipak K
IN  - Agarwal,Mahesh. Department of Biotechnology, School of Life Sciences, Pondicherry University, Puducherry-605014, India. mhsh.agarwal@gmail.com
TI  - Dynamic action of carotenoids in cardioprotection and maintenance of cardiac health. [Review][Retraction in McPhee D. Molecules. 2014;19(3):3850; PMID: 24896014]
SO  - Molecules. 17(4):4755-69, 2012.
AS  - Molecules (Basel). 17(4):4755-69, 2012.
NJ  - Molecules (Basel, Switzerland)
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 100964009
SB  - Index Medicus
CP  - Switzerland
MH  - Animals
MH  - Antioxidants/ch [Chemistry]
MH  - *Antioxidants/pd [Pharmacology]
MH  - Antioxidants/tu [Therapeutic Use]
MH  - Cardiotonic Agents/ch [Chemistry]
MH  - *Cardiotonic Agents/pd [Pharmacology]
MH  - Cardiotonic Agents/tu [Therapeutic Use]
MH  - Carotenoids/ch [Chemistry]
MH  - *Carotenoids/pd [Pharmacology]
MH  - Carotenoids/tu [Therapeutic Use]
MH  - Cell Communication
MH  - Endothelial Cells/me [Metabolism]
MH  - Gap Junctions/me [Metabolism]
MH  - *Heart/de [Drug Effects]
MH  - Humans
MH  - Oxidation-Reduction/de [Drug Effects]
MH  - Reperfusion Injury/dt [Drug Therapy]
MH  - Reperfusion Injury/me [Metabolism]
MH  - Signal Transduction
AB  - Oxidative stress has been considered universally and undeniably implicated in the pathogenesis of all major diseases, including those of the cardiovascular system. Oxidative stress activate transcriptional messengers, such as nuclear factor-kappaB, tangibly contributing to endothelial dysfunction, the initiation and progression of atherosclerosis, irreversible damage after ischemic reperfusion, and even arrhythmia, such as atrial fibrillation. Evidence is rapidly accumulating to support the role of reactive oxygen species (ROS) and reactive nitrogen species (RNS) as intracellular signaling molecules. Despite this connection between oxidative stress and cardiovascular disease (CVD), there are currently no recognized therapeutic interventions to address this important unmet need. Antioxidants that provide a broad, "upstream" approach via ROS/RNS quenching or free radical chain breaking seem an appropriate therapeutic option based on epidemiologic, dietary, and in vivo animal model data. Short-term dietary intervention trials suggest that diets rich in fruit and vegetable intake lead to improvements in coronary risk factors and reduce cardiovascular mortality. Carotenoids are such abundant, plant-derived, fat-soluble pigments that functions as antioxidants. They are stored in the liver or adipose tissue, and are lipid soluble by becoming incorporated into plasma lipoprotein particles during transport. For these reasons, carotenoids may represent one plausible mechanism by which fruits and vegetables reduce the risk of chronic diseases as cardiovascular disease (CVD). This review paper outlines the role of carotenoids in maintaining cardiac health and cardioprotection mediated by several mechanisms including redox signaling.
RN  - 0 (Antioxidants)
RN  - 0 (Cardiotonic Agents)
RN  - 36-88-4 (Carotenoids)
ES  - 1420-3049
IL  - 1420-3049
DO  - http://dx.doi.org/10.3390/molecules17044755
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Retracted Publication
PT  - Review
LG  - English
EP  - 20120423
DP  - 2012
DC  - 20120424
YR  - 2012
ED  - 20120810
RD  - 20140616
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22525440

<346. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22677079
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - O'Keefe JH
AU  - Patil HR
AU  - Lavie CJ
AU  - Magalski A
AU  - Vogel RA
AU  - McCullough PA
FA  - O'Keefe, James H
FA  - Patil, Harshal R
FA  - Lavie, Carl J
FA  - Magalski, Anthony
FA  - Vogel, Robert A
FA  - McCullough, Peter A
IN  - O'Keefe,James H. Mid America Heart Institute of Saint Luke's Hospital of Kansas City, MO, USA. jokeefe@saint-lukes.org
TI  - Potential adverse cardiovascular effects from excessive endurance exercise. [Review][Erratum appears in Mayo Clin Proc. 2012 Jul;87(7):704]
CM  - Comment in: Mayo Clin Proc. 2012 Nov;87(11):1133; author reply 1133-4; PMID: 23127741
SO  - Mayo Clinic Proceedings. 87(6):587-95, 2012 Jun.
AS  - Mayo Clin Proc. 87(6):587-95, 2012 Jun.
NJ  - Mayo Clinic proceedings
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 0405543, lly
OI  - Source: NLM. PMC3538475
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - Animals
MH  - Arrhythmias, Cardiac/pp [Physiopathology]
MH  - Cardiomyopathies/pp [Physiopathology]
MH  - Cardiovascular Diseases/ep [Epidemiology]
MH  - Cardiovascular Diseases/pp [Physiopathology]
MH  - Coronary Vessels/pa [Pathology]
MH  - *Exercise/ph [Physiology]
MH  - Hemodynamics
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - *Physical Endurance/ph [Physiology]
MH  - Risk Assessment
MH  - Risk Factors
MH  - Running/ph [Physiology]
MH  - Stroke Volume
AB  - A routine of regular exercise is highly effective for prevention and treatment of many common chronic diseases and improves cardiovascular (CV) health and longevity. However, long-term excessive endurance exercise may induce pathologic structural remodeling of the heart and large arteries. Emerging data suggest that chronic training for and competing in extreme endurance events such as marathons, ultramarathons, ironman distance triathlons, and very long distance bicycle races, can cause transient acute volume overload of the atria and right ventricle, with transient reductions in right ventricular ejection fraction and elevations of cardiac biomarkers, all of which return to normal within 1 week. Over months to years of repetitive injury, this process, in some individuals, may lead to patchy myocardial fibrosis, particularly in the atria, interventricular septum, and right ventricle, creating a substrate for atrial and ventricular arrhythmias. Additionally, long-term excessive sustained exercise may be associated with coronary artery calcification, diastolic dysfunction, and large-artery wall stiffening. However, this concept is still hypothetical and there is some inconsistency in the reported findings. Furthermore, lifelong vigorous exercisers generally have low mortality rates and excellent functional capacity. Notwithstanding, the hypothesis that long-term excessive endurance exercise may induce adverse CV remodeling warrants further investigation to identify at-risk individuals and formulate physical fitness regimens for conferring optimal CV health and longevity.Copyright © 2012 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.
ES  - 1942-5546
IL  - 0025-6196
DO  - http://dx.doi.org/10.1016/j.mayocp.2012.04.005
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2012 Jun
DC  - 20120608
YR  - 2012
ED  - 20120809
RD  - 20150224
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22677079

<347. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21815874
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kang SY
AU  - Kang HJ
AU  - Chung PW
AU  - Kim KK
AU  - Lee S
AU  - Choi BO
FA  - Kang, Suk Yun
FA  - Kang, Hyun Jae
FA  - Chung, Pil-Wook
FA  - Kim, Kwang Ki
FA  - Lee, Suman
FA  - Choi, Byung Ok
IN  - Kang,Suk Yun. Department of Neurology, Hallym University College of Medicine, Seoul, Republic of Korea. sukyunkang@hanmail.net
TI  - Congestive heart failure after physical exercise in a young patient with myotonic dystrophy type 1.
SO  - International Journal of Neuroscience. 121(11):637-9, 2011 Nov.
AS  - Int J Neurosci. 121(11):637-9, 2011 Nov.
NJ  - The International journal of neuroscience
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - gs4, 0270707
SB  - Index Medicus
CP  - England
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Exercise/ph [Physiology]
MH  - Exercise Therapy/ae [Adverse Effects]
MH  - *Exercise Tolerance/ge [Genetics]
MH  - Heart Failure/di [Diagnosis]
MH  - *Heart Failure/et [Etiology]
MH  - *Heart Failure/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - *Myotonic Dystrophy/co [Complications]
MH  - Myotonic Dystrophy/di [Diagnosis]
MH  - *Myotonic Dystrophy/pp [Physiopathology]
MH  - Physical Fitness/ph [Physiology]
MH  - Young Adult
AB  - Cardiac involvement, such as conduction defects, is common in myotonic dystrophy type 1 (DM1), but congestive heart failure (CHF) is rare in young patients. A 21-year-old recruit was admitted in the department of cardiology with acute CHF after daily physical exercise for about one week in the boot camp. After recovery, neurologic consultation was requested for his general weakness and lean body mass. He was diagnosed as DM1. He denied any prior cardiac symptoms. We cautiously postulated that excessive physical activity might contribute to develop CHF in DM1 patients. Other possible mechanisms will be discussed. Comprehensive cardiac evaluation might be helpful to identifying high-risk patients early to prevent cardiac complications, even without cardiac symptoms.
ES  - 1563-5279
IL  - 0020-7454
DO  - http://dx.doi.org/10.3109/00207454.2011.591514
PT  - Case Reports
PT  - Journal Article
LG  - English
EP  - 20110805
DP  - 2011 Nov
DC  - 20111104
YR  - 2011
ED  - 20120807
RD  - 20141120
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21815874

<348. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22834058
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Anonymous
TI  - My wife and I both take warfarin because we have atrial fibrillation. We've been told to stay away from green vegetables, because they are high in vitamin K. Is there a guideline for a "safe" amount to eat?.
SO  - Heart Advisor. 13(11):8, 2010 Nov.
AS  - Heart Advis. 13(11):8, 2010 Nov.
NJ  - Heart advisor / the Cleveland Clinic
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9892190
SB  - Consumer Health Journals
CP  - United States
MH  - *Anticoagulants/ad [Administration & Dosage]
MH  - Anticoagulants/ae [Adverse Effects]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Diet
MH  - Dose-Response Relationship, Drug
MH  - *Food-Drug Interactions
MH  - Health Behavior
MH  - Health Education
MH  - Humans
MH  - Risk Factors
MH  - *Vegetables
MH  - *Vitamin K/ad [Administration & Dosage]
MH  - Vitamin K/ae [Adverse Effects]
MH  - *Warfarin/ad [Administration & Dosage]
MH  - Warfarin/ae [Adverse Effects]
RN  - 0 (Anticoagulants)
RN  - 12001-79-5 (Vitamin K)
RN  - 5Q7ZVV76EI (Warfarin)
IS  - 1523-9004
IL  - 1523-9004
PT  - Journal Article
LG  - English
DP  - 2010 Nov
DC  - 20120626
YR  - 2010
ED  - 20120802
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=22834058

<349. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22367571
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Van de Heyning CM
AU  - Magne J
AU  - Lancellotti P
AU  - Pierard LA
FA  - Van de Heyning, Caroline M
FA  - Magne, Julien
FA  - Lancellotti, Patrizio
FA  - Pierard, Luc A
IN  - Van de Heyning,Caroline M. University of Liege, University Hospital Sart Tilman, Liege, Belgium.
TI  - The importance of exercise echocardiography for clinical decision making in primary mitral regurgitation. [Review]
SO  - Journal of Cardiovascular Medicine. 13(4):260-5, 2012 Apr.
AS  - J Cardiovasc Med (Hagerstown). 13(4):260-5, 2012 Apr.
NJ  - Journal of cardiovascular medicine (Hagerstown, Md.)
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101259752
SB  - Index Medicus
CP  - United States
MH  - Cardiac Surgical Procedures/ae [Adverse Effects]
MH  - *Echocardiography, Stress
MH  - *Exercise Test
MH  - Hemodynamics
MH  - Humans
MH  - Mitral Valve/pp [Physiopathology]
MH  - Mitral Valve/su [Surgery]
MH  - *Mitral Valve/us [Ultrasonography]
MH  - Mitral Valve Insufficiency/pp [Physiopathology]
MH  - Mitral Valve Insufficiency/su [Surgery]
MH  - *Mitral Valve Insufficiency/us [Ultrasonography]
MH  - Patient Selection
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Risk Assessment
MH  - Risk Factors
MH  - Severity of Illness Index
AB  - Primary mitral regurgitation is generally an insidious disease with late onset of symptoms. Current European and American guidelines recommend surgery in severe primary mitral regurgitation when symptoms, overt left ventricular dysfunction, pulmonary hypertension or atrial fibrillation, occur. However, recent large studies reported an improved outcome in asymptomatic patients with severe mitral regurgitation referred for early mitral valve repair despite the risk of operative mortality or mitral valve replacement. Moreover, primary mitral regurgitation appears to have an important dynamic character in up to one-third of patients. This article provides an overview of the incremental evidence of the ability of exercise echocardiography to assess the functional repercussions of mitral regurgitation and the identification of high-risk patients who might benefit from early referral for surgery.
ES  - 1558-2035
IL  - 1558-2027
DO  - http://dx.doi.org/10.2459/JCM.0b013e3283515c70
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2012 Apr
DC  - 20120308
YR  - 2012
ED  - 20120731
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22367571

<350. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22537534
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lee SP
AU  - Kim YJ
AU  - Lee JM
AU  - Hwang HY
AU  - Kim HK
AU  - Kim KH
AU  - Kim KB
AU  - Sohn DW
AU  - Ahn H
AU  - Oh BH
AU  - Park YB
FA  - Lee, Seung-Pyo
FA  - Kim, Yong-Jin
FA  - Lee, Joo Myung
FA  - Hwang, Ho-Young
FA  - Kim, Hyung-Kwan
FA  - Kim, Kyung-Hwan
FA  - Kim, Ki-Bong
FA  - Sohn, Dae-Won
FA  - Ahn, Hyuk
FA  - Oh, Byung-Hee
FA  - Park, Young-Bae
IN  - Lee,Seung-Pyo. Cardiovascular Center, Seoul National University Hospital, Seoul, Korea; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
TI  - Association of heart rhythm with exercise capacity after operation for chronic mitral regurgitation.
CM  - Comment in: Ann Thorac Surg. 2012 Jun;93(6):1895-6; PMID: 22632490
SO  - Annals of Thoracic Surgery. 93(6):1888-95, 2012 Jun.
AS  - Ann Thorac Surg. 93(6):1888-95, 2012 Jun.
NJ  - The Annals of thoracic surgery
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 15030100R
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - Netherlands
MH  - Aged
MH  - Aged, 80 and over
MH  - Chronic Disease
MH  - *Echocardiography, Three-Dimensional
MH  - *Echocardiography, Transesophageal
MH  - *Exercise Test
MH  - Female
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - *Image Interpretation, Computer-Assisted
MH  - Male
MH  - Middle Aged
MH  - *Mitral Valve Annuloplasty
MH  - *Mitral Valve Insufficiency/su [Surgery]
MH  - *Mitral Valve Insufficiency/us [Ultrasonography]
MH  - *Postoperative Complications/pp [Physiopathology]
MH  - *Postoperative Complications/us [Ultrasonography]
MH  - Prosthesis Design
AB  - BACKGROUND: Although atrial fibrillation (AF) and decreased exercise capacity are common in chronic mitral regurgitation patients, the relationship between rhythm status and exercise capacity after corrective surgery is largely unknown.
AB  - METHODS: Seventy-one patients undergoing repair or replacement of mitral valve for chronic severe mitral regurgitation were examined with preoperative and 6 months' postoperative cardiopulmonary exercise test and two-dimensional echocardiography. Patients were divided into three groups according to preoperative versus postoperative rhythm (sinus/sinus, SS [n=42]; AF/sinus, AS [n=17]; AF/AF, AA group [n=12]).
AB  - RESULTS: Preoperative maximal oxygen consumption was lower and ventilatory efficiency was higher in the AS and AA groups compared with the SS group. However, maximal oxygen consumption improved only in the AS group at 6 months' postoperative cardiopulmonary exercise test (24.0+/-6.9 versus 24.6+/-6.1 mL.kg(-1).min(-1) in the SS group, 19.3+/-5.9 versus 23.2+/-6.4 mL.kg(-1).min(-1) in the AS group, 19.8+/-5.4 versus 18.8+/-5.1 mL.kg(-1).min(-1) in the AA group; p=0.016 for maximal oxygen consumption by analysis of covariance) as well as ventilatory efficiency. Echocardiography verified more significant reduction of left atrial volume in the SS and AS groups than in the AA group (172.2+/-68.0 versus 96.7+/-31.0 mL in the SS group, 247.5+/-77.8 versus 129.2+/-25.7 mL in the AS group, 316.7+/-210.0 versus 192.0+/-95.0 mL in the AA group; p=0.001 for left atrial volume by analysis of covariance) as well as pulmonary artery systolic pressure. When analyzed for significant predictors of postoperative maximal oxygen consumption, being in the AS group but not the SS group was a significant positive predictor when compared with the AA group (beta=5.475; p=0.006).
AB  - CONCLUSIONS: Successful sinus conversion of AF, preferably by maze operation, in patients undergoing surgical correction of chronic severe mitral regurgitation confers improved exercise capacity. Reduction of left atrial volume and pulmonary artery pressure may contribute to this improvement.Copyright © 2012 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
ES  - 1552-6259
IL  - 0003-4975
DO  - http://dx.doi.org/10.1016/j.athoracsur.2012.01.113
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20120425
DP  - 2012 Jun
DC  - 20120528
YR  - 2012
ED  - 20120726
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22537534

<351. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22641983
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Firsovaite V
AU  - Duytschaever M
AU  - Tavernier R
FA  - Firsovaite, Vida
FA  - Duytschaever, Mattias
FA  - Tavernier, Rene
IN  - Firsovaite,Vida. Department of Cardiology, University Hospital Ghent, Ghent, Belgium. vfirsovaite@hotmail.com
TI  - From a wide to a narrow QRS tachycardia and back. What is the mechanism?.
SO  - Acta Cardiologica. 67(2):239-40, 2012 Apr.
AS  - Acta Cardiol. 67(2):239-40, 2012 Apr.
NJ  - Acta cardiologica
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0370570
SB  - Index Medicus
CP  - Belgium
MH  - Adult
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Diagnosis, Differential
MH  - Electrocardiography
MH  - Emergencies
MH  - Exercise
MH  - *Heart Conduction System/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Syncope/et [Etiology]
MH  - *Tachycardia, Ventricular/di [Diagnosis]
MH  - *Tachycardia, Ventricular/pp [Physiopathology]
AB  - A 40-year-old man developed a near syncope during exercise due to a wide complex tachycardia with periods of changing RR intervals accompanied by changes in QRS morphology. The differential diagnosis of this electrocardiographic pattern is discussed.
IS  - 0001-5385
IL  - 0001-5385
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2012 Apr
DC  - 20120530
YR  - 2012
ED  - 20120723
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22641983

<352. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22698551
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Hughes PJ
AU  - Freeman MK
FA  - Hughes, Peter J
FA  - Freeman, Maisha Kelly
IN  - Hughes,Peter J. Samford University Global Drug Information Service, Birmingham, AL 35229, USA. pjhughes@samford.edu
TI  - Dabigatran for the prevention of thromboembolic complications in the elderly: a RE-LY-able alternative to warfarin?.
SO  - Consultant Pharmacist. 27(6):445-52, 2012 Jun.
AS  - Consult Pharm. 27(6):445-52, 2012 Jun.
NJ  - The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9013983
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - *Benzimidazoles/tu [Therapeutic Use]
MH  - Clinical Trials as Topic
MH  - Dabigatran
MH  - *Fibrinolytic Agents/tu [Therapeutic Use]
MH  - Humans
MH  - Prospective Studies
MH  - Stroke/pc [Prevention & Control]
MH  - *Thromboembolism/co [Complications]
MH  - *Thromboembolism/pc [Prevention & Control]
MH  - *Warfarin/tu [Therapeutic Use]
MH  - *beta-Alanine/aa [Analogs & Derivatives]
MH  - beta-Alanine/tu [Therapeutic Use]
AB  - On October 19, 2010, the Food and Drug Administration approved dabigatran (Pradaxa) for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). The use of warfarin sodium has been considered a mainstay therapy for the prevention of thromboembolic complications secondary to AF. Despite its efficacy among oral antithrombotic agents for the prevention of thromboembolic complications secondary to AF, only about 67% of candidates for warfarin receive appropriate antithrombotic therapy. Dosed twice daily, dabigatran offers recipients the ability to forego regular international normalized ratio coagulation monitoring as well as eliminating dietary restrictions (i.e., vitamin K) associated with warfarin therapy. In a 2011 guideline update, dabigatran has been recognized by the American College of Cardiology and the American Heart Association as a useful alternative to warfarin in patients with AF who are at risk for thromboembolic complications and who are without severe renal or hepatic impairment. The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) study is the only direct, prospective, comparative clinical trial of dabigatran versus warfarin to date that enrolled subjects for the purpose of examining the ability of dabigatran to prevent stroke and thromboembolic complications associated with nonvalvular AF. Currently, the published literature has not adequately defined which patient populations would be most suitable to treat with dabigatran. While dabigatran has a place in the therapeutic prevention stroke and systemic embolism associated with AF, careful consideration of the risks and benefits of therapy is recommended.
RN  - 0 (Anticoagulants)
RN  - 0 (Benzimidazoles)
RN  - 0 (Fibrinolytic Agents)
RN  - 11P2JDE17B (beta-Alanine)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - I0VM4M70GC (Dabigatran)
IS  - 0888-5109
IL  - 0888-5109
DO  - http://dx.doi.org/10.4140/TCP.n.2012.445
PT  - Journal Article
LG  - English
DP  - 2012 Jun
DC  - 20120615
YR  - 2012
ED  - 20120717
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22698551

<353. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22419421
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Chan CL
AU  - Wang CW
AU  - Ho RT
AU  - Ho AH
AU  - Ziea ET
AU  - Taam Wong VC
AU  - Ng SM
FA  - Chan, Cecilia Lai-Wan
FA  - Wang, Chong-Wen
FA  - Ho, Rainbow Tin-Hung
FA  - Ho, Andy Hau-Yan
FA  - Ziea, Eric Tat-Chi
FA  - Taam Wong, Vivian Chi-Woon
FA  - Ng, Siu-Man
IN  - Chan,Cecilia Lai-Wan. Centre on Behavioral Health, University of Hong Kong, 5 Sassoon Road, Pokfulam, Hong Kong SAR, China.
TI  - A systematic review of the effectiveness of qigong exercise in cardiac rehabilitation. [Review]
SO  - American Journal of Chinese Medicine. 40(2):255-67, 2012.
AS  - Am J Chin Med. 40(2):255-67, 2012.
NJ  - The American journal of Chinese medicine
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 7901431, 3e4
SB  - Index Medicus
CP  - Singapore
MH  - *Breathing Exercises
MH  - Clinical Trials as Topic
MH  - Heart/pp [Physiopathology]
MH  - Heart Diseases/pp [Physiopathology]
MH  - *Heart Diseases/rh [Rehabilitation]
MH  - Humans
AB  - The objective of this study was to assess evidence for the efficacy and effectiveness of Chinese qigong exercise in rehabilitative programs among cardiac patients. Thirteen databases were searched through to November 2010, and all controlled clinical trials on Chinese qigong exercise among patients with chronic heart diseases were included. For each included study, data was extracted and validity was assessed. Study quality was evaluated and summarized using both the Jadad Scale and the criteria for levels of evidence. Seven randomized controlled trials (RCTs) and one non-randomized controlled clinical trial (CCT) published between 1988 and 2007 met the inclusion criteria. In total, these studies covered 540 patients with various chronic heart diseases including atrial fibrillation, coronary artery disease, myocardial infarct, valve replacement, and ischemic heart disease. Outcome measures emerged in these studies included subjective outcomes such as symptoms and quality of life; and objective outcomes such as blood pressure, ECG findings, and exercise capacity, physical activity, balance, co-ordination, heart rate, and oxygen uptake. Overall, these studies suggest that Chinese qigong exercise seems to be an optimal option for patients with chronic heart diseases who were unable to engage in other forms of physical activity; however, its efficacy and effectiveness in cardiac rehabilitation programs should be further tested.
IS  - 0192-415X
IL  - 0192-415X
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
LG  - English
DP  - 2012
DC  - 20120315
YR  - 2012
ED  - 20120710
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22419421

<354. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22655490
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Yuce M
AU  - Davutoglu V
AU  - Akkoyun C
AU  - Kizilkan N
AU  - Ercan S
AU  - Akcay M
AU  - Sari I
FA  - Yuce, Murat
FA  - Davutoglu, Vedat
FA  - Akkoyun, Cayan
FA  - Kizilkan, Nese
FA  - Ercan, Suleyman
FA  - Akcay, Murat
FA  - Sari, Ibrahim
IN  - Yuce,Murat. Department of Cardiology, Gaziantep University, School of Medicine, Gaziantep, Turkey.
TI  - Interatrial block and P-terminal force: a reflection of mitral stenosis severity on electrocardiography.
SO  - Journal of Heart Valve Disease. 20(6):619-23, 2011 Nov.
AS  - J Heart Valve Dis. 20(6):619-23, 2011 Nov.
NJ  - The Journal of heart valve disease
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - byi, 9312096
SB  - Index Medicus
CP  - England
MH  - Adult
MH  - Case-Control Studies
MH  - Electrocardiography
MH  - Female
MH  - Heart Block/co [Complications]
MH  - *Heart Block/di [Diagnosis]
MH  - Heart Block/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve Stenosis/co [Complications]
MH  - *Mitral Valve Stenosis/di [Diagnosis]
MH  - Mitral Valve Stenosis/pp [Physiopathology]
MH  - Multivariate Analysis
MH  - Severity of Illness Index
AB  - BACKGROUND AND AIM OF THE STUDY: Interatrial block (IAB), a frequently overlooked conduction delay between the atria, is defined as prolonged P-wave on the electrocardiogram (ECG). Previously, IAB has been shown to be an indicator of dilated and impaired left atrial function, and a predictor of both atrial fibrillation and embolic stroke. The study aim was to test the hypothesis that, on ECG, IAB with P-terminal force can reflect the echocardiographic severity of mitral stenosis (MS).
AB  - METHODS: Patients with rheumatic MS who were referred to a single cardiac center for echocardiography between July and October 2009, and who met the study entry criteria (echocardiographically documented rheumatic MS), were invited to participate. Consequently, 116 such patients were studied prospectively, while a group of age- and gender-matched subjects without echocardiographic signs of rheumatic valve involvement served as controls. Transthoracic echocardiography was performed in all subjects.
AB  - RESULTS: A positive correlation was observed between IAB (> or = 120 ms) and the mean mitral valve gradient (R = 0.3, p <0.001). A strong negative correlation was also present between the mitral valve area (MVA) and the presence of IAB (R = -0.3, p <0.001). The presence of pulmonary hypertension and a poor NYHA functional class were associated with a high incidence of significant IAB (R = 0.4, p <0.001; R = 0.3, p <0.001, respectively), and there was a strong correlation between IAB and the P-terminal force (p <0.001). Both, the presence of significant IAB and P-terminal force were correlated with a calcific mitral valve (p <0.001). Only the MVA (beta = 0.3; p = 0.008) was a predictor of IAB in multivariate analysis.
AB  - CONCLUSION: A severe mitral gradient, a decreased MVA, an increased pulmonary artery pressure, and a poor NYHA class were shown to correlate with IAB duration and P-terminal force. Significant IAB (> or = 120 ms) and P-terminal force might be considered as a novel indicator of echocardiographic severity and associated complications during the follow up of MS. However, these interrelations must be clarified in further studies.
IS  - 0966-8519
IL  - 0966-8519
PT  - Journal Article
LG  - English
DP  - 2011 Nov
DC  - 20120604
YR  - 2011
ED  - 20120628
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=22655490

<355. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22218325
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Takagi T
AU  - Takagi A
AU  - Yoshikawa J
FA  - Takagi, Tsutomu
FA  - Takagi, Atsushi
FA  - Yoshikawa, Junichi
IN  - Takagi,Tsutomu. Takagi Cardiology Clinic, Nakagyo-ku, Kyoto, Japan. tcardiol@qb4.so-net.ne.jp
TI  - Altered trans-mitral flow velocity pattern after exercise predicts development of new-onset atrial fibrillation in elderly patients with impaired left ventricular relaxation at rest: prognostic value of diastolic stress echocardiography.
SO  - Journal of Cardiology. 59(2):225-34, 2012 Mar.
AS  - J Cardiol. 59(2):225-34, 2012 Mar.
NJ  - Journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - joa, 8804703
SB  - Index Medicus
CP  - Netherlands
MH  - Aged
MH  - *Atrial Fibrillation/et [Etiology]
MH  - Diastole/ph [Physiology]
MH  - Echocardiography, Doppler
MH  - *Echocardiography, Stress
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - *Mitral Valve/ph [Physiology]
MH  - *Physical Exertion/ph [Physiology]
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Rest
MH  - *Ventricular Function, Left/ph [Physiology]
AB  - OBJECTIVE: This study attempted to determine whether exercise induced left ventricular (LV) diastolic dysfunction estimated by altered trans-mitral flow (TMF) velocity pattern after exercise is associated with increased risk of cardiac events including new-onset atrial fibrillation (AF) in elderly patients with impaired LV relaxation at rest.
AB  - BACKGROUND: Diastolic stress echocardiography has been applied to evaluate LV diastolic function during and post-exercise. Prognostic importance of exercise-induced diastolic dysfunction remains uncertain.
AB  - PATIENTS AND METHODS: We studied 126 patients (70+/-5 years; 70 males) who underwent treadmill stress echocardiography. Doppler measurements were done before exercise and immediately after the post-stress image acquisition, and the ratio between early (E) and atrial (A) TMF velocities was measured. Patients with impaired LV relaxation (E/A<1.0) at rest were studied. Altered TMF velocity pattern was present when patients with E/A<1.0 at rest developed E/A>1.0 after exercise. Primary endpoints for follow-up were combination of major cardiac events and new-onset AF.
AB  - RESULTS: There were 42 patients with altered TMF velocity pattern after exercise. During the 5-year follow-up period, there were 30 cardiac events including 13 new-onset AF. Kaplan-Meier survival plot demonstrated that altered TMF velocity pattern after exercise is associated with increased risk of cardiac events (p<0.0001) including development of new-onset AF (p=0.0003). Cox hazard ratio analysis demonstrated that altered TMF velocity pattern after exercise was the best predictor of cardiac events (hazard ratio 3.939; 95%confidence interval 1.662-9.337; p=0.0018).
AB  - CONCLUSIONS: Altered TMF velocity pattern after exercise provides significant prognostic information for predicting cardiac events including new-onset AF in elderly patients with impaired left ventricular relaxation at rest.Copyright A© 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
ES  - 1876-4738
IL  - 0914-5087
DO  - http://dx.doi.org/10.1016/j.jjcc.2011.11.004
PT  - Journal Article
LG  - English
EP  - 20120102
DP  - 2012 Mar
DC  - 20120228
YR  - 2012
ED  - 20120625
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22218325

<356. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22288675
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kuklina EV
AU  - Tong X
AU  - George MG
AU  - Bansil P
FA  - Kuklina, Elena V
FA  - Tong, Xin
FA  - George, Mary G
FA  - Bansil, Pooja
IN  - Kuklina,Elena V. Division of Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA. ekuklina@cdc.gov
TI  - Epidemiology and prevention of stroke: a worldwide perspective. [Review]
SO  - Expert Review of Neurotherapeutics. 12(2):199-208, 2012 Feb.
AS  - Expert rev. neurotherapeutics. 12(2):199-208, 2012 Feb.
NJ  - Expert review of neurotherapeutics
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101129944
OI  - Source: NLM. HHSPA701341
OI  - Source: NLM. PMC4478589
SB  - Index Medicus
CP  - England
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/pc [Prevention & Control]
MH  - Humans
MH  - Hypertension/co [Complications]
MH  - Hypertension/ep [Epidemiology]
MH  - Hypertension/pc [Prevention & Control]
MH  - Life Style
MH  - Obesity/co [Complications]
MH  - Obesity/ep [Epidemiology]
MH  - Obesity/pc [Prevention & Control]
MH  - Prevalence
MH  - Risk Factors
MH  - Smoking/ae [Adverse Effects]
MH  - Smoking/ep [Epidemiology]
MH  - Smoking/pc [Prevention & Control]
MH  - *Stroke/ep [Epidemiology]
MH  - Stroke/et [Etiology]
MH  - *Stroke/pc [Prevention & Control]
AB  - This paper reviews how epidemiological studies during the last 5 years have advanced our knowledge in addressing the global stroke epidemic. The specific objectives were to review the current evidence supporting management of ten major modifiable risk factors for prevention of stroke: hypertension, current smoking, diabetes, obesity, poor diet, physical inactivity, atrial fibrillation, excessive alcohol consumption, abnormal lipid profile and psychosocial stress/depression.
ES  - 1744-8360
IL  - 1473-7175
DO  - http://dx.doi.org/10.1586/ern.11.99
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
NO  - CC999999 (United States Intramural CDC HHS)
LG  - English
DP  - 2012 Feb
DC  - 20120131
YR  - 2012
ED  - 20120622
RD  - 20151026
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22288675

<357. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22395336
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mobius-Winkler S
AU  - Sandri M
AU  - Mangner N
AU  - Lurz P
AU  - Dahnert I
AU  - Schuler G
FA  - Mobius-Winkler, Sven
FA  - Sandri, Marcus
FA  - Mangner, Norman
FA  - Lurz, Phillip
FA  - Dahnert, Ingo
FA  - Schuler, Gerhard
IN  - Mobius-Winkler,Sven. University of Leipzig Heart Center, Leipzig, Germany. moes@medizin.uni-leipzig.de
TI  - The WATCHMAN left atrial appendage closure device for atrial fibrillation.
SO  - Journal of Visualized Experiments. (60), 2012.
AS  - J. vis. exp.. (60), 2012.
NJ  - Journal of visualized experiments : JoVE
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 101313252
OI  - Source: NLM. PMC3399494
SB  - Index Medicus
CP  - United States
MH  - *Atrial Appendage/su [Surgery]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Cardiac Catheterization/is [Instrumentation]
MH  - Cardiac Catheterization/mt [Methods]
MH  - *Cardiac Surgical Procedures/is [Instrumentation]
MH  - Cardiac Surgical Procedures/mt [Methods]
MH  - Embolism/pc [Prevention & Control]
MH  - Humans
MH  - *Prostheses and Implants
MH  - Warfarin/tu [Therapeutic Use]
AB  - Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting an estimated 6 million people in the United States (1). Since AF affects primarily elderly people, its prevalence increases parallel with age. As such, it is expected that 15.9 million Americans will be affected by the year 2050 (2). Ischemic stroke occurs in 5% of non-anticoagulated AF patients each year. Current treatments for AF include rate control, rhythm control and prevention of stroke (3). The American College of Cardiology, American Heart Association, and European Society of Cardiology currently recommended rate control as the first course of therapy for AF (3). Rate control is achieved by administration of pharmacological agents, such as beta-blockers, that lower the heart rate until it reaches a less symptomatic state (3). Rhythm control aims to return the heart to its normal sinus rhythm and is typically achieved through administration of antiarrhythmic drugs such as amiodarone, electrical cardioversion or ablation therapy. Rhythm control methods, however, have not been demonstrated to be superior to rate-control methods (4-6). In fact, certain antiarrhythmic drugs have been shown to be associated with higher hospitalization rates, serious adverse effects (3), or even increases in mortality in patients with structural heart defects (7). Thus, treatment with antiarrhythmics is more often used when rate-control drugs are ineffective or contraindicated. Rate-control and antiarrhythmic agents relieve the symptoms of AF, including palpitations, shortness of breath, and fatigue (8), but don't reliably prevent thromboembolic events (6). Treatment with the anticoagulant drug warfarin significantly reduces the rate of stroke or embolism (9,10). However, because of problems associated with its use, fewer than 50% of patients are treated with it. The therapeutic dose is affected by drug, dietary, and metabolic interactions, and thus requires detailed monitoring. In addition, warfarin has the potential to cause severe, sometimes lethal, bleeding (2). As an alternative, aspirin is commonly prescribed. While aspirin is typically well tolerated, it is far less effective at preventing stroke (10). Other alternatives to warfarin, such as dabigatran (11) or rivaroxaban (12) demonstrate non-inferiority to warfarin with respect to thromboembolic events (in fact, dabigatran given as a high dose of 150 mg twice a day has shown superiority). While these drugs have the advantage of eliminating dietary concerns and eliminating the need for regular blood monitoring, major bleeding and associated complications, while somewhat less so than with warfarin, remain an issue (13-15). Since 90% of AF-associated strokes result from emboli that arise from the left atrial appendage (LAA) (2), one alternative approach to warfarin therapy has been to exclude the LAA using an implanted device to trap blood clots before they exit. Here, we demonstrate a procedure for implanting the WATCHMAN Left Atrial Appendage Closure Device. A transseptal cannula is inserted through the femoral vein, and under fluoroscopic guidance, inter-atrial septum is crossed. Once access to the left atrium has been achieved, a guidewire is placed in the upper pulmonary vein and the WATCHMAN Access Sheath and dilator are advanced over the wire into the left atrium. The guidewire is removed, and the access sheath is carefully advanced into the distal portion of the LAA over a pigtail catheter. The WATCHMAN Delivery System is prepped, inserted into the access sheath, and slowly advanced. The WATCHMAN device is then deployed into the LAA. The device release criteria are confirmed via fluoroscopy and transesophageal echocardiography (TEE) and the device is released.
RN  - 5Q7ZVV76EI (Warfarin)
ES  - 1940-087X
IL  - 1940-087X
DI  - 3671
DO  - http://dx.doi.org/10.3791/3671
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Video-Audio Media
LG  - English
EP  - 20120228
DP  - 2012
DC  - 20120307
YR  - 2012
ED  - 20120529
RD  - 20150225
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22395336

<358. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22072287
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Manzano-Fernandez S
AU  - Cambronero F
AU  - Caro-Martinez C
AU  - Hurtado-Martinez JA
AU  - Marin F
AU  - Pastor-Perez FJ
AU  - Mateo-Martinez A
AU  - Sanchez-Martinez M
AU  - Pinar-Bermudez E
AU  - Valdes M
FA  - Manzano-Fernandez, Sergio
FA  - Cambronero, Francisco
FA  - Caro-Martinez, Cesar
FA  - Hurtado-Martinez, Jose A
FA  - Marin, Francisco
FA  - Pastor-Perez, Francisco J
FA  - Mateo-Martinez, Alicia
FA  - Sanchez-Martinez, Marianela
FA  - Pinar-Bermudez, Eduardo
FA  - Valdes, Mariano
IN  - Manzano-Fernandez,Sergio. Sergio Manzano-Fernandez, MD, PhD, Cardiology Department, University Hospital Virgen de la Arrixaca, C/ Madrid-Cartagena. s/n. CP 30120, Murcia, Spain, Tel.: +34 968399445, Fax: +34 968369662, E-mail: sergiosmf13@hotmail.com.
TI  - Mild kidney disease as a risk factor for major bleeding in patients with atrial fibrillation undergoing percutaneous coronary stenting.
CM  - Comment in: Thromb Haemost. 2012 Jan;107(1):4-5; PMID: 22159815
SO  - Thrombosis & Haemostasis. 107(1):51-8, 2012 Jan.
AS  - Thromb Haemost. 107(1):51-8, 2012 Jan.
NJ  - Thrombosis and haemostasis
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - vq7, 7608063
SB  - Index Medicus
CP  - Germany
MH  - Aged
MH  - *Angioplasty, Balloon, Coronary/mt [Methods]
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/su [Surgery]
MH  - Diet
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Hemorrhage/di [Diagnosis]
MH  - Humans
MH  - *Kidney Diseases/co [Complications]
MH  - *Kidney Diseases/th [Therapy]
MH  - Male
MH  - Middle Aged
MH  - Models, Statistical
MH  - Prevalence
MH  - Retrospective Studies
MH  - Risk
MH  - Risk Factors
MH  - Stents
AB  - Bleeding risk is increased in patients with atrial fibrillation (AF) and moderate to severe kidney disease (KD); however, the implication of mild KD on bleeding remains unclear. The aim of this study was to determine whether the presence of mild KD increases risk for major bleeding (MB) in patients with AF undergoing percutaneous coronary intervention with stent implantation (PCI-S). Two hundred eighty-five patients were included. Patients were classified into three kidney function groups: moderate to severe KD (n=91; <60 ml/min/1.73 m2), mild KD (n=139; 60-89 ml/min/1.73 m2) and non-KD (n=55; >90 ml/min/1.73 m2). Estimated glomerular filtration rate was calculated using the simplified Modification of Diet in Renal Disease equation. Patients were followed for one year, and the occurrence of MB was obtained in all. A total of 28 patients (9.8%) presented MB. MB complications examined as a function of KD groups revealed that there was a graded increase in MB with worsening renal function (non KD=1.8%, mild KD=7.9%, moderate to severe KD=17.6%; p <0.001). Multivariable Cox regression analysis showed that mild KD was associated with nearly a 2.5-fold (2.43 95% confidence interval 1.11-5.34, p=0.039) increase in the risk of MB as compared with non-KD patients. Other independent predictors of MB were moderate-severe KD, anaemia and triple antithrombotic therapy after PCI-S (C-index=0.76). In this population, mild KD confers a significantly increase in the risk for MB complications. Future studies should assess the potential role of incorporating mild KD into the bleeding risk scales to improve the stratification of these patients.
IS  - 0340-6245
IL  - 0340-6245
DO  - http://dx.doi.org/10.1160/TH11-08-0524
PT  - Journal Article
LG  - English
EP  - 20111110
DP  - 2012 Jan
DC  - 20120104
YR  - 2012
ED  - 20120525
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22072287

<359. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22137254
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Peteiro J
AU  - Bouzas-Mosquera A
AU  - Fernandez X
AU  - Monserrat L
AU  - Pazos P
AU  - Estevez-Loureiro R
AU  - Castro-Beiras A
FA  - Peteiro, Jesus
FA  - Bouzas-Mosquera, Alberto
FA  - Fernandez, Xusto
FA  - Monserrat, Lorenzo
FA  - Pazos, Pablo
FA  - Estevez-Loureiro, Rodrigo
FA  - Castro-Beiras, Alfonso
IN  - Peteiro,Jesus. Laboratory of Stress Echocardiography, Complexo Hospitalario Universitario de A Coruna, University of A Coruna, A Coruna, Spain. pete@canalejo.org
TI  - Prognostic value of exercise echocardiography in patients with hypertrophic cardiomyopathy.
CM  - Comment in: J Am Soc Echocardiogr. 2012 Feb;25(2):190-3; PMID: 22270091
SO  - Journal of the American Society of Echocardiography. 25(2):182-9, 2012 Feb.
AS  - J Am Soc Echocardiogr. 25(2):182-9, 2012 Feb.
NJ  - Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - aof, 8801388
SB  - Index Medicus
CP  - United States
MH  - *Cardiomyopathy, Hypertrophic/ep [Epidemiology]
MH  - *Cardiomyopathy, Hypertrophic/us [Ultrasonography]
MH  - Comorbidity
MH  - *Echocardiography/sn [Statistics & Numerical Data]
MH  - Exercise Test/sn [Statistics & Numerical Data]
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Reproducibility of Results
MH  - Risk Assessment
MH  - Risk Factors
MH  - Sensitivity and Specificity
MH  - Spain/ep [Epidemiology]
MH  - *Ventricular Dysfunction, Left/ep [Epidemiology]
MH  - *Ventricular Dysfunction, Left/us [Ultrasonography]
AB  - BACKGROUND: Although exercise echocardiography may assess left ventricular (LV) function and LV outflow tract (LVOT) gradients during exercise in patients with hypertrophic cardiomyopathy (HCM), its value for predicting outcomes has not been studied. The aim of this study was to determine whether exercise echocardiography predicts outcomes in patients with HCM.
AB  - METHODS: LV function and LVOT gradients were evaluated during exercise echocardiography in 239 patients with HCM.
AB  - RESULTS: Sixty patients (25.1%) had LVOT obstruction at rest, and 43 (18%) developed exercise-induced LVOT obstruction. The mean resting LV ejection fraction was 69 +/- 9%, and the mean resting wall motion score index was 1.00 +/- 0.06. Wall motion abnormalities during exercise were seen in 19 patients (7.9%). During follow-up of 4.1 +/- 2.6 years, 19 patients had hard events (cardiac death, cardiac transplantation, appropriate discharge of a defibrillator, stroke, myocardial infarction, or hospitalization for heart failure), and 41 patients had composite end points of hard or soft events (including atrial fibrillation and syncope). Exercise wall motion abnormalities occurred in 31.5% of patients with hard events compared with 5.9% of patients without hard events (P < .001). After adjustment, LV wall thickness (hazard ratio [HR], 1.13; 95% confidence interval [CI], 1.05-1.21; P = .002), resting wall motion score index (HR, 21.59; 95% CI, 2.38-196.1, P = .006), and metabolic equivalents (HR, 0.74; 95% CI, 0.63-0.88; P = .001) remained independent predictors of hard events. Change in wall motion score index was also independently associated with hard events (HR, 52.30; 95% CI, 3.81-718.5; P = .003) and with the composite end point (HR, 39.51; 95% CI, 3.79-412.4; P = .002). LVOT obstruction was not associated with either end point.
AB  - CONCLUSIONS: Assessment of exercise capacity and LV systolic function during exercise echocardiography may have a role in risk stratification of patients with HCM.Copyright © 2012 American Society of Echocardiography. Published by Mosby, Inc. All rights reserved.
ES  - 1097-6795
IL  - 0894-7317
DO  - http://dx.doi.org/10.1016/j.echo.2011.11.005
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Video-Audio Media
LG  - English
EP  - 20111203
DP  - 2012 Feb
DC  - 20120124
YR  - 2012
ED  - 20120523
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22137254

<360. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22143010
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kalogridaki M
AU  - Souvatzis X
AU  - Mavrakis HE
AU  - Kanoupakis EM
AU  - Panteli A
AU  - Kasotaki S
AU  - Vardas P
AU  - Askitopoulou H
FA  - Kalogridaki, Marina
FA  - Souvatzis, Xenia
FA  - Mavrakis, Hercules E
FA  - Kanoupakis, Emmanuel M
FA  - Panteli, Aikaterini
FA  - Kasotaki, Sophia
FA  - Vardas, Panos
FA  - Askitopoulou, Helen
IN  - Kalogridaki,Marina. Department of Anaesthesiology, University of Crete, Heraklion, Greece.
TI  - Anaesthesia for cardioversion: a prospective randomised comparison of propofol and etomidate combined with fentanyl.
SO  - Hjc Hellenic Journal of Cardiology. 52(6):483-8, 2011 Nov-Dec.
AS  - HJC Hell. J. Cardiol.. 52(6):483-8, 2011 Nov-Dec.
NJ  - Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101257381
SB  - Index Medicus
CP  - Greece
MH  - Aged
MH  - *Analgesia
MH  - *Anesthesia
MH  - *Anesthetics, Combined/ae [Adverse Effects]
MH  - *Anesthetics, Intravenous/ad [Administration & Dosage]
MH  - Atrial Fibrillation/th [Therapy]
MH  - *Electric Countershock
MH  - *Etomidate/ad [Administration & Dosage]
MH  - Female
MH  - *Fentanyl/ad [Administration & Dosage]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Propofol/ad [Administration & Dosage]
MH  - Prospective Studies
AB  - INTRODUCTION: External electrical cardioversion is mostly performed solely under sedatives or hypnotics, although the procedure is painful. The aim of this prospective randomised study was to compare two anaesthetic protocols that included analgesia.
AB  - METHODS: Patients with persistent atrial fibrillation were randomised to receive intravenously either fentanyl 50 mug and propofol 0.5 mg/kg (group P) or fentanyl 50 mug and etomidate 0.1 mg/kg (group E), while breathing spontaneously 100% oxygen. In the case of inadequate anaesthesia, repeated doses of 20 mg propofol (group P) or 4 mg etomidate (group E) were given as often as necessary until loss of eyelid reflex. Cardioversion was achieved with an extracardiac biphasic electrical shock ranging from 200 to 300 J, performed three times at most.
AB  - RESULTS: Forty-six patients (25 in group P, 21 in group E), aged 64 +/- 9 years, were enrolled in the study. There were no differences between the study groups concerning left ventricular ejection fraction, the dimension of the left atrium, the number of shocks needed or the number of unsuccessful cardioversions. Patients in group E had a shorter time from injection of the induction agents until loss of consciousness (49 vs. 118 s, p=0.003) and until the first shock was given (61 vs. 135 s, p=0.004). Systolic blood pressure decreased significantly (repeated measurements ANOVA with Bonferroni adjustment) in group P when the baseline value was compared to that after anaesthesia induction (mean decrease 15.2 mmHg, 95% CI 5.6-24.8 mmHg, p=0.001) and to the value after recovery (mean decrease 15.2 mmHg, 95% CI 4.8-25.7 mmHg, p=0.002). Manual ventilation was required in 7 and 9 patients in groups P and E, respectively (p=0.360).
AB  - CONCLUSION: Both anaesthetic regimens provided excellent conditions for external electric cardioversion. In addition, etomidate in combination with fentanyl had a shorter induction time and ensured haemodynamic stability.
RN  - 0 (Anesthetics, Combined)
RN  - 0 (Anesthetics, Intravenous)
RN  - UF599785JZ (Fentanyl)
RN  - YI7VU623SF (Propofol)
RN  - Z22628B598 (Etomidate)
ES  - 2241-5955
IL  - 1109-9666
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 2011 Nov-Dec
DC  - 20111206
YR  - 2011
ED  - 20120521
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=22143010

<361. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22221947
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wilhelm M
AU  - Nuoffer JM
AU  - Schmid JP
AU  - Wilhelm I
AU  - Saner H
FA  - Wilhelm, Matthias
FA  - Nuoffer, Jean-Marc
FA  - Schmid, Jean-Paul
FA  - Wilhelm, Ilca
FA  - Saner, Hugo
IN  - Wilhelm,Matthias. Department of Cardiology, Division of Cardiovascular Prevention, Rehabilitation and Sports Cardiology, Inselspital, University Hospital of Bern, Switzerland. matthias.wilhelm@insel.ch
TI  - Comparison of pro-atrial natriuretic peptide and atrial remodeling in marathon versus non-marathon runners.
SO  - American Journal of Cardiology. 109(7):1060-5, 2012 Apr 1.
AS  - Am J Cardiol. 109(7):1060-5, 2012 Apr 1.
NJ  - The American journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Algorithms
MH  - *Atrial Fibrillation/bl [Blood]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Flutter/bl [Blood]
MH  - Atrial Flutter/pp [Physiopathology]
MH  - *Atrial Natriuretic Factor/bl [Blood]
MH  - Biomarkers/bl [Blood]
MH  - Case-Control Studies
MH  - Cross-Sectional Studies
MH  - *Heart Atria/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Physical Endurance
MH  - Regression Analysis
MH  - Risk Factors
MH  - *Running
AB  - Long-term endurance sports are associated with atrial remodeling and an increased risk for atrial fibrillation (AF) and atrial flutter. Pro-atrial natriuretic peptide (pro-ANP) is a marker of atrial wall tension and elevated in patients with AF. The aim of this study was to test the hypothesis that atrial remodeling would be perpetuated by repetitive episodes of atrial stretching during strenuous competitions, reflected by elevated levels of pro-ANP. A cross-sectional study was performed on nonelite runners scheduled to participate in the 2010 Grand Prix of Bern, a 10-mile race. Four hundred ninety-two marathon and nonmarathon runners applied for participation, 70 were randomly selected, and 56 entered the final analysis. Subjects were stratified according to former marathon participations: a control group (nonmarathon runners, n = 22), group 1 (1 to 4 marathons, n = 16), and group 2 (>5 marathons, n = 18). Results were adjusted for age, training years, and average weekly endurance training hours. The mean age was 42 +/- 7 years. Compared to the control group, marathon runners in groups 1 and 2 had larger left atria (25 +/- 6 vs 30 +/- 6 vs 34 +/- 7 ml/m(2), p = 0.002) and larger right atria (27 +/- 7 vs 31 +/- 8 vs 35 +/- 5 ml/m(2), p = 0.024). Pro-ANP levels at baseline were higher in marathon runners (1.04 +/- 0.38 vs 1.42 +/- 0.74 vs 1.67 +/- 0.69 nmol/L, p = 0.006). Pro-ANP increased significantly in all groups after the race. In multiple linear regression analysis, marathon participation was an independent predictor of left atrial (beta = 0.427, p <0.001) and right atrial (beta = 0.395, p = 0.006) remodeling. In conclusion, marathon running was associated with progressive left and right atrial remodeling, possibly induced by repetitive episodes of atrial stretching. The altered left and right atrial substrate may facilitate atrial arrhythmias.Copyright A© 2012 Elsevier Inc. All rights reserved.
RN  - 0 (Biomarkers)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
ES  - 1879-1913
IL  - 0002-9149
DO  - http://dx.doi.org/10.1016/j.amjcard.2011.11.039
PT  - Comparative Study
PT  - Journal Article
LG  - English
EP  - 20120103
DP  - 2012 Apr 1
DC  - 20120326
YR  - 2012
ED  - 20120518
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22221947

<362. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21558883
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Chan HT
AU  - So LT
AU  - Li SW
AU  - Siu CW
AU  - Lau CP
AU  - Tse HF
FA  - Chan, Hiu-Ting
FA  - So, Lok-Tsun
FA  - Li, Sheung-Wai
FA  - Siu, Chung-Wah
FA  - Lau, Chu-Pak
FA  - Tse, Hung-Fat
IN  - Chan,Hiu-Ting. Division of Cardiology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, China.
TI  - Effect of herbal consumption on time in therapeutic range of warfarin therapy in patients with atrial fibrillation.
SO  - Journal of Cardiovascular Pharmacology. 58(1):87-90, 2011 Jul.
AS  - J Cardiovasc Pharmacol. 58(1):87-90, 2011 Jul.
NJ  - Journal of cardiovascular pharmacology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 7902492, k78
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrial Fibrillation/bl [Blood]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Cohort Studies
MH  - Follow-Up Studies
MH  - Herb-Drug Interactions/ph [Physiology]
MH  - *Herb-Drug Interactions
MH  - Humans
MH  - International Normalized Ratio/mt [Methods]
MH  - Male
MH  - Middle Aged
MH  - Plant Preparations/bl [Blood]
MH  - *Plant Preparations/tu [Therapeutic Use]
MH  - Surveys and Questionnaires
MH  - Time Factors
MH  - Warfarin/bl [Blood]
MH  - *Warfarin/tu [Therapeutic Use]
AB  - It has been established that herbal intake affects the anticoagulation effects of warfarin, but the long-term impact on anticoagulation control is unclear. We sought to investigate the effect of concomitant herbal intake on anticoagulation control in patients with nonvalvular atrial fibrillation (AF) treated with warfarin. The effects of common herbs were determined by monitoring the international normalized ratio in 250 patients with AF (69 +/- 10 years, 50% male). All the patients had been prescribed warfarin therapy for at least 6 months before enrollment, and their dietary intake, including the type and the frequency of common herbs, was recorded using a standardized questionnaire. Up to 50% of the patients reported consumption of foods with herbal ingredients, including garlic (80.4%), ginger (74.8%), green tea (50.4%), and papaya (55.2%) but rarely herbal drugs such as danshen (1.2%), dong guai (0.8%), fenugreek (1.2%), psyllium seed (0.4%), and ginseng (4%). Infrequent users (1 kind of herb for <4 times per week and nonusers) were more likely to have an international normalized ratio within the optimal therapeutic range (2.0-3.0) than frequent users (>1 kind of herb for >4 times per week) (58.1% vs 51.1%, P = 0.046). In conclusion, the patients with AF treated with warfarin had little knowledge about the potential interaction of herbal substances in foods with warfarin. The patients who consumed common herbs at least 4 times per week had suboptimal anticoagulation control with warfarin.
RN  - 0 (Plant Preparations)
RN  - 5Q7ZVV76EI (Warfarin)
ES  - 1533-4023
IL  - 0160-2446
DO  - http://dx.doi.org/10.1097/FJC.0b013e31821cd888
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 2011 Jul
DC  - 20110713
YR  - 2011
ED  - 20120518
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21558883

<363. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21815962
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Chaldoupi SM
AU  - Linnenbank AC
AU  - Wittkampf FH
AU  - Boldt LH
AU  - VAN Wessel H
AU  - VAN Driel VJ
AU  - Doevendans PA
AU  - Hauer RN
AU  - DE Bakker JM
AU  - Loh P
FA  - Chaldoupi, Sevasti-Maria
FA  - Linnenbank, Andre C
FA  - Wittkampf, Fred H
FA  - Boldt, Leif H
FA  - VAN Wessel, Harry
FA  - VAN Driel, Vincent J
FA  - Doevendans, Pieter A
FA  - Hauer, Richard N
FA  - DE Bakker, Jacques M
FA  - Loh, Peter
IN  - Chaldoupi,Sevasti-Maria. Department of Cardiology, Division of Heart & Lungs, University Medical Center Utrecht, Utrecht, The Netherlands.
TI  - Complex fractionated electrograms in the right atrial free wall and the superior/posterior wall of the left atrium are affected by activity of the autonomic nervous system.
CM  - Comment in: J Cardiovasc Electrophysiol. 2012 Jan;23(1):34-5; PMID: 21914027
SO  - Journal of Cardiovascular Electrophysiology. 23(1):26-33, 2012 Jan.
AS  - J Cardiovasc Electrophysiol. 23(1):26-33, 2012 Jan.
NJ  - Journal of cardiovascular electrophysiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - by4, 9010756
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Analysis of Variance
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Atropine/ad [Administration & Dosage]
MH  - Autonomic Nervous System/de [Drug Effects]
MH  - *Autonomic Nervous System/pp [Physiopathology]
MH  - Chi-Square Distribution
MH  - *Electrophysiologic Techniques, Cardiac
MH  - Female
MH  - *Heart Atria/ir [Innervation]
MH  - Humans
MH  - Male
MH  - Metoprolol/ad [Administration & Dosage]
MH  - Middle Aged
MH  - Parasympatholytics/ad [Administration & Dosage]
MH  - Pilot Projects
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Sympatholytics/ad [Administration & Dosage]
MH  - Time Factors
AB  - BACKGROUND: Complex fractionated atrial electrograms (CFAEs) are supposed to be related to structural and electrical remodeling. Animal studies suggest a role of the autonomic nervous system (ANS). However, this has never been studied in humans.
AB  - OBJECTIVE: The goal of this study was to investigate the influence of ANS on CFAEs in patients with idiopathic atrial fibrillation (AF).
AB  - METHODS: Thirty-six patients (28 men, 55 +/- 9 years) were included before undergoing catheter ablation. In the 24 hours preceding the procedure, 20 patients were in AF (group 1) and 16 were in sinus rhythm (SR, group 2). With 2 decapolar catheters, 1 in the right atrium (RA) and 1 in the left atrium (LA), 20 unipolar electrograms were simultaneously recorded during a 100-second AF-period (in group 2 after induction of AF). After atropine and metoprolol administration, a second 100-second AF-period was recorded 30 minutes later. Five patients of group 2 served as controls and did not receive atropine and metoprolol prior to the second recording. CFAEs were assessed and the prevalence of CFAEs was expressed as percentage of the recording time.
AB  - RESULTS: The prevalence of CFAEs was greater in group 1 than in group 2 in both RA and LA (P = 0.026, P < 0.001, respectively). Atropine and metoprolol significantly reduced CFAEs in group 1 (P < 0.001) and prevented the time-dependent increase of CFAEs in group 2.
AB  - CONCLUSION: The prevalence of CFAEs is greater in long-lasting AF episodes. Atropine and metoprolol administration reduces CFAEs in both atria. Thus, CFAEs are at least partly influenced by the ANS.Copyright © 2011 Wiley Periodicals, Inc.
RN  - 0 (Parasympatholytics)
RN  - 0 (Sympatholytics)
RN  - 7C0697DR9I (Atropine)
RN  - GEB06NHM23 (Metoprolol)
ES  - 1540-8167
IL  - 1045-3873
DO  - http://dx.doi.org/10.1111/j.1540-8167.2011.02145.x
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20110804
DP  - 2012 Jan
DC  - 20120118
YR  - 2012
ED  - 20120515
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=21815962

<364. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21621470
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Formiga F
AU  - Ferrer A
AU  - Mimbrera D
AU  - Badia T
AU  - Fernandez C
AU  - Pujol R
AU  - Grupo de Estudio Octabaix
FA  - Formiga, Francesc
FA  - Ferrer, Assumpta
FA  - Mimbrera, Daniel
FA  - Badia, Teresa
FA  - Fernandez, Coral
FA  - Pujol, Ramon
FA  - Grupo de Estudio Octabaix
IN  - Formiga,Francesc. Geriatric Unit, Internal Medicine Service, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. fformiga@bellvitgehospital.cat
TI  - High rate of anticoagulation therapy in oldest old subjects with atrial fibrillation: the Octabaix study.
SO  - Journal of the American Medical Directors Association. 13(1):8-10, 2012 Jan.
AS  - J AM MED DIR ASSOC. 13(1):8-10, 2012 Jan.
NJ  - Journal of the American Medical Directors Association
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 100893243
SB  - Index Medicus
CP  - United States
MH  - Aged, 80 and over
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - Drug Prescriptions
MH  - Female
MH  - Humans
MH  - Interviews as Topic
MH  - Logistic Models
MH  - Male
MH  - Medical Audit
MH  - Practice Patterns, Physicians'/sn [Statistics & Numerical Data]
MH  - Quality of Life
MH  - Spain/ep [Epidemiology]
AB  - OBJECTIVE: To assess the prevalence of permanent atrial fibrillation (AF) in community-dwelling subjects aged 85 and to determine the anticoagulation therapy rate.
AB  - DESIGN: Community-based survey of inhabitants aged 85 years.
AB  - PARTICIPANTS: Participants were 328 people born in 1924 and assigned to 7 primary health care teams.
AB  - MEASUREMENTS: Sociodemographic variables, Barthel Index, the Spanish version of the Mini-Mental State Examination, Mini Nutritional Assessment, Charlson Index, social risk, quality of life, and prevalent chronic diseases were assessed. Permanent AF was determined by patient interview, treatment prescriptions, and clinical records.
AB  - RESULTS: The sample included 202 women (61.6%) and 126 men. In 41 (12.5%) participants permanent AF was diagnosed; 25 (60.9%) were on anticoagulant oral therapy and 9 (21.9%) were receiving antiplatelet therapy. Using multiple logistic regression analysis, previous diagnosis of heart failure (P < .001, OR 4.170, 95% CI 1.927-9.024) and stroke history (P < .03, OR 2.439, 95% CI 1.101-5.401) were significantly associated with the diagnosis of permanent AF.
AB  - CONCLUSION: AF is quite prevalent in 85-year-old subjects. A large percentage of patients with AF were receiving chronic anticoagulant therapy. The percentage of patients who were not receiving prophylactic treatment was low.Copyright © 2012 American Medical Directors Association, Inc. Published by Elsevier Inc. All rights reserved.
RN  - 0 (Anticoagulants)
ES  - 1538-9375
IL  - 1525-8610
DO  - http://dx.doi.org/10.1016/j.jamda.2011.04.005
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20110531
DP  - 2012 Jan
DC  - 20120102
YR  - 2012
ED  - 20120511
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=21621470

<365. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22545279
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Anonymous
TI  - I've been taking warfarin (Coumadin) for atrial fibrillation. I have to limit my consumption of leafy green vegetables because of the amount of vitamin K they contain. Since vitamin K is important to bone health, are there any substitutes that could provide similar nutrients?.
SO  - Duke Medicine Health News. 18(4):8, 2012 Apr.
AS  - Duke Med Health News. 18(4):8, 2012 Apr.
NJ  - DukeMedicine healthnews
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101510062
SB  - Consumer Health Journals
CP  - United States
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - *Diet
MH  - Humans
MH  - *Vegetables
MH  - *Vitamin K/ae [Adverse Effects]
MH  - *Warfarin/tu [Therapeutic Use]
RN  - 12001-79-5 (Vitamin K)
RN  - 5Q7ZVV76EI (Warfarin)
IS  - 2153-8387
IL  - 2153-8387
PT  - Journal Article
LG  - English
DP  - 2012 Apr
DC  - 20120406
YR  - 2012
ED  - 20120510
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22545279

<366. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22395368
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Yilmaz MB
AU  - Zorlu A
AU  - Bektasoglu G
AU  - Yontar OC
AU  - Tandogan I
FA  - Yilmaz, Mehmet Birhan
FA  - Zorlu, Ali
FA  - Bektasoglu, Gokhan
FA  - Yontar, Osman Can
FA  - Tandogan, Izzet
IN  - Yilmaz,Mehmet Birhan. Department of Cardiology, Medicine Faculty of Cumhuriyet University, Sivas, Turkey. mehmet.birhan.yilmaz@tkd.org.tr
TI  - The product of eGFR and hemoglobin may help predict mortality in systolic heart failure patients without severe anemia and renal failure.
SO  - Turk Kardiyoloji Dernegi Arsivi. 40(1):9-15, 2012 Jan.
AS  - TURK KARDIYOLOJI DERNEGI ARS.. 40(1):9-15, 2012 Jan.
NJ  - Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9426239
SB  - Index Medicus
CP  - Turkey
MH  - Aged
MH  - Anemia/co [Complications]
MH  - Anemia/pp [Physiopathology]
MH  - Female
MH  - *Glomerular Filtration Rate
MH  - Heart Failure, Systolic/co [Complications]
MH  - *Heart Failure, Systolic/mo [Mortality]
MH  - Heart Failure, Systolic/pp [Physiopathology]
MH  - *Hemoglobins
MH  - Humans
MH  - Male
MH  - Predictive Value of Tests
MH  - Renal Insufficiency/co [Complications]
MH  - Renal Insufficiency/pp [Physiopathology]
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Turkey
AB  - OBJECTIVES: Cardiorenal anemia syndrome is defined in patients with heart failure (HF). Although individual influences of renal impairment and anemia were shown previously, complex interaction between the kidney, bone marrow, and the heart renders decision making relatively inefficient in patients with milder forms of these diseases. We aimed to investigate whether product of estimated glomerular filtration rate (eGFR) and hemoglobin (Hb) predicts outcomes in patients with HF.
AB  - STUDY DESIGN: The study included 148 consecutive patients (89 males, 59 females; mean age 68+/-10 years) who were hospitalized with acutely decompensated systolic HF and discharged alive. Discharge Hb levels were measured. Renal function was estimated via the MDRD (Modification of Diet in Renal Disease) formula. The eGFRxHb product was derived, and cut-off was defined using the ROC (receiver operating characteristic) analysis. The influence of eGFRxHb product on mortality was analyzed after a follow-up period of up to 34 months (mean 8.2+/-5.5 months).
AB  - RESULTS: The mean Hb was 12.7+/-2 g/dl, the mean creatinine was 105+/-46 micro mol/l, and the mean eGFR was 61+/-23 ml/min/1.73 m2. Eighty-two patients (55.4%) had an eGFR of <60 ml/kg/m2. During the follow-up, 27 patients died. Optimal cut-off level of eGFRxHb product to predict mortality was found to be <788 with a sensitivity of 82.6% and specificity of 51.3%. In multivariate Cox proportional analysis, only eGFRxHb product <788 (HR 4.488, 95% CI 1.500-13.433, p=0.007) and presence of atrial fibrillation (HR 2.644, 95% CI 1.113-6.280, p=0.028) were independent predictors of mortality in patients with HF.
AB  - CONCLUSION: We concluded that the product of eGFR and Hb might be useful in prediction of mortality among patients with systolic HF.
RN  - 0 (Hemoglobins)
IS  - 1016-5169
IL  - 1016-5169
DO  - http://dx.doi.org/10.5543/tkda.2012.01496
PT  - Evaluation Studies
PT  - Journal Article
LG  - English
DP  - 2012 Jan
DC  - 20120307
YR  - 2012
ED  - 20120510
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22395368

<367. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21524034
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Anonymous
TI  - Information from your family doctor. Subclinical hyperthyroidism: what it means to you.
SO  - American Family Physician. 83(8):943-4, 2011 Apr 15.
AS  - Am Fam Physician. 83(8):943-4, 2011 Apr 15.
NJ  - American family physician
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 3bt, 1272646
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Age Factors
MH  - Aged
MH  - Atrial Fibrillation/et [Etiology]
MH  - Diet/ae [Adverse Effects]
MH  - Goiter, Nodular/co [Complications]
MH  - Humans
MH  - Hyperthyroidism/bl [Blood]
MH  - Hyperthyroidism/co [Complications]
MH  - Hyperthyroidism/et [Etiology]
MH  - *Hyperthyroidism
MH  - Iodine Compounds/ae [Adverse Effects]
MH  - Thyroid Hormones/bl [Blood]
MH  - Virus Diseases/co [Complications]
RN  - 0 (Iodine Compounds)
RN  - 0 (Thyroid Hormones)
ES  - 1532-0650
IL  - 0002-838X
PT  - Patient Education Handout
LG  - English
DP  - 2011 Apr 15
DC  - 20110428
YR  - 2011
ED  - 20120430
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21524034

<368. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22282329
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wu JH
AU  - Lemaitre RN
AU  - King IB
AU  - Song X
AU  - Sacks FM
AU  - Rimm EB
AU  - Heckbert SR
AU  - Siscovick DS
AU  - Mozaffarian D
FA  - Wu, Jason H Y
FA  - Lemaitre, Rozenn N
FA  - King, Irena B
FA  - Song, Xiaoling
FA  - Sacks, Frank M
FA  - Rimm, Eric B
FA  - Heckbert, Susan R
FA  - Siscovick, David S
FA  - Mozaffarian, Dariush
IN  - Wu,Jason H Y. Departments of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA.
TI  - Association of plasma phospholipid long-chain omega-3 fatty acids with incident atrial fibrillation in older adults: the cardiovascular health study.
SO  - Circulation. 125(9):1084-93, 2012 Mar 6.
AS  - Circulation. 125(9):1084-93, 2012 Mar 6.
NJ  - Circulation
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - daw, 0147763
OI  - Source: NLM. NIHMS359857
OI  - Source: NLM. PMC3302663
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Atrial Fibrillation/bl [Blood]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/pc [Prevention & Control]
MH  - Biomarkers/bl [Blood]
MH  - Dietary Fats/ad [Administration & Dosage]
MH  - Docosahexaenoic Acids/bl [Blood]
MH  - Eicosapentaenoic Acid/bl [Blood]
MH  - *Fatty Acids, Omega-3/bl [Blood]
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Proportional Hazards Models
MH  - Risk Factors
MH  - *Seafood
AB  - BACKGROUND: Experimental studies suggest that long-chain n-3 polyunsaturated fatty acids (n-3 PUFAs) may reduce the risk of atrial fibrillation (AF). Prior studies evaluating fish or n-3 PUFA consumption from dietary questionnaires and incident AF have been conflicting. Circulating levels of n-3 PUFAs provide an objective measurement of exposure.
AB  - METHODS AND RESULTS: Among 3326 US men and women >65 years of age and free of AF or heart failure at baseline, plasma phospholipid levels of eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid were measured at baseline by use of standardized methods. Incident AF (789 cases) was identified prospectively from hospital discharge records and study visit ECGs during 31 169 person-years of follow-up (1992-2006). In multivariable Cox models adjusted for other risk factors, the relative risk in the top versus lowest quartile of total n-3 PUFAs (eicosapentaenoic acid+docosapentaenoic acid+docosahexaenoic acid) levels was 0.71 (95% confidence interval, 0.57-0.89; P for trend=0.004) and of DHA levels was 0.77 (95% confidence interval, 0.62-0.96; P for trend=0.01). Eicosapentaenoic acid and docosapentaenoic acid levels were not significantly associated with incident AF. Evaluated nonparametrically, both total n-3 PUFAs and docosahexaenoic acid showed graded and linear inverse associations with incidence of AF. Adjustment for intervening events such as heart failure or myocardial infarction during follow-up did not appreciably alter results.
AB  - CONCLUSIONS: In older adults, higher circulating total long-chain n-3 PUFA and docosahexaenoic acid levels were associated with lower risk of incident AF. These results highlight the need to evaluate whether increased dietary intake of these fatty acids could be effective for the primary prevention of AF.
RN  - 0 (Biomarkers)
RN  - 0 (Dietary Fats)
RN  - 0 (Fatty Acids, Omega-3)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - AAN7QOV9EA (Eicosapentaenoic Acid)
ES  - 1524-4539
IL  - 0009-7322
DO  - http://dx.doi.org/10.1161/CIRCULATIONAHA.111.062653
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
NO  - N01 HC-15103 (United States NHLBI NIH HHS)
NO  - N01 HC-55222 (United States NHLBI NIH HHS)
NO  - N01-HC-35129 (United States NHLBI NIH HHS)
NO  - N01-HC-45133 (United States NHLBI NIH HHS)
NO  - N01-HC-75150 (United States NHLBI NIH HHS)
NO  - N01-HC-85079 (United States NHLBI NIH HHS)
NO  - N01-HC-85086 (United States NHLBI NIH HHS)
NO  - R01 HL-085710-01 (United States NHLBI NIH HHS)
NO  - R01 HL085710 (United States NHLBI NIH HHS)
NO  - R01 HL085710-01 (United States NHLBI NIH HHS)
NO  - U01 HL080295 (United States NHLBI NIH HHS)
LG  - English
EP  - 20120126
DP  - 2012 Mar 6
DC  - 20120306
YR  - 2012
ED  - 20120424
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22282329

<369. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22386293
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lampert R
FA  - Lampert, Rachel
IN  - Lampert,Rachel. Department of Medicine, Yale University School of Medicine, New Haven, CT 06520, USA. rachel.lampert@yale.edu
TI  - Evaluation and management of arrhythmia in the athletic patient. [Review]
SO  - Progress in Cardiovascular Diseases. 54(5):423-31, 2012 Mar-Apr.
AS  - Prog Cardiovasc Dis. 54(5):423-31, 2012 Mar-Apr.
NJ  - Progress in cardiovascular diseases
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - q0i, 0376442
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Arrhythmias, Cardiac/di [Diagnosis]
MH  - Arrhythmias, Cardiac/et [Etiology]
MH  - *Arrhythmias, Cardiac/th [Therapy]
MH  - *Athletes
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/th [Therapy]
MH  - Death, Sudden, Cardiac/et [Etiology]
MH  - Death, Sudden, Cardiac/pc [Prevention & Control]
MH  - Electric Countershock/ae [Adverse Effects]
MH  - *Exercise
MH  - Humans
MH  - Pacemaker, Artificial/ae [Adverse Effects]
MH  - Physical Endurance
MH  - Practice Guidelines as Topic
MH  - Prognosis
MH  - Risk Assessment
MH  - Risk Factors
MH  - Ventricular Premature Complexes/di [Diagnosis]
MH  - Ventricular Premature Complexes/th [Therapy]
AB  - Athletes may present with palpitations, syncope, or arrest resulting in the diagnosis of arrhythmia, or screening may result in diagnosis of conditions with predisposition to arrhythmia. This chapter focuses on 3 common arrhythmic conditions in athletes-atrial fibrillation, premature ventricular contractions (PVCs), and the athlete with an implanted device. (1) Atrial fibrillation: most studies show that atrial fibrillation is more common in competitive athletes, particularly those participating in long-term endurance sports. Postulated mechanisms include morphologic changes such as atrial dilatation, autonomic changes such as increased vagal tone, or inflammatory changes due to sports participation. Treatment options include long-term antiarrhythmic agents, "pill in the pocket" medications, or radiofrequency ablation, a highly successful procedure in athletes. (2) Premature ventricular contractions: data conflict on whether the incidence of PVCs is increased in highly trained individuals. Very frequent PVCs in athletes, however, can be a manifestation of underlying heart disease, and athletes presenting with PVCs should undergo evaluation. In the absence of underlying heart disease, PVCs do not carry a poor prognosis, and US guidelines do not recommend restriction from sports. (3) Implanted devices: the safety of sports for the athlete with an implanted device is unknown, and current guidelines recommend against participation in vigorous competitive sports, based on postulated risks including failure to defibrillate and risk of injury. Many athletes with defibrillators and pacemakers do participate in sports. Ongoing research will better delineate the risks of sports for the athlete with an implanted device.Copyright © 2012 Elsevier Inc. All rights reserved.
ES  - 1873-1740
IL  - 0033-0620
DO  - http://dx.doi.org/10.1016/j.pcad.2012.01.002
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2012 Mar-Apr
DC  - 20120305
YR  - 2012
ED  - 20120423
RD  - 20130502
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22386293

<370. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22279134
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mozaffarian D
AU  - Wu JH
FA  - Mozaffarian, Dariush
FA  - Wu, Jason H Y
IN  - Mozaffarian,Dariush. Division of Cardiovascular Medicine and Channing Laboratory, Brigham and Women's Hospital, Boston, MA, USA. dmozaffa@hsph.harvard.edu
TI  - (n-3) fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary?. [Review]
SO  - Journal of Nutrition. 142(3):614S-625S, 2012 Mar.
AS  - J Nutr. 142(3):614S-625S, 2012 Mar.
NJ  - The Journal of nutrition
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - jev, 0404243
OI  - Source: NLM. PMC3278271
SB  - Index Medicus
CP  - United States
MH  - Animals
MH  - Arachidonic Acid/me [Metabolism]
MH  - Cardiotonic Agents/ad [Administration & Dosage]
MH  - Cardiotonic Agents/me [Metabolism]
MH  - Cardiovascular Diseases/me [Metabolism]
MH  - Cardiovascular Diseases/pc [Prevention & Control]
MH  - *Cardiovascular System/de [Drug Effects]
MH  - Docosahexaenoic Acids/ad [Administration & Dosage]
MH  - Docosahexaenoic Acids/me [Metabolism]
MH  - Drug Synergism
MH  - Eicosapentaenoic Acid/ad [Administration & Dosage]
MH  - Eicosapentaenoic Acid/me [Metabolism]
MH  - *Fatty Acids, Omega-3/ad [Administration & Dosage]
MH  - Fatty Acids, Omega-3/me [Metabolism]
MH  - Hemodynamics/de [Drug Effects]
MH  - Humans
MH  - Ion Channels/de [Drug Effects]
MH  - Ion Channels/me [Metabolism]
MH  - Lipid Metabolism/de [Drug Effects]
MH  - Metabolic Networks and Pathways
MH  - Nutrition Policy
MH  - Oxidative Stress/de [Drug Effects]
MH  - Plant Oils/ad [Administration & Dosage]
MH  - Plant Oils/me [Metabolism]
MH  - Receptors, Cytoplasmic and Nuclear/me [Metabolism]
MH  - Risk Factors
MH  - Seafood/an [Analysis]
MH  - Transcription Factors/me [Metabolism]
AB  - Considerable research supports cardiovascular benefits of consuming omega-3 PUFA, also known as (n-3) PUFA, from fish or fish oil. Whether individual long-chain (n-3) PUFA have shared or complementary effects is not well established. We reviewed evidence for dietary and endogenous sources and cardiovascular effects on biologic pathways, physiologic risk factors, and clinical endpoints of EPA [20:5(n-3)], docosapentaenoic acid [DPA, 22:5(n-3)], and DHA [22:6(n-3)]. DHA requires direct dietary consumption, with little synthesis from or retroconversion to DPA or EPA. Whereas EPA is also largely derived from direct consumption, EPA can also be synthesized in small amounts from plant (n-3) precursors, especially stearidonic acid. In contrast, DPA appears principally derived from endogenous elongation from EPA, and DPA can also undergo retroconversion back to EPA. In experimental and animal models, both EPA and DHA modulate several relevant biologic pathways, with evidence for some differential benefits. In humans, both fatty acids lower TG levels and, based on more limited studies, favorably affect cardiac diastolic filling, arterial compliance, and some metrics of inflammation and oxidative stress. All three (n-3) PUFA reduce ex vivo platelet aggregation and DHA also modestly increases LDL and HDL particle size; the clinical relevance of such findings is uncertain. Combined EPA+DHA or DPA+DHA levels are associated with lower risk of fatal cardiac events and DHA with lower risk of atrial fibrillation, suggesting direct or indirect benefits of DHA for cardiac arrhythmias (although not excluding similar benefits of EPA or DPA). Conversely, EPA and DPA, but not DHA, are associated with lower risk of nonfatal cardiovascular endpoints in some studies, and purified EPA reduced risk of nonfatal coronary syndromes in one large clinical trial. Overall, for many cardiovascular pathways and outcomes, identified studies of individual (n-3) PUFA were relatively limited, especially for DPA. Nonetheless, the present evidence suggests that EPA and DHA have both shared and complementary benefits. Based on current evidence, increasing consumption of either would be advantageous compared to little or no consumption. Focusing on their combined consumption remains most prudent given the potential for complementary effects and the existing more robust literature on cardiovascular benefits of their combined consumption as fish or fish oil for cardiovascular benefits.
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Ion Channels)
RN  - 0 (Plant Oils)
RN  - 0 (Receptors, Cytoplasmic and Nuclear)
RN  - 0 (Transcription Factors)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - AAN7QOV9EA (Eicosapentaenoic Acid)
ES  - 1541-6100
IL  - 0022-3166
DO  - http://dx.doi.org/10.3945/jn.111.149633
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
NO  - RC2-HL-101816 (United States NHLBI NIH HHS)
LG  - English
EP  - 20120125
DP  - 2012 Mar
DC  - 20120221
YR  - 2012
ED  - 20120418
RD  - 20150128
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22279134

<371. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22143126
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Cheung LK
AU  - Agi R
AU  - Hyman DJ
FA  - Cheung, Lily K
FA  - Agi, Rose
FA  - Hyman, David J
IN  - Cheung,Lily K. College of Pharmacy and Health Sciences, Texas Southern University, Houston, 77021, USA. cheunglk@tsu.edu
TI  - Warfarin resistance associated with parenteral nutrition.
CM  - Comment in: Am J Med Sci. 2012 Oct;344(4):340; PMID: 22996140
SO  - American Journal of the Medical Sciences. 343(3):255-8, 2012 Mar.
AS  - Am J Med Sci. 343(3):255-8, 2012 Mar.
NJ  - The American journal of the medical sciences
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 3l2, 0370506
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - International Normalized Ratio
MH  - Middle Aged
MH  - *Parenteral Nutrition
MH  - Serum Albumin/an [Analysis]
MH  - Venous Thrombosis/dt [Drug Therapy]
MH  - *Vitamin K/ad [Administration & Dosage]
MH  - *Warfarin/tu [Therapeutic Use]
AB  - Warfarin is widely used as an oral anticoagulant for the prevention and long-term treatment of venous thromboembolism and for the prevention of thromboembolic complications associated with atrial fibrillation, heart valve replacement and myocardial infarction. Warfarin exerts its anticoagulation effect by inhibiting the enzymes responsible for the cyclic interconversion of vitamin K in the liver. Vitamin K serves as a cofactor required for the carboxylation of the vitamin K-dependent coagulation proteins. By inhibiting the supply of vitamin K in the production of these proteins, warfarin indirectly slows their rate of synthesis. The authors describe a 46-year-old patient readily anticoagulated for a deep venous thrombosis who then required large doses of warfarin after initiation of total parenteral nutrition, which included lipid preparation that contained vitamin K, in addition to vitamin K required for the daily parenteral nutrition. The effect of total parenteral nutrition with vitamin K on anticoagulation is discussed.
RN  - 0 (Anticoagulants)
RN  - 0 (Serum Albumin)
RN  - 12001-79-5 (Vitamin K)
RN  - 5Q7ZVV76EI (Warfarin)
ES  - 1538-2990
IL  - 0002-9629
DO  - http://dx.doi.org/10.1097/MAJ.0b013e3182382553
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2012 Mar
DC  - 20120223
YR  - 2012
ED  - 20120404
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=22143126

<372. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21947642
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gupta R
AU  - Knobel D
AU  - Gunabushanam V
AU  - Agaba E
AU  - Ritter G
AU  - Marini C
AU  - Barrera R
FA  - Gupta, Rajeev
FA  - Knobel, Denis
FA  - Gunabushanam, Vikraman
FA  - Agaba, Emanuel
FA  - Ritter, Gary
FA  - Marini, Corrado
FA  - Barrera, Rafael
IN  - Gupta,Rajeev. North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA. drrgupta@hotmail.com
TI  - The effect of low body mass index on outcome in critically ill surgical patients.
SO  - Nutrition in Clinical Practice. 26(5):593-7, 2011 Oct.
AS  - Nutr Clin Pract. 26(5):593-7, 2011 Oct.
NJ  - Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - ncp, 8606733
SB  - Index Medicus
SB  - Nursing Journal
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - *Body Mass Index
MH  - *Critical Illness/mo [Mortality]
MH  - Female
MH  - *Hospital Mortality
MH  - Humans
MH  - Infection/ep [Epidemiology]
MH  - *Infection/et [Etiology]
MH  - Intensive Care Units
MH  - Length of Stay
MH  - Lung Diseases/ep [Epidemiology]
MH  - *Lung Diseases/et [Etiology]
MH  - Male
MH  - Middle Aged
MH  - *Postoperative Complications/mo [Mortality]
MH  - Prevalence
MH  - Prospective Studies
MH  - Reference Values
MH  - *Thinness/co [Complications]
MH  - Thinness/ep [Epidemiology]
AB  - BACKGROUND: Body mass index (BMI) has been correlated with complications and outcome in surgical patients at the two extremes of the nutrition spectrum.
AB  - OBJECTIVE: To study the relationship between BMI, outcome, hospital length of stay, and complications in patients admitted to the surgical intensive care unit (SICU).
AB  - DESIGN: Review of prospectively acquired data in SICU patients. Data acquired included weight, height, age, gender, Acute Physiology and Chronic Health Evaluation (APACHE) II-III scores, Simplified Acute Physiology II (SAPS II) scores, and morbidity and mortality. Patients who stayed in the unit <24 hours were excluded.
AB  - RESULTS: Of 793 patients, 706 had a normal BMI (NBMI; mean 22.12 kg/m2) and 87 were underweight (UBMI; mean 16.81 kg/m2). There was no statistically significant difference in APACHE II-III and SAPS scores. The NBMI group had more infections, and the UBMI group had more pulmonary complications (chi(2), P < .0087). There was no significant difference in acute respiratory distress syndrome, atrial fibrillation, myocardial infarction, septicemia, or ventilator- associated pneumonia (Fisher exact test, P = 0.38; chi(2), P = .41). The ICU length of stay between the 2 groups was not significantly different (6.7 vs 5.8 days; P = .64). Overall, there was 11.1% (88/793) SICU mortality; 74 of 706 (10.5%) patients expired in the NBMI group, and 14 of 87 (16.1%) patients expired in the UBMI group.
AB  - CONCLUSIONS: Low BMI is associated with increased mortality in SICU patients. A BMI <18.5 kg/m2 is an independent factor affecting outcome in surgical critical care patients.
ES  - 1941-2452
IL  - 0884-5336
DO  - http://dx.doi.org/10.1177/0884533611419666
PT  - Journal Article
LG  - English
DP  - 2011 Oct
DC  - 20110928
YR  - 2011
ED  - 20120327
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21947642

<373. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21986642
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Davidson MH
AU  - Kling D
AU  - Maki KC
FA  - Davidson, Michael H
FA  - Kling, Douglas
FA  - Maki, Kevin C
IN  - Davidson,Michael H. University of Chicago Pritzker School of Medicine, Chicago, IL 60654, USA. mdavidso@medicine.bsd.uchicago.edu
TI  - Novel developments in omega-3 fatty acid-based strategies. [Review]
SO  - Current Opinion in Lipidology. 22(6):437-44, 2011 Dec.
AS  - Curr Opin Lipidol. 22(6):437-44, 2011 Dec.
NJ  - Current opinion in lipidology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - b05, 9010000
SB  - Index Medicus
CP  - England
MH  - Animals
MH  - Arrhythmias, Cardiac/dt [Drug Therapy]
MH  - Biological Availability
MH  - Coronary Artery Disease/dt [Drug Therapy]
MH  - Fatty Acids, Omega-3/ae [Adverse Effects]
MH  - Fatty Acids, Omega-3/pk [Pharmacokinetics]
MH  - *Fatty Acids, Omega-3/tu [Therapeutic Use]
MH  - Heart Failure/pc [Prevention & Control]
MH  - Humans
MH  - Hypercholesterolemia/ci [Chemically Induced]
MH  - Hypertriglyceridemia/dt [Drug Therapy]
MH  - Hypolipidemic Agents/ae [Adverse Effects]
MH  - Hypolipidemic Agents/pk [Pharmacokinetics]
MH  - *Hypolipidemic Agents/tu [Therapeutic Use]
MH  - Randomized Controlled Trials as Topic
AB  - PURPOSE OF REVIEW: Omega-3 polyunsaturated fatty acids (n-3 PUFAs) have been attributed with several health benefits, including triglyceride lowering and cardiovascular disease risk reduction. This review focuses on new prescription omega-3 fatty acid products in development and recently published data regarding omega-3 fatty acid effects on arrhythmias, heart failure, and platelet inactivation.
AB  - RECENT FINDINGS: A free fatty acid form of n-3 PUFA was found to produce a four-fold higher area under the plasma n-3 PUFA curve than prescription omega-3-acid ethyl esters in patients on a low-fat diet. Eicosapentaenoic acid ethyl esters reduced triglyceride without significantly elevating LDL cholesterol in patients with severe hypertriglyceridemia and in those with mixed dyslipidemia. Recent investigations of n-3 PUFA effects on ventricular and atrial arrhythmias, including studies in patients with implanted defibrillators, failed to demonstrate a significant benefit. However, increased fatty fish or n-3 PUFA consumption was associated with a lower rate of hospitalization in heart failure patients. A further important finding was potentiation of the antiplatelet response when n-3 PUFAs were added to aspirin + clopidogrel.
AB  - SUMMARY: Although n-3 PUFA therapy continues to show promise in the prevention and management of cardiovascular diseases, further research is necessary to more fully elucidate its role in specific disorders.
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Hypolipidemic Agents)
ES  - 1473-6535
IL  - 0957-9672
DO  - http://dx.doi.org/10.1097/MOL.0b013e32834bd642
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2011 Dec
DC  - 20111121
YR  - 2011
ED  - 20120315
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21986642

<374. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22089270
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wit M
AU  - Schaap A
AU  - Umans V
FA  - Wit, Mirjam
FA  - Schaap, Annet
FA  - Umans, Victor
IN  - Wit,Mirjam. Department of Cardiology, Medical Center Alkmaar, Alkmaar, The Netherlands.
TI  - A critical pathway for the frail elderly cardiac patient.
SO  - Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine. 10(4):159-63, 2011 Dec.
AS  - Crit. pathw. cardiol.. 10(4):159-63, 2011 Dec.
NJ  - Critical pathways in cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101165286
SB  - Index Medicus
CP  - United States
MH  - Accidental Falls/pc [Prevention & Control]
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Fibrillation/nu [Nursing]
MH  - Atrial Fibrillation/th [Therapy]
MH  - *Atrial Fibrillation
MH  - Cardiology Service, Hospital/st [Standards]
MH  - *Critical Pathways/st [Standards]
MH  - Delirium/nu [Nursing]
MH  - Delirium/th [Therapy]
MH  - *Frail Elderly
MH  - Geriatric Assessment
MH  - Geriatric Nursing/mt [Methods]
MH  - Geriatric Nursing/st [Standards]
MH  - *Geriatric Nursing
MH  - Health Services for the Aged/og [Organization & Administration]
MH  - Heart Failure/nu [Nursing]
MH  - Heart Failure/th [Therapy]
MH  - *Heart Failure
MH  - Humans
MH  - Length of Stay
MH  - Nursing Evaluation Research/mt [Methods]
MH  - Nutrition Assessment
MH  - *Practice Patterns, Nurses'/st [Standards]
AB  - BACKGROUND: The medical community needs to better respond to the predictable complexities associated with admission of frail and elderly cardiac patients who may need specific attention and care programs. The nurse practitioner can play an important role to continue and coordinate nursing and medical care. We propose a new critical pathway designed to improve cardiac and nursing care for frail elderly cardiac patients admitted with heart failure or atrial fibrillation.
AB  - METHOD: The critical pathway is developed by the nurse practitioner who will act as a pathway coordinator and take care of the medical care of these patients in a teaching hospital setting. This critical pathway is applied to all patients aged >75 years who are admitted for heart failure or atrial fibrillation.
AB  - RESULTS: The pathway implementation identified 5 important socio-medical parameters that may account for a delayed length of stay, even in patients without a complicated medical situation: delirium and fall prevention, nutritional awareness, fluid restriction efforts, and information optimization of patients and spouses.
AB  - CONCLUSIONS: We developed a critical care pathway for the frail elderly patients who are admitted for heart failure or atrial fibrillation. In doing so, we have been able to change the medical and social management of these patients at a general cardiology ward in a teaching hospital.
ES  - 1535-2811
IL  - 1535-2811
DO  - http://dx.doi.org/10.1097/HPC.0b013e318237b2d8
PT  - Journal Article
LG  - English
DP  - 2011 Dec
DC  - 20111117
YR  - 2011
ED  - 20120315
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=22089270

<375. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22068081
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Tanel RE
FA  - Tanel, Ronn E
IN  - Tanel,Ronn E. Division of Pediatric Cardiology, Department of Pediatrics, University of California, San Francisco, CA 94143, USA. ronn.tanel@ucsf.edu
TI  - ECGs in the ED.
SO  - Pediatric Emergency Care. 27(11):1097-8, 2011 Nov.
AS  - Pediatr Emerg Care. 27(11):1097-8, 2011 Nov.
NJ  - Pediatric emergency care
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - pau, 8507560
SB  - Index Medicus
CP  - United States
MH  - Adolescent
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Electrocardiography
MH  - Emergencies
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Swimming
ES  - 1535-1815
IL  - 0749-5161
DO  - http://dx.doi.org/10.1097/PEC.0b013e31823c550c
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2011 Nov
DC  - 20111109
YR  - 2011
ED  - 20120315
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=22068081

<376. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21848634
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Hummel JD
AU  - Elsayed-Awad H
FA  - Hummel, John D
FA  - Elsayed-Awad, Hamdy
TI  - Walking the tightrope between deep sedation and general anesthesia: by whom can this safely be done?.
CM  - Comment on: J Cardiovasc Electrophysiol. 2011 Dec;22(12):1339-43; PMID: 21692895
SO  - Journal of Cardiovascular Electrophysiology. 22(12):1344-5, 2011 Dec.
AS  - J Cardiovasc Electrophysiol. 22(12):1344-5, 2011 Dec.
NJ  - Journal of cardiovascular electrophysiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - by4, 9010756
SB  - Index Medicus
CP  - United States
MH  - *Atrial Fibrillation/su [Surgery]
MH  - *Catheter Ablation/mt [Methods]
MH  - *Deep Sedation
MH  - Female
MH  - Humans
MH  - Male
ES  - 1540-8167
IL  - 1045-3873
DO  - http://dx.doi.org/10.1111/j.1540-8167.2011.02151.x
PT  - Comment
PT  - Editorial
LG  - English
EP  - 20110817
DP  - 2011 Dec
DC  - 20111215
YR  - 2011
ED  - 20120301
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21848634

<377. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22137082
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Osbak PS
AU  - Mourier M
AU  - Kjaer A
AU  - Henriksen JH
AU  - Kofoed KF
AU  - Jensen GB
FA  - Osbak, Philip Samuel
FA  - Mourier, Malene
FA  - Kjaer, Andreas
FA  - Henriksen, Jens Henrik
FA  - Kofoed, Klaus Fuglsang
FA  - Jensen, Gorm Boje
IN  - Osbak,Philip Samuel. Department of Cardiology, Hvidovre Hospital, Faculty of Health Sciences, University of Copenhagen, Denmark. philiposbak@yahoo.dk
TI  - A randomized study of the effects of exercise training on patients with atrial fibrillation.
SO  - American Heart Journal. 162(6):1080-7, 2011 Dec.
AS  - Am Heart J. 162(6):1080-7, 2011 Dec.
NJ  - American heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 0370465
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Atrial Fibrillation/rh [Rehabilitation]
MH  - Exercise
MH  - Exercise Test
MH  - *Exercise Therapy
MH  - Exercise Tolerance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
AB  - BACKGROUND: Exercise training is beneficial in ischemic and congestive heart disease. However, the effect on atrial fibrillation (AF) is unknown.
AB  - METHODS: Forty-nine patients with permanent AF (age [mean +/- SD], 70.2 +/- 7.8 years; male-to-female ratio, 0.75; body mass index [mean +/- SD], 29.7 +/- 4.3 kg/m(2)) were randomized to 12-week aerobic exercise training or a control group. Exercise capacity, 6-minute walk test (6MWT), cardiac output, quality of life, and natriuretic peptides were measured. Cardiac output was measured at rest and during ergometer testing, and atrial natriuretic peptide and N-terminal pro-B-type natriuretic peptide were measured before and after the training period. Quality of life was evaluated using the Short-Form 36 and Minnesota Living With Heart Failure (MLHF-Q) questionnaires.
AB  - RESULTS: Improved exercise capacity and 6MWT were observed in the active patients (P < .001), and at study end, there was a significant difference between the active patients and the controls (P = .002). Resting pulse decreased in the active patients (94.8 +/- 22.4 to 86.3 +/- 22.5 beats/min, P = .049) but remained unchanged in the controls. Cardiac output was unchanged from baseline to end-of-study period. The MLHF-Q score improved in the active group (21.1 +/- 18.0 vs 15.4 +/- 17.5, P = .03). Active patients showed progress in 3 of the 8 Short-Form 36 subscales: physical functioning (P = .02), general health perceptions (P = .001), and vitality (P = .02). Natriuretic peptides were unchanged.
AB  - CONCLUSION: Twelve weeks of exercise training increased exercise capacity and 6MWT and decreased resting pulse rate significantly in patients with AF. Overall quality of life increased significantly as measured by the cardiology-related MLHF-Q. Cardiac output and natriuretic peptides were unchanged in both groups.Copyright © 2011 Mosby, Inc. All rights reserved.
ES  - 1097-6744
IL  - 0002-8703
DO  - http://dx.doi.org/10.1016/j.ahj.2011.09.013
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 2011 Dec
DC  - 20111205
YR  - 2011
ED  - 20120301
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=22137082

<378. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22028778
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Botwinick IC
AU  - Shonkwiler RJ
AU  - Steele J
AU  - Yu G
AU  - Chabot JA
FA  - Botwinick, Isadora C
FA  - Shonkwiler, R Joseph
FA  - Steele, John
FA  - Yu, Gary
FA  - Chabot, John A
IN  - Botwinick,Isadora C. Department of Surgery, New York-Presbyterian Hospital, Columbia University Medical Center, Columbia University, New York, New York, United States of America. Isadora.botwinick@gmail.com
TI  - Atrial fibrillation and delayed gastric emptying.
SO  - PLoS ONE [Electronic Resource]. 6(10):e25499, 2011.
AS  - PLoS ONE. 6(10):e25499, 2011.
NJ  - PloS one
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101285081
OI  - Source: NLM. PMC3197587
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrial Fibrillation/et [Etiology]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Female
MH  - *Gastric Emptying
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Pancreaticoduodenectomy/ae [Adverse Effects]
MH  - *Postoperative Complications/et [Etiology]
MH  - *Postoperative Complications/pp [Physiopathology]
MH  - Postoperative Period
MH  - Retrospective Studies
AB  - BACKGROUND: Atrial fibrillation and delayed gastric emptying (DGE) are common after pancreaticoduodenectomy. Our aim was to investigate a potential relationship between atrial fibrillation and DGE, which we defined as failure to tolerate a regular diet by the 7(th) postoperative day.
AB  - METHODS: We performed a retrospective chart review of 249 patients who underwent pancreaticoduodenectomy at our institution between 2000 and 2009. Data was analyzed with Fisher exact test for categorical variables and Mann-Whitney U or unpaired T-test for continuous variables.
AB  - RESULTS: Approximately 5% of the 249 patients included in the analysis experienced at least one episode of postoperative atrial fibrillation. Median age of patients with atrial fibrillation was 74 years, compared with 66 years in patients without atrial fibrillation (p = 0.0005). Patients with atrial fibrillation were more likely to have a history of atrial fibrillation (p = 0.03). 92% of the patients with atrial fibrillation suffered from DGE, compared to 46% of patients without atrial fibrillation (p = 0.0007). This association held true when controlling for age.
AB  - CONCLUSION: Patients with postoperative atrial fibrillation are more likely to experience delayed gastric emptying. Interventions to manage delayed gastric function might be prudent in patients at high risk for postoperative atrial fibrillation.
ES  - 1932-6203
IL  - 1932-6203
DO  - http://dx.doi.org/10.1371/journal.pone.0025499
PT  - Journal Article
LG  - English
EP  - 20111020
DP  - 2011
DC  - 20111026
YR  - 2011
ED  - 20120224
RD  - 20150129
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=22028778

<379. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21864021
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Eerenberg ES
AU  - van Es J
AU  - Sijpkens MK
AU  - Buller HR
AU  - Kamphuisen PW
FA  - Eerenberg, Elise S
FA  - van Es, Josien
FA  - Sijpkens, Meertien K
FA  - Buller, Harry R
FA  - Kamphuisen, Pieter W
IN  - Eerenberg,Elise S. Department of Vascular Medicine, Academic Medical Centre , Amsterdam , the Netherlands.
TI  - New anticoagulants: moving on from scientific results to clinical implementation.
SO  - Annals of Medicine. 43(8):606-16, 2011 Dec.
AS  - Ann Med. 43(8):606-16, 2011 Dec.
NJ  - Annals of medicine
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - amd, 8906388
SB  - Index Medicus
CP  - England
MH  - Acute Coronary Syndrome/dt [Drug Therapy]
MH  - Anticoagulants/pk [Pharmacokinetics]
MH  - *Anticoagulants/pd [Pharmacology]
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - Arthroplasty, Replacement, Hip
MH  - Atrial Fibrillation/co [Complications]
MH  - Benzimidazoles/pk [Pharmacokinetics]
MH  - Benzimidazoles/pd [Pharmacology]
MH  - Benzimidazoles/tu [Therapeutic Use]
MH  - Dabigatran
MH  - Diet
MH  - Drug Interactions
MH  - Factor VIIa/ad [Administration & Dosage]
MH  - Factor Xa Inhibitors
MH  - Humans
MH  - Kidney/de [Drug Effects]
MH  - Life Style
MH  - Monitoring, Physiologic
MH  - Morpholines/pk [Pharmacokinetics]
MH  - Morpholines/pd [Pharmacology]
MH  - Morpholines/tu [Therapeutic Use]
MH  - Recombinant Proteins/ad [Administration & Dosage]
MH  - Rivaroxaban
MH  - Stroke/et [Etiology]
MH  - Stroke/pc [Prevention & Control]
MH  - Thiophenes/pk [Pharmacokinetics]
MH  - Thiophenes/pd [Pharmacology]
MH  - Thiophenes/tu [Therapeutic Use]
MH  - *Venous Thromboembolism/dt [Drug Therapy]
MH  - Venous Thromboembolism/pc [Prevention & Control]
MH  - *Vitamin K/ai [Antagonists & Inhibitors]
MH  - beta-Alanine/aa [Analogs & Derivatives]
MH  - beta-Alanine/pk [Pharmacokinetics]
MH  - beta-Alanine/pd [Pharmacology]
MH  - beta-Alanine/tu [Therapeutic Use]
AB  - Vitamin K antagonists (VKA) are the only registered oral anticoagulants for the treatment of venous thromboembolism (VTE). VKA have an unpredictable and highly variable effect on coagulation, with a high risk of under- and over-treatment. Novel anticoagulants, such as dabigatran and rivaroxaban, could be a very welcome replacement for VKA, as they show a predictable anticoagulant effect. Results of several phase II and III studies have shown the efficacy and safety of dabigatran and rivaroxaban in the prophylaxis and treatment of VTE, and for the prevention of stroke in atrial fibrillation. It remains to be shown whether these new anticoagulants have the same safety profile in daily clinical practice, where more vulnerable patients will be treated. Lack of information on the proper monitoring method or antidote in case of bleeding may also hinder the translation from science to clinical practice.
RN  - 0 (Anticoagulants)
RN  - 0 (Benzimidazoles)
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Morpholines)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Thiophenes)
RN  - 0 (recombinant FVIIa)
RN  - 11P2JDE17B (beta-Alanine)
RN  - 12001-79-5 (Vitamin K)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - EC 3-4-21-21 (Factor VIIa)
RN  - I0VM4M70GC (Dabigatran)
ES  - 1365-2060
IL  - 0785-3890
DO  - http://dx.doi.org/10.3109/07853890.2011.606829
PT  - Journal Article
LG  - English
EP  - 20110824
DP  - 2011 Dec
DC  - 20111107
YR  - 2011
ED  - 20120222
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21864021

<380. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22008491
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Buber J
AU  - Glikson M
AU  - Eldar M
AU  - Luria D
FA  - Buber, Jonathan
FA  - Glikson, Michael
FA  - Eldar, Michael
FA  - Luria, David
IN  - Buber,Jonathan. Leviev Heart Center, Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. yonibuber@gmail.com
TI  - Exercise heart rate acceleration patterns during atrial fibrillation and sinus rhythm.
SO  - Annals of Noninvasive Electrocardiology. 16(4):357-64, 2011 Oct.
AS  - Ann Noninvasive Electrocardiol. 16(4):357-64, 2011 Oct.
NJ  - Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - dzb, 9607443
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/th [Therapy]
MH  - Electric Countershock
MH  - *Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Female
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
AB  - BACKGROUND: Patients with atrial fibrillation sustain a significant lower exercise tolerance compared to those in sinus rhythm, even while seemingly in adequate rate-control.
AB  - METHODS: Exercise testing was performed during atrial fibrillation and after electric cardioversion for 30 patients who were initially treated with AV modifying agents and were considered in adequate rate control. Heart rate parameters were obtained during all exercise stages, and a graphic display of heart rate acceleration was obtained. For those patients who remained in sinus rhythm, an additional exercise test was performed after 1 month.
AB  - RESULTS: During atrial fibrillation, heart rate at the completion of Bruce stage 1 and the peak exercise heart rate were significantly higher when compared to sinus rhythm (120 +/- 10 bpm vs. 98 +/- 11 bpm and 164 +/- 16 bpm vs. 129 +/- 11 bpm respectively, p < 0.001 for both). The time to peak exercise heart rate was significantly shorter during atrial fibrillation (3.5 +/- 1 min vs. 6.5 +/- 1.5 min, p < 0.001), and the total exercise duration was subsequently shorter as well (6 +/- 2 min vs. 8.5 +/- 2 min, p < 0.001). Treatment with beta-blockers prior to exercise did not affect the earlier peaking of the heart rate. After 1 month, similar time to peak heart rate and similar exercise performance were observed among patients, who remained in sinus rhythm, when compared to to the post-cardioversion exercise test.
AB  - CONCLUSIONS: In patients with atrial fibrillation, exercise heart rate acceleration displays a specific pattern of early peaking. Earlier heart rate peaking occurs regardless of ample rate control while at rest or mild physical activity and contributes to overall lower exercise performance.Copyright ©2011, Wiley Periodicals, Inc.
ES  - 1542-474X
IL  - 1082-720X
DO  - http://dx.doi.org/10.1111/j.1542-474X.2011.00463.x
PT  - Journal Article
LG  - English
DP  - 2011 Oct
DC  - 20111019
YR  - 2011
ED  - 20120216
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=22008491

<381. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21988948
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Acharjee S
AU  - Cannon CP
FA  - Acharjee, Subroto
FA  - Cannon, Christopher P
IN  - Acharjee,Subroto. Department of Medicine, SUNY at Buffalo School of Medicine, NY, USA.
TI  - Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism. [Review]
SO  - Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine. 10(2):84-6, 2011 Jun.
AS  - Crit. pathw. cardiol.. 10(2):84-6, 2011 Jun.
NJ  - Critical pathways in cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101165286
SB  - Index Medicus
CP  - United States
MH  - Administration, Oral
MH  - Anticoagulants/ad [Administration & Dosage]
MH  - Anticoagulants/pk [Pharmacokinetics]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/me [Metabolism]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Benzimidazoles/ad [Administration & Dosage]
MH  - Benzimidazoles/pk [Pharmacokinetics]
MH  - *Benzimidazoles
MH  - Biopharmaceutics
MH  - *Blood Coagulation/de [Drug Effects]
MH  - Clinical Trials, Phase III as Topic
MH  - Dabigatran
MH  - Drug Approval
MH  - Drug Dosage Calculations
MH  - Drug Monitoring/mt [Methods]
MH  - Drug Monitoring/st [Standards]
MH  - Humans
MH  - Risk Assessment
MH  - Therapeutic Equivalency
MH  - *Thrombin/ai [Antagonists & Inhibitors]
MH  - Thrombin/me [Metabolism]
MH  - Thromboembolism/me [Metabolism]
MH  - Thromboembolism/pp [Physiopathology]
MH  - *Thromboembolism/pc [Prevention & Control]
MH  - Warfarin/ad [Administration & Dosage]
MH  - Warfarin/pk [Pharmacokinetics]
MH  - *Warfarin
MH  - beta-Alanine/ad [Administration & Dosage]
MH  - *beta-Alanine/aa [Analogs & Derivatives]
MH  - beta-Alanine/pk [Pharmacokinetics]
AB  - For several decades now, oral anticoagulation with warfarin has represented the cornerstone of measures to prevent occurrence of ischemic stroke in high-risk patients with atrial fibrillation. However, the mechanism of action and pharmacokinetic profile of this vitamin K antagonist confers a narrow therapeutic range and makes it prone to drug and dietary interactions, requiring frequent monitoring of its effectiveness. The recently introduced oral direct thrombin antagonist, dabigatran, has been shown in phase III clinical trials to be noninferior in efficacy to warfarin for the prevention of thromboembolic events in patients with atrial fibrillation, as well as in treatment of acute venous thromboembolism. In this article, we review the factors necessitating the development of dabigatran, summarize key clinical trial evidence leading to its approval, and discuss its potential role as an alternative to warfarin in current clinical practice.
RN  - 0 (Anticoagulants)
RN  - 0 (Benzimidazoles)
RN  - 11P2JDE17B (beta-Alanine)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - EC 3-4-21-5 (Thrombin)
RN  - I0VM4M70GC (Dabigatran)
ES  - 1535-2811
IL  - 1535-2811
DO  - http://dx.doi.org/10.1097/HPC.0b013e318224df28
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
LG  - English
DP  - 2011 Jun
DC  - 20111012
YR  - 2011
ED  - 20120214
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21988948

<382. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21450634
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Van der Niepen P
AU  - Thijs V
AU  - Devroey D
AU  - Fieuw A
AU  - Dramaix M
AU  - Van de Borne P
FA  - Van der Niepen, Patricia
FA  - Thijs, Vincent
FA  - Devroey, Dirk
FA  - Fieuw, Ann
FA  - Dramaix, Michele
FA  - Van de Borne, Philippe
IN  - Van der Niepen,Patricia. Department of Nephrology and Hypertension, Universitair Ziekenhuis Brussel, Brussels, Belgium. hemovnnp@uzbrussel.be
TI  - Belgian global implementation of cardiovascular and stroke risk assessment study: methods and baseline data of the BELGICA-STROKE STUDY.
SO  - European Journal of Cardiovascular Prevention & Rehabilitation. 18(4):635-41, 2011 Aug.
AS  - Eur J Cardiovasc Prev Rehabil. 18(4):635-41, 2011 Aug.
NJ  - European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101192000
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - Antihypertensive Agents/tu [Therapeutic Use]
MH  - Attitude of Health Personnel
MH  - Awareness
MH  - Belgium/ep [Epidemiology]
MH  - Blood Pressure
MH  - *Cardiovascular Diseases/et [Etiology]
MH  - Cardiovascular Diseases/mo [Mortality]
MH  - Cardiovascular Diseases/pc [Prevention & Control]
MH  - Decision Support Techniques
MH  - Diet/ae [Adverse Effects]
MH  - Feedback
MH  - Female
MH  - Guideline Adherence
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - *Hypertension/co [Complications]
MH  - Hypertension/mo [Mortality]
MH  - Hypertension/pp [Physiopathology]
MH  - Hypertension/th [Therapy]
MH  - Internet
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Motivation
MH  - Patient Education as Topic
MH  - Practice Guidelines as Topic
MH  - Primary Health Care
MH  - Prospective Studies
MH  - *Research Design
MH  - Risk Assessment
MH  - Risk Factors
MH  - Risk Reduction Behavior
MH  - *Stroke/et [Etiology]
MH  - Stroke/mo [Mortality]
MH  - Stroke/pc [Prevention & Control]
MH  - Time Factors
AB  - OBJECTIVES: BELGICA-STROKE is a longitudinal study to enhance the use of online cardiovascular risk prediction scores based on the SCORE 10-year risk estimates for fatal cardiovascular disease (adapted for Belgium) and the Framingham 10-year stroke risk and to evaluate their impact on the cardiovascular risk profile of hypertensive patients. Methods and baseline characteristics are described here.
AB  - DESIGN: Prospective, multicenter study in primary care.
AB  - METHODS: General practitioners (N=810) recruited consecutive hypertensive patients aged >40 years who were not at blood pressure goal and assessed them every 4 months. The estimated 10-year risks for fatal cardiovascular disease and stroke were available on a secured, specially designed study website. The calculated risk profile of a patient was modifiable by adding treatment goals in order to increase awareness and motivation of both physician and patient. An automated feedback on goal-level attainment and both cardiovascular risk scores was provided.
AB  - RESULTS: Mean age of the 15,744 patients was 66.3 years: 51.9% were men, 77.8% had excess weight, 19.4% were smokers, and 25.9% had diabetes. Left ventricle hypertrophy was present in 20.0%, atrial fibrillation in 5.8%. Mean blood pressure was 153.8/88.2mmHg, mean cholesterol 211.5mg/dl. Most patients (89.2%) received antihypertensive medication, of which 36.9% was monotherapy. Mean estimated 10-year stroke risk was 19.1%, and mean estimated 10-year fatal cardiovascular disease risk 5.9%.
AB  - CONCLUSIONS: The 10-year estimated stroke and fatal cardiovascular disease risks were moderate to high in hypertensive patients not at goal blood pressure, emphasizing the importance of global cardiovascular risk factor assessment.
RN  - 0 (Antihypertensive Agents)
ES  - 1741-8275
IL  - 1741-8267
DO  - http://dx.doi.org/10.1177/1741826710389416
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20110225
DP  - 2011 Aug
DC  - 20111026
YR  - 2011
ED  - 20120206
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21450634

<383. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21535388
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Rasmussen LH
AU  - Larsen TB
AU  - Due KM
AU  - Tjonneland A
AU  - Overvad K
AU  - Lip GY
FA  - Rasmussen, L H
FA  - Larsen, T B
FA  - Due, K M
FA  - Tjonneland, A
FA  - Overvad, K
FA  - Lip, G Y H
IN  - Rasmussen,L H. Department of Cardiology, Aalborg AF Study Group, Aarhus University Hospital, Aalborg, Denmark. lhr@rn.dk
TI  - Impact of vascular disease in predicting stroke and death in patients with atrial fibrillation: the Danish Diet, Cancer and Health cohort study.
SO  - Journal of Thrombosis & Haemostasis. 9(7):1301-7, 2011 Jul.
AS  - J Thromb Haemost. 9(7):1301-7, 2011 Jul.
NJ  - Journal of thrombosis and haemostasis : JTH
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101170508
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - Cause of Death
MH  - Chemoprevention
MH  - Cohort Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Prospective Studies
MH  - Risk Factors
MH  - Stroke/ep [Epidemiology]
MH  - *Stroke/et [Etiology]
MH  - Stroke/pc [Prevention & Control]
MH  - *Vascular Diseases/co [Complications]
MH  - Vascular Diseases/ep [Epidemiology]
AB  - BACKGROUND: The presence of vascular disease (peripheral artery disease [PAD] and/or myocardial infarction [MI]) may impact on the risk of stroke and death among patients with incident atrial fibrillation (AF). To test this hypothesis, we analyzed data from a large Danish prospective cohort, the Danish Diet, Cancer and Health (DCH) study, to assess the risk of stroke or death among those who developed AF according to concomitant presence of vascular disease.
AB  - METHODS: A prospective cohort study of 57, 053 persons (27, 178 men and 29, 876 women, respectively), aged between 50 and 64 years. The risk of stroke or death for patients with vascular disease was assessed amongst 3315 patients with incident AF (mean age, 67.1years; 2130 men, 1185 women) using Cox proportional hazard models, after a median follow-up of 4.8 years.
AB  - RESULTS:  Of the subjects with AF, 417 (12.6%) had 'vascular disease' (PAD and/or prior MI). The risk of the primary endpoint (stroke or death) was significantly higher in patients with vascular disease at 1-year follow-up (crude hazard ratio [HR] 2.51 [1.91-3.29]), with corresponding crude HRs for PAD and MI being 3.51 (2.40-5.13), and 1.99 (1.46-2.72), respectively. For the secondary endpoints of death or stroke individually, these risk estimates were similar (crude HR 2.48 [1.89-3.26] and 1.77 [1.18-2.66], respectively). After adjustment for risk factors within the CHADS(2) score, the adjusted HR for the primary endpoint (stroke or death) in patients with vascular disease was 1.91 (1.44-2.54), which was also significant for death (1.97 [1.48-2.62]).
AB  - CONCLUSION: Vascular disease (prior MI and PAD) is an independent risk factor for the primary endpoint of 'stroke or death' in patients with AF, even after adjustment for the CHADS(2) risk score, although this is driven by the impact on mortality. This reaffirms that patients with vascular disease represent a 'high-risk' population, which necessitates proactive management of all cardiovascular risk factors and effective thromboprophylaxis (i.e. oral anticoagulation), which has been shown to significantly reduce the risk of stroke and death in AF.Copyright © 2011 International Society on Thrombosis and Haemostasis.
RN  - 0 (Anticoagulants)
ES  - 1538-7836
IL  - 1538-7836
DO  - http://dx.doi.org/10.1111/j.1538-7836.2011.04308.x
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2011 Jul
DC  - 20110704
YR  - 2011
ED  - 20120202
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21535388

<384. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21918045
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Maurer AH
AU  - Burshteyn M
AU  - Adler LP
AU  - Steiner RM
FA  - Maurer, Alan H
FA  - Burshteyn, Mark
FA  - Adler, Lee P
FA  - Steiner, Robert M
IN  - Maurer,Alan H. Department of Radiology, Temple University School of Medicine, Philadelphia, PA 19140, USA. amaurer@temple.edu
TI  - How to differentiate benign versus malignant cardiac and paracardiac 18F FDG uptake at oncologic PET/CT. [Review]
SO  - Radiographics. 31(5):1287-305, 2011 Sep-Oct.
AS  - Radiographics. 31(5):1287-305, 2011 Sep-Oct.
NJ  - Radiographics : a review publication of the Radiological Society of North America, Inc
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - rdg, 8302501
SB  - Index Medicus
CP  - United States
MH  - Artifacts
MH  - *Cardiomyopathies/ri [Radionuclide Imaging]
MH  - Cardiovascular Diseases/ri [Radionuclide Imaging]
MH  - Diagnosis, Differential
MH  - Eating
MH  - Fasting
MH  - Fatty Acids/me [Metabolism]
MH  - Fluorine Radioisotopes/pk [Pharmacokinetics]
MH  - *Fluorine Radioisotopes
MH  - Fluorodeoxyglucose F18/pk [Pharmacokinetics]
MH  - *Fluorodeoxyglucose F18
MH  - Glucose/me [Metabolism]
MH  - *Heart Neoplasms/ri [Radionuclide Imaging]
MH  - Humans
MH  - Image Processing, Computer-Assisted
MH  - Insulin/pd [Pharmacology]
MH  - Mediastinal Neoplasms/ri [Radionuclide Imaging]
MH  - *Multimodal Imaging
MH  - Muscles/me [Metabolism]
MH  - Myocardium/me [Metabolism]
MH  - *Positron-Emission Tomography
MH  - Radiopharmaceuticals/pk [Pharmacokinetics]
MH  - *Radiopharmaceuticals
MH  - Tissue Distribution
MH  - *Tomography, X-Ray Computed
MH  - Whole Body Imaging
AB  - Patients undergoing 2-[fluorine 18]fluoro-2-deoxy-d-glucose (FDG) whole-body oncologic positron emission tomography (PET)/computed tomography (CT) are studied while fasting. Cardiac FDG uptake in fasted patients has been widely reported as variable. It is important to understand the normal patterns of cardiac FDG activity that can be seen in oncologic FDG PET/CT studies. These include focal and regional patterns of increased FDG myocardial activity. Focal activity can be observed in papillary muscles, the atria, the base, and the distal anteroapical region of the left ventricle. Regional increased cardiac FDG activity may be diffuse or localized in the posterolateral wall or the base of the left ventricle. Abnormal patterns of cardiac FDG activity not related to malignancy include those associated with lipomatous hypertrophy of the interatrial septum, epicardial and pericardial fat, increased atrial activity associated with atrial fibrillation or a prominent crista terminalis, cardiac sarcoidosis, endocarditis, myocarditis, and pericarditis. Knowledge of these patterns of cardiac FDG activity is important to be able to recognize malignant disease involving the paracardiac spaces, myocardium, and pericardium. With a better understanding of the range of normal and abnormal patterns of cardiac FDG activity, important benign and malignant diseases involving the heart and pericardium can be recognized and diagnosed.
RN  - 0 (Fatty Acids)
RN  - 0 (Fluorine Radioisotopes)
RN  - 0 (Insulin)
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
RN  - IY9XDZ35W2 (Glucose)
ES  - 1527-1323
IL  - 0271-5333
DO  - http://dx.doi.org/10.1148/rg.315115003
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2011 Sep-Oct
DC  - 20110915
YR  - 2011
ED  - 20120120
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21918045

<385. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21905041
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Jaber J
AU  - Cirenza C
AU  - Amaral A
AU  - Jaber J
AU  - Oliveira Filho JA
AU  - de Paola AA
FA  - Jaber, Jefferson
FA  - Cirenza, Claudio
FA  - Amaral, Alessandro
FA  - Jaber, Jeffrey
FA  - Oliveira Filho, Japy A
FA  - de Paola, Angelo A V
IN  - Jaber,Jefferson. Cardiology Division, Department of Medicine, Federal University of Sao Paulo, Sao Paulo, Brazil. jaberjeff@yahoo.com.br
TI  - Correlation between heart rate control during exercise and exercise capacity in patients with chronic atrial fibrillation.
SO  - Clinical Cardiology. 34(9):533-6, 2011 Sep.
AS  - Clin Cardiol. 34(9):533-6, 2011 Sep.
NJ  - Clinical cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - de9, 7903272
SB  - Index Medicus
CP  - United States
MH  - Adrenergic beta-Antagonists/pd [Pharmacology]
MH  - *Atrial Fibrillation
MH  - Chronic Disease
MH  - Confidence Intervals
MH  - *Exercise
MH  - Exercise Test
MH  - *Exercise Tolerance/de [Drug Effects]
MH  - *Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - Multivariate Analysis
MH  - Odds Ratio
MH  - Oxygen Compounds
MH  - Statistics as Topic
MH  - Time Factors
MH  - Walking
AB  - BACKGROUND: Rate control is an acceptable alternative to rhythm control in patients with chronic atrial fibrillation (AF).
AB  - HYPOTHESIS: The aim of this study of AF patients was to understand the correlation between their exercise capacity and both heart rate (HR) and HR variation index during exercise.
AB  - METHODS: The exercise capacity of 85 male patients with chronic AF was measured using a cardiopulmonary exercise test (CPX). Within this population, we compared the exercise tolerance of patients with a normal chronotropic response (maximal HR 85%-115% that of the maximal age-predicted HR during CPX) to those whose HR response exceeded this range. Two similar comparisons were made by dividing the subject population according to (1) whether or not their HR variation index (HRVI) during CPX exceeded 10 bpm/min, and (2) whether their HR during the 6-minute walk test exceeded 110 bpm.
AB  - RESULTS: Patients with an HRVI not over 10 bpm/min showed higher maximal oxygen uptake compared to patients with a higher HRVI (26.7 +/- 6.1 vs 22.8 +/- 4.8 mL O(2) /kg/min, P = 0.002) and a longer distance walked during CPX (705.6 +/- 200.3 vs 520.9 +/- 155.5 m, P<0.001). No other significant influence on exercise capacity was seen. Multivariate regression analysis revealed that both the body mass index and the HRVI during CPX were independent predictors of the maximal oxygen uptake.
AB  - CONCLUSIONS: Better HRVI control on CPX was correlated with better exercise capacity in patients with chronic AF.Copyright © 2011 Wiley Periodicals, Inc.
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Oxygen Compounds)
ES  - 1932-8737
IL  - 0160-9289
DO  - http://dx.doi.org/10.1002/clc.20948
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2011 Sep
DC  - 20110909
YR  - 2011
ED  - 20120112
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21905041

<386. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19654095
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Sorokin AV
AU  - Araujo CG
AU  - Zweibel S
AU  - Thompson PD
FA  - Sorokin, A V
FA  - Araujo, C G S
FA  - Zweibel, S
FA  - Thompson, P D
IN  - Sorokin,A V. Cardiology, Hartford Hospital, 81 Seymour Street, Hartford, CT 06102, USA.
TI  - Atrial fibrillation in endurance-trained athletes. [Review]
SO  - British Journal of Sports Medicine. 45(3):185-8, 2011 Mar.
AS  - BJSM online. 45(3):185-8, 2011 Mar.
NJ  - British journal of sports medicine
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 0432520
SB  - Index Medicus
CP  - England
MH  - Adaptation, Physiological/ph [Physiology]
MH  - *Athletes
MH  - *Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/pa [Pathology]
MH  - Atrial Fibrillation/th [Therapy]
MH  - Biomarkers/bl [Blood]
MH  - Cardiomegaly, Exercise-Induced/ph [Physiology]
MH  - Catheter Ablation
MH  - Heart Atria/pa [Pathology]
MH  - Humans
MH  - *Physical Endurance/ph [Physiology]
MH  - Risk Factors
MH  - *Sports/ph [Physiology]
AB  - BACKGROUND: Endurance exercise training produces multiple cardiac adaptations including changes in electrophysiological function that may make endurance-trained athletes more vulnerable to atrial fibrillation (AF). This possible association is not recognised by many practising cardiologists and sports physicians. Consequently, we performed a literature review to examine the relationship between atrial fibrillation and endurance exercise training among athletes. PubMed was searched from January 1960 through December 2008 to identify articles examining the relationship between endurance exercise training and AF.
AB  - RESULTS: Evidence suggests that athletes are at increased risk for development of AF. Possible factors increasing AF in this population include increased parasympathetic tone, reduced sympathetic tone, increased atrial size and increased inflammation.
AB  - DISCUSSION: Suggested management of AF in athletes should follow similar principles to those used to manage AF in the general population.
RN  - 0 (Biomarkers)
ES  - 1473-0480
IL  - 0306-3674
DO  - http://dx.doi.org/10.1136/bjsm.2009.057885
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20090713
DP  - 2011 Mar
DC  - 20110217
YR  - 2011
ED  - 20111229
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19654095

<387. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 22051327
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mozaffarian D
AU  - Wu JH
FA  - Mozaffarian, Dariush
FA  - Wu, Jason H Y
IN  - Mozaffarian,Dariush. Division of Cardiovascular Medicine and Channing Laboratory, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. dmozaffa@hsph.harvard.edu
TI  - Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. [Review]
SO  - Journal of the American College of Cardiology. 58(20):2047-67, 2011 Nov 8.
AS  - J Am Coll Cardiol. 58(20):2047-67, 2011 Nov 8.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - h50, 8301365
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Animals
MH  - Cardiovascular Diseases/mo [Mortality]
MH  - *Cardiovascular Diseases/pc [Prevention & Control]
MH  - Fatty Acids, Omega-3/me [Metabolism]
MH  - *Fatty Acids, Omega-3/tu [Therapeutic Use]
MH  - Humans
MH  - Risk Factors
MH  - Seafood
AB  - We reviewed available evidence for cardiovascular effects of n-3 polyunsaturated fatty acid (PUFA) consumption, focusing on long chain (seafood) n-3 PUFA, including their principal dietary sources, effects on physiological risk factors, potential molecular pathways and bioactive metabolites, effects on specific clinical endpoints, and existing dietary guidelines. Major dietary sources include fatty fish and other seafood. n-3 PUFA consumption lowers plasma triglycerides, resting heart rate, and blood pressure and might also improve myocardial filling and efficiency, lower inflammation, and improve vascular function. Experimental studies demonstrate direct anti-arrhythmic effects, which have been challenging to document in humans. n-3 PUFA affect a myriad of molecular pathways, including alteration of physical and chemical properties of cellular membranes, direct interaction with and modulation of membrane channels and proteins, regulation of gene expression via nuclear receptors and transcription factors, changes in eicosanoid profiles, and conversion of n-3 PUFA to bioactive metabolites. In prospective observational studies and adequately powered randomized clinical trials, benefits of n-3 PUFA seem most consistent for coronary heart disease mortality and sudden cardiac death. Potential effects on other cardiovascular outcomes are less-well-established, including conflicting evidence from observational studies and/or randomized trials for effects on nonfatal myocardial infarction, ischemic stroke, atrial fibrillation, recurrent ventricular arrhythmias, and heart failure. Research gaps include the relative importance of different physiological and molecular mechanisms, precise dose-responses of physiological and clinical effects, whether fish oil provides all the benefits of fish consumption, and clinical effects of plant-derived n-3 PUFA. Overall, current data provide strong concordant evidence that n-3 PUFA are bioactive compounds that reduce risk of cardiac death. National and international guidelines have converged on consistent recommendations for the general population to consume at least 250 mg/day of long-chain n-3 PUFA or at least 2 servings/week of oily fish.Copyright A© 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
RN  - 0 (Fatty Acids, Omega-3)
ES  - 1558-3597
IL  - 0735-1097
DO  - http://dx.doi.org/10.1016/j.jacc.2011.06.063
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2011 Nov 8
DC  - 20111104
YR  - 2011
ED  - 20111227
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=22051327

<388. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21507821
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Karth A
AU  - Holoshitz N
AU  - Kavinsky CJ
AU  - Trohman R
AU  - McBride BF
FA  - Karth, Abigail
FA  - Holoshitz, Noa
FA  - Kavinsky, Clifford J
FA  - Trohman, Richard
FA  - McBride, Brian F
IN  - Karth,Abigail. Department of Medicine, Rush University Medical Center, Chicago, IL, USA.
TI  - A case report of atrial fibrillation potentially induced by hydroxycut: a multicomponent dietary weight loss supplement devoid of sympathomimetic amines.
SO  - Journal of Pharmacy Practice. 23(3):245-9, 2010 Jun.
AS  - J Pharm Pract. 23(3):245-9, 2010 Jun.
NJ  - Journal of pharmacy practice
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 8900945
SB  - Index Medicus
CP  - United States
MH  - *Anti-Obesity Agents/ae [Adverse Effects]
MH  - Anti-Obesity Agents/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/ci [Chemically Induced]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Catechin/ae [Adverse Effects]
MH  - *Catechin/aa [Analogs & Derivatives]
MH  - Catechin/pd [Pharmacology]
MH  - *Dietary Supplements/ae [Adverse Effects]
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - *Plant Preparations/ae [Adverse Effects]
MH  - Plant Preparations/tu [Therapeutic Use]
MH  - Sympathomimetics/me [Metabolism]
AB  - Multicomponent dietary weight loss supplements comprise the single largest segment of herbal preparations available to the public. As a result of limited de novo regulatory oversight, supplement-related adverse events are underreported secondary to the lack of adequate pharmacodynamic, pharmacokinetic, and clinical data. Here we report the case of an obese 63-year-old caucasian female with a 2-day history of symptomatic paroxysmal atrial fibrillation (AF) with rapid ventricular response following a 2-week course of therapy with hydroxycut, a multicomponent dietary weight loss supplement devoid of sympathomimetic amines. Upon presentation, the patient received 2 doses of intravenous diltiazem, was loaded with intravenous digoxin, and spontaneously converted to normal sinus rhythm 36 hours following her last dose of the product. Epigallocatechin (EGCG), a principal ingredient in the hydroxycut preparation is the suspected causative component. EGCG blocks the atrial-specific KCNA5 potassium channel. Loss of KCNA5 function has been reported in patients with familial lone AF. Thus, causal relationship between hydroxycut and AF in this patient is probable. Given the serious risks associated with AF, patients at risk of developing AF should avoid dietary supplements containing EGCG until more information on the adverse effects of EGCG is known.
RN  - 0 (Anti-Obesity Agents)
RN  - 0 (Plant Preparations)
RN  - 0 (Sympathomimetics)
RN  - 0 (hydroxycut)
RN  - 8R1V1STN48 (Catechin)
RN  - BQM438CTEL (epigallocatechin gallate)
ES  - 1531-1937
IL  - 0897-1900
DO  - http://dx.doi.org/10.1177/0897190010362104
PT  - Case Reports
PT  - Journal Article
LG  - English
EP  - 20100408
DP  - 2010 Jun
DC  - 20110421
YR  - 2010
ED  - 20111219
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21507821

<389. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21297124
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Peters MN
AU  - Dickfeld TM
FA  - Peters, Matthew N
FA  - Dickfeld, Timm M
IN  - Peters,Matthew N. University of Maryland School of Medicine, 655 West Baltimore St, Baltimore, MD 21201, USA. mattpeters25@gmail.com
TI  - Catecholamine-dependent wide QRS complex tachycardia in a 71-year-old male 'super athlete'.
SO  - Europace. 13(8):1201-2, 2011 Aug.
AS  - Europace. 13(8):1201-2, 2011 Aug.
NJ  - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - dxd, 100883649
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - *Atrial Flutter/di [Diagnosis]
MH  - *Atrial Flutter/pp [Physiopathology]
MH  - *Atrioventricular Node/pp [Physiopathology]
MH  - *Catecholamines/ph [Physiology]
MH  - Electrocardiography, Ambulatory
MH  - Exercise/ph [Physiology]
MH  - Humans
MH  - Male
MH  - *Weight Lifting/ph [Physiology]
AB  - Recent studies have suggested an association between increased athletic activity and atrial arrhythmias; however, the mechanism remains unclear. Presented herein is a 71-year-old man with atrial flutter with 1:1 atrioventricular (AV) conduction triggered by high-intensity exercise as well as administration of isoproterenol, suggesting that arrhythmia is autonomically mediated.
RN  - 0 (Catecholamines)
ES  - 1532-2092
IL  - 1099-5129
DO  - http://dx.doi.org/10.1093/europace/eur022
PT  - Case Reports
PT  - Journal Article
LG  - English
EP  - 20110204
DP  - 2011 Aug
DC  - 20110803
YR  - 2011
ED  - 20111207
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21297124

<390. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21750309
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Anthony CJ
AU  - Karim S
AU  - Ackroyd-Stolarz S
AU  - Fry A
AU  - Murphy NG
AU  - Christie R
AU  - Zed PJ
FA  - Anthony, Crystal J
FA  - Karim, Saleema
FA  - Ackroyd-Stolarz, Stacy
FA  - Fry, Amy
FA  - Murphy, Nancy G
FA  - Christie, Russell
FA  - Zed, Peter J
IN  - Anthony,Crystal J. Department of Pharmacy, Mt. Sinai Hospital, Toronto, Ontario, Canada.
TI  - Intensity of anticoagulation with warfarin and risk of adverse events in patients presenting to the emergency department.
SO  - Annals of Pharmacotherapy. 45(7-8):881-7, 2011 Jul.
AS  - Ann Pharmacother. 45(7-8):881-7, 2011 Jul.
NJ  - The Annals of pharmacotherapy
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - bbx, 9203131
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - *Anticoagulants/ae [Adverse Effects]
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Blood Coagulation/de [Drug Effects]
MH  - Canada/ep [Epidemiology]
MH  - Diet/ae [Adverse Effects]
MH  - Female
MH  - *Hemorrhage/ep [Epidemiology]
MH  - Hemorrhage/pp [Physiopathology]
MH  - Hospitals, University
MH  - Humans
MH  - International Normalized Ratio
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk
MH  - Severity of Illness Index
MH  - *Thromboembolism/ep [Epidemiology]
MH  - Thromboembolism/pp [Physiopathology]
MH  - Trauma Centers
MH  - Vitamin K/ad [Administration & Dosage]
MH  - Vitamin K/ae [Adverse Effects]
MH  - *Warfarin/ae [Adverse Effects]
MH  - Warfarin/tu [Therapeutic Use]
AB  - BACKGROUND: The ability of patients receiving warfarin to maintain an international normalized ratio (INR) within the desired therapeutic range is important for both efficacy and risk of adverse events. It is unclear whether the desired INR is maintained in patients receiving warfarin who present to the emergency department (ED) and whether they have a higher rate of adverse events.
AB  - OBJECTIVE: To evaluate the intensity of anticoagulation with warfarin and the risk of bleeding and thromboembolic complications in patients in the ED.
AB  - METHODS: A prospective observational study was performed using a convenience sample of patients receiving warfarin and presenting to the ED over an 18-week period. Data were collected using a standardized form that included chief complaint, history of present illness, past medical history, medication history, and allergy status. Information from the physical examination, laboratory results, and other diagnostic tests obtained as part of routine assessment in the ED, was used as necessary. The primary outcome was the proportion of patients whose INR was within, above, or below the desired therapeutic range. Bleeding complications and thromboembolic events were recorded in an attempt to determine the relationship between the intensity of anticoagulation and adverse outcomes.
AB  - RESULTS: Two hundred one patients were included, with a mean (SD) age of 74.0 (13.2) years; 53.7% were female. Primary indications for warfarin were atrial fibrillation (75.6%) and venous thromboembolic disease (14.9%). A therapeutic INR was observed in 88 patients (43.8%; 95% CI 37.1 to 50.7), while 45 patients (22.4%; 95% CI 17.2 to 28.7) and 68 patients (33.8%; 95% CI 27.6 to 40.6) had subtherapeutic and supratherapeutic INRs, respectively. Overall, there were 28 (18 major and 10 minor) bleeding complications (13.9%; 95% CI 9.8 to 19.4) and 4 thromboembolic events (2.0%; 95% CI 0.6 to 5.2). Among patients with a bleeding complication, 14 (50.0%) had a supratherapeutic INR, while 2 patients who experienced a thromboembolic event (50.0%) had a subtherapeutic INR.
AB  - CONCLUSIONS: The majority of patients receiving warfarin on presentation to the ED had INRs outside the desired therapeutic range. By establishing the impact of warfarin-related adverse events in this population, focused interventions can be established in this setting to address factors that can be targeted to reduce these events.
RN  - 0 (Anticoagulants)
RN  - 12001-79-5 (Vitamin K)
RN  - 5Q7ZVV76EI (Warfarin)
ES  - 1542-6270
IL  - 1060-0280
DO  - http://dx.doi.org/10.1345/aph.1P670
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20110712
DP  - 2011 Jul
DC  - 20110722
YR  - 2011
ED  - 20111207
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21750309

<391. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21712508
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Denetclaw TH
AU  - Oshima N
AU  - Dowling TC
FA  - Denetclaw, Tina H
FA  - Oshima, Nancy
FA  - Dowling, Thomas C
IN  - Denetclaw,Tina H. Pharmacy Department, Marin General Hospital, Greenbrae, CA, USA. denetclawt@pharmacy.ucsf.edu
TI  - Dofetilide dose calculation errors in elderly associated with use of the modification of diet in renal disease equation.
SO  - Annals of Pharmacotherapy. 45(7-8):e44, 2011 Jul.
AS  - Ann Pharmacother. 45(7-8):e44, 2011 Jul.
NJ  - The Annals of pharmacotherapy
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - bbx, 9203131
SB  - Index Medicus
CP  - United States
MH  - Aged, 80 and over
MH  - *Anti-Arrhythmia Agents/ad [Administration & Dosage]
MH  - Anti-Arrhythmia Agents/ae [Adverse Effects]
MH  - Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/me [Metabolism]
MH  - Atrial Fibrillation/th [Therapy]
MH  - Combined Modality Therapy
MH  - Creatinine/bl [Blood]
MH  - Creatinine/me [Metabolism]
MH  - *Drug Dosage Calculations
MH  - Electric Countershock
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Humans
MH  - Male
MH  - Medication Errors/ae [Adverse Effects]
MH  - *Medication Errors/pc [Prevention & Control]
MH  - *Phenethylamines/ad [Administration & Dosage]
MH  - Phenethylamines/ae [Adverse Effects]
MH  - Phenethylamines/tu [Therapeutic Use]
MH  - Renal Insufficiency, Chronic/co [Complications]
MH  - *Renal Insufficiency, Chronic/dh [Diet Therapy]
MH  - Severity of Illness Index
MH  - *Sulfonamides/ad [Administration & Dosage]
MH  - Sulfonamides/ae [Adverse Effects]
MH  - Sulfonamides/tu [Therapeutic Use]
AB  - OBJECTIVE: To report 2 cases of drug dosage calculation errors that occurred when the Modification of Diet in Renal Disease (MDRD) equation was used for initiating drug therapy with dofetilide in elderly patients with chronic kidney disease.
AB  - CASE SUMMARY: An 83-year-old woman and a 92-year-old man were admitted for dofetilide treatment initiation and cardioversion for atrial fibrillation. The estimated glomerular filtration rate (eGFR) determined with use of the MDRD equation was significantly higher than the estimated creatinine clearance (eCrCl) determined with use of the Cockcroft-Gault equation for both cases (85 vs 43 mL/min for the man and 40 vs 24 mL/min for the woman). Initial dofetilide dosages calculated by the MDRD equation were 2-fold higher than those calculated by eCrCl in both cases. Initiation of dose based on the MDRD in the first patient led to a 32% increase in the QTc interval from baseline. Dofetilide therapy was adjusted for QTc interval prolongation based on eCrCl and reinitiated at a lower dose, and the patient did not develop further significant increases in the QTc interval. In the second patient, the lower dose based on eCrCl was initiated and the QTc interval remained within an acceptable range.
AB  - DISCUSSION: The initial dosing of dofetilide is based on eCrCl as specified by the drug manufacturer. Recent widespread use and automated reporting of the eGFR by clinical laboratories has tempted some clinicians to consider using eGFR for calculating drug doses. However, recent data suggest that the eGFR, calculated by the MDRD equation, consistently overestimates eCrCl, leading to dose discrepancies, particularly in the elderly. The cases reported here illustrate the drug dose calculation errors that may occur when using the MDRD equation for initiating doses of dofetilide.
AB  - CONCLUSIONS: Use of the eGFR or MDRD equation for calculation of doses in renal dysfunction has not been validated, and significant drug dose errors have been reported. The use of eGFR to calculate doses of dofetilide should be avoided.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Phenethylamines)
RN  - 0 (Sulfonamides)
RN  - 115256-11-6 (dofetilide)
RN  - AYI8EX34EU (Creatinine)
ES  - 1542-6270
IL  - 1060-0280
DO  - http://dx.doi.org/10.1345/aph.1Q159
PT  - Case Reports
PT  - Journal Article
LG  - English
EP  - 20110628
DP  - 2011 Jul
DC  - 20110722
YR  - 2011
ED  - 20111207
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21712508

<392. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20929979
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Diller GP
AU  - Giardini A
AU  - Dimopoulos K
AU  - Gargiulo G
AU  - Muller J
AU  - Derrick G
AU  - Giannakoulas G
AU  - Khambadkone S
AU  - Lammers AE
AU  - Picchio FM
AU  - Gatzoulis MA
AU  - Hager A
FA  - Diller, Gerhard-Paul
FA  - Giardini, Alessandro
FA  - Dimopoulos, Konstantinos
FA  - Gargiulo, Gaetano
FA  - Muller, Jan
FA  - Derrick, Graham
FA  - Giannakoulas, Georgios
FA  - Khambadkone, Sachin
FA  - Lammers, Astrid E
FA  - Picchio, Fernando Maria
FA  - Gatzoulis, Michael A
FA  - Hager, Alfred
IN  - Diller,Gerhard-Paul. Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital and the National Heart & Lung Institute, Imperial College of Science and Medicine, Sydney Street, SW3 6NP London, UK. g.diller@imperial.ac.uk
TI  - Predictors of morbidity and mortality in contemporary Fontan patients: results from a multicenter study including cardiopulmonary exercise testing in 321 patients.
SO  - European Heart Journal. 31(24):3073-83, 2010 Dec.
AS  - Eur Heart J. 31(24):3073-83, 2010 Dec.
NJ  - European heart journal
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - em8, 8006263
SB  - Index Medicus
CP  - England
MH  - Adolescent
MH  - Adult
MH  - Death, Sudden, Cardiac/ep [Epidemiology]
MH  - Exercise Test
MH  - Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - *Fontan Procedure/mo [Mortality]
MH  - Germany/ep [Epidemiology]
MH  - Heart Defects, Congenital/mo [Mortality]
MH  - *Heart Defects, Congenital/su [Surgery]
MH  - Heart Transplantation/sn [Statistics & Numerical Data]
MH  - Hospitalization/sn [Statistics & Numerical Data]
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Prognosis
MH  - Retrospective Studies
MH  - Young Adult
AB  - AIMS: previous studies have established an association between exercise intolerance and increased morbidity and mortality in congenital heart disease patients. We aimed to clarify if exercise intolerance is associated with poor outcome in Fontan patients and to identify risk factors for mortality, transplantation, and cardiac-related hospitalization.
AB  - METHODS AND RESULTS: a total of 321 Fontan patients (57% male, mean age 20.9 +/- 8.6 years) who underwent cardiopulmonary exercise testing (CPET) at four major European centres between 1997 and 2008 were included. During a median follow-up of 21 months, 22 patients died and 6 patients underwent cardiac transplantation (8.7%), resulting in an estimated 5-year transplant-free survival of 86%. Parameters of CPET were strongly related to increased risk of hospitalization, but-with the exception of heart rate reserve-unrelated to risk of death or transplantation. In contrast, patients with clinically relevant arrhythmia had a 6.0-fold increased risk of death or transplantation (P < 0.001). Furthermore, patients with atriopulmonary/-ventricular Fontan had a 3.7-fold increased risk of death or transplantation compared with total cavopulmonary connection patients (P= 0.009). The combination of clinically relevant arrhythmia, atriopulmonary/-ventricular Fontan, and signs of symptomatic or decompensated heart failure was associated with a particularly poor outcome (3-year mortality 25%).
AB  - CONCLUSION: on short-term follow-up, most parameters of CPET are associated with increased risk of hospitalization but not death or transplantation in contemporary Fontan patients. Only decreased heart rate reserve and a history of clinically relevant arrhythmia, atriopulmonary/-ventricular Fontan, and/or heart failure requiring diuretic therapy are associated with poor prognosis, potentially identifying patients requiring medical and/or surgical attention.
ES  - 1522-9645
IL  - 0195-668X
DO  - http://dx.doi.org/10.1093/eurheartj/ehq356
PT  - Journal Article
PT  - Multicenter Study
LG  - English
EP  - 20101007
DP  - 2010 Dec
DC  - 20101215
YR  - 2010
ED  - 20111207
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20929979

<393. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21861537
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Camm AJ
AU  - Bounameaux H
FA  - Camm, A John
FA  - Bounameaux, Henri
IN  - Camm,A John. Division of Clinical Sciences, St Georges University of London, UK. jcamm@sgul.ac.uk
TI  - Edoxaban: a new oral direct factor xa inhibitor.
SO  - Drugs. 71(12):1503-26, 2011 Aug 20.
AS  - Drugs. 71(12):1503-26, 2011 Aug 20.
NJ  - Drugs
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - ec2, 7600076
SB  - Index Medicus
CP  - New Zealand
MH  - Administration, Oral
MH  - Animals
MH  - Anticoagulants/ad [Administration & Dosage]
MH  - *Anticoagulants/pd [Pharmacology]
MH  - Atrial Fibrillation/co [Complications]
MH  - Blood Coagulation/de [Drug Effects]
MH  - Clinical Trials as Topic
MH  - *Factor Xa Inhibitors
MH  - Humans
MH  - Pyridines/ad [Administration & Dosage]
MH  - *Pyridines/pd [Pharmacology]
MH  - Rabbits
MH  - Rats
MH  - Stroke/et [Etiology]
MH  - *Stroke/pc [Prevention & Control]
MH  - Thiazoles/ad [Administration & Dosage]
MH  - *Thiazoles/pd [Pharmacology]
MH  - Venous Thrombosis/et [Etiology]
MH  - *Venous Thrombosis/pc [Prevention & Control]
AB  - Edoxaban is an oral direct factor Xa inhibitor that is currently undergoing investigation in phase III clinical trials for the prevention of stroke in patients with atrial fibrillation (AF) and for the prevention and treatment of venous thromboembolic events (VTE). Factor Xa is an attractive target for anticoagulant treatment, as it is the primary and rate-limiting source of amplification in the coagulation cascade. Edoxaban is a competitive inhibitor of factor Xa and has >10000-fold greater selectivity for factor Xa relative to thrombin. In phase I clinical trials, the anticoagulant effects of edoxaban included dose-dependent increases in activated partial thromboplastin time and prothrombin time following single edoxaban doses of 10-150mg and after multiple ascending doses (60mg twice daily, 90mg daily and 120mg daily). The anticoagulant effects of edoxaban were rapid in onset (time to peak plasma concentration 1-2 hours) and sustained for up to 24 hours. Prolongation of bleeding time in 8% of subjects was >9.5 minutes (none of which appeared to be clinically significant) 2 hours after initial dosing, and was independent of edoxaban dose, formulation or dietary state. In general, plasma edoxaban concentrations were linearly correlated with coagulation parameters. Phase II clinical trials in patients with AF and VTE suggest that the edoxaban 30mg once-daily and 60mg once-daily regimens had a similar or better safety profile compared with dose-adjusted warfarin (international normalized ratio 2.0-3.0) in terms of bleeding events, and that edoxaban was not associated with hepatotoxicity. In addition, edoxaban was associated with statistically significant dose-dependent reductions in VTE after orthopaedic surgery compared with placebo or dalteparin sodium. Further clinical investigation of the efficacy and safety of once-daily edoxaban is being conducted in phase III clinical trials in comparison with warfarin in patients with AF in the phase III ENGAGE AF-TIMI 48 trial (NCT00781391), and in comparison with low-molecular weight heparin/warfarin in the prevention of recurrent VTE in patients with symptomatic deep vein thrombosis and/or pulmonary embolism in the HOKUSAI VTE trial (NCT00986154).
RN  - 0 (Anticoagulants)
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (Thiazoles)
RN  - 480449-70-5 (edoxaban)
IS  - 0012-6667
IL  - 0012-6667
DO  - http://dx.doi.org/10.2165/11595540-000000000-00000
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
SI  - ClinicalTrials.gov
SA  - ClinicalTrials.gov/NCT00986154
SL  - http://clinicaltrials.gov/search/term=NCT00986154
LG  - English
DP  - 2011 Aug 20
DC  - 20110824
YR  - 2011
ED  - 20111206
RD  - 20141120
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21861537

<394. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21809971
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mattioli AV
FA  - Mattioli, Anna Vittoria
IN  - Mattioli,Anna Vittoria. Department of Biomedical Science, University of Modena and RE, Via del Pozzo 71, Modena 41100, Italy. annavittoria.mattioli@unimore.it
TI  - Lifestyle and atrial fibrillation. [Review]
SO  - Expert Review of Cardiovascular Therapy. 9(7):895-902, 2011 Jul.
AS  - Expert Rev Cardiovasc Ther. 9(7):895-902, 2011 Jul.
NJ  - Expert review of cardiovascular therapy
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101182328
SB  - Index Medicus
CP  - England
MH  - Animals
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - *Diet, Mediterranean
MH  - Health Behavior
MH  - Humans
MH  - *Life Style
MH  - Obesity/co [Complications]
MH  - Risk Factors
MH  - Ventricular Dysfunction/co [Complications]
AB  - Lifestyle factors, in particular dietary intake, have been recognized as important, modifiable risk factors for cardiovascular disease. Consuming a heart-healthy diet lowers the individual's risk for cardiovascular disease. Data on the relationship between lifestyle and atrial fibrillation are controversial; however, the strong association between obesity, atrial/ventricular dysfunction and a nonhealthy lifestyle and atrial fibrillation, suggests that a correction of nutritional habits could prevent the development of arrhythmias through a reduction of underlying cardiac diseases. Today, the Mediterranean diet is considered one of the most effective in terms of its prevention of cardiovascular disease.
ES  - 1744-8344
IL  - 1477-9072
DO  - http://dx.doi.org/10.1586/erc.11.92
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2011 Jul
DC  - 20110803
YR  - 2011
ED  - 20111122
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21809971

<395. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21762871
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Farquharson AL
AU  - Metcalf RG
AU  - Sanders P
AU  - Stuklis R
AU  - Edwards JR
AU  - Gibson RA
AU  - Cleland LG
AU  - Sullivan TR
AU  - James MJ
AU  - Young GD
FA  - Farquharson, Aaron L
FA  - Metcalf, Robert G
FA  - Sanders, Prashanthan
FA  - Stuklis, Robert
FA  - Edwards, James R M
FA  - Gibson, Robert A
FA  - Cleland, Leslie G
FA  - Sullivan, Thomas R
FA  - James, Michael J
FA  - Young, Glenn D
IN  - Farquharson,Aaron L. Discipline of Medicine, University of Adelaide, Adelaide, Australia.
TI  - Effect of dietary fish oil on atrial fibrillation after cardiac surgery.
SO  - American Journal of Cardiology. 108(6):851-6, 2011 Sep 15.
AS  - Am J Cardiol. 108(6):851-6, 2011 Sep 15.
NJ  - The American journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - *Cardiac Surgical Procedures
MH  - Dietary Supplements
MH  - Double-Blind Method
MH  - Female
MH  - *Fish Oils/tu [Therapeutic Use]
MH  - Humans
MH  - Incidence
MH  - Intensive Care Units/sn [Statistics & Numerical Data]
MH  - Length of Stay/sn [Statistics & Numerical Data]
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Placebos
MH  - *Postoperative Complications/pc [Prevention & Control]
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Treatment Outcome
AB  - An open-label study reported that ingestion of a fish oil concentrate decreased the incidence of atrial fibrillation (AF) after coronary artery bypass grafting (CABG) surgery. However, a general cardiac surgery population involves valve and CABG surgeries. We undertook a double-blinded randomized controlled trial to examine the effectiveness of fish oil supplementation on the incidence of postsurgical AF after CABG and valve procedures. The primary end point was incidence of AF in the first 6 days after surgery. Two hundred patients were randomized to receive fish oil (providing 4.6 g/day of long-chain omega-3 fatty acids) or a control oil starting 3 weeks before surgery; 194 subjects completed the study, with 47 of 97 subjects in the control group and 36 of 97 subjects in the fish oil group developing AF (odds ratio 0.63, 95% confidence interval [CI] 0.35 to 1.11). There was a nonstatistically significant delay in time to onset of AF in the fish oil group (hazard ratio 0.66, 95% CI 0.43 to 1.01). There was a significant decrease in mean length of stay in the intensive care unit in the fish oil group (ratio of means 0.71, 95% CI 0.56 to 0.90). In conclusion, in a mixed cardiac surgery population, supplementation with dietary fish oil did not result in a significant decrease in the incidence of postsurgical AF. However, there was a significant decrease in time spent in the intensive care unit.Copyright © 2011 Elsevier Inc. All rights reserved.
RN  - 0 (Fish Oils)
RN  - 0 (Placebos)
ES  - 1879-1913
IL  - 0002-9149
DO  - http://dx.doi.org/10.1016/j.amjcard.2011.04.036
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20110715
DP  - 2011 Sep 15
DC  - 20110902
YR  - 2011
ED  - 20111031
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21762871

<396. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21765246
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Giaccardi M
AU  - Macchi C
AU  - Colella A
AU  - Polcaro P
AU  - Zipoli R
AU  - Cecchi F
AU  - Valecchi D
AU  - Sofi F
AU  - Petrilli M
AU  - Molino-Lova R
FA  - Giaccardi, Marzia
FA  - Macchi, Claudio
FA  - Colella, Andrea
FA  - Polcaro, Paola
FA  - Zipoli, Renato
FA  - Cecchi, Francesca
FA  - Valecchi, Debora
FA  - Sofi, Francesco
FA  - Petrilli, Mario
FA  - Molino-Lova, Raffaele
IN  - Giaccardi,Marzia. Cardiac Rehabilitation Unit, Don Gnocchi Foundation, Florence, Italy.
TI  - Postacute rehabilitation after coronary surgery: the effect of preoperative physical activity on the incidence of paroxysmal atrial fibrillation.
SO  - American Journal of Physical Medicine & Rehabilitation. 90(4):308-15, 2011 Apr.
AS  - Am J Phys Med Rehabil. 90(4):308-15, 2011 Apr.
NJ  - American journal of physical medicine & rehabilitation / Association of Academic Physiatrists
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 8803677, ajo
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Cardiovascular Diseases/co [Complications]
MH  - Cardiovascular Diseases/pp [Physiopathology]
MH  - Cardiovascular Diseases/th [Therapy]
MH  - Cohort Studies
MH  - *Coronary Artery Bypass/rh [Rehabilitation]
MH  - Exercise
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Life Style
MH  - Male
MH  - *Motor Activity
MH  - *Postoperative Complications
MH  - *Rehabilitation Centers
MH  - Risk Factors
MH  - Telemetry
AB  - OBJECTIVE: Postoperative atrial fibrillation (AF) is a frequent complication after cardiac surgery. AF may also occur after hospital discharge during postacute rehabilitation. Several studies have addressed the AF that occurs in the hospital after surgery, and predictors have already been identified. Postoperative AF that occurs after hospital discharge has not been investigated thoroughly, and predictors are still unknown. In this study, we hypothesized that moderate-intensity physical activity in the year before surgery might favorably affect the incidence of AF during postacute rehabilitation.
AB  - DESIGN: We tested our hypothesis in a cohort of 158 older patients admitted to a medical rehabilitation facility for postacute inpatient rehabilitation after coronary surgery and continuously monitored by telemetry for the duration of the rehabilitation.
AB  - RESULTS: Independent of potential confounders, patients who reported low-intensity physical activity in the year before surgery showed a significantly higher incidence of AF during postacute rehabilitation when compared with those who reported moderate-intensity physical activity (32.1% vs. 8.1%; P = 0.029). Other independent predictors of AF during postacute rehabilitation were the occurrence of AF during the patients' stay in hospital, larger left atrial volume, and lower left atrial emptying fraction.
AB  - CONCLUSIONS: These findings confirm our hypothesis that physical activity in the year before surgery affects the incidence of postoperative AF during postacute rehabilitation. The results also provide information regarding possible predictors that may assist in identifying patients who could benefit from preventive treatments.
ES  - 1537-7385
IL  - 0894-9115
DO  - http://dx.doi.org/10.1097/PHM.0b013e31820f9535
PT  - Journal Article
LG  - English
DP  - 2011 Apr
DC  - 20110718
YR  - 2011
ED  - 20111024
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21765246

<397. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21533567
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Bendel SD
AU  - Bona R
AU  - Baker WL
FA  - Bendel, Stephen D
FA  - Bona, Robert
FA  - Baker, William L
IN  - Bendel,Stephen D. Schools of Pharmacy and Medicine, Storrs and Farmington CT & Department of Hematology-Oncology, University of Connecticut, Farmington, USA.
TI  - Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation. [Review]
SO  - Advances in Therapy. 28(6):460-72, 2011 Jun.
AS  - Adv Ther. 28(6):460-72, 2011 Jun.
NJ  - Advances in therapy
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - bcb, 8611864
SB  - Health Technology Assessment Journals
CP  - United States
MH  - Age Factors
MH  - Antithrombins/ae [Adverse Effects]
MH  - Antithrombins/pk [Pharmacokinetics]
MH  - *Antithrombins/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Benzimidazoles/ae [Adverse Effects]
MH  - Benzimidazoles/pk [Pharmacokinetics]
MH  - *Benzimidazoles/tu [Therapeutic Use]
MH  - Dabigatran
MH  - Drug Interactions
MH  - Electric Countershock
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - beta-Alanine/ae [Adverse Effects]
MH  - *beta-Alanine/aa [Analogs & Derivatives]
MH  - beta-Alanine/pk [Pharmacokinetics]
MH  - beta-Alanine/tu [Therapeutic Use]
AB  - Atrial fibrillation (AF) is well known as one of the leading causes of stroke and systemic embolism. Anticoagulation therapy is recommended in all patients at moderate-to-high risk of stroke. The vitamin K antagonist warfarin has traditionally been used in these patients but presents challenges in dosing and monitoring in these patients. The oral direct thrombin inhibitor dabigatran etexilate (Pradaxa; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA) was recently approved for use in the US for preventing stroke and systemic embolism in patients with nonvalvular AF. Clinical trials have shown it to reduce the risk of stroke and systemic embolism when compared with warfarin (goal international normalized ratio [INR] 2-3) with a similar risk for severe bleeding. It can be given twice daily, with the dose adjusted for renal function. It does not have any dietary restrictions, has few drug interactions (except involving permeability [P]-glycoprotein [P-gp] agents), and does not require routine laboratory monitoring. Patients may experience significant dyspepsia with its use. Compared with warfarin there is increased risk for gastrointestinal bleeding and perhaps myocardial infarction. Currently, no reversal agent exists for use in situations of overdose or severe bleeding although some strategies have been suggested. Despite its high acquisition cost compared with warfarin, analysis using theoretical models has shown it to be cost-effective. Dabigatran offers a unique alternative to warfarin in patients with nonvalvular AF and can be beneficial in patients requiring anticoagulation therapy.
RN  - 0 (Antithrombins)
RN  - 0 (Benzimidazoles)
RN  - 11P2JDE17B (beta-Alanine)
RN  - I0VM4M70GC (Dabigatran)
ES  - 1865-8652
IL  - 0741-238X
DO  - http://dx.doi.org/10.1007/s12325-011-0025-1
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20110426
DP  - 2011 Jun
DC  - 20110601
YR  - 2011
ED  - 20110927
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21533567

<398. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21394305
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Park JH
AU  - Jegal Y
AU  - Shim TS
AU  - Lim CM
AU  - Lee SD
AU  - Koh Y
AU  - Kim WS
AU  - Kim WD
AU  - du Bois R
AU  - Do KH
AU  - Kim DS
FA  - Park, Jeong Hyun
FA  - Jegal, Yangjin
FA  - Shim, Tae Sun
FA  - Lim, Chae-Man
FA  - Lee, Sang Do
FA  - Koh, Younsuck
FA  - Kim, Woo Sung
FA  - Kim, Won Dong
FA  - du Bois, Roland
FA  - Do, Kyung-Hyun
FA  - Kim, Dong Soon
IN  - Park,Jeong Hyun. Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan, College of Medicine, 86 Asanbyeongwon-gil, Seoul, Korea.
TI  - Hypoxemia and arrhythmia during daily activities and six-minute walk test in fibrotic interstitial lung diseases.
SO  - Journal of Korean Medical Science. 26(3):372-8, 2011 Mar.
AS  - J Korean Med Sci. 26(3):372-8, 2011 Mar.
NJ  - Journal of Korean medical science
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - ah4, 8703518
OI  - Source: NLM. PMC3051084
SB  - Index Medicus
CP  - Korea (South)
MH  - *Activities of Daily Living
MH  - Aged
MH  - *Anoxia/pp [Physiopathology]
MH  - *Arrhythmias, Cardiac/pp [Physiopathology]
MH  - Dyspnea/pp [Physiopathology]
MH  - Electrocardiography, Ambulatory
MH  - Exercise Test
MH  - Exercise Tolerance
MH  - Female
MH  - Humans
MH  - *Lung Diseases, Interstitial/pp [Physiopathology]
MH  - Male
MH  - Middle Aged
MH  - *Motor Activity/ph [Physiology]
MH  - Oximetry
MH  - Respiratory Function Tests
MH  - Sleep
MH  - Walking
KW  - Anoxia;  Arrhythmias, Cardiac;  Lung Diseases, Interstitial;  Six-Minute Walk Test
AB  - We performed 24-hr monitoring of pulse oximetric saturation (SpO(2)) with ECG and six-minute walk test (6MWT) in 19 patients with fibrotic interstitial lung diseases (ILD) to investigate; 1) The frequency and severity of hypoxemia and dysrhythmia during daily activities and 6MWT, 2) safety of 6MWT, and 3) the parameters of 6MWT which can replace 24-hr continuous monitoring of SpO(2) to predict hypoxemia during daily activities. All patients experienced waking hour hypoxemia, and eight of nineteen patients spent > 10% of waking hours in hypoxemic state. Most patients experienced frequent arrhythmia, mostly atrial premature contractions (APCs) and ventricular premature contractions (VPCs). There were significant correlation between the variables of 6MWT and hypoxemia during daily activities. All of the patients who desaturated below 80% before 300 meters spent more than 10% of waking hour in hypoxemia (P = 0.018). In contrast to waking hour hypoxemia, SpO(2) did not drop significantly during sleep except in the patients whose daytime resting SpO(2) was already low. In conclusion, patients with fibrotic ILD showed significant period of hypoxemia during daily activities and frequent VPCs and APCs. Six-minute walk test is a useful surrogate marker of waking hour hypoxemia and seems to be safe without continuous monitoring of SpO(2).
ES  - 1598-6357
IL  - 1011-8934
DO  - http://dx.doi.org/10.3346/jkms.2011.26.3.372
PT  - Journal Article
LG  - English
EP  - 20110225
DP  - 2011 Mar
DC  - 20110311
YR  - 2011
ED  - 20110916
RD  - 20150204
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21394305

<399. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20167459
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mattioli AV
AU  - Farinetti A
AU  - Miloro C
AU  - Pedrazzi P
AU  - Mattioli G
FA  - Mattioli, A V
FA  - Farinetti, A
FA  - Miloro, C
FA  - Pedrazzi, P
FA  - Mattioli, G
IN  - Mattioli,A V. Department of Biomedical Science, Section of Cardiology, University of Modena and Reggio Emilia, Via del pozzo, 71, 41100 Modena, Italy. annavittoria.mattioli@unimore.it
TI  - Influence of coffee and caffeine consumption on atrial fibrillation in hypertensive patients.
SO  - Nutrition Metabolism & Cardiovascular Diseases. 21(6):412-7, 2011 Jun.
AS  - Nutr Metab Cardiovasc Dis. 21(6):412-7, 2011 Jun.
NJ  - Nutrition, metabolism, and cardiovascular diseases : NMCD
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9111474, DGW
SB  - Index Medicus
CP  - Netherlands
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation/pa [Pathology]
MH  - Blood Pressure
MH  - *Caffeine/ad [Administration & Dosage]
MH  - *Coffee/ae [Adverse Effects]
MH  - *Disease Progression
MH  - Electrocardiography
MH  - Female
MH  - Humans
MH  - *Hypertension/et [Etiology]
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Risk Factors
MH  - Surveys and Questionnaires
AB  - BACKGROUND AND AIMS: Coffee and caffeine are widely consumed in Western countries. Little information is available on the influence of coffee and caffeine consumption on atrial fibrillation (AF) in hypertensive patients. We sought to investigate the relationship between coffee consumption and atrial fibrillation with regard to spontaneous conversion of arrhythmia.
AB  - METHODS AND RESULTS: A group of 600 patients presenting with a first known episode of AF was investigated, and we identified 247 hypertensive patients. The prevalence of nutritional parameters was assessed with a food frequency questionnaire. Coffee and caffeine intake were specifically estimated. Left ventricular hypertrophy was evaluated by electrocardiogram (ECG) and echocardiogram. Coffee consumption was higher in normotensive patients. High coffee consumers were more frequent in normotensive patients compared with hypertensive patients. On the other hand, the intake of caffeine was similar in hypertensive and normotensive patients, owing to a higher intake in hypertensive patients from sources other than coffee. Within normotensive patients, we report that non-habitual and low coffee consumers showed the highest probability of spontaneous conversion (OR 1.93 95%CI 0.88-3.23; p=0.001), whereas, within hypertensive patients, moderate but not high coffee consumers had the lowest probability of spontaneous conversion (OR 1.13 95%CI 0.67-1.99; p=0.05).
AB  - CONCLUSION: Coffee and caffeine consumption influence spontaneous conversion of atrial fibrillation. Normotensive non-habitual coffee consumers are more likely to convert arrhythmia within 48h from the onset of symptoms. Hypertensive patients showed a U-shaped relationship between coffee consumption and spontaneous conversion of AF, moderate coffee consumers were less likely to show spontaneous conversion of arrhythmia. Patients with left ventricular hypertrophy showed a reduced rate of spontaneous conversion of arrhythmia.Copyright © 2009 Elsevier B.V. All rights reserved.
RN  - 0 (Coffee)
RN  - 3G6A5W338E (Caffeine)
ES  - 1590-3729
IL  - 0939-4753
DO  - http://dx.doi.org/10.1016/j.numecd.2009.11.003
PT  - Journal Article
LG  - English
EP  - 20100218
DP  - 2011 Jun
DC  - 20110517
YR  - 2011
ED  - 20110908
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20167459

<400. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21345648
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Punjani S
AU  - Wu WC
AU  - Cohen S
AU  - Sharma SC
AU  - Choudhary G
FA  - Punjani, Shahnaz
FA  - Wu, Wen-Chih
FA  - Cohen, Scott
FA  - Sharma, Satish C
FA  - Choudhary, Gaurav
IN  - Punjani,Shahnaz. Vascular Research Laboratory, Providence VA Medical Center, Providence, Rhode Island 02908, USA.
TI  - Echocardiographic indices of diastolic function relate to functional capacity and quality of life in ambulatory men with atrial fibrillation.
SO  - Journal of the American Society of Echocardiography. 24(5):533-540.e3, 2011 May.
AS  - J Am Soc Echocardiogr. 24(5):533-540.e3, 2011 May.
NJ  - Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - aof, 8801388
SB  - Index Medicus
CP  - United States
MH  - Acceleration
MH  - Aged
MH  - Atrial Fibrillation/pa [Pathology]
MH  - Atrial Fibrillation/px [Psychology]
MH  - *Atrial Fibrillation/us [Ultrasonography]
MH  - Confidence Intervals
MH  - Diastole
MH  - Echocardiography, Doppler
MH  - Exercise Test
MH  - Health Services
MH  - Health Status Indicators
MH  - Humans
MH  - Male
MH  - Odds Ratio
MH  - *Quality of Life
MH  - Reproducibility of Results
MH  - Statistics as Topic
MH  - Surveys and Questionnaires
MH  - Veterans
MH  - *Walking
AB  - OBJECTIVE: We sought to explore the reliability of echocardiographic parameters of diastolic function and determine their relationship with functional capacity (New York Heart Association [NYHA] class and 6-minute walk test [6MWT]) and the domains of a health-related quality of life (HR-QOL) questionnaire (Veterans RAND 36-Item Health Survey) in a cohort of ambulatory patients with atrial fibrillation (AF).
AB  - METHODS: Forty-eight male veterans with persistent or permanent AF underwent clinical examination, echocardiography, and 6MWT, and filled out a Veterans RAND 36-Item Health Survey questionnaire at two visits 1 week apart. Pairwise correlation was performed to evaluate the reliability of echocardiographic parameters and multiple regression analyses to assess the association of these parameters with functional capacity and HR-QOL.
AB  - RESULTS: E/e' average had the highest correlation between the two visits (coefficient: 0.87) and had a significant relationship with NYHA, 6MWT, and physical functioning domain of HR-QOL even after adjusting for confounding variables (odds of NYHA >1: OR 1.5, 95% CI, 1.2-1.9; 6MWT coefficient: -31 +/- 9 ft; physical functioning score coefficient: -1.7 +/- 0.7).
AB  - CONCLUSION: Average E/e' is a reliable diastolic function parameter that also independently relates with functional capacity and HR-QOL in ambulatory patients with atrial fibrillation.Copyright Published by Mosby, Inc.
ES  - 1097-6795
IL  - 0894-7317
DO  - http://dx.doi.org/10.1016/j.echo.2011.01.008
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Validation Studies
LG  - English
EP  - 20110222
DP  - 2011 May
DC  - 20110425
YR  - 2011
ED  - 20110901
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21345648

<401. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21385466
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Rosenfeldt F
AU  - Braun L
AU  - Spitzer O
AU  - Bradley S
AU  - Shepherd J
AU  - Bailey M
AU  - van der Merwe J
AU  - Leong JY
AU  - Esmore D
FA  - Rosenfeldt, Franklin
FA  - Braun, Lesley
FA  - Spitzer, Ondine
FA  - Bradley, Scott
FA  - Shepherd, Judy
FA  - Bailey, Michael
FA  - van der Merwe, Juliana
FA  - Leong, Jee-Yoong
FA  - Esmore, Donald
IN  - Rosenfeldt,Franklin. Cardiac Surgical Research Unit, Alfred Hospital, Department of Surgery, Monash University, Baker IDI Institute Melbourne, Australia. f.rosenfeldt@alfred.org.au
TI  - Physical conditioning and mental stress reduction--a randomised trial in patients undergoing cardiac surgery.
SO  - BMC Complementary & Alternative Medicine. 11:20, 2011.
AS  - BMC Altern Med. 11:20, 2011.
NJ  - BMC complementary and alternative medicine
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 101088661
OI  - Source: NLM. PMC3063826
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/th [Therapy]
MH  - *Cardiac Surgical Procedures/px [Psychology]
MH  - Coronary Artery Bypass
MH  - Evaluation Studies as Topic
MH  - *Exercise Therapy
MH  - Female
MH  - Heart Diseases/su [Surgery]
MH  - Heart Valves/su [Surgery]
MH  - *Holistic Health
MH  - Humans
MH  - Length of Stay
MH  - Male
MH  - Middle Aged
MH  - *Mind-Body Therapies
MH  - Outcome Assessment (Health Care)
MH  - *Physical Fitness
MH  - Postoperative Complications/th [Therapy]
MH  - *Preoperative Care/mt [Methods]
MH  - Quality of Life
MH  - Standard of Care
MH  - *Stress, Psychological/th [Therapy]
MH  - Surveys and Questionnaires
AB  - BACKGROUND: Preoperative anxiety and physical unfitness have been shown to have adverse effects on recovery from cardiac surgery. This study involving cardiac surgery patients was primarily aimed at assessing the feasibility of delivering physical conditioning and stress reduction programs within the public hospital setting. Secondary aims were to evaluate the effect of these programs on quality of life (QOL), rates of postoperative atrial fibrillation (AF) and length of stay (LOS) in hospital.
AB  - METHODS: Elective patients scheduled for coronary artery bypass graft and/or valve surgery at a public hospital in Melbourne, Australia were enrolled. Patients were randomized to receive either holistic therapy (HT) or usual care (UC). HT consisted of a series of light physical exercise sessions together with a mental stress reduction program administered in an outpatient setting for the first two weeks after placement on the waiting list for surgery. A self-administered SF-36 questionnaire was used to measure QOL and hospital records to collect data on LOS and rate of postoperative AF.
AB  - RESULTS: The study population comprised 117 patients of whom 60 received HT and 57 received UC. Both programs were able to be delivered within the hospital setting but ongoing therapy beyond the two week duration of the program was not carried out due to long waiting periods and insufficient resources. HT, as delivered in this study, compared to UC did not result in significant changes in QOL, LOS or AF incidence.
AB  - CONCLUSIONS: Preoperative holistic therapy can be delivered in the hospital setting, although two weeks is insufficient to provide benefits beyond usual care on QOL, LOS or postoperative AF. Further research is now required to determine whether a similar program of longer duration, or targeted to high risk patients can provide measurable benefits.
AB  - TRIAL REGISTRATION: This trial was conducted as part of a larger study and according to the principles contained in the CONSORT statement 2001.
ES  - 1472-6882
IL  - 1472-6882
DO  - http://dx.doi.org/10.1186/1472-6882-11-20
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20110309
DP  - 2011
DC  - 20110325
YR  - 2011
ED  - 20110825
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21385466

<402. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21273106
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Vischer UM
AU  - Giannelli SV
AU  - Weiss L
AU  - Perrenoud L
AU  - Frangos E
AU  - Herrmann FR
FA  - Vischer, U M
FA  - Giannelli, S V
FA  - Weiss, L
FA  - Perrenoud, L
FA  - Frangos, E
FA  - Herrmann, F R
IN  - Vischer,U M. Department of Rehabilitation and Geriatrics, hopital des Trois-Chene, Geneva University Hospitals, 3, chemin du Pont-Bochet, 1226 Thonex, Switzerland. ulrich.vischer@hcuge.ch
TI  - The prevalence, characteristics and metabolic consequences of renal insufficiency in very old hospitalized diabetic patients.
SO  - Diabetes & Metabolism. 37(2):131-8, 2011 Apr.
AS  - Diabetes Metab. 37(2):131-8, 2011 Apr.
NJ  - Diabetes & metabolism
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - cki, 9607599
SB  - Index Medicus
CP  - France
MH  - Aged
MH  - Aged, 80 and over
MH  - Albuminuria/ep [Epidemiology]
MH  - Atrial Fibrillation/co [Complications]
MH  - Blood Glucose/an [Analysis]
MH  - C-Reactive Protein
MH  - Cholesterol, HDL/bl [Blood]
MH  - Comorbidity
MH  - *Diabetic Nephropathies/ep [Epidemiology]
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Heart Failure/co [Complications]
MH  - *Hospitalization
MH  - Humans
MH  - Hypoalbuminemia/co [Complications]
MH  - Hypoalbuminemia/ep [Epidemiology]
MH  - Male
MH  - Malnutrition/co [Complications]
MH  - Malnutrition/ep [Epidemiology]
MH  - Myocardial Infarction/co [Complications]
MH  - *Renal Insufficiency/co [Complications]
MH  - *Renal Insufficiency/ep [Epidemiology]
MH  - Renal Insufficiency/pp [Physiopathology]
MH  - Stroke/co [Complications]
MH  - Vascular Diseases/co [Complications]
MH  - Vascular Diseases/ep [Epidemiology]
AB  - AIMS: We aimed to characterize the determinants and characteristics of renal disease in very old diabetic patients in geriatric care.
AB  - METHODS: Consecutive diabetic patients (96 women, 38 men) admitted to a geriatric service were studied. Glomerular filtration rate (GFR), albuminuria, vascular and general comorbidities, glycaemic control, malnutrition (using the Mini-Nutritional Assessment [MNA], serum albumin and cholesterol levels), haemoglobin and inflammation (CRP levels) were assessed.
AB  - RESULTS: (a) 51.2 and 12.4% patients had moderate or severe renal insufficiency. The prevalence of normo-, micro- and macroalbuminuria was 45.0, 38.9 and 16.0% in the whole population, and was similar in patients with or without moderate renal insufficiency. Renal insufficiency was associated with previous stroke (P=0.024), heart failure (P=0.024), and atrial fibrillation (P=0.008), and possibly myocardial infarction (P=0.059, Mann-Whitney test). (b) Albuminaemia was associated with albuminuria, MNA scores, haemoglobin, total and HDL-cholesterol and CRP. However, in multiple linear regression analysis CRP was the only robust determinant of albuminaemia (P<0.0001). (c) Renal insufficiency was not associated with the MNA, serum albumin, haemoglobin and cholesterol levels.
AB  - CONCLUSION: Renal insufficiency often occurs without albuminuria, suggesting aetiologies distinct from classical diabetic nephropathy, and is strongly associated with vascular comorbidities. Hypoalbuminaemia is more strongly associated with inflammation than with albuminuria and malnutrition. Malnutrition, hypoalbuminaemia, low cholesterol levels and anaemia are not associated with renal insufficiency, likely due to the very high prevalence of these abnormalities in the whole population. These features must be taken into account when organizing the global care of elderly diabetic patients.Copyright © 2010 Elsevier Masson SAS. All rights reserved.
RN  - 0 (Blood Glucose)
RN  - 0 (Cholesterol, HDL)
RN  - 9007-41-4 (C-Reactive Protein)
ES  - 1878-1780
IL  - 1262-3636
DO  - http://dx.doi.org/10.1016/j.diabet.2010.08.007
PT  - Journal Article
LG  - English
EP  - 20110126
DP  - 2011 Apr
DC  - 20110425
YR  - 2011
ED  - 20110811
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21273106

<403. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21487124
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ramadeen A
AU  - Dorian P
FA  - Ramadeen, Andrew
FA  - Dorian, Paul
TI  - Omega-3 polyunsaturated fatty acids: food or medicine?.
CM  - Comment on: Heart. 2011 Jul;97(13):1034-40; PMID: 21478384
SO  - Heart. 97(13):1032-3, 2011 Jul.
AS  - Heart. 97(13):1032-3, 2011 Jul.
NJ  - Heart (British Cardiac Society)
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9602087
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - Diet
MH  - *Dietary Supplements
MH  - *Fatty Acids, Omega-3/tu [Therapeutic Use]
MH  - Humans
MH  - Ventricular Remodeling/de [Drug Effects]
RN  - 0 (Fatty Acids, Omega-3)
ES  - 1468-201X
IL  - 1355-6037
DO  - http://dx.doi.org/10.1136/hrt.2010.221507
PT  - Comment
PT  - Editorial
LG  - English
EP  - 20110412
DP  - 2011 Jul
DC  - 20110606
YR  - 2011
ED  - 20110808
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21487124

<404. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21477372
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Hua TD
AU  - Vormfelde SV
AU  - Abu Abed M
AU  - Schneider-Rudt H
AU  - Sobotta P
AU  - Friede T
AU  - Chenot JF
FA  - Hua, Thanh Duc
FA  - Vormfelde, Stefan Viktor
FA  - Abu Abed, Manar
FA  - Schneider-Rudt, Hannelore
FA  - Sobotta, Petra
FA  - Friede, Tim
FA  - Chenot, Jean-Francois
IN  - Hua,Thanh Duc. Department of General Practice, University Medical Centre Gottingen, Humboldtallee 38, Gottingen, 37073, Germany. thanhduc.hua@med.uni-goettingen.de
TI  - Practice nursed-based, individual and video-assisted patient education in oral anticoagulation--protocol of a cluster-randomized controlled trial.
SO  - BMC Family Practice. 12:17, 2011.
AS  - BMC Fam Pract. 12:17, 2011.
NJ  - BMC family practice
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 100967792
OI  - Source: NLM. PMC3089775
SB  - Index Medicus
CP  - England
MH  - Administration, Oral
MH  - Anticoagulants/ad [Administration & Dosage]
MH  - Anticoagulants/ae [Adverse Effects]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/px [Psychology]
MH  - Clinical Protocols
MH  - Cluster Analysis
MH  - General Practice/mt [Methods]
MH  - Humans
MH  - Medication Adherence
MH  - Nurses/ut [Utilization]
MH  - Pamphlets
MH  - Patient Compliance
MH  - *Patient Education as Topic/mt [Methods]
MH  - Phenprocoumon/ad [Administration & Dosage]
MH  - Phenprocoumon/ae [Adverse Effects]
MH  - Phenprocoumon/tu [Therapeutic Use]
MH  - Primary Health Care
MH  - *Program Development/mt [Methods]
MH  - Program Development/st [Standards]
MH  - Surveys and Questionnaires
MH  - Teaching
MH  - Treatment Outcome
MH  - Videotape Recording
AB  - BACKGROUND: Managing oral anticoagulant treatment (OAT) is a challenge for patients and primary care providers. It requires a high level of patient knowledge and adherence. Studies have shown that insufficient adherence and a low level of patient knowledge about OAT are primary causes for complications. This trial is the first to evaluate the long-term effects of a complex practice nurse-based patient education program in comparison to a patient brochure only.
AB  - METHODS AND DESIGN: This trial will be a cluster-randomized controlled trial in 22 general practices (GPs) recruiting 360 patients with OAT. GPs will be randomized into an intervention group or a control group. A baseline questionnaire will assess pre-existing knowledge about OAT. The patients in the intervention group will be educated by a complex education program which consists of a video, a brochure and individual training by a practice nurse. The video gives information about OAT, nutrition, and instructions about how to manage critical situations. The brochure repeats the content of the video. After 4 to 6 weeks, the intervention will be recapitulated. The control group will receive the brochure only. After 6 months, questionnaires will be used in both groups to assess patient knowledge about OAT as well as patients' subjective feelings of safety. Separately, we will evaluate patient records, looking for documented complications and the time spent in the therapeutic range.
AB  - DISCUSSION: This trial will start in January 2011. This trial will evaluate the long-term effectiveness of a video-assisted education program on patients with OAT in comparison to a patient information brochure. Most previous studies have evaluated knowledge directly after an educational intervention. Our trial will look for long-term differences in basic knowledge of OAT. We expect that our complex patient education program effectively increases long-term basic knowledge about OAT. Although the population of our study is too small to observe differences in adverse effects, we expect to discover differences in secondary outcomes, such as the time spent in the therapeutic range.
AB  - TRIAL REGISTRATION: Deutsches Register Klinischer Studien (German Clinical Trials Register): DRKS00000586Universal Trial Number (UTN U1111-1118-3464).Copyright © 2011 Hua et al; licensee BioMed Central Ltd.
RN  - 0 (Anticoagulants)
RN  - Q08SIO485D (Phenprocoumon)
ES  - 1471-2296
IL  - 1471-2296
DO  - http://dx.doi.org/10.1186/1471-2296-12-17
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20110410
DP  - 2011
DC  - 20110509
YR  - 2011
ED  - 20110808
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21477372

<405. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20697424
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Spence JD
FA  - Spence, J David
IN  - Spence,J David. Stroke Prevention and Atherosclerosis Research Center, 1400 Western Road, London, ON N6G 2V2, Canada. dspence@robarts.ca
TI  - Secondary stroke prevention. [Review]
SO  - Nature Reviews Neurology. 6(9):477-86, 2010 Sep.
AS  - Nat Rev Neurol. 6(9):477-86, 2010 Sep.
NJ  - Nature reviews. Neurology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101500072
SB  - Index Medicus
CP  - England
MH  - Animals
MH  - *Diet, Mediterranean
MH  - Humans
MH  - Hypertension/co [Complications]
MH  - Hypertension/dh [Diet Therapy]
MH  - Risk Factors
MH  - *Risk Reduction Behavior
MH  - *Secondary Prevention/mt [Methods]
MH  - Smoking Cessation/mt [Methods]
MH  - Stroke/dh [Diet Therapy]
MH  - Stroke/et [Etiology]
MH  - *Stroke/pc [Prevention & Control]
AB  - Secondary stroke prevention can reduce the risk of recurrent stroke by approximately 90%. To achieve such a reduction, early implementation of preventative measures and administration of therapy appropriate to the underlying cause of the presenting transient ischemic attack or stroke are crucial. Smoking cessation and a Cretan Mediterranean diet are each more effective than any single medication in reducing the risk of recurrent stroke. Control of resistant hypertension can markedly reduce the risk of intracerebral hemorrhage and lacunar infarction but might require therapy that is specific to the underlying cause. New antiplatelet agents have been developed or are in development that might avoid the issues of resistance and drug interactions that prevail with established agents of this type. Furthermore, new anticoagulants in development offer promise of replacing warfarin, and devices to occlude the atrial appendage are on the horizon for patients with atrial fibrillation. Carotid endarterectomy is appropriate for severe symptomatic carotid stenosis, while stenting might be appropriate for symptomatic stenosis where the surgical risk is high. Most patients with asymptomatic stenosis, however, should be treated with medical therapy, unless indicators of high stroke risk are present. In this narrative Review, I discuss recent advances in secondary stroke prevention.
ES  - 1759-4766
IL  - 1759-4758
DO  - http://dx.doi.org/10.1038/nrneurol.2010.114
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20100810
DP  - 2010 Sep
DC  - 20100902
YR  - 2010
ED  - 20110803
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20697424

<406. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17953770
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Peake ST
AU  - Mehta PA
AU  - Dubrey SW
FA  - Peake, Simon Tc
FA  - Mehta, Paresh A
FA  - Dubrey, Simon W
IN  - Peake,Simon Tc. Department of Cardiology, The Hillingdon Hospital, Middlesex UK. s_peake@doctors.org.uk.
TI  - Atrial fibrillation-related cardiomyopathy: a case report.
SO  - Journal of Medical Case Reports [Electronic Resource]. 1:111, 2007.
AS  - J Med Case Reports. 1:111, 2007.
NJ  - Journal of medical case reports
PI  - Journal available in: Electronic
PI  - Citation processed from: Print
JC  - 101293382
OI  - Source: NLM. PMC2100064
CP  - England
AB  - Sustained chronic tachyarrhythmias often cause a deterioration of cardiac function known as tachycardia-induced cardiomyopathy or tachycardiomyopathy.The incidence of tachycardia-induced cardiomyopathy is unknown, but in selected studies of patients with atrial fibrillation, approximately 25% to 50% of those with left ventricular dysfunction had some degree of tachycardia-induced cardiomyopathy. It is an important clinical entity due to the high incidence and potential reversibility of the disease process.This case describes a cardiomyopathy induced by excess caffeine consumption. Six months following withdrawal of caffeine from the subject's diet, full resolution of symptoms occurred.
ES  - 1752-1947
IL  - 1752-1947
PT  - Journal Article
LG  - English
EP  - 20071022
DP  - 2007
DC  - 20071206
YR  - 2007
ED  - 20110714
RD  - 20120516
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=17953770

<407. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21698809
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lee R
FA  - Lee, Richard
TI  - Ask the doctor. I am 92 years old. I have atrial fibrillation and high blood pressure, both controlled by medication. Every so often when I am relaxed in my chair after dinner, my heart feels like it stops and then starts up again with a jerk. Is this something I should worry about?.
SO  - Harvard Heart Letter. 21(10):8, 2011 Jun.
AS  - Harv Heart Lett. 21(10):8, 2011 Jun.
NJ  - Harvard heart letter : from Harvard Medical School
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9425723, c2z
SB  - Consumer Health Journals
CP  - United States
MH  - Aged, 80 and over
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - *Health Knowledge, Attitudes, Practice
MH  - Heart Rate
MH  - Hemodynamics
MH  - Humans
MH  - Hypertension/co [Complications]
MH  - *Hypertension/pc [Prevention & Control]
MH  - *Rest
MH  - Sensation
IS  - 1051-5313
IL  - 1051-5313
PT  - Journal Article
LG  - English
DP  - 2011 Jun
DC  - 20110614
YR  - 2011
ED  - 20110713
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21698809

<408. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21517644
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Cannon CP
AU  - Stecker EC
FA  - Cannon, Christopher P
FA  - Stecker, Eric C
IN  - Cannon,Christopher P. Harvard Medical School, Harvard University, Division of Cardiology and Brigham and Women's Hospital, Boston, MA, USA.
TI  - New options for stroke prevention in atrial fibrillation. [Review]
SO  - American Journal of Managed Care. 16(10 Suppl):S291-7, 2010 Nov.
AS  - Am J Manag Care. 16(10 Suppl):S291-7, 2010 Nov.
NJ  - The American journal of managed care
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - cw0, 9613960
SB  - Health Administration Journals
CP  - United States
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Benzimidazoles/tu [Therapeutic Use]
MH  - Dabigatran
MH  - Drug Interactions
MH  - Factor Xa Inhibitors
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Stroke/et [Etiology]
MH  - *Stroke/pc [Prevention & Control]
MH  - Warfarin/ad [Administration & Dosage]
MH  - Warfarin/ae [Adverse Effects]
MH  - *Warfarin/tu [Therapeutic Use]
MH  - beta-Alanine/aa [Analogs & Derivatives]
MH  - beta-Alanine/tu [Therapeutic Use]
AB  - Randomized trials have demonstrated that warfarin is effective for stroke prevention in patients with atrial fibrillation (AF), yielding relative risk reductions for ischemic stroke of nearly 70%. However, successful use of warfarin requires frequent monitoring and dose adjustment to maintain an international normalized ratio (INR) within the range of 2.0 to 3.0. Many clinicians and patients have been reluctant to use warfarin therapy in AF, with underuse generally attributed to the inconvenience of INR monitoring, complexities of drug and dietary interactions associated with warfarin, and perceived bleeding risk. The ensuing search for safe, effective alternatives with a lower associated risk of bleeding and no need for monitoring and dose adjustment has focused attention on more specific inhibitors of the clotting cascade, such as factor Xa inhibitors or direct thrombin inhibitors. The direct thrombin inhibitor dabigatran has recently been approved by the US Food and Drug Administration for the prevention of stroke in patients with AF. New factor Xa inhibitors apixaban, rivaroxaban, and edoxaban are also currently being studied in stroke prevention trials in patients with AF to determine their comparability with warfarin. It is anticipated that fixed-dose administration of these new oral agents will provide effective anticoagulation without the need for frequent monitoring and with a lower risk of bleeding events.
RN  - 0 (Benzimidazoles)
RN  - 0 (Factor Xa Inhibitors)
RN  - 11P2JDE17B (beta-Alanine)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - I0VM4M70GC (Dabigatran)
ES  - 1936-2692
IL  - 1088-0224
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
LG  - English
DP  - 2010 Nov
DC  - 20110426
YR  - 2010
ED  - 20110711
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21517644

<409. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19906058
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gash K
AU  - Chambers W
AU  - Ghosh A
AU  - Dixon AR
FA  - Gash, K
FA  - Chambers, W
FA  - Ghosh, A
FA  - Dixon, A R
IN  - Gash,K. Department of Colorectal Surgery, Frenchay Hospital, Bristol, UK.
TI  - The role of laparoscopic surgery for the management of acute large bowel obstruction.
SO  - Colorectal Disease. 13(3):263-6, 2011 Mar.
AS  - Colorectal Dis. 13(3):263-6, 2011 Mar.
NJ  - Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 100883611
SB  - Index Medicus
CP  - England
MH  - Acute Disease
MH  - Aged
MH  - Aged, 80 and over
MH  - Anastomosis, Surgical
MH  - *Colectomy/mt [Methods]
MH  - *Colorectal Neoplasms/co [Complications]
MH  - *Diverticulum/co [Complications]
MH  - Emergency Medical Services
MH  - Female
MH  - Humans
MH  - Intestinal Obstruction/et [Etiology]
MH  - *Intestinal Obstruction/su [Surgery]
MH  - Laparoscopy/ae [Adverse Effects]
MH  - *Laparoscopy/mt [Methods]
MH  - Length of Stay
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications
MH  - Time Factors
MH  - Treatment Outcome
AB  - AIM: The aim of this study was to analyse the outcome of laparoscopic management of large bowel obstruction (LBO).
AB  - METHOD: A prospective electronic database (April 2001-June 2009) was used to identify outcomes in consecutive patients presenting with LBO.
AB  - RESULTS: Twenty-four patients (13 male) median age 68 years (range 56-92 years), ASA grade I (2), II (6), III (14) and IV (2), underwent surgery for LBO secondary to cancer (21) and diverticulosis (3). Supervised trainees performed four operations. Operations included anterior resection (10), Hartmann's resection (6), right/extended hemicolectomy (7) and colectomy with ileorectal anastomosis (1). The median operating time was 100 min (range 65-180 min). There were two (8%) conversions. The median time to normal diet was 24 h (range 2-192 h) and median hospital stay 3 days (range 1-30 days). Complications, seen in six patients, included atrial fibrillation (2), wound infection (2), ileus (2), CO(2) retention (1), stoma necrosis (1), circulatory collapse/bowel ischaemia (1) and anastomotic leak (1). There was one (4%) readmission and two (8%) returns to theatre. One patient died.
AB  - CONCLUSION: Laparoscopic resectional surgery in acute LBO is feasible and safe with a low complication rate that enables early hospital discharge.Copyright © 2011 The Authors. Colorectal Disease © 2011 The Association of Coloproctology of Great Britain and Ireland.
ES  - 1463-1318
IL  - 1462-8910
DO  - http://dx.doi.org/10.1111/j.1463-1318.2009.02123.x
PT  - Journal Article
LG  - English
DP  - 2011 Mar
DC  - 20110215
YR  - 2011
ED  - 20110628
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19906058

<410. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20807278
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lomuscio A
AU  - Belletti S
AU  - Battezzati PM
AU  - Lombardi F
FA  - Lomuscio, Alberto
FA  - Belletti, Sebastiano
FA  - Battezzati, Pier Maria
FA  - Lombardi, Federico
IN  - Lomuscio,Alberto. Cardiologia Medicina Interna VI, Osp. San Paolo, Dipartimento di Medicina, Chirurgia e Odontoiatria, Universita degli Studi di Milano, Milan, Italy.
TI  - Efficacy of acupuncture in preventing atrial fibrillation recurrences after electrical cardioversion.
SO  - Journal of Cardiovascular Electrophysiology. 22(3):241-7, 2011 Mar.
AS  - J Cardiovasc Electrophysiol. 22(3):241-7, 2011 Mar.
NJ  - Journal of cardiovascular electrophysiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - by4, 9010756
SB  - Index Medicus
CP  - United States
MH  - Acupuncture Therapy/ae [Adverse Effects]
MH  - *Acupuncture Therapy
MH  - Aged
MH  - Amiodarone/tu [Therapeutic Use]
MH  - Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Chi-Square Distribution
MH  - *Electric Countershock
MH  - Female
MH  - Humans
MH  - Italy
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Risk Assessment
MH  - Risk Factors
MH  - Secondary Prevention
MH  - Time Factors
MH  - Treatment Outcome
AB  - INTRODUCTION: In traditional Chinese medicine, stimulation of the Neiguan spot has been utilized to treat palpitations. We evaluated whether acupuncture might prevent or reduce the rate of arrhythmia recurrences in patients with persistent atrial fibrillation (AF).
AB  - METHODS AND RESULTS: We studied 80 patients with persistent AF after restoring sinus rhythm with electrical cardioversion. Twenty-six subjects who were already on amiodarone treatment constituted the AMIO reference group. The remaining patients were randomly allocated to receive acupuncture (ACU group, n = 17), sham acupuncture (ACU-sham group, n = 13), or neither acupuncture nor antiarrhythmic therapy (CONTROL group, n = 24). Patients in the ACU and ACU-sham groups attended 10 acupuncture sessions on a once-a-week basis. Only in the former group the Neiguan, Shenmen, and Xinshu spots were punctured. During a 12-month follow-up, AF recurred in 35 patients. Cumulative AF recurrence rates in the AMIO, ACU, ACU-sham, and CONTROL patients were 27%, 35%, 69%, and 54%, respectively (P = 0.0075, log-rank test). Ejection fraction (P = 0.0005), hypertension (0.0293), and left atrial diameter (P = 0.0361) were also significantly associated with AF recurrence. Compared with AMIO group, recurrence rate was similar in ACU patients (hazard ratio: 1.15, 95% CI: 0.38-3.49; P = 0.801) but significantly higher in ACU-sham and CONTROL patients (3.77, 1.39-10; P = 0.009 and 3.15, 1.23-8.06; P = 0.017, respectively) after adjustment for ejection fraction, hypertension, and left atrial diameter using Cox modeling.
AB  - CONCLUSION: Our data indicate that acupuncture treatment prevents arrhythmic recurrences after cardioversion in patients with persistent AF. This minimally invasive procedure was safe and well tolerated.Copyright © 2010 Wiley Periodicals, Inc.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - N3RQ532IUT (Amiodarone)
ES  - 1540-8167
IL  - 1045-3873
DO  - http://dx.doi.org/10.1111/j.1540-8167.2010.01878.x
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
EP  - 20100830
DP  - 2011 Mar
DC  - 20110309
YR  - 2011
ED  - 20110624
RD  - 20141120
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20807278

<411. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20812936
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Khan A
AU  - Mittal S
AU  - Kamath GS
AU  - Garikipati NV
AU  - Marrero D
AU  - Steinberg JS
FA  - Khan, Aslam
FA  - Mittal, Suneet
FA  - Kamath, Ganesh S
FA  - Garikipati, Naga Vamsi
FA  - Marrero, Daniel
FA  - Steinberg, Jonathan S
IN  - Khan,Aslam. Division of Cardiology, Al-Sabah Arrhythmia Institute, St. Luke's and Roosevelt Hospitals, Columbia University College of Physicians & Surgeons, New York, NY, USA.
TI  - Pulmonary vein isolation alone in patients with persistent atrial fibrillation: an ablation strategy facilitated by antiarrhythmic drug induced reverse remodeling.
SO  - Journal of Cardiovascular Electrophysiology. 22(2):142-8, 2011 Feb.
AS  - J Cardiovasc Electrophysiol. 22(2):142-8, 2011 Feb.
NJ  - Journal of cardiovascular electrophysiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - by4, 9010756
SB  - Index Medicus
CP  - United States
MH  - Anti-Arrhythmia Agents/ad [Administration & Dosage]
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Catheter Ablation/mt [Methods]
MH  - Chronic Disease
MH  - Combined Modality Therapy
MH  - Female
MH  - Heart Conduction System/de [Drug Effects]
MH  - *Heart Conduction System/su [Surgery]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Phenethylamines/ad [Administration & Dosage]
MH  - *Pulmonary Veins/su [Surgery]
MH  - *Sulfonamides/ad [Administration & Dosage]
MH  - Treatment Outcome
AB  - INTRODUCTION: Pulmonary vein isolation (PVI) alone has been thought to be insufficient in patients with persistent atrial fibrillation (PersAF). We hypothesized that preablation treatment of PersAF with a potent antiarrhythmic drug (AAD) would facilitate reverse atrial remodeling and result in high procedural efficacy after PVI alone.
AB  - METHODS AND RESULTS: Seventy-one consecutive patients (59.4 +/- 9.8 years) with PersAF and prior AAD failure were treated with oral dofetilide (768 +/- 291 mcg/day) for a median of 85 days pre-PVI. P-wave duration (Pdur) on ECG was used to assess reverse atrial remodeling. Thirty-five patients with paroxysmal (P) AF not treated with an AAD served as controls. All patients underwent PVI alone; dofetilide was discontinued 1-3 mos postablation. In the PersAF patients, the Pdur decreased from 136.3 +/- 21.7 ms (assessed postcardioversion on dofetilide) to 118.6 +/- 20.4 ms (assessed immediately prior to PVI) (P < 0.001). In contrast, no change in Pdur (122.6 +/- 11.5 ms vs. 121.3 +/- 13.7 ms, P = NS) was observed in PAF patients. The 6 and 12 mos AAD-free response to ablation was 76% and 70%, respectively, in PersAF patients, similar to the 80% and 75%, response in PAF patients (P = NS). A decline in Pdur in response to dofetilide was the only predictor of long-term clinical response to PVI in patients with PersAF.
AB  - CONCLUSIONS: Pre-treatment with AAD resulted in a decrease in Pdur suggesting reverse atrial electrical remodeling in PersAF patients. This may explain the excellent clinical outcomes using PVI alone, and may suggest an alternative ablation strategy for PersAF.Copyright © 2010 Wiley Periodicals, Inc.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Phenethylamines)
RN  - 0 (Sulfonamides)
RN  - 115256-11-6 (dofetilide)
ES  - 1540-8167
IL  - 1045-3873
DO  - http://dx.doi.org/10.1111/j.1540-8167.2010.01886.x
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20100831
DP  - 2011 Feb
DC  - 20110214
YR  - 2011
ED  - 20110617
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20812936

<412. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21441766
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Guay DR
FA  - Guay, David R P
IN  - Guay,David R P. Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA. guayx001@umn.edu
TI  - Dabigatran etexilate: a possible replacement for heparinoids and vitamin K antagonists?. [Review]
SO  - Hospital practice (1995) Hospital practice. 39(1):105-25, 2011 Feb.
AS  - Hosp Pract (Minneap). 39(1):105-25, 2011 Feb.
NJ  - Hospital practice (1995)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101268948
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Administration, Oral
MH  - Anticoagulants/ch [Chemistry]
MH  - Anticoagulants/ec [Economics]
MH  - Anticoagulants/pd [Pharmacology]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Arthroplasty, Replacement
MH  - Atrial Fibrillation/co [Complications]
MH  - Benzimidazoles/ch [Chemistry]
MH  - Benzimidazoles/ec [Economics]
MH  - Benzimidazoles/pd [Pharmacology]
MH  - *Benzimidazoles/tu [Therapeutic Use]
MH  - Clinical Trials as Topic
MH  - Dabigatran
MH  - Drug Interactions
MH  - Heparinoids/tu [Therapeutic Use]
MH  - Humans
MH  - Pulmonary Embolism/et [Etiology]
MH  - *Pulmonary Embolism/pc [Prevention & Control]
MH  - Pyridines/ch [Chemistry]
MH  - Pyridines/ec [Economics]
MH  - Pyridines/pd [Pharmacology]
MH  - *Pyridines/tu [Therapeutic Use]
MH  - Stroke/et [Etiology]
MH  - *Stroke/pc [Prevention & Control]
MH  - Venous Thromboembolism/co [Complications]
MH  - *Venous Thromboembolism/pc [Prevention & Control]
MH  - Vitamin K/ai [Antagonists & Inhibitors]
AB  - Dabigatran etexilate is the first oral anticoagulant to be approved in the United States in decades. It works directly by inhibiting clot-bound and free factor IIa (ie, thrombin) and indirectly by inhibiting platelet aggregation induced by thrombin. It is approved in the United States for stroke prophylaxis in nonvalvular atrial fibrillation. There is evidence to suggest that it is also effective for the treatment of acute venous thromboembolism and venous thromboembolism prophylaxis after knee and hip replacement surgery. Dabigatran etexilate therapy does not require laboratory monitoring, an advantage over warfarin. Unlike the earlier direct thrombin inhibitor, ximelagatran, it has demonstrated no potential for serious hepatotoxicity. It is also subject to a much lower degree of interpatient variability in dose response, has no diet-drug interactions, and has fewer clinically significant drug-drug interactions compared with warfarin. Dabigatran etexilate appears to be a valuable addition to our anticoagulant armamentarium.
RN  - 0 (Anticoagulants)
RN  - 0 (Benzimidazoles)
RN  - 0 (Heparinoids)
RN  - 0 (Pyridines)
RN  - 12001-79-5 (Vitamin K)
RN  - I0VM4M70GC (Dabigatran)
IS  - 2154-8331
IL  - 2154-8331
DO  - http://dx.doi.org/10.3810/hp.2011.02.381
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2011 Feb
DC  - 20110328
YR  - 2011
ED  - 20110602
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21441766

<413. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21048051
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Messinger-Rapport B
FA  - Messinger-Rapport, Barbara
IN  - Messinger-Rapport,Barbara. Center for Geriatric Medicine, G10, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. rapporb@ccf.org
TI  - What's new in treating older adults?. [Review]
SO  - Cleveland Clinic Journal of Medicine. 77(11):770-90, 2010 Nov.
AS  - Cleve Clin J Med. 77(11):770-90, 2010 Nov.
NJ  - Cleveland Clinic journal of medicine
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - dbn, 8703441
SB  - Index Medicus
CP  - United States
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Aging
MH  - Antibodies, Monoclonal/tu [Therapeutic Use]
MH  - Antibodies, Monoclonal, Humanized
MH  - Atrial Fibrillation
MH  - Benzimidazoles/tu [Therapeutic Use]
MH  - Cholinesterase Inhibitors/ae [Adverse Effects]
MH  - *Cognition/ph [Physiology]
MH  - Dabigatran
MH  - Delirium
MH  - *Dementia/pc [Prevention & Control]
MH  - Denosumab
MH  - *Exercise/ph [Physiology]
MH  - *Fractures, Bone/pc [Prevention & Control]
MH  - *Geriatrics/td [Trends]
MH  - Humans
MH  - RANK Ligand/tu [Therapeutic Use]
MH  - *Vitamin D/tu [Therapeutic Use]
MH  - beta-Alanine/aa [Analogs & Derivatives]
MH  - beta-Alanine/tu [Therapeutic Use]
AB  - Clinical trials in the past few years have yielded findings that are relevant for clinical practice, not just for geriatricians but for all physicians who have elderly patients.
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Benzimidazoles)
RN  - 0 (Cholinesterase Inhibitors)
RN  - 0 (RANK Ligand)
RN  - 11P2JDE17B (beta-Alanine)
RN  - 1406-16-2 (Vitamin D)
RN  - 4EQZ6YO2HI (Denosumab)
RN  - I0VM4M70GC (Dabigatran)
ES  - 1939-2869
IL  - 0891-1150
DO  - http://dx.doi.org/10.3949/ccjm.77gr.10002
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2010 Nov
DC  - 20101104
YR  - 2010
ED  - 20110602
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21048051

<414. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20920530
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ma TK
AU  - Yan BP
AU  - Lam YY
FA  - Ma, Terry K W
FA  - Yan, Bryan P
FA  - Lam, Yat-Yin
IN  - Ma,Terry K W. Division of Cardiology, SH Ho Cardiovascular and Stroke Centre, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong.
TI  - Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data. [Review]
SO  - Pharmacology & Therapeutics. 129(2):185-94, 2011 Feb.
AS  - Pharmacol Ther. 129(2):185-94, 2011 Feb.
NJ  - Pharmacology & therapeutics
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - p44, 7905840
SB  - Index Medicus
CP  - England
MH  - Administration, Oral
MH  - Anticoagulants/ec [Economics]
MH  - Anticoagulants/pk [Pharmacokinetics]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Arthroplasty, Replacement, Hip
MH  - Arthroplasty, Replacement, Knee
MH  - *Atrial Fibrillation/co [Complications]
MH  - Benzimidazoles/ec [Economics]
MH  - Benzimidazoles/pk [Pharmacokinetics]
MH  - *Benzimidazoles/tu [Therapeutic Use]
MH  - Clinical Trials as Topic
MH  - Dabigatran
MH  - Humans
MH  - Pyridines/ec [Economics]
MH  - Pyridines/pk [Pharmacokinetics]
MH  - *Pyridines/tu [Therapeutic Use]
MH  - *Stroke/pc [Prevention & Control]
MH  - Thrombin/ai [Antagonists & Inhibitors]
MH  - *Venous Thromboembolism/dt [Drug Therapy]
MH  - *Venous Thromboembolism/pc [Prevention & Control]
MH  - Warfarin/ec [Economics]
MH  - *Warfarin/tu [Therapeutic Use]
AB  - For many years, warfarin was the only effective oral anticoagulant to prevent and treat thromboembolism. Nevertheless, its clinical use is limited by a narrow therapeutic window, extensive drug interactions, need of strict dietary control and frequent monitoring. The pharmacological response is also unpredictable and highly variable among patients. Suboptimal anticoagulation can lead to detrimental thromboembolic events or life-threatening bleeding. Direct thrombin inhibitor (DTI) activity represents a new class of anticoagulant activity that was intended to replace warfarin. Ximelagatran was the first DTI shown to have similar efficacy to warfarin, but failed to replace it because of a high incidence of liver toxicity. Dabigatran etexilate is another novel DTI with a more predictable pharmacokinetic profile and fewer drug interactions compared with warfarin. Recent large-scaled, randomized studies have shown that it does not share ximelagatran's hepatotoxicity, and is as effective as conventional anticoagulants for venous thromboembolism (VTE) and prophylaxis in atrial fibrillation (AF). These findings led to the approval of dabigatran etexilate for thromboprophylaxis following hip or knee replacement surgery in Europe, Canada and the United Kingdom. Here we summarize the latest evidence concerning the use of dabigatran etexilate in VTE (BISTRO, RE-MODEL, RE-NOVATE, RE-MOBILIZE and RECOVER) and AF (PETRO and RELY). Potential problems related to dabigatran use are also discussed to examine whether it can truly replace warfarin as the gold standard.Copyright A© 2010 Elsevier Inc. All rights reserved.
RN  - 0 (Anticoagulants)
RN  - 0 (Benzimidazoles)
RN  - 0 (Pyridines)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - EC 3-4-21-5 (Thrombin)
RN  - I0VM4M70GC (Dabigatran)
ES  - 1879-016X
IL  - 0163-7258
DO  - http://dx.doi.org/10.1016/j.pharmthera.2010.09.005
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20101012
DP  - 2011 Feb
DC  - 20110124
YR  - 2011
ED  - 20110524
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20920530

<415. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20664899
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kim KH
AU  - Choi WS
AU  - Lee JH
AU  - Lee H
AU  - Yang DH
AU  - Chae SC
FA  - Kim, Kyun Hee
FA  - Choi, Won Suk
FA  - Lee, Jang Hoon
FA  - Lee, Hyejin
FA  - Yang, Dong Heon
FA  - Chae, Shung Chull
IN  - Kim,Kyun Hee. Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea.
TI  - Relationship between dietary vitamin K intake and the stability of anticoagulation effect in patients taking long-term warfarin.
SO  - Thrombosis & Haemostasis. 104(4):755-9, 2010 Oct.
AS  - Thromb Haemost. 104(4):755-9, 2010 Oct.
NJ  - Thrombosis and haemostasis
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - vq7, 7608063
SB  - Index Medicus
CP  - Germany
MH  - Aged
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/dh [Diet Therapy]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Blood Coagulation Tests
MH  - Diet
MH  - Disease Progression
MH  - Eating
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Treatment Outcome
MH  - *Vitamin K/ad [Administration & Dosage]
MH  - *Warfarin/tu [Therapeutic Use]
AB  - Little study has been performed on the effect of vitamin K intake on the variability of warfarin's anticoagulant effects over long period of time. We estimated average vitamin K intake in the patients taking warfarin and evaluated its relation with the stability of anticoagulation effect. We estimated average daily vitamin K intake based on a three-day food diary in 66 patients taking warfarin regularly for > one year and divided them into three groups of equal number according to vitamin K intake. Stability of anticoagulant effect was compared in these groups using the coefficient of variation (CV) of the prothrombin time expressed in international normalised ratio (INR) and the CV of warfarin doses. Median daily vitamin K intake was 161.3 mug/day (31.3 mug/day - 616.6 mug/day). CVs of both INR and warfarin doses were negatively and independently correlated with dietary vitamin K intake (r=-0.293, p=0.017 and r= -0.350, p=0.004, respectively). CV of INR was significantly different among three groups of vitamin K intake (p<0.05 in ANOVA). High vitamin K intake (>195.7 mug/day) group had lower CV of INR than the low intake (<126.5 mug/day) group (19.2 +/- 8.96 % vs. 25.5 +/- 8.61 %, p<0.05). CV of warfarin doses was also significantly different among the groups (p<0.05 in Jonckheere-Terpstra test). However, the significance of difference between high and low vitamin intake groups was marginal (p=0.046 in Mann-Whitney test). In conclusion, long-term anticoagulation effect of warfarin is more stable in the patients who take greater than a certain amount of dietary vitamin K.
RN  - 0 (Anticoagulants)
RN  - 12001-79-5 (Vitamin K)
RN  - 5Q7ZVV76EI (Warfarin)
IS  - 0340-6245
IL  - 0340-6245
DO  - http://dx.doi.org/10.1160/TH10-04-0257
PT  - Journal Article
LG  - English
EP  - 20100720
DP  - 2010 Oct
DC  - 20101004
YR  - 2010
ED  - 20110511
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20664899

<416. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20738368
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kilickesmez KO
AU  - Ozkan AA
AU  - Abaci O
AU  - Camlica H
AU  - Kocas C
AU  - Kaya A
AU  - Baskurt M
AU  - Yigit Z
AU  - Kucukoglu S
FA  - Kilickesmez, Kadriye Orta
FA  - Ozkan, Alev Arat
FA  - Abaci, Okay
FA  - Camlica, Hakan
FA  - Kocas, Cuneyt
FA  - Kaya, Aysem
FA  - Baskurt, Murat
FA  - Yigit, Zerrin
FA  - Kucukoglu, Serdar
IN  - Kilickesmez,Kadriye Orta. Department of Cardiology, Istanbul University Institute of Cardiology, Istanbul, Turkey. kadriye11@yahoo.com
TI  - Serum N-terminal brain natriuretic peptide indicates exercise induced augmentation of pulmonary artery pressure in patients with mitral stenosis.
SO  - Echocardiography. 28(1):8-14, 2011 Jan.
AS  - Echocardiography. 28(1):8-14, 2011 Jan.
NJ  - Echocardiography (Mount Kisco, N.Y.)
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - bcn, 8511187
SB  - Index Medicus
CP  - United States
MH  - Case-Control Studies
MH  - Echocardiography
MH  - *Exercise Test
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve Stenosis/bl [Blood]
MH  - *Mitral Valve Stenosis/di [Diagnosis]
MH  - Mitral Valve Stenosis/us [Ultrasonography]
MH  - *Natriuretic Peptide, Brain/bl [Blood]
MH  - *Pulmonary Artery/pa [Pathology]
MH  - Pulmonary Artery/us [Ultrasonography]
AB  - INTRODUCTION: To determine whether elevated N-terminal pro-BNP (NT pro-BNP) predicts pulmonary artery systolic pressure increase on exercise stress echocardiography in asymptomatic or mildly symptomatic patients with moderate to severe mitral stenosis.
AB  - METHODS AND RESULTS: Forty-one asymptomatic or mildly symptomatic patients with moderate to severe mitral stenosis and 21 age- and sex-matched healthy subjects. Transthoracic echocardiography was performed in all patients to assess the severity of the valve disease and to measure pulmonary artery pressure before and immediately after treadmill exercise. Blood samples for NT pro-BNP were also collected before and immediately after treadmill exercise at the time of echocardiographic examination. The plasma concentrations of NT pro-BNP levels were significantly higher in patients with mitral stenosis than in control subjects before and after exercise (P < 0.001). Patients with atrial fibrillation had significantly higher NT pro-BNP levels compared to those with sinus rhythm (P < 0.001). Pre- and postexercise NT pro-BNP levels correlated statistically significantly with the left atrial (LA) dimension, right ventricle enddiastolic diameter, exercise duration, heart rate, rest, and exercise pulmonary artery systolic pressure, after exercise mitral valve mean gradient. Area under the receiver-operating characteristic curve for NT pro-BNP as an exercise induced augmentation of pulmonary artery pressure was 0.78. Using an optimized cutoff value of 251 pg/mL for NT pro-BNP, sensitivity was 89.47%. The independent determinants of higher pulmonary artery pressure were LA diameter and pretest NT pro-BNP levels in multivariante analysis.
AB  - CONCLUSION: NT pro-BNP levels correlate with functional class and echocardiographic findings in patients with mitral stenosis and indicate exercise induced augmentation of peak PAP > 60 mmHg. (Echocardiography 2011;28:8-14).Copyright © 2010, Wiley Periodicals, Inc.
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
ES  - 1540-8175
IL  - 0742-2822
DO  - http://dx.doi.org/10.1111/j.1540-8175.2010.01273.x
PT  - Journal Article
LG  - English
EP  - 20100824
DP  - 2011 Jan
DC  - 20110124
YR  - 2011
ED  - 20110502
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20738368

<417. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21036799
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Silverman DE
FA  - Silverman, David E
IN  - Silverman,David E. drdavidsilverman@hotmail.co.uk
TI  - Exercise testing and asymptomatic pre-excitation.
SO  - Heart. 97(7):606, 2011 Apr.
AS  - Heart. 97(7):606, 2011 Apr.
NJ  - Heart (British Cardiac Society)
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9602087
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Electrocardiography
MH  - Exercise Test
MH  - Female
MH  - Humans
MH  - *Pre-Excitation Syndromes/di [Diagnosis]
ES  - 1468-201X
IL  - 1355-6037
DO  - http://dx.doi.org/10.1136/hrt.2009.189092
PT  - Case Reports
PT  - Journal Article
LG  - English
EP  - 20101029
DP  - 2011 Apr
DC  - 20110307
YR  - 2011
ED  - 20110421
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21036799

<418. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21193114
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Weitz JI
FA  - Weitz, Jeffrey I
IN  - Weitz,Jeffrey I. Departments of Medicine and Biochemistry and Biomedical Sciences, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada. weitzj@taari.ca
TI  - Factor Xa and thrombin as targets for new oral anticoagulants.
SO  - Thrombosis Research. 127 Suppl 2:S5-S12, 2011 Jan.
AS  - Thromb Res. 127 Suppl 2:S5-S12, 2011 Jan.
NJ  - Thrombosis research
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - vrn, 0326377
SB  - Index Medicus
CP  - United States
MH  - Acute Coronary Syndrome/dt [Drug Therapy]
MH  - Administration, Oral
MH  - *Anticoagulants/ad [Administration & Dosage]
MH  - Anticoagulants/ae [Adverse Effects]
MH  - Anticoagulants/pk [Pharmacokinetics]
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - Benzimidazoles/ad [Administration & Dosage]
MH  - Clinical Trials as Topic
MH  - Dabigatran
MH  - Drug Discovery
MH  - *Factor Xa Inhibitors
MH  - Humans
MH  - Morpholines/ad [Administration & Dosage]
MH  - Pyrazoles/ad [Administration & Dosage]
MH  - Pyridines/ad [Administration & Dosage]
MH  - Pyridones/ad [Administration & Dosage]
MH  - Rivaroxaban
MH  - Stroke/pc [Prevention & Control]
MH  - Thiazoles/ad [Administration & Dosage]
MH  - Thiophenes/ad [Administration & Dosage]
MH  - *Thrombin/ai [Antagonists & Inhibitors]
MH  - Venous Thromboembolism/dt [Drug Therapy]
MH  - Venous Thromboembolism/pc [Prevention & Control]
MH  - Vitamin K/ai [Antagonists & Inhibitors]
AB  - Although currently available anticoagulants are effective for the prevention and treatment of thromboembolic disorders, they have several drawbacks. Low molecular weight heparin and fondaparinux produce a predictable level of anticoagulation that obviates the need for coagulation monitoring, but they must be given parenterally, which renders them inconvenient for long-term use. Vitamin K antagonists, such as warfarin, are administered orally, but produce a variable anticoagulant response because genetic polymorphisms, dietary vitamin K intake and multiple drug-drug interactions affect their metabolism. Consequently, coagulation monitoring and frequent dose adjustments are needed to ensure that a therapeutic level of anticoagulation is achieved. This is burdensome for patients and physicians, and costly for the healthcare system. These limitations have prompted the development of new oral anticoagulants that target thrombin or factor Xa. The new agents produce such a predictable anticoagulant response that they can be given in fixed doses without monitoring. This paper focuses on the new oral anticoagulants in the most advanced stages of development.Copyright © 2011 Elsevier Ltd. All rights reserved.
RN  - 0 (Anticoagulants)
RN  - 0 (Benzimidazoles)
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Morpholines)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridines)
RN  - 0 (Pyridones)
RN  - 0 (Thiazoles)
RN  - 0 (Thiophenes)
RN  - 12001-79-5 (Vitamin K)
RN  - 3Z9Y7UWC1J (apixaban)
RN  - 480449-70-5 (edoxaban)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - EC 3-4-21-5 (Thrombin)
RN  - I0VM4M70GC (Dabigatran)
ES  - 1879-2472
IL  - 0049-3848
DO  - http://dx.doi.org/10.1016/S0049-3848(10)70147-X
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 2011 Jan
DC  - 20110103
YR  - 2011
ED  - 20110412
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21193114

<419. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21076159
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Baber U
AU  - Howard VJ
AU  - Halperin JL
AU  - Soliman EZ
AU  - Zhang X
AU  - McClellan W
AU  - Warnock DG
AU  - Muntner P
FA  - Baber, Usman
FA  - Howard, Virginia J
FA  - Halperin, Jonathan L
FA  - Soliman, Elsayed Z
FA  - Zhang, Xiao
FA  - McClellan, William
FA  - Warnock, David G
FA  - Muntner, Paul
IN  - Baber,Usman. Zena and Michael A. Wiener Cardiovascular Institute and Marie-Josee and Henry R. Kravis Center for Cardiovascular Health, Mount Sinai School of Medicine, New York, NY, USA.
TI  - Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study.
SO  - Circulation: Arrhythmia and Electrophysiology. 4(1):26-32, 2011 Feb.
AS  - Circ. Arrhythm. electrophysiol.. 4(1):26-32, 2011 Feb.
NJ  - Circulation. Arrhythmia and electrophysiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101474365
OI  - Source: NLM. NIHMS272889
OI  - Source: NLM. PMC3049935
SB  - Index Medicus
CP  - United States
MH  - *African Americans/eh [Ethnology]
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/eh [Ethnology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Chronic Disease
MH  - Cohort Studies
MH  - Cross-Sectional Studies
MH  - Electrocardiography
MH  - *European Continental Ancestry Group/eh [Ethnology]
MH  - Female
MH  - Glomerular Filtration Rate/ph [Physiology]
MH  - Humans
MH  - *Kidney Diseases/co [Complications]
MH  - Kidney Diseases/pp [Physiopathology]
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - *Stroke/ep [Epidemiology]
MH  - *Stroke/eh [Ethnology]
MH  - United States/ep [Epidemiology]
AB  - BACKGROUND: Atrial fibrillation (AF) is common among patients with end-stage renal disease, but few data are available on its prevalence among adults with chronic kidney disease (CKD) of lesser severity. methods and results: We evaluated the association of CKD with ECG-detected AF among 26 917 participants in the REasons for Geographic and Racial Differences in Stroke (REGARDS) study, a population-based cohort of African-American and white US adults >45 years of age. Estimated glomerular filtration rate (eGFR) was calculated using the abbreviated Modification of Diet in Renal Disease study equation and albuminuria was defined as a urinary albumin to creatinine ratio >30 mg/g. Participants were categorized by renal function: no CKD (eGFR >60 mL/min/1.73 m(2) without albuminuria, n=21 081), stage 1 to 2 CKD (eGFR >60 mL/min/1.73 m(2) with albuminuria n=2938), stage 3 CKD (eGFR 30 to 59 mL/min/1.73 m(2), n=2683) and stage 4 to 5 CKD (eGFR <30 mL/min/1.73 m(2), n=215). The prevalence of AF among participants without CKD, and with stage 1 to 2, stage 3, and stage 4 to 5 CKD was 1.0%, 2.8%, 2.7% and 4.2%, respectively. Compared with participants without CKD, the age-, race-, and sex-adjusted odds ratios for prevalent AF were 2.67 (95% confidence interval, 2.04 to 3.48), 1.68 (95% confidence interval, 1.26 to 2.24) and 3.52 (95% confidence interval, 1.73 to 7.15) among those with stage 1 to 2, stage 3, and stage 4 to 5 CKD. The association between CKD and prevalent AF remained statistically significant after further multivariable adjustment and was consistent across numerous subgroups.
AB  - CONCLUSIONS: Regardless of severity, CKD is associated with an increased prevalence of AF among US adults.
ES  - 1941-3084
IL  - 1941-3084
DO  - http://dx.doi.org/10.1161/CIRCEP.110.957100
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
NO  - R01 NS041588 (United States NINDS NIH HHS)
NO  - R01 NS041588-01 (United States NINDS NIH HHS)
NO  - U01 NS041588 (United States NINDS NIH HHS)
NO  - U01 NS041588-02 (United States NINDS NIH HHS)
NO  - U01 NS041588-03 (United States NINDS NIH HHS)
NO  - U01 NS041588-03S1 (United States NINDS NIH HHS)
NO  - U01 NS041588-04 (United States NINDS NIH HHS)
NO  - U01 NS041588-04S1 (United States NINDS NIH HHS)
NO  - U01 NS041588-05 (United States NINDS NIH HHS)
NO  - U01 NS041588-06 (United States NINDS NIH HHS)
NO  - U01 NS041588-07A1 (United States NINDS NIH HHS)
NO  - U01 NS041588-08 (United States NINDS NIH HHS)
NO  - U01 NS041588-08S1 (United States NINDS NIH HHS)
NO  - U01 NS041588-09 (United States NINDS NIH HHS)
NO  - U01 NS041588-09S1 (United States NINDS NIH HHS)
NO  - U01 NS041588-10 (United States NINDS NIH HHS)
NO  - U01-NS041588 (United States NINDS NIH HHS)
LG  - English
EP  - 20101113
DP  - 2011 Feb
DC  - 20110217
YR  - 2011
ED  - 20110411
RD  - 20150205
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21076159

<420. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19383061
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gates P
AU  - Al-Daher S
AU  - Ridley D
AU  - Black A
FA  - Gates, P
FA  - Al-Daher, S
FA  - Ridley, D
FA  - Black, A
IN  - Gates,P. Neuroscience Department, Barwon Health/The Geelong Hospital, Geelong, Victoria, Australia.
TI  - Could exercise be a new strategy to revert some patients with atrial fibrillation?.
SO  - Internal Medicine Journal. 40(1):57-60, 2010 Jan.
AS  - Intern Med J. 40(1):57-60, 2010 Jan.
NJ  - Internal medicine journal
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - d20, 101092952
SB  - Index Medicus
CP  - Australia
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Exercise/ph [Physiology]
MH  - *Exercise Test/mt [Methods]
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
AB  - BACKGROUND: This study is the result of the anecdotal observation that a number of patients with atrial fibrillation (AF) had noted reversion to sinus rhythm (SR) with exercise.We aimed to evaluate the potential role of exercise stress test (EST) for the reversion of AF.
AB  - METHODS: Patients with AF who were scheduled to undergo electrical cardioversion (DCR) underwent EST using a modified Bruce protocol.
AB  - RESULTS: Eighteen patients (16 male); aged 36-74 years (mean 58 years) were studied. Five patients (27.7%) had successful reversion with exercise (group 1). Thirteen patients remained in AF (group 2). No patient who failed to revert with exercise did so spontaneously before DCR 3 h to 7 months later (median 20 days). Comparison between group 1 and group 2 did not reveal any significant difference
AB  - CONCLUSION: This small preliminary study suggests that in some patients it may be possible to revert AF to SR with exercise and avoid DCR and concomitant general anaesthesia. The authors suggest that a larger multicentre randomized trial is warranted to confirm or refute these initial results and if correct identify those who might benefit.
ES  - 1445-5994
IL  - 1444-0903
DO  - http://dx.doi.org/10.1111/j.1445-5994.2009.01940.x
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 2010 Jan
DC  - 20100623
YR  - 2010
ED  - 20110314
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19383061

<421. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21034623
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Long DY
AU  - Ma CS
AU  - Jiang H
AU  - Dong JZ
AU  - Liu XP
AU  - Huang H
AU  - Tang YH
AU  - Wu G
AU  - Huang CX
FA  - Long, De-yong
FA  - Ma, Chang-sheng
FA  - Jiang, Hong
FA  - Dong, Jian-zeng
FA  - Liu, Xing-peng
FA  - Huang, He
FA  - Tang, Yan-hong
FA  - Wu, Gang
FA  - Huang, Cong-xin
IN  - Long,De-yong. Department of Cardiology, Renmin Hospital, Wuhan University, Hubei, China.
TI  - Mitral isthmus ablation in patients with prosthetic mitral valves.
SO  - Chinese Medical Journal. 123(18):2532-6, 2010 Sep.
AS  - Chin Med J. 123(18):2532-6, 2010 Sep.
NJ  - Chinese medical journal
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 0005256, d3b, 7513795
SB  - Index Medicus
CP  - China
MH  - Adult
MH  - *Atrial Fibrillation/su [Surgery]
MH  - *Catheter Ablation/mt [Methods]
MH  - Female
MH  - *Heart Atria/su [Surgery]
MH  - *Heart Valve Prosthesis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mitral Valve/su [Surgery]
AB  - BACKGROUND: Previous studies have investigated the technique of linear ablation at the mitral isthmus (MI) in patients with idopathic atrial fibrillation (AF), but MI ablation in patients with prosthetic natural mitral valves (MVs) was not described in detail. Present study sought to summarize our initial experience of ablating MI in patients with prosthetic MVs
AB  - METHODS: Patients with drug refractory AF and prosthetic MVs were eligible for this study, and the patients with natural MVs but received MI ablation served as control group. Left atrium (LA) mapping and ablation was carried out guided by CARTO system. The anatomy of MI was assessed via computer topography scan.
AB  - RESULTS: During the study period, a consecutive of 19 patients (male/female = 12/7, mean age of (48 +/- 6) years) with prosthetic MVs (16 with metal valves, 3 with biologic valves) entered for AF ablation, other 35 patients served as control group. In study group, mapping along MI documented lower voltages ((2.0 +/- 1.0) vs. (3.1 +/- 1.3) mV, P = 0.002), more fragmented potentials (19/19 vs. 20/15, P < 0.001), and higher impedance ((132 +/- 34) vs. (110 +/- 20) OMEGA, P = 0.004). After initial ablation, more residual gaps along the MI lesions were found in study group (2.4 +/- 0.4 vs. 1.7 +/- 0.3, P < 0.001). The mean length of MI ((6.2 +/- 3.3) vs. (7.1 +/- 2.3) cm, P = 0.25) was comparable between 2 groups, but the MI in study group was much thicker ((3.1 +/- 1.8) vs. (2.1 +/- 1.07) cm, P = 0.01) and all were found as pouch type (19/19 vs. 2/35, P < 0.001). The follow-up results were comparable (65.1% vs. 72.3%, P = 0.30).
AB  - CONCLUSION: For patients with prosthetic MVs, linear ablation at MI could be successfully carried out despite anatomical and pathological changes.
IS  - 0366-6999
IL  - 0366-6999
PT  - Journal Article
LG  - English
DP  - 2010 Sep
DC  - 20101101
YR  - 2010
ED  - 20110308
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21034623

<422. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21127304
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Goldstein LB
AU  - Bushnell CD
AU  - Adams RJ
AU  - Appel LJ
AU  - Braun LT
AU  - Chaturvedi S
AU  - Creager MA
AU  - Culebras A
AU  - Eckel RH
AU  - Hart RG
AU  - Hinchey JA
AU  - Howard VJ
AU  - Jauch EC
AU  - Levine SR
AU  - Meschia JF
AU  - Moore WS
AU  - Nixon JV
AU  - Pearson TA
AU  - American Heart Association Stroke Council
AU  - Council on Cardiovascular Nursing
AU  - Council on Epidemiology and Prevention
AU  - Council for High Blood Pressure Research,
AU  - Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research
FA  - Goldstein, Larry B
FA  - Bushnell, Cheryl D
FA  - Adams, Robert J
FA  - Appel, Lawrence J
FA  - Braun, Lynne T
FA  - Chaturvedi, Seemant
FA  - Creager, Mark A
FA  - Culebras, Antonio
FA  - Eckel, Robert H
FA  - Hart, Robert G
FA  - Hinchey, Judith A
FA  - Howard, Virginia J
FA  - Jauch, Edward C
FA  - Levine, Steven R
FA  - Meschia, James F
FA  - Moore, Wesley S
FA  - Nixon, J V Ian
FA  - Pearson, Thomas A
FA  - American Heart Association Stroke Council
FA  - Council on Cardiovascular Nursing
FA  - Council on Epidemiology and Prevention
FA  - Council for High Blood Pressure Research,
FA  - Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research
IN  - Goldstein,Larry B. American Heart Association/American Stroke Association
TI  - Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.[Erratum appears in Stroke. 2011 Feb;42(2):e26]
SO  - Stroke. 42(2):517-84, 2011 Feb.
AS  - Stroke. 42(2):517-84, 2011 Feb.
NJ  - Stroke; a journal of cerebral circulation
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - v2j, 0235266
SB  - Index Medicus
CP  - United States
MH  - *American Heart Association
MH  - Evidence-Based Medicine/mt [Methods]
MH  - Evidence-Based Medicine/st [Standards]
MH  - *Health Personnel/st [Standards]
MH  - Humans
MH  - Primary Prevention/mt [Methods]
MH  - *Primary Prevention/st [Standards]
MH  - Risk Factors
MH  - Stroke/di [Diagnosis]
MH  - *Stroke/pc [Prevention & Control]
MH  - United States
AB  - BACKGROUND AND PURPOSE: This guideline provides an overview of the evidence on established and emerging risk factors for stroke to provide evidence-based recommendations for the reduction of risk of a first stroke.
AB  - METHODS: Writing group members were nominated by the committee chair on the basis of their previous work in relevant topic areas and were approved by the American Heart Association (AHA) Stroke Council Scientific Statement Oversight Committee and the AHA Manuscript Oversight Committee. The writing group used systematic literature reviews (covering the time since the last review was published in 2006 up to April 2009), reference to previously published guidelines, personal files, and expert opinion to summarize existing evidence, indicate gaps in current knowledge, and when appropriate, formulate recommendations using standard AHA criteria (Tables 1 and 2). All members of the writing group had the opportunity to comment on the recommendations and approved the final version of this document. The guideline underwent extensive peer review by the Stroke Council leadership and the AHA scientific statements oversight committees before consideration and approval by the AHA Science Advisory and Coordinating Committee.
AB  - RESULTS: Schemes for assessing a person's risk of a first stroke were evaluated. Risk factors or risk markers for a first stroke were classified according to potential for modification (nonmodifiable, modifiable, or potentially modifiable) and strength of evidence (well documented or less well documented). Nonmodifiable risk factors include age, sex, low birth weight, race/ethnicity, and genetic predisposition. Well-documented and modifiable risk factors include hypertension, exposure to cigarette smoke, diabetes, atrial fibrillation and certain other cardiac conditions, dyslipidemia, carotid artery stenosis, sickle cell disease, postmenopausal hormone therapy, poor diet, physical inactivity, and obesity and body fat distribution. Less well-documented or potentially modifiable risk factors include the metabolic syndrome, excessive alcohol consumption, drug abuse, use of oral contraceptives, sleep-disordered breathing, migraine, hyperhomocysteinemia, elevated lipoprotein(a), hypercoagulability, inflammation, and infection. Data on the use of aspirin for primary stroke prevention are reviewed.
AB  - CONCLUSIONS: Extensive evidence identifies a variety of specific factors that increase the risk of a first stroke and that provide strategies for reducing that risk.
ES  - 1524-4628
IL  - 0039-2499
DO  - http://dx.doi.org/10.1161/STR.0b013e3181fcb238
PT  - Journal Article
PT  - Practice Guideline
LG  - English
EP  - 20101202
DP  - 2011 Feb
DC  - 20110125
YR  - 2011
ED  - 20110302
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21127304

<423. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21106919
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Shen J
AU  - Johnson VM
AU  - Sullivan LM
AU  - Jacques PF
AU  - Magnani JW
AU  - Lubitz SA
AU  - Pandey S
AU  - Levy D
AU  - Vasan RS
AU  - Quatromoni PA
AU  - Junyent M
AU  - Ordovas JM
AU  - Benjamin EJ
FA  - Shen, Jian
FA  - Johnson, Victor M
FA  - Sullivan, Lisa M
FA  - Jacques, Paul F
FA  - Magnani, Jared W
FA  - Lubitz, Steven A
FA  - Pandey, Shivda
FA  - Levy, Daniel
FA  - Vasan, Ramachandran S
FA  - Quatromoni, Paula A
FA  - Junyent, Mireia
FA  - Ordovas, Jose M
FA  - Benjamin, Emelia J
IN  - Shen,Jian. Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA.
TI  - Dietary factors and incident atrial fibrillation: the Framingham Heart Study.
SO  - American Journal of Clinical Nutrition. 93(2):261-6, 2011 Feb.
AS  - Am J Clin Nutr. 93(2):261-6, 2011 Feb.
NJ  - The American journal of clinical nutrition
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 3ey, 0376027
OI  - Source: NLM. PMC3021424
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Alcohol Drinking
MH  - Animals
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/et [Etiology]
MH  - *Caffeine/ad [Administration & Dosage]
MH  - Diet Surveys
MH  - *Dietary Fats/ad [Administration & Dosage]
MH  - *Dietary Fiber/ad [Administration & Dosage]
MH  - *Fatty Acids, Unsaturated/ad [Administration & Dosage]
MH  - Female
MH  - Fishes
MH  - Humans
MH  - Incidence
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Risk Factors
MH  - Seafood/ae [Adverse Effects]
MH  - Surveys and Questionnaires
AB  - BACKGROUND: There have been conflicting reported associations between dietary factors and incident atrial fibrillation (AF).
AB  - OBJECTIVE: We evaluated associations between consumption of alcohol, caffeine, fiber, and polyunsaturated fatty acids (PUFAs) and incident AF in the Framingham Heart Study.
AB  - DESIGN: Participants without AF (n = 4526; 9640 examinations; mean age: 62 y; 56% women) from the original and offspring cohorts completed food-frequency questionnaires and were followed prospectively for 4 y. We examined the associations between dietary exposures and AF with Cox proportional hazards regression.
AB  - RESULTS: A total of 296 individuals developed AF (177 men, 119 women). In multivariable analyses, there were no significant associations between examined dietary exposures and AF risk. Hazard ratios (HRs) for increasing quartiles of dietary factors were as follows: for alcohol, 0.73 (95% CI: 0.5, 1.05), 0.85 (95% CI: 0.61, 1.18), and 1.12 (95% CI: 0.83, 1.51) (P for trend = 0.48); for caffeine, 0.84 (95% CI: 0.62, 1.15), 0.87 (95% CI: 0.64, 1.2), and 0.98 (95% CI: 0.7, 1.39) (P for trend = 0.84); for total fiber, 0.86 (95% CI: 0.61, 1.2), 0.64 (95% CI: 0.44, 0.92), and 0.81 (95% CI: 0.54, 1.2) (P for trend = 0.16); and for n-3 (omega-3) PUFAs, 1.11 (95% CI: 0.81, 1.54), 0.92 (95% CI: 0.65, 1.29), and 1.18 (95% CI: 0.85, 1.64) (P for trend = 0.57; quartile 1 was the reference group). In exploratory analyses, consumption of >4 servings of dark fish/wk (5 cases and 21 individuals at risk) was significantly associated with AF risk compared with the consumption of <1 serving of dark fish/wk (HR: 6.53; 95% CI: 2.65, 16.06; P < 0.0001).
AB  - CONCLUSIONS: Consumption of alcohol, caffeine, fiber, and fish-derived PUFAs was not significantly associated with AF risk. The observed adverse association between the consumption of dark fish and AF merits further investigation. Our findings suggest that the dietary exposures examined convey limited attributable risk of AF in the general population.
RN  - 0 (Dietary Fats)
RN  - 0 (Fatty Acids, Unsaturated)
RN  - 3G6A5W338E (Caffeine)
ES  - 1938-3207
IL  - 0002-9165
DO  - http://dx.doi.org/10.3945/ajcn.110.001305
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
NO  - 1R01HL102214 (United States NHLBI NIH HHS)
NO  - 6R01-NS17950 (United States NINDS NIH HHS)
NO  - DK075030 (United States NIDDK NIH HHS)
NO  - HL-54776 (United States NHLBI NIH HHS)
NO  - HL092577 (United States NHLBI NIH HHS)
NO  - L30 HL097675 (United States NHLBI NIH HHS)
NO  - N01-HC 25195 (United States NHLBI NIH HHS)
NO  - RC1HL101056 (United States NHLBI NIH HHS)
LG  - English
EP  - 20101124
DP  - 2011 Feb
DC  - 20110121
YR  - 2011
ED  - 20110225
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21106919

<424. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20681943
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lopez-Cuenca A
AU  - Marin F
AU  - Roldan V
AU  - Gonzalez-Conejero R
AU  - Hernandez-Romero D
AU  - Valdes M
AU  - Lip GY
FA  - Lopez-Cuenca, Angel
FA  - Marin, Francisco
FA  - Roldan, Vanessa
FA  - Gonzalez-Conejero, Rocio
FA  - Hernandez-Romero, Diana
FA  - Valdes, Mariano
FA  - Lip, Gregory Y H
IN  - Lopez-Cuenca,Angel. Department of Cardiology, Hospital Universitario Virgen Arrixaca, Murcia, Spain.
TI  - Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk. [Review]
SO  - Annals of Medicine. 42(8):562-75, 2010 Dec.
AS  - Ann Med. 42(8):562-75, 2010 Dec.
NJ  - Annals of medicine
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - amd, 8906388
SB  - Index Medicus
CP  - England
MH  - *Atrial Fibrillation/co [Complications]
MH  - Humans
MH  - *Polymorphism, Single Nucleotide
MH  - Risk Factors
MH  - Stroke/ep [Epidemiology]
MH  - *Stroke/ge [Genetics]
MH  - Thromboembolism/ep [Epidemiology]
MH  - *Thromboembolism/ge [Genetics]
MH  - Thrombophilia/ep [Epidemiology]
MH  - *Thrombophilia/ge [Genetics]
AB  - The pathophysiology of thromboembolism in atrial fibrillation (AF) is a multifactorial and complex process. Abnormalities of haemostasis, fibrinolysis, endothelium, and platelets have all been described in AF. This prothrombotic state observed in AF appears to be additive to the presence of clinical and echocardiography risk factors for thromboembolism. Nonetheless, the precise mechanistic pathway(s) leading to the prothrombotic state in AF remain to be elucidated. Of note, there are limited data on the influence of genetic polymorphisms in thromboembolic risk associated with AF. On the other hand, the response to coumarin derivatives depends on several factors, such as sex, age, diet, or interacting drugs. Optimal anticoagulation control is usually hampered by significant interindividual variability in dose requirements for a given target level of anticoagulation. There is increasing evidence that interindividual sensitivity and side-effects to coumarinics may be largely determined genetically. Thus, genetic polymorphisms could explain the individual risk of developing an adverse drug reaction (bleeding) or drug inefficacy (thrombosis) with oral anticoagulation. In this article, we provide an overview of the limited data about the possible influence of genetic polymorphisms on thromboembolic risk in AF, as well as the genetic influences on anticoagulant drug responsiveness.
ES  - 1365-2060
IL  - 0785-3890
DO  - http://dx.doi.org/10.3109/07853890.2010.507601
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
LG  - English
EP  - 20100804
DP  - 2010 Dec
DC  - 20101112
YR  - 2010
ED  - 20110223
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20681943

<425. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20838006
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gronroos NN
AU  - Alonso A
FA  - Gronroos, Noelle N
FA  - Alonso, Alvaro
IN  - Gronroos,Noelle N. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN 55455, USA.
TI  - Diet and risk of atrial fibrillation - epidemiologic and clinical evidence -. [Review]
SO  - Circulation Journal. 74(10):2029-38, 2010 Oct.
AS  - Circ J. 74(10):2029-38, 2010 Oct.
NJ  - Circulation journal : official journal of the Japanese Circulation Society
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101137683
OI  - Source: NLM. NIHMS233565
OI  - Source: NLM. PMC2951273
SB  - Index Medicus
CP  - Japan
MH  - Alcohol Drinking/ae [Adverse Effects]
MH  - Animals
MH  - Ascorbic Acid/pd [Pharmacology]
MH  - *Atrial Fibrillation/et [Etiology]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - Caffeine/pd [Pharmacology]
MH  - *Diet
MH  - Fatty Acids, Omega-3/pd [Pharmacology]
MH  - Fishes
MH  - Humans
MH  - Risk
AB  - Dietary factors might affect the risk of atrial fibrillation (AF), but available studies have provided inconsistent results. A review of published observational studies and randomized trials identified 4 dietary exposures that had been investigated regarding AF risk: alcohol, fish-derived n-3 polyunsaturated fatty acids, caffeine, and ascorbic acid. Though studies were highly heterogeneous in their design and results, they showed a consistently increased risk of AF in heavy alcohol drinkers, but no risk associated with moderate alcohol intake. High coffee intake was not clearly associated with an increased risk of AF, and a potential U-shaped association (lower AF risk in moderate drinkers) could exist. High intake of fish-derived n-3 polyunsaturated fatty acids from diet or supplements might prevent AF episodes following cardiovascular events, but no consistent evidence supports an effect in primary prevention. Additional large, well-conducted randomized experiments are necessary to address the role of diet in AF prevention.
RN  - 0 (Fatty Acids, Omega-3)
RN  - 3G6A5W338E (Caffeine)
RN  - PQ6CK8PD0R (Ascorbic Acid)
ES  - 1347-4820
IL  - 1346-9843
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
NO  - RC1 HL099452 (United States NHLBI NIH HHS)
NO  - RC1 HL099452-01 (United States NHLBI NIH HHS)
NO  - RC1 HL099452-02 (United States NHLBI NIH HHS)
NO  - RC1HL099452 (United States NHLBI NIH HHS)
NO  - T32 HL07779 (United States NHLBI NIH HHS)
LG  - English
EP  - 20100911
DP  - 2010 Oct
DC  - 20100930
YR  - 2010
ED  - 20110223
RD  - 20141202
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20838006

<426. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20802505
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Shirwany NA
AU  - Zou MH
FA  - Shirwany, Najeeb A
FA  - Zou, Ming-hui
IN  - Shirwany,Najeeb A. Department of Medicine, University of Oklahoma Health Science Center, Oklahoma City, 73104, USA.
TI  - Arterial stiffness: a brief review. [Review]
SO  - Zhongguo Yao Li Xue Bao/Acta Pharmacologica Sinica. 31(10):1267-76, 2010 Oct.
AS  - Chung Kuo Yao Li Hsueh Pao. 31(10):1267-76, 2010 Oct.
NJ  - Acta pharmacologica Sinica
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 1p9, 8100330, dps, 100956087
OI  - Source: NLM. NIHMS262177
OI  - Source: NLM. PMC3078647
SB  - Index Medicus
CP  - United States
MH  - Aging/ph [Physiology]
MH  - Animals
MH  - Arteries/me [Metabolism]
MH  - *Arteries/pp [Physiopathology]
MH  - Cardiovascular Diseases/ge [Genetics]
MH  - Cardiovascular Diseases/me [Metabolism]
MH  - *Cardiovascular Diseases/pp [Physiopathology]
MH  - Diagnostic Techniques, Cardiovascular
MH  - Diet
MH  - *Elasticity
MH  - Endothelium, Vascular/pp [Physiopathology]
MH  - Glucose/ph [Physiology]
MH  - Humans
MH  - Insulin/ph [Physiology]
MH  - Neurosecretory Systems/pp [Physiopathology]
MH  - Risk Factors
MH  - *Vascular Resistance
AB  - Physical stiffening of the large arteries is the central paradigm of vascular aging. Indeed, stiffening in the larger central arterial system, such as the aortic tree, significantly contributes to cardiovascular diseases in older individuals and is positively associated with systolic hypertension, coronary artery disease, stroke, heart failure and atrial fibrillation, which are the leading causes of mortality in the developed countries and also in the developing world as estimated in 2010 by World Health Organizations. Thus, better, less invasive and more accurate measures of arterial stiffness have been developed, which prove useful as diagnostic indices, pathophysiological markers and predictive indicators of disease. This article presents a review of the structural determinants of vascular stiffening, its pathophysiologic determinants and its implications for vascular research and medicine. A critical discussion of new techniques for assessing vascular stiffness is also presented.
RN  - 0 (Insulin)
RN  - IY9XDZ35W2 (Glucose)
ES  - 1745-7254
IL  - 1671-4083
DO  - http://dx.doi.org/10.1038/aps.2010.123
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
NO  - HL074399 (United States NHLBI NIH HHS)
NO  - HL079584 (United States NHLBI NIH HHS)
NO  - HL080499 (United States NHLBI NIH HHS)
NO  - HL089920 (United States NHLBI NIH HHS)
NO  - HL096032 (United States NHLBI NIH HHS)
NO  - R01 HL074399 (United States NHLBI NIH HHS)
NO  - R01 HL079584 (United States NHLBI NIH HHS)
NO  - R01 HL080499 (United States NHLBI NIH HHS)
NO  - R01 HL089920 (United States NHLBI NIH HHS)
NO  - R01 HL096032 (United States NHLBI NIH HHS)
NO  - R01 HL105157 (United States NHLBI NIH HHS)
NO  - R01 HL110488 (United States NHLBI NIH HHS)
LG  - English
EP  - 20100830
DP  - 2010 Oct
DC  - 20101005
YR  - 2010
ED  - 20110217
RD  - 20141203
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20802505

<427. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19477377
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kitaoka H
AU  - Kubo T
AU  - Okawa M
AU  - Hirota T
AU  - Hayato K
AU  - Yamasaki N
AU  - Matsumura Y
AU  - Doi YL
FA  - Kitaoka, Hiroaki
FA  - Kubo, Toru
FA  - Okawa, Makoto
FA  - Hirota, Takayoshi
FA  - Hayato, Kayo
FA  - Yamasaki, Naohito
FA  - Matsumura, Yoshihisa
FA  - Doi, Yoshinori L
IN  - Kitaoka,Hiroaki. Division of Cardiology, Department of Medicine and Geriatrics, Kochi Medical School, Kochi, Japan. kitaokah@kochi-u.ac.jp
TI  - Utility of tissue Doppler imaging to predict exercise capacity in hypertrophic cardiomyopathy: comparison with B-type natriuretic peptide.
SO  - Journal of Cardiology. 53(3):361-7, 2009 Jun.
AS  - J Cardiol. 53(3):361-7, 2009 Jun.
NJ  - Journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - joa, 8804703
SB  - Index Medicus
CP  - Japan
MH  - Adult
MH  - Aged
MH  - Biomarkers/bl [Blood]
MH  - *Cardiomyopathy, Hypertrophic/pp [Physiopathology]
MH  - *Cardiomyopathy, Hypertrophic/us [Ultrasonography]
MH  - *Echocardiography, Doppler
MH  - *Exercise Tolerance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/bl [Blood]
MH  - Predictive Value of Tests
AB  - BACKGROUND: Recent reports suggest that left ventricular diastolic function assessed by tissue Doppler imaging (TDI) and plasma B-type natriuretic peptide (BNP) levels can relate to functional status in patients with hypertrophic cardiomyopathy (HCM). However, it is unclear which is more useful to predict the exercise capacity in HCM patients without systolic impairment and/or atrial fibrillation, TDI or BNP levels.
AB  - PURPOSE: The present study directly compared the clinical relevance of assessing diastolic function using TDI and measuring the plasma BNP level in patients with HCM.
AB  - METHODS AND SUBJECTS: We evaluated diastolic function using TDI as well as plasma BNP levels in 31 patients (52.2+/-16.9 years of age; 20 males) with HCM and examined the relationship of these values to exercise capacity (peak O(2) consumption (VO(2))) measured by cardiopulmonary exercise tests.
AB  - RESULTS: Average peak VO(2) was 18.5+/-4.7 ml/(kg min). Although the E/A ratio by transmitral flow was not correlated with peak VO(2), the lateral E/E(a) ratio assessed by TDI was significantly correlated with peak VO(2) (r=-0.52, p=0.003). On the other hand, plasma BNP level was not significantly related to peak VO(2) but NYHA class.
AB  - CONCLUSIONS: Assessment of diastolic function using TDI, not plasma BNP levels, is more useful for predicting objective exercise capacity in HCM patients without systolic impairment and/or atrial fibrillation.
RN  - 0 (Biomarkers)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
ES  - 1876-4738
IL  - 0914-5087
DO  - http://dx.doi.org/10.1016/j.jjcc.2008.12.012
PT  - Journal Article
LG  - English
EP  - 20090220
DP  - 2009 Jun
DC  - 20090529
YR  - 2009
ED  - 20110216
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19477377

<428. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20814766
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Geleijnse JM
AU  - de Goede J
AU  - Brouwer IA
FA  - Geleijnse, Johanna M
FA  - de Goede, Janette
FA  - Brouwer, Ingeborg A
IN  - Geleijnse,Johanna M. Division of Human Nutrition, Wageningen University, Wageningen, The Netherlands. marianne.geleijnse@wur.nl
TI  - Alpha-linolenic acid: is it essential to cardiovascular health?.
SO  - Current Atherosclerosis Reports. 12(6):359-67, 2010 Nov.
AS  - Curr Atheroscler Rep. 12(6):359-67, 2010 Nov.
NJ  - Current atherosclerosis reports
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 100897685, dyl
OI  - Source: NLM. PMC2943064
SB  - Index Medicus
CP  - United States
MH  - *Cardiovascular Diseases/dt [Drug Therapy]
MH  - *Docosahexaenoic Acids/ad [Administration & Dosage]
MH  - Drug Combinations
MH  - *Eicosapentaenoic Acid/ad [Administration & Dosage]
MH  - Female
MH  - Humans
MH  - Male
MH  - Treatment Outcome
MH  - *alpha-Linolenic Acid/ad [Administration & Dosage]
AB  - There is a large body of scientific evidence that has been confirmed in randomized controlled trials indicating a cardioprotective effect for omega-3 fatty acids from fish. For alpha-linolenic acid (ALA), which is the omega-3 fatty acid from plants, the relation to cardiovascular health is less clear. We reviewed the recent literature on dietary ALA intake, ALA tissue concentrations, and cardiovascular health in humans. Short-term trials (6-12 weeks) in generally healthy participants mostly showed no or inconsistent effects of ALA intake (1.2-3.6 g/d) on blood lipids, low-density lipoprotein oxidation, lipoprotein(a), and apolipoproteins A-I and B. Studies of ALA in relation to inflammatory markers and glucose metabolism yielded conflicting results. With regard to clinical cardiovascular outcomes, there is observational evidence for a protective effect against nonfatal myocardial infarction. However, no protective associations were observed between ALA status and risk of heart failure, atrial fibrillation, and sudden death. Findings from long-term trials of ALA supplementation are awaited to answer the question whether food-based or higher doses of ALA could be important for cardiovascular health in cardiac patients and the general population.
RN  - 0 (Drug Combinations)
RN  - 0 (Omacor)
RN  - 0RBV727H71 (alpha-Linolenic Acid)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - AAN7QOV9EA (Eicosapentaenoic Acid)
ES  - 1534-6242
IL  - 1523-3804
DO  - http://dx.doi.org/10.1007/s11883-010-0137-0
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2010 Nov
DC  - 20100921
YR  - 2010
ED  - 20110208
RD  - 20141202
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20814766

<429. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20689415
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Fukushima R
AU  - Yamazaki E
FA  - Fukushima, Ryoji
FA  - Yamazaki, Eriko
IN  - Fukushima,Ryoji. Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, Japan. ryojif@med.teikyo-u.ac.jp
TI  - Vitamin C requirement in surgical patients. [Review]
SO  - Current Opinion in Clinical Nutrition & Metabolic Care. 13(6):669-76, 2010 Nov.
AS  - Curr Opin Clin Nutr Metab Care. 13(6):669-76, 2010 Nov.
NJ  - Current opinion in clinical nutrition and metabolic care
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 9804399, dgn
SB  - Index Medicus
CP  - England
MH  - *Ascorbic Acid/ad [Administration & Dosage]
MH  - Ascorbic Acid/pd [Pharmacology]
MH  - Ascorbic Acid/tu [Therapeutic Use]
MH  - Ascorbic Acid Deficiency/bl [Blood]
MH  - *Ascorbic Acid Deficiency/dt [Drug Therapy]
MH  - *Critical Illness/th [Therapy]
MH  - *Dietary Supplements
MH  - Humans
MH  - Nutrition Policy
MH  - *Oxidative Stress/de [Drug Effects]
MH  - Parenteral Nutrition
MH  - Postoperative Care/mt [Methods]
MH  - *Postoperative Complications/dt [Drug Therapy]
AB  - PURPOSE OF REVIEW: To summarize recent findings on vitamin C status and assess the requirement and optimal dose of supplementation in surgical patients.
AB  - RECENT FINDINGS: Blood vitamin C concentration falls after uncomplicated surgery and further decreases in surgical intensive care unit patients. The decline may be owing to increased demand caused by increased oxidative stress. To normalize plasma vitamin C concentration, much higher doses than the recommended daily allowance or doses recommended in parenteral nutrition guidelines are needed in these patients. In uncomplicated surgical patients, more than 500 mg/day of vitamin C may be required, with much higher doses in surgical intensive care unit patients. In uncomplicated gastrointestinal surgery, continuous parenteral administration of 500 mg/day of vitamin C reduced postoperative oxidative stress as manifested by reduced urinary excretion of isoprostane. In some studies, postoperative atrial fibrillation was prevented after cardiac surgery by perioperative vitamin C supplementation. In critically ill patients, some prospective randomized controlled trials support parenteral supplementation of high doses of vitamin C, E and trace elements.
AB  - SUMMARY: Vitamin C requirement is increased in surgical patients, and the potential advantage of supplementation is to increase the plasma and tissue levels of vitamin C and thereby reduce oxidative stress. Although some clinical benefits of high-dose vitamin C supplementation have been shown in the critically ill, the optimal dose for supplementation and the clinical benefits remain to be investigated in surgical patients.
RN  - PQ6CK8PD0R (Ascorbic Acid)
ES  - 1473-6519
IL  - 1363-1950
DO  - http://dx.doi.org/10.1097/MCO.0b013e32833e05bc
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2010 Nov
DC  - 20101026
YR  - 2010
ED  - 20110203
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20689415

<430. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20487352
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wozakowska-Kaplon B
AU  - Opolski G
FA  - Wozakowska-Kaplon, Beata
FA  - Opolski, Grzegorz
IN  - Wozakowska-Kaplon,Beata. 1st Clinical Department of Cardiology, Swietokrzyskie Centre of Cardiology in Kielce, ul. Grunwaldzka 45, Kielce, Poland. bw.kaplon@poczta.onet.pl
TI  - Exercise-induced natriuretic peptide secretion predicts cardioversion outcome in patients with persistent atrial fibrillation: discordant ANP and B-type natriuretic peptide response to exercise testing.
SO  - Pacing & Clinical Electrophysiology. 33(10):1203-9, 2010 Oct.
AS  - Pacing Clin Electrophysiol. 33(10):1203-9, 2010 Oct.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - pab, 7803944
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation/bl [Blood]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Atrial Natriuretic Factor/bl [Blood]
MH  - Atrial Natriuretic Factor/se [Secretion]
MH  - Chronic Disease
MH  - Coronary Sinus/pp [Physiopathology]
MH  - *Electric Countershock
MH  - Exercise Test
MH  - Humans
MH  - Middle Aged
MH  - *Natriuretic Peptide, Brain/bl [Blood]
MH  - Natriuretic Peptide, Brain/se [Secretion]
MH  - Prognosis
MH  - Prospective Studies
MH  - Treatment Outcome
AB  - BACKGROUND: Measurement of natriuretic peptide's (NP) release in response to hemodynamic stress may be complementary to its baseline assessment in individuals. Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) increase in patients with atrial fibrillation (AF) and decrease after successful cardioversion, suggesting that AF may stimulate secretion of NPs. However, there are conflicting data on the predictive value of NPs on the cardioversion outcome.
AB  - OBJECTIVES: The purpose of this study was to investigate whether baseline and exercise-induced NP plasma levels can be useful in predicting successful cardioversion of persistent AF and maintenance of sinus rhythm during 6-month follow-up.
AB  - METHODS: A prospective study enrolled 77 consecutive subjects with persistent AF with normal left ventricular function, referred for elective cardioversion. Patients underwent a modified Bruce protocol treadmill exercise test 24 hours before cardioversion. Blood samples for ANP and BNP analyses were obtained at rest and 5 minutes after exercise peak.
AB  - RESULTS: The group of successful cardioversion and stable sinus rhythm presented higher exercise ANP (110.6 +/- 41.2 pg/mL vs 43.8 +/- 36.1; pg/mL, P < 0.0001) and lower BNP increase (5.2 +/- 5.2 pg/mL vs 40.5 +/- 34.2 pg/mL, P < 0.0001) than the group of unsuccessful cardioversion or AF recurrence. Using an optimized cutoff level of <12% of relative exercise-induced increase in BNP concentration, and of >50 pg/mL of ANP increase, successful cardioversion can be predicted with high accuracy.
AB  - CONCLUSIONS: An increase in ANP and stability of BNP plasma concentration during exercise testing are independently associated with successful cardioversion and maintenance of sinus rhythm during 6-month follow-up. (PACE 2010; 33:1203-1209).Copyright ©2010, The Authors. Journal compilation ©2010 Wiley Periodicals, Inc.
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
ES  - 1540-8159
IL  - 0147-8389
DO  - http://dx.doi.org/10.1111/j.1540-8159.2010.02789.x
PT  - Journal Article
LG  - English
DP  - 2010 Oct
DC  - 20100930
YR  - 2010
ED  - 20110201
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20487352

<431. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21094363
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Chao TF
AU  - Suenari K
AU  - Chang SL
AU  - Lin YJ
AU  - Lo LW
AU  - Hu YF
AU  - Tuan TC
AU  - Tai CT
AU  - Tsao HM
AU  - Li CH
AU  - Ueng KC
AU  - Wu TJ
AU  - Chen SA
FA  - Chao, Tze-Fan
FA  - Suenari, Kazuyoshi
FA  - Chang, Shih-Lin
FA  - Lin, Yenn-Jiang
FA  - Lo, Li-Wei
FA  - Hu, Yu-Feng
FA  - Tuan, Ta-Chuan
FA  - Tai, Ching-Tai
FA  - Tsao, Hsuan-Ming
FA  - Li, Cheng-Hung
FA  - Ueng, Kuo-Chang
FA  - Wu, Tsu-Juey
FA  - Chen, Shih-Ann
IN  - Chao,Tze-Fan. Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
TI  - Atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose.
SO  - American Journal of Cardiology. 106(11):1615-20, 2010 Dec 1.
AS  - Am J Cardiol. 106(11):1615-20, 2010 Dec 1.
NJ  - The American journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/su [Surgery]
MH  - *Blood Glucose/me [Metabolism]
MH  - *Body Surface Potential Mapping/mt [Methods]
MH  - *Catheter Ablation
MH  - *Diabetes Mellitus/bl [Blood]
MH  - Fasting/bl [Blood]
MH  - Female
MH  - Follow-Up Studies
MH  - *Glucose Intolerance/bl [Blood]
MH  - Glucose Intolerance/co [Complications]
MH  - Heart Atria/pp [Physiopathology]
MH  - Heart Atria/su [Surgery]
MH  - Humans
MH  - Imaging, Three-Dimensional
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Recurrence
MH  - Tachycardia, Paroxysmal/co [Complications]
MH  - *Tachycardia, Paroxysmal/pp [Physiopathology]
MH  - Tachycardia, Paroxysmal/su [Surgery]
MH  - Young Adult
AB  - Diabetes mellitus has been reported to be an independent risk factor of atrial fibrillation (AF). The present study investigated the atrial substrate properties and clinical outcome of catheter ablation in patients with paroxysmal AF and abnormal glucose metabolism. A total of 228 patients with paroxysmal AF who had undergone catheter ablation for the first time were enrolled. An abnormal glucose metabolism (n = 65) was defined as diabetes mellitus or an impaired fasting glucose. We analyzed the clinical and electrophysiologic characteristics in, and the clinical outcome of, patients with AF with and without an abnormal glucose metabolism. The right atrial (107.2 +/- 15.4 vs 96.0 +/- 16.5 ms, p < 0.001) and left atrial (108.4 +/- 22.3 vs 94.0 +/- 17.5 ms, p < 0.001) total activation times were significantly longer in the patients with AF and an abnormal glucose metabolism than in those without an abnormal metabolism. Furthermore, the right atrial (1.46 +/- 0.61 vs 2.00 +/- 0.70 mV, p < 0.001) and left atrial (1.48 +/- 0.74 vs 2.05 +/- 0.78 mV, p < 0.001) bipolar voltages were significantly lower in those with AF and an abnormal glucose metabolism than in those without. The AF recurrence rate was also greater in the patients with an abnormal glucose metabolism (18.5% vs 8.0%, p = 0.022) than in those without. The follow-up duration was 18.8 +/- 6.4 months. In conclusion, an abnormal glucose metabolism affects the biatrial substrate properties with an intra-atrial conduction delay, decreased voltage, and greater recurrence rate after catheter ablation.Copyright © 2010 Elsevier Inc. All rights reserved.
RN  - 0 (Blood Glucose)
ES  - 1879-1913
IL  - 0002-9149
DO  - http://dx.doi.org/10.1016/j.amjcard.2010.07.038
PT  - Comparative Study
PT  - Journal Article
LG  - English
EP  - 20101014
DP  - 2010 Dec 1
DC  - 20101124
YR  - 2010
ED  - 20110120
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21094363

<432. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 21070922
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Smith JG
AU  - Newton-Cheh C
AU  - Almgren P
AU  - Struck J
AU  - Morgenthaler NG
AU  - Bergmann A
AU  - Platonov PG
AU  - Hedblad B
AU  - Engstrom G
AU  - Wang TJ
AU  - Melander O
FA  - Smith, J Gustav
FA  - Newton-Cheh, Christopher
FA  - Almgren, Peter
FA  - Struck, Joachim
FA  - Morgenthaler, Nils G
FA  - Bergmann, Andreas
FA  - Platonov, Pyotr G
FA  - Hedblad, Bo
FA  - Engstrom, Gunnar
FA  - Wang, Thomas J
FA  - Melander, Olle
IN  - Smith,J Gustav. Department of Clinical Sciences, Lund University, Malmo, Sweden. gustav.smith@med.lu.se
TI  - Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation.
SO  - Journal of the American College of Cardiology. 56(21):1712-9, 2010 Nov 16.
AS  - J Am Coll Cardiol. 56(21):1712-9, 2010 Nov 16.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - h50, 8301365
OI  - Source: NLM. NIHMS248337
OI  - Source: NLM. PMC3005324
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Fibrillation/bl [Blood]
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Natriuretic Factor/bl [Blood]
MH  - *Biomarkers/bl [Blood]
MH  - C-Reactive Protein/me [Metabolism]
MH  - Confidence Intervals
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/bl [Blood]
MH  - Heart Failure/co [Complications]
MH  - *Heart Failure/ep [Epidemiology]
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/bl [Blood]
MH  - Odds Ratio
MH  - Peptide Fragments/bl [Blood]
MH  - Prognosis
MH  - Prospective Studies
MH  - Protein Precursors
MH  - ROC Curve
MH  - *Risk Assessment/mt [Methods]
MH  - Risk Factors
MH  - Sweden/ep [Epidemiology]
MH  - Time Factors
AB  - OBJECTIVES: the purpose of this study was to assess the predictive accuracy of conventional cardiovascular risk factors for incident heart failure and atrial fibrillation, and the added benefit of multiple biomarkers reflecting diverse pathophysiological pathways.
AB  - BACKGROUND: heart failure and atrial fibrillation are interrelated cardiac diseases associated with substantial morbidity and mortality and increasing incidence. Data on prediction and prevention of these diseases in healthy individuals are limited.
AB  - METHODS: in 5,187 individuals from the community-based MDCS (Malmo Diet and Cancer Study), we studied the performance of conventional risk factors and 6 biomarkers including midregional pro-atrial natriuretic peptide (MR-proANP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), midregional pro-adrenomedullin, cystatin C, C-reactive protein (CRP), and copeptin.
AB  - RESULTS: during a mean follow-up of 14 years, 112 individuals were diagnosed with heart failure and 284 individuals with atrial fibrillation. NT-proBNP (hazard ratio [HR]: 1.63 per SD, 95% confidence interval [CI]: 1.29 to 2.06, p < 0.001), CRP (HR: 1.57 per SD, 95% CI: 1.28 to 1.94, p < 0.001), and MR-proANP (HR: 1.26 per SD, 95% CI: 1.02 to 1.56, p = 0.03) predicted incident heart failure independently of conventional risk factors and other biomarkers. MR-proANP (HR: 1.62, 95% CI: 1.42 to 1.84, p < 0.001) and CRP (HR: 1.18, 95% CI: 1.03 to 1.34, p = 0.01) independently predicted atrial fibrillation. Addition of biomarkers to conventional risk factors improved c-statistics from 0.815 to 0.842 for heart failure and from 0.732 to 0.753 for atrial fibrillation and the integrated discrimination improvement for both diseases (p < 0.001). Net reclassification improvement (NRI) with biomarkers was observed in 22% of individuals for heart failure (NRI, p < 0.001) and in 7% for atrial fibrillation (NRI, p = 0.06), mainly due to up-classification of individuals who developed disease (heart failure: 29%, atrial fibrillation: 19%). Addition of CRP to natriuretic peptides did not improve discrimination or reclassification.
AB  - CONCLUSIONS: conventional cardiovascular risk factors predict incident heart failure and atrial fibrillation with reasonable accuracy in middle-age individuals free from disease. Natriuretic peptides, but not other biomarkers, improve discrimination modestly for both diseases above and beyond conventional risk factors and substantially improve risk classification for heart failure.Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
RN  - 0 (Biomarkers)
RN  - 0 (Peptide Fragments)
RN  - 0 (Protein Precursors)
RN  - 0 (midregional pro-atrial natriuretic peptide, human)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
RN  - 9007-41-4 (C-Reactive Protein)
ES  - 1558-3597
IL  - 0735-1097
DO  - http://dx.doi.org/10.1016/j.jacc.2010.05.049
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
NO  - K23 HL074077 (United States NHLBI NIH HHS)
NO  - K23 HL074077-05 (United States NHLBI NIH HHS)
NO  - K23 HL080025 (United States NHLBI NIH HHS)
NO  - K23 HL080025-05 (United States NHLBI NIH HHS)
NO  - K23-HL-080025 (United States NHLBI NIH HHS)
NO  - R01-DK-081572 (United States NIDDK NIH HHS)
NO  - R01-HL-083197 (United States NHLBI NIH HHS)
NO  - R01-HL-086875 (United States NHLBI NIH HHS)
LG  - English
DP  - 2010 Nov 16
DC  - 20101112
YR  - 2010
ED  - 20110111
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=21070922

<433. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19268072
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Facila L
AU  - Bertomeu-Gonzalez V
AU  - Bertomeu V
AU  - Gonzalez-Juanatey JR
AU  - Mazon P
AU  - Morillas P
AU  - RICAR group
FA  - Facila, Lorenzo
FA  - Bertomeu-Gonzalez, Vicente
FA  - Bertomeu, Vicente
FA  - Gonzalez-Juanatey, Jose R
FA  - Mazon, Pilar
FA  - Morillas, Pedro
FA  - RICAR group
IN  - Facila,Lorenzo. Servicio de Cardiologia, Hospital Provincial de Castellon, Avda. Dr. Clara, 19. 12002 Castellon de la Plana, Spain. lfacila@gmail.com
TI  - Importance of recognizing occult renal disease in hypertensive patients.
SO  - Revista Espanola de Cardiologia. 62(3):282-7, 2009 Mar.
AS  - Rev Esp Cardiol. 62(3):282-7, 2009 Mar.
NJ  - Revista espanola de cardiologia
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - rtd, 0404277
SB  - Index Medicus
CP  - Spain
MH  - Aged
MH  - Cross-Sectional Studies
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Humans
MH  - *Hypertension/co [Complications]
MH  - Hypertension/ep [Epidemiology]
MH  - *Kidney Diseases/di [Diagnosis]
MH  - Kidney Diseases/ep [Epidemiology]
MH  - *Kidney Diseases/et [Etiology]
MH  - Kidney Function Tests
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Risk Factors
AB  - INTRODUCTION AND OBJECTIVES: Occult renal disease (ORD) is a condition that characterizes the early stages of renal failure and which cannot be detected by routine monitoring. The aims of this study were to determine the prevalence of ORD in hypertensive patients attending cardiology outpatient clinics and to identify its relationship with specific cardiovascular risk factors or treatment.
AB  - METHODS: A cross-sectional, retrospective, multicenter observational study was carried out in 1214 hypertensive patients attending cardiology outpatient clinics.
AB  - RESULTS: Data from 1190 patients (98%) were analyzed. In 11%, the glomerular filtration rate (GFR) was calculated by the attending cardiologist using the Modification of Diet in Renal Disease equation. Overall, 9.5% of patients were found to have ORD. Affected patients were more likely to be female, to be older, to have a history of dyslipidemia, diabetes, a sedentary lifestyle or atrial fibrillation or a long history of hypertension compared with those without ORD, but were less likely to have a history of dyslipidemia, diabetes or a sedentary lifestyle than those with renal failure. There was no significant difference in treatment. Moreover, ORD was observed in 2.9% (two of 68) of those aged under 50 years, in 3.3% (seven of 210) aged 50-60 years, in 9.3% (37 out of 398) aged 60-70 years and in 13.5% (70 out of 518) aged over 70 years.
AB  - CONCLUSIONS: Almost 10% of hypertensive patients reviewed by a cardiologist had moderate renal dysfunction that had not been investigated. They represent an unrecognized population with an intermediate cardiovascular risk. Consequently, it is recommended that the GFR should be calculated, especially in women and older patients.
ES  - 1579-2242
IL  - 0300-8932
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
LG  - English
LG  - Spanish
DP  - 2009 Mar
DC  - 20090309
YR  - 2009
ED  - 20101208
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19268072

<434. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20720241
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Thomas KS
AU  - Billingsley A
AU  - Amarshi N
AU  - Nair BA
FA  - Thomas, Kelly S
FA  - Billingsley, Amanda
FA  - Amarshi, Naseem
FA  - Nair, Balagopalan A
IN  - Thomas,Kelly S. Central Arkansas Veterans Healthcare System, Little Rock, USA. kelly.thomas@va.gov
TI  - Elevated international normalized ratio associated with concomitant warfarin and erlotinib.
SO  - American Journal of Health-System Pharmacy. 67(17):1426-9, 2010 Sep 1.
AS  - Am J Health-Syst Pharm. 67(17):1426-9, 2010 Sep 1.
NJ  - American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 9503023, cbh
SB  - Index Medicus
CP  - United States
MH  - Adenocarcinoma/dt [Drug Therapy]
MH  - *Anticoagulants/ae [Adverse Effects]
MH  - Carcinoma, Non-Small-Cell Lung/dt [Drug Therapy]
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Erlotinib Hydrochloride
MH  - Humans
MH  - *International Normalized Ratio
MH  - Lung Neoplasms/dt [Drug Therapy]
MH  - Male
MH  - Middle Aged
MH  - *Quinazolines/ae [Adverse Effects]
MH  - Thromboembolism/dt [Drug Therapy]
MH  - *Warfarin/ae [Adverse Effects]
AB  - PURPOSE: The case of a patient who developed elevated International Normalized Ratio (INR) values after concomitant administration of warfarin and erlotinib is reported.
AB  - SUMMARY: A 47-year-old Caucasian man with a history of atrial fibrillation, anxiety, and a 40-pack-year smoking history was diagnosed with advanced, moderately differentiated adenocarcinoma of the lung. Soon after being diagnosed with non-small-cell lung cancer, warfarin was initiated for the treatment of a venous thromboembolism. The patient's warfarin dosage was adjusted to reach a target INR of 2-3. His INR was relatively stable (2.1-3.2) for at least eight weeks before erlotinib was added to the chemotherapy regimen. The patient developed a well-disseminated rash and diarrhea soon after starting erlotinib. Seven days after the initiation of erlotinib therapy, the patient's INR value increased from 2.8 to 5.3, with no concurrent changes in warfarin dosage, other medications, or diet. After withholding two doses of warfarin, the patient's INR value increased to 9.1, and the patient developed an elbow hematoma. His anticoagulation was rapidly reversed with the administration of subcutaneous phytonadione. The patient elected to discontinue erlotinib nine days after its initiation. The next day, his INR value was 2.4. The patient returned to the hematology-oncology clinic for follow-up two days later, where his INR was found to be 0.9.
AB  - CONCLUSION: Concomitant administration of erlotinib and warfarin resulted in an increase in INR values in a 47-year-old man with advanced lung cancer.
RN  - 0 (Anticoagulants)
RN  - 0 (Quinazolines)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - DA87705X9K (Erlotinib Hydrochloride)
ES  - 1535-2900
IL  - 1079-2082
DO  - http://dx.doi.org/10.2146/ajhp090202
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2010 Sep 1
DC  - 20100819
YR  - 2010
ED  - 20101130
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20720241

<435. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20605084
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wassertheil-Smoller S
FA  - Wassertheil-Smoller, Sylvia
IN  - Wassertheil-Smoller,Sylvia. Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, United States. sylvia.smoller@einstein.yu.edu
TI  - Stroke in women. [Review]
SO  - Nutrition Metabolism & Cardiovascular Diseases. 20(6):419-25, 2010 Jul.
AS  - Nutr Metab Cardiovasc Dis. 20(6):419-25, 2010 Jul.
NJ  - Nutrition, metabolism, and cardiovascular diseases : NMCD
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9111474, DGW
OI  - Source: NLM. NIHMS183950
OI  - Source: NLM. PMC3993990
SB  - Index Medicus
CP  - Germany
MH  - Biomarkers/bl [Blood]
MH  - Estrogen Replacement Therapy/ae [Adverse Effects]
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Humans
MH  - Hypertension/co [Complications]
MH  - Hypertension/dt [Drug Therapy]
MH  - Incidence
MH  - Inflammation Mediators/bl [Blood]
MH  - Prevalence
MH  - Risk Factors
MH  - Stroke/co [Complications]
MH  - *Stroke/ep [Epidemiology]
MH  - Stroke/ge [Genetics]
MH  - Stroke/pc [Prevention & Control]
MH  - Women's Health/hi [History]
MH  - *Women's Health
AB  - AIMS: The aim of this article is to provide an overview of stroke in women and describe modifiable and non-modifiable risk factors for stroke.
AB  - DATA SYNTHESIS: Data supporting this article come from the National Center for Health Statistics, from American Heart Association publications, and from some of the large, multicenter trials and observational studies that inform guidelines for prevention of stroke. These data indicate that stroke is the third leading cause of death in women, that risk for stroke rises rapidly with age, and that the strongest risk factors for stroke are high blood pressure and atrial fibrillation, as well as diabetes and smoking. Risk rises rapidly when two or more risk factors are present. Hormone therapy in postmenopausal women increases risk of ischemic, but not hemorrhagic stroke, by 40-50%. Biomarkers of inflammation are associated with stroke risk. Other risk factors include certain lipids, physical inactivity, and low potassium diets. Although there has been improvement in the past decade, control of hypertension is inadequate in older women and many strokes could be prevented by better treatment of hypertension.
AB  - CONCLUSION: Death and disability from stroke can be reduced with modification, treatment, and better control of risk factors like hypertension, diabetes and atrial fibrillation.Copyright 2010 Elsevier B.V. All rights reserved.
RN  - 0 (Biomarkers)
RN  - 0 (Inflammation Mediators)
ES  - 1590-3729
IL  - 0939-4753
DO  - http://dx.doi.org/10.1016/j.numecd.2010.02.017
PT  - Historical Article
PT  - Journal Article
PT  - Review
NO  - N01 WH042119 (United States WHI NIH HHS)
NO  - R01 NS042618 (United States NINDS NIH HHS)
LG  - English
EP  - 20100706
DP  - 2010 Jul
DC  - 20100723
YR  - 2010
ED  - 20101116
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20605084

<436. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20670180
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Grimsmo J
AU  - Arnesen H
FA  - Grimsmo, Jostein
FA  - Arnesen, Harald
TI  - The relationship between exercise and the healthy heart: trouble in paradise?.
SO  - Expert Review of Cardiovascular Therapy. 8(8):1047-8, 2010 Aug.
AS  - Expert Rev Cardiovasc Ther. 8(8):1047-8, 2010 Aug.
NJ  - Expert review of cardiovascular therapy
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101182328
SB  - Index Medicus
CP  - England
MH  - Age Factors
MH  - Aged
MH  - Athletes
MH  - *Atrial Fibrillation/et [Etiology]
MH  - *Exercise
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Physical Endurance
MH  - Risk Factors
ES  - 1744-8344
IL  - 1477-9072
DO  - http://dx.doi.org/10.1586/erc.10.69
PT  - Editorial
LG  - English
DP  - 2010 Aug
DC  - 20100730
YR  - 2010
ED  - 20101104
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20670180

<437. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19769703
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Saura D
AU  - Marin F
AU  - Climent V
AU  - Gonzalez J
AU  - Roldan V
AU  - Hernandez-Romero D
AU  - Oliva MJ
AU  - Sabater M
AU  - de la Morena G
AU  - Lip GY
AU  - Valdes M
FA  - Saura, D
FA  - Marin, F
FA  - Climent, V
FA  - Gonzalez, J
FA  - Roldan, V
FA  - Hernandez-Romero, D
FA  - Oliva, M J
FA  - Sabater, M
FA  - de la Morena, G
FA  - Lip, G Y H
FA  - Valdes, M
IN  - Saura,D. Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
TI  - Left atrial remodelling in hypertrophic cardiomyopathy: relation with exercise capacity and biochemical markers of tissue strain and remodelling.
SO  - International Journal of Clinical Practice. 63(10):1465-71, 2009 Oct.
AS  - Int J Clin Pract. 63(10):1465-71, 2009 Oct.
NJ  - International journal of clinical practice
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - cvt, 9712381
SB  - Index Medicus
CP  - England
MH  - Adult
MH  - *Atrial Fibrillation/pa [Pathology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Function, Left/ph [Physiology]
MH  - *Biomarkers/me [Metabolism]
MH  - C-Reactive Protein/me [Metabolism]
MH  - *Cardiomyopathy, Hypertrophic/pa [Pathology]
MH  - Cardiomyopathy, Hypertrophic/pp [Physiopathology]
MH  - Exercise Test
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - Heart Atria
MH  - Humans
MH  - Male
MH  - Matrix Metalloproteinase 2/me [Metabolism]
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/me [Metabolism]
MH  - Peptide Fragments/me [Metabolism]
MH  - *Stress, Physiological/ph [Physiology]
MH  - Tissue Inhibitor of Metalloproteinase-1/me [Metabolism]
AB  - BACKGROUND: Left atrial remodelling, assessed as left atrial volume (LAV), has been proposed as a good marker of left ventricular diastolic dysfunction. The aim of this study was to analyse the influence of LAV on exercise performance in hypertrophic cardiomyopathy (HCM), and in a subset of subjects, assess the relation of LAV and exercise performance to four biomarkers of disease pathophysiology: matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) (as indices of tissue remodelling), N-terminal portion of pro B-type natriuretic peptide (NT-pro-BNP) (associated with ventricular dysfunction) and C-reactive protein (CRP, an index of inflammation).
AB  - METHODS: We studied 75 consecutive HCM patients (aged 46 +/- 14 years, 56 men) where LAV was calculated assuming the ellipsoid model with two orthogonal planes. LAV was indexed to body surface area. Exercise capacity was evaluated by treadmill exercise test (symptom limited) and assessed with metabolic equivalent units (MET). Basal NT-pro-BNP and CRP levels were measured in 70 patients, whereas MMP-2 and TIMP-1 in 43 patients.
AB  - RESULTS: Enlarged LAV was observed in those patients with previous atrial fibrillation (p = 0.016). Mean LAV was greater in patients with impaired functional New York Heart Association (NYHA) class (p < 0.001). LAV correlated with age (Spearman, r: 0.28), higher maximal left ventricular wall thickness (r: 0.32) and raised E/A ratio (r: 0.37) (all p < 0.01). LAV was significantly correlated with NT-pro-BNP values (r: 0.34; p = 0.04), MMP-2 (r: 0.32; p = 0.034), CRP (r: 0.33; p = 0.005) and correlated inversely with MET units (r: -0.39; p < 0.01). In multivariate analysis, MET units were only associated with NT-pro-BNP (p = 0.002) and LAV (p = 0.010).
AB  - CONCLUSIONS: Enlarged LAV is associated with impaired functional NYHA class and inversely with treadmill exercise capacity. Enlarged LAV is also associated with NT-pro-BNP, MMP-2 and CRP, perhaps as markers of disease severity and tissue remodelling. Age, LAV and NT-pro-BNP are independent predictors of exercise performance.
RN  - 0 (Biomarkers)
RN  - 0 (Peptide Fragments)
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 3-4-24-24 (Matrix Metalloproteinase 2)
ES  - 1742-1241
IL  - 1368-5031
DO  - http://dx.doi.org/10.1111/j.1742-1241.2009.02127.x
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2009 Oct
DC  - 20090922
YR  - 2009
ED  - 20101101
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19769703

<438. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20353898
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Singhal P
AU  - Kejriwal N
FA  - Singhal, P
FA  - Kejriwal, N
IN  - Singhal,P. Department of Cardiothoracic Surgery, Waikato Hospital, Hamilton, New Zealand. singhal_pk@hotmail.com
TI  - Right atrial pacing for prevention of postoperative atrial fibrillation following coronary artery bypass grafting: a prospective observational trial.
SO  - Heart, Lung & Circulation. 19(7):395-9, 2010 Jul.
AS  - Heart Lung Circ. 19(7):395-9, 2010 Jul.
NJ  - Heart, lung & circulation
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 100963739
SB  - Index Medicus
CP  - Australia
MH  - Aged
MH  - *Atrial Fibrillation/et [Etiology]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - *Cardiac Pacing, Artificial/mt [Methods]
MH  - Case-Control Studies
MH  - *Coronary Artery Bypass/ae [Adverse Effects]
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Postoperative Complications/pc [Prevention & Control]
MH  - Prospective Studies
AB  - INTRODUCTION: Atrial fibrillation (AF) is the most common complication after coronary artery bypass grafting (CABG). Conventional clinical practice is to treat AF after its onset in the postoperative period. However effective prophylaxis can result in reduced morbidity and hospital stay. This prospective study was designed to assess the efficacy of right atrial pacing in the prevention of postoperative AF following CABG.
AB  - METHODS: All patients who had isolated first time CABG on cardiopulmonary bypass between January 2007 and June 2007, operated by one surgeon were included in this study (study group). During the same period, isolated CABG carried out by other surgeons in the same unit and not paced served as control (control group). In the study group (n=24) right atrial pacing was continued for 96h in the postoperative period. The end points of the study were occurrence of AF, death in postoperative period or discharge from hospital.
AB  - RESULTS: In the study group 5 patients could not be paced because of persistent tachycardia or failure of atrial electrodes. There was a statistically significant reduction in the incidence of postoperative atrial fibrillation from 31.1% in control group to 5.2% (p-value 0.03) in patients who were paced.
AB  - CONCLUSIONS: The preliminary results of this study suggest that prophylactic right atrial pacing significantly reduced the incidence of AF following CABG. However these results need to be confirmed in a larger cohort of patients in a prospective randomised trial.Copyright (c) 2010 Australasian Society of Cardiac and Thoracic Surgeons and the Cardiac Society of Australia and New Zealand. Published by Elsevier B.V. All rights reserved.
ES  - 1444-2892
IL  - 1443-9506
DO  - http://dx.doi.org/10.1016/j.hlc.2010.02.004
PT  - Journal Article
LG  - English
EP  - 20100329
DP  - 2010 Jul
DC  - 20100715
YR  - 2010
ED  - 20101028
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20353898

<439. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17996968
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mattioli AV
AU  - Bonatti S
AU  - Melotti R
AU  - Mattioli G
FA  - Mattioli, Anna Vittoria
FA  - Bonatti, Silvia
FA  - Melotti, Roberto
FA  - Mattioli, Giorgio
IN  - Mattioli,Anna Vittoria. National Institute of Cardiovascular Research, Laboratory of Cardiology, University of Modena and Reggio Emilia, Italy. mattioli.annavittoria@unimore.it
TI  - Atrial stunning, inflammation and nutritional status after cardioversion from atrial fibrillation.
SO  - International Journal of Cardiology. 129(3):344-7, 2008 Oct 13.
AS  - Int J Cardiol. 129(3):344-7, 2008 Oct 13.
NJ  - International journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - gqw, 8200291
SB  - Index Medicus
CP  - Netherlands
MH  - Aged
MH  - *Atrial Fibrillation/pa [Pathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Atrial Fibrillation/us [Ultrasonography]
MH  - Atrial Function, Left/ph [Physiology]
MH  - Electric Countershock/ae [Adverse Effects]
MH  - *Electric Countershock
MH  - Female
MH  - Humans
MH  - Inflammation/et [Etiology]
MH  - Inflammation/pa [Pathology]
MH  - Inflammation/us [Ultrasonography]
MH  - Iron/bl [Blood]
MH  - Male
MH  - Middle Aged
MH  - Myocardial Stunning/et [Etiology]
MH  - *Myocardial Stunning/pa [Pathology]
MH  - *Myocardial Stunning/th [Therapy]
MH  - Nutritional Status/ph [Physiology]
MH  - *Nutritional Status
AB  - BACKGROUND: Conversion of atrial fibrillation (A-Fib) to sinus rhythm is associated with transient mechanical dysfunction of left atrium and appendage, termed atrial stunning.
AB  - OBJECTIVES: The aim of the present study was to evaluate the relationship between nutritional status and atrial stunning after conversion of A-fib.
AB  - METHODS: Fifty-eight hemodynamically stable patients referred for cardioversion for lone AF were included in this study. To assess nutritional status and inflammation we measured: hemoglobin, erythrocyte mean cell volume, increased transferrin, decreased percent transferrin saturation and ferritin, albumin, CRP and Fe. Usual dietary intake was assessed with the use of a semi-quantitative food frequency questionnaire. LA function was assessed using peak atrial filling velocity, atrial ejection force and peak of emptying and filling velocities of left atrial appendage.
AB  - RESULTS: Patients were categorized in 4 groups according to value of CRP and Fe. Patients with normal value of CRP and normal value of Fe and patients with elevated CRP but normal value of Fe showed no difference in parameters of atrial function. On contrary patients with reduced value of Fe showed significantly reduced parameters of atrial function.
AB  - CONCLUSIONS: Data of the present study showed that patients with a reduction of Fe present a marked dysfunction of atrial contractility in comparison with other groups. We cautiously hypothesize an iron mechanism. The hemodynamic stress due to A-Fib can generate highly toxic hydroxyl radicals. These oxygen free radicals probably damage cells by oxidating various cell components and could be important in inducing myocardial stunning after A-Fib.
RN  - E1UOL152H7 (Iron)
ES  - 1874-1754
IL  - 0167-5273
PT  - Comparative Study
PT  - Journal Article
LG  - English
EP  - 20071109
DP  - 2008 Oct 13
DC  - 20100223
YR  - 2008
ED  - 20100923
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17996968

<440. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20502012
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Smith MB
AU  - Christensen N
AU  - Wang S
AU  - Strohecker J
AU  - Day JD
AU  - Weiss JP
AU  - Crandall BG
AU  - Osborn JS
AU  - Anderson JL
AU  - Horne BD
AU  - Muhlestein JB
AU  - Lappe DL
AU  - Moss H
AU  - Oliver J
AU  - Viau K
AU  - Bunch TJ
FA  - Smith, Megan B
FA  - Christensen, Nedra
FA  - Wang, Shiquan
FA  - Strohecker, Jennifer
FA  - Day, John D
FA  - Weiss, J Peter
FA  - Crandall, Brian G
FA  - Osborn, Jeffrey S
FA  - Anderson, Jeffrey L
FA  - Horne, Benjamin D
FA  - Muhlestein, Joseph B
FA  - Lappe, Donald L
FA  - Moss, Heidi
FA  - Oliver, Jessica
FA  - Viau, Krista
FA  - Bunch, T Jared
IN  - Smith,Megan B. Department of Nutrition, Dietetics and Food Sciences, Utah State University, Logan, Utah, USA.
TI  - Warfarin knowledge in patients with atrial fibrillation: implications for safety, efficacy, and education strategies.
CM  - Comment in: Cardiology. 2010;116(1):59-60; PMID: 20502011
SO  - Cardiology. 116(1):61-9, 2010.
AS  - Cardiology. 116(1):61-9, 2010.
NJ  - Cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - coi, 1266406
SB  - Index Medicus
CP  - Switzerland
MH  - Aged
MH  - *Anticoagulants/ad [Administration & Dosage]
MH  - Anticoagulants/ae [Adverse Effects]
MH  - *Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - Drug Interactions
MH  - Female
MH  - Food
MH  - Health Knowledge, Attitudes, Practice
MH  - Herb-Drug Interactions
MH  - Humans
MH  - International Normalized Ratio
MH  - Male
MH  - Middle Aged
MH  - *Patient Compliance
MH  - *Patient Education as Topic
MH  - Quality of Life
MH  - Risk Factors
MH  - Stroke/ep [Epidemiology]
MH  - Stroke/pc [Prevention & Control]
MH  - Surveys and Questionnaires
MH  - Thromboembolism/ep [Epidemiology]
MH  - *Thromboembolism/pc [Prevention & Control]
MH  - *Warfarin/ad [Administration & Dosage]
MH  - Warfarin/ae [Adverse Effects]
AB  - BACKGROUND: Multiple factors influence warfarin metabolism and can significantly affect the risk of adverse events. The extent to which patients understand the modifiable factors that impact on warfarin safety and efficacy is unclear.
AB  - METHODS: A 52-item questionnaire related to knowledge of warfarin was administered to patients with atrial fibrillation in a face-to-face interview with a dietitian. Results were compiled based on five categories: general warfarin knowledge, compliance, drug interactions, herbal or vitamin interactions, and diet.
AB  - RESULTS: 100 patients were surveyed. Stroke risk factors included hypertension (57%), heart failure (36%), age >75 years (33%), diabetes (22%), and prior stroke/transient ischemic attack (29%). The majority were either high-school (49%) or college graduates (27%). Ten (10%) had a stroke while on warfarin, 11 (11%) had a blood transfusion, and 26 (26%) had at least one fall. The percentages correct for questionnaire items in the five categories were as follows: general knowledge (62%), compliance (71%), drug interactions (17%), herbal or vitamin interactions (7%), and diet (23%). Neither education level nor duration of therapy correlated with warfarin knowledge. Patients at highest risk of stroke had very low knowledge scores in general.
AB  - DISCUSSION: Patients on warfarin have a poor general understanding of the medication, particularly those at highest risk of stroke.Copyright (c) 2010 S. Karger AG, Basel.
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
ES  - 1421-9751
IL  - 0008-6312
DO  - http://dx.doi.org/10.1159/000314936
PT  - Journal Article
LG  - English
EP  - 20100526
DP  - 2010
DC  - 20100604
YR  - 2010
ED  - 20100916
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20502012

<441. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20204533
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Di Carlo I
AU  - Pulvirenti E
AU  - Mannino M
AU  - Toro A
FA  - Di Carlo, Isidoro
FA  - Pulvirenti, Elia
FA  - Mannino, Maurizio
FA  - Toro, Adriana
IN  - Di Carlo,Isidoro. Department of Surgical Sciences, Organ Transplantation, and Advanced Technologies, University of Catania, Catania, Italy, idicarlo@unict.it
TI  - Increased use of percutaneous technique for totally implantable venous access devices. Is it real progress? A 27-year comprehensive review on early complications. [Review] [60 refs]
SO  - Annals of Surgical Oncology. 17(6):1649-56, 2010 Jun.
AS  - Ann Surg Oncol. 17(6):1649-56, 2010 Jun.
NJ  - Annals of surgical oncology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - b9r, 9420840
SB  - Index Medicus
CP  - United States
MH  - Antineoplastic Agents/ad [Administration & Dosage]
MH  - Arteries/in [Injuries]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Catheterization, Central Venous/ae [Adverse Effects]
MH  - *Catheterization, Central Venous/is [Instrumentation]
MH  - Catheterization, Central Venous/sn [Statistics & Numerical Data]
MH  - Catheters, Indwelling/ae [Adverse Effects]
MH  - Hematoma/et [Etiology]
MH  - Hemoptysis/et [Etiology]
MH  - Hemothorax/et [Etiology]
MH  - Humans
MH  - Incidence
MH  - *Infusion Pumps, Implantable/ae [Adverse Effects]
MH  - *Infusion Pumps, Implantable/sn [Statistics & Numerical Data]
MH  - Long-Term Care
MH  - Neoplasms/dt [Drug Therapy]
MH  - Pneumothorax/et [Etiology]
MH  - Quality of Life
AB  - BACKGROUND: First implantation of a totally implantable venous access device (TIVAD) was performed in 1982 with surgical technique. Since then, these devices have permitted infusion of total parenteral nutrition, antibiotics, blood products, and, above all, they have definitively changed the quality of life of patients with cancer. However, with the increase of percutaneous procedures, we have assisted with a concomitant raise of immediate postprocedural life-threatening complications. The aim of this study was to review the literature during a 27-year period, with regard to the changes of incidence of immediate complications after percutaneous or surgical cutdown for TIVAD's implant.
AB  - MATERIALS AND METHODS: An extensive search of relevant literature was carried out by using MEDLINE (PubMed) and Google Scholar. We gathered articles from 1982 to 2009 that quoted patient's number, type of pathology, specialist involved, number of devices implanted, site and technique of implantation (surgical cutdown or percutaneous technique), and immediate complications occurrence.
AB  - RESULTS: A total of 952 reports were screened, and finally only 45 articles addressing all inclusion criteria were used for the present study. A total of 11,430 TIVADs implanted in 11,381 patients were analyzed. Pneumothorax, hemothorax, arterial puncture, and hemoptysis developed only after percutaneous procedures. Atrial fibrillation, hematomas, and malpositioning were more frequent after percutaneous approach. The total amount of immediate complications in patients submitted to percutaneous implant was 4.5%, compared with 0.9% subsequent to cutdown technique.
AB  - CONCLUSIONS: Despite the increased use of percutaneous technique for TIVADs' implantation, surgical cutdown, because of its safety, remains the best approach to avoid possible fatal immediate complications. [References: 60]
RN  - 0 (Antineoplastic Agents)
ES  - 1534-4681
IL  - 1068-9265
DO  - http://dx.doi.org/10.1245/s10434-010-1005-4
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20100305
DP  - 2010 Jun
DC  - 20100512
YR  - 2010
ED  - 20100903
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20204533

<442. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19825009
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Tse HF
AU  - Siu CW
AU  - Lau CP
FA  - Tse, Hung-Fat
FA  - Siu, Chung-Wah
FA  - Lau, Chu-Pak
IN  - Tse,Hung-Fat. Department of Medicine, Cardiology Division, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.. hftse@hkucc.hku.hk
TI  - Impact of right ventricular pacing sites on exercise capacity during ventricular rate regularization in patients with permanent atrial fibrillation.
SO  - Pacing & Clinical Electrophysiology. 32(12):1536-42, 2009 Dec.
AS  - Pacing Clin Electrophysiol. 32(12):1536-42, 2009 Dec.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - pab, 7803944
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Bradycardia/th [Therapy]
MH  - *Cardiac Pacing, Artificial/mt [Methods]
MH  - Exercise Test
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - *Heart Ventricles
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxygen Consumption
AB  - BACKGROUND: The deleterious effects of right ventricular apical (RVA) pacing may offset the potential benefit of ventricular rate (VR) regularization and rate adaptation during an exercise in patient's atrial fibrillation (AF).
AB  - METHODS: We studied 30 patients with permanent AF and symptomatic bradycardia who receive pacemaker implantation with RVA (n = 15) or right ventricular septal (RVS, n = 15) pacing. All the patients underwent an acute cardiopulmonary exercise testing using VVI-mode (VVI-OFF) and VVI-mode with VR regularization (VRR) algorithm on (VVI-ON).
AB  - RESULTS: There were no significant differences in the baseline characteristics between the two groups, except pacing QRS duration was significantly shorter during RVS pacing than RVA pacing (138.9 +/- 5 vs 158.4 +/- 6.1 ms, P = 0.035). Overall, VVI-ON mode increased the peak exercise VR, exercise time, metabolic equivalents (METs), and peak oxygen consumption (VO(2)max), and decreased the VR variability compared with VVI-OFF mode during exercise (P < 0.05), suggesting that VRR pacing improved exercise capacity during exercise. However, further analysis on the impact of VRR pacing with different pacing sites revealed that only patients with RVS pacing but not patients with RVA pacing had significant increased exercise time, METs, and VO(2)max during VVI-ON compared with VVI-OFF, despite similar changes in peaked exercise VR and VR variability.
AB  - CONCLUSION: In patients with permanent AF, VRR pacing at RVS, but not at RVA, improved exercise capacity during exercise.
ES  - 1540-8159
IL  - 0147-8389
DO  - http://dx.doi.org/10.1111/j.1540-8159.2009.02575.x
PT  - Journal Article
LG  - English
EP  - 20091013
DP  - 2009 Dec
DC  - 20100506
YR  - 2009
ED  - 20100813
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19825009

<443. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20164089
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Bouzas-Mosquera A
AU  - Peteiro J
AU  - Broullon FJ
AU  - Alvarez-Garcia N
AU  - Mosquera VX
AU  - Rodriguez-Vilela A
AU  - Casas S
AU  - Castro-Beiras A
FA  - Bouzas-Mosquera, Alberto
FA  - Peteiro, Jesus
FA  - Broullon, Francisco J
FA  - Alvarez-Garcia, Nemesio
FA  - Mosquera, Victor X
FA  - Rodriguez-Vilela, Alejandro
FA  - Casas, Sheyla
FA  - Castro-Beiras, Alfonso
IN  - Bouzas-Mosquera,Alberto. Department of Cardiology, Hospital Universitario A Coruna, As Xubias, 84, 15006 A Coruna, Spain. aboumos@canalejo.org
TI  - Prognostic value of exercise echocardiography in patients with atrial fibrillation.
SO  - European Journal of Echocardiography. 11(4):346-51, 2010 May.
AS  - Eur J Echocardiogr. 11(4):346-51, 2010 May.
NJ  - European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 100890618
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/us [Ultrasonography]
MH  - Coronary Artery Disease/co [Complications]
MH  - *Coronary Artery Disease/us [Ultrasonography]
MH  - Echocardiography
MH  - Exercise Test
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
AB  - AIMS: Non-invasive imaging techniques for the detection of coronary artery disease (CAD) may have technical problems in patients with atrial fibrillation (AF). Although the prognostic value of exercise echocardiography (ExEcho) has been well established in several subgroups of patients, it has not yet been specifically evaluated in these patients.
AB  - METHODS AND RESULTS: From a population of 8095 patients with known or suspected CAD referred for ExEcho, 419 had AF at the time of the tests. Ischaemia was defined as the development of new or worsening wall motion abnormalities with exercise. Endpoints were hard cardiac events (i.e. cardiac death or non-fatal myocardial infarction). Mean age was 68.4 +/- 8.5 years, and 256 patients (61.1%) were men. Ischaemia was detected in 92 patients (22%). Over a mean follow-up of 3.10 +/- 2.98 years, 59 hard cardiac events occurred. The 5-year hard cardiac event rate was 37.3% in patients with ischaemia, when compared with 14.5% in patients without ischaemia (P < 0.001). In multivariate analysis, ischaemia on ExEcho remained an independent predictor of hard cardiac events (hazard ratio 1.99, 95% confidence interval 1.06-3.74, P = 0.03), and also provided incremental value over clinical, resting echocardiographic and treadmill exercise data for the prediction of hard cardiac events (P = 0.04).
AB  - CONCLUSION: ExEcho provides significant prognostic information for predicting hard cardiac events in patients with AF.
ES  - 1532-2114
IL  - 1532-2114
DO  - http://dx.doi.org/10.1093/ejechocard/jep212
PT  - Journal Article
LG  - English
EP  - 20100217
DP  - 2010 May
DC  - 20100503
YR  - 2010
ED  - 20100810
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20164089

<444. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20561675
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - O'Donnell MJ
AU  - Xavier D
AU  - Liu L
AU  - Zhang H
AU  - Chin SL
AU  - Rao-Melacini P
AU  - Rangarajan S
AU  - Islam S
AU  - Pais P
AU  - McQueen MJ
AU  - Mondo C
AU  - Damasceno A
AU  - Lopez-Jaramillo P
AU  - Hankey GJ
AU  - Dans AL
AU  - Yusoff K
AU  - Truelsen T
AU  - Diener HC
AU  - Sacco RL
AU  - Ryglewicz D
AU  - Czlonkowska A
AU  - Weimar C
AU  - Wang X
AU  - Yusuf S
AU  - INTERSTROKE investigators
FA  - O'Donnell, Martin J
FA  - Xavier, Denis
FA  - Liu, Lisheng
FA  - Zhang, Hongye
FA  - Chin, Siu Lim
FA  - Rao-Melacini, Purnima
FA  - Rangarajan, Sumathy
FA  - Islam, Shofiqul
FA  - Pais, Prem
FA  - McQueen, Matthew J
FA  - Mondo, Charles
FA  - Damasceno, Albertino
FA  - Lopez-Jaramillo, Patricio
FA  - Hankey, Graeme J
FA  - Dans, Antonio L
FA  - Yusoff, Khalid
FA  - Truelsen, Thomas
FA  - Diener, Hans-Christoph
FA  - Sacco, Ralph L
FA  - Ryglewicz, Danuta
FA  - Czlonkowska, Anna
FA  - Weimar, Christian
FA  - Wang, Xingyu
FA  - Yusuf, Salim
FA  - INTERSTROKE investigators
IN  - O'Donnell,Martin J. Population Health Research Institute, McMaster University, Hamilton, ON, Canada. odonnm@mcmaster.ca
IR  - O'Donnell M
IR  - Xavier D
IR  - Yusuf S
IR  - Rangarajan S
IR  - Islam S
IR  - Rao-Melacini P
IR  - Chin SL
IR  - DeJesus J
IR  - Agapay S
IR  - Kaszyca J
IR  - Dehghan M
IR  - McQueen M
IR  - Hall K
IR  - Keys J
IR  - Wang X
IR  - Hosangadi A
IR  - Diaz R
IR  - Sposato L
IR  - Bahit C
IR  - Bianchi M
IR  - Pascual A
IR  - Martin ME
IR  - Schygiel P
IR  - Falcone G
IR  - Garrote M
IR  - Varigos J
IR  - Hankey G
IR  - Claxton A
IR  - Wang WY
IR  - Avezum A
IR  - Santos I
IR  - Pereira MP
IR  - Nakamura R
IR  - Takeuti K
IR  - Avezum L
IR  - Faria S
IR  - Teixeira M
IR  - Gaffga A
IR  - Reis H
IR  - Lameira A
IR  - Friedrich M
IR  - Marrone LC
IR  - Saraiva JF
IR  - Carvalho AC
IR  - Rocha I
IR  - Laet VL
IR  - Coutinho M
IR  - Brunel F
IR  - Melges L
IR  - Garbelini CR
IR  - Baruzzi AC
IR  - Reis DA
IR  - O'Donnell M
IR  - Yusuf S
IR  - Ounpuu S
IR  - Kapral MK
IR  - DeJesus J
IR  - Gladstone D
IR  - Valencia G
IR  - Teal P
IR  - Woolfendan A
IR  - Masigan P
IR  - Murray K
IR  - Sancan J
IR  - Shuaib A
IR  - Schwindt B
IR  - Silver F
IR  - Sharma M
IR  - Mortensen M
IR  - Lanas F
IR  - Saavera S
IR  - Liu L
IR  - Zhang H
IR  - Wang X
IR  - Wang W
IR  - Li J
IR  - Liu L
IR  - Sun Y
IR  - Chen J
IR  - Zhou L
IR  - Jia W
IR  - Zhang Z
IR  - Lv J
IR  - Zhang C
IR  - Chen G
IR  - Wang H
IR  - Liu L
IR  - Zhang Y
IR  - Chen Y
IR  - Zheng H
IR  - Zhang Y
IR  - Wang J
IR  - Huang J
IR  - Deng Z
IR  - Zhang W
IR  - Li W
IR  - Jia S
IR  - Wang J
IR  - Wang L
IR  - Wang J
IR  - Shi J
IR  - Gu W
IR  - Shao H
IR  - Hu Y
IR  - Song H
IR  - Ji R
IR  - Hao L
IR  - Zhang J
IR  - Hou F
IR  - Wang D
IR  - Li J
IR  - Meng L
IR  - Duan L
IR  - Jaramillo PL
IR  - Sanchez G
IR  - Garcia R
IR  - Arguello J
IR  - Ruiz N
IR  - Molina DI
IR  - Sotomayor A
IR  - Sotomayor K
IR  - Suarez M
IR  - Rumboldt Z
IR  - Lusic I
IR  - Truelsen T
IR  - Iversen HK
IR  - Back C
IR  - Petersen MM
IR  - Panaherrera E
IR  - Duarte YC
IR  - Caceres S
IR  - Weimar C
IR  - Grau AJ
IR  - Bode B
IR  - Roether J
IR  - Wuttig H
IR  - Busch K
IR  - Pais P
IR  - Xavier D
IR  - Sigamani A
IR  - Mathur NP
IR  - Rahul P
IR  - Rai D
IR  - Roy AK
IR  - Sarma GR
IR  - Mathew T
IR  - Kusumkar G
IR  - Salam KA
IR  - Karadan U
IR  - Achambat L
IR  - Singh Y
IR  - Pandian JD
IR  - Verma R
IR  - Atam V
IR  - Agarwal A
IR  - Chidambaran N
IR  - Umarani R
IR  - Ghanta S
IR  - Babu GK
IR  - Sathyanarayana G
IR  - Sarada G
IR  - Vani SN
IR  - Sundararajan R
IR  - Sivakumar SS
IR  - Wadia RS
IR  - Bandishti S
IR  - Gupta R
IR  - Agarwal RR
IR  - Mohan I
IR  - Joshi S
IR  - Kulkarni S
IR  - Parthasaradhi S
IR  - Joshi P
IR  - Pandharipande M
IR  - Badnerkar N
IR  - Joshi R
IR  - Kalantri SP
IR  - Somkuwar S
IR  - Chavhan S
IR  - Singh H
IR  - Varma S
IR  - Singh H
IR  - Sidhu GK
IR  - Singh R
IR  - Bansal KL
IR  - Bharani A
IR  - Pagare S
IR  - Chouhan A
IR  - Mahanta BN
IR  - Mahanta TG
IR  - Rajkonwar G
IR  - Diwan SK
IR  - Mahajan SN
IR  - Shaikh P
IR  - Oveisgharan S
IR  - Kelishadi R
IR  - Bahonar A
IR  - Mohammadifard N
IR  - Heidari H
IR  - Dehghani A
IR  - Mousavi SA
IR  - Albaker O
IR  - Yusoff K
IR  - Chandramouli A
IR  - Syuhadamohd N
IR  - Damasceno A
IR  - Loureiro S
IR  - Ogah OS
IR  - Ogunniyi A
IR  - Akinyemi R
IR  - Owolabi M
IR  - Oguunniyi A
IR  - Onwuekwe IO
IR  - Mahmoud S
IR  - Owolabi L
IR  - Malaga G
IR  - Salazar Z
IR  - de Leaon PP
IR  - Najar E
IR  - Aphang M
IR  - Dans AL
IR  - Sulit MV
IR  - Collantes E
IR  - del Castillo M
IR  - Morales D
IR  - Lagayan C
IR  - Candela M
IR  - Roxas A
IR  - Tan I
IR  - Recto C
IR  - Lau G
IR  - Czlonkowska A
IR  - Ryglewicz D
IR  - Skowronska M
IR  - Restel M
IR  - Bochynska A
IR  - Chwojnicki K
IR  - Kubach M
IR  - Stowik A
IR  - Wnuk M
IR  - DeVilliers L
IR  - Mayosi B
IR  - Magazi D
IR  - Elsayed AS
IR  - Bukhari A
IR  - Sawaraldahab Z
IR  - Hamad H
IR  - El Taher M
IR  - Abdelhameed A
IR  - Alawad M
IR  - Alkabashi D
IR  - Alsir H
IR  - Rosengren A
IR  - Andreasson M
IR  - Cederin B
IR  - Schander C
IR  - Elgasen AC
IR  - Bertholds E
IR  - Bengtasson K
IR  - Nilanont Y
IR  - Samart N
IR  - Pyatat T
IR  - Prayoonwiwat N
IR  - Phongwarin N
IR  - Suwanwela NC
IR  - Tiamkao S
IR  - Tulyapronchote R
IR  - Boonyakarnkul S
IR  - Hanchaiphiboolkul S
IR  - Muengtaweepongsa S
IR  - Watcharasakslip K
IR  - Sathirapanya P
IR  - Pleumpanupat P
IR  - Oguz A
IR  - Akalin AA
IR  - Mondo C
IR  - Kayima J
IR  - Nakisige M
IR  - Kitoleeko S
IR  - Byanyima P
IR  - Langhorne P
IR  - Sacco R
IR  - Hilbrich L
TI  - Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study.
CM  - Comment in: Lancet. 2010 Jul 10;376(9735):74-5; PMID: 20561674
CM  - Comment in: Lancet. 2010 Nov 6;376(9752):1538-9; author reply 1539; PMID: 21056757
SO  - Lancet. 376(9735):112-23, 2010 Jul 10.
AS  - Lancet. 376(9735):112-23, 2010 Jul 10.
NJ  - Lancet (London, England)
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 2985213r, l0s, 0053266
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - Atrial Fibrillation/co [Complications]
MH  - *Brain Ischemia/co [Complications]
MH  - Case-Control Studies
MH  - *Cerebral Hemorrhage/co [Complications]
MH  - Developed Countries
MH  - Developing Countries
MH  - Female
MH  - Humans
MH  - Hypertension/co [Complications]
MH  - Life Style
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/ep [Epidemiology]
MH  - Myocardial Infarction/et [Etiology]
MH  - Risk Factors
MH  - Stroke/ep [Epidemiology]
MH  - *Stroke/et [Etiology]
MH  - Waist-Hip Ratio
AB  - BACKGROUND: The contribution of various risk factors to the burden of stroke worldwide is unknown, particularly in countries of low and middle income. We aimed to establish the association of known and emerging risk factors with stroke and its primary subtypes, assess the contribution of these risk factors to the burden of stroke, and explore the differences between risk factors for stroke and myocardial infarction.
AB  - METHODS: We undertook a standardised case-control study in 22 countries worldwide between March 1, 2007, and April 23, 2010. Cases were patients with acute first stroke (within 5 days of symptoms onset and 72 h of hospital admission). Controls had no history of stroke, and were matched with cases for age and sex. All participants completed a structured questionnaire and a physical examination, and most provided blood and urine samples. We calculated odds ratios (ORs) and population-attributable risks (PARs) for the association of all stroke, ischaemic stroke, and intracerebral haemorrhagic stroke with selected risk factors.
AB  - FINDINGS: In the first 3000 cases (n=2337, 78%, with ischaemic stroke; n=663, 22%, with intracerebral haemorrhagic stroke) and 3000 controls, significant risk factors for all stroke were: history of hypertension (OR 2.64, 99% CI 2.26-3.08; PAR 34.6%, 99% CI 30.4-39.1); current smoking (2.09, 1.75-2.51; 18.9%, 15.3-23.1); waist-to-hip ratio (1.65, 1.36-1.99 for highest vs lowest tertile; 26.5%, 18.8-36.0); diet risk score (1.35, 1.11-1.64 for highest vs lowest tertile; 18.8%, 11.2-29.7); regular physical activity (0.69, 0.53-0.90; 28.5%, 14.5-48.5); diabetes mellitus (1.36, 1.10-1.68; 5.0%, 2.6-9.5); alcohol intake (1.51, 1.18-1.92 for more than 30 drinks per month or binge drinking; 3.8%, 0.9-14.4); psychosocial stress (1.30, 1.06-1.60; 4.6%, 2.1-9.6) and depression (1.35, 1.10-1.66; 5.2%, 2.7-9.8); cardiac causes (2.38, 1.77-3.20; 6.7%, 4.8-9.1); and ratio of apolipoproteins B to A1 (1.89, 1.49-2.40 for highest vs lowest tertile; 24.9%, 15.7-37.1). Collectively, these risk factors accounted for 88.1% (99% CI 82.3-92.2) of the PAR for all stroke. When an alternate definition of hypertension was used (history of hypertension or blood pressure >160/90 mm Hg), the combined PAR was 90.3% (85.3-93.7) for all stroke. These risk factors were all significant for ischaemic stroke, whereas hypertension, smoking, waist-to-hip ratio, diet, and alcohol intake were significant risk factors for intracerebral haemorrhagic stroke.
AB  - INTERPRETATION: Our findings suggest that ten risk factors are associated with 90% of the risk of stroke. Targeted interventions that reduce blood pressure and smoking, and promote physical activity and a healthy diet, could substantially reduce the burden of stroke.
AB  - FUNDING: Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada, Canadian Stroke Network, Pfizer Cardiovascular Award, Merck, AstraZeneca, and Boehringer Ingelheim.Copyright 2010 Elsevier Ltd. All rights reserved.
ES  - 1474-547X
IL  - 0140-6736
DO  - http://dx.doi.org/10.1016/S0140-6736(10)60834-3
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
NO  - (Canada Canadian Institutes of Health Research)
LG  - English
EP  - 20100617
DP  - 2010 Jul 10
DC  - 20100712
YR  - 2010
ED  - 20100729
RD  - 20150616
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20561675

<445. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20376644
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Reibis RK
AU  - Treszl A
AU  - Wegscheider K
AU  - Ehrlich B
AU  - Dissmann R
AU  - Voller H
FA  - Reibis, Rona K
FA  - Treszl, Andras
FA  - Wegscheider, Karl
FA  - Ehrlich, Bettina
FA  - Dissmann, Rudiger
FA  - Voller, Heinz
IN  - Reibis,Rona K. Department of Cardiology, Rehabilitation Center of Cardiovascular Disease, Klinik am See, Rudersdorf/Berlin, Germany. rona.reibis@hotmail.de
TI  - Exercise capacity is the most powerful predictor of 2-year mortality in patients with left ventricular systolic dysfunction.
SO  - Herz. 35(2):104-10, 2010 Mar.
AS  - Herz. 35(2):104-10, 2010 Mar.
NJ  - Herz
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - f88, 7801231
SB  - Index Medicus
CP  - Germany
MH  - Aged
MH  - Echocardiography
MH  - *Exercise Test
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve Insufficiency/di [Diagnosis]
MH  - Mitral Valve Insufficiency/mo [Mortality]
MH  - Multivariate Analysis
MH  - Myocardial Revascularization
MH  - Patient Readmission/sn [Statistics & Numerical Data]
MH  - Postoperative Complications/di [Diagnosis]
MH  - Postoperative Complications/mo [Mortality]
MH  - Prognosis
MH  - Prospective Studies
MH  - Risk Factors
MH  - *Ventricular Dysfunction, Left/di [Diagnosis]
MH  - *Ventricular Dysfunction, Left/mo [Mortality]
AB  - BACKGROUND: There are few data about predictors of cardiovascular mortality and rehospitalization rate in patients with left ventricular systolic dysfunction (LVSD) after myocardial revascularization and optimization of pharmacological treatment.
AB  - PATIENTS AND METHODS: 1,346 consecutive patients with left ventricular ejection fraction (LVEF) < 45% (64 + or - 10 years, 73% male, LVEF 36.3% + or - 8%), who were referred for inpatient cardiac rehabilitation, were followed prospectively for 731 + or - 215 days in a unicentric prospective longitudinal registry. Multivariate logistic regression Cox models were used to analyze demographic, echocardiographic and exercise variables in order to determine independent predictors of cardiovascular mortality and rehospitalization.
AB  - RESULTS: LVEF failed to show prognostic power (hazard ratio [HR] 0.99 [95% confidence interval, CI, 0.94-1.03]; p = not significant), whereas moderate to severe mitral regurgitation (HR, 5.71 [95% CI 1.75-18.6]; p = 0.004) and atrial fibrillation (HR 1.67 [95% CI 1.15-2.44]; p = 0.008) were associated with a poorer prognosis. In an optimized multivariate model, 6-min walk test (HR 0.93 [95% CI 0.86-1.00] per 50 m; p = 0.049) and symptom-limited maximum exercise capacity test (HR 0.83 [95% CI 0.76-0.91] per 10 W; p < 0.001) as well as female gender (HR 0.58 [95% CI 0.39-0.84]; p = 0.005) were strong predictors for reduced overall mortality.
AB  - CONCLUSION: In patients with LVSD, independently of LVEF, traditional prognostic factors including atrial fibrillation or mitral regurgitation predict poorer survival, whereas symptom-limited exercise capacity and walking distance performed in 6-min walk test were highly predictive for a good prognosis.
ES  - 1615-6692
IL  - 0340-9937
DO  - http://dx.doi.org/10.1007/s00059-010-3226-5
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20100408
DP  - 2010 Mar
DC  - 20100408
YR  - 2010
ED  - 20100715
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20376644

<446. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20403467
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Bouzas-Mosquera A
AU  - Peteiro J
AU  - Broullon FJ
AU  - Alvarez-Garcia N
AU  - Mosquera VX
AU  - Casas S
AU  - Perez A
AU  - Mendez E
AU  - Castro-Beiras A
FA  - Bouzas-Mosquera, Alberto
FA  - Peteiro, Jesus
FA  - Broullon, Francisco J
FA  - Alvarez-Garcia, Nemesio
FA  - Mosquera, Victor X
FA  - Casas, Sheyla
FA  - Perez, Alberto
FA  - Mendez, Elizabet
FA  - Castro-Beiras, Alfonso
IN  - Bouzas-Mosquera,Alberto. Department of Cardiology, Hospital Universitario A Coruna, A Coruna, Spain. aboumos@canalejo.org
TI  - Effect of atrial fibrillation on outcome in patients with known or suspected coronary artery disease referred for exercise stress testing.
SO  - American Journal of Cardiology. 105(9):1207-11, 2010 May 1.
AS  - Am J Cardiol. 105(9):1207-11, 2010 May 1.
NJ  - The American journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/mo [Mortality]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Cause of Death/td [Trends]
MH  - Confidence Intervals
MH  - Coronary Angiography
MH  - Coronary Artery Disease/co [Complications]
MH  - *Coronary Artery Disease/di [Diagnosis]
MH  - Coronary Artery Disease/su [Surgery]
MH  - Diagnosis, Differential
MH  - *Electrocardiography/mt [Methods]
MH  - *Exercise Test/mt [Methods]
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Myocardial Revascularization
MH  - Retrospective Studies
MH  - Spain/ep [Epidemiology]
MH  - Survival Rate/td [Trends]
MH  - Treatment Outcome
AB  - The association of atrial fibrillation (AF) with coronary artery disease (CAD) remains controversial. In addition, the relation of AF to myocardial ischemia and outcomes in patients with known or suspected CAD referred for exercise stress testing has been poorly explored. In this study, 17,100 patients aged > or = 50 years with known or suspected CAD who underwent exercise electrocardiography (n = 11,911) or exercise echocardiography (n = 5,189) were evaluated. End points were all-cause mortality, nonfatal myocardial infarction, and coronary revascularization. Overall, 619 patients presented with AF at the time of the tests. Patients with AF who had interpretable electrocardiograms had a lower likelihood of exercise-induced ischemic ST-segment abnormalities (adjusted odds ratio 0.51, 95% confidence interval 0.34 to 0.76, p = 0.001), and those with AF who underwent exercise echocardiography had a lower likelihood of new or worsening exercise-induced wall motion abnormalities (adjusted odds ratio 0.62, 95% confidence interval 0.44 to 0.87, p = 0.006). During a mean follow-up period of 6.5 + or - 3.9 years, 2,364 patients died, 1,311 had nonfatal myocardial infarctions, 1,615 underwent percutaneous coronary intervention, and 922 underwent coronary artery bypass surgery. The 10-year mortality rate was 43% in patients with AF compared to 19% in those without AF (p <0.001). In multivariate analysis, AF remained an independent predictor of all-cause mortality (adjusted hazard ratio 1.45, 95% confidence interval 1.20 to 1.76, p <0.001), but not of nonfatal myocardial infarction or coronary revascularization. In conclusion, despite being associated with an apparently lower likelihood of myocardial ischemia, AF was an independent predictor of all-cause mortality in patients with known or suspected CAD referred for exercise stress testing.Copyright 2010 Elsevier Inc. All rights reserved.
ES  - 1879-1913
IL  - 0002-9149
DO  - http://dx.doi.org/10.1016/j.amjcard.2009.12.037
PT  - Comparative Study
PT  - Journal Article
LG  - English
EP  - 20100311
DP  - 2010 May 1
DC  - 20100420
YR  - 2010
ED  - 20100615
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20403467

<447. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20172449
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Zhang W
AU  - Shmuylovich L
AU  - Kovacs SJ
FA  - Zhang, Wei
FA  - Shmuylovich, Leonid
FA  - Kovacs, Sandor J
IN  - Zhang,Wei. Cardiovascular Biophysics Laboratory, Department of Physics, College of Arts and Sciences, St. Louis, MO, USA.
TI  - The E-wave delayed relaxation pattern to LV pressure contour relation: model-based prediction with in vivo validation.
SO  - Ultrasound in Medicine & Biology. 36(3):497-511, 2010 Mar.
AS  - Ultrasound Med Biol. 36(3):497-511, 2010 Mar.
NJ  - Ultrasound in medicine & biology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - wne, 0410553
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - Atrial Fibrillation/us [Ultrasonography]
MH  - Female
MH  - Hemodynamics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - *Ventricular Dysfunction, Left/us [Ultrasonography]
AB  - The transmitral Doppler E-wave "delayed relaxation" (DR) pattern is an established sign of diastolic dysfunction (DD). Furthermore, chambers exhibiting a DR filling pattern are also expected to have a prolonged time-constant of isovolumic relaxation (tau). The simultaneous observation of a DR pattern and normal tau in the same heart is not uncommon, however. The simultaneous hemodynamic equivalent of the DR pattern has not been proposed. To determine the feature of the left ventricular (LV) pressure contour during the E-wave that is causally related to its DR pattern we applied kinematic and fluid mechanics based arguments to derive the pressure recovery ratio (PRR). The PRR is dimensionless and is defined by the left ventricular pressure difference between diastasis and minimum pressure, normalized to the pressure difference between a fiducial diastolic filling pressure and minimum pressure [PRR=(P(Diastasis)-P(Min))/(P(Fiducial)-P(Min))]. We analyzed 354 cardiac cycles from 40 normal sinus rhythm (NSR) subjects and 113 beats from nine atrial fibrillation (AF) subjects from our database of simultaneous transmitral flow-micromanometric LV pressure recordings. The fiducial pressure is defined by the end diastolic pressure in NSR and by the pressure at dP/dt(MIN) in the setting of AF. Consistent with derivation, PRR was linearly related to a DR pattern related, model-based relaxation parameter (R(2) = 0.77, 0.83 in NSR and AF, respectively). Furthermore, the PRR successfully differentiated subjects with a DR pattern from subjects with partial DR or normal E-wave pattern (p < 0.05). We conclude that the PRR may differentiate between subjects having a DR pattern and subjects with normal E-waves, even when tau cannot.Copyright 2010 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.
ES  - 1879-291X
IL  - 0301-5629
DO  - http://dx.doi.org/10.1016/j.ultrasmedbio.2009.10.012
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Studies
LG  - English
DP  - 2010 Mar
DC  - 20100222
YR  - 2010
ED  - 20100526
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20172449

<448. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19675720
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Walterspacher S
AU  - Windisch W
AU  - Zissel G
AU  - Saurbier B
AU  - Sorichter S
FA  - Walterspacher, Stephan
FA  - Windisch, Wolfram
FA  - Zissel, Gernot
FA  - Saurbier, Bernward
FA  - Sorichter, Stephan
IN  - Walterspacher,Stephan. University Clinic Freiburg, Department of Pneumology, Freiburg, Germany.
TI  - Acute lung affection in an endurance-trained man under amiodarone medication.
SO  - German Medical Science. 3:Doc03, 2005.
AS  - Ger. med. sci.. 3:Doc03, 2005.
NJ  - German medical science : GMS e-journal
PI  - Journal available in: Electronic
PI  - Citation processed from: Print
JC  - 101227686
OI  - Source: NLM. PMC2703251
CP  - Germany
KW  - amiodarone;  dyspnoe;  pneumonitis;  vital capacity
AB  - Patients undergoing treatment with amiodarone can develop severe pulmonary side effects. This effect, which is often highly underestimated, can lead to dyspnea, pneumonitis, and further fibrosis. A recent change in the labeling of amdiodarone by the American Food and Drug Administration (FDA) supports this suspicion. Tracing the symptoms back to the causing agent can be difficult, as shown in our report. The subject of this case report is an endurance-trained 65 year old male marathon runner who appeared with atrial fibrillation during a routine check up in autumn 2003. After medical cardioversion with flecainide a complaint free interval of 8 months was followed by a relapse, which resulted in a change of medication to amiodarone. Due to misunderstandings the patient kept on taking the amiodarone loading dose for six weeks and returned with severe dyspnea on exertion. Losses in CO diffusing capacity, a lowered macrophages count and a positive lymphocyte transformation test were the only first hand clinical evidence of amiodarone intoxication, despite the sensation of dyspnea. This case shows that special care has to be taken in treatment with amiodarone. Side effects can be hard to trace and do not evidently show a clear connection to amiodarone.
ES  - 1612-3174
IL  - 1612-3174
PT  - Journal Article
LG  - English
EP  - 20050601
DP  - 2005
DC  - 20090813
YR  - 2005
ED  - 20100520
RD  - 20130523
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=19675720

<449. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19936945
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Smith JG
AU  - Platonov PG
AU  - Hedblad B
AU  - Engstrom G
AU  - Melander O
FA  - Smith, J Gustav
FA  - Platonov, Pyotr G
FA  - Hedblad, Bo
FA  - Engstrom, Gunnar
FA  - Melander, Olle
IN  - Smith,J Gustav. Department of Clinical Sciences, Lund University,Clinical Research Center, Malmo University Hospital, Malmo, Sweden. gustav.smith@med.lu.se
TI  - Atrial fibrillation in the Malmo Diet and Cancer study: a study of occurrence, risk factors and diagnostic validity.
SO  - European Journal of Epidemiology. 25(2):95-102, 2010 Feb.
AS  - Eur J Epidemiol. 25(2):95-102, 2010 Feb.
NJ  - European journal of epidemiology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - ere, 8508062
SB  - Index Medicus
CP  - Netherlands
MH  - Adult
MH  - Age Distribution
MH  - Aged
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Bias (Epidemiology)
MH  - Diet
MH  - *Electrocardiography/st [Standards]
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Medical Record Linkage
MH  - *Medical Records/st [Standards]
MH  - Middle Aged
MH  - Neoplasms
MH  - Prevalence
MH  - Prospective Studies
MH  - Registries
MH  - Risk Factors
MH  - Sex Distribution
MH  - Sweden/ep [Epidemiology]
AB  - The validity of atrial fibrillation (AF) diagnoses in national registers for use as endpoints in prospective studies has not been evaluated. We studied the validity of AF diagnoses in Swedish national hospital discharge and cause of death registers and the occurrence of and risk factors for AF in a middle-aged Swedish population using these registers. Our study included the 30,447 individuals(age 44-73) who attended baseline visits in 1991-1996 of the Malmo Diet and Cancer study. Individuals with a first AF diagnosis were identified by record linkage with national registers. A subset of cases was randomly selected for validation by examination of electrocardiograms and patient records. Electrocardiograms were available in 98%of the validation sample (95% definitive AF, 3% no AF).The 2% with ECGs unavailable had probable AF. Baseline AF prevalence was 1.3%, higher in men and increased with age. During 11.2 years of follow-up 1430 first AF diagnoses occurred. Risk factors were age, hypertension, BMI,diabetes, history of heart failure, history of myocardial infarction and, in men but not women, current smoking.The strongest risk factors were history of heart failure(hazard ratio men 4.5, women 8.7) and myocardial infarction(hazard ratio men 2.0, women 1.8). The largest population-attributable risks were observed for hypertension (men 38%, women 34%) and obesity (men 11%, women 10%).In conclusion, case misclassification of AF in national registers is small, indicating feasibility of use in prospective studies. Hypertension and obesity account for large portions of population risk in middle-aged individuals with low prevalence of manifest cardiac disease.
ES  - 1573-7284
IL  - 0393-2990
DO  - http://dx.doi.org/10.1007/s10654-009-9404-1
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Studies
LG  - English
DP  - 2010 Feb
DC  - 20100225
YR  - 2010
ED  - 20100517
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19936945

<450. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20237048
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Auyong DB
AU  - Klein SM
AU  - Gan TJ
AU  - Roche AM
AU  - Olson D
AU  - Habib AS
FA  - Auyong, David B
FA  - Klein, Stephen M
FA  - Gan, Tong J
FA  - Roche, Anthony M
FA  - Olson, Daiwai
FA  - Habib, Ashraf S
IN  - Auyong,David B. Department of Anesthesiology, Virginia Mason Medical Center, Seattle, WA 98101, USA. david.auyong@vmmc.org
TI  - Processed electroencephalogram during donation after cardiac death.
CM  - Comment in: Anesth Analg. 2010 May 1;110(5):1253-4; PMID: 20418285
CM  - Comment in: Anesth Analg. 2010 Dec;111(6):1561-2; author reply 1563; PMID: 21106974
CM  - Comment in: Anesth Analg. 2010 Dec;111(6):1562-3; author reply 1563; PMID: 21106976
CM  - Comment in: Anesth Analg. 2010 Dec;111(6):1562; author reply 1563; PMID: 21106977
SO  - Anesthesia & Analgesia. 110(5):1428-32, 2010 May 1.
AS  - Anesth Analg. 110(5):1428-32, 2010 May 1.
NJ  - Anesthesia and analgesia
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 4r8, 1310650
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Atrial Fibrillation
MH  - Brain Death
MH  - Cause of Death
MH  - Cerebral Hemorrhage/pa [Pathology]
MH  - Cognition/ph [Physiology]
MH  - *Death
MH  - Decision Making
MH  - Electrocardiography
MH  - *Electroencephalography
MH  - Electromyography
MH  - Glasgow Coma Scale
MH  - Humans
MH  - Intracranial Aneurysm/pa [Pathology]
MH  - Male
MH  - Middle Aged
MH  - Monitoring, Physiologic
MH  - *Organ Transplantation/es [Ethics]
MH  - Reproducibility of Results
MH  - Subarachnoid Hemorrhage/pa [Pathology]
MH  - *Tissue Donors
AB  - We present a case series of increased bispectral index values during donation after cardiac death (DCD). During the DCD process, a patient was monitored with processed electroencephalogram (EEG), which showed considerable changes traditionally associated with lighter planes of anesthesia immediately after withdrawal of care. Subsequently, to validate the findings of this case, processed EEG was recorded during 2 other cases in which care was withdrawn without the use of hypnotic or anesthetic drugs. We found that changes in processed EEG immediately after withdrawal of care were not only reproducible, but can happen in the absence of changes in major electromyographic or electrocardiographic artifact. It is well documented that processed EEG is prone to artifacts. However, in the setting of DCD, these changes in processed EEG deserve some consideration. If these changes are not due to artifact, dosing of hypnotic or anesthetic drugs might be warranted. Use of these drugs during DCD based primarily on processed EEG values has never been addressed.
ES  - 1526-7598
IL  - 0003-2999
DO  - http://dx.doi.org/10.1213/ANE.0b013e3181d27067
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20100317
DP  - 2010 May 1
DC  - 20100426
YR  - 2010
ED  - 20100513
RD  - 20101210
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20237048

<451. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20007681
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ananthapanyasut W
AU  - Napan S
AU  - Rudolph EH
AU  - Harindhanavudhi T
AU  - Ayash H
AU  - Guglielmi KE
AU  - Lerma EV
FA  - Ananthapanyasut, Wanwarat
FA  - Napan, Sirikarn
FA  - Rudolph, Earl H
FA  - Harindhanavudhi, Tasma
FA  - Ayash, Husam
FA  - Guglielmi, Kelly E
FA  - Lerma, Edgar V
IN  - Ananthapanyasut,Wanwarat. Department of Medicine, University of Illinois at Chicago, Advocate Christ Medical Center, Oak Lawn, Illinois 60453, USA.
TI  - Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease.
SO  - Clinical Journal of The American Society of Nephrology: CJASN. 5(2):173-81, 2010 Feb.
AS  - Clin J Am Soc Nephrol. 5(2):173-81, 2010 Feb.
NJ  - Clinical journal of the American Society of Nephrology : CJASN
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101271570
OI  - Source: NLM. PMC2827597
SB  - Index Medicus
CP  - United States
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/eh [Ethnology]
MH  - *Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Blood Pressure
MH  - Chronic Disease
MH  - Cross-Sectional Studies
MH  - European Continental Ancestry Group/sn [Statistics & Numerical Data]
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Heart Atria/us [Ultrasonography]
MH  - Heart Failure/co [Complications]
MH  - Heart Failure/ep [Epidemiology]
MH  - Hospitals, Community/sn [Statistics & Numerical Data]
MH  - Humans
MH  - Illinois/ep [Epidemiology]
MH  - *Kidney Diseases/co [Complications]
MH  - Kidney Diseases/di [Diagnosis]
MH  - *Kidney Diseases/ep [Epidemiology]
MH  - Kidney Diseases/eh [Ethnology]
MH  - Kidney Diseases/pp [Physiopathology]
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Prevalence
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
AB  - BACKGROUND AND OBJECTIVES: Chronic kidney disease (CKD) increases systemic inflammation, which is implicated in development and maintenance of atrial fibrillation (AF); therefore, we hypothesized that the prevalence of AF would be increased among nondialysis patients with CKD. This study also reports independent predictors of the presence of AF in this population.
AB  - DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A retrospective, cross-sectional analysis of 1010 consecutive nondialysis patients with CKD from two community-based hospitals was conducted. Estimated GFRs (eGFRs) were calculated using the Modification of Diet in Renal Disease (MDRD) equation. Multivariate logistic regression was used to determine independent predictors.
AB  - RESULTS: Of 1010 nondialysis patients with CKD, 214 (21.2%) had AF. Patients with AF were older than patients without AF (76 +/- 11 versus 63 +/- 15 yr). The prevalence of AF among white patients (42.7%) was higher than among black patients (12.7%) or other races (5.7%). In multivariate analyses, age, white race, increasing left atrial diameter, lower systolic BP, and congestive heart failure were identified as independent predictors of the presence of AF. Although serum high-sensitivity C-reactive protein levels were elevated in our population (5.2 +/- 7.4 mg/L), levels did not correlate with the presence of AF or with eGFR. Finally, eGFR did not correlate with the presence of AF in our population.
AB  - CONCLUSIONS: The prevalence of AF was increased in our population, and independent predictors were age, white race, increasing left atrial diameter, lower systolic BP, and congestive heart failure.
ES  - 1555-905X
IL  - 1555-9041
DO  - http://dx.doi.org/10.2215/CJN.03170509
PT  - Journal Article
PT  - Multicenter Study
LG  - English
EP  - 20091210
DP  - 2010 Feb
DC  - 20100216
YR  - 2010
ED  - 20100507
RD  - 20141204
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20007681

<452. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19939964
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Coronel R
AU  - Langerveld J
AU  - Boersma LV
AU  - Wever EF
AU  - Bon L
AU  - van Dessel PF
AU  - Linnenbank AC
AU  - van Gilst WH
AU  - Ernst SM
AU  - Opthof T
AU  - van Hemel NM
FA  - Coronel, Ruben
FA  - Langerveld, Jorina
FA  - Boersma, Lucas V A
FA  - Wever, Eric F D
FA  - Bon, Laurens
FA  - van Dessel, Pascal F H M
FA  - Linnenbank, Andre C
FA  - van Gilst, Wiek H
FA  - Ernst, Sjef M P G
FA  - Opthof, Tobias
FA  - van Hemel, Norbert M
IN  - Coronel,Ruben. Experimental Cardiology Group , Center for Heart Failure Research, Academic Medical Center, rm K2-112, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. r.coronel@amc.uva.nl
TI  - Left atrial pressure reduction for mitral stenosis reverses left atrial direction-dependent conduction abnormalities.
SO  - Cardiovascular Research. 85(4):711-8, 2010 Mar 1.
AS  - Cardiovasc Res. 85(4):711-8, 2010 Mar 1.
NJ  - Cardiovascular research
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - cor, 0077427
SB  - Index Medicus
CP  - England
MH  - Adult
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Function, Left/ph [Physiology]
MH  - Cardiac Pacing, Artificial
MH  - *Catheterization
MH  - Electrocardiography
MH  - Female
MH  - Fluoroscopy
MH  - *Heart Conduction System/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mitral Valve Stenosis/pp [Physiopathology]
MH  - Mitral Valve Stenosis/ra [Radiography]
MH  - *Mitral Valve Stenosis/th [Therapy]
MH  - Refractory Period, Electrophysiological/ph [Physiology]
MH  - Ventricular Pressure/ph [Physiology]
AB  - AIMS: Left atrial (LA) stretch-associated electrophysiological changes in patients with mitral stenosis (MS) predispose to atrial fibrillation. We hypothesized that the normalization of the pressure gradient by percutaneous transvenous mitral balloon valvotomy (PTMV) affects LA but not right atrial (RA) conduction, depending on the site of stimulation. Because direction-dependent (asymmetric) changes of conduction may contribute to arrhythmogenesis, we assessed conduction symmetry in MS patients and tested whether it is restored by PTMV.
AB  - METHODS AND RESULTS: In nine patients with MS, atrial effective refractory period and local activation times (ATs) were determined during stimulation before and after PTMV, with up to four decapolar catheters (LA and RA). Eight patients with ventricular pre-excitation served as controls. ATs at basic cycle length were similar before and after PTMV. With stimulation from either atrium, they were about 45 ms in the ipsilateral atrium and about 115 ms in the contralateral atrium. With premature stimulation, ATs increased dramatically. The shortest ATs were found in the RA with RA stimulation (78 +/- 9 and 80 +/- 6 ns, before and after PTMV). PTMV caused a shortening in LA-ATs (following LA stimulation) from 118 +/- 14 to 82 +/- 5 ms (before and after; P < 0.05). Asymmetry in conduction properties was therefore normalized by PTMV. PTMV led to a decrease in RA-ATs (following LA stimulation) from 196 +/- 11 to 174 +/- 13 ms (P < 0.02). In addition, following RA stimulation, the dispersion in ATs in the LA decreased significantly by PTMV (from 66 +/- 10 to 34 +/- 7 ms; P < 0.02).
AB  - CONCLUSION: MS is associated with LA conduction delay, increased LA dispersion of conduction, and conduction asymmetry. These changes are immediately reversible by PTMV.
ES  - 1755-3245
IL  - 0008-6363
DO  - http://dx.doi.org/10.1093/cvr/cvp374
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20091125
DP  - 2010 Mar 1
DC  - 20100211
YR  - 2010
ED  - 20100426
RD  - 20121115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19939964

<453. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20082690
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Andersson C
AU  - Gislason GH
AU  - Weeke P
AU  - Hoffmann S
AU  - Hansen PR
AU  - Torp-Pedersen C
AU  - Sogaard P
FA  - Andersson, Charlotte
FA  - Gislason, Gunnar H
FA  - Weeke, Peter
FA  - Hoffmann, Soren
FA  - Hansen, Peter R
FA  - Torp-Pedersen, Christian
FA  - Sogaard, Peter
IN  - Andersson,Charlotte. Department of Cardiology, Gentofte Hospital, University of Copenhagen, Denmark. ca@heart.dk
TI  - Diabetes is associated with impaired myocardial performance in patients without significant coronary artery disease.
SO  - Cardiovascular Diabetology. 9:3, 2010.
AS  - Cardiovasc. diabetol.. 9:3, 2010.
NJ  - Cardiovascular diabetology
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 101147637
OI  - Source: NLM. PMC2818623
SB  - Index Medicus
CP  - England
MH  - Adult
MH  - Aged
MH  - Angina Pectoris/ri [Radionuclide Imaging]
MH  - Coronary Angiography
MH  - Coronary Disease/cl [Classification]
MH  - Coronary Disease/pp [Physiopathology]
MH  - Diabetic Angiopathies/co [Complications]
MH  - *Diabetic Angiopathies/pp [Physiopathology]
MH  - Diastole/ph [Physiology]
MH  - Diet, Diabetic
MH  - Dyslipidemias/ep [Epidemiology]
MH  - Female
MH  - *Heart/pp [Physiopathology]
MH  - Heart Diseases/ri [Radionuclide Imaging]
MH  - Humans
MH  - Hypoglycemic Agents/tu [Therapeutic Use]
MH  - Insulin/tu [Therapeutic Use]
MH  - Male
MH  - Medical History Taking
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Stroke Volume
AB  - BACKGROUND: Patients with diabetes mellitus (DM) have high risk of heart failure. Whether some of the risk is directly linked to metabolic derangements in the myocardium or whether the risk is primarily caused by coronary artery disease (CAD) and hypertension is incompletely understood. Echocardiographic tissue Doppler imaging was therefore performed in DM patients without significant CAD to examine whether DM per se influenced cardiac function.
AB  - METHODS: Patients with a left ventricular (LV) ejection fraction (EF) > 35% and without significant CAD, prior myocardial infarction, cardiac pacemaker, atrial fibrillation, or significant valve disease were identified from a tertiary invasive center register. DM patients were matched with controls on age, gender and presence of hypertension.
AB  - RESULTS: In total 31 patients with diabetes and 31 controls were included. Mean age was 58 +/- 12 years, mean LVEF was 51 +/- 7%, and 48% were women. No significant differences were found in LVEF, left atrial end systolic volume, or left ventricular dimensions. The global longitudinal strain was significantly reduced in patients with DM (15.9 +/- 2.9 vs. 17.7 +/- 2.9, p = 0.03), as were peak longitudinal systolic (S') and early diastolic (E') velocities (5.7 +/- 1.1 vs. 6.4 +/- 1.1 cm/s, p = 0.02 and 6.1 +/- 1.7 vs. 7.7 +/- 2.0 cm/s, p = 0.002). In multivariable regression analyses, DM remained significantly associated with impairments of S' and E', respectively.
AB  - CONCLUSION: In patients without significant CAD, DM is associated with an impaired systolic longitudinal LV function and global diastolic dysfunction. These abnormalities are likely to be markers of adverse prognosis.
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
ES  - 1475-2840
IL  - 1475-2840
DO  - http://dx.doi.org/10.1186/1475-2840-9-3
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20100118
DP  - 2010
DC  - 20100210
YR  - 2010
ED  - 20100423
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20082690

<454. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20144271
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lamb TS
AU  - Thakrar A
AU  - Ghosh M
AU  - Wilson MP
AU  - Wilson TW
FA  - Lamb, Tyler S
FA  - Thakrar, Amar
FA  - Ghosh, Mahua
FA  - Wilson, Merne P
FA  - Wilson, Thomas W
IN  - Lamb,Tyler S. Department of Medicine and Cardiovascular Risk Factor Reduction Unit, University of Saskatchewan, Saskatoon, SK, Canada.
TI  - Comparison of two oscillometric blood pressure monitors in subjects with atrial fibrillation.
SO  - Clinical & Investigative Medicine - Medecine Clinique et Experimentale. 33(1):E54-62, 2010.
AS  - Clin Invest Med. 33(1):E54-62, 2010.
NJ  - Clinical and investigative medicine. Medecine clinique et experimentale
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - dfg, 7804071
SB  - Index Medicus
CP  - Canada
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Automation
MH  - Blood Pressure/ph [Physiology]
MH  - *Blood Pressure Determination/is [Instrumentation]
MH  - Blood Pressure Determination/mt [Methods]
MH  - *Blood Pressure Monitors/st [Standards]
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oscillometry
MH  - Posture
MH  - Sphygmomanometers
AB  - OBJECTIVE: To compare blood pressure readings obtained with two commonly used oscillometric monitors: Omron HEM 711 AC (OM) and Welch-Allyn 52000 series NIBP/oximeter (WA) with mercury sphygmomanometers (Merc) in subjects with atrial fibrillation.
AB  - METHODS: We recruited 51 hemodynamically stable subjects with atrial fibrillation. Fifty four subjects in normal sinus rhythm served as controls. Supine blood pressure readings in each arm were recorded simultaneously using one monitor and Merc. The second monitor then replaced the first and readings were repeated. Merc was then switched to the opposite arm, and both monitors retested. Apical heart rates were ascertained with a stethoscope. We used the averaged, same arm Merc readings as "gold standard".
AB  - RESULTS: Automated blood pressure readings were obtained in all control subjects and in all but three of those with atrial fibrillation. Both monitors, and operators, noted a difference between apical and radial/brachial pulse rates: apical-recorded: Merc 6.1 + or - 15.0; OM 5.5 + or - 13.7; WA 10.0 + or - 21.2 beats per minute. Both monitors were accurate in controls: over 90% of readings were within 10 mmHg of averaged Merc, and both achieved European Hypertension Society standards. In subjects with atrial fibrillation, about one quarter of all oscillometric readings differed from Merc by more than 10 mmHg. Both falsely high and falsely low readings occurred, some up to 30 mmHg. There was no relation between accuracy and heart rate.
AB  - CONCLUSIONS: Single blood pressure readings, taken with oscillometric monitors in subjects with atrial fibrillation differ, often markedly, from those taken manually. Health care professionals should record multiple readings manually, using validated instruments when making therapeutic decisions.
ES  - 1488-2353
IL  - 0147-958X
PT  - Comparative Study
PT  - Journal Article
LG  - English
EP  - 20100201
DP  - 2010
DC  - 20100210
YR  - 2010
ED  - 20100422
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20144271

<455. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20078271
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Aberg H
AU  - Strom G
AU  - Werner I
FA  - Aberg, H
FA  - Strom, G
FA  - Werner, I
IN  - Aberg,H. Department of Internal Medicine, University Hospital, Uppsala, Sweden.
TI  - On the reproducibility of exercise tests in patients with atrial fibrillation.
SO  - Upsala Journal of Medical Sciences. 82(1):27-30, 1977.
AS  - Ups J Med Sci. 82(1):27-30, 1977.
NJ  - Upsala journal of medical sciences
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - wrg, 0332203
SB  - Index Medicus
CP  - England
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Exercise Test
MH  - Heart Rate
MH  - Humans
MH  - Reproducibility of Results
AB  - Fifteen patients with atrial fibrillation, mostly due to advanced valvular heart disease, were examined by a graded work test and an orthostatic test on two occasions, the reason being, to study the reproducibility of the test in such patients. In 6 of the 7 patients with the highest working capacity the agreement between the two tests was good regarding heart rates at maximum work load. In the 8 patients with a low working capacity the results of the two tests differed widely. In the orthostatic test the difference in increase of the heart rate after standing was less than 5 beats/min in 3 patients in one of the tests, and in 2 patients in both tests. The exercise test in patients with atrial fibrillation must be evaluated with caution and has an acceptable reproducibility only in patients with fairly good functional capacity.
ES  - 2000-1967
IL  - 0300-9734
DO  - http://dx.doi.org/10.3109/03009737709179055
PT  - Journal Article
LG  - English
DP  - 1977
DC  - 20100118
YR  - 1977
ED  - 20100405
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=20078271

<456. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20062934
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Weitz JI
FA  - Weitz, Jeffrey I
IN  - Weitz,Jeffrey I. Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada. jweitz@thrombosis.hhscr.org
TI  - New oral anticoagulants in development. [Review] [80 refs]
SO  - Thrombosis & Haemostasis. 103(1):62-70, 2010 Jan.
AS  - Thromb Haemost. 103(1):62-70, 2010 Jan.
NJ  - Thrombosis and haemostasis
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - vq7, 7608063
SB  - Index Medicus
CP  - Germany
MH  - Administration, Oral
MH  - Animals
MH  - *Anticoagulants/ad [Administration & Dosage]
MH  - Anticoagulants/ae [Adverse Effects]
MH  - Atrial Fibrillation/bl [Blood]
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - *Blood Coagulation/de [Drug Effects]
MH  - *Drug Discovery
MH  - Factor Xa Inhibitors
MH  - Hemorrhage/ci [Chemically Induced]
MH  - Humans
MH  - Risk Assessment
MH  - Stroke/bl [Blood]
MH  - Stroke/et [Etiology]
MH  - *Stroke/pc [Prevention & Control]
MH  - Thrombin/ai [Antagonists & Inhibitors]
MH  - Thromboembolism/bl [Blood]
MH  - *Thromboembolism/pc [Prevention & Control]
MH  - Treatment Outcome
AB  - Although currently available anticoagulants are effective for the prevention and treatment of thromboembolic disorders, they have several drawbacks. Low-molecular-weight heparins and fondaparinux produce a predictable level of anticoagulation that obviates the need for coagulation monitoring, but they must be given parenterally, which renders them inconvenient for long-term use. Vitamin K antagonists, such as warfarin, are administered orally, but produce a variable anticoagulant response because genetic polymorphisms, dietary vitamin K intake and multiple drug-drug interactions affect their metabolism. Consequently, coagulation monitoring and frequent dose adjustments are needed to ensure that a therapeutic level of anticoagulation is achieved. This is burdensome for patients and physicians, and costly for the healthcare system. These limitations have prompted the development of new oral anticoagulants that target thrombin or factor Xa and can be given in fixed doses without coagulation monitoring. This paper focuses on the new oral anticoagulants in the most advanced stages of development. [References: 80]
RN  - 0 (Anticoagulants)
RN  - 0 (Factor Xa Inhibitors)
RN  - EC 3-4-21-5 (Thrombin)
IS  - 0340-6245
IL  - 0340-6245
DO  - http://dx.doi.org/10.1160/TH09-07-0434
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
LG  - English
EP  - 20091026
DP  - 2010 Jan
DC  - 20100111
YR  - 2010
ED  - 20100330
RD  - 20141120
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20062934

<457. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20211329
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Berry JD
AU  - Prineas RJ
AU  - van Horn L
AU  - Passman R
AU  - Larson J
AU  - Goldberger J
AU  - Snetselaar L
AU  - Tinker L
AU  - Liu K
AU  - Lloyd-Jones DM
FA  - Berry, Jarett D
FA  - Prineas, Ronald J
FA  - van Horn, Linda
FA  - Passman, Rod
FA  - Larson, Joseph
FA  - Goldberger, Jeffrey
FA  - Snetselaar, Linda
FA  - Tinker, Lesley
FA  - Liu, Kiang
FA  - Lloyd-Jones, Donald M
IN  - Berry,Jarett D. Department of Medicine, Division of Cardiology, University of Texas Southwestern Medical School, Dallas, Texas, USA. jarett.berry@utsouthwestern.edu
TI  - Dietary fish intake and incident atrial fibrillation (from the Women's Health Initiative).
SO  - American Journal of Cardiology. 105(6):844-8, 2010 Mar 15.
AS  - Am J Cardiol. 105(6):844-8, 2010 Mar 15.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 3dq, 0207277
OI  - Source: NLM. NIHMS177565
OI  - Source: NLM. PMC2838232
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Animals
MH  - *Atrial Fibrillation/et [Etiology]
MH  - *Diet
MH  - *Fatty Acids, Omega-3/ad [Administration & Dosage]
MH  - Female
MH  - *Fishes
MH  - Humans
MH  - Middle Aged
AB  - Experimental and clinical trial data have suggested an association between fish oil intake and atrial fibrillation (AF). However, previous observational studies have reported conflicting results regarding this association. Thus, we sought to compare the association between dietary fish intake and incident AF in a large sample of older, postmenopausal women. We included 44,720 participants from the Women's Health Initiative clinical trials who were not enrolled in the dietary modification intervention arm and without AF at baseline. The dietary intake of nonfried fish and omega-3 fatty acid intake was estimated from a Food Frequency Questionnaire at study entry. Incident AF was determined by follow-up electrocardiography at years 3 and 6. The baseline characteristics and rates of incident AF were compared across the quartiles of fish intake. Adjusted logistic regression models were used to evaluate the association between dietary nonfried fish intake and incident AF. A total of 378 incident cases of AF occurred during the follow-up period. In the age-adjusted models, no association was found between dietary nonfried fish intake and incident AF (odds ratio 1.17, 95% confidence interval 0.88 to 1.57 for quartile 4 vs quartile 1 of dietary fish intake). Similar findings were observed in the multivariate models and in the subgroup analyses. In conclusion, in a large cohort of healthy women, we found no evidence of an association between fish or omega-3 fatty acid intake and incident AF.Copyright 2010 Elsevier Inc. All rights reserved.
RN  - 0 (Fatty Acids, Omega-3)
ES  - 1879-1913
IL  - 0002-9149
DO  - http://dx.doi.org/10.1016/j.amjcard.2009.11.039
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
NO  - K23 HL092229 (United States NHLBI NIH HHS)
NO  - K23 HL092229 (United States NHLBI NIH HHS)
NO  - K23 HL092229-01A1 (United States NHLBI NIH HHS)
NO  - R01HL086792-02 (United States NHLBI NIH HHS)
NO  - R21HL085375 (United States NHLBI NIH HHS)
LG  - English
DP  - 2010 Mar 15
DC  - 20100309
YR  - 2010
ED  - 20100329
RD  - 20141204
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20211329

<458. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 20088990
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Chamorro A
FA  - Chamorro, A
IN  - Chamorro,A. Comprehensive Stroke Center, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain. achamorro@ub.edu
TI  - Dual antiplatelet therapy is not optimal for stroke prevention in patients with atrial fibrillation.
SO  - International Journal of Stroke. 5(1):28-9, 2010 Feb.
AS  - Int j. stroke. 5(1):28-9, 2010 Feb.
NJ  - International journal of stroke : official journal of the International Stroke Society
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101274068
SB  - Index Medicus
CP  - England
MH  - *Atrial Fibrillation/co [Complications]
MH  - Drug Therapy, Combination
MH  - Humans
MH  - *Platelet Aggregation Inhibitors/ae [Adverse Effects]
MH  - *Platelet Aggregation Inhibitors/tu [Therapeutic Use]
MH  - Risk Factors
MH  - *Stroke/co [Complications]
MH  - *Stroke/pc [Prevention & Control]
MH  - Vitamin K/ai [Antagonists & Inhibitors]
AB  - The superior efficacy of oral anticoagulation over aspirin for prevention of recurrent stroke in patients with atrial fibrillation is widely acknowledged. However, oral anticoagulation therapy is notorious for having a narrow therapeutic index, numerous drug and dietary interactions, and a significant risk of serious bleeding. The value of dual antiplatelet therapy for stroke prevention in patients with atrial fibrillation has been assessed in the ACTIVE A trial. In this study, the relative risk of primary events was significantly decreased in patients allocated clopidogrel and aspirin compared with patients receiving aspirin alone. However, the relative risk of major bleeding was also significantly increased. This article analyses critically the role of dual antiplatelet therapy for stroke prevention in patients with atrial fibrillation.
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 12001-79-5 (Vitamin K)
ES  - 1747-4949
IL  - 1747-4930
DO  - http://dx.doi.org/10.1111/j.1747-4949.2009.00397.x
PT  - Journal Article
LG  - English
DP  - 2010 Feb
DC  - 20100121
YR  - 2010
ED  - 20100325
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20088990

<459. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19552671
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kihara T
AU  - Gillinov AM
AU  - Takasaki K
AU  - Fukuda S
AU  - Song JM
AU  - Shiota M
AU  - Shiota T
FA  - Kihara, Takashi
FA  - Gillinov, A Marc
FA  - Takasaki, Kunitsugu
FA  - Fukuda, Shota
FA  - Song, Jong-Min
FA  - Shiota, Maiko
FA  - Shiota, Takahiro
IN  - Kihara,Takashi. Department of Cardiovascular Medicine, The Cleveland Clinic, Cleveland, Ohio 90048, USA. shiotat@cshs.org
TI  - Mitral regurgitation associated with mitral annular dilation in patients with lone atrial fibrillation: an echocardiographic study.
CM  - Comment in: Echocardiography. 2010 Feb;27(2):218; author reply 219; PMID: 20380684
SO  - Echocardiography. 26(8):885-9, 2009 Sep.
AS  - Echocardiography. 26(8):885-9, 2009 Sep.
NJ  - Echocardiography (Mount Kisco, N.Y.)
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - bcn, 8511187
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/us [Ultrasonography]
MH  - Dilatation, Pathologic/us [Ultrasonography]
MH  - *Echocardiography
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mitral Valve Insufficiency/co [Complications]
MH  - *Mitral Valve Insufficiency/us [Ultrasonography]
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
AB  - BACKGROUND: Whether and how lone atrial fibrillation (AF) is associated with functional mitral regurgitation (MR) remain unclear.
AB  - METHOD: We studied 12 lone AF patients without left ventricular (LV) dysfunction and/or dilatation, who underwent mitral valve annuloplasty for functional mitral regurgitation (MR). Ten lone AF patients without MR served as controls.
AB  - RESULTS: Lone AF Patients with MR had a greater mitral valve annular area and left atrial area than those without MR. There were no differences in LV volumes or LV ejection fraction.
AB  - CONCLUSIONS: Therefore, we concluded that left atrial dilation and corresponding mitral annular dilation may cause MR in lone AF patients without LV dysfunction and/or dilatation.
ES  - 1540-8175
IL  - 0742-2822
DO  - http://dx.doi.org/10.1111/j.1540-8175.2009.00904.x
PT  - Journal Article
LG  - English
EP  - 20090622
DP  - 2009 Sep
DC  - 20091208
YR  - 2009
ED  - 20100224
RD  - 20100412
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19552671

<460. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19998810
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Cortez-Dias N
AU  - Correia MJ
AU  - Coutinho A
AU  - Fernandes C
AU  - Diogo AN
AU  - Lopes MG
FA  - Cortez-Dias, Nuno
FA  - Correia, Maria Jose
FA  - Coutinho, Ana
FA  - Fernandes, Catarina
FA  - Diogo, A Nunes
FA  - Lopes, Mario G
IN  - Cortez-Dias,Nuno. Unidade de Tratamentos Intensivos Cardiologicos-Arsenio Cordeiro do Servico de Cardiologia, Hospital de Santa Maria, Centro Hospitalar de Lisboa Norte, Lisboa, Portugal. cortezdias@yahoo.com
TI  - Pharmacogenetics and anticoagulant therapy: two cases of genetically determined response to warfarin.
SO  - Revista Portuguesa de Cardiologia. 28(9):995-1004, 2009 Sep.
AS  - Rev Port Cardiol. 28(9):995-1004, 2009 Sep.
NJ  - Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - aow, 8710716
SB  - Index Medicus
CP  - Portugal
MH  - Adult
MH  - Aged
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Female
MH  - Humans
MH  - Male
MH  - Polymorphism, Genetic
MH  - *Pulmonary Embolism/dt [Drug Therapy]
MH  - *Pulmonary Embolism/ge [Genetics]
MH  - *Warfarin/tu [Therapeutic Use]
AB  - Inter- and intra-individual variability of response to warfarin means that its anticoagulant effect must be monitored, given the risk of thromboembolic complications and bleeding. This variability is influenced by gender, age, body mass index, smoking, diet, comorbid conditions, drug interactions and genetic factors. Pharmacogenetics refers to the study of genetic background to predict drug response, effectiveness and risk of adverse effects in a given patient. The authors illustrate its relevance in two case reports. A 40-year-old woman admitted for massive pulmonary thromboembolism underwent anticoagulant and fibrinolytic therapy, following which warfarin was needed in unusually high doses to achieve effective anticoagulation. The genetic variants c.430CC and c.1075AA of the CYP2C9 gene were identified, predisposing to rapid warfarin metabolism, as well as the c.-1639GG variant of the VKORC1 gene, associated with low sensitivity to the drug. Together, these variants give high resistance to warfarin. In the second case, a 76-year-old man with permanent atrial fibrillation developed excessive prolongation of prothrombin time after being treated with 5 mg/day warfarin for 5 days. The genetic variants c.430CC and c.1075AC of the CYP2C9 gene and 1639AA of the VKORC1 gene were identified. Together, these polymorphisms confer high sensitivity to warfarin, necessitating smaller doses to maintain therapeutic anticoagulation levels. The authors review the relevance of the study of genetic polymorphisms related to anticoagulant therapy and discuss its potential usefulness in clinical practice.
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
IS  - 0870-2551
IL  - 0870-2551
PT  - Case Reports
PT  - Journal Article
LG  - English
LG  - Portuguese
DP  - 2009 Sep
DC  - 20091211
YR  - 2009
ED  - 20100126
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19998810

<461. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19880491
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Garcia D
AU  - Libby E
AU  - Crowther MA
FA  - Garcia, David
FA  - Libby, Edward
FA  - Crowther, Mark A
IN  - Garcia,David. University of New Mexico, MSC08-4630, 900 Camino de Salud NE, Albuquerque, NM 87131-0001. davgarcia@salud.unm.edu
TI  - The new oral anticoagulants. [Review] [33 refs]
SO  - Blood. 115(1):15-20, 2010 Jan 7.
AS  - Blood. 115(1):15-20, 2010 Jan 7.
NJ  - Blood
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - a8g, 7603509
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Administration, Oral
MH  - *Anticoagulants/ad [Administration & Dosage]
MH  - *Anticoagulants/pd [Pharmacology]
MH  - Clinical Trials as Topic
MH  - *Drug Discovery
MH  - Humans
AB  - Although their first application in clinical practice occurred in the 1940s, vitamin K antagonists remain the only form of oral anticoagulant medication approved for long-term use. Although the available vitamin K antagonists are highly effective for the prevention and/or treatment of most thrombotic disease, the significant interpatient and intrapatient variability in dose-response, the narrow therapeutic index, and the numerous drug and dietary interactions associated with these agents have led clinicians, patients, and investigators to search for alternative agents. Three new orally administered anticoagulants (apixaban, dabigatran, and rivaroxaban) are in the late stages of development and several others are just entering (or moving through) earlier phases of investigation. These novel anticoagulant medications are being studied for the prevention and treatment of venous thromboembolism, the treatment of acute coronary syndromes and the prevention of stroke in patients with atrial fibrillation. This review summarizes published clinical trial data pertinent to apixaban, dabigatran, and rivaroxaban. [References: 33]
RN  - 0 (Anticoagulants)
ES  - 1528-0020
IL  - 0006-4971
DO  - http://dx.doi.org/10.1182/blood-2009-09-241851
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20091030
DP  - 2010 Jan 7
DC  - 20100108
YR  - 2010
ED  - 20100121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19880491

<462. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19451253
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Haffey TA
FA  - Haffey, Thomas A
IN  - Haffey,Thomas A. Western University of Health Sciences College of Osteopathic Medicine of the Pacific, Pomona, CA, USA. thaffey@yahoo.com
TI  - How to avoid a heart attack: putting it all together. [Review] [47 refs]
CM  - Comment in: J Am Osteopath Assoc. 2010 May;110(5):268-70; PMID: 20538747
SO  - Journal of the American Osteopathic Association. 109(5 Suppl):S14-20, 2009 May.
AS  - J Am Osteopath Assoc. 109(5 Suppl):S14-20, 2009 May.
NJ  - The Journal of the American Osteopathic Association
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 7503065, g90
SB  - Index Medicus
CP  - United States
MH  - Alcohol Drinking
MH  - Attitude to Health
MH  - Combined Modality Therapy
MH  - Diet
MH  - Evidence-Based Medicine
MH  - Exercise
MH  - Female
MH  - Humans
MH  - Hyperlipidemias/co [Complications]
MH  - Hyperlipidemias/th [Therapy]
MH  - Hypertension/co [Complications]
MH  - Hypertension/th [Therapy]
MH  - Male
MH  - *Metabolic Syndrome X/co [Complications]
MH  - Metabolic Syndrome X/th [Therapy]
MH  - *Myocardial Infarction/et [Etiology]
MH  - Myocardial Infarction/mo [Mortality]
MH  - *Myocardial Infarction/pc [Prevention & Control]
MH  - Obesity/co [Complications]
MH  - Obesity/th [Therapy]
MH  - *Primary Prevention/mt [Methods]
MH  - Prognosis
MH  - Psychology
MH  - Risk Assessment
MH  - Smoking/ae [Adverse Effects]
MH  - Survival Rate
AB  - Cardiovascular disease (eg, myocardial infarction, ischemic stroke) is the leading cause of death in patients who have metabolic syndrome and diabetes mellitus. By effectively treating the whole patient, however, the risk of death from cardiovascular disease can be reduced or prevented. The author describes clinical approaches for achieving this goal. He reviews information that is useful to know about patients regarding modifiable and potentially modifiable risk factors for cardiovascular disease, including hypertension, hyperlipidemia, smoking, activity levels, dietary habits, obesity, carotid artery stenosis, and atrial fibrillation. He also notes the importance of evaluating patients for relevant psychosocial factors such as depression. Finally, the author analyzes treatment options for patients, including effective medications, dietary modification, and exercise-emphasizing the use of pedometers-as well as participation by patients in weight-control support groups. [References: 47]
ES  - 1945-1997
IL  - 0098-6151
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
LG  - English
DP  - 2009 May
DC  - 20090519
YR  - 2009
ED  - 20100118
RD  - 20100614
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19451253

<463. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19817530
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wild D
AU  - Murray M
AU  - Donatti C
FA  - Wild, Diane
FA  - Murray, Miranda
FA  - Donatti, Christina
IN  - Wild,Diane. Oxford Outcomes Ltd, Seacourt Tower, West Way, Oxford OX2 OJJ, UK. diane.wild@oxfordoutcomes.com
TI  - Patient perspectives on taking vitamin K antagonists: a qualitative study in the UK, USA and Spain.
SO  - Expert Review of Pharmacoeconomics & Outcomes Research. 9(5):467-74, 2009 Oct.
AS  - Expert rev. pharmacoecon. outcomes res.. 9(5):467-74, 2009 Oct.
NJ  - Expert review of pharmacoeconomics & outcomes research
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101132257
SB  - Index Medicus
CP  - England
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/ae [Adverse Effects]
MH  - *Anticoagulants/pd [Pharmacology]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Data Collection
MH  - Diet
MH  - Drug Monitoring/mt [Methods]
MH  - Female
MH  - Great Britain
MH  - Humans
MH  - International Normalized Ratio
MH  - Male
MH  - Middle Aged
MH  - Patient Satisfaction
MH  - Spain
MH  - United States
MH  - *Venous Thromboembolism/dt [Drug Therapy]
MH  - Venous Thromboembolism/pp [Physiopathology]
MH  - *Vitamin K/ai [Antagonists & Inhibitors]
AB  - AIM: Limitations of vitamin K antagonists (VKAs) include frequent monitoring, dietary restrictions and drug interactions. This study conducted an indepth exploration of perspectives of VKA therapy in respondents with atrial fibrillation or venous thromboembolism.
AB  - METHODS: A total of 60 respondents, recruited from the UK, USA and Spain, were interviewed on their experiences and views of VKA therapy. Thematic analysis was conducted on the data.
AB  - RESULTS: Although there were some differences between the countries and some small differences between atrial fibrillation and venous thromboembolism respondents, many respondents found various aspects of VKA to be burdensome, including the international normalized ratio monitoring and dietary considerations.
AB  - CONCLUSION: Atrial fibrillation and venous thromboembolism respondents accept the limitations of VKAs and the adjustments to their lifestyles, but recognize a lack of alternative treatment.
RN  - 0 (Anticoagulants)
RN  - 12001-79-5 (Vitamin K)
ES  - 1744-8379
IL  - 1473-7167
DO  - http://dx.doi.org/10.1586/erp.09.48
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2009 Oct
DC  - 20091012
YR  - 2009
ED  - 20100106
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19817530

<464. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19351635
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kee YY
AU  - Brooks W
AU  - Bhalla A
FA  - Kee, Y-Y K
FA  - Brooks, W
FA  - Bhalla, A
IN  - Kee,Y-Y K. St Helier Stroke Service, Epsom and St Helier University Hospitals NHS Trust, Carshalton, Surrey, UK. karenkee@doctors.org.uk
TI  - Do older patients receive adequate stroke care? An experience of a neurovascular clinic.
SO  - Postgraduate Medical Journal. 85(1001):115-8, 2009 Mar.
AS  - Postgrad Med J. 85(1001):115-8, 2009 Mar.
NJ  - Postgraduate medical journal
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - pfx, 0234135
SB  - Index Medicus
CP  - England
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - *Delivery of Health Care/st [Standards]
MH  - *Emergency Service, Hospital/st [Standards]
MH  - England
MH  - Female
MH  - *Health Services for the Aged/st [Standards]
MH  - Humans
MH  - Magnetic Resonance Angiography
MH  - Male
MH  - Quality of Health Care
MH  - Risk Assessment
MH  - *Stroke/th [Therapy]
MH  - Waiting Lists
AB  - BACKGROUND: National guidelines and government directives have adopted policies for urgent assessment of patients with a transient ischaemic attack or minor stroke not admitted to hospital. The risk of recurrent stroke increases substantially with age, as does the potential benefit of secondary prevention. In order to develop effective strategies for older patients, it is important to identify how stroke care is currently provided for this patient group.
AB  - METHODS: Between 2004 and 2006, older patients (>75 years) referred to a neurovascular clinic were compared with younger patients (< or =75 years). Sociodemographic details, clinical features, resource use and secondary prevention in a neurovascular clinic were collected.
AB  - RESULTS: Of 379 patients referred to the clinic, 129 (34%) were given a non-stroke diagnosis. Of the remaining 250 patients, 149 (60%) were < or =75 years. Median time from symptom onset to clinic appointment was similar for the two groups (24 (IQR 15-42) vs 24 (IQR 14-43) days; p = 0.58). Older patients were more likely to be in atrial fibrillation (10.1% vs 22.8%, p<0.001) and have lacunar stroke (34.7% vs 22.1%; p = 0.04). CT rates were similar in the two groups (27.8% vs 80.0%, p = 0.75). Scans were performed more quickly in younger patients (p<0.01). MRI scan rates were higher in younger patients (26% vs 4%, p<0.01), as was carotid Doppler imaging (92% vs 77%, p<0.01). There were no differences in prescribed secondary preventive treatments. Older patients experienced less delay for carotid endarterectomy (49 vs 90 days, p<0.01). Younger patients were more likely to be given advice on weight reduction (30.2% vs 12.9%, p<0.01) and diet (46.3% vs 31.7%, p = 0.02) than older patients.
AB  - CONCLUSIONS: Older patients were less likely to receive diagnostic investigations and lifestyle modification advice than younger patients. Guidelines need to be adopted to ensure prompt evidence-based stroke care in the outpatient setting.
ES  - 1469-0756
IL  - 0032-5473
DO  - http://dx.doi.org/10.1136/pgmj.2008.070607
PT  - Journal Article
LG  - English
DP  - 2009 Mar
DC  - 20090408
YR  - 2009
ED  - 20091102
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19351635

<465. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19284627
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Maddox TM
AU  - Ross C
AU  - Ho PM
AU  - Magid D
AU  - Rumsfeld JS
FA  - Maddox, Thomas M
FA  - Ross, Colleen
FA  - Ho, P Michael
FA  - Magid, David
FA  - Rumsfeld, John S
IN  - Maddox,Thomas M. Cardiology Section, Denver VAMC, Denver, CO, USA. thomas.maddox@va.gov
TI  - Impaired heart rate recovery is associated with new-onset atrial fibrillation: a prospective cohort study.
SO  - BMC Cardiovascular Disorders. 9:11, 2009.
AS  - BMC Cardiovasc Disord. 9:11, 2009.
NJ  - BMC cardiovascular disorders
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 100968539
OI  - Source: NLM. PMC2660286
SB  - Index Medicus
CP  - England
MH  - Adrenergic beta-Antagonists/tu [Therapeutic Use]
MH  - Angiotensin-Converting Enzyme Inhibitors/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/pc [Prevention & Control]
MH  - *Autonomic Nervous System Diseases/ep [Epidemiology]
MH  - Autonomic Nervous System Diseases/pp [Physiopathology]
MH  - Cohort Studies
MH  - Confounding Factors (Epidemiology)
MH  - Exercise/ph [Physiology]
MH  - Exercise Test/sn [Statistics & Numerical Data]
MH  - *Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Recovery of Function/de [Drug Effects]
MH  - *Recovery of Function/ph [Physiology]
AB  - BACKGROUND: Autonomic dysfunction appears to play a significant role in the development of atrial fibrillation (AF), and impaired heart rate recovery (HRR) during exercise treadmill testing (ETT) is a known marker for autonomic dysfunction. However, whether impaired HRR is associated with incident AF is unknown. We studied the association of impaired HRR with the development of incident AF, after controlling for demographic and clinical confounders.
AB  - METHODS: We studied 8236 patients referred for ETT between 2001 and 2004, and without a prior history of AF. Patients were categorized by normal or impaired HRR on ETT. The primary outcome was the development of AF. Cox proportional hazards modeling was used to control for demographic and clinical characteristics. Secondary analyses exploring a continuous relationship between impaired HRR and AF, and exploring interactions between cardiac medication use, HRR, and AF were also conducted.
AB  - RESULTS: After adjustment, patients with impaired HRR were more likely to develop AF than patients with normal HRR (HR 1.43, 95% confidence interval (CI) 1.06, 1.93). In addition, there was a linear trend between impaired HRR and AF (HR 1.05 for each decreasing BPM in HRR, 95% CI 0.99, 1.11). No interactions between cardiac medications, HRR, and AF were noted.
AB  - CONCLUSION: Patients with impaired HRR on ETT were more likely to develop new-onset AF, as compared to patients with normal HRR. These findings support the hypothesis that autonomic dysfunction mediates the development of AF, and suggest that interventions known to improve HRR, such as exercise training, may delay or prevent AF.
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
ES  - 1471-2261
IL  - 1471-2261
DO  - http://dx.doi.org/10.1186/1471-2261-9-11
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20090312
DP  - 2009
DC  - 20090325
YR  - 2009
ED  - 20091102
RD  - 20141210
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19284627

<466. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19659817
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kong KH
AU  - Chua SG
AU  - Earnest A
FA  - Kong, K-H
FA  - Chua, S G K
FA  - Earnest, A
IN  - Kong,K-H. Department of Rehabilitation Medicine, Tan Tock Seng Hospital, Singapore. keng_he_kong@ttsh.com.sg
TI  - Deep vein thrombosis in stroke patients admitted to a rehabilitation unit in Singapore.
CM  - Comment in: Int J Stroke. 2010 Apr;5(2):131; PMID: 20446949
SO  - International Journal of Stroke. 4(3):175-9, 2009 Jun.
AS  - Int j. stroke. 4(3):175-9, 2009 Jun.
NJ  - International journal of stroke : official journal of the International Stroke Society
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101274068
SB  - Index Medicus
CP  - England
MH  - Activities of Daily Living
MH  - Age Factors
MH  - Aged
MH  - Ethnic Groups
MH  - Female
MH  - Fibrin Fibrinogen Degradation Products/an [Analysis]
MH  - Fibrin Fibrinogen Degradation Products/me [Metabolism]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Movement/ph [Physiology]
MH  - Muscle Weakness/et [Etiology]
MH  - Prospective Studies
MH  - Recovery of Function
MH  - Regression Analysis
MH  - Rehabilitation Centers
MH  - Sex Factors
MH  - Singapore/ep [Epidemiology]
MH  - *Stroke/co [Complications]
MH  - *Stroke/ep [Epidemiology]
MH  - Venous Thrombosis/di [Diagnosis]
MH  - *Venous Thrombosis/ep [Epidemiology]
MH  - Venous Thrombosis/us [Ultrasonography]
MH  - Walking/ph [Physiology]
AB  - BACKGROUND: Studies have shown that deep vein thrombosis (DVT) is common after an acute stroke. Less common are studies documenting DVT in stroke patients admitted to rehabilitation. The purpose of this study was to determine the frequency and risk factors of DVT in stroke patients admitted to a rehabilitation unit in Singapore.
AB  - METHODS: A prospective observational single-center study of patients with ischemic and hemorrhagic stroke with lower limb paresis admitted to a rehabilitation center in Singapore. The screening protocol consisted of quantitative D-dimer assay (DDA) within 24-48 h of rehabilitation admission followed by duplex ultrasound scan of the paretic lower extremity if DDA level was elevated (equal or greater than 0.34 microg/ml).
AB  - RESULTS: Altogether, 341 patients were screened at a mean of 23 days poststroke. One hundred and ninety-eight (58.1%) patients had an elevated DDA and all underwent ultrasound scans. The frequency of lower limb DVT was 9% (18) - seven proximal and 11 distal. DVT was significantly related to higher D-dimer levels (P=0.029) and cortical strokes (P=0.004), but not to age, gender, race, nature of stroke, atrial fibrillation, severity of lower limb weakness, and ambulatory and functional status. No patients had clinical pulmonary embolism during rehabilitation.
AB  - CONCLUSIONS: Lower limb DVT is uncommon in stroke patients admitted to rehabilitation in Singapore. Future research should include evaluation of the cost-effectiveness of such a screening protocol.
RN  - 0 (Fibrin Fibrinogen Degradation Products)
RN  - 0 (fibrin fragment D)
ES  - 1747-4949
IL  - 1747-4930
DO  - http://dx.doi.org/10.1111/j.1747-4949.2009.00278.x
PT  - Journal Article
LG  - English
DP  - 2009 Jun
DC  - 20090807
YR  - 2009
ED  - 20091023
RD  - 20100507
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19659817

<467. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19659617
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Schmidt M
AU  - Segerson NM
AU  - Marschang H
AU  - Akoum N
AU  - Rittger H
AU  - Clifford SM
AU  - Brachmann J
AU  - Daccarett M
AU  - Marrouche NF
FA  - Schmidt, Martin
FA  - Segerson, Nathan M
FA  - Marschang, Harald
FA  - Akoum, Nazem
FA  - Rittger, Harald
FA  - Clifford, Sarah M
FA  - Brachmann, Johannes
FA  - Daccarett, Marcos
FA  - Marrouche, Nassir F
IN  - Schmidt,Martin. Division of Cardiology, Klinikum Coburg, Coburg, Germany.
TI  - Atrial fibrillation ablation in patients with therapeutic international normalized ratios.
SO  - Pacing & Clinical Electrophysiology. 32(8):995-9, 2009 Aug.
AS  - Pacing Clin Electrophysiol. 32(8):995-9, 2009 Aug.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - pab, 7803944
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/su [Surgery]
MH  - *Catheter Ablation/sn [Statistics & Numerical Data]
MH  - Female
MH  - *Heart Conduction System/su [Surgery]
MH  - Humans
MH  - Male
MH  - Prevalence
MH  - *Pulmonary Veins/su [Surgery]
MH  - Reference Values
MH  - Risk Assessment
MH  - Risk Factors
MH  - Treatment Outcome
MH  - Utah
AB  - AIMS: Pulmonary vein antrum isolation (PVAI) plays a pivotal role in the comprehensive treatment of atrial fibrillation (AF). The need for effective anticoagulation bridging following PVAI is associated with significant vascular complication rates and increased costs. We investigated the safety of PVAI in patients with therapeutic international normalized ratios (INR) the day of the procedure.
AB  - METHODS: A case-control analysis was performed on patients who underwent PVAI with therapeutic INR (>2). Patients with normal preprocedure INR served as controls. The incidence of major and minor hematomas, fistulas, vascular injury, and cardiac perforation or tamponade were catalogued. PVAI was performed under fluoroscopic, electro-anatomical, and intracardiac echocardiographic guidance, with an open irrigation ablation technique.
AB  - RESULTS: A total of 194 patients (mean age 64 +/- 12) were included; 87 patients underwent PVAI with therapeutic INR (cases) and 107 with normal INR (controls). Persistent AF was more prevalent than paroxysmal AF in the therapeutic INR group. The mean INR for cases was 2.8 +/- 0.7 compared to 1.4 +/- 0.3 in the control group (P < 0.01). All procedures were completed without acute complications. Two major adverse events were observed, one in each arm. No significant difference in terms of minor (6.5% vs. 5.7%, P = 0.23) or major (0.93% vs. 1.15%, P = 0.49) vascular events or bleeding was detected between the therapeutic INR and the control group. The combined endpoint of major and minor complications did not differ among groups (9.35% vs. 8.05%, P = 0.19).
AB  - CONCLUSION: Atrial fibrillation ablation in patients with therapeutic INR on the day of a procedure appears to be safe and feasible. Expensive outpatient anti-coagulation bridging may be safely avoided in this type of population.
ES  - 1540-8159
IL  - 0147-8389
DO  - http://dx.doi.org/10.1111/j.1540-8159.2009.02429.x
PT  - Controlled Clinical Trial
PT  - Journal Article
LG  - English
DP  - 2009 Aug
DC  - 20090807
YR  - 2009
ED  - 20091021
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19659617

<468. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19590112
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Cervigon R
AU  - Moreno J
AU  - Reilly RB
AU  - Perez-Villacastin J
AU  - Castells F
FA  - Cervigon, R
FA  - Moreno, J
FA  - Reilly, R B
FA  - Perez-Villacastin, J
FA  - Castells, F
IN  - Cervigon,R. Escuela Universitaria Politecnica, Campus Universitario, Group of Bioengineering Innovation (GIBI), DIEEAC, UCLM, Camino del Pozuelo sn. 16071, Cuenca, Spain. raquel.cervigon@uclm.es
TI  - Ventricular rhythm in atrial fibrillation under anaesthetic infusion with propofol.
SO  - Physiological Measurement. 30(8):833-45, 2009 Aug.
AS  - Physiol Meas. 30(8):833-45, 2009 Aug.
NJ  - Physiological measurement
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - bn5, 9306921
SB  - Index Medicus
CP  - England
MH  - Ablation Techniques
MH  - *Anesthetics, Intravenous/ad [Administration & Dosage]
MH  - *Anesthetics, Intravenous/pd [Pharmacology]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/su [Surgery]
MH  - Autonomic Nervous System/de [Drug Effects]
MH  - Autonomic Nervous System/pp [Physiopathology]
MH  - Electrocardiography/de [Drug Effects]
MH  - Electrophysiological Processes/de [Drug Effects]
MH  - Female
MH  - Heart Atria/de [Drug Effects]
MH  - Heart Atria/pp [Physiopathology]
MH  - Heart Rate/de [Drug Effects]
MH  - *Heart Ventricles/de [Drug Effects]
MH  - *Heart Ventricles/pp [Physiopathology]
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - *Propofol/ad [Administration & Dosage]
MH  - *Propofol/pd [Pharmacology]
AB  - Changes in patients' autonomic tone and specific pharmacologic interventions may modify the ventricular response (actual heart rate) during atrial fibrillation (AF). Hypnotic agents such as propofol may modify autonomic balance as they promote a sedative state. It has been shown that propofol slightly slows atrial fibrillatory activity, but the net global effect on the ventricular response remains unknown. We aimed to evaluate in patients in AF the effect of a propofol bolus on the ventricular rate and regularity at ECG. We analysed the possible relation with local atrial fibrillatory activities, as ratios between atrial and ventricular rates (AVRs), analysing atrial activity from intracardiac electrograms at the free wall of the right and left atria and at the interatrial septum. We compared data at the baseline and after complete hypnosis. Propofol was associated with a more homogeneous ventricular response and lower AVR values at the interatrial septum.
RN  - 0 (Anesthetics, Intravenous)
RN  - YI7VU623SF (Propofol)
IS  - 0967-3334
IL  - 0967-3334
DO  - http://dx.doi.org/10.1088/0967-3334/30/8/008
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20090710
DP  - 2009 Aug
DC  - 20090727
YR  - 2009
ED  - 20091009
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19590112

<469. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19738137
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - de Assis MC
AU  - Rabelo ER
AU  - Avila CW
AU  - Polanczyk CA
AU  - Rohde LE
FA  - de Assis, Michelli C
FA  - Rabelo, Eneida R
FA  - Avila, Christiane W
FA  - Polanczyk, Carisi Anne
FA  - Rohde, Luis E
IN  - de Assis,Michelli C. Cardiovascular Division of Hospital de Clinicas de Porto Alegre, Postgraduation Program in Cardiology and Cardiovascular Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
TI  - Improved oral anticoagulation after a dietary vitamin k-guided strategy: a randomized controlled trial.
SO  - Circulation. 120(12):1115-22, 3 p following 1122, 2009 Sep 22.
AS  - Circulation. 120(12):1115-22, 3 p following 1122, 2009 Sep 22.
NJ  - Circulation
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - *Anticoagulants/ad [Administration & Dosage]
MH  - Cross-Over Studies
MH  - Diet
MH  - Female
MH  - Humans
MH  - International Normalized Ratio
MH  - Male
MH  - Middle Aged
MH  - *Vitamin K/ad [Administration & Dosage]
AB  - BACKGROUND: Dietary vitamin K is thought to be an important factor that interferes with anticoagulation stability, but the clinical applicability of this interaction has not been evaluated adequately in prospective studies.
AB  - METHODS AND RESULTS: In a randomized controlled trial that enrolled outpatients with a recent international normalized ratio (INR) outside the therapeutic target, we compared 2 strategies to optimize long-term oral anticoagulation: (1) a conventional approach based on changes in anticoagulant prescription and (2) a dietary vitamin K-guided strategy based on simple modifications of the amount of vitamin K-rich foods ingested per week. The primary efficacy end point was the percentage of patients who achieved a prespecified INR target at 90 days after randomization. Study population (n=132) predominantly included men with mechanical heart prostheses (58%) or atrial fibrillation (35%). Over time, patients allocated to the vitamin K-guided strategy reached the prespecified INR more frequently so that after 90 days of follow-up, 74% were on target compared with 58% of patients managed conventionally (P=0.04). Patients allocated to the dietary vitamin K-guided strategy had the same magnitude and direction of INR variation as those observed with the conventional approach in the short term (15 days) for both underanticaogulated and overanticoagulated patients. Minor bleeding or use of parenteral vitamin K were also marginally less frequent in patients managed according to the dietary intervention (1 [1.5%] versus 7 [11%]; P=0.06).
AB  - CONCLUSIONS: A vitamin K-guided management strategy to adjust long-term oral anticoagulation is feasible and safe and may result in an increased chance of reaching target levels of INR.
RN  - 0 (Anticoagulants)
RN  - 12001-79-5 (Vitamin K)
ES  - 1524-4539
IL  - 0009-7322
DO  - http://dx.doi.org/10.1161/CIRCULATIONAHA.109.849208
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
SI  - ClinicalTrials.gov
SA  - ClinicalTrials.gov/NCT00355290
SL  - http://clinicaltrials.gov/search/term=NCT00355290
LG  - English
EP  - 20090908
DP  - 2009 Sep 22
DC  - 20090922
YR  - 2009
ED  - 20091008
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19738137

<470. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19229417
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Flores DM
AU  - Kalil RA
AU  - Lima GG
AU  - Abrahao R
AU  - Sant'anna JR
AU  - Prates PR
AU  - Castro I
AU  - Nesralla IA
FA  - Flores, Daniela Marchiori
FA  - Kalil, Renato A K
FA  - Lima, Gustavo Glotz de
FA  - Abrahao, Rogerio
FA  - Sant'anna, Joao Ricardo Michelin
FA  - Prates, Paulo Roberto
FA  - Castro, Iran
FA  - Nesralla, Ivo A
IN  - Flores,Daniela Marchiori. Programa de Pos-Graduacao em Ciencias da Saude, University Cardiology Foundation, Institute of Cardiology of Rio Grande do Sul.
TI  - Chronotropic response to exercise after pulmonary veins isolation or Cox-maze operation.
SO  - Revista Brasileira de Cirurgia Cardiovascular: Orgao Oficial da Sociedade Brasileira de Cirurgia Cardiovascular. 23(4):474-9, 2008 Oct-Dec.
AS  - Rev Bras Cir Cardiovasc. 23(4):474-9, 2008 Oct-Dec.
NJ  - Revista brasileira de cirurgia cardiovascular : orgao oficial da Sociedade Brasileira de Cirurgia Cardiovascular
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 9104279
SB  - Index Medicus
CP  - Brazil
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Analysis of Variance
MH  - *Atrial Fibrillation/su [Surgery]
MH  - Cardiac Surgical Procedures/mt [Methods]
MH  - Catheter Ablation/mt [Methods]
MH  - *Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Female
MH  - Heart Atria/pa [Pathology]
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mitral Valve Insufficiency/su [Surgery]
MH  - Postoperative Period
MH  - Prospective Studies
MH  - *Pulmonary Veins/su [Surgery]
MH  - Young Adult
AB  - OBJECTIVE: To evaluate the chronotropic response to exercise during immediate and late postoperative period after atrial fibrillation and mitral valve surgical treatment by different techniques.
AB  - METHODS: Prospective controlled clinical study of 42 patients presenting chronic AF associated mitral valve disease, who underwent surgery by the techniques of pulmonary veins isolation (n=16), Modified Cox-maze procedure, without cryoablation (n=13), both with isolated mitral valve repair (n=13). The preoperative clinical characteristics, surgical indications, kind and aetiology of valve lesion were similar between groups. The patients were outpatient followed-up and underwent series of ergometric tests.
AB  - RESULTS: In the immediate postoperative period, chronotropic response was similar in the 3 groups with mean of 73.6 +/- 12.3% of maximal calculated heart rate. In the surgical pulmonary veins isolation group, there was an increment of heart rate, from 64.4 +/- 12.4% of maximal heart rate in the immediate postoperative period to 78.9 +/- 10.5% in the 12th month (P=0.012) of postoperative. In the Cox-maze group, heart rate varied, respectively, from 73.9 +/- 11.14% to 78.8 +/- 15.2% (P=1.000) and in the control group (only mitral valve surgery), from 67.2 +/- 14.3% to 71.9 +/- 12.9% (P=0.889).
AB  - CONCLUSION: An attenuation of immediate postoperative chronotropic response to exercise was similar in the postoperative in the three different surgical techniques. There was a significant improvement in this response concerning to postoperative outcome in the pulmonary veins isolation group. These results suggest that simple surgical pulmonary veins isolation may be related to a better preservation of atrial chronotropism.
DI  - S0102-76382008000400004
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
LG  - Portuguese
DP  - 2008 Oct-Dec
DC  - 20090220
YR  - 2008
ED  - 20091006
RD  - 20160303
UP  - 20160304
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=19229417

<471. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19229417
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Flores DM
AU  - Kalil RA
AU  - Lima GG
AU  - Abrahao R
AU  - Sant'anna JR
AU  - Prates PR
AU  - Castro I
AU  - Nesralla IA
FA  - Flores, Daniela Marchiori
FA  - Kalil, Renato A K
FA  - Lima, Gustavo Glotz de
FA  - Abrahao, Rogerio
FA  - Sant'anna, Joao Ricardo Michelin
FA  - Prates, Paulo Roberto
FA  - Castro, Iran
FA  - Nesralla, Ivo A
IN  - Flores,Daniela Marchiori. Programa de Pos-Graduacao em Ciencias da Saude, University Cardiology Foundation, Institute of Cardiology of Rio Grande do Sul.
TI  - Chronotropic response to exercise after pulmonary veins isolation or Cox-maze operation.
SO  - Revista Brasileira de Cirurgia Cardiovascular: Orgao Oficial da Sociedade Brasileira de Cirurgia Cardiovascular. 23(4):474-9, 2008 Oct-Dec.
AS  - Rev Bras Cir Cardiovasc. 23(4):474-9, 2008 Oct-Dec.
NJ  - Revista brasileira de cirurgia cardiovascular : orgao oficial da Sociedade Brasileira de Cirurgia Cardiovascular
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 9104279
SB  - Index Medicus
CP  - Brazil
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Analysis of Variance
MH  - *Atrial Fibrillation/su [Surgery]
MH  - Cardiac Surgical Procedures/mt [Methods]
MH  - Catheter Ablation/mt [Methods]
MH  - *Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Female
MH  - Heart Atria/pa [Pathology]
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mitral Valve Insufficiency/su [Surgery]
MH  - Postoperative Period
MH  - Prospective Studies
MH  - *Pulmonary Veins/su [Surgery]
MH  - Young Adult
AB  - OBJECTIVE: To evaluate the chronotropic response to exercise during immediate and late postoperative period after atrial fibrillation and mitral valve surgical treatment by different techniques.
AB  - METHODS: Prospective controlled clinical study of 42 patients presenting chronic AF associated mitral valve disease, who underwent surgery by the techniques of pulmonary veins isolation (n=16), Modified Cox-maze procedure, without cryoablation (n=13), both with isolated mitral valve repair (n=13). The preoperative clinical characteristics, surgical indications, kind and aetiology of valve lesion were similar between groups. The patients were outpatient followed-up and underwent series of ergometric tests.
AB  - RESULTS: In the immediate postoperative period, chronotropic response was similar in the 3 groups with mean of 73.6 +/- 12.3% of maximal calculated heart rate. In the surgical pulmonary veins isolation group, there was an increment of heart rate, from 64.4 +/- 12.4% of maximal heart rate in the immediate postoperative period to 78.9 +/- 10.5% in the 12th month (P=0.012) of postoperative. In the Cox-maze group, heart rate varied, respectively, from 73.9 +/- 11.14% to 78.8 +/- 15.2% (P=1.000) and in the control group (only mitral valve surgery), from 67.2 +/- 14.3% to 71.9 +/- 12.9% (P=0.889).
AB  - CONCLUSION: An attenuation of immediate postoperative chronotropic response to exercise was similar in the postoperative in the three different surgical techniques. There was a significant improvement in this response concerning to postoperative outcome in the pulmonary veins isolation group. These results suggest that simple surgical pulmonary veins isolation may be related to a better preservation of atrial chronotropism.
ES  - 1678-9741
IL  - 0102-7638
DI  - S0102-76382008000400004
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
LG  - Portuguese
DP  - 2008 Oct-Dec
DC  - 20090220
YR  - 2008
ED  - 20091006
RD  - 20120402
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19229417

<472. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19629889
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Heidt MC
AU  - Vician M
AU  - Stracke SK
AU  - Stadlbauer T
AU  - Grebe MT
AU  - Boening A
AU  - Vogt PR
AU  - Erdogan A
FA  - Heidt, M C
FA  - Vician, M
FA  - Stracke, S K H
FA  - Stadlbauer, T
FA  - Grebe, M T
FA  - Boening, A
FA  - Vogt, P R
FA  - Erdogan, A
IN  - Heidt,M C. Cardiology, University Clinic Giessen, 35392 Giessen, Germany. Martin.C.Heidt@innere.med.uni-giessen.de
TI  - Beneficial effects of intravenously administered N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a prospective randomized study.
CM  - Comment in: Thorac Cardiovasc Surg. 2010 Feb;58(1):60; PMID: 20072984
SO  - Thoracic & Cardiovascular Surgeon. 57(5):276-80, 2009 Aug.
AS  - Thorac Cardiovasc Surg. 57(5):276-80, 2009 Aug.
NJ  - The Thoracic and cardiovascular surgeon
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - vr0, 7903387
SB  - Index Medicus
CP  - Germany
MH  - Aged
MH  - *Anti-Arrhythmia Agents/ad [Administration & Dosage]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - *Coronary Artery Bypass/ae [Adverse Effects]
MH  - Critical Care
MH  - Double-Blind Method
MH  - Electrocardiography
MH  - *Fatty Acids, Omega-3/ad [Administration & Dosage]
MH  - Female
MH  - *Fish Oils/ad [Administration & Dosage]
MH  - Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Infusions, Intravenous
MH  - Length of Stay
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - *Soybean Oil/ad [Administration & Dosage]
MH  - Time Factors
MH  - Treatment Outcome
AB  - BACKGROUND: Atrial fibrillation (AF) is a common complication after coronary artery bypass grafting operation (CABG). Experimental data have shown antiarrhythmic effects of n-3 polyunsaturated fatty acids (PUFA) on myocardial cells. Orally administered PUFA could significantly reduce the rate of postoperative AF. We assessed the efficacy of PUFA for the prevention of AF after CABG. PUFA were given intravenously to prevent variation in bioavailability.
AB  - METHODS AND RESULTS: 52 patients were randomized to the interventional group, 50 served as controls. In the control group free fatty acids (100 mg soya oil/kg body weight/day) were infused via perfusion pump, starting on admission to hospital and ending at discharge from intensive care. In the interventional group PUFA were given at a dosage of 100 mg fish oil/kg body weight/day. Primary end point was the postoperative development of AF, documented by surface ECG. Secondary end point was the length of stay in the ICU. The demographic, clinical and surgical characteristics of the patients in the two groups were similar. Postoperative AF occurred in 15 patients (30.6 %) in the control and in 9 (17.3 %) in the PUFA group ( P < 0.05). After CABG, the PUFA patients had to be treated in the ICU for a shorter time than the control patients. No adverse effects were observed.
AB  - CONCLUSIONS: Perioperative intravenous infusion of PUFA reduces the incidence of AF after CABG and leads to a shorter stay in the ICU and in hospital. Our data suggest that perioperative intravenous infusion of PUFA should be recommended for patients undergoing CABG.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Fish Oils)
RN  - 8001-22-7 (Soybean Oil)
ES  - 1439-1902
IL  - 0171-6425
DO  - http://dx.doi.org/10.1055/s-0029-1185301
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
EP  - 20090723
DP  - 2009 Aug
DC  - 20090724
YR  - 2009
ED  - 20091002
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19629889

<473. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19589114
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Patel D
AU  - Natale A
AU  - Di Biase L
AU  - Burkhardt JD
AU  - Wang Y
AU  - Sanchez JE
AU  - Horton RP
AU  - Khan M
FA  - Patel, Dimpi
FA  - Natale, Andrea
FA  - Di Biase, Luigi
FA  - Burkhardt, J David
FA  - Wang, Yan
FA  - Sanchez, Javier E
FA  - Horton, Rodney P
FA  - Khan, Mohammed
IN  - Patel,Dimpi. Texas Cardiac Arrhythmia Institute, St David's Medical Center, Austin, TX 78705, USA. dimpi.patel.afib@gmail.com
TI  - Catheter ablation for atrial fibrillation: a promising therapy for congestive heart failure. [Review] [40 refs]
SO  - Expert Review of Cardiovascular Therapy. 7(7):779-87, 2009 Jul.
AS  - Expert Rev Cardiovasc Ther. 7(7):779-87, 2009 Jul.
NJ  - Expert review of cardiovascular therapy
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101182328
SB  - Index Medicus
CP  - England
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/su [Surgery]
MH  - Atrioventricular Node/su [Surgery]
MH  - *Catheter Ablation/mt [Methods]
MH  - Exercise
MH  - Heart Failure/co [Complications]
MH  - *Heart Failure/su [Surgery]
MH  - Humans
MH  - Pulmonary Veins/su [Surgery]
MH  - Quality of Life
AB  - Atrial fibrillation (AF) and congestive heart failure (CHF) are cardiovascular epidemics. Catheter ablation of AF is increasingly performed in patients with CHF. Atrioventricular junction ablation (AVJA) and pulmonary vein isolation are the two predominant ablation strategies used to treat AF patients who are refractory to drugs. In patients with CHF refractory to drugs, AVJA with a biventricular device is associated with improvement in exercise capacity and quality of life. However, in a head-to-head comparison, pulmonary vein antrum ablation was shown to be superior to AVJA. Cure of AF in patients with CHF resulted in more significant morphological and functional improvements than AVJA. [References: 40]
ES  - 1744-8344
IL  - 1477-9072
DO  - http://dx.doi.org/10.1586/erc.09.61
PT  - Comparative Study
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2009 Jul
DC  - 20090710
YR  - 2009
ED  - 20090925
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19589114

<474. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19589113
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Smit MD
AU  - Van Gelder IC
FA  - Smit, Marcelle D
FA  - Van Gelder, Isabelle C
IN  - Smit,Marcelle D. Department of Cardiology, Thorax Center, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. m.d.smit@thorax.umcg.nl
TI  - Upstream therapy of atrial fibrillation. [Review] [97 refs]
SO  - Expert Review of Cardiovascular Therapy. 7(7):763-78, 2009 Jul.
AS  - Expert Rev Cardiovasc Ther. 7(7):763-78, 2009 Jul.
NJ  - Expert review of cardiovascular therapy
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101182328
SB  - Index Medicus
CP  - England
MH  - Animals
MH  - Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - Cardiovascular Agents/pd [Pharmacology]
MH  - *Cardiovascular Agents/tu [Therapeutic Use]
MH  - Clinical Trials as Topic
MH  - *Exercise
MH  - Humans
MH  - Primary Prevention/mt [Methods]
MH  - Secondary Prevention/mt [Methods]
AB  - Failure of current pharmacological therapy for atrial fibrillation in maintaining sinus rhythm may be due to structural atrial remodeling caused by inflammation and fibrosis. Upstream therapy that interferes in the structural remodeling process may be effective in maintaining sinus rhythm. This article reviews upstream therapy in atrial fibrillation. Various prospective and retrospective studies demonstrate that upstream therapy, consisting of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, statins, fish oils, glucocorticoids, or moderate physical activity, is associated with a reduced incidence of new-onset atrial fibrillation (i.e., primary prevention) and with a reduced recurrence of atrial fibrillation (i.e., secondary prevention). Larger clinical trials are required to further elucidate the position of upstream therapy in the primary and secondary prevention of atrial fibrillation. [References: 97]
RN  - 0 (Cardiovascular Agents)
ES  - 1744-8344
IL  - 1477-9072
DO  - http://dx.doi.org/10.1586/erc.09.59
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2009 Jul
DC  - 20090710
YR  - 2009
ED  - 20090925
RD  - 20141120
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19589113

<475. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19207785
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Maass AH
AU  - Buck S
AU  - Nieuwland W
AU  - Brugemann J
AU  - van Veldhuisen DJ
AU  - Van Gelder IC
FA  - Maass, Alexander H
FA  - Buck, Sandra
FA  - Nieuwland, Wybe
FA  - Brugemann, Johan
FA  - van Veldhuisen, Dirk J
FA  - Van Gelder, Isabelle C
IN  - Maass,Alexander H. Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
TI  - Importance of heart rate during exercise for response to cardiac resynchronization therapy.
SO  - Journal of Cardiovascular Electrophysiology. 20(7):773-80, 2009 Jul.
AS  - J Cardiovasc Electrophysiol. 20(7):773-80, 2009 Jul.
NJ  - Journal of cardiovascular electrophysiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - by4, 9010756
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Anaerobic Threshold
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Defibrillators, Implantable
MH  - *Electric Countershock/is [Instrumentation]
MH  - Electrocardiography
MH  - *Exercise Test
MH  - *Exercise Tolerance
MH  - Female
MH  - Heart Failure/di [Diagnosis]
MH  - Heart Failure/pp [Physiopathology]
MH  - *Heart Failure/th [Therapy]
MH  - *Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Oxygen Consumption
MH  - Predictive Value of Tests
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Treatment Outcome
AB  - BACKGROUND: Cardiac resynchronization therapy (CRT) is an established therapy for patients with severe heart failure and mechanical dyssynchrony. Response is only achieved in 60-70% of patients.
AB  - OBJECTIVES: To study exercise-related factors predicting response to CRT.
AB  - METHODS: We retrospectively examined consecutive patients in whom a CRT device was implanted. All underwent cardiopulmonary exercise testing prior to implantation and after 6 months. The occurrence of chronotropic incompetence and heart rates exceeding the upper rate of the device, thereby compromising biventricular stimulation, was studied. Response was defined as a decrease in LVESV of 10% or more after 6 months.
AB  - RESULTS: We included 144 patients. After 6 months 86 (60%) patients were responders. Peak VO2 significantly increased in responders. Chronotropic incompetence was more frequently seen in nonresponders (21 [36%] vs 9 [10%], P = 0.03), mostly in patients in SR. At moderate exercise, defined as 25% of the maximal exercise tolerance, that is, comparable to daily life exercise, nonresponders more frequently went above the upper rate of the device (13 [22%] vs 2 [3%], P < 0.0001), most of whom were patients in permanent AF. Multivariate analysis revealed heart rates not exceeding the upper rate of the device during moderate exercise (OR 15.8 [3.3-76.5], P = 0.001) and nonischemic cardiomyopathy (OR 2.4 [1.0-5.7], P = 0.04) as predictive for response.
AB  - CONCLUSIONS: Heart rate exceeding the upper rate during moderate exercise is an independent predictor for nonresponse to CRT in patients with AF, whereas chronotropic incompetence is a predictor for patients in SR.
ES  - 1540-8167
IL  - 1045-3873
DO  - http://dx.doi.org/10.1111/j.1540-8167.2008.01422.x
PT  - Journal Article
LG  - English
EP  - 20090202
DP  - 2009 Jul
DC  - 20090714
YR  - 2009
ED  - 20090918
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19207785

<476. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19562528
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Conen D
AU  - Osswald S
AU  - Albert CM
FA  - Conen, D
FA  - Osswald, S
FA  - Albert, C M
IN  - Conen,D. Department of Medicine, Cardiology Division, University Hospital, Basel, Switzerland. conend@uhbs.ch
TI  - Epidemiology of atrial fibrillation. [Review] [84 refs]
SO  - Swiss Medical Weekly. 139(25-26):346-52, 2009 Jun 27.
AS  - Swiss Med Wkly. 139(25-26):346-52, 2009 Jun 27.
NJ  - Swiss medical weekly
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - d10, 100970884
SB  - Index Medicus
CP  - Switzerland
MH  - *Atrial Fibrillation/et [Etiology]
MH  - Female
MH  - Humans
MH  - *Hypertension/co [Complications]
MH  - Male
MH  - *Obesity/co [Complications]
MH  - Risk Factors
AB  - Atrial fibrillation is the most common sustained cardiac arrhythmia in the general population. Unfortunately, current treatment strategies aiming at the elimination of atrial fibrillation have limited long term success rates and significant risks. In this context, recent publications have provided many insights on potentially treatable risk factors for the occurrence of atrial fibrillation, such as alcohol, blood pressure, obesity, inflammation and nutritional factors. In this review, we summarise the current evidence on these risk factors and indicate areas in need of further investigation. The current evidence shows that blood pressure, hypertension and obesity seem to play a key role in the pathogenesis of atrial fibrillation. Preliminary evidence also suggests that inflammation is an important mediator of these associations. Knowledge of these interrelationships may eventually help to develop new treatment strategies and decrease the burden of atrial fibrillation in the general population. [References: 84]
IS  - 1424-7860
IL  - 0036-7672
DO  - http://dx.doi.org/smw-12500
PT  - Journal Article
PT  - Review
NO  - R21 HL093613 (United States NHLBI NIH HHS)
LG  - English
DP  - 2009 Jun 27
DC  - 20090629
YR  - 2009
ED  - 20090826
RD  - 20140921
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19562528

<477. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19476425
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Dixon DL
AU  - Williams VG
FA  - Dixon, Dave L
FA  - Williams, Virginia G
IN  - Dixon,Dave L. Department of Pharmacy, Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina 27157, USA.
TI  - Interaction between gemfibrozil and warfarin: case report and review of the literature. [Review] [18 refs]
SO  - Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy. 29(6):744-8, 2009 Jun.
AS  - Pharmacotherapy. 29(6):744-8, 2009 Jun.
NJ  - Pharmacotherapy
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - par, 8111305
SB  - Index Medicus
CP  - United States
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - Drug Interactions
MH  - Follow-Up Studies
MH  - *Gemfibrozil/ae [Adverse Effects]
MH  - Gemfibrozil/tu [Therapeutic Use]
MH  - Humans
MH  - *Hypolipidemic Agents/ae [Adverse Effects]
MH  - Hypolipidemic Agents/tu [Therapeutic Use]
MH  - International Normalized Ratio
MH  - Male
MH  - Middle Aged
MH  - Muscular Diseases/ci [Chemically Induced]
MH  - Time Factors
MH  - Treatment Outcome
MH  - *Warfarin/tu [Therapeutic Use]
AB  - Possible procoagulant effects can occur when lipid-lowering fibric acid derivatives, such as gemfibrozil and fenofibrate, are taken concomitantly with warfarin. Although there are several detailed reports of fenofibrate potentiating the anticoagulant effects of warfarin, few case reports have been published regarding an interaction between gemfibrozil and warfarin. We describe a 62-year-old man who was taking warfarin for paroxysmal atrial fibrillation and came to the anticoagulation clinic for a routine follow-up. For 9 months, the patient's international normalized ratio (INR) had been stable (target range 2.0-3.0) with warfarin 45 mg/week. At this clinic visit, however, his INR was supratherapeutic at 5.8; the only identified change in his drug therapy was the addition of gemfibrozil 600 mg twice/day, started 3 weeks earlier. The patient denied any changes in his dietary intake of vitamin K, alcohol use, or addition of nonprescription or herbal agents. Recent laboratory tests revealed no signs of thyroid abnormalities and only an insignificant elevation in his alanine aminotransferase level. His warfarin dose was decreased to 35-37.5 mg/week (a 22% reduction), and a therapeutic INR was maintained until gemfibrozil was later discontinued because of myalgia. After consecutive subtherapeutic INRs, his warfarin dose was increased to 45 mg/week and a therapeutic INR was maintained. Use of the Drug Interaction Probability Scale indicated that the likelihood of the gemfibrozil-warfarin interaction was probable. The exact mechanism of the proposed interactions between fibric acid derivatives and warfarin remains unknown but may be multifactorial through inhibition of cytochrome P450 isoenzymes, displacement from protein binding sites, or changes in coagulation factor synthesis. Regardless of the fibric acid derivative chosen, an empiric dosage reduction of 20% and close INR monitoring are warranted in patients receiving warfarin. [References: 18]
RN  - 0 (Anticoagulants)
RN  - 0 (Hypolipidemic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - Q8X02027X3 (Gemfibrozil)
ES  - 1875-9114
IL  - 0277-0008
DO  - http://dx.doi.org/10.1592/phco.29.6.744
PT  - Case Reports
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2009 Jun
DC  - 20090529
YR  - 2009
ED  - 20090806
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19476425

<478. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19544703
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lubart E
AU  - Segal R
AU  - Yearovoi A
AU  - Fridenson A
AU  - Baumoehl Y
AU  - Leibovitz A
FA  - Lubart, Emilia
FA  - Segal, Refael
FA  - Yearovoi, Alexandra
FA  - Fridenson, Aharon
FA  - Baumoehl, Yehuda
FA  - Leibovitz, Arthur
IN  - Lubart,Emilia. Shmuel Harofe Geriatric Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.
TI  - QT interval disturbances in hospitalized elderly patients.
SO  - Israel Medical Association Journal: Imaj. 11(3):147-50, 2009 Mar.
AS  - Isr Med Assoc J. 11(3):147-50, 2009 Mar.
NJ  - The Israel Medical Association journal : IMAJ
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - dk6, 100930740
SB  - Index Medicus
CP  - Israel
MH  - Aged
MH  - *Arrhythmias, Cardiac/ep [Epidemiology]
MH  - Comorbidity
MH  - Electrocardiography
MH  - Heart Conduction System/de [Drug Effects]
MH  - Heart Conduction System/pp [Physiopathology]
MH  - Heart Failure/ep [Epidemiology]
MH  - Heart Failure/pp [Physiopathology]
MH  - Hospitalization
MH  - Humans
MH  - Hypnotics and Sedatives/pd [Pharmacology]
MH  - Israel/ep [Epidemiology]
MH  - Prevalence
MH  - Retrospective Studies
AB  - BACKGROUND: The QT interval reflects the total duration of ventricular myocardial repolarization. Its prolongation is associated with increased risk of polymorphic ventricular tachycardia, or torsade de pointes, which can be fatal.
AB  - OBJECTIVES: To assess the prevalence of both prolonged and short QT interval in patients admitted to an acute geriatric ward.
AB  - METHODS: This retrospective study included the records over 6 months of all patients hospitalized in an acute geriatric ward. Excluded were patients with pacemaker, bundle branch block and slow or rapid atrial fibrillation. The standard 12 lead electrocardiogram of each patient was used for the QT interval evaluation.
AB  - RESULTS: We screened the files of 422 patients. QTc prolongation based on the mean of 12 ECG leads was detected in 115 patients (27%). Based on lead L2 only, QTc was prolonged in 136 (32%). Associated factors with QT prolongation were congestive heart failure and use of hypnotics. Short QTwas found in 30 patients (7.1%) in lead L2 and in 19 (4.5%) by the mean 12 leads. Short QT was related to a higher heart rate, chronic atrial fibrillation and schizophrenia.
AB  - CONCLUSIONS: Our study detected QT segment disturbances in a considerable number of elderly patients admitted acutely to hospital. Further studies should confirm these results and clinicians should consider a close QT interval follow-up in predisposed patients.
RN  - 0 (Hypnotics and Sedatives)
IS  - 1565-1088
PT  - Journal Article
LG  - English
DP  - 2009 Mar
DC  - 20090623
YR  - 2009
ED  - 20090716
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19544703

<479. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18719758
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Carvalho VO
AU  - Guimaraes GV
AU  - Ciolac EG
AU  - Bocchi EA
FA  - Carvalho, Vitor Oliveira
FA  - Guimaraes, Guilherme Veiga
FA  - Ciolac, Emmanuel Gomes
FA  - Bocchi, Edimar Alcides
IN  - Carvalho,Vitor Oliveira. Laboratorio de Insuficiencia Cardiaca e Transplante, Instituto do Coracao, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil. vitor.carvalho@usp.br
TI  - Heart rate dynamics during a treadmill cardiopulmonary exercise test in optimized beta-blocked heart failure patients.
SO  - Clinics (Sao Paulo, Brazil). 63(4):479-82, 2008 Aug.
AS  - Clinics. 63(4):479-82, 2008 Aug.
NJ  - Clinics (Sao Paulo, Brazil)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101244734, 16240140r
OI  - Source: NLM. PMC2664123
SB  - Index Medicus
CP  - Brazil
MH  - *Adrenergic beta-Antagonists/tu [Therapeutic Use]
MH  - Adult
MH  - *Carbazoles/tu [Therapeutic Use]
MH  - Case-Control Studies
MH  - *Exercise Test/de [Drug Effects]
MH  - Exercise Tolerance/de [Drug Effects]
MH  - Female
MH  - *Heart Failure/dt [Drug Therapy]
MH  - Heart Failure/pp [Physiopathology]
MH  - *Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxygen Consumption/de [Drug Effects]
MH  - *Propanolamines/tu [Therapeutic Use]
MH  - Pulmonary Gas Exchange/de [Drug Effects]
MH  - Treatment Outcome
AB  - BACKGROUND: Calculating the maximum heart rate for age is one method to characterize the maximum effort of an individual. Although this method is commonly used, little is known about heart rate dynamics in optimized beta-blocked heart failure patients.
AB  - AIM: The aim of this study was to evaluate heart rate dynamics (basal, peak and % heart rate increase) in optimized beta-blocked heart failure patients compared to sedentary, normal individuals (controls) during a treadmill cardiopulmonary exercise test.
AB  - METHODS: Twenty-five heart failure patients (49+/-11 years, 76% male), with an average LVEF of 30+/-7%, and fourteen controls were included in the study. Patients with atrial fibrillation, a pacemaker or noncardiovascular functional limitations or whose drug therapy was not optimized were excluded. Optimization was considered to be 50 mg/day or more of carvedilol, with a basal heart rate between 50 to 60 bpm that was maintained for 3 months.
AB  - RESULTS: Basal heart rate was lower in heart failure patients (57+/-3 bpm) compared to controls (89+/-14 bpm; p<0.0001). Similarly, the peak heart rate (% maximum predicted for age) was lower in HF patients (65.4+/-11.1%) compared to controls (98.6+/-2.2; p<0.0001). Maximum respiratory exchange ratio did not differ between the groups (1.2+/-0.5 for controls and 1.15+/-1 for heart failure patients; p=0.42). All controls reached the maximum heart rate for their age, while no patients in the heart failure group reached the maximum. Moreover, the % increase of heart rate from rest to peak exercise between heart failure (48+/-9%) and control (53+/-8%) was not different (p=0.157).
AB  - CONCLUSION: No patient in the heart failure group reached the maximum heart rate for their age during a treadmill cardiopulmonary exercise test, despite the fact that the percentage increase of heart rate was similar to sedentary normal subjects. A heart rate increase in optimized beta-blocked heart failure patients during cardiopulmonary exercise test over 65% of the maximum age-adjusted value should be considered an effort near the maximum. This information may be useful in rehabilitation programs and ischemic tests, although further studies are required.
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Carbazoles)
RN  - 0 (Propanolamines)
RN  - 0K47UL67F2 (carvedilol)
IS  - 1807-5932
IL  - 1807-5932
DI  - S1807-59322008000400011
PT  - Journal Article
LG  - English
DP  - 2008 Aug
DC  - 20080822
YR  - 2008
ED  - 20090716
RD  - 20140903
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18719758

<480. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19284268
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Spiess JL
FA  - Spiess, Jeffrey L
IN  - Spiess,Jeffrey L. Hospice of the Western Reserve, Cleveland, Ohio 44119, USA. JSpiess@hospicewr.org
TI  - Can I stop the warfarin? A review of the risks and benefits of discontinuing anticoagulation. [Review] [32 refs]
SO  - Journal of Palliative Medicine. 12(1):83-7, 2009 Jan.
AS  - J Palliat Med. 12(1):83-7, 2009 Jan.
NJ  - Journal of palliative medicine
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - d0c, 9808462
SB  - Index Medicus
CP  - United States
MH  - *Anticoagulants/ad [Administration & Dosage]
MH  - Anticoagulants/ae [Adverse Effects]
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Thromboembolism
MH  - *Warfarin/ad [Administration & Dosage]
MH  - Warfarin/ae [Adverse Effects]
AB  - Long-term anticoagulant therapy with warfarin is part of standard therapy for several disorders commonly present in patients seen in hospice and palliative care programs. Yet warfarin is also the drug most implicated in adverse drug reactions and its risks rise with increasing age and comorbidity. Clinicians caring for patients with multiple comorbidities or a limited life expectancy often are faced with the decision as to whether anticoagulation should be continued. Published guidelines for the use of warfarin in venous thromboembolism and nonvalvular atrial fibrillation are based on studies in which such patients were underrepresented or excluded. Our review of the randomized trials on which these guidelines are based shows that the annual risk of recurrent venous thromboembolism after stopping warfarin is 2%-10%. No similar evidence is available for patients with atrial fibrillation, but the published CHADS(2) index uses multiple factors to estimate stroke risk. The risk of bleeding complications with warfarin is most closely linked to degree of anticoagulation. Nutritional compromise and changes in drug therapy increase this risk and require that any patient remaining on warfarin must undergo frequent monitoring of anticoagulant effect. [References: 32]
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
ES  - 1557-7740
IL  - 1557-7740
DO  - http://dx.doi.org/10.1089/jpm.2008.0164
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2009 Jan
DC  - 20090316
YR  - 2009
ED  - 20090706
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19284268

<481. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19443992
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ushijima A
AU  - Fukuma N
AU  - Kato Y
AU  - Aisu N
AU  - Mizuno K
FA  - Ushijima, Akiko
FA  - Fukuma, Nagaharu
FA  - Kato, Yuko
FA  - Aisu, Noriko
FA  - Mizuno, Kyoichi
IN  - Ushijima,Akiko. Division of Cardiology, Hepatology, Geriatrics, and Integrated Medicine, Department of Internal Medicine, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. ushijima@nms.ac.jp
TI  - Sympathetic excitation during exercise as a cause of attenuated heart rate recovery in patients with myocardial infarction.
SO  - Journal of Nippon Medical School = Nihon Ika Daigahu Zasshi. 76(2):76-83, 2009 Apr.
AS  - J Nippon Med Sch. 76(2):76-83, 2009 Apr.
NJ  - Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 100935589, dla
SB  - Index Medicus
CP  - Japan
MH  - Aged
MH  - Down-Regulation/ph [Physiology]
MH  - *Exercise/ph [Physiology]
MH  - Exercise Test
MH  - *Heart Rate
MH  - Humans
MH  - Lactic Acid/bl [Blood]
MH  - Male
MH  - Middle Aged
MH  - *Myocardial Infarction/rt [Radiotherapy]
MH  - Natriuretic Peptide, Brain/bl [Blood]
MH  - Norepinephrine/bl [Blood]
MH  - Parasympathetic Nervous System/ph [Physiology]
MH  - Parasympathetic Nervous System/pp [Physiopathology]
MH  - *Sympathetic Nervous System/ph [Physiology]
AB  - BACKGROUND: Heart rate recovery (HRR) after exercise is known as a predictor of cardiac death in patients with heart disease. The mechanism is not fully understood, although a parasympathetic mechanism has been reported. To elucidate the factors that influence HRR, we evaluated the relationship of HRR with exercise performance and plasma norepinephrine (NE), lactic acid and B-type natriuretic peptide (BNP) responses to exercise testing.
AB  - METHODS: The study population consisted of 52 male patients (age 58 +/- 9.6 years) who had experienced myocardial infarction without residual ischemia, uncompensated heart failure or atrial fibrillation. All subjects underwent a symptom-limited cardiopulmonary exercise test without a cool-down period and echocardiography. NE, lactic acid and BNP were measured at rest and at peak exercise.
AB  - RESULTS: HRR did not correlate with the left ventricular ejection fraction, peak VO(2), lactic acid and BNP. HRR significantly correlated with the increment in heart rate (HR) from rest to peak exercise (DeltaHR) (r=0.30, p<0.05). When we divided DeltaHR into two phases at the anaerobic threshold (AT), HRR significantly correlated with DeltaHR (peak-AT) (r=0.409, p<0.01), but not with DeltaHR (AT-rest). There was a significant negative correlation between HRR and NE both at rest and at peak exercise (r=-0.286, p<0.05, r=-0.310, p<0.05). HRR was also correlated significantly with DeltaHR/logDeltaNE as an index of sensitivity to NE (r=0.421, p<0.01). Based on multiple regression analysis, DeltaHR and logDeltaNE predicted HRR (R(2)=0.467, p=0.0027).
AB  - CONCLUSIONS: Present findings suggest that enhanced sympathetic excitation at maximum exercise suppresses parasympathetic reactivation and results in attenuation of HRR.
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 33X04XA5AT (Lactic Acid)
RN  - X4W3ENH1CV (Norepinephrine)
IS  - 1345-4676
IL  - 1345-4676
PT  - Journal Article
LG  - English
DP  - 2009 Apr
DC  - 20090515
YR  - 2009
ED  - 20090630
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19443992

<482. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19363054
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Tse HF
AU  - Wong KK
AU  - Siu CW
AU  - Tang MO
AU  - Tsang V
AU  - Ho WY
AU  - Lau CP
FA  - Tse, Hung-Fat
FA  - Wong, Kwong-Kuen
FA  - Siu, Chung-Wah
FA  - Tang, Man-Oi
FA  - Tsang, Vella
FA  - Ho, Wai-Yin
FA  - Lau, Chu-Pak
IN  - Tse,Hung-Fat. Cardiology Division, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, People's Republic of China. hftse@hkucc.hku.hk
TI  - Impacts of ventricular rate regularization pacing at right ventricular apical vs. septal sites on left ventricular function and exercise capacity in patients with permanent atrial fibrillation.
SO  - Europace. 11(5):594-600, 2009 May.
AS  - Europace. 11(5):594-600, 2009 May.
NJ  - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - dxd, 100883649
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - Aged, 80 and over
MH  - Algorithms
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - *Heart Ventricles/pp [Physiopathology]
MH  - Heart Ventricles/ri [Radionuclide Imaging]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Pacemaker, Artificial
MH  - Prospective Studies
MH  - Stroke Volume/ph [Physiology]
MH  - Ventricular Dysfunction, Left/pp [Physiopathology]
MH  - Ventricular Dysfunction, Right/pp [Physiopathology]
MH  - *Ventricular Function, Left/ph [Physiology]
MH  - *Ventricular Septum/pp [Physiopathology]
MH  - Ventricular Septum/ri [Radionuclide Imaging]
AB  - AIMS: The deleterious effects of right ventricular apex (RVA) pacing may offset the potential benefit of ventricular rate (VR) regularization during atrial fibrillation (AF). Recent studies suggested that right ventricular septal (RVS) pacing may prevent the potential deleterious effects of RVA pacing and enhance the VR regularization (VRR) with ventricular pacing due to closer proximity of the pacing site to the retrograde atrioventricular conduction.
AB  - METHODS AND RESULTS: We randomized 24 patients with permanent AF and symptomatic bradycardia to undergo RVA (n = 12) or RVS (n = 12) pacing. A VRR algorithm was programmed for all patients at 6-month after implantation. All patients underwent 6 min hall walk (6MHW) to assess exercise capacity at 6, 12, and 24 months, and radionuclide ventriculography to determine left ventricular ejection fraction (LVEF) at 6 and 24 months. Baseline characteristics were comparable in both groups except pacing QRS duration was significantly shorter during RVS pacing than RVA pacing (132 +/- 4 vs. 151 +/- 6 ms, P = 0.012). In both groups, VRR significantly increased the percentage of ventricular pacing and reduced VR variability (P < 0.05) without increasing mean VR (P > 0.05). At 6 months, 6MHW and LVEF were comparable in patients with RVA and RVS pacing (P > 0.05). At 24 months, patients with RVA pacing had significant decreases in LVEF and 6MHW after VRR pacing (P < 0.05), whereas RVS pacing with VRR preserved LVEF and improved 6MHW (P < 0.05).
AB  - CONCLUSION: In patients with permanent AF, VRR pacing at RVS, but not at RVA, preserves LVEF and provides incremental benefit for exercise capacity.
ES  - 1532-2092
IL  - 1099-5129
DO  - http://dx.doi.org/10.1093/europace/eup087
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
EP  - 20090410
DP  - 2009 May
DC  - 20090429
YR  - 2009
ED  - 20090626
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19363054

<483. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19378231
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wozakowska-Kaplon B
AU  - Opolski G
FA  - Wozakowska-Kaplon, Beata
FA  - Opolski, Grzegorz
IN  - Wozakowska-Kaplon,Beata. 1st Department of Cardiology, Centre of Cardiology, Kielce, Poland. bw.kaplon@poczta.onet.pl
TI  - Effects of exercise testing on natriuretic peptide secretion in patients with atrial fibrillation.
CM  - Comment in: Kardiol Pol. 2009 Mar;67(3):262-4; PMID: 19469063
SO  - Kardiologia Polska. 67(3):254-61, 2009 Mar.
AS  - Kardiol Pol. 67(3):254-61, 2009 Mar.
NJ  - Kardiologia polska
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - ku4, 0376352
SB  - Index Medicus
CP  - Poland
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation/bl [Blood]
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Natriuretic Factor/bl [Blood]
MH  - Biomarkers/bl [Blood]
MH  - Exercise
MH  - *Exercise Test
MH  - Female
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Natriuretic Peptide, Brain/bl [Blood]
MH  - Oxygen Consumption
MH  - Physical Endurance
MH  - Poland
MH  - Predictive Value of Tests
MH  - Regression Analysis
AB  - BACKGROUND: Assessment of endocrine profile in patients with cardiovascular diseases has become increasingly important during the last decade. Plasma brain natriuretic peptide (BNP) levels have been used as a marker of left ventricular dysfunction. However, the role of BNP in patients with atrial fibrillation (AF) and normal left ventricular function has not yet been determined.
AB  - AIM: To examine changes in the secretion of natriuretic peptides (atrial natriuretic peptide - ANP and BNP) during exercise in patients with persistent or permanent AF.
AB  - METHODS: The study group consisted of 42 patients with permanent AF and 77 patients with persistent AF. There were no significant differences in baseline clinical (except AF duration), echocardiographic and haemodynamic data between the groups. The control group comprised 20 patients. All had normal sinus rhytm without a history of AF and were compatible in age, gender and concomitant diseases with the examined groups. The ANP and BNP samples were obtained at rest and at the peak of the exercise testing. Duration of exercise testing was 10 min.
AB  - RESULTS: The multiple regression analysis showed an association between ANP levels and left atrial volume (p = 0.0001), maximal heart rate (p = 0.0036) and NYHA class (p < 0.0001). There was a trend toward a significant relation between AF duration and ANP levels. There was a significant correlation between BNP levels and heart failure class according to NYHA (p < 0.0001). A significant and strong positive correlation of ANP and BNP concentrations at rest was observed in all groups of AF. Significant variation of natriuretic peptide release in response to exercise (ANPex and BNPex) was observed. The highest increase of ANP level and the lowest increase of BNP level were noted in the control group, and no significant differences were found in ANP and BNP secretion between the groups with persistent and permanent AF.
AB  - CONCLUSIONS: Neurohormonal response to exercise differs between patients with AF and those in sinus rhythm. Exercise testing may be used to assess the ability of cardiac myocytes to increase peptide secretion.
RN  - 0 (Biomarkers)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
IS  - 0022-9032
IL  - 0022-9032
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 2009 Mar
DC  - 20090420
YR  - 2009
ED  - 20090625
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19378231

<484. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19268659
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Horiuchi D
AU  - Iwasa A
AU  - Sasaki K
AU  - Owada S
AU  - Kimura M
AU  - Sasaki S
AU  - Okumura K
FA  - Horiuchi, Daisuke
FA  - Iwasa, Atsushi
FA  - Sasaki, Kenichi
FA  - Owada, Shingen
FA  - Kimura, Masaomi
FA  - Sasaki, Shingo
FA  - Okumura, Ken
IN  - Horiuchi,Daisuke. Department of Cardiology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
TI  - Effect of pilsicainide on dominant frequency in the right and left atria and pulmonary veins during atrial fibrillation: association with its atrial fibrillation terminating effect.
SO  - European Journal of Pharmacology. 608(1-3):54-61, 2009 Apr 17.
AS  - Eur J Pharmacol. 608(1-3):54-61, 2009 Apr 17.
NJ  - European journal of pharmacology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - en6, 1254354
SB  - Index Medicus
CP  - Netherlands
MH  - Aged
MH  - Anti-Arrhythmia Agents/cl [Classification]
MH  - *Anti-Arrhythmia Agents/pd [Pharmacology]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Catheter Ablation
MH  - Echocardiography
MH  - Electrophysiologic Techniques, Cardiac
MH  - Fasting
MH  - Female
MH  - *Heart Atria/de [Drug Effects]
MH  - Humans
MH  - *Lidocaine/aa [Analogs & Derivatives]
MH  - Lidocaine/pd [Pharmacology]
MH  - Male
MH  - Middle Aged
MH  - *Pulmonary Veins/de [Drug Effects]
MH  - Pulmonary Veins/pp [Physiopathology]
MH  - Treatment Outcome
AB  - Dominant frequency reflects the peak cycle length of atrial fibrillation. In 34 patients with atrial fibrillation, bipolar electrograms were recorded from multiple atrial sites and pulmonary veins and the effect of pilsicainide, class Ic antiarrhythmic drug, on dominant frequency was examined. At baseline, mean dominant frequencies (Hz) in the right and left atria, coronary sinus and right and left superior pulmonary veins were 5.87 +/- 0.76, 6.08 +/- 0.60, 5.65 +/- 0.95, 6.12 +/- 0.88 and 6.59 +/- 0.89, respectively (P < 0.05, left superior pulmonary vein vs right atrium and coronary sinus). After pilsicainide (1.0 mg/kg/5 min), dominant frequency decreased at all sites in all patients. Atrial fibrillation was terminated at 5.9 +/- 2.2 min in 16 patients (Group A) with a decrease in the average of mean dominant frequencies at all sites from 5.80 +/- 0.72 to 3.57 +/- 0.63 Hz, was converted to atrial flutter at 7.3 +/- 1.4 min in 5 (Group B) with a decrease in the average dominant frequency from 5.83 +/- 0.48 to 3.08 +/- 0.19 Hz, and was not terminated in the other 13 (Group C) despite the average dominant frequency decrease from 6.59 +/- 0.76 to 4.42 +/- 0.52 Hz. In 14 of the 21 Groups A and B patients (67%), mean dominant frequencies at all recording sites were < 4.0 after pilsicainide, while they were < 4.0 in 1 of the 13 Group C patients (8%, P < 0.01). In conclusion, the degree of dominant frequency decrease by pilsicainide is closely related to its atrial fibrillation terminating effect: When dominant frequency in the atria decreases to < 4.0 Hz, atrial fibrillation is terminated with 93% positive and 63% negative predictive values.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 98PI200987 (Lidocaine)
RN  - AV0X7V6CSE (pilsicainide)
ES  - 1879-0712
IL  - 0014-2999
DO  - http://dx.doi.org/10.1016/j.ejphar.2009.02.040
PT  - Journal Article
LG  - English
EP  - 20090305
DP  - 2009 Apr 17
DC  - 20090401
YR  - 2009
ED  - 20090624
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19268659

<485. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19463518
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Aizer A
AU  - Gaziano JM
AU  - Cook NR
AU  - Manson JE
AU  - Buring JE
AU  - Albert CM
FA  - Aizer, Anthony
FA  - Gaziano, J Michael
FA  - Cook, Nancy R
FA  - Manson, Joann E
FA  - Buring, Julie E
FA  - Albert, Christine M
IN  - Aizer,Anthony. Center for Arrhythmia Prevention, Brigham and Women's Hospital, Boston, Massachusetts, USA. anthony.aizer@nyumc.org
TI  - Relation of vigorous exercise to risk of atrial fibrillation.
SO  - American Journal of Cardiology. 103(11):1572-7, 2009 Jun 1.
AS  - Am J Cardiol. 103(11):1572-7, 2009 Jun 1.
NJ  - The American journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 3dq, 0207277
OI  - Source: NLM. NIHMS102179
OI  - Source: NLM. PMC2687527
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Body Mass Index
MH  - Effect Modifier, Epidemiologic
MH  - *Exercise
MH  - Humans
MH  - Life Style
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Assessment
AB  - Limited data suggest that athletes may have a higher risk of developing atrial fibrillation (AF); however, there has been no large prospective assessment of the relation between vigorous exercise and AF. Logistic regression analyses stratified by time were used to assess the association between frequency of vigorous exercise and risk of developing AF in 16,921 apparently healthy men in the Physicians' Health Study. During 12 years of follow-up, 1,661 men reported developing AF. With increasing frequency of vigorous exercise (0, 1, 1 to 2, 3 to 4, 5 to 7 days/week), multivariate relative risks for the full cohort were 1.0 (referent), 0.90, 1.09, 1.04, and 1.20 (p = 0.04). This risk was not significantly increased when exercise habits were updated or in models excluding variables that may be in the biological pathway through which exercise influences AF risk. In subgroup analyses, this increased risk was observed only in men <50 years of age (1.0, 0.94, 1.20, 1.05, 1.74, p <0.01) and joggers (1.0, 0.91, 1.03, 1.30, 1.53, p <0.01), where risks remained increased in all analyses. In conclusion, frequency of vigorous exercise was associated with an increased risk of developing AF in young men and joggers. This risk decreased as the population aged and was offset by known beneficial effects of vigorous exercise on other AF risk factors.
ES  - 1879-1913
IL  - 0002-9149
DO  - http://dx.doi.org/10.1016/j.amjcard.2009.01.374
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
NO  - CA097193 (United States NCI NIH HHS)
NO  - CA34944 (United States NCI NIH HHS)
NO  - CA40360 (United States NCI NIH HHS)
NO  - HL26490 (United States NHLBI NIH HHS)
NO  - HL34595 (United States NHLBI NIH HHS)
NO  - R01 CA040360 (United States NCI NIH HHS)
NO  - R01 CA040360-17 (United States NCI NIH HHS)
NO  - R01 CA097193 (United States NCI NIH HHS)
NO  - R01 CA097193-07 (United States NCI NIH HHS)
LG  - English
EP  - 20090422
DP  - 2009 Jun 1
DC  - 20090525
YR  - 2009
ED  - 20090618
RD  - 20141209
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19463518

<486. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19138529
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Bobbio A
AU  - Chetta A
AU  - Internullo E
AU  - Ampollini L
AU  - Carbognani P
AU  - Bettati S
AU  - Rusca M
AU  - Olivieri D
FA  - Bobbio, Antonio
FA  - Chetta, Alfredo
FA  - Internullo, Eveline
FA  - Ampollini, Luca
FA  - Carbognani, Paolo
FA  - Bettati, Stefano
FA  - Rusca, Michele
FA  - Olivieri, Dario
IN  - Bobbio,Antonio. Unit of Thoracic Surgery, Department of Surgical Sciences, University of Parma, Italy. antonio.bobbio@unipr.it
TI  - Exercise capacity assessment in patients undergoing lung resection.
SO  - European Journal of Cardio-Thoracic Surgery. 35(3):419-22, 2009 Mar.
AS  - Eur J Cardiothorac Surg. 35(3):419-22, 2009 Mar.
NJ  - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - aoj, 8804069
SB  - Index Medicus
CP  - Germany
MH  - Aged
MH  - *Carcinoma, Non-Small-Cell Lung/pp [Physiopathology]
MH  - Carcinoma, Non-Small-Cell Lung/su [Surgery]
MH  - Cohort Studies
MH  - Exercise Test/mt [Methods]
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - Forced Expiratory Volume/ph [Physiology]
MH  - Humans
MH  - *Lung Neoplasms/pp [Physiopathology]
MH  - Lung Neoplasms/su [Surgery]
MH  - Male
MH  - Middle Aged
MH  - Pneumonectomy/ae [Adverse Effects]
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - *Pulmonary Diffusing Capacity/ph [Physiology]
MH  - Risk Assessment
AB  - BACKGROUND: The value is examined of preoperative functional assessment, including exercise capacity measurement by a cycloergometric maximal exercise test, in the prediction of postoperative cardio-pulmonary complication after lobar resection.
AB  - METHODS: In a prospective study over a 3-year period, all patients who were candidates for lung resection underwent preoperative functional evaluation by means of resting pulmonary function tests, measurement of the lung diffusing capacity for carbon monoxide and cardio-pulmonary exercise test. Patients who had had pneumonectomy or less than anatomical segmentectomy were excluded. The study population consisted of 73 patients. The postoperative morbidity and mortality record was collected.
AB  - RESULTS: Sixty-four patients underwent lobectomy, five bilobectomy and four segmentectomy. Indication for surgery was NSCLC in 71 cases. Two postoperative deaths were recorded (2.7%). A pulmonary (n=19) and/or cardiac (n=17) complication was scored in 30 patients (41%). Mean preoperative FEV(1) and VO(2)max of patients who developed pulmonary complications were significantly lower (p=0.013 and p=0.043 respectively) than those of patients without pulmonary complications. Logistic regression analysis found FEV(1) to be an independent factor in pulmonary complication (p=0.002). With regard to pulmonary complication occurrence, the receiver operating characteristic curve showed an area of 0.69 with VO(2)max expressed in ml/kg min and of 0.62 when VO(2)max was expressed as a percentage of the predicted value. The widest point of the curve was found at a VO(2)max value of 18.7 ml/kg min. Six out of the 14 patients (43%) with a preoperative VO(2)max equal to or lower than 15 ml/kg min had a pulmonary complication. No functional preoperative identifiers were found for the 16 patients who presented with postoperative new onset atrial fibrillation. The mean preoperative value of carbon monoxide lung diffusing capacity was significantly lower (p=0.037) in the 30 patients who had postoperative cardio-pulmonary complications than in the complication-free population.
AB  - CONCLUSIONS: Preoperative exercise capacity assessment helps in stratifying patients at risk for postoperative pulmonary complication. However, it does not appear to be an independent prognostic factor for postoperative outcome.
ES  - 1873-734X
IL  - 1010-7940
DO  - http://dx.doi.org/10.1016/j.ejcts.2008.11.004
PT  - Journal Article
LG  - English
EP  - 20090109
DP  - 2009 Mar
DC  - 20090303
YR  - 2009
ED  - 20090608
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19138529

<487. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19272077
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Singh HR
FA  - Singh, Harinder R
IN  - Singh,Harinder R. Division of Cardiology, The Carman and Ann Adams Department of Pediatrics, Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit, MI 48201, USA. hsingh6@dmc.org
TI  - Unusual cause of recurrent syncope in a child.
CM  - Comment in: Pacing Clin Electrophysiol. 2009 Oct;32(10):1360; PMID: 19732367
SO  - Pacing & Clinical Electrophysiology. 32(3):416-8, 2009 Mar.
AS  - Pacing Clin Electrophysiol. 32(3):416-8, 2009 Mar.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - pab, 7803944
SB  - Index Medicus
CP  - United States
MH  - Child, Preschool
MH  - *Exercise
MH  - Humans
MH  - Male
MH  - Rare Diseases
MH  - Secondary Prevention
MH  - *Syncope/di [Diagnosis]
MH  - *Syncope/pc [Prevention & Control]
AB  - A 5-year-old boy with an unremarkable past medical and family history presented with recurrent syncope precipitated by physical activity. Electrocardiogram performed in the emergency room after one of his episodes revealed atrial flutter. He had a structurally normal heart. Exercise stress test revealed atrial fibrillation with rapid ventricular response immediately on commencement of running. Atrial fibrillation subsequently organized into atrial flutter with variable ventricular response followed by spontaneous conversion to sinus rhythm. This case highlights the use of exercise stress test in a preschool child to elicit an unusual cause of syncope.
ES  - 1540-8159
IL  - 0147-8389
DO  - http://dx.doi.org/10.1111/j.1540-8159.2008.02255.x
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2009 Mar
DC  - 20090310
YR  - 2009
ED  - 20090602
RD  - 20141120
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19272077

<488. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19188413
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Friedlander AH
AU  - Yoshikawa TT
AU  - Chang DS
AU  - Feliciano Z
AU  - Scully C
FA  - Friedlander, Arthur H
FA  - Yoshikawa, Thomas T
FA  - Chang, Donald S
FA  - Feliciano, Zenaida
FA  - Scully, Crispian
IN  - Friedlander,Arthur H. VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA. arthur.friedlander@med.va.gov
TI  - Atrial fibrillation: pathogenesis, medical-surgical management and dental implications. [Review] [90 refs]
CM  - Comment in: J Am Dent Assoc. 2009 May;140(5):515; PMID: 19411511
CM  - Comment in: J Am Dent Assoc. 2009 May;140(5):515; author reply 515-6; PMID: 19411510
SO  - Journal of the American Dental Association. 140(2):167-77; quiz 248, 2009 Feb.
AS  - J Am Dent Assoc. 140(2):167-77; quiz 248, 2009 Feb.
NJ  - Journal of the American Dental Association (1939)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - h5j, 7503060
SB  - Dental Journals
SB  - Index Medicus
CP  - United States
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Dental Care for Chronically Ill/ct [Contraindications]
MH  - Hemorrhage/pc [Prevention & Control]
MH  - Humans
MH  - Oral Surgical Procedures/ct [Contraindications]
MH  - Stroke/pc [Prevention & Control]
MH  - *Warfarin/tu [Therapeutic Use]
AB  - BACKGROUND: Atrial fibrillation (AF) is a cardiac rhythm disturbance arising from disorganized electrical activity in the atria, and it is accompanied by an irregular and often rapid ventricular response. It is the most common clinically significant dysrhythmia in the general and older population.
AB  - TYPES OF STUDIES REVIEWED: The authors conducted a MEDLINE search using the key terms "atrial fibrillation," "epidemiology," "pathophysiology," "treatment" and "dentistry." They selected contemporaneous articles published in peer-reviewed journals and gave preference to articles reporting randomized controlled trials.
AB  - CLINICAL IMPLICATIONS: The anticoagulant warfarin frequently is prescribed to prevent stroke caused by cardiogenic thromboemboli arising from stagnant blood in poorly contracting atria. Most dental procedures and a limited number of surgical procedures can be performed without altering warfarin dosage if the international normalized ratio value is within the therapeutic range of 2.0 to 3.0. Certain analgesic agents, antibiotic agents, antifungal agents and sedative hypnotics, however, should not be prescribed without consultation with the patient's physician because these medications may alter the patient's risk of hemorrhage and stroke.
AB  - CONCLUSIONS: AF affects nearly 2.5 million Americans, most of who are older than 60 years. Consultation with the patient's physician to discuss the planned dental treatment often is appropriate, especially for people who frequently have comorbid diseases such as coronary artery disease, congestive heart failure, diabetes and thyrotoxicosis, which are treated with multiple drug regimens. [References: 90]
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
IS  - 0002-8177
IL  - 0002-8177
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2009 Feb
DC  - 20090203
YR  - 2009
ED  - 20090602
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19188413

<489. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18844728
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Doucet J
AU  - Greboval-Furstenfeld E
AU  - Tavildari A
AU  - M'bello L
AU  - Delaunay O
AU  - Pesque T
AU  - Moirot P
AU  - Mouton-Schleifer D
FA  - Doucet, Jean
FA  - Greboval-Furstenfeld, Emmanuelle
FA  - Tavildari, Alain
FA  - M'bello, Luc
FA  - Delaunay, Olympe
FA  - Pesque, Thierry
FA  - Moirot, P
FA  - Mouton-Schleifer, Dominique
IN  - Doucet,Jean. Service de Medecine Interne Geriatrique, Centre Hospitalo-Universitaire de Rouen, Rouen University Hospital, Rouen F-76031, France. jean.doucet@chu-rouen.fr
TI  - Which parameters differ in very old patients with chronic atrial fibrillation treated by anticoagulant or aspirin? Antithrombotic treatment of atrial fibrillation in the elderly.
SO  - Fundamental & Clinical Pharmacology. 22(5):569-74, 2008 Oct.
AS  - Fundam Clin Pharmacol. 22(5):569-74, 2008 Oct.
NJ  - Fundamental & clinical pharmacology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - f8s, 8710411
SB  - Index Medicus
CP  - England
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/pk [Pharmacokinetics]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Aspirin/pk [Pharmacokinetics]
MH  - *Aspirin/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/me [Metabolism]
MH  - Chronic Disease
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Prospective Studies
MH  - Risk Factors
MH  - Vitamin K/ai [Antagonists & Inhibitors]
AB  - The objective was to determine the main parameters taken into account for the decision of antithrombotic treatment of atrial fibrillation (AF) by vitamin K antagonist or aspirin. This was a prospective clinical study of four clinical services of geriatric medicine. Two hundred and nine inpatients, 84.7 +/- 7 years (women 60.8%), with chronic AF were included. The patients were distributed into two groups (anticoagulant or aspirin) according to medical decision. All the decision criteria for treatment were recorded: cardiopathy, conditions of life, clinical examination (nutrition and autonomy, mini-mental state examination (MMSE), walking evaluation, comorbidity), subjective evaluation of risk of falls and glomerular filtration rate. The thromboembolic risk and the bleeding risk, evaluated subjectively for each patient, were compared with two scores of thrombo-embolic risk and bleeding risk. The evolution of the patients was recorded after 3 months. Student's t-test and chi-squared tests were used for statistical analysis. One hundred and two patients (48.8%) received anticoagulant and 107 patients received aspirin. Patients in the aspirin group were significantly older (86.5 +/- 6.5 vs. 82.9 +/- 7.1 years), with more frequent social isolation, higher systolic blood pressure, and had more important subjective bleeding risk and risk of falls. Patients in the anticoagulant group had significantly more valvulopathies and a more important subjective thromboembolic risk. Thrombo-phlebitis antecedents, dementia, denutrition and walking alterations were only slightly more frequent in patients in the aspirin group. Physicians underestimated thromboembolic risk (one-third of patients) and they overestimated bleeding risk (half of the patients). After 3 months, the two groups did not significantly differ for death, bleeding or ischaemic events. In common practice, the decision of antithrombotic treatment for AF should take into account not only cardiovascular but also geriatric criteria.
RN  - 0 (Anticoagulants)
RN  - 12001-79-5 (Vitamin K)
RN  - R16CO5Y76E (Aspirin)
ES  - 1472-8206
IL  - 0767-3981
DO  - http://dx.doi.org/10.1111/j.1472-8206.2008.00629.x
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
LG  - English
DP  - 2008 Oct
DC  - 20081010
YR  - 2008
ED  - 20090522
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18844728

<490. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18703981
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Purnell C
AU  - Gao S
AU  - Callahan CM
AU  - Hendrie HC
FA  - Purnell, Christianna
FA  - Gao, Sujuan
FA  - Callahan, Christopher M
FA  - Hendrie, Hugh C
IN  - Purnell,Christianna. Regenstrief Institute Inc, Indiana University School of Medicine, Indianapolis, IN, USA.
TI  - Cardiovascular risk factors and incident Alzheimer disease: a systematic review of the literature. [Review] [70 refs]
SO  - Alzheimer Disease & Associated Disorders. 23(1):1-10, 2009 Jan-Mar.
AS  - Alzheimer Dis Assoc Disord. 23(1):1-10, 2009 Jan-Mar.
NJ  - Alzheimer disease and associated disorders
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - alz, 8704771
OI  - Source: NLM. NIHMS84726
OI  - Source: NLM. PMC3689425
SB  - Index Medicus
CP  - United States
MH  - *Alzheimer Disease/co [Complications]
MH  - *Cardiovascular Diseases/co [Complications]
MH  - Humans
MH  - Risk Factors
AB  - OBJECTIVE: The purpose of this study was to conduct a systematic review of the literature of cardiovascular factors pertaining to incident Alzheimer disease (AD).
AB  - METHODS: A systematic literature review was conducted of all studies of cardiovascular risk factors for incident AD listed in PubMed in English from 2000 to 2007. Risk factors included hypertension, diabetes, exercise, alcohol intake, smoking, B complex vitamins, homocysteine, stroke, atrial fibrillation, apolipoprotein E (APOE), lipids, and diet. Inclusion criteria consisted of diagnoses of incident AD and longitudinal studies with cohorts of 500 or more.
AB  - RESULTS: Individual clinically defined risk factors such as hypertension and diabetes were not significantly associated with increased risk for AD. The strength of the association for hypertension could be considerably strengthened by changing criteria such as midlife measurements or using higher cutoffs for systolic blood pressure. APOE epsilon4 was the most consistent risk factor. Interactions between risk factors modify risk particularly for hypertension and diabetes. Interactions modifying risk were also found for exercise and physical function, APOE epsilon4, diabetes, and cholesterol.
AB  - CONCLUSIONS: In this review, the evidence that single clinically defined cardiovascular risk factors are significantly associated with incident AD is inconsistent at best. The strength of the association of cardiovascular risk factors and AD can be influenced greatly by changing the parameters of measurement of risk factors and by identifying interactions between the factors. [References: 70]
ES  - 1546-4156
IL  - 0893-0341
DO  - http://dx.doi.org/10.1097/WAD.0b013e318187541c
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
NO  - K24 AG024078 (United States NIA NIH HHS)
NO  - K24 AG024078 (United States NIA NIH HHS)
NO  - P30 AG024967 (United States NIA NIH HHS)
NO  - P30 AG024967 (United States NIA NIH HHS)
NO  - P30 AG10133 (United States NIA NIH HHS)
NO  - R01 AG009956 (United States NIA NIH HHS)
LG  - English
DP  - 2009 Jan-Mar
DC  - 20090302
YR  - 2009
ED  - 20090519
RD  - 20160513
UP  - 20160516
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=18703981

<491. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18703981
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Purnell C
AU  - Gao S
AU  - Callahan CM
AU  - Hendrie HC
FA  - Purnell, Christianna
FA  - Gao, Sujuan
FA  - Callahan, Christopher M
FA  - Hendrie, Hugh C
IN  - Purnell,Christianna. Regenstrief Institute Inc, Indiana University School of Medicine, Indianapolis, IN, USA.
TI  - Cardiovascular risk factors and incident Alzheimer disease: a systematic review of the literature. [Review] [70 refs]
SO  - Alzheimer Disease & Associated Disorders. 23(1):1-10, 2009 Jan-Mar.
AS  - Alzheimer Dis Assoc Disord. 23(1):1-10, 2009 Jan-Mar.
NJ  - Alzheimer disease and associated disorders
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - alz, 8704771
OI  - Source: NLM. NIHMS84726
OI  - Source: NLM. PMC3689425
SB  - Index Medicus
CP  - United States
MH  - *Alzheimer Disease/co [Complications]
MH  - *Cardiovascular Diseases/co [Complications]
MH  - Humans
MH  - Risk Factors
AB  - OBJECTIVE: The purpose of this study was to conduct a systematic review of the literature of cardiovascular factors pertaining to incident Alzheimer disease (AD).
AB  - METHODS: A systematic literature review was conducted of all studies of cardiovascular risk factors for incident AD listed in PubMed in English from 2000 to 2007. Risk factors included hypertension, diabetes, exercise, alcohol intake, smoking, B complex vitamins, homocysteine, stroke, atrial fibrillation, apolipoprotein E (APOE), lipids, and diet. Inclusion criteria consisted of diagnoses of incident AD and longitudinal studies with cohorts of 500 or more.
AB  - RESULTS: Individual clinically defined risk factors such as hypertension and diabetes were not significantly associated with increased risk for AD. The strength of the association for hypertension could be considerably strengthened by changing criteria such as midlife measurements or using higher cutoffs for systolic blood pressure. APOE epsilon4 was the most consistent risk factor. Interactions between risk factors modify risk particularly for hypertension and diabetes. Interactions modifying risk were also found for exercise and physical function, APOE epsilon4, diabetes, and cholesterol.
AB  - CONCLUSIONS: In this review, the evidence that single clinically defined cardiovascular risk factors are significantly associated with incident AD is inconsistent at best. The strength of the association of cardiovascular risk factors and AD can be influenced greatly by changing the parameters of measurement of risk factors and by identifying interactions between the factors. [References: 70]
ES  - 1546-4156
IL  - 0893-0341
DO  - http://dx.doi.org/10.1097/WAD.0b013e318187541c
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
NO  - K24 AG024078 (United States NIA NIH HHS)
NO  - K24 AG024078 (United States NIA NIH HHS)
NO  - P30 AG010133 (United States NIA NIH HHS)
NO  - P30 AG024967 (United States NIA NIH HHS)
NO  - P30 AG024967 (United States NIA NIH HHS)
NO  - P30 AG10133 (United States NIA NIH HHS)
NO  - R01 AG009956 (United States NIA NIH HHS)
LG  - English
DP  - 2009 Jan-Mar
DC  - 20090302
YR  - 2009
ED  - 20090519
RD  - 20140903
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18703981

<492. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19365009
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Laurent M
FA  - Laurent, Michael
TI  - Incidence of atrial fibrillation among aging runners.
CM  - Comment on: Arch Intern Med. 2008 Aug 11;168(15):1638-46; PMID: 18695077
SO  - Archives of Internal Medicine. 169(7):719, 2009 Apr 13.
AS  - Arch Intern Med. 169(7):719, 2009 Apr 13.
NJ  - Archives of internal medicine
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 0372440, 7fs
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Age Factors
MH  - Aged
MH  - Aging/ph [Physiology]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/et [Etiology]
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Risk Assessment
MH  - *Running
MH  - Survival Rate
ES  - 1538-3679
IL  - 0003-9926
DO  - http://dx.doi.org/10.1001/archinternmed.2009.34
PT  - Comment
PT  - Letter
LG  - English
DP  - 2009 Apr 13
DC  - 20090414
YR  - 2009
ED  - 20090505
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19365009

<493. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18827406
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kato K
AU  - Murakami H
AU  - Isozaki O
AU  - Tsushima T
AU  - Takano K
FA  - Kato, Keiko
FA  - Murakami, Hitomi
FA  - Isozaki, Osamu
FA  - Tsushima, Toshio
FA  - Takano, Kazue
IN  - Kato,Keiko. Department of Endocrinology, Clinical Institute of Endocrinology, Tokyo Women's Medical University, Japan.
TI  - Serum concentrations of BNP and ANP in patients with thyrotoxicosis.
SO  - Endocrine Journal. 56(1):17-27, 2009.
AS  - Endocr J. 56(1):17-27, 2009.
NJ  - Endocrine journal
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - bt5, 9313485
SB  - Index Medicus
CP  - Japan
MH  - Adult
MH  - Aldosterone/bl [Blood]
MH  - Atrial Natriuretic Factor/an [Analysis]
MH  - *Atrial Natriuretic Factor/bl [Blood]
MH  - Case-Control Studies
MH  - Female
MH  - Graves Disease/bl [Blood]
MH  - Graves Disease/co [Complications]
MH  - Graves Disease/ep [Epidemiology]
MH  - Graves Disease/pp [Physiopathology]
MH  - Heart Failure/bl [Blood]
MH  - Heart Failure/co [Complications]
MH  - Heart Failure/ep [Epidemiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/an [Analysis]
MH  - *Natriuretic Peptide, Brain/bl [Blood]
MH  - Osmolar Concentration
MH  - Renin/bl [Blood]
MH  - Renin/me [Metabolism]
MH  - Renin-Angiotensin System/ph [Physiology]
MH  - Thyroid Hormones/bl [Blood]
MH  - *Thyrotoxicosis/bl [Blood]
MH  - Thyrotoxicosis/co [Complications]
MH  - Thyrotoxicosis/ep [Epidemiology]
MH  - Thyrotoxicosis/pp [Physiopathology]
AB  - Serum BNP (brain naturiuretic peptide) and ANP (atrial natriuretic peptide) levels are reportedly elevated in patients with thyrotoxicosis. The increases may not be due to thyrotoxicosis itself but to secondary cardiovascular changes such as chronic heart failure (HF) or atrial fibrillation (AF) which frequently accompany thyrotoxicosis. We measured serum ANP and BNP levels in 130 patients with thyrotoxicosis and correlated them with HF severity and thyroid function. Thirty-seven normal subjects served as controls. Serum BNP levels in thyrotoxic patients were significantly higher than those in control subjects and significantly correlated with serum free T4, free T3 and ANP levels. In untreated Graves' disease serum BNP level was significantly elevated in patients with HF or AF. Multiple regression analysis revealed that HF, free T4, female gender and AF are independent contributing factors to the elevated BNP level, and that these four factors contributed about 40%. On the other hand, HF and AF were contributing variables for ANP level but the overall contribution of these factors was only 10%. After normalization of thyroid function, serum BNP levels were normalized in 70.5% of Graves' patients. BNP level in euthyroid state was dependent on the presence of HF and the BNP value before therapy, but not on thyroid hormone levels or AF. These data suggest that the cardiovascular condition is the major factor responsible for the elevated serum BNP and ANP levels in thyrotoxic patients, while thyrotoxicosis itself is an independent but minor contributing factor. Thus, the determination of serum BNP levels in thyrotoxic patients is useful for monitoring cardiovascular conditions of HF.
RN  - 0 (Thyroid Hormones)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 4964P6T9RB (Aldosterone)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
RN  - EC 3-4-23-15 (Renin)
ES  - 1348-4540
IL  - 0918-8959
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20081001
DP  - 2009
DC  - 20090313
YR  - 2009
ED  - 20090421
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18827406

<494. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19255343
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Go AS
AU  - Fang MC
AU  - Udaltsova N
AU  - Chang Y
AU  - Pomernacki NK
AU  - Borowsky L
AU  - Singer DE
AU  - ATRIA Study Investigators
FA  - Go, Alan S
FA  - Fang, Margaret C
FA  - Udaltsova, Natalia
FA  - Chang, Yuchiao
FA  - Pomernacki, Niela K
FA  - Borowsky, Leila
FA  - Singer, Daniel E
FA  - ATRIA Study Investigators
IN  - Go,Alan S. Division of Research, Kaiser Permanente of Northern California, 2000 Broadway St, 3rd Floor, Oakland, CA 94612, USA. Alan.S.Go@kp.org
TI  - Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study.
CM  - Comment in: Circulation. 2009 Nov 3;120(18):e153; author reply e154; PMID: 19884478
SO  - Circulation. 119(10):1363-9, 2009 Mar 17.
AS  - Circulation. 119(10):1363-9, 2009 Mar 17.
NJ  - Circulation
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - daw, 0147763
OI  - Source: NLM. NIHMS108079
OI  - Source: NLM. PMC2733238
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - California/ep [Epidemiology]
MH  - Chronic Disease
MH  - Comorbidity
MH  - Creatinine/bl [Blood]
MH  - Female
MH  - Fibrinolytic Agents/tu [Therapeutic Use]
MH  - Follow-Up Studies
MH  - *Glomerular Filtration Rate
MH  - Humans
MH  - Kidney Diseases/co [Complications]
MH  - *Kidney Diseases/ep [Epidemiology]
MH  - Kidney Diseases/pp [Physiopathology]
MH  - Kidney Diseases/ur [Urine]
MH  - Male
MH  - Middle Aged
MH  - *Proteinuria/ep [Epidemiology]
MH  - Risk Factors
MH  - Stroke/pc [Prevention & Control]
MH  - *Thromboembolism/ep [Epidemiology]
MH  - Thromboembolism/et [Etiology]
MH  - Thromboembolism/pc [Prevention & Control]
MH  - Warfarin/tu [Therapeutic Use]
AB  - BACKGROUND: Atrial fibrillation (AF) substantially increases the risk of ischemic stroke, but this risk varies among individual patients with AF. Existing risk stratification schemes have limited predictive ability. Chronic kidney disease is a major cardiovascular risk factor, but whether it independently increases the risk for ischemic stroke in persons with AF is unknown.
AB  - METHODS AND RESULTS: We examined how chronic kidney disease (reduced glomerular filtration rate or proteinuria) affects the risk of thromboembolism off anticoagulation in patients with AF. We estimated glomerular filtration rate using the Modification of Diet in Renal Disease equation and proteinuria from urine dipstick results found in laboratory databases. Patient characteristics, warfarin use, and thromboembolic events were ascertained from clinical databases, with validation of thromboembolism by chart review. During 33,165 person-years off anticoagulation among 10,908 patients with AF, we observed 676 incident thromboembolic events. After adjustment for known risk factors for stroke and other confounders, proteinuria increased the risk of thromboembolism by 54% (relative risk, 1.54; 95% CI, 1.29 to 1.85), and there was a graded, increased risk of stroke associated with a progressively lower level of estimated glomerular filtration rate compared with a rate > or =60 mL x min(-1) x 1.73 m(-2): relative risk of 1.16 (95% CI, 0.95 to 1.40) for estimated glomerular filtration rate of 45 to 59 mL x min(-1) x 1.73 m(-2) and 1.39 (95% CI, 1.13 to 1.71) for estimated glomerular filtration rate <45 mL x min(-1) x 1.73 m(-2) (P=0.0082 for trend).
AB  - CONCLUSIONS: Chronic kidney disease increases the risk of thromboembolism in AF independently of other risk factors. Knowing the level of kidney function and the presence of proteinuria may improve risk stratification for decision making about the use of antithrombotic therapy for stroke prevention in AF.
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - AYI8EX34EU (Creatinine)
ES  - 1524-4539
IL  - 0009-7322
DO  - http://dx.doi.org/10.1161/CIRCULATIONAHA.108.816082
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
NO  - AG15478 (United States NIA NIH HHS)
NO  - R01 AG015478 (United States NIA NIH HHS)
NO  - R01 AG015478-04A1 (United States NIA NIH HHS)
NO  - R01 AG015478-05 (United States NIA NIH HHS)
NO  - R01 AG015478-06 (United States NIA NIH HHS)
NO  - R01 AG015478-07 (United States NIA NIH HHS)
NO  - R01 AG015478-08 (United States NIA NIH HHS)
LG  - English
EP  - 20090302
DP  - 2009 Mar 17
DC  - 20090317
YR  - 2009
ED  - 20090416
RD  - 20141210
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19255343

<495. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19026901
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Rundek T
AU  - Sacco RL
FA  - Rundek, Tatjana
FA  - Sacco, Ralph L
IN  - Rundek,Tatjana. Department of Neurology, Miller School of Medicine, University of Miami, Miami, Florida, USA. TRundek@med.miami.edu
TI  - Risk factor management to prevent first stroke. [Review] [193 refs]
SO  - Neurologic Clinics. 26(4):1007-45, ix, 2008 Nov.
AS  - Neurol Clin. 26(4):1007-45, ix, 2008 Nov.
NJ  - Neurologic clinics
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - neu, 8219232
OI  - Source: NLM. NIHMS99238
OI  - Source: NLM. PMC2666965
SB  - Index Medicus
CP  - United States
MH  - Humans
MH  - *Risk Factors
MH  - *Stroke/et [Etiology]
MH  - *Stroke/pc [Prevention & Control]
AB  - This article provides an overview on the management of risk factors to prevent primary strokes, the gaps in successful management, and future directions for the research and management of stroke risk factors. The major focus is given to the management of modifiable risk factors for stroke, including hypertension, diabetes, dyslipidemia, atrial fibrillation and other cardiac conditions, carotid artery stenosis, smoking, poor diet, physical inactivity, and obesity. A brief discussion on the management of potentially modifiable risk factors, such as alcohol and drug abuse, sleep apnea, and hyperhomocysteinemia, is included, as is the use of antiplatelet therapy in primary stroke prevention. Finally, prognostic scores to assess an individual risk for a first stroke are reviewed. [References: 193]
IS  - 0733-8619
IL  - 0733-8619
DO  - http://dx.doi.org/10.1016/j.ncl.2008.09.001
PT  - Journal Article
PT  - Review
NO  - R37 NS029993 (United States NINDS NIH HHS)
NO  - R37 NS029993-16 (United States NINDS NIH HHS)
LG  - English
DP  - 2008 Nov
DC  - 20081125
YR  - 2008
ED  - 20090409
RD  - 20140902
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19026901

<496. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19281919
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Maeder MT
AU  - Kaye DM
FA  - Maeder, Micha T
FA  - Kaye, David M
IN  - Maeder,Micha T. Heart Failure Research Group, Baker IDI Heart and Diabetes Institute, and Heart Center, Alfred Hospital, St Kilda Road, Central Melbourne 8008 VIC, Australia.
TI  - Heart failure with normal left ventricular ejection fraction. [Review] [85 refs]
CM  - Comment in: J Am Coll Cardiol. 2011 Mar 29;57(13):1499; author replies 1499-500; PMID: 21435524
CM  - Comment in: J Am Coll Cardiol. 2009 Jul 28;54(5):488; author reply 488-9; PMID: 19628127
SO  - Journal of the American College of Cardiology. 53(11):905-18, 2009 Mar 17.
AS  - J Am Coll Cardiol. 53(11):905-18, 2009 Mar 17.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - h50, 8301365
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Algorithms
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Biomarkers/bl [Blood]
MH  - Cardiac Pacing, Artificial
MH  - Coronary Artery Disease/pp [Physiopathology]
MH  - Diastole/ph [Physiology]
MH  - Dyspnea/et [Etiology]
MH  - Dyspnea/pp [Physiopathology]
MH  - Echocardiography, Doppler
MH  - Exercise/ph [Physiology]
MH  - Heart Failure/di [Diagnosis]
MH  - *Heart Failure/pp [Physiopathology]
MH  - Heart Failure/us [Ultrasonography]
MH  - Hemodynamics
MH  - Humans
MH  - Natriuretic Peptide, Brain/bl [Blood]
MH  - Oxygen Consumption/ph [Physiology]
MH  - Peptide Fragments/bl [Blood]
MH  - *Stroke Volume
MH  - Systole/ph [Physiology]
MH  - *Ventricular Function, Left/ph [Physiology]
AB  - It is estimated that approximately 50% of the heart failure population has a normal left ventricular ejection fraction, a complex broadly referred to as heart failure with normal left ventricular ejection fraction (HFNEF). While these patients have been considered in epidemiologic studies and clinical trials to represent a single pool of patients, limited more detailed studies indicate that HFNEF patients are a very heterogeneous group, with a number of key pathophysiologic mechanisms. This review summarizes and critically analyzes available data on the pathophysiology of HFNEF, placing it into context with a recently developed diagnostic algorithm. We evaluate the utility of commonly applied echocardiographic measures and biomarkers and integrate mechanistic observations into potential future therapeutic directions. [References: 85]
RN  - 0 (Biomarkers)
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
ES  - 1558-3597
IL  - 0735-1097
DO  - http://dx.doi.org/10.1016/j.jacc.2008.12.007
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
LG  - English
DP  - 2009 Mar 17
DC  - 20090313
YR  - 2009
ED  - 20090331
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19281919

<497. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19170911
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lehto M
AU  - Jurkko R
AU  - Parikka H
AU  - Mantynen V
AU  - Vaananen H
AU  - Montonen J
AU  - Voipio-Pulkki LM
AU  - Toivonen L
AU  - Laine M
FA  - Lehto, Mika
FA  - Jurkko, Raija
FA  - Parikka, Hannu
FA  - Mantynen, Ville
FA  - Vaananen, Heikki
FA  - Montonen, Juha
FA  - Voipio-Pulkki, Liisa-Maria
FA  - Toivonen, Lauri
FA  - Laine, Mika
IN  - Lehto,Mika. Department of Cardiology, Helsinki University Central Hospital, Helsinki, Finland. mika.lehto@fimnet.fi
TI  - Reversal of atrial remodeling after cardioversion of persistent atrial fibrillation measured with magnetocardiography.
SO  - Pacing & Clinical Electrophysiology. 32(2):217-23, 2009 Feb.
AS  - Pacing Clin Electrophysiol. 32(2):217-23, 2009 Feb.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - pab, 7803944
SB  - Index Medicus
CP  - United States
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - Female
MH  - Humans
MH  - *Magnetocardiography/mt [Methods]
MH  - Male
MH  - Middle Aged
MH  - Treatment Outcome
AB  - BACKGROUND: Atrial fibrillation (AF) causes electrical, functional, and structural changes in the atria. We examined electrophysiologic remodeling caused by AF and its reversal noninvasively by applying a new atrial signal analysis based on magnetocardiography (MCG).
AB  - METHODS: In 26 patients with persistent AF, MCG, signal-averaged electrocardiography (SAECG), and echocardiography were performed immediately after electrical cardioversion (CV), and repeated after 1 month in 15 patients who remained in sinus rhythm (SR). Twenty-four matched subjects without history of AF served as controls. P-wave duration (Pd) and dispersion (standard deviation of Pd values in individual channels) and root mean square amplitudes of the P wave over the last 40 ms portions (RMS40) were determined.
AB  - RESULTS: In MCG Pd was longer (122.8 +/- 18.2 ms vs 101.5 +/- 14.6 ms, P < 0.01) and RMS40 was higher (60.4 +/- 28.2 vs 46.9 +/- 19.1 fT) in AF patients immediately after CV as compared to the controls. In SAECG Pd dispersion was increased in AF patients. Mitral A-wave velocity and left atrial (LA) contraction were decreased and LA diameter was increased (all P < 0.01). After 1 month, Pd in MCG still remained longer and LA diameter greater (both P < 0.05), while RMS40 in MCG, Pd dispersion in SAECG, mitral A-wave velocity, and LA contraction were recovered.
AB  - CONCLUSIONS: Magnetocardiographically detected atrial electrophysiologic alterations in persistent AF diminish rapidly although incompletely during maintained SR after CV. This might be related to the known early high and late lower, but still existent tendency to AF relapses.
ES  - 1540-8159
IL  - 0147-8389
DO  - http://dx.doi.org/10.1111/j.1540-8159.2008.02205.x
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2009 Feb
DC  - 20090127
YR  - 2009
ED  - 20090326
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19170911

<498. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19231381
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Diez C
AU  - Mohr P
AU  - Kuss O
AU  - Osten B
AU  - Silber RE
AU  - Hofmann HS
FA  - Diez, Claudius
FA  - Mohr, Peter
FA  - Kuss, Oliver
FA  - Osten, Bernd
FA  - Silber, Rolf-Edgar
FA  - Hofmann, Hans-Stefan
IN  - Diez,Claudius. Department of Cardiothoracic Surgery, University Regensburg, Regensburg, Germany. claudius.diez@t-online.de
TI  - Impact of preoperative renal dysfunction on in-hospital mortality after solitary valve and combined valve and coronary procedures.
SO  - Annals of Thoracic Surgery. 87(3):731-6, 2009 Mar.
AS  - Ann Thorac Surg. 87(3):731-6, 2009 Mar.
NJ  - The Annals of thoracic surgery
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 15030100R
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - Netherlands
MH  - Aged
MH  - Cardiac Surgical Procedures/mt [Methods]
MH  - *Cardiac Surgical Procedures/mo [Mortality]
MH  - *Coronary Vessels/su [Surgery]
MH  - Female
MH  - Glomerular Filtration Rate
MH  - *Heart Valves/su [Surgery]
MH  - *Hospital Mortality/td [Trends]
MH  - Humans
MH  - *Kidney Diseases/pp [Physiopathology]
MH  - Male
MH  - Retrospective Studies
MH  - Risk Factors
AB  - BACKGROUND: Limited information exists on the influence of preoperative renal dysfunction on in-hospital mortality after valve and combined valve and coronary procedures. The impact of preoperative renal dysfunction on patient outcome was investigated.
AB  - METHODS: This was a retrospective observational study of 916 patients who underwent solitary valve or combined procedures. Primary outcome was in-hospital mortality. Preoperative estimated glomerular filtration rate (eGFR) was calculated with the abbreviated Modification of Diet in Renal Disease formula.
AB  - RESULTS: Independent predictors of death were prolonged stay in the intensive care unit (odds ratio [OR], 1.03; 95% confidence interval [CI], 1.01 to 1.05), preoperative atrial fibrillation (OR, 1.61; 95% CI, 1.02 to 2.54), chronic obstructive pulmonary disease (OR, 2.2; 95% CI, 1.06 to 4.55), and prolonged operation time (OR, 1.01; 95% CI, 1.00 to 1.01). Each unit of the eGFR (mL/min/1.73 m(2)) above average exerted a renoprotective effect (OR, 0.97; 95% CI, 0.96 to 0.98). The final regression model showed no lack of fit (Hosmer-Lemeshow test, p = 0.38) and a good discrimination performance in a receiver operating characteristic analysis (area under the curve, 0.84; 95% CI, 0.80 to 0.88). The lower the preoperative eGFR rate, the longer the postoperative stay at the intensive care unit.
AB  - CONCLUSIONS: Renal dysfunction is an important independent predictor of in-hospital mortality in adult patients after valve and combined valve and coronary procedures.
ES  - 1552-6259
IL  - 0003-4975
DO  - http://dx.doi.org/10.1016/j.athoracsur.2008.11.055
PT  - Journal Article
LG  - English
DP  - 2009 Mar
DC  - 20090223
YR  - 2009
ED  - 20090320
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19231381

<499. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19204312
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mont L
AU  - Brugada J
AU  - Elosua R
FA  - Mont, Lluis
FA  - Brugada, Josep
FA  - Elosua, Roberto
TI  - Letter by Mont et al regarding article, "Physical activity and incidence of atrial fibrillation in older adults: the Cardiovascular Health Study".
CM  - Comment on: Circulation. 2008 Aug 19;118(8):800-7; PMID: 18678768
SO  - Circulation. 119(5):e195; author reply e196, 2009 Feb 10.
AS  - Circulation. 119(5):e195; author reply e196, 2009 Feb 10.
NJ  - Circulation
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/et [Etiology]
MH  - *Exercise/ph [Physiology]
MH  - Humans
MH  - Incidence
MH  - Leisure Activities
MH  - Motor Activity/ph [Physiology]
MH  - Risk Factors
ES  - 1524-4539
IL  - 0009-7322
DO  - http://dx.doi.org/10.1161/CIRCULATIONAHA.108.821926
PT  - Comment
PT  - Letter
LG  - English
DP  - 2009 Feb 10
DC  - 20090210
YR  - 2009
ED  - 20090306
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19204312

<500. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18977068
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ono K
AU  - Kawasaki M
AU  - Tanaka R
AU  - Segawa T
AU  - Matsuo H
AU  - Watanabe S
AU  - Takemura G
AU  - Minatoguchi S
FA  - Ono, Koji
FA  - Kawasaki, Masanori
FA  - Tanaka, Ryuhei
FA  - Segawa, Tomonori
FA  - Matsuo, Hitoshi
FA  - Watanabe, Sachiro
FA  - Takemura, Genzou
FA  - Minatoguchi, Shinya
IN  - Ono,Koji. Department of Cardiology, Gifu Prefectural General Medical Center, Gifu, Japan.
TI  - Integrated backscatter and intima-media thickness of the thoracic aorta evaluated by transesophageal echocardiography in hypercholesterolemic patients: effect of pitavastatin therapy.
SO  - Ultrasound in Medicine & Biology. 35(2):193-200, 2009 Feb.
AS  - Ultrasound Med Biol. 35(2):193-200, 2009 Feb.
NJ  - Ultrasound in medicine & biology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - wne, 0410553
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - *Aorta, Thoracic/us [Ultrasonography]
MH  - Atherosclerosis/co [Complications]
MH  - Atherosclerosis/th [Therapy]
MH  - Atherosclerosis/us [Ultrasonography]
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/th [Therapy]
MH  - Atrial Fibrillation/us [Ultrasonography]
MH  - Diet
MH  - *Echocardiography, Transesophageal
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use]
MH  - Hypercholesterolemia/co [Complications]
MH  - Hypercholesterolemia/th [Therapy]
MH  - *Hypercholesterolemia/us [Ultrasonography]
MH  - Middle Aged
MH  - Observer Variation
MH  - Prospective Studies
MH  - *Quinolines/tu [Therapeutic Use]
MH  - Scattering, Radiation
MH  - Treatment Outcome
MH  - Tunica Intima/us [Ultrasonography]
MH  - Tunica Media/us [Ultrasonography]
AB  - The effect of a strong, lipophilic statin (pitavastatin) on the thoracic aorta has not yet been elucidated. The purpose of the present study was to evaluate the effects of pitavastatin (P) therapy on plaque components and morphology in the thoracic aorta by transesophageal echocardiography (TEE) and clarify the impact of the therapy on media and intima in patients with hypercholesterolemia. Sixty-four media and 64 intima of the thoracic aorta were investigated in 32 patients with hypercholesterolemia. The corrected integrated backscatter (c-IBS) values in the thoracic aortic wall and intima-media thickness (IMT) at the same site were measured before and after P therapy or diet (D) for 7 mo. Moreover, c-IBS values in media were measured in 168 patients without hypercholesterolemia to estimate age-dependent changes. C-IBS values in media were correlated with age (r = 0.84, p < 0.001). C-IBS and IMT of media in the P group significantly decreased from -17.8 +/- 2.4 to -20.1 +/- 3.7 dB and from 1.7 +/- 0.3 to 1.5 +/- 0.3 mm, respectively (p < 0.001), whereas those in the D group significantly increased from -18.3 +/- 2.0 to -16.7 +/- 2.1 dB and from 1.6 +/- 0.3 to 1.7 +/- 0.2 mm, respectively (p < 0.001). IMT in intima in the P group significantly decreased from 3.7 +/- 0.4 to 3.3 +/- 0.4 mm (p < 0.001). C-IBS in intima in the P group significantly increased from -10.2 +/- 2.2 to -6.9 +/- 1.7 dB, which indicated plaque stabilization. Pitavastatin improved the atherosis measured by IMT and sclerosis measured by c-IBS values in the media and induced stabilization and regression of plaques in the intima of the thoracic aorta.
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Quinolines)
RN  - M5681Q5F9P (pitavastatin)
ES  - 1879-291X
IL  - 0301-5629
DO  - http://dx.doi.org/10.1016/j.ultrasmedbio.2008.08.011
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
EP  - 20081031
DP  - 2009 Feb
DC  - 20090123
YR  - 2009
ED  - 20090302
RD  - 20121115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18977068

<501. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19025435
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Sobieraj DM
AU  - Wang F
AU  - Kirton OC
FA  - Sobieraj, Diana M
FA  - Wang, Fei
FA  - Kirton, Orlando C
IN  - Sobieraj,Diana M. Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT, USA.
TI  - Warfarin resistance after total gastrectomy and Roux-en-Y esophagojejunostomy.
SO  - Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy. 28(12):1537-41, 2008 Dec.
AS  - Pharmacotherapy. 28(12):1537-41, 2008 Dec.
NJ  - Pharmacotherapy
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - par, 8111305
SB  - Index Medicus
CP  - United States
MH  - Adenocarcinoma/pa [Pathology]
MH  - Adenocarcinoma/su [Surgery]
MH  - Aged
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - Chronic Disease
MH  - *Drug Resistance
MH  - Esophagus/su [Surgery]
MH  - Female
MH  - *Gastrectomy/mt [Methods]
MH  - *Gastric Bypass/mt [Methods]
MH  - Humans
MH  - International Normalized Ratio/sn [Statistics & Numerical Data]
MH  - Jejunum/su [Surgery]
MH  - Stomach Neoplasms/pa [Pathology]
MH  - Stomach Neoplasms/su [Surgery]
MH  - Warfarin/ae [Adverse Effects]
MH  - Warfarin/pk [Pharmacokinetics]
MH  - *Warfarin/tu [Therapeutic Use]
AB  - Nutritional deficiencies due to malabsorption occur after major gastric resection, and drugs that are primarily absorbed in the stomach or duodenum also are likely to exhibit decreased absorption. However, we performed a MEDLINE search (1960-2007) and found no evidence in the literature regarding the specific effects of warfarin absorption after total gastrectomy with Roux-en-Y gastric bypass procedure. We describe a 71-year-old woman receiving warfarin therapy for chronic atrial fibrillation who underwent a completion gastrectomy and Roux-en-Y esophagojejunostomy for an invasive adenocarcinoma of her gastric remnant. Before surgery, her international normalized ratio (INR) had been stable in her target range of 2-3 with warfarin 5-6 mg/day. At the time of her admission for the surgery, however, her INR was subtherapeutic at 1.73; warfarin was discontinued, and heparin and, subsequently, enoxaparin were used throughout her admission. After the surgery, the patient was discharged to a skilled nursing facility to continue bridge therapy with enoxaparin while warfarin was restarted and adjusted to a therapeutic INR of 2-3. Three months after discharge, the patient was hospitalized again for shortness of breath and was found to have an INR of 1.30 on admission, despite good compliance with her drugs. During this admission, the patient demonstrated resistance to warfarin therapy, requiring doses up to 20 mg/day to reach a therapeutic INR. To our knowledge, this is the first case report to demonstrate that patients undergoing a complete gastric resection followed by a Roux-en-Y gastric bypass procedure may display warfarin resistance. Close monitoring and dosage adjustment may be necessary to maintain therapeutic anticoagulation in these patients.
RN  - 5Q7ZVV76EI (Warfarin)
IS  - 0277-0008
IL  - 0277-0008
DO  - http://dx.doi.org/10.1592/phco.28.12.1537
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2008 Dec
DC  - 20081125
YR  - 2008
ED  - 20090223
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19025435

<502. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19025427
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Tisdale JE
AU  - Overholser BR
AU  - Sowinski KM
AU  - Wroblewski HA
AU  - Amankwa K
AU  - Borzak S
AU  - Kingery JR
AU  - Coram R
AU  - Zipes DP
AU  - Flockhart DA
AU  - Kovacs RJ
FA  - Tisdale, James E
FA  - Overholser, Brian R
FA  - Sowinski, Kevin M
FA  - Wroblewski, Heather A
FA  - Amankwa, Kwadwo
FA  - Borzak, Steven
FA  - Kingery, Joanna R
FA  - Coram, Rita
FA  - Zipes, Douglas P
FA  - Flockhart, David A
FA  - Kovacs, Richard J
IN  - Tisdale,James E. Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Purdue University, 1001 W 10th Street, Indianapolis, IN, USA. jtisdale@iupui.edu
TI  - Pharmacokinetics of ibutilide in patients with heart failure due to left ventricular systolic dysfunction.
SO  - Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy. 28(12):1461-70, 2008 Dec.
AS  - Pharmacotherapy. 28(12):1461-70, 2008 Dec.
NJ  - Pharmacotherapy
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - par, 8111305
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - Anti-Arrhythmia Agents/ae [Adverse Effects]
MH  - Anti-Arrhythmia Agents/bl [Blood]
MH  - Anti-Arrhythmia Agents/pk [Pharmacokinetics]
MH  - Area Under Curve
MH  - Arrhythmias, Cardiac/ci [Chemically Induced]
MH  - Catheters, Indwelling
MH  - Electrocardiography/mt [Methods]
MH  - Half-Life
MH  - *Heart Failure/dt [Drug Therapy]
MH  - Heart Failure/me [Metabolism]
MH  - Heart Failure/pp [Physiopathology]
MH  - Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Infusions, Intravenous
MH  - Long QT Syndrome/ci [Chemically Induced]
MH  - Male
MH  - Middle Aged
MH  - Monte Carlo Method
MH  - Prospective Studies
MH  - Remission, Spontaneous
MH  - Severity of Illness Index
MH  - Sulfonamides/ae [Adverse Effects]
MH  - Sulfonamides/bl [Blood]
MH  - *Sulfonamides/pk [Pharmacokinetics]
MH  - Tachycardia/ci [Chemically Induced]
MH  - Time Factors
MH  - *Ventricular Dysfunction, Left/pp [Physiopathology]
AB  - STUDY OBJECTIVE: To assess whether the increased risk of ibutilide-induced torsade de pointes in patients with heart failure may be due to increased ibutilide exposure, we sought to determine if the pharmacokinetics of ibutilide are altered in patients with heart failure due to left ventricular systolic dysfunction.
AB  - DESIGN: Multicenter, prospective pharmacokinetic study.
AB  - SETTING: Four academic medical centers in the United States.
AB  - PATIENTS: Sixteen adult patients with atrial fibrillation or atrial flutter requiring conversion to normal sinus rhythm: six patients who had New York Heart Association (NYHA) class II or III heart failure due to left ventricular dysfunction (mean +/- SD left ventricular ejection fraction [LVEF] 30 +/- 9%); 10 patients who did not have left ventricular dysfunction (mean +/- SD LVEF 54 +/- 5% in six of these 10 patients) served as controls.
AB  - INTERVENTION: All patients received a single dose of ibutilide 1.0 mg administered intravenously over 10 minutes. Blood samples were obtained through an indwelling catheter in the contralateral arm before ibutilide administration, at the end of the infusion, and at 5, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, and 48 hours after the infusion.
AB  - MEASUREMENTS AND MAIN RESULTS: Serum ibutilide concentrations were determined by using high-performance liquid chromatography and mass spectrometry. No significant differences were noted between the heart failure and normal left ventricular function groups in the following parameters: maximum serum ibutilide concentration (median [interquartile range] 3.8 [2.3-5.7] vs 5.8 [3.1-14.4] microg/L, p=0.31), area under the serum concentration-time curve from time zero extrapolated to infinity (mean +/- SD 11.0 +/- 9.4 vs 13.2 +/- 10.6 microg*hr/L, p=0.88), steady-state volume of distribution (1380 +/- 334 vs 1390 +/- 964 L, p=0.99), systemic clearance (129 +/- 60 vs 125 +/- 81 L/hr, p=0.92), or half-life (12.5 +/- 10.7 vs 12.4 +/- 8.6 hrs, p=0.99).
AB  - CONCLUSION: The pharmacokinetics of ibutilide do not appear to be altered in patients with NYHA class II or III heart failure due to left ventricular systolic dysfunction. Therefore, the increased risk of ibutilide-induced torsade de pointes in patients with heart failure does not appear to be due to increased ibutilide exposure.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Sulfonamides)
RN  - 2436VX1U9B (ibutilide)
IS  - 0277-0008
IL  - 0277-0008
DO  - http://dx.doi.org/10.1592/phco.28.12.1461
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2008 Dec
DC  - 20081125
YR  - 2008
ED  - 20090223
RD  - 20121115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19025427

<503. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19219940
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Anonymous
TI  - Leisure activities could help reduce AFib risk. Keeping in shape can help you avoid this "nuisance" arrhythmia.
SO  - Heart Advisor. 11(12):6, 2008 Dec.
AS  - Heart Advis. 11(12):6, 2008 Dec.
NJ  - Heart advisor / the Cleveland Clinic
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9892190
SB  - Consumer Health Journals
CP  - United States
MH  - Aged
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - Humans
MH  - Leisure Activities/cl [Classification]
MH  - Risk Factors
MH  - *Walking
IS  - 1523-9004
IL  - 1523-9004
PT  - Journal Article
LG  - English
DP  - 2008 Dec
DC  - 20090202
YR  - 2008
ED  - 20090219
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19219940

<504. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18838754
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Karsito
AU  - Soeatmadji DW
FA  - Karsito
FA  - Soeatmadji, Djoko W
IN  - Karsito,. Department of Internal Medicine, Brawijaya University, Jalan Veteran, Malang.
TI  - Diabetes and stroke. [Review] [26 refs]
SO  - Acta Medica Indonesiana. 40(3):151-8, 2008 Jul.
AS  - Acta med. Indones.. 40(3):151-8, 2008 Jul.
NJ  - Acta medica Indonesiana
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 7901042
SB  - Index Medicus
CP  - Indonesia
MH  - Carotid Stenosis/su [Surgery]
MH  - *Diabetes Complications/pc [Prevention & Control]
MH  - *Diabetes Mellitus/pp [Physiopathology]
MH  - Endarterectomy, Carotid
MH  - Humans
MH  - Mass Screening
MH  - Risk Factors
MH  - Stents
MH  - Stroke/di [Diagnosis]
MH  - *Stroke/et [Etiology]
MH  - *Stroke/pc [Prevention & Control]
AB  - Diabetes mellitus is a well-established independent risk factor for stroke and is associated with high mortality. Risk factors or risk markers for a first stroke were classified according to their potential for modification (nonmodifiable, modifiable, or potentially modifiable) and strength of evidence (well documented or less well documented). Modifiable risk factors include hypertension, exposure to cigarette smoke, diabetes, atrial fibrillation and certain other cardiac conditions, dyslipidemia, carotid artery stenosis, sickle cell disease, postmenopausal hormone therapy, poor diet, physical inactivity, and obesity and body fat distribution. Some of parameters are usefull as screening test to predict the incidence of stroke in diabetic patients in the future, such as UKPDS Risk Engine, incidence of carotid bruit featuring the stenosis of carotid artery, QTc interval prolongation and proteinuria. The real action must be taken to prevent the stroke when high risk patient is found. The modifiable and potentially modifiable risk factors that have been recommended by numbers of expert committee have to be modified immediately. In case with stenosis of carotid artery, the endarterectomy and carotid stenting have become popular and acceptable treatment in USA and Europe. It must be considered by Indonesian physicians to decrease the incidence of stroke. [References: 26]
IS  - 0125-9326
IL  - 0125-9326
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2008 Jul
DC  - 20081007
YR  - 2008
ED  - 20090213
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18838754

<505. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18648726
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Plisiene J
AU  - Blumberg A
AU  - Haager G
AU  - Knackstedt C
AU  - Latsch J
AU  - Norra C
AU  - Arndt M
AU  - Tuerk S
AU  - Heussen N
AU  - Kelm M
AU  - Predel HG
AU  - Schauerte P
FA  - Plisiene, J
FA  - Blumberg, A
FA  - Haager, G
FA  - Knackstedt, C
FA  - Latsch, J
FA  - Norra, C
FA  - Arndt, M
FA  - Tuerk, S
FA  - Heussen, N
FA  - Kelm, M
FA  - Predel, H G
FA  - Schauerte, P
IN  - Plisiene,J. Department of Cardiology, Pneumology, Vascular Medicine, RWTH University Aachen, Pauwelstrasse 30, 52072, Aachen, Germany.
TI  - Moderate physical exercise: a simplified approach for ventricular rate control in older patients with atrial fibrillation.
SO  - Clinical Research in Cardiology. 97(11):820-6, 2008 Nov.
AS  - Clin. res. cardiol.. 97(11):820-6, 2008 Nov.
NJ  - Clinical research in cardiology : official journal of the German Cardiac Society
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101264123
SB  - Index Medicus
CP  - Germany
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Electrocardiography
MH  - *Exercise
MH  - Exercise Test
MH  - Female
MH  - *Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Satisfaction
MH  - Physical Fitness
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Treatment Outcome
MH  - Walking
AB  - AIMS: This prospective pilot-study was performed to assess whether regular moderate physical activity elevates the parasympathetic tone to the atrio-ventricular node and decreases VR during permanent AF.
AB  - BACKGROUND: Adequate ventricular rate (VR) control in patients with permanent atrial fibrillation (AF) is not easy to accomplish.
AB  - METHODS: 10 patients (mean age 59 +/- 10 years) with permanent AF (duration: 10 +/- 8 years) underwent moderate physical exercise adjusted to their individual physical capability (45 min walking/jogging twice a week). To analyze VR control physical exercise tests and Holter-ECG recordings were performed before and after 4 months. In addition, stepwise lactate tests and psycho-pathometric examinations were obtained.
AB  - RESULTS: After 4 months of training, there was a trend toward a decrease of mean VR in 24 h Holter-ECGs by 12% from 76 +/- 20 to 67 +/- 12 bpm (P = 0.05) while there was no significant decrease of the minimal VR (38 +/- 8 vs. 36.3 +/- 4.5 bpm, P = 0.54). At a lactate threshold of 2 mmol/l there was a trend towards an increase of the running speed from 105 +/- 11 to 116 +/- 12 m/min (P = 0.05). A significant VR decrease of 8% (range 5-10%) was observed at almost all exercise levels during exercise treadmill testing. Increases of exercise capacity and decreases of VR were accompanied by subjective improvements of health perception.
AB  - CONCLUSION: Regular moderate physical activity decreases VR at rest and during exercise while increasing exercise capacity. Physical training should be taken into account for ventricular rate control during AF.
ES  - 1861-0692
IL  - 1861-0684
DO  - http://dx.doi.org/10.1007/s00392-008-0692-3
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20080721
DP  - 2008 Nov
DC  - 20081103
YR  - 2008
ED  - 20090123
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18648726

<506. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18834463
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gould PA
AU  - Esler MD
AU  - Kaye DM
FA  - Gould, Paul A
FA  - Esler, Murray D
FA  - Kaye, David M
IN  - Gould,Paul A. Wynn Department of Metabolic Cardiology, Baker Heart Research Institute, Melbourne, Australia.
TI  - Atrial fibrillation is associated with decreased cardiac sympathetic response to isometric exercise in CHF in comparison to sinus rhythm.
SO  - Pacing & Clinical Electrophysiology. 31(9):1125-9, 2008 Sep.
AS  - Pacing Clin Electrophysiol. 31(9):1125-9, 2008 Sep.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - pab, 7803944
SB  - Index Medicus
CP  - United States
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Blood Pressure
MH  - *Exercise Test
MH  - Female
MH  - *Heart Failure/di [Diagnosis]
MH  - *Heart Failure/pp [Physiopathology]
MH  - Heart Rate
MH  - Humans
MH  - Isometric Contraction
MH  - Male
MH  - Middle Aged
MH  - *Sympathetic Nervous System/pp [Physiopathology]
AB  - BACKGROUND: The presence of atrial fibrillation (AF) in congestive heart failure (CHF) is accompanied by increased mortality, although the exact mechanism is unclear. In previous studies, we have demonstrated cardiac baroreceptor abnormalities in association with AF and CHF. In this study, we sought to examine the effect of cardiac rhythm on the cardiac sympathetic response to exercise in CHF.
AB  - METHODS: In 13 CHF patients (six AF, seven SR, left ventricular ejection fraction 31 +/- 2%, age 61 +/- 1 years), we measured the hemodynamic and cardiac sympathetic response isometric handgrip (IHG) exercise.
AB  - RESULTS: At baseline the groups were well matched. Baseline hemodynamics and cardiac sympathetic activity did not significantly differ between the cohorts. In response to IHG exercise, both groups demonstrated significant hemodynamic responses. In conjunction, the sinus rhythm (SR) group demonstrated a significant increase in cardiac sympathetic response to exercise (P = 0.04) while in contrast the AF group did not (P = 0.6).
AB  - CONCLUSION: In this study, we demonstrate for the first time that the combination of AF and CHF is accompanied by a marked attenuation of the cardiac sympathetic response to acute hemodynamic stress. This implies AF is associated with a further impairment of baroreceptor response in CHF compared to SR. These findings present possible insights to the associated increased mortality and pathogenesis of AF with CHF.
ES  - 1540-8159
IL  - 0147-8389
DO  - http://dx.doi.org/10.1111/j.1540-8159.2008.01152.x
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2008 Sep
DC  - 20081006
YR  - 2008
ED  - 20090123
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18834463

<507. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18983331
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Anand RG
AU  - Peters RW
AU  - Donahue TP
FA  - Anand, Rishi G
FA  - Peters, Robert W
FA  - Donahue, Timothy P
IN  - Anand,Rishi G. Department of Cardiology, Ochsner Clinic Foundation, New Orleans, LA 70121, USA.
TI  - Obesity and dysrhythmias. [Review] [44 refs]
SO  - Journal of the CardioMetabolic Syndrome. 3(3):149-54, 2008.
AS  - J Cardiometab Syndr. 3(3):149-54, 2008.
NJ  - Journal of the cardiometabolic syndrome
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101284690
SB  - Index Medicus
CP  - United States
MH  - Arrhythmias, Cardiac/ep [Epidemiology]
MH  - *Arrhythmias, Cardiac/et [Etiology]
MH  - Arrhythmias, Cardiac/pp [Physiopathology]
MH  - Body Mass Index
MH  - Electrocardiography
MH  - Heart Rate/ph [Physiology]
MH  - *Heart Ventricles/pp [Physiopathology]
MH  - Humans
MH  - Morbidity/td [Trends]
MH  - *Obesity/co [Complications]
MH  - Obesity/ep [Epidemiology]
MH  - Prognosis
MH  - Risk Factors
MH  - United States/ep [Epidemiology]
MH  - Ventricular Function/ph [Physiology]
AB  - In the United States, obesity has reached epidemic proportions. Results from the 2003-2004 National Health and Nutrition Examination Survey estimated that 66% of US adults are either overweight (body mass index [BMI] 25-30 kg/m(2)) or obese (BMI>30 kg/m(2)) as defined by the BMI cutoffs established by the World Health Organization. In the 1970s, only 15% of the US population between the ages of 20 and 74 years was categorized as obese. In 2003, approximately 32% of the adult population was obese. Obesity plays an important role in the evolution of cardiovascular disease. This article reviews the histopathophysiologic changes that occur in cardiac structure and function in response to obesity, explores the relationship between obesity and arrhythmias such as atrial fibrillation and sudden cardiac death, and analyzes electrocardiographic changes in an obese patient. [References: 44]
IS  - 1559-4564
IL  - 1559-4564
DO  - http://dx.doi.org/10.1111/j.1559-4572.2008.00003.x
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2008
DC  - 20081105
YR  - 2008
ED  - 20090115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18983331

<508. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18434722
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Sasson L
AU  - Ureche A
AU  - Manolache G
AU  - Ciubotaru A
AU  - Borer JS
AU  - Schachner A
FA  - Sasson, Lior
FA  - Ureche, Andrei
FA  - Manolache, Gheorghe
FA  - Ciubotaru, Anatol
FA  - Borer, Jeffrey S
FA  - Schachner, Arie
IN  - Sasson,Lior. Angela and Sami Shamoon Cardiothoracic Surgery Department, Edith Wolfson Medical Center, Holon, affiliated with the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
TI  - Nitric oxide synthase inhibitor (MTR-105) during open-heart surgery. A pilot double-blind placebo-controlled study of hemodynamic effects and safety.
SO  - Cardiology. 111(3):181-7, 2008.
AS  - Cardiology. 111(3):181-7, 2008.
NJ  - Cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - coi, 1266406
SB  - Index Medicus
CP  - Switzerland
MH  - Adult
MH  - Aged
MH  - *Blood Pressure/de [Drug Effects]
MH  - *Cardiac Surgical Procedures/mt [Methods]
MH  - Cardiovascular Diseases/su [Surgery]
MH  - Double-Blind Method
MH  - *Enzyme Inhibitors/ad [Administration & Dosage]
MH  - Enzyme Inhibitors/pk [Pharmacokinetics]
MH  - Female
MH  - Half-Life
MH  - Hemodynamics/de [Drug Effects]
MH  - Humans
MH  - Hypotension/dt [Drug Therapy]
MH  - *Hypotension/pc [Prevention & Control]
MH  - Isothiuronium/ad [Administration & Dosage]
MH  - *Isothiuronium/aa [Analogs & Derivatives]
MH  - Isothiuronium/pk [Pharmacokinetics]
MH  - Male
MH  - Middle Aged
MH  - *Nitric Oxide Synthase/ai [Antagonists & Inhibitors]
MH  - Pilot Projects
MH  - Placebos
MH  - Vascular Resistance/de [Drug Effects]
AB  - OBJECTIVES: Hypotension is common immediately following cardiopulmonary bypass. Experimentally, MTR-105 (S-ethylisothiuronium diethylphosphate), a fast-acting synthetic nitric oxide synthase inhibitor, rapidly increases blood pressure. The purpose of the current study was to assess the influence of MTR-105 on hemodynamics early after cardiopulmonary bypass in patients undergoing open-heart surgery.
AB  - METHODS: Thirty-six patients with an ejection fraction >50% undergoing open-heart surgery were randomly assigned to either 50 microg kg(-1) min(-1) MTR-105 (M50, n = 12), 10 microg kg(-1) min(-1) MTR-105 (M10, n = 12) or buffered phosphate solution (placebo control, n = 12). Half suffered from atrial fibrillation and 75% had severe tricuspid regurgitation. Patients received the drug for 6 h after cross-clamp removal. Hemodynamic variables were measured before drug administration until 24 h after operation. Adverse events were recorded from study drug initiation through 30 days after the operation.
AB  - RESULTS: Compared with control, both MTR-105 doses were associated with an immediate increase in systemic blood pressure (16%) and systemic vascular resistance and a decrease in cardiac index. Half-life time of MTR-105 was calculated to be 4.1 +/- 0.8 h (M10) and 4.45 +/- 0.92 h (M50). Three patients died during hospitalization, unrelated to the study medication.
AB  - CONCLUSIONS: At the doses employed, MTR-105 appears hemodynamically active in increasing both blood pressures.Copyright 2008 S. Karger AG, Basel.
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Placebos)
RN  - 22584-04-9 (Isothiuronium)
RN  - 2986-20-1 (etiron)
RN  - EC 1-14-13-39 (Nitric Oxide Synthase)
ES  - 1421-9751
IL  - 0008-6312
DO  - http://dx.doi.org/10.1159/000121601
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20080425
DP  - 2008
DC  - 20080926
YR  - 2008
ED  - 20090108
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18434722

<509. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 19064030
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Cortigiani L
AU  - Rigo F
AU  - Gherardi S
AU  - Galderisi M
AU  - Sicari R
AU  - Picano E
FA  - Cortigiani, Lauro
FA  - Rigo, Fausto
FA  - Gherardi, Sonia
FA  - Galderisi, Maurizio
FA  - Sicari, Rosa
FA  - Picano, Eugenio
IN  - Cortigiani,Lauro. Cardiology Division, Campo di Marte Hospital, Lucca, Italy. lacortig@tin.it
TI  - Prognostic implications of coronary flow reserve on left anterior descending coronary artery in hypertrophic cardiomyopathy.
SO  - American Journal of Cardiology. 102(12):1718-23, 2008 Dec 15.
AS  - Am J Cardiol. 102(12):1718-23, 2008 Dec 15.
NJ  - The American journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Cardiomyopathy, Hypertrophic/pp [Physiopathology]
MH  - Cardiomyopathy, Hypertrophic/us [Ultrasonography]
MH  - *Coronary Circulation
MH  - *Coronary Vessels/pp [Physiopathology]
MH  - Coronary Vessels/us [Ultrasonography]
MH  - Dipyridamole
MH  - Echocardiography, Doppler, Color
MH  - *Echocardiography, Stress
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Observation
MH  - Prognosis
MH  - Prospective Studies
MH  - Vasodilator Agents
AB  - The aim of the study was to prospectively evaluate a cohort of patients with hypertrophic cardiomyopathy (HC) after coronary flow reserve (CFR) assessment of the left anterior descending coronary artery. Sixty-eight patients with HC (40 men, mean +/- SD 58 +/- 12 years of age) underwent dipyridamole (up to 0.84 mg/kg over 6 minutes) echocardiography with CFR evaluation of the left anterior descending coronary artery by Doppler. Seventy-four age- and gender-matched, apparently healthy subjects served as controls. A CFR value <2.0 was considered abnormal. CFR was decreased in patients with HC versus controls (2.12 +/- 0.39 vs 2.78 +/- 0.58, p <0.0001). CFR was abnormal in 26 of 39 symptomatic and in 5 of 29 asymptomatic patients with HC (67% vs 17%, p <0.0001). In addition, patients with HC with left ventricular obstruction had decreased CFR (p <0.0001) compared with those without obstruction. During follow-up (22 +/- 13 months), 27 events occurred: 1 sudden death, 1 nonfatal myocardial infarction, 4 cardioverter-defibrillator implantations, 6 hospitalizations for heart failure, 5 unstable anginas, 2 syncopes, and 8 atrial fibrillations. Three-year event rate was markedly higher in patients with abnormal than in those with normal CFR (79% vs 17%, p <0.0001). Events were more frequent in symptomatic than in asymptomatic patients (62% vs 10%, p <0.0001). However, the latter had a 10-fold increased risk of events in the presence of abnormal CFR (40% vs 4%, p = 0.02). In conclusion, mean CFR is markedly lower in patients with HC than in apparently healthy subjects. Abnormal CFR is a strong and independent predictor of outcome in patients with HC.
RN  - 0 (Vasodilator Agents)
RN  - 64ALC7F90C (Dipyridamole)
ES  - 1879-1913
IL  - 0002-9149
DO  - http://dx.doi.org/10.1016/j.amjcard.2008.08.023
PT  - Journal Article
PT  - Multicenter Study
LG  - English
EP  - 20081009
DP  - 2008 Dec 15
DC  - 20081209
YR  - 2008
ED  - 20081218
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=19064030

<510. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18684368
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Romero-Puche A
AU  - Marin F
AU  - Gonzalez-Carrillo J
AU  - Garcia-Honrubia A
AU  - Climent V
AU  - Feliu E
AU  - Ruiz-Espejo F
AU  - Paya E
AU  - Gimeno-Blanes JR
AU  - de la Morena G
AU  - Valdes-Chavarri M
FA  - Romero-Puche, Antonio
FA  - Marin, Francisco
FA  - Gonzalez-Carrillo, Josefa
FA  - Garcia-Honrubia, Antonio
FA  - Climent, Vicente
FA  - Feliu, Eloisa
FA  - Ruiz-Espejo, Francisco
FA  - Paya, Eduardo
FA  - Gimeno-Blanes, Juan R
FA  - de la Morena, Gonzalo
FA  - Valdes-Chavarri, Mariano
IN  - Romero-Puche,Antonio. Servicio de Cardiologia, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
TI  - Gadolinium-enhanced cardiovascular magnetic resonance and exercise capacity in hypertrophic cardiomyopathy.
SO  - Revista Espanola de Cardiologia. 61(8):853-60, 2008 Aug.
AS  - Rev Esp Cardiol. 61(8):853-60, 2008 Aug.
NJ  - Revista espanola de cardiologia
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - rtd, 0404277
SB  - Index Medicus
CP  - Spain
MH  - *Cardiomyopathy, Hypertrophic/di [Diagnosis]
MH  - *Contrast Media
MH  - *Exercise Test
MH  - Female
MH  - *Gadolinium
MH  - Humans
MH  - Magnetic Resonance Imaging/mt [Methods]
MH  - *Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
AB  - INTRODUCTION AND OBJECTIVES: Using gadolinium-enhanced cardiovascular magnetic resonance, it is possible to evaluate the presence of myocardial fibrosis in hypertrophic cardiomyopathy. Classical disease markers are weak predictors of functional disability in affected patients. Our objective was to study the relationship between the degree of myocardial fibrosis observed by cardiac magnetic resonance and exercise capacity.
AB  - METHODS: We performed cardiac magnetic resonance, echocardiography, exercise testing and Holter monitoring, along with the usual clinical assessments, in 98 patients (age, 46.3+/-15.4 years, 71.4% male) referred from two specialist hypertrophic cardiomyopathy clinics. Cardiac magnetic resonance assessment included quantifying the degree of fibrosis (i.e., the percentage of the myocardium showing enhancement) 10 min after gadolinium infusion. Symptom-limited exercise testing was used to determine exercise capacity (in metabolic equivalent [MET] units). In 71 patients, the basal N-terminal probrain natriuretic peptide (NT-proBNP) level was also measured.
AB  - RESULTS: Late enhancement was observed on cardiac magnetic resonance in 67 (68.4%) patients. These patients had a lower exercise capacity (8.04+/-3.56 MET vs. 10.41+/-3.57 MET; P=.003). There was an inverse correlation between the percentage of fibrosis and exercise capacity (r=-0.21; P=.044). The best predictor of exercise capacity was the logarithm of the NT-proBNP level (r=-0.5; P< .0001). Multivariate analysis confirmed that age, a history of atrial fibrillation, the basal NT-proBNP level and the presence of fibrosis were independent predictors of exercise capacity (r2 for the model=0.47).
AB  - CONCLUSIONS: The observation of areas of late gadolinium enhancement on cardiac magnetic resonance was independently associated with poor exercise capacity in patients with hypertrophic cardiomyopathy.
RN  - 0 (Contrast Media)
RN  - AU0V1LM3JT (Gadolinium)
ES  - 1579-2242
IL  - 0300-8932
PT  - Journal Article
LG  - English
LG  - Spanish
DP  - 2008 Aug
DC  - 20080807
YR  - 2008
ED  - 20081218
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18684368

<511. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18997138
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mergenhagen KA
AU  - Sherman O
FA  - Mergenhagen, Kari A
FA  - Sherman, Olga
IN  - Mergenhagen,Kari A. Infectious Disease, James J. Peters Veterans Affairs Medical Center, Bronx, NY 10468, USA. kari.mergenhagen2@va.gov
TI  - Elevated International Normalized Ratio after concurrent ingestion of cranberry sauce and warfarin.
SO  - American Journal of Health-System Pharmacy. 65(22):2113-6, 2008 Nov 15.
AS  - Am J Health-Syst Pharm. 65(22):2113-6, 2008 Nov 15.
NJ  - American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 9503023, cbh
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Anticoagulants
MH  - *Food-Drug Interactions
MH  - Humans
MH  - *International Normalized Ratio
MH  - Male
MH  - *Vaccinium macrocarpon
MH  - *Warfarin
AB  - PURPOSE: A case of increased International Normalized Ratio (INR) values in a patient receiving warfarin who consumed a large amount of cranberry sauce is reported.
AB  - SUMMARY: A 75-year-old Caucasian man with atrial fibrillation was taking 22.5 mg of warfarin weekly for 10 months and had maintained stable INR values between 2 and 3. During a clinic visit one week after Thanksgiving, the patient's INR was 4.8. The patient was extensively questioned about any changes in his diet, medications, and health. The patient reported consuming approximately 113 g of cranberry sauce for seven consecutive days before the clinic visit. He reported no other diet or health changes. The patient denied alcohol consumption, had not taken nutritional supplements, and did not miss or double any medication doses during this time period. There were no dosing changes or discernible compliance issues in the 10 months preceding the change in INR. The patient's complete blood cell count and results of a chemistry panel and liver function tests were within normal limits. He did not have any bleeding or bruising. The only identifiable change was the addition of store-bought cranberry sauce to his diet. The patient's warfarin dose was held for two days. Subsequently, the patient resumed warfarin at a dosage of 20 mg per week. Seven days after the patient discontinued the cranberry sauce, his INR returned to 2.2 and remained stable over the next month.
AB  - CONCLUSION: Consumption of cranberry sauce led to an increase in INR values in a patient receiving warfarin.
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
ES  - 1535-2900
IL  - 1079-2082
DO  - http://dx.doi.org/10.2146/ajhp080135
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2008 Nov 15
DC  - 20081110
YR  - 2008
ED  - 20081203
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18997138

<512. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18682448
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Agostoni P
AU  - Emdin M
AU  - Corra U
AU  - Veglia F
AU  - Magri D
AU  - Tedesco CC
AU  - Berton E
AU  - Passino C
AU  - Bertella E
AU  - Re F
AU  - Mezzani A
AU  - Belardinelli R
AU  - Colombo C
AU  - La Gioia R
AU  - Vicenzi M
AU  - Giannoni A
AU  - Scrutinio D
AU  - Giannuzzi P
AU  - Tondo C
AU  - Di Lenarda A
AU  - Sinagra G
AU  - Piepoli MF
AU  - Guazzi M
FA  - Agostoni, Piergiuseppe
FA  - Emdin, Michele
FA  - Corra, Ugo
FA  - Veglia, Fabrizio
FA  - Magri, Damiano
FA  - Tedesco, Calogero C
FA  - Berton, Emanuela
FA  - Passino, Claudio
FA  - Bertella, Erika
FA  - Re, Federica
FA  - Mezzani, Alessandro
FA  - Belardinelli, Romualdo
FA  - Colombo, Chiara
FA  - La Gioia, Rocco
FA  - Vicenzi, Marco
FA  - Giannoni, Alberto
FA  - Scrutinio, Domenico
FA  - Giannuzzi, Pantaleo
FA  - Tondo, Claudio
FA  - Di Lenarda, Andrea
FA  - Sinagra, Gianfranco
FA  - Piepoli, Massimo F
FA  - Guazzi, Marco
IN  - Agostoni,Piergiuseppe. Centro Cardiologico Monzino, IRCCS, Istituto di Cardiologia, Universita di Milano, via Parea 4, 20138 Milano, Italy. piergiuseppe.agostoni@unimi.it
TI  - Permanent atrial fibrillation affects exercise capacity in chronic heart failure patients.
SO  - European Heart Journal. 29(19):2367-72, 2008 Oct.
AS  - Eur Heart J. 29(19):2367-72, 2008 Oct.
NJ  - European heart journal
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - em8, 8006263
SB  - Index Medicus
CP  - England
MH  - *Anaerobic Threshold/ph [Physiology]
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Chronic Disease
MH  - Cohort Studies
MH  - Disease Progression
MH  - Electrocardiography
MH  - Exercise Test/mt [Methods]
MH  - Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - Heart Failure/co [Complications]
MH  - *Heart Failure/pp [Physiopathology]
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Retrospective Studies
MH  - Treatment Outcome
AB  - AIMS: The influence of permanent atrial fibrillation on exercise tolerance and cardio-respiratory function during exercise in heart failure (HF) is unknown.
AB  - METHODS AND RESULTS: We retrospectively compared the results of 942 cardiopulmonary exercise tests, performed consecutively at seven Italian laboratories, in HF patients with atrial fibrillation (n = 180) and sinus rhythm (n = 762). By multivariable logistic regression analysis, peak VO(2) (OR 0.376, 95% CI 0.240-0.588, P < 0.0001), O(2)pulse (VO(2)/heart rate, HR) (OR 0.236, 95% CI 0.152-0.366, P < 0.0001), VCO(2) (OR 3.97, 95% CI 2.163-7.287, P < 0.0001), and ventilation (OR 1.38, 95% CI 1.045-1.821, P = 0.0231) were independently associated with atrial fibrillation. Anaerobic threshold (AT) was identified in 132 of 180 (73%) atrial fibrillation and in 649 of 762 (85%) sinus rhythm patients (P = 0.0002). By multivariable logistic regression analysis, only peak VO(2) (OR 0.214, 95% CI 0.155-0.296, P < 0.0001) was independently associated with unidentified AT. At AT, atrial fibrillation HF patients had higher HR (P < 0.0001) and higher VO(2) (P < 0.001) compared with sinus rhythm HF patients. Among AT variables, by multivariable logistic regression analysis, only HR was an independent predictor of atrial fibrillation.
AB  - CONCLUSION: In HF patients with permanent atrial fibrillation, exercise performance is reduced as reflected by reduced peak VO(2). The finding of unidentified AT is associated with a poor performance. In atrial fibrillation patients, VO(2) is higher at AT whereas lower at peak. This last observation raises uncertainties about the use of AT data to define performance and prognosis of HF patients with atrial fibrillation.
ES  - 1522-9645
IL  - 0195-668X
DO  - http://dx.doi.org/10.1093/eurheartj/ehn361
PT  - Journal Article
LG  - English
EP  - 20080805
DP  - 2008 Oct
DC  - 20081002
YR  - 2008
ED  - 20081125
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18682448

<513. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18854765
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Barrios V
AU  - Escobar C
AU  - Murga N
AU  - de Pablo C
AU  - Bertomeu V
AU  - Calderon A
AU  - Echarri R
FA  - Barrios, Vivencio
FA  - Escobar, Carlos
FA  - Murga, Nekane
FA  - de Pablo, Carmen
FA  - Bertomeu, Vicente
FA  - Calderon, Alberto
FA  - Echarri, Rocio
IN  - Barrios,Vivencio. Department of Cardiology, Hospital Ramon y Cajal, Madrid, Spain. vbarriosa@meditex.es
TI  - Clinical profile and management of hypertensive patients with chronic ischemic heart disease and renal dysfunction attended by cardiologists in daily clinical practice.
SO  - Journal of Hypertension. 26(11):2230-5, 2008 Nov.
AS  - J Hypertens. 26(11):2230-5, 2008 Nov.
NJ  - Journal of hypertension
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - iew, 8306882
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - *Cardiology/mt [Methods]
MH  - Creatinine/bl [Blood]
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Humans
MH  - Hypertension/co [Complications]
MH  - Hypertension/dt [Drug Therapy]
MH  - *Hypertension/pp [Physiopathology]
MH  - Kidney Failure, Chronic/co [Complications]
MH  - *Kidney Failure, Chronic/pp [Physiopathology]
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/co [Complications]
MH  - *Myocardial Ischemia/pp [Physiopathology]
MH  - *Professional Practice
AB  - OBJECTIVE: The present study was designed to assess the influence of renal function on the clinical profile and management of the hypertensive outpatients with chronic ischemic heart disease.
AB  - METHODS: A total of 112 investigators, all cardiologists, were asked to consecutively enrol outpatients of at least 18 years of age, both sexes, with an established diagnosis of hypertension and chronic ischemic heart disease. Renal function was assessed by serum creatinine levels and estimated glomerular filtration rate using the Modification of Diet in Renal Disease formula. Renal impairment was considered a serum creatinine of at least 1.2/1.3 mg/dl (women/men) or an estimated glomerular filtration rate less than 60 ml/min/1.73 m2. Blood pressure was considered controlled when it was less than 140/90 mmHg and less than 130/80 mmHg in diabetic patients or patients with chronic kidney disease.
AB  - RESULTS: A total of 2024 patients (66.8+/-10.1 years; 31.7% women) were included. A total of 666 (32.9%) and 498 (24.6%) patients exhibited renal function impairment assessed by estimated glomerular filtration rate and serum creatinine, respectively. The subgroup of patients with renal dysfunction was older, with a higher proportion of women with atrial fibrillation, diabetes, organ damage, associated clinical conditions and a worse blood pressure control. No differences were found in clinical profile when the two subgroups of patients with impaired renal function [serum creatinine >or=1.2/>or=1.3 mg/dl (women/men) vs. estimated glomerular filtration rate <60 ml/min per 1.73 m2] were compared.
AB  - CONCLUSION: Renal function impairment is frequent in the hypertensive population with coronary artery disease. Patients with renal dysfunction represent a subgroup of very high-risk population with more risk factors and comorbidities and worse blood pressure control. The clinical profiles of hypertensive patients with renal function impairment are similar whether renal dysfunction is detected by high serum creatinine or by low estimated glomerular filtration rate.
RN  - AYI8EX34EU (Creatinine)
IS  - 0263-6352
IL  - 0263-6352
DO  - http://dx.doi.org/10.1097/HJH.0b013e328311cdee
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2008 Nov
DC  - 20081015
YR  - 2008
ED  - 20081117
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18854765

<514. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18397873
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Van Wagoner DR
FA  - Van Wagoner, David R
TI  - Evaluating the impact of atrial dilatation on atrial calcium cycling.
CM  - Comment on: Eur Heart J. 2008 May;29(9):1190-7; PMID: 18397872
SO  - European Heart Journal. 29(9):1084-5, 2008 May.
AS  - Eur Heart J. 29(9):1084-5, 2008 May.
NJ  - European heart journal
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - em8, 8006263
SB  - Index Medicus
CP  - England
MH  - *Atrial Fibrillation/et [Etiology]
MH  - *Calcium/me [Metabolism]
MH  - Calcium Channels/de [Drug Effects]
MH  - Calcium Channels/ph [Physiology]
MH  - Cardiomegaly/co [Complications]
MH  - *Cardiomyopathy, Dilated/co [Complications]
MH  - Down-Regulation
MH  - Humans
MH  - Myocardial Contraction
MH  - *Myocytes, Cardiac/me [Metabolism]
RN  - 0 (Calcium Channels)
RN  - SY7Q814VUP (Calcium)
IS  - 0195-668X
IL  - 0195-668X
DO  - http://dx.doi.org/10.1093/eurheartj/ehn051
PT  - Comment
PT  - Editorial
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20080407
DP  - 2008 May
DC  - 20080502
YR  - 2008
ED  - 20081117
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18397873

<515. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18607243
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mattioli AV
AU  - Bonatti S
AU  - Zennaro M
AU  - Melotti R
AU  - Mattioli G
FA  - Mattioli, Anna Vittoria
FA  - Bonatti, Silvia
FA  - Zennaro, Mauro
FA  - Melotti, Roberto
FA  - Mattioli, Giorgio
IN  - Mattioli,Anna Vittoria. Department of Biomedical Science, Italy. annavittoria.mattioli@unimore.it
TI  - Effect of coffee consumption, lifestyle and acute life stress in the development of acute lone atrial fibrillation.
SO  - Journal of Cardiovascular Medicine. 9(8):794-8, 2008 Aug.
AS  - J Cardiovasc Med (Hagerstown). 9(8):794-8, 2008 Aug.
NJ  - Journal of cardiovascular medicine (Hagerstown, Md.)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101259752
SB  - Index Medicus
CP  - United States
MH  - Acute Disease
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/px [Psychology]
MH  - *Coffee/ae [Adverse Effects]
MH  - Confidence Intervals
MH  - Disease Progression
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Italy/ep [Epidemiology]
MH  - *Life Style
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Prognosis
MH  - Risk Factors
MH  - *Stress, Psychological/co [Complications]
MH  - Stress, Psychological/ep [Epidemiology]
MH  - Stress, Psychological/px [Psychology]
MH  - Surveys and Questionnaires
AB  - OBJECTIVE: The study evaluated the relationships between acute stress, lifestyle and coffee consumption, and acute lone atrial fibrillation (AF).
AB  - METHODS: The study group included 400 patients with mean age of 54 +/- 11 years, 205 of whom were men. They all presented with a first episode of AF. Patients underwent a series of cognitive tests to evaluate acute psychological stress (mean life acute stress score). Lifestyle and nutritional parameters (diet, alcohol and espresso coffee consumption, smoking and obesity) were investigated. An age-matched and sex-matched control group was selected and compared.
AB  - RESULTS: Recent stress, high intake of coffee, and obesity were associated with greater risk of AF. Acute stress induces an increase in coffee consumption and changes in lifestyle. The increase in coffee consumption was more marked in nonhabitual drinkers, leading to a higher risk of developing AF [odds ratio (OR) 4.1; 95% confidence interval (CI): 1.98-4.56; P < 0.001]. Spontaneous conversion of AF to sinus rhythm was observed in 191 patients (47%). Patients who experienced AF after an acute stress showed the highest probability of spontaneous conversion. High espresso coffee consumption (OR 0.86; 95% CI: 0.49-1.21; P < 0.01) and obesity (OR 0.88; 95% CI: 0.84-1.20; P < 0.01) were associated with a significantly greater risk of persistent AF.
AB  - CONCLUSION: Acute stress induced changes in lifestyle, including an increase in coffee consumption, leading to a higher risk of AF. Patients who developed AF after an acute stress showed the highest probability of spontaneous conversion. High espresso coffee consumption and obesity were associated with an increased risk of persistent AF.
RN  - 0 (Coffee)
IS  - 1558-2027
IL  - 1558-2027
DO  - http://dx.doi.org/10.2459/JCM.0b013e3282f64554
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 2008 Aug
DC  - 20080708
YR  - 2008
ED  - 20081113
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18607243

<516. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18653581
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Prasad K
AU  - Williams L
AU  - Campbell R
AU  - Elliott PM
AU  - McKenna WJ
AU  - Frenneaux M
FA  - Prasad, K
FA  - Williams, L
FA  - Campbell, R
FA  - Elliott, P M
FA  - McKenna, W J
FA  - Frenneaux, M
IN  - Prasad,K. Department of Cardiovascular Medicine, University of Birmingham, Edgbaston, Birmingham, UK.
TI  - Episodic syncope in hypertrophic cardiomyopathy: evidence for inappropriate vasodilation.
SO  - Heart. 94(10):1312-7, 2008 Oct.
AS  - Heart. 94(10):1312-7, 2008 Oct.
NJ  - Heart (British Cardiac Society)
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 9602087
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - Adolescent
MH  - Adult
MH  - Blood Pressure/ph [Physiology]
MH  - *Cardiomyopathy, Hypertrophic/co [Complications]
MH  - Cardiomyopathy, Hypertrophic/pp [Physiopathology]
MH  - Dilatation, Pathologic/pp [Physiopathology]
MH  - Exercise/ph [Physiology]
MH  - Humans
MH  - Hypotension/et [Etiology]
MH  - Pressoreceptors/ph [Physiology]
MH  - *Syncope/et [Etiology]
MH  - Syncope/pp [Physiopathology]
MH  - Tilt-Table Test
AB  - Symptoms of impaired consciousness (syncope and pre-syncope) occur in 15-25% of patients with hypertrophic cardiomyopathy (HCM).1 In young patients a history of recurrent syncope is associated with an increased risk of sudden death.2(-)5 Syncope usually occurs without warning or symptoms suggestive of the cause. Detailed investigations identify a probable mechanism in a minority, usually paroxysmal atrial fibrillation or ventricular tachycardia. In the majority however no likely mechanism is found despite repeated 24-hour ambulatory echocardiography (ECG) or patient-activated monitoring, exercise testing and invasive electrophysiological studies.1 6 Empirical treatment with amiodarone, a pacemaker or an implantable cardioverter-defibrillator is commonly employed, but is often unsuccessful in relieving the symptoms. We have previously observed that approximately 30% of patients with HCM have abnormal blood pressure response during maximal upright exercise.7 8 This was due in the majority of patients to an exaggerated fall in systemic vascular resistance, possibly arising from abnormal activation of stretch-sensitive left ventricular mechanoreceptors,9 10 by a mechanism similar to that described in aortic stenosis.11 However, in some patients an inadequate cardiac output response to exercise may be responsible.12 We hypothesised that abnormal vasodepressor-mediated hypotension may also occur during daily life in patients with HCM, and that this may be an important mechanism of syncope when conventional investigations fail to reveal a cause.
ES  - 1468-201X
IL  - 1355-6037
DO  - http://dx.doi.org/10.1136/hrt.2008.141507
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
NO  - (United Kingdom British Heart Foundation)
LG  - English
EP  - 20080724
DP  - 2008 Oct
DC  - 20080919
YR  - 2008
ED  - 20081028
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18653581

<517. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18773992
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Hilliard AA
AU  - Miller TD
AU  - Hodge DO
AU  - Gibbons RJ
FA  - Hilliard, Anthony A
FA  - Miller, Todd D
FA  - Hodge, David O
FA  - Gibbons, Raymond J
IN  - Hilliard,Anthony A. Department of Internal Medicine and Cardiovascular Diseases, Mayo Foundation, Rochester, Minnesota, USA.
TI  - Heart rate control in patients with atrial fibrillation referred for exercise testing.
SO  - American Journal of Cardiology. 102(6):704-8, 2008 Sep 15.
AS  - Am J Cardiol. 102(6):704-8, 2008 Sep 15.
NJ  - The American journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adrenergic beta-Antagonists/tu [Therapeutic Use]
MH  - Aged
MH  - Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Calcium Channel Blockers/tu [Therapeutic Use]
MH  - Digoxin/tu [Therapeutic Use]
MH  - *Exercise Test
MH  - Female
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Physical Exertion/ph [Physiology]
MH  - Rest/ph [Physiology]
MH  - Retrospective Studies
AB  - Clinical practice guidelines for patients with atrial fibrillation (AF) recommended a heart rate (HR) of 60 to 80 beats/min at rest and 90 to 115 at moderate exercise. The degree to which HR control at rest and with exercise in patients with AF complies with these recommendations is unknown. HR at rest and at peak exercise was retrospectively examined in 1,097 consecutive patients with AF referred for exercise myocardial perfusion imaging. In a subgroup of 195 patients, HR was also measured at an intermediate "moderate" level. Median HR at rest was 80 beats/min, at the upper end of the recommended range of 60 to 80. Only patients administered a beta blocker (BB; 31%) had lower (p <0.001) median HRs at rest. Median HR at moderate exercise was 128 beats/min, higher than the range of 90 to 115 recommended by the guidelines. Only patients administered a BB had significantly reduced HRs (p <0.003) at moderate exercise. Median peak exercise HR was 147 beats/min. Forty-five percent of patients exceeded their age-predicted maximal HR. Patients administered BBs were significantly less likely (p <0.01) to exceed their age-predicted maximal HR. In conclusion, in patients with AF, HR control at rest and during exercise often did not comply with guideline recommendations. Regimens including a BB were more effective in achieving HR control.
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Calcium Channel Blockers)
RN  - 73K4184T59 (Digoxin)
IS  - 0002-9149
IL  - 0002-9149
DO  - http://dx.doi.org/10.1016/j.amjcard.2008.04.051
PT  - Journal Article
LG  - English
EP  - 20080626
DP  - 2008 Sep 15
DC  - 20080908
YR  - 2008
ED  - 20081016
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18773992

<518. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18678768
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mozaffarian D
AU  - Furberg CD
AU  - Psaty BM
AU  - Siscovick D
FA  - Mozaffarian, Dariush
FA  - Furberg, Curt D
FA  - Psaty, Bruce M
FA  - Siscovick, David
IN  - Mozaffarian,Dariush. Division of Cardiovascular Medicine and Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass., USA. dmozaffa@hsph.harvard.edu
TI  - Physical activity and incidence of atrial fibrillation in older adults: the cardiovascular health study.
CM  - Comment in: Circulation. 2009 Feb 10;119(5):e195; author reply e196; PMID: 19204312
SO  - Circulation. 118(8):800-7, 2008 Aug 19.
AS  - Circulation. 118(8):800-7, 2008 Aug 19.
NJ  - Circulation
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - daw, 0147763
OI  - Source: NLM. NIHMS76456
OI  - Source: NLM. PMC3133958
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/et [Etiology]
MH  - *Exercise/ph [Physiology]
MH  - Female
MH  - Humans
MH  - Incidence
MH  - *Leisure Activities
MH  - Male
MH  - Motor Activity/ph [Physiology]
MH  - Prospective Studies
MH  - Walking/ph [Physiology]
AB  - BACKGROUND: Vigorous exertion and endurance training have been reported to increase atrial fibrillation (AF). Associations of habitual light or moderate activity with AF incidence have not been evaluated.
AB  - METHODS AND RESULTS: We prospectively investigated associations of leisure-time activity, exercise intensity, and walking habits, assessed at baseline and updated during follow-up visits, with incident AF, diagnosed by annual 12-lead ECGs and hospital discharge records, from 1989 to 2001 among 5446 adults > or =65 years of age in the Cardiovascular Health Study. During 47 280 person-years of follow-up, 1061 new AF cases occurred (incidence 22.4/1000 person-years). In multivariable-adjusted analyses, leisure-time activity was associated with lower AF incidence in a graded manner, with 25% (hazard ratio [HR] 0.75, 95% confidence interval [CI] 0.61 to 0.90), 22% (HR 0.78, 95% CI 0.65 to 0.95), and 36% (HR 0.64, 95% CI 0.52 to 0.79) lower risk in quintiles 3, 4, and 5 versus quintile 1 (P for trend <0.001). Exercise intensity had a U-shaped relationship with AF (quadratic P=0.02): Versus no exercise, AF incidence was lower with moderate-intensity exercise (HR 0.72, 95% CI 0.58 to 0.89) but not with high-intensity exercise (HR 0.87, 95% CI 0.64 to 1.19). Walking distance and pace were each associated with lower AF risk in a graded manner (P for trend <0.001); when we assessed the combined effects of distance and pace, individuals in quartiles 2, 3, and 4 had 25% (HR 0.75, 95% CI 0.56 to 0.99), 32% (HR 0.68, 95% CI 0.50 to 0.92), and 44% (HR 0.56, 95% CI 0.38 to 0.82) lower AF incidence than individuals in quartile 1. Findings appeared unrelated to confounding by comorbidity or indication. After evaluation of cut points of moderate leisure-time activity (approximately 600 kcal/week), walking distance (12 blocks per week), and pace (2 mph), 26% of all new AF cases (95% CI 7% to 43%) appeared attributable to absence of these activities.
AB  - CONCLUSIONS: Light to moderate physical activities, particularly leisure-time activity and walking, are associated with significantly lower AF incidence in older adults.
ES  - 1524-4539
IL  - 0009-7322
DO  - http://dx.doi.org/10.1161/CIRCULATIONAHA.108.785626
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
NO  - K08 HL075628 (United States NHLBI NIH HHS)
NO  - K08 HL075628-04 (United States NHLBI NIH HHS)
NO  - K08-HL-075628 (United States NHLBI NIH HHS)
NO  - N01 HC-15103 (United States NHLBI NIH HHS)
NO  - N01 HC-55222 (United States NHLBI NIH HHS)
NO  - N01-HC-35129 (United States NHLBI NIH HHS)
NO  - N01-HC-45133 (United States NHLBI NIH HHS)
NO  - N01-HC-75150 (United States NHLBI NIH HHS)
NO  - N01-HC-85079 (United States NHLBI NIH HHS)
NO  - N01-HC-85086 (United States NHLBI NIH HHS)
NO  - U01 HL080295 (United States NHLBI NIH HHS)
LG  - English
EP  - 20080804
DP  - 2008 Aug 19
DC  - 20080819
YR  - 2008
ED  - 20081014
RD  - 20140905
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18678768

<519. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18589334
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Towfighi A
AU  - Saver JL
AU  - Engelhardt R
AU  - Ovbiagele B
FA  - Towfighi, Amytis
FA  - Saver, Jeffrey L
FA  - Engelhardt, Rita
FA  - Ovbiagele, Bruce
IN  - Towfighi,Amytis. Stroke Center and Department of Neurology, University of California at Los Angeles Medical Center, Los Angeles, California, USA. towfighi@usc.edu
TI  - Factors associated with the steep increase in late-midlife stroke occurrence among US men.
SO  - Journal of Stroke & Cerebrovascular Diseases. 17(4):165-8, 2008 Jul-Aug.
AS  - J STROKE CEREBROVASC DIS. 17(4):165-8, 2008 Jul-Aug.
NJ  - Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 9111633
OI  - Source: NLM. NIHMS122821
OI  - Source: NLM. PMC2728439
SB  - Index Medicus
CP  - United States
MH  - Atherosclerosis/ep [Epidemiology]
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - Comorbidity
MH  - Coronary Disease/ep [Epidemiology]
MH  - Diabetes Mellitus/ep [Epidemiology]
MH  - Dyslipidemias/ep [Epidemiology]
MH  - Headache/ep [Epidemiology]
MH  - Hemoglobin A, Glycosylated/an [Analysis]
MH  - Humans
MH  - Hyperhomocysteinemia/ep [Epidemiology]
MH  - Hypertension/ep [Epidemiology]
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Nutrition Surveys
MH  - Risk Factors
MH  - *Stroke/ep [Epidemiology]
MH  - United States/ep [Epidemiology]
AB  - BACKGROUND: Data on recent stroke prevalence rates among middle-aged men in the United States indicate that men aged 55 to 64 years are 3 times more likely than men aged 45 to 54 years to have experienced a stroke. We aimed to determine potential risk factors that may contribute to this steep increase in late midlife stroke occurrence.
AB  - METHODS: We analyzed the National Health and Nutrition Examination Survey 1999 to 2004 data sets, assessing stroke prevalence, predictors of stroke occurrence, and vascular risk factors in men across their midlife years.
AB  - RESULTS: Crudely, higher glycohemoglobin, history of hypertension, history of diabetes, and history of coronary artery disease significantly predicted stroke in 45- to 54- and 54-to 64-year-old men. Significant stroke risk factors unique to each age group were non-white race, lower ankle-brachial pulsatility index, and occurrence of recent severe headache in the 45- to 54-year age group, whereas elevated serum homocysteine (HCY) level predicted stroke in those aged 55 to 64 years. In multivariable regression analysis, lower ankle-brachial pulsatility index (odds ratio [OR] 1.69, 95% confidence interval [CI] 1.47-1.83, P < .001) and recent severe headache (OR 5.12, 95% CI 1.3-20.1, P = .019) were the only independent predictors of stroke in the 45- to 54-year age group, whereas only elevated HCY predicted stroke in the 55- to 64-year age group (OR 1.708, 95% CI -1.103-2.643, P = .0163).
AB  - CONCLUSION: Elevated serum HCY level is the sole independent predictor of stroke among men aged 55 to 64 years in the United States. Further study to assess the efficacy of HCY-lowering treatment in mitigating a steep increase in late midlife stroke occurrence among men may be warranted.
RN  - 0 (Hemoglobin A, Glycosylated)
ES  - 1532-8511
IL  - 1052-3057
DO  - http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2007.12.007
PT  - Journal Article
NO  - P50 NS044378 (United States NINDS NIH HHS)
NO  - P50 NS044378-06 (United States NINDS NIH HHS)
LG  - English
DP  - 2008 Jul-Aug
DC  - 20080630
YR  - 2008
ED  - 20080930
RD  - 20140903
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18589334

<520. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18157415
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Nery RM
AU  - Barbisan JN
AU  - Mahmud MI
FA  - Nery, Rosane Maria
FA  - Barbisan, Juarez Neuhaus
FA  - Mahmud, Mahmud Ismail
IN  - Nery,Rosane Maria. Health Science Post-Graduate Program at Instituto de Cardiologia do Rio Grande do Sul/Fundacao Universitaria de Cardiologia, Porto Alegre, RS. pesquisa@cardiologia.org.br
TI  - Influence of the practice physical activity in the coronary artery bypass graft surgery results.
CM  - Comment in: Rev Bras Cir Cardiovasc. 2007 Oct-Dec;22(4):520-1; PMID: 18506954
SO  - Revista Brasileira de Cirurgia Cardiovascular: Orgao Oficial da Sociedade Brasileira de Cirurgia Cardiovascular. 22(3):297-302, 2007 Jul-Sep.
AS  - Rev Bras Cir Cardiovasc. 22(3):297-302, 2007 Jul-Sep.
NJ  - Revista brasileira de cirurgia cardiovascular : orgao oficial da Sociedade Brasileira de Cirurgia Cardiovascular
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 9104279
SB  - Index Medicus
CP  - Brazil
MH  - Aged
MH  - *Atrial Fibrillation/et [Etiology]
MH  - *Coronary Artery Bypass
MH  - *Exercise
MH  - Female
MH  - *Health Behavior
MH  - Humans
MH  - Length of Stay/sn [Statistics & Numerical Data]
MH  - Male
MH  - Middle Aged
MH  - *Myocardial Infarction/et [Etiology]
MH  - *Postoperative Complications
MH  - Postoperative Period
MH  - Preoperative Care
MH  - Statistics, Nonparametric
MH  - Treatment Outcome
AB  - OBJECTIVE: To evaluate the frequency changes of physical activity practice in pre- and postoperative of the patients submitted to coronary artery bypass graft surgery (CABG) and the frequency influence on the physical activity practice in the patients' preoperative prognosis.
AB  - METHODS: Cases studies of 55 patients submitted to CABG divided into active and sedentary regarding physical activity practices.
AB  - RESULTS: After CAGB, 14 (47%) patients classified as sedentary before surgery were practicing exercises (p = 0.03). Seventeen (59%) sedentary patients in the preoperative period presented complications after the surgery compared to 8 (31%) active patients (p = 0.04). The hospital length of stay among sedentary patients versus active patients before surgery was 15 (SD=8) and 12 (SD=5) days; p=0.03, respectively.
AB  - CONCLUSION: The present study showed the importance of physical activity practice in the preoperative stage on the outcomes of coronary artery bypass surgery. The patients physically active had a shorter hospital length of stay and a lower number of both trans- and postoperative complications within 1 year. The cardiac surgery promoted the patients' change of habits, increasing the number of physically active patients during the 1-year follow-up.
PT  - Journal Article
LG  - English
LG  - Portuguese
DP  - 2007 Jul-Sep
DC  - 20071224
YR  - 2007
ED  - 20080926
RD  - 20160303
UP  - 20160304
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=18157415

<521. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18157415
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Nery RM
AU  - Barbisan JN
AU  - Mahmud MI
FA  - Nery, Rosane Maria
FA  - Barbisan, Juarez Neuhaus
FA  - Mahmud, Mahmud Ismail
IN  - Nery,Rosane Maria. Health Science Post-Graduate Program at Instituto de Cardiologia do Rio Grande do Sul/Fundacao Universitaria de Cardiologia, Porto Alegre, RS. pesquisa@cardiologia.org.br
TI  - Influence of the practice physical activity in the coronary artery bypass graft surgery results.
CM  - Comment in: Rev Bras Cir Cardiovasc. 2007 Oct-Dec;22(4):520-1; PMID: 18506954
SO  - Revista Brasileira de Cirurgia Cardiovascular: Orgao Oficial da Sociedade Brasileira de Cirurgia Cardiovascular. 22(3):297-302, 2007 Jul-Sep.
AS  - Rev Bras Cir Cardiovasc. 22(3):297-302, 2007 Jul-Sep.
NJ  - Revista brasileira de cirurgia cardiovascular : orgao oficial da Sociedade Brasileira de Cirurgia Cardiovascular
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 9104279
SB  - Index Medicus
CP  - Brazil
MH  - Aged
MH  - *Atrial Fibrillation/et [Etiology]
MH  - *Coronary Artery Bypass
MH  - *Exercise
MH  - Female
MH  - *Health Behavior
MH  - Humans
MH  - Length of Stay/sn [Statistics & Numerical Data]
MH  - Male
MH  - Middle Aged
MH  - *Myocardial Infarction/et [Etiology]
MH  - *Postoperative Complications
MH  - Postoperative Period
MH  - Preoperative Care
MH  - Statistics, Nonparametric
MH  - Treatment Outcome
AB  - OBJECTIVE: To evaluate the frequency changes of physical activity practice in pre- and postoperative of the patients submitted to coronary artery bypass graft surgery (CABG) and the frequency influence on the physical activity practice in the patients' preoperative prognosis.
AB  - METHODS: Cases studies of 55 patients submitted to CABG divided into active and sedentary regarding physical activity practices.
AB  - RESULTS: After CAGB, 14 (47%) patients classified as sedentary before surgery were practicing exercises (p = 0.03). Seventeen (59%) sedentary patients in the preoperative period presented complications after the surgery compared to 8 (31%) active patients (p = 0.04). The hospital length of stay among sedentary patients versus active patients before surgery was 15 (SD=8) and 12 (SD=5) days; p=0.03, respectively.
AB  - CONCLUSION: The present study showed the importance of physical activity practice in the preoperative stage on the outcomes of coronary artery bypass surgery. The patients physically active had a shorter hospital length of stay and a lower number of both trans- and postoperative complications within 1 year. The cardiac surgery promoted the patients' change of habits, increasing the number of physically active patients during the 1-year follow-up.
ES  - 1678-9741
IL  - 0102-7638
PT  - Journal Article
LG  - English
LG  - Portuguese
DP  - 2007 Jul-Sep
DC  - 20071224
YR  - 2007
ED  - 20080926
RD  - 20120402
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18157415

<522. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18760136
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Davy JM
AU  - Herold M
AU  - Hoglund C
AU  - Timmermans A
AU  - Alings A
AU  - Radzik D
AU  - Van Kempen L
AU  - ERATO Study Investigators
FA  - Davy, Jean-Marc
FA  - Herold, Martin
FA  - Hoglund, Christer
FA  - Timmermans, Alphons
FA  - Alings, Antonio
FA  - Radzik, David
FA  - Van Kempen, Louis
FA  - ERATO Study Investigators
IN  - Davy,Jean-Marc. Cardiology Department, University Hospital, CHU Montpellier, Montpellier, France.
IR  - Heidbuchel H
IR  - Blankoff I
IR  - De Roy L
IR  - Vancura V
IR  - Herold M
IR  - Polasek R
IR  - Aumont MC
IR  - Charbonnier B
IR  - Gay A
IR  - Davy JM
IR  - Lascault G
IR  - Ferrari G
IR  - Pedretti R
IR  - Giustiniani S
IR  - Margonato A
IR  - Tramarin R
IR  - Bracke FA
IR  - Meeder JG
IR  - Savalle LH
IR  - Van Gelder IC
IR  - Van Kempen LH
IR  - Kirchhof CJ
IR  - Bos RJ
IR  - Timmermans AJ
IR  - Alings AM
IR  - Boersma LV
IR  - De Ruiter GS
IR  - Leenders CM
IR  - Tracz W
IR  - Dluzniewski M
IR  - Wojciechowski D
IR  - Moro C
IR  - Salvador A
IR  - Moya A
IR  - Hoglund C
IR  - Lonnberg I
IR  - Englund A
IR  - Moccetti T
IR  - Leizorovicz A
IR  - Chimienti M
IR  - Ponikowski P
TI  - Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study.
SO  - American Heart Journal. 156(3):527.e1-9, 2008 Sep.
AS  - Am Heart J. 156(3):527.e1-9, 2008 Sep.
NJ  - American heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 0370465
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Amiodarone/ae [Adverse Effects]
MH  - *Amiodarone/aa [Analogs & Derivatives]
MH  - Amiodarone/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Circadian Rhythm
MH  - Double-Blind Method
MH  - Exercise
MH  - Female
MH  - Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Internationality
MH  - Male
MH  - Middle Aged
MH  - Physical Endurance
MH  - Time Factors
MH  - Treatment Outcome
MH  - *Ventricular Function/de [Drug Effects]
AB  - BACKGROUND: Dronedarone is a new multichannel blocker for atrial fibrillation (AF) previously demonstrated to have both rhythm and rate control properties in paroxysmal and persistent AF. The Efficacy and safety of dRonedArone for The cOntrol of ventricular rate during atrial fibrillation (ERATO) trial assessed the efficacy of dronedarone in the control of ventricular rate in patients with permanent AF, when added to standard therapy.
AB  - METHODS: In this randomized, double-blind, multinational trial, dronedarone, 400 mg twice a day (n = 85), or matching placebo (n = 89) was administered for 6 months to adult patients with permanent AF, in addition to standard therapy. The primary end point was the change in mean ventricular rate between baseline and day 14, as assessed by 24-hour Holter. Ventricular rate was also assessed during submaximal and maximal exercise.
AB  - RESULTS: Dronedarone significantly decreased mean 24-hour ventricular rate. Compared with placebo, the mean treatment effect at day 14 was a reduction of 11.7 beats per minute (beat/min; P < .0001). Comparable reductions were sustained throughout the 6-month trial. During maximal exercise and compared to placebo, there was a mean reduction of 24.5 beat/min (P < .0001), without any reduction in exercise tolerance as measured by maximal exercise duration. The effects of dronedarone were additive to those of other rate-control agents, including beta-blockers, calcium antagonists, and digoxin. Dronedarone was well tolerated, with no organ toxicities or proarrhythmia.
AB  - CONCLUSION: In addition to its reported rhythm-targeting and rate-targeting therapeutic actions in paroxysmal and persistent AF, dronedarone improves ventricular rate control in patients with permanent AF. Dronedarone was well tolerated with no evidence of organ toxicities or proarrhythmias in this short-term study.
RN  - JQZ1L091Y2 (dronedarone)
RN  - N3RQ532IUT (Amiodarone)
ES  - 1097-6744
IL  - 0002-8703
DO  - http://dx.doi.org/10.1016/j.ahj.2008.06.010
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
LG  - English
DP  - 2008 Sep
DC  - 20080901
YR  - 2008
ED  - 20080925
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18760136

<523. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18616066
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - MacIntyre B
AU  - Hamilton J
AU  - Fricke T
AU  - Ma W
AU  - Mehle S
AU  - Michel M
FA  - MacIntyre, Barb
FA  - Hamilton, Jane
FA  - Fricke, Theresa
FA  - Ma, Wenjun
FA  - Mehle, Susan
FA  - Michel, Matt
IN  - MacIntyre,Barb. Cardiovascular Telemetry, HealthEast Saint Joseph's Hospital, St Paul, Minnesota, USA.
TI  - The efficacy of healing touch in coronary artery bypass surgery recovery: a randomized clinical trial.
SO  - Alternative Therapies in Health & Medicine. 14(4):24-32, 2008 Jul-Aug.
AS  - Altern Ther Health Med. 14(4):24-32, 2008 Jul-Aug.
NJ  - Alternative therapies in health and medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9502013, clw
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Anxiety/et [Etiology]
MH  - *Anxiety/pc [Prevention & Control]
MH  - *Coronary Artery Bypass/rh [Rehabilitation]
MH  - Female
MH  - *Holistic Health
MH  - Humans
MH  - Length of Stay/sn [Statistics & Numerical Data]
MH  - Male
MH  - Middle Aged
MH  - Pain Measurement/mt [Methods]
MH  - Pain, Postoperative/th [Therapy]
MH  - Patient Satisfaction
MH  - *Postoperative Care/mt [Methods]
MH  - *Postoperative Complications/th [Therapy]
MH  - Recovery of Function
MH  - *Therapeutic Touch/mt [Methods]
MH  - Treatment Outcome
AB  - CONTEXT: The use of complementary therapies in conjunction with conventional care has great potential to address patient pain, complication rates, and recovery time. Few studies of such therapies have been conducted in hospital settings where some of the most stressful procedures are performed on a regular basis.
AB  - OBJECTIVE: We hypothesized that patients receiving healing touch (HT) would see improved outcomes.
AB  - DESIGN: Patients were randomized into 1 of 3 treatment groups: no intervention, partial intervention (visitors), and an HT group.
AB  - SETTING: This study was conducted in an acute-care hospital in a large metropolitan area.
AB  - PATIENTS OR OTHER PARTICIPANTS: Patients undergoing first-time elective coronary artery bypass surgery were invited to participate. There were 237 study subjects.
AB  - INTERVENTION: HT is an energy-based therapeutic approach to healing that arose out of nursing in the early 1980s. HT aids relaxation and supports the body's natural healing process.
AB  - MAIN OUTCOME MEASURES: This study consisted of 6 outcome measures: postoperative length of stay, incidence of postoperative atrial fibrillation, use of anti-emetic medication, amount of narcotic pain medication, functional status, and anxiety.
AB  - RESULTS: Analysis was conducted for all patients and separately by inpatient/outpatient status. Though no significant decrease in the use of pain medication, anti-emetic medication, or incidence of atrial fibrillation was observed, significant differences were noted in anxiety scores and length ofstay. All HT patients showed a greater decrease in anxiety scores when compared to the visitor and control groups. In addition, there was a significant difference in outpatient HT length of stay when compared to the visitor and control groups.
IS  - 1078-6791
IL  - 1078-6791
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 2008 Jul-Aug
DC  - 20080711
YR  - 2008
ED  - 20080923
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18616066

<524. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18456418
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Swanson DR
FA  - Swanson, Don R
IN  - Swanson,Don R. Division of the Humanities, The University of Chicago, 1115 E 58th Street, Walker 003, Chicago, Illinois 60637, United States. swanson@uchicago.edu
TI  - Running, esophageal acid reflux, and atrial fibrillation: a chain of events linked by evidence from separate medical literatures.
SO  - Medical Hypotheses. 71(2):178-85, 2008 Aug.
AS  - Med Hypotheses. 71(2):178-85, 2008 Aug.
NJ  - Medical hypotheses
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - m0m, 7505668
OI  - Source: NLM. NIHMS59880
OI  - Source: NLM. PMC3690799
SB  - Index Medicus
CP  - Scotland
MH  - *Atrial Fibrillation/co [Complications]
MH  - Databases, Bibliographic
MH  - Electrocardiography
MH  - Esophagus/me [Metabolism]
MH  - Exercise
MH  - *Gastroesophageal Reflux/co [Complications]
MH  - Humans
MH  - Models, Biological
MH  - Models, Theoretical
MH  - Proton Pump Inhibitors/pd [Pharmacology]
MH  - *Running
AB  - Using a previously described approach to generating novel medical hypotheses, this paper shows how two separate medical literatures taken together can suggest new information not apparent in either literature alone. Many studies have demonstrated that aerobic exercise in healthy people can induce esophageal acidic reflux that increases with the duration and intensity of exercise. Separately, independently of exercise, it has been shown that, in patients with gastroesophageal reflux, esophageal acid exposure can lead to atrial fibrillation (AF) and to other heart dysrhythmias. The two arguments together suggest that a regimen of excessive exercise may be conducive to AF mediated by acid reflux, an implicit, but unpublished, hypothesis. Proton pump inhibitors are widely used to treat gastroesophageal reflux. Remarkably, several small clinical trials of these drugs have been shown also to reduce symptoms and frequency of AF episodes in patients with comorbid acid reflux. Plausible mechanisms have been suggested. These small-scale tests in a highly restricted population may be of particular interest in the light of a possible exercise-reflux-AF causal chain of events in a broader population of athletes. Because the minimum degree of esophageal acidity exposure required to induce AF is unknown, further tests of proton pump inhibitors for that purpose are therefore merited without regard to any known prior reflux in a population of runners with lone AF. The prospect of reducing AF burden with a relatively benign agent is attractive in view of the limited options for effective treatment otherwise available. The study of arrhythmia and esophageal reflux in athletes may offer insights on the origin and natural history of lone atrial fibrillation.
RN  - 0 (Proton Pump Inhibitors)
IS  - 0306-9877
IL  - 0306-9877
DO  - http://dx.doi.org/10.1016/j.mehy.2008.02.017
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
NO  - R01 LM007292 (United States NLM NIH HHS)
NO  - R01 LM007292-05 (United States NLM NIH HHS)
LG  - English
EP  - 20080505
DP  - 2008 Aug
DC  - 20080630
YR  - 2008
ED  - 20080919
RD  - 20140903
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18456418

<525. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18366240
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Fodale V
AU  - La Monaca E
FA  - Fodale, Vincenzo
FA  - La Monaca, Enza
IN  - Fodale,Vincenzo. Department of Neurosciences, Psychiatric and Anaesthesiological Sciences, University of Messina, Messina, Italy. vfodale@unime.it
TI  - Propofol infusion syndrome: an overview of a perplexing disease. [Review] [67 refs]
CM  - Comment in: Drug Saf. 2010 Jan 1;33(1):81; PMID: 20025084
SO  - Drug Safety. 31(4):293-303, 2008.
AS  - Drug Saf. 31(4):293-303, 2008.
NJ  - Drug safety
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - ahq, 9002928
SB  - Index Medicus
CP  - New Zealand
MH  - Acidosis/ci [Chemically Induced]
MH  - *Anesthetics, Intravenous/ae [Adverse Effects]
MH  - Arrhythmias, Cardiac/ci [Chemically Induced]
MH  - Heart Failure/ci [Chemically Induced]
MH  - Hepatomegaly/ci [Chemically Induced]
MH  - Humans
MH  - *Hypnotics and Sedatives/ae [Adverse Effects]
MH  - *Propofol/ae [Adverse Effects]
MH  - Renal Insufficiency/ci [Chemically Induced]
MH  - Rhabdomyolysis/ci [Chemically Induced]
MH  - Risk Factors
MH  - Syndrome
AB  - Propofol (2, 6-diisopropylphenol) is a potent intravenous hypnotic agent that is widely used in adults and children for sedation and the induction and maintenance of anaesthesia. Propofol has gained popularity for its rapid onset and rapid recovery even after prolonged use, and for the neuroprotection conferred. However, a review of the literature reveals multiple instances in which prolonged propofol administration (>48 hours) at high doses (>4 mg/kg/h) may cause a rare, but frequently fatal complication known as propofol infusion syndrome (PRIS). PRIS is characterized by metabolic acidosis, rhabdomyolysis of both skeletal and cardiac muscle, arrhythmias (bradycardia, atrial fibrillation, ventricular and supraventricular tachycardia, bundle branch block and asystole), myocardial failure, renal failure, hepatomegaly and death. PRIS has been described as an 'all or none' syndrome with sudden onset and probable death. The literature does not provide evidence of degrees of symptoms, nor of mildness or severity of signs in the clinical course of the syndrome. Recently, a fatal case of PRIS at a low infusion rate (1.9-2.6 mg/kg/h) has been reported. Common laboratory and instrumental findings in PRIS are myoglobinuria, downsloping ST-segment elevation, an increase in plasma creatine kinase, troponin I, potassium, creatinine, azotaemia, malonylcarnitine and C5-acylcarnitine, whereas in the mitochondrial respiratory electron transport chain, the activity of complex IV and cytochrome oxidase ratio is reduced. Propofol should be used with caution for sedation in critically ill children and adults, as well as for long-term anesthesia in otherwise healthy patients, and doses exceeding 4-5 mg/kg/h for long periods (>48 h) should be avoided. If PRIS is suspected, propofol must be stopped immediately and cardiocirculatory stabilization and correction of metabolic acidosis initiated. So, PRIS must be kept in mind as a rare, but highly lethal, complication of propofol use, not necessarily confined to its prolonged use. Furthermore, the safe dosage of propofol may need re-evaluation, and new studies are needed. [References: 67]
RN  - 0 (Anesthetics, Intravenous)
RN  - 0 (Hypnotics and Sedatives)
RN  - YI7VU623SF (Propofol)
IS  - 0114-5916
IL  - 0114-5916
PT  - Case Reports
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2008
DC  - 20080327
YR  - 2008
ED  - 20080826
RD  - 20141117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18366240

<526. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18560289
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lindquist R
AU  - Sendelbach S
AU  - Windenburg DC
AU  - Vanwormer A
AU  - Treat-Jacobson D
AU  - Chose D
FA  - Lindquist, Ruth
FA  - Sendelbach, Sue
FA  - Windenburg, Denise C
FA  - Vanwormer, Arin
FA  - Treat-Jacobson, Diane
FA  - Chose, David
IN  - Lindquist,Ruth. University of Minnesota School of Nursing, Minneapolis, MN 55455, USA. lindq002@umn.edu
TI  - Challenges of implementing a feasibility study of acupuncture in acute and critical care settings.
SO  - AACN Advanced Critical Care. 19(2):202-10, 2008 Apr-Jun.
AS  - AACN Adv Crit Care. 19(2):202-10, 2008 Apr-Jun.
NJ  - AACN advanced critical care
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101269322
SB  - Nursing Journal
CP  - United States
MH  - *Acupuncture
MH  - Acute Disease
MH  - *Critical Care
MH  - Feasibility Studies
MH  - Pilot Projects
AB  - A majority of people in the United States use complementary and alternative therapies, and this use is increasing. With the increasing interest, providers must evaluate potential risks and benefits of these therapies. This article describes challenges of a feasibility study of acupuncture as a potential therapeutic adjunct to prevent atrial fibrillation following coronary artery bypass graft surgery. Institutional review board approval, consent logistics, implementation issues, and rapid changes in clinical practice were the primary challenges faced. Unique technological features of the institution helped address these challenges. The study protocol was acceptable to staff, patients, and family and was considered safe for these patients. However, the protocol was not feasible as designed; therefore, the efficacy of acupuncture could not be determined. Continued research is needed to evaluate the effectiveness of acupuncture to prevent atrial fibrillation following coronary artery bypass graft surgery. Recommendations for future studies of complementary and alternative therapies in acute and critical care settings are offered.
IS  - 1559-7768
IL  - 1559-7768
DO  - http://dx.doi.org/10.1097/01.AACN.0000318123.56759.1c
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
NO  - P20 NR008992 (United States NINR NIH HHS)
LG  - English
DP  - 2008 Apr-Jun
DC  - 20080618
YR  - 2008
ED  - 20080805
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18560289

<527. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18502947
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Sudlow C
FA  - Sudlow, Cathie
IN  - Sudlow,Cathie. Division of Clinical Neurosciences, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, UK. cathie.sudlow@ed.ac.uk
TI  - Preventing further vascular events after a stroke or transient ischaemic attack: an update on medical management. [Review] [63 refs]
SO  - Practical Neurology. 8(3):141-57, 2008 Jun.
AS  - Pract. neurol.. 8(3):141-57, 2008 Jun.
NJ  - Practical neurology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101130961
SB  - Index Medicus
CP  - England
MH  - Blood Pressure/de [Drug Effects]
MH  - *Cardiovascular Agents/tu [Therapeutic Use]
MH  - Cholesterol/me [Metabolism]
MH  - Fibrinolytic Agents
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use]
MH  - *Ischemic Attack, Transient/co [Complications]
MH  - Myocardial Infarction/et [Etiology]
MH  - Myocardial Infarction/pc [Prevention & Control]
MH  - Recurrence
MH  - Risk Factors
MH  - *Stroke/co [Complications]
MH  - *Vascular Diseases/et [Etiology]
MH  - *Vascular Diseases/pc [Prevention & Control]
AB  - After a stroke or transient ischaemic attack (TIA) there is a high risk of stroke, particularly in the early days and weeks, and of other serious vascular events. Several preventive medical treatments can reduce these risks; starting them as early as possible will maximise the absolute risk reduction, as long as the diagnosis is secure, there is no known or suspected net harm from treatment, and they are acceptable to the patient. Medical treatments with clear evidence of benefit include: lowering blood pressure after all types of stroke or TIA; lowering blood cholesterol with a statin after ischaemic stroke or TIA; antiplatelet treatment after ischaemic stroke or TIA; and warfarin instead of antiplatelet treatment in patients with ischaemic stroke or TIA who have atrial fibrillation and no contraindications to anticoagulation. Lifestyle changes (for example, stopping smoking, reducing excess alcohol intake, adopting a healthy diet) and careful management of diabetes are also important. [References: 63]
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 97C5T2UQ7J (Cholesterol)
ES  - 1474-7766
IL  - 1474-7758
DO  - http://dx.doi.org/10.1136/jnnp.2008.148064
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
NO  - 063668 (United Kingdom Wellcome Trust)
NO  - 063688 (United Kingdom Wellcome Trust)
LG  - English
DP  - 2008 Jun
DC  - 20080526
YR  - 2008
ED  - 20080722
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18502947

<528. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18356799
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Valaskatgis P
AU  - Macklin EA
AU  - Schachter SC
AU  - Wayne PM
FA  - Valaskatgis, Peter
FA  - Macklin, Eric A
FA  - Schachter, Steven C
FA  - Wayne, Peter M
IN  - Valaskatgis,Peter. New England School of Acupuncture, Newton, MA, USA. peterval@comcast.net
TI  - Possible effects of acupuncture on atrial fibrillation and post-herpetic neuralgia--a case report.
SO  - Acupuncture in Medicine. 26(1):51-6, 2008 Mar.
AS  - Acupunct Med. 26(1):51-6, 2008 Mar.
NJ  - Acupuncture in medicine : journal of the British Medical Acupuncture Society
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - dz2, 9304117
SB  - Index Medicus
CP  - England
MH  - Acupuncture Analgesia
MH  - *Acupuncture Therapy/mt [Methods]
MH  - Aged
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Cardiac Pacing, Artificial/ae [Adverse Effects]
MH  - Facial Pain/et [Etiology]
MH  - *Facial Pain/th [Therapy]
MH  - Female
MH  - Humans
MH  - Neuralgia, Postherpetic/co [Complications]
MH  - *Neuralgia, Postherpetic/th [Therapy]
MH  - Treatment Outcome
AB  - A 72 year old female with a main complaint of severe post-herpetic neuralgia and a secondary complaint of atrial fibrillation (AF) received two series of acupuncture treatments totalling 20 treatments over a four month period. Her standard medical treatment remained unchanged. The primary focus of the acupuncture was pain relief; however, two acupuncture points (PC6, SP4) were included in both treatment series because of possible effects on both costal or chest pain and cardiac arrhythmias, according to Traditional Chinese Medicine (TCM) teaching and limited research. As recorded by her pacemaker, estimated weekly episodes of AF in the patient decreased significantly, and percentage time in AF decreased with borderline statistical significance, from the pretreatment estimates during the second series of treatments (weekly AF episode estimates: pretreatment=71.4; second series=16.5, difference estimates=-54.9, 95% CI -6.5 to -103.3, P=0.02; percentage time in AF estimates: pretreatment=30.6; 2 second series=18.0, difference estimates=-12.6, 95% CI 0.9 to -26.0, P=0.08). The pain levels were also significantly reduced following the acupuncture treatment series by more than 67%. Further studies are warranted to further explore these observations of a possible effect of acupuncture on both atrial fibrillation and post-herpetic neuralgia.
IS  - 0964-5284
IL  - 0964-5284
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, P.H.S.
NO  - 5 U19 AT002022-02 (United States NCCIH NIH HHS)
LG  - English
DP  - 2008 Mar
DC  - 20080321
YR  - 2008
ED  - 20080722
RD  - 20150615
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18356799

<529. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18540146
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Novoa R
AU  - Hammonds T
FA  - Novoa, Roberto
FA  - Hammonds, Tracy
IN  - Novoa,Roberto. Aultman Heart Center, Aultman Health Foundation, Canton, OH 44714, USA. rnovoa@neo.rr.com
TI  - Clinical hypnosis for reduction of atrial fibrillation after coronary artery bypass graft surgery.
SO  - Cleveland Clinic Journal of Medicine. 75 Suppl 2:S44-7, 2008 Mar.
AS  - Cleve Clin J Med. 75 Suppl 2:S44-7, 2008 Mar.
NJ  - Cleveland Clinic journal of medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - dbn, 8703441
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - Atrial Fibrillation/th [Therapy]
MH  - Autonomic Nervous System/pp [Physiopathology]
MH  - Case-Control Studies
MH  - *Coronary Artery Bypass/ae [Adverse Effects]
MH  - Female
MH  - Humans
MH  - *Hypnosis
MH  - Incidence
MH  - Male
MH  - Retrospective Studies
MH  - Risk Factors
AB  - The belief that postoperative atrial fibrillation (PAF) results from transient autonomic dysfunction suggests that interventions such as clinical hypnosis may reduce the incidence of PAF. To explore this hypothesis, we retrospectively compared outcomes between two groups of patients undergoing coronary artery bypass graft surgery: 50 consecutive patients who received preoperative hypnoidal explanation of the surgical procedure and 50 case-matched historical controls who received no clinical hypnosis. The patients who received hypnosis were significantly less likely to experience an episode of PAF (P = .003) and showed nonsignificant trends toward superior outcomes in terms of length of stay, narcotic use, and total hospital charges. Our findings indicate that prospective randomized trials are warranted to further delineate the potential benefit of clinical hypnosis for prevention of PAF.
IS  - 0891-1150
IL  - 0891-1150
PT  - Journal Article
LG  - English
DP  - 2008 Mar
DC  - 20080610
YR  - 2008
ED  - 20080718
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18540146

<530. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18474276
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Pashkow FJ
AU  - Watumull DG
AU  - Campbell CL
FA  - Pashkow, Fredric J
FA  - Watumull, David G
FA  - Campbell, Charles L
IN  - Pashkow,Fredric J. John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA. fpashkow@cardaxpharma.com
TI  - Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. [Review] [51 refs]
SO  - American Journal of Cardiology. 101(10A):58D-68D, 2008 May 22.
AS  - Am J Cardiol. 101(10A):58D-68D, 2008 May 22.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Animals
MH  - Antioxidants/pd [Pharmacology]
MH  - *Antioxidants/tu [Therapeutic Use]
MH  - *Cardiovascular Diseases/dt [Drug Therapy]
MH  - Cardiovascular Diseases/et [Etiology]
MH  - Cardiovascular Diseases/me [Metabolism]
MH  - Endothelium, Vascular/de [Drug Effects]
MH  - Endothelium, Vascular/me [Metabolism]
MH  - Humans
MH  - *Inflammation/dt [Drug Therapy]
MH  - Inflammation/me [Metabolism]
MH  - Inflammation Mediators/me [Metabolism]
MH  - *Oxidative Stress/de [Drug Effects]
MH  - Reactive Nitrogen Species/me [Metabolism]
MH  - Reactive Oxygen Species/me [Metabolism]
MH  - Xanthophylls/pd [Pharmacology]
MH  - *Xanthophylls/tu [Therapeutic Use]
AB  - Oxidative stress and inflammation are implicated in several different manifestations of cardiovascular disease (CVD). They are generated, in part, from the overproduction of reactive oxygen species (ROS) and reactive nitrogen species (RNS) that activate transcriptional messengers, such as nuclear factor-kappaB, tangibly contributing to endothelial dysfunction, the initiation and progression of atherosclerosis, irreversible damage after ischemic reperfusion, and even arrhythmia, such as atrial fibrillation. Despite this connection between oxidative stress and CVD, there are currently no recognized therapeutic interventions to address this important unmet need. Antioxidants that provide a broad, "upstream" approach via ROS/RNS quenching or free radical chain breaking seem an appropriate therapeutic option based on epidemiologic, dietary, and in vivo animal model data. However, human clinical trials with several different well-known agents, such as vitamin E and beta-carotene, have been disappointing. Does this mean antioxidants as a class are ineffective, or rather that the "right" compound(s) have yet to be found, their mechanisms of action understood, and their appropriate targeting and dosages determined? A large class of potent naturally-occurring antioxidants exploited by nature-the oxygenated carotenoids (xanthophylls)-have demonstrated utility in their natural form but have eluded development as successful targeted therapeutic agents up to the present time. This article characterizes the mechanism by which this novel group of antioxidants function and reviews their preclinical development. Results from multiple species support the antioxidant/anti-inflammatory properties of the prototype compound, astaxanthin, establishing it as an appropriate candidate for development as a therapeutic agent for cardiovascular oxidative stress and inflammation. [References: 51]
RN  - 0 (Antioxidants)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Reactive Nitrogen Species)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Xanthophylls)
RN  - 8XPW32PR7I (astaxanthine)
IS  - 0002-9149
IL  - 0002-9149
DO  - http://dx.doi.org/10.1016/j.amjcard.2008.02.010
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2008 May 22
DC  - 20080513
YR  - 2008
ED  - 20080702
RD  - 20121115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18474276

<531. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18507543
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wiegand U
AU  - Nuernberg M
AU  - Maier SK
AU  - Weiss C
AU  - Sancho-Tello MJ
AU  - Hartmann A
AU  - Schuchert A
AU  - Maier P
AU  - Chan NY
FA  - Wiegand, Uwe
FA  - Nuernberg, Michael
FA  - Maier, Sebastian K G
FA  - Weiss, Christian
FA  - Sancho-Tello, Maria-Jose
FA  - Hartmann, Andreas
FA  - Schuchert, Andreas
FA  - Maier, Petra
FA  - Chan, Ngai-Yin
IN  - Wiegand,Uwe. University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany. uwe.wiegand@uk-sh.de
TI  - The COGNITION study rationale and design: influence of closed loop stimulation on cognitive performance in pacemaker patients.
SO  - Pacing & Clinical Electrophysiology. 31(6):709-13, 2008 Jun.
AS  - Pacing Clin Electrophysiol. 31(6):709-13, 2008 Jun.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - pab, 7803944
SB  - Index Medicus
CP  - United States
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - Atrial Fibrillation/px [Psychology]
MH  - *Biofeedback, Psychology/mt [Methods]
MH  - *Cognition Disorders/pc [Prevention & Control]
MH  - *Cognition Disorders/px [Psychology]
MH  - Germany/ep [Epidemiology]
MH  - Humans
MH  - *Pacemaker, Artificial/px [Psychology]
MH  - *Pacemaker, Artificial/sn [Statistics & Numerical Data]
MH  - *Randomized Controlled Trials as Topic
AB  - BACKGROUND: Several studies showed the beneficial effect of pacemaker implantation on cognitive performance in patients with bradycardia. But it has never been investigated if patients with chronotropic incompetence may improve their cognitive performance if treated by a rate-adaptive system reacting to mental stress in comparison to the most frequently used accelerometer-driven pacing.
AB  - METHODS: The randomized, single-blind, multicenter COGNITION study evaluates if closed loop stimulation (CLS) offers incremental benefit in the speed of cognitive performance and the overall well-being of elderly patients with bradycardia compared with accelerometer-based pacing. Four hundred chronotropically incompetent patients older than 55 years will be randomized 3-6 weeks after implantation to CLS or accelerometer sensor. Follow-up visits are performed after 12 and 24 months. The speed of cognitive performance, which is the underlying function influencing all other aspects of cognitive performance, will be assessed by the number connection test, a standardized psychometric test for the elderly. Secondary endpoints include patient self-assessment of different aspects of health (by visual analogue scales), quality of life (by SF-8 health survey), the incidence of atrial fibrillation (episodes lasting for longer than 24 hours), and the frequency of serious adverse events.
AB  - CONCLUSION: In the ongoing COGNITION study, we aim at long-term comparison of two rate-adaptive systems, focusing on the cognitive performance of the patients, which was neglected in the past evaluation of pacemaker sensors.
ES  - 1540-8159
IL  - 0147-8389
DO  - http://dx.doi.org/10.1111/j.1540-8159.2008.01075.x
PT  - Journal Article
LG  - English
DP  - 2008 Jun
DC  - 20080529
YR  - 2008
ED  - 20080627
RD  - 20091119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18507543

<532. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18399102
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Testini M
AU  - Marzaioli R
AU  - Gurrado A
AU  - Lissidini G
AU  - Piccinni G
FA  - Testini, Mario
FA  - Marzaioli, Rinaldo
FA  - Gurrado, Angela
FA  - Lissidini, Germana
FA  - Piccinni, Giuseppe
IN  - Testini,Mario. Section of General and Thoracic Surgery, Department of Applications in Surgery of Innovative Technologies, University of Bari, Bari, Italy. mario.testini@tin.it
TI  - Massive mesenteric ischemia resulting from a giant strangulated umbilical hernia.
SO  - International Surgery. 92(5):296-9, 2007 Sep-Oct.
AS  - Int Surg. 92(5):296-9, 2007 Sep-Oct.
NJ  - International surgery
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - gup, 0043524
SB  - Index Medicus
CP  - Italy
MH  - Aged
MH  - *Colon/bs [Blood Supply]
MH  - Colon/su [Surgery]
MH  - Female
MH  - *Hernia, Umbilical/co [Complications]
MH  - Hernia, Umbilical/su [Surgery]
MH  - Humans
MH  - *Intestine, Small/bs [Blood Supply]
MH  - Intestine, Small/su [Surgery]
MH  - *Ischemia/et [Etiology]
MH  - Ischemia/su [Surgery]
MH  - *Mesentery/bs [Blood Supply]
MH  - Mesentery/su [Surgery]
MH  - *Peritoneal Diseases/et [Etiology]
MH  - Peritoneal Diseases/su [Surgery]
AB  - Hernia repair is the most commonly practiced operation in the departments of surgery in developed countries. Huge abdominal hernias are uncommon in western civilization. We present a rare case of a 73-year-old woman with a diagnosis at admission of intestinal obstruction caused by a giant strangulated umbilical hernia. At the clinical and radiological examination, the patient showed an enormous strangulated umbilical hernia with acute abdomen, atrial fibrillation, and pulmonary subedema. Emergency laparotomy showed a huge peritoneal umbilical sac containing massive mesenteric ischemia starting from 40 cm after the Treitz ligament and extended to the right colonic flexure. A near-total resection of the small bowel, a right colectomy with double terminal stomas, and a direct hernia repair without prosthetic mesh were performed. Twenty days after the operation, the patient was discharged and begun domiciliary total parenteral nutrition, and 24 months after surgical treatment she is still alive.
IS  - 0020-8868
IL  - 0020-8868
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2007 Sep-Oct
DC  - 20080410
YR  - 2007
ED  - 20080624
RD  - 20091111
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18399102

<533. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18390875
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Molina L
AU  - Mont L
AU  - Marrugat J
AU  - Berruezo A
AU  - Brugada J
AU  - Bruguera J
AU  - Rebato C
AU  - Elosua R
FA  - Molina, Lluis
FA  - Mont, Lluis
FA  - Marrugat, Jaume
FA  - Berruezo, Antonio
FA  - Brugada, Josep
FA  - Bruguera, Jordi
FA  - Rebato, Carolina
FA  - Elosua, Roberto
IN  - Molina,Lluis. Cardiology Department, Hospital del Mar, Passeig Maritim 25-29, 08003 Barcelona, Spain. lmolina@imas.imim.es
TI  - Long-term endurance sport practice increases the incidence of lone atrial fibrillation in men: a follow-up study.
SO  - Europace. 10(5):618-23, 2008 May.
AS  - Europace. 10(5):618-23, 2008 May.
NJ  - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - dxd, 100883649
SB  - Index Medicus
CP  - England
MH  - Adult
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - *Exercise
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - *Physical Endurance
MH  - *Physical Fitness
MH  - Retrospective Studies
MH  - *Risk Assessment/mt [Methods]
MH  - Risk Factors
MH  - *Running/sn [Statistics & Numerical Data]
MH  - Spain/ep [Epidemiology]
AB  - AIMS: The aim of this study is to determine the incidence of lone atrial fibrillation (LAF) in males according to sport practice and to identify possible clinical markers related to LAF among marathon runners.
AB  - METHODS AND RESULTS: A retrospective cohort study was designed. A group of marathon runners (n = 252) and a population-based sample of sedentary men (n = 305) recruited in 1990-92 and 1994-96, respectively, were contacted in 2002-03 and invited to attend an outpatient clinic to identify suggestive symptoms of having experienced an arrhythmia requiring medical attention. In those with suggestive symptoms of atrial fibrillation, medical records were reviewed. Finally, LAF was diagnosed on the basis of the presence of atrial fibrillation in an electrocardiographic recording. In the group of marathon runners, an echocardiogram was performed at inclusion and at the end of the study. The annual incidence rate of LAF among marathon runners and sedentary men was 0.43/100 and 0.11/100, respectively. Endurance sport practice was associated with a higher risk of incident LAF in the multivariate age- and blood pressure-adjusted Cox regression models (hazard ratio = 8.80; 95% confidence interval: 1.26-61.29). In the group of marathon runners, left atrial inferosuperior diameter and left atrial volume were both associated with a higher risk of incident LAF.
AB  - CONCLUSION: Long-term endurance sport practice is associated with a higher risk of symptomatic LAF in men. This risk is associated with a larger left atrial inferosuperior diameter and volume in physically active subjects.
ES  - 1532-2092
IL  - 1099-5129
DO  - http://dx.doi.org/10.1093/europace/eun071
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20080404
DP  - 2008 May
DC  - 20080429
YR  - 2008
ED  - 20080528
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18390875

<534. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18375472
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Johansson B
AU  - Houltz B
AU  - Berglin E
AU  - Brandrup-Wognsen G
AU  - Karlsson T
AU  - Edvardsson N
FA  - Johansson, Birgitta
FA  - Houltz, Birgitta
FA  - Berglin, Eva
FA  - Brandrup-Wognsen, Gunnar
FA  - Karlsson, Thomas
FA  - Edvardsson, Nils
IN  - Johansson,Birgitta. Department of Cardiology, Sahlgrenska University Hospital, S-413 45 Goteborg, Sweden. birgitta.ingrid.johansson@vgregion.se
TI  - Short-term sinus rhythm predicts long-term sinus rhythm and clinical improvement after intraoperative ablation of atrial fibrillation.
SO  - Europace. 10(5):610-7, 2008 May.
AS  - Europace. 10(5):610-7, 2008 May.
NJ  - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - dxd, 100883649
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/su [Surgery]
MH  - *Catheter Ablation
MH  - Combined Modality Therapy
MH  - *Coronary Artery Bypass
MH  - Female
MH  - *Heart Rate
MH  - Humans
MH  - Intraoperative Care/mt [Methods]
MH  - Longitudinal Studies
MH  - Male
MH  - *Outcome Assessment (Health Care)/mt [Methods]
MH  - *Quality of Life
MH  - Treatment Outcome
AB  - AIMS: Our aim was to compare the long-term effects on rhythm and quality of life (QoL) after left atrial epicardial radiofrequency (RF) ablation vs. no ablation in patients undergoing cardiac surgery.
AB  - METHODS AND RESULTS: Thirty-nine patients with ECG documented atrial fibrillation (AF) scheduled for coronary artery bypass grafting (CABG) with or without concomitant valve surgery were consecutively elected for epicardial RF ablation. Thirty-nine age- and gender-matched patients scheduled for CABG with or without concomitant valve surgery only and with documented AF served as controls. The follow-up after ablation was 32 +/- 11 months. The percentage of patients in sinus rhythm (SR) at long-term follow-up was 62 vs. 33% (P = 0.03) after ablation and no ablation, respectively. SR at 3 months was highly predictive of that at 32 months (sensitivity 95%, positive predictive value 86%). Long-term SR was associated with better QoL, fewer symptoms, higher ejection fraction, and smaller left and right atria than AF.
AB  - CONCLUSION: SR at 3 months was highly predictive of long-term SR that was associated with clinical improvement when compared with patients still in AF. AF at 3 months did not preclude a later stabilization to SR.
ES  - 1532-2092
IL  - 1099-5129
DO  - http://dx.doi.org/10.1093/europace/eun066
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20080328
DP  - 2008 May
DC  - 20080429
YR  - 2008
ED  - 20080528
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18375472

<535. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18439172
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Yildiz M
AU  - Pazarli P
AU  - Semiz O
AU  - Kahyaoglu O
AU  - Sakar I
AU  - Altinkaynak S
FA  - Yildiz, Mustafa
FA  - Pazarli, Pinar
FA  - Semiz, Olcay
FA  - Kahyaoglu, Osman
FA  - Sakar, Ismail
FA  - Altinkaynak, Sevin
IN  - Yildiz,Mustafa. Sakarya University School of Health, Sakarya, Turkey. mustafayilldiz@yahoo.com
TI  - Assessment of P-wave dispersion on 12-lead electrocardiography in students who exercise regularly.
SO  - Pacing & Clinical Electrophysiology. 31(5):580-3, 2008 May.
AS  - Pacing Clin Electrophysiol. 31(5):580-3, 2008 May.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - pab, 7803944
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - *Body Mass Index
MH  - *Electrocardiography/mt [Methods]
MH  - *Exercise/ph [Physiology]
MH  - Female
MH  - *Heart Conduction System/ph [Physiology]
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - *Physical Fitness/ph [Physiology]
MH  - Sensitivity and Specificity
MH  - Sex Factors
MH  - *Students/sn [Statistics & Numerical Data]
AB  - BACKGROUND: P-wave dispersion, an electrocardiographic marker, is an independent predictor of atrial fibrillation. P-wave dispersion is associated with inhomogeneous and discontinuous propagation of sinus impulses. The aim of this study was to investigate P-wave dispersion in students who apply for registration to School of Physical Education and Sports.
AB  - METHODS: Totally 984 students (810 boys [mean age: 19.8 +/- 2.0 years] and 174 girls [mean age: 19.0 +/- 1.8 years]) who applied for registration to School of Physical Education and Sports with a training history of some years were included in the study. P-wave duration was calculated in all 12 leads of the surface electrocardiography, which were simultaneously recorded. The difference between P maximum and P minimum durations was defined as P-wave dispersion.
AB  - RESULTS: Age, body mass index (BMI), systolic blood pressure, diastolic blood pressure, P-wave maximal duration, and P-wave dispersion were increased in boys as compared with girls. Of age (P = 0.53), systolic blood pressure (P = 0.42), diastolic blood pressure (P = 0.50), pulse pressure (P = 0.73), gender, heart rate, and BMI tested with univariate linear regression analysis in all subjects; only gender (P < 0.001), BMI (P = 0.01), and heart rate (P = 0.02) were associated with P-wave dispersion (F = 5.16, P < 0.001, R(2)= 0.03).
AB  - CONCLUSIONS: P-wave dispersion was increased in boys as compared with girls who exercise regularly. P-wave dispersion is affected by gender, BMI, and heart rate in healthy students.
ES  - 1540-8159
IL  - 0147-8389
DO  - http://dx.doi.org/10.1111/j.1540-8159.2008.01044.x
PT  - Journal Article
LG  - English
DP  - 2008 May
DC  - 20080428
YR  - 2008
ED  - 20080528
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18439172

<536. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18071013
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Olson LJ
AU  - Arruda-Olson AM
AU  - Somers VK
AU  - Scott CG
AU  - Johnson BD
FA  - Olson, Lyle J
FA  - Arruda-Olson, Adelaide M
FA  - Somers, Virend K
FA  - Scott, Christopher G
FA  - Johnson, Bruce D
IN  - Olson,Lyle J. Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA. olson.lyle@mayo.edu
TI  - Exercise oscillatory ventilation: instability of breathing control associated with advanced heart failure.
SO  - Chest. 133(2):474-81, 2008 Feb.
AS  - Chest. 133(2):474-81, 2008 Feb.
NJ  - Chest
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - 0231335, d1c
OI  - Source: NLM. NIHMS87716
OI  - Source: NLM. PMC2768383
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - *Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Female
MH  - *Heart Failure/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Oxygen Consumption
MH  - Pulmonary Gas Exchange
MH  - *Pulmonary Ventilation/ph [Physiology]
MH  - *Respiration Disorders/pp [Physiopathology]
AB  - BACKGROUND: Instability of breathing control due to heart failure (HF) manifests as exercise oscillatory ventilation (EOV). Prior descriptions of patients with EOV have not been controlled and have been limited to subjects with left ventricular ejection fraction (LVEF) of <or= 0.40. The aim of this study was to compare clinical characteristics including ventilatory responses of subjects with EOV to those of control subjects with HF matched for LVEF.
AB  - METHODS: Subjects (n = 47) were retrospectively identified from 1,340 consecutive patients referred for cardiopulmonary exercise testing. Study inclusion required EOV without consideration of LVEF while control subjects (n = 47) were composed of HF patients with no EOV matched for LVEF. Characteristics for each group were summarized and compared.
AB  - RESULTS: For EOV subjects, the mean LVEF was 0.37 (range, 0.11 to 0.70), and 19 subjects (41%) had an LVEF of >or= 0.40. Compared to control subjects, EOV subjects had increased left atrial dimension, mitral E-wave velocity, and right heart pressures as well as decreased exercise tidal volume response, functional capacity, rest and exercise end-tidal carbon dioxide, and increased ventilatory equivalent for carbon dioxide and dead space ventilation (all p < 0.05). Multivariate analysis demonstrated atrial fibrillation (odds ratio, 6.7; p = 0.006), digitalis therapy (odds ratio, 0.27; p = 0.02), New York Heart Association class (odds ratio, 3.5; p = 0.0006), rest end-tidal carbon dioxide (odds ratio, 0.87; p = 0.005), and peak heart rate (odds ratio, 0.98; p = 0.02) were independently associated with EOV.
AB  - CONCLUSIONS: Patients with EOV have clinical characteristics and exercise ventilatory responses consistent with more advanced HF than patients with comparable LV systolic function; EOV may occur in HF patients with an LVEF of >or= 0.40.
IS  - 0012-3692
IL  - 0012-3692
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
NO  - HL-65175 (United States NHLBI NIH HHS)
NO  - HL-70302 (United States NHLBI NIH HHS)
NO  - HL-73211 (United States NHLBI NIH HHS)
NO  - HL71478 (United States NHLBI NIH HHS)
NO  - HL71478S1 (United States NHLBI NIH HHS)
NO  - R03 AG031347 (United States NIA NIH HHS)
NO  - R03 AG031347-01 (United States NIA NIH HHS)
LG  - English
EP  - 20071210
DP  - 2008 Feb
DC  - 20080206
YR  - 2008
ED  - 20080328
RD  - 20140904
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18071013

<537. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18195171
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Djousse L
AU  - Gaziano JM
FA  - Djousse, Luc
FA  - Gaziano, J Michael
IN  - Djousse,Luc. Division of Aging, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont St, Third Floor, Boston MA 02120, USA. ldjousse@rics.bwh.harvard.edu
TI  - Egg consumption and risk of heart failure in the Physicians' Health Study.
SO  - Circulation. 117(4):512-6, 2008 Jan 29.
AS  - Circulation. 117(4):512-6, 2008 Jan 29.
NJ  - Circulation
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - daw, 0147763
OI  - Source: NLM. NIHMS95256
OI  - Source: NLM. PMC2706003
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cohort Studies
MH  - *Eggs/ae [Adverse Effects]
MH  - Eggs/sn [Statistics & Numerical Data]
MH  - Feeding Behavior
MH  - Follow-Up Studies
MH  - Heart Failure/ep [Epidemiology]
MH  - *Heart Failure/et [Etiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Physicians
MH  - Prospective Studies
MH  - Risk Factors
MH  - Surveys and Questionnaires
AB  - BACKGROUND: Reduction in dietary cholesterol is widely recommended for the prevention of cardiovascular disease. Although eggs are important sources of dietary cholesterol and other nutrients, little is known about the association between egg consumption and heart failure (HF) risk.
AB  - METHODS AND RESULTS: In a prospective cohort study of 21 275 participants from the Physicians' Health Study I, we examined the association between egg consumption and the risk of HF. Egg consumption was assessed with the use of a simple abbreviated food questionnaire, and we used Cox regression to estimate relative risks of HF. After an average follow-up of 20.4 years, a total of 1084 new HF cases occurred in this cohort. Although egg consumption up to 6 times per week was not associated with incident HF, egg consumption of > or = 7 per week was associated with an increased risk of HF. Compared with subjects who reported egg consumption of < 1 per week, hazard ratios (95% confidence intervals) for HF were 1.28 (1.02 to 1.61) and 1.64 (1.08 to 2.49) for egg consumption of 1 per day and > or = 2 per day, respectively, after adjustment for age, body mass index, smoking, alcohol consumption, exercise, and history of atrial fibrillation, hypertension, valvular heart disease, and hypercholesterolemia. Similar results were obtained for HF without antecedent myocardial infarction.
AB  - CONCLUSIONS: Our data suggest that infrequent egg consumption is not associated with the risk of HF. However, egg consumption of > or = 1 per day is related to an increased risk of HF among US male physicians.
ES  - 1524-4539
IL  - 0009-7322
DO  - http://dx.doi.org/10.1161/CIRCULATIONAHA.107.734210
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
NO  - CA-34944 (United States NCI NIH HHS)
NO  - CA-40360 (United States NCI NIH HHS)
NO  - HL-26490 (United States NHLBI NIH HHS)
NO  - HL-34595 (United States NHLBI NIH HHS)
NO  - K01 HL-70444 (United States NHLBI NIH HHS)
NO  - R01 CA034944 (United States NCI NIH HHS)
NO  - R01 CA034944-03 (United States NCI NIH HHS)
NO  - R01 CA040360 (United States NCI NIH HHS)
NO  - R01 CA040360-17 (United States NCI NIH HHS)
NO  - R01 CA097193 (United States NCI NIH HHS)
NO  - R01 CA097193-07 (United States NCI NIH HHS)
NO  - R01 HL026490 (United States NHLBI NIH HHS)
NO  - R01 HL026490-03 (United States NHLBI NIH HHS)
NO  - R01 HL034595 (United States NHLBI NIH HHS)
NO  - R01 HL034595-07 (United States NHLBI NIH HHS)
LG  - English
EP  - 20080114
DP  - 2008 Jan 29
DC  - 20080129
YR  - 2008
ED  - 20080326
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18195171

<538. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18277797
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Jacobsen D
AU  - Sevin C
FA  - Jacobsen, Diane
FA  - Sevin, Cory
IN  - Jacobsen,Diane. Institute for Healthcare Improvement, Cambridge, Massachusetts, USA. djacobsen@ihi.org
TI  - Improved care for patients with congestive heart failure.
SO  - Joint Commission Journal on Quality & Patient Safety. 34(1):13-9, 2008 Jan.
AS  - Jt Comm J Qual Patient Saf. 34(1):13-9, 2008 Jan.
NJ  - Joint Commission journal on quality and patient safety / Joint Commission Resources
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101238023
SB  - Index Medicus
CP  - United States
MH  - Aftercare/st [Standards]
MH  - *Evidence-Based Medicine
MH  - Family
MH  - Health Behavior
MH  - Health Promotion
MH  - Heart Failure/dt [Drug Therapy]
MH  - *Heart Failure/pc [Prevention & Control]
MH  - *Hospitals/st [Standards]
MH  - Humans
MH  - Organizational Objectives
MH  - *Patient Discharge/st [Standards]
MH  - Patient Participation
MH  - Patient Transfer
MH  - *Quality Assurance, Health Care/mt [Methods]
MH  - United States
AB  - BACKGROUND: Congestive heart failure (CHF) affects 4.9 million people, mostly elderly, in the United States; 550,000 new cases are diagnosed each year. Evidence-based treatment approaches offer opportunities to reduce mortality, complications, and rehospitalization rates.
AB  - STRATEGIES TO IMPROVE CARE FOR PATIENTS WITH CONGESTIVE HEART FAILURE: Seven key components of care tailored to the patient's clinical condition and comorbidities that should be provided to all patients with CHF, in the absence of contraindications or intolerance: (1) left ventricular systolic function assessment, (2) angiotension-converting enzyme-inhibitor or angiotensin receptor blockers at discharge for CHF patients with systolic dysfunction (left ventricular ejection fraction < 40%), (3) anticoagulation at discharge for CHF patients with chronic or recurrent atrial fibrillation, (4) smoking cessation advice and counseling, (5) discharge instructions that address activity level, diet, discharge medications, follow-up appointment, weight monitoring, and what to do if symptoms worsen, (6) influenza immunization (seasonal), and (7) pneumococcal immunization. Hospitals should also consider beta-blocker therapy at discharge for stabilized patients without contraindications.
AB  - CONCLUSION: The 5 Million Lives Campaign's focus on delivering reliable, evidence-based care for patients with CHF is part of an overall strategy to reduce medically induced harm.
IS  - 1553-7250
IL  - 1553-7250
PT  - Journal Article
LG  - English
DP  - 2008 Jan
DC  - 20080218
YR  - 2008
ED  - 20080325
RD  - 20130715
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18277797

<539. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18268171
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Sahlin C
AU  - Sandberg O
AU  - Gustafson Y
AU  - Bucht G
AU  - Carlberg B
AU  - Stenlund H
AU  - Franklin KA
FA  - Sahlin, Carin
FA  - Sandberg, Olov
FA  - Gustafson, Yngve
FA  - Bucht, Gosta
FA  - Carlberg, Bo
FA  - Stenlund, Hans
FA  - Franklin, Karl A
IN  - Sahlin,Carin. Department of Respiratory Medicine, Umea University Hospital, SE-901 85 Umea, Sweden.
TI  - Obstructive sleep apnea is a risk factor for death in patients with stroke: a 10-year follow-up.
SO  - Archives of Internal Medicine. 168(3):297-301, 2008 Feb 11.
AS  - Arch Intern Med. 168(3):297-301, 2008 Feb 11.
NJ  - Archives of internal medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0372440, 7fs
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Risk Factors
MH  - Sleep Apnea, Obstructive/et [Etiology]
MH  - *Sleep Apnea, Obstructive/mo [Mortality]
MH  - Stroke/co [Complications]
MH  - *Stroke/mo [Mortality]
MH  - Survival Analysis
AB  - BACKGROUND: Sleep apnea occurs frequently among patients with stroke, but it is still unknown whether a diagnosis of sleep apnea is an independent risk factor for mortality. We aimed to investigate whether obstructive or central sleep apnea was related to reduced long-term survival among patients with stroke.
AB  - METHODS: Of 151 patients admitted for in-hospital stroke rehabilitation in the catchment area of Umea from April 1, 1995, to May 1, 1997, 132 underwent overnight sleep apnea recordings at a mean (SD) of 23 (8) days after the onset of stroke. All patients were followed up prospectively for a mean (SD) of 10.0 (0.6) years, with death as the primary outcome; no one was lost to follow-up. Obstructive sleep apnea was defined when the obstructive apnea-hypopnea index was 15 or greater, and central sleep apnea was defined when the central apnea-hypopnea index was 15 or greater. Patients with obstructive and central apnea-hypopnea indexes of less than 15 served as control subjects.
AB  - RESULTS: Of 132 enrolled patients, 116 had died at follow-up. The risk of death was higher among the 23 patients with obstructive sleep apnea than controls (adjusted hazard ratio, 1.76; 95% confidence interval, 1.05-2.95; P = .03), independent of age, sex, body mass index, smoking, hypertension, diabetes mellitus, atrial fibrillation, Mini-Mental State Examination score, and Barthel index of activities of daily living. There was no difference in mortality between the 28 patients with central sleep apnea and controls (adjusted hazard ratio, 1.07; 95% confidence interval, 0.65-1.76; P = .80).
AB  - CONCLUSIONS: Patients with stroke and obstructive sleep apnea have an increased risk of early death. Central sleep apnea was not related to early death among the present patients.
IS  - 0003-9926
IL  - 0003-9926
DO  - http://dx.doi.org/10.1001/archinternmed.2007.70
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2008 Feb 11
DC  - 20080212
YR  - 2008
ED  - 20080306
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18268171

<540. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17939037
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Myers J
FA  - Myers, Jonathan
IN  - Myers,Jonathan. Cardiology Division (111C), VA Palo Alto Health Care System, Stanford University, 3801 Miranda Ave., Palo Alto, CA 94304, USA. drj993@aol.com
TI  - Principles of exercise prescription for patients with chronic heart failure. [Review] [46 refs]
SO  - Heart Failure Reviews. 13(1):61-8, 2008 Feb.
AS  - Heart Fail Rev. 13(1):61-8, 2008 Feb.
NJ  - Heart failure reviews
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - dyu, 9612481
SB  - Index Medicus
CP  - United States
MH  - Electrocardiography, Ambulatory
MH  - Exercise Test
MH  - Exercise Therapy/ct [Contraindications]
MH  - *Exercise Therapy/mt [Methods]
MH  - Exercise Tolerance
MH  - *Heart Failure/rh [Rehabilitation]
MH  - Heart Transplantation/rh [Rehabilitation]
MH  - Humans
MH  - Weight Lifting
AB  - Chronic heart failure (CHF) is a common and debilitating condition characterized by reduced exercise tolerance. While exercise training was once thought to be contraindicated for patients with CHF, a substantial body of data has been published over the last two decades to support the use of exercise programs for these patients. Improvements in exercise capacity, quality of life, and mortality have been demonstrated among patients with CHF who have participated in formal exercise programs. Exercise prescription is a means of assessing and interpreting clinical information and applying the principles of training to develop an appropriate regimen so that these benefits are achieved. The major principles of the exercise prescription are the mode, frequency, duration, and intensity. Importantly, safe and effective exercise prescription for patients with CHF requires more than the application of these principles; it also requires careful consideration of the individual patients' functional status, comorbid conditions, medications, contraindications, and personal goals and preferences. Recent studies have demonstrated that a wide spectrum of patients with CHF benefit from appropriately applied exercise training, including those with both systolic and diastolic dysfunction, atrial fibrillation, pacemakers, implantable cardioversion devices, and post-cardiac transplantation. Increasingly, the principles of exercise prescription are included as a component of comprehensive CHF management programs. Evidence has accumulated that CHF patients who participate in rehabilitation programs have better health outcomes in terms of reduced morbidity and mortality, as well as lower hospitalization rates and lower overall health care costs. [References: 46]
IS  - 1382-4147
IL  - 1382-4147
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2008 Feb
DC  - 20071214
YR  - 2008
ED  - 20080306
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17939037

<541. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18213749
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Politte LL
FA  - Politte, Lenard L
TI  - Life in moderation.
CM  - Comment on: Mo Med. 2007 Jan-Feb;104(1):4-6; PMID: 17410815
SO  - Missouri Medicine. 104(6):492, 2007 Nov-Dec.
AS  - Mo Med. 104(6):492, 2007 Nov-Dec.
NJ  - Missouri medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - new, 0400744
SB  - Index Medicus
CP  - United States
MH  - *Atrial Fibrillation
MH  - Attitude to Health
MH  - *Clinical Competence
MH  - *Exercise
MH  - Humans
MH  - Physical Endurance
MH  - *Practice Patterns, Physicians'
MH  - *Retirement
IS  - 0026-6620
IL  - 0026-6620
PT  - Comment
PT  - Letter
LG  - English
DP  - 2007 Nov-Dec
DC  - 20080123
YR  - 2007
ED  - 20080212
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18213749

<542. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17965491
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Choi EY
AU  - Shim J
AU  - Kim SA
AU  - Shim CY
AU  - Yoon SJ
AU  - Kang SM
AU  - Choi D
AU  - Ha JW
AU  - Rim SJ
AU  - Jang Y
AU  - Chung N
FA  - Choi, Eui-Young
FA  - Shim, Jaemin
FA  - Kim, Sung-Ai
FA  - Shim, Chi Young
FA  - Yoon, Se-Jung
FA  - Kang, Seok-Min
FA  - Choi, Donghoon
FA  - Ha, Jong-Won
FA  - Rim, Se-Joong
FA  - Jang, Yangsoo
FA  - Chung, Namsik
IN  - Choi,Eui-Young. Cardiology Division, Yonsei Cardiovascular Center and Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, South Korea.
TI  - Value of echo-Doppler derived pulmonary vascular resistance, net-atrioventricular compliance and tricuspid annular velocity in determining exercise capacity in patients with mitral stenosis.
SO  - Circulation Journal. 71(11):1721-7, 2007 Nov.
AS  - Circ J. 71(11):1721-7, 2007 Nov.
NJ  - Circulation journal : official journal of the Japanese Circulation Society
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101137683
SB  - Index Medicus
CP  - Japan
MH  - Adult
MH  - *Atrioventricular Node/ph [Physiology]
MH  - Blood Flow Velocity/ph [Physiology]
MH  - Echocardiography, Doppler
MH  - Exercise Test
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Lung Compliance/ph [Physiology]
MH  - Male
MH  - Middle Aged
MH  - *Mitral Valve Stenosis/pp [Physiopathology]
MH  - *Tricuspid Valve/ph [Physiology]
MH  - *Vascular Resistance/ph [Physiology]
MH  - *Ventricular Function, Right/ph [Physiology]
AB  - BACKGROUND: The present study sought to determine if echo-Doppler-derived pulmonary vascular resistance (PVR echo), net-atrioventricular compliance (Cn) and tricuspid peak systolic annular velocity (Sa), as parameters of right ventricular function, have value in predicting exercise capacity in patients with mitral stenosis (MS).
AB  - METHODS AND RESULTS: Thirty-two patients with moderate or severe MS without left ventricular systolic dysfunction were studied. After comprehensive echo-Doppler measurements, including PVR echo, tricuspid Sa and left-sided Cn, supine bicycle exercise echo and concomitant respiratory gas analysis were performed. Measurements during 5 cardiac cycles representing the mean heart rate were averaged. Increment of resting PVR(echo) (r=-0.416, p=0.018) and decrement of resting Sa (r=0.433, p=0.013) and Cn (r=0.469, p=0.007) were significantly associated with decrease in %VO(2) peak. The predictive accuracy for %VO2 peak could increase by combining these parameters as Sa/PVR echo (r=0.500, p=0.004) or Cn. (Sa/PVR echo) (r=0.572, p=0.001) independent of mitral valve area, mean diastolic pressure gradients or presence of atrial fibrillation.
AB  - CONCLUSIONS: Measurement of PVR echo, Cn and Sa might provide important information about the exercise capacity of patients with MS.
IS  - 1346-9843
IL  - 1346-9843
PT  - Clinical Trial
PT  - Journal Article
LG  - English
DP  - 2007 Nov
DC  - 20071029
YR  - 2007
ED  - 20080212
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17965491

<543. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17982305
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Spodick DH
AU  - Ariyarajah V
AU  - Apiyasawat S
FA  - Spodick, David H
FA  - Ariyarajah, Vignendra
FA  - Apiyasawat, Sirin
IN  - Spodick,David H. Division of Cardiovascular Medicine, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA.
TI  - Higher prevalence of cardiovascular events among patients with abnormal atrial depolarization and coronary artery disease at 18 months' post-exercise tolerance testing.
SO  - American Heart Hospital Journal. 5(4):236-40, 2007.
AS  - Am Heart Hosp J. 5(4):236-40, 2007.
NJ  - The American heart hospital journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101156064
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Arrhythmias, Cardiac/co [Complications]
MH  - Arrhythmias, Cardiac/pp [Physiopathology]
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Cardiovascular Diseases/ep [Epidemiology]
MH  - Cardiovascular Diseases/et [Etiology]
MH  - Coronary Artery Disease/co [Complications]
MH  - Coronary Artery Disease/pp [Physiopathology]
MH  - *Exercise Test
MH  - *Exercise Tolerance
MH  - Female
MH  - Health Status Indicators
MH  - *Heart Atria/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Manitoba/ep [Epidemiology]
MH  - Middle Aged
MH  - Prevalence
MH  - Prognosis
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
AB  - Abnormal atrial depolarization, denoted as interatrial block (IAB; P wave >110 ms), is associated with myocardial ischemia during exercise. The authors conducted an 18-month follow-up for cardiovascular events in 31 consecutive patients with IAB and 60 controls without IAB at rest; participants had coronary artery disease and hypertension and had undergone coronary angiography following positive exercise tolerance test (ETT) results. Atrial fibrillation and need for repeat ETT and coronary artery revascularization were significant with IAB (77.4% vs 20%; P<.001). In patients with such events, IAB, left atrial dilatation, left ventricular hypertrophy, increased left ventricular end-diastolic volume, poorer Duke prognostic treadmill (DPT) scores, and significant coronary artery stenoses were predominant. IAB (hazard ratio [HR], 4.9; 95% confidence interval [CI], 1.3-19.7; P=.02) and DPT scores (HR, 0.84; 95% CI, 0.72-0.98; P=.03) were independently associated with these events. At 18 months' follow-up, IAB at rest was associated with cardiovascular events among those with known coronary artery disease and hypertension.
IS  - 1541-9215
IL  - 1541-9215
PT  - Journal Article
LG  - English
DP  - 2007
DC  - 20071105
YR  - 2007
ED  - 20080208
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17982305

<544. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17823860
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kobza R
AU  - Auf der Maur C
AU  - Kurtz C
AU  - Hoffmann A
AU  - Allgayer B
AU  - Erne P
FA  - Kobza, Richard
FA  - Auf der Maur, Christoph
FA  - Kurtz, Claudia
FA  - Hoffmann, Alexander
FA  - Allgayer, Bernhard
FA  - Erne, Paul
IN  - Kobza,Richard. Division of Cardiology, Kantonsspital Luzern, 6000, Luzern 16, Switzerland.
TI  - Esophagus imaging for radiofrequency ablation of atrial fibrillation using a dual-source computed tomography system: preliminary observations.
SO  - Journal of Interventional Cardiac Electrophysiology. 19(3):167-70, 2007 Sep.
AS  - J Interv Card Electrophysiol. 19(3):167-70, 2007 Sep.
NJ  - Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - c8k, 9708966
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Atrial Fibrillation
MH  - *Cardiology/mt [Methods]
MH  - Case-Control Studies
MH  - Catheter Ablation
MH  - Electrophysiology
MH  - *Esophagus/pa [Pathology]
MH  - Heart/ah [Anatomy & Histology]
MH  - Heart Atria/pa [Pathology]
MH  - Humans
MH  - Image Processing, Computer-Assisted
MH  - Imaging, Three-Dimensional
MH  - Middle Aged
MH  - Models, Anatomic
MH  - *Tomography, X-Ray Computed/mt [Methods]
AB  - OBJECTIVE: The very recent introduction of dual-source computed tomography (DSCT) has significantly improved the temporal resolution of ECG-gated multidetector-row cardiac computed tomography (CT). The aim of the present study was to evaluate whether with a DSCT visualization of the esophagus is feasible without any use of contrast in the esophagus.
AB  - MATERIALS AND METHODS: A total of 20 patients were evaluated. Ten patients underwent examination with a DSCT scanner without a gastric tube. In another ten patients, which served as control group, a CT scan was performed with a radio-opaque gastric tube prior to circumferential pulmonary vein isolation (in seven patients with a 16-slice CT and in three patients with a DSCT).
AB  - RESULTS: In the control group the gastric tube and the left atrium were reconstructed and were well visualized in all ten patients in the electro-anatomic mapping system, independently whether 16-row CT or DSCT scan was used. In the study group integration of the esophagus into the electro-anatomic mapping system was not feasible, due to the lacking contrast counterpart the surrounding tissue.
AB  - CONCLUSIONS: Even with the newest generation of DSCT scanner it is not possible to integrate the esophagus image into the 3-D electroanatomic mapping system without contrast by whatever means. However placing a conventional gastric tube before performing the CT scan allowed visualization and integration of the esophagus into the 3-D electro-anatomical map in all patients.
IS  - 1383-875X
IL  - 1383-875X
PT  - Journal Article
LG  - English
EP  - 20070906
DP  - 2007 Sep
DC  - 20071011
YR  - 2007
ED  - 20080125
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17823860

<545. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18128159
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - KNOX JA
FA  - KNOX, J A C
TI  - Some features of the response of the heart rate to exercise in patients with auricular fibrillation.
SO  - Journal of Physiology. 108(1):Proc., 13, 1949 Mar 1.
AS  - J Physiol (Lond). 108(1):Proc., 13, 1949 Mar 1.
NJ  - The Journal of physiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - jqv, 0266262
OI  - Source: CLML. 4917:89t
SB  - OLDMEDLINE Citations
CP  - Not Available
MH  - *Arrhythmias, Cardiac
MH  - *Atrial Fibrillation
MH  - *Exercise
MH  - *Heart Rate
MH  - Humans
KW  - *ARRHYTHMIA/auricular fibrillation;  *EXERCISE/effects;  *HEART/rate
IS  - 0022-3751
IL  - 0022-3751
PT  - Journal Article
LG  - English
DP  - 1949 Mar 1
DC  - 19491201
YR  - 1949
ED  - 20080117
RD  - 20140812
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=18128159

<546. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17670782
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - de Voogt W
AU  - van Hemel N
AU  - de Vusser P
AU  - Mairesse GH
AU  - van Mechelen R
AU  - Koistinen J
AU  - van den Bos A
AU  - Roose I
AU  - Voitk J
AU  - Yli-Mayry S
AU  - Stockman D
AU  - El Allaf D
AU  - Tse HF
AU  - Lau CP
FA  - de Voogt, Willem
FA  - van Hemel, Norbert
FA  - de Vusser, Philip
FA  - Mairesse, Georges H
FA  - van Mechelen, Rob
FA  - Koistinen, Juhani
FA  - van den Bos, Arjan
FA  - Roose, Indrek
FA  - Voitk, Juri
FA  - Yli-Mayry, Sinikka
FA  - Stockman, Dirk
FA  - El Allaf, Dia
FA  - Tse, Hung-Fat
FA  - Lau, Chu-Pak
IN  - de Voogt,Willem. Department of Cardiology, St Lucas Andreas Hospital, J Toorpstraat 164, 1061AE, Amsterdam, The Netherlands. w.g.devoogt@planet.nl
TI  - No evidence of automatic atrial overdrive pacing efficacy on reduction of paroxysmal atrial fibrillation.
SO  - Europace. 9(9):798-804, 2007 Sep.
AS  - Europace. 9(9):798-804, 2007 Sep.
NJ  - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - dxd, 100883649
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - Algorithms
MH  - Anti-Arrhythmia Agents/pd [Pharmacology]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Atrial Function
MH  - *Cardiac Pacing, Artificial/mt [Methods]
MH  - *Cardiology/mt [Methods]
MH  - Cross-Over Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pacemaker, Artificial
MH  - *Tachycardia, Paroxysmal/pp [Physiopathology]
MH  - *Tachycardia, Paroxysmal/th [Therapy]
MH  - Treatment Outcome
AB  - AIMS: Paroxysmal atrial fibrillation (PAF) is frequently encountered in pacemaker patients, most commonly in sick sinus syndrome. The combination of site-specific pacing in conjunction with an overdrive algorithm combined with antiarrhythmic drugs on the incidence of PAF in patients with a conventional indication for pacing is unknown.
AB  - METHODS AND RESULTS: Patients with pacemaker indication and PAF received a DDDR-pacemaker, which included an automatic atrial overdrive (AO) algorithm. The atrial lead was implanted in either the right atrial appendage (RAA) (n = 83) or the right low-atrial septum (LAS) (n = 94). The algorithm was switched on or off in a 3 month, single blind crossover design and antiarrhythmic drugs were kept stable. A control group of 96 patients (LAS, n = 14; RAA, n = 84) without PAF served as controls to assess any proarrhythmic effect of overdrive pacing. Atrial fibrillation (AF) burden defined as cumulative time in mode switch was not reduced during automatic AO from either the RAA or from the LAS. The reduction was not effective both for AF of short (<24 h) and long (> or =24 h) duration. There was no atrial proarrhythmia induced by the overdrive algorithm in the control group.
AB  - CONCLUSIONS: We could not demonstrate a reduction of AF burden defined as cumulative time in AF by the AO algorithm, in patients who are paced for standard indications and PAF, neither from the RAA nor from the LAS.
RN  - 0 (Anti-Arrhythmia Agents)
IS  - 1099-5129
IL  - 1099-5129
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20070801
DP  - 2007 Sep
DC  - 20070830
YR  - 2007
ED  - 20080114
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17670782

<547. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17971639
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gallego J
AU  - Martinez Vila E
AU  - Munoz R
FA  - Gallego, Jaime
FA  - Martinez Vila, Eduardo
FA  - Munoz, Roberto
IN  - Gallego,Jaime. Stroke Unit, Department of Neurology, Hospital de Navarra, Pamplona, Spain. jgallegoc@meditex.es
TI  - Patients at high risk for ischemic stroke: identification and actions. [Review] [127 refs]
SO  - Cerebrovascular Diseases. 24 Suppl 1:49-63, 2007.
AS  - Cerebrovasc Dis. 24 Suppl 1:49-63, 2007.
NJ  - Cerebrovascular diseases (Basel, Switzerland)
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - c2g, 9100851
SB  - Index Medicus
CP  - Switzerland
MH  - *Brain Ischemia/di [Diagnosis]
MH  - *Brain Ischemia/ep [Epidemiology]
MH  - *Diagnostic Techniques, Cardiovascular
MH  - Humans
MH  - Risk Factors
MH  - *Stroke/di [Diagnosis]
MH  - *Stroke/ep [Epidemiology]
AB  - Atherosclerosis is a disease of chronic inflammation. It is diffuse, multisystemic and affects the vascular, metabolic and immune systems. The traditional evaluation of risk is based on methods of clinical and biological assessments, and conventional imaging. The existence of symptomatic disease and the number of symptomatic sites of atherothrombosis are critical factors in predicting the recurrence of major vascular events. However, these methods are insufficient to predict near-future episodes, above all in the individual standard clinical practice. Active treatment of modifiable risk factors such as hypertension, dyslipidemia and atrial fibrillation can reduce the number of patients who develop a stroke. There is considerable evidence suggesting that a substantial proportion of the population with high blood pressure receives insufficient treatment. More active treatment of this condition is probably the most efficient single measure. Lifestyle factors such as smoking, diet, physical inactivity and obesity contribute to the relatively high incidence of stroke. There is a need to incorporate new systemic markers and new investigation techniques in the future so as to identify the individuals at risk in the population and to administer more individualized intervention therapies.Copyright 2007 S. Karger AG, Basel. [References: 127]
IS  - 1015-9770
IL  - 1015-9770
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
LG  - English
EP  - 20071101
DP  - 2007
DC  - 20071031
YR  - 2007
ED  - 20080102
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17971639

<548. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 18126543
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - KNOX JA
FA  - KNOX, J A C
TI  - The heart rate with exercise in patients with auricular fibrillation.
SO  - British Heart Journal. 11(2):119-25, 1949 Apr.
AS  - Br Heart J. 11(2):119-25, 1949 Apr.
NJ  - British heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - ats, 0370634
OI  - Source: CLML. 4917:4f
OI  - Source: NLM. PMC479362
SB  - OLDMEDLINE Citations
CP  - Not Available
MH  - *Arrhythmias, Cardiac
MH  - *Atrial Fibrillation
MH  - *Exercise
MH  - *Heart Rate
MH  - Humans
KW  - *ARRHYTHMIA/auricular fibrillation;  *EXERCISE/effects;  *HEART/rate
IS  - 0007-0769
IL  - 0007-0769
PT  - Journal Article
LG  - English
DP  - 1949 Apr
DC  - 19491201
YR  - 1949
ED  - 20071227
RD  - 20140812
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=18126543

<549. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17765625
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kistler PM
AU  - Schilling RJ
AU  - Rajappan K
AU  - Sporton SC
FA  - Kistler, Peter M
FA  - Schilling, Richard J
FA  - Rajappan, Kim
FA  - Sporton, Simon C
IN  - Kistler,Peter M. Department of Cardiology, St. Bartholomew's Hospital, London, United Kingdom.
TI  - Image integration for atrial fibrillation ablation--pearls and pitfalls. [Review] [18 refs]
SO  - Heart Rhythm. 4(9):1216-21, 2007 Sep.
AS  - Heart Rhythm. 4(9):1216-21, 2007 Sep.
NJ  - Heart rhythm : the official journal of the Heart Rhythm Society
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - 101200317
SB  - Index Medicus
CP  - United States
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/ra [Radiography]
MH  - *Atrial Fibrillation/su [Surgery]
MH  - *Catheter Ablation/mt [Methods]
MH  - Fasting
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Image Interpretation, Computer-Assisted/is [Instrumentation]
MH  - Image Interpretation, Computer-Assisted/mt [Methods]
MH  - *Pulmonary Veins/ah [Anatomy & Histology]
MH  - Pulmonary Veins/ra [Radiography]
MH  - Respiration
IS  - 1547-5271
IL  - 1547-5271
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
LG  - English
EP  - 20070425
DP  - 2007 Sep
DC  - 20070903
YR  - 2007
ED  - 20071213
RD  - 20091027
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17765625

<550. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17595231
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Husser O
AU  - Husser D
AU  - Stridh M
AU  - Sornmo L
AU  - Corino VD
AU  - Mainardi LT
AU  - Lombardi F
AU  - Klein HU
AU  - Olsson SB
AU  - Bollmann A
FA  - Husser, Oliver
FA  - Husser, Daniela
FA  - Stridh, Martin
FA  - Sornmo, Leif
FA  - Corino, Valentina D A
FA  - Mainardi, Luca T
FA  - Lombardi, Federico
FA  - Klein, Helmut U
FA  - Olsson, S Bertil
FA  - Bollmann, Andreas
IN  - Husser,Oliver. Department of Cardiology, Otto-von-Guericke University, University Hospital, Leipziger Str. 44, 39120 Magdeburg, Germany.
TI  - Exercise testing for non-invasive assessment of atrial electrophysiological properties in patients with persistent atrial fibrillation.
SO  - Europace. 9(8):627-32, 2007 Aug.
AS  - Europace. 9(8):627-32, 2007 Aug.
NJ  - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - dxd, 100883649
SB  - Index Medicus
CP  - England
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Function
MH  - *Diagnosis, Computer-Assisted/mt [Methods]
MH  - *Electrocardiography/mt [Methods]
MH  - *Exercise Test/mt [Methods]
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Recurrence
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
AB  - AIMS: Experimental studies suggest that the autonomic nervous system modulates atrial refractoriness and conduction velocity in atrial fibrillation (AF). These modulatory effects are, however, difficult to assess in the clinical setting. This study sought to non-invasively characterize in patients with persistent AF, the influence of autonomic modulation induced by exercise on atrial fibrillatory rate as marker of atrial refractoriness and to identify clinical and electrocardiographic predictors of atrial rate response.
AB  - METHODS AND RESULTS: In 24 patients (16 males, mean age 60 +/- 13 years) with persistent AF (16 +/- 25 months), continuous ECGs were recorded during bicycle exercise testing. Fibrillatory rate (in fibrillations per minute, fpm) was assessed at baseline and immediately after termination of exercise with spatiotemporal QRST cancellation and time-frequency analysis. Ventricular response was characterized by time-domain HRV indices. Exercise had no influence on mean fibrillatory rate (409 +/- 42 vs. 414 +/- 43 fpm, P = NS). Seven patients responded to exercise with an increase in fibrillatory rate (26 +/- 10 fpm, P < 0.001 and three with a decrease (-21 +/- 8 fpm, P < 0.001), while the remaining 14 patients did not show a response. Responders' HRV indices changed in response to exercise similarly to that of non-responders. Their baseline fibrillatory rate was, however, lower than that of non-responders (387 +/- 18 vs. 425 +/- 48 fpm, P = 0.028). No other clinical or echocardiographic variable was associated with fibrillatory rate response. Twelve weeks after cardioverson, responders were more likely to remain in sinus rhythm than non-responders (88 vs. 46 %, P = 0.04).
AB  - CONCLUSIONS: Exercise-induced autonomic activation produces changes in atrial electrophysiological properties that can be detected by time-frequency analysis. Higher baseline fibrillatory rates are associated with an impaired atrial response to exercise that suggests advanced electrical remodelling and reduced sensitivity to autonomic stimuli.
IS  - 1099-5129
IL  - 1099-5129
PT  - Evaluation Studies
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20070626
DP  - 2007 Aug
DC  - 20070813
YR  - 2007
ED  - 20071213
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17595231

<551. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17984380
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Feng D
AU  - Edwards WD
AU  - Oh JK
AU  - Chandrasekaran K
AU  - Grogan M
AU  - Martinez MW
AU  - Syed IS
AU  - Hughes DA
AU  - Lust JA
AU  - Jaffe AS
AU  - Gertz MA
AU  - Klarich KW
FA  - Feng, DaLi
FA  - Edwards, William D
FA  - Oh, Jae K
FA  - Chandrasekaran, Krishnaswamy
FA  - Grogan, Martha
FA  - Martinez, Matthew W
FA  - Syed, Imran S
FA  - Syed, Imran I
FA  - Hughes, Deborah A
FA  - Lust, John A
FA  - Jaffe, Allan S
FA  - Gertz, Morie A
FA  - Klarich, Kyle W
IN  - Feng,DaLi. Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
TI  - Intracardiac thrombosis and embolism in patients with cardiac amyloidosis.[Erratum appears in Circulation. 2008 Aug 19;118(8):e131 Note: Syed, Imran I [corrected to Syed, Imran S]]
SO  - Circulation. 116(21):2420-6, 2007 Nov 20.
AS  - Circulation. 116(21):2420-6, 2007 Nov 20.
NJ  - Circulation
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Amyloidosis/co [Complications]
MH  - Amyloidosis/mo [Mortality]
MH  - *Amyloidosis/pp [Physiopathology]
MH  - Databases, Factual
MH  - Female
MH  - Heart Diseases/co [Complications]
MH  - Heart Diseases/mo [Mortality]
MH  - *Heart Diseases/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Registries
MH  - Thromboembolism/co [Complications]
MH  - Thromboembolism/mo [Mortality]
MH  - *Thromboembolism/pp [Physiopathology]
AB  - BACKGROUND: Patients with primary amyloidosis (AL type) have a poor prognosis, in part due to frequent cardiac involvement. Although intracardiac thrombus has been reported in anecdotal cases, neither its frequency nor its role in causing mortality is known. Furthermore, the clinical and echocardiographic variables that may be associated with thromboembolism in cardiac amyloidosis have not been defined.
AB  - METHODS AND RESULTS: A total of 116 autopsy or explanted cases of cardiac amyloidosis (55 AL and 61 other type) were identified in the Mayo Clinic. Forty-six fatal nonamyloid trauma cases served as controls. Each heart was examined for intracardiac thrombus. The cause of death was determined from autopsy and clinical notes. Intracardiac thrombosis was identified in 38 hearts (33%). Twenty-three had 1 thrombus, whereas 15 had 2 to 5 thrombi. Although subjects in the AL group were younger and had less atrial fibrillation than those with other types of amyloidosis, the AL group had significantly more intracardiac thrombus (51% versus 16%, P<0.001) and more fatal embolic events (26% versus 8%, P<0.03). Control hearts had no intracardiac thrombus. The presence of both atrial fibrillation and AL was associated with an extremely high risk for thromboembolism (odds ratio 55.0 [95% confidence interval 8.1 to 1131.4]). By multivariate analysis, AL type (odds ratio 8.4 [95% confidence interval 1.8 to 51.2]) and left ventricular diastolic dysfunction (odds ratio 12.2 [95% confidence interval 2.7 to 72.7]) were independently associated with thromboembolism.
AB  - CONCLUSIONS: A high frequency of intracardiac thrombosis was present in cardiac amyloidosis. Furthermore, thromboembolism caused significant fatality. Several risk factors for thromboembolism were identified. Early screening, especially in high-risk patients, and early anticoagulation might reduce morbidity and mortality.
ES  - 1524-4539
IL  - 0009-7322
PT  - Comparative Study
PT  - Journal Article
LG  - English
EP  - 20071105
DP  - 2007 Nov 20
DC  - 20071120
YR  - 2007
ED  - 20071212
RD  - 20080819
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17984380

<552. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17910567
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Cheng EM
AU  - Fung CH
FA  - Cheng, Eric M
FA  - Fung, Constance H
IN  - Cheng,Eric M. Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA. eric.cheng@va.gov
TI  - Quality indicators for the care of stroke and atrial fibrillation in vulnerable elders. [Review] [73 refs]
SO  - Journal of the American Geriatrics Society. 55 Suppl 2:S431-7, 2007 Oct.
AS  - J Am Geriatr Soc. 55 Suppl 2:S431-7, 2007 Oct.
NJ  - Journal of the American Geriatrics Society
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 7503062, h6v
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Alcohol Drinking/ae [Adverse Effects]
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Carotid Stenosis/co [Complications]
MH  - Carotid Stenosis/di [Diagnosis]
MH  - Carotid Stenosis/pc [Prevention & Control]
MH  - Deglutition Disorders/di [Diagnosis]
MH  - Depression/di [Diagnosis]
MH  - Evidence-Based Medicine
MH  - Exercise
MH  - *Frail Elderly
MH  - Health Behavior
MH  - Hormone Replacement Therapy/ae [Adverse Effects]
MH  - Humans
MH  - Hyperlipidemias/co [Complications]
MH  - Hyperlipidemias/di [Diagnosis]
MH  - Hyperlipidemias/th [Therapy]
MH  - Platelet Aggregation Inhibitors/tu [Therapeutic Use]
MH  - Process Assessment (Health Care)
MH  - *Quality Indicators, Health Care
MH  - Secondary Prevention
MH  - Smoking/ae [Adverse Effects]
MH  - Stroke/et [Etiology]
MH  - *Stroke/th [Therapy]
MH  - Thrombolytic Therapy
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
IS  - 0002-8614
IL  - 0002-8614
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
LG  - English
DP  - 2007 Oct
DC  - 20071003
YR  - 2007
ED  - 20071207
RD  - 20141120
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17910567

<553. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16706956
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Szucs TD
AU  - Bramkamp M
FA  - Szucs, T D
FA  - Bramkamp, M
IN  - Szucs,T D. Institute for Social and Preventive Medicine, University of Zurich, Zurich, Switzerland. thomas.szucs@ifspm.unizh.ch
TI  - Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a review. [Review] [40 refs]
SO  - Journal of Thrombosis & Haemostasis. 4(6):1180-5, 2006 Jun.
AS  - J Thromb Haemost. 4(6):1180-5, 2006 Jun.
NJ  - Journal of thrombosis and haemostasis : JTH
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101170508
SB  - Index Medicus
CP  - England
MH  - *Anticoagulants/ec [Economics]
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/ec [Economics]
MH  - Cost-Benefit Analysis
MH  - *Health Care Costs
MH  - Humans
MH  - *Models, Economic
MH  - Quality-Adjusted Life Years
MH  - *Stroke/ec [Economics]
MH  - Stroke/et [Etiology]
MH  - Stroke/pc [Prevention & Control]
MH  - Warfarin/ec [Economics]
MH  - Warfarin/tu [Therapeutic Use]
AB  - INTRODUCTION: Atrial fibrillation (AF) increases the risk of ischemic stroke 5-fold and may not only be responsible for as many as 15% of all strokes that occur but also for larger and more disabling strokes than those attributable to other causes which increase the associated costs of care. Anticoagulation with warfarin in the target INR of 2.5 is a major clinical challenge in real-life practice, given that the complex relationship between warfarin dosage and response is readily altered by a variety of factors such as concurrent medications, illnesses, genetic influences, and dietary/lifestyle changes. Consequently, INR values are out of the target range approximately half of the time in real-life studies compared to clinical trial setting. Current anticoagulation therapies are less likely to be cost-effective in routine clinical practice and need improvement. The aim of this review is to discuss the pharmacoeconomic consequences of this management strategy by analysing the optimal treatment option within specific age and risk groups, confirming current guidelines for a health economic perspective and considering the economic impact on health care policy.
AB  - METHODS: An electronic search of the Medline/PubMed database from 1966 to 2005 was performed to identify articles dealing with all pharmacoeconomic aspects of stroke prevention in atrial fibrillation. The following search terms were used: 'atrial fibrillation', 'stroke', 'cost', 'warfarin'.
AB  - RESULTS: Treatment with warfarin is cost-effective (versus aspirin or no therapy) in patients with AF at moderate-to-high risk of stroke. The cost-effectiveness of anticoagulation therapy is driven by the achieved risk reduction rather than the potential benefits estimated from clinical trials. Failure to maintain optimal anticoagulation places patients at risk of complications, the management of which is a significant cost driver.
AB  - CONCLUSION: Improvement could be achieved by optimising physicians and patient's knowledge driven through prevention campaigns by health care policy. [References: 40]
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
IS  - 1538-7933
IL  - 1538-7836
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2006 Jun
DC  - 20060518
YR  - 2006
ED  - 20071130
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16706956

<554. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17920370
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Supino PG
AU  - Borer JS
AU  - Schuleri K
AU  - Gupta A
AU  - Hochreiter C
AU  - Kligfield P
AU  - Herrold EM
AU  - Preibisz JJ
FA  - Supino, Phyllis G
FA  - Borer, Jeffrey S
FA  - Schuleri, Karlheinz
FA  - Gupta, Anuj
FA  - Hochreiter, Clare
FA  - Kligfield, Paul
FA  - Herrold, Edmund McM
FA  - Preibisz, Jacek J
IN  - Supino,Phyllis G. Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
TI  - Prognostic value of exercise tolerance testing in asymptomatic chronic nonischemic mitral regurgitation.
CM  - Comment in: Am J Cardiol. 2008 Apr 1;101(7):1071-2; PMID: 18359341
SO  - American Journal of Cardiology. 100(8):1274-81, 2007 Oct 15.
AS  - Am J Cardiol. 100(8):1274-81, 2007 Oct 15.
NJ  - The American journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - 3dq, 0207277
OI  - Source: NLM. NIHMS32856
OI  - Source: NLM. PMC3687786
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - Cohort Studies
MH  - Echocardiography
MH  - *Exercise Tolerance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mitral Valve Insufficiency/di [Diagnosis]
MH  - *Mitral Valve Insufficiency/pp [Physiopathology]
MH  - Mitral Valve Insufficiency/us [Ultrasonography]
MH  - Predictive Value of Tests
MH  - Prospective Studies
AB  - In many heart diseases, exercise tolerance testing (ETT) has useful functional correlates and/or prognostic value. However, its predictive value in mitral regurgitation (MR) is undefined. To determine whether ETT descriptors predict death or indications for mitral valve surgery in patients with MR, we prospectively followed, for 7 +/- 3 end-point-free years, a cohort of 38 patients with chronic severe nonischemic MR who underwent modified Bruce ETT; all lacked surgical indications at study entry. Their baseline exercise descriptors were also compared with those from 46 patients with severe MR who, at entry, already had reached surgical indications. End points during follow-up in the cohort included sudden death (n = 1), heart failure symptoms (n = 2), atrial fibrillation (n = 4), left ventricular (LV) ejection fraction <60% (n = 2), LV systolic dimensions > or =45 mm (n = 12) and >40 mm (n = 11), LV ejection fraction <60% plus LV systolic dimensions > or =45 mm (n = 3), and heart failure plus LV systolic dimensions > or =45 mm plus LV ejection fraction <60% (n = 1). In univariate analysis, exercise duration (p = 0.004), chronotropic response (p = 0.007), percent predicted peak heart rate (p = 0.01), and heart rate recovery (p <0.02) predicted events; in multivariate analysis, only exercise duration was predictive (p <0.02). Average annual event risk was fivefold lower (4.62%) with an exercise duration > or =15 versus <15 minutes (average annual risk 23.48%, p = 0.004). Relative risks in patients with and without exercise-inducible ST-segment depression were comparable (< or =1.3, p = NS) whether defined at entry and/or during follow-up. Exercise duration, but not prevalence of exercise-inducible ST-segment depression, was lower (p <0.001) in patients with surgical indications at entry versus initially end-point-free patients. In conclusion, in asymptomatic patients with chronic severe nonischemic MR and no objective criteria for operation, progression to surgical indications generally is rapid. However, those with excellent exercise tolerance have a relatively benign course. Exercise-inducible ST-segment depression has no prognostic value in this population.
IS  - 0002-9149
IL  - 0002-9149
PT  - Evaluation Studies
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
NO  - R01 HL 26504 (United States NHLBI NIH HHS)
NO  - R01 HL026504-05 (United States NHLBI NIH HHS)
LG  - English
EP  - 20070723
DP  - 2007 Oct 15
DC  - 20071008
YR  - 2007
ED  - 20071127
RD  - 20140904
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17920370

<555. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17885258
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ford GA
AU  - Choy AM
AU  - Deedwania P
AU  - Karalis DG
AU  - Lindholm CJ
AU  - Pluta W
AU  - Frison L
AU  - Olsson SB
AU  - SPORTIF III, V Investigators
FA  - Ford, Gary A
FA  - Choy, Anna Maria
FA  - Deedwania, Prakash
FA  - Karalis, Dean G
FA  - Lindholm, Carl-Johan
FA  - Pluta, Wladyslaw
FA  - Frison, Lars
FA  - Olsson, S Bertil
FA  - SPORTIF III, V Investigators
IN  - Ford,Gary A. Institute for Ageing and Health, University of Newcastle upon Tyne, Newcastle upon Tyne, England.
TI  - Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials.
SO  - Stroke. 38(11):2965-71, 2007 Nov.
AS  - Stroke. 38(11):2965-71, 2007 Nov.
NJ  - Stroke; a journal of cerebral circulation
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - v2j, 0235266
SB  - Index Medicus
CP  - United States
MH  - Administration, Oral
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Alanine Transaminase/bl [Blood]
MH  - Alanine Transaminase/de [Drug Effects]
MH  - Anticoagulants/ad [Administration & Dosage]
MH  - Anticoagulants/ae [Adverse Effects]
MH  - *Atrial Fibrillation/co [Complications]
MH  - *Azetidines/ad [Administration & Dosage]
MH  - Azetidines/ae [Adverse Effects]
MH  - *Benzylamines/ad [Administration & Dosage]
MH  - Benzylamines/ae [Adverse Effects]
MH  - Cerebral Hemorrhage/ci [Chemically Induced]
MH  - Cerebral Hemorrhage/ep [Epidemiology]
MH  - Double-Blind Method
MH  - Embolism/dt [Drug Therapy]
MH  - Embolism/et [Etiology]
MH  - Embolism/pc [Prevention & Control]
MH  - Female
MH  - Humans
MH  - *Intracranial Thrombosis/dt [Drug Therapy]
MH  - Intracranial Thrombosis/et [Etiology]
MH  - Intracranial Thrombosis/pc [Prevention & Control]
MH  - Male
MH  - Middle Aged
MH  - Sex Characteristics
MH  - Sex Factors
MH  - *Stroke/dt [Drug Therapy]
MH  - Stroke/et [Etiology]
MH  - Stroke/pc [Prevention & Control]
MH  - *Thrombin/ai [Antagonists & Inhibitors]
MH  - Treatment Outcome
MH  - Up-Regulation/de [Drug Effects]
MH  - Up-Regulation/ph [Physiology]
MH  - *Warfarin/ad [Administration & Dosage]
MH  - Warfarin/ae [Adverse Effects]
AB  - BACKGROUND AND PURPOSE: Warfarin prevents stroke in atrial fibrillation (AF); however, concerns regarding international normalized ratio control and hemorrhage limit its use in the elderly. The oral direct thrombin inhibitors (DTIs) are potential alternatives to warfarin, offering fixed dosing without drug and dietary interactions and the need for international normalized ratio monitoring. Although ximelagatran, a DTI studied in the Stroke Prevention using an ORal Thrombin Inhibitor in atrial Fibrillation trials, has been withdrawn, development of other DTIs continues. We report our experience in elderly high-risk AF patients on ximelagatran compared with warfarin therapy.
AB  - METHODS: Data from patients with AF and stroke risk factors randomized in Stroke Prevention using an ORal Thrombin Inhibitor in atrial Fibrillation III and V trials to ximelagatran or warfarin were analyzed for stroke/systemic emboli, bleeding, and raised alanine aminotransferase levels in those >or=75 (n=2804) and <75 (n=4525) years.
AB  - RESULTS: Ximelagatran was as effective as warfarin in reducing stroke/systemic emboli in the elderly (2.23%/y with ximelagatran vs 2.27%/y with warfarin) as in younger patients (1.25%/y vs 1.28%/y). Total bleeds were significantly lower with ximelagatran compared with warfarin in elderly (40% vs 45%, P=0.01) and younger (27% vs 35%, P<0.001) patients. Raised alanine aminotransferase values (>3-fold elevation) among ximelagatran patients were more common in older (7.5% old vs 5.3% young) patients, particularly women (9.5% elderly women vs 6.1% elderly men).
AB  - CONCLUSIONS: In high-risk elderly AF patients, ximelagatran is as effective as warfarin with less bleeding, but alanine aminotransferase elevations are common, particularly in elderly women. Oral DTIs for stroke prevention show promise in elderly patients.
RN  - 0 (Anticoagulants)
RN  - 0 (Azetidines)
RN  - 0 (Benzylamines)
RN  - 49HFB70472 (ximelagatran)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - EC 2-6-1-2 (Alanine Transaminase)
RN  - EC 3-4-21-5 (Thrombin)
ES  - 1524-4628
IL  - 0039-2499
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
LG  - English
EP  - 20070920
DP  - 2007 Nov
DC  - 20071030
YR  - 2007
ED  - 20071126
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17885258

<556. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17954802
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Djousse L
AU  - Gaziano JM
FA  - Djousse, Luc
FA  - Gaziano, J Michael
IN  - Djousse,Luc. Division of Aging, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont St, Third Floor, Boston, MA 02120, USA. ldjousse@rics.bwh.harvard.edu
TI  - Breakfast cereals and risk of heart failure in the physicians' health study I.
SO  - Archives of Internal Medicine. 167(19):2080-5, 2007 Oct 22.
AS  - Arch Intern Med. 167(19):2080-5, 2007 Oct 22.
NJ  - Archives of internal medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0372440, 7fs
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Cardiac Output, Low/ep [Epidemiology]
MH  - Cardiac Output, Low/pc [Prevention & Control]
MH  - *Edible Grain
MH  - *Heart Failure/ep [Epidemiology]
MH  - Heart Failure/pc [Prevention & Control]
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Physicians
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Surveys and Questionnaires
AB  - BACKGROUND: Heart failure (HF) is the leading cause of hospitalization among the elderly population in the United States. Consumption of grain products and dietary fiber has been shown to reduce the risk of hypertension and myocardial infarction. However, it is not known whether a higher consumption of breakfast cereals is associated with risk of HF.
AB  - METHODS: This study evaluated prospectively the association between breakfast cereal intake and incident HF among 21 376 participants of the Physicians' Health Study I. Cereal consumption was estimated using a semiquantitative food frequency questionnaire. Incident HF was ascertained through annual follow-up questionnaires and validated using Framingham criteria. We used Cox regression models to estimate adjusted relative risk of HF across categories of cereal intake.
AB  - RESULTS: During an average follow-up of 19.6 years, 1018 incident cases of HF occurred. For average weekly cereal consumption of 0 servings, 1 or fewer, 2 to 6, and 7 or more, hazard ratios (95% confidence intervals) for HF were 1 (reference), 0.92 (0.78-1.09), 0.79 (0.67-0.93), and 0.71 (0.60-0.85), respectively (P<.001 for trend), adjusting for age, smoking, alcohol consumption, vegetable consumption, use of multivitamins, exercise, and history of atrial fibrillation, valvular heart disease, and left ventricular hypertrophy. However, the association was limited to the intake of whole grain cereals (P <.001 for trend) but not refined cereals (P = .70 for trend).
AB  - CONCLUSIONS: Our data demonstrate that a higher intake of whole grain breakfast cereals is associated with a lower risk of HF. Additional studies are warranted to confirm these findings and determine specific nutrients that are responsible for such a protection.
IS  - 0003-9926
IL  - 0003-9926
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
NO  - CA-34944 (United States NCI NIH HHS)
NO  - CA-40360 (United States NCI NIH HHS)
NO  - HL-26490 (United States NHLBI NIH HHS)
NO  - HL-34595 (United States NHLBI NIH HHS)
NO  - K01 HL-70444 (United States NHLBI NIH HHS)
NO  - R01 CA097193 (United States NCI NIH HHS)
LG  - English
DP  - 2007 Oct 22
DC  - 20071023
YR  - 2007
ED  - 20071120
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17954802

<557. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17925502
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Huang SS
AU  - Sung SH
AU  - Chiang CE
FA  - Huang, Shao-Sung
FA  - Sung, Shih-Hsien
FA  - Chiang, Chern-En
IN  - Huang,Shao-Sung. Division of Cardiology, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan.
TI  - Chitosan potentiation of warfarin effect.
SO  - Annals of Pharmacotherapy. 41(11):1912-4, 2007 Nov.
AS  - Ann Pharmacother. 41(11):1912-4, 2007 Nov.
NJ  - The Annals of pharmacotherapy
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - bbx, 9203131
SB  - Index Medicus
CP  - United States
MH  - Aged, 80 and over
MH  - Anticoagulants/ad [Administration & Dosage]
MH  - *Anticoagulants/ae [Adverse Effects]
MH  - Anticoagulants/pk [Pharmacokinetics]
MH  - Atrial Fibrillation/co [Complications]
MH  - *Chitosan/ae [Adverse Effects]
MH  - Chitosan/pd [Pharmacology]
MH  - Chronic Disease
MH  - Diabetes Mellitus, Type 2/co [Complications]
MH  - Drug Synergism
MH  - Humans
MH  - Hypertension/co [Complications]
MH  - International Normalized Ratio
MH  - Male
MH  - Self Medication
MH  - Thrombosis/dt [Drug Therapy]
MH  - Thrombosis/et [Etiology]
MH  - Vitamin K/me [Metabolism]
MH  - Vitamins/me [Metabolism]
MH  - Warfarin/ad [Administration & Dosage]
MH  - *Warfarin/ae [Adverse Effects]
MH  - Warfarin/pk [Pharmacokinetics]
AB  - OBJECTIVE: To report a case in which the anticoagulation effect of warfarin appeared to have been potentiated by chitosan, probably due to interference with the absorption of vitamin K.
AB  - CASE SUMMARY: An 83-year-old male with hypertensive cardiovascular disease, type 2 diabetes mellitus, and chronic atrial fibrillation complicated by left atrial thrombus formation was maintained on warfarin 2.5 mg/day. Marked elevation of the international normalized ratio (INR) was noticed after self-medication with chitosan 1200 mg twice daily. He denied taking any other drugs, natural substances, herbal medicines, and nutritional supplements, and stated that he had not changed his dietary habits. After parenteral administration of vitamin K and discontinuation of chitosan, the INR returned to within the target range. However, the patient took chitosan again, and the INR increased to well above the target range. Following strong medical advice, the patient stopped taking chitosan, and the INR remained stable thereafter.
AB  - DISCUSSION: Chitosan is a positively charged polymer that binds to the negatively charged lipids and bile acids in the gastrointestinal tract. It can affect the absorption of vitamins A, D, E, and K. Therefore, the anticoagulation effect of warfarin may be potentiated by chitosan through this mechanism. Use of the Naranjo probability scale revealed that the adverse effect was probably due to chitosan.
AB  - CONCLUSIONS: The interaction between warfarin and chitosan has not previously been reported. Healthcare professionals should be aware of this potential interaction.
RN  - 0 (Anticoagulants)
RN  - 0 (Vitamins)
RN  - 12001-79-5 (Vitamin K)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9012-76-4 (Chitosan)
ES  - 1542-6270
IL  - 1060-0280
PT  - Case Reports
PT  - Journal Article
LG  - English
EP  - 20071009
DP  - 2007 Nov
DC  - 20071019
YR  - 2007
ED  - 20071108
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17925502

<558. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17885315
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Macchi C
AU  - Fattirolli F
AU  - Lova RM
AU  - Conti AA
AU  - Luisi ML
AU  - Intini R
AU  - Zipoli R
AU  - Burgisser C
AU  - Guarducci L
AU  - Masotti G
AU  - Gensini GF
FA  - Macchi, Claudio
FA  - Fattirolli, Francesco
FA  - Lova, Raffaele Molino
FA  - Conti, Andrea A
FA  - Luisi, Maria Luisa Eliana
FA  - Intini, Rosanna
FA  - Zipoli, Renato
FA  - Burgisser, Costanza
FA  - Guarducci, Lorenzo
FA  - Masotti, Giulio
FA  - Gensini, Gian Franco
IN  - Macchi,Claudio. Cardiac Rehabilitation Unit, Don Gnocchi Foundation, Florence, Italy.
TI  - Early and late rehabilitation and physical training in elderly patients after cardiac surgery.
SO  - American Journal of Physical Medicine & Rehabilitation. 86(10):826-34, 2007 Oct.
AS  - Am J Phys Med Rehabil. 86(10):826-34, 2007 Oct.
NJ  - American journal of physical medicine & rehabilitation / Association of Academic Physiatrists
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 8803677, ajo
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Age Factors
MH  - Aged
MH  - *Cardiac Surgical Procedures/rh [Rehabilitation]
MH  - Early Ambulation/ae [Adverse Effects]
MH  - *Early Ambulation
MH  - *Exercise
MH  - Female
MH  - Humans
MH  - Male
MH  - Physical Therapy Modalities/ae [Adverse Effects]
MH  - *Physical Therapy Modalities
MH  - Postoperative Complications/et [Etiology]
AB  - OBJECTIVE: Few randomized trials have enrolled patients who have undergone cardiac surgery, and even fewer have included patients aged 75 yrs or more. Furthermore, the optimal timing of cardiac rehabilitation for postsurgical patients has not yet been codified. The aim of this study was to verify whether rehabilitation outcomes are also favorable in postsurgical patients aged 75 yrs or more and whether an early rehabilitation program is as effective and safe as a late one.
AB  - DESIGN: Three hundred patients who underwent cardiac surgery, 27.7% of whom were at least 75 yrs old, were randomly assigned to a rehabilitation program starting within the second week after operation or within the fourth week. All events occurring during the rehabilitation program or in the following year were recorded.
AB  - RESULTS: During the rehabilitation program, new-onset atrial fibrillation was significantly more frequent in the early rehabilitation group, independent of age class, and anemia was significantly more frequent in older patients, independent of rehabilitation timing. At the end of the rehabilitation program, more than 90% of patients showed significant increases in walking distance, and during the follow-up, no significant difference was found with regard to mortality, nonfatal events, functional ability, or control of cardiovascular risk factors, independent of rehabilitation timing and age class.
AB  - CONCLUSIONS: This study provides evidence that in selected patients who have undergone cardiac surgery, rehabilitation outcomes are also favorable in patients aged 75 yrs or more, and an early rehabilitation program is as effective and safe as a traditionally late one.
IS  - 0894-9115
IL  - 0894-9115
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2007 Oct
DC  - 20070921
YR  - 2007
ED  - 20071019
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17885315

<559. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17926872
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Littmann D
AU  - Castleman B
FA  - Littmann, D
FA  - Castleman, B
TI  - Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 19-1966. Aortic regurgitation in a fifty-eight-year-old man.
SO  - New England Journal of Medicine. 274(16):898-905, 1966 Apr 21.
AS  - N Engl J Med. 274(16):898-905, 1966 Apr 21.
NJ  - The New England journal of medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0255562, now
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aneurysm, Dissecting/et [Etiology]
MH  - *Aneurysm, Dissecting/pa [Pathology]
MH  - *Aorta/pa [Pathology]
MH  - Aortic Aneurysm/et [Etiology]
MH  - *Aortic Aneurysm/pa [Pathology]
MH  - *Aortic Valve Insufficiency/et [Etiology]
MH  - Aortic Valve Insufficiency/su [Surgery]
MH  - Atrial Fibrillation/co [Complications]
MH  - Diagnosis, Differential
MH  - Dyspnea/et [Etiology]
MH  - Electrocardiography
MH  - Fatal Outcome
MH  - Heart/ra [Radiography]
MH  - Heart Valve Prosthesis
MH  - Humans
MH  - Lung/ra [Radiography]
MH  - Male
MH  - Marfan Syndrome/co [Complications]
MH  - *Marfan Syndrome/di [Diagnosis]
MH  - Middle Aged
MH  - Tachycardia, Paroxysmal/co [Complications]
IS  - 0028-4793
IL  - 0028-4793
PT  - Case Reports
PT  - Clinical Conference
PT  - Journal Article
LG  - English
DP  - 1966 Apr 21
DC  - 20071011
YR  - 1966
ED  - 20071019
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=17926872

<560. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17660177
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Yildirim V
AU  - Doganci S
AU  - Bolcal C
AU  - Oz BS
AU  - Kucukarslan N
AU  - Cosar A
AU  - Guzeldemir ME
FA  - Yildirim, Vedat
FA  - Doganci, Suat
FA  - Bolcal, Cengiz
FA  - Oz, Bilgehan Savas
FA  - Kucukarslan, Nezihi
FA  - Cosar, Ahmet
FA  - Guzeldemir, M Erdal
IN  - Yildirim,Vedat. Department of Anesthesiology and Reanimation, Gulhane Military Academy of Medicine, Ankara, Turkey.
TI  - Combination sedoanalgesia with remifentanil and propofol versus remifentanil and midazolam for elective cardioversion after coronary artery bypass grafting.
SO  - Advances in Therapy. 24(3):662-70, 2007 May-Jun.
AS  - Adv Ther. 24(3):662-70, 2007 May-Jun.
NJ  - Advances in therapy
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - bcb, 8611864
SB  - Health Technology Assessment Journals
CP  - United States
MH  - Anesthesia Recovery Period
MH  - *Anesthetics, Intravenous/ad [Administration & Dosage]
MH  - Anesthetics, Intravenous/ae [Adverse Effects]
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Coronary Artery Bypass/ae [Adverse Effects]
MH  - Drug Combinations
MH  - *Electric Countershock
MH  - Female
MH  - Humans
MH  - Male
MH  - Midazolam/ad [Administration & Dosage]
MH  - Midazolam/ae [Adverse Effects]
MH  - *Midazolam/tu [Therapeutic Use]
MH  - Middle Aged
MH  - Patient Satisfaction
MH  - *Piperidines/ad [Administration & Dosage]
MH  - Piperidines/ae [Adverse Effects]
MH  - Propofol/ad [Administration & Dosage]
MH  - Propofol/ae [Adverse Effects]
MH  - *Propofol/tu [Therapeutic Use]
MH  - Prospective Studies
MH  - Single-Blind Method
AB  - Postoperative atrial fibrillation (AF) occurs in up to 50% of cardiac surgery patients and represents the most common postoperative arrhythmic complication. Elective cardioversion, a short but painful procedure, remains an option for patients who do not convert to sinus rhythm with medical therapy. Combinations of remifentanil (a potent analgesic with a short elimination time) with propofol (a hypnotic agent) or midazolam (a sedative agent) produce a synergistic interaction. This study was undertaken to compare these combinations in terms of effectiveness and pain relief when given as sedoanalgesia for elective cardioversion. In this prospective, randomized trial, 60 adult patients with postoperative AF after coronary artery bypass grafting were given a single dose of propofol 1 mg/kg combined with remifentanil 0.1 microg/kg (group 1), or midazolam 0.05 mg/kg combined with remifentanil 0.1 microg/kg (group 2). Cardiorespiratory parameters were monitored and recorded. Demographic data were similar (P>.05) and sufficient sedoanalgesia and successful cardioversion were achieved in both groups. Hemodynamic parameters revealed no significant differences between groups (P>.05); however, induction time, time to eye opening, recuperation time, and time to full recovery of psychomotor function were faster in group 1 than in group 2 (P<.05). The remifentanil/propofol combination provided sufficient analgesia, satisfactory hemodynamic stability, and mild respiratory depression, along with faster recovery and discharge times from the intensive care unit.
RN  - 0 (Anesthetics, Intravenous)
RN  - 0 (Drug Combinations)
RN  - 0 (Piperidines)
RN  - P10582JYYK (remifentanil)
RN  - R60L0SM5BC (Midazolam)
RN  - YI7VU623SF (Propofol)
IS  - 0741-238X
IL  - 0741-238X
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 2007 May-Jun
DC  - 20070730
YR  - 2007
ED  - 20070919
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17660177

<561. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17691948
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lombardi F
AU  - Terranova P
FA  - Lombardi, Federico
FA  - Terranova, Paolo
IN  - Lombardi,Federico. Cardiologia, Dipartimento di Medicina, Chirurgia e Odontoiatria, Osp. San Paolo, University of Milan, Milan, Italy. Federico.Lombardi@unimi.it
TI  - Anti-arrhythmic properties of N-3 poly-unsaturated fatty acids (n-3 PUFA). [Review] [113 refs]
SO  - Current Medicinal Chemistry. 14(19):2070-80, 2007.
AS  - Curr Med Chem. 14(19):2070-80, 2007.
NJ  - Current medicinal chemistry
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - c02, 9440157
SB  - Index Medicus
CP  - Netherlands
MH  - Animals
MH  - Anti-Arrhythmia Agents/ch [Chemistry]
MH  - Anti-Arrhythmia Agents/me [Metabolism]
MH  - *Anti-Arrhythmia Agents/pd [Pharmacology]
MH  - *Arrhythmias, Cardiac/dt [Drug Therapy]
MH  - Arrhythmias, Cardiac/pp [Physiopathology]
MH  - Diet
MH  - Fatty Acids, Omega-3/ch [Chemistry]
MH  - Fatty Acids, Omega-3/me [Metabolism]
MH  - *Fatty Acids, Omega-3/pd [Pharmacology]
MH  - Humans
MH  - Hypertriglyceridemia/dt [Drug Therapy]
MH  - Hypertriglyceridemia/me [Metabolism]
MH  - Ion Channels/de [Drug Effects]
MH  - Ion Channels/ph [Physiology]
MH  - Molecular Structure
AB  - Omega-3 fatty acids (Poly-Unsaturated Fatty Acids or PUFA n-3) have been initially found to reduce plasma levels of triglycerides and to increase levels of high-density lipoprotein in patients with marked hypertriglyceridemia. However, in both bench research studies and clinical trials, omega-3 fatty acid intake has recently been associated with an anti-arrhythmic efficacy. At experimental level, n-3 PUFA administration produces several actions on ionic channels regulating transmembrane action potential. At clinical level, the most significant finding was the reduction in the incidence of sudden death in survivors of MI in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevention trial and the subsequent recommendation for administration of fish oil as part of the post-infarction regimen in European guidelines. More recently, Omega-3 fatty acids administration has been associated with a lower incidence of atrial fibrillation in patients who underwent cardiac surgery. Contrasting results have been instead reported in patients with implantable cardioverter defibrillators. This article reviews in detail the basic and clinical research studies of fish oil as an anti-arrhythmic entity, the types of arrhythmias that have been beneficially affected by fish oil administration, and the presumed and known mechanisms by which the beneficial actions are exerted. [References: 113]
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Ion Channels)
IS  - 0929-8673
IL  - 0929-8673
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
LG  - English
DP  - 2007
DC  - 20070813
YR  - 2007
ED  - 20070918
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17691948

<562. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17483665
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Rosendorff C
AU  - Beeri MS
AU  - Silverman JM
FA  - Rosendorff, Clive
FA  - Beeri, Michal S
FA  - Silverman, Jeremy M
IN  - Rosendorff,Clive. Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA. clive.rosendorff@va.gov
TI  - Cardiovascular risk factors for Alzheimer's disease. [Review] [87 refs]
SO  - American Journal of Geriatric Cardiology. 16(3):143-9, 2007 May-Jun.
AS  - Am J Geriatr Cardiol. 16(3):143-9, 2007 May-Jun.
NJ  - The American journal of geriatric cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - dz4, 9215283
SB  - Index Medicus
CP  - United States
MH  - Age Factors
MH  - Aged
MH  - *Alzheimer Disease/pp [Physiopathology]
MH  - *Cardiovascular Diseases/pp [Physiopathology]
MH  - Homocysteine
MH  - Humans
MH  - Hypercholesterolemia/pp [Physiopathology]
MH  - Hypertension/pp [Physiopathology]
MH  - Risk Factors
AB  - There is now sizable literature on the association between traditional cardiovascular risk factors and Alzheimer's disease (AD). Based on epidemiologic studies, both cross-sectional and longitudinal, there are statistically significant correlations between the prevalence of AD and diabetes, hypercholesterolemia, hypertension, hyperhomocysteinemia, dietary saturated fats, cholesterol, antioxidants, alcohol consumption, smoking, physical activity, the presence of atrial fibrillation, atherosclerotic disease, and the plasma concentration of some hemostatic factors. Most of the cardiovascular risk factors found to be associated with AD are age-dependent, and the prevalence of AD increases with age. Therefore, the association could simply be attributed to aging. On the other hand, the common pathogenetic mechanisms for the generation of both atherosclerotic disease and AD, such as inflammation and the generation of free radicals, suggest a causal link. If this is the case, the identification of modifiable risk factors for dementia becomes a research priority and early intervention aimed at reducing those cardiovascular risk factors a therapeutic imperative. [References: 87]
RN  - 0LVT1QZ0BA (Homocysteine)
IS  - 1076-7460
IL  - 1076-7460
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2007 May-Jun
DC  - 20070507
YR  - 2007
ED  - 20070827
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17483665

<563. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17027102
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Parthenakis FI
AU  - Patrianakos AP
AU  - Skalidis EI
AU  - Diakakis GF
AU  - Zacharis EA
AU  - Chlouverakis G
AU  - Karalis IK
AU  - Vardas PE
FA  - Parthenakis, Frangiskos I
FA  - Patrianakos, Alexandros P
FA  - Skalidis, Emmanuel I
FA  - Diakakis, George F
FA  - Zacharis, Evangelos A
FA  - Chlouverakis, Gregory
FA  - Karalis, Ioannis K
FA  - Vardas, Panos E
IN  - Parthenakis,Frangiskos I. Department of Cardiology, Heraklion University Hospital, Crete, Greece. fparth@med.uoc.gr
TI  - Atrial fibrillation is associated with increased neurohumoral activation and reduced exercise tolerance in patients with non-ischemic dilated cardiomyopathy.
SO  - International Journal of Cardiology. 118(2):206-14, 2007 May 31.
AS  - Int J Cardiol. 118(2):206-14, 2007 May 31.
NJ  - International journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - gqw, 8200291
SB  - Index Medicus
CP  - Netherlands
MH  - *Atrial Fibrillation/bl [Blood]
MH  - *Atrial Fibrillation/et [Etiology]
MH  - *Cardiomyopathy, Dilated/co [Complications]
MH  - Cardiomyopathy, Dilated/us [Ultrasonography]
MH  - Chronic Disease
MH  - Cytokines/bl [Blood]
MH  - Exercise Test
MH  - *Exercise Tolerance
MH  - Female
MH  - *Heart Failure/et [Etiology]
MH  - *Heart Failure/pp [Physiopathology]
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptides/bl [Blood]
MH  - *Neurotransmitter Agents/bl [Blood]
MH  - Oxygen Consumption
MH  - Ventricular Function, Left
AB  - OBJECTIVES: To assess atrial fibrillation (AF) associated differences in proinflammatory cytokines, natriuretic peptide levels and exercise capacity in patients with heart failure (HF) secondary to non-ischemic dilated cardiomyopathy (NIDC).
AB  - METHODS: We studied 147 NIDC patients, mean age 58.3+/-12.5 years, left ventricular (LV) ejection fraction 27.8+/-10.9% and NYHA class II-III. Neurohumoral activation was assessed by measurement of interleukin IL-1, IL-6, tumor necrosis factor-a (TNF-a), its soluble receptors sTNFR I and II, N-terminal atrial (NT-ANP) and -brain (NT-BNP) natriuretic peptide levels, and functional class was assessed by cardiopulmonary exercise test.
AB  - RESULTS: Forty patients (27.5%) had chronic AF and they did not differ in age, LV ejection fraction or HF duration compared to patients in sinus rhythm (SR). AF was associated with increased levels of IL-6 (p=0.001), TNF-a (p=0.002), sTNFRI (p=0.023), NT-ANP (p<0.001) and NT-BNP (p=0.003), decreased exercise duration (p<0.001) and slightly reduced maximal oxygen consumption at peak exercise (p=0.07) compared to SR patients. No significant differences in cytokine and natriuretic peptide levels or exercise tolerance were noted when patients in AF were compared to the subgroup of SR with restrictive LV filling pattern. Multivariate analysis showed that NT-ANP (p=0.003) and IL-6 (p=0.006) plasma levels were independently associated with the presence of AF in our patient population.
AB  - CONCLUSION: AF is associated with increased inflammatory state, natriuretic peptide levels and reduced exercise capacity in patients with HF secondary to NIDC. These findings suggest that the presence of AF in HF represents a more advanced stage of the syndrome.
RN  - 0 (Cytokines)
RN  - 0 (Natriuretic Peptides)
RN  - 0 (Neurotransmitter Agents)
ES  - 1874-1754
IL  - 0167-5273
PT  - Comparative Study
PT  - Journal Article
LG  - English
EP  - 20061004
DP  - 2007 May 31
DC  - 20070423
YR  - 2007
ED  - 20070822
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17027102

<564. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17229055
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wittkowsky AK
AU  - Bussey HI
AU  - Walker MB
AU  - Frei CR
FA  - Wittkowsky, A K
FA  - Bussey, H I
FA  - Walker, M B
FA  - Frei, C R
TI  - Dietary supplement use among anticoagulation clinic patients.
SO  - Journal of Thrombosis & Haemostasis. 5(4):875-7, 2007 Apr.
AS  - J Thromb Haemost. 5(4):875-7, 2007 Apr.
NJ  - Journal of thrombosis and haemostasis : JTH
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - 101170508
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - Ambulatory Care Facilities
MH  - *Anticoagulants/ad [Administration & Dosage]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Dietary Supplements
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Education as Topic
MH  - Plant Preparations/ad [Administration & Dosage]
MH  - Surveys and Questionnaires
MH  - Warfarin/ad [Administration & Dosage]
RN  - 0 (Anticoagulants)
RN  - 0 (Plant Preparations)
RN  - 5Q7ZVV76EI (Warfarin)
IS  - 1538-7933
IL  - 1538-7836
PT  - Letter
LG  - English
EP  - 20070109
DP  - 2007 Apr
DC  - 20070403
YR  - 2007
ED  - 20070813
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17229055

<565. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17536123
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Nielsen FH
AU  - Milne DB
AU  - Klevay LM
AU  - Gallagher S
AU  - Johnson L
FA  - Nielsen, Forrest H
FA  - Milne, David B
FA  - Klevay, Leslie M
FA  - Gallagher, Sandra
FA  - Johnson, LuAnn
IN  - Nielsen,Forrest H. US Department of Agriculture, Agricultural Research Service, Grand Forks Human Nutrition Research Center, Grand Forks, ND 58202-9034, USA. fnielsen@gfhnrc.ars.usda.gov
TI  - Dietary magnesium deficiency induces heart rhythm changes, impairs glucose tolerance, and decreases serum cholesterol in post menopausal women.
SO  - Journal of the American College of Nutrition. 26(2):121-32, 2007 Apr.
AS  - J Am Coll Nutr. 26(2):121-32, 2007 Apr.
NJ  - Journal of the American College of Nutrition
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - h51, 8215879
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/et [Etiology]
MH  - *Blood Glucose/me [Metabolism]
MH  - *Cholesterol/bl [Blood]
MH  - Electrocardiography/mt [Methods]
MH  - Erythrocytes/en [Enzymology]
MH  - Female
MH  - Heart Rate/de [Drug Effects]
MH  - Heart Rate/ph [Physiology]
MH  - *Heart Rate
MH  - Humans
MH  - *Magnesium/ad [Administration & Dosage]
MH  - Magnesium/me [Metabolism]
MH  - *Magnesium Deficiency/co [Complications]
MH  - Middle Aged
MH  - Nutritional Requirements
MH  - Postmenopause
MH  - Superoxide Dismutase/me [Metabolism]
AB  - OBJECTIVE: To determine whether or not dietary magnesium restriction to about 33% of the Recommended Dietary Allowance (RDA) causes changes in glucose, cholesterol and electrolyte metabolism that could lead to pathologic consequences.
AB  - DESIGN: The length of the experiment was 136 days. Subjects were fed a basal Western-type diet that provided 4.16 mmol (101 mg) magnesium per 8.4 MJ (2000 kcal) for 78 days then replenished with magnesium by supplementing the diet with 200 mg magnesium as the gluconate per day for 58 days. If a subject exhibited adverse heart rhythm changes before 78 days of depletion were completed, she entered the repletion period early.
AB  - SETTING: The metabolic research unit of the Grand Forks Human Nutrition Research Center.
AB  - SUBJECTS: A total of 14 post menopausal women were recruited by advertisement throughout the United States. Thirteen women (ages 47 to 75 years) completed the study.
AB  - RESULTS: During magnesium depletion, heart rhythm changes appeared in 5 women and resulted in 4 prematurely entering the magnesium repletion period (42 to 64 days of depletion instead of 78). Three women exhibited atrial fibrillation and flutter that responded quickly to magnesium supplementation. Magnesium deprivation resulted in a non-positive magnesium balance that became highly positive with magnesium repletion. Magnesium deprivation decreased red blood cell membrane magnesium, serum total cholesterol and erythrocyte superoxide dismutase concentrations, increased the urinary excretion of sodium and potassium, and increased serum glucose concentration.
AB  - CONCLUSIONS: Magnesium balance may be a suitable indicator of magnesium depletion under experimental conditions. Magnesium deficiency resulting from feeding a diet that would not be considered having an atypical menu induces heart arrhythmias, impairs glucose homeostasis, and alters cholesterol and oxidative metabolism in post menopausal women. A dietary intake of about 4.12 mmol (100 mg) Mg/8.4 MJ is inadequate for healthy adults and may result in compromised cardiovascular health and glycemic control in post menopausal women.
RN  - 0 (Blood Glucose)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - EC 1-15-1-1 (Superoxide Dismutase)
RN  - I38ZP9992A (Magnesium)
IS  - 0731-5724
IL  - 0731-5724
PT  - Journal Article
LG  - English
DP  - 2007 Apr
DC  - 20070530
YR  - 2007
ED  - 20070730
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17536123

<566. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17521443
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Goodrich DE
AU  - Larkin AR
AU  - Lowery JC
AU  - Holleman RG
AU  - Richardson CR
FA  - Goodrich, David E
FA  - Larkin, Angela R
FA  - Lowery, Julie C
FA  - Holleman, Robert G
FA  - Richardson, Caroline R
IN  - Goodrich,David E. HSR&D Center for Excellence, VA Health Care Medical Center, Ann Arbor, MI 48113-0170, USA. david.goodrich2@va.gov
TI  - Adverse events among high-risk participants in a home-based walking study: a descriptive study.
SO  - International Journal of Behavioral Nutrition & Physical Activity. 4:20, 2007.
AS  - Int. j. behav. nutr. phys. act.. 4:20, 2007.
NJ  - The international journal of behavioral nutrition and physical activity
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 101217089
OI  - Source: NLM. PMC1891313
CP  - England
AB  - BACKGROUND: For high-risk individuals and their healthcare providers, finding the right balance between promoting physical activity and minimizing the risk of adverse events can be difficult. More information on the prevalence and influence of adverse events is needed to improve providers' ability to prescribe effective and safe exercise programs for their patients.
AB  - METHODS: This study describes the type and severity of adverse events reported by participants with cardiovascular disease or at-risk for cardiovascular disease that occurred during an unsupervised, home-based walking study. This multi-site, randomized controlled trial tested the feasibility of a diet and lifestyle activity intervention over 1.5 years. At month 13, 274 eligible participants (male veterans) were recruited who were ambulatory, BMI > 28, and reporting one or more cardiovascular disease risk factors. All participants attended five, face-to-face dietitian-delivered counseling sessions during the six-month intervention. Participants were randomized to three study arms: 1) time-based walking goals, 2) simple pedometer-based walking goals, and 3) enhanced pedometer-based walking goals with Internet-mediated feedback. Two physicians verified adverse event symptom coding.
AB  - RESULTS: Enrolled participants had an average of five medical comorbidities. During 1110 person months of observation, 87 of 274 participants reported 121 adverse events. One serious study-related adverse event (atrial fibrillation) was reported; the individual resumed study participation within three days. Non-serious, study related adverse events made up 12% of all symptoms - predominantly minor musculoskeletal events. Serious, non-study related adverse events represented 32% of all symptoms while non-serious, non-study related adverse events made up 56% of symptoms. Cardiovascular disease events represented over half of the non-study related adverse event symptoms followed by musculoskeletal complaints. Adverse events caused 50 temporary suspensions averaging 26 days in duration before physician medical clearance was obtained to resume walking.
AB  - CONCLUSION: Men at high risk for adverse cardiovascular events can safely be advised to start a progressive walking program. Results suggest that minor to serious medical problems unrelated to exercise are a major barrier to walking adherence. Helping individuals with chronic illness return to physical activity quickly but safely after an adverse event is an important component of any physical activity intervention targeting this population.
ES  - 1479-5868
IL  - 1479-5868
PT  - Journal Article
LG  - English
EP  - 20070523
DP  - 2007
DC  - 20070614
YR  - 2007
ED  - 20070730
RD  - 20100916
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=17521443

<567. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17497490
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Scheike M
AU  - Nilsson S
AU  - Nylander E
FA  - Scheike, Morten
FA  - Nilsson, Staffan
FA  - Nylander, Eva
IN  - Scheike,Morten. Department of Clinical Physiology, Linkoping Heart Center, University Hospital, Linkoping, Sweden. Morten.Scheike@skane.se
TI  - Exercise testing and myocardial perfusion scintigraphy in primary care patients with chest pain of new onset.
SO  - Scandinavian Journal of Primary Health Care. 25(2):117-22, 2007 Jun.
AS  - Scand J Prim Health Care. 25(2):117-22, 2007 Jun.
NJ  - Scandinavian journal of primary health care
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 8510679, sif
OI  - Source: NLM. PMC3379746
SB  - Index Medicus
CP  - Norway
MH  - Adult
MH  - Aged
MH  - Angina Pectoris/di [Diagnosis]
MH  - Angina Pectoris/ri [Radionuclide Imaging]
MH  - *Chest Pain/di [Diagnosis]
MH  - Chest Pain/ri [Radionuclide Imaging]
MH  - Coronary Circulation
MH  - *Exercise Test
MH  - Family Practice
MH  - Female
MH  - *Heart/ri [Radionuclide Imaging]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/di [Diagnosis]
MH  - Myocardial Ischemia/ri [Radionuclide Imaging]
MH  - Primary Health Care
MH  - Prospective Studies
MH  - Risk Factors
AB  - OBJECTIVE: To analyse the outcome of exercise testing and myocardial perfusion scintigraphy (MPS) in primary care patients with chest pain of new onset.
AB  - DESIGN: Prospective, observational. Patients aged 20-79 years, consulting due to chest pain of new onset, were enrolled consecutively.
AB  - SETTING: Three primary care health centres in south-eastern Sweden.
AB  - PATIENTS: 191 patients where the possibility of stable ischaemic heart disease (IHD) could not be excluded by clinical examination alone.
AB  - MAIN OUTCOME MEASURES: Exercise test results, when equivocal completed by MPS.
AB  - RESULTS: Exercise testing revealed IHD in 14 (7%) and no IHD in 134 (70%) of the cases. In 43 (23%) the exercise test results were equivocal. Thirty-nine of these patients underwent MPS, which showed IHD in 19 and no IHD in 20 cases. Among previously diagnosed cardiovascular disease and risk factors only atrial fibrillation in the male group showed a significant correlation to the outcome IHD.
AB  - CONCLUSION: Exercise testing and MPS are both useful when investigating chest pain patients in primary care.
IS  - 0281-3432
IL  - 0281-3432
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2007 Jun
DC  - 20070514
YR  - 2007
ED  - 20070727
RD  - 20140907
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17497490

<568. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17413676
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Venkatachalam V
AU  - D'Attilio K
AU  - Lewis A
AU  - Acevedo M
FA  - Venkatachalam, Varalakshmi
FA  - D'Attilio, Karen
FA  - Lewis, Ann
FA  - Acevedo, Myrtha
IN  - Venkatachalam,Varalakshmi. Hartford Hospital in Hartford, CT 06106, USA.
TI  - Anticoagulation in ambulatory care: an evidence-based review of the literature. [Review] [23 refs]
SO  - Professional Case Management. 12(2):106-11, 2007 Mar-Apr.
AS  - Prof Case Manag. 12(2):106-11, 2007 Mar-Apr.
NJ  - Professional case management
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101291585
SB  - Nursing Journal
CP  - United States
MH  - *Ambulatory Care/og [Organization & Administration]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Case Management/og [Organization & Administration]
MH  - Continuity of Patient Care
MH  - Drug Interactions
MH  - Drug Monitoring/mt [Methods]
MH  - Drug Monitoring/nu [Nursing]
MH  - *Drug Monitoring/st [Standards]
MH  - Evidence-Based Medicine
MH  - Female
MH  - Humans
MH  - International Normalized Ratio
MH  - Male
MH  - Middle Aged
MH  - *Nurse's Role
MH  - Nursing Assessment
MH  - Patient Compliance
MH  - Patient Discharge
MH  - Patient Education as Topic
MH  - Patient Selection
MH  - *Practice Guidelines as Topic
MH  - Prothrombin Time
MH  - Quality Assurance, Health Care
MH  - Venous Thrombosis/dt [Drug Therapy]
AB  - UNLABELLED: PURPOSE OF THE MANUSCRIPT: Anticoagulation is warranted for the treatment of various disorders including cardiac, vascular, and postsurgical causes. Many centers have nurse case managers to coordinate care for patients on anticoagulation. This increases the demand for specific guidelines to assist nurse case managers to ensure quality of care. This review will address guidelines for nurse case managers and providers regarding initiating anticoagulation treatment and monitoring prothrombin time and international normalized ratio. Information will also be provided regarding when the nurse case manager should notify the providers to establish target international normalized ratio. This review will also provide educational tools to serve as standards for patient teaching, including drug and food interactions.
AB  - PRIMARY PRACTICE SETTING(S): This article applies to adult ambulatory practice that includes primary care, cardiology, and vascular and surgical settings.
AB  - IMPLICATIONS FOR CASE MANAGEMENT PRACTICE: The complexity of managing anticoagulation in ambulatory practice warrants case management. The nurse case manager will establish a rapport with patients to improve compliance, providing patient education about diet, dosages, and drug interactions to reduce medication errors and bleeding complications. This review on anticoagulation management will assist nurse case managers and providers to provide better quality of care. [References: 23]
RN  - 0 (Anticoagulants)
IS  - 1932-8087
IL  - 1932-8087
PT  - Case Reports
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2007 Mar-Apr
DC  - 20070406
YR  - 2007
ED  - 20070713
RD  - 20130520
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17413676

<569. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17392117
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Huang CY
FA  - Huang, Chen Ya
IN  - Huang,Chen Ya. Department of Medicine, University of Hong Kong, Hong Kong SAR, China. cyhuang@hku.hk
TI  - Nutrition and stroke. [Review] [83 refs]
SO  - Asia Pacific Journal of Clinical Nutrition. 16 Suppl 1:266-74, 2007.
AS  - Asia Pac J Clin Nutr. 16 Suppl 1:266-74, 2007.
NJ  - Asia Pacific journal of clinical nutrition
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9440304
SB  - Index Medicus
CP  - Australia
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - Diabetes Complications
MH  - Diabetes Mellitus/ep [Epidemiology]
MH  - Diet/st [Standards]
MH  - *Diet
MH  - Humans
MH  - Hypertension/co [Complications]
MH  - Hypertension/ep [Epidemiology]
MH  - Life Style
MH  - *Nutritional Physiological Phenomena
MH  - Obesity/co [Complications]
MH  - Obesity/ep [Epidemiology]
MH  - Risk Factors
MH  - Smoking/ae [Adverse Effects]
MH  - *Stroke/ep [Epidemiology]
MH  - *Stroke/et [Etiology]
MH  - Stroke/pc [Prevention & Control]
AB  - Stroke is one of the leading causes of death and certainly the major cause of disability in the world. WHO has estimated that between 1990 to 2020 the world will witness an increase in stroke mortality of 78% in woman and 106% in man. Much of this increase will be in developing countries which are witnessing rapid change in lifestyle and nutrition, hypertension, diabetes mellitus, smoking, atrial fibrillation, hyperlipidemia, Homocysteinemia, and alcohol are the most significant modifiable risk factors of stroke. Of these, hypertension, diabetes, smoking, hyperlipidemia, homocysteinemia and alcoholism are obviously affected by lifestyle and nutrition. However, whilst epidemiology studies have noted an association of nutritional practice with stroke risk, further research is needed to show how nutritional interventions can be effective in stroke prevention. [References: 83]
IS  - 0964-7058
IL  - 0964-7058
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2007
DC  - 20070329
YR  - 2007
ED  - 20070614
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17392117

<570. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17504290
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Dwyer N
AU  - Smart D
AU  - Reid DW
FA  - Dwyer, N
FA  - Smart, D
FA  - Reid, D W
TI  - Scuba diving, swimming and pulmonary oedema.
SO  - Internal Medicine Journal. 37(5):345-7, 2007 May.
AS  - Intern Med J. 37(5):345-7, 2007 May.
NJ  - Internal medicine journal
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - d20, 101092952
SB  - Index Medicus
CP  - Australia
MH  - Atrial Fibrillation/co [Complications]
MH  - Chronic Disease
MH  - *Diving/ae [Adverse Effects]
MH  - Hot Temperature
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Pulmonary Edema/et [Etiology]
MH  - Recurrence
MH  - *Swimming/in [Injuries]
ES  - 1445-5994
IL  - 1444-0903
PT  - Case Reports
PT  - Letter
LG  - English
DP  - 2007 May
DC  - 20070516
YR  - 2007
ED  - 20070524
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17504290

<571. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17383295
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Atwood JE
AU  - Myers JN
AU  - Tang XC
AU  - Reda DJ
AU  - Singh SN
AU  - Singh BN
FA  - Atwood, J Edwin
FA  - Myers, Jonathan N
FA  - Tang, X Charlene
FA  - Reda, Domenic J
FA  - Singh, Steven N
FA  - Singh, Bramah N
IN  - Atwood,J Edwin. Cardiology Division, Walter Reed Army Medical Center, 6900 Georgia Ave NW, Washington, DC 20307, USA. john.atwood@amedd.army.mil
TI  - Exercise capacity in atrial fibrillation: a substudy of the Sotalol-Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T).
SO  - American Heart Journal. 153(4):566-72, 2007 Apr.
AS  - Am Heart J. 153(4):566-72, 2007 Apr.
NJ  - American heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 0370465
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Amiodarone/tu [Therapeutic Use]
MH  - *Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Double-Blind Method
MH  - *Electric Countershock
MH  - *Exercise Tolerance
MH  - Female
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - *Sotalol/tu [Therapeutic Use]
AB  - BACKGROUND: Therapy for chronic atrial fibrillation (AF) focuses on rate versus rhythm control, but little is known about the effects of common therapeutic interventions on exercise tolerance in AF.
AB  - METHODS: Six hundred fifty-five patients with chronic AF underwent maximal exercise testing at baseline and 8 weeks, 6 months, and 1 year after randomization to sotalol, amiodarone, or placebo therapy and attempted direct current cardioversion. Analyses of baseline determinants of exercise capacity, predictors of change in exercise capacity at 6 months and 1 year, and the short- and long-term effects of cardioversion on exercise capacity were made.
AB  - RESULTS: Age, obesity, and presence of symptoms accompanying AF were inversely associated with baseline exercise capacity, but these factors accounted for only 10% of the variance in exercise capacity. Patients most likely to benefit from cardioversion were those most limited initially, younger, not obese or hypertensive, and with an uncontrolled ventricular rate at baseline. Conversion to sinus rhythm (SR) resulted in significant reductions in resting (approximately 25 beat/min) and peak exercise (approximately 40 beat/min) heart rates at 6 months and 1 year (P < .001). Successful cardioversion improved exercise capacity by 15% at 8 weeks, and these improvements were maintained throughout the year. This improvement was observed both among those who maintained SR and those with intermittent AF.
AB  - CONCLUSION: Cardioversion resulted in a sustained improvement in exercise capacity over the course of 1 year, and this improvement was similar between those in SR and those with SR and recurrent AF. Patients most likely to improve with treatment tended to be younger and nonobese and have the greatest limitations initially.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - A6D97U294I (Sotalol)
RN  - N3RQ532IUT (Amiodarone)
ES  - 1097-6744
IL  - 0002-8703
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
LG  - English
DP  - 2007 Apr
DC  - 20070326
YR  - 2007
ED  - 20070503
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17383295

<572. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17350377
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Bunch TJ
AU  - Chandrasekaran K
AU  - Ehrsam JE
AU  - Hammill SC
AU  - Urban LH
AU  - Hodge DO
AU  - Ommen SR
AU  - Pellikka PA
FA  - Bunch, T Jared
FA  - Chandrasekaran, Krishnaswamy
FA  - Ehrsam, Jo-Ellen
FA  - Hammill, Stephen C
FA  - Urban, Lynn H
FA  - Hodge, David O
FA  - Ommen, Steve R
FA  - Pellikka, Patricia A
IN  - Bunch,T Jared. Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
TI  - Prognostic significance of exercise induced arrhythmias and echocardiographic variables in hypertrophic cardiomyopathy.
SO  - American Journal of Cardiology. 99(6):835-8, 2007 Mar 15.
AS  - Am J Cardiol. 99(6):835-8, 2007 Mar 15.
NJ  - The American journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Arrhythmias, Cardiac/di [Diagnosis]
MH  - Arrhythmias, Cardiac/pp [Physiopathology]
MH  - Arrhythmias, Cardiac/us [Ultrasonography]
MH  - *Cardiomyopathy, Hypertrophic/di [Diagnosis]
MH  - Cardiomyopathy, Hypertrophic/ep [Epidemiology]
MH  - Cardiomyopathy, Hypertrophic/pp [Physiopathology]
MH  - Cardiomyopathy, Hypertrophic/us [Ultrasonography]
MH  - Child
MH  - Cohort Studies
MH  - Echocardiography
MH  - *Exercise Test
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Minnesota/ep [Epidemiology]
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Prospective Studies
MH  - Risk Factors
AB  - Hypertrophic cardiomyopathy (HC) often presents with exercise-induced symptoms, including arrhythmias and sudden death. The investigators prospectively studied whether exercise testing is associated with immediate complications and if stress-induced arrhythmias and echocardiographic variables are associated with long-term adverse outcomes. Exercise echocardiography with 6-channel continuous monitoring for arrhythmias was performed in consecutive patients with HC clinically referred for the test. End points included death, myocardial infarction, revascularization, stroke, atrial fibrillation, ventricular tachycardia, and myectomy. Of 86 patients with HC (mean age 56.6 +/- 16.1 years) who underwent exercise echocardiography, arrhythmias occurred in 39 (45%), including 23 (27%) with premature atrial contractions, 2 (2%) with atrial fibrillation, 28 (33%) with premature ventricular contractions (16 also had atrial arrhythmias), and 1 (1.2%) with nonsustained ventricular tachycardia (hemodynamically stable). During a follow-up of 2.6 +/- 2.8 years, major events occurred in 11 patients (3 deaths, 5 revascularizations, 3 strokes). In addition, 12 patients developed atrial fibrillation, 6 developed nonsustained ventricular tachycardia, and 13 underwent myectomies. Variables associated with major events included hypertension, male gender, and worsening wall motion score index with exercise; increased exercise duration was associated with fewer events. ST-T changes on baseline electrocardiography and premature ventricular contractions were associated with atrial fibrillation risk. In conclusion, in this cohort of patients with HC, exercise testing was safe. Test results were associated with risk for adverse events.
IS  - 0002-9149
IL  - 0002-9149
PT  - Evaluation Studies
PT  - Journal Article
LG  - English
EP  - 20070122
DP  - 2007 Mar 15
DC  - 20070312
YR  - 2007
ED  - 20070426
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17350377

<573. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17086025
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Shoyeb A
AU  - Weinstein H
AU  - Roistacher N
AU  - Spaltro B
AU  - Bates A
AU  - Yusim G
AU  - Steingart R
FA  - Shoyeb, Abu
FA  - Weinstein, Howard
FA  - Roistacher, Nancy
FA  - Spaltro, Barbara
FA  - Bates, Andrew
FA  - Yusim, Galina
FA  - Steingart, Richard
IN  - Shoyeb,Abu. Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. steingar@mskcc.org
TI  - Preoperative exercise echocardiography and perioperative cardiovascular outcomes in elderly patients undergoing cancer surgery.
SO  - American Journal of Geriatric Cardiology. 15(6):338-44, 2006 Nov-Dec.
AS  - Am J Geriatr Cardiol. 15(6):338-44, 2006 Nov-Dec.
NJ  - The American journal of geriatric cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - dz4, 9215283
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - Cardiovascular Diseases/ep [Epidemiology]
MH  - Cardiovascular Diseases/et [Etiology]
MH  - *Cardiovascular Diseases/pp [Physiopathology]
MH  - *Cardiovascular Diseases/us [Ultrasonography]
MH  - *Echocardiography, Stress
MH  - Electrocardiography
MH  - Female
MH  - Heart Rate
MH  - Humans
MH  - Incidence
MH  - Logistic Models
MH  - Male
MH  - *Neoplasms/su [Surgery]
MH  - Postoperative Complications/pp [Physiopathology]
MH  - Postoperative Complications/us [Ultrasonography]
MH  - Predictive Value of Tests
MH  - Research Design
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Stroke Volume
MH  - Survival Analysis
MH  - Treatment Outcome
AB  - Limited information is available on the value of exercise echocardiography (EE) for identifying operative risk in elderly patients undergoing noncardiac surgery. The authors investigated the outcome in 221 consecutive patients 75 years and older who had EE before intermediate- or high-risk cancer surgery. Baseline clinical data, postoperative adverse cardiovascular events (PACE), and 30-day mortality were collected from the medical records and the Social Security Death Index. The mean age +/- SD of the group was 78.9+/-3.5 years; 57% were men. Significant cardiovascular abnormalities (by echocardiography) were present in 71.5%. Mean metabolic equivalents +/- SD achieved during exercise was 4.9+/-1.9. EE identified 50 (22.6%) patients with ischemia and/or infarction. Perioperative beta-blockers were used in 80% of patients with coronary artery disease vs 48.5% without coronary artery disease (P<.0001). There were 31 PACE in 26 (11.8%) patients. Atrial fibrillation was the most common PACE, seen in 18 (8.1%) patients, followed by congestive heart failure in 8 (3.6%), acute coronary syndrome in 2 (0.9%), and cardiac arrest in 1 (0.5%). Thirty-day mortality was only 0.9%. Hospital lengths of stay for patients with and without PACE were 16.8+/-14.9 and 8.5+/-4.8 days (P< or =.0001), respectively. An abnormal EE predicted PACE (22% vs 8.8%; P< .025). Perioperative beta-blockers reduced the incidence of postoperative atrial fibrillation (4.9% vs 12.2%; P=.052). In conclusion, EE is feasible in very elderly patients. There is a high prevalence of cardiac abnormalities in the elderly. An abnormal EE predicts PACE, which, in turn, is associated with increased length of stay.
IS  - 1076-7460
IL  - 1076-7460
PT  - Journal Article
LG  - English
DP  - 2006 Nov-Dec
DC  - 20061106
YR  - 2006
ED  - 20070425
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17086025

<574. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17378769
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ali S
AU  - Hong M
AU  - Antezano ES
AU  - Mangat I
FA  - Ali, Sheharyar
FA  - Hong, Mauricio
FA  - Antezano, Eduardo S
FA  - Mangat, Iqwal
IN  - Ali,Sheharyar. VA Central Iowa Health Care System, Adjunct Clinical Assistant Professor of Medicine, University of Iowa Carver College of Medicine, Des Moines, Iowa, USA.
TI  - Evaluation and management of atrial fibrillation. [Review] [102 refs]
SO  - Cardiovascular & Hematological Disorders - Drug Targets. 6(4):233-44, 2006 Dec.
AS  - Cardiovasc Hematol Disord Drug Targets. 6(4):233-44, 2006 Dec.
NJ  - Cardiovascular & hematological disorders drug targets
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101269160
SB  - Index Medicus
CP  - Netherlands
MH  - Animals
MH  - Atrial Fibrillation/cl [Classification]
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Electric Countershock
MH  - Fibrinolytic Agents/pd [Pharmacology]
MH  - Fibrinolytic Agents/tu [Therapeutic Use]
MH  - Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Risk Factors
MH  - Stroke/co [Complications]
MH  - Stroke/ep [Epidemiology]
MH  - Stroke/pp [Physiopathology]
AB  - Atrial fibrillation (AF) is the most common clinically encountered arrhythmia affecting 0.4% of the general population. Its prevalence increases with age, affecting more than 6% of people over 80 years of age. The annual risk of ischemic stroke in patients with lone AF is approximately 1.3%. This annual risk increases up to 10% -12% in patients with a prior stroke or transient ischemic attack. Randomized clinical trials (RCT) comparing adjusted-dose oral anticoagulation and placebo showed a risk reduction of 61% (95% CI 47% to 71%). The absolute risk reduction for stroke with oral anticoagulants is about 3% per year. Aspirin has been shown in meta-analyses to have on average a 20-25% relative risk reduction, and is inferior to oral anticoagulants. In high risk patients with AF warfarin is a class I ACC/AHA indication unless there is a contraindication for anticoagulation. Unfortunately, this therapy requires frequent monitoring with blood samples and the interaction with food and several medications makes its use difficult and sometimes unreliable. It requires strict patient compliance and its use is also linked to potentially serious bleeding complications. In clinical practice, less than 60% of patients who do not have contraindications to oral anticoagulation are actually receiving them. Additionally, of those that receive oral anticoagulation, less than 50% are consistently within therapeutic targets. As such, the "real world" efficacy of a strategy towards prescribing oral anticoagulants is likely significantly lower than that demonstrated in clinical trials. As such, the need to discover other methods of anticoagulation with oral bioavailability, predictable pharmacokinetics, and minimal interactions with diet and other pharmacological agents is imperative. Low molecular weight heparin has a more predictable bioavailability and a longer half-life, but its subcutaneous mode of administration and long-term risks, in particular, osteoporosis makes the chronic use of this medication non-feasible. Antiplatelet agents such as clopidogrel have proven efficacy and superiority compared to aspirin to prevent systemic vascular events in at-risk patient populations, but currently they do not play an important role in the prevention of AF related thromboembolic events. The ACTIVE study is a randomized trial comparing the combination of clopidogrel and aspirin therapy to oral anticoagulation with warfarin in patients with AF, and was unfortunately terminated prematurely by the data safety and monitoring board because of increased events in the antiplatelet arm. Direct thrombin inhibitors, such as ximelagatran, may be as effective as warfarin for stroke-risk reduction in patients with AF. No anticoagulation monitoring is needed and it has excellent bioavailability, with a twice-daily oral dose. Elevation of liver enzymes was an initial concern regarding the use of this new drug, which is not available for general use. Ongoing pharmacological research and future clinical trials may one day leave the "warfarin days" behind. Unfortunately, the new therapies that are being tested seem to be at least several years away from being available on a widespread basis. In this review, we discuss the underlying pathophysiology of AF and stroke. We also provide a comprehensive discussion regarding various available therapies to treat AF. [References: 102]
RN  - 0 (Fibrinolytic Agents)
IS  - 1871-529X
IL  - 1871-529X
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2006 Dec
DC  - 20070323
YR  - 2006
ED  - 20070416
RD  - 20111209
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17378769

<575. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16815571
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Hegbom F
AU  - Stavem K
AU  - Sire S
AU  - Heldal M
AU  - Orning OM
AU  - Gjesdal K
FA  - Hegbom, Finn
FA  - Stavem, Knut
FA  - Sire, Svein
FA  - Heldal, Magnus
FA  - Orning, Otto M
FA  - Gjesdal, Knut
IN  - Hegbom,Finn. Department of Cardiology, Ulleval University Hospital and University of Oslo, 0407 Oslo, Norway. finn.hegbom@medisin.uio.no
TI  - Effects of short-term exercise training on symptoms and quality of life in patients with chronic atrial fibrillation.
SO  - International Journal of Cardiology. 116(1):86-92, 2007 Mar 2.
AS  - Int J Cardiol. 116(1):86-92, 2007 Mar 2.
NJ  - International journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - gqw, 8200291
SB  - Index Medicus
CP  - Netherlands
MH  - Aged
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/px [Psychology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Chronic Disease
MH  - Exercise Test
MH  - *Exercise Therapy/mt [Methods]
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Satisfaction
MH  - *Quality of Life
AB  - BACKGROUND: A randomised study was conducted to determine if short-term exercise training in patients with chronic atrial fibrillation (AF) might improve symptoms and health-related quality of life (HRQoL).
AB  - METHODS: AF patients (64+/-7 years) were randomised to exercise training (n=15) or a 2-month control period (n=15) followed by an exercise training program (ETP). The ETP consisted of 24 training sessions with aerobic exercise and muscle strengthening. A cycle ergometer test, with recording of perceived exertion on the Borg scale, was performed. The participants completed HRQoL questionnaires, the Short-Form 36 (SF-36) and Symptom and Severity Checklist (SSCL), before and after training. Because there were no changes after two months in the control group, pooled data for all patients are presented before and after training.
AB  - RESULTS: Four of the eight SF-36 scales improved significantly (p<0.05) following training: physical functioning (82+/-14 pre-ETP, 86+/-10 post-ETP), bodily pain (82+/-17 pre-ETP, 92+/-14 post-ETP), vitality (61+/-14 pre-ETP, 68+/-13 post-ETP) and role-emotional (85+/-28 pre-ETP, 94+/-20 post-ETP). The SF-36 physical component summary scale also increased from 49+/-6 pre-ETP to 52+/-6 post-ETP (p<0.05). Significant improvements were also observed for summary and specific symptom scores of the SSCL. Exercise capacity improved by 41+/-20% and perceived exertion during testing by 1.4 points after training (p<0.05 for both).
AB  - CONCLUSIONS: The study demonstrates a significant improvement in HRQoL, symptoms during exercise testing and exercise capacity after a short-term exercise training program in patients with chronic AF.
ES  - 1874-1754
IL  - 0167-5273
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
EP  - 20060630
DP  - 2007 Mar 2
DC  - 20070216
YR  - 2007
ED  - 20070409
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16815571

<576. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16764958
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Korantzopoulos P
AU  - Kolettis TM
AU  - Galaris D
AU  - Goudevenos JA
FA  - Korantzopoulos, Panagiotis
FA  - Kolettis, Theofilos M
FA  - Galaris, Dimitrios
FA  - Goudevenos, John A
IN  - Korantzopoulos,Panagiotis. Department of Internal Medicine, Division of Cardiology, University of Ioannina Medical School, Ioannina, Greece. pkor@oneway.gr
TI  - The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. [Review] [75 refs]
SO  - International Journal of Cardiology. 115(2):135-43, 2007 Feb 7.
AS  - Int J Cardiol. 115(2):135-43, 2007 Feb 7.
NJ  - International journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - gqw, 8200291
SB  - Index Medicus
CP  - Netherlands
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/et [Etiology]
MH  - *Atrial Fibrillation/me [Metabolism]
MH  - Humans
MH  - *Oxidative Stress
MH  - Reactive Oxygen Species/me [Metabolism]
AB  - Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice representing a major health hazard. Owing to relative inefficacy and side effects of classic antiarrhythmic drugs, current interest has shifted to treatments that target AF substrate. Accumulating evidence suggests that there is a link between oxidative processes and AF. In atrial myocardium during AF, there is substantial oxidative damage that may contribute to atrial remodeling. Several pathophysiological changes that possibly associated with increased oxidative stress in AF have been proposed. These include changes in gene transcriptional profiles and mitochondrial DNA, increased activity of enzymes such as NAD(P)H oxidase and xanthine oxidase, inflammatory processes, activation of the renin-angiotensin system and others. Moreover, oxidative stress is involved in the pathophysiology of several predisposing factors and cardiovascular disorders that correspondingly associated with AF. Preliminary studies using dietary antioxidants such as vitamin C have shown promising results. More evidence has been obtained from studies examining agents with pleiotropic effects, including antioxidant, such as inhibitors of the renin-angiotensin system, statins, corticosteroids and carvedilol. Further investigations are needed in order to elucidate the impact of oxidative stress on atrial remodeling. The clarification of these processes in the setting of AF may lead to the development of novel therapeutic strategies. [References: 75]
RN  - 0 (Reactive Oxygen Species)
ES  - 1874-1754
IL  - 0167-5273
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20060609
DP  - 2007 Feb 7
DC  - 20070129
YR  - 2007
ED  - 20070404
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16764958

<577. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17351164
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ozdemir O
AU  - Soylu M
AU  - Demir AD
AU  - Topaloglu S
AU  - Alyan O
AU  - Geyik B
AU  - Kutuk E
FA  - Ozdemir, Ozcan
FA  - Soylu, Mustafa
FA  - Demir, Ahmet Duran
FA  - Topaloglu, Serkan
FA  - Alyan, Omer
FA  - Geyik, Bilal
FA  - Kutuk, Emine
IN  - Ozdemir,Ozcan. Turkiye Yuksek Ihtisas Hospital, Cardiology Clinics, Ankara, Turkey. drozdemir75@yahoo.com
TI  - P-wave durations in patients experiencing atrial fibrillation during exercise testing.
SO  - Angiology. 58(1):97-101, 2007 Feb-Mar.
AS  - Angiology. 58(1):97-101, 2007 Feb-Mar.
NJ  - Angiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 4ua, 0203706
SB  - Index Medicus
CP  - United States
MH  - *Adrenergic beta-Antagonists/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/et [Etiology]
MH  - Case-Control Studies
MH  - Electrocardiography
MH  - *Exercise Test/ae [Adverse Effects]
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Physical Exertion
MH  - Recurrence
AB  - Augmented sympathoadrenal activity during exercise may contribute to occurrence of various arrhythmias including atrial fibrillation (AF). The prolongation of intraatrial and interatrial conduction times and inhomogeneous propagation of sinus impulses are well-known characteristics of the atrium prone to fibrillate and are evaluated by maximum P-wave duration (P max), P-wave dispersion (PWD). To show the increased P max and PWD values in patients experiencing AF during exercise testing and the role of beta blockade on treatment of exercise-induced AF, 22 of these patients were compared with a control group consisting of 41 patients without AF attacks. P max (p = 0.001) and PWD (p = 0.001) values were significantly higher in patients with AF compared to those without AF. The development of AF during exercise testing was found to be positively correlated with P max (r = 0.87, p < 0.001), PWD (r = 0.83, p = 0.001), and work load (r = 0.34, p = 0.002) and negatively correlated with ejection fraction (r = -0.26, p=0.02). After the treatment with beta-blocking agents for 2 weeks, the decrease in P max and PWD values was accompanied by a much lower prevalence of exercise-induced AF. Consequently, the patients with AF had greater P max and PWD values compared to control subjects, and these simple parameters were well correlated with the occurrence of AF during exercise testing. Furthermore, treatment of these patients with beta blockers would appear to decrease the recurrence of exercise-induced AF and to be associated with a decrease in P-wave durations.
RN  - 0 (Adrenergic beta-Antagonists)
IS  - 0003-3197
IL  - 0003-3197
PT  - Journal Article
LG  - English
DP  - 2007 Feb-Mar
DC  - 20070312
YR  - 2007
ED  - 20070403
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17351164

<578. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16678270
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Brouwer IA
AU  - Geelen A
AU  - Katan MB
FA  - Brouwer, Ingeborg A
FA  - Geelen, Anouk
FA  - Katan, Martijn B
IN  - Brouwer,Ingeborg A. Wageningen Centre for Food Sciences and Division of Human Nutrition, Wageningen University, Wageningen, The Netherlands. Ingeborg.Brouwer@wur.nl
TI  - n-3 Fatty acids, cardiac arrhythmia and fatal coronary heart disease. [Review] [69 refs]
SO  - Progress in Lipid Research. 45(4):357-67, 2006 Jul.
AS  - Prog Lipid Res. 45(4):357-67, 2006 Jul.
NJ  - Progress in lipid research
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - pz7, 7900832
SB  - Index Medicus
CP  - England
MH  - Animals
MH  - Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - *Arrhythmias, Cardiac/pc [Prevention & Control]
MH  - Clinical Trials as Topic
MH  - Coronary Disease/mo [Mortality]
MH  - *Coronary Disease/pc [Prevention & Control]
MH  - *Diet/sn [Statistics & Numerical Data]
MH  - *Fatty Acids, Omega-3/ad [Administration & Dosage]
MH  - Fatty Acids, Omega-3/tu [Therapeutic Use]
MH  - Fishes
MH  - Humans
MH  - Seafood
AB  - n-3 Polyunsaturated fatty acids (n-3 PUFA) are suggested to prevent cardiac death via inhibition of cardiac arrhythmia. In this review we discuss the results of human studies on intake of n-3 PUFAs and heart disease and, more specifically, on cardiac arrhythmia. Observational studies indicate that intake of fish is associated with a lower incidence of fatal coronary heart disease in several populations. These studies are fairly consistent, but people that have a high intake of fatty fish might have a healthier lifestyle in general, and such confounding is difficult to remove completely with statistical adjustments and corrections. Evidence from trials is less clear. In two open label trials in patients with a previous myocardial infarction intake of fish or fish oil prevented fatal coronary heart disease. In contrast, a trial in patients with angina suggested a higher risk of sudden cardiac death in patients taking fish oil. Furthermore, results of trials in patients with an implantable cardioverter defibrillator (ICD) that investigated effects of fish oil on arrhythmia in patients already suffering from ventricular tachycardia are not consistent. Also, studies on relationships between intake of n-3 PUFA from fish and less life-threatening forms of arrhythmia, such as atrial fibrillation and premature ventricular complexes (PVCs) are equivocal. Thus, after 35 years of research the question whether fish prevents heart disease remains unanswered, and an anti-arrhythmic effect of fish oil remains unproven although the idea is still viable and is being actively tested in further trials. [References: 69]
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Fatty Acids, Omega-3)
IS  - 0163-7827
IL  - 0163-7827
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
LG  - English
EP  - 20060418
DP  - 2006 Jul
DC  - 20060612
YR  - 2006
ED  - 20070329
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16678270

<579. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17261425
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Afshinnia F
AU  - Spitalewitz S
AU  - Chou SY
AU  - Gunsburg DZ
AU  - Chadow HL
FA  - Afshinnia, Farsad
FA  - Spitalewitz, Samuel
FA  - Chou, Shyan-Yih
FA  - Gunsburg, David Z
FA  - Chadow, Hal L
IN  - Afshinnia,Farsad. Department of Internal Medicine at Memorial Medical Center, Sutter-Gould Medical Foundation Inc, Modesto, CA, USA. afshinnia@hotmail.com
TI  - Left ventricular geometry and renal function in hypertensive patients with diastolic heart failure.
SO  - American Journal of Kidney Diseases. 49(2):227-36, 2007 Feb.
AS  - Am J Kidney Dis. 49(2):227-36, 2007 Feb.
NJ  - American journal of kidney diseases : the official journal of the National Kidney Foundation
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 3h5, 8110075
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - *Blood Pressure/ph [Physiology]
MH  - Cross-Sectional Studies
MH  - Diastole/ph [Physiology]
MH  - Female
MH  - Heart Failure/co [Complications]
MH  - *Heart Failure/pp [Physiopathology]
MH  - Humans
MH  - Hypertension/co [Complications]
MH  - *Hypertension/pp [Physiopathology]
MH  - Hypertrophy, Left Ventricular/co [Complications]
MH  - *Hypertrophy, Left Ventricular/pp [Physiopathology]
MH  - *Kidney/ph [Physiology]
MH  - Kidney Function Tests
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Ventricular Function, Left/ph [Physiology]
AB  - BACKGROUND: The objective is to define the relationship between cardiac geometry and renal function in hypertensive subjects with and without diastolic heart failure (DHF).
AB  - METHODS: This is a prospective observational study in a tertiary-care teaching institute in a 15-month period of consecutive hospitalized hypertensive patients. Patients on dialysis therapy or with atrial fibrillation, systolic heart failure, gross proteinuria, and glomerular diseases were excluded. Two-dimensional echocardiography was performed and stable glomerular filtration rate (GFR) was calculated by using the Modification of Diet in Renal Disease formula. Patients were classified into stage 1 to 5 chronic kidney disease (CKD).
AB  - RESULTS: Five hundred forty hypertensive patients were separated into 2 groups: 286 patients with DHF and 254 patients without DHF. Mean age was 69.1 +/- 13.7 (SD) years in general. In patients with DHF, from stages 1 to 5 CKD, there was a significant graded increase in left ventricular mass index (from 117.3 to 162.4 g/m(2)) and relative wall thickness (from 0.42 to 0.52) and a significant graded decrease in aortic cusp separation (from 1.85 to 1.55 cm). Among echocardiographic variables, left ventricular mass index and relative wall thickness were associated inversely and aortic cusp separation was associated directly with GFR. In the absence of DHF, only left ventricular mass index was associated inversely with GFR, suggesting a prominent role of aortic cusp separation and relative wall thickness in the variability in GFR in patients with DHF through a hemodynamic disturbance.
AB  - CONCLUSION: Hemodynamic alterations have a prominent role in the variability of GFR in patients with CKD with DHF. Adverse cardiac geometry is linked to the severity of CKD in hypertensive patients, raising the possibility of preserving both cardiac and renal function by means of hypertension control.
ES  - 1523-6838
IL  - 0272-6386
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 2007 Feb
DC  - 20070130
YR  - 2007
ED  - 20070314
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17261425

<580. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17215629
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Pippa L
AU  - Manzoli L
AU  - Corti I
AU  - Congedo G
AU  - Romanazzi L
AU  - Parruti G
FA  - Pippa, Lucio
FA  - Manzoli, Lamberto
FA  - Corti, Itala
FA  - Congedo, Gabriele
FA  - Romanazzi, Luigi
FA  - Parruti, Giustino
IN  - Pippa,Lucio. Camillo de Lellis per la Ricera Clinica Applicata, Pescara, Italy.
TI  - Functional capacity after traditional Chinese medicine (qi gong) training in patients with chronic atrial fibrillation: a randomized controlled trial.
SO  - Preventive Cardiology. 10(1):22-5, 2007.
AS  - Prev Cardiol. 10(1):22-5, 2007.
NJ  - Preventive cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9813731
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Breathing Exercises
MH  - Chronic Disease
MH  - Exercise Tolerance
MH  - Female
MH  - Humans
MH  - Male
MH  - *Medicine, Chinese Traditional
MH  - Middle Aged
AB  - Evidence indicates that low energy expenditure protocols derived from traditional Chinese medicine may benefit patients with cardiac impairment; therefore, the authors carried out a randomized controlled trial to test a 16-week medically assisted qi gong training program for the physical rehabilitation of patients with stable chronic atrial fibrillation and preserved left ventricular function. Functional capacity variation was evaluated using the 6-minute walk test, which was performed at baseline, at the end of the intervention, and after 16 weeks. Thirty men and 13 women (mean age, 68+/-8 years) were randomized to the intervention protocol or to a wait-list control group. Qi gong training was well tolerated and, compared with baseline, trained patients walked an average 114 meters more (27%) at the end of treatment (P<.001) and 57 meters more (13.7%) 16 weeks later (P=.008). Control subjects showed no variation in functional capacity. These results seem promising and deserve confirmation with further research.
IS  - 1520-037X
IL  - 1520-037X
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 2007
DC  - 20070111
YR  - 2007
ED  - 20070301
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17215629

<581. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16403583
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Giardini A
AU  - Pace Napoleone C
AU  - Specchia S
AU  - Donti A
AU  - Formigari R
AU  - Oppido G
AU  - Gargiulo G
AU  - Picchio FM
FA  - Giardini, Alessandro
FA  - Pace Napoleone, Carlo
FA  - Specchia, Salvatore
FA  - Donti, Andrea
FA  - Formigari, Roberto
FA  - Oppido, Guido
FA  - Gargiulo, Gaetano
FA  - Picchio, Fernando M
IN  - Giardini,Alessandro. Pediatric Cardiology and Adult Congenital Unit, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy. alessandro5574@iol.it
TI  - Conversion of atriopulmonary Fontan to extracardiac total cavopulmonary connection improves cardiopulmonary function.
SO  - International Journal of Cardiology. 113(3):341-4, 2006 Nov 18.
AS  - Int J Cardiol. 113(3):341-4, 2006 Nov 18.
NJ  - International journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - gqw, 8200291
SB  - Index Medicus
CP  - Netherlands
MH  - Adolescent
MH  - Adult
MH  - *Exercise
MH  - Fontan Procedure
MH  - *Heart/ph [Physiology]
MH  - *Heart Bypass, Right/mt [Methods]
MH  - Heart Defects, Congenital/su [Surgery]
MH  - Humans
MH  - Prospective Studies
AB  - BACKGROUND: Experimental studies showed that extracardiac total cavopulmonary connection provides superior hemodynamics than atriopulmonary Fontan.
AB  - METHODS: We prospectively assessed the impact of conversion of atriopulmonary Fontan to extracardiac total cavopulmonary connection on exercise capacity and cardiac function in 6 consecutive patients.
AB  - RESULTS: Six months after conversion to extracardiac total cavopulmonary connection, we observed an increase in peak oxygen uptake in all patients (p=0.01;+17%). This improvement was associated to an increase of peak O(2) pulse (p=0.01;+16%), but no change in peak heart rate, arterial oxygen saturation at peak exercise, and pulmonary function. Ventricular ejection fraction did not change significantly after surgery. Conversion was associated with an improvement in heart failure symptoms as assessed by the New York Heart Association classification. Patients who had undergone additional anti-arrhythmia surgery for atrial fibrillation had no recurrence of arrhythmia at follow-up.
AB  - CONCLUSION: Data indicate that conversion to extracardiac total cavopulmonary connection is associated with an improvement of cardiopulmonary function and heart failure symptoms. Improved exercise capacity is due to an increase in O(2) pulse and may reflect an improved cardiac stroke volume after the operation.
ES  - 1874-1754
IL  - 0167-5273
PT  - Journal Article
LG  - English
EP  - 20060105
DP  - 2006 Nov 18
DC  - 20061113
YR  - 2006
ED  - 20070125
RD  - 20091124
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16403583

<582. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17136822
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kato T
AU  - Ishida S
AU  - Morooka T
AU  - Inoue T
AU  - Node K
FA  - Kato, Toru
FA  - Ishida, Shiro
FA  - Morooka, Toshifumi
FA  - Inoue, Teruo
FA  - Node, Koichi
IN  - Kato,Toru. Department of Cardiovascular and Renal Medicine, Saga University Faculty of Medicine. katotor@med.saga-u.ac.jp
TI  - Postprandial hyperglycemia is a possible contributor to paroxysmal atrial fibrillation: a case report.
CM  - Comment in: J Cardiol. 2007 Mar;49(3):159; author reply 159-60; PMID: 17444143
SO  - Journal of Cardiology. 48(5):269-72, 2006 Nov.
AS  - J Cardiol. 48(5):269-72, 2006 Nov.
NJ  - Journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - joa, 8804703
SB  - Index Medicus
CP  - Japan
MH  - Aged
MH  - *Atrial Fibrillation/et [Etiology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Diet, Reducing
MH  - Exercise Therapy
MH  - Female
MH  - Humans
MH  - *Hyperglycemia/co [Complications]
MH  - Insulin Resistance
MH  - Obesity/co [Complications]
MH  - *Postprandial Period/ph [Physiology]
AB  - Atrial fibrillation, a major risk factor for stroke, is believed to occur first as paroxysmal episodes, gradually becoming more persistent, and finally progressing to chronic atrial fibrillation. Treatment of paroxysmal atrial fibrillation is an important target to prevent chronic atrial fibrillation. We describe a very unique case with postprandial hyperglycemia and obesity associated with drug-refractory paroxysmal atrial fibrillation. A 73-year-old Japanese woman with postprandial hyperglycemia suffered from drug-refractory paroxysmal atrial fibrillation. A 1600 kcal/day diet and walking three times/day for more than 30 min eliminated paroxysmal atrial fibrillation after 6 months. Diet and exercise should be considered as the initial therapy in patients with paroxysmal atrial fibrillation who also have postprandial hyperglycemia. This case suggests that postprandial hyperglycemia and insulin resistance might be one of the possible underlying mechanisms of paroxysmal atrial fibrillation.
IS  - 0914-5087
IL  - 0914-5087
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2006 Nov
DC  - 20061201
YR  - 2006
ED  - 20070119
RD  - 20070601
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17136822

<583. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16815988
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Guazzi M
AU  - Berti M
AU  - Belletti S
AU  - Reina G
AU  - Guazzi MD
FA  - Guazzi, Marco
FA  - Berti, Marco
FA  - Belletti, Sebastiano
FA  - Reina, Giuseppe
FA  - Guazzi, Maurizio D
IN  - Guazzi,Marco. Endothelial Function and Cardiopulmonary Unit, Cardiology Division, Univ. of Milano, San Paolo Hospital, Via A. di Rudini 8, 20142 Milan, Italy. marco.guazzi@unimi.it
TI  - Exercise metaboreflex activation and endothelial function impairment in atrial fibrillation.
SO  - American Journal of Physiology - Heart & Circulatory Physiology. 291(5):H2396-402, 2006 Nov.
AS  - Am J Physiol Heart Circ Physiol. 291(5):H2396-402, 2006 Nov.
NJ  - American journal of physiology. Heart and circulatory physiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - dkm, 100901228
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Antioxidants/pd [Pharmacology]
MH  - Ascorbic Acid/pd [Pharmacology]
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Brachial Artery/ph [Physiology]
MH  - Brachial Artery/us [Ultrasonography]
MH  - Diabetes Complications/pp [Physiopathology]
MH  - Diabetes Mellitus, Type 2/pp [Physiopathology]
MH  - Double-Blind Method
MH  - Echocardiography
MH  - Electric Countershock
MH  - Endothelium, Vascular/de [Drug Effects]
MH  - *Endothelium, Vascular/ph [Physiology]
MH  - *Exercise
MH  - Female
MH  - Humans
MH  - Hypertension/pp [Physiopathology]
MH  - Male
MH  - Middle Aged
MH  - Reflex/ph [Physiology]
MH  - Regional Blood Flow/ph [Physiology]
AB  - Exercising muscle hypoperfusion stimulates afferents (metaboreceptors) involved in the regulation of ventilation. Atrial fibrillation (AF), particularly when combined with diseases causing endothelial (ED) impairment, such as hypertension (HP) and diabetes mellitus (DM), depresses the ED activity and enhances exercise hyperventilation. The relationship between these two functions and the underlying mechanisms have not been explored previously. In lone AF or AF associated with HP or DM (12 subjects in each cohort), we investigated the brachial artery flow-mediated dilatation (ED function) and ventilation during the recovery phase of handgrip (metaboreflex) exercise for subjects receiving placebo or oral vitamin C (double-blind crossover), both before and after cardioversion (CV) to sinus rhythm. Baseline ED impairment was increasingly more severe and the ergoreflex activity more pronounced in AF + HP and AF + DM compared with lone AF. Vitamin C and CV significantly improved both flow-mediated dilatation and metaboreflex activity in lone AF and AF + HP, and vitamin C did not produce any additive effect when administered after CV. In AF + DM, neither vitamin C nor CV was effective. This study provides the following information: AF generates oxidative injury, which is less when the arrhythmia is lone AF and greater when the arrhythmia is associated with HP. In DM, the oxidative injury generated by AF is refractory to a rather weak antioxidant, like vitamin C, or the baseline damage is such as to prevent any additive influence of AF. In AF, a cause-effect link exists between ED dysfunction and metaboreflex activity. Ventilatory advantages of CV seem to be inversely related with the extension of the underlying ED oxidative impairment.
RN  - 0 (Antioxidants)
RN  - PQ6CK8PD0R (Ascorbic Acid)
IS  - 0363-6135
IL  - 0363-6135
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20060630
DP  - 2006 Nov
DC  - 20061010
YR  - 2006
ED  - 20070112
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16815988

<584. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17064211
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Parrish RH
AU  - Pazdur DE
AU  - O'donnell PJ
FA  - Parrish, Richard H
FA  - Pazdur, Danielle E
FA  - O'donnell, Philip J
IN  - Parrish,Richard H. Department of Pharmacy, Bon Secours St. Mary's Hospital, Richmond, Virginia 23226, USA. rhparrish2@yahoo.com
TI  - Effect of carbamazepine initiation and discontinuation on antithrombotic control in a patient receiving warfarin: case report and review of the literature.
SO  - Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy. 26(11):1650-3, 2006 Nov.
AS  - Pharmacotherapy. 26(11):1650-3, 2006 Nov.
NJ  - Pharmacotherapy
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - par, 8111305
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Analgesics, Non-Narcotic/tu [Therapeutic Use]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Carbamazepine/tu [Therapeutic Use]
MH  - Drug Interactions
MH  - Facial Pain/dt [Drug Therapy]
MH  - Female
MH  - Humans
MH  - International Normalized Ratio
MH  - Stroke/pc [Prevention & Control]
MH  - Thrombosis/pc [Prevention & Control]
MH  - *Warfarin/tu [Therapeutic Use]
AB  - A 72-year-old Caucasian woman with paroxysmal atrial fibrillation had been taking warfarin therapy for 5 years with a stable international normalized ratio (INR). Her dentist then prescribed carbamazepine 200 mg/day to control facial nerve pain. At her next physician visit about 2 weeks after the start of the carbamazepine, the patient's INR had dropped from 3.3 to 1.3; she reported no contributing changes in her diet or warfarin dosage, nor had she taken other interacting drugs. Her warfarin dosage was increased, and the INR returned to the target range of 2.0-3.0 approximately 2 months later. The patient's INR remained stable for approximately 6 more months, until she had facial surgery. During that time, her warfarin was discontinued for 5 days, and the patient had stopped taking the carbamazepine because she had no pain. One month later, her INR increased from 2.2 to 3.6. She did not experience any thrombotic or hemorrhagic episodes. Warfarin undergoes hepatic metabolism through cytochrome P450 2C9, and carbamazepine induces this isoenzyme. Inducing warfarin metabolism necessitates an increase in the warfarin dosage to maintain the INR in the therapeutic target range. To our knowledge, this is the first report documenting the effect of the carbamazepine initiation and discontinuation in a patient receiving anticoagulation therapy with warfarin. In patients taking warfarin, clinicians should monitor the INR closely when carbamazepine is started or discontinued, or when either dosage is changed.
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Anticoagulants)
RN  - 33CM23913M (Carbamazepine)
RN  - 5Q7ZVV76EI (Warfarin)
IS  - 0277-0008
IL  - 0277-0008
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2006 Nov
DC  - 20061026
YR  - 2006
ED  - 20070110
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17064211

<585. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17126638
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Li Z
AU  - Seeram NP
AU  - Carpenter CL
AU  - Thames G
AU  - Minutti C
AU  - Bowerman S
FA  - Li, Zhaoping
FA  - Seeram, Navindra P
FA  - Carpenter, Catherine L
FA  - Thames, Gail
FA  - Minutti, Chayo
FA  - Bowerman, Susan
IN  - Li,Zhaoping. Division of Clinical Nutrition, UCLA Center for Human Nutrition, Geffen School of Medicine at UCLA, 900 Veteran Ave, Room 12-217, Los Angeles, CA 90095-1742, USA. zli@mednet.ucla.edu
TI  - Cranberry does not affect prothrombin time in male subjects on warfarin.
SO  - Journal of the American Dietetic Association. 106(12):2057-61, 2006 Dec.
AS  - J Am Diet Assoc. 106(12):2057-61, 2006 Dec.
NJ  - Journal of the American Dietetic Association
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - h6f, 7503061
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - *Beverages
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - *Food-Drug Interactions
MH  - Humans
MH  - International Normalized Ratio
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - *Prothrombin Time
MH  - Time Factors
MH  - *Vaccinium macrocarpon
MH  - *Warfarin/tu [Therapeutic Use]
AB  - There have been case reports suggesting that cranberry beverages may interact with warfarin. To date, no research study has been conducted to examine the potential interaction of cranberry and warfarin. The current study is a randomized, placebo-controlled, double-blind, crossover study to investigate the effect of cranberry juice on prothrombin time as assessed by the international normalized ratio (INR). Seven subjects with atrial fibrillation on a stable dose of warfarin for 3 months were randomized to consume 250 mL of cranberry juice for 7 days, then placebo for 7 days, or vice versa. The washout period was 7 days. The prothrombin time/INR was measured at baseline, and on days 2, 4, 7, 10, 14, 16, 18, 21, and 24. Data were analyzed by the Student t test for paired values. The baseline INR was 2.28+/-0.54 for the cranberry group and 2.13+/-0.50 for the placebo group. For all test points, the INR did not change significantly from baseline. At day 7 on cranberry juice, the INR was 2.23+/-0.53 for cranberry first group and 2.16+/-0.40 for placebo first group. The mean differences between the cranberry and placebo groups were not statistically significant. Our results suggest no significant interaction between the daily consumption of 250 mL cranberry juice and warfarin. When counseling patients on dietary changes necessary during warfarin treatment, it does not seem necessary to eliminate daily cranberry juice consumption at amounts of 250 mL, but the INR should be followed up closely.
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
IS  - 0002-8223
IL  - 0002-8223
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 2006 Dec
DC  - 20061127
YR  - 2006
ED  - 20070109
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17126638

<586. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17053177
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wiberg B
AU  - Sundstrom J
AU  - Arnlov J
AU  - Terent A
AU  - Vessby B
AU  - Zethelius B
AU  - Lind L
FA  - Wiberg, Bernice
FA  - Sundstrom, Johan
FA  - Arnlov, Johan
FA  - Terent, Andreas
FA  - Vessby, Bengt
FA  - Zethelius, Bjorn
FA  - Lind, Lars
IN  - Wiberg,Bernice. Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala Science Park, SE-751 85 Uppsala, Sweden. bernice.wiberg@akademiska.se
TI  - Metabolic risk factors for stroke and transient ischemic attacks in middle-aged men: a community-based study with long-term follow-up.
SO  - Stroke. 37(12):2898-903, 2006 Dec.
AS  - Stroke. 37(12):2898-903, 2006 Dec.
NJ  - Stroke; a journal of cerebral circulation
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - v2j, 0235266
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - Dietary Fats/ae [Adverse Effects]
MH  - Follow-Up Studies
MH  - Humans
MH  - *Ischemic Attack, Transient/bl [Blood]
MH  - *Ischemic Attack, Transient/ep [Epidemiology]
MH  - Lipoproteins/bl [Blood]
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - *Residence Characteristics
MH  - Risk Factors
MH  - *Stroke/bl [Blood]
MH  - *Stroke/ep [Epidemiology]
MH  - Time Factors
AB  - BACKGROUND AND PURPOSE: The impact of lipometabolic and glucometabolic disturbances on stroke incidence remains to be characterized in detail. We investigated relations of a comprehensive panel of baseline lipometabolic and glucometabolic variables to incident fatal and nonfatal stroke or transient ischemic attack (TIA), and stroke subtypes.
AB  - METHODS: A community-based prospective study of 2313 middle-aged men invited to a health survey at age 50.
AB  - RESULTS: During a follow-up of up to 32 years, 421 developed stroke or TIA. In Cox proportional hazards analyses adjusting for treatment with cardiovascular drugs at baseline, 1-standard deviation increases in body mass index, systolic and diastolic blood pressures, serum proinsulin, and lipoprotein(a) were associated with 11 to 35% increased risk for subsequent stroke/TIA. Electrocardiographic left ventricular hypertrophy and smoking were also associated with a higher risk for stroke/TIA. Essentially the same variables were related to brain infarction/TIA. Higher proportions of palmitic (16:0), palmitoleic (16:1), and oleic acid (18:1) in cholesterol esters were associated with an increased risk, whereas a higher proportion of linoleic acid (18:2 n-6) was protective against stroke/TIA. Further adjusting all models also for hypertension, diabetes, the metabolic syndrome, serum cholesterol, atrial fibrillation, cardiovascular disease, smoking, and physical activity, essentially the same pattern was observed.
AB  - CONCLUSIONS: Indices of an unhealthy dietary fat intake and a high serum lipoprotein (a) level predicted fatal and nonfatal stroke/TIA independently of established risk factors in a community-based sample of middle-aged men followed for 32 years.
RN  - 0 (Dietary Fats)
RN  - 0 (Lipoproteins)
ES  - 1524-4628
IL  - 0039-2499
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20061019
DP  - 2006 Dec
DC  - 20061128
YR  - 2006
ED  - 20061229
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17053177

<587. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16884507
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lukac P
AU  - Hjortdal V
AU  - Pedersen AK
AU  - Jensen HK
AU  - Mortensen PT
AU  - Hansen PS
FA  - Lukac, Peter
FA  - Hjortdal, Vibeke
FA  - Pedersen, Anders K
FA  - Jensen, Henrik K
FA  - Mortensen, Peter T
FA  - Hansen, Peter S
IN  - Lukac,Peter. Department of Cardiology, Aarhus University Hospital at Skejby, Aarhus, Denmark. lukacpe2@hotmail.com
TI  - The superior transseptal surgical approach to mitral valve creates slow conduction.
SO  - Pacing & Clinical Electrophysiology. 29(7):719-26, 2006 Jul.
AS  - Pacing Clin Electrophysiol. 29(7):719-26, 2006 Jul.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - Analysis of Variance
MH  - Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/su [Surgery]
MH  - Atrial Flutter/et [Etiology]
MH  - Atrial Flutter/pp [Physiopathology]
MH  - *Atrial Flutter/su [Surgery]
MH  - *Catheter Ablation
MH  - Electrophysiologic Techniques, Cardiac
MH  - Female
MH  - Heart Conduction System/pp [Physiopathology]
MH  - Heart Septum/su [Surgery]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve Insufficiency/su [Surgery]
MH  - Retrospective Studies
MH  - Statistics, Nonparametric
MH  - Treatment Outcome
AB  - BACKGROUND: Atrial tachycardia is very frequent after mitral valve surgery using the superior transseptal approach.
AB  - METHODS: Sixteen patients operated on for mitral valve disease (superior transseptal approach = Group A, n = 9, and left atrial approach = Group B, n = 7) underwent radiofrequency catheter ablation of atrial tachycardia guided by electroanatomic mapping. Twenty-six consecutive patients without previous cardiac surgery with typical atrial flutter served as controls (Group C).
AB  - RESULTS: Atrial tachycardia occurred earlier after the operation in Group A than in Group B (median 97 vs 2,159 days, P = 0.003). Typical atrial flutter was the most frequent circuit in all groups (Group A-7 patients, Group B-5 patients, Group C-26 patients). Three patients in Group A developed right atrial incisional tachycardia. Ten of 14 tachycardia circuits (typical atrial flutter, n = 7, incisional tachycardia, n = 3) in Group A depended on the corridor between the right atrial part of the atriotomy and the tricuspid annulus. Slow conduction during typical atrial flutter was detected in this corridor in Group A, but not in the corresponding region in Groups B and C (P < 0.001). The cycle length of typical atrial flutter was longer in Groups A and B than in Group C (mean 283 ms and 282 ms vs 233 ms, P = 0.003). Patients in Group B with typical atrial flutter had larger right atria than patients in Group A or Group C (mean 156 mL vs 96 mL and 113 mL, P = 0.033).
AB  - CONCLUSIONS: The superior transseptal incision may predispose to atrial tachycardia by creating slow conduction between the atriotomy and the tricuspid annulus.
IS  - 0147-8389
IL  - 0147-8389
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2006 Jul
DC  - 20060803
YR  - 2006
ED  - 20061207
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16884507

<588. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16864616
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Funck RC
AU  - Blanc JJ
AU  - Mueller HH
AU  - Schade-Brittinger C
AU  - Bailleul C
AU  - Maisch B
AU  - BioPace Study Group
FA  - Funck, Reinhard C
FA  - Blanc, Jean-Jacques
FA  - Mueller, Hans-Helge
FA  - Schade-Brittinger, Carmen
FA  - Bailleul, Christophe
FA  - Maisch, Bernhard
FA  - BioPace Study Group
IN  - Funck,Reinhard C. Department of Cardiology and Angiology, Clinic of Internal Medicine and Cardiology, University Hospital Philipps-University Marburg, Baldingerstr 1, D-35033 Marburg, Germany. funck@mailer.uni-marburg.de
TI  - Biventricular stimulation to prevent cardiac desynchronization: rationale, design, and endpoints of the 'Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization (BioPace)' study.
SO  - Europace. 8(8):629-35, 2006 Aug.
AS  - Europace. 8(8):629-35, 2006 Aug.
NJ  - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - dxd, 100883649
SB  - Index Medicus
CP  - England
MH  - *Cardiac Pacing, Artificial/mt [Methods]
MH  - Defibrillators, Implantable
MH  - Echocardiography
MH  - Endpoint Determination
MH  - Follow-Up Studies
MH  - *Heart Block/pp [Physiopathology]
MH  - *Heart Block/th [Therapy]
MH  - *Heart Conduction System/pp [Physiopathology]
MH  - Heart Ventricles/ir [Innervation]
MH  - *Heart Ventricles/pp [Physiopathology]
MH  - Humans
MH  - Quality of Life
MH  - Surveys and Questionnaires
MH  - Survival Rate
MH  - Walking/ph [Physiology]
AB  - Despite the deleterious effects of cardiac dyssynchrony and the positive effects of cardiac resynchronization therapy, patients with high-degree atrioventricular block continue to receive desynchronizing right ventricular (RV) pacing systems. Although it is unclear whether the negative effects of RV pacing and left bundle branch block (LBBB) are comparable, and whether they depend on the presence and the degree of structural heart disease, one may hypothesize that RV pacing may have similar effects to LBBB. In the BioPace trial, the long-term effects of RV pacing vs. biventricular pacing will be prospectively compared in 1200 pacemaker patients with high likelihood of mostly paced ventricular events, regardless of whether in sinus rhythm or in atrial fibrillation (AF). After echocardiographic examination of left ventricular (LV) function, patients will be randomly assigned to the implantation of an RV vs. a biventricular pacing system and followed for up to 5 years. Primary study endpoints are survival, quality of life (QoL), and the distance covered in a 6-min hall walk (6-MHW) at 24 months after implantation. Secondary endpoints are QoL and the 6-MHW result at 12 months after implantation, hospitalization rate, LV dimensions, LV ejection fraction, and the development of chronic AF and other adverse events.
IS  - 1099-5129
IL  - 1099-5129
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
LG  - English
DP  - 2006 Aug
DC  - 20060725
YR  - 2006
ED  - 20061205
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16864616

<589. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 17071177
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - McLean TR
AU  - Haller CC
FA  - McLean, Thomas R
FA  - Haller, Chris C
IN  - McLean,Thomas R. Department of Surgery, EKVAHCS, 4104 S Fourth Street Trafficway, Leavenworth, KS 66048, USA. Thomas.McLean@med.va.gov
TI  - Stapled diverticulectomy and myotomy for symptomatic Zenker's diverticulum.
SO  - American Journal of Surgery. 192(5):e28-31, 2006 Nov.
AS  - Am J Surg. 192(5):e28-31, 2006 Nov.
NJ  - American journal of surgery
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 3z4, 0370473
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged, 80 and over
MH  - Comorbidity
MH  - *Digestive System Surgical Procedures/mt [Methods]
MH  - *Esophageal Sphincter, Upper/su [Surgery]
MH  - Humans
MH  - Male
MH  - Retrospective Studies
MH  - *Surgical Stapling
MH  - Zenker Diverticulum/ep [Epidemiology]
MH  - *Zenker Diverticulum/su [Surgery]
AB  - BACKGROUND: Few surgeons have extensive experience with the operative management of Zenker's diverticulum (ZD).
AB  - METHODS: Retrospective review of stapled diverticulectomy and cricopharyngeal myotomy (SDM) for ZD. All procedures were performed by midlevel surgery residents supervised by single board-certified surgeon. A drain was not used, and patients were liberally advanced to a regular diet postoperatively.
AB  - RESULTS: Three patients with ZD underwent this procedure during a 6-year period. The mean age of the patients was 81 years, and all had multiple comorbidities. Time to discharge was less than 48 hours in 2 patients and 5 days in 1 patient who developed new atrial fibrillation. There were no deaths or clinical leaks. At a mean follow-up of 33 (range 6-62) months, 1 patient died of an unrelated cause, and the other 2 are free of esophageal-related symptoms.
AB  - CONCLUSIONS: SDM for ZD is a safe and effective operation that is easily taught to surgical residents.
ES  - 1879-1883
IL  - 0002-9610
PT  - Journal Article
LG  - English
DP  - 2006 Nov
DC  - 20061030
YR  - 2006
ED  - 20061121
RD  - 20090520
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17071177

<590. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16309956
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gould PA
AU  - D'Agostino J
AU  - Schneider HG
AU  - Kaye DM
FA  - Gould, P A
FA  - D'Agostino, J
FA  - Schneider, H G
FA  - Kaye, D M
IN  - Gould,P A. Baker Heart Research Institute, Wynn Department of Metabolic Cardiology, PO Box 6492, St. Kilda Road Central, Melbourne Victoria 8008, Australia.
TI  - Influence of atrial fibrillation on cardiac brain natriuretic peptide release during haemodynamic stress in heart failure.
SO  - European Journal of Heart Failure. 8(3):263-9, 2006 May.
AS  - Eur J Heart Fail. 8(3):263-9, 2006 May.
NJ  - European journal of heart failure
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - dr4, 100887595
SB  - Index Medicus
CP  - Netherlands
MH  - Aged
MH  - *Atrial Fibrillation/me [Metabolism]
MH  - *Blood Pressure
MH  - Exercise
MH  - Female
MH  - *Heart Failure/me [Metabolism]
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Myocardium/se [Secretion]
MH  - *Natriuretic Peptide, Brain/se [Secretion]
MH  - Posture
AB  - BACKGROUND: The determinants of release of brain natriuretic peptide (BNP) in heart failure (HF) are incompletely understood, particularly, the effect of heart rhythm and haemodynamic stress.
AB  - AIMS: To investigate the effect of haemodynamic stress on cardiac BNP release in HF and differentiate this response for atrial fibrillation (AF) and sinus rhythm (SR).
AB  - METHODS: In 18 HF patients (ejection fraction<40%, 9 in AF and 9 in SR) haemodynamics and BNP levels were measured from arterial and coronary sinus samples at baseline, after 10 min of 20 degrees passive head up tilt (HUT) and after 10 min of isometric handgrip (IHG) exercise. From these data, we calculated a transcardiac BNP gradient and compared results between the AF and SR cohort.
AB  - RESULTS: During haemodynamic stress in both groups, there were no significance differences in left sided filling pressures. At baseline, there were no differences in BNP measurements between the SR and AF group. The transcardiac BNP gradient increased significantly in the SR (p=0.02) but not the AF cohort, after HUT. During IHG exercise, there was a significant decrease in cardiac BNP release in the AF cohort (p=0.03) but not the SR cohort.
AB  - CONCLUSION: These data imply in HF, cardiac rhythm influences cardiac BNP release in response to haemodynamic stress.
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
IS  - 1388-9842
IL  - 1388-9842
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20051123
DP  - 2006 May
DC  - 20060515
YR  - 2006
ED  - 20061026
RD  - 20110608
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16309956

<591. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16957412
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Moreno O
AU  - Meoro A
AU  - Martinez A
AU  - Rodriguez C
AU  - Pardo C
AU  - Aznar S
AU  - Lopez P
AU  - Serrano J
AU  - Boix E
AU  - Martin MD
AU  - Pico Alfonso AM
FA  - Moreno, O
FA  - Meoro, A
FA  - Martinez, A
FA  - Rodriguez, C
FA  - Pardo, C
FA  - Aznar, S
FA  - Lopez, P
FA  - Serrano, J
FA  - Boix, E
FA  - Martin, M D
FA  - Pico Alfonso, A M
IN  - Moreno,O. Endocrinology and Nutrition Section, Alicante General University Hospital, CP03010, Alicante, Spain. oscarmorenop76@hotmail.com
TI  - Comparison of two low-calorie diets: a prospective study of effectiveness and safety.
SO  - Journal of Endocrinological Investigation. 29(7):633-40, 2006 Jul-Aug.
AS  - J Endocrinol Invest. 29(7):633-40, 2006 Jul-Aug.
NJ  - Journal of endocrinological investigation
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - iam, 7806594
SB  - Index Medicus
CP  - Italy
MH  - Adult
MH  - Blood Glucose
MH  - Blood Pressure
MH  - Body Composition
MH  - Body Mass Index
MH  - Caloric Restriction
MH  - Diet, Reducing/ae [Adverse Effects]
MH  - Diet, Reducing/ec [Economics]
MH  - *Diet, Reducing
MH  - Female
MH  - Humans
MH  - Insulin Resistance
MH  - Male
MH  - Middle Aged
MH  - *Obesity/dh [Diet Therapy]
MH  - Treatment Outcome
MH  - Weight Loss
AB  - OBJECTIVE: To evaluate the cost-effectiveness and safety of two distinct low calorie diets (LCD).
AB  - DESIGN: Prospective controlled study.
AB  - METHODS: 67 obese patients [body mass index (BMI) 40 kg/m2] were included in two study groups. Group A: 26 patients followed a 458 kcal diet given in three meals for 1 month. Group B: 41 patients followed a 800 kcal diet for 3 months and with outpatient control.
AB  - MEASUREMENTS: Anthropometric, cardiovascular risk and nutritional profile changes were evaluated, as well as total direct and indirect costs, and the incidence of complications.
AB  - RESULTS: No significant initial differences were observed between the two study groups. Eighty-six point two per cent of the patients completed the therapy correctly. After treatment a significant decrease was observed in the following variables for both groups, but no differences were detected between Groups A and B: mean weight loss (A= 9.28 kg, B= 8.7 kg), ponderal loss percentage (A/B= 7.2/6.8%), glycemia (A/B= 18.6/12.1 mg/dl), systolic blood pressure (SBP) (A/B= 11.8/6.5 mmHg), diastolic blood pressure (DBP) (A/B 5.9/6.8 mmHg), and final insulin-resistance (IR) index (A= 4.4, B= 4.3). Group A had the highest drop in total cholesterol (37.7 vs 8.1 mg/dl) and triglycerides (54.4 vs 2.5 mg/dl). No changes were observed in ureic acid, renal function and serum albumin. Thirty-six patients (55.3%) suffered trivial complications associated to the VLCD (16.9% gastrointestinal, 20% anxiety), with no differences between groups. Group A patients were on sick leave due to asthenia, and two patients in this group had serious complications (transient ischemic attack and atrial fibrillation). The total cost of Group A treatment was 3018.9 against 582.6 euros for Group B.
AB  - CONCLUSIONS: The 3-month 800 kcal/day VLCD was more cost-effective and safer than the 1-month 458 kcal/day diet.
RN  - 0 (Blood Glucose)
IS  - 0391-4097
IL  - 0391-4097
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
LG  - English
DP  - 2006 Jul-Aug
DC  - 20060907
YR  - 2006
ED  - 20061020
RD  - 20140729
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16957412

<592. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16716014
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - van de Veire NR
AU  - de Winter O
AU  - Gillebert TC
AU  - de Sutter J
FA  - van de Veire, Nico R
FA  - de Winter, Olivier
FA  - Gillebert, Thierry C
FA  - de Sutter, Johan
IN  - van de Veire,Nico R. Department of Cardiovascular Diseases, University Hospital Ghent, De Pintelaan 185, 9000 Gent, Belgium. nico.vandeveire@ugent.be
TI  - Diabetes and impaired fasting glucose as predictors of morbidity and mortality in male coronary artery disease patients with reduced left ventricular function.
SO  - Acta Cardiologica. 61(2):137-43, 2006 Apr.
AS  - Acta Cardiol. 61(2):137-43, 2006 Apr.
NJ  - Acta cardiologica
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0370570
SB  - Index Medicus
CP  - Belgium
MH  - Aged
MH  - *Blood Glucose
MH  - Coronary Artery Disease/bl [Blood]
MH  - *Coronary Artery Disease/mo [Mortality]
MH  - Death
MH  - Diabetes Complications/bl [Blood]
MH  - *Diabetes Complications/mo [Mortality]
MH  - Fasting
MH  - Glucose Intolerance/bl [Blood]
MH  - *Glucose Intolerance/mo [Mortality]
MH  - Hospitalization/sn [Statistics & Numerical Data]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Survival Analysis
MH  - Systole
MH  - Ventricular Dysfunction, Left/bl [Blood]
MH  - *Ventricular Dysfunction, Left/mo [Mortality]
AB  - OBJECTIVES: To evaluate the prognostic value of impaired fasting glucose and diabetes mellitus in male patients with coronary artery disease and poor left ventricular function.
AB  - METHODS AND RESULTS: From a prospective database on patients referred for gated myocardial perfusion imaging between 1998 and 2002 all male patients with a history of coronary artery disease and poor left ventricular function were selected. Poor function was defined as left ventricular ejection fraction < or = 40%. Subjects were classified as non-diabetics with fasting blood glucose levels < 110 mg/dL, non-diabetics with impaired fasting glucose (fasting blood glucose between 110 and 125 mg/dL) and diabetics. Median follow-up was 2.7years. End points were all-cause mortality, cardiac death and hospitalization for heart failure. One hundred and sixty patients were selected (age 65 +/- 9 years and left ventricular ejection fraction 29 +/- 8%). In univariate analysis atrial fibrillation, NYHA class, glycaemia and diabetes mellitus discriminated between survivors and non-survivors. In Cox multivariate regression analysis for all-cause mortality only NYHA class and diabetes mellitus remained significant. Kaplan Meier analysis showed that diabetics had the worst survival and non-diabetics with glucose < 110 mg/dL had the best survival. Non-diabetics with impaired fasting glucose had intermediate survival. Analysis for cardiac death/hospitalization for heart failure showed similar results.
AB  - CONCLUSION: In male patients with coronary artery disease and impaired left ventricular function diabetes mellitus and fasting glucose are strongly predictive of poor outcome. Diabetics have the worst prognosis but non-diabetics with impaired fasting glucose also are at higher risk compared to nondiabetics with low fasting blood glucose.
RN  - 0 (Blood Glucose)
IS  - 0001-5385
IL  - 0001-5385
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2006 Apr
DC  - 20060523
YR  - 2006
ED  - 20061013
RD  - 20090611
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16716014

<593. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16553520
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lee NJ
AU  - Fermo JD
FA  - Lee, Nancy J
FA  - Fermo, Joli D
IN  - Lee,Nancy J. Department of Pharmacy and Clinical Sciences, South Carolina College of Pharmacy, Charleston, South Carolina 29425, USA.
TI  - Warfarin and royal jelly interaction.
SO  - Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy. 26(4):583-6, 2006 Apr.
AS  - Pharmacotherapy. 26(4):583-6, 2006 Apr.
NJ  - Pharmacotherapy
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - par, 8111305
SB  - Index Medicus
CP  - United States
MH  - Aged, 80 and over
MH  - *Anticoagulants/ae [Adverse Effects]
MH  - *Fatty Acids/ae [Adverse Effects]
MH  - *Hematuria/ci [Chemically Induced]
MH  - *Herb-Drug Interactions
MH  - Humans
MH  - *Insect Hormones/ae [Adverse Effects]
MH  - Male
MH  - *Warfarin/ae [Adverse Effects]
AB  - An 87-year-old African-American man came to the internal medicine clinic for a routine anticoagulation management visit. He had no complaints. His medical history was significant for stage IV-A follicular non-Hodgkin's lymphoma, atrial fibrillation, and hypertension. His long-term drug therapy consisted of warfarin, felodopine, lisinopril-hydrochlorothiazide, controlled-release diltiazem, potassium chloride, and oxycodone. He reported adherence with his prescribed drugs and denied taking any over-the-counter or herbal products. Overall, the patient's drug therapy had been consistent during the preceding 3 months, no significant changes had occurred in his clinical status, and no significant changes had been noted in his diet; his international normalized ratio (INR) had ranged from 1.9-2.4 (therapeutic range 2-3). He denied tobacco use, alcohol consumption, and recent travel. Four weeks later, the patient came to the emergency department with hematuria. He denied dysuria, taking more than the prescribed amount of warfarin, any changes in his diet, taking any over-the-counter or herbal products, and any other bleeding. On admission to the hospital, his INR was 6.88, which increased to 7.29 during his hospital stay. On further investigation, the patient admitted that he had started taking an herbal supplement, royal jelly, 1 week earlier. When asked specifically about the ingredients in the supplement, he stated that royal jelly was the only component. Relative to the patient's denial of any other changes in his condition or drug regimen, the most probable explanation for his elevated INR and subsequent bleeding is a possible interaction between royal jelly and warfarin. To our knowledge, no case reports concerning royal jelly and warfarin taken concomitantly have been reported. Clinicians should be proactive and repeatedly provide education regarding the potential dangers of dietary supplements taken with conventional drugs.
RN  - 0 (Anticoagulants)
RN  - 0 (Fatty Acids)
RN  - 0 (Insect Hormones)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 8031-67-2 (royal jelly)
IS  - 0277-0008
IL  - 0277-0008
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2006 Apr
DC  - 20060323
YR  - 2006
ED  - 20061003
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16553520

<594. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16553508
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gillespie EL
AU  - White CM
AU  - Kluger J
AU  - Rancourt JA
AU  - Gallagher R
AU  - Coleman CI
FA  - Gillespie, Effie L
FA  - White, C Michael
FA  - Kluger, Jeffrey
FA  - Rancourt, James A
FA  - Gallagher, Robert
FA  - Coleman, Craig I
IN  - Gillespie,Effie L. University of Connecticut School of Pharmacy, Storrs, Connecticut, USA.
TI  - Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation after cardiothoracic surgery.
SO  - Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy. 26(4):499-504, 2006 Apr.
AS  - Pharmacotherapy. 26(4):499-504, 2006 Apr.
NJ  - Pharmacotherapy
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - par, 8111305
SB  - Index Medicus
CP  - United States
MH  - *Adrenergic beta-Antagonists/tu [Therapeutic Use]
MH  - Aged
MH  - *Amiodarone/tu [Therapeutic Use]
MH  - *Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - Atrial Fibrillation/ec [Economics]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - *Cardiac Surgical Procedures/ae [Adverse Effects]
MH  - Case-Control Studies
MH  - Chemoprevention/ec [Economics]
MH  - Cost-Benefit Analysis
MH  - Female
MH  - Hospital Costs
MH  - Humans
MH  - Length of Stay/ec [Economics]
MH  - Male
MH  - *Postoperative Period
MH  - Retrospective Studies
MH  - Time Factors
AB  - STUDY OBJECTIVE: To determine whether prophylactic amiodarone, dosed according to Atrial Fibrillation Suppression Trial (AFIST) I and II regimens, is a cost-effective strategy for prevention of postoperative atrial fibrillation.
AB  - DESIGN: Cost-effectiveness analysis of retrospective cohort study.
AB  - SETTING: Urban, academic hospital.
AB  - PATIENTS: A total of 2046 patients who underwent cardiothoracic surgery between February 1, 1998, and October 31, 2003. Of these patients, 186 received amiodarone and 1860 served as controls.
AB  - MEASUREMENTS AND MAIN RESULTS: Each patient who received prophylactic amiodarone using the AFIST I or II dosing strategies was matched for age, sex, history of valvular surgery, history of atrial fibrillation, beta-blocker intolerance, and receipt of preoperative digoxin therapy with 10 patients who did not receive prophylactic amiodarone. Occurrence of postoperative atrial fibrillation, total hospital costs, and both intensive care unit (ICU) and total hospital length of stay (LOS) were compared between groups. Nonparametric bootstrapping was conducted to examine study results as part of a quadrant analysis and to calculate confidence intervals for the incremental cost-effectiveness ratio. The ICU and total hospital LOS, and total costs for patients with and without postoperative atrial fibrillation were also compared. Fewer patients receiving prophylactic amiodarone developed postoperative atrial fibrillation compared with controls (23.1% vs 29.9%, p=0.05). Total hospital costs for the amiodarone group were 28% less than those for the control group (24,131 US dollars +/- 26,539 vs 33,518 US dollars +/- 40,892, p=0.002). Approximately 98% of the time, patients receiving amiodarone prophylaxis fell into the quadrant that showed superior efficacy and lower total costs. Patients who developed postoperative atrial fibrillation, compared with those who did not, regardless of amiodarone prophylaxis, had a longer mean +/- SD stay in the ICU (6.9 +/- 17.1 vs 3.7 +/- 7.9 days, p<0.001), a longer mean total hospital LOS (14.8 +/- 18.8 vs 10.2 +/- 10.4 days, p+/-0.001), and higher mean total hospital costs (41,574 US dollars +/- 54,721 vs 28,968 US dollars +/- 31,046, p<0.001).
AB  - CONCLUSION: Prophylactic amiodarone was shown to reduce the occurrence of postoperative atrial fibrillation as well as total hospital costs in patients undergoing cardiothoracic surgery. In patients who developed postoperative atrial fibrillation, both ICU and total hospital LOS as well as total hospital costs were increased.
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Anti-Arrhythmia Agents)
RN  - N3RQ532IUT (Amiodarone)
IS  - 0277-0008
IL  - 0277-0008
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2006 Apr
DC  - 20060323
YR  - 2006
ED  - 20061003
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16553508

<595. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16910441
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Farrar MW
AU  - Bogart DB
AU  - Chapman SS
AU  - Rigden LB
FA  - Farrar, Michael W
FA  - Bogart, Douglas B
FA  - Chapman, Scott S
FA  - Rigden, L Brick
TI  - Atrial fibrillation in athletes. [Review] [60 refs]
CM  - Comment in: Mo Med. 2006 Nov-Dec;103(6):598; PMID: 17256267
CM  - Comment in: Mo Med. 2006 May-Jun;103(3):200-1; PMID: 16910425
SO  - Missouri Medicine. 103(3):297-301, 2006 May-Jun.
AS  - Mo Med. 103(3):297-301, 2006 May-Jun.
NJ  - Missouri medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - new, 0400744
SB  - Index Medicus
CP  - United States
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/th [Therapy]
MH  - *Atrial Fibrillation
MH  - Exercise
MH  - Humans
MH  - Physical Endurance
MH  - Practice Guidelines as Topic
MH  - Running
MH  - *Sports
MH  - Stroke/ep [Epidemiology]
AB  - A 60-year old male physician on staff at North Kansas City Hospital was admitted with paroxysmal atrial fibrillation. The physician is an avid long-distance runner. Ultimately, three other male physicians on staff, all long-distance runners, were identified as having lone atrial fibrillation. This prompted a literature search which initially indicated a higher than normal incidence of atrial fibrillation in endurance and elite athletes. However, recent data has questioned the validity of this observation. The management of the athlete with atrial fibrillation poses special concerns and can be problematic. The incidence, causes, implications, and management of atrial fibrillation in athletes is the subject of this review. [References: 60]
IS  - 0026-6620
IL  - 0026-6620
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2006 May-Jun
DC  - 20060816
YR  - 2006
ED  - 20060928
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16910441

<596. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16910425
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Hagan JC 3rd
FA  - Hagan, John C 3rd
TI  - Fascinating rhythm: atrial fibrillation-the beat goes on.
CM  - Comment on: Mo Med. 2006 May-Jun;103(3):297-301; PMID: 16910441
SO  - Missouri Medicine. 103(3):200-1, 2006 May-Jun.
AS  - Mo Med. 103(3):200-1, 2006 May-Jun.
NJ  - Missouri medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - new, 0400744
SB  - Index Medicus
CP  - United States
MH  - Adrenergic beta-Antagonists/ae [Adverse Effects]
MH  - Adrenergic beta-Antagonists/tu [Therapeutic Use]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Physical Endurance
MH  - Running
RN  - 0 (Adrenergic beta-Antagonists)
IS  - 0026-6620
IL  - 0026-6620
PT  - Case Reports
PT  - Comment
PT  - Editorial
LG  - English
DP  - 2006 May-Jun
DC  - 20060816
YR  - 2006
ED  - 20060928
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16910425

<597. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16470141
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ahmad K
AU  - Dorian P
FA  - Ahmad, Kamran
FA  - Dorian, Paul
IN  - Ahmad,Kamran. Division of Cardiology, St Michael's Hospital and University of Toronto, Toronto, Ontario, Canada.
TI  - Rate control in atrial fibrillation: looking beyond the average heart rate. [Review] [40 refs]
SO  - Current Opinion in Cardiology. 21(2):88-93, 2006 Mar.
AS  - Curr Opin Cardiol. 21(2):88-93, 2006 Mar.
NJ  - Current opinion in cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - bda, 8608087
SB  - Index Medicus
CP  - United States
MH  - Anti-Arrhythmia Agents/ae [Adverse Effects]
MH  - *Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/px [Psychology]
MH  - *Electrocardiography/de [Drug Effects]
MH  - Exercise/ph [Physiology]
MH  - Exercise/px [Psychology]
MH  - Heart Failure/dt [Drug Therapy]
MH  - Heart Failure/pp [Physiopathology]
MH  - Heart Failure/px [Psychology]
MH  - *Heart Rate/de [Drug Effects]
MH  - Heart Rate/ph [Physiology]
MH  - Hemodynamics/de [Drug Effects]
MH  - Hemodynamics/ph [Physiology]
MH  - Humans
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Rest/ph [Physiology]
MH  - Rest/px [Psychology]
AB  - PURPOSE OF REVIEW: The aim of this article is to provide a perspective on rate control in atrial fibrillation which emphasizes patient wellbeing (exercise tolerance, symptoms, quality of life) over attempts to reduce resting or exercise heart rate to an arbitrary range.
AB  - RECENT FINDINGS: Recent trials of rhythm versus rate control strategies of treatment in patients with atrial fibrillation suggest that rate control is a viable first line strategy in many patients. The adverse consequences of atrial fibrillation with rapid ventricular response are partly due to factors other than rate itself, such as irregularity of ventricular response, and variable changes in autonomic nervous system output. Digoxin, calcium channel blockers, and beta-blockers cause a similar reduction in resting heart rate. Beta blockers are the most potent at reducing exercise heart rate, followed by calcium channel blockers and digoxin. Exercise tolerance is occasionally improved by digoxin, sometimes improved by calcium channel blockers and not improved by (and sometimes decreased by) beta-blockers. Information about quality of life with different rate control regimens is sparse.
AB  - SUMMARY: Rate control in atrial fibrillation provides important benefits to patients in terms of symptoms, quality of life and prevention of late consequences of uncontrolled rate (such as tachycardia induced cardiomyopathy). Restricting treatment objectives to achievement of a specific heart rate range on resting or exercise electrocardiogram may result in lack of patient benefit or worsened symptoms. Understanding the nuances of rate control when treating individual patients and interpreting existing evidence allows patients to experience the most benefit from this treatment strategy. [References: 40]
RN  - 0 (Anti-Arrhythmia Agents)
IS  - 0268-4705
IL  - 0268-4705
PT  - Comparative Study
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2006 Mar
DC  - 20060210
YR  - 2006
ED  - 20060928
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16470141

<598. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16966926
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Michael KM
AU  - Shaughnessy M
FA  - Michael, Kathleen M
FA  - Shaughnessy, Marianne
IN  - Michael,Kathleen M. University of Maryland School of Nursing, The Claude D. Pepper Older Americans Independence Center, Baltimore, USA. kmichael@grecc.umaryland.edu
TI  - Stroke prevention and management in older adults. [Review] [38 refs]
SO  - Journal of Cardiovascular Nursing. 21(5 Suppl 1):S21-6, 2006 Sep-Oct.
AS  - J Cardiovasc Nurs. 21(5 Suppl 1):S21-6, 2006 Sep-Oct.
NJ  - The Journal of cardiovascular nursing
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - jcn, 8703516
SB  - Index Medicus
SB  - Nursing Journal
CP  - United States
MH  - Aged
MH  - Antihypertensive Agents/tu [Therapeutic Use]
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/pc [Prevention & Control]
MH  - Carotid Stenosis/co [Complications]
MH  - Carotid Stenosis/pc [Prevention & Control]
MH  - Diabetes Mellitus, Type 2/co [Complications]
MH  - Diabetes Mellitus, Type 2/pc [Prevention & Control]
MH  - Dyslipidemias/co [Complications]
MH  - Dyslipidemias/dt [Drug Therapy]
MH  - Dyslipidemias/pc [Prevention & Control]
MH  - Female
MH  - Geriatric Nursing/mt [Methods]
MH  - *Geriatrics/mt [Methods]
MH  - Humans
MH  - Hypertension/co [Complications]
MH  - Hypertension/dt [Drug Therapy]
MH  - Hypertension/pc [Prevention & Control]
MH  - Hypolipidemic Agents/tu [Therapeutic Use]
MH  - Male
MH  - Platelet Aggregation Inhibitors/tu [Therapeutic Use]
MH  - Primary Prevention/mt [Methods]
MH  - Risk Factors
MH  - Stroke/di [Diagnosis]
MH  - Stroke/et [Etiology]
MH  - *Stroke/th [Therapy]
MH  - Thrombolytic Therapy/mt [Methods]
AB  - Stroke is the third leading cause of death and a foremost cause of serious, long-term disability in the United States. As cardiovascular and metabolic disease incidence rises with age, older people are more likely to experience strokes. Age is the single most important risk factor for stroke. For each successive 10 years after age 55, the stroke rate more than doubles in both men and women. However, stroke is not an inevitable consequence of aging. By identifying and modifying risk factors in older people, nurses can partner with other providers to reduce the incidence, morbidity, and mortality associated with stroke in older adults. Control of hypertension, resolution of dyslipidemia, management of diabetes mellitus, anticoagulation for atrial fibrillation, promotion of exercise and healthy diet, and cessation of cigarette smoking are of particular importance in older adults. Recognition of stroke symptoms, access to emergency evaluation and treatments, and participation in comprehensive rehabilitation may determine stroke outcomes in aging. This article presents stroke risk factors and primary and secondary prevention in the context of aging, with special considerations in the identification and management of acute stroke, recovery, and rehabilitation for older adults who survive stroke. [References: 38]
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
ES  - 1550-5049
IL  - 0889-4655
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
NO  - 5-P60-AG12583 (United States NIA NIH HHS)
LG  - English
DP  - 2006 Sep-Oct
DC  - 20060912
YR  - 2006
ED  - 20060927
RD  - 20101118
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16966926

<599. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16904542
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gasparini M
AU  - Auricchio A
AU  - Regoli F
AU  - Fantoni C
AU  - Kawabata M
AU  - Galimberti P
AU  - Pini D
AU  - Ceriotti C
AU  - Gronda E
AU  - Klersy C
AU  - Fratini S
AU  - Klein HH
FA  - Gasparini, Maurizio
FA  - Auricchio, Angelo
FA  - Regoli, Francois
FA  - Fantoni, Cecilia
FA  - Kawabata, Mihoko
FA  - Galimberti, Paola
FA  - Pini, Daniela
FA  - Ceriotti, Carlo
FA  - Gronda, Edoardo
FA  - Klersy, Catherine
FA  - Fratini, Simona
FA  - Klein, Helmut H
IN  - Gasparini,Maurizio. Department of Cardiology, IRCCS, Istituto Clinico Humanitas Rozzano-Milano, Milan, Italy. maurizio.gasparini@humanitas.it
TI  - Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation.
CM  - Comment in: J Am Coll Cardiol. 2006 Aug 15;48(4):744-6; PMID: 16904543
SO  - Journal of the American College of Cardiology. 48(4):734-43, 2006 Aug 15.
AS  - J Am Coll Cardiol. 48(4):734-43, 2006 Aug 15.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - h50, 8301365
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/su [Surgery]
MH  - *Atrioventricular Node/su [Surgery]
MH  - *Defibrillators, Implantable
MH  - Disease Progression
MH  - Echocardiography
MH  - *Exercise Tolerance
MH  - Female
MH  - Heart Failure/pa [Pathology]
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Pacemaker, Artificial
MH  - Treatment Outcome
MH  - Ventricular Function, Left
AB  - OBJECTIVES: The goal of this study was to investigate the effects of cardiac resynchronization therapy (CRT) in heart failure patients with permanent atrial fibrillation (AF) and the role of atrioventricular junction (AVJ) ablation.
AB  - BACKGROUND: Cardiac resynchronization therapy has been proven effective in heart failure patients with sinus rhythm (SR). However, little is known about the effects of CRT in heart failure patients with permanent AF.
AB  - METHODS: Efficacy of CRT on ventricular function, exercise performance, and reversal of maladaptive remodeling process was prospectively compared in 48 patients with permanent AF in whom ventricular rate was controlled by drugs, thus resulting in apparently adequate delivery of biventricular pacing (>85% of pacing time), and in 114 permanent AF patients, who had undergone AVJ ablation (100% of resynchronization therapy delivery). The clinical and echocardiographic long-term outcomes of both groups were compared with those of 511 SR patients treated with CRT.
AB  - RESULTS: Both SR and AF groups showed significant and sustained improvements of all assessed parameters (model p < 0.001 for all parameters). However, within the AF group, only patients who underwent ablation showed a significant increase of ejection fraction (p < 0.001), reverse remodeling effect (p < 0.001), and improved exercise tolerance (p < 0.001); no improvements were observed in AF patients who did not undergo ablation.
AB  - CONCLUSIONS: Heart failure patients with ventricular conduction disturbance and permanent AF treated with CRT showed large and sustained long-term (up to 4 year) improvements of left ventricular function and functional capacity, similar to patients in SR, only if AVJ ablation was performed.
RN  - 0 (Anti-Arrhythmia Agents)
ES  - 1558-3597
IL  - 0735-1097
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
LG  - English
EP  - 20060724
DP  - 2006 Aug 15
DC  - 20060814
YR  - 2006
ED  - 20060921
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16904542

<600. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16904540
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Singh SN
AU  - Tang XC
AU  - Singh BN
AU  - Dorian P
AU  - Reda DJ
AU  - Harris CL
AU  - Fletcher RD
AU  - Sharma SC
AU  - Atwood JE
AU  - Jacobson AK
AU  - Lewis HD Jr
AU  - Lopez B
AU  - Raisch DW
AU  - Ezekowitz MD
AU  - SAFE-T Investigators
FA  - Singh, Steven N
FA  - Tang, X Charlene
FA  - Singh, Bramah N
FA  - Dorian, Paul
FA  - Reda, Domenic J
FA  - Harris, Crystal L
FA  - Fletcher, Ross D
FA  - Sharma, Satish C
FA  - Atwood, J Edwin
FA  - Jacobson, Alan K
FA  - Lewis, H Daniel Jr
FA  - Lopez, Becky
FA  - Raisch, Dennis W
FA  - Ezekowitz, Michael D
FA  - SAFE-T Investigators
IN  - Singh,Steven N. Department of Veterans Affairs Medical Center, Washington, DC 20422, USA. steve.singh@med.va.gov
TI  - Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy.
CM  - Comment in: J Am Coll Cardiol. 2006 Aug 15;48(4):731-3; PMID: 16904541
SO  - Journal of the American College of Cardiology. 48(4):721-30, 2006 Aug 15.
AS  - J Am Coll Cardiol. 48(4):721-30, 2006 Aug 15.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - h50, 8301365
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Activities of Daily Living
MH  - Aged
MH  - *Amiodarone/tu [Therapeutic Use]
MH  - *Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Double-Blind Method
MH  - *Exercise Tolerance
MH  - Female
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Quality of Life
MH  - Severity of Illness Index
MH  - *Sotalol/tu [Therapeutic Use]
MH  - Veterans
AB  - OBJECTIVES: The purpose of this study was to determine quality of life (QOL) and exercise performance (EP) in patients with persistent atrial fibrillation (AF) converted to sinus rhythm (SR) compared with those remaining in or reverting to AF.
AB  - BACKGROUND: Restoration of SR in patients with AF improving QOL and EP remains controversial.
AB  - METHODS: Patients with persistent AF were randomized double-blind to amiodarone, sotalol, or placebo. Those not achieving SR at day 28 were cardioverted and classified into SR or AF groups at 8 weeks (n = 624) and 1 year (n = 556). The QOL (SF-36), symptom checklist (SCL), specific activity scale (SAS), AF severity scale (AFSS), and EP were assessed.
AB  - RESULTS: Favorable changes were seen in SR patients at 8 weeks in physical functioning (p < 0.001), physical role limitations (p = 0.03), general health (p = 0.002), and vitality (p < 0.001), and at 1 year in general health (p = 0.007) and social functioning (p = 0.02). Changes in the scores for SCL severity (p = 0.01), functional capacity (p = 0.003), and AFSS symptom burden (p < 0.001) at 8 weeks and in SCL severity (p < 0.01) and AF symptom burden (p < 0.001) at 1 year showed significant improvements in SR versus AF. Symptomatic patients were more likely to have improvement. The EP in SR versus AF was greater from baseline to 8 weeks (p = 0.01) and to 1 year (p = 0.02). The EP correlated with physical functioning and functional capacity except in the AF group at 1 year.
AB  - CONCLUSIONS: In patients with persistent AF, restoration and maintenance of SR was associated with improvements in QOL measures and EP. There was a strong correlation between QOL measures and EP.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - A6D97U294I (Sotalol)
RN  - N3RQ532IUT (Amiodarone)
ES  - 1558-3597
IL  - 0735-1097
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
LG  - English
EP  - 20060724
DP  - 2006 Aug 15
DC  - 20060814
YR  - 2006
ED  - 20060921
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16904540

<601. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16893708
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Thaman R
AU  - Esteban MT
AU  - Barnes S
AU  - Gimeno JR
AU  - Mist B
AU  - Murphy R
AU  - Collinson PO
AU  - McKenna WJ
AU  - Elliott PM
FA  - Thaman, Rajesh
FA  - Esteban, Maite Tome
FA  - Barnes, Sophie
FA  - Gimeno, Juan R
FA  - Mist, Bryan
FA  - Murphy, Ross
FA  - Collinson, Paul O
FA  - McKenna, William J
FA  - Elliott, Perry M
IN  - Thaman,Rajesh. The Heart Hospital, University College London, London, United Kingdom.
TI  - Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy.
SO  - American Journal of Cardiology. 98(4):515-9, 2006 Aug 15.
AS  - Am J Cardiol. 98(4):515-9, 2006 Aug 15.
NJ  - The American journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers/bl [Blood]
MH  - *Cardiomyopathy, Hypertrophic/bl [Blood]
MH  - Cardiomyopathy, Hypertrophic/pp [Physiopathology]
MH  - Cardiomyopathy, Hypertrophic/us [Ultrasonography]
MH  - Echocardiography
MH  - Exercise Test
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Contraction/ph [Physiology]
MH  - *Natriuretic Peptide, Brain/bl [Blood]
MH  - *Peptide Fragments/bl [Blood]
MH  - Prognosis
MH  - Protein Precursors/bl [Blood]
MH  - Severity of Illness Index
AB  - Most patients with hypertrophic cardiomyopathy (HC) have reduced maximal oxygen consumption (VO2max) during exercise. The degree of impairment is poorly predicted by the magnitude of hypertrophy, left ventricular (LV) outflow tract obstruction, and other conventional markers of disease severity. The aim of this study was to determine the usefulness of N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) as a marker of exercise performance in HC. Plasma NT-pro-BNP was measured in 171 consecutive patients (mean age 46 +/- 18 years) who underwent echocardiography and cardiopulmonary exercise testing. The mean log NT-pro-BNP was 2.79 +/- 0.5; log NT-pro-BNP levels were higher in women patients (p = 0.001) and patients with chest pain (p = 0.010), in New York Heart Association class > or = II (p = 0.009), with atrial fibrillation (p < 0.001), with systolic impairment (p = 0.025), and with LV outflow tract obstructions (p < 0.0001). NT-pro-BNP levels were also correlated with maximal wall thickness (r = 0.335, p < 0.0001), left atrial size (r = 0.206, p = 0.007), and the mitral Doppler E/A ratio (r = 0.197, p = 0.012). The mean percent VO2max achieved was 73.8 +/- 22.6%; percent VO2max was smaller in patients with systolic impairment (p = 0.044) and LV outflow tract obstructions (p = 0.025). There were inverse correlations between percent VO2max and NT-pro-BNP (r = -0.352, p = 0.001), LV end-systolic cavity size (r = -0.182, p = 0.031), and left atrial size (r = -0.251, p = 0.003). On multivariate analysis, only NT-pro-BNP was correlated with percent VO2max. A NT-pro-BNP level of 316 ng/L had 78% sensitivity and 44% specificity (area under the curve 0.616) for predicting percent VO2max < 80%. In conclusion, NT-pro-BNP levels correlate with peak oxygen consumption in HC and are more predictive of functional impairment than other conventional markers of disease severity.
RN  - 0 (Biomarkers)
RN  - 0 (Peptide Fragments)
RN  - 0 (Protein Precursors)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
IS  - 0002-9149
IL  - 0002-9149
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20060627
DP  - 2006 Aug 15
DC  - 20060808
YR  - 2006
ED  - 20060921
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16893708

<602. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16341904
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mader R
AU  - Dubenski N
AU  - Lavi I
FA  - Mader, R
FA  - Dubenski, N
FA  - Lavi, Idit
IN  - Mader,R. Rheumatic Diseases Unit, Ha'Emek Medical Center, 18101 Afula, Israel. Mader_r@clalit.org.il
TI  - Morbidity and mortality of hospitalized patients with diffuse idiopathic skeletal hyperostosis.
SO  - Rheumatology International. 26(2):132-6, 2005 Dec.
AS  - Rheumatol Int. 26(2):132-6, 2005 Dec.
NJ  - Rheumatology international
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - 8206885, tdz
SB  - Index Medicus
CP  - Germany
MH  - Aged
MH  - *Atrial Fibrillation/mo [Mortality]
MH  - Comorbidity
MH  - Female
MH  - *Hospitalization
MH  - Humans
MH  - *Hyperostosis, Diffuse Idiopathic Skeletal/mo [Mortality]
MH  - Hyperostosis, Diffuse Idiopathic Skeletal/pp [Physiopathology]
MH  - *Hypertension/mo [Mortality]
MH  - Hypertrophy, Left Ventricular/ep [Epidemiology]
MH  - Israel/ep [Epidemiology]
MH  - Male
MH  - Middle Aged
MH  - Patients
AB  - Diffuse idiopathic skeletal hyperostosis (DISH) has been associated with various metabolic disorders considered to be cardiovascular risk factors such as obesity, diabetes mellitus, hyperinsulinemia, and hyperlipidemia. To evaluate morbidity and mortality of hospitalized patients with DISH admitted to the department of medicine. One hundred patients from a cohort of 1020 consecutive patients, aged 45 years and more, admitted to the department of medicine were diagnosed as suffering from DISH. Another group of 100 patients, age- and gender matched, admitted without DISH, served as controls. Clinical and demographic characteristics, diagnoses on admission, previous chronic diseases, chronic medical therapy, laboratory tests, and the rates of in-hospital mortality and readmissions within 1 month of discharge were collected from the hospital database, for the two groups. Uncompensated or paroxysmal atrial fibrillation was more often encountered on admission in patients with DISH (p = 0.038). Patients with DISH were more likely to suffer from elevated body mass index, arterial hypertension, diabetes mellitus, and previous cerebral vascular accidents, although the differences did not reach statistical significance. However, significantly more patients had an electrocardiographic evidence of left ventricular hypertrophy (p = 0.03). The mortality rate was similar between the two groups. The lack of significant associations for cardiovascular risk factors such as diabetes mellitus, hypertension, and high BMI should be interpreted cautiously considering the characteristics of the control group. Identification of comorbid conditions and proper therapeutic interventions may prove useful in reducing the morbidity and mortality associated with this disorder.
IS  - 0172-8172
IL  - 0172-8172
PT  - Journal Article
LG  - English
EP  - 20041110
DP  - 2005 Dec
DC  - 20051212
YR  - 2005
ED  - 20060912
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16341904

<603. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16864926
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Tsuneda T
AU  - Yamashita T
AU  - Fukunami M
AU  - Kumagai K
AU  - Niwano S
AU  - Okumura K
AU  - Inoue H
FA  - Tsuneda, Takayuki
FA  - Yamashita, Takeshi
FA  - Fukunami, Masatake
FA  - Kumagai, Koichiro
FA  - Niwano, Shin-ichi
FA  - Okumura, Ken
FA  - Inoue, Hiroshi
IN  - Tsuneda,Takayuki. The Second Department of Internal Medicine, University of Toyama, Japan.
TI  - Rate control and quality of life in patients with permanent atrial fibrillation: the Quality of Life and Atrial Fibrillation (QOLAF) Study.
SO  - Circulation Journal. 70(8):965-70, 2006 Aug.
AS  - Circ J. 70(8):965-70, 2006 Aug.
NJ  - Circulation journal : official journal of the Japanese Circulation Society
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101137683
SB  - Index Medicus
CP  - Japan
MH  - Adrenergic beta-Antagonists/tu [Therapeutic Use]
MH  - Aged
MH  - Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Cross-Over Studies
MH  - Digitalis Glycosides/tu [Therapeutic Use]
MH  - Electrocardiography
MH  - Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Female
MH  - Health Status
MH  - *Heart Rate/de [Drug Effects]
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - *Quality of Life
MH  - Severity of Illness Index
MH  - Surveys and Questionnaires
MH  - Verapamil/tu [Therapeutic Use]
AB  - BACKGROUND: The present study aimed to determine whether quality of life (QOL) in permanent atrial fibrillation (AF) patients would be improved by monotherapy with beta-blocker (BB) or calcium antagonist (CAA) as compared with digitalis.
AB  - METHODS AND RESULTS: Twenty-nine patients with permanent AF under digitalis were randomized into BB (bisoprolol, atenolol or metoprolol) or CAA (verapamil) monotherapy treatment group. Twenty-five were men and the mean age was 67+/-8 years. After the assigned monotherapy, 12 patients received the other monotherapy in a cross-over fashion. Under each treatment, efficacy of rate control was determined by Holter electrocardiogram (ECG), treadmill testing and QOL questionnaire (Short Form-36 (SF-36) and Quality of Life of Atrial Fibrillation (AFQLQ)), and compared with the baseline digitalis treatment. CAA significantly increased mean and minimum heart rate (HR) in Holter ECG as compared with digitalis, whereas BB increased only minimum HR. Exercise duration in treadmill testing was significantly prolonged by CAA treatment, although it only tended to be prolonged by BB treatment. CAA but not BB improved role function-physical score of SF-36, and frequency and severity of symptoms of AFQLQ.
AB  - CONCLUSION: These results indicate that CAA is preferable to digitalis when monotherapy is selected for short-term improvement of QOL and exercise tolerance in patients with permanent AF.
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Digitalis Glycosides)
RN  - CJ0O37KU29 (Verapamil)
IS  - 1346-9843
IL  - 1346-9843
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
LG  - English
DP  - 2006 Aug
DC  - 20060725
YR  - 2006
ED  - 20060907
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16864926

<604. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16777519
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lauer MS
AU  - Pothier CE
AU  - Chernyak YB
AU  - Brunken R
AU  - Lieber M
AU  - Apperson-Hansen C
AU  - Starobin JM
FA  - Lauer, Michael S
FA  - Pothier, Claire E
FA  - Chernyak, Yuri B
FA  - Brunken, Richard
FA  - Lieber, Michael
FA  - Apperson-Hansen, Carolyn
FA  - Starobin, Joseph M
IN  - Lauer,Michael S. Department of Cardiovascular Medicine, Cleveland Clinic Foundation, OH 44195, USA. lauerm@ccf.org
TI  - Exercise-induced QT/R-R-interval hysteresis as a predictor of myocardial ischemia.
SO  - Journal of Electrocardiology. 39(3):315-23, 2006 Jul.
AS  - J Electrocardiol. 39(3):315-23, 2006 Jul.
NJ  - Journal of electrocardiology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - i0r, 0153605
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Electrocardiography/mt [Methods]
MH  - *Electrocardiography/sn [Statistics & Numerical Data]
MH  - *Exercise Test/mt [Methods]
MH  - *Exercise Test/sn [Statistics & Numerical Data]
MH  - Female
MH  - Humans
MH  - Male
MH  - *Myocardial Ischemia/di [Diagnosis]
MH  - *Myocardial Ischemia/ep [Epidemiology]
MH  - Prevalence
MH  - Prognosis
MH  - Reproducibility of Results
MH  - *Risk Assessment/mt [Methods]
MH  - Risk Factors
MH  - Sensitivity and Specificity
AB  - OBJECTIVES: Exercise-induced QT/RR hysteresis exists when, for a given R-R interval, the QT interval duration is shorter during recovery after exercise than during exercise. We sought to assess the association between QT/RR hysteresis and imaging evidence of myocardial ischemia.
AB  - BACKGROUND: Because ischemia induces cellular disturbances known to decrease membrane action potential duration, we hypothesized a correlation between QT/RR and myocardial ischemia.
AB  - METHODS: We digitally analyzed 4-second samples of QT duration and R-R-interval duration in 260 patients referred for treadmill exercise stress and rest single photon emission computed tomography myocardial perfusion imaging; a cool-down period was used after exercise. None of the patients were in atrial fibrillation or used digoxin, and none had marked baseline electrocardiographic abnormalities. Stress and rest myocardial perfusion images were analyzed visually and quantitatively to define the extent and severity of stress-induced ischemia. QT/RR hysteresis was calculated using a computerized algorithm.
AB  - RESULTS: There were 82 patients (32%) who manifested myocardial ischemia by single photon emission computed tomography myocardial perfusion imaging. The likelihood of ischemia increased with increasing QT/RR hysteresis, with prevalence according to quartiles of 20%, 30%, 26%, and 49% (P = .003 for trend). In analyses adjusting for ST-segment changes, exercise capacity, heart rate recovery, and other confounders, QT/RR hysteresis was independently predictive of presence of myocardial ischemia (adjusted odds ratio for 100-point increase of QT/RR hysteresis, 1.61; 95% confidence interval, 1.22-2.12; P = .0008). QT/RR hysteresis was also predictive of severe ischemia.
AB  - CONCLUSION: Exercise-induced QT/RR hysteresis is a strong and independent predictor of myocardial ischemia and provides additional information beyond that afforded by standard ST-segment measures.
ES  - 1532-8430
IL  - 0022-0736
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2006 Jul
DC  - 20060616
YR  - 2006
ED  - 20060905
RD  - 20091111
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16777519

<605. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16529878
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Johnson JB
AU  - Laub DR
AU  - John S
FA  - Johnson, James B
FA  - Laub, Donald R
FA  - John, Sujit
IN  - Johnson,James B. Department of Surgery, Louisiana State University Medical Center, 2547A Lyon Street, 2nd Floor, San Francisco, CA 94123, USA. jim@jbjmd.com
TI  - The effect on health of alternate day calorie restriction: eating less and more than needed on alternate days prolongs life.
SO  - Medical Hypotheses. 67(2):209-11, 2006.
AS  - Med Hypotheses. 67(2):209-11, 2006.
NJ  - Medical hypotheses
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - m0m, 7505668
SB  - Index Medicus
CP  - Scotland
MH  - *Caloric Restriction
MH  - *Energy Intake
MH  - *Feeding Behavior
MH  - Health
MH  - Humans
MH  - *Longevity
AB  - Restricting caloric intake to 60-70% of normal adult weight maintenance requirement prolongs lifespan 30-50% and confers near perfect health across a broad range of species. Every other day feeding produces similar effects in rodents, and profound beneficial physiologic changes have been demonstrated in the absence of weight loss in ob/ob mice. Since May 2003 we have experimented with alternate day calorie restriction, one day consuming 20-50% of estimated daily caloric requirement and the next day ad lib eating, and have observed health benefits starting in as little as two weeks, in insulin resistance, asthma, seasonal allergies, infectious diseases of viral, bacterial and fungal origin (viral URI, recurrent bacterial tonsillitis, chronic sinusitis, periodontal disease), autoimmune disorder (rheumatoid arthritis), osteoarthritis, symptoms due to CNS inflammatory lesions (Tourette's, Meniere's) cardiac arrhythmias (PVCs, atrial fibrillation), menopause related hot flashes. We hypothesize that other many conditions would be delayed, prevented or improved, including Alzheimer's, Parkinson's, multiple sclerosis, brain injury due to thrombotic stroke atherosclerosis, NIDDM, congestive heart failure. Our hypothesis is supported by an article from 1957 in the Spanish medical literature which due to a translation error has been construed by several authors to be the only existing example of calorie restriction with good nutrition. We contend for reasons cited that there was no reduction in calories overall, but that the subjects were eating, on alternate days, either 900 calories or 2300 calories, averaging 1600, and that body weight was maintained. Thus they consumed either 56% or 144% of daily caloric requirement. The subjects were in a residence for old people, and all were in perfect health and over 65. Over three years, there were 6 deaths among 60 study subjects and 13 deaths among 60 ad lib-fed controls, non-significant difference. Study subjects were in hospital 123 days, controls 219, highly significant difference. We believe widespread use of this pattern of eating could impact influenza epidemics and other communicable diseases by improving resistance to infection. In addition to the health effects, this pattern of eating has proven to be a good method of weight control, and we are continuing to study the process in conjunction with the NIH.
IS  - 0306-9877
IL  - 0306-9877
PT  - Journal Article
LG  - English
EP  - 20060310
DP  - 2006
DC  - 20060612
YR  - 2006
ED  - 20060823
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16529878

<606. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16461374
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Guazzi M
AU  - Belletti S
AU  - Bianco E
AU  - Lenatti L
AU  - Guazzi MD
FA  - Guazzi, Marco
FA  - Belletti, Sebastiano
FA  - Bianco, Elisabetta
FA  - Lenatti, Laura
FA  - Guazzi, Maurizio D
IN  - Guazzi,Marco. Cardiopulmonary Unit, Cardiology Division, University of Milan, San Paolo Hospital, Via A. di Rudini, 8, 20142 Milan, Italy. marco.guazzi@unimi.it
TI  - Endothelial dysfunction and exercise performance in lone atrial fibrillation or associated with hypertension or diabetes: different results with cardioversion.
SO  - American Journal of Physiology - Heart & Circulatory Physiology. 291(2):H921-8, 2006 Aug.
AS  - Am J Physiol Heart Circ Physiol. 291(2):H921-8, 2006 Aug.
NJ  - American journal of physiology. Heart and circulatory physiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - dkm, 100901228
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Antioxidants/pd [Pharmacology]
MH  - Ascorbic Acid/pd [Pharmacology]
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/th [Therapy]
MH  - Brachial Artery/ph [Physiology]
MH  - *Diabetes Complications/pp [Physiopathology]
MH  - *Diabetes Mellitus/pp [Physiopathology]
MH  - Diabetes Mellitus, Type 2/pp [Physiopathology]
MH  - Echocardiography
MH  - *Electric Countershock
MH  - *Endothelium, Vascular/ph [Physiology]
MH  - *Exercise Test
MH  - Female
MH  - Humans
MH  - *Hypertension/co [Complications]
MH  - Hypertension/pp [Physiopathology]
MH  - Male
MH  - Middle Aged
MH  - Myocytes, Cardiac/ph [Physiology]
MH  - Reactive Oxygen Species/me [Metabolism]
MH  - Regional Blood Flow/ph [Physiology]
AB  - Endothelial dysfunction and underperfusion of exercising muscle contribute to exercise intolerance, hyperventilation, and breathlessness in atrial fibrillation (AF). Cardioversion (CV) improves endothelial function and exercise performance. We examined whether CV is equally beneficial in diabetes and hypertension, diseases that cause endothelial dysfunction and are often associated with AF. Cardiopulmonary exercise and pulmonary and endothelial (brachial artery flow-mediated dilation) function were tested before and after CV in patients with AF alone (n = 18, group 1) or AF with hypertension (n = 19, group 2) or diabetes (n = 19, group 3). Compared with group 1, peak exercise workload, O2 consumption (Vo2), O2 pulse, aerobic efficiency (Delta Vo2/Delta WR), and ratio of brachial diameter changes to flow changes (Delta D/Delta F) were reduced in group 2 and, to a greater extent, in group 3; exercise ventilation efficiency (Ve/Vco2 slope) and dead space-to-tidal volume ratio (Vd/Vt) were similar among groups. CV had less effect on peak workload (+7% vs. +18%), peak Vo2 (+12% vs. +17%), O2 pulse (+33% vs. +50%), Delta Vo2/Delta WR (+7% vs. +12%), Ve/Vco2 slope (-6% vs. -12%), Delta D/Delta F (+7% vs. +10%), and breathlessness (Borg scale) in group 2 than in group 1 and was ineffective in group 3. The antioxidant vitamin C, tested in eight additional patients in each cohort, improved flow-mediated dilation in groups 1 and 2 before, but not after, CV and was ineffective in group 3, suggesting that the oxidative injury is least in lone AF, greater in hypertension with AF, and greater still in diabetes with AF. Comorbidities that impair endothelial activity worsen endothelial dysfunction and exercise intolerance in AF. The advantages of CV appear to be inversely related to the extent of the underlying oxidative injury.
RN  - 0 (Antioxidants)
RN  - 0 (Reactive Oxygen Species)
RN  - PQ6CK8PD0R (Ascorbic Acid)
IS  - 0363-6135
IL  - 0363-6135
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20060203
DP  - 2006 Aug
DC  - 20060714
YR  - 2006
ED  - 20060818
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16461374

<607. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16875972
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mozaffarian D
AU  - Prineas RJ
AU  - Stein PK
AU  - Siscovick DS
FA  - Mozaffarian, Dariush
FA  - Prineas, Ronald J
FA  - Stein, Phyllis K
FA  - Siscovick, David S
IN  - Mozaffarian,Dariush. Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. dmozaffa@hsph.harvard.edu
TI  - Dietary fish and n-3 fatty acid intake and cardiac electrocardiographic parameters in humans.
SO  - Journal of the American College of Cardiology. 48(3):478-84, 2006 Aug 1.
AS  - J Am Coll Cardiol. 48(3):478-84, 2006 Aug 1.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - h50, 8301365
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Animals
MH  - Atrioventricular Node/ph [Physiology]
MH  - Cross-Sectional Studies
MH  - *Diet
MH  - *Electrocardiography
MH  - *Fatty Acids, Omega-3/ad [Administration & Dosage]
MH  - Female
MH  - *Fishes
MH  - *Heart/ph [Physiology]
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Ventricular Function
AB  - OBJECTIVES: We evaluated the association between dietary fish intake and several cardiac electrocardiographic parameters in humans relevant to arrhythmic risk.
AB  - BACKGROUND: Fish consumption may reduce the incidence of sudden death and atrial fibrillation, possibly related to anti-arrhythmic effects.
AB  - METHODS: In a population-based study of 5,096 men and women, we evaluated cross-sectional associations between usual dietary fish intake and electrocardiographic measures of heart rate, atrioventricular conduction (PR interval), ventricular repolarization (QT interval), and ventricular conduction (QRS interval). Multivariate models were adjusted for age, gender, race, education, smoking, body mass index, diabetes, coronary heart disease, physical activity, and intakes of beef or pork, fried fish, fruits, vegetables, alcohol, and total calories.
AB  - RESULTS: Consumption of tuna or other broiled or baked fish (comparing the highest to the lowest category of intake) was associated with lower heart rate (-3.2 beats/min, 95% confidence interval [CI] = 1.3 to 5.1; p trend <0.001), slower atrioventricular conduction (PR interval +7.2 ms, 95% CI = 1.4 to 12.9; p trend = 0.03), and substantially lower likelihood of prolonged QT (relative risk = 0.50, 95% CI = 0.27 to 0.95; p trend = 0.03). Tuna/other fish intake was not associated with ventricular conduction (p = 0.60). Findings were similar for estimated intake of marine n-3 fatty acids: a 1 g/day higher intake was associated with 2.3 beats/min lower heart rate (95% CI = 0.9 to 3.7), 7.6 ms longer PR interval (95% CI = 3.3 to 11.9), and 46% lower likelihood of prolonged QT (relative risk = 0.54, 95% CI = 0.33 to 0.88).
AB  - CONCLUSIONS: These findings in this large, population-based study suggest that dietary fish intake is associated with cardiac electrophysiology in humans, including heart rate, atrioventricular conduction, and ventricular repolarization, with potential implications for arrhythmic risk.
RN  - 0 (Fatty Acids, Omega-3)
ES  - 1558-3597
IL  - 0735-1097
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
NO  - K08-HL-075628 (United States NHLBI NIH HHS)
NO  - N01-HC-15103 (United States NHLBI NIH HHS)
NO  - N01-HC-35129 (United States NHLBI NIH HHS)
NO  - N01-HC-85079 (United States NHLBI NIH HHS)
NO  - N01-HC-85080 (United States NHLBI NIH HHS)
NO  - N01-HC-85081 (United States NHLBI NIH HHS)
NO  - N01-HC-85082 (United States NHLBI NIH HHS)
NO  - N01-HC-85083 (United States NHLBI NIH HHS)
NO  - N01-HC-85084 (United States NHLBI NIH HHS)
NO  - N01-HC-85085 (United States NHLBI NIH HHS)
NO  - N01-HC-85086 (United States NHLBI NIH HHS)
LG  - English
EP  - 20060712
DP  - 2006 Aug 1
DC  - 20060731
YR  - 2006
ED  - 20060816
RD  - 20071114
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16875972

<608. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16154710
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Yamagishi S
AU  - Takenaka K
AU  - Inoue H
FA  - Yamagishi, S
FA  - Takenaka, K
FA  - Inoue, H
IN  - Yamagishi,S. Department of Internal Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan. shoichi@med.kurume-u.ac.jp
TI  - Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation.
SO  - Medical Hypotheses. 66(1):118-20, 2006.
AS  - Med Hypotheses. 66(1):118-20, 2006.
NJ  - Medical hypotheses
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - m0m, 7505668
SB  - Index Medicus
CP  - Scotland
MH  - *Angiotensin II Type 1 Receptor Blockers/me [Metabolism]
MH  - Angiotensin II Type 1 Receptor Blockers/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/me [Metabolism]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - *Benzimidazoles/me [Metabolism]
MH  - Benzimidazoles/tu [Therapeutic Use]
MH  - *Benzoates/me [Metabolism]
MH  - Benzoates/tu [Therapeutic Use]
MH  - Humans
MH  - *Insulin Resistance/ph [Physiology]
AB  - Atrial fibrillation (Af) is the most common disorder of cardiac rhythm and is responsible for substantial morbidity and mortality in the general population. A recent community-based observational study revealed that diabetes and hypertension were associated with the development of Af. Since there is no definite evidence to show that type 1 diabetes is at increased risk for the development of Af, insulin resistance rather than hyperglycemia per se could explain the link between diabetes and Af. Several clinical trials suggest that the renin-angiotensin system (RAS) plays a pivotal role in the pathogenesis of insulin resistance. Indeed, interruption of the RAS with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II type 1 receptor blockers (ARBs) has been shown to prevent the onset of diabetes in hypertensive patients. Further, several experimental and clinical studies showed the beneficial role for the inhibition of the RAS in preventing Af as well. However, to what extent the insulin-sensitizing effects of ARBs could account for the prevention of Af remains to be clarified. Recently, telmisartan, an ARB, was found to act as a partial agonist of peroxisome proliferator-activated receptor-gamma (PPAR-gamma). PPAR-gamma influences the gene expression involved in carbohydrate metabolism. In animal study, telmisartan administration caused a significant attenuation of weight gain and reduced glucose, insulin, and triglyceride levels in rats fed a high-fat, high-carbohydrate diet, compared with treatments of losartan, another type of ARB. Furthermore, recently, some clinical papers also reported the insulin-sensitizing effects of telmisartan in hypertensive patients. In this paper, we would like to propose the possible ways of clarifying to what extent the insulin-sensitizing effects of ARBs could account for the prevention of Af. (1) Does telmisartan reduce the development of Af in insulin resistant hypertensive patients? (2) When adjusted for blood pressure, is the effect of telmisartan superior to other ARBs? (3) Does this beneficial effect of telmisartan correlate to its insulin-sensitizing properties? Ongoing clinical trial (ONTARGET) has been designed the efficacy of telmisartan with an ACEI, ramipril, alone or in combination. This randomized, double-blind, multicenter international studies will provide further information whether telmisartan can improve insulin resistance and subsequently reduce the development of Af in high-risk hypertensive patients.
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Benzimidazoles)
RN  - 0 (Benzoates)
RN  - U5SYW473RQ (telmisartan)
IS  - 0306-9877
IL  - 0306-9877
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20050912
DP  - 2006
DC  - 20051108
YR  - 2006
ED  - 20060810
RD  - 20140109
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16154710

<609. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15797107
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Dodge-Khatami A
AU  - Kadner A
AU  - Berger Md F
AU  - Dave H
AU  - Turina MI
AU  - Pretre R
FA  - Dodge-Khatami, Ali
FA  - Kadner, Alexander
FA  - Berger Md, Felix
FA  - Dave, Hitendu
FA  - Turina, Marko I
FA  - Pretre, Rene
IN  - Dodge-Khatami,Ali. Division of Cardiovascular Surgery, Center For Congenital Heart Diseases, Children's Hospital, University of Zurich, Zurich, Switzerland. ali.dodge-khatami@kispi.unizh.ch
TI  - In the footsteps of senning: lessons learned from atrial repair of transposition of the great arteries. [Review] [70 refs]
SO  - Annals of Thoracic Surgery. 79(4):1433-44, 2005 Apr.
AS  - Ann Thorac Surg. 79(4):1433-44, 2005 Apr.
NJ  - The Annals of thoracic surgery
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 15030100R
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - Netherlands
MH  - Arrhythmias, Cardiac/et [Etiology]
MH  - Cardiac Surgical Procedures/ae [Adverse Effects]
MH  - *Cardiac Surgical Procedures
MH  - Exercise
MH  - *Heart Atria/su [Surgery]
MH  - Humans
MH  - Hypertension, Pulmonary/et [Etiology]
MH  - Transposition of Great Vessels/pp [Physiopathology]
MH  - Transposition of Great Vessels/px [Psychology]
MH  - *Transposition of Great Vessels/su [Surgery]
MH  - Tricuspid Valve Insufficiency/et [Etiology]
MH  - Vena Cava, Superior
MH  - Ventricular Dysfunction, Right/et [Etiology]
MH  - Ventricular Function, Left
AB  - The Senning operation has evolved from being the initial surgical correction that allowed survival in complete transposition of the great arteries to an integral part of the anatomic repair of congenitally corrected transposition. In patients with complete transposition, the Senning operation has given satisfactory initial and long-term surgical results, but the potential for right ventricular failure and atrial arrhythmias have drastically reduced its indications in the current era. The long-term follow-up and pertinent postoperative issues of the Senning operation will be reviewed, along with its newfound role in the anatomic repair of congenitally corrected transposition. [References: 70]
ES  - 1552-6259
IL  - 0003-4975
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2005 Apr
DC  - 20050330
YR  - 2005
ED  - 20060809
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15797107

<610. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16781383
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Messika-Zeitoun D
AU  - Johnson BD
AU  - Nkomo V
AU  - Avierinos JF
AU  - Allison TG
AU  - Scott C
AU  - Tajik AJ
AU  - Enriquez-Sarano M
FA  - Messika-Zeitoun, David
FA  - Johnson, Bruce D
FA  - Nkomo, Vuyisile
FA  - Avierinos, Jean-Francois
FA  - Allison, Thomas G
FA  - Scott, Christopher
FA  - Tajik, A Jamil
FA  - Enriquez-Sarano, Maurice
IN  - Messika-Zeitoun,David. Division of Cardiovascular Diseases and Internal Medicine, Mayo College of Medicine, Rochester, Minnesota, USA.
TI  - Cardiopulmonary exercise testing determination of functional capacity in mitral regurgitation: physiologic and outcome implications.
SO  - Journal of the American College of Cardiology. 47(12):2521-7, 2006 Jun 20.
AS  - J Am Coll Cardiol. 47(12):2521-7, 2006 Jun 20.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - h50, 8301365
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Exercise Test
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mitral Valve Insufficiency/pp [Physiopathology]
MH  - Prognosis
MH  - Prospective Studies
AB  - OBJECTIVES: This study was designed to evaluate prevalence, determinants, and clinical outcome implications of reduced functional capacity (FC) in patients with organic mitral regurgitation (MR).
AB  - BACKGROUND: Evaluation of FC by exercise testing is rarely performed in MR because little is known about the clinical determinants and outcome implications of FC.
AB  - METHODS: Cardiopulmonary exercise testing (CPET) was prospectively performed in 134 asymptomatic patients with organic MR to assess FC (peak oxygen consumption [VO2]) simultaneously to Doppler-echocardiographic quantitation of MR (effective regurgitant orifice [ERO]) and left ventricular (LV) systolic and diastolic function.
AB  - RESULTS: Peak VO2 was 26 +/- 6 ml/kg/min (96 +/- 16% of age-predicted), but varied widely (57% to 145% of predicted) and was markedly reduced (< or =84% of predicted) in 19% of patients. Although ERO of MR was univariately associated with reduced FC (26 vs. 9% with ERO > or =40 vs. <40 mm2), independent determinants of reduced FC were LV diastolic function (higher E/E' ratio, p = 0.006), atrial fibrillation (p = 0.01), and lower forward stroke volume (p = 0.03). Clinical events (death, heart failure, new atrial fibrillation) and clinical events or surgery were more frequent with than without reduced FC (3 years, 36 +/- 14% vs. 13 +/- 4%, p = 0.02; and 66 +/- 11% vs. 29 +/- 5%, p = 0.001, respectively), even adjusting (risk ratios 1.80 and 1.54 respectively, both p < or = 0.03) for age and ERO.
AB  - CONCLUSIONS: In asymptomatic organic MR, FC quantitatively assessed by CPET is unexpectedly markedly reduced in one out of every four to five patients. Reduced FC is independently determined by consequences rather than severity of MR and predicts increased subsequent clinical events. Therefore, CPET frequently reveals functional limitations not detected clinically and is an important tool in managing patients with organic MR.
ES  - 1558-3597
IL  - 0735-1097
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
NO  - HL 64928 (United States NHLBI NIH HHS)
NO  - M01-RR00585 (United States NCRR NIH HHS)
LG  - English
EP  - 20060530
DP  - 2006 Jun 20
DC  - 20060619
YR  - 2006
ED  - 20060725
RD  - 20071114
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16781383

<611. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16785347
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Goldstein LB
AU  - Adams R
AU  - Alberts MJ
AU  - Appel LJ
AU  - Brass LM
AU  - Bushnell CD
AU  - Culebras A
AU  - DeGraba TJ
AU  - Gorelick PB
AU  - Guyton JR
AU  - Hart RG
AU  - Howard G
AU  - Kelly-Hayes M
AU  - Nixon JV
AU  - Sacco RL
AU  - American Heart Association
AU  - American Stroke Association Stroke Council
FA  - Goldstein, Larry B
FA  - Adams, Robert
FA  - Alberts, Mark J
FA  - Appel, Lawrence J
FA  - Brass, Lawrence M
FA  - Bushnell, Cheryl D
FA  - Culebras, Antonio
FA  - DeGraba, Thomas J
FA  - Gorelick, Philip B
FA  - Guyton, John R
FA  - Hart, Robert G
FA  - Howard, George
FA  - Kelly-Hayes, Margaret
FA  - Nixon, J V Ian
FA  - Sacco, Ralph L
FA  - American Heart Association
FA  - American Stroke Association Stroke Council
TI  - Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group.[Erratum appears in Circulation. 2006 Nov 28;114(22):e617]
SO  - Circulation. 113(24):e873-923, 2006 Jun 20.
AS  - Circulation. 113(24):e873-923, 2006 Jun 20.
NJ  - Circulation
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Brain Ischemia/co [Complications]
MH  - Humans
MH  - Risk Assessment
MH  - Risk Factors
MH  - *Stroke/et [Etiology]
MH  - *Stroke/pc [Prevention & Control]
AB  - BACKGROUND AND PURPOSE: This guideline provides an overview of the evidence on various established and potential stroke risk factors and provides recommendations for the reduction of stroke risk.
AB  - METHODS: Writing group members were nominated by the committee chair on the basis of each writer's previous work in relevant topic areas and were approved by the American Heart Association Stroke Council's Scientific Statement Oversight Committee. The writers used systematic literature reviews (covering the time period since the last review published in 2001 up to January 2005), reference to previously published guidelines, personal files, and expert opinion to summarize existing evidence, indicate gaps in current knowledge, and when appropriate, formulate recommendations based on standard American Heart Association criteria. All members of the writing group had numerous opportunities to comment in writing on the recommendations and approved the final version of this document. The guideline underwent extensive peer review before consideration and approval by the AHA Science Advisory and Coordinating Committee.
AB  - RESULTS: Schemes for assessing a person's risk of a first stroke were evaluated. Risk factors or risk markers for a first stroke were classified according to their potential for modification (nonmodifiable, modifiable, or potentially modifiable) and strength of evidence (well documented or less well documented). Nonmodifiable risk factors include age, sex, low birth weight, race/ethnicity, and genetic factors. Well-documented and modifiable risk factors include hypertension, exposure to cigarette smoke, diabetes, atrial fibrillation and certain other cardiac conditions, dyslipidemia, carotid artery stenosis, sickle cell disease, postmenopausal hormone therapy, poor diet, physical inactivity, and obesity and body fat distribution. Less well-documented or potentially modifiable risk factors include the metabolic syndrome, alcohol abuse, drug abuse, oral contraceptive use, sleep-disordered breathing, migraine headache, hyperhomocysteinemia, elevated lipoprotein(a), elevated lipoprotein-associated phospholipase, hypercoagulability, inflammation, and infection. Data on the use of aspirin for primary stroke prevention are reviewed.
AB  - CONCLUSIONS: Extensive evidence is available identifying a variety of specific factors that increase the risk of a first stroke and providing strategies for reducing that risk.
ES  - 1524-4539
IL  - 0009-7322
PT  - Journal Article
PT  - Practice Guideline
LG  - English
DP  - 2006 Jun 20
DC  - 20060620
YR  - 2006
ED  - 20060717
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16785347

<612. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16617224
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mertens DJ
FA  - Mertens, Donald J
TI  - Exercise training for patients with chronic atrial fibrillation.
SO  - Journal of Cardiopulmonary Rehabilitation. 26(1):30-1, 2006 Jan-Feb.
AS  - J Cardiopulm Rehabil. 26(1):30-1, 2006 Jan-Feb.
NJ  - Journal of cardiopulmonary rehabilitation
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - cgv, 8511296
SB  - Index Medicus
CP  - United States
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Chronic Disease
MH  - *Exercise Therapy/mt [Methods]
MH  - Follow-Up Studies
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Treatment Outcome
IS  - 0883-9212
IL  - 0883-9212
PT  - Editorial
LG  - English
DP  - 2006 Jan-Feb
DC  - 20060417
YR  - 2006
ED  - 20060711
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16617224

<613. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16617223
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Hegbom F
AU  - Sire S
AU  - Heldal M
AU  - Orning OM
AU  - Stavem K
AU  - Gjesdal K
FA  - Hegbom, Finn
FA  - Sire, Svein
FA  - Heldal, Magnus
FA  - Orning, Otto M
FA  - Stavem, Knut
FA  - Gjesdal, Knut
IN  - Hegbom,Finn. Heart & Lung Center, Ulleval University Hospital, Oslo, Norway. finn.hegbom@medisin.uio.no
TI  - Short-term exercise training in patients with chronic atrial fibrillation: effects on exercise capacity, AV conduction, and quality of life.
SO  - Journal of Cardiopulmonary Rehabilitation. 26(1):24-9, 2006 Jan-Feb.
AS  - J Cardiopulm Rehabil. 26(1):24-9, 2006 Jan-Feb.
NJ  - Journal of cardiopulmonary rehabilitation
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - cgv, 8511296
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/px [Psychology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Atrioventricular Node/pp [Physiopathology]
MH  - Chronic Disease
MH  - Electrocardiography, Ambulatory
MH  - Exercise Test
MH  - *Exercise Therapy/mt [Methods]
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - Follow-Up Studies
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Quality of Life
MH  - Time Factors
MH  - Treatment Outcome
AB  - PURPOSE: A randomized study was conducted to determine whether short-term exercise training in patients with chronic atrial fibrillation (AF) might improve exercise capacity and quality of life (QOL), and influence atrioventricular conduction.
AB  - METHODS: Atrial fibrillation patients (age 64 +/- 7 years) were randomized to exercise training (n = 15) or a 2-month control period (n = 15) followed by the training program. Twenty-four training sessions consisted of aerobic exercise and muscle strengthening. A cycle ergometer test and a 15-minute resting high-frequency spectral electrocardiogram analysis were performed and a QOL questionnaire (SF-36) was completed before and after training. Because there were no changes after 2 months in the control group, pooled data for all patients are presented before and after training.
AB  - RESULTS: Cumulated work at Borg scale 17 increased by 41% +/- 36%. Heart rate at rest and after 10 minutes of exercise decreased from 75 +/- 14 to 68 +/- 14 bpm and 145 +/- 19 to 137 +/- 21 bpm, respectively. HF increased from 81 +/- 17 to 91 +/- 22 milliseconds. Four of the 8 scales and 1 of the 2 summary scales of the Short-Form-36 improved. P <.05 for all results.
AB  - CONCLUSIONS: Exercise capacity, heart rate variability, and QOL improved after 2 months of exercise training in patients with chronic AF. Heart rates at rest and during exercise decreased.
IS  - 0883-9212
IL  - 0883-9212
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
LG  - English
DP  - 2006 Jan-Feb
DC  - 20060417
YR  - 2006
ED  - 20060711
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16617223

<614. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16504414
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Swanson DR
FA  - Swanson, Don R
IN  - Swanson,Don R. Division of the Humanities, The University of Chicago, IL 60637, USA. d-swanson@uchicago.edu
TI  - Atrial fibrillation in athletes: implicit literature-based connections suggest that overtraining and subsequent inflammation may be a contributory mechanism.
SO  - Medical Hypotheses. 66(6):1085-92, 2006.
AS  - Med Hypotheses. 66(6):1085-92, 2006.
NJ  - Medical hypotheses
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - m0m, 7505668
SB  - Index Medicus
CP  - Scotland
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Causality
MH  - Comorbidity
MH  - *Cumulative Trauma Disorders/ep [Epidemiology]
MH  - *Exercise
MH  - *Exercise Movement Techniques/sn [Statistics & Numerical Data]
MH  - Humans
MH  - Incidence
MH  - *Inflammation/ep [Epidemiology]
MH  - Periodicals as Topic/sn [Statistics & Numerical Data]
MH  - *Sports/sn [Statistics & Numerical Data]
AB  - Research on atrial fibrillation (AF), a common heart arrhythmia in the elderly, over many decades has resulted in a literature of more than 16,000 articles indexed in Medline. An exploratory Medline search was conducted in which the subheadings for epidemiology and etiology of AF were combined to form a small subset of the initial records. Further computer-assisted selection led to a few articles that reported an unexpectedly high prevalence of AF in groups of otherwise healthy middle-aged endurance runners and other athletes. Why athletes should be unusually susceptible to AF is mysterious and puzzling. Because relatively few articles are about both AF and endurance exercise, a computer was used first to create a list of important terms that these two separate literatures had in common. Several inflammation-related terms, including C-reactive protein (CRP) and interleukin-6, were on that list. Further searching and literature analysis revealed that excessive endurance exercise or overtraining can lead to chronic systemic inflammation and, separately, that there is a solid association between CRP and AF and that anti-inflammatory agents have been reported to lower CRP and ameliorate AF. No articles were found that brought together all three concepts - AF, inflammation, and exercise. The following hypothesis is plausible, readily testable, and apparently novel: Older athletes diagnosed with AF but otherwise healthy who have engaged in rigorous aerobic endurance exercise for more than a decade will have CRP levels that are higher than those of a similar population of athletes without AF. Corroboration of this hypothesis would then justify a prospective clinical trial of anti-inflammation therapy. It is of particular interest to extend recent studies of inflammation in AF to athletes; athletic behavior that can induce inflammation may contribute to understanding the origins of AF.
IS  - 0306-9877
IL  - 0306-9877
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, N.I.H., Extramural
NO  - R01 LM07292-05 (United States NLM NIH HHS)
LG  - English
EP  - 20060228
DP  - 2006
DC  - 20060327
YR  - 2006
ED  - 20060629
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16504414

<615. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16791946
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Furie KL
FA  - Furie, Karen L
TI  - Ask the doctor. For the last few years, I have been experiencing what I think are mini-strokes. The first time it happened, I lost the sight in one eye for about a minutes. Sometimes the vision in both eyes gets blurred for a few minutes. A few weeks ago I could not think of the word "battery" while talking with a friend. Otherwise, I am a healthy 77-year-old who exercises, isn't overweight, and doesn't smoke. My doctor hasn't suggested any tests of courses of action. Can you?.
SO  - Harvard Heart Letter. 16(10):8, 2006 Jun.
AS  - Harv Heart Lett. 16(10):8, 2006 Jun.
NJ  - Harvard heart letter : from Harvard Medical School
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9425723, c2z
SB  - Consumer Health Journals
CP  - United States
MH  - Aged
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Carotid Artery Diseases/co [Complications]
MH  - Carotid Artery Diseases/di [Diagnosis]
MH  - Humans
MH  - *Ischemic Attack, Transient/et [Etiology]
MH  - Ischemic Attack, Transient/pc [Prevention & Control]
IS  - 1051-5313
IL  - 1051-5313
PT  - Journal Article
LG  - English
DP  - 2006 Jun
DC  - 20060524
YR  - 2006
ED  - 20060623
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16791946

<616. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16675728
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Goldstein LB
AU  - Adams R
AU  - Alberts MJ
AU  - Appel LJ
AU  - Brass LM
AU  - Bushnell CD
AU  - Culebras A
AU  - Degraba TJ
AU  - Gorelick PB
AU  - Guyton JR
AU  - Hart RG
AU  - Howard G
AU  - Kelly-Hayes M
AU  - Nixon JV
AU  - Sacco RL
AU  - American Heart Association/American Stroke Association Stroke Council
AU  - Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group
AU  - Cardiovascular Nursing Council
AU  - Clinical Cardiology Council
AU  - Nutrition, Physical Activity, and Metabolism Council
AU  - Quality of Care and Outcomes Research Interdisciplinary Working Group
AU  - American Academy of Neurology
FA  - Goldstein, Larry B
FA  - Adams, Robert
FA  - Alberts, Mark J
FA  - Appel, Lawrence J
FA  - Brass, Lawrence M
FA  - Bushnell, Cheryl D
FA  - Culebras, Antonio
FA  - Degraba, Thomas J
FA  - Gorelick, Philip B
FA  - Guyton, John R
FA  - Hart, Robert G
FA  - Howard, George
FA  - Kelly-Hayes, Margaret
FA  - Nixon, J V Ian
FA  - Sacco, Ralph L
FA  - American Heart Association/American Stroke Association Stroke Council
FA  - Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group
FA  - Cardiovascular Nursing Council
FA  - Clinical Cardiology Council
FA  - Nutrition, Physical Activity, and Metabolism Council
FA  - Quality of Care and Outcomes Research Interdisciplinary Working Group
FA  - American Academy of Neurology
TI  - Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline.[Erratum appears in Stroke. 2007 Jan;38(1):207]
SO  - Stroke. 37(6):1583-633, 2006 Jun.
AS  - Stroke. 37(6):1583-633, 2006 Jun.
NJ  - Stroke; a journal of cerebral circulation
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - v2j, 0235266
SB  - Index Medicus
CP  - United States
MH  - *Brain Ischemia/co [Complications]
MH  - Humans
MH  - Risk Assessment
MH  - Risk Factors
MH  - *Stroke/et [Etiology]
MH  - *Stroke/pc [Prevention & Control]
AB  - BACKGROUND AND PURPOSE: This guideline provides an overview of the evidence on various established and potential stroke risk factors and provides recommendations for the reduction of stroke risk.
AB  - METHODS: Writing group members were nominated by the committee chair on the basis of each writer's previous work in relevant topic areas and were approved by the American Heart Association Stroke Council's Scientific Statement Oversight Committee. The writers used systematic literature reviews (covering the time period since the last review published in 2001 up to January 2005), reference to previously published guidelines, personal files, and expert opinion to summarize existing evidence, indicate gaps in current knowledge, and when appropriate, formulate recommendations based on standard American Heart Association criteria. All members of the writing group had numerous opportunities to comment in writing on the recommendations and approved the final version of this document. The guideline underwent extensive peer review before consideration and approval by the AHA Science Advisory and Coordinating Committee.
AB  - RESULTS: Schemes for assessing a person's risk of a first stroke were evaluated. Risk factors or risk markers for a first stroke were classified according to their potential for modification (nonmodifiable, modifiable, or potentially modifiable) and strength of evidence (well documented or less well documented). Nonmodifiable risk factors include age, sex, low birth weight, race/ethnicity, and genetic factors. Well-documented and modifiable risk factors include hypertension, exposure to cigarette smoke, diabetes, atrial fibrillation and certain other cardiac conditions, dyslipidemia, carotid artery stenosis, sickle cell disease, postmenopausal hormone therapy, poor diet, physical inactivity, and obesity and body fat distribution. Less well-documented or potentially modifiable risk factors include the metabolic syndrome, alcohol abuse, drug abuse, oral contraceptive use, sleep-disordered breathing, migraine headache, hyperhomocysteinemia, elevated lipoprotein(a), elevated lipoprotein-associated phospholipase, hypercoagulability, inflammation, and infection. Data on the use of aspirin for primary stroke prevention are reviewed.
AB  - CONCLUSIONS: Extensive evidence is available identifying a variety of specific factors that increase the risk of a first stroke and providing strategies for reducing that risk.
ES  - 1524-4628
IL  - 0039-2499
PT  - Journal Article
PT  - Practice Guideline
LG  - English
EP  - 20060504
DP  - 2006 Jun
DC  - 20060529
YR  - 2006
ED  - 20060621
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16675728

<617. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16504529
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wigfield CH
AU  - Lindsey JD
AU  - Munoz A
AU  - Chopra PS
AU  - Edwards NM
AU  - Love RB
FA  - Wigfield, Christopher H
FA  - Lindsey, Joshua D
FA  - Munoz, Alejandro
FA  - Chopra, Paramjeet S
FA  - Edwards, Niloo M
FA  - Love, Robert B
IN  - Wigfield,Christopher H. University of Wisconsin Hospitals and Clinics, Department of Cardiothoracic Surgery, Madison, WI 53792, USA. wigfield@surgery.wisc.edu
TI  - Is extreme obesity a risk factor for cardiac surgery? An analysis of patients with a BMI > or = 40. [Review] [25 refs]
SO  - European Journal of Cardio-Thoracic Surgery. 29(4):434-40, 2006 Apr.
AS  - Eur J Cardiothorac Surg. 29(4):434-40, 2006 Apr.
NJ  - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - aoj, 8804069
SB  - Index Medicus
CP  - Germany
MH  - Acute Kidney Injury/et [Etiology]
MH  - Aged
MH  - Anthropometry
MH  - *Body Mass Index
MH  - *Cardiac Surgical Procedures/ae [Adverse Effects]
MH  - Cardiac Surgical Procedures/mt [Methods]
MH  - Female
MH  - Humans
MH  - Length of Stay
MH  - Male
MH  - Middle Aged
MH  - Obesity/co [Complications]
MH  - *Obesity, Morbid/co [Complications]
MH  - Postoperative Complications
MH  - Reoperation
MH  - Retrospective Studies
MH  - Risk Factors
AB  - BACKGROUND: The increasing prevalence of obesity is a public health concern and perceived as a potential risk factor in open heart surgery. We critically appraised the literature available regarding postoperative complications in obese patients.
AB  - METHODS: A single-center retrospective evaluation of complication rates (1999-2004) in cardiac surgical patients categorized by body mass index (BMI) was conducted. The overall incidence of complications (CX), renal failure (RF), hemodialysis (HD), atrial fibrillation (AF), cardiac arrest (CA), infections (INF), stroke (CVA and TIA), prolonged ventilation (VENT), and pulmonary embolism (PE) were observed. Patients with normal BMI (20-30) served for comparison, obesity and extreme obesity (ExtOb) were defined as BMI 30-40 and > or =40, respectively.
AB  - RESULTS: In our institutional review of 1920 patients, 1780 met the inclusion criteria with BMI<20 (n=53), 20-30 (n=1056), 30-40 (n=592), and > or =40 (n=79) based on National Health and Nutrition Examination Survey (NHANES) criteria. Significant increase in complications (STS database guideline definitions) were observed with a BMI> or =40, 58% versus 47% (p=0.04). Extremely obese patients (ExtOb) had increased length of stay (LOS) (11.4 days vs 9.6 days; p< or =0.01), rate of renal failure (14.3% vs 5%; p< or =0.01) and prolonged ventilation (39%; p=0.01) compared to non-obese patients. Extremely obese had no significant increase in hemodialysis (7.3% vs 3.2%; p=0.11) or stroke (5.2% vs 2.9%; p=0.29). Obese patients (Ob) had increased LOS (10 days vs 9.6 days; p=0.04) and prolonged ventilation (28.3% vs 23.5%; p=0.03).
AB  - CONCLUSIONS: Cardiac surgery can be performed without significant increase in perioperative and 30-day mortality in obese and extremely obese patients. Overall complication rates and LOS in patients with BMI> or =40 is increased and demands attention. We provide evidence that rates of few specific complications increase with extreme obesity. For risk stratification in the setting of an obesity epidemic, we advocate an interdisciplinary approach in obese patients undergoing elective cardiac surgery. [References: 25]
IS  - 1010-7940
IL  - 1010-7940
PT  - Evaluation Studies
PT  - Journal Article
PT  - Review
LG  - English
EP  - 20060228
DP  - 2006 Apr
DC  - 20060320
YR  - 2006
ED  - 20060608
RD  - 20101118
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16504529

<618. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16630085
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Eberhardt F
AU  - Bonnemeier H
AU  - Lipphardt M
AU  - Hofmann UG
AU  - Schunkert H
AU  - Wiegand UK
FA  - Eberhardt, Frank
FA  - Bonnemeier, Hendrik
FA  - Lipphardt, Martin
FA  - Hofmann, Ulrich G
FA  - Schunkert, Heribert
FA  - Wiegand, Uwe K H
IN  - Eberhardt,Frank. University Hospital Schleswig Holstein, Campus Luebeck, Medicine II, Luebeck, Germany. eberhard@uni-luebeck.de
TI  - Atrial near-field and ventricular far-field analysis by automated signal processing at rest and during exercise.
SO  - Annals of Noninvasive Electrocardiology. 11(2):118-26, 2006 Apr.
AS  - Ann Noninvasive Electrocardiol. 11(2):118-26, 2006 Apr.
NJ  - Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - dzb, 9607443
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Algorithms
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Electrocardiography
MH  - *Exercise Test/mt [Methods]
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - *Pacemaker, Artificial
MH  - Posture
MH  - Signal Processing, Computer-Assisted
MH  - Statistics, Nonparametric
MH  - *Ventricular Fibrillation/di [Diagnosis]
MH  - Ventricular Fibrillation/pp [Physiopathology]
AB  - INTRODUCTION: Sophisticated monitoring of atrial activity is a prerequisite for modern pacemaker therapy. Ideally, near-fields and ventricular far-fields ought to be distinguished by beat-to-beat template analysis of the atrial signal. A prerequisite is that atrial signals are stable under different conditions.
AB  - METHODS AND RESULTS: A Matlab routine was developed to analyze atrial electrograms of 23 patients at least 3 months after implantation of a dual chamber pacemaker under several conditions including at rest, bipolar at rest, in an upright position, during treadmill exercise, and postexercise. A near-field and far-field template was created and amplitudes, widths, and slew rates were measured. In bipolar configuration, near-field amplitude at rest was 3.04 +/- 0.94 mV (unipolar)/3.36 +/- 1.0 mV (bipolar) versus 3.18 +/- 1.0 mV (bipolar) at peak exercise. Far-field amplitude at rest was 1.66 +/- 1.18 (unipolar)/0.47 +/- 0.27 mV (bipolar) and 0.41 +/- 0.21 mV (bipolar) at peak exercise (n.s. for bipolar measurements). No overall significant changes were observed for near- and far-field widths and slew rates during exercise. Shorter tip-ring distances of the atrial bipole, lead position, and the presence of sinus node disease did not have any impact on overall near- and far-field signal characteristics. Intraindividual differences between rest and peak exercise were moderate (range: near-field +0.15 to -0.54 mV; range: far-field +0.05 to -0.18 mV).
AB  - CONCLUSIONS: Atrial near and far fields can be automatically classified and quantified by automated signal processing. Signals did not change during exercise or change of posture. This is a prerequisite for the implementation of beat-to-beat template analysis into pacemakers.
IS  - 1082-720X
IL  - 1082-720X
PT  - Journal Article
LG  - English
DP  - 2006 Apr
DC  - 20060424
YR  - 2006
ED  - 20060602
RD  - 20080310
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16630085

<619. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16598527
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Bernhardt P
AU  - Schmidt H
AU  - Sommer T
AU  - Luderitz B
AU  - Omran H
FA  - Bernhardt, P
FA  - Schmidt, H
FA  - Sommer, T
FA  - Luderitz, B
FA  - Omran, H
IN  - Bernhardt,P. Department of Medicine-Cardiology, University of Bonn, Germany. bernhardt@cardiovasc-mri.com
TI  - Atrial fibrillation - patients at high risk for cerebral embolism.
SO  - Clinical Research in Cardiology. 95(3):148-53, 2006 Mar.
AS  - Clin. res. cardiol.. 95(3):148-53, 2006 Mar.
NJ  - Clinical research in cardiology : official journal of the German Cardiac Society
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - 101264123
SB  - Index Medicus
CP  - Germany
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/us [Ultrasonography]
MH  - Comorbidity
MH  - Echocardiography, Transesophageal/sn [Statistics & Numerical Data]
MH  - Female
MH  - Germany
MH  - Humans
MH  - Incidence
MH  - *Intracranial Embolism/di [Diagnosis]
MH  - *Intracranial Embolism/ep [Epidemiology]
MH  - Magnetic Resonance Imaging/sn [Statistics & Numerical Data]
MH  - Male
MH  - Middle Aged
MH  - *Risk Assessment/mt [Methods]
MH  - Risk Factors
AB  - OBJECTIVE: Patients with atrial fibrillation (AF) have a risk of cerebral embolism. Echocardiographic parameters elevate this risk significantly. However, there is little knowledge about the long-term fate and the rate of clinically silent cerebral embolism under continued oral anticoagulation. The aims of our study were to assess prognosis of patients with AF and determine a high risk group with an increased risk of cerebral embolism under oral anticoagulation.
AB  - METHODS: Consecutive patients with persistent or permanent AF and left atrial (LA) thrombi, dense spontaneous echo contrast (SEC) and/or reduced LA appendage peak emptying velocities (LAAv) were included in the study (N = 128). Patients with AF and without echocardiographic risk factors (N = 114) served as controls. All patients were examined with transesophageal echocardiography, cranial magnetic resonance imaging and clinically during a period of three years.
AB  - RESULTS: During the three-year follow-up period 6 (5%) of the high risk patients had cerebral embolism with neurological deficits. 4 (3%) patients died due to embolic events and 17 (13%) patients had silent embolism as documented on MRI. In the control group 8 (7%) patients had embolic events (n = 1 clinically apparent and n = 7 silent embolism) documented on MRI, one was clinically apparent. Study patients with an event had more commonly previous thromboembolism (p < 0.0001).
AB  - CONCLUSIONS: Patients with peristent or permanent AF and LA thrombi, dense SEC or reduced LAAv have an explicitly increased risk of cerebral embolism (21%) despite oral anticoagulation. Previous thromboembolic event is another important predictor for an event.
IS  - 1861-0684
IL  - 1861-0684
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20060112
DP  - 2006 Mar
DC  - 20060406
YR  - 2006
ED  - 20060510
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16598527

<620. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16537778
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Folkeringa RJ
AU  - Hartgers J
AU  - Tieleman RG
AU  - Gorgels AP
AU  - Dassen WR
AU  - Crijns HJ
FA  - Folkeringa, R J
FA  - Hartgers, J
FA  - Tieleman, R G
FA  - Gorgels, A P
FA  - Dassen, W R M
FA  - Crijns, H J G M
TI  - Atrial extrasystoles after exercise predict atrial fibrillation in patients with left ventricular hypertrophy.
SO  - Heart. 92(4):545-6, 2006 Apr.
AS  - Heart. 92(4):545-6, 2006 Apr.
NJ  - Heart (British Cardiac Society)
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 9602087
OI  - Source: NLM. PMC1860875
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - *Atrial Fibrillation/et [Etiology]
MH  - *Atrial Premature Complexes/co [Complications]
MH  - Atrial Premature Complexes/pp [Physiopathology]
MH  - *Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Female
MH  - Humans
MH  - *Hypertrophy, Left Ventricular/co [Complications]
MH  - Hypertrophy, Left Ventricular/pp [Physiopathology]
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Sensitivity and Specificity
MH  - Statistics, Nonparametric
ES  - 1468-201X
IL  - 1355-6037
PT  - Letter
LG  - English
DP  - 2006 Apr
DC  - 20060315
YR  - 2006
ED  - 20060508
RD  - 20140909
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16537778

<621. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16623617
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Papadopoulos V
AU  - Tsakiridis K
AU  - Filippou DK
AU  - Aggelopoulos P
AU  - Nikiforidis D
AU  - Baltatzidis G
FA  - Papadopoulos, Vasilios
FA  - Tsakiridis, Kosmas
FA  - Filippou, Dimitrios K
FA  - Aggelopoulos, Petros
FA  - Nikiforidis, Dimitrios
FA  - Baltatzidis, Georgios
IN  - Papadopoulos,Vasilios. Emergency Department, Xanthi General Hospital, Xanthi, Greece. vaspapmd@hotmail.com
TI  - Comparison of stroke among Christians and Muslims in Thrace, Greece.
SO  - Rural & Remote Health. 6(2):505, 2006 Apr-Jun.
AS  - RURAL REMOTE HEALTH. 6(2):505, 2006 Apr-Jun.
NJ  - Rural and remote health
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101174860
SB  - Index Medicus
CP  - Australia
MH  - Aged
MH  - *Christianity
MH  - Female
MH  - Greece/ep [Epidemiology]
MH  - Humans
MH  - *Islam
MH  - Male
MH  - Prospective Studies
MH  - *Rural Health
MH  - *Stroke/ep [Epidemiology]
AB  - INTRODUCTION:
AB  - BACKGROUND AND PURPOSE: Previous studies have demonstrated significant racial differences in incidence, age of onset, outcome and subsequent risk factors of stroke. However, there is scarce evidence available for Muslim populations worldwide. Xanthi region, a mainly rural and remote area in northern Greece, which is characterized by a mixed Christian/Muslim population, is considered appropriate for further studies in this area.
AB  - METHODS: A prospective clinical study, based on a cohort of 530 consecutive unselected patients, 366 Christians and 164 Muslims, who had their first documented episode of stroke between 1998 and 2002. Chi-square and Fisher's exact test for comparison between discrete parameters, Student's t-test for comparison between quantitative parameters and Pearson's r for correlations (along with Bonferroni's adjustment) were used. A multiple logistic regression model was performed for evaluation of religion and gender as independent predictors of type of stroke.
AB  - RESULTS: Muslims, when compared with Christians: (1) present with ischemic stroke less often (p = 0.049); (2) suffer from stroke at a younger age (67.26 +/- 9.77 vs 71.43 +/- 10.88 years; p < 0.001); (3) show a significantly lower incidence rate (87.2 vs 173.9 cases/100,000 person*years; RR 1.994; p < 0.001); (4) have lower rates of diabetes (p = 0.019) and atrial fibrillation (p < 0.001) and (5) present similar mortality (p = 0.347).
AB  - CONCLUSIONS: Lower diabetes and atrial fibrillation rates among the Muslims of Thrace, Greece, might account for their low incidence of stroke. The contribution of culture-related habits (diet, occupation) remains to be investigated in further studies.
ES  - 1445-6354
IL  - 1445-6354
PT  - Comparative Study
PT  - Journal Article
LG  - English
EP  - 20060412
DP  - 2006 Apr-Jun
DC  - 20060420
YR  - 2006
ED  - 20060504
RD  - 20140729
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16623617

<622. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16569549
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Brouwer IA
AU  - Heeringa J
AU  - Geleijnse JM
AU  - Zock PL
AU  - Witteman JC
FA  - Brouwer, Ingeborg A
FA  - Heeringa, Jan
FA  - Geleijnse, Johanna M
FA  - Zock, Peter L
FA  - Witteman, Jacqueline C M
IN  - Brouwer,Ingeborg A. Wageningen Centre for Food Sciences, Wageningen, The Netherlands. ingeborg.brouwer@wur.nl
TI  - Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study.
SO  - American Heart Journal. 151(4):857-62, 2006 Apr.
AS  - Am Heart J. 151(4):857-62, 2006 Apr.
NJ  - American heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 0370465
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Animals
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/mo [Mortality]
MH  - *Diet
MH  - *Fatty Acids, Omega-3/ad [Administration & Dosage]
MH  - Female
MH  - Fishes
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Netherlands/ep [Epidemiology]
MH  - Proportional Hazards Models
MH  - Prospective Studies
AB  - BACKGROUND: Atrial fibrillation is the most common sustained cardiac arrhythmia. It is a major cause of morbidity and mortality through an increased risk of thromboembolic stroke. Experimental as well as observational evidence suggests that n-3 polyunsaturated fatty acids may have antiarrhythmic effects. The objective of this study was to examine whether high intakes of fish and its very long-chain n-3 fatty acids eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) are associated with risk of incident atrial fibrillation.
AB  - METHODS: We used data from the Rotterdam Study, a prospective cohort study. At baseline, dietary intake data were available for 5184 subjects free from atrial fibrillation. Dietary intake was assessed using a semiquantitative food-frequency questionnaire, and incidence of atrial fibrillation was continuously monitored during follow-up. Cox proportional hazards model (adjusted for lifestyle and disease factors) was used to examine the associations between intakes of EPA plus DHA and of fish with atrial fibrillation.
AB  - RESULTS: After a mean follow-up of 6.4 (+/-1.6) years, 312 subjects developed atrial fibrillation. Intake of EPA and DHA in the third textile compared with first was not associated with risk of atrial fibrillation (relative risk 1.18, 95% CI 0.88-1.57). Furthermore, no association was observed with intake of >20 g/d fish compared with no fish intake (relative risk 1.17, 95% CI 0.87-1.57).
AB  - CONCLUSIONS: In this study, intakes of EPA and DHA and the consumption of fish were not associated with the onset of atrial fibrillation. This finding does not support that n-3 fatty acids have a general antiarrhythmic effect.
RN  - 0 (Fatty Acids, Omega-3)
ES  - 1097-6744
IL  - 0002-8703
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2006 Apr
DC  - 20060329
YR  - 2006
ED  - 20060421
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16569549

<623. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16376765
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lee SH
AU  - Jung JH
AU  - Choi SH
AU  - Lee N
AU  - Oh DJ
AU  - Ryu KH
AU  - Rhim CY
AU  - Lee KH
AU  - Lee Y
FA  - Lee, Sang Hak
FA  - Jung, Jae-Hun
FA  - Choi, Seung-Hyuk
FA  - Lee, Namho
FA  - Oh, Dong-Jin
FA  - Ryu, Kyu-Hyung
FA  - Rhim, Chong-Yun
FA  - Lee, Kwang-Hwak
FA  - Lee, Yung
IN  - Lee,Sang Hak. Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea. shl1106@hallym.ac.kr
TI  - Exercise intolerance in patients with atrial fibrillation: clinical and echocardiographic determinants of exercise capacity.
SO  - Journal of the American Society of Echocardiography. 18(12):1349-54, 2005 Dec.
AS  - J Am Soc Echocardiogr. 18(12):1349-54, 2005 Dec.
NJ  - Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - aof, 8801388
SB  - Index Medicus
CP  - United States
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/us [Ultrasonography]
MH  - Biomarkers/bl [Blood]
MH  - *Exercise Test/mt [Methods]
MH  - *Exercise Tolerance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/bl [Blood]
MH  - *Risk Assessment/mt [Methods]
MH  - Risk Factors
MH  - *Stroke Volume
MH  - Ventricular Dysfunction, Left/et [Etiology]
MH  - Ventricular Dysfunction, Left/pp [Physiopathology]
MH  - *Ventricular Dysfunction, Left/us [Ultrasonography]
AB  - Although exercise intolerance is a major symptom of patients with atrial fibrillation (AF), the factors limiting these patients' exercise capacity remains uncertain. This study evaluated the correlation of clinical and echocardiographic parameters with exercise capacity of patients with AF. In all, 73 patients (61 men and 12 women; mean age 61 years) with chronic AF were included in this study. Those patients with primary valvular diseases were excluded. Standard 2-dimensional and Doppler echocardiography was performed, and we averaged 10 consecutive measurements of each variable. Patients then underwent a symptom-limited treadmill exercise testing. We also measured patients' plasma levels of B-type natriuretic peptide before exercise testing. Of all clinical and echocardiographic parameters we assessed, age (r = -0.45, P = .006), ratio of early mitral inflow velocity to mitral annular velocity (r = -0.35, P = .032), and baseline heart rate were independent predictors of exercise capacity on multivariate regression analysis. In conclusion, patient's age, averaged ratio of early mitral inflow velocity to mitral annular velocity, and baseline heart rate provided useful information on exercise intolerance for patients with AF. Ratio of early mitral inflow velocity to mitral annular velocity, a noninvasive tool for estimating left ventricular filling pressure, may especially have important value for predicting functional capacity in this population as it has in individuals with in sinus rhythm.
RN  - 0 (Biomarkers)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
ES  - 1097-6795
IL  - 0894-7317
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2005 Dec
DC  - 20051226
YR  - 2005
ED  - 20060420
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16376765

<624. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16337500
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Heidbuchel H
AU  - Anne W
AU  - Willems R
AU  - Adriaenssens B
AU  - Van de Werf F
AU  - Ector H
FA  - Heidbuchel, Hein
FA  - Anne, Wim
FA  - Willems, Rik
FA  - Adriaenssens, Bert
FA  - Van de Werf, Frans
FA  - Ector, Hugo
IN  - Heidbuchel,Hein. Department of Cardiology, University Hospital Gasthuisberg, University of Leuven, Herestraat 49, B-3000 Leuven, Belgium. hein.heidbuchel@uz.kuleuven.ac.be
TI  - Endurance sports is a risk factor for atrial fibrillation after ablation for atrial flutter.
SO  - International Journal of Cardiology. 107(1):67-72, 2006 Feb 8.
AS  - Int J Cardiol. 107(1):67-72, 2006 Feb 8.
NJ  - International journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - gqw, 8200291
SB  - Index Medicus
CP  - Ireland
MH  - *Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Flutter/th [Therapy]
MH  - *Catheter Ablation/ae [Adverse Effects]
MH  - *Exercise
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Physical Endurance/ph [Physiology]
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - *Sports/ph [Physiology]
MH  - Surveys and Questionnaires
AB  - INTRODUCTION: Sports activity has been associated with the development of atrial arrhythmias. Atrial fibrillation (AF) is frequently observed after successful ablation for atrial flutter. Sports activity as a risk factor for AF development after flutter ablation has not been studied.
AB  - METHODS: We analyzed outcome in 137 patients (83% men) after ablation for isthmus-dependent atrial flutter (excluding patients with concomitant ablation for atrial tachycardia or fibrillation). Sports activity before and after ablation was evaluated by detailed questionnaires. Endurance sports was defined as (semi-)competitive participation in cycling, running or swimming for > or =3 h/week (and for > or =3 years pre-ablation). Median follow-up was 2.5 years. Survival free of AF was evaluated with Kaplan-Meier curves and log-rank statistics. Multivariate analysis was based on Cox proportional hazard evaluation.
AB  - RESULTS: Acute ablation success was 99% and flutter recurrence 4.4%. Thirty-one patients (23%) had been regularly engaged in endurance sports before ablation and 19 (14%) continued regular sports activity afterwards. Those performing sports were slightly younger. A history of endurance sports was a significant risk factor for post-ablation AF (univariate HR 1.96 (1.19-3.22), p<0.01, and multivariate HR 1.81 (1.10-2.98), p=0.02). Also continuation of endurance sports activity after ablation showed a trend for increased risk to develop AF despite a relatively small sample size (n=19; multivariate HR 1.68 (0.92-3.06), p=0.08). Cox proportional hazard calculations revealed a 10% and 11% increased risk for AF development per weekly hour sport performed before and after ablation respectively (p<0.01 for both).
AB  - CONCLUSION: A history of endurance sports activity is associated with the development of AF after ablation of atrial flutter.
IS  - 0167-5273
IL  - 0167-5273
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2006 Feb 8
DC  - 20051212
YR  - 2006
ED  - 20060413
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16337500

<625. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16153514
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Bernhardt P
AU  - Schmidt H
AU  - Hammerstingl C
AU  - Luderitz B
AU  - Omran H
FA  - Bernhardt, Peter
FA  - Schmidt, Harald
FA  - Hammerstingl, Christoph
FA  - Luderitz, Berndt
FA  - Omran, Heyder
IN  - Bernhardt,Peter. Department of Medicine-Cardiology, University of Bonn, Bonn, Germany. bernhardt@cardiovasc-mri.com
TI  - Patients at high risk with atrial fibrillation: a prospective and serial follow-up during 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging.
SO  - Journal of the American Society of Echocardiography. 18(9):919-24, 2005 Sep.
AS  - J Am Soc Echocardiogr. 18(9):919-24, 2005 Sep.
NJ  - Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - aof, 8801388
SB  - Index Medicus
CP  - United States
MH  - Administration, Oral
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/mo [Mortality]
MH  - Comorbidity
MH  - *Echocardiography, Transesophageal/sn [Statistics & Numerical Data]
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Intracranial Embolism/di [Diagnosis]
MH  - *Intracranial Embolism/dt [Drug Therapy]
MH  - *Intracranial Embolism/mo [Mortality]
MH  - Intracranial Embolism/pc [Prevention & Control]
MH  - *Magnetic Resonance Imaging/sn [Statistics & Numerical Data]
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Risk Assessment/mt [Methods]
MH  - Risk Factors
MH  - Survival Analysis
MH  - Survival Rate
AB  - OBJECTIVE: Patients with atrial fibrillation and echocardiographic risk factors have a relevant risk of cerebral embolism. However, there is little knowledge about the long-term fate and the rate of clinical silent cerebral embolism under continued oral anticoagulation. Our aims were to assess the prognosis of patients with atrial fibrillation and determine a high-risk group with an increased risk of cerebral embolism under oral anticoagulation.
AB  - METHODS: A total of 173 consecutive patients with persistent or permanent atrial fibrillation and left atrial (LA) thrombi, dense spontaneous echocontrast, reduced LA appendage peak emptying velocities, or a combination of these were included in the study. In all, 169 patients with atrial fibrillation and without echocardiographic risk factors served as control patients. We performed serial and prospective transesophageal echocardiography, cranial magnetic resonance imaging, and clinical examinations during a period of 12 months.
AB  - RESULTS: During the follow-up period 7 (4%) of the patients at high risk had cerebral embolism with neurologic deficits. A total of 4 (2%) patients died because of embolic events and 19 (11%) patients had silent embolism as documented on magnetic resonance imaging. In the control group, 10 (6%) patients had embolic events documented on magnetic resonance imaging; one was clinically apparent. Study patients with an event had more often previous thromboembolism (P < .0001).
AB  - CONCLUSIONS: Patients with persistent or permanent atrial fibrillation and LA thrombi, dense spontaneous echocontrast, or reduced LA appendage peak emptying velocities have an explicitly increased risk of cerebral embolism (17%) despite oral anticoagulation. Previous thromboembolic event is another important predictor for an event.
RN  - 0 (Anticoagulants)
ES  - 1097-6795
IL  - 0894-7317
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2005 Sep
DC  - 20050912
YR  - 2005
ED  - 20060411
RD  - 20071102
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16153514

<626. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16228059
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Al Suwaidi J
AU  - Zubaid M
AU  - Al-Mahmeed WA
AU  - Al-Rashdan I
AU  - Amin H
AU  - Bener A
AU  - Hadi HR
AU  - Helmy A
AU  - Hanifah M
AU  - Al-Binali HA
FA  - Al Suwaidi, Jassim
FA  - Zubaid, Mohammad
FA  - Al-Mahmeed, Wael A
FA  - Al-Rashdan, Ibrahim
FA  - Amin, Haitham
FA  - Bener, Abdulbari
FA  - Hadi, Hadi R
FA  - Helmy, Ashraf
FA  - Hanifah, Mohammed
FA  - Al-Binali, Hajar A
IN  - Al Suwaidi,Jassim. Department of Cardiology and Cardiovascular Surgery, Hamad General Hospital and Hamad Medical Corporation, Doha, State of Qatar. jha01@hmc.org.qa
TI  - Impact of fasting in Ramadan in patients with cardiac disease.
SO  - Saudi Medical Journal. 26(10):1579-83, 2005 Oct.
AS  - Saudi Med J. 26(10):1579-83, 2005 Oct.
NJ  - Saudi medical journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - dyw, 7909441
SB  - Index Medicus
CP  - Saudi Arabia
MH  - Adult
MH  - Age Distribution
MH  - Aged
MH  - Bahrain/ep [Epidemiology]
MH  - *Cardiovascular Diseases/di [Diagnosis]
MH  - *Cardiovascular Diseases/ep [Epidemiology]
MH  - Chi-Square Distribution
MH  - Cohort Studies
MH  - Disease Progression
MH  - *Fasting/ae [Adverse Effects]
MH  - Female
MH  - Humans
MH  - *Islam
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Severity of Illness Index
MH  - Sex Distribution
MH  - Statistics, Nonparametric
MH  - Survival Rate
AB  - OBJECTIVES: To investigate whether Ramadan fasting has any effect on patients with heart disease.
AB  - METHODS: We prospectively studied 465 outpatients with heart disease who were fasting during the month of Ramadan from October 24 to November 24, 2003. These studied subjects were from various medical centers in the Gulf region; State of Qatar, Kuwait, United Arab Emirates, and Bahrain. We performed detailed clinical assessments one month before Ramadan, during Ramadan and one month after Ramadan and analyzed predictors of outcome.
AB  - RESULTS: Overall, the mean age was 55.9+/-11.3 years (age range 32-72). Of the 465 patients treated, 363 (78.1%) were males and 102 (21.9%) females. Among them, 119 (25.6%) patients had congestive heart failure, 288 (62%) patients with angina, 22 (4.7%) patients with atrial fibrillation and 11 (2.4%) patients with prosthetic metallic valves. Three hundred and seventy (79%) had prior myocardial infarction (MI), 195 (17.2%) had prior coronary artery bypass surgery (CABG), and 177 (38%) had prior percutaneous coronary interventions (PCI). At the time of follow-up, we found that 91.2% could fast and only 6.7% felt worse while fasting in Ramadan. Of the studied subjects, 82.8% were compliant with cardiac medications and 68.8% were compliant with dietary instructions. We hospitalized 19 patients during Ramadan for cardiac reasons (unstable angina, worsening heart failure, MI, uncontrolled hypertension, subtherapeutic anticoagulation or arrhythmias)
AB  - CONCLUSION: The effects of fasting during Ramadan on stable patients with cardiac disease are minimal. Most patients with stable cardiac disease can fast.
IS  - 0379-5284
IL  - 0379-5284
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2005 Oct
DC  - 20051017
YR  - 2005
ED  - 20060328
RD  - 20080623
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16228059

<627. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16461832
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Chugh A
AU  - Latchamsetty R
AU  - Oral H
AU  - Elmouchi D
AU  - Tschopp D
AU  - Reich S
AU  - Igic P
AU  - Lemerand T
AU  - Good E
AU  - Bogun F
AU  - Pelosi F Jr
AU  - Morady F
FA  - Chugh, Aman
FA  - Latchamsetty, Rakesh
FA  - Oral, Hakan
FA  - Elmouchi, Darryl
FA  - Tschopp, David
FA  - Reich, Scott
FA  - Igic, Petar
FA  - Lemerand, Tammy
FA  - Good, Eric
FA  - Bogun, Frank
FA  - Pelosi, Frank Jr
FA  - Morady, Fred
IN  - Chugh,Aman. Division of Cardiology, University of Michigan Hospitals, Ann Arbor, MI, USA. achugh@umich.edu
TI  - Characteristics of cavotricuspid isthmus-dependent atrial flutter after left atrial ablation of atrial fibrillation.
SO  - Circulation. 113(5):609-15, 2006 Feb 7.
AS  - Circulation. 113(5):609-15, 2006 Feb 7.
NJ  - Circulation
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Atrial Flutter/et [Etiology]
MH  - *Atrial Flutter/pp [Physiopathology]
MH  - Body Surface Potential Mapping
MH  - *Catheter Ablation/ae [Adverse Effects]
MH  - Electrocardiography
MH  - Female
MH  - Heart Atria/pp [Physiopathology]
MH  - Heart Conduction System/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Tricuspid Valve/pp [Physiopathology]
AB  - BACKGROUND: Patients who have previously undergone ablation of atrial fibrillation may experience cavotricuspid isthmus (CTI)-dependent atrial flutter during follow-up. The effects of left atrial (LA) ablation on the characteristics of CTI-dependent flutter have not been described.
AB  - METHODS AND RESULTS: Fifteen patients underwent ablation of CTI-dependent flutter late after LA ablation of AF. The ECG, biatrial activation patterns, and LA voltage maps during flutter were analyzed. Thirty age- and gender-matched patients who underwent ablation of CTI-dependent flutter without prior LA ablation served as control subjects. Among the patients with prior LA ablation, mapping revealed counterclockwise activation around the tricuspid annulus in 12 of 15 patients (80%) and clockwise activation in 3 of 15 patients (20%). The flutter waves in the inferior leads were upright in 9 of the 15 patients (60%) with prior LA ablation and in none of the control subjects (P<0.001). The upright flutter waves in the inferior leads in patients with counterclockwise flutter corresponded to craniocaudal activation of the right atrial free wall. LA activation contributed little to the genesis of the flutter waves in these patients because of a significant reduction in bipolar LA voltage (0.44+/-0.20 versus 1.54+/-0.19 mV in patients with biphasic/negative flutter waves; P<0.001).
AB  - CONCLUSIONS: CTI-dependent flutter that occurs after LA ablation of atrial fibrillation often has atypical ECG characteristics because of altered LA activation. In patients presenting with atrial flutter after LA ablation, entrainment mapping should be performed at the CTI even if the ECG is uncharacteristic of CTI-dependent flutter.
ES  - 1524-4539
IL  - 0009-7322
PT  - Controlled Clinical Trial
PT  - Journal Article
LG  - English
DP  - 2006 Feb 7
DC  - 20060207
YR  - 2006
ED  - 20060310
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16461832

<628. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16442366
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mozaffarian D
AU  - Gottdiener JS
AU  - Siscovick DS
FA  - Mozaffarian, Dariush
FA  - Gottdiener, John S
FA  - Siscovick, David S
IN  - Mozaffarian,Dariush. Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. dmozaffa@hsph.harvard.edu
TI  - Intake of tuna or other broiled or baked fish versus fried fish and cardiac structure, function, and hemodynamics.
SO  - American Journal of Cardiology. 97(2):216-22, 2006 Jan 15.
AS  - Am J Cardiol. 97(2):216-22, 2006 Jan 15.
NJ  - The American journal of cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Animals
MH  - Blood Pressure
MH  - Cardiac Output
MH  - Confounding Factors (Epidemiology)
MH  - Cooking/mt [Methods]
MH  - Heart Rate
MH  - *Hemodynamics
MH  - Humans
MH  - *Seafood
MH  - *Tuna
MH  - Vascular Resistance
AB  - Fish intake is associated with improved cardiovascular health, including a lower risk of arrhythmic death, atrial fibrillation, and heart failure. However, the physiologic effects that may produce these cardiovascular benefits are not well-established. We investigated the cross-sectional associations between a usual dietary intake of fish during the previous year and cardiac structure, function, and hemodynamics as determined by physical examination and 2-dimensional, Doppler, and M-mode transthoracic echocardiography among 5,073 older adults enrolled in the Cardiovascular Health Study. On multivariate-adjusted analyses, consumption of tuna or other broiled or baked fish was associated with a lower heart rate (p < 0.001), lower systemic vascular resistance (p = 0.002), and greater stroke volume (p < 0.001). Tuna/other fish intake was also associated with a higher E/A ratio (p = 0.004), a measure of more normal diastolic function. In contrast, fried fish or fish sandwich (fish burger) intake was associated with left ventricular wall motion abnormalities (p = 0.02), a reduced ejection fraction (p < 0.001), lower cardiac output (p = 0.04), a trend toward a larger left ventricular diastolic dimension (p = 0.07), and higher systemic vascular resistance (p = 0.003). In conclusion, in this large population-based study, the intake of tuna or other broiled or baked fish was associated with improved cardiac hemodynamics, but fried fish intake was associated with structural abnormalities indicative of systolic dysfunction and potential coronary atherosclerosis. These findings suggest potential specific physiologic mechanisms that may, in part, account for the effects of fish intake on cardiovascular health.
IS  - 0002-9149
IL  - 0002-9149
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
NO  - K08-HL-075628 (United States NHLBI NIH HHS)
NO  - N01-HC-15103 (United States NHLBI NIH HHS)
NO  - N01-HC-35129 (United States NHLBI NIH HHS)
NO  - N01-HC-85079 (United States NHLBI NIH HHS)
NO  - N01-HC-85086 (United States NHLBI NIH HHS)
LG  - English
EP  - 20051121
DP  - 2006 Jan 15
DC  - 20060130
YR  - 2006
ED  - 20060303
RD  - 20101118
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16442366

<629. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16377465
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Jacobs LG
FA  - Jacobs, Laurie G
IN  - Jacobs,Laurie G. Division of Geriatrics, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10467, USA. lajacobs@montefiore.org
TI  - Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. [Review] [68 refs]
SO  - Clinics in Geriatric Medicine. 22(1):17-32, vii-viii, 2006 Feb.
AS  - Clin Geriatr Med. 22(1):17-32, vii-viii, 2006 Feb.
NJ  - Clinics in geriatric medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - cln, 8603766
SB  - Index Medicus
CP  - United States
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/ae [Adverse Effects]
MH  - *Anticoagulants/pd [Pharmacology]
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - *Cerebral Hemorrhage/ci [Chemically Induced]
MH  - Cerebral Hemorrhage/pc [Prevention & Control]
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Female
MH  - Follow-Up Studies
MH  - *Gastrointestinal Hemorrhage/ci [Chemically Induced]
MH  - Gastrointestinal Hemorrhage/pc [Prevention & Control]
MH  - Geriatric Assessment
MH  - Humans
MH  - Male
MH  - Maximum Tolerated Dose
MH  - Monitoring, Physiologic
MH  - Prothrombin Time
MH  - Risk Assessment
MH  - Treatment Outcome
MH  - Warfarin/ae [Adverse Effects]
MH  - *Warfarin/pd [Pharmacology]
MH  - Warfarin/tu [Therapeutic Use]
AB  - Elderly patients as a group may present more of a challenge in managing warfarin therapy because of alterations in pharmacokinetics from other medications, diet, and disease; pharmacodynamic changes; increased risk for hemorrhage; and difficulty in monitoring. The elderly, however, may derive the most benefit from warfarin therapy for certain indications, such as the prevention of stroke in atrial fibrillation or recurrent events following deep venous thrombosis. Warfarin can be managed as effectively as in other populations with careful attention to these issues. [References: 68]
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
IS  - 0749-0690
IL  - 0749-0690
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2006 Feb
DC  - 20051226
YR  - 2006
ED  - 20060228
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16377465

<630. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16207542
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Engelmann MD
AU  - Niemann L
AU  - Kanstrup IL
AU  - Skagen K
AU  - Godtfredsen J
FA  - Engelmann, Mads D M
FA  - Niemann, Lea
FA  - Kanstrup, Inge-Lis
FA  - Skagen, Knud
FA  - Godtfredsen, John
IN  - Engelmann,Mads D M. Department of Cardiology, Herlev University Hospital, Herlev, Denmark. engelmann@dadlnet.dk
TI  - Natriuretic peptide response to dynamic exercise in patients with atrial fibrillation.
SO  - International Journal of Cardiology. 105(1):31-9, 2005 Oct 20.
AS  - Int J Cardiol. 105(1):31-9, 2005 Oct 20.
NJ  - International journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - gqw, 8200291
SB  - Index Medicus
CP  - Ireland
MH  - Aged
MH  - Atrial Fibrillation/bl [Blood]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Natriuretic Factor/bl [Blood]
MH  - Blood Pressure/ph [Physiology]
MH  - *Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Female
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - *Natriuretic Peptide, Brain/bl [Blood]
MH  - Oxygen Consumption/ph [Physiology]
MH  - Physical Endurance/ph [Physiology]
MH  - Predictive Value of Tests
MH  - Stroke Volume/ph [Physiology]
AB  - BACKGROUND: In patients with atrial fibrillation (AF) information regarding exercise release of atrial natriuretic peptide (ANP) is sparse and data on plasma brain natriuretic peptide (BNP) response to exercise is lacking. The aim of this study was to investigate plasma ANP and BNP response to exercise in patients with permanent AF and to assess if the response was different from the response in healthy age- and sex-matched control subjects.
AB  - METHODS: Plasma venous concentrations of ANP and BNP were determined at rest, at peak exercise and 30 min from the end of exercise in 38 patients with permanent AF and in 43 age- and sex-matched healthy control subjects.
AB  - RESULTS: Plasma concentrations of ANP and BNP were significantly higher in AF patients compared with the healthy control group at rest, peak exercise and after 30 min of recovery (p<0.0001). ANP and BNP increased significantly during exercise in both patients with AF and in the healthy control subjects (p<0.05). The increase in plasma concentration of ANP and BNP during exercise was significantly higher in AF patients compared with healthy controls (p=0.0002 for ANP; p<0.0001 for BNP). In the recovery period plasma BNP decreased significantly (p<0.0001) where as the decrease in plasma ANP was insignificant (p=0.4).
AB  - CONCLUSIONS: Patients with permanent AF have elevated levels of ANP and BNP at rest and exhibit much higher exercise release compared to healthy control subjects. This enhanced secretion of potent vasodilating and natriuretic agents may represent an important compensatory mechanism to improve exercise capacity in patients with AF.
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
IS  - 0167-5273
IL  - 0167-5273
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 2005 Oct 20
DC  - 20051006
YR  - 2005
ED  - 20060228
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16207542

<631. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16004855
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Nutescu EA
AU  - Helgason CM
FA  - Nutescu, Edith A
FA  - Helgason, Cathy M
IN  - Nutescu,Edith A. Antithrombosis Service, College of Pharmacy-Pharmacy Practice, University of Illinois, 833 South Wood Street, MC 886, Room 164, Chicago, IL 60612, USA. enutescu@uic.edu
TI  - Concomitant drug, dietary, and lifestyle issues in patients with atrial fibrillation receiving anticoagulation therapy for stroke prophylaxis.
SO  - Current Treatment Options in Cardiovascular Medicine. 7(3):241-50, 2005 Jul.
AS  - Curr Treat Options Cardiovasc Med. 7(3):241-50, 2005 Jul.
NJ  - Current treatment options in cardiovascular medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9815942
CP  - United States
AB  - Atrial fibrillation is a common cardiac arrhythmia and the leading risk factor for stroke. In those at moderate to high risk of stroke, oral anticoagulation therapy with warfarin (a vitamin K antagonist) significantly reduces not only the frequency of such events but also their severity and the associated risk of death. However, achieving optimal anticoagulation with this agent is clinically challenging in view of its complex pharmacokinetic and pharmacodynamic profile. In this regard, concomitant drug therapy (both prescription and over-the-counter medications, including herbal products, vitamins, and various nutritional supplements), along with alcohol intake, dietary factors, and changes in lifestyle, can significantly affect anticoagulation control and thereby expose patients to the risk of bleeding or thromboembolic complications (due to over- and underanticoagulation, respectively). Therefore, it is recommended that intensified monitoring of anticoagulation be performed at initiation and discontinuation of concomitant drug therapy, and in the case of significant dietary and lifestyle changes. Moreover, many patients receive inadequate education and are unaware of such risks and their implications, highlighting the need for better awareness and education on this important aspect of anticoagulation therapy.
IS  - 1092-8464
IL  - 1092-8464
PT  - Journal Article
LG  - English
DP  - 2005 Jul
DC  - 20050711
YR  - 2005
ED  - 20060123
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=16004855

<632. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16245959
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Andrawes WF
AU  - Bussy C
AU  - Belmin J
FA  - Andrawes, Wafik Farah
FA  - Bussy, Caroline
FA  - Belmin, Joel
IN  - Andrawes,Wafik Farah. Service de Geriatrie, Hopital Charles Foix et Universite Paris 6, Ivry-sur-Seine, France.
TI  - Prevention of cardiovascular events in elderly people. [Review] [129 refs]
SO  - Drugs & Aging. 22(10):859-76, 2005.
AS  - Drugs Aging. 22(10):859-76, 2005.
NJ  - Drugs & aging
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - bek, 9102074
SB  - Index Medicus
CP  - New Zealand
MH  - Aged
MH  - Aging/de [Drug Effects]
MH  - *Aging
MH  - Antihypertensive Agents/ad [Administration & Dosage]
MH  - Antihypertensive Agents/ae [Adverse Effects]
MH  - *Antihypertensive Agents/tu [Therapeutic Use]
MH  - Blood Pressure/de [Drug Effects]
MH  - Cardiovascular Diseases/mo [Mortality]
MH  - Cardiovascular Diseases/pp [Physiopathology]
MH  - *Cardiovascular Diseases/pc [Prevention & Control]
MH  - Fibrinolytic Agents/ad [Administration & Dosage]
MH  - Fibrinolytic Agents/ae [Adverse Effects]
MH  - *Fibrinolytic Agents/tu [Therapeutic Use]
MH  - Humans
MH  - Hypolipidemic Agents/ad [Administration & Dosage]
MH  - Hypolipidemic Agents/ae [Adverse Effects]
MH  - *Hypolipidemic Agents/tu [Therapeutic Use]
MH  - Life Style
MH  - MEDLINE
MH  - Risk Factors
AB  - BACKGROUND AND OBJECTIVE: Cardiovascular disease has been identified as the leading cause of morbidity and mortality in developed countries. Given the increase in life expectancy and the development of cardiovascular preventive measures, it has become increasingly important to detect and prevent cardiovascular diseases in the elderly. We reviewed the scientific literature concerning cardiovascular prevention to assess the importance of cardiovascular preventive measures in old (> or =65 years of age) individuals.
AB  - METHODS: We undertook a systematic search for references relating to prevention of cardiovascular disease in the elderly, mainly ischaemic stroke, coronary artery disease and heart failure, on the MEDLINE database 1962-2005. For cardiovascular prevention by drugs or surgery, emphasis was placed on randomised controlled trials, review articles and meta-analyses. For cardiovascular prevention by lifestyle modification, major cohort studies were also considered.
AB  - RESULTS: Stroke, coronary heart disease and heart failure were found to be the main targets for cardiovascular prevention in published studies. Antihypertensive treatment has proven its efficacy in primary prevention of fatal or nonfatal stroke in hypertensive and high-risk patients >60 years of age, particularly through treatment of systolic hypertension. Systolic blood pressure reduction is equally important in the secondary prevention of stroke. Similarly, in nonvalvular atrial fibrillation, an adjusted dose of warfarin with a target International Normalized Ratio (INR) of between 2 to 3 prevents ischaemic stroke in elderly patients with an acceptable haemorrhagic risk but is still under prescribed. Antiplatelet agents are indicated in elderly patients with nonembolic strokes. Few large-scale studies have investigated the effect of HMG-CoA reductase inhibitors (statins) on stroke prevention in old individuals. To date, the largest trials suggest a beneficial effect for stroke prevention with use of statins in high-risk elderly subjects < or =82 years of age. Carotid endarterectomy is indicated in carotid artery stenosis >70% and outcomes are even better in elderly than in younger patients. However, medical treatment is still the first-line treatment in asymptomatic elderly patients with <70% stenosis. In ischaemic heart disease, different trials in elderly individuals have shown that use of statins, antithrombotic agents, beta-adrenoceptor antagonists and ACE inhibitors plays an important role either in primary or in secondary cardiovascular prevention. Hormone replacement therapy has been used to treat climacteric symptoms and postmenopausal osteoporosis and was thought to confer a cardiovascular protection. However, controlled trials in elderly individuals changed this false belief when it was found that there was no benefit and even a harmful cardiovascular effect during the first year of treatment. Smoking cessation, regular physical activity and healthy diet are, as in younger individuals, appropriate and effective measures for preventing cardiovascular events in the elderly. Finally, antihypertensive treatment and influenza vaccination are useful for heart failure prevention in elderly individuals.
AB  - CONCLUSIONS: Cardiovascular prevention should be more widely implemented in the elderly, including individuals aged > or =75 years, and this might contribute to improved healthy status and quality of life in this growing population. [References: 129]
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Hypolipidemic Agents)
IS  - 1170-229X
IL  - 1170-229X
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2005
DC  - 20051025
YR  - 2005
ED  - 20060120
RD  - 20101118
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16245959

<633. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16136427
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kosior DA
AU  - Stawicki S
AU  - Wozakowska-Kaplon B
AU  - Szulc M
AU  - Opolski G
AU  - Rabczenko D
FA  - Kosior, Dariusz A
FA  - Stawicki, Slawomir
FA  - Wozakowska-Kaplon, Beata
FA  - Szulc, Marcin
FA  - Opolski, Grzegorz
FA  - Rabczenko, Daniel
IN  - Kosior,Dariusz A. Department of Cardiology, Medical Academy, Warsaw, Poland.
TI  - Impact of sinus rhythm restoration and maintenance on left ventricular function and exercise tolerance in patients with persistent atrial fibrillation.
SO  - Kardiologia Polska. 63(7):36-47; discussion 48-9, 2005 Jul.
AS  - Kardiol Pol. 63(7):36-47; discussion 48-9, 2005 Jul.
NJ  - Kardiologia polska
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - ku4, 0376352
SB  - Index Medicus
CP  - Poland
MH  - Aged
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/th [Therapy]
MH  - *Electric Countershock
MH  - *Exercise Tolerance
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Conduction System/pp [Physiopathology]
MH  - *Heart Failure/pp [Physiopathology]
MH  - *Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Treatment Outcome
MH  - *Ventricular Function, Left
AB  - BACKGROUND: Although early improvement of haemodynamic parameters following successful cardioversion of atrial fibrillation (AF) has been well documented, the long-term benefits of sinus rhythm (SR) restoration are less obvious, mainly due to a high rate of AF relapses.
AB  - AIM: To determine the impact of SR restoration and maintenance on exercise tolerance and heart failure progression in patients with persistent non-valvular AF during a one year follow-up period.
AB  - METHODS AND RESULTS: We studied 104 patients (33 females, 71 males, mean age 60.4+/-7.4 years) with mild to moderate stable heart failure and persistent AF with well-controlled ventricular rate who were scheduled for cardioversion. They underwent submaximal exercise testing 24 hours before cardioversion, as well as 1 and 12 months afterwards. Exercise capacity was determined during symptom-limited exercise testing, according to a modified Bruce protocol. Heart failure symptoms were assessed at the same time-points of follow-up.
AB  - RESULTS: SR was presented in 66 (63.5%) patients one year after cardioversion. In patients with SR, a significant improvement in left ventricular (LV) performance, exercise capacity and heart failure symptoms was noted. There was an increase in LV fractional shortening (29.9+/-7.6% vs 35.6+/-9.3%; p<0.001), maximal workload (4.7+/-2.3 vs 8.5+/-3.0 MET; p<0.001), exercise duration (125.3+/-115.3 vs 294.7+/-216.7 sec.; p<0.001), and improvement in the NYHA functional class (p<0.001). No such changes were observed in patients who had AF relapse during follow-up or in those who had unsuccessful cardioversion.
AB  - CONCLUSIONS: Successful cardioversion of persistent AF resulted in a significant improvement of exercise capacity and a decrease in heart failure symptoms during one year follow-up period only in patients who maintained SR.
IS  - 0022-9032
IL  - 0022-9032
PT  - Comparative Study
PT  - Journal Article
LG  - English
LG  - Polish
DP  - 2005 Jul
DC  - 20050901
YR  - 2005
ED  - 20060112
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16136427

<634. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16105481
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Harris WS
FA  - Harris, William S
IN  - Harris,William S. Lipid and Diabetes Research Center, Mid America Heart Institute, Saint Luke's Health System, Kansas City, MO 64111, USA. wharris@saint-lukes.org
TI  - Extending the cardiovascular benefits of omega-3 Fatty acids. [Review] [39 refs]
SO  - Current Atherosclerosis Reports. 7(5):375-80, 2005 Sep.
AS  - Curr Atheroscler Rep. 7(5):375-80, 2005 Sep.
NJ  - Current atherosclerosis reports
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 100897685, dyl
SB  - Index Medicus
CP  - United States
MH  - Cardiovascular Diseases/bl [Blood]
MH  - *Cardiovascular Diseases/pc [Prevention & Control]
MH  - Endothelium, Vascular/de [Drug Effects]
MH  - *Fatty Acids, Omega-3/tu [Therapeutic Use]
MH  - Humans
MH  - Risk Factors
MH  - Triglycerides/bl [Blood]
AB  - The cardiovascular benefits of omega (n)-3 fatty acids (FA) become clearer with each passing year. Although useful in large doses for lowering serum triglyceride levels, the primary benefits are likely to arise from smaller, nutritional intakes of eicosapentaenoic acid (EPA) and docosahexanoic acid (DHA). Doses of less than 1 g/d appear to reduce risk for fatal coronary heart disease events, perhaps by stabilizing the myocardium and reducing risk for fatal arrhythmias. New evidence points to a possible benefit on atrial fibrillation, particularly in the immediate post-cardiac surgery setting. Studies in women with coronary heart disease now suggest that plaque progression may be slowed by increased intakes of oily fish, even in women with diabetes. The relative importance of the n-6 FA linoleic acid (LA), the short-chain n-3 FA alpha linolenic acid (ALA), and the long-chain n-3 FAs EPA and DHA is becoming clearer. If intakes of the latter are adequate (perhaps over 250 mg/d), then there appears to be little need to consume more ALA or less LA. [References: 39]
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Triglycerides)
IS  - 1523-3804
IL  - 1523-3804
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2005 Sep
DC  - 20050817
YR  - 2005
ED  - 20060105
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16105481

<635. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16105020
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Reiffel JA
FA  - Reiffel, James A
IN  - Reiffel,James A. Electrophysiology Service, Department of Medicine, Division of Cardiology, Columbia University, New York, NY, USA. jar2@columbia.edu
TI  - Atypical proarrhythmia with dofetilide: monomorphic VT and exercise-induced torsade de pointes.
SO  - Pacing & Clinical Electrophysiology. 28(8):877-9, 2005 Aug.
AS  - Pacing Clin Electrophysiol. 28(8):877-9, 2005 Aug.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - *Anti-Arrhythmia Agents/ae [Adverse Effects]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Electrocardiography
MH  - Exercise Test
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Phenethylamines/ae [Adverse Effects]
MH  - *Sulfonamides/ae [Adverse Effects]
MH  - *Tachycardia, Ventricular/ci [Chemically Induced]
MH  - *Torsades de Pointes/et [Etiology]
MH  - *Ventricular Premature Complexes/ci [Chemically Induced]
MH  - Ventricular Premature Complexes/pp [Physiopathology]
AB  - Proarrhythmia with dofetilide has most typically taken the form of torsade de pointes (TdP) and generally occurs early with therapy, such that in-hospital initiation of dofetilide with 3 days of continuous electrocardiogram monitoring is recommended. This article reports two unusual variants of ventricular proarrhythmia with dofetilide: (1) nonsustained runs of monomorphic ventricular tachycardia shortly after taking the first dose of dofetilide, confirmed by rechallenge; and (2) TdP that followed the development of isolated ventricular premature beats during an exercise test in a patient with neither excessive QT prolongation on dofetilide nor any ectopy whatsoever during in-hospital telemetric monitoring but with significant QT interval prolongation after the postectopic pause. These cases demonstrate that clinicians must be alert to the appearance of proarrhythmia with dofetilide at times other than early during drug initiation if the electrophysiological milieu is altered during nonhospital activity and/or of a pattern other than TdP.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Phenethylamines)
RN  - 0 (Sulfonamides)
RN  - 115256-11-6 (dofetilide)
IS  - 0147-8389
IL  - 0147-8389
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2005 Aug
DC  - 20050817
YR  - 2005
ED  - 20060103
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16105020

<636. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16093761
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Leonardi M
AU  - Bissett J
FA  - Leonardi, Marino
FA  - Bissett, Joe
IN  - Leonardi,Marino. Division of Cardiovascular Disease, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA. mleonardi@uams.edu
TI  - Prevention of atrial fibrillation. [Review] [52 refs]
SO  - Current Opinion in Cardiology. 20(5):417-23, 2005 Sep.
AS  - Curr Opin Cardiol. 20(5):417-23, 2005 Sep.
NJ  - Current opinion in cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - bda, 8608087
SB  - Index Medicus
CP  - United States
MH  - Aging
MH  - Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - Cardiac Pacing, Artificial/mt [Methods]
MH  - Heart Diseases/co [Complications]
MH  - Humans
MH  - Hypertension/co [Complications]
MH  - Models, Biological
MH  - Oxidative Stress
MH  - Risk Factors
AB  - PURPOSE OF REVIEW: This review summarizes current concepts on the pathophysiology of atrial fibrillation, identifying predisposing factors to guide primary and secondary preventive approaches.
AB  - RECENT FINDINGS: Many factors contribute to the development and progression of atrial fibrillation, including cardiovascular diseases, age, neurohormones, genetics, diet, autonomic influences, and inflammation. Therapeutic efforts have been directed to modify this altered milieu and prevent the development of atrial electrical and structural remodeling. This nonconventional antiarrhythmic management appears to have an important role also in secondary prevention of atrial fibrillation; the indications for conventional antiarrhythmic agents are decreasing because of side effects and limited efficacy. Interventional electrophysiology techniques have been developed to target the arrhythmia substrate responsible for the initiation or maintenance of atrial fibrillation, achieving high success rates.
AB  - SUMMARY: Atrial fibrillation is the most commonly treated arrhythmia and its incidence is predicted to increase. It is associated with significant morbidity and mortality. Preventive efforts should be initiated early and include diversified interventions to correct predisposing factors and modify the altered atrial substrate. [References: 52]
RN  - 0 (Anti-Arrhythmia Agents)
IS  - 0268-4705
IL  - 0268-4705
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2005 Sep
DC  - 20050811
YR  - 2005
ED  - 20051221
RD  - 20060504
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16093761

<637. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16086936
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Hesse B
AU  - Morise A
AU  - Pothier CE
AU  - Blackstone EH
AU  - Lauer MS
FA  - Hesse, Barbara
FA  - Morise, Anthony
FA  - Pothier, Claire E
FA  - Blackstone, Eugene H
FA  - Lauer, Michael S
IN  - Hesse,Barbara. Department of Cardiology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
TI  - Can we reliably predict long-term mortality after exercise testing? An external validation.
SO  - American Heart Journal. 150(2):307-14, 2005 Aug.
AS  - Am Heart J. 150(2):307-14, 2005 Aug.
NJ  - American heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 0370465
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - Calibration
MH  - Cardiovascular Diseases/ep [Epidemiology]
MH  - Cause of Death
MH  - Cohort Studies
MH  - Diabetes Mellitus/ep [Epidemiology]
MH  - Electrocardiography
MH  - Exercise/ph [Physiology]
MH  - *Exercise Test
MH  - Female
MH  - Follow-Up Studies
MH  - Hemodynamics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mortality
MH  - *Prognosis
MH  - Proportional Hazards Models
MH  - Rest/ph [Physiology]
MH  - Risk Factors
AB  - OBJECTIVE: The aim of the study was to derive and externally validate a mortality prediction rule for patients undergoing exercise testing.
AB  - BACKGROUND: The prognostic value of exercise testing is increasingly appreciated. However, global prognosis estimates ideally should account for numerous routinely obtained variables, including demographics, risk factors, resting electrocardiogram, and multiple exercise test measures.
AB  - METHODS: A prediction rule was derived by parametric hazards modeling on a derivation set of 46047 Cleveland Clinic patients (age 55 +/- 11 years, 67% male) who had no history of heart failure, valve disease, or atrial fibrillation. Twenty-two variables covering demographics, risk factors, exercise hemodynamics, and electrocardiogram findings at rest and during exercise were considered. The resulting model included 16 variables and was tested on 4981 patients (age 50 +/- 12 years, 55% male) who underwent exercise testing at West Virginia University.
AB  - RESULTS: In the derivation cohort there were 3173 deaths during a mean of 7 years of follow-up, whereas in the validation cohort there were 180 deaths during a mean of 5 years of follow-up. Comparisons of predicted and observed death rates showed very good agreement among all patients across all spectrums of risk, as well as among prespecified high-risk subgroups. Model discrimination was also good, with c statistic of c = 0.79 in the derivation group and c = 0.81 in the validation cohort.
AB  - CONCLUSIONS: We have externally validated a mortality prediction rule for patients undergoing exercise testing and confirmed its accuracy among a wide spectrum of patients.
ES  - 1097-6744
IL  - 0002-8703
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Validation Studies
NO  - HL-66004 (United States NHLBI NIH HHS)
LG  - English
DP  - 2005 Aug
DC  - 20050809
YR  - 2005
ED  - 20051202
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16086936

<638. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16133893
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lee VW
AU  - You JH
AU  - Lee KK
AU  - Chau TS
AU  - Waye MM
AU  - Cheng G
FA  - Lee, Vivian W Y
FA  - You, Joyce H S
FA  - Lee, Kenneth K C
FA  - Chau, T S
FA  - Waye, Mary M Y
FA  - Cheng, Gregory
IN  - Lee,Vivian W Y. School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong. vivianlee@cuhk.edu.hk
TI  - Factors affecting the maintenance stable warfarin dosage in Hong Kong Chinese patients.
SO  - Journal of Thrombosis & Thrombolysis. 20(1):33-8, 2005 Aug.
AS  - J Thromb Thrombolysis. 20(1):33-8, 2005 Aug.
NJ  - Journal of thrombosis and thrombolysis
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - ddy, 9502018
SB  - Index Medicus
CP  - Netherlands
MH  - Adult
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - Aryl Hydrocarbon Hydroxylases/ge [Genetics]
MH  - Asian Continental Ancestry Group
MH  - Cardiovascular Diseases/cl [Classification]
MH  - *Cardiovascular Diseases/dt [Drug Therapy]
MH  - Cardiovascular Diseases/ge [Genetics]
MH  - Cytochrome P-450 CYP2C9
MH  - Dose-Response Relationship, Drug
MH  - Exons
MH  - Female
MH  - Hong Kong
MH  - Humans
MH  - International Normalized Ratio
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Genetic
MH  - Polymorphism, Single Nucleotide
MH  - Regression Analysis
MH  - Retrospective Studies
MH  - *Warfarin/tu [Therapeutic Use]
AB  - BACKGROUND: Multiple factors can affect the anticoagulation effect of warfarin. The objective of this study was to determine the relationship between different clinical factors and outcomes of warfarin therapy in Hong Kong Chinese patients.
AB  - METHODS: The study was conducted at the anticoagulation clinic of the Prince of Wales Hospital from 1 April to 31 December 2003. Clinical data collected included demographics, indications of warfarin, dietary vitamin K consumption, and drug-drug interactions. Blood samples were obtained for the genetic polymorphism analysis of CYP 2 C 9. Linear and multiple regression analysis were used for statistical analysis to determine the correlation between variables and the importance of various factors as the determinants of warfarin dosage requirement.
AB  - RESULTS: A total of 63 patients were recruited. The mean warfarin dosage was 3.30+/-2.23 mg/day. The warfarin dosage ranged from 0.75 to 12 mg/day. The mean age was 59+/-14 years old. Age, dietary vitamin K consumption, chronic heart failure, atrial fibrillation, hypertension, smoking and drinking status were found to be factors statistically significant affecting warfarin dosage. We detected no single nucleotide polymorphism in CYP 2 C 9 exon 4.
AB  - CONCLUSION: Age, dietary vitamin K consumption, warfarin indication for atrial fibrillation, co-morbid with CHF, smoking and drinking status were found to be the factors that affected the warfarin requirement in Hong Kong Chinese patients. However, the genetic polymorphism in exon 4 of CYP 2 C 9 may not be associated with the warfarin sensitivity in this patient population.
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - EC 1-14-13 (CYP2C9 protein, human)
RN  - EC 1-14-13 (Cytochrome P-450 CYP2C9)
RN  - EC 1-14-14-1 (Aryl Hydrocarbon Hydroxylases)
IS  - 0929-5305
IL  - 0929-5305
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2005 Aug
DC  - 20050831
YR  - 2005
ED  - 20051115
RD  - 20141120
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16133893

<639. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 16004862
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - PubMed-not-MEDLINE
AU  - Bhakta S
AU  - Dunlap ME
FA  - Bhakta, Shyam
FA  - Dunlap, Mark E
IN  - Bhakta,Shyam. Heart Failure Program, Louis B. Stokes Veterans Affairs Medical Center, 10701 East Boulevard, Cleveland, OH 44106, USA.
TI  - Treatment of heart failure with a normal ejection fraction.
SO  - Current Treatment Options in Cardiovascular Medicine. 7(4):317-25, 2005 Aug.
AS  - Curr Treat Options Cardiovasc Med. 7(4):317-25, 2005 Aug.
NJ  - Current treatment options in cardiovascular medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9815942
CP  - United States
AB  - Treatment of diastolic heart failure is divided into acute and chronic management. During acute management, the focus should be treatment of the presenting syndrome, including correction of volume overload, treating hypertension, alleviating ischemia, and controlling tachyarrhythmias. Therefore, acute treatment should include several components: treating volume overload with sodium restriction and diuretics; treating ischemic heart disease with antiplatelet therapy, anticoagulants, and beta blockers; treating hypertension aggressively, using multiple agents if necessary; and treating atrial tachyarrhythmias such as atrial fibrillation with rate-controlling agents, such as beta blockers and possibly nondihydropyridine calcium channel blockers such as diltiazem and verapamil. Antiarrhythmic agents with or without electrical cardioversion may be necessary. Thoroughly evaluate and manage extracardiac precipitants such as anemia and renal failure. Chronic management should also focus on precipitating factors, for which adequate control of hypertension is paramount. Patient education regarding dietary and medication compliance and lifestyle changes is also important. If ischemic heart disease is present, aggressive anti-ischemic therapy is necessary, including revascularization when indicated.
IS  - 1092-8464
IL  - 1092-8464
PT  - Journal Article
LG  - English
DP  - 2005 Aug
DC  - 20050711
YR  - 2005
ED  - 20051031
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=16004862

<640. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15855192
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Arentz T
AU  - Weber R
AU  - Jander N
AU  - Burkle G
AU  - von Rosenthal J
AU  - Blum T
AU  - Stockinger J
AU  - Haegeli L
AU  - Neumann FJ
AU  - Kalusche D
FA  - Arentz, Thomas
FA  - Weber, Reinhold
FA  - Jander, Nikolaus
FA  - Burkle, Gerd
FA  - von Rosenthal, Jorg
FA  - Blum, Thomas
FA  - Stockinger, Jochem
FA  - Haegeli, Laurent
FA  - Neumann, Franz Josef
FA  - Kalusche, Dietrich
IN  - Arentz,Thomas. Abteilung Rhythmologie, Herz-Zentrum, Sudring 15, 79188 Bad Krozingen, Germany. thomas.arentz@herzzentrum.de
TI  - Pulmonary haemodynamics at rest and during exercise in patients with significant pulmonary vein stenosis after radiofrequency catheter ablation for drug resistant atrial fibrillation.
CM  - Comment in: Eur Heart J. 2005 Jul;26(14):1355-7; PMID: 15911568
SO  - European Heart Journal. 26(14):1410-4, 2005 Jul.
AS  - Eur Heart J. 26(14):1410-4, 2005 Jul.
NJ  - European heart journal
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - em8, 8006263
SB  - Index Medicus
CP  - England
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/su [Surgery]
MH  - *Catheter Ablation/mt [Methods]
MH  - Constriction, Pathologic/et [Etiology]
MH  - Drug Resistance
MH  - *Exercise/ph [Physiology]
MH  - Female
MH  - Hemodynamics
MH  - Humans
MH  - Magnetic Resonance Angiography
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - *Pulmonary Veins
MH  - Tomography, X-Ray Computed
AB  - AIMS: Iatrogenic pulmonary vein (PV) stenosis after radiofrequency catheter ablation for atrial fibrillation (AF) is a new pathology in cardiology. The effects of PV stenosis on the pulmonary circulation are not yet known. We provide long-term follow-up data in patients with significant PV stenosis including magnetic resonance imaging (MRI) and Swan Ganz (SG) right heart catheterization.
AB  - METHODS AND RESULTS: One hundred and seventeen patients had MRI 12-24 months after the AF ablation procedure. Eleven patients (58+/-7 years, nine males) with significant stenosis (n=9) or occlusion of the proximal PV (n=5) at this follow-up were re-examined using MRI and SG right heart catheterization at rest and during exercise (follow-up time since PV ablation 50+/-15 months). None of these underwent previous PV angioplasty. When compared with prior MRI studies, no significant changes were noted. At rest, no patient had pulmonary hypertension. At 100 W, seven patients had elevated pulmonary artery pressures, three of them probably caused, in part, by left ventricular dysfunction.
AB  - CONCLUSION: Significant stenosis/occlusions of one or two PV do not create pulmonary hypertension at rest during long-term follow-up. However, seven of the 11 patients develop pulmonary hypertension during exercise. All three patients with stenosis/occlusions of two PV were affected.
IS  - 0195-668X
IL  - 0195-668X
PT  - Journal Article
LG  - English
EP  - 20050426
DP  - 2005 Jul
DC  - 20050629
YR  - 2005
ED  - 20051020
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15855192

<641. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15899738
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kammer RT
FA  - Kammer, Ryan T
IN  - Kammer,Ryan T. Department of Pharmacy, Moses H. Cone Memorial Hospital, Greensboro, NC 27401, USA.
TI  - Lone atrial fibrillation associated with creatine monohydrate supplementation.
SO  - Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy. 25(5):762-4, 2005 May.
AS  - Pharmacotherapy. 25(5):762-4, 2005 May.
NJ  - Pharmacotherapy
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - par, 8111305
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - *Atrial Fibrillation/ci [Chemically Induced]
MH  - *Creatine/ae [Adverse Effects]
MH  - *Dietary Supplements/ae [Adverse Effects]
MH  - Humans
MH  - Male
AB  - Atrial fibrillation in young patients without structural heart disease is rare. Therefore, when the arrhythmia is present in this population, reversible causes must be identified and resolved. Thyroid disorders, illicit drug or stimulant use, and acute alcohol intoxication are among these causes. We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied. However, when the patient was questioned about use of herbal products and supplements, the use of creatine monohydrate was revealed. The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous diltiazem for rate control and intravenous amiodarone for rate and rhythm control. When discharged less than 24 hours later, he was receiving metoprolol and aspirin, with follow-up plans for echocardiography and nuclear imaging to assess perfusion. Exogenous creatine is used by athletes to theoretically improve exercise performance. Vegetarians may also take creatine to replace what they are not consuming from meat, fish, and other animal products. Previous anecdotal reports have linked creatine to the development of arrhythmia. Clinicians must be diligent when interviewing patients about their drug therapy histories and include questions about their use of herbal products and dietary supplements. In addition, it is important to report adverse effects associated with frequently consumed supplements and herbal products to the Food and Drug Administration and in the literature.
RN  - MU72812GK0 (Creatine)
IS  - 0277-0008
IL  - 0277-0008
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2005 May
DC  - 20050518
YR  - 2005
ED  - 20050902
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15899738

<642. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15886802
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Sconce E
AU  - Khan T
AU  - Mason J
AU  - Noble F
AU  - Wynne H
AU  - Kamali F
FA  - Sconce, Elizabeth
FA  - Khan, Tayyaba
FA  - Mason, Jennifer
FA  - Noble, Faye
FA  - Wynne, Hilary
FA  - Kamali, Farhad
IN  - Sconce,Elizabeth. School of Clinical and Laboratory Sciences, University of Newcastle upon Tyne, UK.
TI  - Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation.
CM  - Comment in: Thromb Haemost. 2005 May;93(5):799-800; PMID: 15886790
SO  - Thrombosis & Haemostasis. 93(5):872-5, 2005 May.
AS  - Thromb Haemost. 93(5):872-5, 2005 May.
NJ  - Thrombosis and haemostasis
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - vq7, 7608063
SB  - Index Medicus
CP  - Germany
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Anticoagulants/pd [Pharmacology]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Blood Coagulation
MH  - *Diet
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - International Normalized Ratio
MH  - Male
MH  - Middle Aged
MH  - Nutritional Status
MH  - Time Factors
MH  - Treatment Outcome
MH  - *Venous Thrombosis/dt [Drug Therapy]
MH  - *Vitamin K/pd [Pharmacology]
MH  - Warfarin/pd [Pharmacology]
AB  - Evidence suggests that alterations in the dietary intake of vitamin K can affect anticoagulation response to warfarin. It is possible that a low and erratic intake of dietary vitamin K is at least partly responsible for the variable response to warfarin in patients with unstable control of anticoagulation. Twenty-six patients with unstable and twenty-six with stable control of anticoagulation completed dietary records of all foods and drinks consumed on a daily basis for two consecutive weeks. The mean daily intake of vitamin K in unstable patients was considerably lower than that for stable patients during the study period (29+/-17 microg v . 76+/-40 microg). The logarithm of vitamin K intake was consistently and significantly lower in the unstable patients than the stable patients over the two week period (5.9+/-0.4 microg v. 6.9+/-0.5 microg; p<0.001; 95% CI: 0.7-1.2). Changes in vitamin K intake between weeks 1 and 2 of the study were negatively correlated with changes in International Normalised Ratio (INR) amongst the unstable patients, however this failed to reach significance (r=-0.25; p=0.22). Daily supplementation with oral vitamin K in unstable patients could lead to a more stable anticoagulation response to warfarin.
RN  - 0 (Anticoagulants)
RN  - 12001-79-5 (Vitamin K)
RN  - 5Q7ZVV76EI (Warfarin)
IS  - 0340-6245
IL  - 0340-6245
PT  - Journal Article
LG  - English
DP  - 2005 May
DC  - 20050511
YR  - 2005
ED  - 20050819
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15886802

<643. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15650978
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Nygard E
AU  - Sorensen LH
AU  - Hviid LB
AU  - Pedersen FM
AU  - Ravn J
AU  - Thomassen L
AU  - Svendsen JH
AU  - Eliasen K
AU  - Krogsgaard K
AU  - Aldershvile J
FA  - Nygard, Eigil
FA  - Sorensen, Lars H
FA  - Hviid, Lamia B
FA  - Pedersen, Finn M
FA  - Ravn, Jesper
FA  - Thomassen, Lars
FA  - Svendsen, Jesper H
FA  - Eliasen, Kirsten
FA  - Krogsgaard, Kim
FA  - Aldershvile, Jan
IN  - Nygard,Eigil. Department of Cardiothoracic Anesthesia, National University Hospital, Rigshopitalet, Copenhagen, Denmark. einy@gentoftehosp.kbhamt.dk
TI  - Effects of amiodarone and thoracic epidural analgesia on atrial fibrillation after coronary artery bypass grafting.
CM  - Comment in: Evid Based Cardiovasc Med. 2005 Jun;9(2):123-5; PMID: 16380008
SO  - Journal of Cardiothoracic & Vascular Anesthesia. 18(6):709-14, 2004 Dec.
AS  - J Cardiothorac Vasc Anesth. 18(6):709-14, 2004 Dec.
NJ  - Journal of cardiothoracic and vascular anesthesia
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - a6i, 9110208
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Amiodarone/ad [Administration & Dosage]
MH  - *Amiodarone/tu [Therapeutic Use]
MH  - *Analgesia, Epidural/mt [Methods]
MH  - Anti-Arrhythmia Agents/ad [Administration & Dosage]
MH  - *Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - *Coronary Artery Bypass/mt [Methods]
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Electrocardiography, Ambulatory/sn [Statistics & Numerical Data]
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Postoperative Complications/et [Etiology]
MH  - *Postoperative Complications/pc [Prevention & Control]
MH  - Prospective Studies
MH  - Time Factors
AB  - OBJECTIVE: This study was designed to assess the effects of a perioperative dosing regimen of amiodarone administration, high thoracic epidural anesthesia (TEA), or a combination of the 2 regimens on atrial fibrillation (AF) after coronary artery bypass grafting (CABG).
AB  - DESIGN AND SETTING: The study was prospective, controlled, and randomized and was performed in a tertiary health care center associated with a university.
AB  - PARTICIPANTS: One hundred sixty-three patients scheduled for coronary artery bypass graft surgery.
AB  - INTERVENTIONS: In this 2 x 2 factorial-designed study the patients were randomized to 1 of 4 regimens in which group E had perioperative TEA, group E+A had TEA and amiodarone, group A had amiodarone, and group C served as control. The epidural catheter was inserted at T1-3 the day before surgery. TEA groups received TEA for 96 hours. The amiodarone regimen consisted of a single loading dose of 1,800 mg of amiodarone orally. Intravenous infusion of amiodarone was started after induction of anesthesia and was administered at 900 mg over 24 hours for the subsequent 3 days.
AB  - MEASUREMENTS AND MAIN RESULTS: AF was documented using Holter monitoring. In group E 22 of 44 (50%), in group E+A 10 of 35 (28.6%), in group A 10 of 36 (27.8%), and in the control group 20 of 48 (41.7%) patients developed AF (odds ratio amiodarone/nonamiodarone 0.47 [0.24-0.90]; P = 0.02).
AB  - CONCLUSIONS: The perioperative amiodarone regimen used in this study was effective in reducing the incidence of AF after CABG while TEA was not.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - N3RQ532IUT (Amiodarone)
IS  - 1053-0770
IL  - 1053-0770
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2004 Dec
DC  - 20050114
YR  - 2004
ED  - 20050802
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15650978

<644. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15745892
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Brackbill ML
AU  - Moberg L
FA  - Brackbill, Marcia L
FA  - Moberg, Lori
IN  - Brackbill,Marcia L. Department of Pharmacy Practice, Bernard J. Dunn School of Pharmacy, Winchester, VA 22601, USA. mbrackbi@su.edu
TI  - Magnesium sulfate for prevention of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting.
SO  - American Journal of Health-System Pharmacy. 62(4):397-9, 2005 Feb 15.
AS  - Am J Health-Syst Pharm. 62(4):397-9, 2005 Feb 15.
NJ  - American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9503023, cbh
SB  - Index Medicus
CP  - United States
MH  - Anti-Arrhythmia Agents/ae [Adverse Effects]
MH  - *Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - *Coronary Artery Bypass/ae [Adverse Effects]
MH  - Female
MH  - Humans
MH  - Injections, Intravenous
MH  - Length of Stay
MH  - Magnesium Sulfate/ae [Adverse Effects]
MH  - *Magnesium Sulfate/tu [Therapeutic Use]
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
AB  - PURPOSE: The effects of i.v. magnesium sulfate on the frequency of postoperative atrial fibrillation (AF) in patients undergoing coronary artery bypass grafting (CABG) and on the frequency of AF at hospital discharge were studied. The effect of postoperative AF on hospital length of stay (LOS) was also assessed.
AB  - METHODS: A retrospective chart review was performed for all patients who underwent CABG surgery by a single surgeon during 2000-2001 at a community medical center. Patients were eligible for inclusion if they had first-time CABG surgery. Patients who underwent CABG surgery in 2000 did not receive magnesium sulfate and served as controls for the study. Patients were included in the magnesium group if they received 2 g of i.v. magnesium sulfate intraoperatively and 2 g every 12 hours postoperatively for at least two consecutive days.
AB  - RESULTS: A total of 262 patients underwent CABG during the study period, and 28 were excluded from the study. Of the remaining 234 patients, 99 were in the magnesium group, and 135 were in the control group. No significant differences were found between the study groups in recorded demographic characteristics. Postoperative AF occurred significantly less frequently in the magnesium group (p = 0.038). There was no significant difference between treatment groups in the number of patients discharged in AF (p = 0.307). Among all patients, those with AF were significantly more likely to have a prolonged LOS (p = 0.036).
AB  - CONCLUSION: CABG patients who received intraoperative and postoperative i.v. magnesium sulfate had a significantly lower rate of AF compared with patients who did not receive the drug. The number of patients discharged with AF was not affected by magnesium administration. AF was associated with a higher likelihood of prolonged postoperative hospitalization.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 7487-88-9 (Magnesium Sulfate)
IS  - 1079-2082
IL  - 1079-2082
PT  - Journal Article
LG  - English
DP  - 2005 Feb 15
DC  - 20050304
YR  - 2005
ED  - 20050620
RD  - 20061013
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15745892

<645. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15866251
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Frost L
AU  - Hune LJ
AU  - Vestergaard P
FA  - Frost, Lars
FA  - Hune, Lone Juul
FA  - Vestergaard, Peter
IN  - Frost,Lars. Department of Cardiology, Aarhus University Hospital, DK 8000 Aarhus C, Denmark. lars.frost@as.aaa.dk
TI  - Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study.
CM  - Comment in: Am J Med. 2006 Jul;119(7):e9; author reply e11; PMID: 16828620
SO  - American Journal of Medicine. 118(5):489-95, 2005 May.
AS  - Am J Med. 118(5):489-95, 2005 May.
NJ  - The American journal of medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0267200, 3ju
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Flutter/ep [Epidemiology]
MH  - *Body Mass Index
MH  - Denmark/ep [Epidemiology]
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Linear Models
MH  - Male
MH  - Middle Aged
MH  - *Obesity/co [Complications]
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Risk Factors
MH  - Sex Distribution
AB  - PURPOSE: We examined the association between the body mass index analyzed as a continuous variable and by categorization according to World Health Organization criteria (normal weight, overweight and obesity) and the risk of a hospital (inpatient as well as outpatient) diagnosis of atrial fibrillation or flutter.
AB  - METHODS: Population-based prospective cohort study conducted from December 1993 to December 2001 among 47589 participants (22482 men and 25107 women) without preexisting cardiovascular or endocrine disease and with a mean age at baseline of 56 years (range 50-64 years) in the Danish Diet, Cancer, and Health Study. Subjects were followed up in the Danish National Registry of Patients and in the Danish Civil Registration System.
AB  - RESULTS: During follow-up (mean, 5.7 years) atrial fibrillation or flutter developed in 553 subjects (372 men and 181 women). The adjusted hazard ratio for atrial fibrillation or flutter per unit of increase in the body mass index was 1.08 (95% confidence interval [CI]: 1.05 to 1.11) in men and 1.06 (95% CI: 1.03 to 1.09) in women. When using normal weight as a reference, the adjusted hazard ratio for atrial fibrillation or flutter by overweight was 1.75 (95% CI: 1.35 to 2.27) in men and 1.39 (95% CI: 0.99 to 1.94) in women. The adjusted hazard ratio by obesity was 2.35 (95% CI: 1.70 to 3.25) in men and 1.99 (95% CI: 1.31 to 3.02) in women.
AB  - CONCLUSION: Overweight and obesity are associated with an increased risk of a diagnosis of atrial fibrillation or flutter.
IS  - 0002-9343
IL  - 0002-9343
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2005 May
DC  - 20050503
YR  - 2005
ED  - 20050527
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15866251

<646. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15640433
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Obel OA
AU  - Davidson C
FA  - Obel, O A
FA  - Davidson, C
IN  - Obel,O A. Royal Sussex County Hospital, Brighton, UK. owen.obel@utsouthwestern.edu
TI  - Arrhythmias in an athlete: the effect of de-training.
SO  - Postgraduate Medical Journal. 81(951):62-4, 2005 Jan.
AS  - Postgrad Med J. 81(951):62-4, 2005 Jan.
NJ  - Postgraduate medical journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pfx, 0234135
OI  - Source: NLM. PMC1743177
SB  - Index Medicus
CP  - England
MH  - Arrhythmias, Cardiac/et [Etiology]
MH  - Arrhythmias, Cardiac/pp [Physiopathology]
MH  - *Arrhythmias, Cardiac/rh [Rehabilitation]
MH  - Electrocardiography, Ambulatory
MH  - *Exercise
MH  - Exercise Test
MH  - Exercise Tolerance
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Sports
AB  - A 53 year old athlete with a history of severe palpitations and lightheadedness presented for a second opinion. He was found to exhibit very frequent atrial ectopy, frequent runs of symptomatic atrial tachyarrhythmia, and sinus bradycardia at rest. During exercise testing, his tachyarrhythmias increased in relation to the duration and intensity of exercise. A therapeutic trial of de-training was suggested. As a result, his symptoms completely resolved with a marked reduction in the frequency of atrial arrhythmia. Repeat exercise testing revealed an excellent exercise tolerance with no atrial ectopy. De-training should be considered when athletes present with arrhythmias.
IS  - 0032-5473
IL  - 0032-5473
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2005 Jan
DC  - 20050110
YR  - 2005
ED  - 20050509
RD  - 20091022
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15640433

<647. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15533612
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Harrison RA
AU  - Elton PJ
FA  - Harrison, R A
FA  - Elton, P J
IN  - Harrison,R A. Bolton Primary Care Trust, University of Manchester, Public Health, St. Peters House, Silverwell Street, BoltonBL1 1PP, UK. roger.harrison@bolton.nhs.uk
TI  - Is there a role for long-chain omega3 or oil-rich fish in the treatment of atrial fibrillation?.
CM  - Comment in: Med Hypotheses. 2005;64(6):1245-6; PMID: 15823733
CM  - Comment in: Med Hypotheses. 2005;65(1):200-1; PMID: 15893149
SO  - Medical Hypotheses. 64(1):59-63, 2005.
AS  - Med Hypotheses. 64(1):59-63, 2005.
NJ  - Medical hypotheses
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - m0m, 7505668
SB  - Index Medicus
CP  - Scotland
MH  - Administration, Oral
MH  - Animals
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/me [Metabolism]
MH  - Clinical Trials as Topic
MH  - Dietary Supplements
MH  - *Fatty Acids, Omega-3/ad [Administration & Dosage]
MH  - *Fish Oils/ad [Administration & Dosage]
MH  - Humans
MH  - Treatment Outcome
AB  - Atrial fibrillation is the most common cardiac arrhythmia in Europe and north America, and recently it was described as an epidemic. Treatment and management of this arrhythmia consists of using drugs, external electrical cardioversion and in extreme cases, internal electrical pacing. Despite treatment, this arrhythmia continues to impact on morbidity and mortality. The possible benefit from dietary interventions in relation to the primary and secondary prevention of atrial fibrillation have largely been overlooked. Our hypothesis is that increasing the intake of long-chain polyunsaturated omega3 fatty acids (LCn3) from eating a diet containing moderate amounts of oil-rich fish, will benefit people with persistent atrial fibrillation. A number of possible anti-arrhythmic actions from LCn3 have been found from animal and laboratory studies, mainly on ventricular arrhythmias. These include reducing pro-arrhythmic eicosanoids and inhibiting sodium and calcium currents. If found to be beneficial to these patients, dietary advice to eat more oil-rich fish, or take LCn3 supplements, could be part of a package of care for people with this arrhythmia. We have currently started a randomised controlled trial to test our hypothesis.
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Fish Oils)
IS  - 0306-9877
IL  - 0306-9877
PT  - Journal Article
LG  - English
DP  - 2005
DC  - 20041109
YR  - 2005
ED  - 20050421
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15533612

<648. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15755825
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Frost L
AU  - Vestergaard P
FA  - Frost, Lars
FA  - Vestergaard, Peter
IN  - Frost,Lars. Department of Cardiology, Aarhus Sygehus, Aarhus University Hospital, Aarhus, Denmark. Lars.Frost@as.aaa.dk
TI  - Caffeine and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study.
CM  - Comment in: Am J Clin Nutr. 2005 Mar;81(3):539-40; PMID: 15755819
SO  - American Journal of Clinical Nutrition. 81(3):578-82, 2005 Mar.
AS  - Am J Clin Nutr. 81(3):578-82, 2005 Mar.
NJ  - The American journal of clinical nutrition
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3ey, 0376027
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Atrial Flutter/ep [Epidemiology]
MH  - Atrial Flutter/et [Etiology]
MH  - Cacao/ch [Chemistry]
MH  - Caffeine/ad [Administration & Dosage]
MH  - *Caffeine/ae [Adverse Effects]
MH  - Carbonated Beverages/an [Analysis]
MH  - Coffee/ch [Chemistry]
MH  - Cohort Studies
MH  - Denmark/ep [Epidemiology]
MH  - Diet Surveys
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Risk Factors
MH  - Tea/ch [Chemistry]
AB  - BACKGROUND: It is not known whether the consumption of caffeine is associated with excess risk of atrial fibrillation.
AB  - OBJECTIVE: We evaluated the risk of atrial fibrillation or flutter in association with daily consumption of caffeine from coffee, tea, cola, cocoa, and chocolate.
AB  - DESIGN: We prospectively examined the association between the amount of caffeine consumed per day and the risk of atrial fibrillation or flutter among 47 949 participants (x age: 56 y) in the Danish Diet, Cancer, and Health Study. Subjects were followed in the Danish National Registry of Patients and in the Danish Civil Registration System. The consumption of caffeine was analyzed by quintiles with Cox proportional-hazard models.
AB  - RESULTS: During follow-up (x: 5.7 y), atrial fibrillation or flutter developed in 555 subjects (373 men and 182 women). When the lowest quintile of caffeine consumption was used as a reference, the adjusted hazard ratios (95% CIs) in quintiles 2, 3, 4, and 5 were 1.12 (0.87, 1.44), 0.85 (0.65, 1.12), 0.92 (0.71, 1.20), and 0.91 (0.70, 1.19), respectively.
AB  - CONCLUSION: Consumption of caffeine was not associated with risk of atrial fibrillation or flutter.
RN  - 0 (Coffee)
RN  - 0 (Tea)
RN  - 3G6A5W338E (Caffeine)
IS  - 0002-9165
IL  - 0002-9165
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2005 Mar
DC  - 20050309
YR  - 2005
ED  - 20050405
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15755825

<649. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 14714767
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Dalinin V
AU  - Lingaas PS
AU  - Hatteland K
AU  - Svennevig JL
FA  - Dalinin, Vadim
FA  - Lingaas, Per Snorre
FA  - Hatteland, Kjell
FA  - Svennevig, Jan L
IN  - Dalinin,Vadim. Department of Thoracic and Cardiovascular Surgery, Rikshospitalet, University of Oslo, Norway.
TI  - Carotid Doppler microembolic signals in patients one year after heart valve surgery.
SO  - Perfusion. 18(6):333-7, 2003 Nov.
AS  - Perfusion. 18(6):333-7, 2003 Nov.
NJ  - Perfusion
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - bdd, 8700166
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - Carotid Artery Thrombosis/ep [Epidemiology]
MH  - *Carotid Artery Thrombosis/et [Etiology]
MH  - Carotid Artery Thrombosis/us [Ultrasonography]
MH  - Cerebral Arteries/pp [Physiopathology]
MH  - Cerebral Arteries/us [Ultrasonography]
MH  - Female
MH  - Heart Valve Diseases/su [Surgery]
MH  - Heart Valve Diseases/us [Ultrasonography]
MH  - *Heart Valve Prosthesis Implantation/ae [Adverse Effects]
MH  - Heart Valve Prosthesis Implantation/sn [Statistics & Numerical Data]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Ultrasonography, Doppler/is [Instrumentation]
AB  - Doppler ultrasound has been used to detect microemboli during and after cardiopulmonary bypass (CPB). The aim of the present study was to examine the frequency of microembolic signals (MES) in patients one year after heart valve replacement, to look for possible risk factors associated with MES and for any correlation with cerebral events. One hundred patients, 69 male and 31 female, mean age 66.3 +/- 12.4 years, were examined one year after heart valve replacement. Thirty patients, 61% male and 39% female, mean age 62.5 +/- 8.7 years, who had undergone cardiovascular operations without heart valve pathology served as controls. A newly developed microemboli detector, EMEX-25 (Hatteland Instrumentering, Norway) was used to detect MES from both carotid arteries. MES were detected in 61% of the valve patients. A correlation was found between the number of MES, previous cardiovascular operations, emergency surgery and EuroSCORE (p <0.05). There was no correlation between the number of MES and the level of anticoagulation expressed as international normalization ratio (INR), atrial fibrillation, serum-cholesterol, New York heart association (NYHA) class, gender, age, valve type or valve position. The average number of MES was not increased in seven patients who had experienced major (three) or minor (transient, four) cerebral events during follow-up. In the 30 nonvalve controls, MES were detected in 46% of the patients. MES were detected in valve patients as well as in nonvalve patients one year after surgery. In valve patients, a significant correlation was found between MES and previous surgery, emergency surgery and EuroSCORE. There was no correlation between the number of MES and INR level or postoperative cerebral events.
IS  - 0267-6591
IL  - 0267-6591
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 2003 Nov
DC  - 20040112
YR  - 2003
ED  - 20050404
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=14714767

<650. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15546303
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Erol-Yilmaz A
AU  - Tukkie R
AU  - De Boo J
AU  - Schrama T
AU  - Wilde A
FA  - Erol-Yilmaz, Ayten
FA  - Tukkie, Raymond
FA  - De Boo, Job
FA  - Schrama, Tim
FA  - Wilde, Arthur
IN  - Erol-Yilmaz,Ayten. Department of Clinical and Experimental Cardiology, Academic Medical Center, Hospital Goes Amsterdam, the Netherlands. a.yilmaz@amc.uva.nl
TI  - Direct comparison of a contractility and activity pacemaker sensor during treadmill exercise testing.
SO  - Pacing & Clinical Electrophysiology. 27(11):1493-9, 2004 Nov.
AS  - Pacing Clin Electrophysiol. 27(11):1493-9, 2004 Nov.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Atrial Fibrillation/th [Therapy]
MH  - Case-Control Studies
MH  - *Exercise Test
MH  - Exercise Tolerance
MH  - Female
MH  - Heart Block/th [Therapy]
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - *Myocardial Contraction/ph [Physiology]
MH  - *Pacemaker, Artificial
MH  - Rest
MH  - Sick Sinus Syndrome/th [Therapy]
MH  - Supine Position
MH  - Time Factors
AB  - There are limited data about the chronotropic capacity of the peak endocardial acceleration (PEA) sensor. This study directly compared the chronotropic function from the PEA and the activity (ACT) sensor. The study included 18 patients (age 73 +/- 7 years) with > or = 75% pacemaker-driven heart rate (HR) and a PEA sensor and 11 healthy controls (age 67 +/- 7 years) underwent a chronotropic assessment exercise protocol (CAEP) exercise test with the pacemaker patients in VVIR mode after programming the sensors in the default setting with adjustment of the upper sensor rate as an age related maximum value (220-age). The ACT sensor was externally strapped on the thorax. Achieved exercise duration for the patients and controls was, respectively, 9.2 +/- 3 vs 18.4 +/- 4 minutes (P <0.001). The maximal achieved HR with the PEA sensor was 124 +/- 25 beats/min, versus the ACT with 140 +/- 23, versus the controls with 153 +/- 26 beats/min (P <0.001 between the groups). For the PEA, ACT, and controls, the time to peak HR was, respectively, 11 +/- 3, 7 +/- 3.6, and 18 +/- 4 (P <0.001 between groups) and HR after 10 minutes recovery was, respectively, 80 +/- 20, 65 +/- 15, and 82 +/- 4 beats/min (P <0.001 between groups). The PEA sensor functions hypochonotroop during exercise programmed as a single sensor system. It is, therefore, preferable to combine the PEA sensor with an activity-based sensor in a dual sensor system. Although both groups had normal left ventricular functions, the exercise capacity of pacemaker patients is significantly lower than in the controls.
IS  - 0147-8389
IL  - 0147-8389
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 2004 Nov
DC  - 20041119
YR  - 2004
ED  - 20050310
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15546303

<651. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15485590
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Harris WS
FA  - Harris, William S
IN  - Harris,William S. St. Luke's Mid America Heart Institute and Department of Medicine, University of Missouri-Kansas City School of Medicine, 4320 Wornall Road, Suite 128, Kansas City, MO 64111, USA. wharris@saint-lukes.org
TI  - Are omega-3 fatty acids the most important nutritional modulators of coronary heart disease risk?. [Review] [13 refs]
SO  - Current Atherosclerosis Reports. 6(6):447-52, 2004 Nov.
AS  - Curr Atheroscler Rep. 6(6):447-52, 2004 Nov.
NJ  - Current atherosclerosis reports
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 100897685, dyl
SB  - Index Medicus
CP  - United States
MH  - Animals
MH  - Arrhythmias, Cardiac/pc [Prevention & Control]
MH  - *Coronary Disease/pc [Prevention & Control]
MH  - *Diet
MH  - *Fatty Acids, Omega-3/ad [Administration & Dosage]
MH  - Fatty Acids, Omega-3/bl [Blood]
MH  - Fishes
MH  - Humans
MH  - Hydrocarbons, Chlorinated/an [Analysis]
MH  - Mercury/an [Analysis]
AB  - With each passing year, the evidence linking an increased risk for coronary heart disease (CHD) death with a chronic dietary deficiency in long-chain omega-3 (n-3) fatty acids (FAs) grows stronger. Recently, a federally mandated evidence-based review in the United States concluded that n-3 FAs, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have clear cardioprotective effects, and national and international expert panels and health organizations have begun to call for increased EPA and DHA intakes. Consumption of between 450 and 1000 mg/d is recommended for those without and with known CHD, respectively. Based on animal and isolated cell studies, these FAs were presumed to have antiarrhythmic effects. The first direct evidence for this in humans was recently published, as were new data linking low n-3 FA intakes with risk for developing atrial fibrillation. The strength of the n-3 story has now led to a proposal that blood levels of EPA plus DHA be considered a new, modifiable, and clinically relevant risk factor for death from CHD. [References: 13]
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Hydrocarbons, Chlorinated)
RN  - FXS1BY2PGL (Mercury)
IS  - 1523-3804
IL  - 1523-3804
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2004 Nov
DC  - 20041015
YR  - 2004
ED  - 20050225
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15485590

<652. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15640459
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Frost L
AU  - Vestergaard P
FA  - Frost, Lars
FA  - Vestergaard, Peter
IN  - Frost,Lars. Department of Cardiology and the Department of Endocrinology and Metabolism, Aarhus Amtssygehus, Aarhus University Hospital, Aarhus, Denmark. rlg041fr@as.aaa.dk
TI  - n-3 Fatty acids consumed from fish and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study.
SO  - American Journal of Clinical Nutrition. 81(1):50-4, 2005 Jan.
AS  - Am J Clin Nutr. 81(1):50-4, 2005 Jan.
NJ  - The American journal of clinical nutrition
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3ey, 0376027
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Animals
MH  - *Atrial Fibrillation/pc [Prevention & Control]
MH  - *Atrial Flutter/pc [Prevention & Control]
MH  - Denmark
MH  - *Diet
MH  - Fatty Acids, Omega-3/ad [Administration & Dosage]
MH  - *Fatty Acids, Omega-3/tu [Therapeutic Use]
MH  - Female
MH  - Fishes
MH  - Humans
MH  - Linear Models
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
AB  - BACKGROUND: Experimental studies have shown that n-3 polyunsaturated fatty acids in fish may have antiarrhythmic properties.
AB  - OBJECTIVE: We examined the association between consumption of n-3 fatty acids from fish and risk of atrial fibrillation or flutter.
AB  - DESIGN: In a prospective cohort study of 47 949 participants (mean age: 56 y) in the Danish Diet, Cancer, and Health Study, we investigated the relation between the consumption of n-3 fatty acids from fish estimated from a detailed semiquantitative food questionnaire and risk of atrial fibrillation or flutter. The subjects were followed up in the Danish National Registry of Patients for the occurrence of atrial fibrillation or flutter and in the Danish Civil Registration System (vital status and emigration). The consumption of n-3 fatty acids from fish was analyzed as sex-specific quintiles with the use of Cox proportional hazards models.
AB  - RESULTS: During follow-up (x: 5.7 y), atrial fibrillation or flutter had developed in 556 subjects (374 men and 182 women). When the lowest quintile of n-3 fatty acids consumed from fish was used as a reference, the unadjusted hazard rate ratios in quintiles 2, 3, 4, and 5 were 0.93, 1.11, 1.10, and 1.44, respectively (P for trend = 0.001). The corresponding adjusted hazard rate ratios were 0.86, 1.08, 1.01, and 1.34 (P for trend = 0.006). Inclusion of information on the frequency of fatty fish consumption did not alter these associations.
AB  - CONCLUSIONS: Consumption of n-3 fatty acids from fish was not associated with a reduction in risk of atrial fibrillation or flutter. We cannot exclude the possibility of residual confounding caused by a lack of information on intake of fish-oil tablets.
RN  - 0 (Fatty Acids, Omega-3)
IS  - 0002-9165
IL  - 0002-9165
PT  - Journal Article
LG  - English
DP  - 2005 Jan
DC  - 20050110
YR  - 2005
ED  - 20050215
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15640459

<653. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15592339
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Oka RK
AU  - Altman M
AU  - Giacomini JC
AU  - Szuba A
AU  - Cooke JP
FA  - Oka, Roberta K
FA  - Altman, Matt
FA  - Giacomini, John C
FA  - Szuba, Andrzej
FA  - Cooke, John P
IN  - Oka,Roberta K. Department of Community Health Systems, School of Nursing, University of California at Los Angeles, 94143, USA.
TI  - Exercise patterns and cardiovascular fitness of patients with peripheral arterial disease.
SO  - Journal of Vascular Nursing. 22(4):109-14; quiz 115-6, 2004 Dec.
AS  - J Vasc Nurs. 22(4):109-14; quiz 115-6, 2004 Dec.
NJ  - Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - aw8, 9014475
SB  - Nursing Journal
CP  - United States
MH  - Activities of Daily Living
MH  - Aged
MH  - California
MH  - *Exercise
MH  - Exercise Test
MH  - Female
MH  - Health Care Surveys
MH  - *Heart Rate
MH  - Humans
MH  - Intermittent Claudication/et [Etiology]
MH  - Life Style
MH  - Linear Models
MH  - Male
MH  - Peripheral Vascular Diseases/co [Complications]
MH  - Peripheral Vascular Diseases/pp [Physiopathology]
MH  - Peripheral Vascular Diseases/px [Psychology]
MH  - *Peripheral Vascular Diseases/rh [Rehabilitation]
MH  - *Physical Fitness
MH  - Predictive Value of Tests
MH  - Quality of Life
MH  - Regression Analysis
MH  - Surveys and Questionnaires
MH  - Walking
AB  - Peripheral arterial disease (PAD) is characterized by walking impairment as the result of claudication, which is improved by exercise. Few studies have examined the impact of existing exercise patterns in community-dwelling patients with PAD on cardiovascular fitness and absolute claudication distance (ACD). This descriptive study examines exercise patterns, walking distance, and cardiovascular fitness in a sample of community-dwelling older adults with PAD. Approximately 50% of subjects reported walking 4 (+/-2) days per week for 38 +/- 24 minutes. ACD (exercisers = 459.9 +/- 272; non-exercisers = 351.2 +/- 266.3, P = .06) and initial claudication distance (exercisers = 198.5 +/- 139.7; non-exercisers = 138.7 +/- 95.8 P = .02) were similar between groups. The workload accomplished was approximately 4.1-4.7 metabolic equivalents. Resting heart rate (HR) was associated with initial claudication distance ( r = -.37, P = .001) and ACD ( r = -.46, P < .01) and was lower in the group of exercisers versus the non-exercisers ( P = .05). Mean resting SBP was elevated and continued to increase at peak exercise with no difference between groups ( P = .75). Quality of life was poor for both groups. Simultaneous multiple regression analysis was performed to determine predictors of peak exercise HR. The model included gender, age, current exercise, ankle-brachial index, coronary artery disease, beta blockers, ACD, and atrial fibrillation (R = 44%, P = .01). Higher peak exercise HR was associated with older age, female gender, no beta blockers, and greater ACD ( P < .01). The findings from this descriptive study demonstrate the need for larger long-term studies to address issues of exercise adherence and the psychologic and functional benefits of exercise.
IS  - 1062-0303
IL  - 1062-0303
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
NO  - KO1NR00150-01 (United States NINR NIH HHS)
NO  - P01AI50153 (United States NIAID NIH HHS)
NO  - R01 HL63685 (United States NHLBI NIH HHS)
LG  - English
DP  - 2004 Dec
DC  - 20041213
YR  - 2004
ED  - 20050210
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15592339

<654. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15657225
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wetzel U
AU  - Boldt A
AU  - Lauschke J
AU  - Weigl J
AU  - Schirdewahn P
AU  - Dorszewski A
AU  - Doll N
AU  - Hindricks G
AU  - Dhein S
AU  - Kottkamp H
FA  - Wetzel, U
FA  - Boldt, A
FA  - Lauschke, J
FA  - Weigl, J
FA  - Schirdewahn, P
FA  - Dorszewski, A
FA  - Doll, N
FA  - Hindricks, G
FA  - Dhein, S
FA  - Kottkamp, H
IN  - Wetzel,U. Department of Electrophysiology, Cardiology, University of Leipzig Heart Centre, Strumpellstrasse 39, D-04289 Leipzig, Germany. ulrike_wetzel@hotmail.com
TI  - Expression of connexins 40 and 43 in human left atrium in atrial fibrillation of different aetiologies.
SO  - Heart. 91(2):166-70, 2005 Feb.
AS  - Heart. 91(2):166-70, 2005 Feb.
NJ  - Heart (British Cardiac Society)
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 9602087
OI  - Source: NLM. PMC1768705
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Atrial Fibrillation/me [Metabolism]
MH  - Blotting, Western
MH  - Case-Control Studies
MH  - *Connexin 43/me [Metabolism]
MH  - *Connexins/me [Metabolism]
MH  - Heart Atria
MH  - Humans
MH  - Middle Aged
MH  - Mitragyna
MH  - *Myocardium/me [Metabolism]
AB  - OBJECTIVE: To test the hypothesis that atrial fibrillation (AF) is associated with changes in the expression of connexins 40 and 43 in the left atrium with more pronounced changes in mitral valve disease than in lone AF.
AB  - METHODS: Protein concentrations of connexin 40 and connexin 43 were analysed in left atrial tissue of patients undergoing cardiac surgery. One group of patients had lone AF (n = 41), one group had AF and mitral valve repair (n = 36), and one group in sinus rhythm served as controls (n = 15).
AB  - RESULTS: Western blot analysis of connexin 40 and connexin 43 expression showed an increase of both gap junctional proteins (connexin 43 > connexin 40) in patients with AF of all forms compared with patients in sinus rhythm (p = 0.01 and p = 0.011, respectively). Subgroup analysis showed increased concentrations of connexin 40 in lone AF and AF with mitral valve disease compared with sinus rhythm (p = 0.06 and p = 0.029, respectively), whereas the same analysis for connexin 43 reached significance only in the mitral valve disease group (p = 0.031). No differences in connexin 40 and connexin 43 expression were detectable between lone AF and AF with mitral valve disease. Within the groups connexin 40 and connexin 43 expression did not differ between patients with paroxysmal AF and patients with chronic AF.
AB  - CONCLUSION: The present study shows for the first time that AF can induce changes in the left atrium with increased connexin expression. Furthermore, no systematic differences between patients with paroxysmal and chronic AF were detected.
RN  - 0 (Connexin 43)
RN  - 0 (Connexins)
RN  - 0 (connexin 40)
ES  - 1468-201X
IL  - 1355-6037
PT  - Journal Article
LG  - English
DP  - 2005 Feb
DC  - 20050119
YR  - 2005
ED  - 20050208
RD  - 20140608
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15657225

<655. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15613608
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Frost L
AU  - Frost P
AU  - Vestergaard P
FA  - Frost, L
FA  - Frost, P
FA  - Vestergaard, P
IN  - Frost,L. Department of Cardiology A, Aarhus University Hospital, DK-8000 Aarhus C, Denmark. rlg041fr@as.aaa.dk
TI  - Work related physical activity and risk of a hospital discharge diagnosis of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study.
SO  - Occupational & Environmental Medicine. 62(1):49-53, 2005 Jan.
AS  - Occup Environ Med. 62(1):49-53, 2005 Jan.
NJ  - Occupational and environmental medicine
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 9422759
OI  - Source: NLM. PMC1740844
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/et [Etiology]
MH  - Atrial Flutter/ep [Epidemiology]
MH  - *Atrial Flutter/et [Etiology]
MH  - Denmark/ep [Epidemiology]
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - *Motor Activity
MH  - Occupational Diseases/ep [Epidemiology]
MH  - *Occupational Diseases/et [Etiology]
MH  - Physical Exertion
MH  - Prospective Studies
MH  - Risk Assessment/mt [Methods]
MH  - Workload
AB  - BACKGROUND AND AIMS: Excessive sporting activities have been associated with risk of atrial fibrillation. To study if work related physical activity also confers risk of atrial fibrillation or flutter, the association between work related physical strain and the risk of a hospital discharge diagnosis (inpatient as well as outpatient) of atrial fibrillation or flutter was examined.
AB  - METHODS: A population based prospective cohort study was conducted from December 1993 to December 2001 among 19 593 men and 18,807 women with a mean age at baseline of 56 years (range 50-65 years) in the Danish Diet, Cancer, and Health Study. The physical strain during working hours was categorised as sedentary, light, or heavy, and analysed using proportional hazard models. Subjects were followed up in the Danish National Registry of Patients and in the Danish Civil Registration System.
AB  - RESULTS: During follow up (mean 5.7 years) a hospital discharge diagnosis of atrial fibrillation or flutter occurred in 305 men and 113 women. When using the risk of atrial fibrillation or flutter associated with sedentary work at a sitting position as a reference, no excess risk (unadjusted as well as adjusted) was found of atrial fibrillation or flutter associated with sedentary work in a standing position, light workload, or heavy workload in men or women.
AB  - CONCLUSION: No evidence was found of an association between physical activities during working hours and risk of a hospital discharge diagnosis of atrial fibrillation or flutter for men and women in the age group of 50-65 years.
ES  - 1470-7926
IL  - 1351-0711
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2005 Jan
DC  - 20041222
YR  - 2005
ED  - 20050126
RD  - 20140608
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15613608

<656. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15262826
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mozaffarian D
AU  - Psaty BM
AU  - Rimm EB
AU  - Lemaitre RN
AU  - Burke GL
AU  - Lyles MF
AU  - Lefkowitz D
AU  - Siscovick DS
FA  - Mozaffarian, Dariush
FA  - Psaty, Bruce M
FA  - Rimm, Eric B
FA  - Lemaitre, Rozenn N
FA  - Burke, Gregory L
FA  - Lyles, Mary F
FA  - Lefkowitz, David
FA  - Siscovick, David S
IN  - Mozaffarian,Dariush. Channing Laboratory, Brigham and Women's Hospital and Harvard Medical School, and Department of Epidemiology, Harvard School of Public Health, Boston, Mass, USA. darymd@hotmail.com
TI  - Fish intake and risk of incident atrial fibrillation.
CM  - Comment in: Circulation. 2005 Feb 1;111(4):e37; author reply e37; PMID: 15687118
SO  - Circulation. 110(4):368-73, 2004 Jul 27.
AS  - Circulation. 110(4):368-73, 2004 Jul 27.
NJ  - Circulation
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - daw, 0147763
OI  - Source: NLM. NIHMS2819
OI  - Source: NLM. PMC1201400
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Animals
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Cardiotonic Agents
MH  - Cohort Studies
MH  - Cooking
MH  - Diet
MH  - Dietary Fats
MH  - Fatty Acids, Omega-3
MH  - Fish Oils
MH  - Fishes
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Massachusetts/ep [Epidemiology]
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Risk
MH  - *Seafood
MH  - Tuna
AB  - BACKGROUND: Atrial fibrillation (AF) is the most common arrhythmia in clinical practice and is particularly common in the elderly. Although effects of fish intake, including potential antiarrhythmic effects, may favorably influence risk of AF, relationships between fish intake and AF incidence have not been evaluated.
AB  - METHODS AND RESULTS: In a prospective, population-based cohort of 4815 adults > or =age 65 years, usual dietary intake was assessed at baseline in 1989 and 1990. Consumption of tuna and other broiled or baked fish correlated with plasma phospholipid long-chain n-3 fatty acids, whereas consumption of fried fish or fish sandwiches (fish burgers) did not. AF incidence was prospectively ascertained on the basis of hospital discharge records and annual electrocardiograms. During 12 years' follow-up, 980 cases of incident AF were diagnosed. In multivariate analyses, consumption of tuna or other broiled or baked fish was inversely associated with incidence of AF, with 28% lower risk with intake 1 to 4 times per week (HR=0.72, 95% CI=0.58 to 0.91, P=0.005), and 31% lower risk with intake > or =5 times per week (HR=0.69, 95% CI=0.52 to 0.91, P=0.008), compared with <1 time per month (P trend=0.004). Results were not materially different after adjustment for preceding myocardial infarction or congestive heart failure. In similar analyses, fried fish/fish sandwich consumption was not associated with lower risk of AF.
AB  - CONCLUSIONS: Among elderly adults, consumption of tuna or other broiled or baked fish, but not fried fish or fish sandwiches, is associated with lower incidence of AF. Fish intake may influence risk of this common cardiac arrhythmia.
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Dietary Fats)
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Fish Oils)
ES  - 1524-4539
IL  - 0009-7322
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
NO  - DK07703 (United States NIDDK NIH HHS)
NO  - K08 HL075628 (United States NHLBI NIH HHS)
NO  - N01-HC-15103 (United States NHLBI NIH HHS)
NO  - N01-HC-35129 (United States NHLBI NIH HHS)
NO  - N01-HC-85086 (United States NHLBI NIH HHS)
LG  - English
EP  - 20040719
DP  - 2004 Jul 27
DC  - 20040727
YR  - 2004
ED  - 20050125
RD  - 20140905
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15262826

<657. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15284065
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Guazzi M
AU  - Belletti S
AU  - Tumminello G
AU  - Fiorentini C
AU  - Guazzi MD
FA  - Guazzi, Marco
FA  - Belletti, Sebastiano
FA  - Tumminello, Gabriele
FA  - Fiorentini, Cesare
FA  - Guazzi, Maurizio D
IN  - Guazzi,Marco. Cardiopulmonary Laboratory, Cardiology Division, Univ. of Milano, San Paolo Hospital, Via A. di Rudini, 8 20144 Milano, Italy. Marco.Guazzi@unimi.it
TI  - Exercise hyperventilation, dyspnea sensation, and ergoreflex activation in lone atrial fibrillation.
SO  - American Journal of Physiology - Heart & Circulatory Physiology. 287(6):H2899-905, 2004 Dec.
AS  - Am J Physiol Heart Circ Physiol. 287(6):H2899-905, 2004 Dec.
NJ  - American journal of physiology. Heart and circulatory physiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - dkm, 100901228
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Brachial Artery/ph [Physiology]
MH  - Carbon Dioxide/me [Metabolism]
MH  - *Dyspnea/pp [Physiopathology]
MH  - *Exercise
MH  - Female
MH  - Humans
MH  - *Hyperventilation/pp [Physiopathology]
MH  - Male
MH  - Middle Aged
MH  - Oxygen/me [Metabolism]
MH  - Oxygen Consumption/ph [Physiology]
MH  - Reflex/ph [Physiology]
MH  - Respiratory Function Tests
AB  - Lone atrial fibrillation may be associated with daily life disability and exercise limitation. The extracardiac pathophysiology of these effects is poorly explored. In 35 subjects with lone atrial fibrillation (mean age 67 +/- 7 yr), we investigated pulmonary function, symptom-limited cardiopulmonary exercise performance, muscle ergoreflex (handgrip exercise) contribution to ventilation, and brachial artery flow-mediated dilation (as a measure of endothelial function) before and after (average interval 20 +/- 5 days) restoring sinus rhythm with external cardioversion. Respiratory volumes and lung diffusing capacity at rest were within normal limits during both atrial fibrillation and after restoring sinus rhythm. Cardioversion was associated with the following changes: a decrease of the slope of exercise ventilation vs. CO2 production (from 35 +/- 5 to 29 +/- 3; P <0.01) and of dyspnea sensation (Borg score from 4 to 2) and an increase of peak oxygen uptake (Vo2; from 16 +/- 4 to 20 +/- 5 ml.min(-1).kg(-1); P <0.01), Vo2 at anaerobic threshold (from 11 +/- 2 to 13 +/- 2 ml.min(-1).kg(-1); P <0.05), and O2 pulse (from 8 +/- 3 to 11 +/- 3 ml/beat; P <0.01). After cardioversion, the observed improvement in ventilatory efficiency was accompanied by a significant peak end-tidal CO2 increase (from 33 +/- 2 to 37 +/- 2 mmHg; P <0.01) and no changes in dead space-to-tidal volume ratio (from 0.23 +/- 0.03 to 0.23 +/- 0.02; P=not significant). In addition, the ergoreflex contribution to ventilation was remarkably attenuated, and the brachial artery flow-mediated dilatation was significantly augmented (from 0.32 +/- 0.07 to 0.42 +/- 0.08 mm; P <0.01). Ten patients had atrial fibrillation relapse and, compared with values after restoration of regular sinus rhythm, invariably showed worsening of endothelial function, exercise ventilatory efficiency, and muscle ergoreflex contribution to ventilation. In subjects with lone atrial fibrillation, an impairment in ventilatory efficiency appears to be involved in the pathophysiology of exercise limitation, and to be primarily related with a demodulated peripheral control of ventilation.
RN  - 142M471B3J (Carbon Dioxide)
RN  - S88TT14065 (Oxygen)
IS  - 0363-6135
IL  - 0363-6135
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20040729
DP  - 2004 Dec
DC  - 20041119
YR  - 2004
ED  - 20050103
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15284065

<658. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15586425
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Anonymous
TI  - Diet surprise: when fish flop as health food.
SO  - Heart Advisor. 7(9):2, 2004 Sep.
AS  - Heart Advis. 7(9):2, 2004 Sep.
NJ  - Heart advisor / the Cleveland Clinic
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9892190
SB  - Consumer Health Journals
CP  - United States
MH  - Animals
MH  - *Atrial Fibrillation/dh [Diet Therapy]
MH  - *Fishes
MH  - *Food Handling/mt [Methods]
MH  - Humans
IS  - 1523-9004
IL  - 1523-9004
PT  - News
LG  - English
DP  - 2004 Sep
DC  - 20040930
YR  - 2004
ED  - 20041213
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15586425

<659. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15477433
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Frost L
AU  - Vestergaard P
FA  - Frost, Lars
FA  - Vestergaard, Peter
IN  - Frost,Lars. Department of Cardiology, Aarhus Amtssygehus, Aarhus University Hospital, Aarhus, Denmark. lars.frost@aas.auh.dk
TI  - Alcohol and risk of atrial fibrillation or flutter: a cohort study.
SO  - Archives of Internal Medicine. 164(18):1993-8, 2004 Oct 11.
AS  - Arch Intern Med. 164(18):1993-8, 2004 Oct 11.
NJ  - Archives of internal medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0372440, 7fs
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Alcohol Drinking/ae [Adverse Effects]
MH  - Alcohol Drinking/ep [Epidemiology]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Atrial Flutter/ep [Epidemiology]
MH  - Atrial Flutter/et [Etiology]
MH  - Cohort Studies
MH  - Denmark/ep [Epidemiology]
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Factors
MH  - Sex Factors
AB  - BACKGROUND: The evidence for an association between alcohol consumption and risk of atrial fibrillation is conflicting.
AB  - METHODS: We prospectively examined the association between alcohol consumption and risk of atrial fibrillation or flutter among 47 949 participants (mean age, 56 years) in the Danish Diet, Cancer, and Health Study. The consumption of alcohol was analyzed as sex-specific quintiles by Cox proportional hazards regression models.
AB  - RESULTS: The mean +/- SD consumption of alcohol per day was 28.2 +/- 25 g in men and 13.9 +/- 15 g in women. During follow-up (mean, 5.7 years), atrial fibrillation or flutter developed in 556 subjects (374 men and 182 women). After adjusting for established risk factors, there was a modest increase in risk of atrial fibrillation or flutter by increasing alcohol consumption in men. When using the lowest quintile of alcohol consumption in men as a reference, the adjusted hazard rate ratios in men in quintiles 2, 3, 4, and 5 were 1.04, 1.44, 1.25, and 1.46, respectively (P for trend, .04). When using the lowest quintile of alcohol consumption in women as a reference, the adjusted hazard rate ratios in women in quintiles 2, 3, 4, and 5 were 1.09, 1.27, 1.23, and 1.14, respectively (P for trend, .69). Inclusion of information on the frequency of alcohol consumption and the preferred source of alcohol did not change these associations.
AB  - CONCLUSIONS: Consumption of alcohol was associated with an increased risk of atrial fibrillation or flutter in men. In women, moderate consumption of alcohol did not seem to be associated with risk of atrial fibrillation or flutter.
IS  - 0003-9926
IL  - 0003-9926
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2004 Oct 11
DC  - 20041012
YR  - 2004
ED  - 20041130
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15477433

<660. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15287931
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Guy-Grand B
AU  - Drouin P
AU  - Eschwege E
AU  - Gin H
AU  - Joubert JM
AU  - Valensi P
FA  - Guy-Grand, B
FA  - Drouin, P
FA  - Eschwege, E
FA  - Gin, H
FA  - Joubert, J-M
FA  - Valensi, P
IN  - Guy-Grand,B. Service de Nutrition, Hotel-Dieu, Paris, France. bernard.guy-grand@htd.ap-hop-paris.fr
TI  - Effects of orlistat on obesity-related diseases - a six-month randomized trial.
SO  - Diabetes, Obesity & Metabolism. 6(5):375-83, 2004 Sep.
AS  - Diabetes Obes Metab. 6(5):375-83, 2004 Sep.
NJ  - Diabetes, obesity & metabolism
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - dw9, 100883645
SB  - Index Medicus
CP  - England
MH  - Aged
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/co [Complications]
MH  - *Diabetes Mellitus, Type 2/ep [Epidemiology]
MH  - Female
MH  - Humans
MH  - Hypertension/co [Complications]
MH  - *Hypertension/ep [Epidemiology]
MH  - Insulin Resistance
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Prevalence
MH  - Risk Assessment
MH  - Sweden/ep [Epidemiology]
AB  - AIM: To assess the effect of orlistat on body weight and concomitant diseases in patients with body mass index (BMI) of > 28 kg/m2 and poorly controlled type 2 diabetes, hypertension or hypercholesterolaemia.
AB  - METHODS: This trial was a six-month, randomized, double-blind, placebo-controlled study of orlistat 120 mg three times daily plus a mildly reduced-calorie diet. 1004 obese patients (BMI 28-40 kg/m2) were included by 253 private endocrinologists and received orlistat (n = 499) or placebo (n = 505). Patients were stratified by concomitant disorder (type 2 diabetes, n = 193; hypertension, n = 614; hypercholesterolaemia, n = 197). Body weight, anthropometry, lipid and glycaemic control parameters and blood pressure.
AB  - RESULTS: After six months, orlistat produced a significantly greater weight loss than placebo in type 2 diabetes (-4.2% vs. -1.4%), hypertension (-6.2% vs. -1.9%) and hypercholesterolaemia (-5.5% vs. -2.3%) groups (p < 0.0001 for all). There was a greater decrease in HbA(1c) in the type 2 diabetes group (-0.54 vs. -0.18%; p = 0.002) and low-density lipoprotein (LDL)-cholesterol in the hypercholesterolaemia group (-11.7% vs. -4.5%; p = 0.004) with orlistat vs. placebo. Early weight loss (> or = 5% at 12 weeks) was associated with the highest weight loss in each group, and the highest decreases in HbA1c, LDL-cholesterol and diastolic blood pressure in patients with type 2 diabetes, hypercholesterolaemia and hypertension, respectively, at six months. The incidence of adverse events was similar for orlistat and placebo, except for certain generally well-tolerated gastrointestinal events that were more common with orlistat.
AB  - CONCLUSION: Orlistat plus a mildly reduced-calorie diet produced clinically meaningful weight loss and improvements in risk factors in overweight and obese patients with poorly controlled type 2 diabetes, hypertension or hypercholesterolaemia.Copyright 2004 Blackwell Publishing Ltd
IS  - 1462-8902
IL  - 1462-8902
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2004 Sep
DC  - 20040803
YR  - 2004
ED  - 20041115
RD  - 20091103
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15287931

<661. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15468967
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Tsujimoto T
AU  - Takano M
AU  - Ishikawa M
AU  - Tsuruzono T
AU  - Matsumura Y
AU  - Kitano H
AU  - Yoneda S
AU  - Yoshiji H
AU  - Yamao J
AU  - Fukui H
FA  - Tsujimoto, Tatsuhiro
FA  - Takano, Masato
FA  - Ishikawa, Masatoshi
FA  - Tsuruzono, Takuya
FA  - Matsumura, Yoshinobu
FA  - Kitano, Hiroyuki
FA  - Yoneda, Satoshi
FA  - Yoshiji, Hitoshi
FA  - Yamao, Junichi
FA  - Fukui, Hiroshi
IN  - Tsujimoto,Tatsuhiro. Department of Gastroenterology, Ishinkai Yao General Hospital, 1-41 Numa, Yao, Osaka 581-0036.
TI  - Onset of ischemic colitis following use of electrical muscle stimulation (EMS) exercise equipment.
SO  - Internal Medicine. 43(8):693-5, 2004 Aug.
AS  - Intern Med. 43(8):693-5, 2004 Aug.
NJ  - Internal medicine (Tokyo, Japan)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - bd6, 9204241
SB  - Index Medicus
CP  - Japan
MH  - Aged
MH  - *Colitis, Ischemic/et [Etiology]
MH  - Colon/bs [Blood Supply]
MH  - *Electric Stimulation Therapy/ae [Adverse Effects]
MH  - Humans
MH  - Male
MH  - Muscle, Skeletal
AB  - Our patient was a 71-year-old man who presented with lower abdominal pain, and bloody and white mucosal stools. He purchased by mail-order an electrical muscle stimulation (EMS) device, which he strapped onto his lower abdomen, and for 2 consecutive days he underwent muscle stimulation comprising 600 contractions at 2.40 mA and 1.20 V over a 10 minute period. He experienced the onset of lower abdominal pain immediately following muscle stimulation on the second day, and then passed stools containing blood and white mucus. The cause was thought to be electrical and mechanical stimulation of the lower abdomen by the EMS equipment, either inducing colonic or vascular spasm, or dislodging thrombi associated with atrial fibrillation or atherosclerosis. This is the first known report of ischemic colitis associated with the use of EMS exercise equipment. We report this case in the belief that this condition is likely to become more common with increasing use of such devices.
IS  - 0918-2918
IL  - 0918-2918
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2004 Aug
DC  - 20041007
YR  - 2004
ED  - 20041109
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15468967

<662. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15464683
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Tse HF
AU  - Newman D
AU  - Ellenbogen KA
AU  - Buhr T
AU  - Markowitz T
AU  - Lau CP
AU  - Atrial Fibrillation SYMPTOMS investigators
FA  - Tse, Hung-Fat
FA  - Newman, David
FA  - Ellenbogen, Kenneth A
FA  - Buhr, Trina
FA  - Markowitz, Toby
FA  - Lau, Chu-Pak
FA  - Atrial Fibrillation SYMPTOMS investigators
IN  - Tse,Hung-Fat. Cardiology Division, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
TI  - Effects of ventricular rate regularization pacing on quality of life and symptoms in patients with atrial fibrillation (Atrial fibrillation symptoms mediated by pacing to mean rates [AF SYMPTOMS study]).
SO  - American Journal of Cardiology. 94(7):938-41, 2004 Oct 1.
AS  - Am J Cardiol. 94(7):938-41, 2004 Oct 1.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Cardiac Pacing, Artificial
MH  - Cross-Over Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Conduction System/pp [Physiopathology]
MH  - Heart Conduction System/su [Surgery]
MH  - *Heart Rate/ph [Physiology]
MH  - Heart Ventricles/pp [Physiopathology]
MH  - Heart Ventricles/su [Surgery]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pacemaker, Artificial
MH  - Prospective Studies
MH  - Quality of Life
MH  - Severity of Illness Index
MH  - Sickness Impact Profile
MH  - Single-Blind Method
MH  - Statistics as Topic
MH  - Treatment Outcome
MH  - Walking/ph [Physiology]
AB  - The aim of this study was to investigate the effect of the Ventricular Response Pacing (VRP) algorithm, which regularizes ventricular rate during atrial fibrillation (AF), on symptoms, quality of life, and functional capacity. VRP regularizes the ventricular rate during AF without increasing the mean ventricular rate, thereby reducing the severity of AF-related symptoms in patients with persistent AF. However, VRP did not improve general quality of life (Medical Outcomes Study 36-item Short-Form General Health Survey), the performance of routine activities (Duke Activity Status Index), or functional capacity (hall walk) in patients with AF.
IS  - 0002-9149
IL  - 0002-9149
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2004 Oct 1
DC  - 20041006
YR  - 2004
ED  - 20041108
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15464683

<663. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15068147
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Erdogan D
AU  - Kocaman O
AU  - Oflaz H
AU  - Goren T
FA  - Erdogan, Dogan
FA  - Kocaman, Orhan
FA  - Oflaz, Huseyin
FA  - Goren, Taner
IN  - Erdogan,Dogan. Istanbul Medical Faculty, Istanbul University, Capa, Istanbul, Turkey.
TI  - Alveolar hemorrhage associated with warfarin therapy: a case report and literature review. [Review] [16 refs]
SO  - The International Journal of Cardiovascular Imaging. 20(2):155-9, 2004 Apr.
AS  - Int J Cardiovasc Imaging. 20(2):155-9, 2004 Apr.
NJ  - The international journal of cardiovascular imaging
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 100969716
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Anticoagulants/ae [Adverse Effects]
MH  - Antifibrinolytic Agents/tu [Therapeutic Use]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Hemorrhage/ci [Chemically Induced]
MH  - Hemorrhage/dt [Drug Therapy]
MH  - Hemorrhage/ra [Radiography]
MH  - Humans
MH  - International Normalized Ratio
MH  - *Lung Diseases/ci [Chemically Induced]
MH  - Lung Diseases/dt [Drug Therapy]
MH  - Lung Diseases/ra [Radiography]
MH  - Male
MH  - *Pulmonary Alveoli/de [Drug Effects]
MH  - *Pulmonary Alveoli/pa [Pathology]
MH  - Tomography, X-Ray Computed
MH  - Vitamin K/tu [Therapeutic Use]
MH  - *Warfarin/ae [Adverse Effects]
AB  - A 75-year-old man was admitted to our clinic with the complaints of palpitation, fever, severe dyspnea, dizziness and bloody sputum associated with coughing. Chest radiographs revealed that the lungs were bilaterally infiltrated. A high resolution computed tomographic study of the thorax disclosed diffuse alveolar hemorrhage, of which presence was proved by histopathological study of bronchoalveolar lavage material. The hemorrhage occured at 8th day of 5 mg daily warfarin therapy, which was given for frequent atrial fibrillation attacks was controlled by fresh frozen plasma and vitamin K. Alveolar hemorrhage is difficult to diagnose and has high mortality if the treatment was not started as soon as possible. This is the first report of alveolar hemorrhage caused by 5 mg daily warfarin therapy. We propose that the patient's age, nutritional status, used drugs should be taken into consideration for true management of patients with atrial fibrillation. [References: 16]
RN  - 0 (Anticoagulants)
RN  - 0 (Antifibrinolytic Agents)
RN  - 12001-79-5 (Vitamin K)
RN  - 5Q7ZVV76EI (Warfarin)
IS  - 1569-5794
IL  - 1569-5794
PT  - Case Reports
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2004 Apr
DC  - 20040407
YR  - 2004
ED  - 20041106
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15068147

<664. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15225173
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - West J
AU  - Logan RF
AU  - Card TR
AU  - Smith C
AU  - Hubbard R
FA  - West, J
FA  - Logan, R F A
FA  - Card, T R
FA  - Smith, C
FA  - Hubbard, R
IN  - West,J. Division of Epidemiology and Public Health, Medical School, Queen's Medical Centre, University of Nottingham, Nottingham, UK. joe.west@nottingham.ac.uk
TI  - Risk of vascular disease in adults with diagnosed coeliac disease: a population-based study.
SO  - Alimentary Pharmacology & Therapeutics. 20(1):73-9, 2004 Jul 1.
AS  - Aliment Pharmacol Ther. 20(1):73-9, 2004 Jul 1.
NJ  - Alimentary pharmacology & therapeutics
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - a5d, 8707234
SB  - Index Medicus
CP  - England
MH  - Adult
MH  - Aged
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Celiac Disease/co [Complications]
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hypercholesterolemia/et [Etiology]
MH  - Hypertension/et [Etiology]
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/et [Etiology]
MH  - Risk Factors
MH  - Survival Analysis
MH  - *Vascular Diseases/et [Etiology]
AB  - BACKGROUND: It has been suggested that vascular disease mortality may be reduced in coeliac disease because of lower levels of blood pressure, cholesterol and body mass.
AB  - AIM: To examine whether people with coeliac disease are at reduced risk of various vascular diseases.
AB  - METHODS: We identified 3,790 adults with diagnosed coeliac disease and 17,925 age- and sex-matched controls in the General Practice Research Database. We estimated odds ratios for diagnosed hypertension, hypercholesterolaemia and atrial fibrillation and hazard ratios for myocardial infarction and stroke.
AB  - RESULTS: Adults with coeliac disease, compared with controls, were less likely to have had a diagnosis of hypertension [11% vs. 15%, odds ratio 0.68 (95% confidence interval: 0.60-0.76)] or hypercholesterolaemia [3.0% vs. 4.8%, odds ration 0.58 (95% confidence interval: 0.47-0.72)] but slightly more likely to have had atrial fibrillation [2.1% vs. 1.7%, odds ratio 1.26 (95% confidence interval: 0.97-1.64)]. The hazard ratio for myocardial infarction was 0.85 (95% confidence interval: 0.63-1.13), while the hazard ratio for stroke was 1.29 (95% confidence interval: 0.98-1.70).
AB  - CONCLUSIONS: Although rates of myocardial infarction and stroke were not substantially different, adults with coeliac disease do have a lower prevalence of hypertension and hypercholesterolaemia compared with the general population. The effect of a gluten-free diet on cardiovascular risk factors should be determined before any screening programmes for coeliac disease are instituted.
IS  - 0269-2813
IL  - 0269-2813
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2004 Jul 1
DC  - 20040630
YR  - 2004
ED  - 20041101
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15225173

<665. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15056823
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Matsumoto M
AU  - Yamashita T
AU  - Fukuda E
AU  - Sagara K
AU  - Iinuma H
AU  - Fu LT
FA  - Matsumoto, Miwa
FA  - Yamashita, Takeshi
FA  - Fukuda, Etsuko
FA  - Sagara, Kouichi
FA  - Iinuma, Hiroyuki
FA  - Fu, Long-Tai
IN  - Matsumoto,Miwa. The Cardiovascular Institute, Tokyo, Japan. matsu@cvi.or.jp
TI  - Relation between variability of ventricular response intervals and exercise capacity in patients with non-valvular atrial fibrillation.
SO  - Circulation Journal. 68(4):294-6, 2004 Apr.
AS  - Circ J. 68(4):294-6, 2004 Apr.
NJ  - Circulation journal : official journal of the Japanese Circulation Society
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101137683
SB  - Index Medicus
CP  - Japan
MH  - Aged
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Dyspnea/et [Etiology]
MH  - Electrocardiography, Ambulatory
MH  - Exercise Test
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - Heart Rate
MH  - *Heart Ventricles/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Quality of Life
MH  - Sensitivity and Specificity
MH  - Time Factors
MH  - Ventricular Dysfunction, Left/pp [Physiopathology]
AB  - BACKGROUND: Reduced variability of the ventricular response interval (VRI) has been reported to predict adverse prognosis in patients with atrial fibrillation (AF). To examine whether it could be related also to the quality of the daily life of patients with AF, the relationships between VRI variability and exercise tolerance, one of the markers for quality of life, were determined in patients with persistent AF.
AB  - METHODS AND RESULTS: Thirty-one patients with idiopathic AF were included in the present study. Holter monitoring results and symptom-limited treadmill exercise testing were correlated in these patients without medications for the rate control of AF. The VRI variability, both the SD of the mean R-R interval (SDNN) and the SD of the 5-min mean R-R interval (SDANN), showed significant positive correlation with the exercise capacity (r=0.583, p=0.0004, and r=0.543, p=0.0013, respectively), whereas age, left ventricular ejection fraction and body mass index did not have any significant relationships. Multiple regression analysis revealed that increased SDNN was the only independent predictor of good exercise capacity during the treadmill exercise testing.
AB  - CONCLUSIONS: Increased VRI variability, independently of other clinical variables, can predict good exercise capacity in patients with idiopathic AF, thus being a new sensitive maker for quality of life in AF.
IS  - 1346-9843
IL  - 1346-9843
PT  - Journal Article
LG  - English
DP  - 2004 Apr
DC  - 20040401
YR  - 2004
ED  - 20041021
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15056823

<666. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15133314
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wang TL
AU  - Hung CR
AU  - Chang H
FA  - Wang, Tzong-Luen
FA  - Hung, Chi-Ren
FA  - Chang, Hang
IN  - Wang,Tzong-Luen. Department of Emergency Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan. M002183@ms.skh.org.tw
TI  - Evolution of plasma D-dimer and fibrinogen in witnessed onset of paroxysmal atrial fibrillation.
SO  - Cardiology. 102(2):115-8, 2004.
AS  - Cardiology. 102(2):115-8, 2004.
NJ  - Cardiology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - coi, 1266406
SB  - Index Medicus
CP  - Switzerland
MH  - Acute Disease
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrial Fibrillation/bl [Blood]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Chronic Disease
MH  - Female
MH  - *Fibrin Fibrinogen Degradation Products/an [Analysis]
MH  - *Fibrinogen/an [Analysis]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Time Factors
AB  - BACKGROUND: Although increased D-dimer and fibrinogen have been proved to be related with atrial fibrillation (AF), their evolution in the course of time remains unclear.
AB  - METHODS: To elucidate the evolution of plasma D-dimer and fibrinogen in AF of different duration. 56 patients (group A) of 3,524 patients in whom the onset of AF had been witnessed in a chest pain clinic were enrolled for study. Plasma D-dimer and fibrinogen concentrations were checked within 30 min after the onset of AF and followed up as scheduled. Another 50 patients (group B) with chronic AF underwent the same protocol and served as controls.
AB  - RESULTS: In group A, the D-dimer levels reached a plateau at the 18th hour (382 +/- 52 vs. 840 +/- 280 ng/ml, p < 0.001 by ANOVA) and the fibrinogen level increased gradually from 4.1 +/- 0.6 g/ml at baseline to 6.1 +/- 0.9 g/ml at the 48th hour (p < 0.001). No subjects had evidence of intra-cardiac thrombi by transesophageal echocardiography. There were significant differences in plasma D-dimer and fibrinogen levels between the two groups at each measurement. At the cut- off value of 500 ng/ml, plasma D-dimer had a sensitivity of 100%, a specificity of 93% in defining AF lasting for less than 12 h. The positive and negative predictive values were 52% and 100%, respectively. Plasma D-dimer increased above the normal range prior to the 12th hour after the onset of AF.
AB  - CONCLUSION: The observations support its use as a screening tool for identifying patients with short duration AF capable of being safely converted.Copyright 2004 S. Karger AG, Basel
RN  - 0 (Fibrin Fibrinogen Degradation Products)
RN  - 0 (fibrin fragment D)
RN  - 9001-32-5 (Fibrinogen)
IS  - 0008-6312
IL  - 0008-6312
PT  - Journal Article
LG  - English
EP  - 20040507
DP  - 2004
DC  - 20040706
YR  - 2004
ED  - 20041005
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15133314

<667. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15404802
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - SCHWARTZ SP
AU  - POOL Nde S
FA  - SCHWARTZ, S P
FA  - POOL, N DE S
TI  - Transient ventricular fibrillation; the effects of bodily rest, atropine sulfate, and exercise on patients with transient ventricular fibrillation during established auriculoventricular dissociation; a study of the influence of the extrinsic nerves on the idioventricular pacemaker of the heart.
SO  - American Heart Journal. 39(3):361-86, 1950 Mar.
AS  - Am Heart J. 39(3):361-86, 1950 Mar.
NJ  - American heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3bw, 0370465
OI  - Source: CLML. 5018:796x:2
SB  - OLDMEDLINE Citations
CP  - Not Available
MH  - *Arrhythmias, Cardiac
MH  - *Atropine
MH  - *Heart
MH  - *Heart Block
MH  - Humans
MH  - *Pacemaker, Artificial
MH  - *Ventricular Fibrillation
KW  - *ARRHYTHMIA
RN  - 7C0697DR9I (Atropine)
IS  - 0002-8703
IL  - 0002-8703
PT  - Journal Article
LG  - English
DP  - 1950 Mar
DC  - 19501201
YR  - 1950
ED  - 20040930
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=15404802

<668. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15353430
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - McAlister FA
AU  - Ezekowitz JA
AU  - Wiebe N
AU  - Rowe B
AU  - Spooner C
AU  - Crumley E
AU  - Hartling L
AU  - Klassen T
AU  - Abraham W
FA  - McAlister, Finlay A
FA  - Ezekowitz, Justin A
FA  - Wiebe, Natasha
FA  - Rowe, Brian
FA  - Spooner, Carol
FA  - Crumley, Ellen
FA  - Hartling, Lisa
FA  - Klassen, Terry
FA  - Abraham, William
IN  - McAlister,Finlay A. The University of Alberta and Capital Health Evidence-based Practice Center, Edmonton, Alberta, Canada. Finlay.McAlister@ualberta.ca
TI  - Systematic review: cardiac resynchronization in patients with symptomatic heart failure. [Review] [52 refs][Erratum appears in Ann Intern Med. 2005 Feb 15;142(4):311]
CM  - Comment in: ACP J Club. 2005 Mar-Apr;142(2):35; PMID: 15739982
CM  - Comment in: Ann Intern Med. 2005 Feb 15;142(4):305-7; author reply 307-8; PMID: 15710966
CM  - Comment in: Ann Intern Med. 2004 Sep 7;141(5):399-400; PMID: 15313731
CM  - Comment in: Ann Intern Med. 2005 Feb 15;142(4):305; author reply 307-8; PMID: 15710967
CM  - Comment in: Ann Intern Med. 2004 Sep 7;141(5):I64; PMID: 15353446
SO  - Annals of Internal Medicine. 141(5):381-90, 2004 Sep 7.
AS  - Ann Intern Med. 141(5):381-90, 2004 Sep 7.
NJ  - Annals of internal medicine
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 0372351
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Cardiac Pacing, Artificial
MH  - Cause of Death
MH  - Heart Failure/dt [Drug Therapy]
MH  - Heart Failure/mo [Mortality]
MH  - *Heart Failure/th [Therapy]
MH  - Hospitalization
MH  - Humans
MH  - Quality of Life
MH  - *Ventricular Fibrillation
MH  - Walking
AB  - BACKGROUND: Even with optimal pharmacotherapy, symptomatic heart failure is associated with substantial morbidity and mortality.
AB  - PURPOSE: To determine the efficacy and safety of cardiac resynchronization therapy in adults with advanced systolic heart failure.
AB  - DATA SOURCES: The Cochrane Central Register of Controlled Trials (2002, volume 4), MEDLINE (1980-2003), EMBASE (1980-2003), other electronic databases, and U.S. Food and Drug Administration reports. We contacted primary study authors and device manufacturers, and we hand searched bibliographies of relevant papers and conference proceedings.
AB  - STUDY SELECTION: Randomized, controlled clinical trials for efficacy and controlled trials plus prospective cohort studies for safety.
AB  - DATA EXTRACTION: Two reviewers chose studies and extracted data independently; random-effects models were used for analyses.
AB  - DATA SYNTHESIS: Nine trials were included in the efficacy review (3216 patients). All trial participants had reduced ejection fraction and prolonged QRS duration, and 85% had New York Heart Association (NYHA) class III or IV symptoms. Cardiac resynchronization therapy improved ejection fraction (weighted mean difference, 0.035 [95% CI, 0.015 to 0.055]), quality of life (weighted mean reduction in score on the Minnesota Living with Heart Failure Questionnaire, 7.6 points [CI, 3.8 to 11.5 points]), and function (58% vs. 37% of patients improved by at least 1 NYHA class). Heart failure hospitalizations were reduced by 32% (relative risk [RR], 0.68 [CI, 0.41 to 1.12]), with benefits most marked in patients with NYHA class III or IV symptoms at baseline (RR, 0.65 [CI, 0.48 to 0.88]; number needed to treat for benefit [NNT(B)], 12). All-cause mortality was reduced by 21% (RR, 0.79 [CI, 0.66 to 0.96]; NNT(B), 24), driven largely by reductions in death from progressive heart failure (RR, 0.60 [CI, 0.36 to 1.01]). Eighteen studies (total of 3701 patients with cardiac resynchronization devices) were included in the safety review. Implant success rate was 90% (CI, 89% to 91%), and 0.4% of patients died during implantation (CI, 0.2% to 0.7%). Over a median 6-month follow-up, leads dislodged in 9% of patients (CI, 7% to 10%) and mechanical malfunctions occurred in 7% (CI, 5% to 8%).
AB  - LIMITATIONS: These trials enrolled only patients with heart failure with NYHA class III or IV symptoms despite medical therapy, a prolonged QRS duration, and reduced ejection fraction; in addition, experienced providers implanted the devices. Because all but one of these trials randomly assigned patients after device implantation, their results may overestimate the potential benefits of cardiac resynchronization. Finally, since few patients in these trials had bradyarrhythmias or atrial fibrillation, the role of cardiac resynchronization in such patients is uncertain.
AB  - CONCLUSIONS: In selected patients with heart failure, cardiac resynchronization therapy improves functional and hemodynamic status, reduces heart failure hospitalizations, and reduces all-cause mortality. [References: 52]
ES  - 1539-3704
IL  - 0003-4819
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
LG  - English
EP  - 20040816
DP  - 2004 Sep 7
DC  - 20040908
YR  - 2004
ED  - 20040928
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15353430

<669. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 14765833
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - El Rouby S
AU  - Mestres CA
AU  - LaDuca FM
AU  - Zucker ML
FA  - El Rouby, Soumaya
FA  - Mestres, Carlos A
FA  - LaDuca, Frank M
FA  - Zucker, Marcia L
IN  - El Rouby,Soumaya. Clinical Research Dept., International Technidyne Corp, Edison, NJ 08820, USA. selrouby@itcmed.com
TI  - Racial and ethnic differences in warfarin response. [Review] [63 refs]
SO  - Journal of Heart Valve Disease. 13(1):15-21, 2004 Jan.
AS  - J Heart Valve Dis. 13(1):15-21, 2004 Jan.
NJ  - The Journal of heart valve disease
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - byi, 9312096
SB  - Index Medicus
CP  - England
MH  - Anticoagulants/ad [Administration & Dosage]
MH  - *Anticoagulants/me [Metabolism]
MH  - Anticoagulants/pd [Pharmacology]
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - *Continental Population Groups
MH  - Cytochrome P-450 Enzyme System/ge [Genetics]
MH  - Food-Drug Interactions
MH  - Humans
MH  - Warfarin/ad [Administration & Dosage]
MH  - *Warfarin/me [Metabolism]
MH  - Warfarin/pd [Pharmacology]
MH  - Warfarin/tu [Therapeutic Use]
AB  - BACKGROUND AND AIM OF THE STUDY: Variability of drug response among individuals is a well-recognized problem that may result in either under- or overtreatment of patients receiving similar drug concentrations. Patients with mechanical heart valves are dependent on adequate anticoagulation to prevent thrombosis development. 'Crystalline warfarin sodium' (warfarin) is the most common antithrombotic drug prescribed to control blood hemostasis in those patients, and also in those with indications such as stroke, myocardial infarction, pulmonary embolism and atrial fibrillation. Warfarin is a narrow therapeutic index agent; a small change in systemic concentration of the drug may lead to significant changes in pharmacodynamic response. Careful clinical management is required to balance the risks of bleeding (over-anticoagulation) with those of thrombosis (under-anticoagulation). The study aim was to summarize environmental, genetic and ethnic factors that affect a patient's response to warfarin and which must be considered for optimal patient outcome.
AB  - METHODS: A Medline search was carried out to summarize various factors that influence a patient's response to warfarin.
AB  - RESULTS: Inter-ethnic differences may have profound implications for the efficacy and safety of warfarin. Ethnic differences can affect pharmacokinetic features such as bioavailability, protein binding and volume of distribution, as well as hepatic metabolism and renal elimination. Environmental factors and genetic variants in human enzymes that metabolize warfarin also contribute to interindividual variations and may render some patients more susceptible to serious or life-threatening adverse events.
AB  - CONCLUSION: Warfarin use is complicated by an unpredictable dose response that depends on factors such as demographics, diet, interacting drugs, genetic polymorphism and ethnic differences. The impact of racial differences on the kinetics of dose response or on drug efficacy is not well defined, as few clinical trials take ethnic variation into account. The use of the point of care and frequent patient self-testing may permit standardized warfarin monitoring across diverse geographical regions and facilitate analysis of ethnic variation among subpopulations. [References: 63]
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9035-51-2 (Cytochrome P-450 Enzyme System)
IS  - 0966-8519
IL  - 0966-8519
PT  - Comparative Study
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2004 Jan
DC  - 20040209
YR  - 2004
ED  - 20040902
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=14765833

<670. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15071245
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Garrigue S
AU  - Bordachar P
AU  - Reuter S
AU  - Jais P
AU  - Haissaguerre M
AU  - Clementy J
FA  - Garrigue, Stephane
FA  - Bordachar, Pierre
FA  - Reuter, Sylvain
FA  - Jais, Pierre
FA  - Haissaguerre, Michel
FA  - Clementy, Jacques
IN  - Garrigue,Stephane. Hopital Cardiologique du Haut-Leveque, University of Bordeaux, Bordeaux-Pessac, France. stephane.garrigue@chu-bordeaux.fr
TI  - Comparison of permanent left ventricular and biventricular pacing in patients with heart failure and chronic atrial fibrillation: a prospective hemodynamic study. [Review] [46 refs]
SO  - Cardiac Electrophysiology Review. 7(4):315-24, 2003 Dec.
AS  - Card Electrophysiol Rev. 7(4):315-24, 2003 Dec.
NJ  - Cardiac electrophysiology review
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9708907
SB  - Index Medicus
CP  - United States
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Cardiac Pacing, Artificial/mt [Methods]
MH  - Chronic Disease
MH  - Comorbidity
MH  - Cross-Over Studies
MH  - Electrophysiologic Techniques, Cardiac
MH  - Exercise/ph [Physiology]
MH  - Exercise Test
MH  - *Heart Failure/ep [Epidemiology]
MH  - Heart Failure/pp [Physiopathology]
MH  - *Heart Failure/th [Therapy]
MH  - Hemodynamics
MH  - Humans
MH  - Prospective Studies
MH  - Treatment Outcome
MH  - Ventricular Function
AB  - BACKGROUND: Left ventricular pacing (LVP) and biventricular pacing (BVP) have been proposed as treatments for patients with advanced heart failure complicated by discoordinate contraction due to intraventricular conduction delay. For patients in sinus rhythm, BVP works in part by modulating the electronic atrial-ventricular time delay and thus optimizing contractile synchrony, the contribution of atrial systole, and reducing mitral regurgitation. However, little is known of the mechanisms of BVP in heart failure patients with drug-resistant chronic atrial fibrillation. HYPOTHESIS AND METHODS: LVP differs from BVP because hemodynamic and clinical improvement occurs in association with prolongation rather than shortening of the QRS duration. We sought to determine if LVP or BVP improves mechanical synchronization in the presence of atrial fibrillation. Thirteen patients with chronic atrial fibrillation, severe heart failure and QRS >or=140 ms received (after His bundle ablation) a pacemaker providing both LVP and BVP. The mean age was 62 +/- 6 years and left ventricular ejection fraction was 24 +/- 8%. After a baseline phase of one month with right ventricular pacing, all patients underwent in random order 2 phases of 2 months (LVP and BVP). At the end of each phase, an echocardiogram, a hemodynamic analysis at rest and during a 6-minute walking test and a cardio-pulmonary exercise test were performed.
AB  - RESULTS: LVP and BVP provided similar performances at rest (p = ns). The 6-minute walking test revealed similar performances in both pacing modes but patients were significantly more symptomatic at the end of the test with LVP ( p = 0.035). The cardio-pulmonary exercise test showed higher performances with BVP (92 +/- 34 Watts) vs. LVP (77 +/- 23; p = 0.03). LVP was associated with significantly more premature ventricular complexes recorded during the 6 minute walking test (49 +/- 71) than BVP (10 +/- 23; p = 0.04).
AB  - CONCLUSIONS: In this small series of patients with atrial fibrillation, congestive heart failure and a prolonged QRS duration, LVP and BVP provided similar hemodynamic effects at rest whereas BVP was associated with better hemodynamic effects during exercise and fewer premature ventricular complexes. Although the mechanisms for the observed differences are uncertain, it is possible that there is worsening of right ventricular function due to a rise in left-to-right electromechanical delay during exercise. Increased catecholamines release might contribute to the lower exercise tolerance and greater number of premature ventricular complexes recorded during exercise observed during LVP compared to BVP.
AB  - RECOMMENDATIONS: Patients with atrial fibrillation, heart failure and QRS prolongation who are candidates for His-bundle ablation and cardiac resynchronization therapy may respond better to BVP rather than to LVP. [References: 46]
IS  - 1385-2264
IL  - 1385-2264
PT  - Comparative Study
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2003 Dec
DC  - 20040408
YR  - 2003
ED  - 20040826
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=15071245

<671. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15014214
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Goette A
AU  - Weber M
AU  - Lendeckel U
AU  - Welte T
AU  - Lutze G
AU  - Klein HU
FA  - Goette, Andreas
FA  - Weber, Mathias
FA  - Lendeckel, Uwe
FA  - Welte, Tobias
FA  - Lutze, Gerd
FA  - Klein, Helmut U
IN  - Goette,Andreas. Department of Internal Medicine, University Hospital Magdeburg, Magdeburg, Germany. andreas.goette@medizin.uni-magdeburg.de
TI  - Effect of physical exercise on platelet activity and the von-Willebrand-factor in patients with persistent lone atrial fibrillation.
SO  - Journal of Interventional Cardiac Electrophysiology. 10(2):139-46, 2004 Apr.
AS  - J Interv Card Electrophysiol. 10(2):139-46, 2004 Apr.
NJ  - Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - c8k, 9708966
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Analysis of Variance
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/rh [Rehabilitation]
MH  - Case-Control Studies
MH  - Chronic Disease
MH  - *Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Activation
MH  - Probability
MH  - Pulmonary Gas Exchange
MH  - Reference Values
MH  - Risk Assessment
MH  - Sampling Studies
MH  - Severity of Illness Index
MH  - *Stroke/pc [Prevention & Control]
MH  - *von Willebrand Factor/an [Analysis]
AB  - BACKGROUND: The risk of stroke is of great clinical importance in patients with atrial fibrillation (AF). It is not known whether physical exercise influences plasma coagulation and platelet aggregability during AF. The purpose of this study was to assess the effect of physical exercise on platelet activity, thrombin generation, and levels of von-Willebrand-factor in patients with persistent AF.
AB  - METHODS: Thirteen patients with lone AF (>or=1 year) were compared with 13 matched patients in sinus rhythm. Patients with AF were anticoagulated effectively with coumarin. All patients underwent bicycle ergometry using a respiratory gas exchange technique for 20 min at one-third of the age-adjusted maximal workload. Thereafter, workload was increased until maximal exercise capacity was reached. Platelet factor-4 (PF-4), beta-thromboglobulin (beta-TG; marker for platelet activation), von-Willebrand-factor (vWF; marker for endothelial dysfunction), prothrombin fragment F1 + 2 (F1 + 2; marker for thrombin generation) and fibrinogen levels were determined throughout the study in all patients.
AB  - RESULTS: Gas exchange variables, hemodynamic parameters and norepinephrine levels were comparable in the groups during moderate (45 +/- 5 W) and heavy exercise (198 +/- 38 W). In contrast to moderate exercise, PF-4 and beta-TG levels increased to 212 +/- 56% ( p < 0.05) and to 145 +/- 24% ( p < 0.05), respectively, in patients with AF during heavy exercise. In contrast, physical exercise had no significant effect on platelet activity in patients with sinus rhythm. Levels of vWF increased by delta24% ( p < 0.05) in all patients during maximal exercise, whereas F1 + 2 levels increased only in patients with sinus rhythm.
AB  - CONCLUSIONS: Heavy physical activity increases platelet activity and vWF levels during AF, whereas moderate exercise has no procoagulatory effect. Coumarin therapy prevents exercise-induced thrombin generation only. Future studies are needed to prove the hypothesis that heavy physical exercise is a risk factor for thromboembolic events in patients with AF.
RN  - 0 (von Willebrand Factor)
IS  - 1383-875X
IL  - 1383-875X
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 2004 Apr
DC  - 20040311
YR  - 2004
ED  - 20040817
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15014214

<672. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15136408
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Yamazaki T
AU  - Myers J
AU  - Froelicher VF
FA  - Yamazaki, Takuya
FA  - Myers, Jonathan
FA  - Froelicher, Victor F
IN  - Yamazaki,Takuya. Division of Cardiovascular Medicine, Stanford University Medical Center, Veterans Affairs Health Care System, Long Beach, CA, USA.
TI  - Effect of age and end point on the prognostic value of the exercise test.
SO  - Chest. 125(5):1920-8, 2004 May.
AS  - Chest. 125(5):1920-8, 2004 May.
NJ  - Chest
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0231335, d1c
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Age Distribution
MH  - Age Factors
MH  - Aged
MH  - Cardiovascular Diseases/di [Diagnosis]
MH  - *Cardiovascular Diseases/mo [Mortality]
MH  - Cardiovascular Diseases/pp [Physiopathology]
MH  - Cause of Death
MH  - *Exercise Test
MH  - Follow-Up Studies
MH  - Hemodynamics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Predictive Value of Tests
MH  - Prognosis
AB  - BACKGROUND: The clinical and exercise test variables chosen for predicting prognosis vary in the available studies. This could be due to the effect of age of the patients tested and the choice of outcomes used as end points in these follow-up studies.
AB  - OBJECTIVE: To evaluate the effect of age and end points on exercise test variables chosen as significantly and independently associated with time to death.
AB  - METHODS: Analyses were performed on the first treadmill test performed on consecutive male veterans at the Palo Alto and Long Beach Veterans Affairs Medical Centers since 1987. After removal of patients with congestive heart failure, coronary interventions, left bundle-branch block, atrial fibrillation, myocardial infarction and/or Q wave, and digoxin use, 3,745 male subjects remained. The outcomes were cardiovascular and all-cause mortality. The study population was divided into subsets according to age; exercise test and clinical variables were analyzed within the age subsets using the Cox hazard model.
AB  - RESULTS: The mean age at the time of testing was 57 +/- 12 years (+/- SD) and they were followed up for a mean of 6.6 years. There were 544 all-cause deaths, with 206 of the deaths being due to cardiovascular causes (38%). When the study group was classified into subsets based on age, exercise capacity (in metabolic equivalents [METs]) was chosen by the Cox hazard model most consistently in the age groups using either end point. Even when age was added to the Duke treadmill score, prediction of death did not improve in those > 70 years of age because of the nonlinear relationship between age, the exercise test variables, and time to death. The most important age cut points for clinically important differences in exercise test predictors appeared to be 70 years and 75 years of age. In the patients 70 to 75 years of age, peak METs was the only variable predictive of all-cause mortality, and exercise-induced ST-segment depression was the only predictor of cardiovascular death; in the patients > 75 years of age, none of the exercise test responses were predictive of either death outcome.
AB  - CONCLUSION: Both age and the outcome selected as an end point affect the exercise test responses chosen for scores to predict prognosis. Differences in age of the subjects tested and/or the outcome selected as the end point can explain the differences in the studies using exercise testing to predict prognosis.
IS  - 0012-3692
IL  - 0012-3692
PT  - Journal Article
LG  - English
DP  - 2004 May
DC  - 20040511
YR  - 2004
ED  - 20040728
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15136408

<673. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15135698
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Cooper HA
AU  - Bloomfield DA
AU  - Bush DE
AU  - Katcher MS
AU  - Rawlins M
AU  - Sacco JD
AU  - Chandler M
AU  - AFFIRM Investigators
FA  - Cooper, Howard A
FA  - Bloomfield, Dennis A
FA  - Bush, David E
FA  - Katcher, Michael S
FA  - Rawlins, Michele
FA  - Sacco, Joseph D
FA  - Chandler, Mary
FA  - AFFIRM Investigators
IN  - Cooper,Howard A. Division of Cardiology, Washington Hospital Center, 100 Irving Street NW, Suite NA 1103, Washington, DC 20010, USA. howard.a.cooper@medstar.net
TI  - Relation between achieved heart rate and outcomes in patients with atrial fibrillation (from the Atrial Fibrillation Follow-up Investigation of Rhythm Management [AFFIRM] Study).
CM  - Comment in: Am J Cardiol. 2004 Oct 15;94(8):1104-5; PMID: 15476641
SO  - American Journal of Cardiology. 93(10):1247-53, 2004 May 15.
AS  - Am J Cardiol. 93(10):1247-53, 2004 May 15.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Anti-Arrhythmia Agents/ad [Administration & Dosage]
MH  - *Anticoagulants/ad [Administration & Dosage]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/mo [Mortality]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Disease-Free Survival
MH  - Exercise
MH  - Female
MH  - *Heart Rate
MH  - Humans
MH  - Male
MH  - Prospective Studies
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Rest
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - United States
AB  - Many patients with atrial fibrillation (AF) are treated with rate control and anticoagulation. However, the relation between the degree of heart rate (HR) control and clinical outcome is uncertain. We assessed whether lower achieved HR at rest and/or lower achieved exercise HR was associated with improved prognosis, quality of life (QoL), and functional status among patients in the AFFIRM study. Patients in the rate control arm and who were in AF at baseline and 2 months were included. Patients were grouped by quartile of achieved HR at rest (44 to 69, 70 to 78, 79 to 87, 88 to 148 beats/min) and achieved exercise HR following a 6-minute walk (53 to 82, 83 to 92, 93 to 106, 107 to 220 beats/min). QoL measurements and functional status were also analyzed. Complete data were available for 680 patients for achieved HR at rest, 349 patients for achieved exercise HR, and 118 patients for QoL. Survival free from cardiac hospitalization and overall survival were not significantly different among quartiles of achieved HR at rest (p = 0.19 and p = 0.8, respectively) or achieved exercise HR (p = 0.77 and p = 0.14, respectively). After controlling for covariates, there remained no significant relation between either achieved HR at rest or achieved exercise HR and event-free survival (hazard ratio 0.95, p = 0.35 and hazard ratio 0.98, p = 0.81) or overall survival (hazard ratio 1.03, p = 0.70 and hazard ratio 1.22, p = 0.13). Furthermore, there was no significant association between achieved HR and QoL measurements, New York Heart Association functional class, or 6-minute walking distance. After 2 months of drug titration, neither achieved HR at rest nor achieved exercise HR predicted survival free from cardiovascular hospitalization, overall survival, QoL, or functional status among patients with AF.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Anticoagulants)
IS  - 0002-9149
IL  - 0002-9149
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, U.S. Gov't, P.H.S.
NO  - N01 HC 55139 (United States NHLBI NIH HHS)
LG  - English
DP  - 2004 May 15
DC  - 20040511
YR  - 2004
ED  - 20040615
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15135698

<674. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 14688636
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Reiffel JA
FA  - Reiffel, James A
IN  - Reiffel,James A. Department of Clinical Medicine, Columbia University, New York, New York, USA. jar2@columbia.edu
TI  - Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation?. [Review] [24 refs]
SO  - Current Opinion in Cardiology. 19(1):58-63, 2004 Jan.
AS  - Curr Opin Cardiol. 19(1):58-63, 2004 Jan.
NJ  - Current opinion in cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - bda, 8608087
SB  - Index Medicus
CP  - United States
MH  - Administration, Oral
MH  - Anticoagulants/ad [Administration & Dosage]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Azetidines/ad [Administration & Dosage]
MH  - *Azetidines/tu [Therapeutic Use]
MH  - Benzylamines
MH  - Clinical Trials as Topic
MH  - Embolism/et [Etiology]
MH  - *Embolism/pc [Prevention & Control]
MH  - Fibrinolytic Agents/ad [Administration & Dosage]
MH  - *Fibrinolytic Agents/tu [Therapeutic Use]
MH  - Humans
MH  - Prothrombin Time/ec [Economics]
MH  - Randomized Controlled Trials as Topic
MH  - Stroke/et [Etiology]
MH  - Stroke/pc [Prevention & Control]
MH  - Venous Thrombosis/et [Etiology]
MH  - Venous Thrombosis/pc [Prevention & Control]
MH  - Warfarin/ad [Administration & Dosage]
MH  - *Warfarin/tu [Therapeutic Use]
AB  - PURPOSE OF REVIEW: Atrial fibrillation is the most frequently encountered tachyarrhythmia requiring therapy. Treatment issues include therapy for any reversible cause; the identification and treatment of any underlying structural disorder; control of the ventricular rate, both for symptom reduction and prevention of tachycardic-induced cardiomyopathy; restoration and maintenance of sinus rhythm when symptoms persist despite rhythm control; and anticoagulation in patients with high-risk markers for systemic embolization: age over 65 years, hypertension, diabetes, ventricular failure, rheumatic valvular disease, and prior stroke or other embolic event. In such patients, anticoagulation with warfarin is currently recommended. Warfarin therapy carries significant risks (especially bleeding), inconveniences (the cost of prothrombin time monitoring, the need for rigid dietary stability, the concerns of drug and herbal interactions), and other concerns (the issue of generic formulation substitution).
AB  - RECENT FINDINGS: Under development are oral thrombin inhibitors. The first to reach clinical approval will likely be ximelagatran. In clinical trials to date, ximelagatran has proven to be equal to or superior to warfarin in the prevention and treatment of thrombophlebitis. In atrial fibrillation patients, the Stroke Prevention Using Oral Thrombin Inhibitor in Atrial Fibrillation (SPORTIF) trials completed so far appear to show a similar or better efficacy for ximelagatran versus warfarin as regards both prevention of embolic events and lower risks of major bleeding, with no serious adverse effects except for apparently reversible alterations in liver function tests in approximately 6% of subjects, all occurring early in therapy to date. If the remaining SPORTIF trial (SPORTIF V) is confirmatory (results to be available in late 2003), it is expected that this exciting new product will be submitted this winter to the Food and Drug Administration for approval. Recent findings also include the observations in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) and Rate Control Versus Electrical Cardioversion (RACE) trials that anticoagulation should not be discontinued despite the restoration and maintenance of sinus rhythm.
AB  - SUMMARY: Oral direct thrombin inhibitors, such as ximelagatran, appear likely to replace the use of warfarin in most patients in the near future, because of a better risk-benefit profile. [References: 24]
RN  - 0 (Anticoagulants)
RN  - 0 (Azetidines)
RN  - 0 (Benzylamines)
RN  - 0 (Fibrinolytic Agents)
RN  - 49HFB70472 (ximelagatran)
RN  - 5Q7ZVV76EI (Warfarin)
IS  - 0268-4705
IL  - 0268-4705
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2004 Jan
DC  - 20031222
YR  - 2004
ED  - 20040603
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=14688636

<675. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15090701
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ueshima K
AU  - Chiba I
AU  - Saitoh M
AU  - Kobayashi N
AU  - Sato M
AU  - Hayashida K
AU  - Sakai T
AU  - Matsui H
AU  - Hiramori K
FA  - Ueshima, Kenji
FA  - Chiba, Ikuo
FA  - Saitoh, Masahiko
FA  - Kobayashi, Noboru
FA  - Sato, Madoka
FA  - Hayashida, Kensei
FA  - Sakai, Toshiaki
FA  - Matsui, Hiroki
FA  - Hiramori, Katsuhiko
IN  - Ueshima,Kenji. Second Department of Internal Medicine, Iwate Medical University, Iwate, Japan.
TI  - Factors affecting ST depression during cardiopulmonary exercise testing in patients with mitral stenosis without significant coronary lesions.
SO  - Japanese Heart Journal. 45(2):251-5, 2004 Mar.
AS  - Jpn Heart J. 45(2):251-5, 2004 Mar.
NJ  - Japanese heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - kh3, 0401175
SB  - Index Medicus
CP  - Japan
MH  - Anti-Arrhythmia Agents/ad [Administration & Dosage]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Digitalis
MH  - Digitalis Glycosides/ad [Administration & Dosage]
MH  - *Electrocardiography
MH  - *Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Female
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve Stenosis/dt [Drug Therapy]
MH  - *Mitral Valve Stenosis/pp [Physiopathology]
AB  - Symptom-limited cardiopulmonary exercise testing was performed in 37 patients with mitral stenosis (MS) without significant coronary artery stenosis to evaluate factors affecting ST depression in exercise electrocardiograms. The degree of ST depression was not associated with gender or exercise tolerance. The incidence of significant ST depression was higher in the patients receiving than in those not receiving digitalis (P < 0.05). In addition, the patients with atrial fibrillation and a higher heart rate response were more likely to have a high prevalence of significant ST depression than those with sinus rhythm and a lower response (P < 0.05). We concluded that atrial fibrillation, a higher maximum heart rate, and oral digitalis administration were involved in ST depression during exercise testing in patients with mitral stenosis without coronary heart disease.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Digitalis Glycosides)
IS  - 0021-4868
IL  - 0021-4868
PT  - Journal Article
LG  - English
DP  - 2004 Mar
DC  - 20040419
YR  - 2004
ED  - 20040601
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15090701

<676. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15063436
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Bunch TJ
AU  - Chandrasekaran K
AU  - Gersh BJ
AU  - Hammill SC
AU  - Hodge DO
AU  - Khan AH
AU  - Packer DL
AU  - Pellikka PA
FA  - Bunch, T Jared
FA  - Chandrasekaran, Krishnaswamy
FA  - Gersh, Bernard J
FA  - Hammill, Stephen C
FA  - Hodge, David O
FA  - Khan, Akbar H
FA  - Packer, Douglas L
FA  - Pellikka, Patricia A
IN  - Bunch,T Jared. Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
TI  - The prognostic significance of exercise-induced atrial arrhythmias.
SO  - Journal of the American College of Cardiology. 43(7):1236-40, 2004 Apr 7.
AS  - J Am Coll Cardiol. 43(7):1236-40, 2004 Apr 7.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - h50, 8301365
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Flutter/di [Diagnosis]
MH  - Atrial Flutter/ep [Epidemiology]
MH  - *Atrial Flutter/pp [Physiopathology]
MH  - *Exercise/ph [Physiology]
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Minnesota
MH  - Multivariate Analysis
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Survival Analysis
MH  - *Tachycardia, Supraventricular/di [Diagnosis]
MH  - Tachycardia, Supraventricular/ep [Epidemiology]
MH  - *Tachycardia, Supraventricular/pp [Physiopathology]
MH  - Time Factors
AB  - OBJECTIVES: The purpose of the study was to determine if atrial ectopy (AE) or atrial arrhythmias during exercise are predictive of an increased risk of cardiac events and death.
AB  - BACKGROUND: Although stress-induced atrial arrhythmias are common during exercise testing, there is a paucity of data regarding the correlation with underlying heart disease and cardiovascular outcomes. Atrial arrhythmias may reflect underlying left atrial enlargement and diastolic dysfunction, which are prognostic of mortality. We hypothesized that these stress-induced arrhythmias are associated with long-term adverse cardiac events.
AB  - METHODS: Exercise echocardiography was performed in 5,375 patients (age 61 +/- 12 years) with known or suspected coronary artery disease. An abnormal result was defined as exercise-induced atrial fibrillation (AF)/atrial flutter, supraventricular tachycardia (SVT), or AE.
AB  - RESULTS: A total of 311 (5.8%) patients died (132 [2.5%] from cardiac causes) over a period of 3.1 +/- 1.7 years. In addition, 193 (3.6%) patients experienced a myocardial infarction (MI) and 531 (9.9%) patients required revascularization. During exercise testing, 1,272 (24%) patients developed AE, 185 (3.4%) developed SVT, and 43 (0.8%) developed AF. The five-year cardiac death rate was not statistically different between groups (none [3.8%], AE [4.3%], SVT [3.7%], AF [0%], p = 0.43). The five-year rate of MI was significantly different between groups (none [5.7%], AE [8.3%], SVT [0%], AF [9.0%], p = 0.005). The five-year rate of revascularization between groups was not significantly different (none [14.2%], AE [17.0%], SVT [11.8%], AF [14.8%], p = 0.50). A composite of all five-year adverse end points was similar between groups (none [22.7%], AE [27.8%], SVT [17.7%], AF [25.7%], p = 0.10). In stepwise multivariate analysis, AE was not predictive of myocardial infarction when taking into account traditional clinical variables and exercise test results.
AB  - CONCLUSIONS: In this large cohort of patients, the occurrence of AE was predictive of an increased risk of MI. However, the association did not persist after adjustment for clinical and exercise variables known to predict adverse long-term cardiovascular outcomes. The rate of long-term cardiac death or revascularization was not influenced by the development of stress-induced atrial arrhythmias.
IS  - 0735-1097
IL  - 0735-1097
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 2004 Apr 7
DC  - 20040405
YR  - 2004
ED  - 20040525
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15063436

<677. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15078736
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Seshadri N
AU  - Gildea TR
AU  - McCarthy K
AU  - Pothier C
AU  - Kavuru MS
AU  - Lauer MS
FA  - Seshadri, Niranjan
FA  - Gildea, Thomas R
FA  - McCarthy, Kevin
FA  - Pothier, Claire
FA  - Kavuru, Mani S
FA  - Lauer, Michael S
IN  - Seshadri,Niranjan. Department of Cardiology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
TI  - Association of an abnormal exercise heart rate recovery with pulmonary function abnormalities.
CM  - Comment in: Chest. 2004 Apr;125(4):1186-90; PMID: 15078721
SO  - Chest. 125(4):1286-91, 2004 Apr.
AS  - Chest. 125(4):1286-91, 2004 Apr.
NJ  - Chest
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0231335, d1c
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Autonomic Nervous System/pp [Physiopathology]
MH  - Echocardiography
MH  - *Exercise
MH  - Female
MH  - Forced Expiratory Volume
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pulmonary Disease, Chronic Obstructive/dt [Drug Therapy]
MH  - *Pulmonary Disease, Chronic Obstructive/pp [Physiopathology]
MH  - Spirometry
AB  - BACKGROUND: Heart rate recovery (HRR) after exercise correlates with decreased vagal tone and mortality. Patients with COPD may have altered autonomic tone. We sought to determine the association of HRR with spirometry measures of pulmonary function.
AB  - METHODS: We analyzed 627 patients (mean [+/- SD] age, 58 +/- 12 years; 65% men; mean FEV(1), 2.6 +/- 0.9 L, 80 +/- 20% predicted; patients receiving inhaled beta(2) agonist therapy, 10%; patients receiving inhaled anticholinergic therapy, 3%; patients receiving inhaled steroids, 5%; patients receiving oral prednisone, 4%) who had undergone maximal exercise testing and had undergone pulmonary function tests < 1 year apart. Patients with heart failure, pacemakers, and atrial fibrillation were excluded. Abnormal HRR was defined as a fall in heart rate during the first minute after exercise of <or= 12 beats/min (<or= 18 beats/min with stress echocardiography). Patients were divided into quartiles based on FEV(1) percent predicted.
AB  - RESULTS: An abnormal HRR was seen in 229 patients (36%). The mean FEV(1) values broken into quartiles 1 to 4 were 54 +/- 11% predicted, 74 +/- 3% predicted, 87 +/- 4% predicted, and 106 +/- 10% predicted. In smokers and nonsmokers, a worsening FEV(1) percent predicted was associated with an abnormal HRR. In a multivariable model accounting for confounding factors including medications and functional capacity, the predictors of an abnormal HRR included FEV(1) percent predicted (adjusted odds ratio for 1 SD decrease, 1.32; 95% confidence interval, 1.07 to 1.65; p = 0.0004), impaired functional capacity, male gender, and age.
AB  - CONCLUSIONS: Abnormalities found on spirometry are associated with abnormal HRR, which may reflect an altered autonomic tone associated with pulmonary dysfunction, either obstructive or restrictive in nature.
IS  - 0012-3692
IL  - 0012-3692
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
NO  - HL 66004 (United States NHLBI NIH HHS)
LG  - English
DP  - 2004 Apr
DC  - 20040413
YR  - 2004
ED  - 20040517
RD  - 20071114
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15078736

<678. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 15016491
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Roberts CG
AU  - Ladenson PW
FA  - Roberts, Caroline G P
FA  - Ladenson, Paul W
IN  - Roberts,Caroline G P. Division of Endocrinology and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
TI  - Hypothyroidism. [Review] [164 refs]
CM  - Comment in: Lancet. 2004 May 8;363(9420):1558; PMID: 15135622
SO  - Lancet. 363(9411):793-803, 2004 Mar 6.
AS  - Lancet. 363(9411):793-803, 2004 Mar 6.
NJ  - Lancet (London, England)
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 2985213r, l0s, 0053266
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - Case-Control Studies
MH  - Humans
MH  - Hypothyroidism/di [Diagnosis]
MH  - Hypothyroidism/dt [Drug Therapy]
MH  - Hypothyroidism/et [Etiology]
MH  - *Hypothyroidism
MH  - Randomized Controlled Trials as Topic
MH  - Thyroxine/tu [Therapeutic Use]
AB  - Hypothyroidism is common, potentially serious, often clinically overlooked, readily diagnosed by laboratory testing, and eminently treatable. The condition is particularly prevalent in older women, in whom autoimmune thyroiditis is common. Other important causes include congenital thyroid disorders, previous thyroid surgery and irradiation, drugs such as lithium carbonate and amiodarone, and pituitary and hypothalamic disorders. Worldwide, dietary iodine deficiency remains an important cause. Hypothyroidism can present with nonspecific constitutional and neuropsychiatric complaints, or with hypercholesterolaemia, hyponatraemia, hyperprolactinaemia, or hyperhomocysteinaemia. Severe untreated hypothyroidism can lead to heart failure, psychosis, and coma. Although these manifestations are neither specific nor sensitive, the diagnosis is confirmed or excluded by measurements of serum thyrotropin and free thyroxine. Thyroxine replacement therapy is highly effective and safe, but suboptimal dosing is common in clinical practice. Patient noncompliance, drug interactions, and pregnancy can lead to inadequate treatment. Iatrogenic thyrotoxicosis can cause symptoms, and, even when mild, provoke atrial fibrillation and osteoporosis. We summarise present understanding of the history, epidemiology, pathophysiology, and clinical diagnosis and management of hypothyroidism. [References: 164]
RN  - Q51BO43MG4 (Thyroxine)
ES  - 1474-547X
IL  - 0140-6736
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2004 Mar 6
DC  - 20040312
YR  - 2004
ED  - 20040420
RD  - 20150616
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15016491

<679. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 14760327
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ellis K
AU  - Pothier CE
AU  - Blackstone EH
AU  - Lauer MS
FA  - Ellis, Keith
FA  - Pothier, Claire E
FA  - Blackstone, Eugene H
FA  - Lauer, Michael S
IN  - Ellis,Keith. Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
TI  - Is systolic blood pressure recovery after exercise a predictor of mortality?.
SO  - American Heart Journal. 147(2):287-92, 2004 Feb.
AS  - Am Heart J. 147(2):287-92, 2004 Feb.
NJ  - American heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 0370465
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Blood Pressure/ph [Physiology]
MH  - Confounding Factors (Epidemiology)
MH  - *Coronary Disease/mo [Mortality]
MH  - Coronary Disease/pp [Physiopathology]
MH  - Diabetes Mellitus/pp [Physiopathology]
MH  - *Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Risk Factors
AB  - BACKGROUND: An attenuated systolic blood pressure recovery after exercise has been associated with the severity of atherosclerotic heart disease.
AB  - METHODS: For 6 years, we observed 12,379 patients who underwent symptom-limited exercise testing. We excluded patients receiving antihypertensive medication and patients with valvular disease, emphysema, end-stage renal disease, heart failure, left ventricular systolic dysfunction, and atrial fibrillation. Blood pressure recovery ratio was defined as the ratio of systolic blood pressure at 3 minutes into recovery to systolic blood pressure at peak exercise; this has been shown to correlate with angiographic severity of coronary disease.
AB  - RESULTS: The blood pressure recovery ratios ranged from 0.36 to 1.62, with values for increasing quartiles of 0.72 +/- 0.05, 0.82 +/- 0.02, 0.88 +/- 0.02, and 0.99 +/- 0.07. During follow-up, there were 430 deaths (3%). Five-year Kaplan Meier survival rates were 0.975, 0.974, 0.969, and 0.966 in quartiles 1 to 4, respectively. Compared with patients in the lowest quartile of blood pressure recovery ratio, patients in the highest quartile were at somewhat increased risk (hazard ratio, 1.71; 95% CI, 1.31-2.24; P <.001). However, after adjusting for age, sex, body mass index, resting heart rate and blood pressure, peak systolic blood pressure, heart rate recovery, exercise chronotropic response, cardiac history, and standard risk factors, this association was no longer present (adjusted hazard ratio, 1.05; 95% CI, 0.8-1.38; P =.74).
AB  - CONCLUSIONS: In this low-risk population, abnormal systolic blood pressure recovery after exercise was not independently predictive of mortality after correcting for differences in baseline and exercise characteristics.
ES  - 1097-6744
IL  - 0002-8703
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
NO  - HL 66004 (United States NHLBI NIH HHS)
LG  - English
DP  - 2004 Feb
DC  - 20040204
YR  - 2004
ED  - 20040326
RD  - 20071114
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=14760327

<680. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 14618198
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wozakowska-Kaplon B
AU  - Opolski G
FA  - Wozakowska-Kaplon, Beata
FA  - Opolski, Grzegorz
IN  - Wozakowska-Kaplon,Beata. Department of Cardiology, Regional District Hospital, Kielce, Poland.
TI  - Improvement in exercise performance after successful cardioversion in patients with persistent atrial fibrillation and symptoms of heart failure.
SO  - Kardiologia Polska. 59(9):213-23, 2003 Sep.
AS  - Kardiol Pol. 59(9):213-23, 2003 Sep.
NJ  - Kardiologia polska
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - ku4, 0376352
SB  - Index Medicus
CP  - Poland
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/th [Therapy]
MH  - *Electric Countershock
MH  - Exercise Test
MH  - *Exercise Tolerance
MH  - *Heart Failure/pp [Physiopathology]
MH  - Heart Failure/th [Therapy]
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxygen/bl [Blood]
MH  - Treatment Outcome
AB  - BACKGROUND: Loss of atrial systolic function as well as fast and irregular ventricular response result in the impairment of hemodynamic function in patients with atrial fibrillation (AF). AF is considered to be a less efficient cardiac rhythm than sinus rhythm (SR), and accounts for the symptoms of reduced exercise tolerance, such as fatigue, tiredness or dyspnoea. In more severe cases, the hemodynamic alterations can result in heart failure.
AB  - AIM: To assess exercise performance before and one month after cardioversion of persistent AF.
AB  - METHODS: We studied 42 patients with mild to moderate clinically stable heart failure and persistent AF (median duration 7 months) with controlled ventricular rate. They underwent submaximal exercise testing 24 hours before cardioversion and one month after cardioversion. Exercise capacity was determined during symptom-limited exercise testing, according to a modified Bruce protocol with peak VO(2) analysis.
AB  - RESULTS: Thirty-five (83%) patients were successfully cardioverted to SR. One month after cardioversion 29 patients remained in SR (SR group) while 6 had recurrence of AF, and, together with patients with unsuccessful cardioversion, formed the AF group (n=13). Baseline patient characteristics did not differ between the SR and AF groups. Left ventricular ejection fraction (52.7+/-10.2% vs 56.5+/-9.6%, NS) and exercise tolerance (peak VO(2) 19.85+/-3.5 ml/min/kg vs 22.2+/-3,4 ml/kg/min, NS; and exercise duration 9.5+/-3.4 min vs 10.6+/-2.4 min; NS) were similar in both groups before cardioversion. Successful cardioversion resulted in a mean decrease in resting heart rate of 28 beats/minute (94.7+/-10.3 vs 66.7+/-9.7 beats/min, p<0.05), measured 30 days after cardioversion, and a significant improvement in exercise tolerance in the SR group: exercise duration increased from 9.5+/-3.4 min to 13.7+/-3.2 min, p<0.05; and peak oxygen consumption increased from 19.85+/-3.5 ml/min/kg to 32.2+/-3.6 ml/min/kg, p<0.05. No improvement was observed in the AF group.
AB  - CONCLUSIONS: Restoration of sinus rhythm in patients with persistent AF is associated with a significant improvement in exercise capacity one month after cardioversion.
RN  - S88TT14065 (Oxygen)
IS  - 0022-9032
IL  - 0022-9032
PT  - Clinical Trial
PT  - Journal Article
LG  - English
DP  - 2003 Sep
DC  - 20031117
YR  - 2003
ED  - 20040324
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=14618198

<681. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 14607208
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Waagstein F
AU  - Stromblad O
AU  - Andersson B
AU  - Bohm M
AU  - Darius M
AU  - Delius W
AU  - Goss F
AU  - Osterziel KJ
AU  - Sigmund M
AU  - Trenkwalder SP
AU  - Wahlqvist I
FA  - Waagstein, F
FA  - Stromblad, O
FA  - Andersson, B
FA  - Bohm, M
FA  - Darius, M
FA  - Delius, W
FA  - Goss, F
FA  - Osterziel, K J
FA  - Sigmund, M
FA  - Trenkwalder, S-P
FA  - Wahlqvist, I
IN  - Waagstein,F. Wallenberg Laboratory and Department of Cardiology, Sahlgrenska University Hospital, SE-413 45 Goteborg, Sweden. Waagstein@wlab.gu.se
TI  - Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or idiopathic dilated cardiomyopathy.
SO  - European Journal of Heart Failure. 5(5):679-91, 2003 Oct.
AS  - Eur J Heart Fail. 5(5):679-91, 2003 Oct.
NJ  - European journal of heart failure
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - dr4, 100887595
SB  - Index Medicus
CP  - Netherlands
MH  - *Adrenergic beta-Antagonists/tu [Therapeutic Use]
MH  - *Cardiomyopathy, Dilated/dt [Drug Therapy]
MH  - Cardiomyopathy, Dilated/pp [Physiopathology]
MH  - Cardiomyopathy, Dilated/ri [Radionuclide Imaging]
MH  - Double-Blind Method
MH  - Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Female
MH  - Gated Blood-Pool Imaging
MH  - Heart/ri [Radionuclide Imaging]
MH  - Humans
MH  - Male
MH  - *Metoprolol/tu [Therapeutic Use]
MH  - Middle Aged
MH  - Mitral Valve Insufficiency/pc [Prevention & Control]
MH  - *Myocardial Ischemia/dt [Drug Therapy]
MH  - Myocardial Ischemia/pp [Physiopathology]
MH  - *Stroke Volume/ph [Physiology]
MH  - Time Factors
MH  - *Ventricular Remodeling/de [Drug Effects]
AB  - BACKGROUND: the effects of long-term administration of beta-blockers on left ventricular (LV) function during exercise in patients with ischemic heart disease (IHD) and idiopathic dilated cardiomyopathy (DCM) are controversial.
AB  - PATIENTS AND METHODS: patients with stable congestive heart failure (CHF) (New York heart association [NYHA] class II and III) and ejection fraction (EF) < or =0.40 were randomized to metoprolol, 50 mg t.i.d. or placebo for 6 months. Patients were divided into two groups: ischemic heart disease (IHD) and idiopathic dilated cardiomyopathy (DCM). The mean EF was 0.29 in both groups and 92% were taking angiotensin-converting enzyme (ACE) inhibitors. In the IHD group, 84% had suffered a myocardial infarction (MI) and 64% had undergone revascularization at least 6 months before the study. LV volumes were measured by equilibrium radionuclide angiography. Mitral regurgitation was assessed by Doppler echocardiography. All values are changes for metoprolol subtracted by changes for placebo.
AB  - RESULTS: metoprolol improved LV function markedly both at rest and during sub-maximal exercise in both groups. The mean increase in EF was 0.069 at rest (P<0.001) and 0.078 during submaximal exercise (P<0.001). LV end-diastolic volume decreased by 22 ml at rest (P=0.006) and by 15 ml during exercise (P=0.006). LV end-systolic volume decreased by 23 ml both at rest (P=0.001) and during exercise (P=0.004). Exercise time increased by 39 s (P=0.08). In the metoprolol group, mitral regurgitation decreased (P=0.0026) and only one patient developed atrial fibrillation vs. eight in the placebo group (P=0.01).
AB  - CONCLUSION: metoprolol improves EF both at rest and during submaximal exercise and prevents LV dilatation in mild to moderate CHF due to IHD or DCM.
RN  - 0 (Adrenergic beta-Antagonists)
RN  - GEB06NHM23 (Metoprolol)
IS  - 1388-9842
IL  - 1388-9842
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2003 Oct
DC  - 20031110
YR  - 2003
ED  - 20040312
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=14607208

<682. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 14516287
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Yigit Z
AU  - Akdur H
AU  - Ersanli M
AU  - Okcun B
AU  - Guven O
FA  - Yigit, Zerrin
FA  - Akdur, Hulya
FA  - Ersanli, Murat
FA  - Okcun, Baris
FA  - Guven, Ozen
IN  - Yigit,Zerrin. Cardiology Department, Cardiology Institute, Istanbul University, Istanbul, Turkey.
TI  - The effect of exercise to P wave dispersion and its evaluation as a predictor of atrial fibrillation.
SO  - Annals of Noninvasive Electrocardiology. 8(4):308-12, 2003 Oct.
AS  - Ann Noninvasive Electrocardiol. 8(4):308-12, 2003 Oct.
NJ  - Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - dzb, 9607443
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Echocardiography, Transesophageal/mt [Methods]
MH  - *Electrocardiography
MH  - Electrophysiology
MH  - *Exercise Test/ae [Adverse Effects]
MH  - Female
MH  - Follow-Up Studies
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Probability
MH  - Reference Values
MH  - Risk Assessment
MH  - Time Factors
AB  - AIM: Prolongation of P wave time and increase of its dispersion as an independent predictor of atrial fibrillation. In patients with paroxysmal atrial fibrillation (PAF) as in healthy people, exercise augments sympathetic activity and therefore can cause the development of atrial fibrillation. The aim of this study is to evaluate the effect of exercise on P wave dispersion and to predict the development of atrial fibrillation.
AB  - METHODS: One hundred and ninety-eight patients (93 women, 105 men, mean age: 59.05 +/- 11.01 years) having the diagnosis of PAF were included in the study. The left atrial diameter of all these patients was more than 4.0 cm. One hundred and fifty-five patients (72 females, 83 males, mean age: 58.41 +/- 10.79 years), with left atrial diameter more than 4.0 cm and without PAF were taken as control group. Symptom limited exercise test with modified Bruce protocol was performed on all patients. Rest, maximum exercise and recovery, and first, third, and fifth-minute 12-derivation ECG was taken in all patients. The velocity of ECG was adjusted to 50 mm/s; shortest and largest P wave durations were measured and P wave dispersion was calculated.
AB  - RESULTS: The mean left atrial diameter was 4.41 +/- 0.58 cm in PAF patients and 4.38 +/- 0.48 cm in control group. No differences were found between PAF patients with the controls in exercise time (10.38 +/- 2.93 vs 10.81 +/- 2.75 minutes); METs (6.98 +/- 1.72 vs 7.28 +/- 1.75 minutes); resting heart rate (79.13 +/- 14.86 vs 79.69 +/- 10.43 bpm); peak heart rate (146.83 +/- 23.21 vs 146.94 +/- 16.13 bpm). Maximum exercise P wave duration and P wave dispersion were greater than the rest measurements in PAF group (respectively P < 0.0001 and P = 0.0004).
AB  - CONCLUSION: In PAF patients, P wave dispersion is significantly longer at rest, maximum exercise and recovery time than in a control group without PAF.
IS  - 1082-720X
IL  - 1082-720X
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2003 Oct
DC  - 20030930
YR  - 2003
ED  - 20040227
RD  - 20080310
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=14516287

<683. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 12796561
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Hart RG
AU  - Pearce LA
AU  - Stroke Prevention in Atrial Fibrillation Investigators
FA  - Hart, Robert G
FA  - Pearce, Lesly A
FA  - Stroke Prevention in Atrial Fibrillation Investigators
TI  - Serum potassium level and dietary potassium intake as risk factors for stroke.
CM  - Comment on: Neurology. 2002 Aug 13;59(3):314-20; PMID: 12177362
SO  - Neurology. 60(11):1869-70; author reply 1870, 2003 Jun 10.
AS  - Neurology. 60(11):1869-70; author reply 1870, 2003 Jun 10.
NJ  - Neurology
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 0401060, nz0
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - Diuretics/tu [Therapeutic Use]
MH  - Female
MH  - Humans
MH  - Male
MH  - *Potassium/bl [Blood]
MH  - Potassium, Dietary/tu [Therapeutic Use]
MH  - Risk Factors
MH  - *Stroke/ep [Epidemiology]
RN  - 0 (Diuretics)
RN  - 0 (Potassium, Dietary)
RN  - RWP5GA015D (Potassium)
ES  - 1526-632X
IL  - 0028-3878
PT  - Clinical Trial
PT  - Comment
PT  - Letter
LG  - English
DP  - 2003 Jun 10
DC  - 20030610
YR  - 2003
ED  - 20040224
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=12796561

<684. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 14933403
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - WETHERBEE DG
AU  - BROWN MG
AU  - HOLZMAN D
FA  - WETHERBEE, D G
FA  - BROWN, M G
FA  - HOLZMAN, D
TI  - Ventricular rate response following exercise during auricular fibrillation and after conversion to normal sinus rhythm.
SO  - American Journal of the Medical Sciences. 223(6):667-70, 1952 Jun.
AS  - Am J Med Sci. 223(6):667-70, 1952 Jun.
NJ  - The American journal of the medical sciences
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3l2, 0370506
OI  - Source: CLML. 5222:19532:49:166
SB  - OLDMEDLINE Citations
CP  - Not Available
MH  - *Atrial Fibrillation
MH  - *Exercise
MH  - *Heart Ventricles
MH  - Humans
KW  - *AURICULAR FIBRILLATION;  *EXERCISE/effects
IS  - 0002-9629
IL  - 0002-9629
PT  - Journal Article
LG  - English
DP  - 1952 Jun
DC  - 19521201
YR  - 1952
ED  - 20040215
RD  - 20051116
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=14933403

<685. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 14740967
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Abdel Latif A
AU  - Messinger-Rapport BJ
FA  - Abdel Latif, Ahmed
FA  - Messinger-Rapport, Barbara J
IN  - Abdel Latif,Ahmed. Department of General Internal Medicine, The Cleveland Clinic Foundation, OH 44195, USA.
TI  - Should nursing home residents with atrial fibrillation be anticoagulated?.
SO  - Cleveland Clinic Journal of Medicine. 71(1):40-4, 2004 Jan.
AS  - Cleve Clin J Med. 71(1):40-4, 2004 Jan.
NJ  - Cleveland Clinic journal of medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - dbn, 8703441
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/ae [Adverse Effects]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Female
MH  - Homes for the Aged/st [Standards]
MH  - *Homes for the Aged
MH  - Humans
MH  - Male
MH  - Nursing Homes/st [Standards]
MH  - *Nursing Homes
MH  - Practice Guidelines as Topic/st [Standards]
MH  - Risk Factors
MH  - Sex Factors
MH  - Stroke/pc [Prevention & Control]
AB  - Most long-term care residents with atrial fibrillation would be at high risk for embolic stroke based on age and comorbidities according to the criteria presented here. Additionally, they are theoretically excellent candidates for adjusted-dose warfarin treatment for atrial fibrillation. They are accessible for monitoring and tend to have less dietary variability, a controlled medication list, and supervised medication administration. Balancing these features is at least a moderate risk of severe bleeding from anticoagulation based on age, comorbidities, and polypharmacy. However, studies suggest that even those long-term care residents identified as ideal candidates for anticoagulation may not receive warfarin. Those residents who do receive warfarin may not be anticoagulated within the therapeutic range much of the time. This treatment pattern may expose older adults with a high stroke risk to dying from a cardioembolic stroke or to acquiring functional deficits that make them more dependent and lower their quality of life.
RN  - 0 (Anticoagulants)
IS  - 0891-1150
IL  - 0891-1150
PT  - Journal Article
LG  - English
DP  - 2004 Jan
DC  - 20040126
YR  - 2004
ED  - 20040211
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=14740967

<686. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 12955800
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Celentano A
AU  - Palmieri V
AU  - Zulati P
AU  - Di Minno G
FA  - Celentano, A
FA  - Palmieri, V
FA  - Zulati, P
FA  - Di Minno, G
TI  - Isolated episodes of atrial fibrillation and acupuncture.
SO  - Nutrition Metabolism & Cardiovascular Diseases. 13(3):183-4, 2003 Jun.
AS  - Nutr Metab Cardiovasc Dis. 13(3):183-4, 2003 Jun.
NJ  - Nutrition, metabolism, and cardiovascular diseases : NMCD
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9111474, DGW
SB  - Index Medicus
CP  - Italy
MH  - *Acupuncture Therapy
MH  - Angiotensin-Converting Enzyme Inhibitors/tu [Therapeutic Use]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Recurrence
MH  - Treatment Outcome
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
IS  - 0939-4753
IL  - 0939-4753
PT  - Case Reports
PT  - Letter
LG  - English
DP  - 2003 Jun
DC  - 20030905
YR  - 2003
ED  - 20040128
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=12955800

<687. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 14684774
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mackinnon AD
AU  - Aaslid R
AU  - Markus HS
FA  - Mackinnon, Andrew D
FA  - Aaslid, Rune
FA  - Markus, Hugh S
IN  - Mackinnon,Andrew D. Department of Clinical Neurosciences, St. George's Hospital Medical School, Cranmer Terr, Tooting, London SW17 0RE, UK.
TI  - Long-term ambulatory monitoring for cerebral emboli using transcranial Doppler ultrasound.
SO  - Stroke. 35(1):73-8, 2004 Jan.
AS  - Stroke. 35(1):73-8, 2004 Jan.
NJ  - Stroke; a journal of cerebral circulation
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - v2j, 0235266
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Fibrillation/co [Complications]
MH  - Carotid Stenosis/co [Complications]
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Intracranial Embolism/co [Complications]
MH  - *Intracranial Embolism/us [Ultrasonography]
MH  - Male
MH  - Middle Aged
MH  - Middle Cerebral Artery/us [Ultrasonography]
MH  - *Monitoring, Ambulatory/is [Instrumentation]
MH  - *Monitoring, Ambulatory/mt [Methods]
MH  - Predictive Value of Tests
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - Time
MH  - *Ultrasonography, Doppler, Transcranial/is [Instrumentation]
MH  - *Ultrasonography, Doppler, Transcranial/mt [Methods]
AB  - BACKGROUND AND PURPOSE: Transcranial Doppler (TCD) monitoring for asymptomatic cerebral emboli is currently limited to short recordings by equipment size, restricting its clinical usefulness. We have developed a first ambulatory TCD system, evaluated it in at-risk patient groups, and used it to study the pattern of embolization in patients with symptomatic carotid stenosis.
AB  - METHODS: The system comprises an 18x11.5x3.2 cm battery-powered Doppler unit (425 g) and a 13-mm servo-controlled 2 MHz transducer probe. The quadrature raw Doppler signal is stored on flash-disk. An autosearch algorithm restores vessel insonation should signal quality fall. Initial evaluation was in 20 ambulatory stroke patients. Subsequently, 12 recently symptomatic carotid patients had recordings for > or =5 hours.
AB  - RESULTS: Recordings were well tolerated and a median of 96% of Doppler signal was suitable for analysis. Embolic signals were detected in 11 of the 12 symptomatic carotid patients. There was marked temporal variability in embolization and prolonging the recording increased the yield of embolic signal positive patients from 58% at 30 minutes to 92% at 150 minutes. In 3 subjects with frequent embolic signals, significant temporal clustering of embolic signals was observed.
AB  - CONCLUSIONS: We have developed the first ambulatory TCD system. Good-quality recordings of > or =5 hours can be obtained. In view of the demonstrated temporal variability in embolization, this technique is likely to improve the predictive value of recording for asymptomatic embolic signals and may be particularly useful in patients in whom embolic signals are relatively infrequent, such as those with asymptomatic carotid stenosis and atrial fibrillation.
ES  - 1524-4628
IL  - 0039-2499
PT  - Evaluation Studies
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20031218
DP  - 2004 Jan
DC  - 20031230
YR  - 2004
ED  - 20040126
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=14684774

<688. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 14697466
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Tsang TS
AU  - Barnes ME
AU  - Gersh BJ
AU  - Bailey KR
AU  - Seward JB
FA  - Tsang, Teresa S M
FA  - Barnes, Marion E
FA  - Gersh, Bernard J
FA  - Bailey, Kent R
FA  - Seward, James B
IN  - Tsang,Teresa S M. Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA. tsang.teresa@mayo.edu
TI  - Risks for atrial fibrillation and congestive heart failure in patients >/=65 years of age with abnormal left ventricular diastolic relaxation.
SO  - American Journal of Cardiology. 93(1):54-8, 2004 Jan 1.
AS  - Am J Cardiol. 93(1):54-8, 2004 Jan 1.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Age Factors
MH  - Aged
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/mo [Mortality]
MH  - Atrial Fibrillation/us [Ultrasonography]
MH  - Cohort Studies
MH  - Diastole
MH  - Disease-Free Survival
MH  - Echocardiography
MH  - Female
MH  - *Heart Failure/ep [Epidemiology]
MH  - Heart Failure/et [Etiology]
MH  - Heart Failure/mo [Mortality]
MH  - Heart Failure/us [Ultrasonography]
MH  - Humans
MH  - Male
MH  - Medical Records
MH  - Minnesota/ep [Epidemiology]
MH  - Retrospective Studies
MH  - Risk Factors
MH  - *Ventricular Dysfunction, Left
AB  - We sought to determine the risk for the first episodes of atrial fibrillation (AF) and congestive heart failure (CHF) in a cohort of patients aged >/=65 years who had abnormal left ventricular (LV) diastolic relaxation. Records were reviewed for all residents of Olmsted County, Minnesota, who had >/=1 transthoracic echocardiogram performed at the Mayo Clinic between 1990 and 1998, and who were in sinus rhythm and did not have a history of AF, CHF, valvular or congenital heart disease, permanent pacemaker, or stroke. Of 994 patients who qualified and had LV diastolic function assessment, abnormal LV relaxation was identified in 569 (57%), 105 of whom (18%) developed a first episode of AF or CHF over a mean follow-up of 4.0 +/- 2.7 years. Age (p <0.0001), history of myocardial infarction (p <0.0001), history of diabetes mellitus (p = 0.041), electrocardiographic LV hypertrophy (p = 0.0223), and indexed left atrial (LA) volume (p = 0.0003) were independent predictors. A stepwise increase in age-adjusted risk was evident when stratified by tertiles of indexed LA volume (<27 ml/m(2); 27 to 37 ml/m(2); >37 ml/m(2)). Compared with patients with normal LV diastolic function (n = 148, 15%), the risks for first episodes of AF or CHF were not different in those with abnormal diastolic relaxation if LA volume was <27 ml/m(2) (p = 0.303). In conclusion, these data suggest the presence of a wide spectrum of risks for AF or CHF in the elderly who have abnormal LV diastolic relaxation, with the highest risks evident in those with the largest left atria. When LA volume was <27 ml/m(2), however, the risks for these events were not different from those with normal LV diastolic function.
IS  - 0002-9149
IL  - 0002-9149
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2004 Jan 1
DC  - 20031230
YR  - 2004
ED  - 20040126
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=14697466

<689. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 14676246
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Yuda S
AU  - Nakatani S
AU  - Kosakai Y
AU  - Satoh T
AU  - Goto Y
AU  - Yamagishi M
AU  - Bando K
AU  - Kitamura S
AU  - Miyatake K
FA  - Yuda, S
FA  - Nakatani, S
FA  - Kosakai, Y
FA  - Satoh, T
FA  - Goto, Y
FA  - Yamagishi, M
FA  - Bando, K
FA  - Kitamura, S
FA  - Miyatake, K
IN  - Yuda,S. Division of Cardiology, National Cardiovascular Centre, Osaka, Japan.
TI  - Mechanism of improvement in exercise capacity after the maze procedure combined with mitral valve surgery.
SO  - Heart. 90(1):64-9, 2004 Jan.
AS  - Heart. 90(1):64-9, 2004 Jan.
NJ  - Heart (British Cardiac Society)
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 9602087
OI  - Source: NLM. PMC1768003
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - Adult
MH  - Aged
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/su [Surgery]
MH  - Atrial Function
MH  - Echocardiography, Doppler
MH  - Electrocardiography
MH  - Exercise Test
MH  - *Exercise Tolerance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve Insufficiency/pp [Physiopathology]
MH  - *Mitral Valve Insufficiency/su [Surgery]
MH  - Mitral Valve Stenosis/pp [Physiopathology]
MH  - *Mitral Valve Stenosis/su [Surgery]
MH  - Oxygen Consumption
MH  - Postoperative Care
MH  - Retrospective Studies
MH  - Treatment Outcome
AB  - OBJECTIVE: To clarify the mechanism of improvement in exercise capacity after the maze procedure.
AB  - DESIGN: Retrospective study.
AB  - SETTING: Tertiary referral centre.
AB  - PATIENTS: 26 patients (mean (SD) age 57 (9) years) with atrial fibrillation (AF) and mitral valve disease were studied with echocardiography and cardiopulmonary exercise testing before and after the maze procedure combined with mitral valve surgery. Of these, eight had persistent AF and 18 had restored sinus rhythm (SR) by the surgery. Six patients (mean (SD) age 59 (12) years) with AF undergoing mitral valve surgery without the maze procedure who had cardiopulmonary exercise testing before and after the surgery formed the control group.
AB  - MAIN OUTCOME MEASURES: Echocardiographic parameters of atrial function were measured from transmitral flow recordings. Peak oxygen uptake (VO2) and the slope of the relation between VO2 and workload (ratio of DeltaVO2 to Delta work) were determined as indices of exercise capacity.
AB  - RESULTS: The degree of improvements in peak VO2 and the ratio of DeltaVO2 to Delta work after the mitral valve surgery was comparable between the maze and control group. It was also comparable between patients with and those without successfully restored SR after the maze procedure. The degree of the increase in peak VO2 correlated with the change in left atrial diameter (r = -0.40, p = 0.047) but atrial contraction did not correlate with the increase.
AB  - CONCLUSIONS: Improvement in exercise capacity may not be caused by restored SR and atrial contraction but may at least partly relate to the reduction of left atrial size and improvement of haemodynamic variables by the surgery.
ES  - 1468-201X
IL  - 1355-6037
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2004 Jan
DC  - 20031216
YR  - 2004
ED  - 20040120
RD  - 20140610
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=14676246

<690. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 14530617
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Stollberger C
AU  - Finsterer J
FA  - Stollberger, Claudia
FA  - Finsterer, Josef
IN  - Stollberger,Claudia. 2nd Medical Department, Krankenanstalt Rudolfstiftung, Vienna, Austria. claudia.stoellberger@chello.at
TI  - Primary and secondary stroke prevention in nonrheumatic atrial fibrillation by oral anticoagulation. [Review] [86 refs]
SO  - European Neurology. 50(3):127-35, 2003.
AS  - Eur Neurol. 50(3):127-35, 2003.
NJ  - European neurology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - enf, 0150760
SB  - Index Medicus
CP  - Switzerland
MH  - Administration, Oral
MH  - Age Factors
MH  - Anticoagulants/ae [Adverse Effects]
MH  - Anticoagulants/ct [Contraindications]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/co [Complications]
MH  - Diabetes Complications
MH  - Drug Administration Schedule
MH  - Drug Interactions
MH  - Embolism/et [Etiology]
MH  - Embolism/pc [Prevention & Control]
MH  - Heart Failure/co [Complications]
MH  - Hemorrhage/et [Etiology]
MH  - Humans
MH  - Hypertension/co [Complications]
MH  - Primary Prevention/mt [Methods]
MH  - *Primary Prevention
MH  - Risk Factors
MH  - *Stroke/et [Etiology]
MH  - *Stroke/pc [Prevention & Control]
AB  - The risk of stroke or embolism in atrial fibrillation (AF) patients can be reduced by 68% by oral anticoagulation (OAC). This review is aimed to (1) summarize indications for OAC in patients with AF, (2) give an overview of the current knowledge of risk factors for bleeding complications of OAC and (3) give practical recommendations for an optimal OAC therapy in the neurological setting. Indications for OAC are increased age (>75 years), arterial hypertension, diabetes mellitus, previous thromboembolism, heart failure and, probably, coronary heart disease. Risk factors for bleeding complications are overanticoagulation with international normalized ratios (INRs) >3.0, increased age, arterial hypertension, diabetes mellitus, previous thromboembolism, polypharmacy, the early phase of OAC therapy and a lack of patients' education. Before initiation of OAC, the patient should be screened for potential bleeding sites. Careful monitoring of OAC comprises fixed appointments for the INR value determination, tracking for the patient, if he does not attend, advices about pain therapy, information about the influence of diet on the INR value and drug interaction, unscheduled INR determination in case of acute disorders and regular assessment if OAC is still indicated. Monitoring of OAC needs an effort, which has to be adequately estimated by the health care system.Copyright 2003 S. Karger AG, Basel [References: 86]
RN  - 0 (Anticoagulants)
IS  - 0014-3022
IL  - 0014-3022
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2003
DC  - 20031007
YR  - 2003
ED  - 20031121
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=14530617

<691. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 12534847
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Messinger-Rapport B
AU  - Pothier Snader CE
AU  - Blackstone EH
AU  - Yu D
AU  - Lauer MS
FA  - Messinger-Rapport, Barbara
FA  - Pothier Snader, Claire E
FA  - Blackstone, Eugene H
FA  - Yu, David
FA  - Lauer, Michael S
IN  - Messinger-Rapport,Barbara. Section of Geriatric Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
TI  - Value of exercise capacity and heart rate recovery in older people.
SO  - Journal of the American Geriatrics Society. 51(1):63-8, 2003 Jan.
AS  - J Am Geriatr Soc. 51(1):63-8, 2003 Jan.
NJ  - Journal of the American Geriatrics Society
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 7503062, h6v
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - Cause of Death
MH  - *Coronary Disease/di [Diagnosis]
MH  - Coronary Disease/pp [Physiopathology]
MH  - Electrocardiography
MH  - *Exercise Test
MH  - *Exercise Tolerance
MH  - Female
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - *Mortality
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Survival Analysis
AB  - OBJECTIVES: To evaluate the prognostic value in older adults of two predictors of mortality: impaired functional capacity and an attenuated heart rate recovery.
AB  - SETTING: Academic medical center.
AB  - DESIGN: Prospective study with mean 3.7 years follow-up.
AB  - PARTICIPANTS: Seven thousand three hundred fifty-four adults aged 65 and older consecutively referred for exercise testing between 1990 and 1999. Patients with heart failure, valvular disease, atrial fibrillation, and pacemakers were excluded.
AB  - MEASUREMENTS: The primary endpoint was all-cause mortality. Impaired functional capacity was defined as the peak exercise workload in the lowest quintile of metabolic equivalents achieved according to prespecified strata of age and sex. Heart rate recovery was defined as the fall in heart rate during the first minute after exercise and was abnormal if 12 or fewer beats per minute, except for patients undergoing stress echocardiography, in which case 18 or fewer beats per minute was abnormal.
AB  - RESULTS: There were 842 deaths. Patients with impaired functional capacity were at increased risk for death (23% vs 9%, hazard ratio (HR) = 2.7, 95% confidence interval (CI) = 2.2-3.1, P <.0001) as were patients with an abnormal heart rate recovery (17% vs 9%, HR = 2.0, 95% CI = 1.8-2.3, P <.0001). After adjusting for age, sex, coronary history, and other confounders, impaired functional capacity (adjusted HR = 2.1, 95% CI = 1.8-2.4) and an abnormal heart rate recovery (adjusted HR = 1.5, 95% CI = 1.3-1.7) independently predicted death. No interactions between these two variables with age were noted.
AB  - CONCLUSIONS: In older patients, impaired functional capacity and heart rate recovery were independent predictors of death.
IS  - 0002-8614
IL  - 0002-8614
PT  - Evaluation Studies
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
NO  - HL 66004-01 (United States NHLBI NIH HHS)
LG  - English
DP  - 2003 Jan
DC  - 20030121
YR  - 2003
ED  - 20031023
RD  - 20080310
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=12534847

<692. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 12916553
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kirshner HS
FA  - Kirshner, Howard S
IN  - Kirshner,Howard S. Department of Neurology, Vanderbilt University School of Medicine, Nashville, TN 37212, USA. Howard.Kirshner@mcmail.vanderbilt.edu
TI  - Medical prevention of stroke, 2003. [Review] [50 refs]
SO  - Southern Medical Journal. 96(4):354-8, 2003 Apr.
AS  - South Med J. 96(4):354-8, 2003 Apr.
NJ  - Southern medical journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - uvh, 0404522
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Anti-Inflammatory Agents, Non-Steroidal/tu [Therapeutic Use]
MH  - *Antihypertensive Agents/tu [Therapeutic Use]
MH  - *Aspirin/tu [Therapeutic Use]
MH  - *Diet
MH  - Female
MH  - Humans
MH  - Hypercholesterolemia/co [Complications]
MH  - Hypercholesterolemia/dt [Drug Therapy]
MH  - *Hypercholesterolemia
MH  - Hypertension/co [Complications]
MH  - Hypertension/dt [Drug Therapy]
MH  - *Hypertension
MH  - *Hypolipidemic Agents/tu [Therapeutic Use]
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Stroke/ep [Epidemiology]
MH  - *Stroke/pc [Prevention & Control]
AB  - Stroke is a preventable tragedy for nearly 750,000 people each year. Primary stroke prevention measures applicable to the general public include a healthy diet containing fruits, vegetables, fish, and low fat; exercise; smoking cessation; limiting alcohol to moderate use; and perhaps avoidance of stress. Screening for hypertension, cholesterol, heart disease, and carotid artery stenosiscan lead to even more effective stroke prevention in high-risk patients. Specific antihypertensive drugs such as angiotensin-converting enzyme inhibitors and angiotensin-converting enzyme receptor blockers may be especially protective against stroke. Secondary stroke prevention in patients who have already had a stroke or transient ischemic attack is even more effective in preventing more serious strokes. Measures include antihypertensive and cholesterol-lowering agents, carotid endarterectomy, anticoagulation for atrial fibrillation and other cardiac sources of embolic stroke, and antiplatelet therapy. Stroke prevention depends on the application of these well-known and widely available treatments to a large number of patients. [References: 50]
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Hypolipidemic Agents)
RN  - R16CO5Y76E (Aspirin)
IS  - 0038-4348
IL  - 0038-4348
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2003 Apr
DC  - 20030814
YR  - 2003
ED  - 20030826
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=12916553

<693. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 12829872
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kurl S
AU  - Laukkanen JA
AU  - Tuomainen TP
AU  - Rauramaa R
AU  - Lakka TA
AU  - Salonen R
AU  - Eranen J
AU  - Sivenius J
AU  - Salonen JT
FA  - Kurl, S
FA  - Laukkanen, J A
FA  - Tuomainen, T-P
FA  - Rauramaa, R
FA  - Lakka, T A
FA  - Salonen, R
FA  - Eranen, J
FA  - Sivenius, J
FA  - Salonen, J T
IN  - Kurl,S. Research Institute of Public Health, Kuopio, Finland.
TI  - Association of exercise-induced, silent ST-segment depression with the risk of stroke and cardiovascular diseases in men.
SO  - Stroke. 34(7):1760-5, 2003 Jul.
AS  - Stroke. 34(7):1760-5, 2003 Jul.
NJ  - Stroke; a journal of cerebral circulation
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - v2j, 0235266
SB  - Index Medicus
CP  - United States
MH  - *Cardiovascular Diseases/di [Diagnosis]
MH  - *Cardiovascular Diseases/ep [Epidemiology]
MH  - Cardiovascular Diseases/pp [Physiopathology]
MH  - Comorbidity
MH  - *Electrocardiography
MH  - Exercise Test
MH  - *Exercise Tolerance
MH  - Follow-Up Studies
MH  - Humans
MH  - Hypercholesterolemia/ep [Epidemiology]
MH  - Hypertension/ep [Epidemiology]
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/di [Diagnosis]
MH  - Myocardial Ischemia/ep [Epidemiology]
MH  - Myocardial Ischemia/pp [Physiopathology]
MH  - Obesity/ep [Epidemiology]
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Smoking/ep [Epidemiology]
MH  - *Stroke/ep [Epidemiology]
MH  - Stroke/pp [Physiopathology]
AB  - BACKGROUND AND PURPOSE: There are few if any data on the prognostic importance of silent myocardial ischemia during exercise with regard to the risk of stroke and cardiovascular diseases (CVDs) among asymptomatic men. In this prospective study, we investigated the relation of silent myocardial ischemia and the risk of stroke and CVD death in men with and without conventional risk factors.
AB  - METHODS: The study sample included 1726 middle-aged men with no history of stroke, coronary heart disease, or atrial fibrillation at baseline. Silent myocardial ischemia was defined as a horizontal or downsloping ST-segment depression (>or=1 mm) during exercise electrocardiography. A total of 86 CVD-related deaths and 78 strokes occurred during an average follow-up of 10 years.
AB  - RESULTS: Men with silent ischemia during exercise had a 3.5-fold increased risk of CVD death and a 2.2-fold increased risk of stroke compared with men without silent ischemia, after adjusting for conventional risk factors. Silent ischemia during exercise was associated with a 3.8-fold (95% confidence interval [CI], 1.5 to 9.5) increased risk for CVD in smokers, a 3.9-fold (95% CI, 2.1 to 7.3) increased risk in hypercholesterolemic subjects, a 3.6-fold (95% CI, 1.9 to 6.8) increased risk in the hypertensives, and 3.8-fold (95% CI, 2.0 to 7.1) increased risk in overweight men. The respective relative risks for stroke were 3.8 (95% CI, 1.1 to 12.5), 3.5 (95% CI, 1.7 to 7.4), 3.4 (95% CI, 1.6 to 7.1), and 2.9 (95% CI, 1.4 to 6.1).
AB  - CONCLUSIONS: Exercise-induced silent myocardial ischemia is an important indicator of increased risk of stroke and CVD in men with other risk factors, such as smoking, hypercholesterolemia, hypertension, and being overweight.
ES  - 1524-4628
IL  - 0039-2499
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
NO  - HL 44199 (United States NHLBI NIH HHS)
LG  - English
EP  - 20030626
DP  - 2003 Jul
DC  - 20030704
YR  - 2003
ED  - 20030801
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=12829872

<694. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 12835154
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Anonymous
TI  - Ask the doctor. I am 75 and have had atrial fibrillation for a while. I take digoxin, lisinopril, Coumadin, and Lipitor. My medications seem to work, but I'm still concerned about the big difference between my systolic and diastolic blood pressure readings. The systolic is usually between 130 and 150 and the diastolic is between 55 and 70. Should I worry about this?.
SO  - Harvard Heart Letter. 13(10):8, 2003 Jun.
AS  - Harv Heart Lett. 13(10):8, 2003 Jun.
NJ  - Harvard heart letter : from Harvard Medical School
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9425723, c2z
SB  - Consumer Health Journals
CP  - United States
MH  - Aged
MH  - *Blood Pressure/ph [Physiology]
MH  - Cardiovascular Diseases/et [Etiology]
MH  - *Cardiovascular Diseases/pc [Prevention & Control]
MH  - Diastole/ph [Physiology]
MH  - *Exercise
MH  - Humans
MH  - Risk Factors
MH  - Systole/ph [Physiology]
IS  - 1051-5313
IL  - 1051-5313
PT  - Journal Article
LG  - English
DP  - 2003 Jun
DC  - 20030701
YR  - 2003
ED  - 20030708
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=12835154

<695. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 12659605
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - MacWalter RS
AU  - Fraser HW
AU  - Armstrong KM
FA  - MacWalter, Ronald S
FA  - Fraser, Hazel W
FA  - Armstrong, Katherine M
IN  - MacWalter,Ronald S. Stroke Studies Centre, Ninewells Hospital and Medical School, Dundee, Scotland. ronald.macwalter@tuht.scot.nhs.uk
TI  - Orlistat enhances warfarin effect.
SO  - Annals of Pharmacotherapy. 37(4):510-2, 2003 Apr.
AS  - Ann Pharmacother. 37(4):510-2, 2003 Apr.
NJ  - The Annals of pharmacotherapy
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - bbx, 9203131
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Anti-Obesity Agents/ad [Administration & Dosage]
MH  - Anti-Obesity Agents/ae [Adverse Effects]
MH  - Anti-Obesity Agents/pd [Pharmacology]
MH  - Anticoagulants/ad [Administration & Dosage]
MH  - Anticoagulants/ae [Adverse Effects]
MH  - Anticoagulants/pd [Pharmacology]
MH  - Drug Interactions
MH  - Humans
MH  - International Normalized Ratio
MH  - *Lactones/ad [Administration & Dosage]
MH  - Lactones/ae [Adverse Effects]
MH  - *Lactones/pd [Pharmacology]
MH  - Male
MH  - Time Factors
MH  - Vitamin K/me [Metabolism]
MH  - *Warfarin/ad [Administration & Dosage]
MH  - Warfarin/ae [Adverse Effects]
MH  - *Warfarin/pd [Pharmacology]
AB  - OBJECTIVE: To report a case of increased international normalized ratio (INR) associated with the addition of orlistat to the drug regimen of a patient receiving warfarin therapy.
AB  - CASE SUMMARY: A 66-year-old white man with a history of chronic atrial fibrillation (treated with a stable dose of warfarin), hypertension, and diet-controlled type 2 diabetes mellitus was started on orlistat for weight reduction. An increased INR was reported after the introduction of orlistat; there had been no other recent changes to medication or medical conditions. Warfarin was withheld and the dose reduced to allow INR control to be reestablished. According to the Naranjo probability scale, this reaction was probable.
AB  - DISCUSSION: Control of the INR within therapeutic limits is always a challenge. Dietary intake of vitamin K, intercurrent illness, concomitant medication, herbal remedies, and other factors can interfere with warfarin dosing. Orlistat use may be associated with patient alteration of diet to compensate for adverse effects or other mechanisms by which orlistat alters warfarin control, including direct effect on absorption of vitamin K.
AB  - CONCLUSIONS: The introduction of chronic dosing of orlistat may reduce the absorption of fat-soluble vitamins, including vitamin K, with the result that a lower dose of warfarin may be required. This may be due in part to change to a lower fat diet with decreased amounts of vitamin K. It may also be due to an effect on vitamin K absorption. Caution should be exercised when these 2 drugs are used concurrently.
RN  - 0 (Anti-Obesity Agents)
RN  - 0 (Anticoagulants)
RN  - 0 (Lactones)
RN  - 12001-79-5 (Vitamin K)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 95M8R751W8 (orlistat)
IS  - 1060-0280
IL  - 1060-0280
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2003 Apr
DC  - 20030327
YR  - 2003
ED  - 20030701
RD  - 20141120
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=12659605

<696. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 12522695
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Edwards MS
AU  - Cherr GS
AU  - Craven TE
AU  - Olsen AW
AU  - Plonk GW
AU  - Geary RL
AU  - Ligush JL
AU  - Hansen KJ
FA  - Edwards, Matthew S
FA  - Cherr, Gregory S
FA  - Craven, Timothy E
FA  - Olsen, Amy W
FA  - Plonk, George W
FA  - Geary, Randolph L
FA  - Ligush, John L
FA  - Hansen, Kimberley J
IN  - Edwards,Matthew S. Division of Surgical Sciences, Section on Vascular Surgery, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
TI  - Acute occlusive mesenteric ischemia: surgical management and outcomes.
SO  - Annals of Vascular Surgery. 17(1):72-9, 2003 Jan.
AS  - Ann Vasc Surg. 17(1):72-9, 2003 Jan.
NJ  - Annals of vascular surgery
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Print
JC  - avs, 8703941
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - Embolism/co [Complications]
MH  - *Embolism/su [Surgery]
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Mesenteric Arteries
MH  - Mesenteric Vascular Occlusion/di [Diagnosis]
MH  - Mesenteric Vascular Occlusion/et [Etiology]
MH  - Mesenteric Vascular Occlusion/mo [Mortality]
MH  - *Mesenteric Vascular Occlusion/su [Surgery]
MH  - Middle Aged
MH  - Morbidity
MH  - Peritonitis/et [Etiology]
MH  - Peritonitis/su [Surgery]
MH  - Retrospective Studies
MH  - Thrombosis/co [Complications]
MH  - *Thrombosis/su [Surgery]
MH  - Treatment Outcome
MH  - Vascular Surgical Procedures
AB  - Acute mesenteric ischemia secondary to arterial occlusion (AMI) remains a highly lethal condition. To examine recent trends in management and associated outcomes, we examined our institutional experience over a recent 10-year period. All patients treated for AMI between January 1990 and January 2000 were identified (76 patients, 77 cases) and their medical records examined. At presentation, 64% demonstrated peritonitis and 30% exhibited hypotension. The interval from symptom onset to treatment exceeded 24 h in 63% of cases. Etiology was mesenteric thrombosis in 44 patients (58%) and embolism in 32 patients (42%). Thirty-five patients (46%) had prior conditions placing them at high risk for the development of AMI including chronic mesenteric ischemia (n = 26) and inadequately anticoagulated chronic atrial fibrillation (n = 9). Surgical management consisted of exploration alone in 16 patients, bowel resection alone in 18 patients, and revascularization in 43 patients, including 28 who required concomitant bowel resection. Overall, intestinal necrosis was present in 81% of cases. Perioperative mortality was 62% and long-term parenteral nutrition (TPN) was required in 31% of survivors. Peritonitis (odds ratio [OR] 9.4, 95% confidence interval [CI] 1.6, 54.0; p = 0.012 and bowel necrosis (OR 10.4, CI 1.9, 56.3; p = 0.007) at presentation were independent predictors of death or survival dependent upon TPN. We conclude that AMI remains a highly lethal condition due in large part to advanced presentation and inadequate recognition and treatment of patients at high risk.
IS  - 0890-5096
IL  - 0890-5096
PT  - Journal Article
LG  - English
EP  - 20030115
DP  - 2003 Jan
DC  - 20030219
YR  - 2003
ED  - 20030530
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=12522695

<697. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 12499628
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Teshima H
AU  - Hayashida N
AU  - Akashi H
AU  - Aoyagi S
FA  - Teshima, Hideki
FA  - Hayashida, Nobuhiko
FA  - Akashi, Hidetoshi
FA  - Aoyagi, Shigeaki
IN  - Teshima,Hideki. Department of Surgery, Kurume University School of Medicine, Japan. tesshi@med.kurume-u.ac.jp
TI  - Surgical treatment of a descending aortic aneurysm in a patient with noncirrhotic portal hypertension and a portal systemic shunt.
SO  - Circulation Journal. 66(12):1176-7, 2002 Dec.
AS  - Circ J. 66(12):1176-7, 2002 Dec.
NJ  - Circulation journal : official journal of the Japanese Circulation Society
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101137683
SB  - Index Medicus
CP  - Japan
MH  - *Aortic Aneurysm, Abdominal/co [Complications]
MH  - *Aortic Aneurysm, Abdominal/su [Surgery]
MH  - Cardiopulmonary Bypass
MH  - Hepatic Encephalopathy/et [Etiology]
MH  - Humans
MH  - *Hyperammonemia/co [Complications]
MH  - Hyperammonemia/th [Therapy]
MH  - *Hypertension, Portal/co [Complications]
MH  - Hypertension, Portal/dh [Diet Therapy]
MH  - Male
MH  - Middle Aged
MH  - *Portal Vein
MH  - Preoperative Care
MH  - *Vascular Fistula/et [Etiology]
AB  - A 63-year-old male with atrial fibrillation and mild mitral valve regurgitation was referred to hospital because of a descending aortic aneurysm. During the evaluation, he developed an encephalopathy because of hyperammoniaemia. Further examination revealed a portal systemic shunt, perhaps caused by the noncirrhotic portal hypertension. The patient underwent successful replacement of the aneurysm after controlling the blood ammonia level by eliminating protein from the diet and removal of nitrogen from the gastrointestinal tract. Cardiovascular surgery in a patient with noncirrhotic portal hypertension and a portal systemic shunt has not been previously reported. Meticulous management of the perioperative blood ammonia concentration is essential.
IS  - 1346-9843
IL  - 1346-9843
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2002 Dec
DC  - 20021224
YR  - 2002
ED  - 20030508
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=12499628

<698. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 13194083
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - CASTLEMAN B
AU  - TOWNE VW
FA  - CASTLEMAN, B
FA  - TOWNE, V W
TI  - Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot.
SO  - New England Journal of Medicine. 251(10):396-400, 1954 Sep 2.
AS  - N Engl J Med. 251(10):396-400, 1954 Sep 2.
NJ  - The New England journal of medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0255562, now
OI  - Source: CLML. 5527:5663:52:156:405
SB  - OLDMEDLINE Citations
CP  - Not Available
MH  - *Atrial Fibrillation
MH  - *Embolism
MH  - *Exercise Therapy
MH  - *Hospitals, General
MH  - Humans
MH  - Massachusetts
MH  - *Rheumatic Heart Disease
KW  - *AURICULAR FIBRILLATION;  *EMBOLISM;  *RHEUMATIC HEART DISEASE
IS  - 0028-4793
IL  - 0028-4793
PT  - Journal Article
LG  - English
DP  - 1954 Sep 2
DC  - 19551201
YR  - 1954
ED  - 20030501
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=13194083

<699. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 12523469
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gebauer MG
AU  - Nyfort-Hansen K
AU  - Henschke PJ
AU  - Gallus AS
FA  - Gebauer, Markus G
FA  - Nyfort-Hansen, Karin
FA  - Henschke, Philip J
FA  - Gallus, Alexander S
IN  - Gebauer,Markus G. Pharmacy Department Repatriation General Hospital, Adelaide, South Australia, Australia. Markus.Gebauer@rgh.sa.gov.au
TI  - Warfarin and acetaminophen interaction.
SO  - Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy. 23(1):109-12, 2003 Jan.
AS  - Pharmacotherapy. 23(1):109-12, 2003 Jan.
NJ  - Pharmacotherapy
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - par, 8111305
SB  - Index Medicus
CP  - United States
MH  - *Acetaminophen/tu [Therapeutic Use]
MH  - Aged
MH  - *Analgesics, Non-Narcotic/tu [Therapeutic Use]
MH  - Anticoagulants/bl [Blood]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - Drug Synergism
MH  - Humans
MH  - *International Normalized Ratio
MH  - Male
MH  - Warfarin/bl [Blood]
MH  - *Warfarin/tu [Therapeutic Use]
AB  - A 74-year-old man who was receiving warfarin for atrial fibrillation experienced an abrupt increase in his international normalized ratio (INR) after taking acetaminophen. To investigate this effect, the patient's anticoagulation therapy was stabilized, and he was given acetaminophen 1 g 4 times/day for 3 days. His INR rose from 2.3 before receiving acetaminophen to 6.4 on the day after acetaminophen was discontinued. Warfarin was stopped for 2 days, and the patient's INR returned to 2.0. Warfarin was restarted at the same dosage, and his INR remained within 2.0-3.0 for 6 months. Factor VII activity decreased from 29.4% before acetaminophen therapy to 15.5% when his INR was 6.4, and factor X activity fell from 27.0% to 20.2%. His warfarin plasma concentration was 1.54 microg/ml before acetaminophen compared with 1.34 microg/ml when his INR was 6.4. No significant changes in drug intake, clinical status, diet, or lifestyle were noted. Changes in INR of this magnitude with the addition of another drug during stable anticoagulation therapy suggest a drug interaction. The lack of an increase in warfarin plasma concentration associated with the increased INR suggests a possible pharmacodynamic mechanism for this interaction. Acetaminophen or a metabolite may enhance the effect of oral coumarin anticoagulants by augmenting vitamin K antagonism. Thus, the anticoagulant effect of warfarin may be significantly elevated after only a few days of acetaminophen therapy. Patients receiving warfarin should be counseled to have their INR monitored more frequently when starting acetaminophen at dosages exceeding 2 g/day.
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Anticoagulants)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 5Q7ZVV76EI (Warfarin)
IS  - 0277-0008
IL  - 0277-0008
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2003 Jan
DC  - 20030113
YR  - 2003
ED  - 20030416
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=12523469

<700. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 12622439
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Yigit Z
AU  - Akdur H
AU  - Arabaci U
AU  - Gurses HN
AU  - Guzelsoy D
FA  - Yigit, Zerrin
FA  - Akdur, Hulya
FA  - Arabaci, Umit
FA  - Gurses, Hulya Nilgun
FA  - Guzelsoy, Deniz
IN  - Yigit,Zerrin. Cardiology Department, Cardiology Institute, Istanbul University, Haseki, Istanbul, Turkey.
TI  - Restoring sinus rhythm improves excessive heart rate response to exercise in patients with atrial fibrillation.
SO  - Japanese Heart Journal. 44(1):73-82, 2003 Jan.
AS  - Jpn Heart J. 44(1):73-82, 2003 Jan.
NJ  - Japanese heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - kh3, 0401175
SB  - Index Medicus
CP  - Japan
MH  - Aged
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Blood Pressure
MH  - *Electric Countershock
MH  - *Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Female
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
AB  - The aim of this study was to investigate improvement in the cardiovascular response to isometric and isotonic exercises after reverting rhythm to sinus in patients with atrial fibrillation. Twenty seven cases with nonvalvular paroxysmal atrial fibrillation were included in the study. Sinus rhythm could not be restored in two cases so they were excluded. The remaining cases were divided into two groups according to the existence of cardiac diseasc. Group 1 (n:14, mean age. 60.8 +/- 14.9 years) included cases with cardiac diseases (8 of the patients had hypertension in addition to the cardiac disease) and group 2 (n:11, mean age. 64.8 +/- 13.9 years) included those without cardiac disease (patients with hypertension and diabetes mellitus). Isometric and isotonic exercise tests were performed in all of the patients before and 48 hours after the rhythm was reverted to sinus and the values in atrial fibrillation were compared with those in sinus rhythm (following cardioversion). The isotonic exercise period increased significantly in only group 1 patients following cardioversion (P = (0.0061). In both groups, the increase in heart rate during atrial fibrillation was significantly higher compared to those after being reverted to sinus, at all stages of the isotonic exercise (in groups 1 and 2, heart rate in patients with atrial fibrillation increased from 96.5 +/- 19.3 to 173.3 +/- 19.3 beats/min and 96.1 +/- 12.6 to 185.0 +/- 12.1 beats/ min, respectively; and in sinus rhythm, it ranged from 85.1 +/- 11.4 to 164.6 +/- 9.1 beats/min and 81.3 +/- 11.4 to 157.6 +/- 15.1 beats/min, respectively). Systolic arterial pressure increased significantly during atrial fibrillation in group 1, at the 2nd stage of the isotonic exercise test (P = 0.0070). In group 2, systolic arterial pressure increased significantly at the 3rd stage in sinus rhythm and at the 4th stage when in rhythm in atrial fibrillation. Also, diastolic arterial pressure increased significantly during atrial fibrillation only at the 3rd stage of the exercise. As a result, restoring sinus rhythm by cardioversion improves excessive heart rate responses to exercise significantly in patients with atrial fibrillation during both isometric and isotonic exercises. Also, we have revealed that the exercise time increased significantly by restoring sinus rhythm in patients with heart disease.
IS  - 0021-4868
IL  - 0021-4868
PT  - Journal Article
LG  - English
DP  - 2003 Jan
DC  - 20030307
YR  - 2003
ED  - 20030318
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=12622439

<701. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 12558126
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Akdur H
AU  - Yigit Z
AU  - Arabaci U
AU  - Polat MG
AU  - Gurses HN
AU  - Guzelsoy D
FA  - Akdur, Hulya
FA  - Yigit, Zerrin
FA  - Arabaci, Umit
FA  - Polat, Mine Gulden
FA  - Gurses, Hulya Nilgun
FA  - Guzelsoy, Deniz
IN  - Akdur,Hulya. Body Training and Sports College, Cardiology Institute, Istanbul University, Turkey.
TI  - Comparison of cardiovascular responses to isometric (static) and isotonic (dynamic) exercise tests in chronic atrial fibrillation.
SO  - Japanese Heart Journal. 43(6):621-9, 2002 Nov.
AS  - Jpn Heart J. 43(6):621-9, 2002 Nov.
NJ  - Japanese heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - kh3, 0401175
SB  - Index Medicus
CP  - Japan
MH  - Aged
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Blood Pressure/ph [Physiology]
MH  - Chronic Disease
MH  - *Exercise Test/mt [Methods]
MH  - Female
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
AB  - The aim of the present study was to evaluate the tolerance to various exercises by determining the cardiovascular response to static and dynamic exercises in patients with nonvalvular atrial fibrillation. Fifty patients (mean age: 63.6 +/- 10.3 years; male: 25, female: 25) with chronic (more than one year) nonvalvular atrial fibrillation were included in the study. All patients underwent exercise tests, adjusted appropriately according to their symptoms, as dynamic exercise on a Marquette Case 15 device according to a modified Bruce protocol. Heart rate, and systolic and diastolic arterial pressures were measured at rest and at all stages of the exercise; and the heart rate-pressure products were evaluated. A handgrip test was also conducted as static exercise. The measurements were made before, at the 1st, 2nd and 3rd minutes, and in the recovery periods of the exercise. The percent values of the changes of the 1st, 2nd and 3rd minute measurements in relation to the initial values for both exercises were compared. In addition, the maximal responses to the exercise tests and the post exercise values were also compared. For statistical evaluations, the paired Student-t test was used. Heart rate and pressure-heart rate product values obtained at 1, 2, and 3 minutes during the treadmill exercise test were significantly high compared to the handgrip values (P < 0.0001). The arterial systolic and diastolic pressure values in the 1st minute were also significantly higher during the handgrip test (P = 0.0100 and P = 0.0320, respectively). The values of diastolic arterial pressure at the 2nd minute during the handgrip test, and systolic arterial pressure at the 3rd minute during the treadmill test were found to be statistically significant (P = 0.0240, P = 0.0340, respectively). The mean exercise time and MET value during the treadmill exercise test were 7.18 +/- 2.65 minutes and 5.32 +/- 1.38 mL.kg(-1) x dk(-1). respectively. During the recovery period, the 5th minute, heart rate and pressure-heart rate product values were significantly high after the treadmill test (P < 0.0001). In this study, we revealed that the heart rate response to static exercise was lower and the patients tolerated the static exercise better. Therefore, we decided that the short duration of static exercise is not harmful for the noncomplicated chronic atrial fibrillation cases.
IS  - 0021-4868
IL  - 0021-4868
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 2002 Nov
DC  - 20030131
YR  - 2002
ED  - 20030220
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=12558126

<702. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 12411914
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - von der Recke G
AU  - Schmidt H
AU  - Illien S
AU  - Luderitz B
AU  - Omran H
FA  - von der Recke, Giso
FA  - Schmidt, Harald
FA  - Illien, Stefan
FA  - Luderitz, Berndt
FA  - Omran, Heyder
IN  - von der Recke,Giso. Department of Medicine-Cardiology, University of Bonn, Germany.
TI  - Use of transesophageal contrast echocardiography for excluding left atrial appendage thrombi in patients with atrial fibrillation before cardioversion.
SO  - Journal of the American Society of Echocardiography. 15(10 Pt 2):1256-61, 2002 Oct.
AS  - J Am Soc Echocardiogr. 15(10 Pt 2):1256-61, 2002 Oct.
NJ  - Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - aof, 8801388
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - *Atrial Appendage/de [Drug Effects]
MH  - Atrial Appendage/pp [Physiopathology]
MH  - *Atrial Appendage/us [Ultrasonography]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Atrial Fibrillation/us [Ultrasonography]
MH  - Blood Flow Velocity/ph [Physiology]
MH  - Diagnosis, Differential
MH  - *Echocardiography
MH  - *Echocardiography, Transesophageal
MH  - *Electric Countershock
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Diseases/pp [Physiopathology]
MH  - *Heart Diseases/th [Therapy]
MH  - *Heart Diseases/us [Ultrasonography]
MH  - Heparin/tu [Therapeutic Use]
MH  - Humans
MH  - Image Enhancement
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Stroke Volume/ph [Physiology]
MH  - Thrombosis/pp [Physiopathology]
MH  - *Thrombosis/th [Therapy]
MH  - *Thrombosis/us [Ultrasonography]
MH  - Treatment Outcome
AB  - Transesophageal echocardiographic (TEE) guidance of cardioversion in patients with atrial fibrillation is an alternative method to conventional anticoagulation. Although TEE is considered the gold standard for excluding left atrial (LA) thrombi, in some patients dense spontaneous echo contrast (SEC) and artifacts may hamper the identification or exclusion of LA thrombi. Often those patients are refused cardioversion. The purpose of this study was to determine whether the application of echo contrast (Optison, Mallinckrodt, San Diego, Calif) facilitates the exclusion of LA appendage thrombi in this patient group and allows for safer cardioversion. Forty-one patients with atrial fibrillation and dense SEC or inconclusive TEE findings were given echo contrast. Fourteen patients with sinus rhythm served as control participants. Echo contrast completely reduced artifacts in 13 of 22 patients. In 12 of 19 patients with SEC, the LA appendage was completely filled after the application of echo contrast and, thus, SEC was completely suppressed. In 13 of 41 patients, it was filled incompletely and in 9 of 41 patients, a new mass resembling a thrombus was detected. In total, of 25 of 41 patients with inconclusive TEE findings an atrial thrombus was definitively excluded. Those patients underwent cardioversion. None of those patients had a cerebral embolic complication as assessed by cranial magnetic resonance imaging. Thus, the application of echo contrast may facilitate the TEE exclusion of LA appendage thrombi and, hence, improve the safety of TEE-guided cardioversion.
RN  - 0 (Anticoagulants)
RN  - 9005-49-6 (Heparin)
IS  - 0894-7317
IL  - 0894-7317
PT  - Comparative Study
PT  - Evaluation Studies
PT  - Journal Article
LG  - English
DP  - 2002 Oct
DC  - 20021104
YR  - 2002
ED  - 20030212
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=12411914

<703. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 12380918
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Rashba EJ
AU  - Osman AF
AU  - MacMurdy K
AU  - Kirk MM
AU  - Sarang S
AU  - Peters RW
AU  - Shorofsky SR
AU  - Gold MR
FA  - Rashba, Eric J
FA  - Osman, Ahmed F
FA  - MacMurdy, Karen
FA  - Kirk, Malcolm M
FA  - Sarang, Samantha
FA  - Peters, Robert W
FA  - Shorofsky, Stephen R
FA  - Gold, Michael R
IN  - Rashba,Eric J. erashba@medicine.umaryland.edu
TI  - Exercise is superior to pacing for T wave alternans measurement in subjects with chronic coronary artery disease and left ventricular dysfunction.
SO  - Journal of Cardiovascular Electrophysiology. 13(9):845-50, 2002 Sep.
AS  - J Cardiovasc Electrophysiol. 13(9):845-50, 2002 Sep.
NJ  - Journal of cardiovascular electrophysiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - by4, 9010756
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Cardiac Pacing, Artificial
MH  - Chronic Disease
MH  - Coronary Artery Disease/ep [Epidemiology]
MH  - *Coronary Artery Disease/pp [Physiopathology]
MH  - *Coronary Artery Disease/th [Therapy]
MH  - Disease-Free Survival
MH  - *Electrocardiography
MH  - Electrophysiologic Techniques, Cardiac
MH  - Endpoint Determination
MH  - *Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - *Long QT Syndrome/di [Diagnosis]
MH  - Long QT Syndrome/pp [Physiopathology]
MH  - Male
MH  - Maryland/ep [Epidemiology]
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Predictive Value of Tests
MH  - Prevalence
MH  - Prospective Studies
MH  - Risk Factors
MH  - Sensitivity and Specificity
MH  - Stroke Volume/ph [Physiology]
MH  - Treatment Outcome
MH  - Ventricular Dysfunction, Left/ep [Epidemiology]
MH  - *Ventricular Dysfunction, Left/pp [Physiopathology]
MH  - *Ventricular Dysfunction, Left/th [Therapy]
AB  - INTRODUCTION: T wave alternans (TWA) is a heart rate-dependent marker of vulnerability to ventricular arrhythmias. Atrial pacing and exercise both are used as provocative stimuli to elicit TWA. However, the prognostic value of the two testing methods has not been compared. The aim of this prospective study was to compare the prognostic value of TWA measured during bicycle exercise and atrial pacing in a large cohort of high-risk patients with ischemic heart disease and left ventricular dysfunction.
AB  - METHODS AND RESULTS: This was a prospective study of 251 patients with coronary artery disease and left ventricular dysfunction who were referred for electrophysiologic studies (EPS) for standard clinical indications. Patients underwent TWA testing using bicycle ergometry (exercise TWA, n = 144) and/or atrial pacing (pacing TWA, n = 178). The primary endpoint was the combined incidence of death, sustained ventricular arrhythmias, and appropriate implantable cardioverter defibrillator therapy. The predictive value of exercise and pacing TWA for EPS results and for endpoint events was determined. Exercise and pacing TWA both were significant predictors of EPS results (odds ratios 3.0 and 2.9 respectively, P < 0.02). Kaplan-Meier survival analysis of the primary endpoint revealed that exercise TWA was a significant predictor of events (hazard ratio 2.2, P = 0.03). In contrast, pacing TWA had no prognostic value for endpoint events (hazard ratio 1.1, P = 0.8).
AB  - CONCLUSION: TWA should be measured during exercise when it is used for clinical risk stratification. EPS results may not be an adequate surrogate for spontaneous events when evaluating new risk stratification tests.
IS  - 1045-3873
IL  - 1045-3873
PT  - Comparative Study
PT  - Evaluation Studies
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2002 Sep
DC  - 20021016
YR  - 2002
ED  - 20030212
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=12380918

<704. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 12373058
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Cnota JF
AU  - Ross JE
AU  - Knilans TK
AU  - Epstein MR
FA  - Cnota, James F
FA  - Ross, Joseph E
FA  - Knilans, Timothy K
FA  - Epstein, Michael R
TI  - Does intermittent accessory pathway block during slow sinus rhythm always imply a low risk for rapid AV conduction of preexcited atrial fibrillation?.
SO  - Cardiology. 98(1-2):106-8, 2002.
AS  - Cardiology. 98(1-2):106-8, 2002.
NJ  - Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - coi, 1266406
SB  - Index Medicus
CP  - Switzerland
MH  - Adolescent
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrioventricular Node/pp [Physiopathology]
MH  - *Electrocardiography
MH  - Exercise
MH  - Female
MH  - Humans
MH  - *Pre-Excitation Syndromes/di [Diagnosis]
MH  - Pre-Excitation Syndromes/ep [Epidemiology]
MH  - *Pre-Excitation Syndromes/pp [Physiopathology]
MH  - Risk Factors
IS  - 0008-6312
IL  - 0008-6312
PT  - Case Reports
PT  - Letter
LG  - English
DP  - 2002
DC  - 20021009
YR  - 2002
ED  - 20030115
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=12373058

<705. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 12490699
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ragozzino MW
AU  - Snyder J
AU  - Nayak HM
FA  - Ragozzino, Mark W
FA  - Snyder, James
FA  - Nayak, Hemal M
TI  - Self-cardioversion of paroxysmal lone atrial fibrillation with exercise.
SO  - New England Journal of Medicine. 347(25):2085-6, 2002 Dec 19.
AS  - N Engl J Med. 347(25):2085-6, 2002 Dec 19.
NJ  - The New England journal of medicine
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 0255562, now
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Electric Countershock
MH  - *Exercise/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
ES  - 1533-4406
IL  - 0028-4793
PT  - Case Reports
PT  - Letter
LG  - English
DP  - 2002 Dec 19
DC  - 20021219
YR  - 2002
ED  - 20021230
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=12490699

<706. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 12074278
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Takahashi N
AU  - Ishibashi Y
AU  - Shimada T
AU  - Sakane T
AU  - Ohata S
AU  - Sugamori T
AU  - Ohta Y
AU  - Inoue S
AU  - Nakamura K
AU  - Shimizu H
AU  - Katoh H
AU  - Murakami Y
FA  - Takahashi, Nobuyuki
FA  - Ishibashi, Yutaka
FA  - Shimada, Toshio
FA  - Sakane, Takeshi
FA  - Ohata, Shuzo
FA  - Sugamori, Takashi
FA  - Ohta, Yoko
FA  - Inoue, Shin-ichi
FA  - Nakamura, Ko
FA  - Shimizu, Hiromi
FA  - Katoh, Harumi
FA  - Murakami, Yo
IN  - Takahashi,Nobuyuki. Fourth Department of Internal Medicine, Shimane Medical University, Izumo, Japan.
TI  - Impaired exercise-induced vasodilatation in chronic atrial fibrillation--role of endothelium-derived nitric oxide.
SO  - Circulation Journal. 66(6):583-8, 2002 Jun.
AS  - Circ J. 66(6):583-8, 2002 Jun.
NJ  - Circulation journal : official journal of the Japanese Circulation Society
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101137683
SB  - Index Medicus
CP  - Japan
MH  - Acetylcholine/pd [Pharmacology]
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Blood Flow Velocity/de [Drug Effects]
MH  - Blood Flow Velocity/ph [Physiology]
MH  - Chronic Disease
MH  - Electric Countershock
MH  - Endothelium, Vascular/de [Drug Effects]
MH  - *Endothelium, Vascular/pp [Physiopathology]
MH  - Female
MH  - Forearm/bs [Blood Supply]
MH  - Hand Strength
MH  - Heart Diseases/co [Complications]
MH  - Heart Diseases/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Nitric Oxide/ph [Physiology]
MH  - Plethysmography
MH  - *Vasodilation/ph [Physiology]
MH  - omega-N-Methylarginine/pd [Pharmacology]
AB  - Exercise capacity is often reduced in patients with atrial fibrillation (AF), but very few studies have focused on changes in endothelial function as a potential mechanism for the exercise limitation. The present study used using venous occlusion plethysmography to investigate whether nitric oxide (NO)-mediated vasodilatation is attenuated during exercise in patients with AF by measuring forearm blood flow (FBF) in 10 patients at rest and immediately after 2 levels of rhythmic handgrip exercise, before and after inhibition of NO synthesis with N(G)-monomethyl-L-arginine (L-NMMA, 100 micromol). The measurements were repeated 1 day after restoration of sinus rhythm by cardioversion. FBF responses to graded doses of acetylcholine (ACh) were also observed before and after cardioversion. Heart rate decreased after cardioversion, but blood pressure did not change. FBF at rest was not affected by cardioversion, but at the highest level of exercise it increased from 28.4+/-2.3 ml x min(-1) x dl(-1) before to 39.4+/-3.2 ml x min(-1) x dl(-1) after cardioversion (p<0.05). L-NMMA significantly decreased FBF at rest (p<0.01) and depressed the increase in FBF response to exercise after (p<0.01), but not before cardioversion. The FBF response to ACh was also accelerated significantly after cardioversion. The present results provide new evidence that NO bioavailability is depressed at rest and during exercise in patients with AF.
RN  - 27JT06E6GR (omega-N-Methylarginine)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - N9YNS0M02X (Acetylcholine)
IS  - 1346-9843
IL  - 1346-9843
PT  - Journal Article
LG  - English
DP  - 2002 Jun
DC  - 20020620
YR  - 2002
ED  - 20021220
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=12074278

<707. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11991367
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - van Campen LC
AU  - De Cock CC
AU  - Visser FC
AU  - Visser CA
FA  - van Campen, Linda C M C
FA  - De Cock, Carel C
FA  - Visser, Frans C
FA  - Visser, Cees A
IN  - van Campen,Linda C M C. Department of Cardiology, Academic Hospital Free University, Amsterdam, The Netherlands. cardiol@azvu.nl
TI  - The effect of rate responsive pacing in patients with angina pectoris on the extent of ischemia on 201-thallium exercise scintigraphy.
SO  - Pacing & Clinical Electrophysiology. 25(4 Pt 1):430-4, 2002 Apr.
AS  - Pacing Clin Electrophysiol. 25(4 Pt 1):430-4, 2002 Apr.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Angina Pectoris/pp [Physiopathology]
MH  - *Angina Pectoris/ri [Radionuclide Imaging]
MH  - Angina Pectoris/th [Therapy]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/ri [Radionuclide Imaging]
MH  - Atrial Fibrillation/th [Therapy]
MH  - Bradycardia/pp [Physiopathology]
MH  - Bradycardia/ri [Radionuclide Imaging]
MH  - Bradycardia/th [Therapy]
MH  - *Cardiac Pacing, Artificial/ct [Contraindications]
MH  - Cardiac Pacing, Artificial/mt [Methods]
MH  - Coronary Disease/pp [Physiopathology]
MH  - *Coronary Disease/ri [Radionuclide Imaging]
MH  - Coronary Disease/th [Therapy]
MH  - Cross-Over Studies
MH  - *Electrocardiography
MH  - *Exercise Test
MH  - Female
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Oxygen Consumption/ph [Physiology]
MH  - *Radionuclide Imaging
MH  - Single-Blind Method
MH  - Thallium Radioisotopes
AB  - In patients with coronary artery disease (CAD), rate responsive pacing is considered to be contraindicated because an increase in heart rate may increase oxygen demand. Although previous studies have shown no subjective increase in ischemia during rate responsive pacing, data from objective assessment have not been documented. The goal of this study was to determine if there was an increase in ischemia on 201-Thallium (201 Tl) exercise scintigraphy in this mode of pacing in patients with CAD and angina. Eighteen consecutive patients with chronic atrial fibrillation and symptomatic bradyarrhythmias with a pacemaker for more than 6 months participated in the study. In VVI and VVIR modes a symptom-limited exercise 201 Tl scintigram was performed in a single blind randomized crossover fashion. Exercise duration, anginal attacks, use of nitroglycerine (NTG) tablets, blood pressure, and analysis of the scintigrams were assessed during each pacing mode. Fifteen men and three women were included (age 65.9 +/- 4.9 years, LVEF 0.44 +/- 0.07). Four were in Class III angina pectoris, and 14 in class II. The mean exercise duration increased 28% in the VVIR group without an increase in anginal attacks per week or the use of NTG tablets. On scintigrams, no differences were seen between the two groups. One patient was withdrawn from the study because of an increase in angina pectoris (AP) attacks during VVIR pacing. Rate responsive pacing is safe and effective in patients with CAD without an increase in subjective and objective signs of ischemia.
RN  - 0 (Thallium Radioisotopes)
IS  - 0147-8389
IL  - 0147-8389
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 2002 Apr
DC  - 20020506
YR  - 2002
ED  - 20021204
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11991367

<708. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 12000159
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Eren M
AU  - Arikan E
AU  - Gorgulu S
AU  - Dagdeviren B
AU  - Bolca O
AU  - Norgaz T
AU  - Tezel T
FA  - Eren, Mehmet
FA  - Arikan, Erdinc
FA  - Gorgulu, Sevket
FA  - Dagdeviren, Bahadir
FA  - Bolca, Osman
FA  - Norgaz, Tugrul
FA  - Tezel, Tuna
IN  - Eren,Mehmet. Siyami Ersek Thoracic and Cardiovascular Surgery Center, Cardiology Clinic, Istanbul, Turkey.
TI  - Relationship between resting parameters of the mitral valve and exercise capacity in patients with mitral stenosis: can the diastolic filling period predict exercise capacity?.
SO  - Journal of Heart Valve Disease. 11(2):191-8, 2002 Mar.
AS  - J Heart Valve Dis. 11(2):191-8, 2002 Mar.
NJ  - The Journal of heart valve disease
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - byi, 9312096
SB  - Index Medicus
CP  - England
MH  - Adult
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Echocardiography
MH  - Exercise Test
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mitral Valve/pp [Physiopathology]
MH  - Mitral Valve/us [Ultrasonography]
MH  - Mitral Valve Stenosis/co [Complications]
MH  - *Mitral Valve Stenosis/pp [Physiopathology]
MH  - Predictive Value of Tests
MH  - Pulmonary Wedge Pressure/ph [Physiology]
MH  - *Rest/ph [Physiology]
MH  - Sex Factors
MH  - Statistics as Topic
MH  - Stroke Volume/ph [Physiology]
AB  - BACKGROUND AND AIMS OF THE STUDY: In order to provide patients with better exercise capacity, interventional therapy to the mitral valve is often carried out in mitral stenosis (MS). Hence, it is crucial to determine exercise capacity before deciding on the time of intervention. The study aim was to demonstrate whether resting parameters of the mitral valve, notably left ventricular diastolic filling period (LVDFP) and mitral valve resistance (MVR), relate to restricted exercise capacity.
AB  - METHODS: Forty-six patients (30 females, 16 males; mean age 44+/-11 years; range: 33-55 years) with rheumatic MS were enrolled. Exercise capacities of patients were grouped according to NYHA classification and maximal exercise tolerance values obtained using exercise testing. Exercise capacity in male patients was quantified. Relationships between patient variables and exercise capacity were evaluated using simple linear regression analysis. In order to identify determinants of exercise capacity, a discriminate multivariate analysis was performed with variables, which were found to correlate significantly in the univariate analysis.
AB  - RESULTS: There were no correlations between echo score, MVR, planimetric mitral valve area (MVA), MVA obtained by the pressure half-time method or calculated by the continuity equation, and transmitral mean gradient and exercise capacity classes as defined by both NYHA and exercise testing. The only predictor of exercise capacity class determined by discriminate multivariate analysis using the significant parameters in the linear regression analysis was LVDFP. The quantified exercise capacity in male patients correlated only with LVDFP (r = 0.64, p = 0.008).
AB  - CONCLUSION: Exercise capacity cannot be predicted using routine resting parameters of the mitral valve (including MVR) in patients with MS. In this respect, the LVDFP may be of value.
IS  - 0966-8519
IL  - 0966-8519
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 2002 Mar
DC  - 20020509
YR  - 2002
ED  - 20021115
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=12000159

<709. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 12122610
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Houltz B
AU  - Darpo B
AU  - Crijns HJ
AU  - Swedberg K
AU  - Blomstrom P
AU  - Jensen SM
AU  - Svernhage E
AU  - Edvardsson N
FA  - Houltz, Birgitta
FA  - Darpo, Borje
FA  - Crijns, Harry J G M
FA  - Swedberg, Karl
FA  - Blomstrom, Per
FA  - Jensen, Steen M
FA  - Svernhage, Elisabeth
FA  - Edvardsson, Nils
IN  - Houltz,Birgitta. Department of Medicine, Sahlgrenska University Hospital/Ostra, Goteborg, Sweden. birgitta.houltz@medfak.gu.se
TI  - QRS aberration during atrial fibrillation at rest and during exercise. Effect of a selective potassium channel blocking agent.
SO  - Journal of Electrocardiology. 35(3):201-12, 2002 Jul.
AS  - J Electrocardiol. 35(3):201-12, 2002 Jul.
NJ  - Journal of electrocardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - i0r, 0153605
SB  - Index Medicus
CP  - United States
MH  - Anti-Arrhythmia Agents/ad [Administration & Dosage]
MH  - *Anti-Arrhythmia Agents/pd [Pharmacology]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Echocardiography
MH  - *Electrocardiography/de [Drug Effects]
MH  - Exercise
MH  - Exercise Test
MH  - Female
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Potassium Channel Blockers/ad [Administration & Dosage]
MH  - *Potassium Channel Blockers/pd [Pharmacology]
MH  - Propanolamines/ad [Administration & Dosage]
MH  - *Propanolamines/pd [Pharmacology]
MH  - Rest
MH  - Sex Factors
MH  - Torsades de Pointes/et [Etiology]
AB  - This study assesses the occurrence of and identifies clinical characteristics associated with the development of aberrant conduction during infusion of the I(kr)-blocker almokalant. Class III drugs may induce aberrant conduction by prolongation of cardiac repolarization, especially during atrial fibrillation (AF). Ninety-two patients with AF received a 6-hour almokalant infusion, aiming at conversion to sinus rhythm (SR). Fiftyfive of the patients received an identical infusion during SR. During almokalant infusion, the number of patients with intermittent QRS aberration during AF increased, from 21% to 80% at rest, and was further increased to 89% during exercise, with predominantly left, and sequential bilateral, bundle branch aberrancy. Patients with aberrant conduction showed signs of more advanced myocardial disease. Predictors of the development of QRS aberration were female gender, arrhythmia duration, and decreased left ventricular ejection fraction, while use of calcium antagonists decreased the probability. No patient showed aberration during regular SR. Twenty-one patients experienced aberrantly conducted supraventricular premature beats. In conclusion, aberrant conduction is common during infusion of the I(kr)-blocker almokalant during AF, and seems to be more frequent in females and in patients with more advanced myocardial disease.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Potassium Channel Blockers)
RN  - 0 (Propanolamines)
RN  - I9NG89L275 (almokalant)
IS  - 0022-0736
IL  - 0022-0736
PT  - Journal Article
LG  - English
DP  - 2002 Jul
DC  - 20020717
YR  - 2002
ED  - 20021017
RD  - 20121115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=12122610

<710. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 12177362
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Green DM
AU  - Ropper AH
AU  - Kronmal RA
AU  - Psaty BM
AU  - Burke GL
AU  - Cardiovascular Health Study
FA  - Green, D M
FA  - Ropper, A H
FA  - Kronmal, R A
FA  - Psaty, B M
FA  - Burke, G L
FA  - Cardiovascular Health Study
IN  - Green,D M. Neuroscience Institute, The Queen's Medical Center, 1301 Punchbowl Street, Honolulu, HI 96813, USA. dgreen@queens.org
TI  - Serum potassium level and dietary potassium intake as risk factors for stroke.
CM  - Comment in: Neurology. 2002 Aug 13;59(3):302-3; PMID: 12177360
CM  - Comment in: Neurology. 2003 Jun 10;60(11):1870; PMID: 14705602
CM  - Comment in: Neurology. 2003 Jun 10;60(11):1869-70; author reply 1870; PMID: 12796561
SO  - Neurology. 59(3):314-20, 2002 Aug 13.
AS  - Neurology. 59(3):314-20, 2002 Aug 13.
NJ  - Neurology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0401060, nz0
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Cohort Studies
MH  - Confidence Intervals
MH  - Diuretics/bl [Blood]
MH  - Diuretics/tu [Therapeutic Use]
MH  - Humans
MH  - Linear Models
MH  - Male
MH  - *Potassium/bl [Blood]
MH  - Potassium, Dietary/bl [Blood]
MH  - *Potassium, Dietary/tu [Therapeutic Use]
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Risk Factors
MH  - *Stroke/bl [Blood]
MH  - *Stroke/dh [Diet Therapy]
AB  - BACKGROUND: Numerous studies have found that low potassium intake and low serum potassium are associated with increased stroke mortality, but data regarding stroke incidence have been limited. Serum potassium levels, dietary potassium intake, and diuretic use in relation to risk for stroke in a prospectively studied cohort were investigated.
AB  - METHODS: The study comprised 5,600 men and women older than 65 years who were free of stroke at enrollment. Baseline data included serum potassium level, dietary potassium intake, and diuretic use. Participants were followed for 4 to 8 years, and the incidence and types of strokes were recorded. Low serum potassium was defined as less than 4.1 mEq/L, and low potassium intake as less than 2.4 g/d.
AB  - RESULTS: Among diuretic users, there was an increased risk for stroke associated with lower serum potassium (relative risk [RR]: 2.5, p < 0.0001). Among individuals not taking diuretics, there was an increased risk for stroke associated with low dietary potassium intake (RR: 1.5, p < 0.005). The small number of diuretic users with lower serum potassium and atrial fibrillation had a 10-fold greater risk for stroke compared with those with higher serum potassium and normal sinus rhythm.
AB  - CONCLUSIONS: A lower serum potassium level in diuretic users, and low potassium intake in those not taking diuretics were associated with increased stroke incidence among older individuals. Lower serum potassium was associated with a particularly high risk for stroke in the small number of diuretic users with atrial fibrillation. Further study is required to determine if modification of these factors would prevent strokes.
RN  - 0 (Diuretics)
RN  - 0 (Potassium, Dietary)
RN  - RWP5GA015D (Potassium)
IS  - 0028-3878
IL  - 0028-3878
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, U.S. Gov't, P.H.S.
NO  - N01 HC 85079 (United States NHLBI NIH HHS)
NO  - N01 HC 85080 (United States NHLBI NIH HHS)
NO  - N01 HC 85081 (United States NHLBI NIH HHS)
NO  - N01 HC 85082 (United States NHLBI NIH HHS)
NO  - N01 HC 85083 (United States NHLBI NIH HHS)
NO  - N01 HC 85084 (United States NHLBI NIH HHS)
NO  - N01 HC 85085 (United States NHLBI NIH HHS)
NO  - N01 HC 85086 (United States NHLBI NIH HHS)
LG  - English
DP  - 2002 Aug 13
DC  - 20020814
YR  - 2002
ED  - 20020903
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=12177362

<711. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11918508
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Hawk TL
AU  - Havrda DE
FA  - Hawk, Toni L
FA  - Havrda, Dawn E
IN  - Hawk,Toni L. Department of Clinical and Administrative Services, College of Pharmacy, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190-5040, USA. tony-hawk@ouhsc.edu
TI  - Effect of stress on international normalized ratio during warfarin therapy.
SO  - Annals of Pharmacotherapy. 36(4):617-20, 2002 Apr.
AS  - Ann Pharmacother. 36(4):617-20, 2002 Apr.
NJ  - The Annals of pharmacotherapy
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - bbx, 9203131
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Anticoagulants/ae [Adverse Effects]
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/bl [Blood]
MH  - *Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - Female
MH  - Humans
MH  - *International Normalized Ratio
MH  - Male
MH  - Middle Aged
MH  - Stress, Physiological/bl [Blood]
MH  - *Stress, Physiological/co [Complications]
MH  - Venous Thrombosis/bl [Blood]
MH  - *Venous Thrombosis/co [Complications]
MH  - Venous Thrombosis/dt [Drug Therapy]
MH  - *Warfarin/ae [Adverse Effects]
MH  - Warfarin/tu [Therapeutic Use]
AB  - OBJECTIVE: To discuss the effect of stress on the international normalized ratio (INR) when patients are taking warfarin.
AB  - CASE SUMMARY: Two patients at a pharmacist-managed anticoagulation clinic who were stable with anticoagulation developed elevated INR values after a stressful event occurred. All other factors known to elevate the INR were unchanged; furthermore, the INR values returned to the prior level of control after resolution of the stressful events.
AB  - DISCUSSION: Management of anticoagulation with warfarin requires the knowledge of factors that may alter an INR. Many of these factors, such as dietary changes, illnesses, drug interactions, patient compliance, and physical activity, have been described. In spite of this understanding, many patients continue to experience variability in their INR values, suggesting there are other factors that can alter the INR that have not been fully described. The cases presented here demonstrate that stressful events, physical or psychological, can elevate the INR. The mechanism for this occurrence is unknown, but may be related to decreased metabolism of warfarin during stress.
AB  - CONCLUSIONS: When an unexplained INR value exists, a stressor should be evaluated as a potential cause.
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
IS  - 1060-0280
IL  - 1060-0280
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2002 Apr
DC  - 20020328
YR  - 2002
ED  - 20020724
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11918508

<712. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11450688
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Harada K
AU  - Sugishita Y
AU  - Shimizu T
AU  - Yao A
AU  - Matsui H
AU  - Kohmoto O
AU  - Serizawa T
AU  - Nagai R
AU  - Takahashi T
FA  - Harada, K
FA  - Sugishita, Y
FA  - Shimizu, T
FA  - Yao, A
FA  - Matsui, H
FA  - Kohmoto, O
FA  - Serizawa, T
FA  - Nagai, R
FA  - Takahashi, T
IN  - Harada,K. Department of Cardiovascular Medicine, University of Tokyo, Japan.
TI  - Left ventricular relaxation abnormality is detectable by analysis of the relaxation time constant in patients with atrial fibrillation.
SO  - Japanese Circulation Journal. 65(7):610-6, 2001 Jul.
AS  - Jpn Circ J. 65(7):610-6, 2001 Jul.
NJ  - Japanese circulation journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - kgn, 7806868
SB  - Index Medicus
CP  - Australia
MH  - Adult
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Blood Pressure
MH  - *Electrocardiography
MH  - Female
MH  - Hemodynamics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Contraction
MH  - Regression Analysis
MH  - Stroke Volume
MH  - *Ventricular Dysfunction, Left/di [Diagnosis]
AB  - Left ventricular (LV) contractility is constantly changing during atrial fibrillation (AF), which is dependent on the force-interval relationships. However, no information has been available on LV relaxation in patients with both AF and impaired LV systolic function. LV pressure was measured with a catheter-tipped micromanometer and the time constant of isovolumic LV pressure decline (tau(bf)) was calculated with best exponential fitting from more than 10 consecutive beats. Patients with AF (5 with mitral valvular disease, 6 with idiopathic dilated cardiomyopathy, and 1 with no underlying disease) were subdivided into 2 groups: group A, with ejection fraction (EF) <0.5 (n=7); and group B, with EF > or =0.5 (n=5). Linear correlation coefficients (r) between tau and RR2, RR2/RR1, LV peak systolic pressure (peak LVP) were calculated. Although tau did not show a discrepancy between the 2 groups, tau(bf) correlated better with RR2/RR1 only in the group A patients. The relation between tau and peak LVP showed a good correlation with a steep slope (R, Deltatau/Deltapeak LVP) only in the group A patients (accentuated afterload-dependence). R was significantly different between the 2 groups. Thus, a beat-to-beat analysis of tau may be a practical and feasible way for detecting LV relaxation abnormality in patients with AF.
IS  - 0047-1828
IL  - 0047-1828
PT  - Journal Article
LG  - English
DP  - 2001 Jul
DC  - 20010711
YR  - 2001
ED  - 20020716
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11450688

<713. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11817566
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Holming K
FA  - Holming, K
IN  - Holming,K. Department of Medicine, Malarsjukhuset, Eskilstuna, Sweden.
TI  - The effect of digitalis or a beta-blocker, alone or in combination, on atrial fibrillation at rest and during exercise.
SO  - Upsala Journal of Medical Sciences. 106(1):77-8, 2001.
AS  - Ups J Med Sci. 106(1):77-8, 2001.
NJ  - Upsala journal of medical sciences
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - wrg, 0332203
SB  - Index Medicus
CP  - Sweden
MH  - Adrenergic beta-Antagonists/ad [Administration & Dosage]
MH  - *Adrenergic beta-Antagonists/tu [Therapeutic Use]
MH  - Adult
MH  - Aged
MH  - Anti-Arrhythmia Agents/ad [Administration & Dosage]
MH  - *Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Digitalis Glycosides/ad [Administration & Dosage]
MH  - *Digitalis Glycosides/tu [Therapeutic Use]
MH  - Drug Therapy, Combination
MH  - *Exercise/ph [Physiology]
MH  - Female
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - *Rest/ph [Physiology]
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Digitalis Glycosides)
IS  - 0300-9734
IL  - 0300-9734
PT  - Journal Article
LG  - English
DP  - 2001
DC  - 20020130
YR  - 2001
ED  - 20020703
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11817566

<714. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 12010933
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Garrigue S
AU  - Bordachar P
AU  - Reuter S
AU  - Jais P
AU  - Kobeissi A
AU  - Gaggini G
AU  - Haissaguerre M
AU  - Clementy J
FA  - Garrigue, S
FA  - Bordachar, P
FA  - Reuter, S
FA  - Jais, P
FA  - Kobeissi, A
FA  - Gaggini, G
FA  - Haissaguerre, M
FA  - Clementy, J
IN  - Garrigue,S. Hopital Cardiologique du Haut-Leveque, University of Bordeaux, Bordeaux-Pessac, France Sorin Biomedica, 9, rue Georges Besse, Bat.4, 92160 Antony, France. stgarrigue@aol.com
TI  - Comparison of permanent left ventricular and biventricular pacing in patients with heart failure and chronic atrial fibrillation: prospective haemodynamic study.
SO  - Heart. 87(6):529-34, 2002 Jun.
AS  - Heart. 87(6):529-34, 2002 Jun.
NJ  - Heart (British Cardiac Society)
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 9602087
OI  - Source: NLM. PMC1767120
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - England
MH  - Adult
MH  - Aged
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Cardiac Pacing, Artificial/mt [Methods]
MH  - Chronic Disease
MH  - Cross-Over Studies
MH  - Echocardiography/mt [Methods]
MH  - Exercise/ph [Physiology]
MH  - Exercise Test
MH  - *Heart Failure/co [Complications]
MH  - Heart Failure/pp [Physiopathology]
MH  - Hemodynamics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxygen Consumption
MH  - Pacemaker, Artificial
MH  - Prospective Studies
MH  - Single-Blind Method
AB  - OBJECTIVE: To compare clinical and haemodynamic variables between left ventricular and biventricular pacing in patients with severe heart failure; and to analyse haemodynamic changes during daily life and maximum exercise during chronic left ventricular and biventricular pacing.
AB  - DESIGN: Prospective single blinded randomised study with crossover.
AB  - SETTING: University hospital (tertiary referral centre).
AB  - PATIENTS AND METHODS: 13 patients (mean (SD) age, 62 (6) years) with chronic atrial fibrillation, severe heart failure (mean ejection fraction 24 (8)%), and QRS prolongation of > or = 140 ms had His bundle ablation and installation of a pacemaker providing left ventricular and biventricular pacing. The pacemaker was equipped with a peak endocardial acceleration (PEA) sensor. The PEA pattern was used as a haemodynamic marker during exercise as it is highly correlated with left ventricular dP/dt. After a baseline period of right ventricular pacing, all patients had two months of left ventricular pacing and two months of biventricular pacing in random order. At the end of each phase, an echocardiogram, a haemodynamic analysis at rest and on exercise during a six minute walk test, and a cardiopulmonary exercise test were performed.
AB  - RESULTS: PEA values were higher with left ventricular pacing (0.58 (0.38) m/s) and biventricular pacing (0.62 (0.24) m/s) than at baseline (0.49 (0.18) m/s) (p < 0.05). The six minute walk test showed similar performance in both pacing modes, but patients had more symptoms with left ventricular pacing at the end of the test (p = 0.035). On cardiopulmonary exercise testing, there was a greater increase in mean percentage variation of PEA with biventricular pacing than with left ventricular pacing (125 (18)% v 97 (36)%, respectively; p = 0.048) and better performance figures (92 (34) W v 77 (23) W; p = 0.03).
AB  - CONCLUSIONS: During symptom limited and daily life exercise tests, chronic biventricular pacing provides better haemodynamic performance than left ventricular pacing. In heart failure patients with wide QRS complexes, the interventricular dyssynchronisation induced by left ventricular pacing may impair myocardial function during exercise.
ES  - 1468-201X
IL  - 1355-6037
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 2002 Jun
DC  - 20020515
YR  - 2002
ED  - 20020618
RD  - 20140612
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=12010933

<715. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11867497
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Manoharan G
AU  - Campbell NP
AU  - O'Brien CJ
FA  - Manoharan, G
FA  - Campbell, N P S
FA  - O'Brien, C J
IN  - Manoharan,G. Regional Medical Cardiology Centre, Royal Victoria Hospital, Grosvenor Road, Belfast BT12 6BA, Northern Ireland, UK. gmanoharan@msn.com
TI  - Syncopal episodes in a young amateur body builder.
SO  - British Journal of Sports Medicine. 36(1):67-8, 2002 Feb.
AS  - Br J Sports Med. 36(1):67-8, 2002 Feb.
NJ  - British journal of sports medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0432520, b2w
OI  - Source: NLM. PMC1724457
SB  - Index Medicus
CP  - England
MH  - Adult
MH  - Anabolic Agents/ad [Administration & Dosage]
MH  - Bradycardia/ci [Chemically Induced]
MH  - *Bromocriptine/ae [Adverse Effects]
MH  - Fasting/ae [Adverse Effects]
MH  - Humans
MH  - Male
MH  - *Substance-Related Disorders/co [Complications]
MH  - *Syncope/ci [Chemically Induced]
MH  - *Weight Lifting
AB  - A 36 year old male weight training enthusiast suffered several syncopal episodes. An electrocardiogram confirmed atrial fibrillation with normal ventricular response. The patient admitted to taking anabolic steroids and bromocriptine. The atrial fibrillation was considered to be due to bromocriptine misuse.
RN  - 0 (Anabolic Agents)
RN  - 3A64E3G5ZO (Bromocriptine)
IS  - 0306-3674
IL  - 0306-3674
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2002 Feb
DC  - 20020227
YR  - 2002
ED  - 20020328
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11867497

<716. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11675844
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lam AY
AU  - Elmer GW
AU  - Mohutsky MA
FA  - Lam, A Y
FA  - Elmer, G W
FA  - Mohutsky, M A
IN  - Lam,A Y. Department of Pharmacy, University of Washington, Seattle 98104-3031, USA. aylam@u.washington.edu
TI  - Possible interaction between warfarin and Lycium barbarum L.
SO  - Annals of Pharmacotherapy. 35(10):1199-201, 2001 Oct.
AS  - Ann Pharmacother. 35(10):1199-201, 2001 Oct.
NJ  - The Annals of pharmacotherapy
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - bbx, 9203131
SB  - Index Medicus
CP  - United States
MH  - Anticoagulants/me [Metabolism]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - *Aryl Hydrocarbon Hydroxylases
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - *Beverages
MH  - Cytochrome P-450 CYP2C9
MH  - Cytochrome P-450 Enzyme System/de [Drug Effects]
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - International Normalized Ratio
MH  - Middle Aged
MH  - *Steroid 16-alpha-Hydroxylase
MH  - Steroid Hydroxylases/de [Drug Effects]
MH  - Warfarin/me [Metabolism]
MH  - *Warfarin/tu [Therapeutic Use]
AB  - OBJECTIVE: To describe a patient who was stabilized on warfarin and developed an elevated international normalized ratio (INR) after drinking a concentrated Chinese herbal tea. Additionally, to determine the effect of the tea on CYP2C9, the isoenzyme responsible for the metabolism of S-warfarin.
AB  - CASE SUMMARY: An elevated INR of 4.1 was observed in a 61-year-old Chinese woman, previously stabilized on anticoagulation therapy (INR 2-3). With no changes in her other medications or lifestyle, a review of her dietary habits revealed four days of drinking a concentrated Chinese herbal tea made from Lycium barbarum L. fruits (3-4 glasses daily) prior to her clinic visit Warfarin was withheld for one day and then resumed at a lower weekly dose. She discontinued the tea, while maintaining consistency with medications and dietary habits. A follow-up INR seven days later was 2.4, and seven subsequent INR values were in the 2.0-2.5 range.
AB  - DISCUSSION: L barbarum L. (family Solanaceae) is a commonly used Chinese herb considered to have a tonic effect on various organs. Any impact of an herbal product on the metabolism of S-warfarin, the enantiomer responsible for most of the anticoagulant activity, could alter the INR values. An herbal-drug interaction was suspected in this case. In vitro evaluation showed inhibition of S-warfarin metabolism by CYP2C9 by the tea of L. barbarum L.; however, the inhibition observed was weak, with a dissociation constant (Ki) value of 3.4 mg/mL, suggesting that the observed interaction may be caused by factors other than the CYP450 system.
AB  - CONCLUSIONS: There is a potential herbal-drug interaction between warfarin and L. barbarum L., based on an increased INRvalue noted with concurrent use. Thus, combination of L. barbarum L. and warfarin should be avoided. Vigilance is needed with other herbal combinations taken with drugs of narrow therapeutic indices.
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9035-51-2 (Cytochrome P-450 Enzyme System)
RN  - EC 1-14 (Steroid Hydroxylases)
RN  - EC 1-14-13 (CYP2C9 protein, human)
RN  - EC 1-14-13 (Cytochrome P-450 CYP2C9)
RN  - EC 1-14-14-1 (Aryl Hydrocarbon Hydroxylases)
RN  - EC 1-14-14-1 (Steroid 16-alpha-Hydroxylase)
IS  - 1060-0280
IL  - 1060-0280
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2001 Oct
DC  - 20011024
YR  - 2001
ED  - 20020305
RD  - 20141120
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11675844

<717. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11725261
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Vitola JV
AU  - Brambatti JC
AU  - Caligaris F
AU  - Lesse CR
AU  - Nogueira PR
AU  - Joaquim AI
AU  - Loyo M
AU  - Salis FV
AU  - Paiva EV
AU  - Chalela WA
AU  - Meneghetti JC
FA  - Vitola, J V
FA  - Brambatti, J C
FA  - Caligaris, F
FA  - Lesse, C R
FA  - Nogueira, P R
FA  - Joaquim, A I
FA  - Loyo, M
FA  - Salis, F V
FA  - Paiva, E V
FA  - Chalela, W A
FA  - Meneghetti, J C
IN  - Vitola,J V. Heart Institute, the Institute for Nuclear Medicine, and the Division of Nuclear Medicine, Medical School, Sao Jose do Rio Preto, Brazil. joaovitola@quantamn.com.br
TI  - Exercise supplementation to dipyridamole prevents hypotension, improves electrocardiogram sensitivity, and increases heart-to-liver activity ratio on Tc-99m sestamibi imaging.
SO  - Journal of Nuclear Cardiology. 8(6):652-9, 2001 Nov-Dec.
AS  - J Nucl Cardiol. 8(6):652-9, 2001 Nov-Dec.
NJ  - Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - cmd, 9423534
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Dipyridamole/tu [Therapeutic Use]
MH  - *Electrocardiography/de [Drug Effects]
MH  - *Exercise Test/de [Drug Effects]
MH  - *Exercise Test/mt [Methods]
MH  - Female
MH  - *Heart/pp [Physiopathology]
MH  - *Heart/ri [Radionuclide Imaging]
MH  - Hemodynamics/de [Drug Effects]
MH  - Hemodynamics/ph [Physiology]
MH  - Humans
MH  - *Hypotension/pc [Prevention & Control]
MH  - *Liver/pp [Physiopathology]
MH  - *Liver/ri [Radionuclide Imaging]
MH  - Lung/pp [Physiopathology]
MH  - Lung/ri [Radionuclide Imaging]
MH  - Male
MH  - Middle Aged
MH  - *Myocardial Ischemia/pp [Physiopathology]
MH  - *Myocardial Ischemia/ri [Radionuclide Imaging]
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - *Radiopharmaceuticals
MH  - Sensitivity and Specificity
MH  - *Technetium Tc 99m Sestamibi
MH  - Tomography, Emission-Computed, Single-Photon
MH  - *Vasodilator Agents/tu [Therapeutic Use]
MH  - Work Capacity Evaluation
AB  - BACKGROUND: Myocardial perfusion imaging with dipyridamole is an alternative with which to evaluate patients who are unable to exercise. Many patients who undergo dipyridamole testing are limited in their ability, but are not completely unable, to exercise. There are benefits from adding low workload exercise to dipyridamole testing, including a reduction of thallium 201 concentration in the liver, leading to a higher heart-to-liver activity ratio and better image quality. This prospective study was designed to evaluate a protocol of exercise supplementation during dipyridamole technetium 99m sestamibi imaging and to verify whether a higher heart-to-liver activity ratio could be obtained. We also evaluated the potential of this combined protocol to prevent hypotension and induce ischemic changes on the electrocardiogram (ECG).
AB  - METHODS AND RESULTS: Ninety consecutive patients who were not completely disabled for exercise underwent dipyridamole Tc-99m sestamibi cardiac single photon emission computed tomography with a protocol of exercise supplementation (DipEx). The heart-to-liver activity ratio, hemodynamics, and electrocardiographic changes were studied. The findings were compared with those of a control group (Dip) composed of 99 patients who underwent dipyridamole infusion alone. Patients with left bundle branch block, pacemaker, and atrial fibrillation were excluded. The DipEx patients tolerated the protocol, exercising 4.2 +/- 1.3 minutes on the treadmill (Bruce protocol). Compared with Dip, patients in the DipEx group had a higher heart-to-liver activity ratio (1.3 +/- 0.4 vs 1.6 +/- 0.5, respectively; P =.00001), had no incidence of hypotension (6% vs 0%, respectively; P =.03), and had a higher sensitivity of the ECG to detect ischemia (6% vs 34%, respectively; P =.003). The increase in sensitivity seen in the DipEx group was accompanied by a significant decrease in specificity compared with the Dip group (67% vs 100%, P =.000001).
AB  - CONCLUSIONS: Our data show that the addition of limited exercise to dipyridamole results in benefits during Tc-99m sestamibi imaging, increasing heart-to-liver activity ratio, preventing vasodilator-induced hypotension, and improving ECG sensitivity for the detection of ischemia. Furthermore, this protocol also provides an estimation of the patient's physical capacity and could be used as an alternative for patients undergoing dipyridamole infusion who are not completely unable to exercise.
RN  - 0 (Radiopharmaceuticals)
RN  - 0 (Vasodilator Agents)
RN  - 64ALC7F90C (Dipyridamole)
RN  - 971Z4W1S09 (Technetium Tc 99m Sestamibi)
IS  - 1071-3581
IL  - 1071-3581
PT  - Clinical Trial
PT  - Journal Article
LG  - English
DP  - 2001 Nov-Dec
DC  - 20011128
YR  - 2001
ED  - 20020111
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11725261

<718. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11757511
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Anonymous
TI  - Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 37-2001. A 76-year-old man with fever, dyspnea, pulmonary infiltrates, pleural effusions, and confusion.
SO  - New England Journal of Medicine. 345(22):1627-34, 2001 Nov 29.
AS  - N Engl J Med. 345(22):1627-34, 2001 Nov 29.
NJ  - The New England journal of medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0255562, now
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Atrial Fibrillation/et [Etiology]
MH  - Bone Marrow/pa [Pathology]
MH  - Confusion/et [Etiology]
MH  - Diagnosis, Differential
MH  - Dyspnea/et [Etiology]
MH  - *Ehrlichia/ip [Isolation & Purification]
MH  - Ehrlichiosis/bl [Blood]
MH  - Ehrlichiosis/co [Complications]
MH  - *Ehrlichiosis/di [Diagnosis]
MH  - Fever/et [Etiology]
MH  - Granulocytes
MH  - Humans
MH  - Lung/pa [Pathology]
MH  - Lung/ra [Radiography]
MH  - Male
MH  - Pleural Effusion/et [Etiology]
MH  - Pneumonia/di [Diagnosis]
MH  - Sexually Transmitted Diseases/di [Diagnosis]
MH  - Tick-Borne Diseases/di [Diagnosis]
MH  - Tomography, X-Ray Computed
IS  - 0028-4793
IL  - 0028-4793
PT  - Case Reports
PT  - Clinical Conference
PT  - Journal Article
LG  - English
DP  - 2001 Nov 29
DC  - 20011119
YR  - 2001
ED  - 20011228
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11757511

<719. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11513435
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Chen MC
AU  - Chang JP
AU  - Guo GB
AU  - Chang HW
FA  - Chen, M C
FA  - Chang, J P
FA  - Guo, G B
FA  - Chang, H W
IN  - Chen,M C. Department of Medicine, Chang Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China.
TI  - Atrial size reduction as a predictor of the success of radiofrequency maze procedure for chronic atrial fibrillation in patients undergoing concomitant valvular surgery.
CM  - Comment in: J Cardiovasc Electrophysiol. 2001 Aug;12(8):875-6; PMID: 11513436
SO  - Journal of Cardiovascular Electrophysiology. 12(8):867-74, 2001 Aug.
AS  - J Cardiovasc Electrophysiol. 12(8):867-74, 2001 Aug.
NJ  - Journal of cardiovascular electrophysiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - by4, 9010756
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/mo [Mortality]
MH  - *Atrial Fibrillation/su [Surgery]
MH  - Cardiac Surgical Procedures/mo [Mortality]
MH  - *Cardiac Surgical Procedures
MH  - *Catheter Ablation
MH  - Chronic Disease
MH  - Cryosurgery/mo [Mortality]
MH  - Echocardiography, Doppler
MH  - Female
MH  - Follow-Up Studies
MH  - *Heart Atria/pp [Physiopathology]
MH  - *Heart Atria/su [Surgery]
MH  - Heart Atria/us [Ultrasonography]
MH  - Heart Rate/ph [Physiology]
MH  - *Heart Valve Diseases/co [Complications]
MH  - Heart Valve Diseases/mo [Mortality]
MH  - *Heart Valve Diseases/su [Surgery]
MH  - Humans
MH  - Length of Stay
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve/su [Surgery]
MH  - Postoperative Care
MH  - Predictive Value of Tests
MH  - Sensitivity and Specificity
MH  - Survival Analysis
MH  - Time Factors
AB  - INTRODUCTION: Previous studies showed that the surgical maze procedure can restore sinus rhythm and atrial transport function in patients with chronic atrial fibrillation (AF). However, no previous studies discussed the association of atrial size reduction and the success of sinus conversion by the radiofrequency (RF) maze procedure for chronic AF.
AB  - METHODS AND RESULTS: A total of 119 chronic AF patients undergoing valvular operations were included in this study. Sixty-one patients received RF and cryoablation to create lesions in both atria to simulate the surgical maze II or III procedure (RF maze II or RF maze III; 13 patients, group 1) or a modified maze pattern (RF maze "IV"; 48 patients, group 2). The other 58 patients who underwent valvular operations alone without the maze procedure served as control (group 3). At 3-month follow-up after operation, sinus rhythm was restored in 73%, 81%, and 11% of patients in groups 1, 2 and 3, respectively. Preoperative left and right atrial sizes were not statistically significant predictors of sinus conversion by the RF maze procedure. However, as a result of postoperative reduction of atrial sizes, postoperative left atrial diameter was significantly smaller in patients who had sinus conversion by the RF maze procedure than in patients who did not regain sinus rhythm (45.0+/-7.0 mm vs 51.0+/-8.0 mm; P = 0.03). Postoperative right atrial area of patients who had sinus conversion by the RF maze procedure also was significantly smaller than that of patients who did not regain sinus rhythm (18.1+/-4.4 cm2 vs 28.5+/-8.2 cm2; P = 0.008).
AB  - CONCLUSION: Atrial size reduction appears to predict the success of sinus conversion with the RF maze procedure used in conjunction with valvular surgery.
RN  - 0 (Anticoagulants)
IS  - 1045-3873
IL  - 1045-3873
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 2001 Aug
DC  - 20010821
YR  - 2001
ED  - 20011221
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11513435

<720. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11696833
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Li W
AU  - Somerville J
AU  - Gibson DG
AU  - Henein MY
FA  - Li, W
FA  - Somerville, J
FA  - Gibson, D G
FA  - Henein, M Y
IN  - Li,W. Royal Brompton Hospital and Imperial College School of Medicine, London University, Sydney Street, London SW3 6NP, UK.
TI  - Disturbed atrioventricular electromechanical function long after Mustard operation for transposition of great arteries: a potential contributing factor to atrial flutter.
SO  - Journal of the American Society of Echocardiography. 14(11):1088-93, 2001 Nov.
AS  - J Am Soc Echocardiogr. 14(11):1088-93, 2001 Nov.
NJ  - Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - aof, 8801388
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - *Atrial Flutter/et [Etiology]
MH  - Atrial Flutter/us [Ultrasonography]
MH  - Atrial Function, Right/ph [Physiology]
MH  - Electrocardiography
MH  - Electrophysiology
MH  - Female
MH  - Heart Conduction System/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - *Transposition of Great Vessels/co [Complications]
MH  - Transposition of Great Vessels/su [Surgery]
AB  - OBJECTIVE: The objectives were to study atrial and ventricular electromechanical function in patients long after Mustard repair for transposition of great arteries and to identify possible causes and physiologic disturbances in those with recurrent atrial flutter.
AB  - METHODS: Electromechanical atrial and ventricular function was assessed in 22 patients (11 women) aged 27 +/- 5 years, 10 to 29 (mean 24) years after initial Mustard operation with electrocardiography and echocardiography. The study subjects involved 12 patients with documented atrial flutter and the remaining 10 without history of atrial arrhythmia served as controls. All patients were studied while in sinus rhythm.
AB  - RESULTS: There was no difference in age, gender, or age at original Mustard surgery between the 2 patient groups. The P wave and QRS duration were significantly broader in patients compared with controls (128 +/- 14 ms vs 100 +/- 10 ms, P <.05 and 120 +/- 20 ms vs 93 +/- 6 ms, P <.01). Right ventricular end diastolic dimension was not different, whereas left ventricular fraction shortening was less (20% +/- 10% vs 35% +/- 12%, P <.01) in the patient group. Left and septal total ventricular long axes amplitude were significantly lower in patients compared with controls (1.4 +/- 0.4 cm vs 1.7 +/- 0.3 cm, P <.05 and 0.6 +/- 0.2 cm vs 1.0 +/- 0.3 cm, P <.01). Right-sided total long axis excursion was equally reduced in the 2 groups (1.0 +/- 0.3 cm). Septal and right-sided but not left-sided "a" wave was smaller in the patients (1.2 +/- 1 mm vs 3 +/- 1.2 mm, P <.001 and 1 +/- 1.3 mm vs 3 +/- 0.9 mm, P <.01). Right atrial electromechanical delay was significantly longer in patients with respect to controls (110 +/- 14 ms vs 84 +/- 25 ms, P <.001), but on the left there was no difference. The P wave duration correlated closely with right atrial electromechanical delay, r = 0.79, P <.003. Significant tricuspid regurgitation was found in 9 of 12 patients but none of the controls.
AB  - CONCLUSION: Right ventricular dysfunction is present long after Mustard operation for transposition of great arteries whether flutter occurs. However, in patients with history of atrial flutter, evidence of left ventricular dysfunction, significant tricuspid regurgitation, impaired right atrial electrical and mechanical function, and reversed onset of atrial systole is also present. The consistent association of the disturbed atrial and ventricular electromechanical behavior suggests a multifactorial etiology for atrial arrhythmia.
IS  - 0894-7317
IL  - 0894-7317
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2001 Nov
DC  - 20011106
YR  - 2001
ED  - 20011218
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11696833

<721. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11444587
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Aldridge MA
AU  - Ito MK
FA  - Aldridge, M A
FA  - Ito, M K
IN  - Aldridge,M A. University of Pacific, Stockton, California, and Veterans Administration San Diego Healthcare System, USA.
TI  - Fenofibrate and warfarin interaction.
SO  - Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy. 21(7):886-9, 2001 Jul.
AS  - Pharmacotherapy. 21(7):886-9, 2001 Jul.
NJ  - Pharmacotherapy
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - par, 8111305
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - *Anticoagulants/pk [Pharmacokinetics]
MH  - Blood Coagulation/de [Drug Effects]
MH  - Blood Coagulation/ph [Physiology]
MH  - Drug Interactions/ph [Physiology]
MH  - Drug Synergism
MH  - *Fenofibrate/pk [Pharmacokinetics]
MH  - Humans
MH  - *Hypolipidemic Agents/pk [Pharmacokinetics]
MH  - International Normalized Ratio
MH  - Male
MH  - *Warfarin/pk [Pharmacokinetics]
AB  - A 79-year-old man with atrial fibrillation and coronary heart disease who was taking warfarin (Coumadin) was converted to fenofibrate from gemfibrozil therapy for persistently elevated triglyceride levels. The patient took fenofibrate for 1 month and subsequently experienced rectal bleeding that required a visit to the emergency room. Before starting fenofibrate therapy, his coagulation values were within therapeutic range, but when measured in the emergency room the international normalized ratio (INR) was grossly elevated. The patient denied any changes in diet, alcohol ingestion, compliance with therapy, or use of other new drugs except for fenofibrate. His drug therapy profile consisted of digoxin, fosinopril, and furosemide for chronic heart failure, allopurinol for gout, and potassium supplementation. To minimize the risk of supratherapeutic INR values and/or hemorrhagic events, clinicians should perform serial monitoring of INR when initiating fenofibrate therapy in a patient previously stabilized on a coumarin anticoagulant.
RN  - 0 (Anticoagulants)
RN  - 0 (Hypolipidemic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - U202363UOS (Fenofibrate)
IS  - 0277-0008
IL  - 0277-0008
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2001 Jul
DC  - 20010710
YR  - 2001
ED  - 20011204
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11444587

<722. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11432217
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Futterman LG
AU  - Lemberg L
FA  - Futterman, L G
FA  - Lemberg, L
IN  - Futterman,L G. Division of Cardiology, Department of Medicine, University of Miami School of Medicine, Miami, Fla., USA.
TI  - Heart failure: update on treatment and prognosis.
SO  - American Journal of Critical Care. 10(4):285-93, 2001 Jul.
AS  - Am J Crit Care. 10(4):285-93, 2001 Jul.
NJ  - American journal of critical care : an official publication, American Association of Critical-Care Nurses
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - bum, 9211547
SB  - Index Medicus
SB  - Nursing Journal
CP  - United States
MH  - Adrenergic beta-Antagonists/tu [Therapeutic Use]
MH  - Angiotensin-Converting Enzyme Inhibitors/tu [Therapeutic Use]
MH  - Critical Care/mt [Methods]
MH  - Diet, Sodium-Restricted
MH  - Diuretics/tu [Therapeutic Use]
MH  - Exercise
MH  - Heart Failure/et [Etiology]
MH  - Heart Failure/pp [Physiopathology]
MH  - *Heart Failure/th [Therapy]
MH  - Heart-Assist Devices
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mineralocorticoid Receptor Antagonists/tu [Therapeutic Use]
MH  - Patient Compliance
MH  - Prognosis
MH  - Ventricular Remodeling
AB  - HF is a prevalent and debilitating disease, affecting nearly 5 million patients and perhaps an equal number with asymptomatic left ventricular dysfunction who are at high risk of atrial fibrillation developing. An estimated 550,000 new cases occur every year. HF is the most common diagnosis in hospitalized patients aged 65 and over and is a major cause of death. The median survival after onset is 1.7 years in men and 3.2 years in women. The majority of cardiac deaths in patients with HF are sudden and arrhythmogenic: the rest are due to progressive hemodynamic deterioration. A significant advance in the past decade has been the recognition of the importance of inhibiting the neurohormonal action in HF with the use of beta-blockers, angiotensin receptor, and aldosterone antagonists. In addition, a new concept in HF therapy has evolved. The view that chronic HF is an irreversible, end-stage process is being supplanted by the fact that it is possible to effect biological improvement in the intrinsic defects of function and structure in hearts afflicted with chronic HF. Reversibility of HF has been reported by (1) unloading the failing heart using an LVAD, (2) the sophisticated use of diuretic combinations and neurohormonal blocking drugs, or (3) employing continuous arteriovenous hemofiltration. Thus it is now possible to reverse a process that has long been considered irreversible. Exercise programs designed for patients with HF that have been advocated recently can be difficult to apply. Fine tuning of an exercise regimen is required because a reduction in cardiac work is mandatory when treating HF, where the concern is that the heart may not be capable of supplying the metabolic needs of the body, even in resting states. Finally, although not emphasized in the recent literature on HF, the use of diuretics and sodium restriction continue to be the mainstays of therapy without which compensation of HF is not possible.
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Diuretics)
RN  - 0 (Mineralocorticoid Receptor Antagonists)
IS  - 1062-3264
IL  - 1062-3264
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2001 Jul
DC  - 20010702
YR  - 2001
ED  - 20011204
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11432217

<723. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11511429
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Agarwal AK
AU  - Venugopalan P
FA  - Agarwal, A K
FA  - Venugopalan, P
IN  - Agarwal,A K. Department of Cardiology, College of Medicine, Sultan Qaboos University, P.O. Box 35, PC 123, Muscat, Sultanate of Oman. ajita@omantel.net.om
TI  - Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy.
SO  - European Journal of Heart Failure. 3(4):437-40, 2001 Aug.
AS  - Eur J Heart Fail. 3(4):437-40, 2001 Aug.
NJ  - European journal of heart failure
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - dr4, 100887595
SB  - Index Medicus
CP  - Netherlands
MH  - Adult
MH  - Aged
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - *Carbazoles/ad [Administration & Dosage]
MH  - Cardiomyopathy, Dilated/co [Complications]
MH  - *Cardiomyopathy, Dilated/dt [Drug Therapy]
MH  - *Digitalis Glycosides/ad [Administration & Dosage]
MH  - Exercise
MH  - Female
MH  - Heart Failure/co [Complications]
MH  - *Heart Failure/dt [Drug Therapy]
MH  - Heart Function Tests
MH  - *Heart Rate/de [Drug Effects]
MH  - Heart Rate/ph [Physiology]
MH  - Hemodynamics/de [Drug Effects]
MH  - Hemodynamics/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Probability
MH  - *Propanolamines/ad [Administration & Dosage]
MH  - Reference Values
MH  - Sensitivity and Specificity
MH  - Treatment Outcome
AB  - Fourteen digitalised patients diagnosed with heart failure (NYHA Functional class II) with idiopathic dilated cardiomyopathy in chronic established atrial fibrillation were administered carvedilol in addition to their anti-heart failure medications in an attempt to improve their heart rate control. Fourteen matched patients who did not receive carvedilol acted as control subjects. Patients treated with carvedilol showed significantly reduced resting heart rates (10-36%), maximal heart rates on exercise (5-20%) and an increased exercise time (2-30%) on treadmill stress tests (all P=0.001). Ventricular ectopic activity was also diminished. This was associated with symptomatic improvement in effort intolerance and palpitations. NYHA functional class, left ventricular dimensions and ejection fractions did not improve during the study period of 3 months. Thus, addition of carvedilol to digoxin had a beneficial effect on exercise tolerance in patients with idiopathic dilated cardiomyopathy in atrial fibrillation by virtue of an improved heart rate control both at rest and on exercise. Carvedilol was well tolerated despite impaired myocardial function.
RN  - 0 (Carbazoles)
RN  - 0 (Digitalis Glycosides)
RN  - 0 (Propanolamines)
RN  - 0K47UL67F2 (carvedilol)
IS  - 1388-9842
IL  - 1388-9842
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
LG  - English
DP  - 2001 Aug
DC  - 20010820
YR  - 2001
ED  - 20011018
RD  - 20130528
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11511429

<724. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11346250
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Li-Saw-Hee FL
AU  - Blann AD
AU  - Edmunds E
AU  - Gibbs CR
AU  - Lip GY
FA  - Li-Saw-Hee, F L
FA  - Blann, A D
FA  - Edmunds, E
FA  - Gibbs, C R
FA  - Lip, G Y
IN  - Li-Saw-Hee,F L. University Department of Medicine, City Hospital, Birmingham, United Kingdom.
TI  - Effect of acute exercise on the raised plasma fibrinogen, soluble P-selectin and von Willebrand factor levels in chronic atrial fibrillation.
SO  - Clinical Cardiology. 24(5):409-14, 2001 May.
AS  - Clin Cardiol. 24(5):409-14, 2001 May.
NJ  - Clinical cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - de9, 7903272
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation/bl [Blood]
MH  - Chronic Disease
MH  - *Exercise/ph [Physiology]
MH  - Female
MH  - *Fibrinogen/an [Analysis]
MH  - Hemostasis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *P-Selectin/bl [Blood]
MH  - *von Willebrand Factor/an [Analysis]
AB  - BACKGROUND: There is increasing evidence that chronic atrial fibrillation (AF) is associated with a prothrombotic or hypercoagulable state.
AB  - HYPOTHESIS: This study was undertaken to determine whether short-term exercise in patients with chronic AF would shift the overall hemostatic balance toward a more prothrombotic state with a reduction in fibrinolytic potential.
AB  - METHODS: We recruited 20 patients (13 men; mean age 65 years +/- 11 standard deviation [SD]) with chronic AF who were not treated with antithrombotic therapy and exercised them to exhaustion using a multistage treadmill exercise (standard Bruce) protocol. Blood samples were taken pre exercise, immediately after cessation of exercise, and at 20 min post exercise. The prothrombotic state was quantified by fibrinogen (an index of hemorheology and a coagulation factor), soluble P-selectin (sP-sel, marking platelet activation), von Willebrand factor (vWF, an index of endothelial dysfunction), and plasminogen activator inhibitor-1 (PAI-1, a regulator of fibrinolytic activity) levels. There were two groups of age- and gender-matched controls in sinus rhythm: (1) healthy controls, and (2) "hospital controls" who were patients with vascular disease.
AB  - RESULTS: Baseline levels of vWf (p = 0.034) and fibrinogen (p < 0.0001), but not sP-sel (p = 0.075) were significantly elevated in patients with AF compared with both control groups in sinus rhythm. The PAI-1 levels were highest in the hospital control patients, but not in chronic AF (p = 0.041). Following treadmill exercise, achieving a mean metabolic equivalent of 4.9 METS (+/- 1.75 SD) and total exercise duration of 4.9 min (+/- 2 SD), there was a significant rise in plasma fibrinogen (repeated measures analysis of variance [ANOVA] p = 0.047) and a reduction in PAI-1 levels (p = 0.025) in patients with AF. There were no significant changes seen in vWf (p = 0.308) or sP-sel (p = 0.071) levels. No significant changes in these indices were seen in hospital controls (all p = not significant), despite a much longer duration of exercise with greater workload.
AB  - CONCLUSION: Patients with chronic AF have increased vWf and fibrinogen levels compared with sinus rhythm. Exercise to exhaustion influences the hypercoagulable state in chronic AF, with a rise in plasma fibrinogen and possible increase in fibrinolytic activity. Nevertheless, acute exercise does not appear to have a significant influence on endothelial dysfunction or platelet activation in patients with AF.
RN  - 0 (P-Selectin)
RN  - 0 (von Willebrand Factor)
RN  - 9001-32-5 (Fibrinogen)
IS  - 0160-9289
IL  - 0160-9289
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2001 May
DC  - 20010510
YR  - 2001
ED  - 20010927
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11346250

<725. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11452333
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Howes CJ
AU  - Reid MC
AU  - Brandt C
AU  - Ruo B
AU  - Yerkey MW
AU  - Prasad B
AU  - Lin C
AU  - Peduzzi P
AU  - Ezekowitz MD
FA  - Howes, C J
FA  - Reid, M C
FA  - Brandt, C
FA  - Ruo, B
FA  - Yerkey, M W
FA  - Prasad, B
FA  - Lin, C
FA  - Peduzzi, P
FA  - Ezekowitz, M D
IN  - Howes,C J. Yale School of Medicine New Haven, CT, USA.
TI  - Exercise tolerance and quality of life in elderly patients with chronic atrial fibrillation.
SO  - Journal of Cardiovascular Pharmacology & Therapeutics. 6(1):23-9, 2001 Jan.
AS  - J Cardiovasc Pharmacol Ther. 6(1):23-9, 2001 Jan.
NJ  - Journal of cardiovascular pharmacology and therapeutics
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - dk2, 9602617
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/co [Complications]
MH  - Chronic Disease
MH  - Comorbidity
MH  - *Exercise Tolerance
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Quality of Life
AB  - BACKGROUND: Atrial fibrillation is the most common arrhythmia affecting the elderly. Although the risk of cardioembolic stroke is well defined, the effects of chronic atrial fibrillation on exercise tolerance and quality of life have been less well quantified.
AB  - METHODS: We compared a group of 52 elderly patients with chronic atrial fibrillation to a group of 48 control patients in sinus rhythm. Each patient underwent an interview that incorporated the Short Form-36 Health Survey (SF-36) to quantify individual perceptions on quality of life. In addition each person underwent physiologic testing that included a Modified Bruce Protocol exercise tolerance test, 24-hour ambulatory monitor test, and an echocardiogram.
AB  - RESULTS: Both groups were elderly, 77 vs 76 years of age (P=0.35). The two groups had similar ejection fractions, 55.4% vs 58.4% (P=0.10). The atrial fibrillation patients demonstrated a higher level of comorbidity based on the Charlson Comorbidity Index, 2.46 vs 1.57 (P=0.03). On formal exercise testing there was no statistical difference in exercise duration between the two groups 9.0 vs 10.1 minutes (P=0.24). Similarly the Physical Summary Score (PCS) and the Mental Summary Score (MCS) of the SF-36 quality of life survey did not demonstrate a statistical difference between the two groups. PCS: 43.0 vs 45.9 (P=0.24);
AB  - MCS: 52.5 vs 55.7 (P=0.07).
AB  - CONCLUSIONS: Despite a higher level of comorbidity, elderly, ambulatory patients with chronic atrial fibrillation demonstrate similar exercise tolerance and report similar quality of life to a group of age-matched control patients in sinus rhythm. There is a cohort of patients in chronic atrial fibrillation in whom a strategy of rate control and anticoagulation may be appropriate.
RN  - 0 (Anticoagulants)
IS  - 1074-2484
IL  - 1074-2484
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2001 Jan
DC  - 20010713
YR  - 2001
ED  - 20010830
RD  - 20140728
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11452333

<726. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11465231
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Albage A
AU  - van der Linden J
AU  - Bengtsson L
AU  - Lindblom D
AU  - Kenneback G
AU  - Berglund H
FA  - Albage, A
FA  - van der Linden, J
FA  - Bengtsson, L
FA  - Lindblom, D
FA  - Kenneback, G
FA  - Berglund, H
IN  - Albage,A. Department of Cardiothoracic Surgery and Anesthesiology, Karolinska Institutet at Huddinge University Hospital, Stockholm, Sweden. anders.albage@thsurg.hs.sll.se
TI  - Elevations in antidiuretic hormone and aldosterone as possible causes of fluid retention in the Maze procedure.
SO  - Annals of Thoracic Surgery. 72(1):58-64, 2001 Jul.
AS  - Ann Thorac Surg. 72(1):58-64, 2001 Jul.
NJ  - The Annals of thoracic surgery
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 683, 15030100r
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - *Aldosterone/bl [Blood]
MH  - Angiotensin II/bl [Blood]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/su [Surgery]
MH  - Atrial Natriuretic Factor/bl [Blood]
MH  - Coronary Artery Bypass
MH  - Female
MH  - Heart Atria/pp [Physiopathology]
MH  - Heart Atria/su [Surgery]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/bl [Blood]
MH  - Postoperative Complications/pp [Physiopathology]
MH  - *Vasopressins/bl [Blood]
MH  - *Water-Electrolyte Balance/ph [Physiology]
AB  - BACKGROUND: Reduced levels of atrial natriuretic peptide (ANP) has been suggested as a cause of fluid retention after combined Maze and valvular surgery. This study aimed to assess hormonal activation in the perioperative setting of isolated Maze procedures.
AB  - METHODS: Changes in ANP, brain natriuretic peptide (BNP), antidiuretic hormone (ADH), aldosterone, and angiotensin II were measured in 16 patients (mean age 53+/-9 years) without concomitant heart disease undergoing the Maze (III) procedure. Ten matched patients (mean age 56+/-9 years) undergoing multivessel coronary artery bypass grafting served as controls. Measurements with hemodynamic correlates were obtained at baseline and after ventricular pacing (100 stimulations/minute), directly preoperatively, postoperatively and the first postoperative day. Weight gain and diuretic requirements were recorded.
AB  - RESULTS: The major differences in hormonal response were significantly higher plasma levels of ADH (Maze preoperative 1.1+/-0.4, postoperative 24.9+/-16.7 pmol/L; controls preoperative 1.1+/-0.1, postoperative 3.7+/-3.5 pmol/L) and aldosterone (Maze preoperative 106+/-94, postoperative 678+/-343 pmol/L; controls preoperative 124+/-79, postoperative 171+/-93 pmol/L) in the Maze group on the first postoperative day (p < 0.001). Preoperative baseline plasma levels of ANP and pulmonary capillary wedge pressures (PCWP) were higher in the Maze group but this difference was abolished by pacing, and postoperatively, ANP levels changed in parallel to the PCWP in both groups. Diuretic requirements were significantly higher in the Maze group.
AB  - CONCLUSIONS: Substantial increases in ADH and aldosterone were observed after the Maze procedure, indicating these hormones as important determinants in postoperative fluid retention. The role for ANP in this setting may be a less prominent than previously reported.
RN  - 11000-17-2 (Vasopressins)
RN  - 11128-99-7 (Angiotensin II)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 4964P6T9RB (Aldosterone)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
IS  - 0003-4975
IL  - 0003-4975
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 2001 Jul
DC  - 20010723
YR  - 2001
ED  - 20010809
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11465231

<727. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11309001
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mayr A
AU  - Knotzer H
AU  - Pajk W
AU  - Luckner G
AU  - Ritsch N
AU  - Dunser M
AU  - Ulmer H
AU  - Schobersberger W
AU  - Hasibeder W
FA  - Mayr, A
FA  - Knotzer, H
FA  - Pajk, W
FA  - Luckner, G
FA  - Ritsch, N
FA  - Dunser, M
FA  - Ulmer, H
FA  - Schobersberger, W
FA  - Hasibeder, W
IN  - Mayr,A. Division of General and Surgical Intensive Care Medicine, Department of Anesthesia and Critical Care Medicine, The Leopold Franzens University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria.
TI  - Risk factors associated with new onset tachyarrhythmias after cardiac surgery--a retrospective analysis.
SO  - Acta Anaesthesiologica Scandinavica. 45(5):543-9, 2001 May.
AS  - Acta Anaesthesiol Scand. 45(5):543-9, 2001 May.
NJ  - Acta anaesthesiologica Scandinavica
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0370270
SB  - Index Medicus
CP  - Denmark
MH  - Aged
MH  - *Cardiac Surgical Procedures/ae [Adverse Effects]
MH  - Female
MH  - Hemodynamics/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Models, Statistical
MH  - Regression Analysis
MH  - Retrospective Studies
MH  - Risk Factors
MH  - *Tachycardia/ep [Epidemiology]
MH  - Tachycardia/pp [Physiopathology]
AB  - BACKGROUND: Tachyarrhythmias (TA) represent a frequent and serious problem after cardiac surgery. We retrospectively analyzed 987 cardiac surgery patients admitted to a surgical intensive care unit between 1996 and 1999 to assess incidence and risk factors associated with development of postoperative TA in the intensive care unit.
AB  - METHODS: TA (n=149) were defined as non-sinus rhythm with a heart rate (HR) > or =100 bpm in patients with preoperative sinus rhythm or as heart rate > or =130 bpm in patients with preoperative atrial fibrillation. A total of 787 patients served as controls (C). Demographic, premorbidity and perioperative data, admission SAPS and MODS-score, presence of clinical syndromes systemic inflammatory response syndrome (SIRS) and sepsis were univariately compared between groups. For prediction of independent risk factors for TA-development two multiple logistic regression models were finally established.
AB  - RESULTS: Concerning TA, atrial fibrillation and flutter (76%) were observed most frequently, followed by paroxysmal supraventricular tachycardia (15%) and ventricular tachycardia/fibrillation (11%). Age, a history or presence of congestive heart failure, development of SIRS and sepsis, severity of multiple organ dysfunction syndrome and in particular severity of cardiovascular failure proved to be independent risk factors for development of TA.
AB  - CONCLUSION: In cardiac surgery patients, age, a history or presence of congestive heart failure, postoperative development of a systemic inflammatory response syndrome or sepsis and the severity of multiple organ function syndrome were independent predictors for development of TA in the intensive care unit. The association of severity of cardiovascular dysfunction with TA strongly suggests a causal relationship between catecholamine therapy and TA-development.
IS  - 0001-5172
IL  - 0001-5172
PT  - Journal Article
LG  - English
DP  - 2001 May
DC  - 20010419
YR  - 2001
ED  - 20010705
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11309001

<728. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11329541
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ohta Y
AU  - Shimada T
AU  - Yoshitomi H
AU  - Inoue S
AU  - Murakami Y
AU  - Shimizu H
AU  - Nakamura K
AU  - Ohta T
AU  - Katoh H
AU  - Ishibashi Y
FA  - Ohta, Y
FA  - Shimada, T
FA  - Yoshitomi, H
FA  - Inoue, S
FA  - Murakami, Y
FA  - Shimizu, H
FA  - Nakamura, K
FA  - Ohta, T
FA  - Katoh, H
FA  - Ishibashi, Y
IN  - Ohta,Y. Shimane Medical University, Enya-cho, Japan.
TI  - Drop in plasma brain natriuretic peptide levels after successful direct current cardioversion in chronic atrial fibrillation.
SO  - Canadian Journal of Cardiology. 17(4):415-20, 2001 Apr.
AS  - Can J Cardiol. 17(4):415-20, 2001 Apr.
NJ  - The Canadian journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - chp, 8510280
SB  - Index Medicus
CP  - Canada
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Atrial Fibrillation/us [Ultrasonography]
MH  - Chronic Disease
MH  - *Electric Countershock
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Natriuretic Peptide, Brain/bl [Blood]
AB  - BACKGROUND: According to previous reports, plasma atrial natriuretic peptide levels increase in atrial fibrillation (AF) and decrease after successful direct current (DC) cardioversion, but there have been no reports on plasma brain natriuretic peptide (BNP).
AB  - OBJECTIVE: To determine whether plasma BNP levels decrease after successful direct DC cardioversion in patients with chronic AF.
AB  - PATIENTS AND METHODS: Twenty patients who remained in sinus rhythm for at least seven days after cardioversion, and 20 normal control subjects, were studied. Group A consisted of 10 patients with underlying heart disease, including dilated cardiomyopathy (n=2), hypertrophic cardiomyopathy (n=1), mitral valve disease (n=3), hypertensive heart disease (n=3) and status after atrial septal closure (n=1). Group B consisted of 10 patients with just AF. Group C (serving as controls) comprised 20 subjects with normal sinus rhythm and no risk factors.
AB  - RESULTS: Before cardioversion, plasma BNP levels were higher in group A (176.7+/-128.1 ng/mL) and in group B (96.8+/-51.7 ng/ml) than in group C (6.3+/-3.8 ng/ml) (P<0.01 for all). After successful cardioversion, mean plasma BNP levels in groups A and B decreased from 136.8+/-105.5 ng/mL to 46.4+/-44.2 ng/mL (P<0.01). In group A, plasma BNP levels decreased from 176.7+/-128.1 ng/mL to 62.5+/-54.6 ng/mL (P<0.01), and in group B, plasma BNP levels decreased from 96.8+/-51.7 ng/mL to 30.3+/-23.8 ng/mL (P<0.01).
AB  - CONCLUSIONS: Lone AF raises plasma BNP levels, which is more marked if there is underlying structural heart disease present, and cardioversion reduces plasma BNP levels. Therefore, high plasma BNP levels in patients with chronic AF are likely to be caused by AF and reflect cardiac overloading associated with, although contributed to in part by, underlying heart diseases.
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
IS  - 0828-282X
IL  - 0828-282X
PT  - Journal Article
LG  - English
DP  - 2001 Apr
DC  - 20010501
YR  - 2001
ED  - 20010607
RD  - 20080409
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11329541

<729. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11196551
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Chen SA
FA  - Chen, S A
TI  - How to find the fibrillating site? Brain exercise versus fancy mapping tools.
CM  - Comment on: J Cardiovasc Electrophysiol. 2000 Dec;11(12):1300-5; PMID: 11196550
SO  - Journal of Cardiovascular Electrophysiology. 11(12):1306-8, 2000 Dec.
AS  - J Cardiovasc Electrophysiol. 11(12):1306-8, 2000 Dec.
NJ  - Journal of cardiovascular electrophysiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - by4, 9010756
SB  - Index Medicus
CP  - United States
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Cardiac Catheterization/is [Instrumentation]
MH  - Cardiac Catheterization/mt [Methods]
MH  - Electrocardiography
MH  - Electrodes
MH  - Electrophysiologic Techniques, Cardiac/is [Instrumentation]
MH  - *Electrophysiologic Techniques, Cardiac/mt [Methods]
MH  - *Heart Conduction System/pp [Physiopathology]
MH  - Humans
MH  - *Pulmonary Veins/pp [Physiopathology]
IS  - 1045-3873
IL  - 1045-3873
PT  - Comment
PT  - Editorial
LG  - English
DP  - 2000 Dec
DC  - 20010122
YR  - 2000
ED  - 20010301
RD  - 20121115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11196551

<730. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11139947
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wozakowska-Kaplon B
AU  - Opolski G
AU  - Kosior D
AU  - Janion M
FA  - Wozakowska-Kaplon, B
FA  - Opolski, G
FA  - Kosior, D
FA  - Janion, M
IN  - Wozakowska-Kaplon,B. Department of Cardiology, Regional District Hospital, Kielce, Poland. energo_kap@poczta.onet.pl
TI  - An increase in plasma atrial natriuretic peptide concentration during exercise predicts a successful cardioversion and maintenance of sinus rhythm in patients with chronic atrial fibrillation.
SO  - Pacing & Clinical Electrophysiology. 23(11 Pt 2):1876-9, 2000 Nov.
AS  - Pacing Clin Electrophysiol. 23(11 Pt 2):1876-9, 2000 Nov.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - United States
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation/bl [Blood]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Atrial Natriuretic Factor/bl [Blood]
MH  - Blood Pressure
MH  - Chronic Disease
MH  - *Electric Countershock
MH  - Electrocardiography
MH  - Exercise Test
MH  - Female
MH  - *Heart Rate
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Oxygen Consumption
MH  - Predictive Value of Tests
MH  - Recurrence
AB  - The aim of this study was to determine the value of an increase in plasma atrial natriuretic peptide (ANP) concentrations during submaximal exercise as a predictor of return of sinus rhythm (SR), and of its maintenance over a period of 6 months after cardioversion (CV) of chronic atrial fibrillation (AF). The study group included 42 patients with AF (mean duration 7 +/- 7 months) and a controlled ventricular rate. They underwent submaximal exercise testing 24 hours before CV. Blood samples were collected at rest and at peak of exercise for measurement of plasma ANP concentrations. Thirty-five of 42 patients were successfully cardioverted to SR. At 6 months, 23 patients remained in SR, while 12 had recurrence of AF. The plasma ANP concentrations before CV increased insignificantly during exercise in patients with unsuccessful CV or with recurrence of AF (60.8 +/- 17.3 pg/mL to 64 +/- 13.5 pg/mL, NS). The mean increase in plasma ANP concentration during exercise was significantly greater in the 23 patients who remained in SR than in the 19 patients unsuccessfully cardioverted or with recurrence of AF (17.5 +/- 7.6 pg/mL vs 5.8 +/- 4.5 pg/mL, P < 0.01). In multivariate logistic regression analysis, an increase in ANP plasma concentration was independently associated with successful CV and maintenance of SR up to 6 months of observation. In patients with chronic AF an exercise-induced increase in ANP concentration predicts successful CV and maintenance of SR.
RN  - 85637-73-6 (Atrial Natriuretic Factor)
IS  - 0147-8389
IL  - 0147-8389
PT  - Clinical Trial
PT  - Journal Article
LG  - English
DP  - 2000 Nov
DC  - 20010103
YR  - 2000
ED  - 20010222
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11139947

<731. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11144040
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Vanhees L
AU  - Schepers D
AU  - Defoor J
AU  - Brusselle S
AU  - Tchursh N
AU  - Fagard R
FA  - Vanhees, L
FA  - Schepers, D
FA  - Defoor, J
FA  - Brusselle, S
FA  - Tchursh, N
FA  - Fagard, R
IN  - Vanhees,L. Department of Rehabilitation Sciences, University of Leuven, Belgium. Luc.Vanhees@uz.kuleuven.ac.be
TI  - Exercise performance and training in cardiac patients with atrial fibrillation.
SO  - Journal of Cardiopulmonary Rehabilitation. 20(6):346-52, 2000 Nov-Dec.
AS  - J Cardiopulm Rehabil. 20(6):346-52, 2000 Nov-Dec.
NJ  - Journal of cardiopulmonary rehabilitation
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - cgv, 8511296
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/rh [Rehabilitation]
MH  - Blood Pressure
MH  - Exercise Test
MH  - *Exercise Therapy
MH  - Heart Rate
MH  - Humans
MH  - Middle Aged
MH  - Oxygen Consumption
MH  - Treatment Outcome
AB  - PURPOSE: Exercise training in cardiac patients with chronic atrial fibrillation (AF) has received little attention in the literature. Therefore, this study compared exercise performance and the effect of an exercise training program over a period of 3 months in patients with and without AF.
AB  - METHODS: Data in patients with AF (n = 19) were compared with a control group of patients in sinus rhythm (n = 44), drawn from a database of 2,116 patients. Patients performed a maximal exercise test on the bicycle until exhaustion before and after an ambulatory exercise training program where exercise training was offered 3 times a week for 3 months.
AB  - RESULTS: Before training, peak oxygen uptake (VO2) was significantly lower in patients with AF compared with the control group (1271 +/- 368 versus 1496 +/- 414 mL/min, P < 0.05). Exercise training significantly increased peak VO2 in both groups (+31%, P < 0.001 in AF and +25%, P < 0.001 in the control group). The gain in peak VO2 did not significantly differ between both groups. A significant decrease in resting heart rate was achieved in both groups after exercise training. AF was also a significant and independent determinant of peak VO2 in the total database, but not of the change in peak VO2.
AB  - CONCLUSIONS: Exercise training significantly improves exercise performance in cardiac patients with AF. AF affects exercise performance but does not impair the beneficial effects of training. Patients with chronic AF should therefore not be dissuaded from participating in exercise training after a cardiac event.
IS  - 0883-9212
IL  - 0883-9212
PT  - Journal Article
LG  - English
DP  - 2000 Nov-Dec
DC  - 20001219
YR  - 2000
ED  - 20010222
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11144040

<732. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11073348
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kallinen M
AU  - Era P
AU  - Heikkinen E
FA  - Kallinen, M
FA  - Era, P
FA  - Heikkinen, E
IN  - Kallinen,M. Peurunka-Medical Rehabilitation and Physical Exercise Center, Laukaa, Finland. mauri.kallinen@peurunka.fi
TI  - Cardiac adverse effects and acute exercise in elderly subjects.
SO  - Aging-Clinical & Experimental Research. 12(4):287-94, 2000 Aug.
AS  - AGING CLIN. EXP. RES.. 12(4):287-94, 2000 Aug.
NJ  - Aging (Milan, Italy)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9102503
SB  - Index Medicus
CP  - ITALY
MH  - Aged
MH  - *Aging/ph [Physiology]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Electrocardiography, Ambulatory
MH  - *Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Female
MH  - *Heart Diseases/et [Etiology]
MH  - Humans
MH  - Male
MH  - Medical Records
MH  - Sex Characteristics
AB  - Cardiac arrhythmias, ST segment depressions and other cardiac adverse effects are occasionally seen in relation to physical exercise in elderly people. However, the magnitude, quality, and time-dependence of these events need to be clarified. During voluntary maximal cycle ergometer exercise (CEE), immediate cardiac disturbances as a reason for exercise termination were registered in a sample of 75-year-old men and women (N=203) (population group, PG). Any referrals to hospital following cardiac incidents within 24 hours post-CEE were obtained from patient records. Ambulatory ECG was recorded 24 hours before and after CEE in 23 elderly subjects (12 men, 11 women) capable of maximal effort (Holter group, HG). In the PG, 23.4% of the men and 6.4% of the women had to terminate CEE because of cardiac disturbances. One subject was referred to hospital because of exercise-induced atrial fibrillation. In the HG, no long-lasting effect of exercise on the occurrence of cardiac disturbances was found in elderly subjects capable of maximal effort.
IS  - 0394-9532
IL  - 0394-9532
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2000 Aug
DC  - 20010205
YR  - 2000
ED  - 20010215
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11073348

<733. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11156667
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Levy T
AU  - Walker S
AU  - Mason M
AU  - Spurrell P
AU  - Rex S
AU  - Brant S
AU  - Paul V
FA  - Levy, T
FA  - Walker, S
FA  - Mason, M
FA  - Spurrell, P
FA  - Rex, S
FA  - Brant, S
FA  - Paul, V
IN  - Levy,T. Department of Cardiology, Royal Brompton and Harefield NHS Trust, Harefield Hospital, Harefield, Middlesex, UB9 6JH, UK. terry@levy77.freeserve.co.uk
TI  - Importance of rate control or rate regulation for improving exercise capacity and quality of life in patients with permanent atrial fibrillation and normal left ventricular function: a randomised controlled study.
SO  - Heart. 85(2):171-8, 2001 Feb.
AS  - Heart. 85(2):171-8, 2001 Feb.
NJ  - Heart (British Cardiac Society)
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 9602087
OI  - Source: NLM. PMC1729623
SB  - Index Medicus
CP  - ENGLAND
MH  - Aged
MH  - Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Cardiac Pacing, Artificial
MH  - Cardiovascular Agents/tu [Therapeutic Use]
MH  - Catheter Ablation
MH  - Combined Modality Therapy
MH  - Exercise Test
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - Follow-Up Studies
MH  - Health Status Indicators
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Quality of Life
MH  - *Ventricular Function, Left/ph [Physiology]
AB  - OBJECTIVE: To determine the importance of rhythm regulation or rate control in patients with permanent atrial fibrillation (AF) and normal left ventricular function.
AB  - PATIENTS AND INTERVENTIONS: Thirty six patients with a mixed fast and slow ventricular response rate to their AF were randomised to either His bundle ablation (HBA) and VVIR pacemaker (HBA group) or VVI pacemaker and atrioventricular modifying drugs (Med group). Outcomes assessed at one, three, six, and 12 months included exercise duration and quality of life.
AB  - RESULTS: Exercise duration significantly improved from baseline in both groups. There was no difference in outcome between the groups (Med +40% v HBA +20%, p = NS). The heart rate profile on exercise was similarly slowed in both groups compared to baseline. Quality of life significantly improved in both treatment arms for the modified Karolinska questionnaire (KQ) (Med +50% v HBA +50%, p = NS) and the Nottingham health profile (NHP) (Med +40% v HBA +20%, p = NS). However, for the individual symptom scores of each questionnaire more were improved in the Med group (KQ-Med 6 improved v HBA 4, NHP-Med 3 v HBA 1). Left ventricular function was equally preserved by both treatments during follow up.
AB  - CONCLUSION: In these patients control of ventricular response rate with either HBA + VVIR pacemaker or atrioventricular modifying drugs + VVI pacemaker will lead to a significant improvement in exercise duration and quality of life. Rhythm regulation by HBA did not confer additional benefit, suggesting rate control alone is necessary for the successful symptomatic treatment of these patients in permanent AF.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Cardiovascular Agents)
ES  - 1468-201X
IL  - 1355-6037
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 2001 Feb
DC  - 20010130
YR  - 2001
ED  - 20010208
RD  - 20140615
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11156667

<734. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11083192
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Thomas GS
AU  - Prill NV
AU  - Majmundar H
AU  - Fabrizi RR
AU  - Thomas JJ
AU  - Hayashida C
AU  - Kothapalli S
AU  - Payne JL
AU  - Payne MM
AU  - Miyamoto MI
FA  - Thomas, G S
FA  - Prill, N V
FA  - Majmundar, H
FA  - Fabrizi, R R
FA  - Thomas, J J
FA  - Hayashida, C
FA  - Kothapalli, S
FA  - Payne, J L
FA  - Payne, M M
FA  - Miyamoto, M I
IN  - Thomas,G S. Mission Internal Medical Group, Mission Viejo, Calif. 92691, USA. gregthomas1@home.com
TI  - Treadmill exercise during adenosine infusion is safe, results in fewer adverse reactions, and improves myocardial perfusion image quality.
SO  - Journal of Nuclear Cardiology. 7(5):439-46, 2000 Sep-Oct.
AS  - J Nucl Cardiol. 7(5):439-46, 2000 Sep-Oct.
NJ  - Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - cmd, 9423534
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Adenosine/ad [Administration & Dosage]
MH  - Adenosine/ae [Adverse Effects]
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Coronary Circulation
MH  - *Coronary Disease/ri [Radionuclide Imaging]
MH  - Exercise Test/ae [Adverse Effects]
MH  - *Exercise Test
MH  - Female
MH  - Hemodynamics
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Radiopharmaceuticals
MH  - Retrospective Studies
MH  - Technetium Tc 99m Sestamibi
MH  - Thallium Radioisotopes
MH  - *Tomography, Emission-Computed, Single-Photon
AB  - BACKGROUND: Combining low-level treadmill exercise with adenosine infusion may result in fewer bradyarrhythmic complications by increasing sympathetic tone and may improve myocardial perfusion image quality by decreasing background activity.
AB  - METHODS: Patients referred for outpatient pharmacologic stress myocardial perfusion imaging performed simultaneous treadmill exercise (mean 2.2 metabolic equivalents) throughout 6-minute adenosine infusion (adenosine-exercise n = 507). Patients unable to exercise and those with left bundle branch block received adenosine infusion alone (adenosine-nonexercise n = 286). Adverse reaction data were collected on all patients and compared by sex. Background-to-target activity was calculated in a blinded fashion on 200 randomly selected patients.
AB  - RESULTS: During the period from April 1996 to December 1998, 507 patients (64%) underwent adenosine-exercise testing, whereas 286 (36%) underwent adenosine-nonexercise testing. Hypotensive and arrhythmic (atrioventricular block, sinus bradycardia, and new onset atrial fibrillation or flutter) adverse reactions occurred less often during adenosine-exercise than during adenosine-nonexercise. Neither death nor myocardial infarction occurred in either group. In the adenosine-exercise group, 2.8% of patients experienced an adverse reaction versus 5.6% of the adenosine-nonexercise group (P = .04). The reduction in adverse reactions occurred in both men and women, although women had significantly more adverse reactions than men (5.7% vs 1.8%, P = .004). Liver/heart and gut/heart ratios were lower in the adenosine-exercise group (1.05+/-0.42 vs. 1.21+/-0.55 , P = .01; 0.61+/-0.21 vs. 0.69+/-0.24, P = .03, respectively).
AB  - CONCLUSIONS: Compared with adenosine infusion alone, combining low-level treadmill exercise with adenosine in outpatients is safe, better tolerated, and improves image quality. Women were more likely to experience adverse reactions than men.
RN  - 0 (Radiopharmaceuticals)
RN  - 0 (Thallium Radioisotopes)
RN  - 971Z4W1S09 (Technetium Tc 99m Sestamibi)
RN  - K72T3FS567 (Adenosine)
IS  - 1071-3581
IL  - 1071-3581
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 2000 Sep-Oct
DC  - 20010122
YR  - 2000
ED  - 20010201
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11083192

<735. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11099628
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Benatar A
AU  - Feenstra A
AU  - Decraene T
AU  - Vandenplas Y
FA  - Benatar, A
FA  - Feenstra, A
FA  - Decraene, T
FA  - Vandenplas, Y
IN  - Benatar,A. Department of Pediatric Cardiology, Academisch Ziekenhuis, Free University of Brussels, Brussels, Belgium.
TI  - Effects of cisapride on corrected QT interval, heart rate, and rhythm in infants undergoing polysomnography.
SO  - Pediatrics. 106(6):E85, 2000 Dec.
AS  - Pediatrics. 106(6):E85, 2000 Dec.
NJ  - Pediatrics
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - oxv, 0376422
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Arrhythmias, Cardiac/ci [Chemically Induced]
MH  - *Cisapride/ae [Adverse Effects]
MH  - Electrocardiography/de [Drug Effects]
MH  - Gastroesophageal Reflux/dt [Drug Therapy]
MH  - Gastrointestinal Agents/ae [Adverse Effects]
MH  - *Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Infant
MH  - *Long QT Syndrome/ci [Chemically Induced]
MH  - *Polysomnography
MH  - Prospective Studies
AB  - OBJECTIVE: To evaluate the effects of cisapride, a prokinetic gastrointestinal drug, on the electrocardiographic QT interval, heart rate, and rhythm in infants during routine 8-hour polysomnography. Reported electrocardiogram (ECG) and rhythm disturbances in a small number of patients with the use of cisapride provided the impetus for this prospective study.
AB  - STUDY DESIGN: Two hundred fifty-two infants born at term were enrolled. Of these, 134 were on cisapride therapy for suspected gastroesophageal reflux and 118 were not on cisapride and served as controls. Cisapride-treated and control infants were from the outset divided into 3 age groups; group 1: under 3 months of age; group 2: between 3 and 6 months of age; and group 3: >6 months of age. Continuous ECG bipolar limb lead I recording, saturation monitoring, and electroencephalography were conducted. QT intervals and heart rate were measured at hourly intervals.
AB  - RESULTS: Cisapride doses were: group 1 mean, 0.80 mg/kg/day (range: 0.38-1.55); group 2 mean, 0.80 mg/kg/day (range: 0. 23-1.38); and group 3 mean, 0.72 mg/kg/day (range: 0.32-1.41). Heart rate was higher in the younger infants, with a gradual decrease with age. No difference in heart rate was detected between the cisapride and control groups. The QTc interval in patients in group 1 was statistically longer than the controls, when applying both Bazett's and Hodges' formulae for QT correction. The other age groups did not differ. No arrhythmia or atrioventricular conduction abnormalities were observed.
AB  - CONCLUSION: Infants under 3 months of age on cisapride treatment had significantly longer QTc intervals (with Bazett's formula, the 98th percentile was 504 ms in the cisapride group vs 447 ms in controls). The clinical significance and risk of the increased QTc interval in these infants are unclear and need further evaluation and risk stratification. Meanwhile, cisapride should be judiciously prescribed in infants <3 months of age.
RN  - 0 (Gastrointestinal Agents)
RN  - UVL329170W (Cisapride)
ES  - 1098-4275
IL  - 0031-4005
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
LG  - English
DP  - 2000 Dec
DC  - 20001205
YR  - 2000
ED  - 20001214
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11099628

<736. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11092104
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ebrahim S
FA  - Ebrahim, S
IN  - Ebrahim,S. Department of Social Medicine, University of Bristol, UK.
TI  - Cost-effectiveness of stroke prevention. [Review] [43 refs]
SO  - British Medical Bulletin. 56(2):557-70, 2000.
AS  - Br Med Bull. 56(2):557-70, 2000.
NJ  - British medical bulletin
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - b4g, 0376542
SB  - Index Medicus
CP  - ENGLAND
MH  - Anticholesteremic Agents/tu [Therapeutic Use]
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - Antihypertensive Agents/tu [Therapeutic Use]
MH  - Cost-Benefit Analysis
MH  - Endarterectomy, Carotid/ec [Economics]
MH  - Humans
MH  - Platelet Aggregation Inhibitors/tu [Therapeutic Use]
MH  - *Stroke/ec [Economics]
MH  - *Stroke/pc [Prevention & Control]
AB  - Stroke is a preventable disease and there are several interventions that might have an important role in reducing the burden of disease. Economic appraisal of these different interventions is essential as resources are scarce and it is logical to attempt to obtain the greatest reduction in disease for the lowest cost. Anticoagulation for non-rheumatic atrial fibrillation is highly effective, but is expensive and cost-effectiveness analyses show that use of aspirin alone would prevent almost as many strokes at much lower cost. Antiplatelet drugs are both effective and inexpensive and their use in secondary prevention would potentially save the NHS about 900 Pounds per life year gained. Carotid endarterectomy and the associated screening costs are poor value for money but recent attempts to use predictive models to determine which patients will benefit from surgery may improve its cost-effectiveness. Current evidence is dominated by pharmacological interventions and much less good evidence is available for life-style modifications such as dietary change and physical exercise. Modification of major cardiovascular risk factors (blood cholesterol, high blood pressure and smoking) is very cost-effective but needs to be better targeted if potential health gain is to be realised. [References: 43]
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Anticoagulants)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
IS  - 0007-1420
IL  - 0007-1420
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2000
DC  - 20001208
YR  - 2000
ED  - 20001208
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11092104

<737. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11041095
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ueshima K
AU  - Nasu M
AU  - Segawa I
AU  - Kamata J
AU  - Kobayashi N
AU  - Nakamura M
AU  - Chiba N
AU  - Hiramori K
FA  - Ueshima, K
FA  - Nasu, M
FA  - Segawa, I
FA  - Kamata, J
FA  - Kobayashi, N
FA  - Nakamura, M
FA  - Chiba, N
FA  - Hiramori, K
IN  - Ueshima,K. Memorial Heart Center, Second Department of Internal Medicine, Iwate Medical University, Japan.
TI  - What determines the heart rate response to exercise in patients with atrial fibrillation?.
SO  - Japanese Heart Journal. 41(4):445-50, 2000 Jul.
AS  - Jpn Heart J. 41(4):445-50, 2000 Jul.
NJ  - Japanese heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - kh3, 0401175
SB  - Index Medicus
CP  - JAPAN
MH  - Aged
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Echocardiography
MH  - *Exercise Test
MH  - Female
MH  - *Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Severity of Illness Index
AB  - We evaluated the factors that determine the heart rate response to exercise in 60 patients with atrial fibrillation (25 men and 35 women, with a mean age of 61+/-10 years) who underwent symptom limited cardiopulmonary exercise testing with blood sampling of atrial natriuretic peptide (ANP), 2-dimensional echocardiography and cardiac catheterization. Atrial muscles resected during the Maze operation were examined histologically in 12 patients. The heart rate response to exercise depended on the severity of the atrial organic injury, which was expressed as left atrial diameter, ANP secretion during the maximal exercise testing and the histological findings of atrial tissue. Conversely, we believe that the severity of the atrial injury can be predicted from the heart rate response to exercise in patients with atrial fibrillation.
IS  - 0021-4868
IL  - 0021-4868
PT  - Journal Article
LG  - English
DP  - 2000 Jul
DC  - 20001020
YR  - 2000
ED  - 20001102
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11041095

<738. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11011342
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Omran H
AU  - Rang B
AU  - Schmidt H
AU  - Illien S
AU  - Schimpf R
AU  - Maccarter D
AU  - Kubini R
AU  - Von Der Recke G
AU  - Tiemann K
AU  - Becher H
AU  - Luderitz B
FA  - Omran, H
FA  - Rang, B
FA  - Schmidt, H
FA  - Illien, S
FA  - Schimpf, R
FA  - Maccarter, D
FA  - Kubini, R
FA  - Von Der Recke, G
FA  - Tiemann, K
FA  - Becher, H
FA  - Luderitz, B
IN  - Omran,H. Department of Medicine-Cardiology, University of Bonn, Germany. omran@uni-bonn.de
TI  - Incidence of left atrial thrombi in patients in sinus rhythm and with a recent neurologic deficit.
SO  - American Heart Journal. 140(4):658-62, 2000 Oct.
AS  - Am Heart J. 140(4):658-62, 2000 Oct.
NJ  - American heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 0370465
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aortic Valve Stenosis/co [Complications]
MH  - Aortic Valve Stenosis/pp [Physiopathology]
MH  - Aortic Valve Stenosis/us [Ultrasonography]
MH  - Atrial Appendage/pp [Physiopathology]
MH  - Atrial Appendage/us [Ultrasonography]
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/us [Ultrasonography]
MH  - *Brain Ischemia/co [Complications]
MH  - Brain Ischemia/et [Etiology]
MH  - Coronary Disease/co [Complications]
MH  - Echocardiography, Transesophageal
MH  - Female
MH  - Heart Atria/pp [Physiopathology]
MH  - Heart Atria/us [Ultrasonography]
MH  - *Heart Atria
MH  - *Heart Diseases/ep [Epidemiology]
MH  - Heart Diseases/et [Etiology]
MH  - Heart Diseases/pp [Physiopathology]
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve Stenosis/co [Complications]
MH  - Mitral Valve Stenosis/pp [Physiopathology]
MH  - Mitral Valve Stenosis/us [Ultrasonography]
MH  - Prognosis
MH  - Prospective Studies
MH  - Risk Factors
MH  - Single-Blind Method
MH  - Stroke Volume
MH  - *Thrombosis/ep [Epidemiology]
MH  - Thrombosis/et [Etiology]
MH  - Thrombosis/pp [Physiopathology]
AB  - OBJECTIVES: We sought to determine the incidence of left atrial (LA) thrombi in patients in sinus rhythm (SR) and with a recent neurologic deficit and to analyze the relation between LA thrombi and LA chamber and appendage function in patients in SR.
AB  - METHODS: A prospective study was conducted in 869 consecutive patients. The study group consisted of 583 patients in SR (67%). The remaining 286 patients had atrial fibrillation (AF) and served as controls (33%).
AB  - RESULTS: The incidence of LA thrombi was significantly higher in patients with AF (n = 39 [14%]) compared with patients in SR (n = 6 [1%]; P <.001). Three of 6 patients with thrombi in SR had mitral stenosis, 1 patient had aortic stenosis, 1 patient had coronary artery disease, and another patient had a cardiomyopathy. Of the patients with detected thrombi, those in SR did not receive anticoagulation, whereas those with AF did in 18 cases. Patients with thrombi in SR and with AF did not significantly differ in LA diameter (5.1 +/- 0.8 cm vs 4.8 +/- 0.7 cm; 95% confidence interval [CI], -0.78 to 0.45), left ventricular ejection fraction (46% +/- 13% vs 42% +/- 15%; 95% CI, -18.7 to 7.4), LA appendage area (5.8 +/- 2.7 cm(2) vs 6.7 +/- 3.2 cm(2); 95% CI, -1.9 to 3.6), peak emptying velocity of the LA appendage (0.19 +/- 0.08 m/s vs 0.17 +/- 0.07 m/s; 95% CI, -0.08 to 0.04), or LA spontaneous echo contrast (3. 5 +/- 0.6 vs 3.9 +/- 0.5; 95% CI, -0.06 to 0.45).
AB  - CONCLUSIONS: LA appendage thrombi are an infrequent cause of thromboembolism in patients in SR and are associated either with mitral valve disease or LA chamber and appendage dysfunction. Routine transesophageal echocardiography for the exclusion of LA thrombi is not recommended in patients in SR without underlying heart disease and normal LA function as assessed by transthoracic echocardiography.
ES  - 1097-6744
IL  - 0002-8703
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 2000 Oct
DC  - 20001018
YR  - 2000
ED  - 20001102
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11011342

<739. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 11022052
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Yokoyama T
AU  - Date C
AU  - Kokubo Y
AU  - Yoshiike N
AU  - Matsumura Y
AU  - Tanaka H
FA  - Yokoyama, T
FA  - Date, C
FA  - Kokubo, Y
FA  - Yoshiike, N
FA  - Matsumura, Y
FA  - Tanaka, H
IN  - Yokoyama,T. Department of Epidemiology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan.
TI  - Serum vitamin C concentration was inversely associated with subsequent 20-year incidence of stroke in a Japanese rural community. The Shibata study.
SO  - Stroke. 31(10):2287-94, 2000 Oct.
AS  - Stroke. 31(10):2287-94, 2000 Oct.
NJ  - Stroke; a journal of cerebral circulation
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - v2j, 0235266
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Age Distribution
MH  - Aged
MH  - *Ascorbic Acid/bl [Blood]
MH  - Cerebral Hemorrhage/bl [Blood]
MH  - Cerebral Hemorrhage/ep [Epidemiology]
MH  - Cerebral Infarction/bl [Blood]
MH  - Cerebral Infarction/ep [Epidemiology]
MH  - Cohort Studies
MH  - Comorbidity
MH  - Diet/sn [Statistics & Numerical Data]
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Japan/ep [Epidemiology]
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Odds Ratio
MH  - Risk Factors
MH  - Rural Population/sn [Statistics & Numerical Data]
MH  - Sex Distribution
MH  - *Stroke/bl [Blood]
MH  - *Stroke/ep [Epidemiology]
AB  - BACKGROUND AND PURPOSE: Epidemiological evidence suggests that vitamin C may decrease the risk of stroke. The purpose of the present study was to examine the association of serum vitamin C concentration with the subsequent incidence of stroke.
AB  - METHODS: In a Japanese rural community, a cohort of 880 men and 1241 women aged 40 years and older who were initially free of stroke was examined in 1977 and followed until 1997. The baseline examination included a measurement of serum vitamin C concentration. The incidence of stroke was determined by annual follow-up examinations and registry.
AB  - RESULTS: During the 20-year observation period, 196 incident cases of all stroke, including 109 cerebral infarctions and 54 hemorrhagic strokes, were documented. Strong inverse associations were observed between serum vitamin C concentration and all stroke (sex- and age-adjusted hazard ratios were 0.93, 0.72, and 0.59, respectively, for the second, third, and fourth quartiles compared with the first quartile; P for trend=0.002), cerebral infarction (0.71, 0.59, and 0.51; P for trend=0.015), and hemorrhagic stroke (0.89, 0.75, and 0. 45; P for trend=0.013). Additional adjustments for blood pressure, serum total cholesterol, body mass index, physical activity, smoking, alcohol drinking, antihypertensive medication, atrial fibrillation, and history of ischemic heart disease did not attenuate these associations markedly.
AB  - CONCLUSIONS: Serum vitamin C concentration was inversely related to the subsequent incidence of stroke. This relationship was significant for both cerebral infarction and hemorrhagic stroke. Additional mechanistic hypotheses may be required to explain our findings.
RN  - PQ6CK8PD0R (Ascorbic Acid)
ES  - 1524-4628
IL  - 0039-2499
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2000 Oct
DC  - 20001013
YR  - 2000
ED  - 20001026
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11022052

<740. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 10966583
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lee TH
FA  - Lee, T H
TI  - Ask the doctor. Recently I read that aspirin can actually increase a person's risk for a stroke by causing bleeding in the brain. I have atrial fibrillation and my doctor wants me to take a blood thinner - if not warfarin, then at least aspirin. I've already had a heart attack and I don't want to run the risk of a stroke, so I have refused. What should I do?.
SO  - Harvard Heart Letter. 11(1):7, 2000 Sep.
AS  - Harv Heart Lett. 11(1):7, 2000 Sep.
NJ  - Harvard heart letter : from Harvard Medical School
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9425723, c2z
SB  - Consumer Health Journals
CP  - UNITED STATES
MH  - Aspirin/ae [Adverse Effects]
MH  - *Aspirin/tu [Therapeutic Use]
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Brain Ischemia/et [Etiology]
MH  - *Brain Ischemia/pc [Prevention & Control]
MH  - Cerebral Hemorrhage/ci [Chemically Induced]
MH  - Humans
MH  - Platelet Aggregation Inhibitors/ae [Adverse Effects]
MH  - *Platelet Aggregation Inhibitors/tu [Therapeutic Use]
MH  - Stroke/pc [Prevention & Control]
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
IS  - 1051-5313
IL  - 1051-5313
PT  - Journal Article
LG  - English
DP  - 2000 Sep
DC  - 20000925
YR  - 2000
ED  - 20000925
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=10966583

<741. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 10742705
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Owen A
AU  - Croucher L
FA  - Owen, A
FA  - Croucher, L
IN  - Owen,A. Department of Cardiology, Kent & Canterbury Hospital, Ethelbert Road, Canterbury, UK.
TI  - Effect of an exercise programme for elderly patients with heart failure.
SO  - European Journal of Heart Failure. 2(1):65-70, 2000 Mar.
AS  - Eur J Heart Fail. 2(1):65-70, 2000 Mar.
NJ  - European journal of heart failure
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - dr4, 100887595
SB  - Index Medicus
CP  - NETHERLANDS
MH  - Aged
MH  - Aged, 80 and over
MH  - Cross-Over Studies
MH  - *Exercise Therapy
MH  - Exercise Tolerance
MH  - Feasibility Studies
MH  - Female
MH  - *Heart Failure/rh [Rehabilitation]
MH  - Humans
MH  - Male
MH  - Quality of Life
AB  - AIMS: Benefit from exercise training programmes for patients with chronic heart failure has been demonstrated in relatively young (mean age 60 years) and predominantly male subjects. This study was undertaken to assess the effect of an exercise programme for older subjects more representative of the general heart failure population.
AB  - METHODS AND RESULTS: Twenty-two patients with chronic heart failure of mean age 81+/-4 years were recruited into the study. Twenty-five percent were female and 31% were in chronic atrial fibrillation. A crossover study design was employed. The programme consisted of once weekly exercise sessions tailored to the abilities of elderly subjects and lasted for 12 weeks. Fifteen subjects completed the exercise component and nine the control component. The programme resulted in a 20% relative increase in 6-min walk test distance (ANCOVA: P<0.012). There was no improvement in quality of life as measured by the Living With Heart Failure Questionnaire, but the majority of subjects reported subjective improvement in wellbeing.
AB  - CONCLUSION: Elderly patients with chronic heart failure can benefit from an appropriately designed exercise programme and should not be excluded from future large scale trials.
IS  - 1388-9842
IL  - 1388-9842
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 2000 Mar
DC  - 20000823
YR  - 2000
ED  - 20000823
RD  - 20110608
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=10742705

<742. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 10846147
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Veehof L
AU  - Stewart R
AU  - Haaijer-Ruskamp F
AU  - Jong BM
FA  - Veehof, L
FA  - Stewart, R
FA  - Haaijer-Ruskamp, F
FA  - Jong, B M
IN  - Veehof,L. Department of General Practice and Northern Centre of Health Care, University of Groningen, Groningen, The Netherlands.
TI  - The development of polypharmacy. A longitudinal study.
SO  - Family Practice. 17(3):261-7, 2000 Jun.
AS  - Fam Pract. 17(3):261-7, 2000 Jun.
NJ  - Family practice
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 8500875, fam
SB  - Index Medicus
CP  - ENGLAND
MH  - Aged
MH  - Aged, 80 and over
MH  - *Chronic Disease/dt [Drug Therapy]
MH  - Chronic Disease/ep [Epidemiology]
MH  - Cohort Studies
MH  - Confidence Intervals
MH  - Drug Administration Schedule
MH  - *Drug Utilization/sn [Statistics & Numerical Data]
MH  - Family Practice/sn [Statistics & Numerical Data]
MH  - Female
MH  - Health Status
MH  - Humans
MH  - Incidence
MH  - Long-Term Care
MH  - Longitudinal Studies
MH  - Male
MH  - Netherlands
MH  - Odds Ratio
MH  - *Polypharmacy
MH  - Practice Patterns, Physicians'/sn [Statistics & Numerical Data]
MH  - Probability
MH  - Program Development
MH  - Program Evaluation
MH  - Registries
AB  - BACKGROUND: To date, only a few studies have been carried out on the development and progress of polypharmacy in relation to morbidity in general practices in The Netherlands.
AB  - OBJECTIVE: The aim of this study was to investigate the relationship between an increase in long-term drug use and the incidence and severity of some chronic diseases, particularly in the elderly.
AB  - METHODS: Data on medication and morbidity of 1544 elderly people were collected for the period 1994-1997 from three family practices in the medication and morbidity Registration Network of Groningen (RNG) in the northern part of The Netherlands. Polypharmacy is defined as the long-term simultaneous use of two or more drugs; long-term is defined as >240 days in a year. We looked for differences in incidences of some chronic diseases in those subgroups of the elderly in whom multiple long-term drug use respectively increased, stayed constant or did not exist. Polypharmacy at the end of the period was predicted using regression analysis.
AB  - RESULTS: Polypharmacy occurred in 42% of the elderly at the end of 1997, with major polypharmacy (>5 drugs) in only 4%. The average number of drugs used long-term increased from 1.3 to 1.8 in 4 years. Predictors for the increase of polypharmacy were the number of drugs at the start, age, diabetes, coronary ischaemic diseases and use of medication without a clear indication (P < 0.005). The average number of diseases also increased, especially in the elderly who showed the greatest increase in long-term drug use; however, there was no significant difference from the groups with a slow or no increase in drug use.
AB  - DISCUSSION: Polypharmacy showed a slow increase over 4 years: almost 20% of the elderly developed polypharmacy, i.e. going from no drugs or one drug to two or more drugs. Polypharmacy develops mainly in elderly patients who already use several drugs, who are known to suffer from cardiovascular diseases, diabetes or stomach symptoms, those who often take drugs (especially sedatives/hypnotics) without clear indication and those who develop hypertension or atrial fibrillation over time.
IS  - 0263-2136
IL  - 0263-2136
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 2000 Jun
DC  - 20000811
YR  - 2000
ED  - 20000811
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=10846147

<743. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 10812161
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ringelstein EB
AU  - Nabavi D
FA  - Ringelstein, E B
FA  - Nabavi, D
IN  - Ringelstein,E B. Klinik und Poliklinik fur Neurologie, Westfalische Wilhelms Univeritat Munster, Munster, Germany.
TI  - Long-term prevention of ischaemic stroke and stroke recurrence. [Review] [92 refs]
SO  - Thrombosis Research. 98(3):83-96, 2000 May 1.
AS  - Thromb Res. 98(3):83-96, 2000 May 1.
NJ  - Thrombosis research
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - vrn, 0326377
SB  - Index Medicus
CP  - UNITED STATES
MH  - Arteriosclerosis/co [Complications]
MH  - Arteriosclerosis/pc [Prevention & Control]
MH  - Brain Ischemia/et [Etiology]
MH  - *Brain Ischemia/pc [Prevention & Control]
MH  - Cardiovascular Diseases/co [Complications]
MH  - Cardiovascular Diseases/pc [Prevention & Control]
MH  - Carotid Stenosis/co [Complications]
MH  - Carotid Stenosis/pc [Prevention & Control]
MH  - Embolism/co [Complications]
MH  - Embolism/pc [Prevention & Control]
MH  - Humans
MH  - Recurrence
MH  - Risk Factors
MH  - Stroke/et [Etiology]
MH  - *Stroke/pc [Prevention & Control]
MH  - Thrombophilia/co [Complications]
MH  - Thrombophilia/pc [Prevention & Control]
AB  - Stroke is the third most important cause of mortality, but the leading cause of severe handicap, dependency, and loss of social competence. Because of the high recurrence rate, active secondary prevention is mandatory once a stroke has occurred. Secondary prevention of stroke implies the primary prevention of cardiovascular disorders as well. Among the modifiable risk factors hypertension is worst and should be normalized according to recent WHO criteria, also in the elderly. Smoking is another major risk factor and hard to delete. Diabetes mellitus and hyperlipidaemia are also important risk factors and should be treated consequently by diet and medication. Moderate alcohol intake, normalization of body weight and regular physical activity also contribute considerably to prevention of stroke. Whether hyperhomocysteinaemia should be normalized has not yet been clarified. Cardiovascular disorders are an important source of ischemic strokes, particularly atrial fibrillation. Low dose anticoagulation can dramatically reduce stroke risk. Carotid endarterectomy in symptomatic stenoses is the most expensive means of stroke prevention. In less severe stenoses, or ICA occlusions, antiplatelet agents are the treatment of choice. Composite drugs with ASS and other antiplatelet agents seem to be superior to either compound alone. Dissections of the cervical arteries should not be operated on but may be treated by anticoagulation or antiplatelet agents in the acute and subacute phase. The potency of a consequent and comprehensive stroke prevention in preventing disability and death is much greater than any sophisticated acute stroke treatment. [References: 92]
IS  - 0049-3848
IL  - 0049-3848
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2000 May 1
DC  - 20000727
YR  - 2000
ED  - 20000727
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=10812161

<744. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 10727781
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ide K
AU  - Secher NH
FA  - Ide, K
FA  - Secher, N H
IN  - Ide,K. The Copenhagen Muscle Research Centre, Department of Anaesthesia, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100, Copenhagen, Denmark. ide@rh.dk
TI  - Cerebral blood flow and metabolism during exercise. [Review] [115 refs]
SO  - Progress in Neurobiology. 61(4):397-414, 2000 Jul.
AS  - Prog Neurobiol. 61(4):397-414, 2000 Jul.
NJ  - Progress in neurobiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - q3r, 0370121
SB  - Index Medicus
SB  - National Aeronautics and Space Administration (NASA) Journals
CP  - ENGLAND
MH  - Blood Pressure
MH  - *Brain/bs [Blood Supply]
MH  - *Brain/me [Metabolism]
MH  - Brain/ri [Radionuclide Imaging]
MH  - Cardiac Output/ph [Physiology]
MH  - *Cerebrovascular Circulation/ph [Physiology]
MH  - *Exercise/ph [Physiology]
MH  - Humans
MH  - MAP Kinase Signaling System/ph [Physiology]
MH  - Microspheres
MH  - Middle Cerebral Artery/ph [Physiology]
MH  - Oxygen Consumption/ph [Physiology]
MH  - Regional Blood Flow/ph [Physiology]
MH  - Spectroscopy, Near-Infrared
MH  - Tomography, Emission-Computed
MH  - Ultrasonography, Doppler, Transcranial
AB  - During exercise regional cerebral blood flow (rCBF), as blood velocity in major cerebral arteries and also blood flow in the internal carotid artery increase, suggesting an increase in blood flow to a large part of the brain. Such an increase in CBF is independent of the concomitant increase in blood pressure but is modified by the alteration in arterial carbon dioxide tension (PaCO(2)). Also, the increase in middle cerebral artery mean blood velocity (MCA V(mean)) reported with exercise appears to depend on the ability to increase cardiac output (CO), as demonstrated in response to beta-1 blockade and in patients with cardiac insufficiency or atrial fibrillation.Near-infrared spectroscopy (NIRS) determined cerebral oxygenation supports the alterations in MCA V(mean) during exercise. Equally, the observation that the cerebrovascular CO(2)-reactivity appears to be smaller in the standing than in the sitting and especially in the supine position could relate to the progressively smaller CO. In contrast, during exercise "global" cerebral blood flow (gCBF), as determined by the Kety-Schmidt technique is regarded as being constant. One limitation of the Kety-Schmidt method for measuring CBF is that blood flow in the two internal jugular veins depends on the origin of drainage and it has not been defined which internal jugular venous flow is evaluated. Such a consideration is equally relevant for an evaluation of cerebral metabolism during exercise. While the regional cerebral uptake of oxygen (O(2)) increases during exercise, the global value is regarded as being constant. Yet, during high intensity exercise lactate is taken up by the brain and its O(2) uptake also increases. Furthermore, in the initial minutes of recovery immediately following exercise, brain glucose and O(2) uptake are elevated and lactate uptake remains high.A maintained substrate uptake by the brain after exercise suggests a role for brain glycogen in cerebral activation, but the fate of brain substrate uptake has not yet been determined. [References: 115]
IS  - 0301-0082
IL  - 0301-0082
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
LG  - English
DP  - 2000 Jul
DC  - 20000630
YR  - 2000
ED  - 20000630
RD  - 20091103
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=10727781

<745. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 10678592
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Brown MJ
AU  - Haydock S
FA  - Brown, M J
FA  - Haydock, S
IN  - Brown,M J. Clinical Pharmacology Unit, Addenbrookes Hospital, University of Cambridge, England.
TI  - Pathoaetiology, epidemiology and diagnosis of hypertension. [Review] [48 refs]
SO  - Drugs. 59 Suppl 2:1-12; discussion 39-40, 2000.
AS  - Drugs. 59 Suppl 2:1-12; discussion 39-40, 2000.
NJ  - Drugs
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - ec2, 7600076
SB  - Index Medicus
CP  - NEW ZEALAND
MH  - Adult
MH  - Animals
MH  - Humans
MH  - Hypertension/di [Diagnosis]
MH  - *Hypertension/ep [Epidemiology]
MH  - *Hypertension/et [Etiology]
MH  - Hypertension/pa [Pathology]
AB  - Hypertension is currently defined in terms of levels of blood pressure associated with increased cardiovascular risk. A cut-off of 140/90 mm Hg is accepted as a threshold level above which treatment should at least be considered. This would give a prevalence of hypertension of about 20% of the adult population in most developed countries. Hypertension is associated with increased risk of stroke, myocardial infarction, atrial fibrillation, heart failure, peripheral vascular disease and renal impairment. Hypertension results from the complex interaction of genetic factors and environmental influences. Many of the genetic factors remain to be discovered, but environmental influences such as salt intake, diet and alcohol form the basis of nonpharmacological methods of blood pressure reduction. Investigation of the individual hypertensive patient aims to identify possible secondary causes of hypertension and also to assess the individual's overall cardiovascular risk, which determines the need for prompt and aggressive therapy. Cardiovascular risk can be determined from (i) target organ damage to the eyes, heart and kidneys; (ii) other medical conditions associated with increased risk; and (iii) lifestyle factors such as obesity and smoking. Secondary causes of hypertension are individually rare. Screening tests should be initially simple, with more expensive and invasive tests reserved for those in whom a secondary cause is suspected or who have atypical features to their presentation. The main determinants of blood pressure are cardiac output and peripheral resistance. The typical haemodynamic finding in patients with established hypertension is of normal cardiac output and increased peripheral resistance. Treatment of hypertension should initially use nonpharmacological methods. Selection of initial drug therapy should be based upon the strength of evidence for reduction of cardiovascular mortality in controlled clinical trials, and should also take into account coexisting medical conditions that favour or limit the usefulness of any given drug. Given this approach, it would be reasonable to use a thiazide diuretic and/or a beta-blocker as first-line therapy unless there are indications to the contrary. Individual response to given drug classes is highly variable and is related to the underlying variability in the abnormal pathophysiology. There are data to suggest that the renin-angiotensin system is more important in young patients. The targeting of this system in patients under the age of 50 years with a beta-blocker (or ACE inhibitor), and the use of a thiazide diuretic (or calcium antagonist) in patients over 50 years, may enable blood pressure to be controlled more quickly. [References: 48]
IS  - 0012-6667
IL  - 0012-6667
PT  - Journal Article
PT  - Review
LG  - English
DP  - 2000
DC  - 20000308
YR  - 2000
ED  - 20000308
RD  - 20051116
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=10678592

<746. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 10678304
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wagner JL
AU  - Dent LA
FA  - Wagner, J L
FA  - Dent, L A
IN  - Wagner,J L. Wal-Mart Pharmacy, Pendelton, Oregon, USA.
TI  - Epistaxis associated with elevation of INR in a patient switched to generic warfarin.
SO  - Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy. 20(2):240-3, 2000 Feb.
AS  - Pharmacotherapy. 20(2):240-3, 2000 Feb.
NJ  - Pharmacotherapy
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - par, 8111305
SB  - Index Medicus
CP  - UNITED STATES
MH  - 3',5'-Cyclic-GMP Phosphodiesterases/ai [Antagonists & Inhibitors]
MH  - *Anticoagulants/ae [Adverse Effects]
MH  - Anticoagulants/bl [Blood]
MH  - Atrial Fibrillation/co [Complications]
MH  - *Drugs, Generic
MH  - *Epistaxis/ci [Chemically Induced]
MH  - Humans
MH  - *International Normalized Ratio
MH  - Male
MH  - Middle Aged
MH  - Phosphodiesterase Inhibitors/ae [Adverse Effects]
MH  - Piperazines/ae [Adverse Effects]
MH  - Purines
MH  - Sildenafil Citrate
MH  - Sulfones
MH  - *Warfarin/ae [Adverse Effects]
MH  - Warfarin/bl [Blood]
AB  - A 61-year-old man with atrial fibrillation receiving Coumadin brand warfarin was switched to Barr brand warfarin without his knowledge as a result of a retail pharmacy dispensing error. The patient took the same dosage for 6-7 days and experienced severe epistaxis that required two visits to the emergency room. Previously, his coagulation values were within therapeutic range, but when tested at the emergency room the international normalized ratio was elevated. The patient denied changes in therapy compliance, diet, alcohol ingestion, or use of other drugs. His only other drug, taken periodically, was sildenafil for erectile dysfunction. Clinicians should be aware of differences between branded and generic compounds.
RN  - 0 (Anticoagulants)
RN  - 0 (Drugs, Generic)
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 0 (Piperazines)
RN  - 0 (Purines)
RN  - 0 (Sulfones)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - BW9B0ZE037 (Sildenafil Citrate)
RN  - EC 3-1-4-35 (3',5'-Cyclic-GMP Phosphodiesterases)
IS  - 0277-0008
IL  - 0277-0008
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 2000 Feb
DC  - 20000308
YR  - 2000
ED  - 20000308
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=10678304

<747. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 10678340
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Segal JB
AU  - McNamara RL
AU  - Miller MR
AU  - Kim N
AU  - Goodman SN
AU  - Powe NR
AU  - Robinson K
AU  - Yu D
AU  - Bass EB
FA  - Segal, J B
FA  - McNamara, R L
FA  - Miller, M R
FA  - Kim, N
FA  - Goodman, S N
FA  - Powe, N R
FA  - Robinson, K
FA  - Yu, D
FA  - Bass, E B
IN  - Segal,J B. The Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
TI  - The evidence regarding the drugs used for ventricular rate control. [Review] [67 refs]
SO  - Journal of Family Practice. 49(1):47-59, 2000 Jan.
AS  - J. FAM. PRACT.. 49(1):47-59, 2000 Jan.
NJ  - The Journal of family practice
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 7502590
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Adrenergic beta-Antagonists/tu [Therapeutic Use]
MH  - Adult
MH  - *Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Bias (Epidemiology)
MH  - *Calcium Channel Blockers/tu [Therapeutic Use]
MH  - Digoxin/tu [Therapeutic Use]
MH  - Diltiazem/tu [Therapeutic Use]
MH  - *Evidence-Based Medicine
MH  - Exercise
MH  - *Heart Rate/de [Drug Effects]
MH  - Humans
MH  - *Research Design/st [Standards]
MH  - Rest
MH  - Treatment Outcome
MH  - *Ventricular Function/de [Drug Effects]
MH  - Verapamil/tu [Therapeutic Use]
AB  - OBJECTIVE: Our goal was to determine what drugs are most efficacious for controlling the ventricular rate in patients with atrial fibrillation.
AB  - SEARCH STRATEGY: We conducted a systematic review of the literature published before May 1998, beginning with searches of The Cochrane Collaboration's CENTRAL database and MEDLINE.
AB  - SELECTION CRITERIA: We included English-language articles describing randomized controlled trials of drugs used for heart rate control in adults with atrial fibrillation.
AB  - DATA COLLECTION/ANALYSIS: Abstracts of trials were reviewed independently by 2 members of the study team. We reviewed English-language abstracts of non-English-language publications to assess qualitative consistency with our results.
AB  - MAIN RESULTS: Forty-five articles evaluating 17 drugs met our criteria for review. In the 5 trials of verapamil and 5 of diltiazem, heart rate was reduced significantly (P <.05), both at rest and with exercise, compared with placebo, with equivalent or improved exercise tolerance in 6 of 7 comparisons. In 7 of 12 comparisons of a beta-blocker with placebo, the beta-blocker was efficacious for control of resting heart rate, with evidence that the effect is drug specific, as nadolol and atenolol proved to be most efficacious. All 9 comparisons demonstrated good heart rate control with beta-blockers during exercise, although exercise tolerance was compromised in 3 of 9 comparisons. In 7 of 8 trials, digoxin administered alone slowed the resting heart rate more than placebo, but it did not significantly slow the rate during exercise in 4 studies. The trials evaluating other drugs yielded insufficient evidence to support their use, but those drugs may yet be promising.
AB  - CONCLUSIONS: The calcium-channel blockers verapamil or diltiazem, or select beta-blockers are efficacious for heart rate control at rest and during exercise for patients with atrial fibrillation without a clinically important decrease in exercise tolerance. Digoxin is useful when rate control during exercise is less a concern. [References: 67]
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Calcium Channel Blockers)
RN  - 73K4184T59 (Digoxin)
RN  - CJ0O37KU29 (Verapamil)
RN  - EE92BBP03H (Diltiazem)
IS  - 0094-3509
IL  - 0094-3509
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
NO  - 290-97-006 (United States PHS HHS)
LG  - English
DP  - 2000 Jan
DC  - 20000224
YR  - 2000
ED  - 20000224
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=10678340

<748. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 10666751
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Brunner-La Rocca HP
AU  - Rickli H
AU  - Weilenmann D
AU  - Duru F
AU  - Candinas R
FA  - Brunner-La Rocca, H P
FA  - Rickli, H
FA  - Weilenmann, D
FA  - Duru, F
FA  - Candinas, R
IN  - Brunner-La Rocca,H P. Department of Internal Medicine, University Hospital, Zurich, Switzerland. hanspeter.brunner@baker.edu.au
TI  - Importance of ventricular rate after mode switching during low intensity exercise as assessed by clinical symptoms and ventilatory gas exchange.
SO  - Pacing & Clinical Electrophysiology. 23(1):32-9, 2000 Jan.
AS  - Pacing Clin Electrophysiol. 23(1):32-9, 2000 Jan.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Atrial Fibrillation/pc [Prevention & Control]
MH  - *Cardiac Pacing, Artificial
MH  - Cross-Over Studies
MH  - *Exercise
MH  - Exercise Test
MH  - Female
MH  - Heart Block/di [Diagnosis]
MH  - Heart Block/pp [Physiopathology]
MH  - *Heart Block/th [Therapy]
MH  - *Heart Rate/ph [Physiology]
MH  - *Heart Ventricles/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - *Pulmonary Gas Exchange/ph [Physiology]
MH  - Single-Blind Method
AB  - Automatic mode switching from DDD(R) to DDI(R) or VVI(R) pacing modes has improved dual chamber pacing in patients at high risk for supraventricular tachyarrhythmias. However, little is known about the effect of ventricular pacing rate adaptation after mode switching. We conducted a single-blinded, crossover study in 15 patients (58 +/- 21 years) with a DDD pacemaker who had AV block and normal sinus node function to investigate the influence of pacing rate adaptation to intrinsic heart rate during low intensity exercise. Patients performed two tests (A/B) of low intensity treadmill exercise (0.5 W/kg) in randomized order. They initially walked for 6 minutes while paced in DDD mode. The pacing mode was then switched to VVI with a pacing rate of either 70 beats/min (test A) or matched to the intrinsic heart rate (95 +/- 11 beats/min test B). Respiratory gas exchange variables were determined and patients classified the effort before and after mode switching on a Borg scale from 6 to 20. Percentage changes of respiratory gas exchange measurements were significantly larger (O2 consumption: -8.2 +/- 5.0% vs. -0.6 +/- 7.2%; ventilatory equivalent of CO2 exhalation: 5.3 +/- 4.9% vs. 1.5 +/- 4.3%; respiratory exchange ratio: 7.0 +/- 2.2% vs. 3.5 +/- 3.0%; end-tidal CO2: -5.7 +/- 2.9% vs. -1.8 +/- 2.7%; all P < 0.01) and the increase in subjective assessment of the effort tended to be higher (mean increase on Borg scale: 1.6 +/- 1.9 vs. 1.1 +/- 1.8, P = 0.07) after heart rate unadjusted than after adjusted mode switching. Mode switching from DDD to VVI pacing is better tolerated and gas exchange measurements are less influenced if ventricular pacing rate is adjusted to the level of physical activity. Thus, pacing rate adjustment should be considered as part of automatic mode switch algorithms.
IS  - 0147-8389
IL  - 0147-8389
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 2000 Jan
DC  - 20000218
YR  - 2000
ED  - 20000218
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=10666751

<749. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 10598967
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Natale A
AU  - Zimerman L
AU  - Tomassoni G
AU  - Newby K
AU  - Leonelli F
AU  - Fanelli R
AU  - Beheiry S
AU  - Pisano E
FA  - Natale, A
FA  - Zimerman, L
FA  - Tomassoni, G
FA  - Newby, K
FA  - Leonelli, F
FA  - Fanelli, R
FA  - Beheiry, S
FA  - Pisano, E
IN  - Natale,A. University of Kentucky Lexington, 40536-0284, USA.
TI  - AV node ablation and pacemaker implantation after withdrawal of effective rate-control medications for chronic atrial fibrillation: effect on quality of life and exercise performance.
SO  - Pacing & Clinical Electrophysiology. 22(11):1634-9, 1999 Nov.
AS  - Pacing Clin Electrophysiol. 22(11):1634-9, 1999 Nov.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Anti-Arrhythmia Agents/ad [Administration & Dosage]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/su [Surgery]
MH  - Atrioventricular Node/pp [Physiopathology]
MH  - *Atrioventricular Node/su [Surgery]
MH  - *Catheter Ablation
MH  - Chronic Disease
MH  - Combined Modality Therapy
MH  - Electrocardiography, Ambulatory/de [Drug Effects]
MH  - Exercise Test/de [Drug Effects]
MH  - *Exercise Test
MH  - Female
MH  - Heart Rate/de [Drug Effects]
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Pacemaker, Artificial
MH  - *Quality of Life
AB  - We assess whether AV node ablation and pacemaker implantation after discontinuation of effective rate-control medical therapy for chronic atrial fibrillation had a positive impact on quality of life and exercise performance. To assess the possibility of a placebo effect following pacemaker implantation, the study included three groups of patients. Group 1 underwent an echocardiogram, treadmill exercise, and quality of life measurement 1 month prior to and 6 months following AV node ablation and pacemaker implantation associated with discontinuation of rate-control medications. Group 2 underwent AV node ablation and pacemaker implantation without discontinuation of antiarrhythmic rate-control drugs. Group 3 underwent pacemaker implantation without performing AV node ablation and continuing rate-control medical therapy. At the 1- and 6-month evaluation, the patients in group 1 showed a significant improvement of left ventricular ejection fraction, quality of life, and activity scores. The exercise duration and the maximal VO2 consumption, however, did not change significantly. A slight improvement of the quality of life and physical activity scores was observed in the group undergoing AV node ablation without withdrawal of medications. However, no significant changes were observed in the group receiving only the pacemaker without modification of medical therapy and with intact AV node conduction. In conclusion, in patients with chronic atrial fibrillation, discontinuation of effective rate-control medical therapy followed by AV node ablation and permanent pacing appeared to improve quality of life and activity scores despite no change in exercise duration. The improvement observed does not seem to reflect a placebo effect.
RN  - 0 (Anti-Arrhythmia Agents)
IS  - 0147-8389
IL  - 0147-8389
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1999 Nov
DC  - 20000128
YR  - 1999
ED  - 20000128
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=10598967

<750. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 10553183
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Futterman LG
AU  - Lemberg L
FA  - Futterman, L G
FA  - Lemberg, L
IN  - Futterman,L G. Department of Medicine, University of Miami School of Medicine, Fla., USA.
TI  - Stroke risk, cholesterol and statins.[Erratum appears in Am J Crit Care 2000 Jan;9(1):79]
SO  - American Journal of Critical Care. 8(6):416-9, 1999 Nov.
AS  - Am J Crit Care. 8(6):416-9, 1999 Nov.
NJ  - American journal of critical care : an official publication, American Association of Critical-Care Nurses
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - bum, 9211547
SB  - Index Medicus
SB  - Nursing Journal
CP  - UNITED STATES
MH  - Aged
MH  - *Aspirin/tu [Therapeutic Use]
MH  - *Diabetes Complications
MH  - Female
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use]
MH  - *Hypertension/co [Complications]
MH  - Life Style
MH  - Middle Aged
MH  - *Platelet Aggregation Inhibitors/tu [Therapeutic Use]
MH  - Risk Factors
MH  - Stroke/dt [Drug Therapy]
MH  - Stroke/et [Etiology]
MH  - Stroke/pc [Prevention & Control]
MH  - *Stroke
MH  - *Warfarin/tu [Therapeutic Use]
AB  - The natural statins should be used as first line agents in the prevention of stroke. The effects of the synthetic statins on the prevention of coronary events and stroke have not been reported at this time. The National Stroke Association's Stroke Prevention Advisory Board has prepared a consensus statement on risk reducing intervention. The Board identified hypertension, MI, atrial fibrillation, hyperlipidemia and asymptomatic carotid artery stenosis (60% to 99% occlusion) as proven stroke risk factors. The Board's recommendations for the prevention of a first stroke are: 1. Hypertension should be treated with lifestyle, pharmacologic and multidisciplinary management strategies. 2. Aspirin post MI and warfarin (international normalized ratio, 2 to 3) for patients with atrial fibrillation, left ventricular thrombus or significant left ventricular dysfunction. Statin agents should be used post MI. 3. Atrial fibrillation patients age 75 or older should be treated with warfarin. Younger patients 65 to 75 with atrial fibrillation and risk factors should be treated with warfarin [corrected]. Younger patients 65 to 75 with atrial fibrillation without risk factors should be treated with warfarin or aspirin [corrected]. 4. Patients with hyperlipidemia and coronary artery disease should be on statin agents. 5. Carotid endarterectomy is recommended for asymptomatic carotid stenosis (60% to 99%) when surgical morbidity and mortality are less than 3%. 6. Adherence to a low-fat diet, smoking avoidance, mild alcohol use, and physical activity should follow published guidelines.
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - R16CO5Y76E (Aspirin)
IS  - 1062-3264
IL  - 1062-3264
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1999 Nov
DC  - 19991207
YR  - 1999
ED  - 19991207
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=10553183

<751. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 10528423
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Crippa G
AU  - Sverzellati E
AU  - Giorgi-Pierfranceschi M
AU  - Carrara GC
FA  - Crippa, G
FA  - Sverzellati, E
FA  - Giorgi-Pierfranceschi, M
FA  - Carrara, G C
IN  - Crippa,G. Dipartimento di Medicina Interna, Ospedale Civile di Piacenza.
TI  - Magnesium and cardiovascular drugs: interactions and therapeutic role. [Review] [51 refs]
SO  - Annali Italiani di Medicina Interna. 14(1):40-5, 1999 Jan-Mar.
AS  - Ann Ital Med Int. 14(1):40-5, 1999 Jan-Mar.
NJ  - Annali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - auz, 8806705
SB  - Index Medicus
CP  - ITALY
MH  - Cardiovascular Agents/pd [Pharmacology]
MH  - *Cardiovascular Agents/tu [Therapeutic Use]
MH  - Cardiovascular Diseases/dt [Drug Therapy]
MH  - Cardiovascular Diseases/et [Etiology]
MH  - Drug Interactions
MH  - Humans
MH  - Magnesium/ad [Administration & Dosage]
MH  - Magnesium/pd [Pharmacology]
MH  - *Magnesium/ph [Physiology]
MH  - Magnesium Deficiency/co [Complications]
MH  - Magnesium Deficiency/pc [Prevention & Control]
AB  - Numerous experimental, epidemiological and clinical studies have pointed out a relevant role for magnesium deficiency in the development of many cardiovascular diseases. Some pharmacological treatments may interfere with magnesium turnover, and magnesium deficiency may alter the pharmacokinetics and pharmacodynamics of some cardiovascular drugs. Loop and thiazide-like diuretics increase magnesiuresis, and total bodily magnesium deficiency may appear during prolonged treatment with diuretically active doses of these drugs. The potassium retaining agents, such as amiloride, triamterene and spironolactone, tend to retain magnesium but they are not magnesium-retaining substances to the extent to which they are potassium-retaining diuretics. The interaction between magnesium and digitalis is complex. Magnesium, acting as an indirect antagonist of digoxin at the sarcolemma Na(+)-K(+)-ATPase pump, reduces cardiac arrhythmias due to digoxin poisoning. Recent controlled studies have shown that treatment with magnesium significantly reduces the frequency and complexity of ventricular arrhythmias in digoxin-treated patients with congestive heart failure without digoxin toxicity. Magnesium improves the efficacy of digoxin in slowing the ventricular response in atrial fibrillation. Digoxin reduces tubular magnesium reabsorption, and in patients with congestive heart failure this interaction may be cumulative with other causes of magnesium deficiency (diuretics, diet, poor intestinal absorption). The complex and potentially life-threatening interactions between magnesium and some cardiovascular drugs suggest that magnesium status should be carefully monitored in patients receiving such drugs. Therapy with magnesium is rapidly acting, has a safe toxic-therapeutic ratio, is easy to administer and titrate. The correction of magnesium deficit should therefore always be considered for patients with cardiopathy. [References: 51]
RN  - 0 (Cardiovascular Agents)
RN  - I38ZP9992A (Magnesium)
IS  - 0393-9340
IL  - 0393-9340
PT  - Journal Article
PT  - Review
LG  - English
DP  - 1999 Jan-Mar
DC  - 19991104
YR  - 1999
ED  - 19991104
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=10528423

<752. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 10450477
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Hood S
AU  - Northcote RJ
FA  - Hood, S
FA  - Northcote, R J
IN  - Hood,S. Department of Cardiology, Victoria Infirmary, Glasgow, Scotland.
TI  - Cardiac assessment of veteran endurance athletes: a 12 year follow up study.
SO  - British Journal of Sports Medicine. 33(4):239-43, 1999 Aug.
AS  - Br J Sports Med. 33(4):239-43, 1999 Aug.
NJ  - British journal of sports medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0432520, b2w
OI  - Source: NLM. PMC1756191
SB  - Index Medicus
CP  - ENGLAND
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Fibrillation/th [Therapy]
MH  - Cohort Studies
MH  - Coronary Angiography
MH  - Coronary Circulation/ph [Physiology]
MH  - Dilatation, Pathologic/di [Diagnosis]
MH  - Echocardiography
MH  - Electrocardiography, Ambulatory
MH  - Exercise Test
MH  - Follow-Up Studies
MH  - *Heart/ph [Physiology]
MH  - Heart Arrest/th [Therapy]
MH  - Heart Block/th [Therapy]
MH  - Humans
MH  - Hypertrophy, Left Ventricular/di [Diagnosis]
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/pp [Physiopathology]
MH  - Pacemaker, Artificial
MH  - *Physical Endurance/ph [Physiology]
MH  - Physical Exertion/ph [Physiology]
MH  - Rest
MH  - *Running/ph [Physiology]
AB  - OBJECTIVES: Sustained aerobic dynamic exercise is beneficial in preventing cardiovascular disease. The effect of lifelong endurance exercise on cardiac structure and function is less well documented, however. A 12 year follow up of 20 veteran athletes was performed, as longitudinal studies in such cohorts are rare.
AB  - METHODS: Routine echocardiography was repeated as was resting, exercise, and 24 hour electrocardiography.
AB  - RESULTS: Nineteen returned for screening. Mean (SD) age was 67 (6.2) years (range 56-83). Two individuals had had permanent pacemakers implanted (one for symptomatic atrial fibrillation with complete heart block, the other for asystole lasting up to 15 seconds). Only two athletes had asystolic pauses in excess of two seconds compared with seven athletes in 1985. Of these seven, five had no asystole on follow up. Two of these five had reduced their average running distance by about 15-20 miles a week. One athlete sustained an acute myocardial infarction during a competitive race in 1988. Three athletes had undergone coronary arteriography during the 12 years of follow up but none had obstructive coronary artery disease. Ten of 19 (53%) had echo evidence of left ventricular hypertrophy in 1997 but only two (11%) had left ventricular dilatation. Ten athletes had ventricular couplets on follow up compared with only two in 1985.
AB  - CONCLUSIONS: Although the benefits of moderate regular exercise are undisputed, high intensity lifelong endurance exercise may be associated with altered cardiac structure and function. These adaptations to more extreme forms of exercise merit caution in the interpretation of standard cardiac investigations in the older athletic population. On rare occasions, these changes may be deleterious.
IS  - 0306-3674
IL  - 0306-3674
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 1999 Aug
DC  - 19991029
YR  - 1999
ED  - 19991029
RD  - 20140615
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=10450477

<753. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 10451787
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ide K
AU  - Gullov AL
AU  - Pott F
AU  - Van Lieshout JJ
AU  - Koefoed BG
AU  - Petersen P
AU  - Secher NH
FA  - Ide, K
FA  - Gullov, A L
FA  - Pott, F
FA  - Van Lieshout, J J
FA  - Koefoed, B G
FA  - Petersen, P
FA  - Secher, N H
IN  - Ide,K. Copenhagen Muscle Research Centre, Department of Anaesthesia, Rigshospitalet, University of Copenhagen, Denmark.
TI  - Middle cerebral artery blood velocity during exercise in patients with atrial fibrillation.
SO  - Clinical Physiology. 19(4):284-9, 1999 Jul.
AS  - Clin Physiol. 19(4):284-9, 1999 Jul.
NJ  - Clinical physiology (Oxford, England)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - dkg, 8309768
SB  - Index Medicus
SB  - National Aeronautics and Space Administration (NASA) Journals
CP  - ENGLAND
MH  - Aged
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Blood Flow Velocity/ph [Physiology]
MH  - Blood Gas Analysis
MH  - Blood Pressure/ph [Physiology]
MH  - Cardiac Output/ph [Physiology]
MH  - *Cerebral Arteries/ph [Physiology]
MH  - *Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Female
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Ventricular Function, Left/ph [Physiology]
AB  - Atrial fibrillation limits the ability to increase cardiac output during exercise and may, in turn, affect the exercise-associated elevation in cerebral perfusion. In nine patients with atrial fibrillation (AF) and in five age-matched healthy subjects, middle cerebral artery blood velocity (MCA Vmean) was measured during incremental exercise using the transcranial Doppler. The AF patient group exhibited a lower aerobic capacity than the control group [peak work rate: 106 W (71-153 W; median and range) vs. 129 W (118-1.9 W) and maximal oxygen uptake: 1.4 l min-1 (1.0-1.9 l min-1) vs. 1.7 l min-1 (1.4-2.2 l min-1); P = 0.05]. At rest, MCA Vmean was not significantly different between the two groups [43 cm s-1 (39-56 cm s-1) vs. 52 cm s-1 (40-68 cm s-1)]. During intense cycling, the increase in MCA Vmean was to 51 cm s-1 (40-78 cm s-1) (9%) in the AF group and lower than in the healthy subjects [to 62 cm s-1 (50-81 cm s-1) 23%; P < 0.05], which corresponded with the smaller than expected increase in cardiac output [156% (130-169%) vs. 180%]. Thus, there was a correlation between the increase in MCA Vmean and the ability to increase cardiac output (r2 = 0.55, P < 0.01). We suggest that, during exercise with a large muscle mass, atrial fibrillation affects the ability to elevate cerebral perfusion, and this results from an impaired ability to increase cardiac output.
IS  - 0144-5979
IL  - 0144-5979
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1999 Jul
DC  - 19991012
YR  - 1999
ED  - 19991012
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=10451787

<754. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 10363464
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Knowlton CH
AU  - Thomas OV
AU  - Williamson A
AU  - Gammaitoni AR
AU  - Kirchain WR
AU  - Buttaro ML
AU  - Zarus SA
FA  - Knowlton, C H
FA  - Thomas, O V
FA  - Williamson, A
FA  - Gammaitoni, A R
FA  - Kirchain, W R
FA  - Buttaro, M L
FA  - Zarus, S A
IN  - Knowlton,C H. Hospice Pharmacia, Philadelphia, PA 19103, USA.
TI  - Establishing community pharmacy-based anticoagulation education and monitoring programs.
SO  - Journal of the American Pharmaceutical Association. 39(3):368-74, 1999 May-Jun.
AS  - J Am Pharm Assoc (Wash). 39(3):368-74, 1999 May-Jun.
NJ  - Journal of the American Pharmaceutical Association (Washington,D.C. : 1996)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9601004, cil
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - Anticoagulants/ae [Adverse Effects]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Monitoring, Physiologic
MH  - *Patient Education as Topic
MH  - *Pharmacies/st [Standards]
MH  - Pilot Projects
MH  - Prothrombin Time
MH  - United States
AB  - OBJECTIVE: To determine the process for establishing community pharmacy-based anticoagulation education and monitoring programs using fingerstick capillary whole blood testing.
AB  - DESIGN: Pilot community-based intervention study using convenience sample of patients.
AB  - SETTING: Three community pharmacies with pre-established health education centers and laboratories certified for moderate complexity.
AB  - PARTICIPANTS: 26 patients were referred to the clinics by 2 primary care physicians for each pharmacy, most with a diagnosis of atrial fibrillation.
AB  - INTERVENTION: Patient assessment, including adherence to prescribed regimens; changes in medication use, including prescription and nonprescription medications, vitamins, health foods, and nutrition supplements; changes in diet and ethanol consumption; assessment of adverse experiences; and needed changes in warfarin dosage.
AB  - MAIN OUTCOME MEASURES: Percentage of international normalized ratio (INR) values within therapeutic range, major bleeding events, and thrombotic events.
AB  - RESULTS: A total of 21 patient charts were available for analysis. More than 80% of patients had INR values within their targeted range (+/- 0.2) 60% or more of the time, comparable with values reported for anticoagulation clinics. Of the 235 INR values obtained during the study, 75% were within the individualized targeted therapeutic range (e.g., 2 to 3 +/- 0.2). One patient experienced a major bleeding event related to an underlying cancer. None of the patients experienced a thrombotic event.
AB  - CONCLUSION: Community pharmacies can effectively implement an anticoagulation education and monitoring program.
RN  - 0 (Anticoagulants)
IS  - 1086-5802
IL  - 1086-5802
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1999 May-Jun
DC  - 19990831
YR  - 1999
ED  - 19990831
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=10363464

<755. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 10335687
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Davis TM
AU  - Millns H
AU  - Stratton IM
AU  - Holman RR
AU  - Turner RC
FA  - Davis, T M
FA  - Millns, H
FA  - Stratton, I M
FA  - Holman, R R
FA  - Turner, R C
IN  - Davis,T M. Department of Medicine, University of Western Australia, Fremantle.
TI  - Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29.
CM  - Comment in: Arch Intern Med. 1999 May 24;159(10):1033-4; PMID: 10335678
SO  - Archives of Internal Medicine. 159(10):1097-103, 1999 May 24.
AS  - Arch Intern Med. 159(10):1097-103, 1999 May 24.
NJ  - Archives of internal medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0372440, 7fs
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Atrial Fibrillation/co [Complications]
MH  - Blood Glucose/me [Metabolism]
MH  - Body Mass Index
MH  - Cerebrovascular Disorders/bl [Blood]
MH  - *Cerebrovascular Disorders/et [Etiology]
MH  - Cerebrovascular Disorders/pc [Prevention & Control]
MH  - *Diabetes Mellitus, Type 2/co [Complications]
MH  - Exercise
MH  - Female
MH  - Great Britain
MH  - Humans
MH  - Hypertension/co [Complications]
MH  - Lipids/bl [Blood]
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Risk Factors
MH  - Sex Factors
MH  - Smoking/ae [Adverse Effects]
AB  - OBJECTIVE: To investigate modifiable and nonmodifiable risk factors for stroke in type 2 diabetes mellitus.
AB  - PATIENTS AND METHODS: A total of 3776 patients aged 25 to 65 years newly diagnosed as having type 2 diabetes mellitus without known cardiovascular or other serious disease were studied for a median of 7.9 years. An initial stepwise evaluation of risk factors was done in 2704 patients with all risk factors measured, with the final Cox model analysis being of 3776 patients who had complete data on the selected variables.
AB  - RESULTS: Of 3776 patients, 99 (2.6%) had a stroke. Significant risk factors for stroke in a multivariate model were age (estimated hazard ratio [95% confidence interval], 4.78 [2.56-8.92] for > or =60 vs <50 years), male sex (1.63 [1.08-2.47)] vs female), hypertension (2.47 [1.64-3.74)] vs normotension), and in 3728 patients who had electrocardiography at study entry, atrial fibrillation (8.05 [3.52-18.44] vs sinus rhythm). Obesity, lack of exercise, smoking, poor glycemic control, hyperinsulinemia, dyslipidemia, and microalbuminuria were not significantly associated with stroke in the model.
AB  - CONCLUSION: In patients with type 2 diabetes, aggressive antihypertensive therapy and routine anticoagulation therapy for atrial fibrillation may reduce the risk of stroke.
RN  - 0 (Blood Glucose)
RN  - 0 (Lipids)
IS  - 0003-9926
IL  - 0003-9926
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
LG  - English
DP  - 1999 May 24
DC  - 19990602
YR  - 1999
ED  - 19990602
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=10335687

<756. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 10208225
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Atwood JE
AU  - Myers J
AU  - Quaglietti S
AU  - Grumet J
AU  - Gianrossi R
AU  - Umman T
FA  - Atwood, J E
FA  - Myers, J
FA  - Quaglietti, S
FA  - Grumet, J
FA  - Gianrossi, R
FA  - Umman, T
IN  - Atwood,J E. Cardiology Division, Palo Alto Veterans Affairs Health Care System and Stanford University, CA 94304, USA.
TI  - Effect of betaxolol on the hemodynamic, gas exchange, and cardiac output response to exercise in chronic atrial fibrillation.
SO  - Chest. 115(4):1175-80, 1999 Apr.
AS  - Chest. 115(4):1175-80, 1999 Apr.
NJ  - Chest
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0231335, d1c
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Adrenergic beta-Antagonists/tu [Therapeutic Use]
MH  - Aged
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Betaxolol/tu [Therapeutic Use]
MH  - Cardiac Output/de [Drug Effects]
MH  - Chronic Disease
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - *Exercise Test
MH  - Exercise Tolerance
MH  - Heart Rate/de [Drug Effects]
MH  - *Hemodynamics/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Pulmonary Gas Exchange/de [Drug Effects]
MH  - Stroke Volume/de [Drug Effects]
AB  - BACKGROUND: beta-blockade controls the ventricular response to exercise in chronic atrial fibrillation (AF), but the effects of beta-blockers on exercise capacity in AF have been debated.
AB  - METHODS: Twelve men with AF (65+/-8 years) participated in a randomized, double-blind, placebo-controlled study of betaxolol (20 mg daily). Patients underwent maximal exercise testing with ventilatory gas exchange analysis, and a separate, submaximal test (50% of maximum) during which cardiac output was measured by a CO2 rebreathing technique.
AB  - RESULTS: After betaxolol therapy, heart rate was reduced both at rest (92+/-27 vs 62+/-12 beats/min; p < 0.001) and at peak exercise (173+/-22 vs 116+/-24 beats/min; p < 0.001). Maximal oxygen uptake (VO2) was reduced by 19% after betaxolol (21.8+/-5.3 with placebo vs 17.6+/-5.1 mL/kg/min with betaxolol; p < 0.05), with similar reductions observed for maximal exercise time, minute ventilation, and CO2 production. VO2 was reduced by a similar extent (19%) at the ventilatory threshold. Submaximal cardiac output was reduced by 15% during betaxolol therapy (12.9+/-2.3 vs 10.9+/-1.3 L/min; p < 0.05), and stroke volume was higher (88.0+/-21 vs 105.6+/-19 mL/beat; p < 0.05).
AB  - CONCLUSION: Betaxolol therapy in patients with AF effectively controlled the ventricular rate at rest and during exercise, but also caused considerable reductions in maximal VO2 and cardiac output during exercise. The observed increase in stroke volume could not adequately compensate for reduced heart rate to maintain VO2 during exercise.
RN  - 0 (Adrenergic beta-Antagonists)
RN  - O0ZR1R6RZ2 (Betaxolol)
IS  - 0012-3692
IL  - 0012-3692
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 1999 Apr
DC  - 19990506
YR  - 1999
ED  - 19990506
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=10208225

<757. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9990640
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Tse HF
AU  - Lau CP
AU  - Ayers GM
FA  - Tse, H F
FA  - Lau, C P
FA  - Ayers, G M
IN  - Tse,H F. Department of Medicine, University of Hong Kong, Queen Mary Hospital, China.
TI  - Detection of atrial fibrillation during sinus tachycardia induced by exercise in patients with implantable atrial defibrillators.
SO  - Pacing & Clinical Electrophysiology. 22(1 Pt 2):247-52, 1999 Jan.
AS  - Pacing Clin Electrophysiol. 22(1 Pt 2):247-52, 1999 Jan.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Algorithms
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Defibrillators, Implantable
MH  - *Electric Countershock/is [Instrumentation]
MH  - *Electrophysiology/mt [Methods]
MH  - Exercise
MH  - Exercise Test/ae [Adverse Effects]
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Reproducibility of Results
MH  - Tachycardia, Sinus/et [Etiology]
MH  - *Tachycardia, Sinus/pp [Physiopathology]
AB  - Accurate detection of atrial fibrillation (AF) is essential for appropriate operation of an implantable atrial defibrillator (IAD). However, during episodes of sinus tachycardia, distinction between AF and sinus rhythm (SR) using the "quiet interval" and "baseline crossing" analysis in the detection algorithm of the IAD may be difficult. The efficacy of this AF detection algorithm was tested in five patients implanted with an IAD (METRIX, Model 3000 or 3020, InControl Inc.) during treadmill exercise testing. The IADs were programmed to Monitor Mode with a wake up cycle of 1 minute for AF detection using the device nominal parameters or modified parameters, and to mark rhythms appropriate for shock delivery. A mean peak heart rate of 137 +/- 26 beats/min was reached during maximum exercise, and one patient developed transient AF. Seventy-eight (75 in SR, 3 in AF) and 91 (89 in SR, 2 in AF) runs of AF detection were performed using the nominal and modified parameters, respectively. The IAD detected AF and SR accurately, except for one episode of false-positive AF detection during sinus tachycardia at the nominal settings, but inappropriate shocks were prevented by minimum RR interval criteria that limited discharge at high heart rate. These results indicate that the AF detection algorithm in the IAD may become more vulnerable to false-positive AF detection during sinus tachycardia, which were avoided by reprogramming the Quiet Interval and minimum RR interval criteria for AF detection. Exercise testing appeared useful to program optimal settings of the IAD in preparation for daily activities.
IS  - 0147-8389
IL  - 0147-8389
PT  - Journal Article
LG  - English
DP  - 1999 Jan
DC  - 19990413
YR  - 1999
ED  - 19990413
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9990640

<758. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 10188663
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gorelick PB
AU  - Sacco RL
AU  - Smith DB
AU  - Alberts M
AU  - Mustone-Alexander L
AU  - Rader D
AU  - Ross JL
AU  - Raps E
AU  - Ozer MN
AU  - Brass LM
AU  - Malone ME
AU  - Goldberg S
AU  - Booss J
AU  - Hanley DF
AU  - Toole JF
AU  - Greengold NL
AU  - Rhew DC
FA  - Gorelick, P B
FA  - Sacco, R L
FA  - Smith, D B
FA  - Alberts, M
FA  - Mustone-Alexander, L
FA  - Rader, D
FA  - Ross, J L
FA  - Raps, E
FA  - Ozer, M N
FA  - Brass, L M
FA  - Malone, M E
FA  - Goldberg, S
FA  - Booss, J
FA  - Hanley, D F
FA  - Toole, J F
FA  - Greengold, N L
FA  - Rhew, D C
IN  - Gorelick,P B. Department of Neurological Science, Rush Medical College, Chicago, IL 60612, USA.
TI  - Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. [Review] [128 refs]
CM  - Comment in: JAMA. 1999 Dec 1;282(21):1999-2000; author reply 2000-1; PMID: 10591379
CM  - Comment in: ACP J Club. 1999 Sep-Oct;131(2):30-1
CM  - Comment in: JAMA. 1999 Dec 1;282(21):2000-1; PMID: 10591380
SO  - JAMA. 281(12):1112-20, 1999 Mar 24-31.
AS  - JAMA. 281(12):1112-20, 1999 Mar 24-31.
NJ  - JAMA
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 7501160
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Alcohol Drinking
MH  - Atrial Fibrillation/pc [Prevention & Control]
MH  - Carotid Artery Diseases/pc [Prevention & Control]
MH  - Cerebrovascular Disorders/ep [Epidemiology]
MH  - *Cerebrovascular Disorders/pc [Prevention & Control]
MH  - Diabetes Mellitus/pc [Prevention & Control]
MH  - Exercise
MH  - Humans
MH  - Hypertension/pc [Prevention & Control]
MH  - Life Style
MH  - Myocardial Infarction/pc [Prevention & Control]
MH  - *Practice Guidelines as Topic
MH  - Risk Factors
AB  - OBJECTIVE: To establish, in a single resource, up-to-date recommendations for primary care physicians regarding prevention strategies for a first stroke.
AB  - PARTICIPANTS: Members of the National Stroke Association's (NSA's) Stroke Prevention Advisory Board and Cedars-Sinai Health System Department of Health Services Research convened on April 9, 1998, in an open meeting. The conference attendees, selected to participate by the NSA, were recognized experts in neurology (9), cardiology (2), family practice (1), nursing (1), physician assistant practices (1), and health services research (2).
AB  - EVIDENCE: A literature review was carried out by the Department of Health Services Research, Cedars-Sinai Health System, Los Angeles, Calif, using the MEDLINE database search for 1990 through April 1998 and updated in November 1998. English-language guidelines, statements, meta-analyses, and overviews on prevention of a first stroke were reviewed.
AB  - CONSENSUS PROCESS: At the meeting, members of the advisory board identified 6 important stroke risk factors (hypertension, myocardial infarction [MI], atrial fibrillation, diabetes mellitus, blood lipids, asymptomatic carotid artery stenosis), and 4 lifestyle factors (cigarette smoking, alcohol use, physical activity, diet).
AB  - CONCLUSIONS: Several interventions that modify well-documented and treatable cardiovascular and cerebrovascular risk factors can reduce the risk of a first stroke. Good evidence for direct stroke reduction exists for hypertension treatment; using warfarin for patients after MI who have atrial fibrillation, decreased left ventricular ejection fraction, or left ventricular thrombus; using 3-hydroxy-3 methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors for patients after MI; using warfarin for patients with atrial fibrillation and specific risk factors; and performing carotid endarterectomy for patients with stenosis of at least 60%. Observational studies support the role of modifying lifestyle-related risk factors (eg, smoking, alcohol use, physical activity, diet) in stroke prevention. Measures to help patients improve adherence are an important component of a stroke prevention plan. [References: 128]
IS  - 0098-7484
IL  - 0098-7484
PT  - Consensus Development Conference
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
LG  - English
DP  - 1999 Mar 24-31
DC  - 19990407
YR  - 1999
ED  - 19990407
RD  - 20140917
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=10188663

<759. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 10091823
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kochiadakis GE
AU  - Igoumenidis NE
AU  - Parthenakis FI
AU  - Chlouverakis GI
AU  - Vardas PE
FA  - Kochiadakis, G E
FA  - Igoumenidis, N E
FA  - Parthenakis, F I
FA  - Chlouverakis, G I
FA  - Vardas, P E
IN  - Kochiadakis,G E. Cardiology Department, University Hospital of Heraklion, Crete, Greece.
TI  - Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study.
SO  - Journal of the American College of Cardiology. 33(4):966-71, 1999 Mar 15.
AS  - J Am Coll Cardiol. 33(4):966-71, 1999 Mar 15.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - h50, 8301365
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Amiodarone/ae [Adverse Effects]
MH  - *Amiodarone/tu [Therapeutic Use]
MH  - Anti-Arrhythmia Agents/ae [Adverse Effects]
MH  - *Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Chronic Disease
MH  - Electrocardiography/de [Drug Effects]
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Propafenone/ae [Adverse Effects]
MH  - *Propafenone/tu [Therapeutic Use]
MH  - Treatment Outcome
AB  - OBJECTIVES: The purpose of this study was to investigate the efficacy and safety of amiodarone and propafenone in the conversion of chronic atrial fibrillation in a prospective, randomized, placebo-controlled study.
AB  - BACKGROUND: The effectiveness of amiodarone and propafenone in the treatment of patients with chronic atrial fibrillation has not been adequately studied.
AB  - METHODS: One hundred one patients (48 men, mean age 64 +/- 9 years) with atrial fibrillation lasting >3 weeks participated in the study. Thirty-four patients received amiodarone (300 mg intravenously over 1 h, followed by 20 mg/kg over the next 24 h plus 600 mg orally, in three doses, for 1 week, then 400 mg/day orally, for three weeks), 32 received propafenone (2 mg/kg intravenously over 15 min, followed by 10 mg/kg over 24 h and then 450 mg/day orally, for one month) and the remaining 35 served as control subjects. All patients received digoxin and anticoagulant treatment as indicated (International Normalized Ratio 2 to 3).
AB  - RESULTS: Conversion to sinus rhythm was achieved in 16 (47.05%) patients who received amiodarone, in 13 (40.62%) who received propafenone and in none of the control subjects (p < 0.001 for both groups vs. control subjects). Those who converted had smaller atria than those who did not and atrial fibrillation of shorter duration in both the amiodarone and propafenone groups. Treatment was discontinued in one patient of the propafenone group because of significant QRS widening.
AB  - CONCLUSIONS: Amiodarone and propafenone appear to be safe and equally effective in the termination of chronic atrial fibrillation. Left atrial diameter and arrhythmia duration are independent predictors of conversion.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 68IQX3T69U (Propafenone)
RN  - N3RQ532IUT (Amiodarone)
IS  - 0735-1097
IL  - 0735-1097
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 1999 Mar 15
DC  - 19990407
YR  - 1999
ED  - 19990407
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=10091823

<760. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9920373
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kahaly GJ
AU  - Nieswandt J
AU  - Mohr-Kahaly S
FA  - Kahaly, G J
FA  - Nieswandt, J
FA  - Mohr-Kahaly, S
IN  - Kahaly,G J. Endocrinology/Metabolism, Gutenberg-University Hospital, Mainz, Germany.
TI  - Cardiac risks of hyperthyroidism in the elderly. [Review] [25 refs]
SO  - Thyroid. 8(12):1165-9, 1998 Dec.
AS  - Thyroid. 8(12):1165-9, 1998 Dec.
NJ  - Thyroid : official journal of the American Thyroid Association
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - bjw, 9104317
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Cardiovascular Diseases/et [Etiology]
MH  - Cerebrovascular Disorders/et [Etiology]
MH  - Exercise
MH  - Heart/pp [Physiopathology]
MH  - Humans
MH  - *Hyperthyroidism/co [Complications]
MH  - Hyperthyroidism/di [Diagnosis]
MH  - Hyperthyroidism/dt [Drug Therapy]
MH  - Hyperthyroidism/pp [Physiopathology]
MH  - Lung/pp [Physiopathology]
MH  - Middle Aged
AB  - The importance of cardiovascular system involvement in hyperthyroidism has been recognized for many years. In the elderly patient, often with mild but prolonged elevation of plasma thyroid hormones, symptoms and signs of heart failure and complicating atrial fibrillation (AF) may dominate the clinical picture and mask the more classic endocrine manifestations of the disease. Impaired cardiopulmonary function and exercise capacity, significantly more marked in older patients, is observed in hyperthyroidism. Thyrotoxicosis can aggravate pre-existing heart disease and can also lead to AF, congestive heart failure, or worsening of angina pectoris. Regarding the high incidence of AF in older patients with hyperthyroidism, it is also important to detect subclinical hyperthyroidism in older patients with AF, thus warranting the measurement of the serum thyrotropin (TSH) concentration for early recognition and treatment. Most cardiac abnormalities return to normal once a euthyroid state has been achieved, although AF may persist in a minority. Optimal treatment requires rapid and definitive antithyroid therapy. Furthermore, anticoagulation is recommended for thyrotoxic patients with AF older than 50 years, those who have histories of previous emboli, hypertension, or with echocardiographic evidence of left atrial enlargement and/or myxomatous valves. [References: 25]
IS  - 1050-7256
IL  - 1050-7256
PT  - Journal Article
PT  - Review
LG  - English
DP  - 1998 Dec
DC  - 19990407
YR  - 1998
ED  - 19990407
RD  - 20051116
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9920373

<761. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 10027440
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ramos-Barbon D
AU  - Fitchett D
AU  - Gibbons WJ
AU  - Latter DA
AU  - Levy RD
FA  - Ramos-Barbon, D
FA  - Fitchett, D
FA  - Gibbons, W J
FA  - Latter, D A
FA  - Levy, R D
IN  - Ramos-Barbon,D. Department of Medicine, Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada.
TI  - Maximal exercise testing for the selection of heart transplantation candidates: limitation of peak oxygen consumption.
CM  - Comment in: Chest. 1999 Oct;116(4):1141-2; PMID: 10531194
SO  - Chest. 115(2):410-7, 1999 Feb.
AS  - Chest. 115(2):410-7, 1999 Feb.
NJ  - Chest
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0231335, d1c
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Female
MH  - *Heart Failure/pp [Physiopathology]
MH  - *Heart Failure/su [Surgery]
MH  - Heart Rate
MH  - *Heart Transplantation
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Oxygen Consumption
MH  - *Patient Selection
AB  - BACKGROUND: Peak exercise oxygen consumption (peak VO2), which is considered an indicator of prognosis in advanced heart failure, is currently being used as a major criterion in many centers for the selection of candidates for heart transplantation. Available studies suggest that patients with peak VO2 < 14 mL/min/kg have improved survival and significant functional benefit with transplantation. Since patients may terminate symptom-limited exercise tests for a variety of reasons, peak VO2 does not necessarily reflect maximal VO2, leading to the possibility of inappropriate selection for transplantation. Therefore, we investigated the proportion of transplant candidates referred for exercise testing considered to have achieved maximal results from studies.
AB  - METHODS: Fifty-five patients with heart failure, aged 51+/-9 years, (mean +/- SD) underwent maximum symptom-limited exercise tests on a cycle ergometer utilizing a Jones stage 1 incremental protocol. Tests were considered maximal if subjects achieved peak heart rate (HR) > 85% predicted ("cardiocirculatory limitation") or peak minute ventilation (VE) > 85% predicted ("ventilatory limitation"), and achieved an anaerobic threshold (AT) by noninvasive measures.
AB  - RESULTS: Seven tests were terminated because of chest pain, ST-segment abnormalities, or ventricular arrhythmias. Of the remaining 48 studies, the reasons for stopping exercise were leg fatigue in 52%, dyspnea in 16%, and both symptoms in 23%. Sixteen of the 48 patients (33%) had peak VO2 < 14 mL/min/kg. In 8 of these 16 patients, both peak HR and VE were < 85% predicted. Of these eight without apparent HR or ventilatory limitation, none had oxygen desaturation below 90% or fall in BP, two were in atrial fibrillation, and only three had evidence that an AT was achieved.
AB  - CONCLUSIONS: Among the patients with peak VO2 < 14 mL/min/kg, there were no objective signs of a cardiocirculatory or a respiratory limitation to exercise in half of them, and 31% did not achieve an AT either, thus not meeting any criteria to support evidence of maximal exercise. Exercise tests without objective evidence of cardiocirculatory or ventilatory limitation may not represent maximal performance. Consequently, peak VO2 may misclassify an appreciable proportion of candidates if the test results are submaximal.
AB  - CLINICAL IMPLICATIONS: Clinical exercise studies indicating low peak VO2 must be interpreted in the context of whether a defined objective exercise limitation is evident to avoid biasing the selection of heart transplant candidates.
IS  - 0012-3692
IL  - 0012-3692
PT  - Journal Article
LG  - English
DP  - 1999 Feb
DC  - 19990304
YR  - 1999
ED  - 19990304
RD  - 20140729
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=10027440

<762. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9987042
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Olivotto I
AU  - Montereggi A
AU  - Mazzuoli F
AU  - Cecchi F
FA  - Olivotto, I
FA  - Montereggi, A
FA  - Mazzuoli, F
FA  - Cecchi, F
IN  - Olivotto,I. UO Cardiologia II, Azienda Ospedaliera Careggi, Firenze.
TI  - Clinical utility and safety of exercise testing in patients with hypertrophic cardiomyopathy.
SO  - Giornale Italiano di Cardiologia. 29(1):11-9, 1999 Jan.
AS  - G Ital Cardiol. 29(1):11-9, 1999 Jan.
NJ  - Giornale italiano di cardiologia
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - fbe, 1270331
SB  - Index Medicus
CP  - ITALY
MH  - Adult
MH  - Arrhythmias, Cardiac/et [Etiology]
MH  - Blood Pressure
MH  - *Cardiomyopathy, Hypertrophic/di [Diagnosis]
MH  - Cardiomyopathy, Hypertrophic/pp [Physiopathology]
MH  - Electrocardiography, Ambulatory
MH  - Exercise Test/ae [Adverse Effects]
MH  - *Exercise Test
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Safety
AB  - BACKGROUND: Exercise testing has long been employed in patients with hypertrophic cardiomyopathy (HCM), although concerns have constantly been expressed regarding its safety. This study reviews a large number of exercise tests performed in a community-based population with HCM, in terms of safety and clinical utility.
AB  - METHODS: We analyzed a total of 243 maximal symptom-limited cycloergometer exercise tests performed at our institution in 138 patients with HCM (age 42 +/- 14 years, M/F 99/39), who were followed systematically for 9.4 +/- 6.5 years.
AB  - RESULTS: In none of the 243 exercise tests did cardiac arrest, hemodynamic collapse or malignant arrhythmia occur, although 53 of the study patients (38%) had > or = 1 risk factors including previous cardiac arrest, recurrent syncope, malignant family history and resting left ventricular outflow obstruction. Early termination of the test was necessary in only 8 patients due to symptomatic hypotension with dizziness, but none had syncope. Mean predicted functional capacity achieved by the study group was 77 +/- 22%. Poor performance (< 60% of predicted functional capacity) was observed in 32 patients (23%), and it was associated with a NYHA functional class > 1 and an abnormal blood pressure response to exercise. Non-malignant arrhythmias occurred in 41 patients (30%), including multiple premature ventricular beats (PVB), paroxysmal atrial fibrillation, non-sustained ventricular (NSVT) and supraventricular tachycardia. The combined presence of multiple exercise-induced PVB and NSVT on Holter ECG had a 14% positive but a 97% negative predictive value for sudden death or cardiac arrest.
AB  - CONCLUSIONS: 1) Exercise testing is safe in a community-based population of patients with HCM, and provides useful information regarding functional capacity, efficacy of treatment, blood pressure response to exercise and inducible ischemia. Thus, ergometry should routinely be included in the standard evaluation and follow-up protocols of HCM patients. 2) Conversely, the utility of ergometry in the evaluation of the arrhythmic risk in HCM patients appears to be limited to the identification of low-risk patients.
IS  - 0046-5968
IL  - 0046-5968
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 1999 Jan
DC  - 19990302
YR  - 1999
ED  - 19990302
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9987042

<763. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9973007
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Farshi R
AU  - Kistner D
AU  - Sarma JS
AU  - Longmate JA
AU  - Singh BN
FA  - Farshi, R
FA  - Kistner, D
FA  - Sarma, J S
FA  - Longmate, J A
FA  - Singh, B N
IN  - Farshi,R. Division of Cardiology, West Los Angeles VA Medical Center, UCLA School of Medicine, California 90073, USA.
TI  - Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens.
SO  - Journal of the American College of Cardiology. 33(2):304-10, 1999 Feb.
AS  - J Am Coll Cardiol. 33(2):304-10, 1999 Feb.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - h50, 8301365
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - *Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - Atenolol/tu [Therapeutic Use]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Calcium Channel Blockers/tu [Therapeutic Use]
MH  - *Circadian Rhythm/ph [Physiology]
MH  - Cross-Over Studies
MH  - Digoxin/tu [Therapeutic Use]
MH  - Diltiazem/tu [Therapeutic Use]
MH  - Drug Therapy, Combination
MH  - Electrocardiography, Ambulatory
MH  - *Exercise/ph [Physiology]
MH  - Female
MH  - Follow-Up Studies
MH  - *Heart Rate
MH  - Heart Ventricles/de [Drug Effects]
MH  - *Heart Ventricles/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Middle Aged
AB  - OBJECTIVES: We compared the effects of five pharmacologic regimens on the circadian rhythm and exercise-induced changes of ventricular rate (VR) in patients with chronic atrial fibrillation (CAF).
AB  - BACKGROUND: Systematic comparison of standardized drug regimens on 24 h VR control in CAF have not been reported.
AB  - METHODS: In 12 patients (11 male, 69+/-6 yr) with CAF, the effects on VR by 5 standardized daily regimens: 1) 0.25 mg digoxin, 2) 240 mg diltiazem-CD, 3) 50 mg atenolol, 4) 0.25 mg digoxin + 240 mg diltiazem-CD, and 5) 0.25 mg digoxin + 50 mg atenolol; were studied after 2 week treatment assigned in random order. The VR data were analyzed by ANOVA with repeated measures. The circadian phase differences were evaluated by cosinor analysis.
AB  - RESULTS: The 24-h mean (+/-SD) values of VR (bpm) were - digoxin: 78.9 +/- 16.3, diltiazem: 80.0+/-15.5, atenolol: 75.9+/-11.7, digoxin + diltiazem: 67.3+/-14.1 and digoxin + atenolol: 65.0+/-9.4. Circadian patterns were significant in each treatment group (p < 0.001). The VR on digoxin + atenolol was significantly lower than that on digoxin (p < 0.0001), diltiazem (p < 0.0002) and atenolol (p < 0.001). The time of peak VR on Holter was significantly delayed with regimens 3 and 5 which included atenolol (p < 0.03). During exercise, digoxin and digoxin + atenolol treatments resulted in the highest and lowest mean VR respectively. The exercise Time-VR plots of all groups were nearly parallel (p = ns). The exercise duration was similar in all treatment groups (p = ns).
AB  - CONCLUSIONS: This study indicates that digoxin and diltiazem, as single agents at the doses tested, are least effective for controlling ventricular rate in atrial fibrillation during daily activity. Digoxin + atenolol produced the most effective rate control reflecting a synergistic effect on the AV node. The data provides a basis for testing the effects of chronic suppression of diurnal fluctuations of VR on left atrial and ventricular function in CAF.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Calcium Channel Blockers)
RN  - 50VV3VW0TI (Atenolol)
RN  - 73K4184T59 (Digoxin)
RN  - EE92BBP03H (Diltiazem)
IS  - 0735-1097
IL  - 0735-1097
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1999 Feb
DC  - 19990302
YR  - 1999
ED  - 19990302
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9973007

<764. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9825343
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Holt ND
AU  - Brady S
AU  - Dark JH
AU  - McComb JM
FA  - Holt, N D
FA  - Brady, S
FA  - Dark, J H
FA  - McComb, J M
IN  - Holt,N D. Regional Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne, United Kingdom.
TI  - Exercise response of the recipient atrial remnant after orthotopic cardiac transplantation: implications for recipient atrial triggered pacing.
SO  - Pacing & Clinical Electrophysiology. 21(11 Pt 2):2331-7, 1998 Nov.
AS  - Pacing Clin Electrophysiol. 21(11 Pt 2):2331-7, 1998 Nov.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Atrial Function/ph [Physiology]
MH  - Cardiac Pacing, Artificial/mt [Methods]
MH  - Electrocardiography
MH  - *Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Heart Atria
MH  - *Heart Rate/ph [Physiology]
MH  - *Heart Transplantation/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Pacemaker, Artificial
AB  - The assumption that the recipient atrial remnant in the cardiac transplant recipient is normal has led to the suggestion that it is an appropriate trigger for permanent pacing in transplant recipients who need pacing or to restore chronotropic competence and/or mechanical synchrony of the composite atrium. We examined the chronotropic response to exercise in 12 orthotopic cardiac transplant recipients (mean age 49 years) at a mean time of 17 months posttransplantation. Recipient and donor atrial rates were noted and compared and chronotropic competence determined. Two of 12 recipient atrial remnants were in atrial fibrillation. Only six of the remaining 10 recipient atria exhibited chronotropic competence. Seven of 10 recipient atria had rates higher than that of the donor. Only four of ten recipient atria in sinus rhythm satisfied both criteria. Two of these had abnormally high atrial responses early into exercise. Of the remaining two, only one recipient atrial remnant demonstrated a > or = 20% increase in heart rate above that of the donor at peak exercise. Hence only 1 of 12 (8.3%) transplant recipients potentially could benefit from recipient atrial triggered pacing. While recipient atrial triggered pacing is an attractive theoretical concept for restoring chronotropic competence following orthotopic cardiac transplantation, it may rarely be practical because the recipient atrial remnant displays rhythm abnormalities, chronotropic incompetence, and abnormalities in its exercise response.
IS  - 0147-8389
IL  - 0147-8389
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1998 Nov
DC  - 19990210
YR  - 1998
ED  - 19990210
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9825343

<765. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9793092
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Zimmermann M
AU  - Adamec R
AU  - Metzger J
FA  - Zimmermann, M
FA  - Adamec, R
FA  - Metzger, J
IN  - Zimmermann,M. Department of Internal Medicine, University Hospital, Geneva, Switzerland.
TI  - Atrial vulnerability in patients with paroxysmal "lone" atrial fibrillation.
SO  - Pacing & Clinical Electrophysiology. 21(10):1949-58, 1998 Oct.
AS  - Pacing Clin Electrophysiol. 21(10):1949-58, 1998 Oct.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Function/ph [Physiology]
MH  - Cardiac Pacing, Artificial
MH  - Electrocardiography
MH  - Electrophysiology
MH  - Female
MH  - *Heart Conduction System/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Sensitivity and Specificity
AB  - Little is known about the electrophysiological properties of the atrium predisposing to paroxysmal atrial fibrillation (AF), especially in patients without structural heart disease. This study was conducted to analyze intraatrial conduction, atrial refractoriness, and arrhythmia inducibility in patients with lone paroxysmal AF. An electrophysiological study was performed in 24 patients with a documented history of lone paroxysmal AF but in sinus rhythm at the time of the electrophysiological study. Twelve patients without any history of atrial arrhythmias served as controls. The patients with lone paroxysmal AF showed a significant prolonged local conduction time S1A1 (70 +/- 21 ms vs 36 +/- 12 ms, P < 0.0001), a lack of rate adaptation of the functional refractory period (FRP changes/cycle length changes < 10% in 15 of 24 patients with lone paroxysmal AF vs 1/12 controls, P = 0.002) and a higher incidence of inducible AF with only one extrastimulus (13/24 vs 0/12, P = 0.0014). The total P wave duration in the surface ECG (89 +/- 14 ms vs 83 +/- 8 ms, P = 0.15), the intraatrial conduction time (36 +/- 14 ms vs 28 +/- 8 ms, P = 0.07), the presence of a fragmented atrial electrogram (16/24 vs 7/12, P = 0.62), the absolute value of the effective refractory period (204 +/- 28 ms vs 212 +/- 23 ms, P = 0.42), and the vulnerability index (3.0 +/- 1.5 vs 3.6 +/- 1.5, P = 0.26) were not statistically different between the two groups. The presence of a prolonged (> 50 ms) S1A1 and/or the presence of a lack of rate adaptation of the FRP and/or the presence of inducible AF identified patients with spontaneous lone paroxysmal AF with a sensitivity of 96%, a specificity of 67%, a positive predictive value of 85%, and a negative predictive value of 89%. In patients with lone paroxysmal AF, the electrophysiological study using conventional techniques allows not only to detect AF inducibility using a nonaggressive protocol, but also to reveal several electrophysiological abnormalities related to the atrial substrate itself. This atrial vulnerability may explain the high incidence of recurrences in patients with lone paroxysmal AF.
IS  - 0147-8389
IL  - 0147-8389
PT  - Journal Article
LG  - English
DP  - 1998 Oct
DC  - 19981221
YR  - 1998
ED  - 19981221
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9793092

<766. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9803957
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wolf PA
FA  - Wolf, P A
IN  - Wolf,P A. Department of Neurology, Boston University School of Medicine, MA 02118-2526, USA.
TI  - Prevention of stroke. [Review] [23 refs]
SO  - Lancet. 352 Suppl 3:SIII15-8, 1998 Oct.
AS  - Lancet. 352 Suppl 3:SIII15-8, 1998 Oct.
NJ  - Lancet (London, England)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 2985213r, l0s, 0053266
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - ENGLAND
MH  - Anticholesteremic Agents/tu [Therapeutic Use]
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/th [Therapy]
MH  - Carotid Stenosis/su [Surgery]
MH  - *Cerebrovascular Disorders/et [Etiology]
MH  - *Cerebrovascular Disorders/pc [Prevention & Control]
MH  - Cholesterol, LDL/bl [Blood]
MH  - Exercise
MH  - Folic Acid/tu [Therapeutic Use]
MH  - Homocysteine/bl [Blood]
MH  - Humans
MH  - Hypercholesterolemia/dt [Drug Therapy]
MH  - Hypertension/th [Therapy]
MH  - Patient Selection
MH  - Smoking Cessation
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Anticoagulants)
RN  - 0 (Cholesterol, LDL)
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - 935E97BOY8 (Folic Acid)
IS  - 0140-6736
IL  - 0140-6736
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
NO  - 2-RO1-NS-17950-17 (United States NINDS NIH HHS)
NO  - NIH-NO1-HC-38038 (United States NHLBI NIH HHS)
NO  - R01-HL40423 (United States NHLBI NIH HHS)
LG  - English
DP  - 1998 Oct
DC  - 19981110
YR  - 1998
ED  - 19981110
RD  - 20150616
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9803957

<767. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9731832
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Hoffman MS
AU  - Lynch CM
FA  - Hoffman, M S
FA  - Lynch, C M
IN  - Hoffman,M S. Department of Obstetrics and Gynecology, College of Medicine, University of South Florida, Tampa, USA.
TI  - Minilaparotomy hysterectomy.
CM  - Comment in: Am J Obstet Gynecol. 1999 Oct;181(4):1037-8; PMID: 10521946
SO  - American Journal of Obstetrics & Gynecology. 179(2):316-20, 1998 Aug.
AS  - Am J Obstet Gynecol. 179(2):316-20, 1998 Aug.
NJ  - American journal of obstetrics and gynecology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3ni, 0370476
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Humans
MH  - *Hysterectomy, Vaginal/mt [Methods]
MH  - *Laparotomy
MH  - Middle Aged
AB  - OBJECTIVE: This article reports our experience with minilaparotomy hysterectomy.
AB  - STUDY DESIGN: Minilaparotomy was defined as a skin incision < or = 6 cm in length. From January 1, 1996, to June 30, 1997, data were collected on all patients who underwent hysterectomy by means of a minilaparotomy.
AB  - RESULTS: During the study a total of 250 hysterectomies were performed. Twenty-six of those were performed by means of a minilaparotomy. The mean age of the patients was 54 years. Seven had endometrial cancer and 8 had an adnexal mass. In 1 patient the incision was extended for staging of an ovarian cancer. The only intraoperative complication was rupture of a 6-cm ovarian tumor. After operation, 2 patients had febrile morbidity, 1 had a prolonged ileus, and in 1 atrial fibrillation developed. The mean uterine weight was 123 g. Median day of Foley catheter removal and mean day of ambulation, regular diet, and discharge were 1 day, 1.2 days, 2.4 days, and 3.4 days, respectively.
AB  - CONCLUSION: Minilaparotomy is a safe and feasible route of hysterectomy for a selected group of patients.
IS  - 0002-9378
IL  - 0002-9378
PT  - Journal Article
LG  - English
DP  - 1998 Aug
DC  - 19980917
YR  - 1998
ED  - 19980917
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9731832

<768. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9711185
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Fukuda N
AU  - Oki T
AU  - Iuchi A
AU  - Tabata T
AU  - Yamada H
AU  - Takeichi N
AU  - Shinohara H
AU  - Soeki T
AU  - Yui Y
AU  - Tamura Y
FA  - Fukuda, N
FA  - Oki, T
FA  - Iuchi, A
FA  - Tabata, T
FA  - Yamada, H
FA  - Takeichi, N
FA  - Shinohara, H
FA  - Soeki, T
FA  - Yui, Y
FA  - Tamura, Y
IN  - Fukuda,N. Institute for Clinical Research, Zentsuji National Hospital, Japan.
TI  - Right heart flow dynamics after tricuspid valve annuloplasty. Characteristics and time course.
SO  - Japanese Heart Journal. 39(3):339-46, 1998 May.
AS  - Jpn Heart J. 39(3):339-46, 1998 May.
NJ  - Japanese heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - kh3, 0401175
SB  - Index Medicus
CP  - JAPAN
MH  - Adult
MH  - Aged
MH  - Echocardiography, Doppler, Color/is [Instrumentation]
MH  - Echocardiography, Doppler, Color/mt [Methods]
MH  - Echocardiography, Doppler, Color/sn [Statistics & Numerical Data]
MH  - *Heart/pp [Physiopathology]
MH  - Humans
MH  - Jugular Veins/pp [Physiopathology]
MH  - Middle Aged
MH  - Postoperative Period
MH  - Pulse
MH  - *Tricuspid Valve/pp [Physiopathology]
MH  - Tricuspid Valve/su [Surgery]
MH  - *Tricuspid Valve Insufficiency/pp [Physiopathology]
MH  - Tricuspid Valve Insufficiency/su [Surgery]
AB  - To evaluate the effect of tricuspid annuloplasty (TAP) on right heart flow dynamics, we analyzed tricuspid inflow velocity pattern, jugular venous pulse and color Doppler flow signal of tricuspid regurgitation (TR) before and after surgery in 16 patients who underwent TAP (TAP group). Cardiac rhythm was atrial fibrillation in all patients. Twelve patients with lone atrial fibrillation served as controls (AF group). Patients in the TAP group were studied before and serially after surgery with a mean follow-up period of 2.7 years. TAP was performed according to the modified De Vega technique in all patients. In a comparison of the most recent data in the TAP group and the data in the AF group, the maximum tricuspid inflow velocity was significantly increased, and both the deceleration time of the tricuspid inflow velocity wave and the y-h interval of the jugular venous pulse were significantly prolonged in the TAP group compared to the AF group. Immediately after surgery, in the TAP group, the area of the TR jet was markedly decreased, and the deceleration time of the tricuspid inflow velocity wave was significantly prolonged compared to those before surgery. The area of the TR jet was dramatically decreased and remained small during the follow-up period. Thus, TAP may produce mild tricuspid stenosis but may also confer sustained preventive effects against TR.
IS  - 0021-4868
IL  - 0021-4868
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 1998 May
DC  - 19980902
YR  - 1998
ED  - 19980902
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9711185

<769. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9708660
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Maki T
AU  - Toivonen L
AU  - Koskinen P
AU  - Naveri H
AU  - Harkonen M
AU  - Leinonen H
FA  - Maki, T
FA  - Toivonen, L
FA  - Koskinen, P
FA  - Naveri, H
FA  - Harkonen, M
FA  - Leinonen, H
IN  - Maki,T. Department of Clinical Chemistry, Helsinki University Central Hospital, Finland.
TI  - Effect of ethanol drinking, hangover, and exercise on adrenergic activity and heart rate variability in patients with a history of alcohol-induced atrial fibrillation.
SO  - American Journal of Cardiology. 82(3):317-22, 1998 Aug 1.
AS  - Am J Cardiol. 82(3):317-22, 1998 Aug 1.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adrenergic beta-Agonists/pd [Pharmacology]
MH  - Adult
MH  - Alcohol Drinking/bl [Blood]
MH  - *Alcohol Drinking/pp [Physiopathology]
MH  - Atrial Fibrillation/bl [Blood]
MH  - Atrial Fibrillation/ci [Chemically Induced]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Catecholamines/bl [Blood]
MH  - Cyclic AMP/bi [Biosynthesis]
MH  - Cyclic AMP/bl [Blood]
MH  - Electrocardiography, Ambulatory
MH  - *Ethanol/ae [Adverse Effects]
MH  - Ethanol/bl [Blood]
MH  - *Exercise
MH  - Exercise Test
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Isoproterenol/pd [Pharmacology]
MH  - Lactic Acid/bl [Blood]
MH  - Lymphocytes/me [Metabolism]
MH  - Male
MH  - Middle Aged
MH  - Radioimmunoassay
MH  - *Receptors, Adrenergic, beta/bl [Blood]
MH  - Substance Withdrawal Syndrome/bl [Blood]
MH  - *Substance Withdrawal Syndrome/pp [Physiopathology]
AB  - To elucidate the mechanism of alcohol-induced atrial fibrillation (AF) we studied the heart rate variability and parameters of the adrenergic system during alcohol intake, hangover, and exercise in 6 men (mean age 43 years) prone to alcohol-induced AF, together with 6 age-matched controls. The ambulatory (15 hour) electrocardiogram was recorded and blood samples were taken for lymphocytic beta adrenoceptor, plasma catecholamine, and cyclic adenosine monophosphate (cAMP) measurements before and after alcohol intake (blood alcohol 1.5 per thousand), during hangover, and after a standardized bicycle exercise test. The beta-adrenoceptor density in lymphocytes was unchanged in the control group after alcohol intake or during hangover. Each of the AF patients had an increase in beta-adrenoceptor density after ethanol drinking (mean increase 29%, p <0.05). The hangover or exercise beta-receptor values did not differ from those in corresponding controls. Plasma adrenaline concentration tended to decrease and noradrenaline to increase after drinking and during hangover in both groups. Plasma cAMP levels were lower in patients after drinking than in controls (p <0.05). The exercise values of the adrenergic parameters were very similar in AF patients whether or not preceded by alcohol. Analysis of ambulatory electrocardiography showed a very low rate of ectopic beats in both AF patients and controls. Analysis of heart rate variability revealed a tendency toward an increase in sympathetic/parasympathetic component ratio (low-frequency/high-frequency ratio) in AF patients, but not in controls, after ethanol drinking. In conclusion, no signs of arrhythmogenic cardiac disease were detected in patients with AF to explain the tendency toward AF. Increases in beta-adrenoceptor density and low-frequency/high-frequency ratio during ethanol intoxication in patients with AF suggest an exaggerated sympathetic reaction.
RN  - 0 (Adrenergic beta-Agonists)
RN  - 0 (Catecholamines)
RN  - 0 (Receptors, Adrenergic, beta)
RN  - 33X04XA5AT (Lactic Acid)
RN  - 3K9958V90M (Ethanol)
RN  - E0399OZS9N (Cyclic AMP)
RN  - L628TT009W (Isoproterenol)
IS  - 0002-9149
IL  - 0002-9149
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1998 Aug 1
DC  - 19980901
YR  - 1998
ED  - 19980901
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9708660

<770. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9699572
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Yoshihara F
AU  - Nishikimi T
AU  - Kosakai Y
AU  - Isobe F
AU  - Matsuoka H
AU  - Takishita S
AU  - Kawashima Y
AU  - Saito Y
AU  - Matsuo H
AU  - Kangawa K
FA  - Yoshihara, F
FA  - Nishikimi, T
FA  - Kosakai, Y
FA  - Isobe, F
FA  - Matsuoka, H
FA  - Takishita, S
FA  - Kawashima, Y
FA  - Saito, Y
FA  - Matsuo, H
FA  - Kangawa, K
IN  - Yoshihara,F. Division of Hypertension and Cardiovascular Surgery, National Cardiovascular Center, Suita, Osaka, Japan.
TI  - Atrial natriuretic peptide secretion and body fluid balance after bilateral atrial appendectomy by the maze procedure.
SO  - Journal of Thoracic & Cardiovascular Surgery. 116(2):213-9, 1998 Aug.
AS  - J Thorac Cardiovasc Surg. 116(2):213-9, 1998 Aug.
NJ  - The Journal of thoracic and cardiovascular surgery
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - k9j, 0376343
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Atrial Fibrillation/bl [Blood]
MH  - Atrial Fibrillation/su [Surgery]
MH  - Atrial Natriuretic Factor/bl [Blood]
MH  - *Atrial Natriuretic Factor/se [Secretion]
MH  - *Body Fluids/ph [Physiology]
MH  - *Cardiac Surgical Procedures
MH  - Chronic Disease
MH  - Diuretics/tu [Therapeutic Use]
MH  - Dopamine/tu [Therapeutic Use]
MH  - Exercise/ph [Physiology]
MH  - Female
MH  - Follow-Up Studies
MH  - Furosemide/tu [Therapeutic Use]
MH  - *Heart Atria/su [Surgery]
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/me [Metabolism]
MH  - Postoperative Complications/pc [Prevention & Control]
AB  - OBJECTIVES: One of the earliest recognized postoperative complications of the maze procedure was the fluid retention in the immediate postoperative period. Routine postoperative administration of diuretics markedly reduces the frequency and severity of the fluid retention. However, the cause of the abnormal fluid balance is still uncertain.
AB  - METHODS: We evaluated 24 patients: 15 patients underwent the maze procedure (maze group) and 9 patients did not (nonmaze group). Blood samples were obtained before and in the time course after operation for atrial natriuretic peptide measurement. To evaluate the influence of atrial natriuretic peptide on the body fluid balance, we also measured the amount of body fluid balance and the total doses of furosemide and dopamine administered after operation. To examine the effect of the maze procedure on atrial natriuretic peptide secretion in chronic phase, we measured plasma atrial natriuretic peptide levels during dynamic exercise in 21 patients who had undergone cardiac operations 2 years before.
AB  - RESULTS: Plasma atrial natriuretic peptide levels in the nonmaze group significantly increased after operation. In contrast, plasma atrial natriuretic peptide levels in the maze group did not increase, and these levels were significantly lower than in the nonmaze group. Although significantly greater doses of furosemide and dopamine were administered to the maze group than to the nonmaze group, the body fluid balance in the maze group was comparable with that in the nonmaze group in the early postoperative period. The response of atrial natriuretic peptide secretion by exercise was significantly attenuated in the maze group (n = 12) compared with the nonmaze group (n = 9) even 2 years after surgery, although there were no significant differences in heart rate or blood pressure during exercise between two groups.
AB  - CONCLUSIONS: These results suggest that the maze procedure attenuates atrial natriuretic peptide secretion in the early postoperative period and persists in chronic phase. This attenuated atrial natriuretic peptide secretion may reduce the ability of the kidneys to handle fluid load early after surgery.
RN  - 0 (Diuretics)
RN  - 7LXU5N7ZO5 (Furosemide)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
RN  - VTD58H1Z2X (Dopamine)
IS  - 0022-5223
IL  - 0022-5223
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 1998 Aug
DC  - 19980825
YR  - 1998
ED  - 19980825
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9699572

<771. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9579815
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Hsieh MH
AU  - Chen SA
AU  - Wen ZC
AU  - Tai CT
AU  - Chiang CE
AU  - Ding YA
AU  - Chang MS
FA  - Hsieh, M H
FA  - Chen, S A
FA  - Wen, Z C
FA  - Tai, C T
FA  - Chiang, C E
FA  - Ding, Y A
FA  - Chang, M S
IN  - Hsieh,M H. Department of Medicine, National Yang-Ming University, School of Medicine, and Veterans General Hospital, Taipei, Taiwan.
TI  - Effects of antiarrhythmic drugs on variability of ventricular rate and exercise performance in chronic atrial fibrillation complicated with ventricular arrhythmias.
SO  - International Journal of Cardiology. 64(1):37-45, 1998 Mar 13.
AS  - Int J Cardiol. 64(1):37-45, 1998 Mar 13.
NJ  - International journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - gqw, 8200291
SB  - Index Medicus
SB  - National Aeronautics and Space Administration (NASA) Journals
CP  - IRELAND
MH  - Aged
MH  - *Anti-Arrhythmia Agents/ad [Administration & Dosage]
MH  - Arrhythmias, Cardiac/co [Complications]
MH  - Arrhythmias, Cardiac/di [Diagnosis]
MH  - *Arrhythmias, Cardiac/dt [Drug Therapy]
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Blood Pressure/de [Drug Effects]
MH  - Chi-Square Distribution
MH  - Chronic Disease
MH  - Electrocardiography, Ambulatory
MH  - *Exercise Tolerance/de [Drug Effects]
MH  - Female
MH  - *Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Procainamide/ad [Administration & Dosage]
MH  - Propafenone/ad [Administration & Dosage]
MH  - Sotalol/ad [Administration & Dosage]
MH  - Tilt-Table Test
MH  - Treatment Outcome
MH  - Ventricular Dysfunction, Left/co [Complications]
MH  - Ventricular Dysfunction, Left/di [Diagnosis]
MH  - *Ventricular Dysfunction, Left/dt [Drug Therapy]
AB  - For conversion of atrial fibrillation to sinus rhythm and management of ventricular arrhythmias, antiarrhythmic drugs were frequently used. However, the effects of antiarrhythmic drugs on exercise performance and on the variability of ventricular rate were not available. This study included 37 patients who had chronic atrial fibrillation complicated with symptomatic ventricular arrhythmias. The patients were divided into three groups and received sotalol, propafenone, and procainamide, respectively. Before and after taking the drugs for 14 days, these patients received treadmill exercise test, 24 h Holter electrocardiogram, and tilt table test for evaluation of the exercise performance and the variability of ventricular rate (including the mean RR intervals, mRR, the standard deviation of RR intervals, SDRR, and the root mean square of the difference in successive RR intervals, rMSSD). All these antiarrhythmic drugs could suppress ventricular arrhythmia but only sotalol could significantly increase the exercise duration (374+/-50 to 476+/-55 s, P=0.02), and reduce the maximal heart rate (186+/-23 to 136+/-16 beats/min, P=0.01) during exercise test. Furthermore, only sotalol increased the mRR (777+/-60 to 885+/-66 ms, P=0.02), SDRR (190+/-40 to 216+/-48 ms, P=0.04) and rMSSD (223+/-48 to 253+/-40 ms, P=0.03) during 24 h Holter electrocardiogram. With head-up tilt, the mRR, SDRR and rMSSD all decreased significantly before drug therapy, and these changes were still present only after propafenone therapy. Therefore, comparisons among sotalol, propafenone and procainamide showed that sotalol increased the exercise performance and the variability of ventricular rate in patients who had chronic atrial fibrillation complicated with symptomatic ventricular arrhythmias.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 68IQX3T69U (Propafenone)
RN  - A6D97U294I (Sotalol)
RN  - L39WTC366D (Procainamide)
IS  - 0167-5273
IL  - 0167-5273
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1998 Mar 13
DC  - 19980709
YR  - 1998
ED  - 19980709
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9579815

<772. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9584297
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Carmouche DG
AU  - Bubien RS
AU  - Kay GN
FA  - Carmouche, D G
FA  - Bubien, R S
FA  - Kay, G N
IN  - Carmouche,D G. University of Alabama at Birmingham Bye 352, USA.
TI  - The effect of maximum heart rate on oxygen kinetics and exercise performance at low and high workloads.
SO  - Pacing & Clinical Electrophysiology. 21(4 Pt 1):679-86, 1998 Apr.
AS  - Pacing Clin Electrophysiol. 21(4 Pt 1):679-86, 1998 Apr.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - Anaerobiosis
MH  - Atrial Fibrillation/su [Surgery]
MH  - Atrioventricular Node/su [Surgery]
MH  - Catheter Ablation
MH  - *Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Female
MH  - Heart Block/pp [Physiopathology]
MH  - Heart Block/th [Therapy]
MH  - *Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Oxygen Consumption
MH  - *Pacemaker, Artificial
AB  - The normal heart rate is linearly related to oxygen consumption during exercise. The maximum heart rate of the normal sinus node is approximated by the formula: HRmax = (220-age) with a variance of approximately 15%. However, the nominal upper rate of most permanent pacemakers is 120 beats/min, a value that remains unchanged for many patients. As this nominal setting falls well below the maximum predicted heart rate for most patients, it is possible that the chronotropic response of rate adaptive pacemakers during moderate and maximal exercise workloads may be less than optimal. The purpose of this study was to determine the effect of the upper programmed rate on oxygen kinetics during submaximal exercise workloads and maximum exercise performance during symptom-limited treadmill exercise. Exercise performance with an upper rate programmed to 220-age was compared with an upper rate of 120 beats/min. Eleven patients (5 men and 6 women, mean age 54 +/- 10 years) with complete heart block following catheter ablation of the atrioventricular junction for refractory atrial fibrillation who were implanted with permanent, rate-modulating VVIR pacemakers comprised the study population. The rate adaptive sensors were based on activity in 8 patients, minute ventilation in 2 patients, and mixed venous oxygen saturation in 1 patient. After performing a symptom-limited treadmill exercise test to determine maximum exercise capacity and to optimized programming of the rate adaptive sensor, each subject performed two treadmill exercise tests in random sequence with a rest period of at least 1 hour between tests. During one of the tests the upper rate was programmed to a value calculated by the formula: HRmax = (220-age). During the other exercise test the upper rate was programmed to 120 beats/min. Patients were blinded as to their programmed values and to the hypothesis of the study. A novel treadmill exercise protocol was used that consisted of a 6 minute, constant-workload phase at approximately 50% of maximum workload followed immediately by incremental, symptom-limited exercise using a modified Chronotropic Assessment Exercise Protocol(CAEP) with 1 minute stages until; peak exertion. Breath-by-breath analysis of expired gases was performed with subjective scoring of exertional difficulty at the end of the constant workload phase and during each stage of incremental exercise using the Borg Perceived Exertion Scale. Exercise duration was significantly longer (637 +/- 47 vs 611 +/- 48 seconds, P < 0.005) with the higher programmed upper rate. Oxygen kinetics were also significantly improved with an age predicted upper rate with a lower O2 deficit (258 +/- 88 vs 395 +/- 155 mL, P = 0.002) and higher VO2 rate constant (3.6 +/- 1.0 vs 2.4 +/- 0.7, P < 0.001). The VO2max during peak exertion was higher with an age predicted upper rate than with an upper rate of 120 beats/min (1807 +/- 751 vs 1716 +/- 702 mL/min, P = 0.04). The mean Borg score was lower during the last common treadmill stage during maximum exercise with an age predicted upper rate than with an upper rate of 120 beats/min (15.7 +/- 2.0 vs 16.5 +/- 1.9, P = 0.04). The mean Borg score during submaximal, constant workload exercise was also lower with a higher upper rate (9.0 +/- 2.5 vs 9.6 +/- 2.2, P = 0.10). Programming the upper rate of rate adaptive pacemakers based on the age of the patient improves exercise performance and exertional symptoms during both low and high exercise workloads as compared with a standard nominal value of 120 beats/min.
IS  - 0147-8389
IL  - 0147-8389
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 1998 Apr
DC  - 19980702
YR  - 1998
ED  - 19980702
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9584297

<773. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9624065
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Karjalainen J
AU  - Kujala UM
AU  - Kaprio J
AU  - Sarna S
AU  - Viitasalo M
FA  - Karjalainen, J
FA  - Kujala, U M
FA  - Kaprio, J
FA  - Sarna, S
FA  - Viitasalo, M
IN  - Karjalainen,J. Central Military Hospital, Box 50, 00301 Helsinki, Finland. jouko.karjalainen@pp.inet.fi
TI  - Lone atrial fibrillation in vigorously exercising middle aged men: case-control study.
SO  - BMJ. 316(7147):1784-5, 1998 Jun 13.
AS  - BMJ. 316(7147):1784-5, 1998 Jun 13.
NJ  - BMJ (Clinical research ed.)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 8900488, bmj, 101090866
OI  - Source: NLM. PMC28577
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - ENGLAND
MH  - Adult
MH  - Age Factors
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/et [Etiology]
MH  - Case-Control Studies
MH  - *Exercise/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Running/ph [Physiology]
IS  - 0959-8138
IL  - 0959-535X
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1998 Jun 13
DC  - 19980701
YR  - 1998
ED  - 19980701
RD  - 20140617
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9624065

<774. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9558681
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Garrigue S
AU  - Chaix C
AU  - Gencel L
AU  - Jais P
AU  - Dartigues JF
AU  - Haissaguerre M
AU  - Clementy J
FA  - Garrigue, S
FA  - Chaix, C
FA  - Gencel, L
FA  - Jais, P
FA  - Dartigues, J F
FA  - Haissaguerre, M
FA  - Clementy, J
IN  - Garrigue,S. Hopital Cardiologique du Haut-Leveque, Pessac, France.
TI  - Scoring method for assessing rate adaptive pacemakers: application to two different activity sensors.
SO  - Pacing & Clinical Electrophysiology. 21(3):509-19, 1998 Mar.
AS  - Pacing Clin Electrophysiol. 21(3):509-19, 1998 Mar.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adaptation, Physiological
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Chronic Disease
MH  - *Circadian Rhythm/ph [Physiology]
MH  - Electric Impedance
MH  - Electrocardiography
MH  - Exercise/ph [Physiology]
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Mathematics
MH  - Middle Aged
MH  - *Pacemaker, Artificial/st [Standards]
MH  - Regression Analysis
AB  - To optimize programming of rate adaptive pacemakers (RAPs), we explored a new mathematical method to assess the performance of RAPs during daily-life tests, using customized Windows-based software. By stepwise discriminant analysis and linear regression, this method allows calculation of the acceleration and deceleration capacity of pacemakers and their general behavior during effort and recovery phases. Twenty-three patients (10 females and 13 males; 68 +/- 8 years) with chronic atrial fibrillation and a slow ventricular response were evaluated. They randomly received an accelerometer-controlled VVIR Dash Intermedics pacemaker (10 patients) or a vibration piezoelectric-controlled VVIR Sensolog III Siemens pacemaker (13 patients). All patients underwent the same test protocol: 6 minutes walking, 1.5 minutes climbing stairs, 1.5 minutes descending stairs, and 0.5 minutes sit-ups. By definition, the pacemaker responsiveness slope was programmed so that the heart rate response of paced patients during the walking test corresponded best to that of healthy controls. The slope was left unchanged for the other tests. We considered four scores: an acceleration score (EA score), an effort rate score (ER score), a deceleration score (RD score), and a recovery rate score (RR score). Scores ranged from -10 (hypochronotropic behavior of the pacemaker) to +10 (hyperchronotropic behavior), based on daily-life tests of 15 healthy controls (7 females and 8 males, 65 +/- 9 years). A score of 0 represented exact concordance with healthy controls. During stair descent, the Sensolog III produced excessive acceleration (EA score = +2.9 +/- 1.1) compared to: (1) stair climbing (EA score = -4.0 +/- 1.9; P = 0.01, with the same pacemakers); and (2) the Dash (+1.8 +/- 1.9; P = 0.04) and healthy controls (P = 0.02). The sit-up tests revealed a hypochronotropic response of both pacemakers compared to healthy controls, with a larger difference for the Sensolog III (EA score = -2.0 +/- 5.8; P = 0.04; RD score = -6.8 +/- 3.8' P = 0.02). We conclude that activity-driven pacemakers can accommodate brief activities, except for isovolumetric exercise such as sit-ups. During daily activities, accelerometer-driven pacemakers seem to provide a heart rate resoibse closer to that of healthy controls. Our new mathematical analysis is a simple and reproducible method for evaluating and quantifying the efficacy of any sensor-driven pacemaker.
IS  - 0147-8389
IL  - 0147-8389
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 1998 Mar
DC  - 19980604
YR  - 1998
ED  - 19980604
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9558681

<775. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9456462
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Schenck CH
AU  - Boyd JL
AU  - Mahowald MW
FA  - Schenck, C H
FA  - Boyd, J L
FA  - Mahowald, M W
IN  - Schenck,C H. Department of Psychiatry, Hennepin County Medical Center, Minneapolis, MN 55415, USA.
TI  - A parasomnia overlap disorder involving sleepwalking, sleep terrors, and REM sleep behavior disorder in 33 polysomnographically confirmed cases. [Review] [83 refs]
SO  - Sleep. 20(11):972-81, 1997 Nov.
AS  - Sleep. 20(11):972-81, 1997 Nov.
NJ  - Sleep
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - sws, 7809084
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Age Distribution
MH  - Aged
MH  - Atrial Fibrillation/co [Complications]
MH  - Brain Diseases/co [Complications]
MH  - Child
MH  - Child, Preschool
MH  - Diagnosis, Computer-Assisted
MH  - Female
MH  - Humans
MH  - MMPI
MH  - Male
MH  - Mental Disorders/co [Complications]
MH  - Middle Aged
MH  - *Polysomnography/mt [Methods]
MH  - Psychiatric Status Rating Scales
MH  - Severity of Illness Index
MH  - Sex Distribution
MH  - Sleep Wake Disorders/co [Complications]
MH  - *Sleep Wake Disorders/di [Diagnosis]
MH  - *Sleep, REM
AB  - A series of 33 patients with combined (injurious) sleepwalking, sleep terrors, and rapid eye movement (REM) sleep behavior disorder (viz. "parasomnia overlap disorder") was gathered over an 8-year period. Patients underwent clinical and polysomnographic evaluations. Mean age was 34 +/- 14 (SD) years; mean age of parasomnia onset was 15 +/- 16 years (range 1-66); 70% (n = 23) were males. An idiopathic subgroup (n = 22) had a significantly earlier mean age of parasomnia onset (9 +/- 7 years) than a symptomatic subgroup (n = 11) (27 +/- 23 years, p = 0.002), whose parasomnia began with either of the following: neurologic disorders, n = 6 [congenital Mobius syndrome, narcolepsy, multiple sclerosis, brain tumor (and treatment), brain trauma, indeterminate disorder (exaggerated startle response/atypical cataplexy)]; nocturnal paroxysmal atrial fibrillation, n = 1; posttraumatic stress disorder/major depression, n = 1; chronic ethanol/amphetamine abuse and withdrawal, n = 1; or mixed disorders (schizophrenia, brain trauma, substance abuse), n = 2. The rate of DSM-III-R (Diagnostic and Statistical Manual, 3rd edition, revised) Axis 1 psychiatric disorders was not elevated; group scores on various psychometric tests were not elevated. Forty-five percent (n = 15) had previously received psychologic or psychiatric therapy for their parasomnia, without benefit. Treatment outcome was available for n = 20 patients; 90% (n = 18) had substantial parasomnia control with bedtime clonazepam (n = 13), alprazolam and/or carbamazepine (n = 4), or self-hypnosis (n = 1). Thus, "parasomnia overlap disorder" is a treatable condition that emerges in various clinical settings and can be understood within the context of current knowledge on parasomnias and motor control/dyscontrol during sleep. [References: 83]
IS  - 0161-8105
IL  - 0161-8105
PT  - Comparative Study
PT  - Journal Article
PT  - Review
LG  - English
DP  - 1997 Nov
DC  - 19980423
YR  - 1997
ED  - 19980423
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9456462

<776. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9474651
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Liu Z
AU  - Hayano M
AU  - Hirata T
AU  - Tsukahara K
AU  - Quin Y
AU  - Nakao K
AU  - Nonaka M
AU  - Ishimatsu T
AU  - Ueyama C
AU  - Yano K
FA  - Liu, Z
FA  - Hayano, M
FA  - Hirata, T
FA  - Tsukahara, K
FA  - Quin, Y
FA  - Nakao, K
FA  - Nonaka, M
FA  - Ishimatsu, T
FA  - Ueyama, C
FA  - Yano, K
IN  - Liu,Z. Third Department of Internal Medicine, Nagasaki University School of Medicine, Japan.
TI  - Abnormalities of electrocardiographic P wave morphology and their relation to electrophysiological parameters of the atrium in patients with sick sinus syndrome.
SO  - Pacing & Clinical Electrophysiology. 21(1 Pt 1):79-86, 1998 Jan.
AS  - Pacing Clin Electrophysiol. 21(1 Pt 1):79-86, 1998 Jan.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - Arrhythmias, Cardiac/pp [Physiopathology]
MH  - *Atrial Function
MH  - Cardiac Catheterization
MH  - Electric Stimulation
MH  - Electrocardiography
MH  - Electrophysiology/mt [Methods]
MH  - Female
MH  - Heart Atria/pp [Physiopathology]
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Sick Sinus Syndrome/di [Diagnosis]
MH  - *Sick Sinus Syndrome/pp [Physiopathology]
AB  - We examined the incidence of long P wave duration in lead II and increased P terminal force in lead V1 (PTFV1), and their relationship to electrophysiological findings of atrial muscle in 34 patients with sick sinus syndrome (SSS). Patients were divided into three groups: Group I, consisting of 20 patients with various cardiac arrhythmias other than SSS and paroxysmal atrial fibrillation (PAF) who served as controls; Group II, consisting of 18 patients with SSS but without PAF; and Group III consisted of 16 patients with SSS and PAF. P wave duration was significantly longer in Group III (122 +/- 11 ms, mean +/- SD, P < 0.0001) and Group II (111 +/- 15 ms, P < 0.002) than in Group I (98 +/- 10 ms). PTFV1 was greater in Group III (0.052 +/- 0.025 ms) than in Group I (0.028 +/- 0.011 ms, P < 0.05). P wave duration and PTFV1 had significantly and/or borderline correlations with longest duration of right atrial electrograms (r = 0.84, P < 0.0001 and 0.47, P < 0.02, respectively), maximal number of fragmented deflections of atrial electrograms (r = 0.69, P < 0.0001 and r = 0.51, P < 0.02, respectively), repetitive atrial firing zone (RAFZ) (r = 0.81, P < 0.0001 and 0.48, P < 0.05, respectively) and fragmented atrial activity zone (FAAZ)(r = 0.53, P < 0.01 and r = 0.45, P = 0.06, respectively). We concluded that long P wave duration and increased PTFV1 are electrocardiographic indicators for coexistence of electrophysiological abnormalities in the atria in SSS without recognizable heart disease.
IS  - 0147-8389
IL  - 0147-8389
PT  - Journal Article
LG  - English
DP  - 1998 Jan
DC  - 19980318
YR  - 1998
ED  - 19980318
RD  - 20121115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9474651

<777. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9470871
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Pardaens K
AU  - Van Cleemput J
AU  - Vanhaecke J
AU  - Fagard RH
FA  - Pardaens, K
FA  - Van Cleemput, J
FA  - Vanhaecke, J
FA  - Fagard, R H
IN  - Pardaens,K. Department of Molecular and Cardiovascular Research, Faculty of Medicine, University of Leuven, Belgium.
TI  - Atrial fibrillation is associated with a lower exercise capacity in male chronic heart failure patients.
SO  - Heart. 78(6):564-8, 1997 Dec.
AS  - Heart. 78(6):564-8, 1997 Dec.
NJ  - Heart (British Cardiac Society)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9602087
OI  - Source: NLM. PMC1892336
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - ENGLAND
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/ri [Radionuclide Imaging]
MH  - Cardiac Catheterization
MH  - Exercise Test
MH  - *Exercise Tolerance
MH  - *Heart Failure/co [Complications]
MH  - Heart Failure/pp [Physiopathology]
MH  - Heart Failure/ri [Radionuclide Imaging]
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Oxygen Consumption
MH  - Radionuclide Angiography
AB  - OBJECTIVE: To study the influence of atrial fibrillation on peak oxygen uptake (peak VO2) in chronic heart failure. An unfavourable effect of atrial fibrillation has been shown in several patient populations, but the results have not been consistent in chronic heart failure.
AB  - METHODS: Data were analysed from male heart transplant candidates who were able to perform graded bicycle ergometry until exhaustion with respiratory gas analysis and measurement of heart rate. Patients in atrial fibrillation (n = 18) were compared with patients in sinus rhythm (n = 93).
AB  - RESULTS: Age, weight, height, and aetiology of chronic heart failure did not differ significantly between the two groups. Cardiac catheterisation at supine rest showed that heart rate was comparable, but that stroke volume and cardiac output were lower (p < 0.05) in atrial fibrillation. Systolic and diastolic left ventricular function, assessed by radionuclide angiography at rest, were not significantly different. Peak VO2 (mean (SD): 13.8 (3.6) v 17.1 (5.6) ml/kg/min; p < 0.01) and peak work load (78 (27) v 98 (36) W; p < 0.05) were lower in the patients with atrial fibrillation, though respiratory gas exchange ratio and Borg score were similar in the two groups. Patients with atrial fibrillation had a higher heart rate sitting at rest before exercise (93 (16) v 84 (16) beats/min) and at peak effort (156 (23) v 140 (25) beats/min) (p < 0.05).
AB  - CONCLUSIONS: Atrial fibrillation is associated with a 20% lower peak VO2 in patients with chronic heart failure, suggesting that preserved atrial contraction or a regular rhythm, or both, are critical to maintain cardiac output and exercise performance.
IS  - 1355-6037
IL  - 1355-6037
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1997 Dec
DC  - 19980219
YR  - 1997
ED  - 19980219
RD  - 20140617
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9470871

<778. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9391286
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Omran H
AU  - Jung W
AU  - Rabahieh R
AU  - MacCarter D
AU  - Illien S
AU  - Rang B
AU  - Hagendorff A
AU  - Schimpf R
AU  - Luderitz B
FA  - Omran, H
FA  - Jung, W
FA  - Rabahieh, R
FA  - MacCarter, D
FA  - Illien, S
FA  - Rang, B
FA  - Hagendorff, A
FA  - Schimpf, R
FA  - Luderitz, B
IN  - Omran,H. Department of Medicine, University of Bonn, Germany.
TI  - Left atrial appendage function in patients with atrial flutter.
SO  - Heart. 78(3):250-4, 1997 Sep.
AS  - Heart. 78(3):250-4, 1997 Sep.
NJ  - Heart (British Cardiac Society)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9602087
OI  - Source: NLM. PMC484926
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - ENGLAND
MH  - Aged
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/us [Ultrasonography]
MH  - *Atrial Flutter/co [Complications]
MH  - Atrial Flutter/pp [Physiopathology]
MH  - Atrial Flutter/us [Ultrasonography]
MH  - *Atrial Function, Left
MH  - Blood Flow Velocity
MH  - Echocardiography
MH  - Echocardiography, Transesophageal
MH  - Electric Countershock
MH  - Electrocardiography, Ambulatory
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Prospective Studies
MH  - Risk Factors
MH  - Single-Blind Method
MH  - Statistics, Nonparametric
MH  - Thromboembolism/pc [Prevention & Control]
AB  - OBJECTIVE: To determine whether echocardiographic markers thromboembolic risk differ between patients with pure atrial flutter and patients with atrial flutter and intermittent atrial fibrillation.
AB  - DESIGN: Patients with atrial flutter were followed up prospectively for 12 months to identify intermittent atrial fibrillation. After the follow up period, transthoracic and multiplane transoesophageal echocardiography were performed to assess left atrial chamber and appendage size, peak emptying velocities, and emptying fraction of the left atrial appendage. The presence of spontaneous echo contrast was also determined.
AB  - SETTING: Tertiary cardiac care centre.
AB  - PATIENTS: 20 consecutive patients with atrial flutter; 11 healthy subjects in sinus rhythm served as controls.
AB  - RESULTS: Intermittent atrial fibrillation was documented in 11 patients by Holter monitoring or surface ECG; atrial fibrillation was not found in the other nine patients. Compared with the patients with pure atrial flutter, patients with atrial flutter and intermittent atrial fibrillation had larger left atrial chamber (mean (SD) 4.5 (0.6) v 3.8 (0.5) cm; 95% confidence interval 0.2 to 1.2; P = 0.01) and appendage areas (6.7 (2.2) v 4.8 (4.9) cm; 95% CI 0.4 to 3.5; P = 0.02), lower left atrial appendage emptying fractions (33 (11)% v 52 (11)%; 95% CI 8 to 29; P = 0.008), and also lower left atrial appendage emptying velocities (0.44 (0.21) v 0.79 (0.27) m/s; 95% CI 0.13 to 0.56; P = 0.005). In addition, a higher incidence of spontaneous echo contrast (11% v 36%) was observed in patients with atrial flutter and intermittent atrial fibrillation.
AB  - CONCLUSIONS: Left atrial appendage function is depressed and spontaneous echo contrast more frequent in patients with atrial flutter and intermittent atrial fibrillation, as opposed to patients with pure atrial flutter. These data support the concept that patients with atrial flutter and intermittent atrial fibrillation have an increased risk of thromboembolic events and should therefore receive adequate anticoagulant treatment.
RN  - 0 (Anticoagulants)
IS  - 1355-6037
IL  - 1355-6037
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 1997 Sep
DC  - 19971217
YR  - 1997
ED  - 19971217
RD  - 20140617
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9391286

<779. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9347782
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Patterson C
AU  - Feightner J
FA  - Patterson, C
FA  - Feightner, J
IN  - Patterson,C. Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ont. pattec@ihis.cmh.on.ca
TI  - Promoting the health of senior citizens. [Review] [52 refs]
SO  - CMAJ Canadian Medical Association Journal. 157(8):1107-13, 1997 Oct 15.
AS  - CMAJ. 157(8):1107-13, 1997 Oct 15.
NJ  - CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9711805
OI  - Source: NLM. PMC1228269
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - CANADA
MH  - *Aged
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/pc [Prevention & Control]
MH  - Attitude to Health
MH  - Automobile Driving
MH  - Cardiovascular Diseases/pc [Prevention & Control]
MH  - Cardiovascular Diseases/th [Therapy]
MH  - Cerebrovascular Disorders/dt [Drug Therapy]
MH  - Diet Therapy
MH  - Exercise
MH  - *Health Promotion
MH  - Humans
MH  - Hypertension/pc [Prevention & Control]
MH  - Influenza Vaccines/tu [Therapeutic Use]
MH  - Influenza, Human/pc [Prevention & Control]
MH  - Quality of Life
MH  - Tobacco Use Disorder/pc [Prevention & Control]
AB  - Canada is experiencing a dramatic increase in the number of older people in its population. Adopting strategies that involve physician actions, a societal approach and individual participation may substantially improve the health of senior citizens. This article presents ways to improve the quality of life and reduce the risk of premature death through manoeuvres that can be initiated by physicians in the context of the periodic health examination. The authors highlight the role of evidence in choosing the most appropriate interventions, speculate on areas of future importance and emphasize a societal approach to population health. [References: 52]
RN  - 0 (Anticoagulants)
RN  - 0 (Influenza Vaccines)
IS  - 0820-3946
IL  - 0820-3946
PT  - Journal Article
PT  - Review
LG  - English
DP  - 1997 Oct 15
DC  - 19971128
YR  - 1997
ED  - 19971128
RD  - 20140617
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9347782

<780. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9358144
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Anonymous
TI  - Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-1997. A 65-year-old woman with a dry cough and pulmonary nodules.
SO  - New England Journal of Medicine. 337(20):1449-58, 1997 Nov 13.
AS  - N Engl J Med. 337(20):1449-58, 1997 Nov 13.
NJ  - The New England journal of medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0255562, now
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - *Amiodarone/ae [Adverse Effects]
MH  - *Anti-Arrhythmia Agents/ae [Adverse Effects]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - Cough/et [Etiology]
MH  - Diagnosis, Differential
MH  - Diarrhea/et [Etiology]
MH  - Female
MH  - Granulomatosis with Polyangiitis/co [Complications]
MH  - *Granulomatosis with Polyangiitis/di [Diagnosis]
MH  - Granulomatosis with Polyangiitis/ra [Radiography]
MH  - Humans
MH  - *Lung/pa [Pathology]
MH  - Lung/ra [Radiography]
MH  - Pneumonia/ci [Chemically Induced]
MH  - Pneumonia/co [Complications]
MH  - *Pneumonia/pa [Pathology]
MH  - Pneumonia/ra [Radiography]
RN  - 0 (Anti-Arrhythmia Agents)
RN  - N3RQ532IUT (Amiodarone)
IS  - 0028-4793
IL  - 0028-4793
PT  - Case Reports
PT  - Clinical Conference
PT  - Journal Article
LG  - English
DP  - 1997 Nov 13
DC  - 19971113
YR  - 1997
ED  - 19971113
RD  - 20141120
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9358144

<781. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9296241
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Le AT
AU  - Hasson NK
AU  - Lum BL
FA  - Le, A T
FA  - Hasson, N K
FA  - Lum, B L
IN  - Le,A T. University of the Pacific, School of Pharmacy, Montara, CA 94037, USA.
TI  - Enhancement of warfarin response in a patient receiving etoposide and carboplatin chemotherapy.
SO  - Annals of Pharmacotherapy. 31(9):1006-8, 1997 Sep.
AS  - Ann Pharmacother. 31(9):1006-8, 1997 Sep.
NJ  - The Annals of pharmacotherapy
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - bbx, 9203131
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - *Antineoplastic Agents/tu [Therapeutic Use]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Carboplatin/tu [Therapeutic Use]
MH  - Drug Interactions
MH  - *Etoposide/tu [Therapeutic Use]
MH  - Germinoma/dt [Drug Therapy]
MH  - Germinoma/sc [Secondary]
MH  - Humans
MH  - Male
MH  - Mediastinal Neoplasms/dt [Drug Therapy]
MH  - Mediastinal Neoplasms/sc [Secondary]
MH  - Testicular Neoplasms/pa [Pathology]
MH  - *Warfarin/tu [Therapeutic Use]
AB  - OBJECTIVE: To report a case of a possible drug interaction between warfarin, carboplatin, and etoposide resulting in a marked increase in a patient's response to warfarin, and to outline monitoring strategies for this interaction.
AB  - CASE SUMMARY: A 74-year-old white man receiving warfarin (average dose 42.5 mg/wk) for atrial fibrillation was diagnosed with a right testicular non-seminoma mixed germ cell tumor. Mediastinal metastases were subsequently discovered, and the patient was treated with a chemotherapy regimen including carboplatin and etoposide. Sixteen days after the first course of chemotherapy, the international normalized ratio (INR) was increased to 12.6 from a baseline range of 1.15-2.11 that was observed over the previous 8 months of therapy, indicating a clinically significant alteration in the pharmacodynamic response to warfarin.
AB  - DISCUSSION: This patient had no concomitant disease or dietary changes to explain the altered response to warfarin. Carboplatin and etoposide have not been reported to inhibit warfarin metabolism. However, previous reports have suggested that etoposide may displace warfarin from its protein binding sites, resulting in an early elevation in prothrombin time following chemotherapy. The late elevation of INR observed in our patient suggests that his response to warfarin may have been due to the displacement of warfarin by elemental platinum, which has a long plasma half-life.
AB  - CONCLUSIONS: This case report suggests a possible drug interaction between carboplatin, etoposide, and warfarin. Because of the risk associated with an increased response to warfarin, we recommend close monitoring of the INR, perhaps twice weekly, early and later in the time course following chemotherapy with these agents. Appropriate dosage adjustments of warfarin should be performed if an altered response to warfarin is observed.
RN  - 0 (Anticoagulants)
RN  - 0 (Antineoplastic Agents)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - BG3F62OND5 (Carboplatin)
IS  - 1060-0280
IL  - 1060-0280
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 1997 Sep
DC  - 19971021
YR  - 1997
ED  - 19971021
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9296241

<782. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9296238
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Recker MW
AU  - Kier KL
FA  - Recker, M W
FA  - Kier, K L
IN  - Recker,M W. Lima Memorial Hospital, OH 45804, USA.
TI  - Potential interaction between clarithromycin and warfarin.
SO  - Annals of Pharmacotherapy. 31(9):996-8, 1997 Sep.
AS  - Ann Pharmacother. 31(9):996-8, 1997 Sep.
NJ  - The Annals of pharmacotherapy
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - bbx, 9203131
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Aged, 80 and over
MH  - *Anti-Bacterial Agents/tu [Therapeutic Use]
MH  - *Anticoagulants/tu [Therapeutic Use]
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Bronchitis/co [Complications]
MH  - *Bronchitis/dt [Drug Therapy]
MH  - *Clarithromycin/tu [Therapeutic Use]
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - *Warfarin/tu [Therapeutic Use]
AB  - OBJECTIVE: To report a possible drug interaction between clarithromycin and warfarin in a patient with chronic atrial fibrillation.
AB  - CASE SUMMARY: A patient with chronic atrial fibrillation was placed on warfarin therapy. International normalized ratios (INRs) ranged from 1.61 to 3.99 while the dosage was being adjusted during the first 5 months of warfarin therapy. The dosage was titrated to 20 mg/wk; laboratory tests obtained 2 weeks after this dosage was started indicated an INR of 2.1. The same dosage was continued. Clarithromycin 500 mg bid was started for an acute exacerbation of bronchitis 10 days after the last INR was obtained and was continued for 14 days of therapy. An INR obtained 3 days after completion of the clarithromycin therapy was 16.8. The warfarin was withheld and vitamin K 20 mg im was administered. The INR obtained the next day was 1.52. The warfarin was restarted and the dosage was titrated to between 22.5 and 25 mg/wk, with INRs ranging from 0.85 to 3.14.
AB  - DISCUSSION: Many factors influence the metabolism of warfarin, including disease states, medications, age, and diet. Data collected in this case suggested clarithromycin may have contributed to the increase in the effect of warfarin. Inhibition of the cytochrome P450 oxidizing system appears to be the reason for the increase. Numerous drugs and disease states affect the rate at which this system metabolizes drugs.
AB  - CONCLUSIONS: The potential interaction between clarithromycin and warfarin warrants prudent monitoring of the INR during concurrent administration of these drugs. Warfarin dosages may need to be reduced during concurrent clarithromycin therapy to prevent bleeding complications. Further controlled clinical trials are needed to substantiate the interaction between clarithromycin and warfarin.
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - H1250JIK0A (Clarithromycin)
IS  - 1060-0280
IL  - 1060-0280
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 1997 Sep
DC  - 19971021
YR  - 1997
ED  - 19971021
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9296238

<783. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9247903
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - FitzGerald WA
FA  - FitzGerald, W A
TI  - Observations on sleeping position and essential hypertension.
SO  - Medical Hypotheses. 49(1):27-30, 1997 Jul.
AS  - Med Hypotheses. 49(1):27-30, 1997 Jul.
NJ  - Medical hypotheses
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - m0m, 7505668
SB  - Index Medicus
CP  - ENGLAND
MH  - Adult
MH  - African Continental Ancestry Group/ge [Genetics]
MH  - Aged
MH  - Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Diet/ae [Adverse Effects]
MH  - Humans
MH  - *Hypertension/et [Etiology]
MH  - Hypertension/ge [Genetics]
MH  - Hypertension/pp [Physiopathology]
MH  - Hypertension, Malignant/et [Etiology]
MH  - Hypertension, Malignant/pp [Physiopathology]
MH  - Jogging/ph [Physiology]
MH  - Male
MH  - Middle Aged
MH  - Models, Cardiovascular
MH  - Oxygen Consumption
MH  - *Posture/ph [Physiology]
MH  - *Sleep/ph [Physiology]
MH  - Stress, Psychological/co [Complications]
MH  - Stress, Psychological/pp [Physiopathology]
MH  - Syndrome
AB  - A hypertensive black male, at risk for episodic attacks of pseudo-malignant hypertension and self-induced atrial fibrillation, seeks to discover possible clues to the pathogeneses of these strange disorders through self-study and concludes they might be associated with impaired oxygen intake, secondary to sleeping position in bed.
IS  - 0306-9877
IL  - 0306-9877
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 1997 Jul
DC  - 19970929
YR  - 1997
ED  - 19970929
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9247903

<784. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9249620
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ricci S
AU  - Celani MG
AU  - Righetti E
AU  - Caruso A
AU  - De Medio G
AU  - Trovarelli G
AU  - Romoli S
AU  - Stragliotto E
AU  - Spizzichino L
FA  - Ricci, S
FA  - Celani, M G
FA  - Righetti, E
FA  - Caruso, A
FA  - De Medio, G
FA  - Trovarelli, G
FA  - Romoli, S
FA  - Stragliotto, E
FA  - Spizzichino, L
IN  - Ricci,S. Centro di Coordinamento IST-Italia, Ospedale Silvestrini, Perugia, Italy. istitaly@unipg.it
TI  - Fatty acid dietary intake and the risk of ischaemic stroke: a multicentre case-control study. UFA Study Group.
SO  - Journal of Neurology. 244(6):360-4, 1997 Jun.
AS  - J Neurol. 244(6):360-4, 1997 Jun.
NJ  - Journal of neurology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - jb7, 0423161
SB  - Index Medicus
CP  - GERMANY
MH  - *Brain Ischemia/et [Etiology]
MH  - Case-Control Studies
MH  - *Dietary Fats/ae [Adverse Effects]
MH  - *Fatty Acids/ae [Adverse Effects]
MH  - Female
MH  - Humans
MH  - Italy
MH  - Male
MH  - Risk Factors
AB  - A low dietary intake of unsaturated fatty acids has been found in male patients with stroke as compared with controls in Italy, and a high consumption of meat has been associated with an increased risk of stroke in Australia. We present a case-control study, comparing the unsaturated and saturated fatty acids content of red cell membranes (which reflects the dietary intake of saturated and unsaturated fats) in 89 patients with ischaemic stroke and 89 controls matched for age and sex. In univariate analysis, besides hypertension, atrial fibrillation, ischaemic changes in ECG and hypercholesterolaemia, stroke patients showed a lower level of oleic acid (P = 0.000), but a higher level of eicosatrienoic acid (P = 0.009). Conditional logistic regression (dependent variable; being a case) showed that the best model included atrial fibrillation, hypertension, oleic acid and eicosatrienoic acids. These results confirm a possible protective role of unsaturated fatty acids against vascular diseases; however, we did not find any difference in the content of omega3 acids, which have been considered in the past to protect against coronary heart disease. We conclude that the preceding diet of patients with ischaemic stroke may be poor in unsaturated fatty acids (namely, oleic acid), and this defect is independent of other vascular risk factors. Only further studies will show whether changes in diet and/or supplement of unsaturated fatty acids might reduce the incidence of ischaemic stroke.
RN  - 0 (Dietary Fats)
RN  - 0 (Fatty Acids)
IS  - 0340-5354
IL  - 0340-5354
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1997 Jun
DC  - 19970912
YR  - 1997
ED  - 19970912
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9249620

<785. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9151243
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Seino F
AU  - Date C
AU  - Nakayama T
AU  - Yoshiike N
AU  - Yokoyama T
AU  - Yamaguchi M
AU  - Tanaka H
FA  - Seino, F
FA  - Date, C
FA  - Nakayama, T
FA  - Yoshiike, N
FA  - Yokoyama, T
FA  - Yamaguchi, M
FA  - Tanaka, H
IN  - Seino,F. Department of Epidemiology, Tokyo Medical and Dental University, Japan.
TI  - Dietary lipids and incidence of cerebral infarction in a Japanese rural community.
SO  - Journal of Nutritional Science & Vitaminology. 43(1):83-99, 1997 Feb.
AS  - J Nutr Sci Vitaminol (Tokyo). 43(1):83-99, 1997 Feb.
NJ  - Journal of nutritional science and vitaminology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - jfd, 0402640
SB  - Index Medicus
CP  - JAPAN
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Cerebral Infarction/ep [Epidemiology]
MH  - Cerebral Infarction/et [Etiology]
MH  - Cholesterol/bl [Blood]
MH  - Cohort Studies
MH  - *Dietary Fats/ae [Adverse Effects]
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Japan/ep [Epidemiology]
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Risk Factors
MH  - Rural Population
MH  - Surveys and Questionnaires
AB  - OBJECTIVE: To assess the relationship between dietary lipids and incidence of cerebral infarction in a Japanese rural population.
AB  - DESIGN: A cohort study from July 1977 through December 1992.
AB  - SETTING: Akadani-Ijimino (A-I) district, Niigata Prefecture, Japan.
AB  - SUBJECTS AND METHODS: All the residents, 1,182 men and 1,469 women, aged 40 years and over. Out of these members, 954 men and 1,329 women who were initially free of stroke completed a semiquantitative food frequency questionnaire in 1977, and were then subjected to a follow-up for 15.5 years. The occurrence of stroke was determined by the annual follow-up examination and registry. Dietary lipid was adjusted for total energy or fat intake by the residual method. Sex- and age-stratified and blood pressure- and atrial fibrillation-adjusted relative risk for cerebral infarction was estimated by the Cox proportional hazard model.
AB  - RESULTS: There were 75 new cases of cerebral infarction during the observation period. The relative risk for cerebral infarction was less than one in the highest quartile level of total fat, saturated fatty acids (S), Keys score and westernized dietary pattern: 0.68-0.94. It ranged between 1.36 and 1.57 in the highest level of polyunsaturated (P), n-3 and n-6 fatty acids, and P/S ratio.
AB  - CONCLUSION: This study suggests the possibility that the traditional Japanese diet, very low fat intake, was likely to increase the risk of stroke through the low level of serum cholesterol as an intermediary factor.
RN  - 0 (Dietary Fats)
RN  - 97C5T2UQ7J (Cholesterol)
IS  - 0301-4800
IL  - 0301-4800
PT  - Journal Article
LG  - English
DP  - 1997 Feb
DC  - 19970826
YR  - 1997
ED  - 19970826
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9151243

<786. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9146445
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Chin MH
AU  - Goldman L
FA  - Chin, M H
FA  - Goldman, L
IN  - Chin,M H. Department of Medicine, Brigham and Women's Hospital, Boston, Mass, USA.
TI  - Factors contributing to the hospitalization of patients with congestive heart failure.
SO  - American Journal of Public Health. 87(4):643-8, 1997 Apr.
AS  - Am J Public Health. 87(4):643-8, 1997 Apr.
NJ  - American journal of public health
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 1254074, 3xw
OI  - Source: NLM. PMC1380846
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Aged, 80 and over
MH  - Angina Pectoris/co [Complications]
MH  - Angiotensin-Converting Enzyme Inhibitors/tu [Therapeutic Use]
MH  - Blood Pressure
MH  - Cross-Sectional Studies
MH  - Female
MH  - Heart Failure/co [Complications]
MH  - Heart Failure/dt [Drug Therapy]
MH  - *Heart Failure/pp [Physiopathology]
MH  - Heart Rate
MH  - *Hospitalization
MH  - Humans
MH  - Hypertension/co [Complications]
MH  - Male
MH  - Middle Aged
MH  - Respiratory Tract Infections/co [Complications]
AB  - OBJECTIVES: This study identifies acute precipitants of hospitalization and evaluates utilization of angiotension-converting enzyme inhibitors in patients admitted with congestive heart failure.
AB  - METHODS: Cross-sectional chart-review study was done of 435 patients admitted nonelectively from February 1993 to February 1994 to an urban university hospital with a complaint of shortness of breath or fatigue and evidence of congestive heart failure.
AB  - RESULTS: The most common identifiable abnormalities associated with clinical deterioration prior to admission were acute anginal chest pain (33%), respiratory infection (16%), uncontrolled hypertension with initial systolic blood pressure > or = 180 mm Hg (15%), atrial arrhythmia with heart rate > or = 120 (8%), and noncompliance with medications (15%) or diet (6%); in 34% of patients, no clear cause could be identified. After exclusion of those who were already on a different vasodilator or who had relative contraindications, 18 (32%) of the patients with ejection fractions < or = 0.35 measured prior to admission were not taking an angiotensin-converting enzyme inhibitor on presentation to the hospital.
AB  - CONCLUSIONS: Interventions to improve compliance, the control of hypertension, and the appropriate use of angiotensin-converting enzyme inhibitors may prevent many hospitalizations of heart-failure patients.
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
IS  - 0090-0036
IL  - 0090-0036
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
NO  - 5-K12-AG-00488 (United States NIA NIH HHS)
LG  - English
DP  - 1997 Apr
DC  - 19970721
YR  - 1997
ED  - 19970721
RD  - 20130918
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9146445

<787. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9121953
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kelly PA
AU  - MacAulay-Hunter E
AU  - Astridge PS
AU  - Lowry PJ
AU  - Perrins EJ
AU  - Kaye GC
FA  - Kelly, P A
FA  - MacAulay-Hunter, E
FA  - Astridge, P S
FA  - Lowry, P J
FA  - Perrins, E J
FA  - Kaye, G C
IN  - Kelly,P A. Department of Cardiology, Leeds General Infirmary, United Kingdom.
TI  - Failure of plasma atrial natriuretic peptide levels to increase during exercise in patients with chronic atrial fibrillation.
SO  - Pacing & Clinical Electrophysiology. 20(1 Pt 1):10-6, 1997 Jan.
AS  - Pacing Clin Electrophysiol. 20(1 Pt 1):10-6, 1997 Jan.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation/bl [Blood]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Natriuretic Factor/bl [Blood]
MH  - Cardiac Pacing, Artificial/mt [Methods]
MH  - Chronic Disease
MH  - Cross-Over Studies
MH  - Echocardiography
MH  - Electrocardiography
MH  - Exercise Test
MH  - Female
MH  - Heart Atria/pp [Physiopathology]
MH  - Heart Block/bl [Blood]
MH  - Heart Block/th [Therapy]
MH  - Heart Rate
MH  - Heart Ventricles/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Contraction
MH  - Oxygen Consumption
MH  - *Physical Exertion/ph [Physiology]
MH  - Rest/ph [Physiology]
MH  - Single-Blind Method
AB  - It is generally accepted that plasma atrial natriuretic peptide release occurs secondary to atrial stretch. The influence of coordinated atrial contraction (AC) upon this process is not fully appreciated. The aim of the study was to determine the importance of coordinated AC upon peripheral atrial natriuretic peptide levels (alpha-hANP) during exercise. Peripheral alpha-hANP levels were measured at rest and during exercise in 12 patients with complete heart block (CHB) and permanent rate responsive pacemakers. Seven patients had coordinated AC and five had chronic atrial fibrillation (AF). Each patient performed three treadmill exercise tests. Maximal inspired oxygen volume (VO2 max) was determined during test 1. Tests 2 and 3 were performed to 70% VO2 max, the pacemaker being programmed to either VVI or VVIR mode. Plasma alpha-hANP was measured using a two-site immunoradiometric assay. At rest there was a small but significant difference between the two patient groups: AF 60.2 pg/mL versus AC97.6 pg/mL; P = 0.03. During exercise in the AC patients, there was a significant increase in alpha-hANP levels, in VVIR mode, to 238.4 pg/mL, and in VVI mode, to 207.9 pg/mL, P = 0.002 and 0.003, respectively. In those patients with chronic AF, there was no significant rise or fall in alpha-hANP levels in either pacing mode, VVIR 65.2 pg/mL, VVI 46.6 pg/mL. Previous workers have suggested that alpha-hANP release by nonfunctioning atria is normal. We have shown that the presence of coordinated AC is required for the release of alpha-hANP during exercise in patients with CHB, and that this appears to be independent of ventricular rate.
RN  - 85637-73-6 (Atrial Natriuretic Factor)
IS  - 0147-8389
IL  - 0147-8389
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
LG  - English
DP  - 1997 Jan
DC  - 19970422
YR  - 1997
ED  - 19970422
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9121953

<788. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9119803
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ito Y
AU  - Arakawa M
AU  - Noda T
AU  - Miwa H
AU  - Kagawa K
AU  - Nishigaki K
AU  - Fujiwara H
FA  - Ito, Y
FA  - Arakawa, M
FA  - Noda, T
FA  - Miwa, H
FA  - Kagawa, K
FA  - Nishigaki, K
FA  - Fujiwara, H
IN  - Ito,Y. Second Department of Internal Medicine, Gifu University School of Medicine, Japan.
TI  - Atrial reservoir and active transport function after cardioversion of chronic atrial fibrillation.
SO  - Heart & Vessels. 11(1):30-8, 1996.
AS  - Heart Vessels. 11(1):30-8, 1996.
NJ  - Heart and vessels
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - her, 8511258
SB  - Index Medicus
CP  - JAPAN
MH  - Aged
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Atrial Fibrillation/us [Ultrasonography]
MH  - *Atrial Function, Left/ph [Physiology]
MH  - *Atrial Function, Right/ph [Physiology]
MH  - Blood Flow Velocity/ph [Physiology]
MH  - Chronic Disease
MH  - *Echocardiography, Doppler
MH  - *Echocardiography, Transesophageal
MH  - *Electric Countershock
MH  - Female
MH  - *Hemodynamics/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Myocardial Contraction/ph [Physiology]
MH  - Pulmonary Veins/pp [Physiopathology]
MH  - Pulmonary Veins/us [Ultrasonography]
MH  - Stroke Volume/ph [Physiology]
MH  - Treatment Outcome
MH  - Ventricular Function, Left/ph [Physiology]
AB  - Atrial reservoir function has not been studied after successful cardioversion of chronic atrial fibrillation. Using transthoracic and transesophageal Doppler echocardiography, we measured flow velocity-time integrals of the systolic forward (Sa), diastolic forward (Da), and diastolic reversed (rAa) waves of flow velocity waveforms in the pulmonary vein and the superior vena cava, and those of the early diastolic (Ea) and late diastolic (Aa) waves of the transmitral and transtricuspid flow velocity waveforms. The left and right atrial storage fractions (LASF, RASF), indexes of atrial reservoir function, were determined as the ratios of the atrial storage volume to the ventricular stroke volume; (Sa - rAa)/(Sa - rAa + Da). The left and right atrial active contraction fractions (LAACF, RAACF), indexes of atrial active transport function, were also determined as the ratios of the atrial active contraction volume to the left ventricular stroke volume; Aa/(Ea + Aa). These indices were evaluated periodically in 12 patients with non-valvular chronic atrial fibrillation before and 1-4 days after direct current cardioversion of atrial fibrillation; in 8 of the patients, the indices were also evaluated 1-3 months after the cardioversion. An additional 10 patients in sinus rhythm served as controls. Both the LASF and RASF were low during atrial fibrillation; the values increased significantly 14 days after successful cardioversion (P < 0.01 P < 0.01), and continued to increase at 1-3 months. The LASF and RASF values 1-3 months after cardioversion were comparable to those in control subjects. Both the LAACF and RAACF also increased significantly from 1-4 days to 1-3 months after cardioversion (P < 0.05, P < 0.01), becoming comparable to those in control subjects. During the 3 months after successful cardioversion of non-valvular chronic atrial fibrillation, left and right atrial reservoir function and left and right atrial active transport function increased progressively, becoming comparable to values in the control subjects.
IS  - 0910-8327
IL  - 0910-8327
PT  - Journal Article
LG  - English
DP  - 1996
DC  - 19970422
YR  - 1996
ED  - 19970422
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9119803

<789. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9093041
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Buys EM
AU  - van Hemel NM
AU  - Kelder JC
AU  - Ascoop CA
AU  - van Dessel PF
AU  - Bakema L
AU  - Kingma JH
FA  - Buys, E M
FA  - van Hemel, N M
FA  - Kelder, J C
FA  - Ascoop, C A
FA  - van Dessel, P F
FA  - Bakema, L
FA  - Kingma, J H
IN  - Buys,E M. Department of Cardiology, St Antonius Hospital, Nieuwegein, The Netherlands.
TI  - Exercise capacity after His bundle ablation and rate response ventricular pacing for drug refractory chronic atrial fibrillation.
SO  - Heart. 77(3):238-41, 1997 Mar.
AS  - Heart. 77(3):238-41, 1997 Mar.
NJ  - Heart (British Cardiac Society)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9602087
OI  - Source: NLM. PMC484689
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - ENGLAND
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/su [Surgery]
MH  - Atrial Fibrillation/th [Therapy]
MH  - *Bundle of His/su [Surgery]
MH  - *Cardiac Pacing, Artificial
MH  - *Catheter Ablation
MH  - Combined Modality Therapy
MH  - Exercise Test
MH  - *Exercise Tolerance
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pacemaker, Artificial
AB  - OBJECTIVE: To evaluate exercise capacity of patients with chronic atrial fibrillation in whom His bundle ablation followed by ventricular rate response pacing (VVIR) was carried out because of drug refractoriness.
AB  - DESIGN: Prospective study.
AB  - PATIENTS: 25 consecutive patients, all with chronic symptomatic drug refractory atrial fibrillation, underwent His bundle ablation. Before this intervention all patients were on antiarrhythmic drugs to attain acceptable heart rate control and to relief symptoms.
AB  - MAIN OUTCOME MEASURES: Exercise capacity, including measurements of VO2, was examined before and after a mean interval of seven months following His bundle ablation.
AB  - RESULTS: Exercise capacity after His bundle ablation increased from a mean of 109 (SD 49) W to 118 (46) W (P < 0.002), but VO2 at peak exercise did not change significantly. Maximum exercise capacity was achieved with a significantly lower maximum driven heart rate than the spontaneous heart rate before ablation.
AB  - CONCLUSIONS: Exercise capacity of patients who underwent His bundle ablation followed by VVIR pacing remained unchanged or improved during a mean follow up of seven months. Larger patient populations with longer follow up are necessary to examine determinants of improved exercise capacity.
IS  - 1355-6037
IL  - 1355-6037
PT  - Journal Article
LG  - English
DP  - 1997 Mar
DC  - 19970417
YR  - 1997
ED  - 19970417
RD  - 20130918
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9093041

<790. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9070546
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Cohen A
AU  - Weber H
AU  - Chauvel C
AU  - Monin JL
AU  - Dib JC
AU  - Diebold B
AU  - Gueret P
FA  - Cohen, A
FA  - Weber, H
FA  - Chauvel, C
FA  - Monin, J L
FA  - Dib, J C
FA  - Diebold, B
FA  - Gueret, P
IN  - Cohen,A. Saint-Antoine University Hospital, Paris, France.
TI  - Comparison of arbutamine and exercise echocardiography in diagnosing myocardial ischemia.
SO  - American Journal of Cardiology. 79(6):713-6, 1997 Mar 15.
AS  - Am J Cardiol. 79(6):713-6, 1997 Mar 15.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - Cardiotonic Agents/ae [Adverse Effects]
MH  - *Cardiotonic Agents
MH  - Catecholamines/ae [Adverse Effects]
MH  - *Catecholamines
MH  - Coronary Angiography
MH  - Echocardiography/de [Drug Effects]
MH  - *Echocardiography/mt [Methods]
MH  - Echocardiography/sn [Statistics & Numerical Data]
MH  - Exercise Test/de [Drug Effects]
MH  - *Exercise Test/mt [Methods]
MH  - Exercise Test/sn [Statistics & Numerical Data]
MH  - Female
MH  - Hemodynamics/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Myocardial Ischemia/di [Diagnosis]
MH  - Myocardial Ischemia/pp [Physiopathology]
MH  - Sensitivity and Specificity
AB  - Arbutamine is a new catecholamine designed for use as a pharmacologic stress agent. This study compared the sensitivity of arbutamine with symptom-limited exercise to induce echocardiographic signs of ischemia. Arbutamine was administered by a computerized closed-loop delivery system that controls the infusion rate of arbutamine toward a predefined rate of heart rate increase and maximum heart rate limit. Beta blockers were stopped > or = 48 hours before both tests. Stress was stopped for intolerable symptoms, or clinical, electrocardiographic or echocardiographic signs of ischemia (new or worsening wall motion abnormality), target heart rate (> or = 85% age predicted maximum heart rate), or plateau of heart rate response. Thirty-seven patients were entered into the study (35 arbutamine and exercise, 1 arbutamine only, 1 exercise only), of which 30 had angiographic evidence of coronary artery disease (> or = 50% lumen diameter narrowing). Rate-pressure product increased significantly in response to both stress modalities (p < 0.001) and was significantly greater with exercise (11,308 +/- 2,443) than with arbutamine (9,486 +/- 2,479, p < 0.001). The time to maximum heart rate was longer during arbutamine stress echocardiography than during exercise testing (17.3 +/- 9.4 versus 9.3 +/- 4.2 minutes, respectively, p < 0.001). There were more patients with interpretable echo data for arbutamine (82%) than for exercise (67%). Sensitivity for recognition of myocardial ischemia was 94% (95% confidence interval 70% to 100%) and 88% (95% confidence interval 62% to 98%), respectively. The most frequent adverse events during arbutamine (n = 36) were dyspnea (5.6%) and tremor (5.6%). Two arbutamine stress tests were discontinued due to arrhythmias: 1 patient had premature atrial and ventricular beats, and the other had premature atrial contractions and atrial fibrillation. Arrhythmias were well tolerated and resolved without sequelae. In conclusion, the sensitivity of arbutamine to induce echocardiographic signs of ischemia was similar to that of exercise despite a lower rate-pressure product. Arbutamine was well tolerated and provides a reliable alternative to exercise echocardiography.
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Catecholamines)
RN  - B07L15YAEV (arbutamine)
IS  - 0002-9149
IL  - 0002-9149
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1997 Mar 15
DC  - 19970409
YR  - 1997
ED  - 19970409
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9070546

<791. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 9060896
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Santini M
AU  - Pandozi C
AU  - Toscano S
AU  - Castro A
AU  - Altamura G
AU  - Jesi A
AU  - Villani M
FA  - Santini, M
FA  - Pandozi, C
FA  - Toscano, S
FA  - Castro, A
FA  - Altamura, G
FA  - Jesi, A
FA  - Villani, M
IN  - Santini,M. Department of Heart Disease, San Filippo Neri Hospital, Rome, Italy.
TI  - Changes in intracardiac atrial cardioversion threshold at rest and during exercise.
SO  - Journal of the American College of Cardiology. 29(3):576-81, 1997 Mar 1.
AS  - J Am Coll Cardiol. 29(3):576-81, 1997 Mar 1.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - h50, 8301365
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Chronic Disease
MH  - *Electric Countershock
MH  - *Exercise/ph [Physiology]
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
AB  - OBJECTIVES: We sought to analyze in patients with chronic atrial fibrillation (AF) the change in the intracardiac atrial defibrillation threshold (ADT) at rest and during exercise, to quantify the effective risk of low energy endocavitary cardioversion during the effort and to compare the ADT of chronic and reinduced AF.
AB  - BACKGROUND: Low energy endocavitary cardioversion is a new alternative to transthoracic shock in patients with chronic AF. Nevertheless, patient discomfort and possible induction of ventricular arrhythmias should be further evaluated.
AB  - METHODS: Sixteen patients with chronic AF were included in the study. Two 6F custom-made catheters (Electro-Catheter, Inc.) were used for shock delivery and one tetrapolar lead for ventricular synchronization. Without sedation and in a random order, patients underwent two sequences of shocks to determine the ADT at rest and during exercise. Exercise was performed isometrically by the superior limbs. Atrial fibrillation was reinduced by atrial pacing. After each shock, the patients were requested to grade their discomfort with a score from 1 to 5. The power of the study was > 90% in detecting a 25% difference in the ADT between groups.
AB  - RESULTS: Patients were classified into two groups: Nine patients (group A) underwent the first cardioversion during exercise; seven patients (group B) underwent the first cardioversion at rest. In total, the mean (+/-SD) ADT was 6.70 +/- 1.54 J during exercise and 7.02 +/- 1.82 J at rest (p = 0.59). A significantly lower ADT was observed in the second shock sequence than the first one (6.32 +/- 2.09 J vs. 7.40 +/- 0.87 J, p < 0.05). The discomfort score was 3.25 +/- 0.86 at rest and 2.94 +/- 0.77 during exercise (p = 0.09). No complications occurred.
AB  - CONCLUSIONS: Low energy endocavitary cardioversion is a safe and effective procedure in patients with chronic AF. Discomfort is not generally severe enough to result in procedure termination. The ADT is not influenced by exercise and is higher in chronic than in reinduced AF.
IS  - 0735-1097
IL  - 0735-1097
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 1997 Mar 1
DC  - 19970404
YR  - 1997
ED  - 19970404
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9060896

<792. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8930942
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Grobbee DE
AU  - Koudstaal PJ
AU  - Bots ML
AU  - Amaducci LA
AU  - Elwood PC
AU  - Ferro J
AU  - Freire de Concalves A
AU  - Kruger O
AU  - Inzitari D
AU  - Nikitin Y
AU  - Salonen JT
AU  - Sivenius J
AU  - Scheuermann W
AU  - Thelle DS
AU  - Trichopoulou A
AU  - Tuomilehto JT
FA  - Grobbee, D E
FA  - Koudstaal, P J
FA  - Bots, M L
FA  - Amaducci, L A
FA  - Elwood, P C
FA  - Ferro, J
FA  - Freire de Concalves, A
FA  - Kruger, O
FA  - Inzitari, D
FA  - Nikitin, Y
FA  - Salonen, J T
FA  - Sivenius, J
FA  - Scheuermann, W
FA  - Thelle, D S
FA  - Trichopoulou, A
FA  - Tuomilehto, J T
IN  - Grobbee,D E. Department of Epidemiology and Biostatistics Erasmus University Medical School, Rotterdam, (The Netherlands).
TI  - Incidence and risk factors of ischaemic and haemorrhagic stroke in Europe. EUROSTROKE: A collaborative study among research centres in Europe: rationale and design.
SO  - Neuroepidemiology. 15(6):291-300, 1996.
AS  - Neuroepidemiology. 15(6):291-300, 1996.
NJ  - Neuroepidemiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - nxy, 8218700
SB  - Index Medicus
CP  - SWITZERLAND
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain Ischemia/et [Etiology]
MH  - *Brain Ischemia/mo [Mortality]
MH  - Case-Control Studies
MH  - Cause of Death
MH  - Cerebral Hemorrhage/et [Etiology]
MH  - *Cerebral Hemorrhage/mo [Mortality]
MH  - Cerebrovascular Disorders/et [Etiology]
MH  - *Cerebrovascular Disorders/mo [Mortality]
MH  - Cohort Studies
MH  - Cross-Cultural Comparison
MH  - Cross-Sectional Studies
MH  - Europe/ep [Epidemiology]
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Factors
AB  - EUROSTROKE is a collaborative study among ten European research centres to investigate (1) the variation in incidence of fatal and non-fatal ischaemic and haemorrhagic stroke among populations in different European countries; (2) whether the observed differences in stroke incidence across countries can be explained by differences in prevalence of established cardiovascular risk factors; (3) the relative importance of selected dietary factors (potassium intake, smoking, alcohol consumption), haemostatic disturbances (fibrinogen) and co-morbidity (rheumatic heart disease, atrial fibrillation) compared to established risk factors as determinants of the occurrence of ischaemic and haemorrhagic stroke. The EUROSTROKE database is drawn from ten European population-based prospective follow-up studies (cohorts) and is designed as a case-control study nested within these ten ongoing studies.
IS  - 0251-5350
IL  - 0251-5350
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1996
DC  - 19970402
YR  - 1996
ED  - 19970402
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=8930942

<793. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8994734
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ostermaier RH
AU  - Lampert S
AU  - Dalla Vecchia L
AU  - Ravid S
FA  - Ostermaier, R H
FA  - Lampert, S
FA  - Dalla Vecchia, L
FA  - Ravid, S
IN  - Ostermaier,R H. Lown Cardiovascular Center, Brookline, MA 02146, USA.
TI  - The effect of atrial fibrillation and the ventricular rate control on exercise capacity.
SO  - Clinical Cardiology. 20(1):23-7, 1997 Jan.
AS  - Clin Cardiol. 20(1):23-7, 1997 Jan.
NJ  - Clinical cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - de9, 7903272
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Exercise Test
MH  - *Exercise Tolerance
MH  - Female
MH  - *Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Ventricular Function, Left
AB  - BACKGROUND: Atrial fibrillation (AF) is a common cardiac arrhythmia, affecting approximately 1.5 million patients in the United States.
AB  - HYPOTHESIS: This study was designed to determine the effect of AF and the ventricular rate control during AF on cardiovascular performance as measured by exercise endurance on a standard Bruce protocol.
AB  - METHODS: Sixty-three patients with AF who underwent exercise stress testing during both sinus rhythm and AF were analyzed. Heart rate, blood pressure, heart rate acceleration, exercise duration, and left ventricular (LV) systolic function were measured.
AB  - RESULTS: Atrial fibrillation resulted in a small but statistically significant decrease in exercise endurance (426 +/- 180 vs. 402 +/- 168 s, p < 0.05). The drop in exercise tolerance was consistent regardless of the underlying heart condition or adequate ventricular rate control during AF. Heart rate in AF was consistently faster than in sinus rhythm, at rest, and at peak exercise (63 vs. 79 beats/min and 125 vs. 149 beats/min, respectively, p < 0.001).
AB  - CONCLUSION: Our analyses indicated that (1) the loss of atrioventricular synchrony had minimal effect on cardiovascular performance in patients with preserved LV function, (2) the decrease in cardiovascular performance was related to loss of atrioventricular synchrony but not to underlying heart disease or ventricular rate control, and (3) compensation for the loss of the atrial contribution was provided by consistently faster heart rate during AF.
IS  - 0160-9289
IL  - 0160-9289
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1997 Jan
DC  - 19970313
YR  - 1997
ED  - 19970313
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=8994734

<794. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8945029
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kamalvand K
AU  - Kotsakis A
AU  - Tan K
AU  - Bucknall C
AU  - Sulke N
FA  - Kamalvand, K
FA  - Kotsakis, A
FA  - Tan, K
FA  - Bucknall, C
FA  - Sulke, N
IN  - Kamalvand,K. Guy's & St. Thomas' Hospital Trust, London, United Kingdom.
TI  - Evaluation of a new pacing algorithm to prevent rapid tracking of atrial tachyarrhythmias.
SO  - Pacing & Clinical Electrophysiology. 19(11 Pt 2):1714-8, 1996 Nov.
AS  - Pacing Clin Electrophysiol. 19(11 Pt 2):1714-8, 1996 Nov.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Activities of Daily Living
MH  - *Algorithms
MH  - Atrial Fibrillation/pc [Prevention & Control]
MH  - Atrial Function
MH  - *Cardiac Pacing, Artificial/mt [Methods]
MH  - Electrocardiography, Ambulatory
MH  - Electronics, Medical/is [Instrumentation]
MH  - Equipment Design
MH  - Evaluation Studies as Topic
MH  - Exercise Test
MH  - Female
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pacemaker, Artificial
MH  - Rest
MH  - *Tachycardia, Paroxysmal/pc [Prevention & Control]
MH  - Ventricular Function
MH  - Walking
AB  - The new SMARTracking (SMT) algorithm was evaluated in seven patients with the Intermedics Relay DDDR pacemakers and a history of atrial tachyarrhythmias. The SMT algorithm uses the sensor calculated rate to define a physiological band whose upper limit is defined by the SMT rate. Pacemakers were programmed to DDDR with SMT (DDDRSM), DDDR with Conditional Ventricular Tracking Limit (DDDRC), DDDR with standard upper rate behavior, and VVIR, for a period of one month each. Patients underwent a CAEP exercise test and 24-hour ECG Holter monitoring in each mode. They also had ambulatory ECG monitoring during daily activities including rest, slow and fast walk, stairs ascent and descent. Three patients were in atrial fibrillation during the daily activities protocol. Their ventricular rates were paced and highly irregular, in both DDDRSM and DDDRC modes. The heart rate was lower in DDDRSM than DDDRC at rest and low levels of exercise but not during more strenuous activity. Two patients in DDDRSM and 3 in DDDRC requested early change of their mode due to unacceptable symptoms. Two patients exhibited Wenckebach behavior at atrial rates below the upper rate limit in both DDDRSM and DDDRC modes. In conclusion, CVTL or SMARTracking are not adequate protection against atrial tachyarrythmias in patients with DDDR pacemakers.
IS  - 0147-8389
IL  - 0147-8389
PT  - Journal Article
LG  - English
DP  - 1996 Nov
DC  - 19970306
YR  - 1996
ED  - 19970306
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=8945029

<795. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8945027
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Delay M
AU  - Bruls A
AU  - Mounier C
AU  - Verboven Y
AU  - Somody E
AU  - Puel J
FA  - Delay, M
FA  - Bruls, A
FA  - Mounier, C
FA  - Verboven, Y
FA  - Somody, E
FA  - Puel, J
IN  - Delay,M. Purpan Hospital, Toulouse, France.
TI  - Evaluation of a new sensor-based algorithm to protect against atrial arrhythmias.
SO  - Pacing & Clinical Electrophysiology. 19(11 Pt 2):1704-7, 1996 Nov.
AS  - Pacing Clin Electrophysiol. 19(11 Pt 2):1704-7, 1996 Nov.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Acceleration
MH  - Aged
MH  - *Algorithms
MH  - *Arrhythmias, Cardiac/pc [Prevention & Control]
MH  - Atrial Function
MH  - Cardiac Pacing, Artificial/mt [Methods]
MH  - Electrocardiography
MH  - *Electronics, Medical/is [Instrumentation]
MH  - Equipment Design
MH  - Evaluation Studies as Topic
MH  - Female
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - *Pacemaker, Artificial
MH  - Physical Exertion/ph [Physiology]
MH  - Rest/ph [Physiology]
MH  - Sinoatrial Node/pp [Physiopathology]
MH  - Ventricular Function
MH  - Walking/ph [Physiology]
AB  - UNLABELLED: The SmarTracking (ST) algorithm (Marathon 294-09, Intermedics Inc.) uses the sensor-calculated rate (SCR) to define a "variation band" for the intrinsic sinus rate. If the sinus rate exceeds the upper limit of the band, the ventricular pacing rate is limited by the ST rate (STR) and Wenckebach behavior is observed. The present study was aimed at evaluating the behavior of the ST mechanism in patients with healthy sinus node, during exercise and at rest.
AB  - METHODS: Twenty-one patients (15 men; mean age 67.8 +/- 9.7 years) with normal sinus function were studied. Heart rate was recorded via the rate profile of the implanted pacemaker (Relay 294-03, Intermedics Inc.), and STR and SCR were obtained via a previously calibrated strap-on pacemaker. A 15-minute protocol was used during which subjects alternated periods of walking with periods of rest.
AB  - RESULTS: The relative difference between the average STR and the average sinus rate (DST) was calculated for each phase of the protocol as well as the maximum number of patients showing inappropriate Wenckebach behavior (#W). At nominal settings, DST was always positive and did not fall below 20%. #W was maximum at rest (5) and during heavy exercise (3). By increasing the STR at rest to 95 ppm and the maximum pacing rate to 150 ppm, the #W was reduced to zero for all types of activity except during very fast walk where #W was 1.
AB  - CONCLUSION: In general, there was no competition observed between the STR and the intrinsic rhythm. In some cases, the STR at rest and the maximum pacing rate had to be reprogrammed for optimal performance.
IS  - 0147-8389
IL  - 0147-8389
PT  - Journal Article
LG  - English
DP  - 1996 Nov
DC  - 19970306
YR  - 1996
ED  - 19970306
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=8945027

<796. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8878172
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Aranda-Michel J
AU  - Morgan SL
FA  - Aranda-Michel, J
FA  - Morgan, S L
IN  - Aranda-Michel,J. Department of Nutrition Sciences, School of Medicine, University of Alabama at Birmingham, USA.
TI  - Overfeeding in a patient with Kwashiorkor syndrome.
SO  - Nutrition. 12(9):623-5, 1996 Sep.
AS  - Nutrition. 12(9):623-5, 1996 Sep.
NJ  - Nutrition (Burbank, Los Angeles County, Calif.)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - beu, 8802712
SB  - Index Medicus
CP  - UNITED STATES
MH  - Atrial Fibrillation/et [Etiology]
MH  - Energy Intake
MH  - Female
MH  - Humans
MH  - Hypercapnia/et [Etiology]
MH  - *Kwashiorkor/th [Therapy]
MH  - Magnesium Deficiency
MH  - Middle Aged
MH  - Nitrogen/ur [Urine]
MH  - *Parenteral Nutrition, Total/ae [Adverse Effects]
MH  - Syndrome
MH  - Tachycardia/et [Etiology]
MH  - Urea/ur [Urine]
RN  - 8W8T17847W (Urea)
RN  - N762921K75 (Nitrogen)
IS  - 0899-9007
IL  - 0899-9007
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 1996 Sep
DC  - 19970122
YR  - 1996
ED  - 19970122
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=8878172

<797. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8823827
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lau CP
AU  - Leung SK
AU  - Lee IS
FA  - Lau, C P
FA  - Leung, S K
FA  - Lee, I S
IN  - Lau,C P. Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong.
TI  - Delayed exercise rate response kinetics due to sensor cross-checking in a dual sensor rate adaptive pacing system: the importance of individual sensor programming.
SO  - Pacing & Clinical Electrophysiology. 19(7):1021-5, 1996 Jul.
AS  - Pacing Clin Electrophysiol. 19(7):1021-5, 1996 Jul.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Algorithms
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Cardiac Pacing, Artificial/mt [Methods]
MH  - Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Female
MH  - *Heart Block/th [Therapy]
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Pacemaker, Artificial
MH  - Software
MH  - Time Factors
AB  - By cross-checking the relative sensor activation between a nonspecific and specific sensor during extraneous interference, a multisensor rate adaptive pacemaker may be able to limit inappropriate rate responses. The effects of activity (ACT) sensor programming on rate response kinetics of a QT and ACT dual sensor VVIR pacemaker with sensor cross-checking algorithm were studied in four patients with atrial fibrillation and complete heart block. The rate adaptive setting of each sensor was individually optimized, and an equal rate contribution for the QT and ACT sensors (QT = ACT) was used in the dual sensor VVIR mode. Three maximal treadmill exercise tests were performed in random order in three different VVIR modes driven by QT only, QT = ACT, and in the dual sensor mode with the most sensitive (low threshold) ACT setting. In the two dual sensor modes, the time for onset of rate response (delay time) was reduced (both < 15 sec) compared with QT only VVIR mode (233 +/- 70 sec). However, the time to 50% of rate response in the low ACT threshold dual sensor mode was delayed compared with to QT = ACT (450 +/- 110 [95% confidence interval 234-666] vs 311 +/- 103 [109-513]sec, P < 0.05) and was similar to the QT only mode (401 +/- 120 [166-636]sec). The time to reach 90% of rate response was similar in the three modes tested. The resting activity counts registered by the ACT sensor were < 5 and 16 +/- 2 counts/min in the optimally programmed and low threshold ACT settings, respectively. This resulted in sensor cross-checking at rest in the overprogrammed dual sensor VVIR mode, thereby limiting the rate response. Thus, the combined sensor system provides a faster initial response to exercise than the QT only sensor. Programming the ACT threshold to low will prevent this faster response because of sensor cross-checking.
IS  - 0147-8389
IL  - 0147-8389
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 1996 Jul
DC  - 19961210
YR  - 1996
ED  - 19961210
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=8823827

<798. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 14314203
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - BENCHIMOL A
AU  - LOWE HM
AU  - AKRE PR
FA  - BENCHIMOL, A
FA  - LOWE, H M
FA  - AKRE, P R
TI  - CARDIOVASCULAR RESPONSE TO EXERCISE DURING ATRIAL FIBRILLATION AND AFTER CONVERSION TO SINUS RHYTHM.
SO  - American Journal of Cardiology. 16:31-41, 1965 Jul.
AS  - Am J Cardiol. 16:31-41, 1965 Jul.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - OLDMEDLINE Citations
CP  - UNITED STATES
MH  - *Atrial Fibrillation
MH  - *Blood Pressure
MH  - *Cardiac Output
MH  - *Heart
MH  - *Heart Function Tests
MH  - *Heart Rate
MH  - *Hemodynamics
MH  - Humans
MH  - *Physical Exertion
MH  - *Vascular Resistance
KW  - *AURICULAR FIBRILLATION;  *BLOOD PRESSURE;  *CARDIAC OUTPUT;  *EXERTION;  *HEART;  *HEART FUNCTION TESTS;  *HEART RATE;  *HEMODYNAMICS;  *VASCULAR RESISTANCE
IS  - 0002-9149
IL  - 0002-9149
PT  - Journal Article
LG  - English
DP  - 1965 Jul
DC  - 19651001
YR  - 1965
ED  - 19961201
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=14314203

<799. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 14232806
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - GRAYBIEL A
FA  - GRAYBIEL, A
TI  - AURICULAR FIBRILLATION IN AN ASYMPTOMATIC YOUNG MAN. EFFECTS OF EXERCISE, DIGITALIZATION, ATROPINIZATION AND THE RESTORATION OF NORMAL RHYTHM.
SO  - American Journal of Cardiology. 14:828-36, 1964 Dec.
AS  - Am J Cardiol. 14:828-36, 1964 Dec.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - OLDMEDLINE Citations
CP  - UNITED STATES
MH  - *Atrial Fibrillation
MH  - *Atropine
MH  - *Digitalis Glycosides
MH  - *Drug Therapy
MH  - *Electrocardiography
MH  - *Exercise
MH  - Humans
MH  - Male
MH  - *Physical Exertion
MH  - *Quinidine
KW  - *ATROPINE;  *AURICULAR FIBRILLATION;  *DIGITALIS GLYCOSIDES;  *DRUG THERAPY;  *ELECTROCARDIOGRAPHY;  *EXERTION;  *QUINIDINE
RN  - 0 (Digitalis Glycosides)
RN  - 7C0697DR9I (Atropine)
RN  - ITX08688JL (Quinidine)
IS  - 0002-9149
IL  - 0002-9149
PT  - Journal Article
LG  - English
DP  - 1964 Dec
DC  - 19650301
YR  - 1964
ED  - 19961201
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=14232806

<800. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 14133354
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - SWAN DM
FA  - SWAN, D M
TI  - LONG TERM OFFICE ANTICOAGULATION.
SO  - Journal of the Maine Medical Association. 55:44-6, 1964 Mar.
AS  - J Maine Med Assoc. 55:44-6, 1964 Mar.
NJ  - The Journal of the Maine Medical Association
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - ixz, 7505619
SB  - OLDMEDLINE Citations
CP  - UNITED STATES
MH  - *Arteriosclerosis
MH  - *Atrial Fibrillation
MH  - *Cerebrovascular Disorders
MH  - *Coronary Disease
MH  - *Dicumarol
MH  - *Diet
MH  - *Diet Therapy
MH  - *Family Practice
MH  - *General Practice
MH  - Humans
MH  - *Intracranial Embolism
MH  - *Intracranial Embolism and Thrombosis
MH  - *Myocardial Infarction
MH  - *Prothrombin Time
MH  - *Thrombosis
MH  - *Vitamin K
MH  - *Warfarin
KW  - *ARTERIOSCLEROSIS;  *AURICULAR FIBRILLATION;  *BISHYDROXYCOUMARIN;  *CEREBRAL EMBOLISM AND THROMBOSIS;  *CEREBROVASCULAR DISORDERS;  *CORONARY DISEASE;  *DIET THERAPY;  *GENERAL PRACTICE;  *MYOCARDIAL INFARCT;  *PROTHROMBIN TIME;  *VITAMIN K;  *WARFARIN
RN  - 12001-79-5 (Vitamin K)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 7QID3E7BG7 (Dicumarol)
IS  - 0025-0694
IL  - 0025-0694
PT  - Journal Article
LG  - English
DP  - 1964 Mar
DC  - 19640801
YR  - 1964
ED  - 19961201
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=14133354

<801. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 14062727
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - GROGONO AW
FA  - GROGONO, A W
TI  - ANAESTHESIA FOR ATRIAL DEFIBRILLATION: EFFECT OF QUINIDINE ON MUSCULAR RELAXATION.
SO  - Lancet. 2(7316):1039-40, 1963 Nov 16.
AS  - Lancet. 2(7316):1039-40, 1963 Nov 16.
NJ  - Lancet (London, England)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 2985213r, l0s, 0053266
SB  - OLDMEDLINE Citations
CP  - ENGLAND
MH  - *Anesthesia
MH  - *Anesthesia, Local
MH  - *Anesthesiology
MH  - *Atrial Fibrillation
MH  - *Electric Countershock
MH  - *Electric Stimulation Therapy
MH  - Humans
MH  - *Meperidine
MH  - *Preanesthetic Medication
MH  - *Quinidine
MH  - *Scopolamine Hydrobromide
MH  - *Succinylcholine
MH  - *Thiopental
KW  - *ANESTHESIA, LOCAL;  *AURICULAR FIBRILLATION;  *ELECTROTHERAPY;  *MEPERIDINE;  *PREANESTHETIC MEDICATION;  *QUINIDINE;  *SCOPOLAMINE;  *SUCCINYLCHOLINE;  *THIOPENTAL
RN  - 451IFR0GXB (Scopolamine Hydrobromide)
RN  - 76-75-5 (Thiopental)
RN  - 9E338QE28F (Meperidine)
RN  - ITX08688JL (Quinidine)
RN  - J2R869A8YF (Succinylcholine)
IS  - 0140-6736
IL  - 0140-6736
PT  - Journal Article
LG  - English
DP  - 1963 Nov 16
DC  - 19640201
YR  - 1963
ED  - 19961201
RD  - 20150616
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=14062727

<802. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8841327
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Bornstein NM
AU  - Aronovich BD
AU  - Karepov VG
AU  - Gur AY
AU  - Treves TA
AU  - Oved M
AU  - Korczyn AD
FA  - Bornstein, N M
FA  - Aronovich, B D
FA  - Karepov, V G
FA  - Gur, A Y
FA  - Treves, T A
FA  - Oved, M
FA  - Korczyn, A D
IN  - Bornstein,N M. Department of Neurology, Tel Aviv Medical Center, Israel.
TI  - The Tel Aviv Stroke Registry. 3600 consecutive patients.
SO  - Stroke. 27(10):1770-3, 1996 Oct.
AS  - Stroke. 27(10):1770-3, 1996 Oct.
NJ  - Stroke; a journal of cerebral circulation
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - v2j, 0235266
SB  - Index Medicus
CP  - UNITED STATES
MH  - Africa/eh [Ethnology]
MH  - Aged
MH  - Asia/eh [Ethnology]
MH  - Cerebrovascular Disorders/eh [Ethnology]
MH  - Cerebrovascular Disorders/mo [Mortality]
MH  - Cerebrovascular Disorders/pp [Physiopathology]
MH  - *Cerebrovascular Disorders
MH  - Europe/eh [Ethnology]
MH  - Female
MH  - Hospital Mortality
MH  - Humans
MH  - Israel/ep [Epidemiology]
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Recurrence
MH  - *Registries
MH  - Risk Factors
MH  - United States/eh [Ethnology]
AB  - BACKGROUND AND PURPOSE: We undertook to estimate the frequency of various risk factors and the type and severity of stroke in different ethnic groups documented in a large hospital-based stroke registry. Tel Aviv is a metropolis with about 400000 inhabitants and about 600000 daily visitors and workers. The Tel Aviv Medical Center (TAMC) is the only tertiary medical care facility to which all patients with acute stroke are referred. Israel is a country with a heterogeneous population, of which a significant proportion was born abroad. The people differ in their genetic background, as well as in their early environmental conditions, lifelong diet, and other habits. This variety has proved to be a fertile ground for the study of different neurological diseases, including stroke.
AB  - METHODS: A prospective hospital-based registry using systematic computer coding of data of all consecutive stroke patients admitted to the TAMC has been conducted since May 1988. Different aspects of the amassed data were analyzed statistically.
AB  - RESULTS: From May 1988 until April 1994, 3600 stroke patients were admitted to the TAMC. The mean age was 73.2 years, and 58.2% were males. Cerebral infarctions were diagnosed in 80.9%, primary intracerebral hemorrhages in 8.0%, and transient ischemic attacks in 11.1%. There were 861 patients (24%) who were admitted with recurrent strokes. Past medical history of hypertension was the major risk factor (occurring in 52.2% of the patients), followed by ischemic heart disease (29.7%), diabetes mellitus (25.2%), smoking (17.0%), atrial fibrillation (14.3%), and hyperlipidemia (8.4%). Ischemic heart disease and atrial fibrillation were more frequent in patients from Europe and America (Ashkenazi group), whereas diabetes mellitus and smoking were more prominent in the other groups. The in-hospital mortality rate was 13.8% and was similar in both ethnic groups.
AB  - CONCLUSIONS: This registry allows the study of the risk factors, natural history, and clinical manifestations of stroke in different ethnic groups.
IS  - 0039-2499
IL  - 0039-2499
PT  - Journal Article
LG  - English
DP  - 1996 Oct
DC  - 19961115
YR  - 1996
ED  - 19961115
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=8841327

<803. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8761840
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mertens DJ
AU  - Kavanagh T
FA  - Mertens, D J
FA  - Kavanagh, T
IN  - Mertens,D J. Toronto Rehabilitation Centre, Ontario, Canada.
TI  - Exercise training for patients with chronic atrial fibrillation.
SO  - Journal of Cardiopulmonary Rehabilitation. 16(3):193-6, 1996 May-Jun.
AS  - J Cardiopulm Rehabil. 16(3):193-6, 1996 May-Jun.
NJ  - Journal of cardiopulmonary rehabilitation
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - cgv, 8511296
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Atrial Fibrillation/me [Metabolism]
MH  - *Atrial Fibrillation/rh [Rehabilitation]
MH  - Body Mass Index
MH  - Chronic Disease
MH  - Energy Metabolism
MH  - *Exercise Therapy/mt [Methods]
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxygen Consumption
MH  - Physical Exertion
MH  - Referral and Consultation
MH  - Walking/ph [Physiology]
AB  - BACKGROUND: Patients with atrial fibrillation (AF) referred for exercise rehabilitation exemplify the problem inherent in reliance on pulse rate to prescribe and monitor training intensity.
AB  - METHODS: Exercise training was accomplished by specifying a training walking pace based on 60% to 80% of the peak oxygen intake (VO2max), as determined by the analysis of expired air (Horizon metabolic cart), and/or the ventilatory threshold (VT), together with a perceived exertion of 12 to 14 on the original Borg scale of perceived exertion.
AB  - RESULTS: At the end of 1 year, a significant training effect was demonstrated (VO2max average increase 15%, 14.8 +/- 3.6 mL/kg/min to 17.0 +/- 3.6 mL/kg/min, P < .02; VO2 at VT, average increase 14%, 11.2 +/- 2.2 to 12.8 +/- 2.6 mL/kg/min, P < .01; peak power output increase 21%, 92.5 +/- 29.3 Watts to 112 +/- 3.7 Watts, P < .05) in a group of 20 patients (13 men, 7 women) with chronic atrial fibrillation.
AB  - CONCLUSIONS: Patients with chronic atrial fibrillation can achieve significant functional gains from an exercise rehabilitation program.
IS  - 0883-9212
IL  - 0883-9212
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
LG  - English
DP  - 1996 May-Jun
DC  - 19961023
YR  - 1996
ED  - 19961023
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=8761840

<804. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8800273
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Shimamoto T
AU  - Iso H
AU  - Iida M
AU  - Komachi Y
FA  - Shimamoto, T
FA  - Iso, H
FA  - Iida, M
FA  - Komachi, Y
IN  - Shimamoto,T. Institute of Community Medicine, University of Tsukuba, Japan.
TI  - Epidemiology of cerebrovascular disease: stroke epidemic in Japan. [Review] [37 refs]
SO  - Journal of Epidemiology. 6(3 Suppl):S43-7, 1996 Aug.
AS  - J Epidemiol. 6(3 Suppl):S43-7, 1996 Aug.
NJ  - Journal of epidemiology / Japan Epidemiological Association
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - cl8, 9607688
SB  - Index Medicus
CP  - JAPAN
MH  - *Cerebrovascular Disorders/ep [Epidemiology]
MH  - Cerebrovascular Disorders/pc [Prevention & Control]
MH  - *Disease Outbreaks/sn [Statistics & Numerical Data]
MH  - Female
MH  - Humans
MH  - Hypertension/ep [Epidemiology]
MH  - Japan/ep [Epidemiology]
MH  - Male
MH  - Risk Factors
AB  - Japan had the highest mortality from stroke among developed countries in 1960, but experienced rapid changes in diet and other lifestyles with economic growth between the 1960s and the 1980s, which provided an unique opportunity to observe a natural experiment of changes in risk factors and stroke. Blood pressure levels declined due to improvements of drug treatment for hypertension and to dietary improvements such as sodium reduction. An increase in mean values of ethanol intake and body mass index did not correspond with a decline of blood pressure levels. Serum total cholesterol increased with an increased intake of meat, egg, milk and dairy products. Age-adjusted mortality rate of stroke declined 70% between 1960 and 1990. The changes of diet, blood pressure levels and stroke were more evident in rural populations than in urban populations. Risk factors of stroke has been investigated prospectively, and hypertension was found to be the most important risk factor. A low blood cholesterol was associated with the increased risk of intracerebral hemorrhage, which has been confirmed in several Japanese populations, Japanese Americans and Caucasian Americans. Thus, a rise in serum cholesterol suggested to contribute in part to a decline in intracerebral hemorrhage. Risk factors for cerebral infarction include age, atrial fibrillation and hypertensive endorgan effects such as resting electrocardiogram and fundscopic examination. A community-based hypertension control program for stroke prevention has been evaluated; a larger decline in stroke incidence in the intervention community (69%) than in the reference community (49%, the difference: p < 0.001). Effective community programs stimulated the formation of the 1982 national act on health and medical care in which every municipal government is required to conduct health screenings and education for residents aged 40 and over to prevent cardiovascular diseases. [References: 37]
IS  - 0917-5040
IL  - 0917-5040
PT  - Journal Article
PT  - Review
LG  - English
DP  - 1996 Aug
DC  - 19961018
YR  - 1996
ED  - 19961018
RD  - 20051116
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=8800273

<805. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8711581
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - McGovern BA
AU  - Liberthson R
FA  - McGovern, B A
FA  - Liberthson, R
IN  - McGovern,B A. Cardiac Unit, Massachusetts General Hospital, Boston, USA.
TI  - Arrhythmias induced by exercise in athletes and others. [Review] [22 refs]
SO  - South African Medical Journal. Suid-Afrikaanse Tydskrif Vir Geneeskunde. 86 Suppl 2:C78-82, 1996 Apr.
AS  - SAMJ, S. Afr. med. j.. 86 Suppl 2:C78-82, 1996 Apr.
NJ  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0404520
SB  - Index Medicus
CP  - SOUTH AFRICA
MH  - Adolescent
MH  - Adult
MH  - Arrhythmias, Cardiac/di [Diagnosis]
MH  - *Arrhythmias, Cardiac/et [Etiology]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Atrial Flutter/et [Etiology]
MH  - Bradycardia/et [Etiology]
MH  - Cardiomyopathies
MH  - Humans
MH  - *Sports
MH  - Wolff-Parkinson-White Syndrome/et [Etiology]
AB  - Athletes are subject to the same arrhythmias as the general population, but the frequency and significance of the arrhythmias may be different. Cardiovascular conditioning slows the heart rate and may make athletes more vulnerable to neurocardiogenic syncope and atrial fibrillation. Tachyarrhythmias may be precipitated by vigorous exercise and more severe rate-related symptoms may result because of the high sympathetic drive during sports activities. For those with pre-existing cardiovascular abnormalities, athletic activity may be beneficial in some cases, but dangerous and even life-threatening in others. A review of the subject and recommendations based on our personal experience and a recent consensus conference are provided. [References: 22]
IS  - 0256-9574
PT  - Journal Article
PT  - Review
LG  - English
DP  - 1996 Apr
DC  - 19960910
YR  - 1996
ED  - 19960910
RD  - 20140912
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=8711581

<806. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8691499
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Friedman AW
AU  - Lipman RC
AU  - Silver SJ
AU  - Minella RA
AU  - Hoover JL
FA  - Friedman, A W
FA  - Lipman, R C
FA  - Silver, S J
FA  - Minella, R A
FA  - Hoover, J L
TI  - Cardiac rehabilitation/exercise in patients with implantable cardioverter defibrillators.
SO  - Journal of the National Medical Association. 88(6):374-8, 1996 Jun.
AS  - J Natl Med Assoc. 88(6):374-8, 1996 Jun.
NJ  - Journal of the National Medical Association
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - j9z, 7503090
OI  - Source: NLM. PMC2608098
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Arrhythmias, Cardiac/dt [Drug Therapy]
MH  - *Arrhythmias, Cardiac/rh [Rehabilitation]
MH  - *Defibrillators, Implantable
MH  - Exercise Test
MH  - *Exercise Therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Care
AB  - There have been no specific exercise or daily activity guidelines determined for patients with automatic implantable cardioverter defibrillators. Two patients, one with a Ventritex Cadence Model V-100 defibrillator and one with a CPI Ventak Model 1550 defibrillator were enrolled in monitored cardiac rehabilitation. One patient had symptoms of syncope and cardiodefibrillation during a vigorous short walk prior to cardiac rehabilitation and became fearful of any activity. Stress testing on this patient was terminated early because his atrial fibrillation rate approached the defibrillization rate. A low dose of beta blockade was added to his regimen. He underwent repeat stress testing and was placed in cardiac rehabilitation. This patient had no further shocks, and it was assumed that his shock was due to high atrial fibrillation rates. The second patient experienced recurrent shocks on amiodarone, propafenone, and mexiletine with presyncope. However, stress testing did not disclose abnormalities. The patient was fearful of any activity and was placed in cardiac rehabilitation. During an average of 26 sessions of cardiac rehabilitation, no symptoms have been noted, and the patients have returned to a more normal lifestyle. Specific exercise and lifestyle criteria should be given to patients with cardioverter defibrillators. Stress testing with monitored exercise can develop such a program. Larger numbers of patients need to be studied.
IS  - 1943-4693
IL  - 0027-9684
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 1996 Jun
DC  - 19960827
YR  - 1996
ED  - 19960827
RD  - 20151225
UP  - 20151228
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=8691499

<807. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8691499
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Friedman AW
AU  - Lipman RC
AU  - Silver SJ
AU  - Minella RA
AU  - Hoover JL
FA  - Friedman, A W
FA  - Lipman, R C
FA  - Silver, S J
FA  - Minella, R A
FA  - Hoover, J L
TI  - Cardiac rehabilitation/exercise in patients with implantable cardioverter defibrillators.
SO  - Journal of the National Medical Association. 88(6):374-8, 1996 Jun.
AS  - J Natl Med Assoc. 88(6):374-8, 1996 Jun.
NJ  - Journal of the National Medical Association
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - j9z, 7503090
OI  - Source: NLM. PMC2608098
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Arrhythmias, Cardiac/dt [Drug Therapy]
MH  - *Arrhythmias, Cardiac/rh [Rehabilitation]
MH  - *Defibrillators, Implantable
MH  - Exercise Test
MH  - *Exercise Therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Care
AB  - There have been no specific exercise or daily activity guidelines determined for patients with automatic implantable cardioverter defibrillators. Two patients, one with a Ventritex Cadence Model V-100 defibrillator and one with a CPI Ventak Model 1550 defibrillator were enrolled in monitored cardiac rehabilitation. One patient had symptoms of syncope and cardiodefibrillation during a vigorous short walk prior to cardiac rehabilitation and became fearful of any activity. Stress testing on this patient was terminated early because his atrial fibrillation rate approached the defibrillization rate. A low dose of beta blockade was added to his regimen. He underwent repeat stress testing and was placed in cardiac rehabilitation. This patient had no further shocks, and it was assumed that his shock was due to high atrial fibrillation rates. The second patient experienced recurrent shocks on amiodarone, propafenone, and mexiletine with presyncope. However, stress testing did not disclose abnormalities. The patient was fearful of any activity and was placed in cardiac rehabilitation. During an average of 26 sessions of cardiac rehabilitation, no symptoms have been noted, and the patients have returned to a more normal lifestyle. Specific exercise and lifestyle criteria should be given to patients with cardioverter defibrillators. Stress testing with monitored exercise can develop such a program. Larger numbers of patients need to be studied.
IS  - 0027-9684
IL  - 0027-9684
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 1996 Jun
DC  - 19960827
YR  - 1996
ED  - 19960827
RD  - 20130919
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=8691499

<808. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8686967
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kuroda T
AU  - Okamura K
AU  - Sato K
AU  - Inokuchi K
AU  - Mizokami T
AU  - Fujishima M
FA  - Kuroda, T
FA  - Okamura, K
FA  - Sato, K
FA  - Inokuchi, K
FA  - Mizokami, T
FA  - Fujishima, M
IN  - Kuroda,T. Second Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
TI  - Acute exacerbation of masked hyperthyroidism after iodine restriction followed by thyrotoxic atrial fibrillation and cerebral embolism. A case report.
SO  - Angiology. 47(7):709-12, 1996 Jul.
AS  - Angiology. 47(7):709-12, 1996 Jul.
NJ  - Angiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 4ua, 0203706
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - *Atrial Fibrillation/et [Etiology]
MH  - Female
MH  - *Graves Disease/co [Complications]
MH  - Humans
MH  - *Intracranial Embolism and Thrombosis/et [Etiology]
MH  - Intracranial Embolism and Thrombosis/ra [Radiography]
MH  - *Thyrotoxicosis/co [Complications]
MH  - Tomography, X-Ray Computed
AB  - The authors present a seventy-two-year-old woman complaining of diffuse and firm goiter. At the first visit, she looked almost euthyroid with regular pulse rate of 78 per minute. After iodine restriction, however, she became severely thyrotoxic and developed cerebral embolism associated with atrial fibrillation due to Graves' hyperthyroidism. In conclusion, sudden withdrawal of dietary iodine might lead to exacerbation of Graves' hyperthyroidism resulting in serious cardiovascular or cerebrovascular complications, especially in elderly patients.
IS  - 0003-3197
IL  - 0003-3197
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 1996 Jul
DC  - 19960820
YR  - 1996
ED  - 19960820
RD  - 20051117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=8686967

<809. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8648883
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Honda T
AU  - Doi O
AU  - Hayasaki K
AU  - Honda T
FA  - Honda, T
FA  - Doi, O
FA  - Hayasaki, K
FA  - Honda, T
IN  - Honda,T. Division of Cardiology, Saiseikai Kumamoto Hospital, Japan.
TI  - Augmented sympathoadrenal activity during treadmill exercise in patients with Wolff-Parkinson-White syndrome and atrial fibrillation.
SO  - Japanese Circulation Journal. 60(1):43-9, 1996 Jan.
AS  - Jpn Circ J. 60(1):43-9, 1996 Jan.
NJ  - Japanese circulation journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - kgn, 7806868
SB  - Index Medicus
CP  - JAPAN
MH  - *Adrenal Glands/pp [Physiopathology]
MH  - *Atrial Fibrillation/et [Etiology]
MH  - Epinephrine/bl [Blood]
MH  - *Exercise Test
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Norepinephrine/bl [Blood]
MH  - *Sympathetic Nervous System/pp [Physiopathology]
MH  - Wolff-Parkinson-White Syndrome/co [Complications]
MH  - *Wolff-Parkinson-White Syndrome/pp [Physiopathology]
AB  - It is believed that reciprocating tachycardia and accessory pathways play important roles in atrial fibrillation (AF) in patients with Wolff-Parkinson-White (WPW) syndrome. However, the mechanism by which AF occurs is not yet fully understood. This study was performed to evaluate the contribution of sympathoadrenal activity to the onset of AF in patients with WPW syndrome. Symptom-limited treadmill exercise testing was performed and plasma norepinephrine and epinephrine concentrations were measured simultaneously in 27 patients with WPW syndrome and 20 control subjects. In 13 patients with WPW syndrome and AF, plasma norepinephrine and epinephrine concentrations increased to 3.69 +/- 2.44 and 0.76 +/- 0.69 ng/ml at maximum exercise, respectively. These values were significantly higher (p < 0.001) than those in control subjects and in patients without AF. Pretreatment with 0.2 mg/kg of propranolol significantly reduced the incidence of exercise-induced atrial premature complexes (chi 2 = 7.33, p < 0.05). With oral beta-blockade for an average of 22.8 months, the incidence of AF decreased significantly from 1.77 +/- 0.53/patient per year to 0.33 +/- 0.57/patient per year (p < 0.001). Augmented sympathoadrenal activity in patients with WPW syndrome may contribute to AF.
RN  - X4W3ENH1CV (Norepinephrine)
RN  - YKH834O4BH (Epinephrine)
IS  - 0047-1828
IL  - 0047-1828
PT  - Journal Article
LG  - English
DP  - 1996 Jan
DC  - 19960719
YR  - 1996
ED  - 19960719
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=8648883

<810. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8642803
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Scemama M
AU  - Fevrier B
AU  - Beucler I
AU  - Dairou F
FA  - Scemama, M
FA  - Fevrier, B
FA  - Beucler, I
FA  - Dairou, F
IN  - Scemama,M. Institut de Recherches Internationales Servier, Courbevoie, France.
TI  - Lipid profile and antihypertensive efficacy in hyperlipidemic hypertensive patients: comparison of rilmenidine and captopril.
SO  - Journal of Cardiovascular Pharmacology. 26 Suppl 2:S34-9, 1995.
AS  - J Cardiovasc Pharmacol. 26 Suppl 2:S34-9, 1995.
NJ  - Journal of cardiovascular pharmacology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 7902492, k78
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Adrenergic alpha-Agonists/tu [Therapeutic Use]
MH  - Adult
MH  - Aged
MH  - *Angiotensin-Converting Enzyme Inhibitors/tu [Therapeutic Use]
MH  - *Antihypertensive Agents/tu [Therapeutic Use]
MH  - *Captopril/tu [Therapeutic Use]
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - *Hyperlipoproteinemia Type II/bl [Blood]
MH  - Hyperlipoproteinemia Type II/co [Complications]
MH  - *Hyperlipoproteinemia Type II/dt [Drug Therapy]
MH  - *Hypertension/bl [Blood]
MH  - Hypertension/co [Complications]
MH  - *Hypertension/dt [Drug Therapy]
MH  - *Lipids/bl [Blood]
MH  - Male
MH  - Middle Aged
MH  - *Oxazoles/tu [Therapeutic Use]
AB  - In hypertensive patients with lipid abnormalities, an ideal antihypertensive agent would control blood pressure without interfering with lipid metabolism. The aim of the present study was to assess whether in addition to angiotensin-converting enzyme inhibitors, calcium antagonists, and alpha 1-antagonists, rilmenidine (RIL), the first antihypertensive drug that is selective to imidazoline receptors, fulfills these requirements. To assess the effects of RIL (daily doses of 1 mg o.d. or b.i.d.) in comparison to captopril (CAP) (doses of 25 or 50 mg b.i.d.), an 8-week, double-blind, randomized, parallel-group study was carried out. Fifty-one patients (mean age: 56.3 +/- 1.5 years) with mild-to-moderate hypertension (supine systolic/diastolic blood pressure, 165.1 +/- 2.0/99.1 +/- 0.6 mm Hg) and type 2a or 2b hyperlipidemia (low-density lipoprotein (LDL) cholesterol: 5.38 +/- 0.16 mmol/L) were included in the study, and they were followed by their general practitioner at 4-week intervals. Twenty-six patients received RIL, and 25 received CAP. The permanence of hypercholesterolemia was checked twice before inclusion into the study, at 3-week intervals, for patients who had already been on a hypocholesterolemic diet for 6 weeks. Plasma lipid evaluation included total, LDL and high-density lipoprotein (HDL) cholesterol, triglycerides, apolipoproteins A1 and B, lipoprotein (a), and, last, a uric acid assay. Assays were centralized at the Lipid Laboratory, CHU Pitie-Salpetriere, Paris. In each group, 1 patient withdrew from the study for personal reasons, and four patients required a dose adjustment (double dose) at the week 4 visit. After 8 weeks of therapy, systolic blood pressure decreased significantly in both groups, with no statistically significant difference between groups (RIL, 20.5 mm Hg; CAP, 21.3 mm Hg; NS). Diastolic blood pressure also decreased (RIL, 13.9 mm Hg; CAP, 15.1 mm Hg; NS). No difference between groups was observed on the changes of lipid parameters between week 0 and week 8 visits. No severe adverse event occurred other than an asymptomatic atrial fibrillation in a CAP group patient at week 8. This study provides evidence that over a follow-up period of 8 weeks, both RIL and CAP are efficient and well-tolerated drugs in the first-line treatment of hypertensive patients with lipid abnormalities.
RN  - 0 (Adrenergic alpha-Agonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Lipids)
RN  - 0 (Oxazoles)
RN  - 54187-04-1 (rilmenidine)
RN  - 9G64RSX1XD (Captopril)
IS  - 0160-2446
IL  - 0160-2446
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 1995
DC  - 19960712
YR  - 1995
ED  - 19960712
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=8642803

<811. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8643915
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Novotny V
AU  - Brandejsky P
AU  - BarackovaM
AU  - Boudova L
AU  - Vilikus Z
AU  - Streda A
AU  - Novotny A
FA  - Novotny, V
FA  - Brandejsky, P
FA  - BarackovaM
FA  - Boudova, L
FA  - Vilikus, Z
FA  - Streda, A
FA  - Novotny, A
IN  - Novotny,V. Institute of Sports Medicine, 1st Medical Faculty, Charles University, Prague, Czech Republic.
TI  - Medical and anthropological study of a world and Olympic champion, long-distance runner, 35 years after the end his racing career.
SO  - Sbornik Lekarsky. 95(2):139-55, 1994.
AS  - Sb Lek. 95(2):139-55, 1994.
NJ  - Sbornik lekarsky
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - uaw, 0025770
SB  - Index Medicus
CP  - CZECH REPUBLIC
MH  - Aged
MH  - *Aging
MH  - *Anthropometry
MH  - Blood Chemical Analysis
MH  - Exercise Test
MH  - *Health Status
MH  - Hemodynamics
MH  - Humans
MH  - Male
MH  - Osteoporosis/di [Diagnosis]
MH  - Respiratory Mechanics
MH  - *Running
AB  - E.Z. former world champion and holder of several gold and silver medals from Olympic Games as long-distance runner, underwent at the age of 71 comprehensive investigations. In 1993 following methods were used to establish E.Z. body build and health: Family, personal and sports history, anthropometry, somatotype, body composition posture values, sports medicine examination, ECG at rest, X-rays of the lung and heart, echocardiography at rest, systolic time intervals at rest, spirography at rest, hematology, biochemistry, X-rays of bones, exercise ECG changes and spiroergometry. Today, a typical feature of E.Z.'s bodybuild is a great amount of body fats, flabby musculature, faulty posture, restricted mobility of the spinal column and surprisingly good foot arches. The clinical findings are appropriate for his age, on his ECG at rest are signs of subendocardial ischemia above the left ventricle, atrial fibrillation and ventricular extrasystoles (Lown 1 a-b). Exercise ECG resulted in a deepening of the ischaemic changes already at a working load of 50 W. Hematology revealed normochromic macrocyt anaemia, biochemistry a borderline mineralogram, hyperuricaemia, higher S-GMT and HDL-C, T-C at the limit of normal values. X-rays of the bones were remarkable in two findings of that age. The pelvis, lumbar spine and knee joints were free of the usual pathological findings (osteoarthrosis), but presented with an exceptionally advanced osteoporosis.
IS  - 0036-5327
IL  - 0036-5327
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 1994
DC  - 19960712
YR  - 1994
ED  - 19960712
RD  - 20091111
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=8643915

<812. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8607429
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Cohen-Solal A
FA  - Cohen-Solal, A
TI  - Effect of atrial fibrillation on exercise capacity in mitral stenosis.
CM  - Comment on: Am J Cardiol. 1995 Aug 1;76(4):282-6; PMID: 7618625
SO  - American Journal of Cardiology. 77(4):328-9, 1996 Feb 1.
AS  - Am J Cardiol. 77(4):328-9, 1996 Feb 1.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Atrial Fibrillation/co [Complications]
MH  - *Exercise Tolerance
MH  - Humans
MH  - *Mitral Valve Stenosis/co [Complications]
IS  - 0002-9149
IL  - 0002-9149
PT  - Comment
PT  - Letter
LG  - English
DP  - 1996 Feb 1
DC  - 19960521
YR  - 1996
ED  - 19960521
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=8607429

<813. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8603565
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Futrell N
AU  - Millikan CH
FA  - Futrell, N
FA  - Millikan, C H
IN  - Futrell,N. Division of Neurology, Stroke Unit, Medical College of Ohio, Toledo, USA.
TI  - Stroke is an emergency. [Review] [198 refs]
SO  - Disease-A-Month. 42(4):199-264, 1996 Apr.
AS  - Dis Mon. 42(4):199-264, 1996 Apr.
NJ  - Disease-a-month : DM
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - eav, 0370657
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - Cerebrovascular Disorders/et [Etiology]
MH  - Cerebrovascular Disorders/pp [Physiopathology]
MH  - Cerebrovascular Disorders/pc [Prevention & Control]
MH  - *Cerebrovascular Disorders/th [Therapy]
MH  - Emergencies
MH  - Humans
MH  - Risk Factors
AB  - Stroke is an emergency. Ischemic stroke is similar to myocardial infarction in that the pathogenesis is loss of blood supply to the tissue, which can result in irreversible damage if blood flow is not restored quickly. Public education is needed to emphasize the warning signs of stroke. Patients should seek medical help immediately, using emergency transport systems. Therapy geared toward minimizing the damage from an acute stroke should be started without delay in the emergency room. This includes measures to protect brain tissue, support perfusion pressure, and minimize cerebral edema. Strategies for improving recovery should also begin immediately. All major medical centers need stroke teams and stroke units. Stroke prevention should be given high priority as a public health strategy. Risk factor management should be part of general health care and should begin in childhood, with emphasis on nutrition, exercise, weight control, and avoidance of tobacco. Health screening and early treatment of hypertension and hypercholesterolemia has decreased the incidence of stroke and heart disease, but these efforts need to be expanded to reach all segments of the population. Basic research has opened the door to new therapies aimed at re-establishing blood flow and limiting tissue damage. Clinical trials have already led to changes in stroke prevention, including studies of carotid endarterectomy and ticlopidine and warfarin therapy (for patients with atrial fibrillation). Trials in progress are testing the usefulness of ancrod, neuroprotective agents, antioxidant agents, anti-inflammatory agents, low-molecular-weight heparin, thrombolytic drugs, and angioplasty. Any delay starting therapy after an acute stroke will result in progressive, irreversible loss of brain tissue. Clinicians should remember that for a stroke patient, time is brain tissue. [References: 198]
RN  - 0 (Anticoagulants)
IS  - 0011-5029
IL  - 0011-5029
PT  - Journal Article
PT  - Review
LG  - English
DP  - 1996 Apr
DC  - 19960515
YR  - 1996
ED  - 19960515
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=8603565

<814. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8586479
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - van den Berg MP
AU  - Crijns HJ
AU  - Bouwmeester TR
AU  - Smit AJ
AU  - Lie KI
FA  - van den Berg, M P
FA  - Crijns, H J
FA  - Bouwmeester, T R
FA  - Smit, A J
FA  - Lie, K I
IN  - van den Berg,M P. Department of Cardiology, Thoraxcenter, University Hospital Groningen, The Netherlands.
TI  - Cardiac asystole post-exercise: a report of two cases.
SO  - International Journal of Cardiology. 51(3):296-300, 1995 Oct.
AS  - Int J Cardiol. 51(3):296-300, 1995 Oct.
NJ  - International journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - gqw, 8200291
SB  - Index Medicus
CP  - IRELAND
MH  - Adult
MH  - Arrhythmia, Sinus/et [Etiology]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Bradycardia/et [Etiology]
MH  - Electrocardiography, Ambulatory
MH  - *Heart Arrest/et [Etiology]
MH  - Heart Arrest/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - *Physical Exertion/ph [Physiology]
MH  - Reproducibility of Results
MH  - Syncope/et [Etiology]
MH  - Syncope/pp [Physiopathology]
MH  - Vagus Nerve/pp [Physiopathology]
MH  - Vasomotor System/pp [Physiopathology]
AB  - Two patients are described with reproducible cardiac asystole post-exercise. No structural heart disease was demonstrable. At autonomic function testing no abnormal responses were noted. Also, head-up tilt tests were normal. However, electrophysiologic testing and heart rate variability during 24-h Holter monitoring were indicative of a high vagal tone in both patients. The findings suggest that post-exertional asystole may not be due solely to a vasovagal mechanism; excessive rebound vagotonia per se may also play a role.
IS  - 0167-5273
IL  - 0167-5273
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 1995 Oct
DC  - 19960325
YR  - 1995
ED  - 19960325
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=8586479

<815. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7586324
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kannel WB
FA  - Kannel, W B
IN  - Kannel,W B. Department of Medicine, Boston (Mass) University School of Medicine/Framingham Heart Study 02118, USA.
TI  - Clinical misconceptions dispelled by epidemiological research. [Review] [108 refs]
SO  - Circulation. 92(11):3350-60, 1995 Dec 1.
AS  - Circulation. 92(11):3350-60, 1995 Dec 1.
NJ  - Circulation
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Cardiovascular Diseases/bl [Blood]
MH  - Cardiovascular Diseases/ep [Epidemiology]
MH  - Cardiovascular Diseases/pc [Prevention & Control]
MH  - *Cardiovascular Diseases
MH  - Epidemiologic Methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Factors
AB  - The epidemiological approach to investigation of cardiovascular disease was innovated in 1948 by Ancel Keys' Seven Countries Study and T.R. Dawber's Framingham Heart Study. Conducted in representative samples of the general population, these investigations provided an undistorted perception of the clinical spectrum of cardiovascular disease, its incidence and prognosis, the lifestyles and personal attributes that predispose to cardiovascular disease, and clues to pathogenesis. The many insights gained corrected numerous widely held misconceptions derived from clinical studies. It was learned, for example, that the adverse consequences of hypertension do not derive chiefly from the diastolic pressure, left ventricular hypertrophy was not an incidental compensatory phenomenon, and small amounts of proteinuria were more than orthostatic trivia. Exercise was considered dangerous for cardiovascular disease candidates; smoking, cholesterol, and a fatty diet were regarded as questionable promoters of atherosclerosis. The entities of sudden death and unrecognized myocardial infarction were not widely appreciated as prominent features of coronary disease, and the disabling and lethal nature of cardiac failure and atrial fibrillation was underestimated. It took epidemiological research to coin the term "risk factor" and dispel the notion that cardiovascular disease must have a single origin. Epidemiological investigation provided health professionals with multifactorial risk profiles to more efficiently target candidates for cardiovascular disease for preventive measures. Clinicians now look to epidemiological research to provide definitive information about possible predisposing factors for cardiovascular disease and preventive measures that are justified. As a result, clinicians are less inclined to regard usual or average values as acceptable and are more inclined to regard optimal values as "normal." Cardiovascular events are coming to be regarded as a medical failure rather than the first indication of treatment. [References: 108]
IS  - 0009-7322
IL  - 0009-7322
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
NO  - N01-HV-52971 (United States NHLBI NIH HHS)
NO  - N01-HV-92922 (United States NHLBI NIH HHS)
LG  - English
DP  - 1995 Dec 1
DC  - 19951228
YR  - 1995
ED  - 19951228
RD  - 20071114
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=7586324

<816. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7587418
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kolling K
AU  - Lehmann G
AU  - Dennig K
AU  - Rudolph W
FA  - Kolling, K
FA  - Lehmann, G
FA  - Dennig, K
FA  - Rudolph, W
IN  - Kolling,K. German Heart Centre, Department of Cardiology, Munich, Federal Republic of Germany.
TI  - Acute alterations of oxygen uptake and symptom-limited exercise time in patients with mitral stenosis after balloon valvuloplasty.
SO  - Chest. 108(5):1206-13, 1995 Nov.
AS  - Chest. 108(5):1206-13, 1995 Nov.
NJ  - Chest
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0231335, d1c
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - *Catheterization
MH  - Exercise Test
MH  - Female
MH  - Hemodynamics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mitral Valve Stenosis/pp [Physiopathology]
MH  - Mitral Valve Stenosis/th [Therapy]
MH  - *Oxygen Consumption
MH  - Respiratory Dead Space
MH  - Tidal Volume
MH  - Treatment Outcome
AB  - STUDY OBJECTIVES: To determine the acute influence of improvement in orifice area in mitral stenosis by percutaneous transluminal valvuloplasty (PTVP) on cardiopulmonary exercise capacity, treadmill walking time (TWT), oxygen uptake parameters at maximum exercise as well as at highest comparable workloads and parameters of breathing work were assessed pre- and post-PTVP.
AB  - PATIENTS AND INTERVENTIONS: PTVP was carried out in 16 patients who had moderately severe mitral stenosis, bringing about an average increase in mitral valve orifice area from 1.0 +/- 0.1 cm2 to 2.2 +/- 0.5 cm2 (p < 0.0005). Based on standardized conditions, the patients (six in functional class A, five in class B, and five in class C according to Weber's classification) underwent symptom-limited treadmill cardiopulmonary exercise testing before as well as 2 days after PTVP. In addition, subgroup analysis (eight patients in sinus rhythm, eight patients in atrial fibrillation) was performed to determine a potential influence of the underlying cardiac rhythm on cardiopulmonary exercise parameters. To rule out a PTVP-independent training effect, a control group of ten patients with mitral stenosis underwent the same kind of cardiopulmonary exercise testing on 2 consecutive days.
AB  - MEASUREMENTS AND RESULTS: After-PTVP, TWT augmented by 19% (p < 0.0005) in all patients. Maximum oxygen uptake in percent of predicted maximal values at peak exercise and at anaerobic threshold was enhanced by 10% (p < 0.005). Ventilation at highest comparable workload was diminished by 10% (p < 0.025), whereas oxygen uptake and oxygen pulse at highest comparable workload did not differ, reflecting both unaltered cardiac output at comparable workloads and a more economic ventilation, respectively. Furthermore, PTVP-mediated alterations of TWT, but not of oxygen uptake at peak exercise were more pronounced in patients in sinus rhythm than in those in atrial fibrillation, reflecting more effective economization of cardiac work and ventilation in the former subgroup. Except for a statistically significant increase of TWT of 5%, no clinically relevant differences between both exercise tests were found with respect to oxygen uptake in the control group.
AB  - CONCLUSIONS: Impaired cardiopulmonary fitness in patients with moderately severe mitral stenosis is improved substantially by PTVP immediately after the intervention, mainly the result of acute reduction of pulmonary congestion and subsequent decrease in dead space to tidal volume ratio. Adherence to standardized conditions is considered crucial for comparability of cardiopulmonary data.
IS  - 0012-3692
IL  - 0012-3692
PT  - Journal Article
LG  - English
DP  - 1995 Nov
DC  - 19951220
YR  - 1995
ED  - 19951220
RD  - 20121115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=7587418

<817. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7479204
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Teague AC
AU  - Garnett WR
AU  - Briggs GC
AU  - Stanley HR
FA  - Teague, A C
FA  - Garnett, W R
FA  - Briggs, G C
FA  - Stanley, H R
IN  - Teague,A C. Department of Pharmacy and Pharmaceutics, Medical College of Virginia/Virginia Commonwealth University, USA.
TI  - The effect of age and everyday exercise on steady-state plasma digoxin concentrations.
SO  - Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy. 15(4):502-8, 1995 Jul-Aug.
AS  - Pharmacotherapy. 15(4):502-8, 1995 Jul-Aug.
NJ  - Pharmacotherapy
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - par, 8111305
SB  - Index Medicus
CP  - UNITED STATES
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - *Aging/bl [Blood]
MH  - *Anti-Arrhythmia Agents/bl [Blood]
MH  - *Digoxin/bl [Blood]
MH  - *Exercise/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Rest/ph [Physiology]
MH  - Walking/ph [Physiology]
AB  - Age-related physiologic changes may significantly alter the disposition and pharmacologic characteristics of many drugs. The elderly are the most frequent users of digoxin because of increased prevalence of atrial fibrillation and congestive heart failure. This study was conducted to confirm the decrease in digoxin concentrations during exercise, to determine if age is a factor in this decrease, and to explore the difference between chronologic age and physiologic age. Eighteen men age 50-85 years were treated with digoxin for more than 1 month before enrolling and had serum digoxin concentrations of 0.4-2.0 micrograms/L. They were evaluated during a 3-hour period in the morning (A.M. dose withheld). Blood samples were obtained every 10 minutes during sequential 60-minute periods of rest (phase I), walking (phase II), and rest (phase III). There were no significant differences in mean concentration between phases II and I (p < 0.76), phases III and phase I (p < 0.70), or phases II and III (p < 0.37). The effect of age was positively correlated with the mean concentration of phase II but was not statistically significant (p < 0.62). Statistically significant correlations were seen only between the exercise phase and serum albumin and Mini-Mental Status Examination scores. We conclude that exercise has minimal, if any, clinically relevant effects on plasma digoxin concentrations. Increasing chronologic age has no influence on a decrease in the concentrations with exercise; a younger physiologic age may play a role.
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 73K4184T59 (Digoxin)
IS  - 0277-0008
IL  - 0277-0008
PT  - Journal Article
LG  - English
DP  - 1995 Jul-Aug
DC  - 19951218
YR  - 1995
ED  - 19951218
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=7479204

<818. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7566006
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Anonymous
TI  - Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 34-1995. A 77-year old woman with 17 years of gastrointestinal bleeding.
SO  - New England Journal of Medicine. 333(19):1273-9, 1995 Nov 9.
AS  - N Engl J Med. 333(19):1273-9, 1995 Nov 9.
NJ  - The New England journal of medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0255562, now
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Arteriovenous Malformations/co [Complications]
MH  - *Arteriovenous Malformations/di [Diagnosis]
MH  - Atrial Fibrillation/co [Complications]
MH  - Cholecystitis/co [Complications]
MH  - *Cholecystitis/di [Diagnosis]
MH  - Cholelithiasis/co [Complications]
MH  - *Cholelithiasis/di [Diagnosis]
MH  - Chronic Disease
MH  - Diagnosis, Differential
MH  - Female
MH  - Gastrointestinal Hemorrhage/co [Complications]
MH  - *Gastrointestinal Hemorrhage/et [Etiology]
MH  - Hernia, Ventral/di [Diagnosis]
MH  - Humans
MH  - *Intestine, Small/bs [Blood Supply]
MH  - Ulcer
IS  - 0028-4793
IL  - 0028-4793
PT  - Case Reports
PT  - Clinical Conference
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1995 Nov 9
DC  - 19951109
YR  - 1995
ED  - 19951109
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=7566006

<819. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7620642
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Li HG
AU  - Yee R
AU  - Klein GJ
FA  - Li, H G
FA  - Yee, R
FA  - Klein, G J
IN  - Li,H G. Department of Medicine, University of Western Ontario, London, Canada.
TI  - Effect of isoproterenol on accessory pathways without overt retrograde conduction.
SO  - Journal of Cardiovascular Electrophysiology. 6(3):170-3, 1995 Mar.
AS  - J Cardiovasc Electrophysiol. 6(3):170-3, 1995 Mar.
NJ  - Journal of cardiovascular electrophysiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - by4, 9010756
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Accessory Nerve/de [Drug Effects]
MH  - Accessory Nerve/ph [Physiology]
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Atrioventricular Node/ph [Physiology]
MH  - Bundle of His/ph [Physiology]
MH  - Electrocardiography
MH  - Exercise/ph [Physiology]
MH  - Female
MH  - Humans
MH  - *Isoproterenol/pd [Pharmacology]
MH  - Male
MH  - Middle Aged
MH  - Neural Conduction/de [Drug Effects]
MH  - *Neural Conduction/ph [Physiology]
MH  - *Retrograde Degeneration/ph [Physiology]
MH  - Tachycardia/pp [Physiopathology]
MH  - Tachycardia, Atrioventricular Nodal Reentry/pp [Physiopathology]
MH  - Tachycardia, Ventricular/pp [Physiopathology]
AB  - INTRODUCTION: Absence of overt retrograde accessory pathway conduction may be related to low resting sympathetic tone in patients with apparent unidirectional anterogradely conducting accessory pathways (UACAP).
AB  - METHODS AND RESULTS: To test this hypothesis, we studied the effect of isoproterenol on accessory pathway function and tachycardia induction in 18 patients (12 men and 6 women, ages 34 +/- 16 years [mean +/- SD]) with UACAP. After baseline study in the drug-free state, electrphysiologic testing was repeated during infusion of isoproterenol (0.5 to 1.5 micrograms/min, titrated to increase heart rate by 20%). Isoproterenol shortened the anterograde effective refractory period (398 +/- 117 vs 305 +/- 63 msec; P < 0.01; basic drive cycle length 600 msec) of the accessory pathway. However, retrograde accessory pathway conduction and atrioventricular reentrant tachycardia were exposed in only 3 (17%) patients by isoproterenol infusion. All 3 patients with retrograde accessory pathway revealed after isoproterenol had clinically documented tachycardia (supraventricular tachycardia in 2, atrial fibrillation in 1) during exercise, while none of the patients with persistent absence of retrograde accessory pathway conduction had this symptom.
AB  - CONCLUSIONS: We conclude that absence of overt retrograde conduction over accessory pathways may be related to low resting sympathetic tone in some individuals. Restoration of retrograde conduction with isoproterenol is unusual and most likely to be observed in patients with clinically documented paroxysmal supraventricular tachycardia related to exercise.
RN  - L628TT009W (Isoproterenol)
IS  - 1045-3873
IL  - 1045-3873
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1995 Mar
DC  - 19950831
YR  - 1995
ED  - 19950831
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=7620642

<820. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7621644
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lindqvist A
FA  - Lindqvist, A
IN  - Lindqvist,A. Department of Clinical Physiology, Lund University Hospital, Sweden.
TI  - Beat-to-beat agreement of non-invasive finger artery and invasive radial artery blood pressure in hypertensive patients taking cardiovascular medication.
SO  - Clinical Physiology. 15(3):219-29, 1995 May.
AS  - Clin Physiol. 15(3):219-29, 1995 May.
NJ  - Clinical physiology (Oxford, England)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - dkg, 8309768
SB  - Index Medicus
CP  - ENGLAND
MH  - Adult
MH  - Aged
MH  - *Antihypertensive Agents/tu [Therapeutic Use]
MH  - *Blood Pressure/ph [Physiology]
MH  - *Blood Pressure Determination/mt [Methods]
MH  - Exercise/ph [Physiology]
MH  - Female
MH  - *Fingers/bs [Blood Supply]
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Hypertension/dt [Drug Therapy]
MH  - *Hypertension/pp [Physiopathology]
MH  - Male
MH  - Middle Aged
MH  - *Radial Artery/ph [Physiology]
MH  - Regional Blood Flow/de [Drug Effects]
MH  - Regional Blood Flow/ph [Physiology]
AB  - The aim of this study was to investigate and quantify the agreement between simultaneous and ipsilateral non-invasive finger artery blood pressure (Finapres) and intra-arterial radial blood pressure among 13 volunteer hypertensive patients, aged 36-71 years and taking cardiovascular medication, during steady-state fluctuation of arterial blood pressure and during an increase in blood pressure induced by static exercise. Eight patients were being treated with beta-blocking agents, eight with calcium antagonists, four with angiotensin-converting enzyme inhibitors, four with diuretics and one with prazosin in combination therapy. Their auscultatory brachial artery blood pressures ranged in systole from 142 to 206 mmHg and in diastole from 88 to 120 mmHg during the treatment. The mean systolic finger artery blood pressure deviated by -14 +/- 5 mmHg (P = 0.02, mean value +/- SEM) and the diastolic finger artery blood pressure deviated by 0.6 +/- 3 mmHg (P = 0.70) from the corresponding radial artery pressure. The maximal beat-to-beat difference between systolic and diastolic finger and radial artery pressure, respectively, showed that a range of less than 10 mmHg in the steady state after individual adjustment for bias. In general, neither systolic nor diastolic differences between the methods exceeded the limits of +/- 10 mmHg, and the bias did not significantly increase (P > or = 0.12) during a 10-mmHg increase in arterial blood pressure caused by static exercise. Among three subjects, an increase in bias and poorer agreement was associated with atrial fibrillation and steplike changes in the Finapres output after autocalibration. The results support usage of the Finapres technique to measure beat-to-beat changes of peripheral arterial blood pressure in hypertensive patients taking cardiovascular medication, with a feasible agreement with beat-to-beat radial artery blood pressure.
RN  - 0 (Antihypertensive Agents)
IS  - 0144-5979
IL  - 0144-5979
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1995 May
DC  - 19950828
YR  - 1995
ED  - 19950828
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=7621644

<821. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7618625
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Triposkiadis F
AU  - Trikas A
AU  - Tentolouris K
AU  - Pitsavos C
AU  - Chlapoutakis E
AU  - Kyriakidis M
AU  - Gialafos J
AU  - Toutouzas P
FA  - Triposkiadis, F
FA  - Trikas, A
FA  - Tentolouris, K
FA  - Pitsavos, C
FA  - Chlapoutakis, E
FA  - Kyriakidis, M
FA  - Gialafos, J
FA  - Toutouzas, P
IN  - Triposkiadis,F. Department of Cardiology, University of Athens Medical School, Greece.
TI  - Effect of atrial fibrillation on exercise capacity in mitral stenosis.
CM  - Comment in: Am J Cardiol. 1996 Feb 1;77(4):328-9; PMID: 8607429
SO  - American Journal of Cardiology. 76(4):282-6, 1995 Aug 1.
AS  - Am J Cardiol. 76(4):282-6, 1995 Aug 1.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Atrial Fibrillation/co [Complications]
MH  - Case-Control Studies
MH  - Echocardiography, Doppler
MH  - *Exercise Tolerance
MH  - Female
MH  - Heart Valve Prosthesis
MH  - Hemodynamics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve
MH  - Mitral Valve Stenosis/co [Complications]
MH  - *Mitral Valve Stenosis/pp [Physiopathology]
MH  - Mitral Valve Stenosis/su [Surgery]
MH  - Oxygen Consumption
MH  - Postoperative Period
AB  - To determine the preoperative and postoperative effect of atrial fibrillation (AF) on exercise capacity in mitral stenosis, 12 digitalized patients in AF (7 women and 5 men, age 52 +/- 6.1 years) and 10 in sinus rhythm (5 women and 5 men, age 46 +/- 5 years) underwent maximal cardiopulmonary exercise testing according to Weber's protocol and Doppler echocardiographic examination before and at 3 and 6 months after mitral valve replacement. The ratio of right ventricular acceleration to ejection time was used as an estimate of mean pulmonary artery pressure. Preoperative exercise duration (6.8 +/- 1 vs 8 +/- 2 minutes), peak oxygen consumption (9.7 +/- 3 vs 12.3 +/- 3 ml/kg/min), and right ventricular acceleration to ejection time ratio (0.34 +/- 0.07 vs 0.34 +/- 0.08) were not significantly different between patients with AF and those in sinus rhythm. Postoperative improvement in these parameters was lower in patients with AF than in those in sinus rhythm: exercise duration at 3 months, 7.5 +/- 2 vs 11.9 +/- 2 minutes (p < 0.001); at 6 months, 9 +/- 2 vs 12 +/- 2 minutes (p < 0.001); peak oxygen consumption at 3 months, 10.8 +/- 3 vs 17.5 +/- 3 ml/kg/min (p < 0.001); and at 6 months, 11.9 +/- 3 vs 17.8 +/- 3 ml/kg/min (p < 0.001); right ventricular acceleration to ejection time ratio at 3 months, 0.35 +/- 0.08 vs 0.42 +/- 0.05 (p < 0.05); and at 6 months, 0.38 +/- 0.05 vs 0.44 +/- 0.05 (p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
IS  - 0002-9149
IL  - 0002-9149
PT  - Journal Article
LG  - English
DP  - 1995 Aug 1
DC  - 19950824
YR  - 1995
ED  - 19950824
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=7618625

<822. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7612505
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Niioka T
AU  - Conway MA
AU  - Allis JL
AU  - Bolas NM
AU  - Radda GK
FA  - Niioka, T
FA  - Conway, M A
FA  - Allis, J L
FA  - Bolas, N M
FA  - Radda, G K
IN  - Niioka,T. Department of Environmental Medicine and Informatics, Graduate School of Environmental Earth Science, Sapporo, Japan.
TI  - Electrocardiogram monitoring at rest and during exercise in 31P magnetic resonance spectroscopy studies of the human heart at 1.9 tesla.
SO  - Frontiers of Medical & Biological Engineering. 6(4):309-17, 1995.
AS  - Front Med Biol Eng. 6(4):309-17, 1995.
NJ  - Frontiers of medical and biological engineering : the international journal of the Japan Society of Medical Electronics and Biological Engineering
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - ayk, 9011464
SB  - Index Medicus
CP  - NETHERLANDS
MH  - Atrial Fibrillation
MH  - Electrocardiography/is [Instrumentation]
MH  - Electrocardiography/mt [Methods]
MH  - *Electrocardiography
MH  - Electrodes
MH  - *Exercise/ph [Physiology]
MH  - *Heart/ah [Anatomy & Histology]
MH  - Humans
MH  - *Magnetic Resonance Spectroscopy/mt [Methods]
MH  - Male
MH  - *Monitoring, Physiologic
MH  - Phosphorus Isotopes
MH  - *Rest/ph [Physiology]
AB  - An electrocardiogram (ECG) monitoring system has been developed and evaluated in normal volunteers (n = 7) and patients with various cardiac diseases (n = 24) in a 1.9 tesla magnet during magnetic resonance spectroscopy studies. To minimize an ECG signal path, and thus to reduce motion-related artifacts on the ECG during a dynamic exercise test, one coaxial cable was used to obtain the ECG signal from two electrodes placed parallel to the longitudinal body axis on the left side of the chest. A fiber optic link and an inductor-capacitor low-pass filter were used to remove extraneous radiofrequency (RF) noise and RF pulse artifacts respectively, and the examination bed was solidly supported on the base of the magnet. The ECG monitoring system provided a useful means for continuous recording of the ECG independently of the R-R interval in the high magnetic field, and permitted reliable monitoring of the QRS complex of the subject at rest and during exercise.
RN  - 0 (Phosphorus Isotopes)
IS  - 0921-3775
IL  - 0921-3775
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
NO  - HL18708 (United States NHLBI NIH HHS)
LG  - English
DP  - 1995
DC  - 19950823
YR  - 1995
ED  - 19950823
RD  - 20071114
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=7612505

<823. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7614511
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Staffeld CG
AU  - Pastan SO
FA  - Staffeld, C G
FA  - Pastan, S O
IN  - Staffeld,C G. Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
TI  - Cardiac disease in patients with end-stage renal disease. [Review] [99 refs]
SO  - Cardiology Clinics. 13(2):209-23, 1995 May.
AS  - Cardiol Clin. 13(2):209-23, 1995 May.
NJ  - Cardiology clinics
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - cok, 8300331
SB  - Index Medicus
CP  - UNITED STATES
MH  - Cardiovascular Agents/tu [Therapeutic Use]
MH  - *Heart Diseases/co [Complications]
MH  - Humans
MH  - Hypertension, Renal/co [Complications]
MH  - Hypotension/et [Etiology]
MH  - *Kidney Failure, Chronic/co [Complications]
MH  - Renal Dialysis/ae [Adverse Effects]
MH  - Risk Factors
AB  - Cardiovascular diseases remain the leading cause of death in ESRF patients. Coronary risk factors such as hypertension and lipid abnormalities are prevalent in the dialysis population and may be difficult to control. Special factors contributing to the imbalance between myocardial oxygen supply and demand include anemia, arteriovenous fistula, and the hemodialysis procedure itself. LVH and left ventricular dilation frequently result in symptomatic CHF. Atrial and ventricular arrhythmias are common; pericarditis may also occur. Control of the extracellular fluid volume through ultrafiltration with dialysis and the dietary avoidance of salt and water is critical to controlling hypertension in the dialysis population. The potential for drug side effects and the altered pharmacokinetics of medications in renal failure patients should be considered when prescribing cardiovascular drugs. [References: 99]
RN  - 0 (Cardiovascular Agents)
IS  - 0733-8651
IL  - 0733-8651
PT  - Journal Article
PT  - Review
LG  - English
DP  - 1995 May
DC  - 19950818
YR  - 1995
ED  - 19950818
RD  - 20051116
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=7614511

<824. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7770362
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lau CP
AU  - Tai YT
AU  - Lee PW
FA  - Lau, C P
FA  - Tai, Y T
FA  - Lee, P W
IN  - Lau,C P. Department of Medicine, University of Hong Kong, Queen Mary Hospital.
TI  - The effects of radiofrequency ablation versus medical therapy on the quality-of-life and exercise capacity in patients with accessory pathway-mediated supraventricular tachycardia: a treatment comparison study.
SO  - Pacing & Clinical Electrophysiology. 18(3 Pt 1):424-32, 1995 Mar.
AS  - Pacing Clin Electrophysiol. 18(3 Pt 1):424-32, 1995 Mar.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - *Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - Cardiac Pacing, Artificial
MH  - *Catheter Ablation
MH  - *Exercise Test
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Quality of Life
MH  - Tachycardia, Supraventricular/pp [Physiopathology]
MH  - *Tachycardia, Supraventricular/th [Therapy]
AB  - This study aims to evaluate the impact of transcatheter radiofrequency ablation on quality-of-life (QOL) and exercise capacity in patients with paroxysmal supraventricular tachycardia (SVT) on stable medical therapy and the extent of symptomatic benefits of this treatment in patients with SVT of different clinical severity. A total of 55 patients with SVT on stable medications for 3 months were randomly selected for either radiofrequency ablation treatment (46 patients) or continuation of medical therapy (medical control group, 9 patients). Severity of SVT was classified based on the frequency and duration of SVT episodes, hemodynamic disturbance, and the presence of preexcited atrial fibrillation during an episode. Treadmill exercise capacity (Bruce protocol) and QOL (questionnaire study and interview) were assessed before and at 3-month intervals for 1 year after the radiofrequency procedure and at 3 months in the medical control group. Thirty-six of 46 patients were successfully ablated in one session, and a QOL measure before and at 3 months after ablation in these patients showed an improvement in total scores for "General Health Questionnaire" (20.3 +/- 6.2 vs 16.9 +/- 5.3, P < 0.01), "Somatic Symptoms Inventory" (73.0 +/- 6.0 vs 76.1 +/- 4.1, P < 0.02), and "Sickness Impact Profile" (12.6 +/- 1.7 vs 4.9 +/- 3.9, P < 0.01). This improvement in QOL was progressive and sustained over a 1-year period. Major arrhythmia limitations, such as apprehension of strenuous activities and long distance travel, were alleviated after a successful procedure. The extent of improvement in QOL was significant for patients considered to have "mild" or "severe" arrhythmia.(ABSTRACT TRUNCATED AT 250 WORDS)
RN  - 0 (Anti-Arrhythmia Agents)
IS  - 0147-8389
IL  - 0147-8389
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1995 Mar
DC  - 19950705
YR  - 1995
ED  - 19950705
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=7770362

<825. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7743684
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wang JA
AU  - Lau CP
AU  - Tai YT
AU  - Wu BZ
FA  - Wang, J A
FA  - Lau, C P
FA  - Tai, Y T
FA  - Wu, B Z
IN  - Wang,J A. Department of Medicine, University of Hong Kong, Queen Mary Hospital.
TI  - Effects of flecainide on exercise hemodynamics and electrocardiography in patients without structural heart disease.
SO  - Clinical Cardiology. 18(3):140-4, 1995 Mar.
AS  - Clin Cardiol. 18(3):140-4, 1995 Mar.
NJ  - Clinical cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - de9, 7903272
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Blood Pressure/de [Drug Effects]
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - *Electrocardiography
MH  - Exercise Test
MH  - *Exercise Tolerance/de [Drug Effects]
MH  - Female
MH  - *Flecainide/pd [Pharmacology]
MH  - Heart Conduction System/de [Drug Effects]
MH  - Heart Rate/de [Drug Effects]
MH  - *Hemodynamics/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Tachycardia, Paroxysmal/pp [Physiopathology]
MH  - *Tachycardia, Supraventricular/pp [Physiopathology]
AB  - Although exercise testing has been advocated to unmask proarrhythmic potentials in patients receiving flecainide acetate, the effects of this drug on exercise parameters in individuals without structural heart disease have not been reported. This study was undertaken to assess the effects of flecainide on hemodynamics and electrocardiographic changes during exercise testing in 24 patients with paroxysmal supraventricular tachyarrhythmias, who had normal cardiac structure and sinus node function. Paired treadmill exercise tests using the Bruce protocol were performed after 1 week of treatment with flecainide (200 mg/day) or placebo in a double-blind, randomized design. Exercise testing was terminated because of either fatigue or dyspnea in all subjects. Although resting heart rate was unaffected, flecainide reduced the exercise heart rate (expressed as a percentage of age-predicted maximum) compared with placebo (84 +/- 12% vs. 92 +/- 9%, p < 0.001). Neither resting and exercise systolic blood pressure nor exercise duration were affected. PR interval shortening with exercise was not affected by flecainide, whereas QRS was prolonged compared with placebo (20 +/- 9% vs. 0 +/- 8%, p < 0.01). Compared with placebo, flecainide significantly shortened QTc (-7 +/- 12% vs. 0 +/- 8%, p < 0.05) and JTc (-34 +/- 11% vs. -21 +/- 11%, p < 0.01) intervals during exercise. During exercise, flecainide produced significant depression in the sinus node automaticity and manifested use-dependent slowing of ventricular conduction and acceleration in ventricular repolarization.
RN  - K94FTS1806 (Flecainide)
IS  - 0160-9289
IL  - 0160-9289
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1995 Mar
DC  - 19950615
YR  - 1995
ED  - 19950615
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=7743684

<826. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7730532
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Sullivan DH
AU  - Walls RC
AU  - Bopp MM
FA  - Sullivan, D H
FA  - Walls, R C
FA  - Bopp, M M
IN  - Sullivan,D H. Geriatric Research Education and Clinical Center, John L McClellan Memorial Veterans Hospital, Little Rock, AR 72205, USA.
TI  - Protein-energy undernutrition and the risk of mortality within one year of hospital discharge: a follow-up study.
SO  - Journal of the American Geriatrics Society. 43(5):507-12, 1995 May.
AS  - J Am Geriatr Soc. 43(5):507-12, 1995 May.
NJ  - Journal of the American Geriatrics Society
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 7503062, h6v
SB  - Index Medicus
CP  - UNITED STATES
MH  - Activities of Daily Living
MH  - Aged
MH  - Aged, 80 and over
MH  - Cohort Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Geriatric Assessment
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mortality
MH  - *Patient Discharge
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - *Protein-Energy Malnutrition
MH  - Risk Factors
AB  - OBJECTIVE: The primary objective of this study was to confirm the results of a previous study that demonstrated a strong independent correlation between the severity of protein-energy undernutrition and the risk of 1-year postdischarge mortality in a population of older rehabilitation patients.
AB  - DESIGN: Prospective survey (cohort study).
AB  - SETTING: The Geriatric Rehabilitation Unit (GRU) of a Veterans Administration hospital.
AB  - PARTICIPANTS: Of 350 randomly selected admissions to the GRU, 322 were discharged alive from the hospital. These 322 patients represented the study population, of whom 99% were male, and 75% were white. The average age of the study patients was 76 years.
AB  - MEASUREMENTS: At admission and again at discharge, each patient completed a comprehensive medical, functional, neuropsychological, socioeconomic, and nutritional assessment. After discharge, each subject was tracked for 1 year.
AB  - MAIN RESULTS: Within the 1-year posthospital discharge follow-up period, 64 study subjects (20%) died. This included 17% of the patients discharged home and 34% of the patients discharged to a nursing home (P < .01). Based on the Cox Proportional Hazards survival model, the variable most strongly associated with mortality was the discharge serum albumin, followed by discharge weight expressed as a percentage of ideal, self-dressing ability, and a discharge diagnosis of cardiac arrhythmia (usually atrial fibrillation). When all four of these variables were included in the analysis, the model was able to differentiate the survivors from those who died by years end with a sensitivity of 69%, a specificity of 69%, and an overall predictive accuracy of 69%. When tested using the data from the previous study, the model differentiated the patients who died from those who had not at a sensitivity of 62%, a specificity of 68%, and an overall predictive accuracy of 64%.
AB  - CONCLUSIONS: Protein-energy undernutrition appears to be a strong independent risk factor for 1-year postdischarge mortality.
IS  - 0002-8614
IL  - 0002-8614
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
LG  - English
DP  - 1995 May
DC  - 19950601
YR  - 1995
ED  - 19950601
RD  - 20080310
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=7730532

<827. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7729026
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Tamai J
AU  - Kosakai Y
AU  - Yoshioka T
AU  - Ohnishi E
AU  - Takaki H
AU  - Okano Y
AU  - Kawashima Y
FA  - Tamai, J
FA  - Kosakai, Y
FA  - Yoshioka, T
FA  - Ohnishi, E
FA  - Takaki, H
FA  - Okano, Y
FA  - Kawashima, Y
IN  - Tamai,J. Department of Medicine, National Cardiovascular Center, Osaka, Japan.
TI  - Delayed improvement in exercise capacity with restoration of sinoatrial node response in patients after combined treatment with surgical repair for organic heart disease and the Maze procedure for atrial fibrillation.
SO  - Circulation. 91(9):2392-9, 1995 May 1.
AS  - Circulation. 91(9):2392-9, 1995 May 1.
NJ  - Circulation
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Combined Modality Therapy
MH  - Exercise
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Sinoatrial Node/pp [Physiopathology]
MH  - Ventricular Function, Left
AB  - BACKGROUND: Although the Maze procedure successfully restores sinus rhythm in patients with heart disease and atrial fibrillation, it is still uncertain whether an addition of the Maze procedure in cardiac surgery is beneficial for exercise performance of the patients after surgery.
AB  - METHODS AND RESULTS: The Maze procedure was performed in 25 patients (age, 37 to 70 years) during valve surgery (18 patients) or closure of atrial septal defect (7 patients). A cardiopulmonary exercise test using ramp incremental protocol (15 W/min) was performed before and 1 month, 6 months, and 1 year after surgery. Sinus conversion was obtained in 23 of 25 patients 1 month after surgery. However, sinoatrial (SA) node response to exercise was attenuated by surgery: Mean heart rate (HR) was 83 +/- 13/min at rest, 94 +/- 13/min at 60 W, and 107 +/- 17/min at peak exercise. Peak oxygen uptake (PVO2) was unchanged at this period (before, 17.6 +/- 4.5 mL.min-1.kg-1; 1 month after, 17.5 +/- 4.2 mL.min-1.kg-1). Thereafter, SA node response was restored 6 months after surgery: Mean HR was 84 +/- 13/min at rest, 104 +/- 16/min at 60 W, and 130 +/- 20/min at peak exercise (P < .01 versus 1 month). PVO2 was also improved at this period (20.7 +/- 4.0 mL.min-1.kg-1, P < .01). The increase in PVO2 from 1 month to 6 months after surgery was correlated with the increase in peak HR (y = 0.73x +/- 3.6, r = .79). There were no further changes in heart rate response or PVO2 from 6 months to 1 year after surgery.
AB  - CONCLUSIONS: Atrial fibrillation was successfully treated by combined treatment with surgical repair for organic heart disease and the Maze procedure. However, SA node response to exercise was attenuated early after surgery. Thus, exercise capacity was improved at the late phase after surgery, which was related to the extent of restoration in SA node response.
IS  - 0009-7322
IL  - 0009-7322
PT  - Journal Article
LG  - English
DP  - 1995 May 1
DC  - 19950601
YR  - 1995
ED  - 19950601
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=7729026

<828. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7728799
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ueshima K
AU  - Myers J
AU  - Ribisl PM
AU  - Morris CK
AU  - Kawaguchi T
AU  - Liu J
AU  - Froelicher VF
FA  - Ueshima, K
FA  - Myers, J
FA  - Ribisl, P M
FA  - Morris, C K
FA  - Kawaguchi, T
FA  - Liu, J
FA  - Froelicher, V F
IN  - Ueshima,K. Cardiology Divisions, Palo Alto, Veterans Affairs Medical Centers, Iwate, CA 94304, USA.
TI  - Exercise capacity and prognosis in patients with chronic atrial fibrillation. [Review] [22 refs]
SO  - Cardiology. 86(2):108-13, 1995.
AS  - Cardiology. 86(2):108-13, 1995.
NJ  - Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - coi, 1266406
SB  - Index Medicus
CP  - SWITZERLAND
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/mo [Mortality]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/us [Ultrasonography]
MH  - Chronic Disease
MH  - Echocardiography
MH  - *Exercise/ph [Physiology]
MH  - Exercise Test
MH  - *Heart Diseases/co [Complications]
MH  - Heart Diseases/us [Ultrasonography]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Regression Analysis
MH  - Survival Analysis
AB  - To evaluate the response of patients with chronic atrial fibrillation (AF) to exercise and to demonstrate if prognosis could be predicted, 200 male patients (64 +/- 1 years) with AF were identified retrospectively who underwent resting echocardiography and symptom-limited treadmill testing. They were classified by underlying disease into three subgroups: hypertension or no underlying disease (LONE; n = 102), ischemic heart disease (IHD; n = 45) and history of congestive heart failure or valvular disease (CHF-VD; n = 53). Maximal exercise capacities for LONE, IHD and CHF-VD were (mean +/- 1 SEM) 8.0 +/- 0.3, 6.4 +/- 0.4 and 6.0 +/- 0.3 metabolic equivalents, respectively (p < 0.01), and resting left ventricular ejection fractions were 61.7 +/- 1.6, 60.1 +/- 2.2 and 49.5 +/- 1.9%, respectively (p < 0.01). Stepwise multiple regression analysis demonstrated that, except for group classification (R2 = 0.13, p < 0.01), no clinical, exercise or morphologic variables could predict exercise capacity. After a mean 39.1-month follow-up (range 1-78), 17 of the 200 had died from cardiovascular causes. The rate of cardiac death using Kaplan-Meier survival analysis was significantly greater in CHF-VD patients (p < 0.01). However, Cox hazard function and Kaplan-Meier survival analysis demonstrated that neither echocardiographic measurements of cardiac size or function at rest, nor exercise or clinical variables were significant predictors of outcome. AF patients with a history of CHF and/or VD demonstrated a reduced exercise tolerance ad a worse prognosis than those without morphologic heart disease or those with IHD.(ABSTRACT TRUNCATED AT 250 WORDS) [References: 22]
IS  - 0008-6312
IL  - 0008-6312
PT  - Journal Article
PT  - Review
LG  - English
DP  - 1995
DC  - 19950601
YR  - 1995
ED  - 19950601
RD  - 20051116
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=7728799

<829. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7715647
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Anonymous
TI  - Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 15-1995. A 70-year old woman with atrial fibrillation and the rapid onset of hemorrhagic manifestations.
SO  - New England Journal of Medicine. 332(20):1363-70, 1995 May 18.
AS  - N Engl J Med. 332(20):1363-70, 1995 May 18.
NJ  - The New England journal of medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0255562, now
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - Cerebral Hemorrhage/et [Etiology]
MH  - *Cerebral Hemorrhage/pa [Pathology]
MH  - Diagnosis, Differential
MH  - Female
MH  - Hemiplegia/et [Etiology]
MH  - Humans
MH  - *Quinidine/ae [Adverse Effects]
MH  - *Thrombocytopenia/ci [Chemically Induced]
MH  - Thrombocytopenia/co [Complications]
RN  - ITX08688JL (Quinidine)
IS  - 0028-4793
IL  - 0028-4793
PT  - Case Reports
PT  - Clinical Conference
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1995 May 18
DC  - 19950518
YR  - 1995
ED  - 19950518
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=7715647

<830. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7697851
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Roos-Hesselink J
AU  - Perlroth MG
AU  - McGhie J
AU  - Spitaels S
FA  - Roos-Hesselink, J
FA  - Perlroth, M G
FA  - McGhie, J
FA  - Spitaels, S
IN  - Roos-Hesselink,J. Division of Cardiology, Erasmus University, Rotterdam, Netherlands.
TI  - Atrial arrhythmias in adults after repair of tetralogy of Fallot. Correlations with clinical, exercise, and echocardiographic findings.
CM  - Comment in: Circulation. 1995 Apr 15;91(8):2118-9; PMID: 7697838
SO  - Circulation. 91(8):2214-9, 1995 Apr 15.
AS  - Circulation. 91(8):2214-9, 1995 Apr 15.
NJ  - Circulation
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Arrhythmias, Cardiac/di [Diagnosis]
MH  - *Arrhythmias, Cardiac/ep [Epidemiology]
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/ep [Epidemiology]
MH  - Atrial Flutter/di [Diagnosis]
MH  - *Atrial Flutter/ep [Epidemiology]
MH  - Echocardiography
MH  - Electrocardiography
MH  - Exercise Test
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Morbidity
MH  - Tachycardia, Supraventricular/di [Diagnosis]
MH  - Tachycardia, Supraventricular/ep [Epidemiology]
MH  - Tetralogy of Fallot/ep [Epidemiology]
MH  - *Tetralogy of Fallot/su [Surgery]
MH  - Time Factors
AB  - BACKGROUND: The long-term success of intracardiac repair of tetralogy of Fallot is hampered by the occurrence of arrhythmias. Numerous studies have stressed the potential role of ventricular arrhythmias. However, the importance of other arrhythmias in the morbidity of these patients appears to be underestimated. Furthermore, most follow-up studies have been limited to children or adolescents, whereas many patients have reached adulthood after earlier repair of tetralogy of Fallot. The aim of the present study was to determine the incidence of atrial fibrillation, atrial flutter, and other supraventricular arrhythmias in adult patients after intracardiac repair for tetralogy of Fallot and their correlation with surgical and clinical findings.
AB  - METHODS AND RESULTS: The study group consisted of 53 consecutive patients referred to the Thoraxcenter adult congenital heart disease clinic. They underwent repair at a mean age of 9.1 years (range, 0.7 to 55 years). The median age at the time of study was 23.2 years (range, 15 to 57 years; mean age, 26.6 years), and the mean duration of follow-up of 17.5 years (range, 1.4 to 32 years) after surgery. Records were reviewed extensively for evidence of arrhythmias. The follow-up study included routine 12-lead ECG, 24-hour continuous ambulatory monitoring, and echocardiography, and 46 patients underwent exercise testing. Sinus node dysfunction was recorded in 19 patients (36%), of whom 4 required a permanent pacemaker. Atrial fibrillation or flutter was found in 12 patients, and other supraventricular tachycardias were found in 6. The former were more frequently of older age at follow-up. Antiarrhythmic therapy and cardioversion were typically directed at control of atrial (and not ventricular) tachyarrhythmias. Ten patients (19%) showed nonsustained ventricular tachycardia; they were older at initial surgery and older at follow-up and had more intracardiac repairs and longer cardiopulmonary bypass times.
AB  - CONCLUSIONS: Despite an emphasis on ventricular ectopy in past series, the main sources of morbidity in adult patients after surgical correction of tetralogy of Fallot emanated from atrial arrhythmias, which were present in one third of the patients.
IS  - 0009-7322
IL  - 0009-7322
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1995 Apr 15
DC  - 19950504
YR  - 1995
ED  - 19950504
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=7697851

<831. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7700833
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Roberts DH
AU  - Baxter SE
AU  - Brennan PT
AU  - Gammage MD
FA  - Roberts, D H
FA  - Baxter, S E
FA  - Brennan, P T
FA  - Gammage, M D
IN  - Roberts,D H. Department of Cardiology, Birmingham General Hospital, United Kingdom.
TI  - Comparison of externally strapped versus implanted accelerometer- or vibration-based rate adaptive pacemakers during various physical activities.
SO  - Pacing & Clinical Electrophysiology. 18(1 Pt 1):65-9, 1995 Jan.
AS  - Pacing Clin Electrophysiol. 18(1 Pt 1):65-9, 1995 Jan.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Exercise/ph [Physiology]
MH  - Female
MH  - Heart Block/pp [Physiopathology]
MH  - Heart Block/th [Therapy]
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Pacemaker, Artificial
AB  - The ability of externally strapped accelerometer- (Excel [Cardiac Pacemakers, Inc.]) and vibration-based (Activitrax [Medtronic, Inc.]) rate adaptive pacemakers to reproduce the rate response of the same implanted devices with identical programming was evaluated in ten patients by ambulatory Holter monitoring. The resting and postexercise external pacemaker rates closely resembled those of the respective implanted devices. During short bursts and more prolonged exercise, both types of strapped-on devices underestimated maximal implanted pacemaker rate response by 4%-10% when programmed to nominal rate adaptive settings. Studies evaluating chronotropic responses from either type of externally strapped activity sensor appear valid, provided the modest attenuation in maximal rate increase by this method is appreciated.
IS  - 0147-8389
IL  - 0147-8389
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 1995 Jan
DC  - 19950501
YR  - 1995
ED  - 19950501
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=7700833

<832. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7851059
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Edner M
AU  - Jogestrand T
FA  - Edner, M
FA  - Jogestrand, T
IN  - Edner,M. Department of Cardiology, Karolinska Hospital, Stockholm, Sweden.
TI  - Effect of physical activity on the day-to-day variation in serum digoxin concentration.
SO  - Clinical Physiology. 14(6):627-32, 1994 Nov.
AS  - Clin Physiol. 14(6):627-32, 1994 Nov.
NJ  - Clinical physiology (Oxford, England)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - dkg, 8309768
SB  - Index Medicus
CP  - ENGLAND
MH  - Administration, Oral
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Circadian Rhythm/ph [Physiology]
MH  - Cross-Over Studies
MH  - Digoxin/ad [Administration & Dosage]
MH  - *Digoxin/bl [Blood]
MH  - Digoxin/tu [Therapeutic Use]
MH  - Dose-Response Relationship, Drug
MH  - *Exercise/ph [Physiology]
MH  - Female
MH  - Heart Rate/de [Drug Effects]
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Motor Activity/ph [Physiology]
MH  - Time Factors
AB  - Physical exercise has been found to increase digoxin binding in working skeletal muscle along with a concomitant decrease in serum digoxin concentration. In a recent study on healthy volunteers, moderate physical activity during maintenance digoxin treatment was shown to decrease the renal excretion of digoxin secondary to this redistribution of the drug, thereby affecting the body content of digoxin. In the present study the influence of changes in everyday physical activities, carried out during a 10-h period after ingestion of the daily maintenance digoxin dose, on the steady-state serum digoxin concentration (24 h after the last dose) was studied in 10 digoxin-treated outpatients (61-81 years of age). Compared to normal daily activity, complete bed rest for 10 h after ingestion of the maintenance dose did not affect the steady-state serum digoxin concentration. The lack of such an influence may be explained either by a low degree of everyday physical activity in the investigated patients or to a compensatory increase in the renal excretion of digoxin during the night preceding the serum digoxin measurement. Thus, standardization of physical activity 1-2 h before blood sampling is adequate when analysing the serum digoxin concentration in elderly outpatients.
RN  - 73K4184T59 (Digoxin)
IS  - 0144-5979
IL  - 0144-5979
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1994 Nov
DC  - 19950316
YR  - 1994
ED  - 19950316
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=7851059

<833. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7845779
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lau CP
AU  - Tai YT
AU  - Leung SK
AU  - Leung WH
AU  - Chung FL
AU  - Lee IS
FA  - Lau, C P
FA  - Tai, Y T
FA  - Leung, S K
FA  - Leung, W H
FA  - Chung, F L
FA  - Lee, I S
IN  - Lau,C P. Department of Medicine, Queen Mary Hospital, University of Hong Kong.
TI  - Long-term stability of P wave sensing in single lead VDDR pacing: clinical versus subclinical atrial undersensing.
SO  - Pacing & Clinical Electrophysiology. 17(11 Pt 2):1849-53, 1994 Nov.
AS  - Pacing Clin Electrophysiol. 17(11 Pt 2):1849-53, 1994 Nov.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cardiac Pacing, Artificial/mt [Methods]
MH  - *Cardiac Pacing, Artificial
MH  - Electrocardiography
MH  - Electrocardiography, Ambulatory
MH  - Exercise
MH  - Female
MH  - Heart Atria/pp [Physiopathology]
MH  - Heart Block/pp [Physiopathology]
MH  - Heart Block/th [Therapy]
MH  - Humans
MH  - Male
MH  - Middle Aged
AB  - Optimal function of a single lead P wave synchronous rate adaptive ventricular pacing system (VDDR) requires reliable P wave sensing over time and during daily activities. The stability of P wave sensing and the incidence of sensitivity reprogramming in a single pass lead with a diagonally arranged bipole was assessed in 30 patients with complete atrioventricular block over a follow-up period of 12 +/- 1 months (range 6 months to 3 years). Atrial sensing was assessed during clinic visits, by physical maneuvers (postural changes, breathing, Valsalva maneuver, walking and isometric exercise), maximum treadmill exercise and Holter recordings. P wave amplitude at implantation was 1.21 +/- 0.09 (0.5-3.6) mV, and the atrial sensing threshold remained stable over the entire period of follow-up. Using an atrial sensitivity based on twice the sensing threshold at 1 month, P wave undersensing was found in 2, 4, 3, and 7 patients during clinic visit, physical maneuvers, exercise, and Holter recordings, respectively. Atrial sensitivity reprogramming was performed in three patients based on the correction of undersensing during physical maneuvers. Although eight patients had atrial undersensing on Holter recordings, the number of undersensed P waves was small (total 101 beats or 0.013% +/- 0.001% of total ventricular beats) and no patient was symptomatic. One patient had intermittent atrial undersensing at the highest sensitivity, but the VDDR mode was still functional most of the time. No patient had myopotential interference at the programmed sensitivity. One patient developed chronic atrial fibrillation and was programmed to the VVIR mode. Thus, single lead VDDR pacing is a stable pacing mode in 97% of patients.(ABSTRACT TRUNCATED AT 250 WORDS)
IS  - 0147-8389
IL  - 0147-8389
PT  - Journal Article
LG  - English
DP  - 1994 Nov
DC  - 19950306
YR  - 1994
ED  - 19950306
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=7845779

<834. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7993151
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Poldermans D
AU  - Fioretti PM
AU  - Boersma E
AU  - Thomson IR
AU  - Cornel JH
AU  - ten Cate FJ
AU  - Arnese M
AU  - van Urk H
AU  - Roelandt JR
FA  - Poldermans, D
FA  - Fioretti, P M
FA  - Boersma, E
FA  - Thomson, I R
FA  - Cornel, J H
FA  - ten Cate, F J
FA  - Arnese, M
FA  - van Urk, H
FA  - Roelandt, J R
IN  - Poldermans,D. Department of Vascular Surgery, University Hospital Rotterdam-Dijkzigt, The Netherlands.
TI  - Dobutamine-atropine stress echocardiography in elderly patients unable to perform an exercise test. Hemodynamic characteristics, safety, and prognostic value.
SO  - Archives of Internal Medicine. 154(23):2681-6, 1994 Dec 12-26.
AS  - Arch Intern Med. 154(23):2681-6, 1994 Dec 12-26.
NJ  - Archives of internal medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0372440, 7fs
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Aged, 80 and over
MH  - Analysis of Variance
MH  - Atropine/ae [Adverse Effects]
MH  - *Atropine
MH  - Dobutamine/ae [Adverse Effects]
MH  - *Dobutamine
MH  - *Echocardiography/mt [Methods]
MH  - Female
MH  - *Hemodynamics/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - Odds Ratio
MH  - Regression Analysis
AB  - OBJECTIVE: To establish the hemodynamic effects, safety, and prognostic value of dobutamine-atropine stress echocardiography in patients 70 years of age or older.
AB  - DESIGN AND SETTING: Observational study at a university hospital.
AB  - PATIENTS: One hundred seventy-nine patients (mean age, 75 years; range, 70 to 90 years) referred for chest pain (n = 73) or preoperative risk assessment for major vascular noncardiac surgery (n = 106).
AB  - MEASUREMENTS: All patients underwent clinical evaluation and dobutamine-atropine stress test.
AB  - RESULTS: One hundred seventy-nine stress tests were performed. Test end points were the target heart rate (85% of theoretical maximum heart rate), reached in 165 tests (92%); inadequate echo images, two tests (1%); and side effects, 12 tests (7%). Side effects that caused a premature end of the test were severe chest pain (n = 5 [2.8%]), electrocardiographic changes (n = 1 [0.6%]), hypotension (n = 2 [1.1%]), chills (n = 2 [1.1%]), and cardiac arrhythmias (paroxysmal atrial fibrillation) (n = 2 [1.1%]). New wall motion abnormalities as a marker of myocardial ischemia occurred in 50 tests (28%). No death or myocardial infarction occurred during the test. Perioperative events occurred in 12 patients (four cardiac deaths, three myocardial infarctions, and five episodes of unstable angina). During 16 +/- 6 months (mean +/- SD) of follow-up of 166 patients, 22 cardiac events occurred (eight cardiac deaths, four myocardial infarctions, and 10 episodes of unstable angina pectoris). By multivariate regression analysis, only perioperative cardiac events (odds ratio, 51; 95% confidence interval, 5.8 to 454) and late cardiac events (odds ratio, 5.2; 95% confidence interval, 2.0 to 14) were correlated with new wall motion abnormalities during stress.
AB  - CONCLUSION: Dobutamine-atropine stress echocardiography is a feasible and safe test for assessing elderly patients with suspected and/or proven coronary artery disease, providing useful prognostic information for perioperative and late cardiac risk with relatively few side effects.
RN  - 3S12J47372 (Dobutamine)
RN  - 7C0697DR9I (Atropine)
IS  - 0003-9926
IL  - 0003-9926
PT  - Journal Article
LG  - English
DP  - 1994 Dec 12-26
DC  - 19950111
YR  - 1994
ED  - 19950111
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=7993151

<835. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7948800
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Jacquet L
AU  - Evenepoel M
AU  - Marenne F
AU  - Evrard P
AU  - Verhelst R
AU  - Dion R
AU  - Goenen M
FA  - Jacquet, L
FA  - Evenepoel, M
FA  - Marenne, F
FA  - Evrard, P
FA  - Verhelst, R
FA  - Dion, R
FA  - Goenen, M
IN  - Jacquet,L. Cardiac Surgical Intensive Care Unit, University Hospital St. Luc, Brussels, Belgium.
TI  - Hemodynamic effects and safety of sotalol in the prevention of supraventricular arrhythmias after coronary artery bypass surgery.
SO  - Journal of Cardiothoracic & Vascular Anesthesia. 8(4):431-6, 1994 Aug.
AS  - J Cardiothorac Vasc Anesth. 8(4):431-6, 1994 Aug.
NJ  - Journal of cardiothoracic and vascular anesthesia
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - a6i, 9110208
SB  - Index Medicus
CP  - UNITED STATES
MH  - Administration, Oral
MH  - *Arrhythmias, Cardiac/pc [Prevention & Control]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Atrial Flutter/et [Etiology]
MH  - Bradycardia/ci [Chemically Induced]
MH  - Cardiac Output/de [Drug Effects]
MH  - Cardiopulmonary Bypass
MH  - Coronary Artery Bypass/ae [Adverse Effects]
MH  - *Coronary Artery Bypass
MH  - Female
MH  - Heart Rate/de [Drug Effects]
MH  - Hemodynamics/de [Drug Effects]
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Safety
MH  - Sotalol/ad [Administration & Dosage]
MH  - Sotalol/ae [Adverse Effects]
MH  - Sotalol/bl [Blood]
MH  - *Sotalol/tu [Therapeutic Use]
MH  - Tachycardia, Supraventricular/et [Etiology]
MH  - Vascular Resistance/de [Drug Effects]
AB  - Sotalol is a beta-adrenergic blocking drug with the additional property of lengthening the cardiac action potential. These electrophysiologic properties render the drug attractive for use in the prevention of postoperative supraventricular arrhythmias (SVA), and previous studies have suggested that it was indeed effective. The hemodynamic response to sotalol and its safety early after coronary artery bypass graft (CABG) surgery were therefore studied. Forty-two patients undergoing CABG were randomly assigned either to receive sotalol to prevent postoperative SVA (25 patients) or to serve as controls (17 patients). Sotalol was started 6 hours after surgery if patients had a cardiac index > 2.8 L/min/m2 with a pulmonary capillary wedge pressure < 15 mmHg, and if they had no contraindications to the use of beta-blockers. The drug was given as a loading infusion of 1 mg/kg over 2 hours, followed by a maintenance infusion of 0.15 mg/kg/h for 24 hours. Three hours later, patients received the first oral dose of 80 mg to be repeated every 8 or 12 hours. Adverse effects necessitating discontinuation of the drug (bradycardia < 50 beats/min, systolic blood pressure < 90 mmHg, or cardiac index < 2.2 L/min/m2) occurred in six patients (24%) and were mainly related to the loading infusion. The hemodynamic data for patients who completed the study were characterized by a significant fall of the cardiac index caused by a lower heart rate without significant change of the stroke volume index. The incidence of supraventricular arrhythmias was not significantly different in the two groups (3/19 in the sotalol group, 5/17 in the control group).(ABSTRACT TRUNCATED AT 250 WORDS)
RN  - A6D97U294I (Sotalol)
IS  - 1053-0770
IL  - 1053-0770
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 1994 Aug
DC  - 19941206
YR  - 1994
ED  - 19941206
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=7948800

<836. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7954563
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Hwang JJ
AU  - Li YH
AU  - Lin JM
AU  - Wang TL
AU  - Shyu KG
AU  - Ko YL
AU  - Lin JL
AU  - Chen JJ
AU  - Kuan P
AU  - Lien WP
FA  - Hwang, J J
FA  - Li, Y H
FA  - Lin, J M
FA  - Wang, T L
FA  - Shyu, K G
FA  - Ko, Y L
FA  - Lin, J L
FA  - Chen, J J
FA  - Kuan, P
FA  - Lien, W P
IN  - Hwang,J J. Department of Internal Medicine, National Taiwan University Hospital, Taipei, ROC.
TI  - Left atrial appendage function determined by transesophageal echocardiography in patients with rheumatic mitral valve disease.
SO  - Cardiology. 85(2):121-8, 1994.
AS  - Cardiology. 85(2):121-8, 1994.
NJ  - Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - coi, 1266406
SB  - Index Medicus
CP  - SWITZERLAND
MH  - Adult
MH  - Aged
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/us [Ultrasonography]
MH  - *Atrial Function, Left/ph [Physiology]
MH  - Echocardiography, Doppler
MH  - *Echocardiography, Transesophageal
MH  - Female
MH  - Heart Atria/pa [Pathology]
MH  - Heart Atria/us [Ultrasonography]
MH  - Heart Diseases/pp [Physiopathology]
MH  - Heart Diseases/us [Ultrasonography]
MH  - Heart Valve Diseases/pp [Physiopathology]
MH  - Heart Valve Diseases/us [Ultrasonography]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mitral Valve/pp [Physiopathology]
MH  - Mitral Valve/us [Ultrasonography]
MH  - Mitral Valve Insufficiency/pp [Physiopathology]
MH  - Mitral Valve Insufficiency/us [Ultrasonography]
MH  - Mitral Valve Stenosis/pp [Physiopathology]
MH  - Mitral Valve Stenosis/us [Ultrasonography]
MH  - Myocardial Contraction/ph [Physiology]
MH  - Prospective Studies
MH  - Reproducibility of Results
MH  - *Rheumatic Heart Disease/pp [Physiopathology]
MH  - Rheumatic Heart Disease/us [Ultrasonography]
MH  - Thrombosis/pp [Physiopathology]
MH  - Thrombosis/us [Ultrasonography]
AB  - Left atrial thrombi have been considered to be the major source of systemic arterial embolization in patients with rheumatic mitral valve disease. Almost half of the left atrial thrombi are found in the left atrial appendage (LAA). To investigate LAA size and LAA contractile function in patients with rheumatic mitral valve disease, transesophageal echocardiographic and Doppler studies were performed in 61 patients. Among them, 46 patients were in atrial fibrillation (group 1), while the other 15 were in sinus rhythm (group 2). Thirty-six patients with nonrheumatic atrial fibrillation were chosen as control to group 1. Another 22 patients with various cardiovascular diseases and sinus rhythm served as control to group 2. When compared to the patients with nonrheumatic atrial fibrillation (control group), group 1 patients tended to have a larger LAA maximal area (9.7 +/- 5.2 vs. 5.9 +/- 2.8 cm2; p < 0.001). LAA ejection fraction and LAA peak emptying velocity were also lower. A significantly higher incidence of LAA spontaneous echo contrast (SEC) and thrombus formation was also found in these patients. Group 2 patients were also found to have a larger LAA maximal area when compared to the control group (8.8 +/- 3.7 vs. 5.2 +/- 3.0 cm2; p < 0.001). LAA ejection fraction and LAA peak emptying velocity were lower in this group, too. A higher incidence of LAA SEC formation was found in these patients with rheumatic mitral valve disease (4/15 vs. 0/22; p = 0.021). There was no significant difference, however, in LAA thrombus formation between group 2 and its control group (1/15 vs. 1/22; p = NS).(ABSTRACT TRUNCATED AT 250 WORDS)
IS  - 0008-6312
IL  - 0008-6312
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
LG  - English
DP  - 1994
DC  - 19941201
YR  - 1994
ED  - 19941201
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=7954563

<837. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7917690
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gosselink AT
AU  - Crijns HJ
AU  - van den Berg MP
AU  - van den Broek SA
AU  - Hillege H
AU  - Landsman ML
AU  - Lie KI
FA  - Gosselink, A T
FA  - Crijns, H J
FA  - van den Berg, M P
FA  - van den Broek, S A
FA  - Hillege, H
FA  - Landsman, M L
FA  - Lie, K I
IN  - Gosselink,A T. Department of Cardiology, University Hospital Groningen, Groningen, The Netherlands.
TI  - Functional capacity before and after cardioversion of atrial fibrillation: a controlled study.
SO  - British Heart Journal. 72(2):161-6, 1994 Aug.
AS  - Br Heart J. 72(2):161-6, 1994 Aug.
NJ  - British heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - ats, 0370634
OI  - Source: NLM. PMC1025481
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - ENGLAND
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Electric Countershock
MH  - Exercise/ph [Physiology]
MH  - Female
MH  - *Heart/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Oxygen Consumption/ph [Physiology]
MH  - Prognosis
MH  - Prospective Studies
MH  - Recurrence
AB  - OBJECTIVE: To evaluate the effect of cardioversion on peak oxygen consumption (peak VO2) in patients with long-standing atrial fibrillation, to assess the importance of underlying heart disease with respect to the response to exercise, and to relate functional capacity to long-term arrhythmia outcome.
AB  - DESIGN: Prospective controlled clinical trial.
AB  - SETTING: Tertiary referral centre.
AB  - PATIENTS: 63 consecutive patients with chronic atrial fibrillation accepted for treatment with electrical cardioversion. Before cardioversion all patients were treated with digoxin, verapamil, or a combination of both to attain a resting heart rate < or = 100 beats per minute.
AB  - INTERVENTIONS: Electrical cardioversion.
AB  - MAIN OUTCOME MEASURES: Peak VO2 measured before and 1 month after electrical cardioversion to compare patients who were in sinus rhythm and those in atrial fibrillation at these times. Maintenance of sinus rhythm for a mean follow up of 19 (7) months.
AB  - RESULTS: Mean (1SD) peak VO2 in patients in sinus rhythm after 1 month (n = 37) increased from 21.4 (5.8) to 23.7 (6.4) ml/min/kg (+11%, P < 0.05), whereas in patients with a recurrence of atrial fibrillation 1 month after cardioversion (n = 26) peak VO2 was unchanged. In patients who were in sinus rhythm both those with and without underlying heart disease improved, and improvement was not related to functional capacity or left ventricular function before cardioversion. Baseline peak VO2 was not a predictive factor for long-term arrhythmia outcome.
AB  - CONCLUSION: Restoration of sinus rhythm improved peak VO2 in patients with atrial fibrillation, irrespective of the presence of underlying heart disease. Peak VO2 was not a predictive factor for long-term arrhythmia outcome after cardioversion of atrial fibrillation. These findings suggest that cardioversion is the best method of improving functional capacity in patients with atrial fibrillation, whether or not they have underlying heart disease and whatever their functional state.
IS  - 0007-0769
IL  - 0007-0769
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1994 Aug
DC  - 19941101
YR  - 1994
ED  - 19941101
RD  - 20130922
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=7917690

<838. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7913614
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - van den Berg MP
AU  - Crijns HJ
AU  - Gosselink AT
AU  - van den Broek SA
AU  - Hillege HJ
AU  - van Veldhuisen DJ
AU  - Lie KI
FA  - van den Berg, M P
FA  - Crijns, H J
FA  - Gosselink, A T
FA  - van den Broek, S A
FA  - Hillege, H J
FA  - van Veldhuisen, D J
FA  - Lie, K I
IN  - van den Berg,M P. Department of Cardiology, University Hospital, Groningen, The Netherlands.
TI  - Chronotropic response to exercise in patients with atrial fibrillation: relation to functional state.
SO  - British Heart Journal. 70(2):150-3, 1993 Aug.
AS  - Br Heart J. 70(2):150-3, 1993 Aug.
NJ  - British heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - ats, 0370634
OI  - Source: NLM. PMC1025276
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - ENGLAND
MH  - Adrenergic beta-Antagonists/pd [Pharmacology]
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Chronic Disease
MH  - *Exercise/ph [Physiology]
MH  - Female
MH  - Heart Rate/de [Drug Effects]
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxygen Consumption
AB  - OBJECTIVE: To determine the relation between functional capacity and heart rate response to exercise in patients with atrial fibrillation.
AB  - SUBJECTS: 73 consecutive patients with chronic atrial fibrillation.
AB  - MAIN OUTCOME MEASURES: Relation between functional capacity, measured as peak oxygen consumption (peak VO2; ml/min/kg), and heart rate at all stages of exercise in univariate and multivariate analyses.
AB  - RESULTS: Peak VO2 showed no correlation with resting heart rate, but it showed a negative correlation with heart rate during the first stage of exercise (r = -0.94, p < 0.01). Indeed, heart rate during the early stages of exercise (stages 1-5) was higher in patients with a peak VO2 less than or equal to 20 ml/mm/kg than in those with a peak VO2 greater than 20 ml/min/kg (heart rate 140 v 125 beats/min, p < 0.05). At maximal exercise, however, peak VO2 was positively correlated with heart rate (r = 2.15, p < 0.0001).
AB  - CONCLUSION: In patients with atrial fibrillation and impaired functional capacity heart rate at low levels of exercise is augmented but maximal heart rate attenuated compared with patients with preserved functional capacity. Excessive heart rate responses to minor exercise may have deleterious effects on left ventricular function and thereby further limit functional capacity.
RN  - 0 (Adrenergic beta-Antagonists)
IS  - 0007-0769
IL  - 0007-0769
PT  - Journal Article
LG  - English
DP  - 1993 Aug
DC  - 19940825
YR  - 1993
ED  - 19940825
RD  - 20130922
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=7913614

<839. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8013765
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Auricchio A
AU  - Auricchio U
AU  - Chiariello L
FA  - Auricchio, A
FA  - Auricchio, U
FA  - Chiariello, L
IN  - Auricchio,A. Cattedra di Cardiochirurgia, Universita di Roma Tor Vergata, European Hospital.
TI  - Partial reversal by exercise of protective effect in atrial fibrillation inducibility in patients with an accessory atrioventricular connection: comparison between flecainide and propafenone.
SO  - Giornale Italiano di Cardiologia. 24(2):131-6, 1994 Feb.
AS  - G Ital Cardiol. 24(2):131-6, 1994 Feb.
NJ  - Giornale italiano di cardiologia
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - fbe, 1270331
SB  - Index Medicus
CP  - ITALY
MH  - Adult
MH  - Arrhythmias, Cardiac/et [Etiology]
MH  - *Arrhythmias, Cardiac/pc [Prevention & Control]
MH  - Electric Stimulation
MH  - Exercise Test
MH  - Female
MH  - *Flecainide/tu [Therapeutic Use]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Physical Exertion
MH  - *Propafenone/tu [Therapeutic Use]
MH  - Prospective Studies
MH  - *Wolff-Parkinson-White Syndrome/dt [Drug Therapy]
MH  - Wolff-Parkinson-White Syndrome/pp [Physiopathology]
AB  - We have prospectively evaluated the reversibility of the protective effect of propafenone (P) and flecainide (F) on atrial fibrillation (AFib) inducibility in 31 patients with a symptomatic accessory atrioventricular connection during exercise. Each patient underwent repeated transesophageal stimulation and exercise testing after a drug-free week, or after a week of P (900 mg/daily), or F (300 mg/daily) given orally. The end point of the transesophageal stimulation was the induction of AFib. Because no AFib could be induced both at rest and at peak exercise, P or F was considered effective in 5 patients (16%) and 4 patients (13%), respectively. In contrast, drug therapy with P was totally ineffective in 10 patients (32%), while F was completely unable to control AFib induction in 14 patients (45%). A partial efficacy of antiarrhythmic drug therapy, in terms of AFib inducibility only at peak exercise, was achieved in 16 patients (52%) treated with P, and in 13 patients (40%) with F. The comparison of the mean R-R intervals during AFib between patients considered partial responders to drug therapy (AFib inducibility only at peak exercise) and those who completely failed any drug therapy did not show significant differences both at rest or during exercise. No correlation in the plasma concentration of P or F and AFib inducibility or duration was found. Thus, the data of this study shows that the reversible protective effect of IC antiarrhythmic class drugs by exercise seems related to inappropriate control on the substrate for AFib inducibility, and there exists a partially discrepant antiarrhythmic effect between the heart rate control during AFib and the inducibility of AFib.
RN  - 68IQX3T69U (Propafenone)
RN  - K94FTS1806 (Flecainide)
IS  - 0046-5968
IL  - 0046-5968
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 1994 Feb
DC  - 19940726
YR  - 1994
ED  - 19940726
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=8013765

<840. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8198013
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wood MA
AU  - Ellenbogen KA
AU  - Stambler BS
FA  - Wood, M A
FA  - Ellenbogen, K A
FA  - Stambler, B S
TI  - Atrial fibrillation from liquid protein diet.
SO  - American Heart Journal. 127(6):1667-8, 1994 Jun.
AS  - Am Heart J. 127(6):1667-8, 1994 Jun.
NJ  - American heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3bw, 0370465
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - *Atrial Fibrillation/et [Etiology]
MH  - Dietary Proteins/ad [Administration & Dosage]
MH  - *Dietary Proteins/ae [Adverse Effects]
MH  - Energy Intake
MH  - Humans
MH  - Male
RN  - 0 (Dietary Proteins)
IS  - 0002-8703
IL  - 0002-8703
PT  - Case Reports
PT  - Letter
LG  - English
DP  - 1994 Jun
DC  - 19940629
YR  - 1994
ED  - 19940629
RD  - 20060227
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=8198013

<841. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8174582
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Cohen-Solal A
AU  - Aupetit JF
AU  - Dahan M
AU  - Baleynaud S
AU  - Slama M
AU  - Gourgon R
FA  - Cohen-Solal, A
FA  - Aupetit, J F
FA  - Dahan, M
FA  - Baleynaud, S
FA  - Slama, M
FA  - Gourgon, R
IN  - Cohen-Solal,A. Service de Cardiologie, Hopital Beaujon, Clichy, France.
TI  - Peak oxygen uptake during exercise in mitral stenosis with sinus rhythm or atrial fibrillation: lack of correlation with valve area. A study in 70 patients.
SO  - European Heart Journal. 15(1):37-44, 1994 Jan.
AS  - Eur Heart J. 15(1):37-44, 1994 Jan.
NJ  - European heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - em8, 8006263
SB  - Index Medicus
CP  - ENGLAND
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Echocardiography, Doppler
MH  - Exercise Test
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve/us [Ultrasonography]
MH  - Mitral Valve Stenosis/co [Complications]
MH  - *Mitral Valve Stenosis/pp [Physiopathology]
MH  - Mitral Valve Stenosis/us [Ultrasonography]
MH  - *Oxygen Consumption/ph [Physiology]
MH  - Pulmonary Gas Exchange/ph [Physiology]
AB  - Although the haemodynamic response during submaximal supine exercise in mitral stenosis has been well described, the determinants of peak oxygen uptake during maximal upright exercise are poorly characterized and may differ in sinus rhythm and atrial fibrillation. Seventy patients with isolated mitral stenosis underwent Doppler-echocardiography and bicycle exercise with respiratory gas analysis. Forty-two patients were in sinus rhythm (Group I) and 28 in atrial fibrillation (Group II). Peak oxygen uptake was 21.3 +/- 5.6 ml.min-1.kg-1 in group I and 18.1 +/- 5.1 ml.min-1.kg-1 in group II (P < 0.05). There was no significant correlation between indices of exercise tolerance (exercise duration, ventilatory threshold, peak oxygen uptake, indexed peak oxygen uptake, peak oxygen pulse) and valve area or gradient in either group. Indexed peak oxygen uptake was not correlated to delta oxygen pulse but was linearly related (r = 0.43) to delta heart rate (delta heart rate = peak heart rate/rest heart rate) in Group I but not in Group II. Thus, in patients with mitral stenosis, no correlation was found between the mitral valve area or the gradient at rest and maximal upright exercise tolerance, suggesting that peripheral adaptation and, in sinus rhythm, chronotropic reserve, are important compensatory mechanisms.
IS  - 0195-668X
IL  - 0195-668X
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1994 Jan
DC  - 19940607
YR  - 1994
ED  - 19940607
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=8174582

<842. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8282208
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Anonymous
TI  - Vascular dementia: an updated approach to patient management. A roundtable discussion: Part 3.
SO  - Geriatrics. 49(1):39-40, 43-6, 1994 Jan.
AS  - Geriatrics. 49(1):39-40, 43-6, 1994 Jan.
NJ  - Geriatrics
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 2985102r, fo1
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Dementia, Vascular/co [Complications]
MH  - Dementia, Vascular/pc [Prevention & Control]
MH  - *Dementia, Vascular/th [Therapy]
MH  - Depression/et [Etiology]
MH  - Humans
AB  - A new clinical approach to the prevention and treatment of vascular dementia is evolving. The physician has numerous options to consider when the patient is in an asymptomatic "brain-at-risk" stage. These include treatment of hypertension, elevated cholesterol, and atrial fibrillation, as well as smoking cessation, exercise, and dietary changes. When there are early signs of cerebrovascular disease, such as TIAs and subtle cognitive changes, more aggressive therapy may be warranted, including carotid endarterectomy, anticoagulants, aspirin, and ticlopidine. For patients with vascular dementia, treatment focuses on preventing further cerebrovascular damage and managing related symptoms, such as depression.
IS  - 0016-867X
IL  - 0016-867X
PT  - Journal Article
LG  - English
DP  - 1994 Jan
DC  - 19940215
YR  - 1994
ED  - 19940215
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=8282208

<843. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8213550
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Biffi A
AU  - Ammirati F
AU  - Caselli G
AU  - Fernando F
AU  - Cardinale M
AU  - Faletra E
AU  - Mazzuca V
AU  - Verdile L
AU  - Santini M
FA  - Biffi, A
FA  - Ammirati, F
FA  - Caselli, G
FA  - Fernando, F
FA  - Cardinale, M
FA  - Faletra, E
FA  - Mazzuca, V
FA  - Verdile, L
FA  - Santini, M
IN  - Biffi,A. Department of Medicine, Sports Science Institute-Italian Olympic Committee, Rome.
TI  - Usefulness of transesophageal pacing during exercise for evaluating palpitations in top-level athletes.
SO  - American Journal of Cardiology. 72(12):922-6, 1993 Oct 15.
AS  - Am J Cardiol. 72(12):922-6, 1993 Oct 15.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adolescent
MH  - Adult
MH  - *Arrhythmias, Cardiac/di [Diagnosis]
MH  - Arrhythmias, Cardiac/pp [Physiopathology]
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Flutter/di [Diagnosis]
MH  - Atrial Flutter/pp [Physiopathology]
MH  - *Cardiac Pacing, Artificial/mt [Methods]
MH  - Esophagus
MH  - Exercise Test
MH  - Female
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - *Physical Exertion/ph [Physiology]
MH  - Rest/ph [Physiology]
MH  - *Sports/ph [Physiology]
MH  - Tachycardia/di [Diagnosis]
MH  - Tachycardia/pp [Physiopathology]
MH  - Tachycardia, Atrioventricular Nodal Reentry/di [Diagnosis]
MH  - Tachycardia, Atrioventricular Nodal Reentry/pp [Physiopathology]
MH  - Tachycardia, Paroxysmal/di [Diagnosis]
MH  - Tachycardia, Paroxysmal/pp [Physiopathology]
AB  - The aim of this study was to verify the use of transesophageal atrial pacing in reproducing tachyarrhythmias in 22 top-level athletes symptomatic for palpitations, with no evidence of arrhythmias or cardiac anomalies by the standard noninvasive diagnostic techniques. The transesophageal stimulation protocol was divided in 2 sections: at rest and during exercise on the bicycle ergometer in the upright position. Although transesophageal pacing at rest did not induce any arrhythmias in 18 of 22 athletes, during exercise it induced tachyarrhythmias. This occurred in all 16 athletes who had palpitations during physical activity. Electrophysiologic characteristics of induced atrial tachyarrhythmia suggested reentry within the atrioventricular node in 9 of 18 athletes: atrial fibrillation in 5, atrial flutter in 2, orthodromic reciprocating tachycardia due to concealed anomalous pathway in 1, and automatic atrial tachycardia in 1. This study stresses the clinical importance of palpitations during physical exercise and shows that transesophageal pacing performed during exercise is an important diagnostic tool in reproducing the previously described symptoms and in detecting the underlying tachyarrhythmias.
IS  - 0002-9149
IL  - 0002-9149
PT  - Journal Article
LG  - English
DP  - 1993 Oct 15
DC  - 19931118
YR  - 1993
ED  - 19931118
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=8213550

<844. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8213428
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ueshima K
AU  - Myers J
AU  - Morris CK
AU  - Atwood JE
AU  - Kawaguchi T
AU  - Froelicher VF
FA  - Ueshima, K
FA  - Myers, J
FA  - Morris, C K
FA  - Atwood, J E
FA  - Kawaguchi, T
FA  - Froelicher, V F
IN  - Ueshima,K. Cardiology Division, Palo Alto Veterans Affairs Medical Center, CA 94304.
TI  - The effect of cardioversion on exercise capacity in patients with atrial fibrillation.
SO  - American Heart Journal. 126(4):1021-4, 1993 Oct.
AS  - Am Heart J. 126(4):1021-4, 1993 Oct.
NJ  - American heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3bw, 0370465
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Chronic Disease
MH  - *Electric Countershock
MH  - *Exercise Tolerance
MH  - Hemodynamics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pulmonary Gas Exchange
IS  - 0002-8703
IL  - 0002-8703
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 1993 Oct
DC  - 19931101
YR  - 1993
ED  - 19931101
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=8213428

<845. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8369683
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Shinton R
AU  - Sagar G
FA  - Shinton, R
FA  - Sagar, G
IN  - Shinton,R. University of Birmingham, Department of Medicine, Dudley Road Hospital.
TI  - Lifelong exercise and stroke.[Erratum appears in BMJ 1993 Sep 18;307(6906):706]
SO  - BMJ. 307(6898):231-4, 1993 Jul 24.
AS  - BMJ. 307(6898):231-4, 1993 Jul 24.
NJ  - BMJ (Clinical research ed.)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 8900488, bmj, 101090866
OI  - Source: NLM. PMC1678135
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - ENGLAND
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Case-Control Studies
MH  - *Cerebrovascular Disorders/pc [Prevention & Control]
MH  - *Exercise
MH  - Female
MH  - Humans
MH  - Life Style
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
AB  - OBJECTIVES: To examine the potential of lifelong patterns of increased physical activity to prevent stroke.
AB  - DESIGN: Case-control study.
AB  - SETTING: 11 general practices in west Birmingham.
AB  - SUBJECTS: 125 men and women who had just had their first stroke and were aged 35-74 and 198 controls frequency matched for age and sex recruited over 24 months during 1988-90. Exclusion criteria were a previous history of stroke, mitral valvular heart disease combined with atrial fibrillation, primary or metastatic cerebral neoplasm, or coagulation disorder or myeloproliferative disease.
AB  - MAIN OUTCOME MEASURES: Odds ratios for stroke related to lifetime history of exercise after 15 years of age.
AB  - RESULTS: A history of vigorous exercise during the ages 15-25 appeared to protect from stroke: odds ratio adjusted for age and sex 0.33 (95% confidence interval 0.2 to 0.6). This effect was independent of other potential risk factors. Increasing years of participation in vigorous exercise between the ages of 15 and 55 produced an increasing protection from stroke (p < 0.001). In the 65 cases and 169 controls who were free of cardiac ischaemia, peripheral vascular disease, and poor health recent vigorous exercise and walking were protective against stroke: odds ratios of 0.41 (0.2 to 1.0) for recent vigorous exercise and 0.30 (0.1 to 0.7) for recent walking.
AB  - CONCLUSIONS: Appreciable protection from stroke in later life is conferred by vigorous exercise in early adulthood. This increased level of physical activity should, if possible, be continued lifelong.
IS  - 0959-8138
IL  - 0959-535X
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
NO  - (United Kingdom Wellcome Trust)
LG  - English
DP  - 1993 Jul 24
DC  - 19931014
YR  - 1993
ED  - 19931014
RD  - 20130919
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=8369683

<846. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8362771
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Van Gelder IC
AU  - Crijns HJ
AU  - Blanksma PK
AU  - Landsman ML
AU  - Posma JL
AU  - Van Den Berg MP
AU  - Meijler FL
AU  - Lie KI
FA  - Van Gelder, I C
FA  - Crijns, H J
FA  - Blanksma, P K
FA  - Landsman, M L
FA  - Posma, J L
FA  - Van Den Berg, M P
FA  - Meijler, F L
FA  - Lie, K I
IN  - Van Gelder,I C. Department of Cardiology, Thoraxcenter, University Hospital Groningen, The Netherlands.
TI  - Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease.
SO  - American Journal of Cardiology. 72(7):560-6, 1993 Sep 1.
AS  - Am J Cardiol. 72(7):560-6, 1993 Sep 1.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Analysis of Variance
MH  - Atrial Fibrillation/ep [Epidemiology]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/th [Therapy]
MH  - Chronic Disease
MH  - *Electric Countershock
MH  - Exercise Test/mt [Methods]
MH  - Exercise Test/sn [Statistics & Numerical Data]
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - *Heart Valve Diseases/pp [Physiopathology]
MH  - Hemodynamics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Time Factors
AB  - This study prospectively assessed the time course, magnitude and mechanism of the hemodynamic changes after restoration of sinus rhythm in patients with chronic atrial fibrillation (AF) unassociated with valvular disease. Severe cardiac dysfunction may occur after chronic supraventricular tachycardia in patients with and without underlying cardiac disease. Improvement may follow abolishment of the arrhythmia or adequate slowing of the ventricular rate. Eight patients were studied with a mean previous duration of AF of 10 +/- 9 months. Ejection fraction, exercise capacity and the atrial contribution to the left ventricular filling (only during sinus rhythm) were studied before cardioversion, after cardioversion and 1 week, 1 month and 6 months thereafter. A significant improvement in ejection fraction from 36 +/- 13 to 53 +/- 8% (p < 0.05) occurred at 1 month after cardioversion. Concomitantly, peak oxygen consumption had increased at 1 month, from 20.1 +/- 7 to 25.2 +/- 6 ml/min/kg (p < 0.05). Thereafter, no further improvement in hemodynamic parameters occurred. The atrial systole improved already at 1 week (from 3 +/- 5 to 16 +/- 11%, p < 0.05) and remained unchanged thereafter. Thus, restoration of sinus rhythm was associated with a delayed improvement in ejection fraction and maximal exercise capacity, preceded by an early restoration of atrial contractility and an acute slowing of the heart rate. The discrepancy in time course of restoration of atrial and ventricular function parameters suggests that an intrinsic left ventricular cardiomyopathy is present in patients with AF.
IS  - 0002-9149
IL  - 0002-9149
PT  - Journal Article
LG  - English
DP  - 1993 Sep 1
DC  - 19930929
YR  - 1993
ED  - 19930929
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=8362771

<847. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7689213
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Cowell R
AU  - Morris-Thurgood J
AU  - Paul V
AU  - Ilsley C
AU  - Camm AJ
FA  - Cowell, R
FA  - Morris-Thurgood, J
FA  - Paul, V
FA  - Ilsley, C
FA  - Camm, A J
IN  - Cowell,R. Department of Cardiology, Harefield Hospital, United Kingdom.
TI  - Are we being driven to two sensors?: clinical benefits of sensor cross-checking.
SO  - Pacing & Clinical Electrophysiology. 16(7 Pt 1):1441-4, 1993 Jul.
AS  - Pacing Clin Electrophysiol. 16(7 Pt 1):1441-4, 1993 Jul.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Angina Pectoris/co [Complications]
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/th [Therapy]
MH  - Cardiac Pacing, Artificial
MH  - Heart Block/co [Complications]
MH  - Heart Block/th [Therapy]
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Pacemaker, Artificial
MH  - Vibration
MH  - Walking
AB  - Sensor cross-checking within dual sensor rate responsive pacemakers is designed to reduce the incidence of inappropriate rate response. We describe a patient in whom sensor cross-checking prevented the occurrence of angina during automotive transport.
IS  - 0147-8389
IL  - 0147-8389
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 1993 Jul
DC  - 19930923
YR  - 1993
ED  - 19930923
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=7689213

<848. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1307536
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gupta MS
AU  - Gupta D
FA  - Gupta, M S
FA  - Gupta, D
IN  - Gupta,M S. Department of Medicine, Medical College and Hospital, Haryana, India.
TI  - Diltiazem as adjunctive oral therapy in patients with chronic atrial fibrillation.
SO  - Journal of the Association of Physicians of India. 40(11):737-9, 1992 Nov.
AS  - J Assoc Physicians India. 40(11):737-9, 1992 Nov.
NJ  - The Journal of the Association of Physicians of India
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - hg7, 7505585
SB  - Index Medicus
CP  - INDIA
MH  - Administration, Oral
MH  - Aged
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Chronic Disease
MH  - Digoxin/tu [Therapeutic Use]
MH  - Diltiazem/ad [Administration & Dosage]
MH  - *Diltiazem/tu [Therapeutic Use]
MH  - Drug Therapy, Combination
MH  - Exercise/ph [Physiology]
MH  - Female
MH  - Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - Middle Aged
AB  - Digoxin frequently fails to control the heart rate in patients of chronic atrial fibrillation particularly during exertion. We have studied in 20 such patients the effect of adding diltiazem (180 mg/day) on resting and peak exercise heart rates. An attempt was also made to determine its effects on exercise tolerance by using treadmill and 6 minute walk test. Addition of diltiazem resulted in significant attenuation of heart rate both at rest and at peak exercise. The resting and exercise mean heart rates on digoxin alone were 98.9 +/- 21.5 b.p.m. and 160.2 +/- 35.68 b.p.m. respectively. After diltiazem this reduced to 78.7 +/- 12.30 b.p.m. at rest and 132.4 +/- 40.4 b.p.m. at peak exercise (p < 0.01). There was no significant effect on exercise tolerance. In conclusion, the addition of diltiazem substantially reduced the excessive heart rate response to exercise in digitalised patients of chronic atrial fibrillation.
RN  - 73K4184T59 (Digoxin)
RN  - EE92BBP03H (Diltiazem)
IS  - 0004-5772
IL  - 0004-5772
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1992 Nov
DC  - 19930908
YR  - 1992
ED  - 19930908
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1307536

<849. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8322688
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Blatt CM
AU  - Lampert S
AU  - Graboys TB
FA  - Blatt, C M
FA  - Lampert, S
FA  - Graboys, T B
IN  - Blatt,C M. Harvard School of Public Health, Lown Cardiovascular Center, Brookline, MA 02146.
TI  - Is exercise testing safe in patients treated with flecainide for atrial arrhythmia?.
SO  - American Heart Journal. 126(1):268-9, 1993 Jul.
AS  - Am Heart J. 126(1):268-9, 1993 Jul.
NJ  - American heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3bw, 0370465
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Exercise Test/ct [Contraindications]
MH  - Flecainide/pd [Pharmacology]
MH  - *Flecainide/tu [Therapeutic Use]
MH  - Humans
MH  - Quinidine/tu [Therapeutic Use]
MH  - *Tachycardia, Supraventricular/dt [Drug Therapy]
MH  - Tachycardia, Supraventricular/pp [Physiopathology]
RN  - ITX08688JL (Quinidine)
RN  - K94FTS1806 (Flecainide)
IS  - 0002-8703
IL  - 0002-8703
PT  - Editorial
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1993 Jul
DC  - 19930803
YR  - 1993
ED  - 19930803
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=8322688

<850. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8322686
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ueshima K
AU  - Myers J
AU  - Graettinger WF
AU  - Atwood JE
AU  - Morris CK
AU  - Kawaguchi T
AU  - Froelicher VF
FA  - Ueshima, K
FA  - Myers, J
FA  - Graettinger, W F
FA  - Atwood, J E
FA  - Morris, C K
FA  - Kawaguchi, T
FA  - Froelicher, V F
IN  - Ueshima,K. Division of Cardiology, Palo Alto VA Medical Center, CA 94304.
TI  - Exercise and morphologic comparison of chronic atrial fibrillation and normal sinus rhythm.
SO  - American Heart Journal. 126(1):260-1, 1993 Jul.
AS  - Am Heart J. 126(1):260-1, 1993 Jul.
NJ  - American heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3bw, 0370465
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Atrial Fibrillation/me [Metabolism]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Function
MH  - Case-Control Studies
MH  - Chronic Disease
MH  - Electrocardiography
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Hemodynamics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardium/me [Metabolism]
MH  - Oxygen Consumption
MH  - Regression Analysis
IS  - 0002-8703
IL  - 0002-8703
PT  - Journal Article
LG  - English
DP  - 1993 Jul
DC  - 19930803
YR  - 1993
ED  - 19930803
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=8322686

<851. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8509545
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Manning WJ
AU  - Silverman DI
AU  - Katz SE
AU  - Douglas PS
FA  - Manning, W J
FA  - Silverman, D I
FA  - Katz, S E
FA  - Douglas, P S
IN  - Manning,W J. Charles A. Dana Research Institute, Boston, Massachusetts.
TI  - Atrial ejection force: a noninvasive assessment of atrial systolic function.
CM  - Comment in: J Am Coll Cardiol. 1995 Feb;25(2):552-3; PMID: 7829813
SO  - Journal of the American College of Cardiology. 22(1):221-5, 1993 Jul.
AS  - J Am Coll Cardiol. 22(1):221-5, 1993 Jul.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - h50, 8301365
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/th [Therapy]
MH  - Atrial Function
MH  - *Atrial Function, Left/ph [Physiology]
MH  - Biomechanical Phenomena
MH  - Blood Flow Velocity
MH  - Echocardiography, Doppler
MH  - Electric Countershock
MH  - Electrocardiography
MH  - Female
MH  - Heart Atria/us [Ultrasonography]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Systole/ph [Physiology]
AB  - OBJECTIVES: The purpose of this study was to define atrial ejection force and to develop a method for its noninvasive measurement from echocardiographic data.
AB  - BACKGROUND: Assessment of diastolic function through measurement of the components of ventricular filling has largely neglected the vigor of atrial systole, in part because this has been difficult to quantify. However, atrial ejection force, defined as that force exerted by the left atrium to accelerate blood into the left ventricle during atrial systole, can be assessed noninvasively by combined two-dimensional imaging and Doppler echocardiography. This index of atrial function, based on classic newtonian mechanics, provides a physiologic assessment of atrial systolic function.
AB  - METHODS: To evaluate the usefulness of atrial ejection force, we studied the return of left atrial ejection force in 29 patients after elective cardioversion for atrial fibrillation. Transmitral Doppler inflow patterns at rest were assessed immediately after cardioversion and at 24 h, 1 week, 1 month and > 3 months later. A healthy adult group (n = 10) served as control subjects.
AB  - RESULTS: After successful cardioversion, atrial ejection force was significantly depressed compared with that in the control group (5.2 +/- 6.8 vs. 16.3 +/- 4.7 kdynes; p < 0.0001). Over successive weeks, atrial ejection force improved in the subgroup of patients who remained in sinus rhythm (n = 18), whereas no improvement was seen during the period of maintained sinus rhythm in the patients with subsequent reversion to atrial fibrillation (n = 11).
AB  - CONCLUSIONS: Atrial ejection force provides a physiologic assessment of atrial systolic function and is a potentially useful index for assessing atrial contribution to diastolic performance. In patients who successfully underwent cardioversion from atrial fibrillation, atrial ejection force improved over several weeks only in the subgroup in which sinus rhythm was maintained.
IS  - 0735-1097
IL  - 0735-1097
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
NO  - AG00294 (United States NIA NIH HHS)
LG  - English
DP  - 1993 Jul
DC  - 19930715
YR  - 1993
ED  - 19930715
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=8509545

<852. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8098276
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Satoh Y
AU  - Taniguchi K
AU  - Koike A
AU  - Adachi H
AU  - Yajima T
AU  - Iizumi T
AU  - Shiigai T
AU  - Hiroe M
AU  - Marumo F
FA  - Satoh, Y
FA  - Taniguchi, K
FA  - Koike, A
FA  - Adachi, H
FA  - Yajima, T
FA  - Iizumi, T
FA  - Shiigai, T
FA  - Hiroe, M
FA  - Marumo, F
IN  - Satoh,Y. Second Department of Internal Medicine, Tokyo Medical and Dental University, Japan.
TI  - Short-term effects of denopamine on anaerobic threshold and related parameters in patients with chronic heart failure: a double-blind crossover study.
SO  - Clinical Pharmacology & Therapeutics. 53(5):562-9, 1993 May.
AS  - Clin Pharmacol Ther. 53(5):562-9, 1993 May.
NJ  - Clinical pharmacology and therapeutics
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - dhr, 0372741
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Adrenergic beta-Agonists/pd [Pharmacology]
MH  - Adult
MH  - Aged
MH  - *Anaerobic Threshold/de [Drug Effects]
MH  - Blood Pressure/de [Drug Effects]
MH  - *Cardiotonic Agents/pd [Pharmacology]
MH  - Chronic Disease
MH  - Double-Blind Method
MH  - *Ethanolamines/pd [Pharmacology]
MH  - Female
MH  - *Heart Diseases/me [Metabolism]
MH  - Heart Diseases/pp [Physiopathology]
MH  - Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - Middle Aged
AB  - BACKGROUND: The short-term effects of denopamine, an orally available beta-stimulant, on exercise capacity were studied in patients with chronic heart failure.
AB  - METHODS AND RESULTS: Nineteen patients entered the study. Three patients had ischemic heart disease, 13 had dilated cardiomyopathy, and three had valvular disease; 16 patients were in New York Heart Association class II, and three patients were in New York Heart Association class III. Symptom-limited exercise testing (ramp protocol) on a bicycle ergometer with gas exchange analysis was conducted 1 hour after oral administration of either 20 mg denopamine or placebo. Drug administration sequence was randomly assigned in a double-blind crossover method, with 1 week between drugs. Peak VO2 was 20.4 +/- 3.2 and 21.2 +/- 3.1 ml/min/kg, respectively, for those administered the placebo and the drug, and anaerobic threshold was 13.1 +/- 2.1 and 14.0 +/- 2.0 ml/min/kg. There was a significant increase in peak VO2 (p < 0.05) and anaerobic threshold (p < 0.01) with denopamine, whereas no significant change was observed in peak work rate or exercise time. Denopamine increased heart rate in patients with atrial fibrillation but had little effect on heart rate in patients with sinus rhythm.
AB  - CONCLUSION: Data obtained from gas exchange analysis are more sensitive and potentially more useful in the detection of short-term changes in exercise capacity than data obtained from either exercise time or peak work rate, indexes that are commonly used to assess drug therapy. Patients with mild-to-moderate heart failure with sinus rhythm, but not those with atrial fibrillation because of its frequent induction of tachycardia, may be good candidates for denopamine therapy.
RN  - 0 (Adrenergic beta-Agonists)
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Ethanolamines)
RN  - V5F60UPD8P (denopamine)
IS  - 0009-9236
IL  - 0009-9236
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 1993 May
DC  - 19930616
YR  - 1993
ED  - 19930616
RD  - 20121115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=8098276

<853. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8480581
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ueshima K
AU  - Myers J
AU  - Ribisl PM
AU  - Atwood JE
AU  - Morris CK
AU  - Kawaguchi T
AU  - Liu J
AU  - Froelicher VF
FA  - Ueshima, K
FA  - Myers, J
FA  - Ribisl, P M
FA  - Atwood, J E
FA  - Morris, C K
FA  - Kawaguchi, T
FA  - Liu, J
FA  - Froelicher, V F
IN  - Ueshima,K. Cardiology Divisions, Palo Alto, CA.
TI  - Hemodynamic determinants of exercise capacity in chronic atrial fibrillation.
SO  - American Heart Journal. 125(5 Pt 1):1301-5, 1993 May.
AS  - Am Heart J. 125(5 Pt 1):1301-5, 1993 May.
NJ  - American heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3bw, 0370465
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/us [Ultrasonography]
MH  - Chronic Disease
MH  - Echocardiography
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Hemodynamics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxygen Consumption
MH  - Respiratory Transport
AB  - To evaluate the response of patients with chronic atrial fibrillation (AF) to exercise, 79 male patients (mean age 64 +/- 1 years) with AF underwent resting two-dimensional and M-mode echocardiography and symptom-limited treadmill testing with ventilatory gas exchange analysis. Patients were classified by underlying disease into five subgroups: no underlying disease (LONE: n = 17), hypertension (HT: n = 11), ischemic heart disease (n = 13), cardiomyopathy or history of congestive heart failure (CHF: n = 26), and valvular disease (n = 12). A higher maximal heart rate than expected for age was observed (175 vs 157 beats/min), which was most notable in the LONE and HT subgroups. Maximal oxygen uptake (VO2 max) was lower than expected for age in all groups. Patients with CHF had a lower resting ejection fraction than all other patients (p < 0.001), a lower VO2 max, and a lower maximal heart rate than LONE and HT patients (p < 0.001). Stepwise regression analysis demonstrated that echocardiographic measurements at rest were poor predictors of VO2 max and VO2 at the ventilatory threshold. Among clinical, morphologic, and exercise variables, maximal systolic blood pressure accounted for the greatest variance in exercise capacity, but it explained only 35%. In patients with AF the higher than predicted maximal heart rates may be a compensatory mechanism for maintaining exercise capacity after the loss of normal atrial function. However, even in the absence of underlying disease, it does not appear to compensate fully for a compromised exercise capacity.(ABSTRACT TRUNCATED AT 250 WORDS)
IS  - 0002-8703
IL  - 0002-8703
PT  - Journal Article
LG  - English
DP  - 1993 May
DC  - 19930527
YR  - 1993
ED  - 19930527
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=8480581

<854. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1284162
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Steinbeck G
AU  - Reuschel-Janetschek E
FA  - Steinbeck, G
FA  - Reuschel-Janetschek, E
IN  - Steinbeck,G. Medizinische Klinik I, Universitat Munchen, Klinikum Grosshadern, Germany.
TI  - Slow-release gallopamil evaluated by exercise test and long-term electrocardiography.
SO  - Journal of Cardiovascular Pharmacology. 20 Suppl 7:S83-7, 1992.
AS  - J Cardiovasc Pharmacol. 20 Suppl 7:S83-7, 1992.
NJ  - Journal of cardiovascular pharmacology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 7902492, k78
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - *Angina Pectoris/dt [Drug Therapy]
MH  - Angina Pectoris/pp [Physiopathology]
MH  - Delayed-Action Preparations
MH  - *Electrocardiography/de [Drug Effects]
MH  - Exercise Test
MH  - Female
MH  - Gallopamil/ad [Administration & Dosage]
MH  - *Gallopamil/tu [Therapeutic Use]
MH  - Humans
MH  - Male
MH  - Middle Aged
AB  - The effects of slow-release gallopamil (100 mg b.i.d.) were studied on exercise-induced ST-segment depression as well as on spontaneous myocardial ischemia detected by long-term electrocardiography (ECG) monitoring for 48 h in 26 patients with coronary artery disease and angina pectoris. Eight patients had to be excluded (because of paroxysmal atrial fibrillation in four patients, development of unstable angina pectoris in three patients, and frequent ventricular premature beats in one patient). In the remaining 18 patients, gallopamil led to an increase of work load (W x min) evaluated by bicycle ergometry, paralleled by an increase of exercise duration until the occurrence of ST-segment depression of > or = 0.1 mV in the nonblinded part of the trial. The number of spontaneous episodes of myocardial ischemia during long-term ECG recording, ranging from 0 to 14 during control, decreased in patients with two or more episodes during control, paralleled by a decrease in the total duration of ischemic episodes and a decrease in the ischemic score (duration of episodes x maximal ST-segment depression). During long-term ECG monitoring, we observed asymptomatic episodes of spontaneous second degree atrioventricular block of the Wenckebach type in three patients. No other adverse effects of slow-release gallopamil were observed. Therefore, these preliminary results of the non-blinded protocol confirm the anti-ischemic effects of slow-release gallopamil given 100 mg b.i.d.; however, these promising results will have to be confirmed in the consecutive double-blind, placebo-controlled part of the trial.
RN  - 0 (Delayed-Action Preparations)
RN  - 39WPC8JHR8 (Gallopamil)
IS  - 0160-2446
IL  - 0160-2446
PT  - Journal Article
LG  - English
DP  - 1992
DC  - 19930412
YR  - 1992
ED  - 19930412
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1284162

<855. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 8435244
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Haywood GA
AU  - Katritsis D
AU  - Ward J
AU  - Leigh-Jones M
AU  - Ward DE
AU  - Camm AJ
FA  - Haywood, G A
FA  - Katritsis, D
FA  - Ward, J
FA  - Leigh-Jones, M
FA  - Ward, D E
FA  - Camm, A J
IN  - Haywood,G A. Department of Cardiological Sciences, St George's Hospital Medical School, London.
TI  - Atrial adaptive rate pacing in sick sinus syndrome: effects on exercise capacity and arrhythmias.
SO  - British Heart Journal. 69(2):174-8, 1993 Feb.
AS  - Br Heart J. 69(2):174-8, 1993 Feb.
NJ  - British heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - ats, 0370634
OI  - Source: NLM. PMC1024946
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - ENGLAND
MH  - Aged
MH  - Arrhythmias, Cardiac/pp [Physiopathology]
MH  - *Arrhythmias, Cardiac/pc [Prevention & Control]
MH  - *Cardiac Pacing, Artificial/mt [Methods]
MH  - *Exercise Tolerance/ph [Physiology]
MH  - Female
MH  - Heart Atria
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Sick Sinus Syndrome/pp [Physiopathology]
MH  - *Sick Sinus Syndrome/th [Therapy]
MH  - Single-Blind Method
AB  - OBJECTIVE: To test the hypotheses that adaptive rate atrial (AAIR) pacing: significantly increases maximal exercise capacity, and results in significant suppression of supraventricular and ventricular arrhythmia compared with fixed rate atrial (AAI) pacing.
AB  - DESIGN: Prospective, randomised, single blind, crossover study with maximal treadmill exercise testing and 24 hour ambulatory electrocardiographic monitoring in AAIR and AAI modes.
AB  - SETTING: Regional pacing centre.
AB  - PATIENTS: 30 consecutive patients (mean SD age 65 (12) years) with sick sinus syndrome who required permanent pacing, without evidence of conduction disturbance on 12 lead electrocardiograms or 24 hour ambulatory electrocardiographic monitoring and without other cardiovascular or systemic disease.
AB  - INTERVENTIONS: Activity sensing or minute ventilation driven systems (AAI/AAIR) were implanted alternately.
AB  - RESULTS: The mean (SD) peak heart rate in AAI mode was 122(28)v 130(22) in AAIR mode (p < 0.02) for the whole group and 104(17) v 120(5) (p < 0.003) for the patients with chronotropic incompetence. Exercise time was 12.3 (4.1) minutes in AAI and 12.3 (3.8) minutes in AAIR mode (NS) in the chronotropically incompetent patients. There were no significant differences in the Borg scores at peak exercise in AAI v AAIR mode in either group. The frequency per hour of atrial and ventricular arrhythmias showed no significant differences between the two modes in either the group as a whole or in the subgroups with chronotropic incompetence.
AB  - CONCLUSION: AAIR pacing confers little benefit in sick sinus syndrome compared with AAI pacing.
IS  - 0007-0769
IL  - 0007-0769
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1993 Feb
DC  - 19930323
YR  - 1993
ED  - 19930323
RD  - 20130919
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=8435244

<856. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1279554
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Provenier F
AU  - van Acker R
AU  - Backers J
AU  - van Wassenhove E
AU  - de Meyer V
AU  - Jordaens L
FA  - Provenier, F
FA  - van Acker, R
FA  - Backers, J
FA  - van Wassenhove, E
FA  - de Meyer, V
FA  - Jordaens, L
IN  - Provenier,F. Department of Cardiology, University Hospital, Ghent, Belgium.
TI  - Clinical observations with a dual sensor rate adaptive single chamber pacemaker.
SO  - Pacing & Clinical Electrophysiology. 15(11 Pt 2):1821-5, 1992 Nov.
AS  - Pacing Clin Electrophysiol. 15(11 Pt 2):1821-5, 1992 Nov.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Acceleration
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Algorithms
MH  - *Cardiac Pacing, Artificial/mt [Methods]
MH  - Equipment Design
MH  - Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Female
MH  - Heart Block/th [Therapy]
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Pacemaker, Artificial
MH  - Sick Sinus Syndrome/th [Therapy]
MH  - Time Factors
AB  - The Topaz model 515 (Vitatron B.V.) is a dual sensor rate responsive pacemaker for single chamber stimulation. It can be driven by activity counts (ACT) and QT interval measurements. Inappropriate rate modulation due to one sensor can be corrected by "sensor cross-checking." It was implanted in ten patients (20-86 years) of whom seven had complete heart block and atrial arrhythmias. After implantation T-wave amplitude ranged from 0.9 mV-3.5 mV. T-wave sensing ranged from 88%-99% in 9/10 patients at the follow-up of 3 weeks. Eight patients remained in default setting of the activity threshold, after evaluation with a short walking test. An exercise test was performed on all patients. In one test, QT sensing was marginal because of lead implantation in the right ventricular outflow tract. Therefore, this pacing rate was only modulated by ACT sensing. All others were tested with equal contribution of information from both sensors (ACT = QT). In 7/9, rate response was satisfactory. When the treadmill was repeated with ACT in five of these seven patients, rate generally accelerated too fast. In one patient the setting was adjusted to "QT > ACT," because of inappropriate acceleration due to activity sensing, in another it was adjusted to "QT < ACT" because of delayed response to activity. The pacing rate and the ACT during treadmill tests in "QT = ACT" mode were more closely correlated in the first 3 minutes, compared with the last 3 minutes. We feel that rate modulation with this new pacemaker is adequate. Sensor blending and sensor cross-checking are of clinical importance.
IS  - 0147-8389
IL  - 0147-8389
PT  - Journal Article
LG  - English
DP  - 1992 Nov
DC  - 19921216
YR  - 1992
ED  - 19921216
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1279554

<857. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1279553
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - van Krieken FM
AU  - Perrins JP
AU  - Sigmund M
FA  - van Krieken, F M
FA  - Perrins, J P
FA  - Sigmund, M
IN  - van Krieken,F M. Vitatron Medical B.V., Dieren, The Netherlands.
TI  - Clinical results of automatic slope adaptation in a dual sensor VVIR pacemaker.
SO  - Pacing & Clinical Electrophysiology. 15(11 Pt 2):1815-20, 1992 Nov.
AS  - Pacing Clin Electrophysiol. 15(11 Pt 2):1815-20, 1992 Nov.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Acceleration
MH  - Aged
MH  - Algorithms
MH  - Atrial Fibrillation/th [Therapy]
MH  - Atrial Flutter/th [Therapy]
MH  - *Cardiac Pacing, Artificial/mt [Methods]
MH  - Equipment Design
MH  - Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Female
MH  - Heart Block/th [Therapy]
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - *Pacemaker, Artificial
MH  - Sensitivity and Specificity
MH  - Time Factors
AB  - Manual slope programming in rate adaptive pacemakers can be time consuming. This may become worse with dual sensor devices. The remedy is to let the pacemaker automatically learn the slopes. Fast learning replaces initial manual slope programming. Daily learning is a continuous process to determine and optimize slopes during daily life. Both methods are known for a QT sensing pacemaker. Fast learning is known for other single sensor devices. The aim of this study was to follow daily learning in a QT and activity dual sensor pacemaker, starting with factory slope settings. Six patients were studied for about 8 weeks. The daily learning algorithm appeared to be effective, showing the desired regulation processes. It took 2-5 weeks to reach full rate response.
IS  - 0147-8389
IL  - 0147-8389
PT  - Journal Article
LG  - English
DP  - 1992 Nov
DC  - 19921216
YR  - 1992
ED  - 19921216
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1279553

<858. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1279550
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Bongiorni MG
AU  - Soldati E
AU  - Arena G
AU  - de Simone L
AU  - Capucci A
AU  - Galli R
AU  - Parlapiano M
AU  - Cazzin R
AU  - Moracchini P
AU  - Leonardi C
AU  - et al
FA  - Bongiorni, M G
FA  - Soldati, E
FA  - Arena, G
FA  - de Simone, L
FA  - Capucci, A
FA  - Galli, R
FA  - Parlapiano, M
FA  - Cazzin, R
FA  - Moracchini, P
FA  - Leonardi, C
IN  - Bongiorni,M G. Clinical Physiology Institute, Pisa, Italy.
TI  - Multicenter clinical evaluation of a new SSIR pacemaker.
SO  - Pacing & Clinical Electrophysiology. 15(11 Pt 2):1798-803, 1992 Nov.
AS  - Pacing Clin Electrophysiol. 15(11 Pt 2):1798-803, 1992 Nov.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Acceleration
MH  - Aged
MH  - Atrial Fibrillation/th [Therapy]
MH  - *Cardiac Pacing, Artificial/mt [Methods]
MH  - Electrocardiography, Ambulatory
MH  - Equipment Design
MH  - Evaluation Studies as Topic
MH  - Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Female
MH  - Heart Block/th [Therapy]
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - *Pacemaker, Artificial
MH  - Sensitivity and Specificity
MH  - Sick Sinus Syndrome/th [Therapy]
AB  - A multicenter clinical evaluation of Sorin Swing 100, a new SSIR pacemaker with a gravimetric sensor, was performed by seven different centers enrolling a total of 89 patients, 56 men and 33 women, mean age 73.1 years, for pacemaker implantation (73 patients) or pacemaker replacement (16 patients). Pacing mode was VVIR in 73 patients and AAIR in 16. The behavior of pacing rate was evaluated 3 months after the implant by performing a 24-hour Holter monitor, an exercise stress test, and tests for the assessment of mechanical external interference (MEI). A physiological behavior of the paced rate was always observed during Holter monitoring. In 52 completely paced patients mean diurnal, nocturnal, and maximal heart rate were, respectively, 74.9 +/- 5.7 ppm, 58.1 +/- 5.8 ppm, and 113.4 +/- 12.7 ppm; a paced rate exceeding 100 ppm was reached on the average 5.6 times/Holter monitor. In all but two patients the sleep rate (55 ppm) was reached during the night or long resting time. During exercise stress test a direct correlation between the increase in pacing rate and the increase in workload was observed; the mean maximal heart rate reached in 49 completely paced patients was, respectively, 102.8 +/- 9 ppm in 17 patients who accomplished stage 1, 116.2 +/- 13.6 ppm in 28 patients who accomplished stage 2, and 133 +/- 6.7 ppm in 10 patients who accomplished stage 3 of the Bruce protocol. MEI testing never increased the pacing rate over the noise rate (10 ppm over the basic rate). In only seven patients the results obtained suggested to change the nominal set up of the pacemaker.(ABSTRACT TRUNCATED AT 250 WORDS)
IS  - 0147-8389
IL  - 0147-8389
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
LG  - English
DP  - 1992 Nov
DC  - 19921216
YR  - 1992
ED  - 19921216
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1279550

<859. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1423382
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wilkoff BL
AU  - Miller RE
FA  - Wilkoff, B L
FA  - Miller, R E
IN  - Wilkoff,B L. Department of Cardiology, Cleveland Clinic Foundation, Ohio.
TI  - Exercise testing for chronotropic assessment. [Review] [46 refs]
SO  - Cardiology Clinics. 10(4):705-17, 1992 Nov.
AS  - Cardiol Clin. 10(4):705-17, 1992 Nov.
NJ  - Cardiology clinics
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - cok, 8300331
SB  - Index Medicus
CP  - UNITED STATES
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Electrocardiography/is [Instrumentation]
MH  - *Exercise Test/is [Instrumentation]
MH  - Heart Conduction System/pp [Physiopathology]
MH  - *Heart Rate/ph [Physiology]
MH  - Hemodynamics/ph [Physiology]
MH  - Humans
MH  - *Pacemaker, Artificial
MH  - Reference Values
MH  - *Signal Processing, Computer-Assisted/is [Instrumentation]
AB  - Cardiac chronotropic analysis has only begun to develop into a clinically relevant science. In the past, formal exercise testing was usually relegated to the assessment of ischemia or cardiac rehabilitation. The establishment of rate-responsive pacemakers as a potentially effective treatment for chronotropic incompetence forced the definition of cardiac chronotropism and assessment of the pacemaker response. Little is known about the normal chronotropic response and less has been established about patients with ventricular dysfunction or ischemia, but standards are being set and modern pacemakers have produced the ideal clinical laboratory for investigation. Advanced telemetry, including sensor and actual rate trends, histography and sensorgraphy produce previously unobtainable clinical data. Now scientific inquiry demands that chronotropic evaluations seek to match the pacemaker-augmented response of the chronotropically incompetent patient to the metabolic requirements of the body. Only with formal exercise testing will this goal be achieved. [References: 46]
IS  - 0733-8651
IL  - 0733-8651
PT  - Journal Article
PT  - Review
LG  - English
DP  - 1992 Nov
DC  - 19921209
YR  - 1992
ED  - 19921209
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1423382

<860. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1439510
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gullestad L
AU  - Dolva LO
AU  - Waage A
AU  - Falch D
AU  - Fagerthun H
AU  - Kjekshus J
FA  - Gullestad, L
FA  - Dolva, L O
FA  - Waage, A
FA  - Falch, D
FA  - Fagerthun, H
FA  - Kjekshus, J
IN  - Gullestad,L. Department of Medicine, Baerum Hospital, Sandvika, Norway.
TI  - Magnesium deficiency diagnosed by an intravenous loading test.
SO  - Scandinavian Journal of Clinical & Laboratory Investigation. 52(4):245-53, 1992 Jun.
AS  - Scand J Clin Lab Invest. 52(4):245-53, 1992 Jun.
NJ  - Scandinavian journal of clinical and laboratory investigation
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - ucp, 0404375
SB  - Index Medicus
CP  - ENGLAND
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Alcoholism/bl [Blood]
MH  - Alcoholism/co [Complications]
MH  - Evaluation Studies as Topic
MH  - Female
MH  - Humans
MH  - Hypertension/bl [Blood]
MH  - Hypertension/co [Complications]
MH  - Infusions, Intravenous
MH  - *Magnesium/ad [Administration & Dosage]
MH  - Magnesium/bl [Blood]
MH  - Magnesium Deficiency/bl [Blood]
MH  - Magnesium Deficiency/co [Complications]
MH  - *Magnesium Deficiency/di [Diagnosis]
MH  - Male
MH  - Middle Aged
AB  - Magnesium deficiency is common but difficult to diagnose and to assess in clinical practice. The use of a magnesium loading test was therefore evaluated to diagnose magnesium deficiency in 661 hospitalized patients with medical conditions assumed to interfere with magnesium uptake and excretion. Thirty millimoles of magnesium sulphate were administered intravenously during 8 h as a loading test and related to the urinary excretion in the following 24 h. A group of 30 patients without any known predisposition for magnesium deficiency and a group of 27 healthy volunteers served as controls. The mean (with 95% confidence interval) magnesium retention was 4 (-2-10)% in the control group of patients and 3 (-2-8)% in healthy subjects. A significantly higher retention was observed in all the groups of the patients: atrial fibrillation 18 (11-25)%, other arrhythmias 18 (11-24)%, hypertension 27 (20-33)%, coronary artery disease 25 (20-30)%, congestive heart failure 31 (26-37)%, cerebrovascular events 38 (24-51)%, gastrointestinal disorders 22 (14-29)%, diabetes mellitus 16 (9-22)%, and alcoholics 33 (29-36)%. The percentage of patients with a retention greater than mean + 2 SD of the two control groups varied between 22% and 54% among the different patient groups. The mean serum magnesium among the patient groups was similar to the control group of patients, except for the alcoholics, hypertensives and young healthy controls, who had significantly reduced levels. Magnesium retention was significantly correlated to age and renal function, and among the alcoholics negatively correlated to serum magnesium.(ABSTRACT TRUNCATED AT 250 WORDS)
RN  - I38ZP9992A (Magnesium)
IS  - 0036-5513
IL  - 0036-5513
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1992 Jun
DC  - 19921203
YR  - 1992
ED  - 19921203
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1439510

<861. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1383962
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lau CP
AU  - Tai YT
AU  - Fong PC
AU  - Li JP
AU  - Chung FL
FA  - Lau, C P
FA  - Tai, Y T
FA  - Fong, P C
FA  - Li, J P
FA  - Chung, F L
IN  - Lau,C P. Department of Medicine, University of Hong Kong, Queen Mary Hospital.
TI  - Atrial arrhythmia management with sensor controlled atrial refractory period and automatic mode switching in patients with minute ventilation sensing dual chamber rate adaptive pacemakers.
SO  - Pacing & Clinical Electrophysiology. 15(10 Pt 1):1504-14, 1992 Oct.
AS  - Pacing Clin Electrophysiol. 15(10 Pt 1):1504-14, 1992 Oct.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Algorithms
MH  - Atrioventricular Node/pp [Physiopathology]
MH  - Bradycardia/pp [Physiopathology]
MH  - *Bradycardia/th [Therapy]
MH  - *Cardiac Pacing, Artificial/mt [Methods]
MH  - Equipment Design
MH  - Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Heart Block/pp [Physiopathology]
MH  - *Heart Block/th [Therapy]
MH  - Humans
MH  - *Pacemaker, Artificial
MH  - Tachycardia/pc [Prevention & Control]
AB  - Although a long postventricular atrial refractory period (PVARP) may prevent the occurrence of pacemaker mediated tachycardias and inadvertent tracking of atrial arrhythmias in dual chamber (DDD) pacing, the maximum upper rate will necessarily be compromised. We tested the feasibility of using minute ventilation sensing in a dual chamber rate adaptive pacemaker (DDDR) to shorten the PVARP during exercise in 13 patients with bradycardias (resting PVARP = 463 +/- 29 msec) to avoid premature upper rate behavior. Graded treadmill exercise tests in the DDD and DDDR modes at this PVARP resulted in maximum ventricular rates of 98 +/- 8 and 142 +/- 3 beats/min, respectively (P < 0.0001), due to chronotropic incompetence and upper rate limitation in the DDD mode, both circumvened with the use of sensor. In order to stimulate atrial arrhythmias, chest wall stimulation was applied for 30 seconds at a rate of 250 beats/min at a mean unipolar atrial sensitivity of 0.82 mV. Irregular ventricular responses occurred in the DDD mode (the rates at a PVARP of 280 and 463 +/- 29 msec were, respectively 92 +/- 5 and 66 +/- 3 msec; P < 0.0001). In the DDDR mode at a PVARP of 463 +/- 29 msec, regular ventricular pacing at 53 +/- 2 beats/min occurred due to mode switching to VVIR mode in the presence of repetitive sensed atrial events within the PVARP. One patient developed spontaneous atrial fibrillation on follow-up, which was correctly identified by the pacemaker algorithm, resulting in mode switch from DDDR to regular VVIR pacing and preservation of rate response. In conclusion, sensor controlled PVARP allows a long PVARP to be used at rest without limiting the maximum rate during exercise. In addition, to offer protection against retrograde conduction, a long PVARP and mode switching also limit the rate during atrial arrhythmias and allow regular ventricular rate responses according to the physiological demands.
IS  - 0147-8389
IL  - 0147-8389
PT  - Journal Article
LG  - English
DP  - 1992 Oct
DC  - 19921125
YR  - 1992
ED  - 19921125
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1383962

<862. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1395736
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lundstrom T
AU  - Karlsson O
FA  - Lundstrom, T
FA  - Karlsson, O
IN  - Lundstrom,T. Department of Cardiology, Central Hospital, Skovde, Sweden.
TI  - Improved ventilatory response to exercise after cardioversion of chronic atrial fibrillation to sinus rhythm.
SO  - Chest. 102(4):1017-22, 1992 Oct.
AS  - Chest. 102(4):1017-22, 1992 Oct.
NJ  - Chest
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0231335, d1c
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Blood Pressure
MH  - Cardiac Output
MH  - Chronic Disease
MH  - *Electric Countershock
MH  - *Exercise Test
MH  - Exercise Tolerance
MH  - Female
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Pulmonary Gas Exchange
MH  - Stroke Volume
AB  - The purpose of this study was to assess hemodynamic and respiratory measures of submaximal and maximal exercise performance in patients with chronic atrial fibrillation, before and one month after cardioversion to sinus rhythm. Restoration of sinus rhythm (n = 16) produced significant reductions in resting and exercise heart rates, 14 percent to 20 percent (p < 0.01). Due to a proportionately larger increase in stroke volume, cardiac output increased by 9 percent during low-level exercise (p < 0.01) and by 7 percent during exercise above the anaerobic threshold (p < 0.05). Minute ventilation was reduced by 7 percent during low-level exercise (p < 0.01) and by 9 percent above the anaerobic threshold (p < 0.05). The ratio between minute ventilation and carbon dioxide elimination was significantly reduced (p < 0.01). Maximum oxygen uptake (+8 percent; p < 0.01) and maximal tolerated work load (+6 percent; p < 0.05) increased. Hemodynamic changes during exercise were similar in patients with (n = 7) or without (n = 9) disopyramide prophylaxis. Restoration of sinus rhythm induced improvement in hemodynamics and in efficiency of ventilation, thereby reducing the ventilatory demand during submaximal exercise.
IS  - 0012-3692
IL  - 0012-3692
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1992 Oct
DC  - 19921105
YR  - 1992
ED  - 19921105
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1395736

<863. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1529904
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Auricchio A
FA  - Auricchio, A
IN  - Auricchio,A. Department of Cardiac Surgery, University of Rome, Tor Vergata, European Hospital, Italy.
TI  - Reversible protective effect of propafenone or flecainide during atrial fibrillation in patients with an accessory atrioventricular connection.
SO  - American Heart Journal. 124(4):932-7, 1992 Oct.
AS  - Am Heart J. 124(4):932-7, 1992 Oct.
NJ  - American heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3bw, 0370465
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrioventricular Node/pp [Physiopathology]
MH  - Cardiac Pacing, Artificial
MH  - *Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Female
MH  - *Flecainide/tu [Therapeutic Use]
MH  - *Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - *Propafenone/tu [Therapeutic Use]
MH  - Prospective Studies
MH  - *Wolff-Parkinson-White Syndrome/dt [Drug Therapy]
MH  - Wolff-Parkinson-White Syndrome/ep [Epidemiology]
MH  - Wolff-Parkinson-White Syndrome/pp [Physiopathology]
AB  - In 34 patients with a symptomatic accessory atrioventricular connection the reversible protective effect of orally administered flecainide (300 mg/day) and of propafenone (900 mg/day) in control of ventricular response during atrial fibrillation by exercise was assessed. The study consisted of three sections of 1 week each: an initial treatment phase during which propafenone or flecainide was administered, a drug-free phase, and a period of crossover to treatment with the other drug. At the end of each phase, transesophageal stimulation was performed during physical exercise to induce atrial fibrillation episodes: the goal was to control the persistence of drug effectiveness. At rest, the mean and shortest R-R interval during the period of induced atrial fibrillation in patients who were treated with flecainide or propafenone increased significantly as compared with the drug-free period. On the other hand, at maximum exercise levels no difference in both shortest and mean R-R intervals during atrial fibrillation was observed between patients who were treated with flecainide and those who were treated with propafenone, as well as between flecainide treatment and the drug-free period, whereas a slightly significant difference persisted with propafenone treatment (p less than 0.05). In addition, at maximum exercise levels no significant difference in the number of preexcited QRS complexes among the three treatments was noted. The data from this study suggests that a reversible protective effect against rapid ventricular rate as the result of an episode of atrial fibrillation exists during exercise in patients with a symptomatic accessory atrioventricular connection who are treated with flecainide or propafenone.
RN  - 68IQX3T69U (Propafenone)
RN  - K94FTS1806 (Flecainide)
IS  - 0002-8703
IL  - 0002-8703
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
LG  - English
DP  - 1992 Oct
DC  - 19921022
YR  - 1992
ED  - 19921022
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1529904

<864. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1381084
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Chimienti M
AU  - Li Bergolis M
AU  - Moizi M
AU  - Klersy C
AU  - Negroni MS
AU  - Salerno JA
FA  - Chimienti, M
FA  - Li Bergolis, M
FA  - Moizi, M
FA  - Klersy, C
FA  - Negroni, M S
FA  - Salerno, J A
IN  - Chimienti,M. Department of Internal Medicine, S. Matteo University Hospital, Pavia, Italy.
TI  - Comparison of isoproterenol and exercise tests in asymptomatic subjects with Wolff-Parkinson-White syndrome.
SO  - Pacing & Clinical Electrophysiology. 15(8):1158-66, 1992 Aug.
AS  - Pacing Clin Electrophysiol. 15(8):1158-66, 1992 Aug.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - *Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Cardiac Pacing, Artificial
MH  - Electrophysiology
MH  - *Exercise Test
MH  - *Heart Conduction System/pp [Physiopathology]
MH  - Humans
MH  - *Isoproterenol
MH  - Male
MH  - *Wolff-Parkinson-White Syndrome/di [Diagnosis]
MH  - Wolff-Parkinson-White Syndrome/pp [Physiopathology]
AB  - In order to evaluate the effects of increases of sympathetic tone in ventricular response during atrial fibrillation and in the relationship between the accessory pathway effective refractory period (ERP) and ventricular rate during atrial fibrillation, 20 male subjects, aged 19 +/- 6 years, were studied electrophysiologically in basal conditions, after isoproterenol infusion (2-4 micrograms/min) and during submaximal bicycle exercise test, at a constant workload equal to that which increases the sinus rate to the same extent (140 beats/min) induced by isoproterenol infusion. Accessory pathway ERP was evaluated at the same driven rate (150 beats/min) in both instances. In the control study as during both tests atrial fibrillation paroxysms were induced by burst stimulation. In control conditions the rate increase from 100 to 150 beats/min induced a reduction of accessory pathway ERP from 266 +/- 27 msec to 244 +/- 22 msec (P less than 0.005). At the same driven rate of 150 beats/min, isoproterenol infusion and exercise test induced a more marked shortening of accessory pathway ERP to 211 +/- 28 msec (P less than 0.005) and to 214 +/- 29 msec (P less than 0.005), respectively. Atrial fibrillation paroxysms lasting more than 10 seconds were induced in 20/20 cases in the control study, in 15/20 during isoproterenol infusion and in 13/19 cases during exercise test. The shortest cycle length during atrial fibrillation was reduced from a basal value of 253 +/- 72 msec to 204 +/- 27 msec (P less than 0.05) during isoproterenol infusion and to 236 +/- 32 msec (NS) during exercise test.(ABSTRACT TRUNCATED AT 250 WORDS)
RN  - L628TT009W (Isoproterenol)
IS  - 0147-8389
IL  - 0147-8389
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 1992 Aug
DC  - 19921001
YR  - 1992
ED  - 19921001
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1381084

<865. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1632398
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ehlert FA
AU  - Goldberger JJ
AU  - Rosenthal JE
AU  - Kadish AH
FA  - Ehlert, F A
FA  - Goldberger, J J
FA  - Rosenthal, J E
FA  - Kadish, A H
IN  - Ehlert,F A. Department of Medicine, Northwestern University Medical School, Chicago, Illinois.
TI  - Relation between QT and RR intervals during exercise testing in atrial fibrillation.
SO  - American Journal of Cardiology. 70(3):332-8, 1992 Aug 1.
AS  - Am J Cardiol. 70(3):332-8, 1992 Aug 1.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Electrocardiography
MH  - *Exercise Test
MH  - Female
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Reproducibility of Results
AB  - The ability to predict the RR-QT relation over a range of heart rates was evaluated in 10 patients with atrial fibrillation (AF) and in 10 control subjects in sinus rhythm. The data from each subject were fitted by regression into 3 QT prediction formulas (the square root formula of Bazett, the cube root formula of Fridericia and the exponential formula of Sarma) applied in standard form and modified with a weighted average of the preceding 5 RR intervals. The goodness-of-fit of each formula was evaluated using mean square residual and Akaike information criterion. For AF, the mean square residuals did not differ among the 3 standard QT prediction formulas (Bazett 624 +/- 274, Fridericia 625 +/- 274 and Sarma 611 +/- 267) and among the 3 modified QT prediction formulas (Bazett 507 +/- 325, Fridericia 496 +/- 255 and Sarma 495 +/- 328). The weighted average modification produced a significant decrease in mean square residuals for all 3 equations (p less than 0.05) in all patients. These findings were confirmed by Akaike information criterion. Goodness-of-fit in sinus rhythm was similar to previously published reports, and significantly better than the fit for AF (p less than 0.0001). For 9 of the 10 patients with AF, sinus rhythm electrocardiograms were obtained and the above regression equations were used to predict QT intervals.(ABSTRACT TRUNCATED AT 250 WORDS)
IS  - 0002-9149
IL  - 0002-9149
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
NO  - HL40667 (United States NHLBI NIH HHS)
LG  - English
DP  - 1992 Aug 1
DC  - 19920820
YR  - 1992
ED  - 19920820
RD  - 20071114
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1632398

<866. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1607846
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Cantwell JD
AU  - Lammert S
FA  - Cantwell, J D
FA  - Lammert, S
IN  - Cantwell,J D. Cardiac Rehabilitation and the Internal Medicine Residency Program, Georgia Baptist Medical Center, Atlanta 30312-1239.
TI  - Cardiac arrhythmias in presidents and other athletes.
SO  - Journal of the Medical Association of Georgia. 81(6):311-5, 1992 Jun.
AS  - J Med Assoc Ga. 81(6):311-5, 1992 Jun.
NJ  - Journal of the Medical Association of Georgia
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - izb, 7505620
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Arrhythmias, Cardiac/dt [Drug Therapy]
MH  - *Arrhythmias, Cardiac/et [Etiology]
MH  - Arrhythmias, Cardiac/pp [Physiopathology]
MH  - Electrocardiography
MH  - Female
MH  - Humans
MH  - Male
MH  - *Running/in [Injuries]
AB  - We presented examples of both supraventricular and ventricular rhythm disorders which can occur in athletic individuals, even presidents. The vast majority of rhythm problems we deal with in athletes are fortunately benign, entities such as frequent atrial ectopic beats or VPBs. In each patient encountered, we ask ourselves the five questions noted in the discussion pertaining to symptomatology, anatomic source of the arrhythmia, presence or absence of underlying cardiac disease, and precipitating factors. The most common more sustained SVTs we see are AVNRT and atrial fibrillation. Atrial flutter is less common. These are more of a nuisance to patients rather than a threat to their lives, although rarely cerebral embolic events can occur. Therapy includes avoidance of precipitating factors and, when necessary, a sequential trial of available drugs, carefully documenting the response and watching closely for any pro-arrhythmic events. We infrequently see NSVT in athletes, even triplets of VPBs on exercise testing, and rarely see instances of sustained VT. The latter merits a careful search for underlying cardiac disease and usually electrophysiology-guided drug therapy. New techniques such as radiofrequency ablation of the dysrhythmic focus may obviate the need for chronic drug therapy in selected cases.
IS  - 0025-7028
IL  - 0025-7028
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 1992 Jun
DC  - 19920723
YR  - 1992
ED  - 19920723
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1607846

<867. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1815975
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Norgaard A
AU  - Botker HE
AU  - Klitgaard NA
AU  - Toft P
FA  - Norgaard, A
FA  - Botker, H E
FA  - Klitgaard, N A
FA  - Toft, P
IN  - Norgaard,A. Department of Cardiology, Aarhus University Hospital, Denmark.
TI  - Digitalis enhances exercise-induced hyperkalaemia.
SO  - European Journal of Clinical Pharmacology. 41(6):609-11, 1991.
AS  - Eur J Clin Pharmacol. 41(6):609-11, 1991.
NJ  - European journal of clinical pharmacology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - en4, 1256165
SB  - Index Medicus
CP  - GERMANY
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Coronary Disease/co [Complications]
MH  - Digoxin/ad [Administration & Dosage]
MH  - Digoxin/bl [Blood]
MH  - *Digoxin/tu [Therapeutic Use]
MH  - *Exercise Test
MH  - Humans
MH  - *Hyperkalemia/et [Etiology]
MH  - Male
MH  - Middle Aged
MH  - Potassium/bl [Blood]
AB  - In 9 patients with atrial fibrillation the effect of zero, low and high levels of serum digoxin on exercise-induced hyperkalemia was assessed by bicycle exercise tests. Exercise at each level of serum digoxin was associated with a significant (up to 20%) rise in plasma potassium. At a work load of 75 W the highest level of serum digoxin was associated with a significantly higher maximum plasma potassium concentration as compared to the maximum valueatazero serum digoxin. The enhancement of exercise-induced hyperkalemia may add to the arrhythmogenic effect of digitalis.
RN  - 73K4184T59 (Digoxin)
RN  - RWP5GA015D (Potassium)
IS  - 0031-6970
IL  - 0031-6970
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1991
DC  - 19920629
YR  - 1991
ED  - 19920629
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1815975

<868. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1558438
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Dattilo GL
AU  - Eiriksson CE Jr
AU  - Vestal RE
FA  - Dattilo, G L
FA  - Eiriksson, C E Jr
FA  - Vestal, R E
IN  - Dattilo,G L. Clinical Pharmacology and Gerontology Research Unit, Veterans Affairs Medical Center, Boise, Idaho 83702.
TI  - Increased ventricular response rate during exercise in patients with atrial fibrillation treated with theophylline.
SO  - Archives of Internal Medicine. 152(4):797-803, 1992 Apr.
AS  - Arch Intern Med. 152(4):797-803, 1992 Apr.
NJ  - Archives of internal medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0372440, 7fs
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Analysis of Variance
MH  - Atrial Fibrillation/bl [Blood]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Chronic Disease
MH  - Double-Blind Method
MH  - Epinephrine/bl [Blood]
MH  - Exercise Test/de [Drug Effects]
MH  - *Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Norepinephrine/bl [Blood]
MH  - Random Allocation
MH  - Regression Analysis
MH  - *Theophylline/pd [Pharmacology]
AB  - The effect of theophylline on atrioventricular conduction in atrial fibrillation was investigated by determining ventricular response rates at rest and during exercise treadmill tests in eight patients (mean [+/- SEM] age, 64.2 +/- 2.0 years) with chronic atrial fibrillation. Tests were performed before and after 7 days of oral theophylline treatment (plasma level, 87.7 +/- 7.8 mumol/L). There was no significant change in baseline ventricular rate or duration of exercise, but the maximum ventricular rate with theophylline treatment was 12.3% +/- 2.4% higher than that with placebo (176.3 +/- 7.5 vs 158.1 +/- 8.8 beats per minute), and, during each stage of exercise, the ventricular rate with theophylline exceeded that with placebo. The increased heart rate during theophylline administration occurred without a significant difference in the exercise-induced increase in circulating plasma catecholamine levels. We conclude that treatment with theophylline may contribute to difficulties with rate control in acutely ill patients with coexisting atrial fibrillation.
RN  - C137DTR5RG (Theophylline)
RN  - X4W3ENH1CV (Norepinephrine)
RN  - YKH834O4BH (Epinephrine)
IS  - 0003-9926
IL  - 0003-9926
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
LG  - English
DP  - 1992 Apr
DC  - 19920507
YR  - 1992
ED  - 19920507
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1558438

<869. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1542908
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Sloan MA
AU  - Mattioni TA
FA  - Sloan, M A
FA  - Mattioni, T A
IN  - Sloan,M A. Department of Neurology, University of Maryland School of Medicine, Baltimore.
TI  - Concurrent myocardial and cerebral infarctions after intranasal cocaine use.
SO  - Stroke. 23(3):427-30, 1992 Mar.
AS  - Stroke. 23(3):427-30, 1992 Mar.
NJ  - Stroke; a journal of cerebral circulation
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - v2j, 0235266
SB  - Index Medicus
CP  - UNITED STATES
MH  - Administration, Intranasal
MH  - Adult
MH  - *Cerebral Infarction/ci [Chemically Induced]
MH  - Cerebral Infarction/co [Complications]
MH  - *Cocaine/ae [Adverse Effects]
MH  - Cold Temperature
MH  - Humans
MH  - Jogging
MH  - Male
MH  - *Myocardial Infarction/ci [Chemically Induced]
MH  - Myocardial Infarction/co [Complications]
AB  - BACKGROUND AND PURPOSE: Cardiac and cerebrovascular complications associated with cocaine abuse have increasingly been reported, but concurrent development of cocaine-induced cardiac disease and stroke has rarely been reported.
AB  - CASE DESCRIPTION: A 37-year-old man with a remote history of intravenous heroin and amphetamine use, cardiomyopathy, and recent cocaine use developed chest pain and ventricular tachycardia 30 minutes after intranasal cocaine hydrochloride use and jogging on a cold winter morning. Ventricular tachycardia was converted to atrial fibrillation. He was proven to have a small myocardial infarction. Within 6 hours of cocaine use he suffered a left hemisphere stroke. Cardiac electrophysiologic evaluation revealed inducible ventricular tachycardia.
AB  - CONCLUSIONS: To our knowledge, this is the first report of concurrent myocardial infarction, life-threatening ventricular arrhythmias, and cerebral infarction temporally related to cocaine use. It is probable that one mechanism by which cocaine use causes stroke is to trigger expression of a known cardiac source of embolism.
RN  - I5Y540LHVR (Cocaine)
IS  - 0039-2499
IL  - 0039-2499
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 1992 Mar
DC  - 19920408
YR  - 1992
ED  - 19920408
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1542908

<870. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1542730
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Buckingham TA
AU  - Janosik DL
AU  - Pearson AC
FA  - Buckingham, T A
FA  - Janosik, D L
FA  - Pearson, A C
IN  - Buckingham,T A. St Louis University Medical Center, MO.
TI  - Pacemaker hemodynamics: clinical implications. [Review] [76 refs]
SO  - Progress in Cardiovascular Diseases. 34(5):347-66, 1992 Mar-Apr.
AS  - Prog Cardiovasc Dis. 34(5):347-66, 1992 Mar-Apr.
NJ  - Progress in cardiovascular diseases
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - q0i, 0376442
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Coronary Disease/mo [Mortality]
MH  - Coronary Disease/pp [Physiopathology]
MH  - Coronary Disease/th [Therapy]
MH  - Exercise/ph [Physiology]
MH  - Heart Rate/ph [Physiology]
MH  - *Hemodynamics/ph [Physiology]
MH  - Humans
MH  - Myocardial Contraction/ph [Physiology]
MH  - *Pacemaker, Artificial
MH  - Prosthesis Failure
MH  - Rest/ph [Physiology]
MH  - Time Factors
AB  - Our review of the current literature and experience in caring for pacemaker patients suggests that a consideration of hemodynamics is a logical way to approach pacemaker selection and programming. Multiple clinical factors enter into the selection of a pacemaker or pacemaker programming settings in each case. It appears that in patients with sinus node disease, atrial-inhibited or dual-chamber pacing provides the best chance for preventing the development of chronic atrial fibrillation with its attendant risks of embolism and stroke. It is clear that AV synchrony has beneficial hemodynamic effects at rest in most patients. The results of Labovitz would suggest that in patients with marked left atrial enlargement, this may be less so. The results of Stewart et al would further suggest that in patients with retrograde VA conduction, dual-chamber pacing is preferable. Retrograde VA conduction can be intermittent and this makes it difficult to use its absence on a single test to decide on the type of pacemaker to use. It appears that baseline left ventricular function does not determine the relative improvement in cardiac output observed with AV synchrony or rate-adaptive pacing. However, in patients with severe congestive heart failure even a small improvement in cardiac output may result in significant clinical improvement. Studies have shown that in any given patient, there may be an optimal AV interval at rest. In general, this ranges from 100 to 150 milliseconds. In normal individuals the optimal AV interval shortens with increased heart rate during exercise in a predictable and linear fashion. The hemodynamic benefits of a shortened AV interval with faster heart rates in pacemaker patients have not yet been shown. Intuitively, however, this would appear to be a desirable approach and will probably be added to the design of future generations of dual-chamber pacemakers. Studies of the effect of different pacing modes on secretion of atrial natriuretic factor are intriguing and may contribute more to our understanding of pacing hemodynamics in the future. During exercise, heart rate increase is more important than AV synchrony and this has been shown by several studies. Thus, in active patients with chronotropic incompetence due to sick sinus syndrome, the addition of rate-adaptive pacing is important. Because single-chamber rate-adaptive atrial pacing leaves the patient exposed to the risk of future development of AV block and DDD pacing does not provide chronotropic support, it is likely that the new rate-adaptive dual-chamber (DDDR) devices will be used in a significant number of these patients.(ABSTRACT TRUNCATED AT 250 WORDS) [References: 76]
IS  - 0033-0620
IL  - 0033-0620
PT  - Journal Article
PT  - Review
LG  - English
DP  - 1992 Mar-Apr
DC  - 19920408
YR  - 1992
ED  - 19920408
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1542730

<871. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1721152
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Favale S
AU  - Minafra F
AU  - Pitzalis MV
AU  - Sorgente L
AU  - Rizzon P
FA  - Favale, S
FA  - Minafra, F
FA  - Pitzalis, M V
FA  - Sorgente, L
FA  - Rizzon, P
IN  - Favale,S. Division of Cardiology, University of Bari, Italy.
TI  - Patterns of atrioventricular conduction during postexercise recovery in patients with atrial fibrillation and Wolff-Parkinson-White syndrome.
SO  - Pacing & Clinical Electrophysiology. 14(11 Pt 1):1622-9, 1991 Nov.
AS  - Pacing Clin Electrophysiol. 14(11 Pt 1):1622-9, 1991 Nov.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrioventricular Node/pp [Physiopathology]
MH  - Atropine
MH  - *Cardiac Pacing, Artificial/mt [Methods]
MH  - Electrocardiography
MH  - *Exercise/ph [Physiology]
MH  - Exercise Test
MH  - Female
MH  - Humans
MH  - Male
MH  - Wolff-Parkinson-White Syndrome/co [Complications]
MH  - Wolff-Parkinson-White Syndrome/di [Diagnosis]
MH  - *Wolff-Parkinson-White Syndrome/pp [Physiopathology]
AB  - The effects of the postexercise recovery phase on the functional anterograde conduction properties of the accessory pathway (AP) were evaluated. Twenty-nine patients with Wolff-Parkinson-White (WPW) syndrome were submitted to supine maximal bicycle exercise testing. In seven patients (group I), in whom sustained atrial fibrillation (AF) could be induced by transesophageal pacing (TP), mean ventricular rate (MVR), the shortest R-R interval (SRR) between preexcited beats, and the observed percentage of preexcited beats were evaluated at rest, after each step of exercise and 2 minutes after the end of exercise. In 22 patients (group II), in whom sustained AF could not be induced, decremental TP was performed to evaluate the shortest atrial cycle length (SCL) with 1:1 conduction over AP at rest, after each step of exercise, and 2 minutes after the end of exercise. In four patients in group I, the protocol was repeated with atropine injected during the last minute of exercise. In 12 patients (three from group I and nine from group II), catecholamine plasma levels were measured at rest, at peak exercise, and during recovery. MVR was 144 +/- 20 beats/min at rest, 186 +/- 21 beats/min at peak exercise (P less than 0.001 vs rest), and 179 +/- 21 beats/min during recovery (P less than 0.001 vs rest; P less than 0.05 vs peak exercise). SRR was 289 +/- 73 msec at rest, 223 +/- 25 msec at peak exercise (P less than 0.05 vs rest), and 227 +/- 29 msec during recovery.(ABSTRACT TRUNCATED AT 250 WORDS)
RN  - 7C0697DR9I (Atropine)
IS  - 0147-8389
IL  - 0147-8389
PT  - Journal Article
LG  - English
DP  - 1991 Nov
DC  - 19920123
YR  - 1991
ED  - 19920123
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1721152

<872. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1742909
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wikner J
AU  - Larsen FF
AU  - Nordlander R
AU  - Pehrsson K
AU  - Astrom H
FA  - Wikner, J
FA  - Larsen, F F
FA  - Nordlander, R
FA  - Pehrsson, K
FA  - Astrom, H
IN  - Wikner,J. Division of Cardiology, Karolinska Hospital, Stockholm, Sweden.
TI  - Exercise performance and beta-adrenergic blockade in patients with complete heart block treated with ventricular inhibited pacing.
SO  - Clinical Cardiology. 14(9):749-52, 1991 Sep.
AS  - Clin Cardiol. 14(9):749-52, 1991 Sep.
NJ  - Clinical cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - de9, 7903272
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Combined Modality Therapy
MH  - Double-Blind Method
MH  - *Exercise Test/de [Drug Effects]
MH  - Female
MH  - Heart Block/pp [Physiopathology]
MH  - *Heart Block/th [Therapy]
MH  - Heart Ventricles/de [Drug Effects]
MH  - Heart Ventricles/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Pacemaker, Artificial
MH  - *Propranolol/tu [Therapeutic Use]
AB  - The effect of beta-adrenergic blockade (propranolol) on exercise performance was studied in 15 patients (12 men and 3 women, mean age 70 years) with complete heart block treated with a ventricular-inhibited pacemaker (VVI). In a double-blind procedure, the patients were randomly given either 0.1 mg/kg of propranolol or saline solution i.v. before a first exercise test and vice versa before a second test. The interval between the tests was 24 hours. Nine patients were in sinus rhythm, 4 patients had atrial flutter, and 2 others had atrial fibrillation. The exercise capacity was on an average 11% lower with propranolol than with placebo (p less than 0.001). The most marked reductions (20 and 33%) were found in the two patients with atrial fibrillation. The atrial rate in patients with sinus rhythm was significantly lower with propranolol than placebo both at rest (68 vs. 83 beats/min, p less than 0.001) and at maximal work load (91 vs. 141 beats/min, p less than 0.001). The present findings show that beta blockade has negative effects on exercise capacity in patients with complete heart block treated with VVI pacemakers. This finding should be considered in the selection of drug treatment in patients with fixed rate pacing and concomitant hypertension and/or ischemic heart disease.
RN  - 9Y8NXQ24VQ (Propranolol)
IS  - 0160-9289
IL  - 0160-9289
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 1991 Sep
DC  - 19920114
YR  - 1991
ED  - 19920114
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1742909

<873. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1959393
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Matsuda M
AU  - Matsuda Y
AU  - Tada T
AU  - Yamagishi T
AU  - Kusukawa R
FA  - Matsuda, M
FA  - Matsuda, Y
FA  - Tada, T
FA  - Yamagishi, T
FA  - Kusukawa, R
IN  - Matsuda,M. School of Allied Health Sciences, Yamaguchi University, Japan.
TI  - Absence of atrial contraction and exercise in patients with isolated atrial fibrillation.
SO  - Chest. 100(6):1549-52, 1991 Dec.
AS  - Chest. 100(6):1549-52, 1991 Dec.
NJ  - Chest
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0231335, d1c
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Anaerobic Threshold
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Blood Pressure
MH  - Heart Atria/pp [Physiopathology]
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Myocardial Contraction
MH  - Oxygen Consumption
MH  - *Physical Exertion
AB  - The aim of the study was to assess the effect of absence of atrial contraction during exercise. During the incremental ergometer exercise tests, heart rate, oxygen uptake, and oxygen pulse in patients with isolated atrial fibrillation were compared with those in control subjects at rest, at the exercise level of gas exchange anaerobic threshold, and at peak exercise. The study population consisted of 51 subjects aged 40 years or more: 12 patients with isolated atrial fibrillation and 39 control subjects with normal sinus rhythm. Heart rate in control subjects was lower than that in patients with isolated atrial fibrillation, at rest, anaerobic threshold, and peak exercise (74 +/- 12 vs 85 +/- 8 beats/min at rest, 108 +/- 16 vs 134 +/- 18 beats/min at anaerobic threshold, and 151 +/- 16 vs 173 +/- 22 beats/min at peak exercise, all p less than 0.01). During exercise, oxygen uptake in patients with isolated atrial fibrillation was not significantly different from that in control subjects. Oxygen pulse in patients with isolated atrial fibrillation was lower than that in control subjects during exercise (6.45 +/- 2.04 vs 7.84 +/- 1.63 ml/beat at anaerobic threshold, 7.79 +/- 2.28 vs 9.16 +/- 1.79 ml/beat at peak exercise, both p less than 0.05). In patients with isolated atrial fibrillation, the oxygen pulse might be reduced due to the lack of atrial contraction during exercise. However, the oxygen uptake that represents the exercise capacity would be preserved with the increase in heart rate.
IS  - 0012-3692
IL  - 0012-3692
PT  - Journal Article
LG  - English
DP  - 1991 Dec
DC  - 19920108
YR  - 1991
ED  - 19920108
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1959393

<874. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1951122
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ochi H
AU  - Izumi S
AU  - Murakami R
AU  - Shimada T
AU  - Morioka S
AU  - Moriyama K
FA  - Ochi, H
FA  - Izumi, S
FA  - Murakami, R
FA  - Shimada, T
FA  - Morioka, S
FA  - Moriyama, K
IN  - Ochi,H. Fourth Department of Internal Medicine, Shimane Medical University, Izumo-City, Japan.
TI  - Superior vena cava flow and tricuspid anular motion after cardioversion of atrial fibrillation, and role of right atrial relaxation on systolic venous return.
SO  - American Journal of Cardiology. 68(13):1335-9, 1991 Nov 15.
AS  - Am J Cardiol. 68(13):1335-9, 1991 Nov 15.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Atrial Function, Right/ph [Physiology]
MH  - *Electric Countershock
MH  - Female
MH  - *Hemodynamics/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Contraction/ph [Physiology]
MH  - *Tricuspid Valve/pp [Physiopathology]
MH  - *Vena Cava, Superior/pp [Physiopathology]
AB  - To determine whether atrial relaxation or systolic descent of the tricuspid anulus is the predominant factor determining systolic venous return, 22 patients with atrial fibrillation were studied. Venous return (i.e., superior vena cava (SVC) flow) was measured using pulsed Doppler echocardiography. Systolic descent of the tricuspid anulus (i.e., total excursion of tricuspid anulus during systole) was also measured using echocardiography. Serial examinations were performed before and after cardioversion of atrial fibrillation in 15 patients. In 11 patients, both the total excursion of the tricuspid anulus and SVC flow were examined in relation to the ratio of the preceding to the pre-preceding RR interval (R2/R1). Systolic forward flow of SVC increased as the ratio of late diastolic to total excursion of the tricuspid anulus (i.e., right atrial systolic function) increased. It correlated significantly with the ratio of late diastolic to total excursion of the tricuspid anulus but not with total excursion. Total excursion of the tricuspid anulus correlated significantly with R2/R1, but systolic forward flow of SVC did not. These results indicate that atrial relaxation rather than systolic descent of the tricuspid anulus was the predominant factor determining systolic forward flow in the SVC.
IS  - 0002-9149
IL  - 0002-9149
PT  - Journal Article
LG  - English
DP  - 1991 Nov 15
DC  - 19911213
YR  - 1991
ED  - 19911213
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1951122

<875. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1889058
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Matsuda M
AU  - Matsuda Y
AU  - Yamagishi T
AU  - Takahashi T
AU  - Haraguchi M
AU  - Tada T
AU  - Kusukawa R
FA  - Matsuda, M
FA  - Matsuda, Y
FA  - Yamagishi, T
FA  - Takahashi, T
FA  - Haraguchi, M
FA  - Tada, T
FA  - Kusukawa, R
IN  - Matsuda,M. School of Allied Health Sciences, Yamaguchi University, Japan.
TI  - Effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation.
SO  - Cardiovascular Research. 25(6):453-7, 1991 Jun.
AS  - Cardiovasc Res. 25(6):453-7, 1991 Jun.
NJ  - Cardiovascular research
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - cor, 0077427
SB  - Index Medicus
CP  - ENGLAND
MH  - Aged
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Chronic Disease
MH  - *Digoxin/tu [Therapeutic Use]
MH  - *Exercise/ph [Physiology]
MH  - Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxygen Consumption/de [Drug Effects]
MH  - *Propranolol/tu [Therapeutic Use]
MH  - *Verapamil/tu [Therapeutic Use]
AB  - STUDY OBJECTIVE: The aim was to evaluate the effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation.
AB  - DESIGN: Patients with chronic isolated atrial fibrillation underwent maximal exercise testing before and after the administration of digoxin, propranolol, or verapamil. Heart rate, oxygen uptake and oxygen pulse were observed at rest, at gas exchange anaerobic threshold, and at peak exercise.
AB  - SUBJECTS: The subjects were 10 patients (aged 48-78 years, mean age 60, SD 9, years) with chronic isolated atrial fibrillation.
AB  - MEASUREMENTS AND MAIN RESULTS: During exercise without medication, the heart rate was 85 (SD 8) beats.min-1 at rest, 127(19) at the level of anaerobic threshold, and 175(17) at peak exercise. With digoxin, heart rate was reduced to 75(9) beats.min-1 at rest (control v digoxin, p less than 0.01). However, reduction of heart rate was not seen at anaerobic threshold or at peak exercise. With propranolol, heart rate was 63(7) beats.min-1 at rest, 99(16) at anaerobic threshold, and 138(28) at peak exercise (control v propranolol, all p less than 0.01). Heart rate with verapamil was 70(13) beats.min-1 at rest, 107(30) at anaerobic threshold, and 138(28) at peak exercise (control v verapamil, p less than 0.05 at rest and at anaerobic threshold, p less than 0.01 at peak exercise. Neither digoxin, nor propranolol, nor verapamil changed the oxygen uptake during exercise. Without medication, oxygen pulse was 6.5(2.0) ml.beat-1 at anaerobic threshold and 7.7(2.1) ml.beat-1 at peak exercise. With digoxin, the change of oxygen pulse, versus without medication, was not significant at rest or at anaerobic threshold but was increased at peak exercise, at 8.3(2.1) v 7.7(2.1) ml.beat-1, p less than 0.05. With propranolol, oxygen pulse was increased to 8.2(1.9) ml.beat-1 at anaerobic threshold and 9.2(2.3) ml.beat-1 at peak exercise (control v propranolol, both p less than 0.01). With verapamil, oxygen pulse was increased to 8.7(1.8) ml.beat-1 at anaerobic threshold and 10.0(2.1) ml.beat-1 at peak exercise (control v verapamil, both p less than 0.01).
AB  - CONCLUSIONS: Digoxin was effective in reducing heart rate at rest, but failed to reduce it during exercise. Propranolol and verapamil reduced heart rate at all levels of exercise as well as at rest. Oxygen uptake during exercise (total exercise capacity) was not reduced with propranolol or verapamil; this was thought to have been accomplished by an increased oxygen pulse.
RN  - 73K4184T59 (Digoxin)
RN  - 9Y8NXQ24VQ (Propranolol)
RN  - CJ0O37KU29 (Verapamil)
IS  - 0008-6363
IL  - 0008-6363
PT  - Journal Article
LG  - English
DP  - 1991 Jun
DC  - 19911016
YR  - 1991
ED  - 19911016
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1889058

<876. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2071253
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Hsu TS
AU  - Lee YS
FA  - Hsu, T S
FA  - Lee, Y S
IN  - Hsu,T S. Cardiovascular Division, Chang Gung Memorial Hospital Taipei, Taiwan, Republic of China.
TI  - Endpoints of treadmill exercise testing for functional evaluation of patients with mitral stenosis.
SO  - International Journal of Cardiology. 31(1):81-7, 1991 Apr.
AS  - Int J Cardiol. 31(1):81-7, 1991 Apr.
NJ  - International journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - gqw, 8200291
SB  - Index Medicus
CP  - NETHERLANDS
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Analysis of Variance
MH  - Arrhythmias, Cardiac/et [Etiology]
MH  - Blood Pressure
MH  - Chi-Square Distribution
MH  - Exercise Test/ae [Adverse Effects]
MH  - *Exercise Test
MH  - Female
MH  - Heart Rate
MH  - Heart Ventricles
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mitral Valve Stenosis/pp [Physiopathology]
AB  - The study was performed on 122 patients proved by catheterization to have dominant mitral stenosis so as to define proper endpoints of exercise testing for functional evaluation. This represents the 14-year experience with mitral stenosis in our exercise laboratory. Of them, we investigated 126 who completed clinically event-free Naughton treadmill exercise tests. Excess peak exercise heart rates (over 150 beats per minute, 63%) and exertional hypotensive responses (59%, probably including factitious responses due to unreliable indirect pressure readings) did not correlate with the severity of mitral stenosis. Without limiting symptoms and major ventricular arrhythmias, either of the above as endpoints may cause the test to be halted prematurely in half the cases. Ventricular arrhythmias (60%; in complex forms, 20%; possibly contaminated by aberrancy in atrial fibrillation and aggravated by digitalis/diuretics) did not correlate with severity of stenosis either, but the only one major complication we met was secondary to ventricular tachyarrhythmia. Limiting symptoms (83%; of them 94% being dyspnea/fatigue correlating with severity at P less than 0.01) and complex ventricular arrhythmias as endpoints terminated 85% of the tests safely in this series. Atrial thrombuses (34%, all non-floating) did not cause any related complications. Thus, we concluded that limiting symptoms and complex ventricular arrhythmias are the proper endpoints in evaluating the exercise capacity of patients with mitral stenosis after prior echocardiographic exclusion of those with potentially risky floating thrombus.
IS  - 0167-5273
IL  - 0167-5273
PT  - Journal Article
LG  - English
DP  - 1991 Apr
DC  - 19910821
YR  - 1991
ED  - 19910821
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=2071253

<877. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2055672
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Opolski G
AU  - Stanislawska J
AU  - Slomka K
AU  - Kraska T
FA  - Opolski, G
FA  - Stanislawska, J
FA  - Slomka, K
FA  - Kraska, T
IN  - Opolski,G. Department of Cardiology, Medical Academy, Warsaw, Poland.
TI  - Value of the atrial signal-averaged electrocardiogram in identifying patients with paroxysmal atrial fibrillation.
SO  - International Journal of Cardiology. 30(3):315-9, 1991 Mar.
AS  - Int J Cardiol. 30(3):315-9, 1991 Mar.
NJ  - International journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - gqw, 8200291
SB  - Index Medicus
CP  - NETHERLANDS
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - *Electrocardiography/mt [Methods]
MH  - Exercise
MH  - Female
MH  - Heart Atria/pp [Physiopathology]
MH  - Heart Function Tests
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Signal Processing, Computer-Assisted
AB  - Atrial signal-averaged electrocardiogram was compared between 25 patients with paroxysmal atrial fibrillation and 20 healthy persons without atrial arrhythmias (control). The duration time of the high frequency (50-250 Hz) P wave was significantly (P less than 0.01) prolonged in the groups of patients with paroxysmal atrial fibrillation compared with the control group (116 +/- 16.4 versus 92 +/- 8.1 msec). The diagnostic value of the duration of the high frequency P wave for identifying patients with paroxysmal atrial fibrillation was 104 msec. Using this criterion, a sensitivity of 76% and a specificity of 90% were achieved. Our observation has shown that the atrial signal-averaged electrocardiogram is a useful technique for identifying patients with paroxysmal atrial fibrillation.
IS  - 0167-5273
IL  - 0167-5273
PT  - Journal Article
LG  - English
DP  - 1991 Mar
DC  - 19910801
YR  - 1991
ED  - 19910801
RD  - 20060712
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=2055672

<878. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2054244
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Botker HE
AU  - Toft P
AU  - Klitgaard NA
AU  - Simonsen EE
FA  - Botker, H E
FA  - Toft, P
FA  - Klitgaard, N A
FA  - Simonsen, E E
IN  - Botker,H E. Department of Internal Medicine, Haderslev Hospital, Denmark.
TI  - Influence of physical exercise on serum digoxin concentration and heart rate in patients with atrial fibrillation.
SO  - British Heart Journal. 65(6):337-41, 1991 Jun.
AS  - Br Heart J. 65(6):337-41, 1991 Jun.
NJ  - British heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - ats, 0370634
OI  - Source: NLM. PMC1024678
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - ENGLAND
MH  - Adult
MH  - Atrial Fibrillation/bl [Blood]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Coronary Disease/pp [Physiopathology]
MH  - *Digoxin/bl [Blood]
MH  - Digoxin/tu [Therapeutic Use]
MH  - Heart Rate/de [Drug Effects]
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Physical Exertion/ph [Physiology]
AB  - Heart rate and serum digoxin concentration in eight patients with atrial fibrillation were studied at rest and during exercise when initial serum digoxin concentrations were zero and at low and high therapeutic values. Eight patients with ischemic heart disease and in sinus rhythm were studied for comparison. Though the serum digoxin concentration decreased significantly during exercise, the absolute reduction in heart rate was the same at rest and during exercise in patients with atrial fibrillation. Compared with the control patients in sinus rhythm, the heart rate in patients with atrial fibrillation was not adequately controlled during exercise by any serum digoxin concentration tested despite a reduction in heart rate with increasing digoxin concentration. The effects of digoxin on heart rate regulation in atrial fibrillation are complex and include direct effects on the myocardium as well as indirect effects mediated by modulation of the autonomic nervous system; the present results indicate that the drug is not displaced from the target organs by decreasing serum concentrations during exercise. In atrial fibrillation, because the demands on the filter function of the atrioventricular node are highly unphysiological, the effect of digoxin on heart rate during exercise is not adequate.
RN  - 73K4184T59 (Digoxin)
IS  - 0007-0769
IL  - 0007-0769
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1991 Jun
DC  - 19910731
YR  - 1991
ED  - 19910731
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=2054244

<879. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1828196
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Berglund H
AU  - Jensen-Urstad M
AU  - Theodorsson E
AU  - Bevegard S
FA  - Berglund, H
FA  - Jensen-Urstad, M
FA  - Theodorsson, E
FA  - Bevegard, S
IN  - Berglund,H. Department of Clinical Physiology, Sodersjukhuset, Stockholm, Sweden.
TI  - Plasma levels of atrial natriuretic peptide at rest and during exercise in heart failure--influence of cardiac rhythm and haemodynamics.
SO  - Clinical Physiology. 11(2):183-96, 1991 Mar.
AS  - Clin Physiol. 11(2):183-96, 1991 Mar.
NJ  - Clinical physiology (Oxford, England)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - dkg, 8309768
SB  - Index Medicus
CP  - ENGLAND
MH  - Adult
MH  - Aged
MH  - Arginine Vasopressin/bl [Blood]
MH  - Arginine Vasopressin/ph [Physiology]
MH  - *Atrial Natriuretic Factor/bl [Blood]
MH  - Atrial Natriuretic Factor/ph [Physiology]
MH  - Blood Pressure
MH  - *Cardiac Output, Low/bl [Blood]
MH  - Cardiac Output, Low/pp [Physiopathology]
MH  - *Exercise
MH  - Female
MH  - *Hemodynamics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pulmonary Wedge Pressure
MH  - Radioimmunoassay
MH  - Rest
AB  - The relationship between plasma levels of immunoreactive atrial natriuretic peptide (ir-ANP), arginine vasopressin (AVP), cardiac rhythm and different haemodynamic variables were studied at rest and during exercise in 16 patients with heart failure undergoing heart catheterization for clinically indicated reasons. Even though there was no significant relationship between pulmonary capillary wedge pressure (PCW) and ir-ANP at rest (r = 0.39; P = 0.14) changes in these variables with exercise correlated well (r = 0.71; P = 0.002). Change in right atrial mean pressure, heart rate, mean arterial blood pressure or cardiac index did not significantly influence change in plasma levels of ir-ANP. The correlation between PCW and AVP at rest (r = 0.92; P less than 0.001) disappeared during exercise. Calculated ir-ANP/PCW ratios decreased slightly during exercise, but were not influenced by initial atrial pressures or atrial fibrillation. These observations provide evidence for a similar responsiveness of ANP in patients with sinus rhythm and atrial fibrillation. The ability of rapid change in ANP plasma levels during exercise was preserved and proportional to changes in PCW over a wide pressure range in the studied patient group. This finding indicates that left atrium distension rather than right atrium distension is the major determinant for the release of ANP in patients with congestive heart failure. The observed rapid responsiveness of ANP to change in left atrial pressure may allow the hormone to modulate haemodynamic response during short periods of exercise.
RN  - 113-79-1 (Arginine Vasopressin)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
IS  - 0144-5979
IL  - 0144-5979
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1991 Mar
DC  - 19910708
YR  - 1991
ED  - 19910708
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1828196

<880. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2013988
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Weigel TJ
AU  - Porter CJ
AU  - Mottram CD
AU  - Driscoll DJ
FA  - Weigel, T J
FA  - Porter, C J
FA  - Mottram, C D
FA  - Driscoll, D J
IN  - Weigel,T J. Section of Pediatric Cardiology, Mayo Clinic, Rochester, MN 55905.
TI  - Detecting arrhythmia by exercise electrocardiography in pediatric patients: assessment of sensitivity and influence on clinical management.
SO  - Mayo Clinic Proceedings. 66(4):379-86, 1991 Apr.
AS  - Mayo Clin Proc. 66(4):379-86, 1991 Apr.
NJ  - Mayo Clinic proceedings
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0405543, lly
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adolescent
MH  - Adult
MH  - Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - *Arrhythmias, Cardiac/di [Diagnosis]
MH  - Arrhythmias, Cardiac/pp [Physiopathology]
MH  - Arrhythmias, Cardiac/th [Therapy]
MH  - Cardiac Pacing, Artificial
MH  - Child
MH  - Child, Preschool
MH  - *Electrocardiography
MH  - Electrocardiography, Ambulatory
MH  - *Exercise Test
MH  - Female
MH  - Heart Block/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Retrospective Studies
MH  - Sensitivity and Specificity
AB  - We studied 49 patients with suspected arrhythmias (group 1) and 92 patients with previously documented arrhythmias (group 2) who underwent exercise electrocardiography (EECG) at our institution between 1979 and 1987. Among group 1 patients, all of whom had sinus rhythm before exercise, 10 (20%) had abnormal findings on EECG, and treatment was modified in 4 of these 10 (8% of group 1). Further testing (24-hour ambulatory or transtelephonic electrocardiographic monitoring or electrophysiologic study) of the 39 patients with normal EECG findings revealed 8 additional patients with arrhythmias. In group 1, the sensitivity of EECG was 56%, and its negative predictive value was 79%. Group 2 consisted of 38 patients with atrial arrhythmias, 31 with ventricular arrhythmias, and 23 with atrioventricular conduction abnormalities before EECG. Of these 92 patients, 68 (74%) had abnormal EECG findings. All but 1 of the 24 patients with normal findings underwent further testing, and rhythm abnormalities were induced in 16. Patients with atrial arrhythmias were more likely to have normal EECG results (42%) than were those with ventricular arrhythmias (23%) or an atrioventricular conduction abnormality (4%). Of the 35 patients who had been referred for suppression of an arrhythmia, 25 (71%) had abnormal rhythm suppressed during exercise. Clinical management was modified in 27% of group 2 patients on the basis of EECG findings.
RN  - 0 (Anti-Arrhythmia Agents)
IS  - 0025-6196
IL  - 0025-6196
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 1991 Apr
DC  - 19910510
YR  - 1991
ED  - 19910510
RD  - 20131213
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=2013988

<881. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2073646
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mezzani A
AU  - Giovannini T
AU  - Michelucci A
AU  - Padeletti L
AU  - Resina A
AU  - Cupelli V
AU  - Musante R
FA  - Mezzani, A
FA  - Giovannini, T
FA  - Michelucci, A
FA  - Padeletti, L
FA  - Resina, A
FA  - Cupelli, V
FA  - Musante, R
IN  - Mezzani,A. Clinica Medica I, Universita di Firenze, Italia.
TI  - Effects of training on the electrophysiologic properties of atrium and accessory pathway in athletes with Wolff-Parkinson-White syndrome.
SO  - Cardiology. 77(4):295-302, 1990.
AS  - Cardiology. 77(4):295-302, 1990.
NJ  - Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - coi, 1266406
SB  - Index Medicus
CP  - SWITZERLAND
MH  - Adolescent
MH  - Adult
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Function
MH  - *Electrocardiography
MH  - Exercise/ph [Physiology]
MH  - Female
MH  - Humans
MH  - Male
MH  - Risk Factors
MH  - *Sports
MH  - *Wolff-Parkinson-White Syndrome/pp [Physiopathology]
AB  - Twenty-two subjects with Wolff-Parkinson-White (WPW) electrocardiographic pattern performing agonistic physical activity were referred to our laboratory to assess arrhythmogenic risk (group 1). This allowed us to evaluate a less known aspect, namely that of effects of training on the electrophysiologic properties of the atrium and accessory pathway. This was done utilizing a control group of 10 WPW patients who did not perform agonistic physical activity (group 2). All subjects were symptom free, and without signs of associated cardiopathy if we exclude 1 patient of group 1, who presented moderate mitral valve prolapse. Group 1 patients showed significantly higher mean values for basic cycle length (p less than 0.001), atrial effective (p less than 0.04) and functional (p less than 0.02) refractory period, and anterograde effective refractory period of the accessory pathway (p less than 0.02). The different behavior observed in group 1 patients could be explained considering the known influence of training on the equilibrium of the autonomic nervous system. Moreover, it is noteworthy that the two groups did not differ for inducibility of atrial fibrillation (AF). This should be taken into account considering the importance of AF in WPW. In conclusion, our study does not demonstrate any negative electrophysiologic effects of training in patients with WPW.
IS  - 0008-6312
IL  - 0008-6312
PT  - Journal Article
LG  - English
DP  - 1990
DC  - 19910415
YR  - 1990
ED  - 19910415
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=2073646

<882. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2287050
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Toyomasu K
AU  - Nishiyama Y
AU  - Yoshida N
AU  - Sugimoto S
AU  - Noda T
AU  - Motonaga I
AU  - Koga Y
AU  - Toshima H
FA  - Toyomasu, K
FA  - Nishiyama, Y
FA  - Yoshida, N
FA  - Sugimoto, S
FA  - Noda, T
FA  - Motonaga, I
FA  - Koga, Y
FA  - Toshima, H
IN  - Toyomasu,K. 3rd Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan.
TI  - Physical training in patients with valvular heart disease after surgery.
SO  - Japanese Circulation Journal. 54(11):1451-8, 1990 Nov.
AS  - Jpn Circ J. 54(11):1451-8, 1990 Nov.
NJ  - Japanese circulation journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - kgn, 7806868
SB  - Index Medicus
CP  - JAPAN
MH  - Adult
MH  - *Cardiac Surgical Procedures/rh [Rehabilitation]
MH  - Exercise Test
MH  - *Exercise Therapy
MH  - Female
MH  - Heart Rate
MH  - Heart Valve Diseases/pp [Physiopathology]
MH  - *Heart Valve Diseases/rh [Rehabilitation]
MH  - Humans
MH  - Male
MH  - Middle Aged
AB  - The necessity, the methodology and clinical benefit of physical training were evaluated in 85 patients with valvular heart surgery. In 21 patients who had undergone the exercise stress test before surgery, corrective valvular surgery increased maximal oxygen uptake (max.VO2) from 15.4 before to 18.9 ml/min/kg, while 11 (52%) of them failed to increase exercise capacity over 5 METs. Of the total 85 patients, 41 (58%) again showed reduced exercise capacity in the initial postoperative stress test, suggesting that a return to work might be difficult without rehabilitation in these patients. We then compared two training programs: program A of short duration and frequent exercise and program B of longer duration and less frequent exercise, both using a bicycle exercise set at an intensity of 70% of the max.VO2. Both programs similarly increased max.VO2, while patients preferred program A, suggesting that exercise of longer duration could not be tolerated because of deconditioning. Program A was then prescribed to 62 patients, and it increased max.VO2 from 18.2 to 20.7 ml/min/kg after 4 weeks training without any complication. In 9 patients who served as controls undergoing no physical training, no spontaneous improvement in exercise capacity was observed. Of the 76 patients who received either program A or B, 28 patients failed to increase the max.VO2 by 10% or more. These patients presented atrial fibrillation, a cardiothoracic ratio greater than or equal to 60% or exercise-induced ST depression more frequently, suggesting that residual cardiac dysfunction might inhibit the training effects.(ABSTRACT TRUNCATED AT 250 WORDS)
IS  - 0047-1828
IL  - 0047-1828
PT  - Journal Article
LG  - English
DP  - 1990 Nov
DC  - 19910322
YR  - 1990
ED  - 19910322
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=2287050

<883. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1704552
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Spencer WH 3rd
AU  - Markowitz T
AU  - Alagona P
FA  - Spencer, W H 3rd
FA  - Markowitz, T
FA  - Alagona, P
IN  - Spencer,W H 3rd. Baylor College of Medicine, Houston, TX 75246.
TI  - Rate augmentation and atrial arrhythmias in DDDR pacing.
SO  - Pacing & Clinical Electrophysiology. 13(12 Pt 2):1847-51, 1990 Dec.
AS  - Pacing Clin Electrophysiol. 13(12 Pt 2):1847-51, 1990 Dec.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Activities of Daily Living
MH  - Aged
MH  - Arrhythmias, Cardiac/pp [Physiopathology]
MH  - *Arrhythmias, Cardiac/th [Therapy]
MH  - Atrioventricular Node/pp [Physiopathology]
MH  - Cardiac Pacing, Artificial/ae [Adverse Effects]
MH  - *Cardiac Pacing, Artificial/mt [Methods]
MH  - Electrocardiography, Ambulatory
MH  - Exercise/ph [Physiology]
MH  - Female
MH  - Heart Block/pp [Physiopathology]
MH  - Heart Block/th [Therapy]
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Sick Sinus Syndrome/pp [Physiopathology]
MH  - Sick Sinus Syndrome/th [Therapy]
MH  - Single-Blind Method
AB  - Dual chamber, rate-modulated pacemakers provide the capability of augmenting the heart rate of patients with chronotropic incompetence but also may cause atrial arrhythmias because of high rate, competitive atrial pacing. We studied ten patients with two consecutive 24-hour Holter monitors during which they were alternately programmed to either DDD or DDDR pacing in random order. Maximum heart rates (max HR) were measured at every 15-minute interval during each 24-hour period. DDDR pacing showed rate augmentation, 80 +/- 7 average max HR when compared with DDD pacing, average max HR 76 +/- 5. These results were even more striking when waking hours (7 am to 10 pm) were compared: average max HR 86 +/- 7 DDDR versus 78 +/- 4 average max HR DDD. Several patients showed marked rate augmentation. Seven of ten patients preferred DDDR pacing over DDD pacing. In the entire population, DDDR pacing did not result in an increased number of atrial arrhythmias (1.25 atrial events/24 hour) when compared to DDD pacing (1.75 atrial events/24 hour). We conclude that DDDR pacing provides heart rate augmentation during daily life in a clinical population while not resulting in a significant increase in atrial arrhythmias.
IS  - 0147-8389
IL  - 0147-8389
PT  - Journal Article
LG  - English
DP  - 1990 Dec
DC  - 19910319
YR  - 1990
ED  - 19910319
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1704552

<884. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1704537
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Langenfeld H
AU  - Schneider B
AU  - Grimm W
AU  - Beer M
AU  - Knoche M
AU  - Riegger G
AU  - Kochsiek K
FA  - Langenfeld, H
FA  - Schneider, B
FA  - Grimm, W
FA  - Beer, M
FA  - Knoche, M
FA  - Riegger, G
FA  - Kochsiek, K
IN  - Langenfeld,H. University Hospital of Internal Medicine, Wurzburg, Federal Republic of Germany.
TI  - The six-minute walk--an adequate exercise test for pacemaker patients?.
SO  - Pacing & Clinical Electrophysiology. 13(12 Pt 2):1761-5, 1990 Dec.
AS  - Pacing Clin Electrophysiol. 13(12 Pt 2):1761-5, 1990 Dec.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/th [Therapy]
MH  - Dyspnea/pp [Physiopathology]
MH  - Electrocardiography
MH  - *Exercise Test/mt [Methods]
MH  - Female
MH  - Heart Block/pp [Physiopathology]
MH  - Heart Block/th [Therapy]
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - *Pacemaker, Artificial
MH  - Physical Exertion/ph [Physiology]
MH  - Sick Sinus Syndrome/pp [Physiopathology]
MH  - Sick Sinus Syndrome/th [Therapy]
MH  - Time Factors
MH  - *Walking
AB  - In many pacemaker patients bicycle and treadmill ergometry are not practicable. As an alternative, we performed a 6-minute walk on a 20-m corridor in 97 pacemaker patients, who were asked to walk as far as possible determining their speed by themselves. Results were compared with those of bicycle ergometry in 42 of these patients and with treadmill exercise of a group of 92 other pacemaker patients. In the 6-minute walk, performance and maximal heart rate were slightly lower (49 +/- 18 W; 96 +/- 23 beats/min) than in bicycle (57 +/- 16 W; 110 +/- 26 beats/min) and treadmill ergometry (50 +/- 37 W; 102 +/- 35 beats/min). A good correlation was found between walking and bicycling (r = 0.74) and in subgroups of patients with different pacemaker indications. All patients preferred the walk to bicycle ergometry considering it to be more related to daily physical activity. In conclusion, a 6-minute walk is a simple and physiological exercise test for nearly all pacemaker patients with good correlation to other types of exercise. It seems to be preferable to other tests because of its better acceptance and practicability.
IS  - 0147-8389
IL  - 0147-8389
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 1990 Dec
DC  - 19910319
YR  - 1990
ED  - 19910319
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1704537

<885. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1704535
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Sermasi S
AU  - Marconi M
AU  - Marzaloni M
FA  - Sermasi, S
FA  - Marconi, M
FA  - Marzaloni, M
IN  - Sermasi,S. Department of Cardiology, Ospedale Infermi, Rimini-Nord, Italy.
TI  - Usefulness of 1-hour and 24-hour heart rate Holter inbuilt in new TX* rate adaptive pacemakers.
SO  - Pacing & Clinical Electrophysiology. 13(12 Pt 2):1751-4, 1990 Dec.
AS  - Pacing Clin Electrophysiol. 13(12 Pt 2):1751-4, 1990 Dec.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/th [Therapy]
MH  - Cardiac Pacing, Artificial/mt [Methods]
MH  - Computers
MH  - Electrocardiography
MH  - Electrocardiography, Ambulatory/is [Instrumentation]
MH  - *Electrocardiography, Ambulatory
MH  - Equipment Design
MH  - Exercise/ph [Physiology]
MH  - Heart Block/pp [Physiopathology]
MH  - Heart Block/th [Therapy]
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Information Storage and Retrieval
MH  - *Pacemaker, Artificial
MH  - Time Factors
AB  - The rate adaptive TX* pacemaker uses the evoked QT interval as an indicator of physiological demand. In order to obtain a rate adaptation close to physiological patterns we used in the past, in each patient, on the slope value and/or the T wave sensing window, controlling via exercise stress testing and Holter the results achieved. It was an expensive method, but the system produced effective rate responsive pacing. The new series of TX* pacemakers (Quintech 919 and Rhythmyx), beside the dynamic slope feature, are equipped with a 1-hour heart rate Holter (HRH) that can be used during effort without the need for manually recording the heart rate. In this mode TX* pacemakers calculate the average heart rate over 20-second periods and stores the values continuously for 1 hour. In addition, a 24-hour HRH is available, which calculates the average heart rate over 7.5-minute periods, showing heart rate trend during the last day prior to interrogation. Each HRH can be accessed by the programmer and printed out. Using four Quintech 919* and five Rhythmyx units, the inbuilt HRH proved its utility by making the heart rate adaptation checking procedure easier, faster, and more economic.
IS  - 0147-8389
IL  - 0147-8389
PT  - Journal Article
LG  - English
DP  - 1990 Dec
DC  - 19910319
YR  - 1990
ED  - 19910319
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1704535

<886. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2379945
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Friberg P
AU  - Meredith I
AU  - Jennings G
AU  - Lambert G
AU  - Fazio V
AU  - Esler M
FA  - Friberg, P
FA  - Meredith, I
FA  - Jennings, G
FA  - Lambert, G
FA  - Fazio, V
FA  - Esler, M
IN  - Friberg,P. Clinical Research Unit, Baker Medical Research Institute/Alfred Hospital, Prahran, Victoria, Australia.
TI  - Evidence for increased renal norepinephrine overflow during sodium restriction in humans.
SO  - Hypertension. 16(2):121-30, 1990 Aug.
AS  - Hypertension. 16(2):121-30, 1990 Aug.
NJ  - Hypertension (Dallas, Tex. : 1979)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - gk7, 7906255
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Atrial Fibrillation/et [Etiology]
MH  - Blood Pressure
MH  - Desipramine/pd [Pharmacology]
MH  - *Diet, Sodium-Restricted
MH  - Humans
MH  - Kidney/ir [Innervation]
MH  - *Kidney/se [Secretion]
MH  - Male
MH  - Middle Aged
MH  - *Norepinephrine/se [Secretion]
MH  - Sympathetic Nervous System/ph [Physiology]
AB  - To investigate the differentiated pattern of efferent sympathetic nerve activity by means of analyzing norepinephrine kinetics in response to sodium restriction, cardiorenal sympathetic activity during rest and mental stress was studied in 12 subjects (33.3 +/- 2.6 years old, SEM) exposed to a low and a normal sodium diet; 5-40 mmol and 160-200 mmol/24 hours, respectively (crossover design). Organ norepinephrine release was calculated from organ plasma flow, arteriovenous plasma concentration gradient across the organ and the organ's fractional extraction of radiolabeled norepinephrine. Body weight and urinary sodium/24 hr fell significantly and urinary potassium/24 hr and both supine and standing blood pressure remained unchanged. Total norepinephrine release to plasma and norepinephrine plasma clearance were similar in both phases (approximately 460 ng/min and 1.90 l/min, respectively). A 138% increase in renal norepinephrine overflow was observed during sodium restriction (from 112 to 267 ng/min, p less than 0.025), which was due to elevated renal vein norepinephrine (434 versus 290 pg/ml, p less than 0.01) because renal plasma flow and renal norepinephrine extraction were unaltered. Similarly, sodium restriction caused a 168% elevation of renal renin secretion (p less than 0.05). Resting cardiac norepinephrine spillover and cardiac norepinephrine reuptake were unchanged between the two salt phases. Total and cardiac norepinephrine release, supine blood pressure, and heart rate increased to about the same extent in response to mental testing regardless of salt phase. In conclusion, sodium restriction induced a differential and physiological increase in resting renal sympathetic nervous activity, leaving cardiac norepinephrine overflow unchanged. Cardiac norepinephrine uptake was normal, which further supports the concept of a true increase of efferent renal nerve activity.
RN  - TG537D343B (Desipramine)
RN  - X4W3ENH1CV (Norepinephrine)
IS  - 0194-911X
IL  - 0194-911X
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1990 Aug
DC  - 19900910
YR  - 1990
ED  - 19900910
RD  - 20160726
UP  - 20160727
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=2379945

<887. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2379945
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Friberg P
AU  - Meredith I
AU  - Jennings G
AU  - Lambert G
AU  - Fazio V
AU  - Esler M
FA  - Friberg, P
FA  - Meredith, I
FA  - Jennings, G
FA  - Lambert, G
FA  - Fazio, V
FA  - Esler, M
IN  - Friberg,P. Clinical Research Unit, Baker Medical Research Institute/Alfred Hospital, Prahran, Victoria, Australia.
TI  - Evidence for increased renal norepinephrine overflow during sodium restriction in humans.
SO  - Hypertension. 16(2):121-30, 1990 Aug.
AS  - Hypertension. 16(2):121-30, 1990 Aug.
NJ  - Hypertension
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - gk7, 7906255
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Atrial Fibrillation/et [Etiology]
MH  - Blood Pressure
MH  - Desipramine/pd [Pharmacology]
MH  - *Diet, Sodium-Restricted
MH  - Humans
MH  - Kidney/ir [Innervation]
MH  - *Kidney/se [Secretion]
MH  - Male
MH  - Middle Aged
MH  - *Norepinephrine/se [Secretion]
MH  - Sympathetic Nervous System/ph [Physiology]
AB  - To investigate the differentiated pattern of efferent sympathetic nerve activity by means of analyzing norepinephrine kinetics in response to sodium restriction, cardiorenal sympathetic activity during rest and mental stress was studied in 12 subjects (33.3 +/- 2.6 years old, SEM) exposed to a low and a normal sodium diet; 5-40 mmol and 160-200 mmol/24 hours, respectively (crossover design). Organ norepinephrine release was calculated from organ plasma flow, arteriovenous plasma concentration gradient across the organ and the organ's fractional extraction of radiolabeled norepinephrine. Body weight and urinary sodium/24 hr fell significantly and urinary potassium/24 hr and both supine and standing blood pressure remained unchanged. Total norepinephrine release to plasma and norepinephrine plasma clearance were similar in both phases (approximately 460 ng/min and 1.90 l/min, respectively). A 138% increase in renal norepinephrine overflow was observed during sodium restriction (from 112 to 267 ng/min, p less than 0.025), which was due to elevated renal vein norepinephrine (434 versus 290 pg/ml, p less than 0.01) because renal plasma flow and renal norepinephrine extraction were unaltered. Similarly, sodium restriction caused a 168% elevation of renal renin secretion (p less than 0.05). Resting cardiac norepinephrine spillover and cardiac norepinephrine reuptake were unchanged between the two salt phases. Total and cardiac norepinephrine release, supine blood pressure, and heart rate increased to about the same extent in response to mental testing regardless of salt phase. In conclusion, sodium restriction induced a differential and physiological increase in resting renal sympathetic nervous activity, leaving cardiac norepinephrine overflow unchanged. Cardiac norepinephrine uptake was normal, which further supports the concept of a true increase of efferent renal nerve activity.
RN  - TG537D343B (Desipramine)
RN  - X4W3ENH1CV (Norepinephrine)
IS  - 0194-911X
IL  - 0194-911X
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1990 Aug
DC  - 19900910
YR  - 1990
ED  - 19900910
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=2379945

<888. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2358610
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lundstrom T
AU  - Ryden L
FA  - Lundstrom, T
FA  - Ryden, L
IN  - Lundstrom,T. Department of Cardiology, Central Hospital, Skovde, Sweden.
TI  - Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil.
SO  - Journal of the American College of Cardiology. 16(1):86-90, 1990 Jul.
AS  - J Am Coll Cardiol. 16(1):86-90, 1990 Jul.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - h50, 8301365
OI  - Source: NASA. 90293309
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
SB  - National Aeronautics and Space Administration (NASA) Journals
CP  - UNITED STATES
MH  - Aged
MH  - Anaerobic Threshold/de [Drug Effects]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Diltiazem/ae [Adverse Effects]
MH  - *Diltiazem/tu [Therapeutic Use]
MH  - Electrocardiography, Ambulatory
MH  - Female
MH  - Hemodynamics/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxygen Consumption/de [Drug Effects]
MH  - *Physical Exertion/de [Drug Effects]
MH  - Pulmonary Gas Exchange/de [Drug Effects]
MH  - Verapamil/ae [Adverse Effects]
MH  - *Verapamil/tu [Therapeutic Use]
AB  - The effects of two calcium channel blockers, diltiazem (270 mg/day) and verapamil (240 mg/day), were studied in 18 patients with chronic atrial fibrillation. During 24 h Holter electrocardiographic monitoring, mean ventricular rate (beats/min) decreased from 88 +/- 14 with placebo to 76 +/- 13 (p less than 0.001) with diltiazem and 80 +/- 11 (p less than 0.01) with verapamil. Maximal symptom-limited exercise tolerance (W) increased from 127 +/- 39 during the placebo period to 136 +/- 42 (p less than 0.01) with diltiazem and 137 +/- 39 (p less than 0.01) with verapamil. Ventricular rate and rate-pressure product were lower at rest and during exercise with diltiazem and verapamil than with placebo (p less than 0.001), with the drugs being similarly effective. Ventricular rate at maximal exercise (beats/min) was 179 +/- 13 with placebo compared with 159 +/- 21 with diltiazem and 158 +/- 23 with verapamil. Maximal oxygen uptake (ml/kg per min) was 22.3 +/- 4.5 with placebo, 23.7 +/- 4.9 (p less than 0.05) with diltiazem and 22.9 +/- 4.5 with verapamil (p = NS). Respiratory gas exchange anaerobic threshold was reached at a work load (W) of 76 +/- 21 with placebo, 84 +/- 27 (p less than 0.05) with diltiazem and 85 +/- 23 (p less than 0.01) with verapamil. In conclusion, patients with chronic atrial fibrillation have modestly improved exercise tolerance with calcium channel blockade therapy. The dromotropic responses and the effects on physical performance are of similar magnitude for diltiazem and verapamil.
RN  - CJ0O37KU29 (Verapamil)
RN  - EE92BBP03H (Diltiazem)
IS  - 0735-1097
IL  - 0735-1097
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1990 Jul
DC  - 19900731
YR  - 1990
ED  - 19900731
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=2358610

<889. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1693198
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Jordaens L
AU  - Backers J
AU  - Moerman E
AU  - Clement DL
FA  - Jordaens, L
FA  - Backers, J
FA  - Moerman, E
FA  - Clement, D L
IN  - Jordaens,L. Department of Cardiology, University Hospital, Ghent, Belgium.
TI  - Catecholamine levels and pacing behavior of QT-driven pacemakers during exercise.
SO  - Pacing & Clinical Electrophysiology. 13(5):603-7, 1990 May.
AS  - Pacing Clin Electrophysiol. 13(5):603-7, 1990 May.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Fibrillation/bl [Blood]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/th [Therapy]
MH  - *Epinephrine/bl [Blood]
MH  - *Exercise/ph [Physiology]
MH  - Female
MH  - Heart Block/bl [Blood]
MH  - *Heart Block/pp [Physiopathology]
MH  - Heart Block/th [Therapy]
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Norepinephrine/bl [Blood]
MH  - Oxygen Consumption/ph [Physiology]
MH  - *Pacemaker, Artificial
AB  - It is thought that increasing catecholamine levels in the heart are partly responsible for shortening of the repolarization time and so indirectly for the pacing behavior of the QT driven pacemaker. Adrenaline and noradrenaline (NA) plasma levels were determined at rest, during symptom-limited exercise, and during recovery more than 1 month after the implantation of a 919 or a Rhythmyx pacemaker (Vitatron, The Netherlands) in eight patients (age 54-85 yrs). Significant increases were detected in NA level (from 0.57 +/- 0.23 ng/mL to 2.15 +/- 0.76 ng/mL), but not in the circulating adrenaline level. The correlation coefficient of the mean pacing rate and the mean NA level during exercise and recovery was 0.963 (P less than 0.0001), the correlation coefficient with the mean oxygen consumption was 0.888 (P less than 0.01). No correlation with the adrenaline level was observed. The correlation coefficient of the changes of pacing rate and the changes of NA level during exercise and recovery was 0.882 (P less than 0.005). The pacing rate of the new generation of QT driven pacemakers is closely correlated with the noradrenaline spillover in the plasma, not with the adrenaline level. A short delay (less than 1 minute) is observed in the adaptation.
RN  - X4W3ENH1CV (Norepinephrine)
RN  - YKH834O4BH (Epinephrine)
IS  - 0147-8389
IL  - 0147-8389
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 1990 May
DC  - 19900705
YR  - 1990
ED  - 19900705
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1693198

<890. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1692533
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lewis RV
AU  - Tregaskis B
AU  - McLay J
AU  - Service E
AU  - McDevitt DG
FA  - Lewis, R V
FA  - Tregaskis, B
FA  - McLay, J
FA  - Service, E
FA  - McDevitt, D G
IN  - Lewis,R V. Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, Scotland.
TI  - Oral magnesium reduces ventricular ectopy in digitalised patients with chronic atrial fibrillation.
SO  - European Journal of Clinical Pharmacology. 38(2):107-10, 1990.
AS  - Eur J Clin Pharmacol. 38(2):107-10, 1990.
NJ  - European journal of clinical pharmacology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - en4, 1256165
SB  - Index Medicus
CP  - GERMANY, WEST
MH  - Aged
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Cardiac Complexes, Premature/ci [Chemically Induced]
MH  - *Cardiac Complexes, Premature/pc [Prevention & Control]
MH  - *Digoxin/ae [Adverse Effects]
MH  - Digoxin/bl [Blood]
MH  - Electrocardiography
MH  - Exercise
MH  - Exercise Test
MH  - Female
MH  - Heart Rate/de [Drug Effects]
MH  - Humans
MH  - *Magnesium/pd [Pharmacology]
MH  - Magnesium Deficiency/bl [Blood]
MH  - Male
MH  - Middle Aged
AB  - We have examined the effects of magnesium replacement therapy upon post-exercise heart rate and incidence of ventricular premature beats (VPB) in digitalised patients with AF. In 11 such patients, all of whom had serum magnesium concentrations of less than 0.85 mmol/l, treatment with magnesium glycerophosphate was associated with a significant reduction in number of VPBs (982 v. 416 VPB/24 h). Five patients had a high prevalence of ventricular ectopy (greater than 300 VPB/24 h) and these subjects showed particularly marked decreases in VPBs during magnesium treatment (1998 v. 690 VPB/24 h). Three patients had slightly increased QTc intervals but these did not change during magnesium replacement. No significant changes were seen in the mean post-exercise heart rate although 2 subjects did show falls of 25% or more during magnesium replacement. We conclude that treatment with magnesium glycerophosphate may be associated with a decreased prevalence of ventricular ectopy in some digitalised patients with chronic AF and mild-moderate hypomagnesaemia.
RN  - 73K4184T59 (Digoxin)
RN  - I38ZP9992A (Magnesium)
IS  - 0031-6970
IL  - 0031-6970
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 1990
DC  - 19900620
YR  - 1990
ED  - 19900620
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1692533

<891. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2697904
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Marti Masso JF
FA  - Marti Masso, J F
TI  - Current trends in treatment of transient ischemic attacks. [Review] [45 refs]
SO  - Recenti Progressi in Medicina. 80(12):701-5, 1989 Dec.
AS  - Recenti Prog Med. 80(12):701-5, 1989 Dec.
NJ  - Recenti progressi in medicina
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - r1t, 0401271
SB  - Index Medicus
CP  - ITALY
MH  - Anticoagulants/tu [Therapeutic Use]
MH  - Fibrinolytic Agents/tu [Therapeutic Use]
MH  - Humans
MH  - Ischemic Attack, Transient/dt [Drug Therapy]
MH  - Ischemic Attack, Transient/su [Surgery]
MH  - *Ischemic Attack, Transient/th [Therapy]
MH  - Risk Factors
AB  - Current trends in treatment of transient ischemic attacks (TIAs) are reviewed. Patients with TIAs should be treated individually, the main goals of therapy being to avoid cerebral infarction and vascular death. Management of risk factors includes control of high blood pressure, dyslipoproteinemias, diabetes mellitus, atrial fibrillation, cardiac arrhythmias, and overweight. A healthy diet, exercising and non-smoking are additional useful measures. The most commonly used antiplatelet drug is aspirin. Doses of 325 mg per day are as effective as doses of 1,300 mg per day but have fewer side effects. Ticlopidine seems the best antiplatelet drug currently available; it is given in doses of 500 mg per day for a month and then 250 mg per day for the rest of the patient's life. Anticoagulants have not shown their advantages over drugs that prevent platelet aggregation. However, when a patient under treatment with warfarin with an adequate dose range suffers recurrent TIAs, warfarin can be used in association with ticlopidine. On the other hand, if patients under treatment with ticlopidine have further TIAs, they should be switched to anticoagulants for 6 months and then back to antiplatelet drugs. With regard to surgery, an effective means of prolonging survival seems to be the treatment of coronary artery disease before carotid endarterectomy is considered. The effectiveness of carotid endarterectomy is being evaluated in ongoing multicentric, randomized, controlled clinical trials. [References: 45]
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
IS  - 0034-1193
IL  - 0034-1193
PT  - Journal Article
PT  - Review
LG  - English
DP  - 1989 Dec
DC  - 19900423
YR  - 1989
ED  - 19900423
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=2697904

<892. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1689834
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Corbelli R
AU  - Masterson M
AU  - Wilkoff BL
FA  - Corbelli, R
FA  - Masterson, M
FA  - Wilkoff, B L
IN  - Corbelli,R. Cleveland Clinic Foundation, Ohio 44195-5064.
TI  - Chronotropic response to exercise in patients with atrial fibrillation.
SO  - Pacing & Clinical Electrophysiology. 13(2):179-87, 1990 Feb.
AS  - Pacing Clin Electrophysiol. 13(2):179-87, 1990 Feb.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Fibrillation/me [Metabolism]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/th [Therapy]
MH  - Blood Pressure/ph [Physiology]
MH  - Bradycardia/pp [Physiopathology]
MH  - Cardiac Pacing, Artificial/mt [Methods]
MH  - Electrocardiography, Ambulatory
MH  - Energy Metabolism
MH  - Exercise Test
MH  - Female
MH  - *Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Physical Exertion
MH  - Retrospective Studies
MH  - Tachycardia/pp [Physiopathology]
AB  - The exercise chronotropic response of patients with chronic atrial fibrillation requiring pacemaker therapy for bradycardia was assessed to characterize the chronotropic response and identify patients who would potentially benefit from a rate adaptive pacemaker. The population consisted of all patients who received a VVI pacemaker between January 1980 and November 1987 who underwent exercise tolerance testing (n = 130) and were in atrial fibrillation (n = 19). There were 11 males and 8 females with a mean age of 62 +/- 14 years. Left ventricular function was normal in eight patients, mildly impaired in three, and severely impaired in two. Long-term medications were continued until the morning of the test; digoxin 73%, beta blockers 21%, calcium channel blockers 26%, and nitrates 21%. Maximal exercise tolerance tests were performed. Parameters assessed were: (a) heart rate at rest, the end of each stage, and at peak exercise; (b) percent heart rate reserve per stage; and (c) percent metabolic reserve per stage. Results were compared to 100 normal subjects on no medications and without evidence of medical illness or cardiac disease. Heart rates were depressed in 58% of the study patients (21% early, 53% late) and elevated in 74% (74% early, 32% late). All 19 (100%) patients had abnormal heart rate responses at some point during the exercise test. Only four patients (21%) had a response within one standard deviation from the mean of the normal population during either the early or late segment of the exercise test. Patients in chronic atrial fibrillation requiring pacemakers for bradycardiac support at rest have an abnormal chronotropic response to exercise.(ABSTRACT TRUNCATED AT 400 WORDS)
IS  - 0147-8389
IL  - 0147-8389
PT  - Journal Article
LG  - English
DP  - 1990 Feb
DC  - 19900406
YR  - 1990
ED  - 19900406
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1689834

<893. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2621189
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gupta R
AU  - Yadav NV
FA  - Gupta, R
FA  - Yadav, N V
TI  - Correlation of exercise induced hypotension and development of complications during treadmill stress test.
SO  - Journal of the Association of Physicians of India. 37(8):519, 1989 Aug.
AS  - J Assoc Physicians India. 37(8):519, 1989 Aug.
NJ  - The Journal of the Association of Physicians of India
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - hg7, 7505585
SB  - Index Medicus
CP  - INDIA
MH  - *Coronary Disease/co [Complications]
MH  - Coronary Disease/di [Diagnosis]
MH  - *Exercise Test
MH  - Humans
MH  - *Hypotension/et [Etiology]
MH  - Risk Factors
AB  - Exercise induced hypotension was observed in 41 of 354 patients studied. Fourteen of 41 as against 3 out of the remaining 313 developed complications, like atrial and ventricular arrhythmias, heart block, severe angina and left ventricular failure. Close monitoring of BP during exercise testing is mandatory.
IS  - 0004-5772
IL  - 0004-5772
PT  - Journal Article
LG  - English
DP  - 1989 Aug
DC  - 19900328
YR  - 1989
ED  - 19900328
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=2621189

<894. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2613638
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kaul U
AU  - Sundar AS
AU  - Bhatia ML
FA  - Kaul, U
FA  - Sundar, A S
FA  - Bhatia, M L
TI  - Experience with activity sensing rate responsive ventricular pacing. A study based upon assessment of exercise tolerance.
SO  - Journal of the Association of Physicians of India. 37(5):318-22, 1989 May.
AS  - J Assoc Physicians India. 37(5):318-22, 1989 May.
NJ  - The Journal of the Association of Physicians of India
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - hg7, 7505585
SB  - Index Medicus
CP  - INDIA
MH  - Adolescent
MH  - Adult
MH  - *Arrhythmias, Cardiac/pp [Physiopathology]
MH  - Arrhythmias, Cardiac/th [Therapy]
MH  - *Cardiac Pacing, Artificial/mt [Methods]
MH  - Child
MH  - Electrocardiography, Ambulatory
MH  - *Exercise/ph [Physiology]
MH  - Exercise Test
MH  - *Heart Block/pp [Physiopathology]
MH  - Heart Block/th [Therapy]
MH  - Heart Rate
MH  - Humans
MH  - Middle Aged
AB  - Fourteen patients (mean age 41 years) who received rate responsive activity sensing VVI pacemakers were studied to evaluate the relationship between the rate response and exercise tolerance by analysing the symptom limited maximum treadmill time both during fixed rate VVI oacubg abd dyrubg VVI + activity mode pacing (RRP). The proper functioning of RRP mode was confirmed by Holter monitoring in all. The indications for pacing were, sino-atrial block with high grade AV block, tachybrady syndrome, atrial fibrillation with complete heart block, congenital complete heart block and persistent slow junctional rhythm. Basic rate was programmed to 70 PPM in both pacing modes; rate response and activity threshold were programmed to 5 and medium respectively. The order in which two pacing modes were tested was chosen randomly. The maximum treadmill time (MTT) was 25.4% longer in the RRP than in VVI mode with a mean of 11.4 minutes in RRP and 8.5 mins in VVI(p less than 0.01). for the subgroup of patients who demonstrated paced only rhythm the average increase in MTT was 31.4% with a mean of 11.8 minutes in RRP and 8.1 mins in VVI (p less than 0.01). Five patients who showed intermittent spontaneous rhythm, increased their average MTT by 22.3% with a mean of 11.2 minutes in RRP and 8.7 mins in VVI mode (p less than 0.05). During RRP a significance positive correlationship was seen between MTT and the increase in heart rate (N = 14, r = 0.85, p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
IS  - 0004-5772
IL  - 0004-5772
PT  - Journal Article
LG  - English
DP  - 1989 May
DC  - 19900302
YR  - 1989
ED  - 19900302
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=2613638

<895. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2478981
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Fearnot NE
AU  - Smith HJ
AU  - Sellers D
AU  - Boal B
FA  - Fearnot, N E
FA  - Smith, H J
FA  - Sellers, D
FA  - Boal, B
IN  - Fearnot,N E. Purdue University, West Lafayette, Indiana 47907.
TI  - Evaluation of the temperature response to exercise testing in patients with single chamber, rate adaptive pacemakers: a multicenter study.
SO  - Pacing & Clinical Electrophysiology. 12(11):1806-15, 1989 Nov.
AS  - Pacing Clin Electrophysiol. 12(11):1806-15, 1989 Nov.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Arrhythmias, Cardiac/th [Therapy]
MH  - *Body Temperature/ph [Physiology]
MH  - Electrocardiography
MH  - Equipment Design
MH  - Exercise/ph [Physiology]
MH  - *Exercise Test
MH  - Female
MH  - Heart Rate/ph [Physiology]
MH  - Humans
MH  - Male
MH  - Multicenter Studies as Topic
MH  - *Pacemaker, Artificial
MH  - Telemetry
AB  - UNLABELLED: Temperature responsive pacemakers were implanted in 45 patients (ages 44 to 90); 31 patients were evaluated by randomized, paired treadmill exercise tests 1 month postimplant. Of 28 males and 17 females, 19 had coronary artery disease; 8 had congestive heart failure. Pacing indications included sinus node disease (26), atrial fibrillation (15), AV block (10), and brady/tachy syndrome (10); some had multiple indications. Blood temperature (every 10 seconds, resolution = 0.004 degrees C) and pacing rate (every minute) were telemetered from the pacemaker. Average heart rate, exercise duration (5.7 min VVI; 6.7 min VVIR), VVIR response time (22 sec), initial temperature drop (0.23 degrees C) and maximum rate of drop (0.65 degrees C/min), temperature rise (0.31 degrees C VVI; 0.38 degrees C VVIR) and rate of rise (0.27 degrees C/min) were studied in a subset of patients. In pacer-dependent patients, average paired increases in exercise duration and heart rate was 56% and 34%, respectively. Including all (31) patients, some with intermittent sinus rhythm, increases were 28% and 9%, respectively. Because exercise duration increased, temperature rise was higher with rate adaptation. Rate adaptation was obtainable in all patients and patients averaged 99 +/- 48 increases above basic pacing rate per day at nominal temperature sensitivity.
AB  - CONCLUSION: Beneficial rate adaptation is achievable using blood temperature to modify rate in a sensor based system.
IS  - 0147-8389
IL  - 0147-8389
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
LG  - English
DP  - 1989 Nov
DC  - 19891218
YR  - 1989
ED  - 19891218
RD  - 20140728
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=2478981

<896. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2816702
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Atwood JE
AU  - Myers J
AU  - Sullivan M
AU  - Forbes S
AU  - Sandhu S
AU  - Callaham P
AU  - Froelicher V
FA  - Atwood, J E
FA  - Myers, J
FA  - Sullivan, M
FA  - Forbes, S
FA  - Sandhu, S
FA  - Callaham, P
FA  - Froelicher, V
IN  - Atwood,J E. Cardiology Department, Long Beach Veterans Administration Medical Center, CA 90822.
TI  - The effect of cardioversion on maximal exercise capacity in patients with chronic atrial fibrillation.
SO  - American Heart Journal. 118(5 Pt 1):913-8, 1989 Nov.
AS  - Am Heart J. 118(5 Pt 1):913-8, 1989 Nov.
NJ  - American heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3bw, 0370465
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Anaerobic Threshold
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Chronic Disease
MH  - Echocardiography
MH  - *Electric Countershock
MH  - Exercise Test
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Physical Endurance
MH  - Pulmonary Gas Exchange
MH  - Rest
AB  - To evaluate the effect of cardioversion on exercise capacity, 11 male patients (59 +/- 8 years) with chronic atrial fibrillation underwent maximal exercise testing using gas exchange techniques before and after successful cardioversion to normal sinus rhythm. Testing was conducted 1 day prior to and a mean of 39 (range 10 to 95) days following cardioversion. Heart rate, blood pressure, and respiratory gas exchange responses were evaluated at rest, at a standard submaximal workload (3.0 mph/0% grade), at the gas exchange anaerobic threshold, and at maximal exertion. Cardioversion resulted in a mean decrease in resting heart rate of 37 beats/min (113 +/- 16 versus 76 +/- 10 beats/min, p less than 0.001). While mean heart rate was approximately 50 beats/min lower following cardioversion at both submaximal stages of exercise p less than 0.001), oxygen uptake was not different. At maximal exercise, heart rate was markedly reduced (192 +/- 24 to 144 +/- 21 beats/min, p less than 0.001) and maximal oxygen uptake was higher (1.86 +/- 0.5 to 2.06 +/- 0.5 L/min, p less than 0.05) after cardioversion. In addition, an improved efficiency of ventilation was observed at exercise levels exceeding 60% of maximal oxygen uptake.
IS  - 0002-8703
IL  - 0002-8703
PT  - Journal Article
LG  - English
DP  - 1989 Nov
DC  - 19891205
YR  - 1989
ED  - 19891205
RD  - 20060227
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=2816702

<897. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2808984
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kay GN
AU  - Bubien RS
AU  - Epstein AE
AU  - Plumb VJ
FA  - Kay, G N
FA  - Bubien, R S
FA  - Epstein, A E
FA  - Plumb, V J
IN  - Kay,G N. Department of Medicine, University of Alabama, Birmingham 35294.
TI  - Rate-modulated cardiac pacing based on transthoracic impedance measurements of minute ventilation: correlation with exercise gas exchange.
SO  - Journal of the American College of Cardiology. 14(5):1283-9, 1989 Nov 1.
AS  - J Am Coll Cardiol. 14(5):1283-9, 1989 Nov 1.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - h50, 8301365
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - *Cardiac Pacing, Artificial/mt [Methods]
MH  - Cardiography, Impedance/de [Drug Effects]
MH  - *Cardiography, Impedance
MH  - Exercise Test
MH  - Female
MH  - Heart Block/pp [Physiopathology]
MH  - *Heart Block/th [Therapy]
MH  - Humans
MH  - Isoproterenol/pd [Pharmacology]
MH  - Male
MH  - Middle Aged
MH  - Oxygen Consumption
MH  - *Plethysmography, Impedance
MH  - Prospective Studies
MH  - *Pulmonary Gas Exchange
AB  - The relation of pacing rate to physiologic variables of metabolic demand was examined in 10 consecutive patients with a minute ventilation-sensing, rate-modulating ventricular pacemaker implanted for complete heart block. All patients had paroxysmal (seven patients) or chronic (three patients) atrial fibrillation and were referred for catheter ablation of the atrioventricular junction. Treadmill exercise testing with measurement of expired gas exchange and respiratory flow was performed before ablation and 4 weeks after pacemaker implantation, with the pacemaker programmed to both the fixed-rate VVI and rate-modulating minute ventilation VVIR pacing modes in random sequence. The relation of pacing rate to oxygen consumption (VO2), expired carbon dioxide concentration (VCO2), respiratory quotient, tidal volume, respiratory rate and minute ventilation was determined during exercise in the rate-modulating minute ventilation pacing mode. Pacing rate was highly correlated with minute ventilation (r = 0.89), respiratory quotient (r = 0.89), VCO2 (r = 0.87), tidal volume (r = 0.87), VO2 (r = 0.84) and respiratory rate (r = 0.84). The mean exercise duration increased from 8.3 +/- 2.8 min in the fixed rate pacing mode to 10.2 +/- 3.4 min in the rate-modulating, minute ventilation mode (p = 0.0001). The maximal VO2 increased from 13.4 +/- 3.4 to 16.3 +/- 4.1 cc/kg per min (p = 0.0004). The maximal heart rate achieved in the minute ventilation pacing mode was 136 +/- 9.7 beats/min, similar to that observed in the patient's intrinsic cardiac rhythm before ablation (134.9 +/- 30.1 beats/min, p = NS).(ABSTRACT TRUNCATED AT 250 WORDS)
RN  - L628TT009W (Isoproterenol)
IS  - 0735-1097
IL  - 0735-1097
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 1989 Nov 1
DC  - 19891205
YR  - 1989
ED  - 19891205
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=2808984

<898. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2776144
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kraemer MD
AU  - Sullivan M
AU  - Atwood JE
AU  - Forbes S
AU  - Myers J
AU  - Froelicher V
FA  - Kraemer, M D
FA  - Sullivan, M
FA  - Atwood, J E
FA  - Forbes, S
FA  - Myers, J
FA  - Froelicher, V
IN  - Kraemer,M D. Cardiology Section, Long Beach Veterans Administration Medical Center, Calif.
TI  - Reproducibility of treadmill exercise data in patients with atrial fibrillation.
SO  - Cardiology. 76(3):234-42, 1989.
AS  - Cardiology. 76(3):234-42, 1989.
NJ  - Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - coi, 1266406
OI  - Source: NASA. 89376355
SB  - Index Medicus
SB  - National Aeronautics and Space Administration (NASA) Journals
CP  - SWITZERLAND
MH  - Aged
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - *Electrocardiography
MH  - *Exercise Test
MH  - Follow-Up Studies
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Physical Exertion
MH  - Pulmonary Gas Exchange
MH  - Reproducibility of Results
AB  - Serial submaximal treadmill tests are often used to evaluate the efficacy of therapy in patients with atrial fibrillation. Since the response to serial tests can be influenced by a 'learning phenomenon', we performed maximal exercise tests on 9 patients (mean age 63 +/- 4 years) with chronic atrial fibrillation. Points of analysis for the initial and follow-up treadmill exercise tests were 3 mph/0% grade, the gas exchange anaerobic threshold, and maximal exertion. Significant (p less than 0.05) reductions in ventilation (l/min) and oxygen uptake (ml/kg/min) were observed on follow-up at a standard submaximal work load of 3.0 mph/0% grade and at the gas exchange anaerobic threshold. There was no significant alteration in these variables at maximal exertion. A reduction in heart rate was observed throughout exercise during the follow-up test with the most marked reduction (21 beats/min) occurring at 3.0 mph/0% grade. There were no differences in respiratory exchange ratio or systolic blood pressure at any point. The reduction in submaximal heart rate and gas exchange variables without a significant change in these variables at maximal exertion is consistent with a learning effect. Therefore, studies comparing consecutive submaximal exercise test responses in patients with atrial fibrillation can be misleading.
IS  - 0008-6312
IL  - 0008-6312
PT  - Journal Article
LG  - English
DP  - 1989
DC  - 19891018
YR  - 1989
ED  - 19891018
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=2776144

<899. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2565683
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Yeh SJ
AU  - Lin FC
AU  - Wu DL
FA  - Yeh, S J
FA  - Lin, F C
FA  - Wu, D L
IN  - Yeh,S J. Department of Medicine, Chang Gung Memorial Hospital, Chang Gung Medical College, Taipei, Taiwan, Republic of China.
TI  - The mechanisms of exercise provocation of supraventricular tachycardia.
SO  - American Heart Journal. 117(5):1041-9, 1989 May.
AS  - Am Heart J. 117(5):1041-9, 1989 May.
NJ  - American heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3bw, 0370465
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adrenergic beta-Agonists/tu [Therapeutic Use]
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Digoxin/tu [Therapeutic Use]
MH  - Drug Therapy, Combination
MH  - Electrocardiography
MH  - Electrophysiology
MH  - *Exercise
MH  - Exercise Test
MH  - Female
MH  - Humans
MH  - Isoproterenol
MH  - Male
MH  - Middle Aged
MH  - Tachycardia, Supraventricular/dt [Drug Therapy]
MH  - *Tachycardia, Supraventricular/et [Etiology]
MH  - Tachycardia, Supraventricular/pp [Physiopathology]
MH  - Verapamil/tu [Therapeutic Use]
AB  - Treadmill exercise tests, electrophysiologic studies, and isoproterenol infusions were performed in 14 patients with exercise provocable supraventricular tachycardia to delineate the mechanisms of exercise provocation of paroxysmal supraventricular tachycardia. Treadmill exercise tests reproducibly provoked supraventricular tachycardia in all patients. Supraventricular tachycardia similar to that provoked by exercise occurred spontaneously during isoproterenol infusions in 9 of 11 patients tested. The specific supraventricular tachycardia diagnoses of all patients were atrial reentrant tachycardia (two patients), automatic atrial tachycardia (three), atrial flutter-fibrillation (one), atypical junctional tachycardia (two), and orthodromic atrioventricular (AV) reentrant tachycardia (six) as defined by electrophysiologic studies. Various mechanisms of exercise or isoproterenol induction of supraventricular tachycardia were identified. A critical heart rate and/or appropriate sympathetic state was found to provoke all instances of reentrant or automatic atrial tachycardia and atypical junctional tachycardia. A properly timed atrial premature beat provoked five of six cases of AV reentrant tachycardia and the only case of atrial flutter-fibrillation. The remaining case of AV reentrant tachycardia was induced by a ventricular premature beat. In conclusion, the mechanisms of exercise provocation of reentrant or automatic supraventricular tachycardia are multiple and include a critical sinus rate, increased sympathetic tone, and properly timed atrial or ventricular premature beats.
RN  - 0 (Adrenergic beta-Agonists)
RN  - 73K4184T59 (Digoxin)
RN  - CJ0O37KU29 (Verapamil)
RN  - L628TT009W (Isoproterenol)
IS  - 0002-8703
IL  - 0002-8703
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1989 May
DC  - 19890605
YR  - 1989
ED  - 19890605
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=2565683

<900. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2468920
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lewis RV
AU  - McMurray J
AU  - McDevitt DG
FA  - Lewis, R V
FA  - McMurray, J
FA  - McDevitt, D G
IN  - Lewis,R V. Department of Pharmacology and Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, Scotland.
TI  - Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation.
SO  - Journal of Cardiovascular Pharmacology. 13(1):1-6, 1989 Jan.
AS  - J Cardiovasc Pharmacol. 13(1):1-6, 1989 Jan.
NJ  - Journal of cardiovascular pharmacology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 7902492, k78
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Adrenergic beta-Agonists/tu [Therapeutic Use]
MH  - Aged
MH  - *Atenolol/tu [Therapeutic Use]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Chronic Disease
MH  - Digitalis Glycosides/tu [Therapeutic Use]
MH  - Exercise Test
MH  - Female
MH  - *Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Lactates/bl [Blood]
MH  - Male
MH  - Middle Aged
MH  - *Propanolamines/tu [Therapeutic Use]
MH  - *Verapamil/tu [Therapeutic Use]
MH  - Xamoterol
AB  - The aim of the study was to compare the effects of atenolol (50 mg b.i.d.), verapamil (80 mg b.i.d.), xamoterol (200 mg b.i.d.), and matching placebo on heart rate (HR) and exercise tolerance in digitalised patients with chronic atrial fibrillation. Each treatment was taken for 4 weeks, and digoxin was continued throughout the study. During treatment with placebo (digoxin alone), the mean postexercise heart rate was 164 beats/min, and four subjects had rates of greater than or equal to 170 beats/min. Atenolol, verapamil, and xamoterol achieved significantly better control of exercise-induced tachycardia, mean postexercise heart rates being reduced to 120, 131, and 130 beats/min, respectively (p less than 0.01 for each). However, minimum HRs less than or equal to 45 beats/min occurred during treatment with placebo, atenolol, and verapamil, whereas treatment with xamoterol was associated with a minimum heart rate of 56 beats/min. Treatment with atenolol was associated with a marked reduction in maximum treadmill walking distance (mean 356 m) as compared both with placebo (mean 421 m, p less than 0.01) and verapamil (mean 439 m, p less than 0.01). Xamoterol reduced maximum walking distances as compared with verapamil (402 vs. 439 m; p less than 0.05) but not placebo (402 vs. 421 m; NSS). Thus, atenolol, verapamil, and xamoterol achieved better control of exercise-induced tachycardia than digoxin, but atenolol clearly impaired exercise tolerance whereas verapamil did not. Xamoterol achieved more even control of ventricular response rates and prevented the resting bradycardias that occurred with the other treatments. However, walking distances were significantly lower than those noted during treatment with verapamil.
RN  - 0 (Adrenergic beta-Agonists)
RN  - 0 (Digitalis Glycosides)
RN  - 0 (Lactates)
RN  - 0 (Propanolamines)
RN  - 50VV3VW0TI (Atenolol)
RN  - 7HE0JQL703 (Xamoterol)
RN  - CJ0O37KU29 (Verapamil)
IS  - 0160-2446
IL  - 0160-2446
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 1989 Jan
DC  - 19890602
YR  - 1989
ED  - 19890602
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=2468920

<901. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3239449
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Axelsson K
AU  - Asplund K
AU  - Norberg A
AU  - Alafuzoff I
FA  - Axelsson, K
FA  - Asplund, K
FA  - Norberg, A
FA  - Alafuzoff, I
IN  - Axelsson,K. Department of Advanced Nursing, University of Umea, Sweden.
TI  - Nutritional status in patients with acute stroke.
SO  - Acta Medica Scandinavica. 224(3):217-24, 1988.
AS  - Acta Med Scand. 224(3):217-24, 1988.
NJ  - Acta medica Scandinavica
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0370330
SB  - Index Medicus
CP  - SWEDEN
MH  - Acute Disease
MH  - Aged
MH  - *Cerebrovascular Disorders/co [Complications]
MH  - Deficiency Diseases/et [Etiology]
MH  - Female
MH  - Hospital Units
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nutrition Disorders/et [Etiology]
MH  - *Nutritional Status
AB  - By measuring three anthropometric variables (relative weight, triceps skinfold thickness and arm muscle circumference) and three circulating proteins (albumin, transferrin and prealbumin), nutritional status was assessed in 100 consecutive patients with acute stroke. On admission to hospital, two or more indicators showed subnormal values for 16%; this was associated with the female sex, high age and a history of atrial fibrillation. At discharge, 22% had two or more subnormal indicators. Poor nutritional status during the hospital stay appeared to be related to infections, the male sex, the intake of cardiovascular drugs and high age. Fewer of the patients with two or more subnormal nutritional indicators were able to return home than of the patients with none or one subnormal nutritional indicator. We conclude that undernutrition is not uncommon at the onset of stroke and that certain risk groups for the development of undernutrition during hospital stay can be identified.
IS  - 0001-6101
IL  - 0001-6101
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1988
DC  - 19890421
YR  - 1988
ED  - 19890421
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=3239449

<902. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2918876
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Anonymous
TI  - Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10-1989. A 60-year-old man with a large right atrial mass.
SO  - New England Journal of Medicine. 320(10):652-60, 1989 Mar 9.
AS  - N Engl J Med. 320(10):652-60, 1989 Mar 9.
NJ  - The New England journal of medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0255562, now
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adipose Tissue/pa [Pathology]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Cardiomyopathies/di [Diagnosis]
MH  - Diagnosis, Differential
MH  - Heart Neoplasms/di [Diagnosis]
MH  - Heart Neoplasms/pa [Pathology]
MH  - *Heart Septum/pa [Pathology]
MH  - Humans
MH  - Hypertrophy
MH  - Lipoma/di [Diagnosis]
MH  - Lipoma/pa [Pathology]
MH  - Lung Diseases, Obstructive/co [Complications]
MH  - Male
MH  - Middle Aged
MH  - Venae Cavae/pa [Pathology]
IS  - 0028-4793
IL  - 0028-4793
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1989 Mar 9
DC  - 19890328
YR  - 1989
ED  - 19890328
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=2918876

<903. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2463557
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Fearnot NE
AU  - Evans ML
FA  - Fearnot, N E
FA  - Evans, M L
IN  - Fearnot,N E. Hillenbrand Biomedical Engineering Center, Purdue University, West Lafayette, Indiana.
TI  - Heart rate correlation, response time and effect of previous exercise using an advanced pacing rate algorithm for temperature-based rate modulation.
SO  - Pacing & Clinical Electrophysiology. 11(11 Pt 2):1846-52, 1988 Nov.
AS  - Pacing Clin Electrophysiol. 11(11 Pt 2):1846-52, 1988 Nov.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Algorithms
MH  - *Body Temperature
MH  - *Cardiac Pacing, Artificial/mt [Methods]
MH  - Exercise Test
MH  - Female
MH  - *Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Pacemaker, Artificial
MH  - *Physical Exertion
AB  - A temperature-based algorithm to produce pacing rate that resembles chronotropic response to activity was developed. Measurement criteria for the algorithm included workload dependent rate increases with activity and response time within 60 seconds of exercise onset. To evaluate the algorithm, right ventricular blood temperature was recorded during rest and treadmill exercise in 25 patients with implanted Kelvin 500 pacemakers (Cook Pacemaker). Patients included 16 males and nine females, ages 44-81 (mean 72). Indications for pacing were sinus node disease, atrioventricular block and atrial fibrillation with slow ventricular response. Temperature changes reflected physical activity as well as emotional stress. The algorithm was based on the rate of change (dT/dt), the relative change (delta T) and the baseline history (T) of temperature. At exercise onset, a rapid, brief drop in temperature (dT/dt) typically occurred due to peripheral vasodilation, causing prompt increase in pacing rate. As exercise continued, the increase in metabolic rate caused dT/dt as well as delta T to increase, further increasing pacing rate. After exercise, temperature returned to resting level which correspondingly decreased the pacing rate. Sensitivity of the algorithm to temperature variations, and the upper and lower pacing rate limits were programmable to adapt to individual patient needs. The rates produced by the algorithm mimicked intrinsic rate response for various activity levels and produced a mean response time of 16 seconds from exercise onset. Previous exercise had no significant effect on response time. Correlation between normal chronotropic response and simulated pacing rate from five exercise tests was 0.92. These results show good specificity and refute the statement that blood temperature yields a slow response.
IS  - 0147-8389
IL  - 0147-8389
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1988 Nov
DC  - 19890223
YR  - 1988
ED  - 19890223
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=2463557

<904. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3208777
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Vergara G
AU  - Furlanello F
AU  - Disertori M
AU  - Inama G
AU  - Guarnerio M
AU  - Bettini R
AU  - Cozzi F
FA  - Vergara, G
FA  - Furlanello, F
FA  - Disertori, M
FA  - Inama, G
FA  - Guarnerio, M
FA  - Bettini, R
FA  - Cozzi, F
IN  - Vergara,G. Division of Cardiology and Arrhythmologic Centre, S. Chiara Hospital, Trento, Italy.
TI  - Induction of supraventricular tachyarrhythmia at rest and during exercise with transoesophageal atrial pacing in the electrophysiological evaluation of asymptomatic athletes with Wolff-Parkinson-White syndrome.
SO  - European Heart Journal. 9(10):1119-25, 1988 Oct.
AS  - Eur Heart J. 9(10):1119-25, 1988 Oct.
NJ  - European heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - em8, 8006263
SB  - Index Medicus
CP  - ENGLAND
MH  - Adolescent
MH  - Adult
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Flutter/pp [Physiopathology]
MH  - *Cardiac Pacing, Artificial/mt [Methods]
MH  - Child
MH  - *Electrocardiography
MH  - *Exercise Test
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Atria/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - *Sports
MH  - *Tachycardia, Supraventricular/pp [Physiopathology]
MH  - *Wolff-Parkinson-White Syndrome/pp [Physiopathology]
AB  - Even today there is controversy as regards the best approach to asymptomatic or slightly symptomatic athletes with the WPW syndrome as regards fitness for sports activity, especially in some countries where the doctor is responsible for certifying sports fitness. This study concerns 84 asymptomatic or slightly symptomatic athletes (66 males, 18 females, mean age 21.7 years, range 12-44 years) who underwent a stimulation protocol the end-point of which was the induction of atrial fibrillation (or, if not possible, atrial tachyarrhythmia) in the basal state and during bicycle stress test with transesophageal atrial pacing. The 81 athletes in whom the end-point was reached were divided into two groups: Group I includes the 32 athletes with the shortest R-R interval between pre-excited beats less than or equal to 240 ms in the basal state and/or less than or equal to 210 ms during bicycle ergometer test, Group II includes the other 49 patients. The evaluation during exercise was not carried out in four athletes because of serious haemodynamic compromise due to the arrhythmia induced in the basal state. Only 21/32 athletes would have been included in Group I if only evaluated in the basal state. In 30/81 athletes (37%), there was discrepancy between the result of stimulation and the result of the usual non-invasive evaluation (Holter monitoring, ergometric stress test, ajmaline test). On average, 40 min are required for the performance of the study protocol except when the induced arrhythmia lasts more than 5 min.(ABSTRACT TRUNCATED AT 250 WORDS)
IS  - 0195-668X
IL  - 0195-668X
PT  - Journal Article
LG  - English
DP  - 1988 Oct
DC  - 19890210
YR  - 1988
ED  - 19890210
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=3208777

<905. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2562880
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Wilmshurst PT
AU  - Nuri M
AU  - Crowther A
AU  - Webb-Peploe MM
FA  - Wilmshurst, P T
FA  - Nuri, M
FA  - Crowther, A
FA  - Webb-Peploe, M M
IN  - Wilmshurst,P T. Department of Cardiology, St. Thomas' Hospital, London.
TI  - Cold-induced pulmonary oedema in scuba divers and swimmers and subsequent development of hypertension.
SO  - Lancet. 1(8629):62-5, 1989 Jan 14.
AS  - Lancet. 1(8629):62-5, 1989 Jan 14.
NJ  - Lancet (London, England)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 2985213r, l0s, 0053266
OI  - Source: NASA. 89082167
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
SB  - National Aeronautics and Space Administration (NASA) Journals
CP  - ENGLAND
MH  - Acute Disease
MH  - Adult
MH  - Blood Flow Velocity
MH  - Blood Gas Monitoring, Transcutaneous
MH  - Blood Pressure
MH  - *Cold Temperature/ae [Adverse Effects]
MH  - *Diving/ae [Adverse Effects]
MH  - Diving/pp [Physiopathology]
MH  - Female
MH  - Follow-Up Studies
MH  - Forearm/bs [Blood Supply]
MH  - Heart Rate
MH  - Humans
MH  - *Hypertension/et [Etiology]
MH  - Male
MH  - Middle Aged
MH  - *Pulmonary Edema/et [Etiology]
MH  - Pulmonary Edema/pp [Physiopathology]
MH  - Recurrence
MH  - *Swimming
MH  - Vascular Resistance
AB  - The effect of cold and/or a raised partial pressure of oxygen was examined in eleven people with no demonstrable cardiac abnormality but who had pulmonary oedema when scuba diving or surface swimming, and in ten normal divers. These stimuli induced pathological vasoconstriction in the pulmonary oedema group, nine of whom also showed signs of cardiac decompensation when so stimulated. The pulmonary oedema patients have been followed-up for an average of 8 years. Seven have become hypertensive. Except for the onset of lone atrial fibrillation in one normotensive female diver and development of Raynaud's phenomenon in a normotensive man, there have been no cardiovascular events and no deaths.
IS  - 0140-6736
IL  - 0140-6736
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 1989 Jan 14
DC  - 19890209
YR  - 1989
ED  - 19890209
RD  - 20150616
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=2562880

<906. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2909159
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Atwood JE
AU  - Myers J
AU  - Sandhu S
AU  - Lachterman B
AU  - Friis R
AU  - Oshita A
AU  - Forbes S
AU  - Walsh D
AU  - Froelicher V
FA  - Atwood, J E
FA  - Myers, J
FA  - Sandhu, S
FA  - Lachterman, B
FA  - Friis, R
FA  - Oshita, A
FA  - Forbes, S
FA  - Walsh, D
FA  - Froelicher, V
IN  - Atwood,J E. Cardiology Section, Long Beach Veterans Administration Medical Center, California 94304.
TI  - Optimal sampling interval to estimate heart rate at rest and during exercise in atrial fibrillation.
SO  - American Journal of Cardiology. 63(1):45-8, 1989 Jan 1.
AS  - Am J Cardiol. 63(1):45-8, 1989 Jan 1.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - Electrocardiography
MH  - Exercise Test
MH  - *Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Physical Exertion
MH  - Time Factors
AB  - To investigate the ideal sampling interval for the estimation of heart rate (HR) at rest and during exercise in atrial fibrillation (AF), maximal exercise testing with continuous electrocardiographic acquisition was performed in 10 patients with chronic AF (mean age 66 +/- 4 years) and 10 subjects in normal sinus rhythm (mean age 31 +/- 6 years). Measurements of HR were obtained at 9 different sampling intervals (1, 2, 3, 6, 10, 15, 20, 30 and 60 seconds) at rest and 7 different sampling intervals (1, 2, 3, 6, 10, 15 and 20 seconds) during the last 30 seconds of each minute during exercise. The HR obtained from each interval was compared with true HR (determined by a 4-minute sample at rest and by the last 30 seconds of each minute during exercise). Among patients with AF, large differences were observed between the HR obtained and true HR, both at rest and during exercise, using small sampling intervals. The mean of these differences ranged between 16 +/- 11 beats/min (range 14 to 22) using 1-second sampling intervals and 2.2 +/- 2.0 beats/min (range 1.6 to 4.4) using 20-second sampling intervals during progressive exercise. Variability of the HR obtained from a given random sample was also high when short sampling intervals were used among patients with AF. These observations were contrasted by subjects in normal sinus rhythm, among whom neither variability nor measurement error were influenced remarkably by changing the sampling interval or increasing HR.
IS  - 0002-9149
IL  - 0002-9149
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 1989 Jan 1
DC  - 19890126
YR  - 1989
ED  - 19890126
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=2909159

<907. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2462216
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mehta D
AU  - Lau CP
AU  - Ward DE
AU  - Camm AJ
FA  - Mehta, D
FA  - Lau, C P
FA  - Ward, D E
FA  - Camm, A J
IN  - Mehta,D. Department of Cardiological Sciences, St. George's Hospital Medical School, London, England.
TI  - Comparative evaluation of chronotropic responses of QT sensing and activity sensing rate responsive pacemakers.
SO  - Pacing & Clinical Electrophysiology. 11(10):1405-12, 1988 Oct.
AS  - Pacing Clin Electrophysiol. 11(10):1405-12, 1988 Oct.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrioventricular Node/ph [Physiology]
MH  - Electrocardiography
MH  - Evaluation Studies as Topic
MH  - *Heart Conduction System/ph [Physiology]
MH  - *Heart Rate
MH  - Humans
MH  - Jogging
MH  - Middle Aged
MH  - *Pacemaker, Artificial
MH  - Physical Exertion
MH  - Time Factors
AB  - The rate responses of activity sensing (ATS) and QT sensing (QTS) rate responsive pacemakers to different forms and durations of exercises were compared. Nine patients with ATS and five with QTS were studied. All had complete heart block and atrial arrhythmias. At the onset, the pacemakers were programmed to achieve a pacing rate of 100-110 bpm by the end of stage 1 of the Bruce protocol, and to a pacing rate range of 70-150 bpm. With progressive exercise, using a treadmill (Bruce protocol), the maximum pacing rates in the two groups were not significantly different (mean +/- SD: 123 +/- 18 vs 129 +/- 23 bpm, ATS vs QTS). The time taken to return to the baseline pacing rate during recovery was significantly longer with QTS (178 +/- 70 vs 264 +/- 68 s, p less than 0.05). Brief exercise tests on a treadmill were performed for 3 min each with different combinations of treadmill speeds (1.2 and 2.5 mph) and gradients (0, 5, 10 and 15%). In both groups of patients, faster walking speed was associated with a faster pacing rate at each gradient. However, with increasing gradients, at each speed, there was a rise in the maximum pacing rate only in patients with QTS. During brief exercise tests, the maximum rate was achieved by the end of exercise in patients with ATS, but was delayed by 33 +/- 20 s after exercise in patients with QTS.(ABSTRACT TRUNCATED AT 250 WORDS)
IS  - 0147-8389
IL  - 0147-8389
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 1988 Oct
DC  - 19890118
YR  - 1988
ED  - 19890118
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=2462216

<908. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3173171
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Evans ML
AU  - Fearnot NE
FA  - Evans, M L
FA  - Fearnot, N E
IN  - Evans,M L. MED Institute, Inc. West Lafayette, IN 47906.
TI  - Evaluation of the pacing rate response to treadmill exercise using computer simulation of a temperature-based, rate-adaptive algorithm.
SO  - Medical Instrumentation. 22(4):182-8, 1988 Aug.
AS  - Med Instrum. 22(4):182-8, 1988 Aug.
NJ  - Medical instrumentation
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0361136, m12
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Algorithms
MH  - *Body Temperature
MH  - *Cardiac Pacing, Artificial/st [Standards]
MH  - *Computer Simulation
MH  - Female
MH  - *Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Physical Exertion
MH  - Reference Values
AB  - A temperature-based, rate-adaptive, pacing algorithm was developed to benefit the patient. Rate-adaptive pacemakers use a physiologic parameter to identify the need for increased pacing rate. Parameters that have been clinically investigated include venous pH, Q-T interval, respiration, body motion, and blood temperature. The objective of this study was to provide pacing rates resembling normal heart rates in response to various levels and types of activity. A rapid response time (within 30 s of exercise onset) was also sought. Blood temperature, which reflects metabolic activity of all regions, was selected as the physiologic parameter. Right ventricular blood temperature was recorded in 25 patients with implanted Kelvin 500 pacemakers (Cook Pacemaker) during rest and treadmill exercise. The patient population included 16 men and 9 women, age 44-81 years (mean = 72). Indications for pacing were sinus node disease, atrioventricular block, and atrial fibrillation with slow ventricular response. The temperature changed with physical activity and emotional stress. Temperature typically dropped briefly at exercise onset, increased with continued exercise, and returned to the resting level after exercise. These components were employed in developing the temperature-based rate-adaptive algorithm, which was designed to use the rate of temperature change (dT/dt), temperature change (delta T), and baseline temperature (T). The temperature profiles were used to produce simulated pacing rates as determined by the algorithm. The drop in temperature at onset of activity was utilized to provide a rapid increase in pacing rate. As dT/dt became positive and delta T increased, pacing rate was further increased.(ABSTRACT TRUNCATED AT 250 WORDS)
IS  - 0090-6689
IL  - 0090-6689
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1988 Aug
DC  - 19881121
YR  - 1988
ED  - 19881121
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=3173171

<909. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3169046
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lewis RV
AU  - Irvine N
AU  - McDevitt DG
FA  - Lewis, R V
FA  - Irvine, N
FA  - McDevitt, D G
IN  - Lewis,R V. Department of Pharmacology and Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, Scotland.
TI  - Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem.
SO  - European Heart Journal. 9(7):777-81, 1988 Jul.
AS  - Eur Heart J. 9(7):777-81, 1988 Jul.
NJ  - European heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - em8, 8006263
OI  - Source: NASA. 89005166
SB  - Index Medicus
SB  - National Aeronautics and Space Administration (NASA) Journals
CP  - ENGLAND
MH  - Aged
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Cardiac Output/de [Drug Effects]
MH  - Chronic Disease
MH  - *Digoxin/tu [Therapeutic Use]
MH  - *Diltiazem/tu [Therapeutic Use]
MH  - *Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Middle Aged
MH  - *Physical Exertion/de [Drug Effects]
MH  - *Verapamil/tu [Therapeutic Use]
AB  - Six patients with chronic atrial fibrillation (AF) took single doses of digoxin, verapamil and diltiazem, alone and in combination. Three hours after dosing, resting and post-exercise heart rate, exercise tolerance and resting and post-exercise cardiac output were measured. Post-exercise heart rates ranged from 167 bpm (after placebo) to 122 bpm (after digoxin plus diltiazem) (P less than 0.05). However, the lower ventricular rates seen after treatment with the calcium antagonists were not associated with improved exercise tolerance, which did not differ significantly between the various treatments. Reduction of the ventricular rate was associated with a small increase in stroke volume but the benefits of this were offset by a rate related reduction in cardiac output. Further reduction of the rapid ventricular rates seen in digitalized patients with AF does not appear to be of benefit in terms of improving either exercise tolerance or cardiac output.
RN  - 73K4184T59 (Digoxin)
RN  - CJ0O37KU29 (Verapamil)
RN  - EE92BBP03H (Diltiazem)
IS  - 0195-668X
IL  - 0195-668X
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
LG  - English
DP  - 1988 Jul
DC  - 19881103
YR  - 1988
ED  - 19881103
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=3169046

<910. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3421175
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kay GN
AU  - Bubien RS
AU  - Epstein AE
AU  - Plumb VJ
FA  - Kay, G N
FA  - Bubien, R S
FA  - Epstein, A E
FA  - Plumb, V J
IN  - Kay,G N. Department of Medicine, University of Alabama, Birmingham 35294.
TI  - Effect of catheter ablation of the atrioventricular junction on quality of life and exercise tolerance in paroxysmal atrial fibrillation.
SO  - American Journal of Cardiology. 62(10 Pt 1):741-4, 1988 Oct 1.
AS  - Am J Cardiol. 62(10 Pt 1):741-4, 1988 Oct 1.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Atrial Fibrillation/px [Psychology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Atrioventricular Node/su [Surgery]
MH  - *Electrocoagulation
MH  - Female
MH  - *Heart Conduction System/su [Surgery]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pacemaker, Artificial
MH  - *Physical Exertion
MH  - *Quality of Life
AB  - The effect of catheter ablation of the atrioventricular junction (AV) and implantation of a rate-adaptive pacemaker on quality of life and exercise capacity was evaluated prospectively in 12 consecutive patients with paroxysmal atrial fibrillation (AF). All patients had been demonstrated to have paroxysmal AF that was refractory to medical therapy over a long period of time (mean 9 +/- 7 years). Patients performed a symptom-limited treadmill exercise test on the day before catheter ablation and 6 weeks after hospital discharge. Quality of life was measured using the physical dimension of the McMaster Health Index Questionnaire and the Psychological General Well-Being Index before and 6 weeks after ablation. There were no serious complications related to catheter ablation or permanent pacemaker implantation. All patients remain in complete AV block with a completely paced rhythm at a mean follow-up of 8 +/- 2 months. The McMaster Health Index scores increased from a mean of 0.69 +/- 0.20 before to 0.92 +/- 0.14 after ablation (p = 0.002). The mean Psychological General Well-Being score improved from 59.8 +/- 14.8 at baseline to 84.9 +/- 13.6 6 weeks after discharge (p = 0.001). Treadmill exercise duration increased from 6.4 +/- 4.6 to 9.9 +/- 2.6 minutes (p = 0.03) and correlated strongly with changes in functional capacity measured with the McMaster Health Index (r = 0.70, p = 0.03). These results suggest that catheter ablation of the AV junction and implantation of a rate-adaptive pace-maker significantly improve the quality of life and exercise capacity of patients with paroxysmal AF refractory to medical therapy.
IS  - 0002-9149
IL  - 0002-9149
PT  - Journal Article
LG  - English
DP  - 1988 Oct 1
DC  - 19881027
YR  - 1988
ED  - 19881027
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=3421175

<911. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3398242
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Jordaens L
AU  - de Backer G
AU  - Clement DL
FA  - Jordaens, L
FA  - de Backer, G
FA  - Clement, D L
IN  - Jordaens,L. Department of Cardiology, Akademisch Ziekenhuis, State University Ghent, Belgium.
TI  - Physiologic pacing in the elderly. Effects on exercise capacity and exercise-induced arrhythmias.
SO  - Japanese Heart Journal. 29(1):35-44, 1988 Jan.
AS  - Jpn Heart J. 29(1):35-44, 1988 Jan.
NJ  - Japanese heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - kh3, 0401175
SB  - Index Medicus
CP  - JAPAN
MH  - Aged
MH  - Aged, 80 and over
MH  - Arrhythmias, Cardiac/et [Etiology]
MH  - *Arrhythmias, Cardiac/pp [Physiopathology]
MH  - Arrhythmias, Cardiac/th [Therapy]
MH  - *Cardiac Pacing, Artificial/mt [Methods]
MH  - Exercise Test
MH  - Female
MH  - Heart Block/pp [Physiopathology]
MH  - Heart Block/th [Therapy]
MH  - Heart Ventricles/pp [Physiopathology]
MH  - Hemodynamics
MH  - Humans
MH  - Male
MH  - Pacemaker, Artificial
MH  - *Physical Exertion
AB  - It is not clear whether hemodynamic and other benefits from dual-chamber pacing also exist in elderly patients. We studied a group of 18 elderly patients (mean age 74 +/- 4 yrs) with exercise testing in DDD and VVI modes in a randomized way to compare the effects of these pacing modes on exercise capacity, atrial rate and exercise-induced arrhythmias. Patients were selected when complete heart block was present without clinical evidence of sinus node dysfunction. Significant differences were observed: atrial rate was lower during exercise in DDD-mode (p less than 0.01); exercise time and cumulative load increased (p less than 0.05); maximal oxygen uptake was improved (p less than 0.05). Some of these differences were less clear in a subgroup with replacement of a VVI-device by DDD-stimulation. No differences could be observed in severity of exercise-induced arrhythmias. No evidence of sinus node dysfunction was found during exercise. Reprogramming of atrial sensitivity was required in 3 patients, with reprogramming to DVI because of paroxysmal atrial fibrillation once. Two patients died within a mean follow-up period of 13 months. Sinus rhythm was present at the most recent evaluation in all patients, including the patient stimulated in the DVI mode. Physiologic stimulation is of value for elderly patients with an active life style and complete heart block. Reprogramming to another pacing mode is only seldom necessary.
IS  - 0021-4868
IL  - 0021-4868
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 1988 Jan
DC  - 19880907
YR  - 1988
ED  - 19880907
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=3398242

<912. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3382569
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lipkin DP
AU  - Frenneaux M
AU  - Stewart R
AU  - Joshi J
AU  - Lowe T
AU  - McKenna WJ
FA  - Lipkin, D P
FA  - Frenneaux, M
FA  - Stewart, R
FA  - Joshi, J
FA  - Lowe, T
FA  - McKenna, W J
IN  - Lipkin,D P. Cardiovascular Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London.
TI  - Delayed improvement in exercise capacity after cardioversion of atrial fibrillation to sinus rhythm.
SO  - British Heart Journal. 59(5):572-7, 1988 May.
AS  - Br Heart J. 59(5):572-7, 1988 May.
NJ  - British heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - ats, 0370634
OI  - Source: NLM. PMC1276898
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - ENGLAND
MH  - Aged
MH  - Atrial Fibrillation/me [Metabolism]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Electric Countershock
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Contraction
MH  - Oxygen Consumption
MH  - *Physical Exertion
MH  - Time Factors
AB  - In some patients symptoms improve after the restoration of sinus rhythm from atrial fibrillation. To assess the size and mechanism of such change, exercise capacity and pulsed Doppler left ventricular inflow velocities were assessed in 20 patients with established atrial fibrillation. Treadmill exercise capacity was assessed by measuring maximal oxygen consumption and anaerobic threshold before and on day 1 and 28 days after elective DC cardioversion. The relative contribution of atrial contraction to left ventricular filling was determined by relating the maximum height of the A wave to the maximum height of the E wave (A/E) of the Doppler velocity time curve. Cardioversion was successful in 14 patients. Maximal oxygen consumption and anaerobic threshold were unchanged on day 1 and increased by day 28 in all 14 patients. The percentage improvement was inversely related to the baseline values; however, the absolute improvement was small in all patients. The mean A/E ratio increased significantly from day 1 to day 28 in all 14 patients. Thus the restoration of sinus rhythm was associated with a delayed improvement in exercise capacity that may in part be due to a slow improvement in atrial contractility and peak cardiac output after cardioversion.
IS  - 0007-0769
IL  - 0007-0769
PT  - Journal Article
LG  - English
DP  - 1988 May
DC  - 19880809
YR  - 1988
ED  - 19880809
RD  - 20131001
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=3382569

<913. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3383412
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Mirsky I
AU  - Corin WJ
AU  - Murakami T
AU  - Grimm J
AU  - Hess OM
AU  - Krayenbuehl HP
FA  - Mirsky, I
FA  - Corin, W J
FA  - Murakami, T
FA  - Grimm, J
FA  - Hess, O M
FA  - Krayenbuehl, H P
IN  - Mirsky,I. Department of Medicine, Harvard Medical School, Boston, MA 02115.
TI  - Correction for preload in assessment of myocardial contractility in aortic and mitral valve disease. Application of the concept of systolic myocardial stiffness.
SO  - Circulation. 78(1):68-80, 1988 Jul.
AS  - Circulation. 78(1):68-80, 1988 Jul.
NJ  - Circulation
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - *Aortic Valve Insufficiency/pp [Physiopathology]
MH  - Aortic Valve Insufficiency/su [Surgery]
MH  - *Aortic Valve Stenosis/pp [Physiopathology]
MH  - Aortic Valve Stenosis/su [Surgery]
MH  - Blood Pressure
MH  - Blood Volume
MH  - Cineangiography
MH  - Female
MH  - Hemodynamics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mitral Valve Insufficiency/pp [Physiopathology]
MH  - Mitral Valve Insufficiency/su [Surgery]
MH  - *Myocardial Contraction
MH  - Stroke Volume
AB  - With single-beat analysis, the new concept of systolic myocardial stiffness is applied to provide a new approach for the assessment of myocardial contractility in aortic and mitral valve disease. Seventy patients underwent diagnostic right and left heart catheterization. Twenty-six patients had aortic stenosis, 18 had aortic insufficiency, and 26 had mitral regurgitation. Patients with aortic stenosis were divided into two groups on the basis of left ventricular mass index less than 172 g/m2 (AS1) and mass index greater than or equal to 172 g/m2 (AS2). The mitral regurgitation patients were divided into those in normal sinus rhythm (MR1) and those in atrial fibrillation (MR2). Nine patients without significant coronary or cardiovascular disease served as controls. Thirteen patients with aortic stenosis and eight with aortic insufficiency were evaluated (average, approximately 18 months) after successful aortic valve replacement. With simultaneous left ventricular pressure and cineangiographic methods, myocardial contractility was assessed by the conventional ejection fraction-afterload relation (uncorrected for preload) and by two new methods that permit the correction of the ejection fraction for preload. Assessments of the contractile state by these two new methods differed from those by the conventional method in 20-40% of the cases studied. Contractile state improved postoperatively in aortic stenosis and aortic insufficiency even in patients with preoperative depressed contractile states. In patients with mitral regurgitation, there was considerable heterogeneity of contractile function preoperatively. Severe left ventricular hypertrophy in aortic stenosis was not a marker for postoperative outcome since contractility was normal postoperatively in AS1 and AS2 in equal numbers. This study demonstrates that preload correction is important in a preoperative assessment of contractility in aortic and mitral valve disease but that it is less important postoperatively, presumably because of reductions in the preload.
IS  - 0009-7322
IL  - 0009-7322
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
NO  - HL-34596 (United States NHLBI NIH HHS)
LG  - English
DP  - 1988 Jul
DC  - 19880804
YR  - 1988
ED  - 19880804
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=3383412

<914. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3367001
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Buckingham TA
AU  - Woodruff RC
AU  - Pennington DG
AU  - Redd RM
AU  - Janosik DL
AU  - Labovitz AJ
AU  - Graves R
AU  - Kennedy HL
FA  - Buckingham, T A
FA  - Woodruff, R C
FA  - Pennington, D G
FA  - Redd, R M
FA  - Janosik, D L
FA  - Labovitz, A J
FA  - Graves, R
FA  - Kennedy, H L
IN  - Buckingham,T A. Department of Internal Medicine, St. Louis University, Missouri.
TI  - Effect of ventricular function on the exercise hemodynamics of variable rate pacing.
SO  - Journal of the American College of Cardiology. 11(6):1269-77, 1988 Jun.
AS  - J Am Coll Cardiol. 11(6):1269-77, 1988 Jun.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - h50, 8301365
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Atrioventricular Node/pp [Physiopathology]
MH  - *Cardiac Pacing, Artificial/mt [Methods]
MH  - Child
MH  - *Exercise Test
MH  - Female
MH  - *Heart Block/pp [Physiopathology]
MH  - Heart Failure/pp [Physiopathology]
MH  - Heart Function Tests
MH  - *Heart Rate
MH  - Heart Ventricles/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Stroke Volume
AB  - To determine the effect of ventricular function on the exercise hemodynamics of variable rate pacing, 16 selected patients underwent paired, double-blind, randomized exercise tests in single rate demand (VVI) or variable rate (VVIR) pacing modes. Ejection fraction and cardiac index were determined by two-dimensional and Doppler echocardiography at baseline and during peak exercise. Baseline ejection fraction ranged from 14 to 73% and was less than 40% in 6 patients (Group 1) and greater than or equal to 40% in 10 patients (Group 2). Duration of exercise was longer during the VVIR mode (502 s) than during the VVI mode (449 s) (p less than 0.01) and unrelated to baseline ejection fraction. Heart rate during exercise increased 9% in the VVI mode and 35% in the VVIR mode (p less than 0.005). Cardiac index increased 49% in the VVI mode and 83% in the VVIR mode. Analysis of variance for repeated measures showed a significant effect of pacing mode (p less than 0.01) and exercise (p less than 0.001), but not baseline ejection fraction, on cardiac index. Baseline ejection fraction did not correlate with the increase in cardiac index in either pacing mode or with the difference in increase between modes. There was no significant difference between Groups 1 and 2 in exercise duration, peak heart rate-blood pressure (rate-pressure) product, baseline or peak heart rate or baseline or peak cardiac index. Therefore, in selected patients, VVIR pacing during exercise results in an increase in heart rate, duration of exercise and cardiac index that is unrelated to the degree of baseline left ventricular dysfunction.(ABSTRACT TRUNCATED AT 250 WORDS)
IS  - 0735-1097
IL  - 0735-1097
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1988 Jun
DC  - 19880620
YR  - 1988
ED  - 19880620
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=3367001

<915. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3343453
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Atwood JE
AU  - Myers J
AU  - Sullivan M
AU  - Forbes S
AU  - Friis R
AU  - Pewen W
AU  - Callaham P
AU  - Hall P
AU  - Froelicher V
FA  - Atwood, J E
FA  - Myers, J
FA  - Sullivan, M
FA  - Forbes, S
FA  - Friis, R
FA  - Pewen, W
FA  - Callaham, P
FA  - Hall, P
FA  - Froelicher, V
IN  - Atwood,J E. Cardiology Section, Veterans Administration Medical Center, Long Beach, California 90822.
TI  - Maximal exercise testing and gas exchange in patients with chronic atrial fibrillation.
SO  - Journal of the American College of Cardiology. 11(3):508-13, 1988 Mar.
AS  - J Am Coll Cardiol. 11(3):508-13, 1988 Mar.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - h50, 8301365
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Chronic Disease
MH  - Coronary Disease/co [Complications]
MH  - *Exercise Test
MH  - Heart Rate
MH  - Hemodynamics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxygen Consumption
MH  - *Pulmonary Gas Exchange
MH  - Regression Analysis
AB  - To evaluate the response of patients with chronic atrial fibrillation to exercise, 50 men (mean age 65 +/- 8 years) with atrial fibrillation underwent a maximal exercise test using respiratory gas exchange techniques. Patients were classified by the presence (n = 29) or absence ("lone atrial fibrillation," n = 21) of underlying heart disease. Responses were evaluated at a standard submaximal work load (3.0 mph, [4.8 km/h] 0% grade), at the gas exchange anaerobic threshold and at maximal exercise. For all 50 patients, the mean maximal oxygen uptake was 20.6 ml/kg per min, which approximates 85% of the aerobic capacity predicted for age-matched normal individuals. Patients with lone atrial fibrillation demonstrated normal exercise capacity in contrast to patients with atrial fibrillation and known heart disease (22.7 +/- 5 versus 19.1 +/- 5.0 ml/kg per min, p less than 0.05). The mean maximal heart rate (176 +/- 30 beats/min) was approximately 20 beats/min higher than that expected for age, was extremely variable and accounted for only 8% of the variance in maximal oxygen uptake. Maximal heart rate in subjects with lone atrial fibrillation was higher than that of subjects with atrial fibrillation and known heart disease (189 +/- 32 versus 166 +/- 24 beats/min, p less than 0.01). Stepwise regression analysis revealed that maximal systolic blood pressure accounted for 19% of the variance in maximal oxygen uptake (VO2 max), suggesting that systolic function is an important determinant of exercise performance in atrial fibrillation.(ABSTRACT TRUNCATED AT 250 WORDS)
IS  - 0735-1097
IL  - 0735-1097
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1988 Mar
DC  - 19880328
YR  - 1988
ED  - 19880328
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=3343453

<916. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3335153
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Atwood JE
AU  - Myers JN
AU  - Sullivan MJ
AU  - Forbes SM
AU  - Pewen WF
AU  - Froelicher VF
FA  - Atwood, J E
FA  - Myers, J N
FA  - Sullivan, M J
FA  - Forbes, S M
FA  - Pewen, W F
FA  - Froelicher, V F
IN  - Atwood,J E. Cardiology Section, Veterans Administration Medical Center, Long Beach, CA 90822.
TI  - Diltiazem and exercise performance in patients with chronic atrial fibrillation.
SO  - Chest. 93(1):20-5, 1988 Jan.
AS  - Chest. 93(1):20-5, 1988 Jan.
NJ  - Chest
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0231335, d1c
OI  - Source: NASA. 88081780
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
SB  - National Aeronautics and Space Administration (NASA) Journals
CP  - UNITED STATES
MH  - Aged
MH  - Anaerobiosis
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Blood Pressure/de [Drug Effects]
MH  - Chronic Disease
MH  - *Diltiazem/tu [Therapeutic Use]
MH  - Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Physical Exertion
MH  - Pulmonary Gas Exchange/de [Drug Effects]
AB  - To evaluate the influence of calcium entry blockade (diltiazem 60 mg qid) on exercise capacity in patients with chronic atrial fibrillation, nine men (mean age 65 years) with atrial fibrillation underwent maximal treadmill exercise on and off diltiazem therapy. Heart rate, blood pressure, and measured ventilatory parameters were assessed at a standard submaximal workload (3.0 mph/0% grade), the gas exchange anaerobic threshold (ATge), and maximal exercise. Significant reductions in heart rate at all stages of exercise were demonstrated: maximum heart rate decreased from 171 +/- 30 beats/min to 142 +/- 27 beats/min (17 percent, p less than .01) and submaximal exercise heart rate decreased from 123 +/- 22 beats/min to 96 +/- 16 beats/min (22 percent, p less than .01). However, there were no significant changes in blood pressure or gas exchange data, ie, oxygen uptake, minute ventilation, or respiratory exchange ratio at any of the exercise workloads. These data demonstrate that in patients with chronic atrial fibrillation, diltiazem controls the ventricular rate response throughout exercise without attenuating blood pressure or exercise capacity.
RN  - EE92BBP03H (Diltiazem)
IS  - 0012-3692
IL  - 0012-3692
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1988 Jan
DC  - 19880210
YR  - 1988
ED  - 19880210
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=3335153

<917. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2446275
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Faerestrand S
AU  - Breivik K
AU  - Ohm OJ
FA  - Faerestrand, S
FA  - Breivik, K
FA  - Ohm, O J
IN  - Faerestrand,S. University of Bergen, School of Medicine, Norway.
TI  - Assessment of the work capacity and relationship between rate response and exercise tolerance associated with activity-sensing rate-responsive ventricular pacing.
SO  - Pacing & Clinical Electrophysiology. 10(6):1277-90, 1987 Nov.
AS  - Pacing Clin Electrophysiol. 10(6):1277-90, 1987 Nov.
NJ  - Pacing and clinical electrophysiology : PACE
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - pab, 7803944
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Coronary Disease/pp [Physiopathology]
MH  - *Electrocardiography
MH  - *Exercise Test
MH  - *Heart Block/pp [Physiopathology]
MH  - Heart Block/th [Therapy]
MH  - Heart Rate
MH  - *Heart Ventricles/pp [Physiopathology]
MH  - Humans
MH  - Middle Aged
MH  - Monitoring, Physiologic
MH  - *Pacemaker, Artificial
MH  - Sinoatrial Block/pp [Physiopathology]
AB  - The relationship between rate response and exercise tolerance was studied by measuring the symptom-limited maximum treadmill time (MTT)both during fixed rate VVI pacing and during VVI + activity mode pacing (RRP) in 15 patients (mean age, 73 years) who had received rate-responsive ventricular pacemakers. Their indications were atrioventricular block, sino-atrial block, and atrial fibrillation with slow ventricular response. Basic rate was programmed to 60 ppm in both pacing modes; rate response and activity threshold were programmed to 5 and medium, respectively. The order in which the two pacing modes were tested was randomly determined. The MTT was, on average, 29% longer in RRP than in VVI mode with a mean of 12 minutes in VVI and 14.8 minutes in RRP (p less than 0.001). For the subgroup of eight patients with paced-only rhythm the average increase in MTT was 38% with a mean of 9.5 minutes in VVI and 12.8 minutes in RRP (p less than 0.01). Seven patients who showed episodes of spontaneous rhythm, increased their average MTT by 17% (mean in VVI, 14.9 minutes; in RRP, 17.1 minutes; p less than 0.02). During RRP, a significant positive correlation existed between MTT and the increase in heart rate (N = 15; r = 0.83; p less than 0.001). In 12 patients with paced-only rhythm, the pacing rate remained at the programmed basic rate when the patients were lying, sitting, and standing and increased to 86 +/- 4 ppm during casual walking, and to 101 +/- 4 ppm during jumping up and down with the pacemaker programmed to the above-mentioned parameters. The maximum pacing rate during jumping corresponded with the maximum pacing rates measured from Holter recordings during normal daily activities.
IS  - 0147-8389
IL  - 0147-8389
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 1987 Nov
DC  - 19880119
YR  - 1987
ED  - 19880119
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=2446275

<918. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2445572
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Areskog NH
FA  - Areskog, N H
IN  - Areskog,N H. Department of Clinical Physiology, University Hospital, Linkoping, Sweden.
TI  - Exercise-induced arrhythmias in valvular heart disease.
SO  - European Heart Journal. 8 Suppl D:43-5, 1987 Aug.
AS  - Eur Heart J. 8 Suppl D:43-5, 1987 Aug.
NJ  - European heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - em8, 8006263
SB  - Index Medicus
CP  - ENGLAND
MH  - Aortic Valve Insufficiency/co [Complications]
MH  - Aortic Valve Stenosis/co [Complications]
MH  - *Arrhythmias, Cardiac/et [Etiology]
MH  - Arrhythmias, Cardiac/pp [Physiopathology]
MH  - Atrial Fibrillation/co [Complications]
MH  - Cardiac Complexes, Premature/co [Complications]
MH  - Cardiac Complexes, Premature/pp [Physiopathology]
MH  - *Heart Valve Diseases/co [Complications]
MH  - Humans
MH  - *Physical Exertion
IS  - 0195-668X
IL  - 0195-668X
PT  - Journal Article
LG  - English
DP  - 1987 Aug
DC  - 19880104
YR  - 1987
ED  - 19880104
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=2445572

<919. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3678259
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Brugada P
FA  - Brugada, P
IN  - Brugada,P. Department of Cardiology, University of Limburg, University Hospital, Maastricht, The Netherlands.
TI  - Relative value of exercise electrocardiography, long-term electrocardiographic monitoring and programmed electrical stimulation of the heart in the treatment of cardiac arrhythmias.
SO  - European Heart Journal. 8 Suppl D:3-5, 1987 Aug.
AS  - Eur Heart J. 8 Suppl D:3-5, 1987 Aug.
NJ  - European heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - em8, 8006263
SB  - Index Medicus
CP  - ENGLAND
MH  - Arrhythmias, Cardiac/pp [Physiopathology]
MH  - *Arrhythmias, Cardiac/th [Therapy]
MH  - *Cardiac Pacing, Artificial
MH  - *Electrocardiography
MH  - *Exercise Test
MH  - Humans
MH  - *Monitoring, Physiologic/mt [Methods]
MH  - Time Factors
AB  - A long time ago, Senac (1683-1770) treated palpitations with quinine. Three centuries later Wenckebach rediscovered the value of quinine in atrial fibrillation and now gets the credit for it, at least in the American literature. Life has plenty of paradoxes; the history of the treatment of arrhythmias too. Pope Clement XI (1649-1721) has become known in history for his opposition to adapting Catholic rituals to Chinese habits. He will never be credited as the man, however, who supported the first 'epidemiological' study on sudden death. It was 1705 when he ordered Lancisi to study by autopsy the cause of any unexpected death among Roman nobles. The results were rather disappointing. We have come a long way since then. While good clinical judgement and common sense remain the most important tools in the treatment of cardiac arrhythmias, technicological progress has provided us with refined techniques for studying that problem. Among them, long-term electrocardiographic monitoring, exercise testing and programmed electrical stimulation of the heart. However, and as Zipes pointed out, we are far from perfection in the treatment of cardiac arrhythmias. Whether it was Senac or Wenckebach who first observed that quinine could change an irregular heart rhythm (atrial fibrillation) into a regular one (sinus rhythm), we are not far from their empiricism. However refined they may look, our present methods of diagnosis and treatment of arrhythmias are regrettably imperfect. These techniques have to be used carefully and rationally. Their present value and limitations will be outlined here.
IS  - 0195-668X
IL  - 0195-668X
PT  - Journal Article
LG  - English
DP  - 1987 Aug
DC  - 19880104
YR  - 1987
ED  - 19880104
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=3678259

<920. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2887542
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Myers J
AU  - Atwood JE
AU  - Sullivan M
AU  - Forbes S
AU  - Friis R
AU  - Pewen W
AU  - Froelicher V
FA  - Myers, J
FA  - Atwood, J E
FA  - Sullivan, M
FA  - Forbes, S
FA  - Friis, R
FA  - Pewen, W
FA  - Froelicher, V
TI  - Perceived exertion and gas exchange after calcium and beta-blockade in atrial fibrillation.
SO  - Journal of Applied Physiology. 63(1):97-104, 1987 Jul.
AS  - J Appl Physiol. 63(1):97-104, 1987 Jul.
NJ  - Journal of applied physiology (Bethesda, Md. : 1985)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - heg, 8502536
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Adrenergic beta-Antagonists/tu [Therapeutic Use]
MH  - Aged
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Blood Pressure/de [Drug Effects]
MH  - Carbon Dioxide
MH  - Celiprolol
MH  - Chronic Disease
MH  - Clinical Trials as Topic
MH  - Digoxin/tu [Therapeutic Use]
MH  - *Diltiazem/tu [Therapeutic Use]
MH  - Double-Blind Method
MH  - Heart Rate/de [Drug Effects]
MH  - *Hemodynamics/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxygen/bl [Blood]
MH  - Oxygen Consumption
MH  - *Physical Exertion
MH  - *Propanolamines/tu [Therapeutic Use]
MH  - Random Allocation
AB  - Nine male patients (mean age 65 yr) with chronic atrial fibrillation underwent maximal exercise testing during placebo, beta-adrenergic (celiprolol, 600 mg), or calcium (diltiazem, 30 or 60 mg four times daily) channel blockade. The results were analyzed to determine which factors most closely related to ratings of perceived exertion (RPE) during exercise. Heart rate (HR), blood pressure (BP), oxygen uptake (VO2), minute ventilation (VE), and carbon dioxide production (VCO2) were evaluated at rest, 3.0 mph/0% grade, the gas exchange anaerobic threshold (ATge), 80% of placebo maximal O2 uptake, and maximal exercise. Both beta-adrenergic and calcium channel blockade significantly reduced heart rate and systolic blood pressure relative to placebo; these effects were more profound during beta-adrenergic blockade and as exercise progressed. Correlation coefficients and estimates of slope were derived for changes in RPE during exercise vs. changes in HR, VO2, VE, and VCO2 during the three treatments (r = 0.76 to 0.92, P less than 0.001). Although RPE was significantly correlated with HR during placebo and diltiazem therapy (r = 0.45, P less than 0.01), this was not the case during beta-adrenergic blockade (r = 0.31, NS). Slope of the regression lines between RPE and VO2, VE, and VCO2 did not differ between the three treatments. Slope of the regression lines between RPE and HR differed only during calcium channel blockade. Because the presence of atrial fibrillation and beta-adrenergic blockade altered the associations between RPE, VO2, and HR, these results suggest that VE is more closely related to RPE than the other parameters.
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Propanolamines)
RN  - 142M471B3J (Carbon Dioxide)
RN  - 73K4184T59 (Digoxin)
RN  - DRB57K47QC (Celiprolol)
RN  - EE92BBP03H (Diltiazem)
RN  - S88TT14065 (Oxygen)
IS  - 8750-7587
IL  - 0161-7567
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1987 Jul
DC  - 19870925
YR  - 1987
ED  - 19870925
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=2887542

<921. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2885354
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Atwood JE
AU  - Sullivan M
AU  - Forbes S
AU  - Myers J
AU  - Pewen W
AU  - Olson HG
AU  - Froelicher VF
FA  - Atwood, J E
FA  - Sullivan, M
FA  - Forbes, S
FA  - Myers, J
FA  - Pewen, W
FA  - Olson, H G
FA  - Froelicher, V F
TI  - Effect of beta-adrenergic blockade on exercise performance in patients with chronic atrial fibrillation.
SO  - Journal of the American College of Cardiology. 10(2):314-20, 1987 Aug.
AS  - J Am Coll Cardiol. 10(2):314-20, 1987 Aug.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - h50, 8301365
OI  - Source: NASA. 87251799
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
SB  - National Aeronautics and Space Administration (NASA) Journals
CP  - UNITED STATES
MH  - *Adrenergic beta-Antagonists/tu [Therapeutic Use]
MH  - Aged
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Blood Pressure/de [Drug Effects]
MH  - Celiprolol
MH  - Double-Blind Method
MH  - Exercise Test
MH  - Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Physical Exertion
MH  - Propanolamines/pd [Pharmacology]
MH  - *Propanolamines/tu [Therapeutic Use]
MH  - Pulmonary Gas Exchange/de [Drug Effects]
MH  - Random Allocation
AB  - Beta-adrenergic blocking agents are commonly used in combination with digitalis to control excessive heart rate during exercise in patients with chronic atrial fibrillation. However, little is known about the effect of beta-adrenergic blockade on exercise capacity in these patients. Accordingly, a randomized, double-blind, cross-over placebo-controlled study was performed to assess the efficacy of celiprolol, a new cardioselective beta-blocker with partial intrinsic sympathomimetic activity, on exercise performance in nine men with chronic atrial fibrillation. All but one patient was receiving maintenance digitalis during the study. Heart rate, blood pressure and gas exchange variables were measured at rest and during treadmill exercise testing while the patients were receiving maintenance celiprolol or placebo. Significant reductions in heart rate and systolic blood pressure compared with control values were observed at submaximal exercise, at the gas exchange anaerobic threshold and at maximal exertion while the patients were taking celiprolol. However, oxygen uptake at the gas exchange anaerobic threshold during celiprolol therapy was 12.3 versus 14.0 ml oxygen/kg per min during placebo administration (a 12% difference, p less than 0.01). Similarly, oxygen uptake at maximal exertion during celiprolol therapy was 17.6 versus 21.0 ml/kg per min during placebo administration (a 16% difference, p less than 0.01). Treadmill time was also reduced during the celiprolol phase compared with placebo (11.3 versus 10.3 minutes; a 19% difference, p less than 0.01). These results indicate that in patients with atrial fibrillation the major beneficial effects of beta-adrenergic blockade--reduced submaximal and maximal exercise heart rate and blood pressure--must be weighed against the decrease in exercise capacity.
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Propanolamines)
RN  - DRB57K47QC (Celiprolol)
IS  - 0735-1097
IL  - 0735-1097
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1987 Aug
DC  - 19870824
YR  - 1987
ED  - 19870824
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=2885354

<922. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3599409
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Furui H
AU  - Taniguchi N
AU  - Yamauchi K
AU  - Sotobata I
AU  - Saito H
AU  - Inagaki H
FA  - Furui, H
FA  - Taniguchi, N
FA  - Yamauchi, K
FA  - Sotobata, I
FA  - Saito, H
FA  - Inagaki, H
TI  - Effects of treadmill exercise on platelet function, blood coagulability and fibrinolytic activity in patients with atrial fibrillation.
SO  - Japanese Heart Journal. 28(2):177-84, 1987 Mar.
AS  - Jpn Heart J. 28(2):177-84, 1987 Mar.
NJ  - Japanese heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - kh3, 0401175
SB  - Index Medicus
CP  - JAPAN
MH  - Adenosine Diphosphate/pd [Pharmacology]
MH  - Adult
MH  - Atrial Fibrillation/bl [Blood]
MH  - Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Blood Coagulation
MH  - *Blood Platelets/ph [Physiology]
MH  - *Fibrinolysis
MH  - Hemodynamics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Physical Exertion
MH  - Platelet Aggregation/de [Drug Effects]
MH  - Risk
MH  - Thromboembolism/et [Etiology]
AB  - The effects of treadmill exercise on platelet function, blood coagulability and fibrinolytic activity were evaluated in 20 patients with lone atrial fibrillation (AF) and 15 age-matched normal controls (normals). Multistage treadmill exercise up to 85% of the predicted maximal heart rate was performed, and blood for measurements was obtained pre-exercise, and immediately and 6 min post-exercise. There was an increase in the platelet sensitivity to ADP-aggregation after exercise in both groups. Pre-exercise plasma beta-thromboglobulin (beta-TG) levels were higher in AF than in normals. Beta-TG increased after exercise in both groups (immediate post-exercise; 35.1 ng/ml for normals and 62.8 ng/ml for AF), and the increase was greater in AF than in normals. PT and APTT shortened, and plasma fibrinogen levels increased after exercise in both groups. Pre-exercise levels of plasma ATIII and protein C were lower in AF than in normals. These two proteins increased after exercise in both groups. However, the increase was greater in normals. Plasma alpha 2-PI increased after exercise in both groups; the level was lower in AF than in normals at each exercise stage. In conclusion, enhanced platelet activity, and lower levels of anticoagulant and antifibrinolytic activity were observed in AF not only at rest but also after treadmill exercise. These changes might reflect the hypercoagulable state in patients with AF. It is speculated that the risk of thromboembolic complications may be enhanced with exercise in AF patients.
RN  - 61D2G4IYVH (Adenosine Diphosphate)
IS  - 0021-4868
IL  - 0021-4868
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 1987 Mar
DC  - 19870814
YR  - 1987
ED  - 19870814
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=3599409

<923. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3829363
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Podrid PJ
AU  - Graboys TB
AU  - Lampert S
AU  - Blatt C
FA  - Podrid, P J
FA  - Graboys, T B
FA  - Lampert, S
FA  - Blatt, C
TI  - Exercise stress testing for exposure of arrhythmias.
SO  - Circulation. 75(4 Pt 2):III60-8, 1987 Apr.
AS  - Circulation. 75(4 Pt 2):III60-8, 1987 Apr.
NJ  - Circulation
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Anti-Arrhythmia Agents/tu [Therapeutic Use]
MH  - *Arrhythmias, Cardiac/di [Diagnosis]
MH  - Arrhythmias, Cardiac/dt [Drug Therapy]
MH  - Arrhythmias, Cardiac/pp [Physiopathology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Exercise Test
MH  - Heart Ventricles/pp [Physiopathology]
MH  - Humans
MH  - Monitoring, Physiologic
MH  - Prognosis
MH  - Sympathetic Nervous System/pp [Physiopathology]
MH  - Tachycardia/pp [Physiopathology]
RN  - 0 (Anti-Arrhythmia Agents)
IS  - 0009-7322
IL  - 0009-7322
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
NO  - HL-07776 (United States NHLBI NIH HHS)
LG  - English
DP  - 1987 Apr
DC  - 19870427
YR  - 1987
ED  - 19870427
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=3829363

<924. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3814458
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Jacob LH
AU  - Carron DB
FA  - Jacob, L H
FA  - Carron, D B
TI  - Atrial fibrillation precipitated by tyramine containing foods.
SO  - British Heart Journal. 57(2):205-6, 1987 Feb.
AS  - Br Heart J. 57(2):205-6, 1987 Feb.
NJ  - British heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - ats, 0370634
OI  - Source: NLM. PMC1277109
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - ENGLAND
MH  - *Atrial Fibrillation/et [Etiology]
MH  - Coronary Disease/co [Complications]
MH  - *Food
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Tyramine/ae [Adverse Effects]
AB  - Episodes of atrial fibrillation that occurred after meals developed in a 60 year old man with a history of ischaemic heart disease. The attacks were precipitated by precursors and metabolites of tyramine and tyramine containing foods and drinks, in the absence of monoamine oxidase inhibitors. The patient has remained free of atrial fibrillation for the past twelve months on a diet that does not contain tyramine.
RN  - X8ZC7V0OX3 (Tyramine)
IS  - 0007-0769
IL  - 0007-0769
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 1987 Feb
DC  - 19870416
YR  - 1987
ED  - 19870416
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=3814458

<925. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3805530
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Steinberg JS
AU  - Katz RJ
AU  - Bren GB
AU  - Buff LA
AU  - Varghese PJ
FA  - Steinberg, J S
FA  - Katz, R J
FA  - Bren, G B
FA  - Buff, L A
FA  - Varghese, P J
TI  - Efficacy of oral diltiazem to control ventricular response in chronic atrial fibrillation at rest and during exercise.
SO  - Journal of the American College of Cardiology. 9(2):405-11, 1987 Feb.
AS  - J Am Coll Cardiol. 9(2):405-11, 1987 Feb.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - h50, 8301365
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Digoxin/tu [Therapeutic Use]
MH  - *Diltiazem/tu [Therapeutic Use]
MH  - Drug Evaluation
MH  - Female
MH  - Heart Rate/de [Drug Effects]
MH  - Hemodynamics/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Physical Exertion
MH  - Rest
MH  - Tachycardia, Supraventricular/et [Etiology]
MH  - *Tachycardia, Supraventricular/pc [Prevention & Control]
AB  - Although digoxin is often the first choice for control of ventricular response in chronic atrial fibrillation, it fails to slow exercise rates. Diltiazem, a calcium channel antagonist that slows atrioventricular conduction, was administered to 16 patients who failed to achieve adequate rate control on low level exercise testing despite digoxin therapy. Therapeutic response to diltiazem was assessed with submaximal and maximal exercise tests and 24 hour ambulatory electrocardiographic monitoring. During the diltiazem treatment phase, ventricular response at rest diminished (96 +/- 17 versus 69 +/- 10 beats/min, p less than 0.001) as did rate during submaximal exercise (155 +/- 28 versus 116 +/- 26, p less than 0.001), maximal exercise (163 +/- 14 versus 133 +/- 26, p less than 0.001) and average ventricular response during 24 hour monitoring (87 +/- 13 versus 69 +/- 10, p less than 0.001). Rate at rest decreased 26 +/- 15% and submaximal exercise rate diminished 24 +/- 12%. Thirteen (81%) of the 16 patients exhibited at least 15% slowing of rate at rest and during submaximal exercise. Eleven patients (69%) reported alleviation of symptoms. There was no change in serum digoxin levels during diltiazem treatment (1.3 +/- 0.5 versus 1.3 +/- 0.6 ng/ml, p = NS). On withdrawal of diltiazem, ventricular response returned to baseline values. Diltiazem is an effective agent for control of ventricular response, both at rest and during exercise, in digoxin-treated patients with chronic atrial fibrillation.
RN  - 73K4184T59 (Digoxin)
RN  - EE92BBP03H (Diltiazem)
IS  - 0735-1097
IL  - 0735-1097
PT  - Journal Article
LG  - English
DP  - 1987 Feb
DC  - 19870306
YR  - 1987
ED  - 19870306
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=3805530

<926. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3799704
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Vacek JL
AU  - Valentin-Stone P
AU  - Wolfe M
AU  - Davis WR
FA  - Vacek, J L
FA  - Valentin-Stone, P
FA  - Wolfe, M
FA  - Davis, W R
TI  - The value of standardized exercise testing in the noninvasive evaluation of mitral stenosis.
SO  - American Journal of the Medical Sciences. 292(6):335-43, 1986 Dec.
AS  - Am J Med Sci. 292(6):335-43, 1986 Dec.
NJ  - The American journal of the medical sciences
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3l2, 0370506
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Cardiac Catheterization
MH  - Echocardiography
MH  - Evaluation Studies as Topic
MH  - *Exercise Test
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mitral Valve Stenosis/pp [Physiopathology]
MH  - Oxygen Consumption
MH  - Prospective Studies
MH  - Regression Analysis
AB  - The determination of functional impairment is an important portion of the evaluation of patients with mitral stenosis and frequently is instrumental in the determination to proceed with invasive testing. To test the hypothesis that patients with slowly evolving disability from mitral stenosis frequently do not recognize the degree of their limitations and to determine the utility of formal exercise testing, 24 consecutive patients with pure or predominant mitral stenosis were evaluated for NYHA functional category (NYHA class) by historical determination of functional impairment, echocardiographic mitral valve area (echo MVA), exercise duration, estimated maximum oxygen consumption, and functional aerobic impairment during a symptom-limited Bruce protocol exercise test and multiple catheterization-derived parameters. The data revealed no difference in exercise duration or mitral valve area between NYHA classes, but demonstrated an excellent correlation between exercise duration and severity of mitral valve stenosis determined at cardiac catheterization (cath MVA). This relationship was similar to that of echo MVA to cath MVA and exceeded that of exercise time to any other parameter measured during catheterization. Estimation of maximum oxygen consumption or functional aerobic impairment did not improve the exercise duration to valve area relationship. The data presented thus demonstrate that Bruce protocol exercise testing is a valuable adjunct to other noninvasive tests in the initial evaluation of selected patients with mitral stenosis. By virtue of being easily repeated at low risk, exercise testing may also be useful in long term follow-up of medically treated mitral stenosis patients.
IS  - 0002-9629
IL  - 0002-9629
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 1986 Dec
DC  - 19870203
YR  - 1986
ED  - 19870203
RD  - 20121115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=3799704

<927. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3780339
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Smith T
FA  - Smith, T
TI  - A new method of cardioversion.
SO  - Chest. 90(6):928, 1986 Dec.
AS  - Chest. 90(6):928, 1986 Dec.
NJ  - Chest
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0231335, d1c
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Atrial Fibrillation/th [Therapy]
MH  - *Electric Countershock/mt [Methods]
MH  - Male
MH  - Pulse
MH  - Running
IS  - 0012-3692
IL  - 0012-3692
PT  - Case Reports
PT  - Letter
LG  - English
DP  - 1986 Dec
DC  - 19870106
YR  - 1986
ED  - 19870106
RD  - 20031114
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=3780339

<928. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3019116
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Morise AP
AU  - Goodwin C
FA  - Morise, A P
FA  - Goodwin, C
TI  - Exercise radionuclide angiography in patients with mitral stenosis: value of right ventricular response.
SO  - American Heart Journal. 112(3):509-17, 1986 Sep.
AS  - Am Heart J. 112(3):509-17, 1986 Sep.
NJ  - American heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3bw, 0370465
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - Erythrocytes
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve Stenosis/pp [Physiopathology]
MH  - *Mitral Valve Stenosis/ri [Radionuclide Imaging]
MH  - *Physical Exertion
MH  - Sodium Pertechnetate Tc 99m
MH  - Stroke Volume
AB  - We observed 26 patients with mitral stenosis and 19 normal volunteers with exercise gated radionuclide angiography. Although no differences were seen between normal subjects and patients with mitral stenosis at rest in left (LV) and right (RV) ventricular ejection fraction, significant differences were found for exercise change in ejection fraction for both ventricles, exercise time, exercise workload, and the percent change in LV end-diastolic, LV stroke, and RV end-systolic counts (ESC). Because nearly all of the normals (18/19) had a decrease in RVESC, patients with stenosis were divided into two groups according to whether RVESC increased or decreased. Significant differences were found between these two groups for age, New York Heart Association class, prevalence of atrial fibrillation, echocardiographic mitral valve area, and prognosis, that is, number undergoing catheterization and surgery. We conclude that exercise radionuclide angiography does yield information that has significant clinical and prognostic value in patients with mitral stenosis.
RN  - A0730CX801 (Sodium Pertechnetate Tc 99m)
IS  - 0002-8703
IL  - 0002-8703
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1986 Sep
DC  - 19860929
YR  - 1986
ED  - 19860929
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=3019116

<929. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3699047
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Tak T
AU  - Cats VM
AU  - Dunning AJ
FA  - Tak, T
FA  - Cats, V M
FA  - Dunning, A J
TI  - Ambulatory ECG recording during competitive parachute jumping in apparently healthy young men: more evidence for intermittent vagal dominance during enhanced sympathetic activity.
SO  - European Heart Journal. 7(2):110-4, 1986 Feb.
AS  - Eur Heart J. 7(2):110-4, 1986 Feb.
NJ  - European heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - em8, 8006263
SB  - Index Medicus
CP  - ENGLAND
MH  - Adult
MH  - Arrhythmias, Cardiac/et [Etiology]
MH  - *Aviation
MH  - *Electrocardiography
MH  - Exercise Test
MH  - *Heart Rate
MH  - Humans
MH  - Male
MH  - Stress, Physiological/co [Complications]
AB  - Using two-channel 24-hour ambulatory ECG recording we studied seven healthy young men during one day of parachute jumping competition (day 1), as compared to one control day (day 2). A symptom limited exercise test was also performed on day 2. Maximal heart rates attained during exercise testing were of the same order as during parachute jumping. In the phases just prior to 'exit', short periods of striking sinus arrhythmia with slow atrial rhythm were present in 3 subjects. Only one of these had slow atrial rhythm during the control day. Atrial and ventricular premature complexes, when present, disappeared with higher heart rates under all circumstances. No AV conduction disturbances were found.
IS  - 0195-668X
IL  - 0195-668X
PT  - Journal Article
LG  - English
DP  - 1986 Feb
DC  - 19860612
YR  - 1986
ED  - 19860612
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=3699047

<930. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3914580
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Altura BM
AU  - Altura BT
FA  - Altura, B M
FA  - Altura, B T
TI  - New perspectives on the role of magnesium in the pathophysiology of the cardiovascular system. I. Clinical aspects. [Review] [163 refs]
SO  - Magnesium. 4(5-6):226-44, 1985.
AS  - Magnesium. 4(5-6):226-44, 1985.
NJ  - Magnesium
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 8219687, lb9
SB  - Index Medicus
CP  - SWITZERLAND
MH  - Adult
MH  - Arrhythmias, Cardiac/dt [Drug Therapy]
MH  - Arrhythmias, Cardiac/et [Etiology]
MH  - Blood Vessels/me [Metabolism]
MH  - *Cardiovascular Diseases/et [Etiology]
MH  - Cerebrovascular Disorders/et [Etiology]
MH  - Child
MH  - Coronary Disease/et [Etiology]
MH  - Death, Sudden/et [Etiology]
MH  - Diabetes Mellitus/et [Etiology]
MH  - Diet
MH  - Eclampsia/et [Etiology]
MH  - Female
MH  - Humans
MH  - Hypertension/dt [Drug Therapy]
MH  - Hypertension/et [Etiology]
MH  - Hypokalemia/co [Complications]
MH  - Intensive Care Units
MH  - Magnesium/bl [Blood]
MH  - Magnesium/me [Metabolism]
MH  - *Magnesium/ph [Physiology]
MH  - Magnesium/tu [Therapeutic Use]
MH  - Magnesium Deficiency/co [Complications]
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/dt [Drug Therapy]
MH  - Myocardial Infarction/et [Etiology]
MH  - Myocardium/me [Metabolism]
MH  - Pre-Eclampsia/et [Etiology]
MH  - Pregnancy
MH  - Risk
MH  - Type A Personality
MH  - Water Supply
AB  - Until relatively recently, it was generally believed that hypomagnesemia was a rare entity in clinical practice. It is clear, however, from newer studies that the overall incidence of hypomagnesemia in hospitalized patients can range from 7 to 52%. The greatest association of hypomagnesemia in hospitalized patients appears to be in hypokalemic states and in patients confined to intensive care units. Most of these patients demonstrate cardiovascular abnormalities, ranging from cardiac arrhythmias and atrial fibrillation to hypertension. On the basis of primarily epidemiologic and experimental findings, it has been suggested that there may be a strong association between the dietary intake of Mg (and errors in the Mg metabolism and distribution of Mg in the body), the concentration of this element in the myocardium and blood vessels, and the risk for development of cardiac arrhythmias, sudden death ischemic heart disease, hypertension, transient ischemic attacks, strokes and pre-eclampsia-eclampsia. During the past 5-6 years, a considerable amount of new, quantitative clinical evidence has been found which lends considerable support to these tenets. Clinical trials utilizing Mg as a therapeutic tool to treat refractory arrhythmias, digitalis toxicity-associated arrhythmias, myocardial infarctions, diabetic angiopathy, transient ischemic attacks, cerebral resuscitation, hypertension and 'classical' migraine are under way, and to an extent have been successful. Careful assessment of serum, blood cells, and urine for free versus bound Mg should be done routinely in cardiovascular disease and high-risk patients. [References: 163]
RN  - I38ZP9992A (Magnesium)
IS  - 0252-1156
IL  - 0252-1156
PT  - Journal Article
PT  - Review
LG  - English
DP  - 1985
DC  - 19860530
YR  - 1985
ED  - 19860530
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=3914580

<931. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3006891
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Johnston DL
AU  - Kostuk WJ
FA  - Johnston, D L
FA  - Kostuk, W J
TI  - Effects of severity of mitral stenosis on left and right ventricular function at rest and during exercise.
SO  - Canadian Journal of Cardiology. 2(1):10-5, 1986 Jan-Feb.
AS  - Can J Cardiol. 2(1):10-5, 1986 Jan-Feb.
NJ  - The Canadian journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - chp, 8510280
SB  - Index Medicus
CP  - CANADA
MH  - Adult
MH  - Aged
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Blood Pressure
MH  - Cardiac Catheterization
MH  - Cardiac Output
MH  - Echocardiography
MH  - *Exercise Test
MH  - Female
MH  - Heart Rate
MH  - *Heart Ventricles/pp [Physiopathology]
MH  - Heart Ventricles/ri [Radionuclide Imaging]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mitral Valve Stenosis/pp [Physiopathology]
MH  - Mitral Valve Stenosis/ri [Radionuclide Imaging]
MH  - Myocardial Contraction
MH  - Sodium Pertechnetate Tc 99m
AB  - Few studies have assessed the effect of severity of mitral stenosis (MS) on ventricular function. Using equilibrium radionuclide ventriculography to measure ejection fraction and volume changes, 63 patients were studied during supine, symptom-limited exercise. To more carefully assess the 12 patients with MS and impaired left ventricular function, 2 groups of patients were formed. Group I (n = 51) had a normal (less than 50%) resting left ventricular (LV) ejection fraction (EF) and group II (n = 12) had an abnormally low (less than 50%) resting LVEF. Both groups were divided into mild (greater than 1.4 cm2), moderate (1.1-1.4 cm2) and severe (less than 1.0 cm2) MS. There were no differences in mean rest or exercise LVEF for group I. Exercise LVEF increased significantly (p less than 0.05) from rest with mild MS, but not with moderate or severe MS. The decrease in exercise LVEF was due to a decrease in exercise end-diastolic volume of 9 +/- 23% and 15 +/- 18% for moderate and severe MS, respectively. Exercise end-systolic volume decreased normally for all degrees of MS severity. Exercise right ventricular (RV)EF did not increase for any degree of MS severity due to an increase in end-systolic volume. All patients in group II had an RVEF of less than 40%. For this group, severity of MS had no effect on resting LVEF and the response to exercise was similar to group I. We conclude that in patients with MS, resting LVEF is unaffected by MS severity whereas exercise LVEF decreases with increased severity of MS due to impaired diastolic filling.(ABSTRACT TRUNCATED AT 250 WORDS)
RN  - A0730CX801 (Sodium Pertechnetate Tc 99m)
IS  - 0828-282X
IL  - 0828-282X
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1986 Jan-Feb
DC  - 19860522
YR  - 1986
ED  - 19860522
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=3006891

<932. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 2418970
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ellestad MH
FA  - Ellestad, M H
TI  - Exercise-induced arrhythmias and hypotension: significance and clinical management.
SO  - Cardiovascular Clinics. 15(2):125-31, 1985.
AS  - Cardiovasc Clin. 15(2):125-31, 1985.
NJ  - Cardiovascular clinics
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - col, 0213744
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Arrhythmias, Cardiac/et [Etiology]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Atrial Flutter/et [Etiology]
MH  - Bundle-Branch Block/et [Etiology]
MH  - Cardiac Complexes, Premature/et [Etiology]
MH  - Coronary Disease/et [Etiology]
MH  - Exercise Test
MH  - Heart Block/et [Etiology]
MH  - Humans
MH  - *Hypotension/et [Etiology]
MH  - *Physical Exertion
MH  - Sick Sinus Syndrome/et [Etiology]
MH  - Tachycardia/et [Etiology]
MH  - Tachycardia, Paroxysmal/et [Etiology]
MH  - Wolff-Parkinson-White Syndrome/et [Etiology]
IS  - 0069-0384
IL  - 0069-0384
PT  - Journal Article
LG  - English
DP  - 1985
DC  - 19860410
YR  - 1985
ED  - 19860410
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=2418970

<933. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3953353
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Leak D
FA  - Leak, D
TI  - Intravenous amiodarone in the treatment of refractory life-threatening cardiac arrhythmias in the critically ill patient.
SO  - American Heart Journal. 111(3):456-62, 1986 Mar.
AS  - Am Heart J. 111(3):456-62, 1986 Mar.
NJ  - American heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3bw, 0370465
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - Amiodarone/ad [Administration & Dosage]
MH  - *Amiodarone/tu [Therapeutic Use]
MH  - *Arrhythmias, Cardiac/dt [Drug Therapy]
MH  - Arrhythmias, Cardiac/mo [Mortality]
MH  - Arrhythmias, Cardiac/pp [Physiopathology]
MH  - *Benzofurans/tu [Therapeutic Use]
MH  - Blood Pressure/de [Drug Effects]
MH  - Dopamine/tu [Therapeutic Use]
MH  - Electrocardiography
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Hypotension/dt [Drug Therapy]
MH  - Infusions, Parenteral
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/dt [Drug Therapy]
MH  - Myocarditis/dt [Drug Therapy]
MH  - Time Factors
AB  - Eleven critically ill patients with life-threatening cardiac arrhythmias refractory to currently approved antiarrhythmic drugs were treated with intravenous amiodarone. Two patients had acute myocarditis, five had acute myocardial infarction, two had left ventricular failure secondary to ischemic heart disease, one had Wolff-Parkinson-White syndrome, and one manifested postoperative atrial fibrillation. Eight of the patients had severe cardiac failure and five had hypotension requiring intravenous dopamine. Five patients were treated for recurrent ventricular fibrillation, two for recurrent ventricular tachycardia, and four for recurrent atrial arrhythmias. Six patients had repeated cardioversions. The arrhythmias had lasted a mean of 88.3 hours resistant to a mean of 2.7 different intravenous antiarrhythmic drugs. The ventricular arrhythmias did not recur after commencing intravenous amiodarone, but some minor atrial arrhythmias occurred for 24 hours. One patient died of intractable left ventricular failure, chronic obstructive lung disease, and respiratory arrest during treatment. The dose of amiodarone was 150 mg over 5 minutes, followed by 600 mg/24 hr for 3 to 4 days; one patient on total parenteral nutrition required intravenous amiodarone for 20 days. Hypotension, cardiac failure, and bradyarrhythmias were not induced by this treatment. Intravenous amiodarone can be used safely in critically ill patients with impaired left ventricular function to control life-threatening refractory cardiac arrhythmias.
RN  - 0 (Benzofurans)
RN  - N3RQ532IUT (Amiodarone)
RN  - VTD58H1Z2X (Dopamine)
IS  - 0002-8703
IL  - 0002-8703
PT  - Journal Article
LG  - English
DP  - 1986 Mar
DC  - 19860407
YR  - 1986
ED  - 19860407
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=3953353

<934. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3943166
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Roth A
AU  - Harrison E
AU  - Mitani G
AU  - Cohen J
AU  - Rahimtoola SH
AU  - Elkayam U
FA  - Roth, A
FA  - Harrison, E
FA  - Mitani, G
FA  - Cohen, J
FA  - Rahimtoola, S H
FA  - Elkayam, U
TI  - Efficacy and safety of medium- and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation.
SO  - Circulation. 73(2):316-24, 1986 Feb.
AS  - Circulation. 73(2):316-24, 1986 Feb.
NJ  - Circulation
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - *Benzazepines/tu [Therapeutic Use]
MH  - Blood Pressure/de [Drug Effects]
MH  - *Digoxin/ad [Administration & Dosage]
MH  - Digoxin/bl [Blood]
MH  - Diltiazem/ad [Administration & Dosage]
MH  - Diltiazem/ae [Adverse Effects]
MH  - Diltiazem/bl [Blood]
MH  - *Diltiazem/tu [Therapeutic Use]
MH  - Exercise Test
MH  - Female
MH  - Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Rest
AB  - We evaluated the efficacy and the safety of medium-(240 mn/day) and high-dose (360 mg/day) diltiazem alone and in combination with digoxin when used for control of heart rate in 12 patients with chronic atrial fibrillation. Medium-dose diltiazem was comparable to therapeutic dose of digoxin at rest (88 +/- 19 vs 86 +/- 12 beats/min) but superior during peak exercise (154 +/- 23 vs 170 +/- 20 beats/min; p less than .05). High-dose diltiazem resulted in better control of heart rate than digoxin both at rest (79 +/- 17 beats/min; p less than .05) and exercise (136 +/- 25 beats/min; p less than .05) but was associated with side effects in 75% of the patients. Combined therapy of digoxin and diltiazem enhanced the effect of digoxin alone and resulted in significantly better control of heart rate at rest (67 +/- beats/min with medium-dose and 65 +/- beats/min with high-dose diltiazem) and during peak exercise (132 +/- 32 and 121 +/- 24 beats/min, respectively). However, the difference in heart rate between these two doses was not significant. Reduction of heart rate combined with concomitant effect on blood pressure resulted in a significant fall in pressure-rate product at rest from 10,077 +/- 1708 mm Hg/min on digoxin alone to 7877 +/- 1818 mm Hg/min after the addition of medium-dose diltiazem (p less than .05) and during exercise form 25,670 +/- 3606 to 18,439 +/- 4115 mm Hg/min (p less than .05). Continued therapy with digoxin combined with diltiazem 240 mg/day for 21 +/- 8 days in nine patients showed persistent effect on heart rate and blood pressure without any toxic manifestations or change in serum digoxin (1.5 +/- 0.4 vs 1.3 +/- 0.4 ng/ml) or plasma diltiazem concentrations (204 +/- 72 vs 232 +/- 129 ng/ml). In conclusion, medium-dose diltiazem when combined with digoxin is an effective and safe regimen for the treatment of patients with chronic atrial fibrillation and enhances digoxin-mediated control of heart rate both at rest and during exercise.
RN  - 0 (Benzazepines)
RN  - 73K4184T59 (Digoxin)
RN  - EE92BBP03H (Diltiazem)
IS  - 0009-7322
IL  - 0009-7322
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
NO  - N 8RR-43 (United States NCRR NIH HHS)
LG  - English
DP  - 1986 Feb
DC  - 19860306
YR  - 1986
ED  - 19860306
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=3943166

<935. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3941219
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Nakamura Y
AU  - Konishi T
AU  - Nonogi H
AU  - Sakurai T
AU  - Sasayama S
AU  - Kawai C
FA  - Nakamura, Y
FA  - Konishi, T
FA  - Nonogi, H
FA  - Sakurai, T
FA  - Sasayama, S
FA  - Kawai, C
TI  - Myocardial relaxation in atrial fibrillation.
SO  - Journal of the American College of Cardiology. 7(1):68-73, 1986 Jan.
AS  - J Am Coll Cardiol. 7(1):68-73, 1986 Jan.
NJ  - Journal of the American College of Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - h50, 8301365
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Cardiac Catheterization
MH  - Cineangiography
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Myocardial Contraction
MH  - Systole
MH  - Time Factors
AB  - Although myocardial contractility has been known to vary from beat to beat in atrial fibrillation, myocardial relaxation in this arrhythmia has not been investigated. In this study, left ventricular relaxation was examined in seven patients with atrial fibrillation (four with mitral valve disease, one with aortic regurgitation, one with secundum type atrial septal defect and one with apical left ventricular hypertrophy). The left ventricular pressure was measured with a micromanometer-tipped catheter and the time constant of isovolumic left ventricular pressure decline (the relaxation time constant) was calculated by means of exponential curve fitting from more than 20 consecutive beats in each patient. The maximal rate of rise of left ventricular pressure (dP/dt) and the relaxation time constant were examined in relation to the preceding RR interval (RR2) and to the ratio of the RR2 interval to the pre-preceding RR interval (RR2/RR1), and the correlation coefficients were obtained. The dP/dt correlated better with RR2/RR1 than with the RR2 interval (0.82 +/- 0.05 versus 0.48 +/- 0.2), but the relaxation time constant did not show any correlation with RR2/RR1 or the RR2 interval (0.03 +/- 0.21 and 0.06 +/- 0.21, respectively). The relaxation time constant was fairly constant in each patient even when the RR2 interval and RR2/RR1 varied greatly. Thus, relaxation in atrial fibrillation is independent of changes in contractility as seen in the relation between postextrasystolic relaxation and postextrasystolic potentiation of contractility.
IS  - 0735-1097
IL  - 0735-1097
PT  - Journal Article
LG  - English
DP  - 1986 Jan
DC  - 19860131
YR  - 1986
ED  - 19860131
RD  - 20121115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=3941219

<936. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3930962
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Anonymous
TI  - Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 43-1985. A 70-year-old man with diarrhea, weight loss, and recurrent atrial fibrillation.
SO  - New England Journal of Medicine. 313(17):1070-9, 1985 Oct 24.
AS  - N Engl J Med. 313(17):1070-9, 1985 Oct 24.
NJ  - The New England journal of medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0255562, now
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Amyloid/an [Analysis]
MH  - Amyloidosis/co [Complications]
MH  - Amyloidosis/di [Diagnosis]
MH  - *Amyloidosis/pa [Pathology]
MH  - Atrial Fibrillation/co [Complications]
MH  - Biopsy
MH  - Diagnosis, Differential
MH  - Diarrhea/et [Etiology]
MH  - Histocytochemistry
MH  - Humans
MH  - Immunoglobulin kappa-Chains/an [Analysis]
MH  - Immunoglobulin lambda-Chains/an [Analysis]
MH  - *Intestinal Diseases/pa [Pathology]
MH  - Intestine, Small/pa [Pathology]
MH  - Malabsorption Syndromes/et [Etiology]
MH  - Male
MH  - Multiple Myeloma/co [Complications]
MH  - Multiple Myeloma/di [Diagnosis]
MH  - *Multiple Myeloma/pa [Pathology]
MH  - Plasma Cells/ul [Ultrastructure]
MH  - Stomach Diseases/di [Diagnosis]
MH  - *Stomach Diseases/pa [Pathology]
RN  - 0 (Amyloid)
RN  - 0 (Immunoglobulin kappa-Chains)
RN  - 0 (Immunoglobulin lambda-Chains)
IS  - 0028-4793
IL  - 0028-4793
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1985 Oct 24
DC  - 19851114
YR  - 1985
ED  - 19851114
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=3930962

<937. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 4049440
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Tanaka H
AU  - Hayashi M
AU  - Date C
AU  - Imai K
AU  - Asada M
AU  - Shoji H
AU  - Okazaki K
AU  - Yamamoto H
AU  - Yoshikawa K
AU  - Shimada T
AU  - et al
FA  - Tanaka, H
FA  - Hayashi, M
FA  - Date, C
FA  - Imai, K
FA  - Asada, M
FA  - Shoji, H
FA  - Okazaki, K
FA  - Yamamoto, H
FA  - Yoshikawa, K
FA  - Shimada, T
TI  - Epidemiologic studies of stroke in Shibata, a Japanese provincial city: preliminary report on risk factors for cerebral infarction.
SO  - Stroke. 16(5):773-80, 1985 Sep-Oct.
AS  - Stroke. 16(5):773-80, 1985 Sep-Oct.
NJ  - Stroke; a journal of cerebral circulation
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - v2j, 0235266
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - Analysis of Variance
MH  - Blood Pressure
MH  - Body Weight
MH  - *Cerebral Infarction/ep [Epidemiology]
MH  - Cerebral Infarction/pp [Physiopathology]
MH  - *Cerebrovascular Disorders/ep [Epidemiology]
MH  - Cerebrovascular Disorders/pp [Physiopathology]
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Japan
MH  - Life Style
MH  - Male
MH  - Middle Aged
MH  - Risk
AB  - A 6.5-year prospective study of cerebral infarction among residents 40 years and older was conducted at the Akadani-Ijimino district in Shibata City, Niigata Prefecture, Japan. The response rate for the initial examination was 85% of 1,182 males and 93% of 1,469 females. Nine hundred and sixty males and 1,339 females who were initially free of stroke were followed up from July 1977 through December 1983. Statistically significant risk factors for cerebral infarction appeared to be age, elevated blood pressure, high R, ST-T changes and atrial fibrillation on ECG, and albuminuria. The ECG abnormalities and albuminuria were due to the high blood pressure persisted over a long period of time. The strength of association of blood pressure with cerebral infarction got weak in comparison with other factors, and funduscopic changes which had been regarded as a risk factor for stroke in 1965-1974 did not reach statistical significance because of the spread of the community-based hypertension control. Even in 1977-1983 when Japanese dietary habits were westernized, neither hyperlipidemia nor obesity appeared to be related to the development of cerebral infarction.
IS  - 0039-2499
IL  - 0039-2499
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1985 Sep-Oct
DC  - 19851028
YR  - 1985
ED  - 19851028
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=4049440

<938. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 4015920
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Crick JC
AU  - Davies DW
AU  - Holt P
AU  - Curry PV
AU  - Sowton E
FA  - Crick, J C
FA  - Davies, D W
FA  - Holt, P
FA  - Curry, P V
FA  - Sowton, E
TI  - Effect of exercise on ventricular response to atrial fibrillation in Wolff-Parkinson-White syndrome.
SO  - British Heart Journal. 54(1):80-5, 1985 Jul.
AS  - Br Heart J. 54(1):80-5, 1985 Jul.
NJ  - British heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - ats, 0370634
OI  - Source: NLM. PMC481853
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - ENGLAND
MH  - Adolescent
MH  - Adult
MH  - *Atrial Fibrillation/co [Complications]
MH  - Atrioventricular Node/pp [Physiopathology]
MH  - Electrocardiography
MH  - Exercise Test
MH  - Female
MH  - Heart Ventricles/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Posture
MH  - Wolff-Parkinson-White Syndrome/co [Complications]
MH  - *Wolff-Parkinson-White Syndrome/pp [Physiopathology]
AB  - Ten patients with Wolff-Parkinson-White syndrome underwent cardiac electrophysiological study extended to include the induction of atrial fibrillation at maximum exercise in the upright position. This was performed using a new temporary bipolar lead with a helical active fixation tip for atrial pacing. The highest rate of atrioventricular conduction via the accessory pathway was greater during exercise than at rest in all 10 patients (mean increase 28%). In three cases the resulting ventricular rate exceeded 300 beats/min, but no patient had severe symptoms or ventricular arrhythmias. The exercise induced enhancement of accessory pathway conduction may significantly but unpredictably affect the risk from spontaneous atrial fibrillation especially in patients with coronary artery disease or in those taking antiarrhythmic drugs. The test procedure was sufficiently simple and well tolerated to be included in our routine electrophysiological investigation.
IS  - 0007-0769
IL  - 0007-0769
PT  - Journal Article
LG  - English
DP  - 1985 Jul
DC  - 19850828
YR  - 1985
ED  - 19850828
RD  - 20130929
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=4015920

<939. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 3917348
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Beasley R
AU  - Smith DA
AU  - McHaffie DJ
FA  - Beasley, R
FA  - Smith, D A
FA  - McHaffie, D J
TI  - Exercise heart rates at different serum digoxin concentrations in patients with atrial fibrillation.
SO  - British Medical Journal Clinical Research Ed.. 290(6461):9-11, 1985 Jan 5.
AS  - Br Med J (Clin Res Ed). 290(6461):9-11, 1985 Jan 5.
NJ  - British medical journal (Clinical research ed.)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - b4x, 8302911
OI  - Source: NLM. PMC1415415
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - ENGLAND
MH  - Adult
MH  - Atrial Fibrillation/bl [Blood]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Digoxin/bl [Blood]
MH  - Digoxin/tu [Therapeutic Use]
MH  - Double-Blind Method
MH  - Female
MH  - *Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Physical Exertion
AB  - Heart rate at rest and during increasing workloads was measured in a double blind study of 12 patients with chronic atrial fibrillation when serum concentrations of digoxin were nil and at low and high therapeutic values. Twelve normal subjects were studied for comparison. The heart rate at all levels of exercise in most patients with atrial fibrillation was not adequately controlled by any serum digoxin concentration tested despite a reduction in heart rate with increasing serum digoxin concentrations. Control of the resting heart rate, even in patients with high serum digoxin concentrations, did not ensure adequate control of the heart rate during work rates equivalent to regular daily activities.
RN  - 73K4184T59 (Digoxin)
IS  - 0267-0623
IL  - 0267-0623
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
LG  - English
DP  - 1985 Jan 5
DC  - 19850220
YR  - 1985
ED  - 19850220
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=3917348

<940. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 6148872
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - DiBianco R
AU  - Morganroth J
AU  - Freitag JA
AU  - Ronan JA Jr
AU  - Lindgren KM
AU  - Donohue DJ
AU  - Larca LJ
AU  - Chadda KD
AU  - Olukotun AY
FA  - DiBianco, R
FA  - Morganroth, J
FA  - Freitag, J A
FA  - Ronan, J A Jr
FA  - Lindgren, K M
FA  - Donohue, D J
FA  - Larca, L J
FA  - Chadda, K D
FA  - Olukotun, A Y
TI  - Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin.
SO  - American Heart Journal. 108(4 Pt 2):1121-7, 1984 Oct.
AS  - Am Heart J. 108(4 Pt 2):1121-7, 1984 Oct.
NJ  - American heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3bw, 0370465
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Adrenergic beta-Antagonists/tu [Therapeutic Use]
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Clinical Trials as Topic
MH  - *Digoxin/tu [Therapeutic Use]
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Electrocardiography
MH  - Female
MH  - *Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nadolol
MH  - *Physical Exertion
MH  - *Propanolamines/tu [Therapeutic Use]
MH  - Random Allocation
MH  - Time Factors
AB  - Nadolol, a long-acting beta-adrenergic-blocking agent, was evaluated in 20 patients with chronic atrial fibrillation by means of a randomized, double-blind, crossover study. Patients were required either to demonstrate resting heart rates in excess of 80 bpm or to show a rate of 120 bpm or an increment of greater than 50 bpm during mild treadmill exercise provocation (3 minutes, 1.75 mph, 10% grade). With placebo the group averaged a heart rate of 92 +/- 19 bpm, determined by 24 hours of ambulatory ECG recordings; this rate was significantly reduced to 73 +/- 16 bpm (p less than 0.001) with nadolol (mean dosage, 87 +/- 43 mg/day). During standardized exercise testing, heart rates increased to 153 +/- 26 bpm with placebo and to 111 +/- 24 bpm with nadolol (p less than 0.001), representing 65% and 52% increments, respectively. Digoxin blood levels averaged 0.8 +/- 0.5 ng/ml with placebo and were similar with nadolol (0.9 +/- 0.4; p = NS). Total exercise time on a modified Bruce treadmill protocol was 466 +/- 143 seconds with placebo and was significantly decreased by nadolol (380 +/- 143; p less than 0.01). During initial dose titration with nadolol, one patient was dropped from study for intolerable fatigue and one for worsened claudication. No patients were dropped from the double-blind treatment periods, although two patients receiving nadolol and one patient receiving placebo complained of moderate fatigue. We conclude that nadolol is a safe and effective agent for the control of spontaneous and exercise-provoked heart rates in patients with chronic atrial fibrillation who were already receiving digoxin treatment.
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Propanolamines)
RN  - 42200-33-9 (Nadolol)
RN  - 73K4184T59 (Digoxin)
IS  - 0002-8703
IL  - 0002-8703
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 1984 Oct
DC  - 19841109
YR  - 1984
ED  - 19841109
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=6148872

<941. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 6148092
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Molajo AO
AU  - Coupe MO
AU  - Bennett DH
FA  - Molajo, A O
FA  - Coupe, M O
FA  - Bennett, D H
TI  - Effect of Corwin (ICI 118587) on resting and exercise heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation.
SO  - British Heart Journal. 52(4):392-5, 1984 Oct.
AS  - Br Heart J. 52(4):392-5, 1984 Oct.
NJ  - British heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - ats, 0370634
OI  - Source: NLM. PMC481647
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - ENGLAND
MH  - *Adrenergic beta-Agonists/tu [Therapeutic Use]
MH  - Adult
MH  - Aged
MH  - Atrial Fibrillation/bl [Blood]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Chronic Disease
MH  - Clinical Trials as Topic
MH  - Digoxin/bl [Blood]
MH  - Digoxin/tu [Therapeutic Use]
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Electrocardiography
MH  - Female
MH  - Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Physical Exertion/de [Drug Effects]
MH  - *Physical Exertion
MH  - *Propanolamines/tu [Therapeutic Use]
MH  - Xamoterol
AB  - The effect of Corwin, a new oral beta, partial agonist, on the ventricular response to atrial fibrillation was studied in digitalised patients during 24 hour ambulatory electrocardiography and during exercise on a treadmill in a double blind placebo controlled crossover trial. Corwin reduced the maximum heart rate during exercise from 162(16) beats/min to 120(9) beats/min and reduced the peak heart rate during ambulatory electrocardiography from 113(11) to 90(6) beats/min consistent with a beta adrenoreceptor antagonist action at higher levels of sympathetic nervous system activity. Minimum heart rate during ambulatory electrocardiography was increased from 62(5) to 70(5) beats/min indicating that at lower levels of sympathetic activity the drug acts as a beta agonist. The drug increased exercise tolerance significantly. Serum digoxin concentrations were not affected by the drug. Thus Corwin appears to be effective in stabilising heart rate during atrial fibrillation both at rest and during exercise in digitalised patients.
RN  - 0 (Adrenergic beta-Agonists)
RN  - 0 (Propanolamines)
RN  - 73K4184T59 (Digoxin)
RN  - 7HE0JQL703 (Xamoterol)
IS  - 0007-0769
IL  - 0007-0769
PT  - Clinical Trial
PT  - Journal Article
LG  - English
DP  - 1984 Oct
DC  - 19841109
YR  - 1984
ED  - 19841109
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=6148092

<942. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 6465017
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Pennestri F
AU  - Loperfido F
AU  - Salvatori MP
AU  - Mongiardo R
AU  - Ferrazza A
AU  - Guccione P
AU  - Manzoli U
FA  - Pennestri, F
FA  - Loperfido, F
FA  - Salvatori, M P
FA  - Mongiardo, R
FA  - Ferrazza, A
FA  - Guccione, P
FA  - Manzoli, U
TI  - Assessment of tricuspid regurgitation by pulsed Doppler ultrasonography of the hepatic veins.
SO  - American Journal of Cardiology. 54(3):363-8, 1984 Aug 1.
AS  - Am J Cardiol. 54(3):363-8, 1984 Aug 1.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adolescent
MH  - Adult
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Blood Flow Velocity
MH  - Diastole
MH  - *Echocardiography
MH  - Female
MH  - Heart Atria/pp [Physiopathology]
MH  - *Hepatic Veins/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Systole
MH  - *Tricuspid Valve Insufficiency/pp [Physiopathology]
AB  - Pulsed Doppler echocardiography was tested to assess the degree of tricuspid regurgitation (TR), classified by right ventriculography, in 47 patients. Forty-eight subjects without TR served as controls (39 with sinus rhythm and 9 with atrial fibrillation). Two Doppler methods were used: the distance of systolic turbulence within right atrium from the tricuspid plane and the quantitative analysis of the flow-velocity traces from the hepatic veins (HVs). Right atrial systolic turbulence was found in 41 of 47 patients with TR and in none of the control subjects, and moderately correlated with the angiographic grading (r = 0.57). In control subjects, TR flow-velocity traces from the HVs showed 2 anterograde flow waves, systolic and diastolic. The ratio of anterograde systolic/anterograde diastolic velocity was more than 0.6 in 38 subjects with sinus rhythm and in 8 with atrial fibrillation. Twenty-two control subjects had a positive wave (designated as "v") coincident with the end of T wave. In 30 patients with TR, a retrograde holosystolic wave was present. Of the remaining patients, 12 had a ratio of anterograde systolic/anterograde diastolic velocity less than 0.6. Fifteen had an end-systolic "v-like" wave, which occurred earlier than the v wave in control subjects (p less than 0.001). In patients with TR, maximal velocities of the anterograde diastolic and retrograde systolic flow correlated with angiographic grading (r = 0.74 and 0.73, respectively). An anterograde diastolic flow velocity more than 26 cm/s and a retrograde systolic flow velocity more than 16 cm/s excluded mild TR. Analysis of Doppler recordings of the HVs is valuable to semiquantitatively assess TR, complementing the right atrial Doppler findings.
IS  - 0002-9149
IL  - 0002-9149
PT  - Journal Article
LG  - English
DP  - 1984 Aug 1
DC  - 19840829
YR  - 1984
ED  - 19840829
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=6465017

<943. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 6359848
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Panidis IP
AU  - Morganroth J
AU  - Baessler C
FA  - Panidis, I P
FA  - Morganroth, J
FA  - Baessler, C
TI  - Effectiveness and safety of oral verapamil to control exercise-induced tachycardia in patients with atrial fibrillation receiving digitalis.
SO  - American Journal of Cardiology. 52(10):1197-201, 1983 Dec 1.
AS  - Am J Cardiol. 52(10):1197-201, 1983 Dec 1.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Atrial Fibrillation/co [Complications]
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Flutter/co [Complications]
MH  - Atrial Flutter/dt [Drug Therapy]
MH  - Chronic Disease
MH  - Clinical Trials as Topic
MH  - *Digitalis
MH  - Digoxin/bl [Blood]
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Physical Exertion/de [Drug Effects]
MH  - Placebos
MH  - *Plants, Medicinal
MH  - *Plants, Toxic
MH  - Random Allocation
MH  - *Tachycardia/dt [Drug Therapy]
MH  - Tachycardia/et [Etiology]
MH  - Verapamil/ad [Administration & Dosage]
MH  - *Verapamil/ae [Adverse Effects]
AB  - The safety and efficacy of oral verapamil to control exercise tachycardia in 27 patients with atrial fibrillation and 3 with atrial flutter receiving digitalis was evaluated in a double-blind, randomized, crossover study. The heart rate in patients who received verapamil compared with placebo group was lower at rest (mean 69 +/- 13 versus 87 +/- 20 beats/min, p less than 0.01), as was the degree of tachycardia at the end of 3 minutes of a standardized exercise test (104 +/- 14 versus 136 +/- 23 beats/min, p less than 0.01). Doses of verapamil required to achieve suppression of tachycardia were 240 mg/day in 18 patients, 320 mg/day in 6 patients, and 480 mg/day in 3 patients. Only 3 patients complained of adverse effects from verapamil during the double-blind phase of the study. Two patients were discontinued from the study because of adverse reactions. No clinically significant changes during verapamil therapy were observed on the electrocardiogram, chest roentgenogram, echocardiogram or in the laboratory evaluation. Digoxin blood levels were higher in patients who received concomitant verapamil compared with placebo (1.23 +/- 0.59 versus 0.85 +/- 0.46 ng/ml, p less than 0.01), but no patient had signs or symptoms of digitalis toxicity. Thus, oral verapamil given in addition to digitalis is a safe and effective agent in the treatment of patients with chronic atrial fibrillation or flutter to decrease exercise-induced tachycardia.
RN  - 0 (Placebos)
RN  - 73K4184T59 (Digoxin)
RN  - CJ0O37KU29 (Verapamil)
IS  - 0002-9149
IL  - 0002-9149
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 1983 Dec 1
DC  - 19840107
YR  - 1983
ED  - 19840107
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=6359848

<944. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 6846125
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lang R
AU  - Klein HO
AU  - Di Segni E
AU  - Gefen J
AU  - Sareli P
AU  - Libhaber C
AU  - David D
AU  - Weiss E
AU  - Guerrero J
AU  - Kaplinsky E
FA  - Lang, R
FA  - Klein, H O
FA  - Di Segni, E
FA  - Gefen, J
FA  - Sareli, P
FA  - Libhaber, C
FA  - David, D
FA  - Weiss, E
FA  - Guerrero, J
FA  - Kaplinsky, E
TI  - Verapamil improves exercise capacity in chronic atrial fibrillation: double-blind crossover study.
SO  - American Heart Journal. 105(5):820-5, 1983 May.
AS  - Am Heart J. 105(5):820-5, 1983 May.
NJ  - American heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3bw, 0370465
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - Blood Pressure/de [Drug Effects]
MH  - Digoxin/bl [Blood]
MH  - Double-Blind Method
MH  - Exercise Test
MH  - Female
MH  - Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Physical Exertion
MH  - Prospective Studies
MH  - Random Allocation
MH  - *Verapamil/tu [Therapeutic Use]
AB  - Oral verapamil has previously been shown to reduce heart rate at rest and during mild exercise in chronic atrial fibrillation. Its efficacy in improving cardiovascular performance at higher levels of exercise and its safety were investigated in a prospective, randomized, placebo controlled double-blind study preceded by an open label titration phase in 20 digitalized patients with chronic atrial fibrillation. Maximal exercise capacity was improved (from 522 +/- 257 to 806 +/- 348 work units, p less than 0.0005) when tested by a standardized multistage ergometry exercise test. Heart rate was also reduced at rest, at the end of 3 minutes of 300 KPM exercise, and at the point of maximal exercise. Blood pressure and double product were also reduced. Its efficacy and safety may make verapamil the treatment of choice in chronic atrial fibrillation.
RN  - 73K4184T59 (Digoxin)
RN  - CJ0O37KU29 (Verapamil)
IS  - 0002-8703
IL  - 0002-8703
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 1983 May
DC  - 19830610
YR  - 1983
ED  - 19830610
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=6846125

<945. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 6837463
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - German LD
AU  - Gallagher JJ
AU  - Broughton A
AU  - Guarnieri T
AU  - Trantham JL
FA  - German, L D
FA  - Gallagher, J J
FA  - Broughton, A
FA  - Guarnieri, T
FA  - Trantham, J L
TI  - Effects of exercise and isoproterenol during atrial fibrillation in patients with Wolff-Parkinson-White syndrome.
SO  - American Journal of Cardiology. 51(7):1203-6, 1983 Apr.
AS  - Am J Cardiol. 51(7):1203-6, 1983 Apr.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Exercise Test
MH  - Humans
MH  - *Isoproterenol
MH  - Risk
MH  - Ventricular Fibrillation/di [Diagnosis]
MH  - Ventricular Fibrillation/et [Etiology]
MH  - Wolff-Parkinson-White Syndrome/co [Complications]
MH  - *Wolff-Parkinson-White Syndrome/di [Diagnosis]
AB  - The effects of exercise and isoproterenol on atrial fibrillation (AF) were studied in 17 patients with Wolff-Parkinson-White syndrome (WPW) to assess the risk of developing a rapid ventricular response. Mean cycle length (R-R interval) and shortest R-R interval between both preexcited and nonpreexcited QRS complexes were recorded, as well as the percentage of preexcited complexes during control periods, during bicycle exercise, and during isoproterenol infusion. Exercise resulted in significantly shorter mean cycle length and the shortest R-R interval between nonpreexcited complexes. Exercise also resulted in a significantly lower percentage of preexcited complexes during AF, but had no effect on the R-R intervals between preexcited complexes. Isoproterenol had a variable effect on the percentage of preexcited QRS complexes, but resulted in significant shortening of mean cycle length and the shortest R-R interval between both normal and preexcited complexes. With isoproterenol, 12 of 17 patients had shortest preexcited R-R intervals less than or equal to 215 ms, compared with 6 of 17 in the control state. Isoproterenol infusion increased the rate of conduction over the accessory pathway during AF and allowed better assessment of the risk of excessively rapid rates occurring during AF. Exercise is not an adequate test for this purpose.
RN  - L628TT009W (Isoproterenol)
IS  - 0002-9149
IL  - 0002-9149
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
NO  - HL-15190 (United States NHLBI NIH HHS)
LG  - English
DP  - 1983 Apr
DC  - 19830505
YR  - 1983
ED  - 19830505
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=6837463

<946. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 6812785
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Sheehan J
AU  - White A
FA  - Sheehan, J
FA  - White, A
TI  - Diuretic-associated hypomagnesaemia.
SO  - British Medical Journal Clinical Research Ed.. 285(6349):1157-9, 1982 Oct 23.
AS  - Br Med J (Clin Res Ed). 285(6349):1157-9, 1982 Oct 23.
NJ  - British medical journal (Clinical research ed.)
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - b4x, 8302911
OI  - Source: NLM. PMC1500130
SB  - Index Medicus
CP  - ENGLAND
MH  - Aged
MH  - Alcohol Drinking
MH  - Atrial Fibrillation/et [Etiology]
MH  - Diet
MH  - *Diuretics/ae [Adverse Effects]
MH  - Female
MH  - Humans
MH  - *Magnesium/bl [Blood]
MH  - Magnesium/tu [Therapeutic Use]
MH  - Magnesium Deficiency/bl [Blood]
MH  - *Magnesium Deficiency/ci [Chemically Induced]
MH  - Magnesium Deficiency/dt [Drug Therapy]
MH  - Male
MH  - Middle Aged
MH  - Water Supply
AB  - Clinically suspected hypomagnesaemia was confirmed in 21 patients over 12 months; all patients had been exposed to either short-term vigorous diuretic treatment or moderate-dosage long-term treatment. Magnesium depletion was compounded by a hospital diet surprisingly low in magnesium, a local soft water supply, and, in some patients, high alcohol intake. Common presenting symptoms included depression, muscle weakness, refractory hypokalaemia, and atrial fibrillation refractory to digoxin treatment. The administration of magnesium supplements resulted in prompt improvement of all symptoms particularly in the case of refractory atrial fibrillation. Chronic low-grade magnesium deficiency from diuretic treatment is more common than published reports suggest. Older patients are at risk, particularly those who have excessive alcohol intake, a diet low in magnesium, or a soft water supply.
RN  - 0 (Diuretics)
RN  - I38ZP9992A (Magnesium)
IS  - 0267-0623
IL  - 0267-0623
PT  - Journal Article
LG  - English
DP  - 1982 Oct 23
DC  - 19821221
YR  - 1982
ED  - 19821221
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=6812785

<947. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 6982689
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Williams JB
AU  - Stephensen LW
AU  - Holford FD
AU  - Langer T
AU  - Dunkman WB
AU  - Josephson ME
FA  - Williams, J B
FA  - Stephensen, L W
FA  - Holford, F D
FA  - Langer, T
FA  - Dunkman, W B
FA  - Josephson, M E
TI  - Arrhythmia prophylaxis using propranolol after coronary artery surgery.
SO  - Annals of Thoracic Surgery. 34(4):435-8, 1982 Oct.
AS  - Ann Thorac Surg. 34(4):435-8, 1982 Oct.
NJ  - The Annals of thoracic surgery
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 683, 15030100r
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Arrhythmias, Cardiac/pc [Prevention & Control]
MH  - Coronary Artery Bypass
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Postoperative Complications/pc [Prevention & Control]
MH  - Premedication
MH  - *Propranolol/ad [Administration & Dosage]
MH  - Propranolol/tu [Therapeutic Use]
AB  - Sixty patients undergoing coronary artery bypass grafting operations with cold potassium cardioplegia as the method of myocardial preservation either received low-dose oral propranolol (10 mg every 6 hours; 28 patients) or served as controls (32 patients). The study period began after extubation and ended at the time of hospital discharge. On the fourth postoperative day, 24-hour Holter monitoring was performed to assess additional subtle differences in arrhythmias. The overall incidence of symptomatic postoperative arrhythmias was 31% in the control group: 6 patients (19%) had atrial fibrillation or flutter and 4 patients (12%), ventricular arrhythmias. By contrast, 1 patient (4%) in the propranolol group had atrial fibrillation, and no patient had ventricular arrhythmias. The difference in overall arrhythmia rates between the two groups is significant (p less than 0.025). Twenty-four-hour Holter monitoring demonstrated no additional differences in the frequency of simple or complex atrial or ventricular ectopy between the two groups. We conclude that the incidence of postoperative arrhythmias following coronary artery bypass operation is diminished by the oral administration of prophylactic low-dose propranolol. When compared with our previous study [1], in which the method of myocardial preservation was intermittent aortic cross-clamping and moderate hypothermia, there is no difference in the overall incidence of postoperative arrhythmias.
RN  - 9Y8NXQ24VQ (Propranolol)
IS  - 0003-4975
IL  - 0003-4975
PT  - Journal Article
LG  - English
DP  - 1982 Oct
DC  - 19821216
YR  - 1982
ED  - 19821216
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=6982689

<948. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7124589
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Pantano JA
AU  - Oriel RJ
FA  - Pantano, J A
FA  - Oriel, R J
TI  - Prevalence and nature of cardiac arrhythmias in apparently normal well-trained runners.
SO  - American Heart Journal. 104(4 Pt 1):762-8, 1982 Oct.
AS  - Am Heart J. 104(4 Pt 1):762-8, 1982 Oct.
NJ  - American heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3bw, 0370465
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Arrhythmias, Cardiac/di [Diagnosis]
MH  - *Arrhythmias, Cardiac/ep [Epidemiology]
MH  - Exercise Test
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Running
AB  - Sixty well-conditioned runners were evaluated for arrhythmias by Holter monitor during both a distance run and a maximal treadmill test. Twenty-seven percent of subjects had ventricular arrhythmias during treadmill testing, only 3% having grades higher than just an occasional isolated premature ventricular complex (PVC), compared with 60% during the monitored run, of which ventricular bigeminy occurred in 10%, ventricular couplets in 10%, and multiform PVCs in 5%. Treadmill testing significantly underestimated the frequency and grade of both atrial and ventricular arrhythmias: 57% of subjects who had ventricular arrhythmias while running had none on the treadmill, and 11 of 16 who had ventricular arrhythmias on the treadmill had up to 3 grades higher on the run. The discovery of frequent high-grade atrial and ventricular arrhythmias in subjects considered to be completely fit and healthy suggests that such variations in heart rhythm are a normal phenomenon and no more specific for heart disease or risk than ventricular arrhythmias during maximal treadmill exercise testing.
IS  - 0002-8703
IL  - 0002-8703
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1982 Oct
DC  - 19821203
YR  - 1982
ED  - 19821203
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=7124589

<949. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7114981
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Flessas AP
AU  - Ryan TJ
FA  - Flessas, A P
FA  - Ryan, T J
TI  - Cardiovascular responses to isometric exercise in patients with mitral stenosis. Comparison with normal subjects and patients with depressed ejection fraction.
SO  - Archives of Internal Medicine. 142(9):1629-33, 1982 Sep.
AS  - Arch Intern Med. 142(9):1629-33, 1982 Sep.
NJ  - Archives of internal medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0372440, 7fs
OI  - Source: NASA. 82283025
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
SB  - National Aeronautics and Space Administration (NASA) Journals
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - Arrhythmia, Sinus/pp [Physiopathology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Blood Pressure
MH  - Cardiomyopathies/pp [Physiopathology]
MH  - Coronary Disease/pp [Physiopathology]
MH  - Female
MH  - Heart Rate
MH  - *Hemodynamics
MH  - Humans
MH  - *Isometric Contraction
MH  - Male
MH  - Middle Aged
MH  - *Mitral Valve Stenosis/pp [Physiopathology]
MH  - *Physical Exertion
MH  - Pulmonary Circulation
MH  - Stroke Volume
AB  - The hemodynamic response to isometric handgrip was evaluated in 15 patients with mitral stenosis (MS), 12 normal subjects, and 13 patients with severe left ventricular failure (LVF). Acceleration of heart rate and rise in left ventricular systolic pressure were not significantly different between the three groups. Left ventricular end-diastolic pressure did not change in normal subjects and patients with MS during handgrip, but it was raised markedly in patients with LVF. Cardiac index increased in normal subjects but did not change in patients with MS and LVF. Stroke index declined in patients with LVF. In all groups there was a modest and similar increase in oxygen consumption and significant widening of the arteriovenous oxygen difference in patients with LVF. In patients with MS, pulmonary capillary pressure increased by an average of 10.6 mm Hg, with a parallel rise in mean pulmonary vascular resistance. It is concluded that patients with MS demonstrate a normal chronotropic and pressor response to isometric exercise. Normal left ventricular end-diastolic pressure response to isometric handgrip stress in patients with MS suggests good left ventricular performance.
IS  - 0003-9926
IL  - 0003-9926
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 1982 Sep
DC  - 19821021
YR  - 1982
ED  - 19821021
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=7114981

<950. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7099227
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Anonymous
TI  - Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 34-1982. Fever, heart murmur, and artrial fibrillation in a 72-year-old woman.
SO  - New England Journal of Medicine. 307(9):543-9, 1982 Aug 26.
AS  - N Engl J Med. 307(9):543-9, 1982 Aug 26.
NJ  - The New England journal of medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0255562, now
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Abscess/pa [Pathology]
MH  - Acute Disease
MH  - Aged
MH  - *Aortic Valve/pa [Pathology]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Diagnosis, Differential
MH  - Endocarditis, Bacterial/di [Diagnosis]
MH  - *Endocarditis, Bacterial/pa [Pathology]
MH  - Female
MH  - Heart Murmurs
MH  - Humans
MH  - Myocardium/pa [Pathology]
MH  - Pericardium/pa [Pathology]
MH  - Streptococcal Infections/di [Diagnosis]
MH  - *Streptococcal Infections/pa [Pathology]
IS  - 0028-4793
IL  - 0028-4793
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1982 Aug 26
DC  - 19820910
YR  - 1982
ED  - 19820910
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=7099227

<951. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7040581
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Ritterman JB
AU  - Hossack KF
AU  - Bruce RA
FA  - Ritterman, J B
FA  - Hossack, K F
FA  - Bruce, R A
TI  - Acute and chronic effects of diltiazem on A-V conduction at rest and during exercise.
SO  - Journal of Electrocardiology. 15(1):41-6, 1982 Jan.
AS  - J Electrocardiol. 15(1):41-6, 1982 Jan.
NJ  - Journal of electrocardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - i0r, 0153605
SB  - Index Medicus
CP  - UNITED STATES
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrioventricular Node/de [Drug Effects]
MH  - *Benzazepines/pd [Pharmacology]
MH  - Cardiomyopathy, Hypertrophic/pp [Physiopathology]
MH  - Clinical Trials as Topic
MH  - *Coronary Disease/pp [Physiopathology]
MH  - Diltiazem/ad [Administration & Dosage]
MH  - *Diltiazem/pd [Pharmacology]
MH  - Double-Blind Method
MH  - *Electrocardiography
MH  - Female
MH  - *Heart Conduction System/de [Drug Effects]
MH  - Heart Rate/de [Drug Effects]
MH  - Heart Ventricles/de [Drug Effects]
MH  - Heart Ventricles/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Physical Exertion
MH  - Placebos
MH  - Random Allocation
MH  - Rest
AB  - The acute and chronic electrocardiographic effects of diltiazem, a drug which inhibits calcium passage through slow channels, were examined both at rest and during symptom-limited exercise. In the acute study, 12 patients with coronary artery disease (CAD), three patients with hypertrophic cardiomyopathy (HCM), and one patient with both CAD and HCM performed symptom-limited upright exercise prior to and one hour after receiving 120 mg oral dose of diltiazem. In the chronic study, three dose levels of diltiazem (120 mg/day, 180 mg/day, 240 mg/day) were compared with placebo in ten patients with CAD. Each patient received one week of placebo followed by placebo or diltiazem in a double-blind random cross-over fashion, so that each patient received four weeks of placebo and three weeks of diltiazem, one week at each dose level. Each week, symptom-limited upright exercise testing was performed. In the acute study, diltiazem did not significantly affect the mean PR, QRS, QTC intervals or the heart rate at rest or at maximal exercise. In one patient, diltiazem markedly slowed the ventricular response to atrial fibrillation and in another patient, provoked transient Mobitz I block. In the chronic study, the only significant difference observed was a prolongation of the resting PR interval on the 240 mg/day dose schedule (p less than .005).
RN  - 0 (Benzazepines)
RN  - 0 (Placebos)
RN  - EE92BBP03H (Diltiazem)
IS  - 0022-0736
IL  - 0022-0736
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
NO  - HL 23404 (United States NHLBI NIH HHS)
NO  - RR-37 (United States NCRR NIH HHS)
LG  - English
DP  - 1982 Jan
DC  - 19820621
YR  - 1982
ED  - 19820621
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=7040581

<952. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7317895
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Degre S
AU  - Longo B
AU  - Thirion M
AU  - Stoupel E
AU  - Sobolski J
AU  - Berkenboom G
AU  - Vandermoten P
AU  - Brion JC
FA  - Degre, S
FA  - Longo, B
FA  - Thirion, M
FA  - Stoupel, E
FA  - Sobolski, J
FA  - Berkenboom, G
FA  - Vandermoten, P
FA  - Brion, J C
TI  - Analysis of exercise-induced R-wave-amplitude changes in detection of coronary artery disease in patients with typical or atypical chest pain under digitalis treatment.
SO  - Cardiology. 68 Suppl 2:178-85, 1981.
AS  - Cardiology. 68 Suppl 2:178-85, 1981.
NJ  - Cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - coi, 1266406
SB  - Index Medicus
CP  - SWITZERLAND
MH  - Adult
MH  - Aged
MH  - Angiography
MH  - *Coronary Disease/di [Diagnosis]
MH  - Coronary Disease/dt [Drug Therapy]
MH  - *Digitalis
MH  - *Electrocardiography
MH  - *Exercise Test
MH  - Humans
MH  - Middle Aged
MH  - *Pain/et [Etiology]
MH  - *Plants, Medicinal
MH  - *Plants, Toxic
MH  - Radioisotopes
MH  - Thallium
MH  - *Thorax
AB  - Specificity and sensitivity of exercise ECG were compared to exercise stress thallium 201 scanning and coronary arteriograms in 70 male patients with typical or atypical chest pain complaints, without previous myocardial infarction. 50 patients (group I) did not receive any treatment; 20 patients (group II) received digitalis as preventive treatment of atrial arrhythmias or for no particular reason. Only subjects with concordant results in radionuclide and angiography examinations were considered as coronary artery disease patients. Exercise stress tests were performed sitting on the bicycle ergometer using a progressive loading profile (30 W for 3 min), to the symptom-limited capacity (VO2SL). Positive exercise ECG were confirmed on ST decrease (1.5 mm) or on absence or increase in R-wave-amplitude modifications (V5). In the group I patients, ECG-ST-modification sensitivity, specificity, predictive value (+) and efficiency were, respectively, 92, 82, 86 and 88%. R-wave-variation sensitivity, specificity, predictive value (+) and efficiency were, respectively, 41, 74, 65 and 56%. In the group II patients, ST-depression sensitivity, specificity, predictive value (+) and efficiency were, respectively, 100, 33, 59 and 65%. R-wave-variation sensitivity, specificity, predictive value (+) and efficiency were, respectively, 50, 70, 63 and 60%. It was concluded that R-wave-amplitude variations induced lower false positive responses than ST-segment depression in patients under digitalis treatment. False negative responses were unfortunately 50% using the R-wave criterion. Exercise ECG was finally judged as a poor indicator of CAD in patients under digitalis treatment.
RN  - 0 (Radioisotopes)
RN  - AD84R52XLF (Thallium)
IS  - 0008-6312
IL  - 0008-6312
PT  - Journal Article
LG  - English
DP  - 1981
DC  - 19820313
YR  - 1981
ED  - 19820313
RD  - 20151119
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=7317895

<953. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7302503
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Luca C
FA  - Luca, C
TI  - Nonparoxysmal AV junctional tachycardia with 2/1 exit block during atrial fibrillation in the absence of digitalis toxicity. The effect of exercise.
SO  - Medecine Interne. 19(3):247-9, 1981 Jul-Sep.
AS  - Med Interne. 19(3):247-9, 1981 Jul-Sep.
NJ  - Medecine interne
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - t3b, 7506353
SB  - Index Medicus
CP  - ROMANIA
MH  - *Atrial Fibrillation/co [Complications]
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Digoxin/ae [Adverse Effects]
MH  - Electrocardiography
MH  - Exercise Test
MH  - Female
MH  - Heart Rate
MH  - Humans
MH  - Middle Aged
MH  - Tachycardia/di [Diagnosis]
MH  - *Tachycardia/et [Etiology]
RN  - 73K4184T59 (Digoxin)
IS  - 0377-1202
IL  - 0377-1202
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 1981 Jul-Sep
DC  - 19820109
YR  - 1981
ED  - 19820109
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=7302503

<954. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7274225
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - van Dam I
AU  - van Zwieten G
AU  - Vogel JA
AU  - Meijler FL
FA  - van Dam, I
FA  - van Zwieten, G
FA  - Vogel, J A
FA  - Meijler, F L
TI  - Left ventricular (diastolic) dimensions and relaxation in patients with atrial fibrillation.
SO  - European Heart Journal. Suppl A:149-56, 1980.
AS  - Eur Heart J. Suppl A:149-56, 1980.
NJ  - European heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - em8, 8006263
SB  - Index Medicus
CP  - ENGLAND
MH  - Adult
MH  - Aged
MH  - Atrial Fibrillation/pa [Pathology]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Diastole
MH  - Electrocardiography
MH  - Female
MH  - *Heart/pp [Physiopathology]
MH  - Heart Rate
MH  - Heart Ventricles/ah [Anatomy & Histology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Myocardial Contraction
IS  - 0195-668X
IL  - 0195-668X
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
DP  - 1980
DC  - 19811118
YR  - 1980
ED  - 19811118
RD  - 20061115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=7274225

<955. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7447586
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Force T
AU  - Graboys TB
FA  - Force, T
FA  - Graboys, T B
TI  - Exercise testing and ambulatory monitoring in patients with preexcitation syndrome.
SO  - Archives of Internal Medicine. 141(1):88-90, 1981 Jan.
AS  - Arch Intern Med. 141(1):88-90, 1981 Jan.
NJ  - Archives of internal medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0372440, 7fs
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adolescent
MH  - Adult
MH  - *Arrhythmias, Cardiac/di [Diagnosis]
MH  - Exercise Test
MH  - Female
MH  - *Heart Function Tests/mt [Methods]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Monitoring, Physiologic
AB  - Documentation of arrhythmia in symptomatic patients with preexcitation syndromes may be difficult despite extended ambulatory monitoring (MON). We, therefore, examined 12 patients with Wolff-Parkinson-White (WPW) and ten with Lown-Ganong-Levine ECG anomalies to compare the yield of tachyarrhythmia on maximal treadmill testing (MTT) and on MON. Nineteen patients were free of associated heart disease. Average age for the group was 45 years (11 men and 11 women). Sustained atrial arrhythmias developed in four of 22 patients during MTT. All four were free of arrhythmia on subsequent MON. An additional four patients exhibited these arrhythmias on MON. We conclude that the use of both monitoring and exercise testing will enhance detection of arrhythmia in patients with symptomatic preexcitation.
IS  - 0003-9926
IL  - 0003-9926
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
NO  - HL-07776 (United States NHLBI NIH HHS)
NO  - HL-18783 (United States NHLBI NIH HHS)
LG  - English
DP  - 1981 Jan
DC  - 19810226
YR  - 1981
ED  - 19810226
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=7447586

<956. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 7356362
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Sands MP
AU  - Dillard DH
AU  - Hessel EA 2nd
AU  - Miller DW Jr
FA  - Sands, M P
FA  - Dillard, D H
FA  - Hessel, E A 2nd
FA  - Miller, D W Jr
TI  - Improved anesthesia for deep surface-induced hypothermia: the halothane-diethyl ether azeotrope.
SO  - Annals of Thoracic Surgery. 29(2):123-9, 1980 Feb.
AS  - Ann Thorac Surg. 29(2):123-9, 1980 Feb.
NJ  - The Annals of thoracic surgery
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 683, 15030100r
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Animals
MH  - Blood Gas Analysis
MH  - Blood Pressure
MH  - *Cardiac Surgical Procedures
MH  - Dogs
MH  - Drug Combinations
MH  - *Ether
MH  - *Ethyl Ethers
MH  - *Halothane
MH  - Heart Rate
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - *Hypothermia, Induced
MH  - Infant
MH  - Lactates/bl [Blood]
MH  - Movement Disorders/et [Etiology]
AB  - The halothane-diethyl ether azeotrope was evaluated in dogs as the anesthetic agent for deep surface hypothermia with total circulatory arrest for open-heart operation. All 10 animals given azeotrope in 100% oxygen (O2) experienced atrial arrhythmias during cooling, and 1 had ventricular fibrillation prior to the completion of cooling at 18 degrees to 20 degrees C. After only 30 minutes' arrest, 8 of the 10 dogs had postoperative motor disturbances. Administering the azeotrope in 95% O2 and 5% carbon dioxide (CO2) yielded markedly improved results characterized by a rapid, smooth cooling course, easy resuscitation following circulatory arrest, and rapid rewarming, and 3 out of 10 dogs experienced mild motor disturbance after 60 minutes of circulatory arrest. This method, when compared with our standard method of ether in 100% O2, resulted in reduced blood lactates and a striking improvement in clinical status on the first postoperative morning. In limited clinical trials, infants undergoing repair of congenital cardiac defects have done well and responded as expected based on the laboratory experience. Since the results with the azeotrope in 95% O2 and 5% CO2 were at least as good as, and in several instances better than, those with the standard method employing either, the nonexplosive characteristic of the azeotrope warrants continued evaluation of this agent.
RN  - 0 (Drug Combinations)
RN  - 0 (Ethyl Ethers)
RN  - 0 (Lactates)
RN  - 0F5N573A2Y (Ether)
RN  - UQT9G45D1P (Halothane)
IS  - 0003-4975
IL  - 0003-4975
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
LG  - English
DP  - 1980 Feb
DC  - 19800423
YR  - 1980
ED  - 19800423
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=7356362

<957. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 6965579
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Stephenson LW
AU  - MacVaugh H 3rd
AU  - Tomasello DN
AU  - Josephson ME
FA  - Stephenson, L W
FA  - MacVaugh, H 3rd
FA  - Tomasello, D N
FA  - Josephson, M E
TI  - Propranolol for prevention of postoperative cardiac arrhythmias: a randomized study.
SO  - Annals of Thoracic Surgery. 29(2):113-6, 1980 Feb.
AS  - Ann Thorac Surg. 29(2):113-6, 1980 Feb.
NJ  - The Annals of thoracic surgery
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 683, 15030100r
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Arrhythmias, Cardiac/pc [Prevention & Control]
MH  - *Coronary Artery Bypass
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Postoperative Complications/pc [Prevention & Control]
MH  - Propranolol/ad [Administration & Dosage]
MH  - *Propranolol/tu [Therapeutic Use]
MH  - Random Allocation
AB  - Two hundred twenty-three patients were randomly selected to receive propranolol, 10 mg orally every 6 hours, or to serve as controls after coronary artery bypass grafting. The study began at the time of discharge from the intensive care unit. Patients were ineligible if they had cardiac arrhythmias while in the intensive care unit, low cardiac output requiring catecholamine support, or bradycardia requiring a pacemaker. In the control group, cardiac arrhythmias for which treatment was necessary developed in 31 of 136 patients (23%), atrial fibrillation or flutter in 24 patients (18%), and ventricular arrhythmias in 7 (5%). In the group receiving propranolol, cardiac arrhythmias requiring treatment developed in 9 of 87 patients (10%), atrial fibrillation or flutter in 7 (8%), and ventricular arrhythmias in 2 (2%). The difference in frequency with which cardiac arrhythmias occurred between the two groups is significantly different (p less than 0.05). We conclude that propranolol is effective in the prevention of cardiac arrhythmias following coronary artery bypass grafting.
RN  - 9Y8NXQ24VQ (Propranolol)
IS  - 0003-4975
IL  - 0003-4975
PT  - Journal Article
LG  - English
DP  - 1980 Feb
DC  - 19800423
YR  - 1980
ED  - 19800423
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=6965579

<958. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 6101296
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - McKenna WJ
AU  - Chetty S
AU  - Oakley CM
AU  - Goodwin JF
FA  - McKenna, W J
FA  - Chetty, S
FA  - Oakley, C M
FA  - Goodwin, J F
TI  - Arrhythmia in hypertrophic cardiomyopathy: exercise and 48 hour ambulatory electrocardiographic assessment with and without beta adrenergic blocking therapy.
SO  - American Journal of Cardiology. 45(1):1-5, 1980 Jan.
AS  - Am J Cardiol. 45(1):1-5, 1980 Jan.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Adrenergic beta-Antagonists/tu [Therapeutic Use]
MH  - Adult
MH  - Aged
MH  - *Ambulatory Care
MH  - *Arrhythmias, Cardiac/co [Complications]
MH  - Arrhythmias, Cardiac/dt [Drug Therapy]
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Cardiomyopathy, Hypertrophic/co [Complications]
MH  - *Electrocardiography
MH  - Exercise Test
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Systole/de [Drug Effects]
MH  - Tachycardia/dt [Drug Therapy]
MH  - Time Factors
AB  - Submaximal treadmill exercise electrocardiography and 48 hour ambulatory electrocardiographic monitoring were performed in 30 patients with hypertrophic cardiomyopathy both with and without beta adrenergic blocking therapy. During ambulatory electrocardiographic monitoring 1 patient (3 percent) had no arrhythmia, 14 patients (46 percent) had supraventricular tachycardia or paroxysmal atrial fibrillation, 13 (43 percent) had multiform or paired ventricular extrasystoles and 8 (26 percent) had ventricular tachycardia. The frequency of these ventricular arrhythmias was almost identical with and without beta adrenergic blocking drugs (mean dose in "propranolol equivalents" 280 mg daily). With beta blocking therapy fewer patients had supraventricular tachycardia; however, the difference was not significant. During exercise testing 18 patients (60 percent) had ventricular extrasystoles and 3 patients (10 percent) had paired ventricular extrasystoles and the frequency was almost identical with and without beta adrenergic blocking therapy. No routine echocardiographic or hemodynamic measurement predicted the serious ventricular arrhythmias. It is concluded that asymptomatic ventricular arrhythmia is a common occurrence in patients with hypertrophic cardiomyopathy and its frequency is not reduced with beta adrenergic blocking therapy. Because occult arrhythmia may be the cause of sudden death it is important to detect it in these patients so that an effort can be made to improve prognosis with specific antiarrhythmic treatment.
RN  - 0 (Adrenergic beta-Antagonists)
IS  - 0002-9149
IL  - 0002-9149
PT  - Journal Article
LG  - English
DP  - 1980 Jan
DC  - 19800228
YR  - 1980
ED  - 19800228
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=6101296

<959. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 315019
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lolley DM
AU  - Ray JF 3rd
AU  - Myers WO
AU  - Sautter RD
AU  - Tewksbury DA
FA  - Lolley, D M
FA  - Ray, J F 3rd
FA  - Myers, W O
FA  - Sautter, R D
FA  - Tewksbury, D A
TI  - Importance of preoperative myocardial glycogen levels in human cardiac preservation. Preliminary report.
SO  - Journal of Thoracic & Cardiovascular Surgery. 78(5):678-87, 1979 Nov.
AS  - J Thorac Cardiovasc Surg. 78(5):678-87, 1979 Nov.
NJ  - The Journal of thoracic and cardiovascular surgery
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - k9j, 0376343
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aorta/su [Surgery]
MH  - Arrhythmias, Cardiac/pc [Prevention & Control]
MH  - Cardiac Surgical Procedures/mo [Mortality]
MH  - *Cardiac Surgical Procedures
MH  - Constriction
MH  - Coronary Artery Bypass/mo [Mortality]
MH  - *Coronary Disease/pc [Prevention & Control]
MH  - Dietary Fats
MH  - Energy Intake
MH  - Female
MH  - Glucose/tu [Therapeutic Use]
MH  - *Glycogen/me [Metabolism]
MH  - *Heart Arrest, Induced/ae [Adverse Effects]
MH  - Heart Arrest, Induced/mo [Mortality]
MH  - Humans
MH  - Intraoperative Complications/pc [Prevention & Control]
MH  - Male
MH  - Middle Aged
MH  - Myocardial Contraction
MH  - Myocardial Infarction/mo [Mortality]
MH  - Myocardial Infarction/pc [Prevention & Control]
MH  - *Myocardium/me [Metabolism]
MH  - Postoperative Complications/mo [Mortality]
MH  - Postoperative Complications/pc [Prevention & Control]
MH  - Potassium Chloride/pd [Pharmacology]
MH  - Preoperative Care
MH  - Prospective Studies
AB  - One hundred seventeen patients undergoing elective coronary bypass were divided into four groups according to prebypass myocardial glycogen levels and the use of potassium chloride cardioplegia. Myocardial glycogen levels were enhanced with a preoperative fat loading diet and overnight glucose loading. The control group (n = 27) which had mean cardiac glycogen levels of 750 mg/100 gm heart weight and no cardioplegia, had a transmural myocardial infarct rate of 14.4%; 35% had severe atrial arrhythmias 65% had severe ventricular arrhythmias, and 31% had severe vasopressor dependence. The group (n = 30) with low cardiac glycogen (736 mg/100 gm) and with potassium chloride cardioplegia had an infarct rate of 6.4%; 6.7% had severe atrial arrhythmias, 18% had severe ventricular arrhythmias, and 16.7% had severe vasopressor dependence. However, the group (n = 26) which had high cardiac glycogen levels (1,208 mg/100 gm) and no cardioplegia had no myocardial infarctions; 3.8% had severe atrial arrhythmias, 27% had severe ventricular arrhythmias, and only 7.8% had severe vasopressor need. The group (n = 34) which had high glycogen levels (1,516 mg/100 gm) and potassium chloride cardioplegia did best of all with no myocardial infarctions or no severe atrial arrhythmias; 14% had severe ventricular arrhythmias and 2.81% severe vasopressor need. The lessening of vasopressor dependence and severe atrial and ventricular arrhythmias were significant by chi square contingency tables at p less than 0.05 and p less than 0.001, respectively. One cardiac-related death each occurred in the two groups with low glycogen and none in those with high glycogen levels. This suggests that better preoperative cardiac nutrition as represented by enhanced cardiac glycogen helps that heart tolerate anoxic stress whether cardioplegia is utilized or not and is additive to potassium chloride cardioplegia.
RN  - 0 (Dietary Fats)
RN  - 660YQ98I10 (Potassium Chloride)
RN  - 9005-79-2 (Glycogen)
RN  - IY9XDZ35W2 (Glucose)
IS  - 0022-5223
IL  - 0022-5223
PT  - Journal Article
LG  - English
DP  - 1979 Nov
DC  - 19791229
YR  - 1979
ED  - 19791229
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=315019

<960. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 313765
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lolley DM
AU  - Ray JF 3rd
AU  - Myers WO
AU  - Sheldon G
AU  - Sautter RD
FA  - Lolley, D M
FA  - Ray, J F 3rd
FA  - Myers, W O
FA  - Sheldon, G
FA  - Sautter, R D
TI  - Reduction of intraoperative myocardial infarction by means of exogenous anaerobic substrate enhancement: prospective randomized study.
SO  - Annals of Thoracic Surgery. 26(6):515-24, 1978 Dec.
AS  - Ann Thorac Surg. 26(6):515-24, 1978 Dec.
NJ  - The Annals of thoracic surgery
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 683, 15030100r
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Arrhythmias, Cardiac/et [Etiology]
MH  - Arrhythmias, Cardiac/pc [Prevention & Control]
MH  - Cardiopulmonary Bypass/ae [Adverse Effects]
MH  - *Cardiopulmonary Bypass/mt [Methods]
MH  - *Coronary Artery Bypass/mt [Methods]
MH  - Evaluation Studies as Topic
MH  - Female
MH  - *Glucose/tu [Therapeutic Use]
MH  - Glucose Solution, Hypertonic/ad [Administration & Dosage]
MH  - *Glucose Solution, Hypertonic/tu [Therapeutic Use]
MH  - Humans
MH  - Infusions, Parenteral
MH  - Insulin/ad [Administration & Dosage]
MH  - *Insulin/tu [Therapeutic Use]
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/et [Etiology]
MH  - *Myocardial Infarction/pc [Prevention & Control]
MH  - Potassium Chloride/ad [Administration & Dosage]
MH  - *Potassium Chloride/tu [Therapeutic Use]
MH  - Prospective Studies
AB  - In a prospective study, patients who had an ejection fraction of 40% or more and who were undergoing elective coronary artery operation were randomly divided into three groups that differed in the method of anaerobic substrate enhancement during cardiopulmonary bypass. Group 1, the controls (n = 157), received no additional glucose, insulin, and potassium solutions and experienced immediate spontaneous defibrillation (10%), transmural myocardial infarction (10.3%), malignant ventricular arrhythmias (26%), and severe atrial arrhythmias (20%). Group 2 (n = 120) received a bolus of hypertonic glucose, insulin, and potassium in the pump perfusate before aortic cross-clamping. In this group, the rate of spontaneous defibrillation was 41%, of transmural infarction, 8.3%, of malignant ventricular arrhythmias, 31%, and of severe atrial arrhythmias, 19%. Group 3 (n = 114) had the aortic root continuously infused with glucose, insulin, and potassium solution at 4 degrees C during aortic cross-clamping. This group was significantly improved; the rate of spontaneous defibrillation was 60%, there were no transmural myocardial infarctions and the incidence of severe atrial arrhythmias was 6% and that of malignant ventricular arrhythmias, 5%. It is proposed that the superior clinical results in Group 3 resulted from better myocardial preservation achieved by more efficient means of providing continuous anaerobic substrate, coronary washout, and elution of lactic acidosis, uniform global hypothermia, and direct supplemental myocardial potassium in addition to mere cardioplegic effects.
RN  - 0 (Glucose Solution, Hypertonic)
RN  - 0 (Insulin)
RN  - 660YQ98I10 (Potassium Chloride)
RN  - IY9XDZ35W2 (Glucose)
IS  - 0003-4975
IL  - 0003-4975
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
LG  - English
DP  - 1978 Dec
DC  - 19790925
YR  - 1978
ED  - 19790925
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=313765

<961. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 452946
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Khalsa A
AU  - Olsson SB
FA  - Khalsa, A
FA  - Olsson, S B
TI  - Verapamil-induced ventricular regularity in atrial fibrillation. Effects of exercise, isoproterenol, atropine and conversion to sinus rhythm.
SO  - Acta Medica Scandinavica. 205(6):509-15, 1979.
AS  - Acta Med Scand. 205(6):509-15, 1979.
NJ  - Acta medica Scandinavica
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0370330
SB  - Index Medicus
CP  - SWEDEN
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atropine/pd [Pharmacology]
MH  - Electrocardiography
MH  - Exercise Test
MH  - Female
MH  - *Heart Rate/de [Drug Effects]
MH  - Heart Ventricles/de [Drug Effects]
MH  - Humans
MH  - *Isoproterenol/pd [Pharmacology]
MH  - Male
MH  - Middle Aged
MH  - *Physical Exertion
MH  - *Verapamil/tu [Therapeutic Use]
AB  - The effects of physical exercise, isoproterenol and atropine upon the ventricular rate and regularity were studied in 12 patients with atrial fibrillation (AF) during verapamil-induced regular ventricular rhythm. Physical exercise, isoproterenol and atropine all caused a gradual loss of ventricular regularity during AF. Verapamil caused a reduction of exercise heart rate during AF and, to a minor extent, even during sinus rhythm. The regular ventricular rhythm induced by verapamil during AF is interpreted as a total AV-nodal block with nodal escape rhythm. Possible clinical benefits of this rhythm are discussed.
RN  - 7C0697DR9I (Atropine)
RN  - CJ0O37KU29 (Verapamil)
RN  - L628TT009W (Isoproterenol)
IS  - 0001-6101
IL  - 0001-6101
PT  - Journal Article
LG  - English
DP  - 1979
DC  - 19790829
YR  - 1979
ED  - 19790829
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=452946

<962. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 154981
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Savage DD
AU  - Seides SF
AU  - Maron BJ
AU  - Myers DJ
AU  - Epstein SE
FA  - Savage, D D
FA  - Seides, S F
FA  - Maron, B J
FA  - Myers, D J
FA  - Epstein, S E
TI  - Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic cardiomyopathy.
SO  - Circulation. 59(5):866-75, 1979 May.
AS  - Circulation. 59(5):866-75, 1979 May.
NJ  - Circulation
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Arrhythmias, Cardiac/di [Diagnosis]
MH  - *Arrhythmias, Cardiac/et [Etiology]
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Cardiomegaly/co [Complications]
MH  - *Cardiomyopathies/co [Complications]
MH  - *Cardiomyopathy, Hypertrophic/co [Complications]
MH  - Child
MH  - Echocardiography
MH  - Electrocardiography
MH  - Exercise Test
MH  - Female
MH  - Heart Septum
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Monitoring, Physiologic
MH  - Sleep/ph [Physiology]
MH  - Syncope
MH  - Tachycardia/di [Diagnosis]
MH  - Tachycardia/et [Etiology]
AB  - Many patients with hypertrophic cardiomyopathy die suddenly and unexpectedly, a significant number perhaps due to arrhythmia. Of 100 patients initially evaluated for signs or symptoms suggestive of heart disease or a family history of hypertrophic cardiomyopathy, 51 were selected solely because they met the echocardiographic criteria for the disease, and 49 patients were selected primarily because they had: 1) normal sinus rhythm despite left atrial enlargement, 2) a history of syncope, 3) a family history of premature death, or 4) a history of paroxysmal atrial fibrillation. All 100 patients were studied by 24-hour ambulatory electrocardiographic monitoring and 74 of them also underwent treadmill exercise testing. More than 50% of patients in repetitive ventricular premature depolarizations, including 19% who had ventricular tachycardia. Monitoring was superior to exercise testing for exposing these arrhythmias. Two patients experienced cardiac arrest within 2 months of monitoring; in each, monitoring had revealed ventricular tachycardia. Two patients with paroxysms of supraventricular tachycardia during monitoring developed fixed atrial fibrillation within 1 year. These preliminary observations suggest that monitoring may help identify patients at increased risk for significant arrhythmic events.
IS  - 0009-7322
IL  - 0009-7322
PT  - Journal Article
LG  - English
DP  - 1979 May
DC  - 19790629
YR  - 1979
ED  - 19790629
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=154981

<963. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 710493
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Malcolm AD
AU  - Ahuja SP
FA  - Malcolm, A D
FA  - Ahuja, S P
TI  - The electrocardiographic response to exercise in 44 patients with leaflet prolapse.
SO  - European Journal of Cardiology. 8(3):359-70, 1978 Oct.
AS  - Eur J Cardiol. 8(3):359-70, 1978 Oct.
NJ  - European journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - en2, 0404054
SB  - Index Medicus
CP  - NETHERLANDS
MH  - Adult
MH  - Aged
MH  - *Electrocardiography
MH  - Exercise Test
MH  - Female
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mitral Valve Prolapse/pp [Physiopathology]
AB  - The response to electrocardiographically monitored submaximal exercise stress testing has been studied in 44 patients with mitral leaflet prolapse (MLP). With exercise, ventricular premature contractions occurred in 7, ventricular tachycardia in 1, and atrial fibrillation in 1. Exercise was terminated short of target heart rate in 18 patients, because of chest pain (5), fatigue (7), ventricular arrhythmia (4), dizziness (1) or ST segment depression (1). 23 patients developed postexercise ST segment abnormalities, of whom 5 had 'ischemic' patterns and arteriographically proven coronary artery disease (CAD); among the 18 others, the ST segments were depressed and minimally downsloping in 2, slowly ascending from depressed J point in 3, horizontal for greater than or equal to 80 msec with J depression of less than 1 mm in 12, and cupped in 1. The incidence of arrhythmias provoked by submaximal exercise stress testing in patients with MLP was lower than suggested in previous reports. In all 5 cases where MLP and CAD coexisted, the classical 'ischemic' electrocardiographic response to exercise was not obscured. Even in the absence of CAD, postexercise ST segment abnormalities were common with MLP (18/39 = 46%) and differed from the progressively resolving ST segment deviation characteristic of CAD with angina. Exercise testing can safely be recommended, subject to standard contraindications, in patients with MLP and yields useful information.
IS  - 0301-4711
IL  - 0301-4711
PT  - Journal Article
LG  - English
DP  - 1978 Oct
DC  - 19790124
YR  - 1978
ED  - 19790124
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=710493

<964. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 630965
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Peters RW
AU  - Norman A
AU  - Parmley WW
AU  - Emilson BB
AU  - Scheinman MM
AU  - Cheitlin M
FA  - Peters, R W
FA  - Norman, A
FA  - Parmley, W W
FA  - Emilson, B B
FA  - Scheinman, M M
FA  - Cheitlin, M
TI  - Effect of therapy with methylprednisolone on the size of myocardial infarcts in man.
SO  - Chest. 73(4):483-8, 1978 Apr.
AS  - Chest. 73(4):483-8, 1978 Apr.
NJ  - Chest
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0231335, d1c
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Adrenal Cortex Hormones/tu [Therapeutic Use]
MH  - Adult
MH  - Aged
MH  - Creatine Kinase/bl [Blood]
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Methylprednisolone/ad [Administration & Dosage]
MH  - *Methylprednisolone/tu [Therapeutic Use]
MH  - Middle Aged
MH  - *Myocardial Infarction/dt [Drug Therapy]
MH  - Myocardial Infarction/pa [Pathology]
AB  - The use of steroids to decrease the size of the infarct and the mortality in patients with acute myocardial infarction has long been the subject of controversy. In the present study, two large doses of methylprednisolone were administered intravenously to 14 patients with relatively uncomplicated myocardial infarction within 17 hours after the onset of symptoms, whereas a comparable group of 15 patients with myocardial infarction served as controls. The size of the infarct was assessed utilizing serial measurements of serum levels of creatine phosphokinase and its myocardial isoenzyme, the MB form of creatine phosphokinase. There was no significant difference between the two groups of patients with regard to peak cumulative levels of total creatine phosphokinase and the MB form of creatine phosphokinase. Similarly, there was no difference between the two groups in mortality or in the incidence of malignant ventricular arrhythmias, atrioventricular block, congestive heart failure, or extensions of the infarct. We conclude that high intravenous doses of steroids given early in the course of myocardial infarction have neither deleterious nor beneficial effects.
RN  - 0 (Adrenal Cortex Hormones)
RN  - EC 2-7-3-2 (Creatine Kinase)
RN  - X4W7ZR7023 (Methylprednisolone)
IS  - 0012-3692
IL  - 0012-3692
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
LG  - English
DP  - 1978 Apr
DC  - 19780524
YR  - 1978
ED  - 19780524
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=630965

<965. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 907598
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Sekiguchi C
AU  - Yamaguchi O
AU  - Kitajima T
AU  - Ueda Y
FA  - Sekiguchi, C
FA  - Yamaguchi, O
FA  - Kitajima, T
FA  - Ueda, Y
TI  - Continuous ECG monitoring on civil air crews during flight operations.
SO  - Aviation Space & Environmental Medicine. 48(9):872-6, 1977 Sep.
AS  - Aviat Space Environ Med. 48(9):872-6, 1977 Sep.
NJ  - Aviation, space, and environmental medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 9ja, 7501714
OI  - Source: NASA. 78019665
SB  - Index Medicus
SB  - National Aeronautics and Space Administration (NASA) Journals
CP  - UNITED STATES
MH  - *Accidents, Aviation/pc [Prevention & Control]
MH  - Aerospace Medicine
MH  - *Cardiovascular Diseases/di [Diagnosis]
MH  - *Electrocardiography
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Monitoring, Physiologic
MH  - *Space Flight
AB  - Cardiovascular disease is one of the disorders resulting in sudden incapacitation and is the most common malady leading to medical retirement. It is very important for us to control this disease among pilots. Generally, pilots undergo medical checkups at health control service on the ground, but they do not undergo these checkups during flight operations. We obtained a continuous ECG recording on four pilots to assess cardiac reserve capacity for mental load during flight operation. Results show that no significant ischemic changes of ST-segment and T-wave during flight were noticed except in one case of atrial fibrillation in which significant depression of ST-segment occurred while walking up a stairway after flight. An increased number of ectopic beats was found in another normal case. In general, it was suspected that mental load is greater at landing than takeoff.
IS  - 0095-6562
IL  - 0095-6562
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 1977 Sep
DC  - 19771125
YR  - 1977
ED  - 19771125
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=907598

<966. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 998508
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Tilkian AG
AU  - Schroeder JS
AU  - Kao J
AU  - Hultgren H
FA  - Tilkian, A G
FA  - Schroeder, J S
FA  - Kao, J
FA  - Hultgren, H
TI  - Effect of lithium on cardiovascular performance: report on extended ambulatory monitoring and exercise testing before and during lithium therapy.
SO  - American Journal of Cardiology. 38(6):701-8, 1976 Nov 23.
AS  - Am J Cardiol. 38(6):701-8, 1976 Nov 23.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - *Arrhythmias, Cardiac/ci [Chemically Induced]
MH  - Arrhythmias, Cardiac/pp [Physiopathology]
MH  - Cardiovascular System/de [Drug Effects]
MH  - Electrocardiography
MH  - *Exercise Test
MH  - Female
MH  - Heart Diseases/co [Complications]
MH  - Humans
MH  - Lithium/ae [Adverse Effects]
MH  - *Lithium/tu [Therapeutic Use]
MH  - Male
MH  - Mental Disorders/co [Complications]
MH  - *Mental Disorders/dt [Drug Therapy]
MH  - Middle Aged
MH  - Monitoring, Physiologic
MH  - Physical Exertion
MH  - Sleep
AB  - To assess the effect of long-term lithium therapy on cardiac arrhythmias and cardiovascular performance, extended ambulatory electrocardiographic monitoring was performed in 12 patients, and rest and exercise electrocardiograms in 10 of 12, before and during lithium therapy. Lithium increased the frequency of premature ventricular contractions in three patients, decreased it in one, and produced no change in eight. Three of four patients with atrial arrhythmias showed improvement during lithium therapy. Exercise performance was unchanged. Although 7 of the 12 patients manifested T wave flattening in the resting electrocardiogram, none had S-T segment displacement at rest or on treadmill exercise. Before lithium therapy, arrhythmias on exercise included premature atrial contractions in four patients, ventricular arrhythmias in four (premature ventricular contractions in four, with couplets in two and with ventricular tachycardia in one). During lithium therapy, exercise did not provoke premature atrial contractions or ventricular tachycardia in any of the patients, but three patients had premature ventricular contractions (with couplets in one case). We conclude that lithium at therapeutic levels may precipitate or aggravate ventricular arrhythmias. When administered to patients with heart disease, factors that interfere with renal clearance of lithium (heart failure, salt restriction, long-term diuretic therapy) must be recognized and doses must be adjusted accordingly. Careful follow-up and electrocardiographic monitoring are advisable if lithium is to be used in the presence of ventricular arrhythmias. Cardiovascular performance as assessed by treadmill exercise testing was not affected by long-term lithium therapy.
RN  - 9FN79X2M3F (Lithium)
IS  - 0002-9149
IL  - 0002-9149
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
LG  - English
DP  - 1976 Nov 23
DC  - 19770125
YR  - 1976
ED  - 19770125
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=998508

<967. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 958247
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Anonymous
TI  - Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 39-1976.
SO  - New England Journal of Medicine. 295(13):718-24, 1976 Sep 23.
AS  - N Engl J Med. 295(13):718-24, 1976 Sep 23.
NJ  - The New England journal of medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0255562, now
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Aortic Valve/su [Surgery]
MH  - *Aspergillosis/pa [Pathology]
MH  - Aspergillus/ip [Isolation & Purification]
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Diagnosis, Differential
MH  - Endocarditis/di [Diagnosis]
MH  - Endocarditis/et [Etiology]
MH  - Endocarditis/mi [Microbiology]
MH  - *Endocarditis/pa [Pathology]
MH  - Focal Infection, Dental
MH  - Heart Arrest/di [Diagnosis]
MH  - *Heart Valve Prosthesis/ae [Adverse Effects]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pericarditis/pa [Pathology]
IS  - 0028-4793
IL  - 0028-4793
PT  - Case Reports
PT  - Journal Article
LG  - English
DP  - 1976 Sep 23
DC  - 19761101
YR  - 1976
ED  - 19761101
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=958247

<968. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1267990
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Atkins JM
AU  - Matthews OA
AU  - Blomqvist CG
AU  - Mullins CB
FA  - Atkins, J M
FA  - Matthews, O A
FA  - Blomqvist, C G
FA  - Mullins, C B
TI  - Incidence of arrhythmias induced by isometric and dynamic exercise.
SO  - British Heart Journal. 38(5):465-71, 1976 May.
AS  - Br Heart J. 38(5):465-71, 1976 May.
NJ  - British heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - ats, 0370634
OI  - Source: NASA. 76184359
OI  - Source: NLM. PMC483018
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
SB  - National Aeronautics and Space Administration (NASA) Journals
CP  - ENGLAND
MH  - Adult
MH  - Aged
MH  - Arrhythmias, Cardiac/di [Diagnosis]
MH  - *Arrhythmias, Cardiac/et [Etiology]
MH  - Blood Pressure
MH  - Cardiac Catheterization
MH  - Cardiomyopathies/co [Complications]
MH  - Coronary Disease/co [Complications]
MH  - Female
MH  - *Heart Diseases/co [Complications]
MH  - Heart Rate
MH  - Heart Valve Diseases/co [Complications]
MH  - Heart Ventricles
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Physical Exertion
MH  - Tachycardia/et [Etiology]
AB  - The incidence of arrhythmias during isometric sustained handgrip exercise and during dynamic graded bicycle exercise was compared in a group of 45 patients with various forms of heart disease on no antiarrhythmic therapy. Atrial arrhythmias were equally common during handgrip and bicycle exercise but ventricular arrhythmias were more frequent during handgrip exercise. Of the 45 patients, 38 per cent developed ventricular arrhythmias during isometric exercise, with ventricular tachycardia occurring in 15 per cent. During dynamic exercise 22 per cent of the 45 patients developed ventricular arrhythmias, with ventricular tachycardia occurring in 2 per cent. Patients with coronary artery disease and/or depressed left ventricular function developed twice the incidence of ventricular arrhythmias with isometric than with dynamic exercise. Thus, isometric exercise testing is of more value than dynamic exercise testing in unmasking latent ventricular arrhythmias in patients with heart disease.
IS  - 0007-0769
IL  - 0007-0769
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
LG  - English
DP  - 1976 May
DC  - 19760802
YR  - 1976
ED  - 19760802
RD  - 20121115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=1267990

<969. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1259828
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kalmanson D
AU  - Veyrat C
AU  - Bernier A
AU  - Witchitz S
AU  - Chiche P
FA  - Kalmanson, D
FA  - Veyrat, C
FA  - Bernier, A
FA  - Witchitz, S
FA  - Chiche, P
TI  - Opening snap and isovolumic relaxation period in relation to mitral valve flow in patients with mitral stenosis. Significance of A2--OS interval.
SO  - British Heart Journal. 38(2):135-46, 1976 Feb.
AS  - Br Heart J. 38(2):135-46, 1976 Feb.
NJ  - British heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - ats, 0370634
OI  - Source: NLM. PMC482984
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - ENGLAND
MH  - Adult
MH  - Atrial Fibrillation/co [Complications]
MH  - Blood Flow Velocity
MH  - Blood Pressure
MH  - Calcinosis/co [Complications]
MH  - Female
MH  - *Heart Auscultation
MH  - *Heart Sounds
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve/pp [Physiopathology]
MH  - Mitral Valve Stenosis/co [Complications]
MH  - *Mitral Valve Stenosis/pp [Physiopathology]
MH  - Phonocardiography
MH  - Statistics as Topic
MH  - Time Factors
AB  - In 15 patients with pure or predominant mitral stenosis and in a control group of 11 patients without mitral stenosis the blood flow velocity through the mitral valve orifice was recorded by means of a directional Doppler ultrasound velocity catheter introduced transeptally and positioned in the orifice of the mitral valve. A simultaneous surface phonocardiogram was obtained. The timing of the mitral opening snap in relation to the blood velocity record of the flow through the valve supported the hypothesis that the opening snap is due to a sudden tensing of the valve leaflets by the chordae tendineae. Determination of the exact time of mitral valve opening, made possible by the blood velocity record, led to the division of the classical A2-0S interval (aortic valve closure to opening snap) into two components representing respectively the diastolic isovolumic relaxation period and the time of excursion of the mitral valve cusps. The durations of the isovolumic relaxation period were compared with those in the control patients and were found to correlate with the severity of the mitral stenosis, whereas those of the excursion time of the mitral cusps were influenced by the presence or absence of mitral valve calcification.
IS  - 0007-0769
IL  - 0007-0769
PT  - Comparative Study
PT  - Journal Article
LG  - English
DP  - 1976 Feb
DC  - 19760706
YR  - 1976
ED  - 19760706
RD  - 20081120
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=1259828

<970. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1243194
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Steinbach M
AU  - Constantineanu M
AU  - Harnagea P
AU  - Theodorini S
AU  - Popescu I
AU  - Vulpescu S
AU  - Bujar H
AU  - Georgescu M
AU  - Cretescu R
AU  - Manicatide M
AU  - Nicolaescu V
AU  - Voiosu R
AU  - Tanaseanu S
AU  - Tanasescu C
AU  - Georgescu A
AU  - Cucu F
AU  - Suciu A
FA  - Steinbach, M
FA  - Constantineanu, M
FA  - Harnagea, P
FA  - Theodorini, S
FA  - Popescu, I
FA  - Vulpescu, S
FA  - Bujar, H
FA  - Georgescu, M
FA  - Cretescu, R
FA  - Manicatide, M
FA  - Nicolaescu, V
FA  - Voiosu, R
FA  - Tanaseanu, S
FA  - Tanasescu, C
FA  - Georgescu, A
FA  - Cucu, F
FA  - Suciu, A
TI  - Coronary heart disease and risk factors in some special type collectivities.
SO  - Medecine Interne. 13(2):87-93, 1975.
AS  - Med Interne. 13(2):87-93, 1975.
NJ  - Medecine interne
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - t3b, 7506353
SB  - Index Medicus
CP  - ROMANIA
MH  - Adult
MH  - *Coronary Disease/ep [Epidemiology]
MH  - Coronary Disease/et [Etiology]
MH  - Diet
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Occupations
MH  - Risk
MH  - Romania
MH  - Rural Population
MH  - Urban Population
AB  - Transversal epidemiologic investigations carried out in different populations from several regions of Romania : Gurghiu Valley (lumberjacks from a mountain region), Danube Delta and Razelm lagoon complex (fishermen), and Bucharest have shown that, in spite of the high caloric value of food and even of a high intake of saturated fats, mean serum cholesterol is lower in the rural areas than in Bucharest, probably owing to the strenuous physical work. However, except myocardial infarction, more frequent in the urban than in the rural regions, the other forms of coronary heart disease have a relatively higher frequency in villages, particularly atrial fibrillation and ECG signs of ischemia. These findings might be explained by a greater prevalence of hypertension in these populations. It is concluded that the risk factors, which act synergically, depend on the complex structure of the "ecologic niche".
IS  - 0377-1202
IL  - 0377-1202
PT  - Journal Article
LG  - English
DP  - 1975
DC  - 19760305
YR  - 1975
ED  - 19760305
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=1243194

<971. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 1145900
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Aberg H
AU  - Furberg B
FA  - Aberg, H
FA  - Furberg, B
TI  - Atrial activity during exercise in patients with atrial flutter or atrial fibrillation.
SO  - Upsala Journal of Medical Sciences. 80(1):20-3, 1975.
AS  - Ups J Med Sci. 80(1):20-3, 1975.
NJ  - Upsala journal of medical sciences
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - wrg, 0332203
SB  - Index Medicus
CP  - SWEDEN
MH  - Adult
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Atrial Flutter/pp [Physiopathology]
MH  - Electrocardiography
MH  - Female
MH  - Heart Atria/pp [Physiopathology]
MH  - Heart Conduction System/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Physical Exertion
AB  - The atrial activity was studied at rest and during exercise in 6 patients with atrial flutter and in 7 patients with atrial fibrillation. In the latter, a special recording technique was used which permitted identification of the f-waves. No increase in the frequency of the atrial waves was found. Thus the increase of the ventricular rate during work in patients with atrial flutter or atrial fibrillation seems to be caused by a change in the atrio-ventricular conduction.
IS  - 0300-9734
IL  - 0300-9734
PT  - Journal Article
LG  - English
DP  - 1975
DC  - 19751003
YR  - 1975
ED  - 19751003
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=1145900

<972. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 4430114
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Chirife R
AU  - Foerster JM
AU  - Bing OH
FA  - Chirife, R
FA  - Foerster, J M
FA  - Bing, O H
TI  - Left ventricular ejection time by densitometry in patients at rest and during exercise, atrial pacing and atrial fibrillation. Comparison with central aortic pressure measurements.
SO  - Circulation. 50(6):1200-4, 1974 Dec.
AS  - Circulation. 50(6):1200-4, 1974 Dec.
NJ  - Circulation
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Cardiac Catheterization
MH  - *Densitometry/mt [Methods]
MH  - Evaluation Studies as Topic
MH  - Female
MH  - *Heart/pp [Physiopathology]
MH  - *Heart Function Tests/mt [Methods]
MH  - Heart Rate
MH  - Heart Ventricles/pp [Physiopathology]
MH  - Humans
MH  - Male
MH  - *Physical Exertion
MH  - Regression Analysis
MH  - Statistics as Topic
IS  - 0009-7322
IL  - 0009-7322
PT  - Journal Article
LG  - English
DP  - 1974 Dec
DC  - 19750218
YR  - 1974
ED  - 19750218
RD  - 20121115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=4430114

<973. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 4414219
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Marcus GB
FA  - Marcus, G B
TI  - Letter: Exercise testing in mitral valve disease.
SO  - American Journal of Cardiology. 34(5):620, 1974 Oct 3.
AS  - Am J Cardiol. 34(5):620, 1974 Oct 3.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Atrial Fibrillation/co [Complications]
MH  - *Exercise Test
MH  - Female
MH  - Humans
MH  - *Mitral Valve Insufficiency/di [Diagnosis]
IS  - 0002-9149
IL  - 0002-9149
PT  - Journal Article
LG  - English
DP  - 1974 Oct 3
DC  - 19741219
YR  - 1974
ED  - 19741219
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=4414219

<974. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 4810020
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gooch AS
AU  - Natarajan G
AU  - Goldberg H
FA  - Gooch, A S
FA  - Natarajan, G
FA  - Goldberg, H
TI  - Influence of exercise on arrhythmias induced by digitalis-diuretic therapy in patients with atrial fibrillation.
SO  - American Journal of Cardiology. 33(2):230-7, 1974 Feb.
AS  - Am J Cardiol. 33(2):230-7, 1974 Feb.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Arrhythmias, Cardiac/ci [Chemically Induced]
MH  - Arrhythmias, Cardiac/di [Diagnosis]
MH  - *Atrial Fibrillation/ci [Chemically Induced]
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - *Digoxin/ae [Adverse Effects]
MH  - *Diuretics/ae [Adverse Effects]
MH  - *Electrocardiography
MH  - *Exercise Test
MH  - Humans
MH  - Tachycardia/ci [Chemically Induced]
RN  - 0 (Diuretics)
RN  - 73K4184T59 (Digoxin)
IS  - 0002-9149
IL  - 0002-9149
PT  - Journal Article
LG  - English
DP  - 1974 Feb
DC  - 19740313
YR  - 1974
ED  - 19740313
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=4810020

<975. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 4744262
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Master AM
FA  - Master, A M
TI  - Cardiac arrhythmias elicited by the two-step exercise test.
SO  - American Journal of Cardiology. 32(6):766-71, 1973 Nov.
AS  - Am J Cardiol. 32(6):766-71, 1973 Nov.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Aged
MH  - Angina Pectoris/co [Complications]
MH  - Angina Pectoris/pp [Physiopathology]
MH  - Arrhythmias, Cardiac/co [Complications]
MH  - *Arrhythmias, Cardiac/di [Diagnosis]
MH  - Arrhythmias, Cardiac/et [Etiology]
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Bundle-Branch Block/di [Diagnosis]
MH  - Bundle-Branch Block/et [Etiology]
MH  - Electrocardiography
MH  - *Exercise Test
MH  - Female
MH  - Heart Atria/pp [Physiopathology]
MH  - Heart Block/di [Diagnosis]
MH  - Heart Block/et [Etiology]
MH  - Humans
MH  - Hypertension/pp [Physiopathology]
MH  - Male
MH  - Middle Aged
MH  - Time Factors
MH  - Wolff-Parkinson-White Syndrome/di [Diagnosis]
MH  - Wolff-Parkinson-White Syndrome/et [Etiology]
IS  - 0002-9149
IL  - 0002-9149
PT  - Journal Article
LG  - English
DP  - 1973 Nov
DC  - 19731214
YR  - 1973
ED  - 19731214
RD  - 20071115
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=4744262

<976. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 4726548
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Berman RH
FA  - Berman, R H
TI  - Acupuncture for cardioversion.
SO  - Annals of Internal Medicine. 79(2):285, 1973 Aug.
AS  - Ann Intern Med. 79(2):285, 1973 Aug.
NJ  - Annals of internal medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0372351, 5a6
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Acupuncture Therapy
MH  - Aged
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Tachycardia/th [Therapy]
IS  - 0003-4819
IL  - 0003-4819
PT  - Journal Article
LG  - English
DP  - 1973 Aug
DC  - 19731028
YR  - 1973
ED  - 19731028
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=4726548

<977. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 4704790
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Bleecker ET
AU  - Engel BT
FA  - Bleecker, E T
FA  - Engel, B T
TI  - Learned control of ventricular rate in patients with atrial fibrillation.
SO  - Psychosomatic Medicine. 35(2):161-75, 1973 Mar-Apr.
AS  - Psychosom Med. 35(2):161-75, 1973 Mar-Apr.
NJ  - Psychosomatic medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - qgr, 0376505
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Atropine/pd [Pharmacology]
MH  - *Autogenic Training
MH  - Edrophonium/pd [Pharmacology]
MH  - Electrocardiography
MH  - Female
MH  - Heart Rate/de [Drug Effects]
MH  - *Heart Rate
MH  - Humans
MH  - Isoproterenol/pd [Pharmacology]
MH  - Male
MH  - Middle Aged
MH  - Propranolol/pd [Pharmacology]
MH  - *Rheumatic Heart Disease/rh [Rehabilitation]
MH  - Volition
RN  - 70FP3JLY7N (Edrophonium)
RN  - 7C0697DR9I (Atropine)
RN  - 9Y8NXQ24VQ (Propranolol)
RN  - L628TT009W (Isoproterenol)
IS  - 0033-3174
IL  - 0033-3174
PT  - Journal Article
LG  - English
DP  - 1973 Mar-Apr
DC  - 19730711
YR  - 1973
ED  - 19730711
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=4704790

<978. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 5084773
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gooch AS
FA  - Gooch, A S
TI  - Exercise testing for detecting changes in cardiac rhythm and conduction.
SO  - American Journal of Cardiology. 30(7):741-6, 1972 Nov.
AS  - Am J Cardiol. 30(7):741-6, 1972 Nov.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - *Arrhythmias, Cardiac/di [Diagnosis]
MH  - Arrhythmias, Cardiac/pp [Physiopathology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Bundle-Branch Block/pp [Physiopathology]
MH  - Electrocardiography
MH  - *Exercise Test
MH  - *Heart Conduction System/pp [Physiopathology]
MH  - Heart Rate
MH  - Humans
MH  - Middle Aged
MH  - Pacemaker, Artificial
MH  - Physical Exertion
MH  - Tachycardia, Paroxysmal/pp [Physiopathology]
IS  - 0002-9149
IL  - 0002-9149
PT  - Journal Article
LG  - English
DP  - 1972 Nov
DC  - 19730109
YR  - 1972
ED  - 19730109
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=5084773

<979. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 4260835
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Vedin JA
AU  - Wilhelmsson CE
AU  - Wilhelmsen L
AU  - Bjure J
AU  - Ekstrom-Jodal B
FA  - Vedin, J A
FA  - Wilhelmsson, C E
FA  - Wilhelmsen, L
FA  - Bjure, J
FA  - Ekstrom-Jodal, B
TI  - Relation of resting and exercise-induced ectopic beats to other ischemic manifestations and to coronary risk factors. Men born in 1913.
SO  - American Journal of Cardiology. 30(1):25-31, 1972 Jul 11.
AS  - Am J Cardiol. 30(1):25-31, 1972 Jul 11.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - *Arrhythmias, Cardiac/di [Diagnosis]
MH  - Arrhythmias, Cardiac/mo [Mortality]
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Blood Glucose
MH  - Blood Pressure
MH  - Cardiomegaly/ra [Radiography]
MH  - Coronary Disease/co [Complications]
MH  - Death, Sudden
MH  - Electrocardiography
MH  - Exercise Test
MH  - Heart Block/di [Diagnosis]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Physical Exertion
MH  - Posture
MH  - Prognosis
MH  - Sweden
RN  - 0 (Blood Glucose)
IS  - 0002-9149
IL  - 0002-9149
PT  - Journal Article
LG  - English
DP  - 1972 Jul 11
DC  - 19720818
YR  - 1972
ED  - 19720818
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=4260835

<980. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 5032675
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Aberg H
AU  - Strom G
AU  - Werner I
FA  - Aberg, H
FA  - Strom, G
FA  - Werner, I
TI  - Heart rate during exercise in patients with atrial fibrillation.
SO  - Acta Medica Scandinavica. 191(4):315-20, 1972 Apr.
AS  - Acta Med Scand. 191(4):315-20, 1972 Apr.
NJ  - Acta medica Scandinavica
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0370330
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - SWEDEN
MH  - Adult
MH  - Aged
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Digitalis Glycosides/tu [Therapeutic Use]
MH  - Exercise Test
MH  - Female
MH  - Heart Defects, Congenital/co [Complications]
MH  - *Heart Rate
MH  - Heart Valve Diseases/co [Complications]
MH  - Humans
MH  - Hypertension/co [Complications]
MH  - Male
MH  - Middle Aged
MH  - *Physical Exertion
MH  - Posture
RN  - 0 (Digitalis Glycosides)
IS  - 0001-6101
IL  - 0001-6101
PT  - Journal Article
LG  - English
DP  - 1972 Apr
DC  - 19720809
YR  - 1972
ED  - 19720809
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=5032675

<981. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 5031539
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Aberg H
AU  - Strom G
AU  - Werner I
FA  - Aberg, H
FA  - Strom, G
FA  - Werner, I
TI  - The effect of digitalis on the heart rate during exercise in patients with atrial fibrillation.
SO  - Acta Medica Scandinavica. 191(5):441-5, 1972 May.
AS  - Acta Med Scand. 191(5):441-5, 1972 May.
NJ  - Acta medica Scandinavica
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0370330
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - SWEDEN
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - *Digitalis Glycosides/ad [Administration & Dosage]
MH  - Digitalis Glycosides/tu [Therapeutic Use]
MH  - Exercise Test
MH  - Female
MH  - Heart/pp [Physiopathology]
MH  - *Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - *Physical Exertion
RN  - 0 (Digitalis Glycosides)
IS  - 0001-6101
IL  - 0001-6101
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
LG  - English
DP  - 1972 May
DC  - 19720808
YR  - 1972
ED  - 19720808
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=5031539

<982. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 5124263
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Redfors A
FA  - Redfors, A
TI  - Digoxin dosage and ventricular rate at rest and exercise in patients with atrial fibrillation.
SO  - Acta Medica Scandinavica. 190(4):321-33, 1971 Oct.
AS  - Acta Med Scand. 190(4):321-33, 1971 Oct.
NJ  - Acta medica Scandinavica
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0370330
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - SWEDEN
MH  - *Atrial Fibrillation/dt [Drug Therapy]
MH  - *Digoxin/ad [Administration & Dosage]
MH  - Exercise Test
MH  - Female
MH  - Heart Function Tests
MH  - *Heart Rate/de [Drug Effects]
MH  - Heart Ventricles/pp [Physiopathology]
MH  - Humans
MH  - Male
RN  - 73K4184T59 (Digoxin)
IS  - 0001-6101
IL  - 0001-6101
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
LG  - English
DP  - 1971 Oct
DC  - 19720210
YR  - 1971
ED  - 19720210
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=5124263

<983. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 5579149
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Resnekov L
AU  - McDonald L
FA  - Resnekov, L
FA  - McDonald, L
TI  - Electroversion of lone atrial fibrillation and flutter including haemodynamic studies at rest and on exercise.
SO  - British Heart Journal. 33(3):339-50, 1971 May.
AS  - Br Heart J. 33(3):339-50, 1971 May.
NJ  - British heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - ats, 0370634
OI  - Source: NASA. 71205921
OI  - Source: NLM. PMC458416
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
SB  - National Aeronautics and Space Administration (NASA) Journals
CP  - ENGLAND
MH  - Adult
MH  - Aged
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/th [Therapy]
MH  - Atrial Flutter/dt [Drug Therapy]
MH  - *Atrial Flutter/th [Therapy]
MH  - Blood Pressure
MH  - Brachial Artery
MH  - Cardiac Output
MH  - Cardiac Volume
MH  - Electric Countershock/ae [Adverse Effects]
MH  - *Electric Countershock
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Rate
MH  - *Hemodynamics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxygen/bl [Blood]
MH  - Oxygen Consumption
MH  - *Physical Exertion
MH  - Pulmonary Artery
MH  - Quinidine/tu [Therapeutic Use]
RN  - ITX08688JL (Quinidine)
RN  - S88TT14065 (Oxygen)
IS  - 0007-0769
IL  - 0007-0769
PT  - Journal Article
LG  - English
DP  - 1971 May
DC  - 19710720
YR  - 1971
ED  - 19710720
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=5579149

<984. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 5108433
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kato K
AU  - Watanabe H
FA  - Kato, K
FA  - Watanabe, H
TI  - Hemodynamic responses to exercise in patients with coronary heart disease.
SO  - Japanese Circulation Journal. 35(1):29-33, 1971 Jan.
AS  - Jpn Circ J. 35(1):29-33, 1971 Jan.
NJ  - Japanese circulation journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - kgn, 7806868
SB  - Index Medicus
CP  - JAPAN
MH  - Angina Pectoris/pp [Physiopathology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Blood Circulation Time
MH  - *Coronary Disease/pp [Physiopathology]
MH  - *Hemodynamics
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/pp [Physiopathology]
MH  - Oxygen Consumption
MH  - *Physical Exertion
IS  - 0047-1828
IL  - 0047-1828
PT  - Journal Article
LG  - English
DP  - 1971 Jan
DC  - 19710706
YR  - 1971
ED  - 19710706
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=5108433

<985. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 5429488
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Bootsma BK
AU  - Hoelsen AJ
AU  - Strackee J
AU  - Meijler FL
FA  - Bootsma, B K
FA  - Hoelsen, A J
FA  - Strackee, J
FA  - Meijler, F L
TI  - Analysis of R-R intervals in patients with atrial fibrillation at rest and during exercise.
SO  - Circulation. 41(5):783-94, 1970 May.
AS  - Circulation. 41(5):783-94, 1970 May.
NJ  - Circulation
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - *Atrial Fibrillation
MH  - Computers
MH  - Digitalis Glycosides/pd [Pharmacology]
MH  - Electrocardiography
MH  - Female
MH  - Heart Conduction System/de [Drug Effects]
MH  - Heart Conduction System/pp [Physiopathology]
MH  - *Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Physical Exertion
MH  - *Rest
MH  - Statistics as Topic
RN  - 0 (Digitalis Glycosides)
IS  - 0009-7322
IL  - 0009-7322
PT  - Journal Article
LG  - English
DP  - 1970 May
DC  - 19700903
YR  - 1970
ED  - 19700903
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=5429488

<986. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 5791868
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gilbert R
AU  - Auchincloss JH Jr
FA  - Gilbert, R
FA  - Auchincloss, J H Jr
TI  - Cardiac and pulmonary function at the exercise breaking point in cardiac patients.
SO  - American Journal of the Medical Sciences. 257(6):370-81, 1969 Jun.
AS  - Am J Med Sci. 257(6):370-81, 1969 Jun.
NJ  - The American journal of the medical sciences
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3l2, 0370506
OI  - Source: NASA. 69228761
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
SB  - National Aeronautics and Space Administration (NASA) Journals
CP  - UNITED STATES
MH  - Adolescent
MH  - Adult
MH  - Aortic Valve Insufficiency/pp [Physiopathology]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Carbon Dioxide/bl [Blood]
MH  - Cardiac Output
MH  - Dyspnea
MH  - Female
MH  - *Heart/pp [Physiopathology]
MH  - *Heart Diseases/pp [Physiopathology]
MH  - Heart Failure/pp [Physiopathology]
MH  - Heart Rate
MH  - Heart Septal Defects, Atrial/pp [Physiopathology]
MH  - Humans
MH  - Lactates/bl [Blood]
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve Insufficiency/pp [Physiopathology]
MH  - Oxygen/bl [Blood]
MH  - *Physical Exertion
MH  - Pulmonary Valve Stenosis/pp [Physiopathology]
MH  - *Respiration
RN  - 0 (Lactates)
RN  - 142M471B3J (Carbon Dioxide)
RN  - S88TT14065 (Oxygen)
IS  - 0002-9629
IL  - 0002-9629
PT  - Journal Article
LG  - English
DP  - 1969 Jun
DC  - 19690822
YR  - 1969
ED  - 19690822
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=5791868

<987. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 4888876
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Brown RW
AU  - Goble AJ
FA  - Brown, R W
FA  - Goble, A J
TI  - Effect of propranolol on exercise tolerance of patients with atrial fibrillation.
SO  - British Medical Journal. 2(5652):279-80, 1969 May 3.
AS  - Br Med J. 2(5652):279-80, 1969 May 3.
NJ  - British medical journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - b4w, 0372673
OI  - Source: NLM. PMC1983196
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - ENGLAND
MH  - Adult
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Blood Pressure/de [Drug Effects]
MH  - Clinical Trials as Topic
MH  - Digitalis Glycosides/tu [Therapeutic Use]
MH  - Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Physical Exertion
MH  - Placebos
MH  - *Propranolol/pd [Pharmacology]
AB  - Six patients with atrial fibrillation who were taking digitalis were exercised before and after 30 mg. of propranolol twice daily. Though there was a lower pulse rate at rest and on exercise in all patients, three suffered deterioration of exercise tolerance. It is concluded that propranolol does not improve the exercise tolerance of patients with atrial fibrillation whose resting ventricular rate is controlled with digitalis.
RN  - 0 (Digitalis Glycosides)
RN  - 0 (Placebos)
RN  - 9Y8NXQ24VQ (Propranolol)
IS  - 0007-1447
IL  - 0007-1447
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
LG  - English
DP  - 1969 May 3
DC  - 19690605
YR  - 1969
ED  - 19690605
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=4888876

<988. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 5699498
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Master AM
AU  - Rosenfeld I
FA  - Master, A M
FA  - Rosenfeld, I
TI  - Current status of the two-step exercise test.
SO  - Journal of Electrocardiology. 1(1):5-6, 1968.
AS  - J Electrocardiol. 1(1):5-6, 1968.
NJ  - Journal of electrocardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - i0r, 0153605
SB  - Index Medicus
CP  - UNITED STATES
MH  - Arrhythmias, Cardiac/di [Diagnosis]
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Coronary Disease/di [Diagnosis]
MH  - Electrocardiography
MH  - *Exercise Test
MH  - Humans
MH  - Methods
MH  - Monitoring, Physiologic
MH  - Pain
MH  - Tachycardia/di [Diagnosis]
IS  - 0022-0736
IL  - 0022-0736
PT  - Journal Article
LG  - English
DP  - 1968
DC  - 19690110
YR  - 1968
ED  - 19690110
RD  - 20091111
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=5699498

<989. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 5696148
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Kaplan MA
AU  - Gray RE
AU  - Iseri LT
FA  - Kaplan, M A
FA  - Gray, R E
FA  - Iseri, L T
TI  - Metabolic and hemodynamic responses to exercise during atrial fibrillation and sinus rhythm.
SO  - American Journal of Cardiology. 22(4):543-9, 1968 Oct.
AS  - Am J Cardiol. 22(4):543-9, 1968 Oct.
NJ  - The American journal of cardiology
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 3dq, 0207277
OI  - Source: NASA. 69031680
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
SB  - National Aeronautics and Space Administration (NASA) Journals
CP  - UNITED STATES
MH  - Adult
MH  - Aged
MH  - Atrial Fibrillation/bl [Blood]
MH  - *Atrial Fibrillation/me [Metabolism]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Blood Circulation Time
MH  - Cardiac Output
MH  - Electric Countershock
MH  - Female
MH  - *Heart/pp [Physiopathology]
MH  - Heart Rate
MH  - Humans
MH  - Lactates/bl [Blood]
MH  - Male
MH  - Middle Aged
MH  - *Physical Exertion/ph [Physiology]
MH  - Pyruvates/bl [Blood]
MH  - Regional Blood Flow
RN  - 0 (Lactates)
RN  - 0 (Pyruvates)
IS  - 0002-9149
IL  - 0002-9149
PT  - Journal Article
LG  - English
DP  - 1968 Oct
DC  - 19690103
YR  - 1968
ED  - 19690103
RD  - 20081121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=5696148

<990. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 4172518
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Peter RH
AU  - Gracey JG
AU  - Beach TB
FA  - Peter, R H
FA  - Gracey, J G
FA  - Beach, T B
TI  - A clinical profile of idiopathic atrial fibrillation. A functional disorder of atrial rhythm.
SO  - Annals of Internal Medicine. 68(6):1288-95, 1968 Jun.
AS  - Ann Intern Med. 68(6):1288-95, 1968 Jun.
NJ  - Annals of internal medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0372351, 5a6
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adolescent
MH  - Adult
MH  - Alcoholic Beverages
MH  - Atrial Fibrillation/di [Diagnosis]
MH  - Atrial Fibrillation/et [Etiology]
MH  - Atrial Fibrillation/th [Therapy]
MH  - *Atrial Fibrillation
MH  - Blood Glucose/an [Analysis]
MH  - Blood Pressure Determination
MH  - Body Weight
MH  - Cough
MH  - Diet
MH  - Digitoxin/tu [Therapeutic Use]
MH  - Electric Countershock
MH  - Electrocardiography
MH  - Emotions
MH  - Fatigue
MH  - Female
MH  - Heart/ra [Radiography]
MH  - Humans
MH  - Hypnotics and Sedatives/tu [Therapeutic Use]
MH  - Male
MH  - Middle Aged
MH  - Pain
MH  - Posture
MH  - Quinidine/tu [Therapeutic Use]
MH  - Rest
MH  - Thyroid Function Tests
MH  - Vagus Nerve/pp [Physiopathology]
MH  - Vomiting
RN  - 0 (Blood Glucose)
RN  - 0 (Hypnotics and Sedatives)
RN  - E90NZP2L9U (Digitoxin)
RN  - ITX08688JL (Quinidine)
IS  - 0003-4819
IL  - 0003-4819
PT  - Journal Article
LG  - English
DP  - 1968 Jun
DC  - 19680730
YR  - 1968
ED  - 19680730
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=4172518

<991. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 5649079
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Hornsten TR
AU  - Bruce RA
FA  - Hornsten, T R
FA  - Bruce, R A
TI  - Effects of atrial fibrillation on exercise performance in patients with cardiac disease.
SO  - Circulation. 37(4):543-8, 1968 Apr.
AS  - Circulation. 37(4):543-8, 1968 Apr.
NJ  - Circulation
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - daw, 0147763
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Atrial Fibrillation/et [Etiology]
MH  - *Atrial Fibrillation/pp [Physiopathology]
MH  - Blood Pressure
MH  - Digitalis Glycosides/tu [Therapeutic Use]
MH  - Electrocardiography
MH  - *Exercise Test
MH  - Female
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Rheumatic Heart Disease/co [Complications]
MH  - Rheumatic Heart Disease/dt [Drug Therapy]
MH  - Sex Factors
RN  - 0 (Digitalis Glycosides)
IS  - 0009-7322
IL  - 0009-7322
PT  - Journal Article
LG  - English
DP  - 1968 Apr
DC  - 19680704
YR  - 1968
ED  - 19680704
RD  - 20041117
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=5649079

<992. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 5694607
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Winters WL Jr
AU  - McDonough MT
AU  - Hafer J
AU  - Dietz R
FA  - Winters, W L Jr
FA  - McDonough, M T
FA  - Hafer, J
FA  - Dietz, R
TI  - Diazepam. A useful hypnotic drug for direct-current cardioversion.
SO  - JAMA. 204(10):926-8, 1968 Jun 3.
AS  - JAMA. 204(10):926-8, 1968 Jun 3.
NJ  - JAMA
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 7501160
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - UNITED STATES
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Arrhythmias, Cardiac/th [Therapy]
MH  - Atrial Fibrillation/th [Therapy]
MH  - Atrial Flutter/th [Therapy]
MH  - Blood Pressure/de [Drug Effects]
MH  - *Diazepam/tu [Therapeutic Use]
MH  - *Electric Countershock
MH  - Female
MH  - Heart Rate/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Respiration/de [Drug Effects]
MH  - Tachycardia/th [Therapy]
MH  - Ventricular Fibrillation/th [Therapy]
RN  - Q3JTX2Q7TU (Diazepam)
IS  - 0098-7484
IL  - 0098-7484
PT  - Journal Article
LG  - English
DP  - 1968 Jun 3
DC  - 19680628
YR  - 1968
ED  - 19680628
RD  - 20140917
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=5694607

<993. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 5634967
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Beiser GD
AU  - Epstein SE
AU  - Stampfer M
AU  - Robinson B
AU  - Braunwald E
FA  - Beiser, G D
FA  - Epstein, S E
FA  - Stampfer, M
FA  - Robinson, B
FA  - Braunwald, E
TI  - Studies on digitalis. XVII. Effects of ouabain on the hemodynamic response to exercise in patients with mitral stenosis in normal sinus rhythm.
SO  - New England Journal of Medicine. 278(3):131-7, 1968 Jan 18.
AS  - N Engl J Med. 278(3):131-7, 1968 Jan 18.
NJ  - The New England journal of medicine
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 0255562, now
OI  - Source: NASA. 68094376
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
SB  - National Aeronautics and Space Administration (NASA) Journals
CP  - UNITED STATES
MH  - Adult
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - Blood Pressure/de [Drug Effects]
MH  - Cardiac Output/de [Drug Effects]
MH  - Electrocardiography
MH  - Exercise Test
MH  - Female
MH  - Heart Rate/de [Drug Effects]
MH  - *Hemodynamics/de [Drug Effects]
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mitral Valve Stenosis/dt [Drug Therapy]
MH  - *Mitral Valve Stenosis/pp [Physiopathology]
MH  - *Ouabain/pd [Pharmacology]
MH  - Ouabain/tu [Therapeutic Use]
MH  - Oxygen Consumption/de [Drug Effects]
MH  - *Physical Exertion
MH  - Pulmonary Artery
MH  - Vascular Resistance/de [Drug Effects]
RN  - 5ACL011P69 (Ouabain)
IS  - 0028-4793
IL  - 0028-4793
PT  - Journal Article
LG  - English
DP  - 1968 Jan 18
DC  - 19680215
YR  - 1968
ED  - 19680215
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=5634967

<994. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 6039163
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Lewes D
AU  - Hill DW
FA  - Lewes, D
FA  - Hill, D W
TI  - Application of multipoint electrodes to telemetry in patient-monitoring and during physical exercise.
SO  - British Heart Journal. 29(5):689-99, 1967 Sep.
AS  - Br Heart J. 29(5):689-99, 1967 Sep.
NJ  - British heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - ats, 0370634
OI  - Source: NLM. PMC459178
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - ENGLAND
MH  - Adult
MH  - Atrial Fibrillation/dt [Drug Therapy]
MH  - Digoxin/tu [Therapeutic Use]
MH  - *Electrocardiography
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Monitoring, Physiologic
MH  - Myocardial Infarction
MH  - Physical Exertion
MH  - Propranolol/tu [Therapeutic Use]
MH  - Radio
MH  - *Telemetry
RN  - 73K4184T59 (Digoxin)
RN  - 9Y8NXQ24VQ (Propranolol)
IS  - 0007-0769
IL  - 0007-0769
PT  - Journal Article
LG  - English
DP  - 1967 Sep
DC  - 19671031
YR  - 1967
ED  - 19671031
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=6039163

<995. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 5911555
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Gazetopoulos N
AU  - Davies H
FA  - Gazetopoulos, N
FA  - Davies, H
TI  - Ventilatory response to exercise in patients with left-to-right shunts.
SO  - British Heart Journal. 28(5):590-8, 1966 Sep.
AS  - Br Heart J. 28(5):590-8, 1966 Sep.
NJ  - British heart journal
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - ats, 0370634
OI  - Source: NLM. PMC459091
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - ENGLAND
MH  - Adolescent
MH  - Adult
MH  - Atrial Fibrillation
MH  - Cardiac Catheterization
MH  - *Ductus Arteriosus, Patent/pp [Physiopathology]
MH  - Female
MH  - *Heart Septal Defects/pp [Physiopathology]
MH  - Hemodynamics
MH  - Humans
MH  - Hypertension, Pulmonary/pp [Physiopathology]
MH  - Male
MH  - Middle Aged
MH  - Oxygen Consumption
MH  - *Physical Exertion
MH  - *Respiratory Function Tests
IS  - 0007-0769
IL  - 0007-0769
PT  - Journal Article
LG  - English
DP  - 1966 Sep
DC  - 19661126
YR  - 1966
ED  - 19661126
RD  - 20130925
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=5911555

<996. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 5843708
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - MEDLINE
AU  - Epstein S
AU  - Robinson BF
AU  - Kahler RL
AU  - Braunwald E
FA  - Epstein, S
FA  - Robinson, B F
FA  - Kahler, R L
FA  - Braunwald, E
TI  - Effects of beta-adrenergic blockade on the cardiac response to maximal and submaximal exercise in man.
SO  - Journal of Clinical Investigation. 44(11):1745-53, 1965 Nov.
AS  - J Clin Invest. 44(11):1745-53, 1965 Nov.
NJ  - The Journal of clinical investigation
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - hs7, 7802877
OI  - Source: NASA. 66041748
OI  - Source: NLM. PMC289674
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
SB  - National Aeronautics and Space Administration (NASA) Journals
CP  - UNITED STATES
MH  - Adult
MH  - Atrial Fibrillation/pp [Physiopathology]
MH  - *Autonomic Nerve Block
MH  - Blood Circulation
MH  - Cardiac Output
MH  - Cardiomyopathies/pp [Physiopathology]
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve Stenosis/pp [Physiopathology]
MH  - Oximetry
MH  - *Physical Exertion
MH  - Propranolol/pd [Pharmacology]
MH  - *Sympathetic Nervous System/ph [Physiology]
MH  - *Sympatholytics/pd [Pharmacology]
RN  - 0 (Sympatholytics)
RN  - 9Y8NXQ24VQ (Propranolol)
IS  - 0021-9738
IL  - 0021-9738
PT  - Journal Article
LG  - English
DP  - 1965 Nov
DC  - 19660202
YR  - 1965
ED  - 19660202
RD  - 20131121
UP  - 20151216
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med1&AN=5843708

<997. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26707792
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - In-Process
AU  - Jeong WK
AU  - Choi JH
AU  - Son JP
AU  - Lee S
AU  - Lee MJ
AU  - Choe YH
AU  - Bang OY
FA  - Jeong, Woo Kyo
FA  - Choi, Jin-Ho
FA  - Son, Jeong Pyo
FA  - Lee, Suyeon
FA  - Lee, Mi Ji
FA  - Choe, Yeon Hyeon
FA  - Bang, Oh Young
IN  - Jeong,Woo Kyo. Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
IN  - Choi,Jin-Ho. Department Cardiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
IN  - Son,Jeong Pyo. Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea.
IN  - Lee,Suyeon. Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea.
IN  - Lee,Mi Ji. Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
IN  - Choe,Yeon Hyeon. Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
IN  - Bang,Oh Young. Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea,. Electronic address: ohyoung.bang@samsung.com.
TI  - Volume and morphology of left atrial appendage as determinants of stroke subtype in patients with atrial fibrillation.
CM  - Comment in: Heart Rhythm. 2016 Apr;13(4):828-9; PMID: 26776556
SO  - Heart Rhythm. 13(4):820-7, 2016 Apr.
AS  - Heart Rhythm. 13(4):820-7, 2016 Apr.
NJ  - Heart rhythm : the official journal of the Heart Rhythm Society
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101200317
SB  - Index Medicus
CP  - United States
KW  - Atrial fibrillation;  Cardiac anatomy;  Coronary computed tomography;  Embolism;  Stroke
AB  - BACKGROUND: Atrial fibrillation (AF) is a leading cause of stroke, but not all cases of stroke in patients with AF are due to AF.
AB  - OBJECTIVE: The purpose of this study was to determine whether morphometric or volumetric parameters of left atrial appendage (LAA) would be related to the development of cardioembolism in subjects with AF.
AB  - METHODS: A total of 433 consecutive patients with acute ischemic stroke underwent multidetector cardiac computed tomography (MDCT). Of these patients, 88 with AF were divided into cardioembolic stroke (CES; n = 57) and non-CES (n = 31) groups, and 95 age- and sex-matched patients with non-CES without AF served as controls. Clinical factors, echocardiographic findings, and MDCT parameters were evaluated.
AB  - RESULTS: Brain infarct volume, LAA orifice diameter, and LAA volume were larger in patients with CES with AF than in those with non-CES with AF (P<.05 in all cases), but no difference was observed between patients with non-CES with AF and those with non-CES without AF. MDCT and echocardiographic parameters of left atrial (LA) dysfunction were different depending on the presence of AF but not between patients with CES with AF vs non-CES with AF. After adjusting for covariates, LAA orifice diameter (odds ratio 1.19, 95% confidence interval 1.06-1.33, P = .004) and LAA volume (odds ratio 12.20, 95% confidence interval 2.58-57.79, P = .002) were independently associated with CES with AF, as was infarct volume.
AB  - CONCLUSION: In patients with AF, LAA orifice diameter and LAA volume, but not left atrial dysfunction, were determinants of CES and were useful for stratifying noncardioembolic risk in patients with AF.Copyright © 2016 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.
ES  - 1556-3871
IL  - 1547-5271
DI  - S1547-5271(15)01552-0
DO  - http://dx.doi.org/10.1016/j.hrthm.2015.12.026
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
LG  - English
EP  - 20151218
DP  - 2016 Apr
DC  - 20160321
YR  - 2016
UP  - 20160722
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=26707792

<998. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 27381759
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - In-Data-Review
AU  - Lo LW
AU  - Chang HY
AU  - Scherlag BJ
AU  - Lin YJ
AU  - Chou YH
AU  - Lin WL
AU  - Chen SA
AU  - Po SS
FA  - Lo, Li-Wei
FA  - Chang, Hung-Yu
FA  - Scherlag, Benjamin J
FA  - Lin, Yenn-Jiang
FA  - Chou, Yu-Hui
FA  - Lin, Wei-Lun
FA  - Chen, Shih-Ann
FA  - Po, Sunny S
IN  - Lo,Li-Wei. Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan Institute of Clinical Medicine, and Cardiovascular Research Institute, National Yang-Ming University, Taipei, Taiwan.
IN  - Chang,Hung-Yu. Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan Institute of Clinical Medicine, and Cardiovascular Research Institute, National Yang-Ming University, Taipei, Taiwan.
IN  - Scherlag,Benjamin J. Department of Medicine and Heart Rhythm Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK.
IN  - Lin,Yenn-Jiang. Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan Institute of Clinical Medicine, and Cardiovascular Research Institute, National Yang-Ming University, Taipei, Taiwan.
IN  - Chou,Yu-Hui. Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
IN  - Lin,Wei-Lun. Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan Institute of Clinical Medicine, and Cardiovascular Research Institute, National Yang-Ming University, Taipei, Taiwan.
IN  - Chen,Shih-Ann. Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan Institute of Clinical Medicine, and Cardiovascular Research Institute, National Yang-Ming University, Taipei, Taiwan epsachen@ms41.hinet.net sunny-po@ouhsc.edu.
IN  - Po,Sunny S. Department of Medicine and Heart Rhythm Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK epsachen@ms41.hinet.net sunny-po@ouhsc.edu.
TI  - Temporary Suppression of Cardiac Ganglionated Plexi Leads to Long-Term Suppression of Atrial Fibrillation: Evidence of Early Autonomic Intervention to Break the Vicious Cycle of "AF Begets AF".
SO  - Journal of the American Heart Association. 5(7), 2016 Jul.
AS  - J Am Heart Assoc. 5(7), 2016 Jul.
NJ  - Journal of the American Heart Association
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 101580524
SB  - Index Medicus
CP  - England
KW  - atrial fibrillation;  autonomic;  botulinum toxin;  remodeling;  sinus rhythm
AB  - BACKGROUND: Botulinum toxin (BTX), temporarily suppressing cholinergic transmission (<3 weeks), has been reported to suppress atrial fibrillation (AF) for >1 year. We aimed to investigate the mechanism underlying long-term suppression of AF caused by injecting BTX into major atrial ganglionated plexi (GPs).
AB  - METHODS AND RESULTS: Bilateral thoracotomies in anesthetized dogs allowed programmed stimulation at 4 pulmonary veins, biatrial appendages, and the superior vena cava to determine the effective refractory period (ERP) in the first operation. Group 1 (n=10) received BTX injection into all GPs; group 2 (n=7) received no injection. Groups 1 and 2 received rapid atrial pacing (800 bpm) 6 days a week. Group 3 (n=7) did not undergo thoracotomy or rapid atrial pacing to serve as controls for histological studies. A second operation and the same measurements were made 3 months later. During the first operation in group 1, ERPs of 4 pulmonary veins, but not biatrial appendages or superior vena cava, increased immediately after BTX injection. AF burdens increased significantly from the fifth week after the first operation in group 2 but not in group 1. In the second operation, ERPs remained unchanged compared with ERPs before BTX injection in group 1, whereas ERPs shortened significantly at all sites except the superior vena cava in group 2. There was no difference of autonomic nerve density between group 1 and group 3. The GP choline acetyltransferase (+) and atrial tyrosine hydroxylase (+) nerve densities were higher in group 2 than in group 1 and group 3.
AB  - CONCLUSIONS: Temporary suppression of major atrial GPs by BTX prevents autonomic remodeling and provides long-term suppression of AF, indicating the critical role of GPs in AF progression.Copyright © 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.
ES  - 2047-9980
IL  - 2047-9980
DI  - e003309
DO  - http://dx.doi.org/10.1161/JAHA.116.003309
PT  - Journal Article
LG  - English
EP  - 20160705
DP  - 2016 Jul
DC  - 20160706
YR  - 2016
UP  - 20160715
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=27381759

<999. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26962786
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - In-Process
AU  - Violi F
AU  - Lip GY
AU  - Pignatelli P
AU  - Pastori D
FA  - Violi, Francesco
FA  - Lip, Gregory Yh
FA  - Pignatelli, Pasquale
FA  - Pastori, Daniele
IN  - Violi,Francesco. From the Center of Atherothrombosis (FV, PP, DP), I Medical Clinic, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Umberto I Policlinic of Rome, Rome, Italy; and Centre for Cardiovascular Sciences (GYHL), City Hospital, University of Birmingham, Birmingham, UK.
TI  - Interaction Between Dietary Vitamin K Intake and Anticoagulation by Vitamin K Antagonists: Is It Really True?: A Systematic Review.
SO  - Medicine. 95(10):e2895, 2016 Mar.
AS  - Medicine (Baltimore). 95(10):e2895, 2016 Mar.
NJ  - Medicine
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - mny, 2985248r
SB  - Core Clinical Journals (AIM)
SB  - Index Medicus
CP  - United States
AB  - Educational advice is often given to patients starting treatment with vitamin K Antagonists (VKAs). A great emphasis is made on nutritional information. Common belief is that dietary vitamin K intake could counteract the anticoagulant effect by VKAs and for many years, patients have been discouraged to consume vitamin-K-rich foods, such as green leafy vegetables.The objective of this study is to summarize the current evidence supporting the putative interaction between dietary vitamin K intake and changes in INR with the VKAs.Data sources are MEDLINE via PubMed and Cochrane database.All clinical studies investigating the relationship between dietary vitamin K and measures of anticoagulation were included. We excluded all studies of supplementation of vitamin K alone.We performed a systematic review of the literature up to October 2015, searching for a combination of "food," "diet," "vitamin K," "phylloquinone," "warfarin," "INR," "coagulation," and "anticoagulant."Two dietary interventional trials and 9 observational studies were included. We found conflicting evidence on the effect of dietary intake of vitamin K on coagulation response. Some studies found a negative correlation between vitamin K intake and INR changes, while others suggested that a minimum amount of vitamin K is required to maintain an adequate anticoagulation. Median dietary intake of vitamin K1 ranged from 76 to 217 mug/day among studies, and an effect on coagulation may be detected only for high amount of vitamin intake (>150 mug/day).Most studies included patients with various indications for VKAs therapy, such as atrial fibrillation, prosthetic heart valves, and venous thromboembolism. Thus, INR target was dishomogeneous and no subanalyses for specific populations or different anticoagulants were conducted. Measures used to evaluate anticoagulation stability were variable.The available evidence does not support current advice to modify dietary habits when starting therapy with VKAs. Restriction of dietary vitamin K intake does not seem to be a valid strategy to improve anticoagulation quality with VKAs. It would be, perhaps, more relevant to maintain stable dietary habit, avoiding wide changes in the intake of vitamin K.
ES  - 1536-5964
IL  - 0025-7974
DO  - http://dx.doi.org/10.1097/MD.0000000000002895
PT  - Journal Article
LG  - English
DP  - 2016 Mar
DC  - 20160311
YR  - 2016
UP  - 20160713
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=26962786

<1000. >
VN  - Ovid Technologies
DB  - Ovid MEDLINE(R)
UI  - 26219490
RO  - From MEDLINE, a database of the U.S. National Library of Medicine.
ST  - In-Process
AU  - Signorelli F
AU  - Nogueira F
AU  - Domingues V
AU  - Mariz HA
AU  - Levy RA
FA  - Signorelli, Flavio
FA  - Nogueira, Felipe
FA  - Domingues, Vinicius
FA  - Mariz, Henrique Ataide
FA  - Levy, Roger A
IN  - Signorelli,Flavio. Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. flasigno@hotmail.com.
IN  - Signorelli,Flavio. Hospital Universitario Pedro Ernesto, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil. flasigno@hotmail.com.
IN  - Nogueira,Felipe. Faculdade de Ciencias Medicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
IN  - Domingues,Vinicius. New York University Langone Medical Center, New York University School of Medicine, New York, USA.
IN  - Mariz,Henrique Ataide. Faculdade de Ciencias Medicas, Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil.
IN  - Levy,Roger A. Faculdade de Ciencias Medicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
IN  - Levy,Roger A. Centro de Imunoterapia de Ipanema - CITIPA, Rio de Janeiro, Brazil.
TI  - Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases.
SO  - Clinical Rheumatology. 35(3):801-5, 2016 Mar.
AS  - Clin Rheumatol. 35(3):801-5, 2016 Mar.
NJ  - Clinical rheumatology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 8211469, di6
SB  - Index Medicus
CP  - Germany
KW  - Anticoagulants;  Antiphospholipid syndrome;  Rivaroxaban;  Thrombosis;  Warfarin
AB  - The current treatment for antiphospholipid syndrome (APS) with thrombotic manifestation is long-term anticoagulation. Vitamin K antagonists (VKA) are usually the agents of choice. However, VKA limitations, such as unpredictable anticoagulation effects due to interaction with diet and other drugs, require regular monitoring. This may impact on patients' quality of life. Since the approval of new oral anticoagulants (NOAC) for non-valvular atrial fibrillation and deep vein thrombosis prevention, much has been speculated about its use in APS patients. We report here a series of eight APS patients with failure of thrombotic prevention during rivaroxaban use. All patients had venous thrombosis as the initial manifestation of APS, and two of them also had arterial manifestations. Three patients had triple antibody positivity. Five patients developed arterial events during the treatment with rivaroxaban. Until the results of ongoing trials of rivaroxaban for APS are presented, NOAC should not be recommended to APS patients. Our preliminary experience as well cases previously reported in the literature suggest that there is a high-risk group that is less protected with rivaroxaban, namely those with previous arterial thrombosis or triple positivity. VKA remains to be the mainstay treatment for thrombotic APS.
ES  - 1434-9949
IL  - 0770-3198
DO  - http://dx.doi.org/10.1007/s10067-015-3030-y
PT  - Journal Article
LG  - English
EP  - 20150730
DP  - 2016 Mar
DC  - 20160310
YR  - 2016
UP  - 20160711
XL  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=26219490